data_2hga_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2hga _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 19.1 t70 . . . . . 0 C--O 1.233 0.188 0 CA-C-O 121.759 0.79 . . . . 0.0 110.395 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 115.64 148.89 9.38 Favored Glycine 0 N--CA 1.446 -0.686 0 CA-C-N 115.344 -0.844 . . . . 0.0 111.36 -177.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.545 HG23 ' HB ' ' A' ' 48' ' ' ILE . 17.7 m -102.59 129.73 53.68 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 CA-C-O 121.195 0.522 . . . . 0.0 110.511 178.102 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . 0.414 ' HG3' ' O ' ' A' ' 46' ' ' LEU . 61.8 tt0 -110.66 149.73 30.02 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 121.187 0.517 . . . . 0.0 111.298 -175.941 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.487 HG23 HD13 ' A' ' 102' ' ' ILE . 74.3 mt -82.31 117.85 29.0 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 115.361 -0.836 . . . . 0.0 109.93 177.741 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.557 ' HB3' ' HB3' ' A' ' 103' ' ' ARG . 12.6 t70 -79.13 -65.1 1.04 Allowed 'General case' 0 C--N 1.317 -0.837 0 CA-C-N 116.235 -0.439 . . . . 0.0 109.84 178.912 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 5.5 p -150.06 156.53 41.85 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.91 -0.586 . . . . 0.0 111.31 -177.087 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.5 ' CG1' ' HA ' ' A' ' 39' ' ' SER . 56.2 t -116.18 113.73 44.03 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.229 -177.712 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 30.3 m -105.71 153.46 39.94 Favored Pre-proline 0 N--CA 1.445 -0.693 0 CA-C-N 116.512 -0.313 . . . . 0.0 110.569 178.505 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 29.0 Cg_endo -62.7 150.95 86.3 Favored 'Trans proline' 0 C--N 1.346 0.4 0 C-N-CA 123.023 2.482 . . . . 0.0 112.339 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 109.73 3.49 30.34 Favored Glycine 0 N--CA 1.45 -0.371 0 N-CA-C 111.081 -0.808 . . . . 0.0 111.081 -176.029 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' SER . . . . . 0.52 ' HB3' ' HA3' ' A' ' 101' ' ' GLY . 50.8 p -125.26 147.95 59.18 Favored Pre-proline 0 N--CA 1.447 -0.609 0 CA-C-N 115.17 -0.515 . . . . 0.0 109.862 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . 0.426 ' HD3' ' HA2' ' A' ' 89' ' ' GLY . 16.8 Cg_exo -67.31 -23.37 44.78 Favored 'Trans proline' 0 N--CA 1.463 -0.297 0 C-N-CA 122.031 1.82 . . . . 0.0 110.894 175.645 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -75.29 -7.93 55.28 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.179 -0.918 . . . . 0.0 111.927 -177.616 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.5 ' HA ' ' CG1' ' A' ' 32' ' ' VAL . 73.0 m -53.33 -31.24 43.31 Favored 'General case' 0 CA--C 1.533 0.303 0 N-CA-C 112.671 0.619 . . . . 0.0 112.671 -175.152 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 42.2 mtmt -128.99 21.21 5.84 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.822 0.344 . . . . 0.0 111.307 179.838 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 88.3 t -103.68 -50.95 9.06 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-O 120.931 0.396 . . . . 0.0 110.754 179.341 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -112.3 -179.82 3.78 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.383 0.611 . . . . 0.0 111.589 -179.393 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' THR . . . . . 0.573 ' O ' ' HG ' ' A' ' 46' ' ' LEU . 8.5 m -116.47 138.31 24.3 Favored Pre-proline 0 C--N 1.317 -0.823 0 CA-C-N 115.011 -0.995 . . . . 0.0 109.948 -178.851 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 21.0 Cg_endo -64.34 141.87 76.75 Favored 'Trans proline' 0 N--CA 1.46 -0.499 0 C-N-CA 121.665 1.577 . . . . 0.0 111.171 171.525 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 99.49 -7.78 59.91 Favored Glycine 0 C--N 1.32 -0.32 0 C-N-CA 120.6 -0.809 . . . . 0.0 113.159 -179.083 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . 0.573 ' HG ' ' O ' ' A' ' 43' ' ' THR . 27.9 mt -81.79 163.29 22.48 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 117.077 0.438 . . . . 0.0 110.612 -178.269 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 44.6 t -113.32 126.73 70.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.415 -178.129 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.545 ' HB ' HG23 ' A' ' 27' ' ' VAL . 75.1 mt -84.59 113.01 22.57 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-O 120.862 0.363 . . . . 0.0 110.141 178.931 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 66.6 mt-10 -83.9 -46.45 12.1 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.8 -177.074 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 17.1 p -162.8 152.09 15.29 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.045 0.45 . . . . 0.0 111.875 -178.449 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.483 HG23 ' OD1' ' A' ' 52' ' ' ASN . 12.1 mt -103.27 172.46 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 175.524 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' ASN . . . . . 0.822 ' HB3' ' HB3' ' A' ' 76' ' ' ASN . 17.8 p-10 -56.08 101.89 0.06 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.275 0.56 . . . . 0.0 112.243 -176.257 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 74.99 1.78 63.77 Favored Glycine 0 N--CA 1.451 -0.311 0 CA-C-N 115.527 -0.76 . . . . 0.0 113.042 178.836 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 49.9 mtm -138.14 96.69 10.03 Favored Pre-proline 0 C--N 1.325 -0.484 0 O-C-N 122.684 -0.304 . . . . 0.0 110.659 -175.652 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -73.88 133.85 19.0 Favored 'Trans proline' 0 N--CA 1.462 -0.344 0 C-N-CA 122.667 2.244 . . . . 0.0 111.968 178.679 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.408 HG22 ' HA ' ' A' ' 62' ' ' TYR . 17.7 p -110.83 83.8 1.82 Allowed 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.247 0.546 . . . . 0.0 111.675 -175.861 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 22.3 m -91.92 -13.48 31.14 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.249 177.011 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -128.11 173.79 9.79 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 -175.4 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 65.1 mt -78.72 -39.19 37.08 Favored 'General case' 0 N--CA 1.444 -0.77 0 CA-C-O 121.18 0.514 . . . . 0.0 110.059 177.797 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 3.1 m -67.11 -42.45 84.51 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.552 -0.749 . . . . 0.0 111.236 -178.862 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 1.2 p -65.63 -32.42 73.98 Favored 'General case' 0 C--N 1.333 -0.133 0 CA-C-O 120.797 0.332 . . . . 0.0 111.036 179.802 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' TYR . . . . . 0.408 ' HA ' HG22 ' A' ' 56' ' ' THR . 86.4 t80 -62.06 -44.52 96.5 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.007 -0.542 . . . . 0.0 109.669 174.318 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' SER . . . . . 0.487 ' O ' ' HG3' ' A' ' 67' ' ' LYS . 5.7 t -68.12 -41.68 81.37 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.293 179.732 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -60.69 -34.71 74.75 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 121.161 0.505 . . . . 0.0 110.859 -179.221 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . 0.409 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -73.1 -45.58 56.25 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.119 176.346 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -60.23 -38.24 82.8 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.996 -177.442 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . 0.487 ' HG3' ' O ' ' A' ' 63' ' ' SER . 68.6 mttm -65.4 -14.43 60.87 Favored 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 112.297 0.48 . . . . 0.0 112.297 -176.857 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 68.0 p -99.34 -13.14 19.74 Favored 'General case' 0 C--N 1.326 -0.447 0 C-N-CA 120.814 -0.354 . . . . 0.0 111.528 -179.691 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.409 HG12 ' O ' ' A' ' 65' ' ' ALA . 14.5 mm -88.75 144.24 9.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 120.904 0.383 . . . . 0.0 110.413 -176.445 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 54.4 m -104.06 171.0 7.59 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.534 -0.303 . . . . 0.0 111.351 -178.458 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 39.1 t -81.39 117.98 28.36 Favored 'Isoleucine or valine' 0 C--O 1.233 0.224 0 CA-C-O 120.905 0.383 . . . . 0.0 110.539 -178.397 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 102.58 -1.64 49.38 Favored Glycine 0 N--CA 1.448 -0.527 0 N-CA-C 111.463 -0.655 . . . . 0.0 111.463 -177.498 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 56.0 tt0 -87.65 149.08 24.5 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.35 -0.425 . . . . 0.0 109.878 179.527 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 64.3 t -111.13 124.89 68.33 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.782 -177.139 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 25.2 pt -110.07 164.32 6.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.316 -179.553 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . 0.822 ' HB3' ' HB3' ' A' ' 52' ' ' ASN . 6.7 t30 -107.53 114.94 29.28 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.043 -177.158 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.538 HG21 HG21 ' A' ' 48' ' ' ILE . 70.6 mt -117.48 115.21 47.93 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-O 120.982 0.42 . . . . 0.0 111.153 -175.877 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' THR . . . . . 0.523 ' HA ' ' HA ' ' A' ' 83' ' ' THR . 97.8 m -93.0 125.4 37.57 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.872 -0.604 . . . . 0.0 109.969 176.237 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.523 HG23 ' HA ' ' A' ' 48' ' ' ILE . 68.0 p -124.19 177.46 5.82 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.237 179.095 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -57.86 -33.7 68.96 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.5 0.667 . . . . 0.0 110.251 174.1 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 16.5 mm100 -90.73 17.33 7.78 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-N 115.223 -0.899 . . . . 0.0 111.242 -177.054 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 107.71 178.41 22.31 Favored Glycine 0 N--CA 1.446 -0.687 0 CA-C-N 115.525 -0.761 . . . . 0.0 112.419 175.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' THR . . . . . 0.523 ' HA ' ' HA ' ' A' ' 78' ' ' THR . 63.7 m -94.56 131.57 40.16 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-O 120.775 0.322 . . . . 0.0 110.638 179.035 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 91.1 m-85 -125.23 159.75 30.88 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.249 -0.432 . . . . 0.0 109.995 178.198 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 44.9 m80 -106.57 124.31 49.41 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 174.295 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.446 HD12 ' HA ' ' A' ' 86' ' ' LEU . 2.9 mm? -116.69 135.95 53.36 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-O 121.425 0.631 . . . . 0.0 111.811 -174.836 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 87.4 tttt -95.18 135.84 36.26 Favored 'General case' 0 C--N 1.31 -1.133 0 CA-C-N 114.981 -1.009 . . . . 0.0 109.071 174.12 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' THR . . . . . 0.614 ' HB ' ' HA ' ' A' ' 98' ' ' ALA . 55.1 p -65.14 143.45 57.86 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 120.925 0.393 . . . . 0.0 111.061 179.511 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.539 ' HA3' ' O ' ' A' ' 99' ' ' TYR . . . . . . . . 0 N--CA 1.439 -1.123 0 CA-C-N 115.647 -0.706 . . . . 0.0 113.411 -175.124 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . 0.614 ' HA ' ' HB ' ' A' ' 88' ' ' THR . . . . . . . . 0 N--CA 1.462 0.142 0 CA-C-O 120.77 0.319 . . . . 0.0 111.504 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . 0.539 ' O ' ' HA3' ' A' ' 89' ' ' GLY . 2.3 t80 -111.58 95.97 5.82 Favored 'General case' 0 C--N 1.325 -0.466 0 C-N-CA 119.805 -0.758 . . . . 0.0 109.895 -176.829 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' MET . . . . . 0.634 ' HG3' HG12 ' A' ' 102' ' ' ILE . 50.8 tpp -46.95 -54.17 10.69 Favored 'General case' 0 N--CA 1.466 0.35 0 O-C-N 123.746 0.654 . . . . 0.0 112.002 -173.391 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . 0.52 ' HA3' ' HB3' ' A' ' 36' ' ' SER . . . 99.31 -2.24 57.64 Favored Glycine 0 C--O 1.226 -0.375 0 C-N-CA 120.504 -0.855 . . . . 0.0 113.185 175.399 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.634 HG12 ' HG3' ' A' ' 100' ' ' MET . 36.7 pt -114.58 140.6 34.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 N-CA-C 109.633 -0.506 . . . . 0.0 109.633 178.14 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . 0.557 ' HB3' ' HB3' ' A' ' 30' ' ' ASP . 18.4 ttp180 -69.52 125.37 26.49 Favored 'General case' 0 N--CA 1.446 -0.648 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 178.535 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -135.52 142.03 45.35 Favored 'General case' 0 C--N 1.311 -1.104 0 CA-C-N 116.048 -0.523 . . . . 0.0 110.582 -175.465 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 31.9 m -153.39 157.45 39.99 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.05 179.575 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . 0.405 ' HA ' ' HA ' ' A' ' 27' ' ' VAL . 25.5 p-10 . . . . . 0 C--N 1.322 -0.623 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.798 -179.653 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 16.8 t70 . . . . . 0 N--CA 1.464 0.251 0 CA-C-O 121.057 0.456 . . . . 0.0 111.743 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . 0.545 ' HA2' ' HA ' ' A' ' 57' ' ' SER . . . 146.68 136.06 2.82 Favored Glycine 0 N--CA 1.444 -0.782 0 N-CA-C 110.932 -0.867 . . . . 0.0 110.932 -174.003 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.49 HG22 ' HB ' ' A' ' 48' ' ' ILE . 30.0 m -80.99 142.38 13.92 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-O 121.272 0.558 . . . . 0.0 110.86 -178.743 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . 0.508 ' HG3' ' O ' ' A' ' 46' ' ' LEU . 5.8 tt0 -116.38 155.4 28.57 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.482 -179.634 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.468 HD11 HD11 ' A' ' 102' ' ' ILE . 45.2 mm -81.56 110.51 17.0 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 178.01 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.45 ' HB3' ' CB ' ' A' ' 103' ' ' ARG . 14.4 t70 -70.43 -63.19 1.14 Allowed 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 115.933 -0.576 . . . . 0.0 109.591 179.479 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 17.3 m -150.03 148.99 29.71 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.734 -178.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.421 ' CG1' ' HA ' ' A' ' 39' ' ' SER . 97.3 t -114.6 114.07 45.55 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 N-CA-C 108.825 -0.805 . . . . 0.0 108.825 173.406 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.508 HG22 ' O ' ' A' ' 101' ' ' GLY . 4.6 m -75.11 153.13 86.43 Favored Pre-proline 0 C--N 1.324 -0.505 0 CA-C-N 116.51 -0.314 . . . . 0.0 111.355 -175.093 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 40.1 Cg_endo -69.77 116.58 4.63 Favored 'Trans proline' 0 N--CA 1.461 -0.404 0 C-N-CA 122.388 2.058 . . . . 0.0 111.033 172.613 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 94.99 -179.56 36.73 Favored Glycine 0 N--CA 1.445 -0.706 0 N-CA-C 110.63 -0.988 . . . . 0.0 110.63 -173.413 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' SER . . . . . 0.722 ' HB3' ' HD2' ' A' ' 37' ' ' PRO . 31.9 m 69.16 168.48 0.12 Allowed Pre-proline 0 CA--C 1.54 0.564 0 CA-C-N 117.072 0.436 . . . . 0.0 110.888 -179.052 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . 0.722 ' HD2' ' HB3' ' A' ' 36' ' ' SER . 32.8 Cg_endo -65.04 155.11 70.04 Favored 'Trans proline' 0 C--N 1.344 0.329 0 C-N-CA 122.348 2.032 . . . . 0.0 112.747 179.035 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.436 ' HB1' HD23 ' A' ' 86' ' ' LEU . . . 76.68 -12.22 1.07 Allowed 'General case' 0 N--CA 1.471 0.621 0 C-N-CA 123.718 0.807 . . . . 0.0 112.146 177.012 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.421 ' HA ' ' CG1' ' A' ' 32' ' ' VAL . 11.4 t -64.31 -30.87 71.9 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.618 -175.554 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -103.96 16.64 25.85 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.024 -175.687 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.431 ' HB ' HD13 ' A' ' 42' ' ' LEU . 30.8 t -125.29 -54.05 2.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 N-CA-C 111.705 0.261 . . . . 0.0 111.705 -177.672 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.431 HD13 ' HB ' ' A' ' 41' ' ' VAL . 7.6 mp -97.47 176.98 5.67 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.373 0.606 . . . . 0.0 111.909 -173.057 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' THR . . . . . 0.424 ' O ' ' HG ' ' A' ' 46' ' ' LEU . 28.5 m -135.5 134.32 20.98 Favored Pre-proline 0 C--N 1.321 -0.64 0 CA-C-N 115.186 -0.915 . . . . 0.0 109.39 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -62.13 139.46 78.51 Favored 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 122.105 1.87 . . . . 0.0 112.474 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 105.69 -13.11 46.56 Favored Glycine 0 CA--C 1.521 0.408 0 C-N-CA 120.641 -0.79 . . . . 0.0 113.808 179.308 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . 0.508 ' O ' ' HG3' ' A' ' 28' ' ' GLN . 56.9 mt -79.83 163.32 24.49 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 117.481 0.64 . . . . 0.0 111.044 -177.035 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 42.2 t -111.28 137.26 44.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 116.528 -0.306 . . . . 0.0 110.304 178.182 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.49 ' HB ' HG22 ' A' ' 27' ' ' VAL . 61.9 mt -92.62 124.93 45.24 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-O 121.16 0.505 . . . . 0.0 111.23 -178.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 11.3 tp10 -77.23 -53.93 7.12 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.624 176.378 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 5.3 p -161.83 156.01 22.1 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.341 -0.845 . . . . 0.0 111.576 -176.184 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.626 HG12 HG12 ' A' ' 77' ' ' ILE . 58.5 mt -123.17 106.86 18.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 115.478 -0.783 . . . . 0.0 109.475 176.396 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' ASN . . . . . 0.44 ' CG ' ' H ' ' A' ' 53' ' ' GLY . 12.0 t-20 61.26 -152.23 0.38 Allowed 'General case' 0 CA--C 1.533 0.307 0 N-CA-C 108.061 -1.089 . . . . 0.0 108.061 -175.425 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.44 ' H ' ' CG ' ' A' ' 52' ' ' ASN . . . -73.61 9.67 7.86 Favored Glycine 0 CA--C 1.525 0.657 0 C-N-CA 120.781 -0.723 . . . . 0.0 113.156 179.533 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 3.3 mpp? -114.96 105.31 53.25 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 120.721 0.296 . . . . 0.0 110.423 178.091 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -73.96 130.42 14.4 Favored 'Trans proline' 0 N--CA 1.458 -0.569 0 C-N-CA 122.04 1.827 . . . . 0.0 111.949 177.615 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.42 ' O ' ' HA2' ' A' ' 26' ' ' GLY . 16.7 p -98.12 75.96 2.34 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 121.249 0.547 . . . . 0.0 111.692 -176.595 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' SER . . . . . 0.545 ' HA ' ' HA2' ' A' ' 26' ' ' GLY . 32.3 t -88.89 -12.2 42.41 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.583 -0.735 . . . . 0.0 109.831 176.033 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 8.9 t-20 -129.32 177.89 6.84 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 115.846 -0.615 . . . . 0.0 109.361 -177.234 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.911 ' HG ' ' HB3' ' A' ' 106' ' ' ASN . 3.8 mt -90.08 -34.2 16.01 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-O 121.051 0.453 . . . . 0.0 109.806 176.661 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 28.5 m -63.7 -38.82 92.53 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.249 176.678 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 21.4 p -64.09 -38.07 89.72 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.484 177.851 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 89.1 t80 -65.48 -43.76 89.24 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.893 -0.594 . . . . 0.0 109.898 177.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 8.6 t -64.64 -48.03 76.31 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.455 179.684 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -65.54 -31.1 71.97 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.958 -0.564 . . . . 0.0 111.586 -177.223 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . 0.602 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -74.11 -45.04 51.52 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.328 179.6 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 1.6 tt -59.88 -43.8 94.55 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.134 -177.45 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 57.8 mtpt -63.13 -22.65 67.0 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.587 -0.733 . . . . 0.0 112.206 -178.153 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 40.6 p -92.18 -13.58 30.38 Favored 'General case' 0 C--N 1.329 -0.321 0 C-N-CA 120.971 -0.292 . . . . 0.0 111.571 179.465 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.602 HG12 ' O ' ' A' ' 65' ' ' ALA . 44.5 mm -78.14 138.99 19.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.841 0.353 . . . . 0.0 110.105 -179.265 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 6.1 m -88.46 165.7 14.72 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.971 -177.825 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 94.8 t -72.43 133.96 30.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.454 177.112 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 70.95 27.61 71.92 Favored Glycine 0 C--N 1.331 0.257 0 C-N-CA 120.959 -0.639 . . . . 0.0 111.984 179.005 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 9.7 tp10 -99.04 152.52 19.73 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 -177.443 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.413 ' HA ' ' O ' ' A' ' 86' ' ' LEU . 58.9 t -108.24 111.48 36.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.119 -179.459 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.612 HG13 ' HB3' ' A' ' 86' ' ' LEU . 15.0 pt -109.65 154.15 11.2 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.635 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.98 -177.815 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . 0.413 ' O ' ' HA ' ' A' ' 51' ' ' ILE . 19.9 t30 -95.17 114.4 26.19 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 115.302 -0.863 . . . . 0.0 110.726 -179.4 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.626 HG12 HG12 ' A' ' 51' ' ' ILE . 50.9 mt -113.19 104.55 17.2 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-O 121.641 0.734 . . . . 0.0 110.015 177.274 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 11.7 m -89.63 124.57 34.69 Favored 'General case' 0 C--N 1.314 -0.952 0 CA-C-N 115.036 -0.984 . . . . 0.0 109.275 178.075 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 60.0 p -117.17 172.33 7.36 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 121.024 0.44 . . . . 0.0 111.172 -178.004 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -56.45 -32.71 65.18 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.245 -0.889 . . . . 0.0 111.444 177.434 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 30.5 mm-40 -104.39 16.48 26.06 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 112.373 0.508 . . . . 0.0 112.373 -175.507 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 136.6 172.66 12.64 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 119.969 -1.11 . . . . 0.0 113.674 175.528 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 19.6 m -99.19 121.53 41.16 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 110.278 -0.267 . . . . 0.0 110.278 -179.876 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -115.63 158.71 22.32 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.189 0.519 . . . . 0.0 111.153 -177.051 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 23.4 m80 -102.51 125.63 49.3 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.619 -0.719 . . . . 0.0 109.237 179.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.612 ' HB3' HG13 ' A' ' 75' ' ' ILE . 0.4 OUTLIER -114.16 136.71 52.64 Favored 'General case' 0 C--N 1.315 -0.895 0 CA-C-O 120.978 0.418 . . . . 0.0 110.069 -176.848 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' LYS . . . . . 0.45 ' N ' HD13 ' A' ' 86' ' ' LEU . 78.7 tttt -127.08 115.71 19.59 Favored 'General case' 0 C--N 1.312 -1.046 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 176.45 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' THR . . . . . 0.533 HG21 ' HB2' ' A' ' 98' ' ' ALA . 73.4 p -69.35 142.44 54.0 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.766 -0.652 . . . . 0.0 111.812 -173.199 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.9 0 CA-C-N 115.674 -0.693 . . . . 0.0 112.777 -177.701 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . 0.533 ' HB2' HG21 ' A' ' 88' ' ' THR . . . . . . . . 0 N--CA 1.461 0.077 0 CA-C-O 121.597 0.713 . . . . 0.0 110.234 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 29.1 t80 -81.82 119.98 24.59 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.64 -0.709 . . . . 0.0 110.306 -172.548 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 26.0 mmt -98.66 151.58 20.56 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.597 -179.698 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . 0.508 ' O ' HG22 ' A' ' 33' ' ' VAL . . . -124.36 26.67 5.72 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.45 -0.881 . . . . 0.0 112.555 -179.828 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.468 HD11 HD11 ' A' ' 29' ' ' ILE . 45.6 pt -136.3 162.41 35.82 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-O 121.112 0.482 . . . . 0.0 110.549 179.686 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . 0.45 ' CB ' ' HB3' ' A' ' 30' ' ' ASP . 28.5 mmt85 -102.18 146.34 28.11 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 115.487 -0.779 . . . . 0.0 109.421 176.056 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 16.5 p -131.59 154.49 48.8 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.225 0.536 . . . . 0.0 111.61 -179.6 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 15.7 p -122.88 171.09 9.46 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.903 -0.59 . . . . 0.0 109.692 175.539 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . 0.911 ' HB3' ' HG ' ' A' ' 59' ' ' LEU . 19.8 p-10 . . . . . 0 C--N 1.321 -0.659 0 N-CA-C 111.812 0.301 . . . . 0.0 111.812 -175.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 16.0 t70 . . . . . 0 CA--C 1.528 0.106 0 CA-C-O 121.02 0.438 . . . . 0.0 111.134 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . 0.561 ' HA2' ' HA ' ' A' ' 57' ' ' SER . . . 165.59 172.04 32.52 Favored Glycine 0 N--CA 1.45 -0.367 0 N-CA-C 111.141 -0.784 . . . . 0.0 111.141 -177.795 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.529 HG22 ' HB ' ' A' ' 48' ' ' ILE . 30.7 m -124.0 148.16 28.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-O 121.242 0.544 . . . . 0.0 111.117 179.147 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . 0.518 ' HG3' ' O ' ' A' ' 46' ' ' LEU . 60.0 tt0 -128.34 152.06 48.59 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.007 -179.248 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.471 HD12 ' HB2' ' A' ' 46' ' ' LEU . 2.8 pt -86.5 122.16 38.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 121.238 0.542 . . . . 0.0 111.245 179.345 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.605 ' HB3' ' CB ' ' A' ' 103' ' ' ARG . 15.8 t70 -64.44 -61.74 2.03 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 114.699 -1.137 . . . . 0.0 110.828 -179.13 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.457 ' HA ' ' CB ' ' A' ' 44' ' ' PRO . 51.3 p -166.94 161.81 15.3 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.602 -0.726 . . . . 0.0 110.936 -175.582 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.543 ' HA ' HG23 ' A' ' 102' ' ' ILE . 85.2 t -98.81 129.14 49.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.788 177.314 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 47.0 t -92.69 129.67 39.52 Favored Pre-proline 0 C--N 1.322 -0.621 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.006 -179.749 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_exo -56.64 123.74 14.58 Favored 'Trans proline' 0 C--O 1.234 0.291 0 C-N-CA 122.584 2.189 . . . . 0.0 111.929 178.07 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 117.27 18.05 5.54 Favored Glycine 0 N--CA 1.447 -0.594 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.379 -176.152 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' SER . . . . . 0.633 ' HB3' ' HA3' ' A' ' 101' ' ' GLY . 54.3 p -121.54 149.79 53.43 Favored Pre-proline 0 C--N 1.322 -0.615 0 CA-C-N 115.58 -0.31 . . . . 0.0 110.801 -177.111 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_endo -71.14 -25.41 22.42 Favored 'Trans proline' 0 N--CA 1.463 -0.271 0 C-N-CA 122.338 2.025 . . . . 0.0 111.949 176.112 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -72.45 -10.62 60.01 Favored 'General case' 0 C--O 1.234 0.245 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.808 -175.611 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.534 ' HA ' HG12 ' A' ' 32' ' ' VAL . 24.7 p -59.16 -28.75 66.88 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.91 -177.85 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 65.0 mttm -110.92 15.06 21.99 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.879 0.371 . . . . 0.0 111.083 179.858 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 53.8 t -101.66 -59.49 3.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-O 120.972 0.415 . . . . 0.0 110.368 178.599 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -130.66 169.28 15.85 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.118 -179.868 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 18.3 p -105.15 138.96 19.68 Favored Pre-proline 0 C--N 1.318 -0.775 0 CA-C-N 115.624 -0.717 . . . . 0.0 110.182 177.705 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.457 ' CB ' ' HA ' ' A' ' 31' ' ' SER . 32.1 Cg_endo -65.18 141.85 71.14 Favored 'Trans proline' 0 N--CA 1.462 -0.373 0 C-N-CA 122.34 2.027 . . . . 0.0 112.31 -179.188 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 110.24 -1.27 29.68 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.8 -177.206 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . 0.518 ' O ' ' HG3' ' A' ' 28' ' ' GLN . 90.1 mt -85.36 163.39 18.58 Favored 'General case' 0 C--N 1.328 -0.351 0 O-C-N 122.459 -0.436 . . . . 0.0 110.84 178.938 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.449 ' HB ' ' HB2' ' A' ' 80' ' ' ASP . 47.0 t -105.44 135.2 44.53 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.264 -179.233 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.529 ' HB ' HG22 ' A' ' 27' ' ' VAL . 69.4 mt -95.5 119.12 43.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 N-CA-C 110.118 -0.327 . . . . 0.0 110.118 -179.733 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 29.8 mt-10 -86.66 -46.15 10.33 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.332 -0.394 . . . . 0.0 111.216 -178.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' SER . . . . . 0.561 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 36.1 p -159.69 155.07 25.41 Favored 'General case' 0 C--N 1.325 -0.482 0 C-N-CA 120.326 -0.55 . . . . 0.0 112.028 -177.759 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 55.6 mt -112.93 97.38 5.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 115.372 -0.831 . . . . 0.0 111.003 179.195 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 49.2 t30 58.52 35.4 24.6 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.171 -0.922 . . . . 0.0 111.874 171.291 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 108.95 -27.4 13.01 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.057 178.835 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' MET . . . . . 0.411 ' HA ' ' HD3' ' A' ' 55' ' ' PRO . 71.6 mtm -98.88 106.88 40.35 Favored Pre-proline 0 C--N 1.324 -0.51 0 N-CA-C 109.978 -0.378 . . . . 0.0 109.978 178.723 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.561 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 6.1 Cg_exo -77.61 150.02 27.46 Favored 'Trans proline' 0 N--CA 1.457 -0.633 0 C-N-CA 122.669 2.246 . . . . 0.0 112.095 -177.626 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 19.8 p -123.13 106.72 11.02 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 120.915 0.388 . . . . 0.0 111.399 -178.241 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' SER . . . . . 0.561 ' HA ' ' HA2' ' A' ' 26' ' ' GLY . 15.1 p -99.0 -22.16 15.87 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 121.038 0.447 . . . . 0.0 110.788 178.283 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . 0.488 ' HB3' ' OG1' ' A' ' 61' ' ' THR . 17.3 t-20 -117.18 172.23 7.43 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.091 -0.504 . . . . 0.0 109.733 179.264 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 40.3 mt -79.43 -42.6 25.06 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.469 -179.843 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 27.8 m -65.8 -29.49 69.99 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.778 177.652 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' THR . . . . . 0.488 ' OG1' ' HB3' ' A' ' 58' ' ' ASN . 1.5 m -66.56 -37.42 84.93 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.177 0.513 . . . . 0.0 110.009 176.357 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 62.5 t80 -62.91 -45.76 90.98 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.217 -0.902 . . . . 0.0 109.4 174.345 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' SER . . . . . 0.521 ' O ' ' HG2' ' A' ' 67' ' ' LYS . 59.6 m -59.48 -48.77 80.37 Favored 'General case' 0 N--CA 1.444 -0.744 0 CA-C-N 115.243 -0.889 . . . . 0.0 111.695 177.565 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -60.3 -31.08 69.93 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.721 -178.454 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . 0.401 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -76.2 -42.87 44.86 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.334 0.588 . . . . 0.0 109.885 176.995 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . 0.439 HD22 ' HA ' ' A' ' 66' ' ' LEU . 0.2 OUTLIER -58.06 -32.96 68.52 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 114.958 -1.019 . . . . 0.0 111.382 178.803 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . 0.521 ' HG2' ' O ' ' A' ' 63' ' ' SER . 31.5 mmmt -56.01 -35.14 66.48 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.944 -179.938 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 24.5 p -92.84 -12.74 30.3 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 112.317 0.488 . . . . 0.0 112.317 -174.851 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.504 HG23 HG22 ' A' ' 88' ' ' THR . 46.2 mm -74.47 136.92 24.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 120.888 0.375 . . . . 0.0 110.571 -178.129 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' SER . . . . . 0.403 ' HB2' ' HB2' ' A' ' 73' ' ' GLU . 6.0 m -89.17 161.82 16.26 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.748 -178.452 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 11.4 t -80.34 115.12 22.28 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 N-CA-C 108.672 -0.862 . . . . 0.0 108.672 171.848 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 99.13 9.45 51.6 Favored Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 120.751 -0.738 . . . . 0.0 111.271 -173.364 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.403 ' HB2' ' HB2' ' A' ' 70' ' ' SER . 10.7 tp10 -80.81 149.14 29.7 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 179.054 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 58.3 t -111.01 108.13 24.69 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.989 0 N-CA-C 109.273 -0.639 . . . . 0.0 109.273 176.872 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 17.1 pt -101.08 153.62 4.81 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 CA-C-O 121.44 0.638 . . . . 0.0 111.662 -176.366 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 3.9 t30 -107.4 104.41 13.99 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 114.949 -1.023 . . . . 0.0 109.716 -176.226 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 65.0 mt -106.85 110.7 32.64 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.011 0 CA-C-O 121.317 0.58 . . . . 0.0 111.241 -173.799 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' THR . . . . . 0.469 ' HA ' ' HA ' ' A' ' 83' ' ' THR . 91.8 m -85.19 114.34 22.23 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-N 115.595 -0.73 . . . . 0.0 109.271 174.694 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 50.1 p -103.42 175.66 5.41 Favored 'General case' 0 N--CA 1.443 -0.797 0 CA-C-O 121.061 0.458 . . . . 0.0 110.387 179.85 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . 0.449 ' HB2' ' HB ' ' A' ' 47' ' ' VAL . 9.3 t70 -51.71 -33.42 34.25 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.006 -0.997 . . . . 0.0 112.515 179.43 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 5.3 mt-30 -115.29 16.06 16.85 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 112.704 0.631 . . . . 0.0 112.704 -173.27 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 140.58 169.83 11.87 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.237 -0.983 . . . . 0.0 113.073 176.661 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' THR . . . . . 0.469 ' HA ' ' HA ' ' A' ' 78' ' ' THR . 30.0 m -96.59 133.4 41.13 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.794 0.331 . . . . 0.0 111.122 -179.507 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 82.5 m-85 -123.19 157.21 33.52 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.232 177.561 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 1.7 p-80 -108.12 120.11 41.4 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.104 0.478 . . . . 0.0 110.273 176.486 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -109.95 146.95 34.35 Favored 'General case' 0 N--CA 1.444 -0.741 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.852 -176.841 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 77.7 tttt -111.82 124.17 51.8 Favored 'General case' 0 C--N 1.32 -0.693 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 174.516 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' THR . . . . . 0.504 HG22 HG23 ' A' ' 69' ' ' ILE . 13.4 p -80.69 132.26 35.55 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 120.981 0.419 . . . . 0.0 111.562 -178.648 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.651 0 C-N-CA 120.977 -0.63 . . . . 0.0 111.863 179.253 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.465 0.29 0 CA-C-O 120.957 0.408 . . . . 0.0 111.895 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 11.4 t80 -136.97 134.47 36.71 Favored 'General case' 0 C--N 1.323 -0.561 0 C-N-CA 120.851 -0.339 . . . . 0.0 110.32 -179.751 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' MET . . . . . 0.479 ' SD ' HG21 ' A' ' 88' ' ' THR . 4.3 mpp? -86.92 -16.25 36.48 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.537 -0.301 . . . . 0.0 111.57 -177.468 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . 0.633 ' HA3' ' HB3' ' A' ' 36' ' ' SER . . . 90.58 30.33 12.07 Favored Glycine 0 CA--C 1.519 0.33 0 C-N-CA 120.878 -0.677 . . . . 0.0 112.866 178.931 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.543 HG23 ' HA ' ' A' ' 32' ' ' VAL . 36.6 pt -135.42 167.05 26.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-O 120.908 0.385 . . . . 0.0 110.584 -178.751 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . 0.605 ' CB ' ' HB3' ' A' ' 30' ' ' ASP . 36.9 mtt180 -98.53 155.54 17.23 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.666 173.286 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 3.3 m -139.1 149.98 45.16 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 121.092 0.473 . . . . 0.0 110.345 177.269 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 32.0 m -142.02 178.42 7.54 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 115.365 -0.834 . . . . 0.0 109.198 -178.337 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 10.4 p30 . . . . . 0 C--N 1.325 -0.496 0 CA-C-O 120.592 0.234 . . . . 0.0 110.874 177.637 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 14.5 t70 . . . . . 0 N--CA 1.465 0.283 0 CA-C-O 121.155 0.502 . . . . 0.0 110.718 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . 0.475 ' HA2' ' HA ' ' A' ' 57' ' ' SER . . . 156.93 131.8 1.39 Allowed Glycine 0 N--CA 1.449 -0.486 0 CA-C-N 115.745 -0.661 . . . . 0.0 111.694 -179.597 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.449 HG21 ' HB ' ' A' ' 48' ' ' ILE . 31.5 m -72.7 140.15 18.42 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-O 121.218 0.532 . . . . 0.0 111.352 -177.931 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 4.1 tp-100 -107.45 133.76 51.48 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.651 -0.704 . . . . 0.0 111.11 -177.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.523 HD11 ' HB2' ' A' ' 46' ' ' LEU . 61.5 mt -73.29 105.87 2.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 CA-C-N 115.637 -0.711 . . . . 0.0 109.815 175.524 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 21.3 t70 -62.91 -65.21 0.72 Allowed 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.254 -178.037 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 12.4 p -156.46 152.53 27.55 Favored 'General case' 0 N--CA 1.444 -0.731 0 CA-C-N 115.21 -0.905 . . . . 0.0 110.724 -179.727 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.792 HG23 HG21 ' A' ' 102' ' ' ILE . 66.8 t -87.74 120.47 36.91 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.542 174.903 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.543 HG21 ' O ' ' A' ' 101' ' ' GLY . 22.7 m -82.05 160.53 62.94 Favored Pre-proline 0 C--N 1.325 -0.492 0 CA-C-N 116.777 -0.192 . . . . 0.0 110.534 -177.307 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_exo -66.86 99.24 0.45 Allowed 'Trans proline' 0 C--O 1.236 0.376 0 C-N-CA 122.584 2.19 . . . . 0.0 112.434 178.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.416 ' O ' ' HB2' ' A' ' 39' ' ' SER . . . 145.13 -165.17 27.82 Favored Glycine 0 N--CA 1.447 -0.592 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.566 178.762 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 51.0 p 64.37 157.76 0.12 Allowed Pre-proline 0 N--CA 1.473 0.682 0 C-N-CA 124.598 1.159 . . . . 0.0 112.168 179.194 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 2.0 Cg_endo -82.78 -5.53 11.51 Favored 'Trans proline' 0 N--CA 1.46 -0.497 0 C-N-CA 122.984 2.456 . . . . 0.0 112.102 175.756 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -96.68 -0.7 47.99 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.414 -176.575 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.416 ' HB2' ' O ' ' A' ' 35' ' ' GLY . 32.1 t -60.87 -30.78 70.34 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.617 -176.224 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 62.9 tttp -107.39 7.72 29.23 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.929 0.395 . . . . 0.0 110.739 -179.326 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 57.6 t -91.2 -55.69 5.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-O 120.962 0.411 . . . . 0.0 110.129 178.755 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 5.2 mp -108.61 162.04 14.51 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.266 -0.425 . . . . 0.0 109.974 178.061 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 20.5 p -112.42 155.64 43.4 Favored Pre-proline 0 C--N 1.317 -0.84 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 177.403 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -70.0 146.05 57.56 Favored 'Trans proline' 0 N--CA 1.459 -0.548 0 C-N-CA 121.65 1.567 . . . . 0.0 111.464 178.133 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 94.84 12.41 55.52 Favored Glycine 0 CA--C 1.522 0.521 0 C-N-CA 120.615 -0.802 . . . . 0.0 113.618 179.938 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . 0.523 ' HB2' HD11 ' A' ' 29' ' ' ILE . 86.8 mt -98.0 162.03 13.43 Favored 'General case' 0 C--N 1.334 -0.105 0 CA-C-N 117.499 0.65 . . . . 0.0 110.904 177.063 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 59.6 t -110.79 128.31 67.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.781 -177.608 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.449 ' HB ' HG21 ' A' ' 27' ' ' VAL . 76.4 mt -91.66 121.34 42.04 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.396 179.743 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 61.9 mt-10 -82.54 -50.0 9.28 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.702 -179.279 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' SER . . . . . 0.555 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 15.2 p -159.29 153.88 24.32 Favored 'General case' 0 N--CA 1.45 -0.441 0 CA-C-O 121.223 0.535 . . . . 0.0 112.122 -172.757 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 64.2 mt -122.78 101.58 9.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 115.158 -0.928 . . . . 0.0 110.113 176.616 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 35.0 t-20 55.26 67.9 0.95 Allowed 'General case' 0 N--CA 1.464 0.274 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.2 176.443 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 79.59 -46.14 3.02 Favored Glycine 0 CA--C 1.519 0.304 0 CA-C-N 115.559 -0.746 . . . . 0.0 112.944 178.639 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 64.0 mtm -80.96 114.28 47.36 Favored Pre-proline 0 C--N 1.324 -0.511 0 N-CA-C 110.157 -0.312 . . . . 0.0 110.157 -178.838 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.555 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 98.1 Cg_endo -80.02 146.13 17.99 Favored 'Trans proline' 0 N--CA 1.458 -0.597 0 C-N-CA 122.351 2.034 . . . . 0.0 112.573 -176.966 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 22.3 p -110.41 76.26 0.97 Allowed 'General case' 0 N--CA 1.447 -0.618 0 CA-C-O 121.355 0.598 . . . . 0.0 111.062 -179.473 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' SER . . . . . 0.475 ' HA ' ' HA2' ' A' ' 26' ' ' GLY . 16.5 m -84.6 -15.07 46.9 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.175 177.643 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 6.3 t-20 -140.12 175.79 9.3 Favored 'General case' 0 N--CA 1.449 -0.476 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.091 -179.336 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.447 ' HG ' ' OD1' ' A' ' 106' ' ' ASN . 28.6 mt -75.4 -31.35 60.39 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.858 179.508 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 1.5 m -65.39 -43.3 91.07 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.634 178.292 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 7.2 p -64.92 -37.18 86.79 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.055 0.455 . . . . 0.0 110.325 177.083 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' TYR . . . . . 0.43 ' O ' ' HB2' ' A' ' 66' ' ' LEU . 84.4 t80 -62.85 -44.66 95.54 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.771 -0.65 . . . . 0.0 109.857 174.928 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 47.2 m -61.98 -47.16 86.08 Favored 'General case' 0 N--CA 1.446 -0.644 0 CA-C-N 115.286 -0.87 . . . . 0.0 111.997 179.225 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.44 -30.62 71.66 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.187 -178.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . 0.448 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -77.58 -44.2 29.24 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 121.09 0.471 . . . . 0.0 110.011 177.14 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . 0.455 HD22 ' HA ' ' A' ' 66' ' ' LEU . 0.2 OUTLIER -57.47 -36.43 71.45 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.358 -0.837 . . . . 0.0 112.166 -176.768 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 19.7 ptmt -71.95 -18.34 62.01 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 120.772 -0.371 . . . . 0.0 111.662 -177.676 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 44.6 p -92.12 -13.49 30.64 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.978 0.418 . . . . 0.0 110.767 -178.876 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.506 HD13 HG21 ' A' ' 75' ' ' ILE . 19.6 mm -83.35 144.91 9.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.356 -0.384 . . . . 0.0 109.998 -178.888 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 13.0 m -105.28 164.38 11.88 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.497 -0.319 . . . . 0.0 110.469 -179.438 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 36.2 t -77.5 119.48 26.21 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 175.349 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 88.63 22.83 38.35 Favored Glycine 0 N--CA 1.45 -0.409 0 N-CA-C 111.046 -0.822 . . . . 0.0 111.046 -175.57 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 5.2 tp10 -99.65 148.54 24.23 Favored 'General case' 0 C--N 1.324 -0.5 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 -179.826 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 52.9 t -104.39 127.95 58.3 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 177.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.506 HG21 HD13 ' A' ' 69' ' ' ILE . 16.1 pt -125.61 161.22 30.8 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-O 121.342 0.591 . . . . 0.0 111.903 -176.733 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 7.9 t30 -106.92 105.91 16.18 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.211 -0.904 . . . . 0.0 110.285 -179.069 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 72.6 mt -108.36 114.02 45.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-O 121.528 0.68 . . . . 0.0 110.496 -177.232 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' THR . . . . . 0.442 ' HA ' ' HA ' ' A' ' 83' ' ' THR . 10.2 m -95.15 120.4 35.31 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 115.58 -0.737 . . . . 0.0 109.496 -179.559 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 45.8 p -112.61 175.65 5.35 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.535 -0.302 . . . . 0.0 110.522 -178.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 15.9 t70 -59.22 -28.24 66.48 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.016 179.296 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 1.5 mp0 -98.05 16.83 19.93 Favored 'General case' 0 C--O 1.235 0.294 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.887 -177.551 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 121.86 177.72 15.53 Favored Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 120.391 -0.909 . . . . 0.0 113.452 174.901 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' THR . . . . . 0.442 ' HA ' ' HA ' ' A' ' 78' ' ' THR . 3.9 m -90.28 119.53 30.66 Favored 'General case' 0 C--N 1.324 -0.526 0 C-N-CA 122.609 0.364 . . . . 0.0 110.782 -178.708 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -116.69 157.18 25.85 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 121.149 0.499 . . . . 0.0 110.554 178.468 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 43.0 p-80 -111.97 129.98 56.01 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-N 115.614 -0.721 . . . . 0.0 109.223 176.8 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 7.5 tt -126.86 149.78 49.57 Favored 'General case' 0 C--N 1.314 -0.957 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.255 -173.716 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 1.7 tmtp? -124.9 124.14 41.42 Favored 'General case' 0 C--N 1.316 -0.874 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.316 179.778 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' THR . . . . . 0.484 HG22 ' HB3' ' A' ' 98' ' ' ALA . 73.5 p -74.73 127.95 34.39 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.592 -177.609 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.445 -0.738 0 C-N-CA 119.564 -1.303 . . . . 0.0 114.457 -177.535 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . 0.484 ' HB3' HG22 ' A' ' 88' ' ' THR . . . . . . . . 0 N--CA 1.465 0.31 0 CA-C-O 121.384 0.612 . . . . 0.0 111.788 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 26.8 m-85 -89.23 109.35 20.24 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.457 -178.076 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 61.0 mtm -86.19 -35.27 20.17 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.344 -178.708 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . 0.543 ' O ' HG21 ' A' ' 33' ' ' VAL . . . 114.46 -13.74 20.77 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.382 -0.914 . . . . 0.0 113.755 176.443 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.792 HG21 HG23 ' A' ' 32' ' ' VAL . 2.7 pp -120.06 149.37 22.79 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.791 0 O-C-N 122.429 -0.454 . . . . 0.0 110.422 179.79 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -88.91 137.09 32.63 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 176.291 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -109.48 145.58 36.0 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.317 -177.523 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 32.2 p -137.67 168.27 20.02 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.619 -0.719 . . . . 0.0 109.576 176.256 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . 0.447 ' OD1' ' HG ' ' A' ' 59' ' ' LEU . 1.0 OUTLIER . . . . . 0 C--N 1.319 -0.758 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.23 -178.423 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.708 ' HA ' ' HB3' ' A' ' 57' ' ' SER . 30.7 t0 . . . . . 0 N--CA 1.469 0.49 0 CA-C-O 122.299 1.047 . . . . 0.0 109.255 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 146.81 148.8 4.83 Favored Glycine 0 N--CA 1.444 -0.779 0 CA-C-N 114.648 -1.16 . . . . 0.0 111.448 176.041 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.421 HG22 ' HB ' ' A' ' 48' ' ' ILE . 29.3 m -122.51 144.1 33.05 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-O 121.018 0.437 . . . . 0.0 111.085 -179.63 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 35.0 tt0 -112.32 153.32 27.4 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 110.004 -0.369 . . . . 0.0 110.004 175.697 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 60.3 mt -78.86 112.55 17.04 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-N 116.314 -0.403 . . . . 0.0 109.921 178.85 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.612 ' HB3' ' HB2' ' A' ' 103' ' ' ARG . 22.5 t70 -64.32 -65.11 0.72 Allowed 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.789 -0.641 . . . . 0.0 109.713 178.559 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 20.7 p -156.8 154.39 29.85 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.166 -0.925 . . . . 0.0 110.586 179.103 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.601 HG22 HG21 ' A' ' 102' ' ' ILE . 13.5 p -91.25 143.67 10.77 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 176.884 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 61.6 t -97.13 114.88 65.42 Favored Pre-proline 0 C--N 1.321 -0.636 0 N-CA-C 110.16 -0.311 . . . . 0.0 110.16 177.708 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -55.19 122.3 11.47 Favored 'Trans proline' 0 C--N 1.346 0.411 0 C-N-CA 123.094 2.529 . . . . 0.0 112.033 178.761 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 122.05 7.92 7.57 Favored Glycine 0 N--CA 1.446 -0.695 0 CA-C-N 115.55 -0.75 . . . . 0.0 111.711 -176.505 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 72.3 p -121.33 150.19 53.69 Favored Pre-proline 0 C--N 1.325 -0.457 0 CA-C-O 120.676 0.274 . . . . 0.0 110.497 -179.013 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -67.59 -16.33 46.7 Favored 'Trans proline' 0 C--N 1.346 0.421 0 C-N-CA 122.639 2.226 . . . . 0.0 112.513 179.648 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.487 ' HA ' HD13 ' A' ' 86' ' ' LEU . . . -60.34 -36.82 78.87 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.568 -177.518 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 22.9 t -64.69 -23.68 67.33 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.617 -176.533 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 63.4 tttp -82.0 -26.03 34.21 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.027 0.441 . . . . 0.0 110.683 -177.505 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 38.6 t -99.22 -55.86 5.67 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.503 -175.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 1.9 pp -108.81 -178.02 3.47 Favored 'General case' 0 CA--C 1.516 -0.334 0 CA-C-O 121.527 0.68 . . . . 0.0 111.959 -177.472 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 5.4 p -127.85 143.53 48.04 Favored Pre-proline 0 C--N 1.315 -0.894 0 CA-C-N 114.94 -1.027 . . . . 0.0 110.645 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -66.69 146.19 78.13 Favored 'Trans proline' 0 N--CA 1.462 -0.347 0 C-N-CA 122.39 2.06 . . . . 0.0 111.627 175.643 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 102.55 -7.74 54.03 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.568 -178.105 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 89.1 mt -80.63 163.34 23.7 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.91 0.386 . . . . 0.0 110.772 179.061 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.423 ' O ' ' HA ' ' A' ' 79' ' ' THR . 44.3 t -103.24 137.15 32.68 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 N-CA-C 109.422 -0.585 . . . . 0.0 109.422 176.858 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.421 ' HB ' HG22 ' A' ' 27' ' ' VAL . 63.2 mt -103.15 121.26 54.16 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-O 120.786 0.327 . . . . 0.0 110.603 -179.213 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -82.71 -47.44 12.0 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.018 0.437 . . . . 0.0 110.848 177.501 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' SER . . . . . 0.596 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 6.1 p -152.15 146.28 25.36 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 121.176 0.512 . . . . 0.0 112.244 -174.185 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 47.4 mm -110.89 101.47 12.6 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-N 114.699 -1.137 . . . . 0.0 108.211 173.488 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 4.6 t-20 66.13 -152.15 0.23 Allowed 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 -172.493 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -73.42 7.28 12.64 Favored Glycine 0 CA--C 1.523 0.554 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.656 177.143 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 2.1 mpt? -111.62 102.53 53.57 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 120.812 0.339 . . . . 0.0 110.131 -179.667 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.596 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 44.5 Cg_endo -71.67 124.27 10.11 Favored 'Trans proline' 0 N--CA 1.46 -0.458 0 C-N-CA 122.146 1.897 . . . . 0.0 112.215 179.661 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 16.8 p -92.13 96.89 10.58 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.877 -0.602 . . . . 0.0 111.358 -176.369 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' SER . . . . . 0.708 ' HB3' ' HA ' ' A' ' 25' ' ' ASP . 14.2 m -94.75 -19.65 20.19 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.303 178.857 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 76.2 m-20 -123.92 164.32 19.53 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.13 -178.886 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 84.5 mt -75.81 -30.47 59.05 Favored 'General case' 0 N--CA 1.443 -0.802 0 CA-C-O 121.185 0.517 . . . . 0.0 109.906 177.924 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 9.6 m -69.17 -39.47 78.74 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.611 -0.722 . . . . 0.0 111.152 178.512 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -71.05 -27.9 63.98 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.628 0.251 . . . . 0.0 111.065 179.909 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 87.1 t80 -64.41 -40.72 96.32 Favored 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 173.069 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' SER . . . . . 0.4 ' O ' ' HD3' ' A' ' 67' ' ' LYS . 7.0 t -66.68 -43.33 84.73 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.732 -0.667 . . . . 0.0 109.855 176.596 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.31 -33.21 74.22 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 121.164 0.507 . . . . 0.0 110.793 179.693 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . 0.679 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -69.01 -49.3 58.96 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.946 -0.57 . . . . 0.0 109.831 176.357 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 11.2 mt -58.57 -36.47 73.99 Favored 'General case' 0 N--CA 1.448 -0.575 0 CA-C-N 116.002 -0.544 . . . . 0.0 112.129 -177.387 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . 0.4 ' HD3' ' O ' ' A' ' 63' ' ' SER . 2.4 mptm? -77.52 -7.04 55.65 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 112.494 0.553 . . . . 0.0 112.494 -179.029 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 9.0 p -110.41 -13.69 14.24 Favored 'General case' 0 C--N 1.323 -0.557 0 C-N-CA 120.807 -0.357 . . . . 0.0 111.785 178.755 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.679 HG12 ' O ' ' A' ' 65' ' ' ALA . 33.4 mm -73.33 148.33 8.91 Favored 'Isoleucine or valine' 0 C--O 1.234 0.237 0 N-CA-C 110.17 -0.307 . . . . 0.0 110.17 177.685 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' SER . . . . . 0.576 ' HB2' ' HB2' ' A' ' 73' ' ' GLU . 3.2 m -84.89 164.63 18.27 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.269 177.675 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 26.7 t -82.2 123.13 37.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 177.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 81.9 21.73 60.84 Favored Glycine 0 N--CA 1.448 -0.548 0 C-N-CA 120.574 -0.822 . . . . 0.0 111.549 -178.496 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.576 ' HB2' ' HB2' ' A' ' 70' ' ' SER . 34.4 tt0 -96.5 150.12 20.98 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -178.561 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 48.0 t -100.33 120.44 49.79 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.759 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.285 -177.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 27.7 pt -113.86 154.53 15.23 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-N 115.998 -0.547 . . . . 0.0 110.913 -179.47 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 13.0 t30 -93.33 118.18 30.97 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.467 179.676 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 51.3 mt -114.34 103.99 16.22 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.832 0 CA-C-O 121.417 0.627 . . . . 0.0 109.85 178.335 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 15.9 m -90.41 111.17 22.32 Favored 'General case' 0 C--N 1.315 -0.929 0 CA-C-N 115.701 -0.682 . . . . 0.0 109.729 179.225 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.423 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 73.3 p -107.63 171.81 7.18 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.961 0.41 . . . . 0.0 111.692 -176.74 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -52.34 -33.37 42.53 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.159 -0.928 . . . . 0.0 112.826 -178.501 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 17.4 mt-30 -127.0 27.07 6.02 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 112.334 0.494 . . . . 0.0 112.334 -174.101 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 161.32 146.23 4.57 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 119.764 -1.208 . . . . 0.0 114.053 174.788 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 8.8 m -98.57 109.75 22.46 Favored 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 175.113 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 59.7 m-85 -115.36 158.53 22.3 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.806 0.336 . . . . 0.0 110.801 -174.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 14.3 p80 -118.9 114.57 22.8 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 121.312 0.577 . . . . 0.0 110.022 174.241 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.487 HD13 ' HA ' ' A' ' 38' ' ' ALA . 3.5 mm? -107.33 148.59 28.84 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-N 115.297 -0.865 . . . . 0.0 111.247 -173.449 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 40.3 ttmt -98.77 130.31 45.22 Favored 'General case' 0 C--N 1.321 -0.664 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 173.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' THR . . . . . 0.472 HG21 HG23 ' A' ' 69' ' ' ILE . 15.1 p -71.05 129.69 39.61 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-O 121.0 0.429 . . . . 0.0 110.558 176.43 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.434 -1.457 0 N-CA-C 110.936 -0.865 . . . . 0.0 110.936 -179.776 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.467 0.409 0 CA-C-O 121.185 0.517 . . . . 0.0 110.124 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 46.4 t80 -120.83 128.35 52.77 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.411 -167.129 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 46.4 tpp -108.06 120.24 41.76 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 173.868 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -86.52 57.17 4.72 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.788 -0.72 . . . . 0.0 114.124 -170.79 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.601 HG21 HG22 ' A' ' 32' ' ' VAL . 2.6 pp -143.82 148.92 18.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 173.066 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . 0.612 ' HB2' ' HB3' ' A' ' 30' ' ' ASP . 43.4 mtp180 -90.87 143.34 26.82 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 116.376 -0.374 . . . . 0.0 110.264 176.749 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 2.1 p -115.82 143.4 45.45 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 121.063 0.458 . . . . 0.0 110.962 178.924 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 37.3 t -136.3 169.57 17.44 Favored 'General case' 0 C--N 1.317 -0.832 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 177.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 5.4 p30 . . . . . 0 C--N 1.31 -1.109 0 CA-C-O 122.031 0.919 . . . . 0.0 109.692 178.701 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 12.1 t70 . . . . . 0 N--CA 1.467 0.404 0 CA-C-O 121.901 0.858 . . . . 0.0 110.12 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 173.7 140.89 3.35 Favored Glycine 0 N--CA 1.446 -0.662 0 CA-C-N 114.792 -1.094 . . . . 0.0 111.266 177.139 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 28.8 m -120.76 146.4 25.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 116.819 0.309 . . . . 0.0 110.319 179.279 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -123.0 159.45 28.33 Favored 'General case' 0 C--N 1.322 -0.594 0 C-N-CA 120.503 -0.479 . . . . 0.0 110.997 -178.722 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 56.5 mt -81.7 106.14 12.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 115.907 -0.588 . . . . 0.0 109.949 179.641 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 14.8 t70 -68.03 -63.78 0.99 Allowed 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 116.054 -0.521 . . . . 0.0 109.88 -177.568 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 2.2 p -155.41 140.47 17.4 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.912 -0.586 . . . . 0.0 111.829 -177.312 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.624 HG23 HG21 ' A' ' 102' ' ' ILE . 96.5 t -86.91 126.45 40.84 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.208 -0.451 . . . . 0.0 109.819 177.89 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 5.6 m -103.38 129.19 25.94 Favored Pre-proline 0 N--CA 1.451 -0.419 0 CA-C-O 121.117 0.484 . . . . 0.0 111.863 -175.659 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -69.3 164.25 34.81 Favored 'Trans proline' 0 C--O 1.235 0.331 0 C-N-CA 122.743 2.295 . . . . 0.0 112.048 176.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 98.12 -34.13 5.46 Favored Glycine 0 N--CA 1.449 -0.436 0 N-CA-C 110.661 -0.976 . . . . 0.0 110.661 -174.605 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' SER . . . . . 0.403 ' HB2' ' HD2' ' A' ' 37' ' ' PRO . 0.7 OUTLIER -104.84 169.86 6.66 Favored Pre-proline 0 C--N 1.317 -0.835 0 CA-C-N 114.721 -0.74 . . . . 0.0 109.569 175.347 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . 0.403 ' HD2' ' HB2' ' A' ' 36' ' ' SER . 42.3 Cg_endo -68.59 -170.26 0.31 Allowed 'Trans proline' 0 CA--C 1.534 0.492 0 C-N-CA 122.264 1.976 . . . . 0.0 112.74 177.827 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 74.53 6.19 4.53 Favored 'General case' 0 N--CA 1.471 0.577 0 C-N-CA 123.575 0.75 . . . . 0.0 112.343 179.733 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 23.1 t -52.35 -62.18 1.8 Allowed 'General case' 0 C--O 1.233 0.232 0 O-C-N 123.448 0.467 . . . . 0.0 110.608 -179.712 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 3.3 tmtp? -111.24 65.37 0.62 Allowed 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 172.328 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 36.5 t -137.94 -49.77 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.382 -0.826 . . . . 0.0 109.292 175.793 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 6.3 mp -119.58 171.49 8.33 Favored 'General case' 0 C--O 1.234 0.262 0 CA-C-N 115.625 -0.716 . . . . 0.0 109.88 176.079 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' THR . . . . . 0.442 ' HG1' HD11 ' A' ' 46' ' ' LEU . 7.3 p -126.65 146.58 57.47 Favored Pre-proline 0 C--N 1.322 -0.612 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.487 177.474 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 76.9 Cg_endo -76.95 157.03 34.62 Favored 'Trans proline' 0 C--O 1.233 0.246 0 C-N-CA 122.549 2.166 . . . . 0.0 111.975 178.402 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 90.62 11.71 61.84 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.58 -0.819 . . . . 0.0 112.697 179.063 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . 0.442 HD11 ' HG1' ' A' ' 43' ' ' THR . 64.7 mt -103.47 164.36 11.7 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.809 0.304 . . . . 0.0 110.207 178.042 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 48.1 t -105.98 137.66 35.0 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 N-CA-C 110.315 -0.254 . . . . 0.0 110.315 176.307 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 60.3 mt -95.72 129.78 45.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 121.097 0.475 . . . . 0.0 110.846 -178.411 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 22.3 tt0 -86.66 -56.02 3.6 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.635 -0.711 . . . . 0.0 110.198 175.612 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' SER . . . . . 0.568 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 13.7 p -148.99 152.49 36.4 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.243 -0.889 . . . . 0.0 112.067 -170.556 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 49.7 mm -111.41 85.44 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.043 -0.98 . . . . 0.0 109.742 176.315 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' ASN . . . . . 0.558 ' HB2' ' H ' ' A' ' 76' ' ' ASN . 62.3 t30 54.72 78.88 0.16 Allowed 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 114.843 -1.072 . . . . 0.0 111.949 176.727 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 83.37 -49.06 4.16 Favored Glycine 0 N--CA 1.447 -0.579 0 CA-C-N 115.541 -0.754 . . . . 0.0 112.459 178.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 58.4 mtm -85.56 111.78 39.64 Favored Pre-proline 0 C--N 1.324 -0.521 0 N-CA-C 110.387 -0.227 . . . . 0.0 110.387 -179.718 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.568 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 70.6 Cg_endo -75.1 134.04 17.16 Favored 'Trans proline' 0 N--CA 1.458 -0.577 0 C-N-CA 122.054 1.836 . . . . 0.0 111.833 178.921 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 24.5 p -109.34 93.37 4.47 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 121.47 0.652 . . . . 0.0 111.547 -175.497 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 19.3 m -99.74 -14.31 18.92 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 115.229 -0.896 . . . . 0.0 110.155 177.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 52.7 m-80 -125.98 159.27 33.1 Favored 'General case' 0 C--N 1.319 -0.74 0 C-N-CA 120.502 -0.479 . . . . 0.0 109.887 -179.268 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 96.6 mt -70.74 -28.29 64.59 Favored 'General case' 0 N--CA 1.44 -0.954 0 CA-C-N 115.734 -0.666 . . . . 0.0 109.387 177.144 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 5.1 m -69.54 -48.92 58.8 Favored 'General case' 0 N--CA 1.448 -0.565 0 CA-C-N 115.254 -0.884 . . . . 0.0 110.629 178.557 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 1.7 p -67.42 -34.37 77.08 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.77 0.319 . . . . 0.0 111.042 178.095 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 25.8 t80 -62.54 -40.11 95.77 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.308 0.575 . . . . 0.0 109.618 175.381 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' SER . . . . . 0.522 ' O ' ' HG3' ' A' ' 67' ' ' LYS . 8.1 t -67.33 -45.13 77.32 Favored 'General case' 0 N--CA 1.452 -0.37 0 CA-C-N 115.459 -0.791 . . . . 0.0 110.36 178.576 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -60.02 -38.35 82.45 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.811 -179.217 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . 0.507 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -65.11 -46.0 82.84 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.377 -179.49 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 2.3 tt -58.58 -42.3 87.72 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.756 -0.657 . . . . 0.0 110.544 -179.413 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . 0.522 ' HG3' ' O ' ' A' ' 63' ' ' SER . 96.0 mttt -63.33 -23.51 67.45 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.566 -0.743 . . . . 0.0 112.483 -177.102 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 77.5 p -90.9 -13.07 34.3 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.779 0.323 . . . . 0.0 111.35 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.519 HG21 HG23 ' A' ' 88' ' ' THR . 45.9 mm -72.68 136.42 25.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 121.174 0.511 . . . . 0.0 111.265 -176.789 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 4.4 m -82.45 143.99 30.77 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.84 -0.618 . . . . 0.0 109.588 174.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 16.8 t -71.72 115.83 12.53 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-N 116.372 -0.377 . . . . 0.0 110.467 -177.074 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . 0.444 ' HA2' ' O ' ' A' ' 88' ' ' THR . . . 98.27 4.88 57.31 Favored Glycine 0 N--CA 1.447 -0.63 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.076 179.71 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -90.68 154.96 19.18 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 120.715 0.293 . . . . 0.0 110.27 -178.087 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 49.0 t -94.32 118.73 40.97 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.582 -178.486 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 32.5 pt -103.01 167.7 2.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.728 178.728 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . 0.558 ' H ' ' HB2' ' A' ' 52' ' ' ASN . 43.3 t30 -120.06 106.56 12.11 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.883 -172.283 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 57.6 mt -105.49 109.32 27.41 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.808 0 CA-C-O 121.328 0.585 . . . . 0.0 110.769 -174.675 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 31.1 m -89.72 114.78 26.5 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.494 -0.775 . . . . 0.0 109.72 176.485 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 69.4 p -112.55 174.15 6.03 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 110.29 -0.263 . . . . 0.0 110.29 179.02 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 12.4 t70 -63.27 -30.36 71.51 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.342 178.244 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 8.2 tp-100 -95.64 14.57 22.57 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.333 0.587 . . . . 0.0 110.891 -176.345 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 127.36 179.67 15.94 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.53 176.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 55.6 m -109.92 129.45 55.65 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-O 120.696 0.284 . . . . 0.0 110.561 -178.329 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 23.5 m-85 -128.43 152.42 48.23 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 -179.607 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 7.8 p-80 -109.24 133.21 53.33 Favored 'General case' 0 C--N 1.322 -0.621 0 C-N-CA 120.62 -0.432 . . . . 0.0 110.011 174.041 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.474 HD22 ' N ' ' A' ' 87' ' ' LYS . 5.5 tt -118.97 137.53 53.43 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 115.918 -0.583 . . . . 0.0 109.734 -175.085 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' LYS . . . . . 0.474 ' N ' HD22 ' A' ' 86' ' ' LEU . 62.1 tttp -98.41 117.05 31.95 Favored 'General case' 0 C--N 1.311 -1.1 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 179.049 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' THR . . . . . 0.519 HG23 HG21 ' A' ' 69' ' ' ILE . 16.9 p -66.95 135.41 53.75 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 121.152 0.501 . . . . 0.0 111.154 -176.465 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.439 -1.155 0 N-CA-C 111.004 -0.838 . . . . 0.0 111.004 177.03 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.463 0.2 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 46.4 t80 -112.11 128.8 56.32 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 121.304 0.573 . . . . 0.0 111.887 -171.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 20.6 ptp -94.17 141.59 28.38 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.277 174.565 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -84.52 37.15 2.92 Favored Glycine 0 CA--C 1.519 0.319 0 C-N-CA 121.099 -0.572 . . . . 0.0 114.2 -170.836 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.624 HG21 HG23 ' A' ' 32' ' ' VAL . 33.6 pt -138.24 154.06 27.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 117.204 0.502 . . . . 0.0 110.481 178.095 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 55.7 mtp180 -93.66 117.11 29.66 Favored 'General case' 0 C--N 1.318 -0.788 0 N-CA-C 108.336 -0.987 . . . . 0.0 108.336 171.476 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -111.03 137.18 48.99 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-O 121.344 0.592 . . . . 0.0 110.624 -178.017 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 19.1 m -156.97 164.24 38.23 Favored 'General case' 0 C--N 1.31 -1.115 0 CA-C-N 115.543 -0.753 . . . . 0.0 109.462 -178.866 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 14.9 p30 . . . . . 0 C--N 1.319 -0.728 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 169.008 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 17.0 p-10 . . . . . 0 C--O 1.233 0.212 0 CA-C-O 120.969 0.414 . . . . 0.0 111.23 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 134.53 162.94 10.05 Favored Glycine 0 N--CA 1.445 -0.73 0 N-CA-C 111.587 -0.605 . . . . 0.0 111.587 -179.255 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.478 HG21 ' HB ' ' A' ' 48' ' ' ILE . 15.3 m -99.73 134.37 39.32 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-O 121.13 0.491 . . . . 0.0 110.957 176.942 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 6.6 tp60 -97.58 133.5 42.06 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.786 -176.577 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.541 ' HB ' ' H ' ' A' ' 46' ' ' LEU . 36.7 mm -72.65 112.66 8.89 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-N 115.706 -0.679 . . . . 0.0 109.773 173.155 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 16.7 t70 -76.15 -69.75 0.48 Allowed 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.09 -179.289 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 7.7 p -148.96 142.66 25.54 Favored 'General case' 0 N--CA 1.447 -0.594 0 CA-C-O 121.398 0.618 . . . . 0.0 111.553 -178.203 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.496 HG13 ' HA ' ' A' ' 39' ' ' SER . 61.4 t -98.55 119.35 46.43 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-N 114.96 -1.018 . . . . 0.0 109.185 173.945 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.502 HG11 ' O ' ' A' ' 101' ' ' GLY . 10.9 p -91.69 131.85 34.74 Favored Pre-proline 0 C--N 1.324 -0.527 0 CA-C-O 120.776 0.322 . . . . 0.0 110.294 -178.329 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -58.34 147.23 86.11 Favored 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.816 2.344 . . . . 0.0 112.226 -179.469 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 91.64 24.74 25.01 Favored Glycine 0 N--CA 1.448 -0.526 0 C-N-CA 120.759 -0.734 . . . . 0.0 111.82 -177.374 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' SER . . . . . 0.535 ' CB ' ' HA3' ' A' ' 101' ' ' GLY . 61.3 p -125.85 157.35 69.32 Favored Pre-proline 0 C--N 1.325 -0.49 0 N-CA-C 110.155 -0.313 . . . . 0.0 110.155 -179.934 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 29.5 Cg_endo -64.07 -30.77 65.97 Favored 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.424 2.082 . . . . 0.0 112.099 176.901 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.48 ' HB2' HD12 ' A' ' 86' ' ' LEU . . . -80.15 -13.52 59.19 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.436 -177.894 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.496 ' HA ' HG13 ' A' ' 32' ' ' VAL . 22.9 t -61.46 -27.95 68.94 Favored 'General case' 0 CA--C 1.532 0.283 0 N-CA-C 112.249 0.463 . . . . 0.0 112.249 -174.468 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 52.2 mtmt -103.18 -13.81 16.63 Favored 'General case' 0 C--N 1.326 -0.44 0 C-N-CA 120.88 -0.328 . . . . 0.0 111.645 -176.334 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.44 ' HB ' HD11 ' A' ' 42' ' ' LEU . 35.3 t -103.92 -38.73 5.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-N 116.565 -0.289 . . . . 0.0 111.519 -174.319 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.44 HD11 ' HB ' ' A' ' 41' ' ' VAL . 6.5 mp -113.8 168.59 9.66 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.131 0.491 . . . . 0.0 111.119 -177.213 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 7.4 p -129.75 156.4 78.93 Favored Pre-proline 0 C--N 1.321 -0.643 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.026 177.17 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -73.56 154.13 49.79 Favored 'Trans proline' 0 N--CA 1.463 -0.273 0 C-N-CA 122.285 1.99 . . . . 0.0 112.368 179.641 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 81.89 28.78 40.73 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.891 -0.671 . . . . 0.0 113.323 177.551 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . 0.554 HD22 ' HB2' ' A' ' 81' ' ' GLN . 53.6 mt -109.2 162.01 14.69 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 117.066 0.433 . . . . 0.0 110.519 176.214 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 62.1 t -110.99 130.2 64.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 N-CA-C 110.035 -0.357 . . . . 0.0 110.035 178.227 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.487 HD11 HD11 ' A' ' 29' ' ' ILE . 76.7 mt -89.66 121.19 39.56 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-O 121.042 0.449 . . . . 0.0 110.894 -179.573 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 10.6 tt0 -77.32 -57.0 4.07 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.403 -0.817 . . . . 0.0 110.06 176.208 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' SER . . . . . 0.584 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 14.7 p -146.8 152.82 39.38 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.194 -0.912 . . . . 0.0 111.988 -172.126 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 42.9 mm -111.91 97.15 5.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.262 176.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' ASN . . . . . 0.532 ' HA ' ' HB3' ' A' ' 76' ' ' ASN . 6.5 t30 67.43 -80.78 0.03 OUTLIER 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 114.884 -1.053 . . . . 0.0 111.905 174.262 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -126.73 3.39 7.52 Favored Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 120.581 -0.819 . . . . 0.0 112.103 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 54.5 mtm -131.39 117.61 16.78 Favored Pre-proline 0 C--N 1.325 -0.488 0 N-CA-C 110.393 -0.225 . . . . 0.0 110.393 -177.73 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.584 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 56.0 Cg_endo -71.26 130.8 18.05 Favored 'Trans proline' 0 N--CA 1.463 -0.313 0 C-N-CA 122.325 2.017 . . . . 0.0 112.073 178.72 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 25.6 p -108.63 94.63 5.16 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 121.24 0.543 . . . . 0.0 111.269 -176.47 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 5.5 m -95.55 -12.72 25.27 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.574 -0.739 . . . . 0.0 111.118 -177.828 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 6.9 t-20 -129.58 166.78 19.03 Favored 'General case' 0 C--N 1.321 -0.671 0 C-N-CA 120.597 -0.441 . . . . 0.0 109.92 176.769 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.5 ' HB2' ' HB2' ' A' ' 106' ' ' ASN . 0.4 OUTLIER -77.09 -36.45 55.68 Favored 'General case' 0 C--N 1.311 -1.098 0 CA-C-N 115.495 -0.775 . . . . 0.0 109.617 -179.011 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 6.3 m -68.09 -39.09 82.94 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.702 179.621 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 8.0 p -72.23 -37.43 69.18 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.111 0.481 . . . . 0.0 110.456 177.338 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' TYR . . . . . 0.461 ' OH ' ' HE2' ' A' ' 100' ' ' MET . 72.2 t80 -61.04 -43.72 98.47 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.239 175.232 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 4.7 t -65.3 -38.98 91.89 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.396 178.744 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -65.89 -33.91 76.93 Favored 'General case' 0 C--O 1.232 0.153 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.881 179.709 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -71.98 -45.16 62.03 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.253 178.499 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . 0.405 HD23 ' HA ' ' A' ' 66' ' ' LEU . 8.2 mt -62.09 -33.42 74.4 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.245 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 37.0 ttmt -59.26 -21.98 60.45 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.869 -0.605 . . . . 0.0 111.519 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 61.0 p -100.73 -13.88 18.29 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 112.234 0.457 . . . . 0.0 112.234 -176.543 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 45.6 mm -74.5 138.01 21.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.974 0.416 . . . . 0.0 110.557 -176.773 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 7.8 m -104.03 172.92 6.54 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.611 -174.433 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 61.3 t -82.94 136.42 22.87 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.139 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.532 177.924 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 87.64 -8.59 76.97 Favored Glycine 0 N--CA 1.448 -0.516 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 -177.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 23.3 tt0 -80.73 145.77 31.37 Favored 'General case' 0 N--CA 1.445 -0.682 0 CA-C-N 114.916 -0.642 . . . . 0.0 109.679 -177.088 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.485 HG23 ' HG3' ' A' ' 87' ' ' LYS . 39.6 t -113.49 116.85 53.79 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 CA-C-N 115.984 -0.553 . . . . 0.0 109.994 -176.839 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 16.4 pt -106.15 153.49 7.52 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-O 121.481 0.658 . . . . 0.0 111.532 -178.739 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . 0.532 ' HB3' ' HA ' ' A' ' 52' ' ' ASN . 15.1 t30 -101.81 104.73 15.51 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 114.881 -1.054 . . . . 0.0 110.219 -178.042 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 52.6 mt -105.1 105.46 18.67 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.883 0 CA-C-O 121.191 0.52 . . . . 0.0 111.001 -174.314 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' THR . . . . . 0.507 ' HG1' HG22 ' A' ' 83' ' ' THR . 35.2 m -85.65 120.48 27.13 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.369 175.062 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 70.7 p -121.37 175.12 6.32 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 120.918 0.39 . . . . 0.0 111.148 -178.038 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -62.42 -18.55 61.94 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.544 -0.753 . . . . 0.0 111.101 176.011 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . 0.554 ' HB2' HD22 ' A' ' 46' ' ' LEU . 7.3 tp-100 -102.84 4.42 37.74 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.147 0.498 . . . . 0.0 111.142 -177.419 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 128.74 175.88 14.23 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 120.57 -0.824 . . . . 0.0 112.623 179.438 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' THR . . . . . 0.507 HG22 ' HG1' ' A' ' 78' ' ' THR . 20.0 m -96.78 109.14 21.87 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-O 120.71 0.29 . . . . 0.0 110.819 -178.455 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 -107.1 169.81 8.33 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.973 0.416 . . . . 0.0 110.622 -178.205 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 7.4 p80 -129.57 126.91 39.59 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 175.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.488 HD22 ' N ' ' A' ' 87' ' ' LYS . 4.2 tt -117.89 138.71 51.94 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.113 0.482 . . . . 0.0 110.512 -174.002 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' LYS . . . . . 0.488 ' N ' HD22 ' A' ' 86' ' ' LEU . 60.5 tttp -116.71 121.02 40.43 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.535 -0.757 . . . . 0.0 109.354 179.831 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 29.6 p -71.57 139.42 49.41 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 120.733 0.302 . . . . 0.0 111.072 -178.844 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.511 -0.198 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.558 -174.744 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.457 -0.083 0 CA-C-O 120.573 0.225 . . . . 0.0 111.018 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 4.1 t80 -121.28 126.97 50.84 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 109.522 -0.548 . . . . 0.0 109.522 179.451 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' MET . . . . . 0.461 ' HE2' ' OH ' ' A' ' 62' ' ' TYR . 63.4 mtm -105.94 -33.22 8.0 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.461 -0.336 . . . . 0.0 111.135 -175.819 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . 0.535 ' HA3' ' CB ' ' A' ' 36' ' ' SER . . . 94.6 27.1 11.97 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.582 -0.818 . . . . 0.0 111.907 179.228 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.454 HG23 ' HA ' ' A' ' 32' ' ' VAL . 2.7 pp -136.01 150.43 28.21 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 178.339 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 4.1 mpt_? -104.18 139.44 39.22 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 175.566 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.9 p -117.63 161.44 19.64 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.8 179.156 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 66.8 m -143.95 161.95 37.41 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.334 175.857 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . 0.5 ' HB2' ' HB2' ' A' ' 59' ' ' LEU . 2.5 t-20 . . . . . 0 C--N 1.309 -1.178 0 N-CA-C 107.563 -1.273 . . . . 0.0 107.563 174.286 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 21.2 t70 . . . . . 0 CA--C 1.515 -0.39 0 CA-C-O 121.232 0.539 . . . . 0.0 110.726 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . 0.561 ' HA2' ' HA ' ' A' ' 57' ' ' SER . . . 171.27 164.43 26.94 Favored Glycine 0 N--CA 1.442 -0.913 0 CA-C-N 115.263 -0.88 . . . . 0.0 111.188 -178.829 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 33.9 m -109.15 150.8 11.68 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.866 0 CA-C-O 120.768 0.318 . . . . 0.0 110.368 178.076 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -117.82 163.03 17.14 Favored 'General case' 0 C--N 1.32 -0.702 0 C-N-CA 120.751 -0.379 . . . . 0.0 110.45 176.937 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.535 HD12 ' HB2' ' A' ' 46' ' ' LEU . 56.6 mt -78.73 107.44 11.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-O 120.959 0.409 . . . . 0.0 110.273 -178.409 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.606 ' HB3' ' HB2' ' A' ' 103' ' ' ARG . 14.9 t70 -65.67 -70.6 0.23 Allowed 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 115.185 -0.916 . . . . 0.0 110.638 -176.068 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.432 ' HA ' ' HB3' ' A' ' 44' ' ' PRO . 4.2 p -148.59 144.87 27.54 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.596 -0.729 . . . . 0.0 111.128 -178.566 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.528 ' HA ' HG22 ' A' ' 102' ' ' ILE . 96.2 t -94.86 126.54 47.26 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.207 178.606 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 48.4 t -109.0 123.87 35.76 Favored Pre-proline 0 C--N 1.327 -0.379 0 CA-C-N 116.461 -0.336 . . . . 0.0 110.631 179.767 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -58.97 154.39 45.08 Favored 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.972 2.448 . . . . 0.0 112.175 178.1 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 104.26 6.91 41.38 Favored Glycine 0 N--CA 1.45 -0.4 0 N-CA-C 110.849 -0.9 . . . . 0.0 110.849 -175.397 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' SER . . . . . 0.524 ' CB ' ' HA3' ' A' ' 101' ' ' GLY . 60.4 p -130.16 159.17 71.64 Favored Pre-proline 0 C--N 1.322 -0.623 0 CA-C-N 115.185 -0.508 . . . . 0.0 110.054 -179.457 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_exo -66.89 -23.2 47.75 Favored 'Trans proline' 0 N--CA 1.463 -0.27 0 C-N-CA 122.359 2.039 . . . . 0.0 111.669 176.142 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -73.56 -16.77 61.25 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.914 -0.585 . . . . 0.0 111.365 -177.5 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 14.2 m -65.27 -16.84 63.99 Favored 'General case' 0 C--O 1.233 0.192 0 CA-C-O 120.904 0.383 . . . . 0.0 111.051 -179.708 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 35.5 ttpt -116.89 11.42 14.4 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.1 -177.769 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 58.5 t -126.96 -47.99 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.377 -177.427 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 87.1 mt -108.22 161.3 15.12 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.245 0.545 . . . . 0.0 111.412 -175.644 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 15.4 p -126.82 146.38 57.08 Favored Pre-proline 0 C--N 1.319 -0.746 0 CA-C-N 115.022 -0.99 . . . . 0.0 109.844 176.803 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.432 ' HB3' ' HA ' ' A' ' 31' ' ' SER . 53.8 Cg_endo -70.47 149.96 63.18 Favored 'Trans proline' 0 N--CA 1.461 -0.384 0 C-N-CA 122.09 1.86 . . . . 0.0 111.937 -178.064 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 99.23 -13.54 61.63 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.832 179.65 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . 0.535 ' HB2' HD12 ' A' ' 29' ' ' ILE . 82.0 mt -72.92 164.45 26.63 Favored 'General case' 0 C--N 1.327 -0.386 0 O-C-N 122.672 -0.31 . . . . 0.0 110.684 179.694 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 42.1 t -115.28 139.95 39.12 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.191 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 65.0 mt -97.83 125.87 50.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 121.181 0.515 . . . . 0.0 110.347 -179.482 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -91.02 -42.52 10.48 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-N 115.834 -0.621 . . . . 0.0 109.894 179.955 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 37.0 p -159.37 153.77 24.0 Favored 'General case' 0 CA--C 1.512 -0.51 0 CA-C-O 120.976 0.417 . . . . 0.0 110.621 178.825 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.776 HG13 HG12 ' A' ' 77' ' ' ILE . 10.8 tt -127.4 123.72 62.33 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 CA-C-N 115.582 -0.735 . . . . 0.0 109.126 174.821 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 2.3 t-20 58.61 -151.85 0.41 Allowed 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 108.922 -0.769 . . . . 0.0 108.922 -177.528 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -81.0 12.7 35.33 Favored Glycine 0 CA--C 1.525 0.681 0 C-N-CA 120.394 -0.908 . . . . 0.0 113.002 177.739 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 2.6 mpp? -124.43 107.26 29.76 Favored Pre-proline 0 C--N 1.333 -0.121 0 CA-C-N 117.227 0.513 . . . . 0.0 111.154 -178.183 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -70.34 121.22 7.79 Favored 'Trans proline' 0 N--CA 1.458 -0.598 0 C-N-CA 121.691 1.594 . . . . 0.0 111.457 174.297 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 20.3 p -97.92 110.17 22.79 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.884 -174.047 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' SER . . . . . 0.561 ' HA ' ' HA2' ' A' ' 26' ' ' GLY . 15.5 m -98.2 -18.96 18.16 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.921 -0.582 . . . . 0.0 111.118 179.831 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 5.3 m120 -115.47 166.33 12.01 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 -179.127 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 39.2 mt -75.8 -34.45 60.17 Favored 'General case' 0 N--CA 1.447 -0.582 0 CA-C-O 121.035 0.445 . . . . 0.0 109.955 171.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 7.9 m -72.22 -40.5 67.76 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.646 -0.706 . . . . 0.0 111.34 -178.514 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 3.2 p -67.76 -32.16 72.56 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.006 0.431 . . . . 0.0 110.425 177.443 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 51.3 t80 -66.74 -39.78 88.06 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.313 0.577 . . . . 0.0 109.497 173.66 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 69.0 m -63.62 -47.52 81.05 Favored 'General case' 0 N--CA 1.447 -0.6 0 CA-C-N 115.485 -0.779 . . . . 0.0 111.348 177.889 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.42 -35.71 78.31 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.619 177.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . 0.52 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -68.17 -41.9 80.82 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.474 178.835 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 6.7 mt -62.32 -33.88 75.54 Favored 'General case' 0 N--CA 1.447 -0.6 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.136 178.273 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 40.4 ttmt -60.16 -37.26 79.61 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.868 179.161 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.6 p -82.26 -11.81 58.43 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 112.345 0.498 . . . . 0.0 112.345 -179.067 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.52 HG12 ' O ' ' A' ' 65' ' ' ALA . 45.8 mm -79.98 137.68 21.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 N-CA-C 110.055 -0.35 . . . . 0.0 110.055 178.313 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 19.1 t -103.36 176.91 4.99 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 110.108 -0.33 . . . . 0.0 110.108 -179.886 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 46.3 t -90.52 125.92 43.33 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.74 -177.653 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 99.93 -0.32 56.32 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.931 -0.652 . . . . 0.0 111.945 179.419 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 35.4 tt0 -90.24 147.31 23.62 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.82 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 39.9 t -106.01 104.34 16.85 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.116 -178.614 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.453 HD12 HD11 ' A' ' 51' ' ' ILE . 15.8 pt -96.08 154.7 3.5 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 121.363 0.602 . . . . 0.0 111.296 -175.916 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 5.5 t30 -91.13 136.6 32.98 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.631 -179.117 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.776 HG12 HG13 ' A' ' 51' ' ' ILE . 60.1 mt -135.46 108.79 9.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-O 121.057 0.456 . . . . 0.0 110.232 178.485 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 4.3 m -84.85 130.17 34.7 Favored 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 176.371 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 76.0 p -126.49 175.77 7.66 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.267 0.556 . . . . 0.0 111.978 -176.204 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 25.2 t70 -49.76 -42.82 47.32 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 114.625 -1.17 . . . . 0.0 112.74 -178.756 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 22.9 mt-30 -117.93 23.67 11.51 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 112.555 0.576 . . . . 0.0 112.555 -172.291 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 152.31 -178.63 29.4 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 119.771 -1.204 . . . . 0.0 112.929 175.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 22.2 m -114.74 126.84 55.32 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-O 120.892 0.377 . . . . 0.0 110.129 179.376 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 99.5 m-85 -121.02 161.33 21.83 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 120.938 0.399 . . . . 0.0 110.696 -178.348 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 44.6 m-70 -125.37 123.93 40.42 Favored 'General case' 0 C--N 1.321 -0.661 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 176.181 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.506 HD21 HD12 ' A' ' 77' ' ' ILE . 3.8 mm? -113.72 140.92 47.86 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.395 -173.886 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -105.14 124.35 49.38 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 115.63 -0.714 . . . . 0.0 109.488 177.467 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 17.8 p -69.92 132.02 45.32 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-O 121.379 0.609 . . . . 0.0 112.038 -176.66 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.445 -0.757 0 CA-C-N 115.433 -0.803 . . . . 0.0 111.418 177.41 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.239 0 CA-C-O 121.743 0.782 . . . . 0.0 109.681 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 80.3 t80 -96.36 102.04 13.77 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.611 -170.541 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 81.1 mtp -72.31 -43.22 64.49 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.16 176.469 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . 0.524 ' HA3' ' CB ' ' A' ' 36' ' ' SER . . . 101.56 -12.59 58.18 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.802 176.477 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.528 HG22 ' HA ' ' A' ' 32' ' ' VAL . 2.7 pp -114.89 144.73 21.81 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-O 120.851 0.358 . . . . 0.0 110.322 179.241 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . 0.606 ' HB2' ' HB3' ' A' ' 30' ' ' ASP . 39.3 mtp180 -84.46 147.58 27.01 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.179 178.321 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 14.2 p -124.63 122.1 36.58 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.555 177.331 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 19.3 m -127.59 154.84 44.73 Favored 'General case' 0 C--N 1.318 -0.799 0 N-CA-C 109.165 -0.68 . . . . 0.0 109.165 178.35 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 16.0 p30 . . . . . 0 C--N 1.314 -0.958 0 CA-C-O 121.09 0.472 . . . . 0.0 110.018 177.195 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 18.6 t70 . . . . . 0 C--O 1.234 0.241 0 CA-C-O 121.309 0.576 . . . . 0.0 109.628 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . 0.501 ' HA2' ' HA ' ' A' ' 57' ' ' SER . . . 165.21 165.58 22.76 Favored Glycine 0 N--CA 1.447 -0.6 0 N-CA-C 110.574 -1.011 . . . . 0.0 110.574 -177.851 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.568 HG12 HD21 ' A' ' 106' ' ' ASN . 33.6 m -122.54 151.06 26.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 117.44 0.62 . . . . 0.0 110.739 178.675 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . 0.506 ' OE1' ' HB2' ' A' ' 105' ' ' SER . 0.0 OUTLIER -128.19 163.9 23.68 Favored 'General case' 0 C--N 1.324 -0.531 0 C-N-CA 120.703 -0.399 . . . . 0.0 110.767 177.139 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 57.2 mt -90.96 115.7 30.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.951 -176.165 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.72 ' HB3' ' HB2' ' A' ' 103' ' ' ARG . 23.7 t70 -66.65 -58.96 4.06 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.417 0.627 . . . . 0.0 109.873 176.005 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.426 ' HA ' ' HB3' ' A' ' 44' ' ' PRO . 12.4 p -165.19 162.05 19.77 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.22 -0.9 . . . . 0.0 110.204 -178.938 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.568 HG13 ' HA ' ' A' ' 39' ' ' SER . 45.3 t -98.24 138.25 23.45 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 N-CA-C 109.527 -0.545 . . . . 0.0 109.527 177.565 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.536 HG13 ' H ' ' A' ' 35' ' ' GLY . 45.7 t -85.89 118.9 71.35 Favored Pre-proline 0 C--N 1.323 -0.563 0 CA-C-N 116.453 -0.339 . . . . 0.0 110.809 -176.351 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -65.46 -12.94 37.29 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.866 2.377 . . . . 0.0 112.825 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.536 ' H ' HG13 ' A' ' 33' ' ' VAL . . . -95.19 23.02 35.34 Favored Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 120.897 -0.668 . . . . 0.0 111.545 177.935 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' SER . . . . . 0.669 ' HB3' ' HD2' ' A' ' 37' ' ' PRO . 54.1 m -149.36 170.9 6.95 Favored Pre-proline 0 C--N 1.325 -0.458 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.033 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . 0.669 ' HD2' ' HB3' ' A' ' 36' ' ' SER . 56.4 Cg_endo -71.13 -168.26 0.32 Allowed 'Trans proline' 0 C--N 1.349 0.555 0 C-N-CA 122.331 2.021 . . . . 0.0 112.443 177.199 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.476 ' HB2' HD13 ' A' ' 42' ' ' LEU . . . 68.78 -9.71 0.54 Allowed 'General case' 0 N--CA 1.47 0.567 0 N-CA-C 113.017 0.747 . . . . 0.0 113.017 176.63 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.568 ' HA ' HG13 ' A' ' 32' ' ' VAL . 27.8 t -70.08 -6.84 36.66 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.741 0.305 . . . . 0.0 111.293 -177.75 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . 0.674 ' HZ1' ' HB2' ' A' ' 40' ' ' LYS . 0.1 OUTLIER -118.79 12.68 13.03 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 121.003 0.43 . . . . 0.0 110.391 177.103 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.468 ' HB ' HD11 ' A' ' 42' ' ' LEU . 46.8 t -120.76 -55.6 3.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.234 -176.987 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.476 HD13 ' HB2' ' A' ' 38' ' ' ALA . 6.0 mp -96.1 171.49 8.57 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.036 0.446 . . . . 0.0 111.145 -177.159 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 49.1 m -122.72 127.25 25.84 Favored Pre-proline 0 C--N 1.321 -0.639 0 CA-C-N 115.741 -0.663 . . . . 0.0 109.736 176.834 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.426 ' HB3' ' HA ' ' A' ' 31' ' ' SER . 41.7 Cg_endo -68.3 149.02 75.32 Favored 'Trans proline' 0 N--CA 1.464 -0.245 0 C-N-CA 122.294 1.996 . . . . 0.0 111.939 179.123 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 99.05 -2.93 58.23 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.541 -0.838 . . . . 0.0 112.634 -179.307 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 81.0 mt -90.33 164.2 14.44 Favored 'General case' 0 C--N 1.328 -0.366 0 O-C-N 122.583 -0.363 . . . . 0.0 110.765 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 48.0 t -102.45 139.94 22.15 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 N-CA-C 110.022 -0.362 . . . . 0.0 110.022 178.255 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.488 ' HB ' HG22 ' A' ' 27' ' ' VAL . 66.1 mt -93.2 121.71 44.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 121.127 0.489 . . . . 0.0 110.631 -177.601 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 3.4 tm-20 -81.96 -50.8 8.73 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 115.594 -0.73 . . . . 0.0 109.501 178.284 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' SER . . . . . 0.555 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 13.6 p -163.94 159.22 20.63 Favored 'General case' 0 C--O 1.236 0.394 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.97 -175.638 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.416 ' HA ' ' O ' ' A' ' 76' ' ' ASN . 61.1 mt -115.96 107.77 23.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 115.556 -0.747 . . . . 0.0 110.545 176.259 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' ASN . . . . . 0.574 ' HA ' ' HB3' ' A' ' 76' ' ' ASN . 15.1 t-20 66.86 -81.66 0.03 OUTLIER 'General case' 0 N--CA 1.468 0.464 0 CA-C-N 115.43 -0.805 . . . . 0.0 110.759 178.816 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -133.46 -5.33 2.95 Favored Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 120.882 -0.675 . . . . 0.0 111.782 177.161 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 60.6 mtm -111.74 115.18 51.47 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 120.743 0.306 . . . . 0.0 110.429 -177.161 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.555 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 72.9 Cg_endo -78.99 132.45 10.55 Favored 'Trans proline' 0 N--CA 1.454 -0.806 0 C-N-CA 122.273 1.982 . . . . 0.0 112.006 177.428 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 3.3 p -95.06 103.43 15.28 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 121.008 0.432 . . . . 0.0 111.69 -177.841 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' SER . . . . . 0.501 ' HA ' ' HA2' ' A' ' 26' ' ' GLY . 32.7 t -93.48 -24.27 18.07 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.747 -0.661 . . . . 0.0 110.482 179.41 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 8.4 t-20 -133.18 176.08 8.82 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.519 -0.31 . . . . 0.0 110.385 -179.111 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 97.6 mt -81.47 -33.06 32.23 Favored 'General case' 0 N--CA 1.44 -0.965 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.64 -179.003 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 2.6 m -65.08 -43.68 91.38 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.928 0.395 . . . . 0.0 110.841 179.451 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 12.7 t -67.28 -26.7 66.68 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.103 179.881 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 32.6 t80 -68.16 -47.66 67.42 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.9 -0.591 . . . . 0.0 109.989 173.279 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 8.5 t -60.76 -39.93 90.6 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.486 -0.779 . . . . 0.0 110.358 179.675 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -69.7 -31.97 70.3 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.175 178.003 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . 0.626 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -69.24 -46.64 66.85 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.346 178.217 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 6.6 tp -58.08 -38.45 76.4 Favored 'General case' 0 N--CA 1.447 -0.617 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.338 179.164 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 40.4 ttmt -57.66 -38.49 75.17 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.004 -0.998 . . . . 0.0 111.709 178.426 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 17.7 p -86.87 -13.17 45.66 Favored 'General case' 0 C--N 1.329 -0.31 0 N-CA-C 112.615 0.598 . . . . 0.0 112.615 -175.842 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.626 HG12 ' O ' ' A' ' 65' ' ' ALA . 44.4 mm -76.23 140.84 16.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 C-N-CA 120.906 -0.317 . . . . 0.0 110.167 -179.537 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' SER . . . . . 0.442 ' HB2' ' HB2' ' A' ' 73' ' ' GLU . 4.8 m -94.03 161.26 14.36 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.709 -0.223 . . . . 0.0 110.764 179.357 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 2.2 t -82.63 118.37 30.22 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 177.01 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 97.08 8.71 56.56 Favored Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 120.501 -0.857 . . . . 0.0 111.129 -175.477 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.442 ' HB2' ' HB2' ' A' ' 70' ' ' SER . 30.9 tt0 -89.62 145.48 25.22 Favored 'General case' 0 N--CA 1.45 -0.441 0 N-CA-C 109.19 -0.671 . . . . 0.0 109.19 179.563 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 44.4 t -96.2 112.53 28.58 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.022 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.083 -178.865 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 30.8 pt -109.2 154.42 10.62 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-O 121.198 0.523 . . . . 0.0 110.986 -177.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . 0.574 ' HB3' ' HA ' ' A' ' 52' ' ' ASN . 35.5 t-20 -109.63 113.11 25.62 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-N 115.127 -0.942 . . . . 0.0 109.901 -176.617 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.443 HD11 HD22 ' A' ' 86' ' ' LEU . 71.7 mt -104.16 103.73 15.69 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.035 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 175.878 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 30.7 m -88.99 120.14 30.14 Favored 'General case' 0 C--N 1.312 -1.03 0 CA-C-N 115.387 -0.824 . . . . 0.0 109.524 -179.782 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 73.7 p -106.71 171.35 7.41 Favored 'General case' 0 C--N 1.322 -0.606 0 N-CA-C 110.241 -0.281 . . . . 0.0 110.241 179.705 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 19.8 t70 -62.06 -22.56 65.86 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.047 0.451 . . . . 0.0 111.1 -179.819 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 28.7 mt-30 -117.0 17.73 14.85 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 112.548 0.573 . . . . 0.0 112.548 -172.761 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 151.07 163.99 11.74 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 119.909 -1.138 . . . . 0.0 113.748 177.788 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 4.2 m -107.33 137.18 45.86 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 110.056 -0.35 . . . . 0.0 110.056 -179.57 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 26.5 m-85 -134.87 147.39 49.86 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.717 0.294 . . . . 0.0 110.394 177.9 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 4.2 p-80 -130.66 122.52 27.53 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 121.134 0.493 . . . . 0.0 110.086 174.095 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.463 HD23 ' N ' ' A' ' 86' ' ' LEU . 0.9 OUTLIER -130.76 156.87 44.23 Favored 'General case' 0 N--CA 1.444 -0.728 0 CA-C-N 115.571 -0.741 . . . . 0.0 111.115 -173.503 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' LYS . . . . . 0.447 ' HE2' ' HB3' ' A' ' 87' ' ' LYS . 32.4 ttpt -91.94 132.88 36.17 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.03 177.359 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 32.3 p -73.26 143.44 47.05 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.524 179.688 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.464 0 C-N-CA 120.911 -0.662 . . . . 0.0 112.226 177.87 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.455 -0.191 0 CA-C-O 120.798 0.333 . . . . 0.0 111.148 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 6.0 t80 -146.17 134.4 21.72 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 178.493 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -94.08 -31.34 14.24 Favored 'General case' 0 C--N 1.326 -0.45 0 C-N-CA 121.2 -0.2 . . . . 0.0 110.933 179.508 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 102.52 45.17 1.71 Allowed Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.285 -0.959 . . . . 0.0 113.811 173.3 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.452 HG22 HG11 ' A' ' 32' ' ' VAL . 32.6 pt -137.69 159.07 34.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-N 117.278 0.539 . . . . 0.0 110.345 175.058 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . 0.72 ' HB2' ' HB3' ' A' ' 30' ' ' ASP . 97.9 mtt180 -88.93 130.46 35.43 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 109.53 -0.544 . . . . 0.0 109.53 174.444 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 2.6 p -110.62 122.86 48.81 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-O 121.204 0.526 . . . . 0.0 111.022 178.803 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.506 ' HB2' ' OE1' ' A' ' 28' ' ' GLN . 45.7 m -116.23 163.55 15.82 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.79 178.162 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . 0.568 HD21 HG12 ' A' ' 27' ' ' VAL . 0.6 OUTLIER . . . . . 0 C--N 1.317 -0.825 0 CA-C-O 121.072 0.463 . . . . 0.0 109.798 -178.806 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 2.1 p30 . . . . . 0 C--O 1.231 0.109 0 CA-C-O 121.847 0.832 . . . . 0.0 109.751 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 136.2 157.34 7.77 Favored Glycine 0 N--CA 1.442 -0.949 0 CA-C-N 114.91 -1.041 . . . . 0.0 110.824 -176.813 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.633 HG23 ' CD2' ' A' ' 62' ' ' TYR . 35.7 m -114.14 149.92 16.31 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.871 0 CA-C-N 116.913 0.356 . . . . 0.0 110.559 178.909 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . 0.403 HE21 ' HB2' ' A' ' 28' ' ' GLN . 0.0 OUTLIER -129.67 154.65 46.93 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 174.951 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.583 HG21 HD11 ' A' ' 48' ' ' ILE . 2.2 pt -83.48 110.18 18.01 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.446 0 CA-C-O 121.673 0.749 . . . . 0.0 111.064 179.168 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -64.01 -59.15 4.84 Favored 'General case' 0 C--N 1.319 -0.761 0 CA-C-N 114.235 -1.348 . . . . 0.0 110.925 -177.616 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 49.0 m -153.51 166.71 31.86 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.621 -0.718 . . . . 0.0 111.384 -171.08 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.535 ' HA ' HG21 ' A' ' 102' ' ' ILE . 99.4 t -115.49 134.44 58.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 115.694 -0.685 . . . . 0.0 109.689 176.175 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 53.0 t -103.21 107.28 55.01 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 120.863 0.363 . . . . 0.0 111.089 -177.256 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -61.5 120.81 8.65 Favored 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 122.833 2.355 . . . . 0.0 111.575 178.907 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 126.32 -19.04 6.42 Favored Glycine 0 N--CA 1.447 -0.615 0 N-CA-C 111.011 -0.836 . . . . 0.0 111.011 -175.394 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' SER . . . . . 0.677 ' HB3' ' HD2' ' A' ' 37' ' ' PRO . 32.0 m -114.61 169.53 6.52 Favored Pre-proline 0 C--N 1.32 -0.7 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 176.499 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . 0.677 ' HD2' ' HB3' ' A' ' 36' ' ' SER . 21.1 Cg_endo -61.1 173.24 2.53 Favored 'Trans proline' 0 C--N 1.345 0.359 0 C-N-CA 122.487 2.124 . . . . 0.0 112.893 179.139 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 73.77 -11.29 0.97 Allowed 'General case' 0 N--CA 1.469 0.515 0 CA-C-N 115.541 -0.754 . . . . 0.0 112.403 179.672 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 53.4 m -69.33 2.76 2.69 Favored 'General case' 0 CA--C 1.535 0.377 0 N-CA-C 112.457 0.54 . . . . 0.0 112.457 -177.554 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 50.8 tptt -143.53 19.59 1.86 Allowed 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.43 0.633 . . . . 0.0 109.711 179.168 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 94.1 t -119.91 -63.8 1.76 Allowed 'Isoleucine or valine' 0 C--O 1.237 0.396 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.064 -178.54 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 1.1 pp -97.85 179.85 4.67 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.542 0.687 . . . . 0.0 112.204 -174.717 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 16.7 p -127.31 130.61 23.7 Favored Pre-proline 0 C--N 1.317 -0.831 0 CA-C-N 114.85 -1.068 . . . . 0.0 110.058 178.319 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.431 ' HB3' HG23 ' A' ' 32' ' ' VAL . 50.1 Cg_endo -67.46 159.04 54.26 Favored 'Trans proline' 0 C--O 1.236 0.404 0 C-N-CA 122.425 2.083 . . . . 0.0 112.277 -177.353 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 93.25 0.85 67.31 Favored Glycine 0 CA--C 1.522 0.495 0 C-N-CA 120.752 -0.737 . . . . 0.0 113.849 178.388 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . 0.507 ' HB2' HD12 ' A' ' 29' ' ' ILE . 91.2 mt -92.14 167.18 12.23 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 117.43 0.615 . . . . 0.0 111.001 -179.582 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 46.7 t -109.17 138.71 35.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.001 178.675 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.583 HD11 HG21 ' A' ' 29' ' ' ILE . 58.5 mt -101.62 133.7 44.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 C-N-CA 122.33 0.252 . . . . 0.0 110.353 -178.429 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 27.4 tt0 -91.67 -48.52 6.78 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.277 177.854 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' SER . . . . . 0.61 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 39.6 p -150.24 157.66 43.32 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 113.147 0.795 . . . . 0.0 113.147 -171.883 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.565 HD12 ' CE2' ' A' ' 62' ' ' TYR . 43.7 mt -116.3 117.53 55.79 Favored 'Isoleucine or valine' 0 C--O 1.235 0.34 0 CA-C-N 114.861 -1.063 . . . . 0.0 110.297 174.553 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' ASN . . . . . 0.545 ' HA ' ' HB3' ' A' ' 76' ' ' ASN . 25.4 t-20 65.6 -81.37 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.744 -0.662 . . . . 0.0 111.417 177.005 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -140.09 1.67 2.25 Favored Glycine 0 N--CA 1.447 -0.583 0 C-N-CA 121.052 -0.594 . . . . 0.0 111.768 177.251 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 59.5 mtm -120.74 123.48 27.98 Favored Pre-proline 0 C--N 1.324 -0.512 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 -177.721 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.61 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 72.7 Cg_endo -74.97 143.28 28.97 Favored 'Trans proline' 0 N--CA 1.459 -0.504 0 C-N-CA 122.353 2.035 . . . . 0.0 112.496 -179.125 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 17.8 p -110.79 95.21 5.41 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.226 0.536 . . . . 0.0 111.35 -177.637 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 5.1 p -91.06 -14.2 31.75 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.747 -0.66 . . . . 0.0 111.385 -178.881 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 34.2 m-80 -131.06 164.26 25.81 Favored 'General case' 0 C--N 1.318 -0.765 0 N-CA-C 109.698 -0.482 . . . . 0.0 109.698 178.464 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.411 HD21 ' HA ' ' A' ' 59' ' ' LEU . 13.1 mt -77.28 -31.14 54.63 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.215 0.531 . . . . 0.0 109.881 179.0 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 2.6 p -65.18 -45.76 83.57 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.647 173.64 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 4.6 m -56.67 -44.52 81.48 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.49 173.762 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' TYR . . . . . 0.633 ' CD2' HG23 ' A' ' 27' ' ' VAL . 11.6 t80 -60.59 -42.27 96.42 Favored 'General case' 0 CA--C 1.529 0.145 0 CA-C-O 121.508 0.67 . . . . 0.0 109.773 177.705 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 57.9 m -62.21 -47.14 85.78 Favored 'General case' 0 N--CA 1.446 -0.652 0 CA-C-N 115.069 -0.968 . . . . 0.0 111.636 178.139 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.89 -33.39 74.13 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.831 179.369 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . 0.583 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -68.22 -46.99 69.06 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.922 -0.581 . . . . 0.0 109.96 176.5 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 13.7 mt -58.49 -38.45 77.65 Favored 'General case' 0 N--CA 1.448 -0.538 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.894 178.22 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 59.7 mmtt -52.48 -37.69 57.72 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.816 -0.629 . . . . 0.0 112.056 176.744 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 50.1 p -87.77 -13.77 41.43 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 111.914 0.338 . . . . 0.0 111.914 -176.558 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.583 HG12 ' O ' ' A' ' 65' ' ' ALA . 36.7 mm -81.64 141.98 14.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-O 120.995 0.426 . . . . 0.0 110.259 -179.067 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 15.4 m -107.22 162.36 13.96 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.738 -178.801 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . 0.401 HG22 ' HA ' ' A' ' 98' ' ' ALA . 97.1 t -77.75 126.69 38.3 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-O 120.987 0.422 . . . . 0.0 110.627 -179.143 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 93.4 22.25 27.34 Favored Glycine 0 N--CA 1.447 -0.576 0 N-CA-C 111.216 -0.753 . . . . 0.0 111.216 -176.217 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 14.8 tp10 -109.5 151.97 26.04 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.262 -0.469 . . . . 0.0 109.847 -179.311 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.405 ' HA ' ' O ' ' A' ' 86' ' ' LEU . 61.1 t -110.98 120.3 61.38 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.752 0 CA-C-N 116.099 -0.5 . . . . 0.0 109.768 179.803 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 23.9 pt -117.05 154.29 18.73 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.026 -178.674 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . 0.545 ' HB3' ' HA ' ' A' ' 52' ' ' ASN . 44.1 t30 -91.05 132.92 35.72 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.845 -0.616 . . . . 0.0 109.947 -179.66 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 66.3 mt -129.74 109.78 18.61 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-O 121.179 0.514 . . . . 0.0 109.621 178.619 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 25.5 m -95.94 110.27 22.5 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.944 178.647 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.468 HG22 HG12 ' A' ' 48' ' ' ILE . 69.2 p -107.28 175.25 5.56 Favored 'General case' 0 N--CA 1.448 -0.556 0 CA-C-O 120.814 0.34 . . . . 0.0 111.057 -179.105 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 27.6 t70 -45.06 -43.64 9.62 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.058 -0.974 . . . . 0.0 113.383 -175.84 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 32.2 mt-30 -132.86 17.62 4.21 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 111.989 0.366 . . . . 0.0 111.989 -176.707 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -157.15 123.8 1.34 Allowed Glycine 0 C--N 1.319 -0.384 0 C-N-CA 119.581 -1.295 . . . . 0.0 113.31 -177.012 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 26.0 m -108.99 106.74 16.83 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 175.535 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 20.7 p90 -133.13 177.39 7.71 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 121.53 0.681 . . . . 0.0 111.59 -174.51 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 4.9 p80 -124.81 127.98 48.01 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-N 114.849 -1.069 . . . . 0.0 110.055 178.863 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.405 ' O ' ' HA ' ' A' ' 74' ' ' VAL . 7.4 tt -106.5 143.6 34.38 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.498 -175.302 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 86.5 tttt -106.79 116.4 31.87 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.447 -0.797 . . . . 0.0 109.392 178.367 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' THR . . . . . 0.632 HG22 ' HB1' ' A' ' 98' ' ' ALA . 55.7 p -67.04 136.53 55.39 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 121.231 0.539 . . . . 0.0 111.872 -175.212 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.442 -0.958 0 CA-C-N 115.664 -0.698 . . . . 0.0 112.18 -179.225 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . 0.632 ' HB1' HG22 ' A' ' 88' ' ' THR . . . . . . . . 0 N--CA 1.462 0.164 0 CA-C-O 121.079 0.466 . . . . 0.0 110.67 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 27.5 t80 -89.16 114.53 25.82 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.204 0.526 . . . . 0.0 110.452 -173.342 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' MET . . . . . 0.499 ' HE3' HG13 ' A' ' 102' ' ' ILE . 11.3 ptm -70.47 -30.04 66.74 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.351 -0.84 . . . . 0.0 111.725 -178.27 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 86.61 -2.64 87.34 Favored Glycine 0 N--CA 1.453 -0.184 0 C-N-CA 120.991 -0.624 . . . . 0.0 112.918 177.467 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.535 HG21 ' HA ' ' A' ' 32' ' ' VAL . 24.5 pt -132.16 158.31 43.26 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 121.068 0.461 . . . . 0.0 110.695 -177.568 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . 0.418 HH11 ' HD2' ' A' ' 103' ' ' ARG . 18.2 mtp180 -90.36 145.32 25.05 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.796 -0.638 . . . . 0.0 109.591 178.113 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 2.2 p -133.8 151.14 51.48 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 120.708 0.29 . . . . 0.0 111.169 178.397 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 84.1 p -138.49 -174.18 3.75 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.113 -0.494 . . . . 0.0 109.787 177.677 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 14.0 p30 . . . . . 0 C--N 1.321 -0.65 0 CA-C-N 116.527 -0.306 . . . . 0.0 110.86 -179.557 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.83 ' HA ' ' HB3' ' A' ' 57' ' ' SER . 31.9 t70 . . . . . 0 N--CA 1.468 0.454 0 CA-C-O 121.954 0.883 . . . . 0.0 109.954 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 172.26 151.7 8.04 Favored Glycine 0 N--CA 1.441 -0.967 0 CA-C-N 114.949 -1.023 . . . . 0.0 111.245 176.252 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 28.8 m -137.14 153.88 29.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 120.924 0.392 . . . . 0.0 110.94 -177.686 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . 0.474 ' HB2' ' O ' ' A' ' 46' ' ' LEU . 2.0 pt20 -126.02 161.37 27.71 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 110.124 -0.324 . . . . 0.0 110.124 176.314 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.475 HG23 HD12 ' A' ' 102' ' ' ILE . 65.9 mt -75.19 115.58 16.75 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 N-CA-C 109.009 -0.737 . . . . 0.0 109.009 174.885 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.481 ' HB2' ' HB2' ' A' ' 105' ' ' SER . 22.9 t70 -79.22 -64.77 1.11 Allowed 'General case' 0 C--N 1.317 -0.816 0 CA-C-O 121.014 0.435 . . . . 0.0 110.334 -178.232 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 19.6 m -145.2 153.92 41.86 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.281 -177.685 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.562 HG12 HG23 ' A' ' 102' ' ' ILE . 94.6 t -116.87 131.01 70.78 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.292 -178.458 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 57.5 t -104.51 124.82 35.83 Favored Pre-proline 0 C--N 1.328 -0.367 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.943 -178.432 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -56.11 151.18 44.08 Favored 'Trans proline' 0 C--N 1.346 0.415 0 C-N-CA 123.068 2.512 . . . . 0.0 112.541 178.222 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 128.5 -16.25 5.96 Favored Glycine 0 N--CA 1.447 -0.578 0 C-N-CA 120.889 -0.672 . . . . 0.0 111.508 -177.906 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 35.9 p -124.89 156.36 68.97 Favored Pre-proline 0 C--N 1.322 -0.63 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 177.035 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo -64.9 -15.9 52.72 Favored 'Trans proline' 0 C--N 1.345 0.384 0 C-N-CA 122.342 2.028 . . . . 0.0 111.813 176.829 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -62.74 -23.09 67.02 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.526 -0.761 . . . . 0.0 111.542 -179.103 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.53 ' HA ' HG11 ' A' ' 32' ' ' VAL . 20.2 t -66.8 -22.12 66.02 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.249 -178.363 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 81.5 tttt -107.65 -2.12 20.48 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.03 0.443 . . . . 0.0 110.475 -178.679 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 89.9 t -105.23 -48.86 9.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.442 179.286 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 94.8 mt -94.33 174.35 7.18 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.052 -179.257 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' THR . . . . . 0.454 ' O ' ' HG ' ' A' ' 46' ' ' LEU . 45.0 m -143.57 131.06 10.77 Favored Pre-proline 0 C--N 1.321 -0.655 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 -179.755 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_endo -63.69 142.63 84.2 Favored 'Trans proline' 0 N--CA 1.459 -0.519 0 C-N-CA 122.273 1.982 . . . . 0.0 111.776 178.221 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 94.14 2.64 64.08 Favored Glycine 0 CA--C 1.523 0.548 0 C-N-CA 120.748 -0.739 . . . . 0.0 113.538 -178.546 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . 0.507 HD22 ' HG2' ' A' ' 81' ' ' GLN . 66.0 mt -88.63 164.11 15.5 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-N 117.475 0.638 . . . . 0.0 110.805 179.269 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 48.8 t -108.1 130.13 61.14 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.248 0 CA-C-O 120.511 0.196 . . . . 0.0 110.693 -177.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 53.8 mt -98.52 128.29 50.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-O 120.937 0.399 . . . . 0.0 110.881 -176.134 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.5 mm-40 -87.68 -48.32 7.97 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.652 176.823 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' SER . . . . . 0.516 ' CB ' ' HA ' ' A' ' 55' ' ' PRO . 16.2 p -171.82 161.59 5.92 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-O 121.013 0.435 . . . . 0.0 111.849 -174.838 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.444 HG23 ' OD1' ' A' ' 52' ' ' ASN . 27.5 mm -103.67 169.44 2.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 N-CA-C 107.929 -1.137 . . . . 0.0 107.929 173.413 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' ASN . . . . . 0.689 ' HB3' ' HB3' ' A' ' 76' ' ' ASN . 24.0 p-10 -53.97 99.97 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.825 0.821 . . . . 0.0 112.251 -175.996 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 75.72 3.77 74.09 Favored Glycine 0 N--CA 1.447 -0.593 0 CA-C-N 115.352 -0.84 . . . . 0.0 112.695 178.46 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' MET . . . . . 0.477 ' HE1' HD12 ' A' ' 69' ' ' ILE . 56.1 mtm -137.32 92.08 13.92 Favored Pre-proline 0 C--N 1.325 -0.467 0 CA-C-O 120.689 0.28 . . . . 0.0 110.504 -176.488 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.516 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 15.8 Cg_exo -66.87 135.28 37.52 Favored 'Trans proline' 0 N--CA 1.46 -0.49 0 C-N-CA 122.311 2.007 . . . . 0.0 111.608 178.606 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.454 HG22 ' CD2' ' A' ' 62' ' ' TYR . 10.9 p -105.24 98.31 8.03 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-O 121.283 0.563 . . . . 0.0 111.731 -175.429 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' SER . . . . . 0.83 ' HB3' ' HA ' ' A' ' 25' ' ' ASP . 4.2 m -101.52 -17.16 16.54 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.774 176.284 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 14.3 m120 -127.24 160.89 29.93 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.142 -177.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 96.5 mt -77.62 -31.97 53.19 Favored 'General case' 0 N--CA 1.438 -1.044 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.061 177.583 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 84.7 m -70.42 -37.4 74.43 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.749 -0.659 . . . . 0.0 110.928 176.467 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 16.6 p -69.6 -33.3 72.49 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.867 0.365 . . . . 0.0 110.351 178.561 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' TYR . . . . . 0.454 ' CD2' HG22 ' A' ' 56' ' ' THR . 24.8 t80 -61.52 -45.97 91.95 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.444 0.64 . . . . 0.0 109.427 173.438 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 6.3 m -65.55 -42.69 91.62 Favored 'General case' 0 N--CA 1.449 -0.522 0 CA-C-N 115.108 -0.951 . . . . 0.0 112.126 177.75 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.99 -33.74 76.06 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.994 -179.768 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . 0.553 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -69.52 -45.54 68.61 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.047 -0.524 . . . . 0.0 109.807 177.483 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 14.3 mt -55.2 -38.62 68.62 Favored 'General case' 0 N--CA 1.447 -0.615 0 CA-C-N 115.375 -0.829 . . . . 0.0 111.677 179.184 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 28.0 mmmt -57.29 -28.44 63.03 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.832 -0.622 . . . . 0.0 112.49 179.703 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 28.4 p -99.85 -14.05 18.94 Favored 'General case' 0 C--N 1.327 -0.413 0 N-CA-C 112.373 0.508 . . . . 0.0 112.373 -177.544 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.553 HG12 ' O ' ' A' ' 65' ' ' ALA . 49.1 mm -70.63 128.65 34.17 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-O 121.175 0.512 . . . . 0.0 110.622 -176.658 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 16.3 m -80.62 163.49 23.59 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.372 -176.81 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 57.9 t -84.84 127.64 39.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 115.92 -0.582 . . . . 0.0 109.455 175.773 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 88.32 15.12 60.95 Favored Glycine 0 N--CA 1.448 -0.51 0 N-CA-C 110.571 -1.012 . . . . 0.0 110.571 -173.689 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 7.1 tp10 -87.36 148.16 25.16 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 114.952 -0.624 . . . . 0.0 109.321 178.862 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 59.0 t -113.53 102.13 13.46 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.994 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 174.705 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 29.9 pt -97.37 161.9 2.74 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.855 0 CA-C-N 115.674 -0.694 . . . . 0.0 111.29 -174.314 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . 0.689 ' HB3' ' HB3' ' A' ' 52' ' ' ASN . 11.7 t30 -102.17 122.52 44.32 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 115.389 -0.823 . . . . 0.0 109.999 179.292 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 61.8 mt -122.63 103.94 13.92 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 176.687 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' THR . . . . . 0.433 ' HA ' ' HA ' ' A' ' 83' ' ' THR . 37.7 m -91.98 114.1 26.55 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 115.279 -0.873 . . . . 0.0 109.832 179.411 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 69.6 p -102.66 171.86 7.18 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 176.653 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -72.8 -14.67 61.57 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 121.63 0.729 . . . . 0.0 109.469 176.095 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . 0.507 ' HG2' HD22 ' A' ' 46' ' ' LEU . 2.7 mp0 -95.37 10.07 37.63 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.302 -0.863 . . . . 0.0 110.652 178.979 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 127.27 164.81 11.76 Favored Glycine 0 CA--C 1.519 0.32 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.902 178.473 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' THR . . . . . 0.433 ' HA ' ' HA ' ' A' ' 78' ' ' THR . 28.0 m -90.48 129.86 36.6 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 110.387 -0.227 . . . . 0.0 110.387 177.621 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 60.6 m-85 -128.34 155.45 44.65 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.013 0.435 . . . . 0.0 110.654 179.421 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 38.6 m80 -108.46 136.85 47.4 Favored 'General case' 0 C--N 1.321 -0.674 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 174.553 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 21.2 tp -123.44 138.87 54.5 Favored 'General case' 0 C--N 1.315 -0.899 0 C-N-CA 120.208 -0.597 . . . . 0.0 110.746 -179.782 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 37.0 ttpt -105.67 121.08 43.26 Favored 'General case' 0 C--N 1.313 -0.988 0 CA-C-N 115.316 -0.856 . . . . 0.0 109.139 177.722 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' THR . . . . . 0.587 HG21 ' HB1' ' A' ' 98' ' ' ALA . 43.5 p -78.43 128.67 33.94 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-O 121.275 0.56 . . . . 0.0 111.508 -176.967 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.836 0 CA-C-N 115.65 -0.705 . . . . 0.0 111.889 -178.674 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . 0.587 ' HB1' HG21 ' A' ' 88' ' ' THR . . . . . . . . 0 C--O 1.233 0.2 0 CA-C-O 121.25 0.548 . . . . 0.0 111.362 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 51.3 t80 -79.78 97.23 6.54 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 121.173 0.511 . . . . 0.0 111.299 -173.328 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 50.3 ttm -86.5 -58.41 2.63 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.309 173.626 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 88.27 24.05 35.44 Favored Glycine 0 C--N 1.33 0.23 0 C-N-CA 120.889 -0.672 . . . . 0.0 113.709 171.042 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.562 HG23 HG12 ' A' ' 32' ' ' VAL . 19.0 pt -120.03 145.72 25.9 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 CA-C-N 117.179 0.49 . . . . 0.0 110.488 177.597 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.72 140.81 29.21 Favored 'General case' 0 C--N 1.319 -0.747 0 N-CA-C 108.974 -0.75 . . . . 0.0 108.974 174.868 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.7 m -109.59 149.0 30.31 Favored 'General case' 0 C--N 1.314 -0.966 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 -179.076 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.481 ' HB2' ' HB2' ' A' ' 30' ' ' ASP . 41.0 t -116.67 172.24 7.36 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-N 115.94 -0.573 . . . . 0.0 109.705 -178.3 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . 0.412 HD21 ' HA ' ' A' ' 106' ' ' ASN . 1.1 t-20 . . . . . 0 C--N 1.316 -0.872 0 CA-C-O 121.551 0.691 . . . . 0.0 109.53 -172.947 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 38.9 t70 . . . . . 0 C--O 1.232 0.171 0 CA-C-O 121.185 0.516 . . . . 0.0 111.147 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 82.73 122.55 0.75 Allowed Glycine 0 N--CA 1.448 -0.526 0 CA-C-N 115.321 -0.854 . . . . 0.0 112.621 178.913 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 34.9 m -98.09 149.45 5.22 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.881 0 CA-C-O 120.862 0.363 . . . . 0.0 110.583 -179.641 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . 0.462 ' HB2' ' O ' ' A' ' 46' ' ' LEU . 3.7 pt20 -128.97 159.58 35.44 Favored 'General case' 0 C--N 1.318 -0.779 0 C-N-CA 120.558 -0.457 . . . . 0.0 110.868 176.875 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.578 HG21 HD11 ' A' ' 48' ' ' ILE . 0.2 OUTLIER -82.58 111.62 19.22 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.357 178.42 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 22.8 t70 -71.2 -62.8 1.27 Allowed 'General case' 0 C--N 1.318 -0.784 0 CA-C-N 115.363 -0.835 . . . . 0.0 111.481 -174.978 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 8.4 p -155.31 145.08 21.4 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.681 -176.464 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.556 HG11 ' HA ' ' A' ' 39' ' ' SER . 89.0 t -90.41 132.39 35.16 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.762 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.406 178.964 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.463 ' HA ' ' HD3' ' A' ' 34' ' ' PRO . 17.5 m -107.29 134.07 20.09 Favored Pre-proline 0 N--CA 1.449 -0.524 0 CA-C-O 121.015 0.436 . . . . 0.0 111.476 -178.251 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . 0.463 ' HD3' ' HA ' ' A' ' 33' ' ' VAL . 21.9 Cg_exo -66.44 142.24 64.74 Favored 'Trans proline' 0 C--O 1.236 0.389 0 C-N-CA 123.108 2.539 . . . . 0.0 112.141 178.302 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 112.99 -16.13 23.11 Favored Glycine 0 N--CA 1.448 -0.538 0 N-CA-C 111.232 -0.747 . . . . 0.0 111.232 -176.939 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 26.0 m -123.53 165.22 24.03 Favored Pre-proline 0 C--N 1.324 -0.539 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 179.853 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -74.72 -168.62 0.52 Allowed 'Trans proline' 0 CA--C 1.533 0.428 0 C-N-CA 122.753 2.302 . . . . 0.0 112.489 178.383 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.498 ' HB1' HD11 ' A' ' 86' ' ' LEU . . . 78.62 -6.3 1.93 Allowed 'General case' 0 N--CA 1.468 0.436 0 CA-C-N 115.473 -0.785 . . . . 0.0 112.354 175.457 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.556 ' HA ' HG11 ' A' ' 32' ' ' VAL . 3.8 m -58.69 -30.9 67.74 Favored 'General case' 0 CA--C 1.531 0.243 0 CA-C-O 120.817 0.342 . . . . 0.0 111.661 -177.2 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 64.6 mmtt -119.33 20.7 12.47 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.19 0.519 . . . . 0.0 110.928 -179.675 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 89.6 t -107.84 -47.04 7.82 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 115.938 -0.573 . . . . 0.0 110.043 178.678 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.554 ' HB3' ' CZ ' ' A' ' 84' ' ' PHE . 0.6 OUTLIER -118.61 171.83 7.92 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 121.078 0.466 . . . . 0.0 111.256 178.884 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 11.7 m -115.84 126.15 27.97 Favored Pre-proline 0 C--N 1.315 -0.895 0 CA-C-N 115.452 -0.795 . . . . 0.0 110.061 -179.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_endo -62.2 142.35 91.41 Favored 'Trans proline' 0 N--CA 1.46 -0.461 0 C-N-CA 122.099 1.866 . . . . 0.0 111.422 177.4 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 97.72 -5.42 62.05 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.995 -179.248 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . 0.462 ' O ' ' HB2' ' A' ' 28' ' ' GLN . 75.2 mt -85.09 164.03 18.44 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.931 0.366 . . . . 0.0 110.968 179.589 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 47.4 t -101.51 143.28 14.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.457 178.516 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.578 HD11 HG21 ' A' ' 29' ' ' ILE . 60.0 mt -104.36 127.42 58.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 C-N-CA 122.535 0.334 . . . . 0.0 110.209 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 27.9 mt-10 -89.51 -47.88 7.69 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.777 176.382 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' SER . . . . . 0.551 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 19.5 p -157.38 153.15 26.81 Favored 'General case' 0 N--CA 1.446 -0.671 0 CA-C-O 121.599 0.714 . . . . 0.0 112.202 -172.877 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.45 HG23 ' H ' ' A' ' 52' ' ' ASN . 16.0 mt -96.86 -179.93 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 169.735 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' ASN . . . . . 0.625 ' HB2' ' H ' ' A' ' 76' ' ' ASN . 36.0 t-20 -49.58 93.67 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 112.264 0.468 . . . . 0.0 112.264 -177.434 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 73.12 -2.59 34.63 Favored Glycine 0 CA--C 1.519 0.321 0 CA-C-N 115.976 -0.557 . . . . 0.0 113.275 179.493 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 36.1 mtt -124.8 98.85 36.13 Favored Pre-proline 0 C--N 1.325 -0.484 0 CA-C-N 116.875 0.337 . . . . 0.0 110.654 -173.096 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.551 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 70.4 Cg_endo -77.27 130.89 11.36 Favored 'Trans proline' 0 N--CA 1.46 -0.447 0 C-N-CA 122.151 1.901 . . . . 0.0 112.005 178.257 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.425 HG22 ' HA ' ' A' ' 62' ' ' TYR . 37.5 p -116.63 103.84 10.79 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 121.089 0.471 . . . . 0.0 111.614 -176.307 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 26.9 t -89.05 -34.63 16.72 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.965 177.207 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 2.3 m-20 -103.34 158.44 16.33 Favored 'General case' 0 C--N 1.318 -0.797 0 O-C-N 122.065 -0.397 . . . . 0.0 110.153 -176.804 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 87.4 mt -68.81 -33.8 74.45 Favored 'General case' 0 N--CA 1.443 -0.801 0 CA-C-O 121.215 0.531 . . . . 0.0 109.955 175.519 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 1.6 m -66.04 -41.82 90.39 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.668 -0.696 . . . . 0.0 111.081 177.547 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 18.4 p -68.07 -28.46 67.38 Favored 'General case' 0 CA--C 1.528 0.114 0 CA-C-O 120.811 0.339 . . . . 0.0 110.55 178.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' TYR . . . . . 0.477 ' HH ' ' HG3' ' A' ' 100' ' ' MET . 46.1 t80 -67.19 -38.41 85.31 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 176.105 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 21.6 t -66.07 -48.28 71.53 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.768 179.097 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.03 -32.78 74.22 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.346 -177.773 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . 0.474 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -73.29 -43.88 60.16 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.311 179.586 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 3.2 tt -57.04 -45.99 82.74 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.705 -0.679 . . . . 0.0 110.494 -179.6 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -59.69 -26.88 65.95 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.63 -0.714 . . . . 0.0 112.173 -178.199 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 43.5 p -89.24 -14.03 36.82 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 112.049 0.388 . . . . 0.0 112.049 -177.454 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.474 HG12 ' O ' ' A' ' 65' ' ' ALA . 40.9 mm -74.83 142.81 14.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.652 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' SER . . . . . 0.449 ' HB2' ' HB2' ' A' ' 73' ' ' GLU . 4.9 m -93.18 157.64 16.17 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.673 0.273 . . . . 0.0 111.084 -178.157 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 75.3 t -70.29 129.79 34.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.109 177.146 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 79.63 10.14 86.12 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.612 -0.804 . . . . 0.0 111.606 179.759 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.449 ' HB2' ' HB2' ' A' ' 70' ' ' SER . 23.7 tt0 -92.86 149.57 21.17 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 -179.719 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 44.9 t -105.1 124.05 59.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-O 121.35 0.595 . . . . 0.0 110.579 -175.806 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 15.7 pt -110.27 154.04 11.9 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.122 179.193 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . 0.625 ' H ' ' HB2' ' A' ' 52' ' ' ASN . 6.3 t30 -105.8 110.49 22.8 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 115.312 -0.858 . . . . 0.0 109.736 -177.755 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 65.0 mt -105.95 119.41 55.21 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 CA-C-O 121.34 0.59 . . . . 0.0 110.992 -174.087 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 11.9 m -93.68 118.5 31.47 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.278 -0.873 . . . . 0.0 109.616 177.847 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 43.4 p -120.36 178.12 4.77 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.82 0.343 . . . . 0.0 111.165 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 28.5 t70 -58.59 -34.88 71.6 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.598 -0.728 . . . . 0.0 111.351 178.798 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 10.7 mm100 -96.48 14.24 25.24 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.125 -0.489 . . . . 0.0 112.103 -176.136 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 123.26 -171.51 15.85 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.177 -1.011 . . . . 0.0 112.631 176.246 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 24.1 m -112.06 138.23 49.0 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.75 0.309 . . . . 0.0 110.721 -176.855 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . 0.554 ' CZ ' ' HB3' ' A' ' 42' ' ' LEU . 10.3 p90 -139.16 168.83 18.96 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 121.378 0.609 . . . . 0.0 110.949 175.494 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -109.82 138.34 46.33 Favored 'General case' 0 C--N 1.314 -0.951 0 CA-C-N 115.142 -0.935 . . . . 0.0 110.016 178.158 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.498 HD11 ' HB1' ' A' ' 38' ' ' ALA . 17.8 tp -130.08 143.85 51.02 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.106 -177.755 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 24.3 ttpp -114.18 125.43 53.93 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.093 -178.277 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' THR . . . . . 0.633 HG23 ' HB3' ' A' ' 98' ' ' ALA . 77.0 p -73.99 148.17 42.31 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 115.969 -0.559 . . . . 0.0 111.38 -178.716 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.805 0 N-CA-C 110.952 -0.859 . . . . 0.0 110.952 174.866 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . 0.633 ' HB3' HG23 ' A' ' 88' ' ' THR . . . . . . . . 0 CA--C 1.523 -0.083 0 CA-C-O 121.339 0.59 . . . . 0.0 109.903 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 29.5 p90 -86.89 148.57 25.3 Favored 'General case' 0 N--CA 1.444 -0.747 0 CA-C-N 115.865 -0.607 . . . . 0.0 112.164 -167.238 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' MET . . . . . 0.477 ' HG3' ' HH ' ' A' ' 62' ' ' TYR . 93.5 mmm -98.06 126.55 43.55 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.05 -0.977 . . . . 0.0 109.341 175.358 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -86.92 35.19 3.43 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.806 -177.046 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.532 HG21 ' HA ' ' A' ' 32' ' ' VAL . 2.8 pp -140.2 162.71 24.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 120.801 0.334 . . . . 0.0 110.434 179.655 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . 0.411 ' NE ' ' HA ' ' A' ' 103' ' ' ARG . 2.9 mmp_? -93.01 142.07 27.7 Favored 'General case' 0 C--N 1.315 -0.915 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 171.377 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.3 m -111.17 150.52 29.38 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-O 121.085 0.469 . . . . 0.0 110.387 179.455 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.411 ' OG ' ' HG3' ' A' ' 28' ' ' GLN . 6.7 p -136.16 169.08 18.2 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.158 175.809 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 . . . . . 0 C--N 1.32 -0.704 0 CA-C-O 120.686 0.279 . . . . 0.0 111.261 -172.575 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 21.4 t70 . . . . . 0 C--O 1.233 0.218 0 CA-C-O 121.083 0.468 . . . . 0.0 111.447 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . 0.56 ' HA2' ' HA ' ' A' ' 57' ' ' SER . . . 157.25 167.2 17.99 Favored Glycine 0 N--CA 1.443 -0.869 0 N-CA-C 111.039 -0.824 . . . . 0.0 111.039 -177.124 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.483 HG21 ' HB ' ' A' ' 48' ' ' ILE . 28.5 m -108.06 127.42 64.26 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 CA-C-O 121.253 0.549 . . . . 0.0 110.984 178.787 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 18.9 tt0 -99.21 142.78 30.26 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.07 178.01 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.428 HG12 ' O ' ' A' ' 46' ' ' LEU . 8.0 pt -87.36 119.52 35.16 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-O 121.612 0.72 . . . . 0.0 111.579 -178.069 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.4 ' HB3' ' CB ' ' A' ' 103' ' ' ARG . 11.4 t70 -61.12 -58.47 8.22 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 114.272 -1.331 . . . . 0.0 109.983 177.23 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' SER . . . . . 0.569 ' HA ' ' HB3' ' A' ' 44' ' ' PRO . 7.8 p -159.69 158.96 32.36 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.432 -0.804 . . . . 0.0 111.145 -174.407 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.555 ' HA ' HG22 ' A' ' 102' ' ' ILE . 91.4 t -110.44 119.7 59.83 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 115.689 -0.687 . . . . 0.0 109.404 177.846 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.443 ' C ' ' H ' ' A' ' 35' ' ' GLY . 53.9 t -83.63 123.52 76.3 Favored Pre-proline 0 C--N 1.324 -0.513 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.721 -175.978 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . 0.42 ' HD3' ' HA ' ' A' ' 33' ' ' VAL . 11.4 Cg_exo -72.95 31.16 0.3 Allowed 'Trans proline' 0 CA--C 1.532 0.42 0 C-N-CA 123.269 2.646 . . . . 0.0 112.775 179.291 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.443 ' H ' ' C ' ' A' ' 33' ' ' VAL . . . -121.69 20.43 8.24 Favored Glycine 0 N--CA 1.449 -0.462 0 N-CA-C 111.27 -0.732 . . . . 0.0 111.27 179.172 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 49.1 m -148.17 160.9 36.08 Favored Pre-proline 0 C--N 1.323 -0.578 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 179.425 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_exo -59.81 -13.56 22.92 Favored 'Trans proline' 0 C--N 1.348 0.533 0 C-N-CA 122.985 2.457 . . . . 0.0 113.669 -176.297 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.406 ' HB2' HD11 ' A' ' 42' ' ' LEU . . . -78.6 -6.94 56.97 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 111.794 0.294 . . . . 0.0 111.794 -177.333 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 28.0 t -60.43 -28.45 68.3 Favored 'General case' 0 CA--C 1.533 0.294 0 N-CA-C 112.153 0.427 . . . . 0.0 112.153 -175.657 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 21.0 ttpt -106.96 13.53 27.5 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.947 0.403 . . . . 0.0 110.678 -177.388 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.469 ' HB ' HD12 ' A' ' 42' ' ' LEU . 46.4 t -115.34 -59.2 3.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 C-N-CA 120.776 -0.37 . . . . 0.0 111.65 -175.23 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.469 HD12 ' HB ' ' A' ' 41' ' ' VAL . 6.6 mp -92.45 175.46 6.83 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.291 0.567 . . . . 0.0 111.516 -173.478 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 91.1 m -140.89 123.94 9.91 Favored Pre-proline 0 C--N 1.32 -0.674 0 CA-C-N 115.405 -0.816 . . . . 0.0 108.946 175.544 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.569 ' HB3' ' HA ' ' A' ' 31' ' ' SER . 42.3 Cg_endo -64.52 152.05 83.17 Favored 'Trans proline' 0 CA--C 1.531 0.339 0 C-N-CA 122.893 2.396 . . . . 0.0 112.905 -173.811 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 103.17 -11.92 55.36 Favored Glycine 0 CA--C 1.52 0.368 0 C-N-CA 121.072 -0.585 . . . . 0.0 112.695 -179.496 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . 0.698 HD23 ' HB3' ' A' ' 80' ' ' ASP . 81.6 mt -84.74 164.62 18.43 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.975 0.417 . . . . 0.0 111.098 -177.981 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 46.6 t -108.12 135.09 47.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 116.075 -0.511 . . . . 0.0 109.843 177.129 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.483 ' HB ' HG21 ' A' ' 27' ' ' VAL . 69.0 mt -87.65 123.7 40.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-O 121.204 0.526 . . . . 0.0 110.536 179.862 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 6.5 tm-20 -79.22 -47.06 16.62 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.921 -179.54 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' SER . . . . . 0.516 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 7.7 p -162.73 153.77 17.32 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.388 -177.648 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 48.5 mm -107.24 102.96 14.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.901 -0.59 . . . . 0.0 109.732 176.679 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' ASN . . . . . 0.575 ' HA ' ' HB3' ' A' ' 76' ' ' ASN . 38.9 t-20 64.08 -85.26 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.384 0 C-N-CA 123.552 0.741 . . . . 0.0 111.056 179.343 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -132.79 8.05 5.21 Favored Glycine 0 N--CA 1.447 -0.569 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 177.005 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 1.5 mpt? -118.59 103.35 48.92 Favored Pre-proline 0 N--CA 1.448 -0.571 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 -178.737 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.516 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 41.8 Cg_endo -68.81 121.68 8.57 Favored 'Trans proline' 0 N--CA 1.462 -0.367 0 C-N-CA 122.124 1.882 . . . . 0.0 112.461 -179.118 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.427 ' HA ' ' HB ' ' A' ' 61' ' ' THR . 6.9 p -89.47 87.99 7.28 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.54 179.834 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' SER . . . . . 0.56 ' HA ' ' HA2' ' A' ' 26' ' ' GLY . 8.6 t -93.53 -14.26 26.82 Favored 'General case' 0 C--N 1.318 -0.797 0 CA-C-N 115.416 -0.811 . . . . 0.0 109.875 -179.476 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 61.1 t30 -140.5 178.23 7.46 Favored 'General case' 0 N--CA 1.445 -0.714 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 178.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 68.8 mt -76.16 -33.39 59.37 Favored 'General case' 0 N--CA 1.445 -0.72 0 CA-C-O 120.921 0.391 . . . . 0.0 111.067 -178.424 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 13.1 m -66.48 -34.33 77.68 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.977 179.869 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' THR . . . . . 0.427 ' HB ' ' HA ' ' A' ' 56' ' ' THR . 0.0 OUTLIER -66.0 -35.33 80.26 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.992 0.425 . . . . 0.0 110.372 176.838 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 55.4 t80 -62.33 -37.45 85.66 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.857 176.842 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 33.2 t -68.25 -46.19 71.16 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.52 -0.764 . . . . 0.0 110.435 177.287 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -66.32 -26.34 67.26 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.865 -0.607 . . . . 0.0 112.13 -175.761 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . 0.421 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -79.27 -44.03 22.54 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.078 0.466 . . . . 0.0 110.431 177.487 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . 0.408 ' HG ' ' HE2' ' A' ' 100' ' ' MET . 1.7 tt -63.55 -42.64 98.38 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.556 -0.747 . . . . 0.0 111.357 -175.824 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 22.4 ptmt -60.37 -12.37 9.14 Favored 'General case' 0 CA--C 1.536 0.414 0 N-CA-C 112.899 0.704 . . . . 0.0 112.899 -174.117 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 20.8 p -106.93 -13.17 15.28 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 112.386 0.514 . . . . 0.0 112.386 -178.128 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.45 HG22 HG23 ' A' ' 88' ' ' THR . 37.2 mm -79.73 143.85 11.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.748 -0.205 . . . . 0.0 110.956 -175.256 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 3.2 m -92.45 164.52 13.44 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.508 -0.315 . . . . 0.0 110.471 179.888 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 16.5 t -78.6 118.09 25.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 120.677 0.275 . . . . 0.0 110.266 179.304 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 88.32 23.52 37.03 Favored Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 120.422 -0.894 . . . . 0.0 111.671 -178.846 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 28.6 tt0 -99.56 147.5 25.27 Favored 'General case' 0 C--N 1.323 -0.587 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 -179.851 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 51.0 t -95.14 114.29 31.39 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.779 0 CA-C-O 121.136 0.493 . . . . 0.0 110.56 -179.122 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 26.7 pt -104.21 174.79 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.787 0 CA-C-N 115.637 -0.71 . . . . 0.0 110.87 179.27 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . 0.575 ' HB3' ' HA ' ' A' ' 52' ' ' ASN . 43.6 t30 -122.16 130.54 53.31 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.586 -0.734 . . . . 0.0 109.813 -175.536 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.416 HG23 HG23 ' A' ' 79' ' ' THR . 62.5 mt -134.8 110.33 12.71 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-O 121.212 0.529 . . . . 0.0 111.112 -176.922 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' THR . . . . . 0.609 ' HA ' ' HA ' ' A' ' 83' ' ' THR . 98.1 m -85.91 123.53 31.35 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.986 -0.552 . . . . 0.0 109.685 173.597 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.416 HG23 HG23 ' A' ' 77' ' ' ILE . 67.3 p -124.72 -173.45 2.79 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.922 0.392 . . . . 0.0 111.364 -177.472 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . 0.698 ' HB3' HD23 ' A' ' 46' ' ' LEU . 7.4 t70 -53.78 -41.55 67.34 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.216 -0.902 . . . . 0.0 111.583 177.173 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 28.2 mm-40 -95.23 12.94 27.13 Favored 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 111.931 0.345 . . . . 0.0 111.931 -175.759 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 119.43 -175.32 15.75 Favored Glycine 0 N--CA 1.447 -0.63 0 C-N-CA 120.164 -1.017 . . . . 0.0 113.038 175.342 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' THR . . . . . 0.609 ' HA ' ' HA ' ' A' ' 78' ' ' THR . 32.6 m -92.67 117.17 29.7 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.115 0.484 . . . . 0.0 111.396 -176.565 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 88.9 m-85 -113.89 164.8 13.29 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.43 -178.735 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 19.3 p-80 -117.27 130.01 56.28 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.285 178.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.481 HD23 ' N ' ' A' ' 87' ' ' LYS . 8.2 tt -120.48 145.48 47.23 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 116.231 -0.44 . . . . 0.0 109.947 -173.985 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' LYS . . . . . 0.481 ' N ' HD23 ' A' ' 86' ' ' LEU . 88.1 tttt -114.66 117.59 31.28 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 109.132 -0.692 . . . . 0.0 109.132 176.216 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' THR . . . . . 0.45 HG23 HG22 ' A' ' 69' ' ' ILE . 22.3 p -64.03 131.92 49.03 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 121.142 0.496 . . . . 0.0 111.729 -174.997 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.441 -1.012 0 C-N-CA 120.975 -0.631 . . . . 0.0 111.797 179.61 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.254 0 CA-C-O 121.177 0.513 . . . . 0.0 112.29 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 14.5 t80 -107.45 120.74 43.0 Favored 'General case' 0 C--N 1.319 -0.718 0 C-N-CA 120.76 -0.376 . . . . 0.0 110.07 -178.58 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' MET . . . . . 0.525 ' HG2' HG12 ' A' ' 102' ' ' ILE . 0.7 OUTLIER -71.86 -20.18 61.85 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.169 -179.038 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 78.91 35.2 31.83 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.866 -0.683 . . . . 0.0 113.113 175.201 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.555 HG22 ' HA ' ' A' ' 32' ' ' VAL . 35.4 pt -142.02 154.01 18.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-O 120.849 0.356 . . . . 0.0 110.063 178.933 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . 0.4 ' CB ' ' HB3' ' A' ' 30' ' ' ASP . 21.4 mtp85 -91.74 134.66 34.53 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 173.463 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 2.8 m -133.21 155.14 49.89 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.962 0.41 . . . . 0.0 111.055 -176.308 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 32.6 t -149.1 -174.88 4.76 Favored 'General case' 0 C--N 1.321 -0.636 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 179.44 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 14.8 p30 . . . . . 0 C--N 1.324 -0.518 0 CA-C-O 120.635 0.255 . . . . 0.0 111.044 179.211 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 27.9 t70 . . . . . 0 N--CA 1.465 0.323 0 CA-C-O 122.013 0.911 . . . . 0.0 110.364 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 106.52 115.94 4.08 Favored Glycine 0 N--CA 1.445 -0.72 0 CA-C-N 114.471 -1.24 . . . . 0.0 111.751 176.597 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 34.5 m -78.79 153.83 4.92 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 CA-C-O 120.941 0.4 . . . . 0.0 110.721 -178.737 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 4.4 tt0 -115.53 149.24 38.48 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-O 121.293 0.568 . . . . 0.0 111.349 -177.585 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.469 HD11 HD11 ' A' ' 102' ' ' ILE . 26.8 mm -73.11 107.62 3.86 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.214 -0.903 . . . . 0.0 109.432 175.742 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.692 ' HB3' ' HB2' ' A' ' 103' ' ' ARG . 41.9 t0 -69.98 -53.54 17.28 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-O 121.401 0.62 . . . . 0.0 109.529 -178.671 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 51.0 p -161.47 173.51 14.76 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.189 -0.914 . . . . 0.0 110.798 177.103 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.467 HG21 HG22 ' A' ' 102' ' ' ILE . 84.9 t -119.25 124.46 73.1 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 CA-C-N 115.813 -0.631 . . . . 0.0 109.382 175.95 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 7.4 p -106.7 131.02 22.04 Favored Pre-proline 0 C--N 1.323 -0.545 0 CA-C-O 120.783 0.325 . . . . 0.0 110.421 -177.67 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo -64.97 87.85 0.18 Allowed 'Trans proline' 0 C--N 1.343 0.289 0 C-N-CA 122.79 2.327 . . . . 0.0 112.408 179.426 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -164.75 14.21 0.09 OUTLIER Glycine 0 N--CA 1.449 -0.447 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.862 176.032 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' SER . . . . . 0.665 ' HB2' ' HA3' ' A' ' 101' ' ' GLY . 60.4 m -157.65 160.44 30.16 Favored Pre-proline 0 C--N 1.327 -0.401 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 -178.972 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_exo -63.31 -15.34 47.66 Favored 'Trans proline' 0 C--N 1.349 0.568 0 C-N-CA 122.87 2.38 . . . . 0.0 112.71 -178.132 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -67.07 -15.12 63.52 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.922 -177.426 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.44 ' HA ' HG13 ' A' ' 32' ' ' VAL . 47.7 t -65.21 -13.55 58.54 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.71 -177.041 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 23.9 ttmm -128.42 25.39 5.77 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.346 0.594 . . . . 0.0 110.06 179.244 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.529 ' HB ' HD13 ' A' ' 42' ' ' LEU . 45.6 t -122.16 -55.3 2.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.905 179.381 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.529 HD13 ' HB ' ' A' ' 41' ' ' VAL . 5.0 mp -109.17 164.19 12.67 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.789 0.328 . . . . 0.0 110.588 -178.033 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 12.7 p -116.54 144.54 33.39 Favored Pre-proline 0 C--N 1.323 -0.548 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.62 177.1 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.444 ' HA ' ' CG2' ' A' ' 29' ' ' ILE . 57.2 Cg_endo -72.55 149.41 49.53 Favored 'Trans proline' 0 C--O 1.235 0.332 0 C-N-CA 122.299 1.999 . . . . 0.0 112.496 -179.422 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 101.14 -12.52 58.8 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.999 -179.555 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 83.4 mt -77.43 164.27 25.62 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 121.046 0.451 . . . . 0.0 111.46 -179.235 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 46.0 t -108.76 136.19 45.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.785 177.933 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.416 HG21 HG22 ' A' ' 77' ' ' ILE . 70.9 mt -93.79 122.71 45.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-N 116.496 -0.32 . . . . 0.0 110.981 179.55 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -79.82 -44.97 19.6 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.5 -0.318 . . . . 0.0 110.951 174.809 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' SER . . . . . 0.58 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 16.4 p -169.03 161.22 10.45 Favored 'General case' 0 CA--C 1.515 -0.404 0 CA-C-O 120.888 0.375 . . . . 0.0 111.408 -174.559 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.509 HD13 HD11 ' A' ' 75' ' ' ILE . 8.1 tt -135.95 122.19 31.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.148 177.473 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 11.0 m120 58.85 22.88 10.69 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-N 115.642 -0.708 . . . . 0.0 112.536 176.094 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 104.71 -26.22 23.19 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.655 -0.783 . . . . 0.0 112.433 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 4.4 mpp? -91.94 112.8 56.6 Favored Pre-proline 0 C--N 1.325 -0.491 0 N-CA-C 109.682 -0.488 . . . . 0.0 109.682 177.577 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.58 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 72.6 Cg_endo -78.02 128.07 8.9 Favored 'Trans proline' 0 N--CA 1.454 -0.799 0 C-N-CA 122.09 1.86 . . . . 0.0 112.501 -178.748 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 21.5 p -91.64 81.13 5.31 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 115.649 -0.705 . . . . 0.0 111.026 -177.944 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 12.6 m -81.34 -18.5 45.49 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.69 178.561 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 42.7 m-80 -138.34 164.85 28.25 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.733 -178.729 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.487 HD22 ' HA ' ' A' ' 105' ' ' SER . 66.2 mt -68.75 -35.14 76.72 Favored 'General case' 0 N--CA 1.446 -0.653 0 CA-C-O 120.908 0.385 . . . . 0.0 110.576 178.222 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 1.5 m -62.22 -35.32 78.53 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.509 176.513 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -66.65 -43.25 85.1 Favored 'General case' 0 N--CA 1.452 -0.356 0 CA-C-N 115.998 -0.547 . . . . 0.0 110.374 178.326 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 33.3 t80 -64.14 -37.53 87.79 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.931 -0.577 . . . . 0.0 109.635 177.473 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 66.8 m -61.46 -50.94 70.75 Favored 'General case' 0 N--CA 1.445 -0.693 0 CA-C-N 115.387 -0.824 . . . . 0.0 111.397 178.012 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.95 -33.93 76.42 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.989 179.623 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . 0.572 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -72.79 -41.27 65.16 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.269 -179.866 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 1.2 tt -57.42 -39.31 75.92 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.252 179.407 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 93.7 mttt -59.23 -39.41 82.65 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.801 179.375 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 17.5 p -77.84 -14.37 59.59 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 111.985 0.365 . . . . 0.0 111.985 -178.701 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.572 HG12 ' O ' ' A' ' 65' ' ' ALA . 43.0 mm -75.29 142.75 14.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 N-CA-C 110.495 -0.187 . . . . 0.0 110.495 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 3.0 m -102.11 168.96 9.04 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.713 0.292 . . . . 0.0 110.925 179.761 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 16.4 t -82.11 122.19 36.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.294 178.809 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 83.32 25.72 46.59 Favored Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 120.61 -0.805 . . . . 0.0 111.807 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 18.9 tt0 -105.81 153.32 22.07 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 179.917 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 26.5 t -97.9 113.78 33.42 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 CA-C-O 120.866 0.365 . . . . 0.0 110.167 -179.014 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.509 HD11 HD13 ' A' ' 51' ' ' ILE . 9.3 pt -101.33 154.8 4.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.164 -179.03 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . 0.433 ' O ' ' HA ' ' A' ' 51' ' ' ILE . 10.8 t30 -119.33 104.95 10.84 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 121.151 0.5 . . . . 0.0 111.076 -173.292 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.466 HD11 HD23 ' A' ' 86' ' ' LEU . 67.1 mt -103.12 118.83 50.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 115.37 -0.832 . . . . 0.0 110.405 -177.459 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 19.6 m -95.62 115.37 27.33 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.628 -0.715 . . . . 0.0 109.664 177.368 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 82.0 p -111.15 169.75 8.57 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.42 -179.736 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -61.98 -25.55 67.69 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.088 179.257 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 8.4 tp-100 -98.51 11.85 37.0 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.171 0.51 . . . . 0.0 111.097 -176.69 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 134.44 176.11 14.21 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.315 -0.945 . . . . 0.0 113.002 176.153 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 18.1 m -105.27 120.11 40.73 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 -179.523 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 63.4 m-85 -126.57 152.16 46.96 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.759 0.314 . . . . 0.0 110.243 -179.426 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -131.49 131.15 43.23 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-O 121.299 0.571 . . . . 0.0 110.422 177.079 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.488 HD21 ' N ' ' A' ' 86' ' ' LEU . 0.9 OUTLIER -127.13 157.42 39.77 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.319 -0.855 . . . . 0.0 111.106 -173.535 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 40.0 ttmt -99.56 130.6 45.81 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.057 178.545 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 33.9 p -71.63 131.19 42.84 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 121.064 0.459 . . . . 0.0 111.036 179.548 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.442 -0.908 0 C-N-CA 120.491 -0.861 . . . . 0.0 112.322 -177.637 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.135 0 CA-C-O 121.174 0.511 . . . . 0.0 110.153 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -70.34 110.75 5.46 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.22 -171.178 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 25.4 mmt -82.84 111.02 18.36 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 173.268 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . 0.665 ' HA3' ' HB2' ' A' ' 36' ' ' SER . . . -81.28 30.22 2.75 Favored Glycine 0 C--O 1.228 -0.236 0 C-N-CA 120.814 -0.707 . . . . 0.0 113.263 -174.958 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.469 HD11 HD11 ' A' ' 29' ' ' ILE . 42.9 pt -147.69 173.29 2.16 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 -179.98 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . 0.692 ' HB2' ' HB3' ' A' ' 30' ' ' ASP . 65.7 mtt-85 -109.94 134.37 52.17 Favored 'General case' 0 C--N 1.317 -0.834 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 173.344 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.5 p -119.79 124.5 46.3 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-O 120.944 0.402 . . . . 0.0 110.72 178.353 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.487 ' HA ' HD22 ' A' ' 59' ' ' LEU . 42.3 m -145.64 163.43 34.86 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.248 -179.083 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 86.6 m-20 . . . . . 0 C--N 1.325 -0.474 0 CA-C-O 121.853 0.835 . . . . 0.0 109.061 173.474 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 25.2 t0 . . . . . 0 N--CA 1.466 0.353 0 CA-C-O 121.047 0.451 . . . . 0.0 111.164 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . 0.423 ' HA2' ' O ' ' A' ' 56' ' ' THR . . . 171.02 134.07 1.71 Allowed Glycine 0 N--CA 1.444 -0.785 0 C-N-CA 120.9 -0.667 . . . . 0.0 111.724 -179.958 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.49 HG21 ' HB ' ' A' ' 48' ' ' ILE . 19.0 m -76.3 153.94 5.89 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-O 120.69 0.281 . . . . 0.0 110.445 179.672 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 31.7 tt0 -115.8 149.51 38.42 Favored 'General case' 0 C--N 1.323 -0.579 0 C-N-CA 120.28 -0.568 . . . . 0.0 110.986 -179.371 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 68.9 mt -80.18 114.5 21.16 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-N 115.814 -0.63 . . . . 0.0 109.878 177.543 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . 0.573 ' HB3' ' HB3' ' A' ' 103' ' ' ARG . 16.2 t70 -70.39 -67.57 0.49 Allowed 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.392 0.615 . . . . 0.0 110.064 -178.95 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 6.9 p -159.14 153.9 24.63 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.109 179.804 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.785 HG21 HG21 ' A' ' 102' ' ' ILE . 95.3 t -82.24 128.63 38.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 177.95 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.404 ' HB ' ' HD2' ' A' ' 34' ' ' PRO . 27.5 m -92.16 159.14 38.08 Favored Pre-proline 0 N--CA 1.446 -0.664 0 CA-C-N 116.575 -0.284 . . . . 0.0 110.382 -178.417 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . 0.404 ' HD2' ' HB ' ' A' ' 33' ' ' VAL . 21.0 Cg_endo -62.88 106.23 0.51 Allowed 'Trans proline' 0 N--CA 1.461 -0.416 0 C-N-CA 122.271 1.981 . . . . 0.0 111.591 174.505 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 135.72 150.58 5.99 Favored Glycine 0 N--CA 1.448 -0.565 0 CA-C-N 115.905 -0.589 . . . . 0.0 112.067 -177.652 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 50.5 m 71.11 153.73 0.15 Allowed Pre-proline 0 CA--C 1.535 0.382 0 C-N-CA 123.038 0.535 . . . . 0.0 111.719 179.704 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -83.22 14.18 2.44 Favored 'Trans proline' 0 C--N 1.347 0.449 0 C-N-CA 122.95 2.434 . . . . 0.0 113.416 -176.267 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.575 ' HB2' ' O ' ' A' ' 100' ' ' MET . . . -59.79 -35.12 74.01 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.865 0.364 . . . . 0.0 111.478 -179.192 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.544 ' HB3' HG13 ' A' ' 32' ' ' VAL . 0.8 OUTLIER -65.93 -22.45 66.49 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.04 -0.527 . . . . 0.0 112.374 -175.063 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 19.8 ptpt -100.27 1.34 41.64 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.691 0.281 . . . . 0.0 110.896 179.829 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 83.6 t -110.59 -55.86 4.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 116.476 -0.329 . . . . 0.0 111.017 -178.23 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 1.2 pp -118.51 -178.81 3.62 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.395 0.617 . . . . 0.0 111.932 -177.051 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 23.3 m -119.95 134.4 23.97 Favored Pre-proline 0 C--N 1.316 -0.864 0 CA-C-N 115.084 -0.962 . . . . 0.0 109.964 -179.609 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.518 ' HB3' HG23 ' A' ' 32' ' ' VAL . 31.4 Cg_endo -65.67 145.58 81.85 Favored 'Trans proline' 0 N--CA 1.464 -0.242 0 C-N-CA 122.131 1.887 . . . . 0.0 111.738 176.553 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 97.83 11.0 51.6 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.517 -0.849 . . . . 0.0 112.917 -178.926 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 80.4 mt -98.04 164.9 12.15 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.772 0.32 . . . . 0.0 110.524 177.276 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.447 ' HB ' ' HB2' ' A' ' 80' ' ' ASP . 39.7 t -97.08 140.94 16.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 116.325 -0.398 . . . . 0.0 109.99 177.633 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.503 HG21 HG22 ' A' ' 77' ' ' ILE . 72.1 mt -103.86 115.51 45.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-O 120.839 0.352 . . . . 0.0 110.519 178.493 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 7.7 tt0 -78.98 -55.11 5.38 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.598 0.713 . . . . 0.0 110.3 177.142 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' SER . . . . . 0.58 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 8.0 p -148.15 146.65 28.84 Favored 'General case' 0 C--N 1.315 -0.908 0 CA-C-N 115.423 -0.808 . . . . 0.0 112.157 -173.023 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.476 ' HA ' ' O ' ' A' ' 76' ' ' ASN . 49.1 mt -117.29 114.91 47.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-N 114.96 -1.018 . . . . 0.0 109.225 173.577 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 7.6 t-20 61.91 -152.62 0.36 Allowed 'General case' 0 C--O 1.234 0.25 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 -171.746 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -79.57 21.45 4.5 Favored Glycine 0 CA--C 1.523 0.532 0 C-N-CA 120.307 -0.949 . . . . 0.0 112.258 175.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 61.0 mtm -123.66 106.3 32.29 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 120.805 0.336 . . . . 0.0 110.19 -178.835 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.58 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 65.1 Cg_endo -73.99 150.18 43.04 Favored 'Trans proline' 0 N--CA 1.46 -0.48 0 C-N-CA 122.133 1.889 . . . . 0.0 112.602 -179.36 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.423 ' O ' ' HA2' ' A' ' 26' ' ' GLY . 33.5 p -120.72 106.07 11.36 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.74 -178.234 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 12.6 p -96.03 -22.45 17.35 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.927 -179.723 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 27.5 p-10 -146.63 -169.41 3.27 Favored 'General case' 0 N--CA 1.447 -0.59 0 CA-C-O 121.271 0.558 . . . . 0.0 110.594 175.457 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.556 ' HG ' ' HB2' ' A' ' 106' ' ' ASN . 19.1 mt -68.43 -35.29 77.41 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.142 -0.935 . . . . 0.0 111.813 -178.683 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 7.7 m -65.77 -45.71 81.51 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.758 0.313 . . . . 0.0 111.324 -177.555 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 1.6 p -66.29 -33.38 75.6 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.137 0.494 . . . . 0.0 110.528 178.257 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 76.1 t80 -62.01 -46.8 87.61 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.311 -0.859 . . . . 0.0 110.526 174.73 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 5.3 t -63.75 -45.1 91.37 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.593 -179.458 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -66.36 -26.8 67.44 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.965 -0.562 . . . . 0.0 111.682 -177.265 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -78.68 -43.64 25.55 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.011 0.434 . . . . 0.0 110.365 176.657 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -59.66 -42.0 91.85 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.456 -0.793 . . . . 0.0 111.354 -176.506 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 15.2 ptmm? -64.97 -6.86 9.48 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 112.595 0.591 . . . . 0.0 112.595 -174.565 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 49.6 p -106.28 -14.59 15.07 Favored 'General case' 0 C--N 1.326 -0.426 0 C-N-CA 120.768 -0.373 . . . . 0.0 111.402 -179.753 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.407 HD11 HG21 ' A' ' 75' ' ' ILE . 45.0 mm -72.06 140.0 18.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 120.863 0.363 . . . . 0.0 111.23 -174.355 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' SER . . . . . 0.601 ' HB2' ' HB2' ' A' ' 73' ' ' GLU . 2.5 m -89.33 151.22 22.2 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.372 179.031 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 48.9 t -73.91 118.2 19.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 120.988 0.423 . . . . 0.0 110.055 177.327 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 93.02 9.07 61.14 Favored Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 120.605 -0.807 . . . . 0.0 111.993 -179.073 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . 0.601 ' HB2' ' HB2' ' A' ' 70' ' ' SER . 35.7 tt0 -86.45 148.75 25.41 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 120.809 0.338 . . . . 0.0 110.092 179.626 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . 0.411 ' HA ' ' HA ' ' A' ' 87' ' ' LYS . 60.1 t -92.1 113.17 26.93 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 176.919 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.407 HG21 HD11 ' A' ' 69' ' ' ILE . 27.3 pt -108.62 154.45 9.93 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-O 121.314 0.578 . . . . 0.0 111.224 -177.441 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . 0.476 ' O ' ' HA ' ' A' ' 51' ' ' ILE . 6.0 t30 -95.85 127.26 41.72 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.151 178.382 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.512 HD11 HD23 ' A' ' 86' ' ' LEU . 54.3 mt -125.26 106.31 16.16 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 CA-C-O 121.288 0.566 . . . . 0.0 109.846 176.362 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 4.3 m -78.59 102.48 7.97 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 115.32 -0.854 . . . . 0.0 109.239 178.302 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 70.7 p -94.6 167.65 11.34 Favored 'General case' 0 C--N 1.323 -0.545 0 C-N-CA 120.474 -0.49 . . . . 0.0 110.697 -178.569 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . 0.447 ' HB2' ' HB ' ' A' ' 47' ' ' VAL . 23.8 t70 -52.52 -33.38 45.0 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.267 -0.878 . . . . 0.0 111.834 -179.858 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 28.1 mt-30 -118.73 28.0 8.57 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 112.185 0.439 . . . . 0.0 112.185 -173.481 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 150.18 151.29 5.49 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.208 -0.996 . . . . 0.0 113.487 173.854 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 26.4 m -94.81 106.72 18.72 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 109.697 -0.483 . . . . 0.0 109.697 176.361 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 84.8 m-85 -114.66 158.52 21.64 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.058 0.456 . . . . 0.0 110.874 -176.395 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 17.4 p-80 -123.66 129.13 50.65 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.814 -0.63 . . . . 0.0 109.508 173.141 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.512 HD23 HD11 ' A' ' 77' ' ' ILE . 0.6 OUTLIER -134.24 156.07 49.05 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 115.989 -0.55 . . . . 0.0 111.031 -176.614 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' LYS . . . . . 0.411 ' HA ' ' HA ' ' A' ' 74' ' ' VAL . 58.8 tttm -96.35 131.59 42.73 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.675 -179.022 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 39.9 p -69.75 139.46 53.32 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-O 121.158 0.504 . . . . 0.0 111.127 178.714 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.433 -1.564 0 N-CA-C 111.146 -0.782 . . . . 0.0 111.146 176.63 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.465 0.281 0 CA-C-O 121.346 0.593 . . . . 0.0 110.712 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -96.49 112.7 24.35 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.406 -171.413 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' MET . . . . . 0.575 ' O ' ' HB2' ' A' ' 38' ' ' ALA . 1.4 pmm? -63.5 -31.09 72.15 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.701 -179.498 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 104.73 1.46 42.91 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.466 -0.873 . . . . 0.0 113.295 175.898 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.785 HG21 HG21 ' A' ' 32' ' ' VAL . 2.8 pp -130.08 148.03 33.19 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.61 0 CA-C-O 121.003 0.43 . . . . 0.0 110.771 179.55 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . 0.573 ' HB3' ' HB3' ' A' ' 30' ' ' ASP . 1.0 OUTLIER -80.73 137.93 36.29 Favored 'General case' 0 C--N 1.321 -0.638 0 N-CA-C 108.242 -1.022 . . . . 0.0 108.242 172.89 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.7 m -112.25 153.23 27.44 Favored 'General case' 0 C--N 1.31 -1.14 0 CA-C-O 120.802 0.334 . . . . 0.0 110.394 -177.491 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 23.8 p -135.67 163.92 29.06 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 115.96 -0.564 . . . . 0.0 109.976 -179.873 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . 0.556 ' HB2' ' HG ' ' A' ' 59' ' ' LEU . 65.8 t30 . . . . . 0 C--N 1.317 -0.839 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 -177.111 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 38.9 t70 . . . . . 0 N--CA 1.463 0.194 0 CA-C-O 120.99 0.424 . . . . 0.0 111.544 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . 0.546 ' HA2' ' HA ' ' A' ' 57' ' ' SER . . . 167.48 151.3 6.89 Favored Glycine 0 N--CA 1.446 -0.686 0 N-CA-C 111.247 -0.741 . . . . 0.0 111.247 -177.664 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.551 HG21 ' HB ' ' A' ' 48' ' ' ILE . 29.5 m -102.81 145.26 12.49 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-O 121.021 0.439 . . . . 0.0 110.82 -179.038 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 29.4 tt0 -115.82 150.18 37.38 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.704 -178.567 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.453 HD11 ' HB2' ' A' ' 46' ' ' LEU . 48.3 mt -76.85 107.94 8.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.011 178.003 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 22.5 t70 -62.29 -62.19 1.93 Allowed 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.551 0.691 . . . . 0.0 109.871 177.213 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 13.4 p -158.11 149.2 21.0 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.205 -0.907 . . . . 0.0 110.625 179.253 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.49 HG21 HG21 ' A' ' 102' ' ' ILE . 44.8 t -99.11 117.94 44.96 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 N-CA-C 109.519 -0.548 . . . . 0.0 109.519 177.272 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.503 ' HA ' ' HD3' ' A' ' 34' ' ' PRO . 11.9 m -80.91 117.37 67.75 Favored Pre-proline 0 N--CA 1.447 -0.594 0 CA-C-O 120.982 0.42 . . . . 0.0 110.572 -179.95 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . 0.503 ' HD3' ' HA ' ' A' ' 33' ' ' VAL . 16.7 Cg_exo -69.73 25.82 0.17 Allowed 'Trans proline' 0 N--CA 1.478 0.605 0 C-N-CA 123.918 3.079 . . . . 0.0 113.85 -174.208 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . 0.449 ' H ' ' C ' ' A' ' 33' ' ' VAL . . . -120.56 15.08 9.87 Favored Glycine 0 N--CA 1.446 -0.636 0 N-CA-C 110.645 -0.982 . . . . 0.0 110.645 174.339 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 7.5 m -139.1 177.33 2.11 Favored Pre-proline 0 C--N 1.325 -0.477 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 -177.358 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . 0.408 ' C ' ' H ' ' A' ' 39' ' ' SER . 24.8 Cg_exo -64.9 -172.86 0.22 Allowed 'Trans proline' 0 C--N 1.35 0.656 0 C-N-CA 122.255 1.97 . . . . 0.0 112.214 174.107 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.518 ' HB1' HD11 ' A' ' 86' ' ' LEU . . . 72.38 -23.25 0.2 Allowed 'General case' 0 N--CA 1.47 0.538 0 C-N-CA 123.493 0.717 . . . . 0.0 112.867 177.108 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.408 ' H ' ' C ' ' A' ' 37' ' ' PRO . 37.0 m -61.64 -29.61 70.17 Favored 'General case' 0 CA--C 1.531 0.233 0 CA-C-O 121.018 0.437 . . . . 0.0 111.842 -176.439 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 17.0 tppt? -97.06 -6.01 36.2 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.003 0.43 . . . . 0.0 110.51 -178.843 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 46.9 t -102.06 -52.69 8.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.712 -174.117 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 1.2 pp -127.49 -177.54 4.12 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-O 121.366 0.603 . . . . 0.0 112.026 -175.343 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 2.9 p -125.09 151.96 69.92 Favored Pre-proline 0 C--N 1.32 -0.696 0 CA-C-N 115.008 -0.996 . . . . 0.0 110.62 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -70.47 156.01 62.37 Favored 'Trans proline' 0 C--N 1.343 0.278 0 C-N-CA 122.404 2.069 . . . . 0.0 112.191 178.457 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 100.11 -13.36 60.35 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.606 -0.807 . . . . 0.0 112.491 -178.56 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . 0.453 ' HB2' HD11 ' A' ' 29' ' ' ILE . 91.9 mt -79.4 164.62 23.86 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.833 0.349 . . . . 0.0 110.803 179.597 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 48.4 t -105.98 135.12 45.45 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.528 -178.368 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.551 ' HB ' HG21 ' A' ' 27' ' ' VAL . 8.4 mm -88.14 100.38 10.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 175.758 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 57.1 mt-10 -78.31 -48.23 16.09 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.049 -177.624 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' SER . . . . . 0.555 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 5.4 p -159.92 145.81 15.66 Favored 'General case' 0 N--CA 1.447 -0.592 0 CA-C-O 121.203 0.525 . . . . 0.0 111.797 -176.895 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 67.9 mt -115.38 106.25 20.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-N 115.099 -0.955 . . . . 0.0 108.595 175.791 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' ASN . . . . . 0.428 ' C ' ' H ' ' A' ' 54' ' ' MET . 3.1 m-20 59.96 -152.14 0.4 Allowed 'General case' 0 C--O 1.236 0.392 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 -171.778 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -76.14 28.61 1.41 Allowed Glycine 0 CA--C 1.524 0.63 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.696 176.913 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' MET . . . . . 0.428 ' H ' ' C ' ' A' ' 52' ' ' ASN . 57.4 mtm -130.44 101.83 17.23 Favored Pre-proline 0 C--N 1.326 -0.414 0 N-CA-C 109.676 -0.49 . . . . 0.0 109.676 176.934 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.555 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 60.0 Cg_endo -72.19 150.99 54.48 Favored 'Trans proline' 0 N--CA 1.46 -0.494 0 C-N-CA 122.027 1.818 . . . . 0.0 112.306 179.972 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' THR . . . . . 0.416 ' O ' ' HA2' ' A' ' 26' ' ' GLY . 6.2 p -111.33 83.66 1.81 Allowed 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 121.242 0.544 . . . . 0.0 111.863 -177.326 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' SER . . . . . 0.546 ' HA ' ' HA2' ' A' ' 26' ' ' GLY . 20.9 m -91.11 -13.64 32.69 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.571 -0.74 . . . . 0.0 109.846 176.507 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 5.4 m120 -125.5 164.64 20.06 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.672 -0.694 . . . . 0.0 109.939 -177.877 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 41.5 mt -73.81 -31.75 63.4 Favored 'General case' 0 N--CA 1.446 -0.665 0 CA-C-O 121.516 0.674 . . . . 0.0 109.774 172.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -68.28 -40.54 81.79 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.176 -0.92 . . . . 0.0 111.734 178.891 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 12.6 p -60.9 -39.6 89.94 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.72 0.295 . . . . 0.0 110.959 175.857 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 87.3 t80 -62.04 -43.51 98.69 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-O 121.478 0.656 . . . . 0.0 109.676 175.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 61.4 m -65.1 -48.9 72.05 Favored 'General case' 0 N--CA 1.446 -0.638 0 CA-C-N 115.08 -0.964 . . . . 0.0 111.757 179.28 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.53 -32.45 73.91 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.97 -176.575 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . 0.61 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -70.5 -48.34 56.1 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.014 -0.539 . . . . 0.0 109.928 178.58 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . 0.41 ' HA ' HD23 ' A' ' 66' ' ' LEU . 4.0 mt -63.81 -35.28 80.1 Favored 'General case' 0 N--CA 1.449 -0.477 0 CA-C-N 115.451 -0.795 . . . . 0.0 111.94 -176.438 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 59.8 mtpt -70.48 -21.98 62.71 Favored 'General case' 0 C--N 1.33 -0.273 0 N-CA-C 112.115 0.413 . . . . 0.0 112.115 -178.357 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 71.6 p -90.47 -13.54 34.56 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.864 0.364 . . . . 0.0 111.425 -179.636 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.61 HG12 ' O ' ' A' ' 65' ' ' ALA . 41.8 mm -79.85 143.8 11.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.449 -0.342 . . . . 0.0 110.599 -177.758 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 3.5 m -83.72 157.13 22.27 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 176.723 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 25.1 t -74.26 119.68 22.06 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 176.239 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 91.67 21.29 34.56 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.668 -0.777 . . . . 0.0 111.523 -177.422 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 29.9 tt0 -98.91 146.46 25.96 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 179.858 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 57.5 t -98.38 110.81 26.64 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.848 0 CA-C-O 121.052 0.453 . . . . 0.0 110.473 -178.134 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.54 HG13 HD12 ' A' ' 77' ' ' ILE . 23.3 pt -103.84 163.57 3.86 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.679 179.773 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 6.3 t30 -115.9 117.07 29.14 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.782 -177.219 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.54 HD12 HG13 ' A' ' 75' ' ' ILE . 4.6 mp -113.5 118.93 59.53 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-O 121.26 0.552 . . . . 0.0 110.293 -177.301 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 32.5 m -91.93 117.17 29.55 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.39 175.796 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 71.7 p -114.35 170.89 7.97 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 110.179 -0.304 . . . . 0.0 110.179 -179.928 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 9.0 t70 -53.68 -41.75 67.2 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.931 -0.577 . . . . 0.0 112.064 179.54 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 6.7 tp-100 -109.15 31.09 5.98 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.906 0.384 . . . . 0.0 111.451 -171.487 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 140.28 176.17 14.94 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 120.133 -1.032 . . . . 0.0 113.12 173.384 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 7.0 m -117.5 123.89 47.42 Favored 'General case' 0 C--N 1.318 -0.775 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 178.802 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 66.4 m-85 -121.21 154.27 36.5 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.982 0.42 . . . . 0.0 110.726 -176.747 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 56.1 p-80 -111.3 130.88 55.53 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 108.989 -0.745 . . . . 0.0 108.989 173.185 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.518 HD11 ' HB1' ' A' ' 38' ' ' ALA . 3.8 tt -124.09 137.44 54.57 Favored 'General case' 0 C--N 1.311 -1.084 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.053 -172.634 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' LYS . . . . . 0.446 ' N ' HD23 ' A' ' 86' ' ' LEU . 78.8 tttt -102.67 111.32 23.58 Favored 'General case' 0 C--N 1.311 -1.077 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 178.154 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' THR . . . . . 0.472 HG22 HG22 ' A' ' 69' ' ' ILE . 26.4 p -59.52 142.93 51.51 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.812 -0.631 . . . . 0.0 112.616 -172.405 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.887 0 N-CA-C 111.017 -0.833 . . . . 0.0 111.017 176.824 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.461 0.123 0 CA-C-O 121.056 0.455 . . . . 0.0 112.167 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 18.6 t80 -120.98 135.55 55.19 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 178.05 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 49.6 ttm -77.35 -53.32 7.83 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.972 -178.231 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 117.31 17.07 5.84 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.162 -1.018 . . . . 0.0 113.398 176.88 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.49 HG21 HG21 ' A' ' 32' ' ' VAL . 39.0 pt -130.17 153.05 38.37 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-O 120.857 0.36 . . . . 0.0 110.67 179.342 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 42.8 mtp85 -82.01 123.36 28.83 Favored 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 108.185 -1.042 . . . . 0.0 108.185 168.191 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -113.77 148.97 35.59 Favored 'General case' 0 C--N 1.314 -0.956 0 C-N-CA 120.643 -0.423 . . . . 0.0 110.479 -177.965 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 54.0 m -155.33 160.29 40.63 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 176.917 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 86.8 m-20 . . . . . 0 C--N 1.317 -0.83 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 177.604 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 35.9 t70 . . . . . 0 N--CA 1.463 0.209 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 90.44 128.39 3.78 Favored Glycine 0 N--CA 1.443 -0.9 0 CA-C-N 115.38 -0.827 . . . . 0.0 111.696 -175.664 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.516 HG23 ' HB ' ' A' ' 48' ' ' ILE . 4.6 m -69.28 141.56 17.17 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 N-CA-C 109.605 -0.516 . . . . 0.0 109.605 178.728 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . 0.433 ' HB3' HG13 ' A' ' 47' ' ' VAL . 8.3 pt20 -125.45 152.99 44.16 Favored 'General case' 0 C--N 1.319 -0.736 0 C-N-CA 119.17 -1.012 . . . . 0.0 111.879 -178.698 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.412 HG12 HD11 ' A' ' 102' ' ' ILE . 50.1 mt -77.32 130.81 35.83 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.61 0 CA-C-N 115.23 -0.896 . . . . 0.0 110.82 -178.784 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -89.94 -50.27 6.13 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.244 174.954 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 23.6 p -161.96 166.78 25.6 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 116.587 -0.279 . . . . 0.0 110.917 -179.301 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.465 HG13 HG22 ' A' ' 102' ' ' ILE . 45.8 t -110.38 140.36 29.78 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 N-CA-C 109.365 -0.605 . . . . 0.0 109.365 174.755 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 7.1 p -60.78 140.12 93.28 Favored Pre-proline 0 CA--C 1.537 0.473 0 N-CA-C 110.317 -0.253 . . . . 0.0 110.317 179.735 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 15.7 Cg_exo -69.46 65.39 1.62 Allowed 'Trans proline' 0 C--N 1.348 0.5 0 C-N-CA 122.925 2.416 . . . . 0.0 112.173 176.175 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 165.59 -169.26 39.92 Favored Glycine 0 N--CA 1.446 -0.7 0 N-CA-C 111.34 -0.704 . . . . 0.0 111.34 -179.707 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' SER . . . . . 0.764 ' HB2' ' HD2' ' A' ' 37' ' ' PRO . 60.6 p 56.39 179.46 0.03 OUTLIER Pre-proline 0 CA--C 1.545 0.761 0 C-N-CA 123.448 0.699 . . . . 0.0 111.513 179.432 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . 0.764 ' HD2' ' HB2' ' A' ' 36' ' ' SER . 58.4 Cg_endo -73.1 -159.45 0.08 OUTLIER 'Trans proline' 0 C--N 1.349 0.586 0 C-N-CA 121.967 1.778 . . . . 0.0 111.636 169.712 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.401 ' HB3' HD12 ' A' ' 86' ' ' LEU . . . 77.36 -33.43 0.19 Allowed 'General case' 0 N--CA 1.471 0.612 0 C-N-CA 123.395 0.678 . . . . 0.0 112.321 172.712 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 35.0 t -65.15 -21.18 66.75 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.595 -0.275 . . . . 0.0 111.082 -178.884 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 61.9 mttp -99.35 -0.06 41.86 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.918 0.39 . . . . 0.0 110.378 178.273 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.491 ' HB ' HD11 ' A' ' 42' ' ' LEU . 45.9 t -105.08 -53.73 6.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.899 -175.928 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.491 HD11 ' HB ' ' A' ' 41' ' ' VAL . 5.2 mp -106.88 164.08 12.42 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.997 0.427 . . . . 0.0 110.55 -178.578 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' THR . . . . . 0.439 ' O ' ' HG ' ' A' ' 46' ' ' LEU . 40.1 m -109.42 124.46 33.81 Favored Pre-proline 0 C--N 1.319 -0.729 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.87 177.109 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo -59.36 134.48 58.99 Favored 'Trans proline' 0 N--CA 1.46 -0.468 0 C-N-CA 122.277 1.985 . . . . 0.0 111.965 177.834 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 107.93 -16.52 36.28 Favored Glycine 0 N--CA 1.446 -0.638 0 C-N-CA 120.631 -0.795 . . . . 0.0 112.976 -179.695 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . 0.439 ' HG ' ' O ' ' A' ' 43' ' ' THR . 75.6 mt -71.89 164.16 26.55 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.844 0.354 . . . . 0.0 110.642 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.433 HG13 ' HB3' ' A' ' 28' ' ' GLN . 23.1 t -107.46 142.63 19.72 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 116.194 -0.457 . . . . 0.0 109.939 179.8 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.516 ' HB ' HG23 ' A' ' 27' ' ' VAL . 10.6 mm -84.68 125.7 40.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 179.625 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -90.23 -54.05 4.19 Favored 'General case' 0 C--N 1.321 -0.674 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 176.143 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' SER . . . . . 0.461 ' CB ' ' HA ' ' A' ' 55' ' ' PRO . 20.6 m -154.44 152.63 30.37 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.419 -174.536 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.447 HG23 ' N ' ' A' ' 52' ' ' ASN . 46.3 mm -99.47 167.27 1.96 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.823 0 N-CA-C 107.64 -1.245 . . . . 0.0 107.64 171.871 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' ASN . . . . . 0.583 ' HB2' ' H ' ' A' ' 76' ' ' ASN . 54.1 t30 -50.51 103.44 0.05 Allowed 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 112.304 0.483 . . . . 0.0 112.304 -176.86 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 83.18 -15.36 34.05 Favored Glycine 0 N--CA 1.451 -0.343 0 CA-C-N 115.898 -0.592 . . . . 0.0 113.053 176.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 40.7 mtm -130.29 106.95 16.12 Favored Pre-proline 0 C--N 1.326 -0.447 0 O-C-N 122.643 -0.328 . . . . 0.0 110.87 -173.518 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.461 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 42.5 Cg_endo -68.06 148.96 76.61 Favored 'Trans proline' 0 C--N 1.343 0.242 0 C-N-CA 122.552 2.168 . . . . 0.0 112.199 -179.726 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 20.8 p -126.82 97.02 4.83 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 112.102 0.408 . . . . 0.0 112.102 -175.532 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 22.9 t -102.01 -14.18 17.26 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 121.362 0.601 . . . . 0.0 109.734 174.871 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 32.3 m-80 -124.29 167.36 14.43 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.174 -178.57 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 1.6 mt -68.99 -35.27 76.52 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.322 -0.399 . . . . 0.0 109.97 173.387 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 19.5 m -64.11 -38.8 92.36 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.219 179.472 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 3.3 p -66.98 -33.32 75.32 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 120.804 0.335 . . . . 0.0 110.887 178.566 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 55.2 t80 -71.63 -35.14 70.33 Favored 'General case' 0 C--N 1.331 -0.217 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 176.29 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 69.0 m -66.62 -50.06 64.23 Favored 'General case' 0 N--CA 1.444 -0.729 0 CA-C-N 115.365 -0.834 . . . . 0.0 111.296 178.39 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.43 -31.96 73.26 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.747 -0.661 . . . . 0.0 111.39 -178.194 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . 0.471 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -76.93 -34.61 57.65 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.161 0.505 . . . . 0.0 110.639 -179.842 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 1.5 tt -68.71 -44.18 74.45 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.892 -177.445 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 14.6 ptmm? -60.43 -23.47 64.43 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.924 -174.044 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 17.7 p -87.53 -14.15 41.08 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 112.043 0.386 . . . . 0.0 112.043 -179.869 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.471 HG12 ' O ' ' A' ' 65' ' ' ALA . 21.7 mm -85.65 136.81 22.03 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-O 120.84 0.352 . . . . 0.0 110.601 -177.87 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 50.9 m -106.92 162.49 13.78 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.669 178.762 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 79.4 t -62.01 135.22 26.83 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.249 0 O-C-N 123.436 0.46 . . . . 0.0 110.518 175.353 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 94.33 -14.94 64.32 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.873 -0.68 . . . . 0.0 112.655 176.001 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 -80.29 150.3 30.03 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.128 0.49 . . . . 0.0 110.385 -177.379 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 47.3 t -106.34 124.76 61.94 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 CA-C-N 115.67 -0.696 . . . . 0.0 109.643 179.099 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 18.3 pt -119.6 157.34 21.78 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 121.377 0.608 . . . . 0.0 111.886 -176.749 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . 0.583 ' H ' ' HB2' ' A' ' 52' ' ' ASN . 4.5 t30 -99.08 127.16 44.97 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 114.861 -1.063 . . . . 0.0 110.034 179.43 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 72.4 mt -132.36 112.64 19.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-O 121.088 0.47 . . . . 0.0 110.514 -177.471 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' THR . . . . . 0.55 ' HA ' ' HA ' ' A' ' 83' ' ' THR . 93.0 m -91.0 124.72 35.45 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.146 177.32 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 50.8 p -107.77 173.31 6.38 Favored 'General case' 0 C--N 1.319 -0.747 0 N-CA-C 109.457 -0.572 . . . . 0.0 109.457 174.703 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -63.17 -24.43 67.88 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 120.979 0.418 . . . . 0.0 111.259 -178.954 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 -106.77 16.86 23.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.444 -0.344 . . . . 0.0 111.606 -177.74 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 134.08 166.76 11.36 Favored Glycine 0 CA--C 1.516 0.123 0 C-N-CA 120.176 -1.011 . . . . 0.0 113.255 176.035 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' THR . . . . . 0.55 ' HA ' ' HA ' ' A' ' 78' ' ' THR . 35.2 m -98.07 137.83 36.27 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 120.934 0.397 . . . . 0.0 111.204 -179.709 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 74.9 m-85 -130.42 158.32 40.19 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.051 177.517 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 48.2 p-80 -112.43 130.39 56.0 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 174.401 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.401 HD12 ' HB3' ' A' ' 38' ' ' ALA . 28.4 tp -118.19 152.06 36.41 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.989 -173.01 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 60.4 tttp -119.95 123.82 44.47 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 178.152 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 25.7 p -72.62 137.48 46.14 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.325 0.583 . . . . 0.0 111.613 -177.613 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . 0.523 ' H ' ' HE1' ' A' ' 99' ' ' TYR . . . . . . . . 0 N--CA 1.448 -0.515 0 CA-C-N 115.642 -0.708 . . . . 0.0 111.797 177.123 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 -0.143 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . 0.523 ' HE1' ' H ' ' A' ' 89' ' ' GLY . 6.2 p90 -67.14 -30.48 70.48 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 114.76 -1.109 . . . . 0.0 113.631 -160.575 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 24.3 mmt 60.45 95.56 0.03 OUTLIER 'General case' 0 N--CA 1.465 0.279 0 CA-C-O 121.313 0.578 . . . . 0.0 110.501 -173.356 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -83.75 29.2 3.77 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.829 -0.701 . . . . 0.0 112.846 -175.362 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.465 HG22 HG13 ' A' ' 32' ' ' VAL . 37.4 pt -136.94 154.54 31.54 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.742 0 CA-C-O 121.066 0.46 . . . . 0.0 109.988 -179.689 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . 0.418 ' HD3' ' HA ' ' A' ' 103' ' ' ARG . 7.8 tpp180 -92.8 144.52 25.2 Favored 'General case' 0 C--N 1.315 -0.908 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 175.809 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.4 t -145.47 154.68 42.5 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-O 121.417 0.627 . . . . 0.0 111.266 178.443 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 9.3 p -128.6 171.44 12.15 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-N 114.643 -1.162 . . . . 0.0 109.884 177.838 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 59.6 t30 . . . . . 0 C--N 1.317 -0.84 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.579 -174.348 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 28.5 p-10 . . . . . 0 C--O 1.233 0.234 0 N-CA-C 112.135 0.42 . . . . 0.0 112.135 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 96.53 133.02 7.5 Favored Glycine 0 N--CA 1.446 -0.689 0 N-CA-C 111.15 -0.78 . . . . 0.0 111.15 -176.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.423 ' HA ' ' HA ' ' A' ' 106' ' ' ASN . 19.6 m -78.78 140.4 16.94 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.742 0 CA-C-O 120.98 0.419 . . . . 0.0 110.842 -176.93 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . 0.472 ' HB2' ' O ' ' A' ' 46' ' ' LEU . 2.8 pt20 -109.84 157.59 19.04 Favored 'General case' 0 C--N 1.317 -0.823 0 C-N-CA 120.22 -0.592 . . . . 0.0 109.778 175.662 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.565 HG23 HD13 ' A' ' 48' ' ' ILE . 2.2 pt -79.84 98.49 3.26 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.14 176.523 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -53.78 -55.64 24.62 Favored 'General case' 0 CA--C 1.504 -0.816 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.13 177.509 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 6.2 p -155.99 144.56 20.18 Favored 'General case' 0 N--CA 1.441 -0.908 0 CA-C-N 115.045 -0.979 . . . . 0.0 111.438 -178.152 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.623 HG23 HG23 ' A' ' 102' ' ' ILE . 52.3 t -87.62 141.34 14.46 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.01 0 CA-C-N 114.965 -1.016 . . . . 0.0 108.664 171.651 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.57 HG21 ' HH ' ' A' ' 99' ' ' TYR . 48.3 t -83.18 105.38 5.12 Favored Pre-proline 0 C--N 1.322 -0.592 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 174.937 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . 0.51 ' HD3' ' O ' ' A' ' 32' ' ' VAL . 31.5 Cg_exo -58.19 113.64 1.62 Allowed 'Trans proline' 0 C--O 1.236 0.406 0 C-N-CA 122.774 2.316 . . . . 0.0 112.179 -175.305 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 133.61 -20.84 4.08 Favored Glycine 0 N--CA 1.446 -0.687 0 N-CA-C 111.227 -0.749 . . . . 0.0 111.227 -178.455 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 56.4 p -81.87 161.13 61.89 Favored Pre-proline 0 C--N 1.323 -0.575 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 177.692 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -59.03 -24.83 75.31 Favored 'Trans proline' 0 C--N 1.344 0.312 0 C-N-CA 122.36 2.04 . . . . 0.0 111.743 175.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -66.78 -27.86 67.93 Favored 'General case' 0 N--CA 1.454 -0.24 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.553 -179.359 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.52 ' HA ' HG11 ' A' ' 32' ' ' VAL . 13.2 m -63.2 -22.39 66.84 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.91 0.386 . . . . 0.0 111.454 -177.65 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 65.3 mttm -97.27 -17.58 19.72 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.487 -175.76 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.634 ' HB ' HD21 ' A' ' 42' ' ' LEU . 60.6 t -98.23 -49.52 11.68 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.871 -172.354 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.634 HD21 ' HB ' ' A' ' 41' ' ' VAL . 0.3 OUTLIER -117.12 178.23 4.43 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.561 0.696 . . . . 0.0 112.343 -173.745 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 56.8 m -128.42 128.99 23.6 Favored Pre-proline 0 C--N 1.322 -0.602 0 CA-C-N 114.693 -1.14 . . . . 0.0 109.593 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -64.66 152.95 79.96 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.611 2.207 . . . . 0.0 112.305 -177.643 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 99.82 -1.92 56.85 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.553 -0.832 . . . . 0.0 112.582 -178.024 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . 0.482 ' HB2' HD13 ' A' ' 29' ' ' ILE . 85.1 mt -89.81 164.15 14.75 Favored 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 110.286 -0.264 . . . . 0.0 110.286 177.271 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 40.4 t -103.27 141.1 19.77 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 178.005 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.565 HD13 HG23 ' A' ' 29' ' ' ILE . 57.5 mt -99.76 120.23 48.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 121.051 0.453 . . . . 0.0 110.0 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 14.5 tt0 -78.81 -56.23 4.57 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 121.489 0.661 . . . . 0.0 109.834 176.781 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' SER . . . . . 0.656 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 11.8 p -146.89 149.15 32.68 Favored 'General case' 0 N--CA 1.444 -0.741 0 CA-C-N 115.342 -0.844 . . . . 0.0 112.551 -171.001 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.54 ' HA ' ' O ' ' A' ' 76' ' ' ASN . 55.4 mt -126.7 114.03 35.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 114.561 -1.2 . . . . 0.0 108.573 172.751 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 6.4 t-20 63.13 -152.65 0.33 Allowed 'General case' 0 CA--C 1.532 0.278 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 -171.01 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -76.84 3.61 55.82 Favored Glycine 0 CA--C 1.52 0.392 0 C-N-CA 120.533 -0.841 . . . . 0.0 112.97 179.509 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 3.8 mpp? -111.76 105.39 56.59 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 120.725 0.298 . . . . 0.0 110.76 -178.894 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.656 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 47.0 Cg_endo -69.3 148.57 68.35 Favored 'Trans proline' 0 N--CA 1.462 -0.362 0 C-N-CA 122.303 2.002 . . . . 0.0 112.186 176.243 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 20.8 p -109.96 95.71 5.77 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.663 -176.484 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 14.7 p -92.85 -19.87 21.26 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.059 0.457 . . . . 0.0 110.738 177.367 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 14.2 m120 -125.56 173.52 8.89 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 178.153 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -82.48 -33.53 28.35 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 121.225 0.536 . . . . 0.0 110.257 176.683 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 6.1 m -70.08 -29.54 66.55 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.043 179.344 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 24.6 p -67.82 -38.5 83.32 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 121.136 0.493 . . . . 0.0 109.999 176.34 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 67.2 t80 -59.26 -44.15 92.41 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-N 115.437 -0.801 . . . . 0.0 109.709 173.475 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' SER . . . . . 0.415 ' O ' ' HG3' ' A' ' 67' ' ' LYS . 70.3 m -63.71 -46.09 87.03 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.135 -0.938 . . . . 0.0 111.832 179.314 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.85 -33.68 74.62 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.118 179.652 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . 0.41 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -77.77 -36.17 50.83 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.147 0.499 . . . . 0.0 110.194 178.586 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -60.61 -29.91 69.52 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.139 179.124 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . 0.415 ' HG3' ' O ' ' A' ' 63' ' ' SER . 58.7 mtpt -58.79 -32.46 69.34 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.448 178.63 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 34.8 p -91.06 -14.71 30.8 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 112.216 0.45 . . . . 0.0 112.216 -175.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.41 HG12 ' O ' ' A' ' 65' ' ' ALA . 30.5 mm -82.26 140.53 16.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 N-CA-C 110.283 -0.266 . . . . 0.0 110.283 -177.695 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 14.3 t -115.64 178.04 4.45 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 120.958 0.409 . . . . 0.0 110.849 -179.575 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 20.9 t -79.99 120.78 32.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.858 -178.105 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 98.17 5.65 57.12 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.645 -0.788 . . . . 0.0 111.879 -179.815 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 15.2 tp10 -81.36 147.98 29.57 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.301 -0.45 . . . . 0.0 109.913 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 57.3 t -109.38 108.95 26.61 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.856 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.37 179.252 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.454 HD12 ' HE1' ' A' ' 100' ' ' MET . 21.6 pt -109.84 153.84 11.5 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.773 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.193 -175.375 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . 0.54 ' O ' ' HA ' ' A' ' 51' ' ' ILE . 5.4 t30 -90.07 132.16 35.55 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.647 177.633 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.43 HG23 HG23 ' A' ' 79' ' ' THR . 61.7 mt -128.53 116.5 41.83 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-O 121.295 0.569 . . . . 0.0 110.465 -179.645 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 4.6 m -99.3 102.25 13.81 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.141 177.783 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.457 HG21 HG12 ' A' ' 48' ' ' ILE . 73.4 p -102.16 170.15 8.28 Favored 'General case' 0 C--N 1.324 -0.519 0 C-N-CA 120.674 -0.41 . . . . 0.0 110.296 178.081 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -51.07 -38.76 53.55 Favored 'General case' 0 N--CA 1.466 0.365 0 O-C-N 123.801 0.688 . . . . 0.0 112.649 -176.279 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 31.4 mt-30 -127.44 20.25 6.74 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 111.92 0.341 . . . . 0.0 111.92 -174.659 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -165.68 119.96 0.9 Allowed Glycine 0 N--CA 1.446 -0.653 0 C-N-CA 119.751 -1.214 . . . . 0.0 113.465 179.04 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 13.6 m -106.3 109.21 21.07 Favored 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 172.479 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . 0.438 ' CZ ' ' HB3' ' A' ' 42' ' ' LEU . 7.3 p90 -145.68 177.46 8.87 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 121.225 0.536 . . . . 0.0 111.807 -172.972 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 1.0 OUTLIER -111.9 150.82 29.93 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.388 -0.823 . . . . 0.0 109.756 172.055 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.425 HD23 ' HG3' ' A' ' 100' ' ' MET . 7.5 tt -134.11 141.39 47.11 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-O 121.218 0.533 . . . . 0.0 110.706 -176.81 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 82.3 tttt -94.21 116.38 28.77 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.044 -0.98 . . . . 0.0 109.275 177.51 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 32.1 p -59.25 123.49 16.87 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.584 0.707 . . . . 0.0 111.414 -176.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.434 -1.453 0 CA-C-N 114.991 -1.004 . . . . 0.0 111.403 -178.363 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.455 -0.186 0 CA-C-O 120.837 0.351 . . . . 0.0 110.565 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . 0.57 ' HH ' HG21 ' A' ' 33' ' ' VAL . 69.8 t80 -110.88 -23.84 10.76 Favored 'General case' 0 C--N 1.323 -0.559 0 C-N-CA 120.746 -0.382 . . . . 0.0 110.465 -178.21 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' MET . . . . . 0.454 ' HE1' HD12 ' A' ' 75' ' ' ILE . 44.3 ttm 70.63 -59.96 0.51 Allowed 'General case' 0 N--CA 1.468 0.455 0 CA-C-N 115.551 -0.749 . . . . 0.0 111.184 179.46 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 124.21 9.31 5.63 Favored Glycine 0 C--O 1.227 -0.326 0 C-N-CA 121.023 -0.608 . . . . 0.0 113.11 178.259 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.623 HG23 HG23 ' A' ' 32' ' ' VAL . 2.8 pp -136.97 165.71 27.4 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-O 120.909 0.385 . . . . 0.0 110.51 -179.028 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . 0.414 ' HD3' ' HA ' ' A' ' 103' ' ' ARG . 9.1 mmt180 -114.63 129.63 56.7 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.12 172.023 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 104' ' ' THR . . . . . 0.577 HG22 HD12 ' A' ' 102' ' ' ILE . 3.1 p -110.05 143.19 40.43 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.007 0.432 . . . . 0.0 111.724 -177.836 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 18.0 m -151.24 151.11 31.4 Favored 'General case' 0 C--N 1.318 -0.765 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 173.487 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . 0.423 ' HA ' ' HA ' ' A' ' 27' ' ' VAL . 13.4 m120 . . . . . 0 C--N 1.317 -0.845 0 CA-C-O 121.653 0.74 . . . . 0.0 109.845 -178.203 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 . . . . . 0 N--CA 1.466 0.337 0 CA-C-O 120.79 0.328 . . . . 0.0 110.941 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . 0.56 ' HA2' ' HA ' ' A' ' 57' ' ' SER . . . 106.81 176.1 23.01 Favored Glycine 0 N--CA 1.443 -0.86 0 N-CA-C 111.208 -0.757 . . . . 0.0 111.208 -175.271 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.525 HG22 ' HB ' ' A' ' 48' ' ' ILE . 19.6 m -102.06 131.08 50.79 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.812 0 CA-C-O 121.393 0.616 . . . . 0.0 110.978 177.717 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 36.4 tp60 -97.04 135.04 39.6 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.456 -0.793 . . . . 0.0 110.557 -178.8 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.536 HD11 ' HB2' ' A' ' 46' ' ' LEU . 57.8 mt -78.59 112.56 16.76 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.546 176.441 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -74.12 -69.22 0.46 Allowed 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.932 -176.921 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 9.6 p -149.49 148.97 30.04 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.434 -177.05 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.554 HG11 HG22 ' A' ' 102' ' ' ILE . 57.4 t -96.07 114.07 31.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-N 115.642 -0.708 . . . . 0.0 109.773 176.915 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 47.0 t -98.2 128.1 34.51 Favored Pre-proline 0 C--N 1.318 -0.779 0 CA-C-N 116.062 -0.517 . . . . 0.0 109.998 -176.403 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo -63.59 86.25 0.13 Allowed 'Trans proline' 0 C--O 1.234 0.32 0 C-N-CA 122.748 2.299 . . . . 0.0 112.494 -179.923 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -151.48 20.08 0.92 Allowed Glycine 0 N--CA 1.446 -0.643 0 CA-C-N 115.529 -0.76 . . . . 0.0 111.455 177.574 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' SER . . . . . 0.436 ' HB2' ' HD2' ' A' ' 37' ' ' PRO . 67.8 p -174.9 160.97 2.43 Favored Pre-proline 0 C--N 1.328 -0.36 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 -178.525 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . 0.436 ' HD2' ' HB2' ' A' ' 36' ' ' SER . 29.4 Cg_endo -63.65 -5.21 8.29 Favored 'Trans proline' 0 CA--C 1.532 0.405 0 C-N-CA 122.581 2.187 . . . . 0.0 112.631 179.075 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -67.95 -23.59 65.08 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.619 -0.264 . . . . 0.0 111.066 -179.862 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' SER . . . . . 0.506 ' HA ' HG13 ' A' ' 32' ' ' VAL . 26.7 m -65.07 -24.87 67.58 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.188 0.518 . . . . 0.0 111.427 -178.687 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 1.6 tmtp? -88.14 -26.76 22.29 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.519 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . 0.518 ' HB ' HD12 ' A' ' 42' ' ' LEU . 46.3 t -92.17 -49.92 12.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.8 -173.217 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.518 HD12 ' HB ' ' A' ' 41' ' ' VAL . 6.6 mp -95.38 168.38 10.75 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.329 0.585 . . . . 0.0 111.638 -172.956 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -133.01 144.03 51.06 Favored Pre-proline 0 C--N 1.322 -0.622 0 CA-C-N 115.204 -0.907 . . . . 0.0 109.861 176.418 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 78.8 Cg_endo -78.69 155.21 27.3 Favored 'Trans proline' 0 N--CA 1.463 -0.316 0 C-N-CA 122.721 2.281 . . . . 0.0 113.389 -176.0 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 94.08 20.99 29.0 Favored Glycine 0 N--CA 1.448 -0.528 0 C-N-CA 120.619 -0.801 . . . . 0.0 113.273 177.646 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . 0.536 ' HB2' HD11 ' A' ' 29' ' ' ILE . 44.1 mt -108.33 164.26 12.47 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 117.028 0.414 . . . . 0.0 110.928 -179.226 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 61.5 t -108.42 135.14 48.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.096 177.599 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.525 ' HB ' HG22 ' A' ' 27' ' ' VAL . 64.1 mt -96.29 124.63 49.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-O 120.964 0.411 . . . . 0.0 110.837 -179.594 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -84.51 -50.57 7.61 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.049 178.099 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' SER . . . . . 0.604 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 24.2 p -149.17 152.21 35.66 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.919 -0.582 . . . . 0.0 112.234 -175.126 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 45.7 mm -111.98 98.99 7.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 114.954 -1.021 . . . . 0.0 110.489 177.05 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' ASN . . . . . 0.461 ' HA ' ' HB3' ' A' ' 76' ' ' ASN . 6.8 t-20 57.72 41.7 24.84 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-N 115.336 -0.847 . . . . 0.0 111.823 172.867 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 104.99 -30.23 10.36 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.641 176.539 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 72.0 mtm -97.53 112.25 60.76 Favored Pre-proline 0 C--N 1.326 -0.422 0 N-CA-C 109.673 -0.491 . . . . 0.0 109.673 178.308 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.604 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 56.0 Cg_endo -69.67 139.48 40.65 Favored 'Trans proline' 0 N--CA 1.459 -0.537 0 C-N-CA 122.26 1.974 . . . . 0.0 112.794 -175.743 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 31.3 p -113.57 83.27 1.82 Allowed 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.346 0.593 . . . . 0.0 111.149 -178.518 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' SER . . . . . 0.56 ' HA ' ' HA2' ' A' ' 26' ' ' GLY . 48.0 t -91.88 -13.97 30.44 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.419 179.616 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 81.8 m-20 -129.16 -179.85 5.36 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 109.195 -0.669 . . . . 0.0 109.195 -178.674 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.415 HD21 ' HA ' ' A' ' 59' ' ' LEU . 17.5 mt -75.93 -45.42 35.25 Favored 'General case' 0 N--CA 1.447 -0.602 0 CA-C-O 120.793 0.33 . . . . 0.0 110.902 175.104 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 6.9 m -61.62 -36.47 80.84 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.42 -177.552 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 19.3 p -64.5 -37.3 87.08 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.133 0.492 . . . . 0.0 110.498 176.217 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 70.7 t80 -70.43 -39.19 74.52 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.69 -0.686 . . . . 0.0 109.504 179.285 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 61.3 m -62.29 -48.53 79.46 Favored 'General case' 0 N--CA 1.444 -0.732 0 CA-C-N 115.314 -0.857 . . . . 0.0 111.666 176.894 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.62 -34.42 75.63 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.987 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -74.01 -44.35 54.81 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.965 -0.562 . . . . 0.0 110.425 179.239 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -61.9 -35.95 79.88 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.454 -176.738 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -55.86 -34.71 65.71 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.929 -176.807 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 71.3 p -78.94 -14.24 59.33 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.722 0.296 . . . . 0.0 111.719 -177.574 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.479 HD12 HG23 ' A' ' 75' ' ' ILE . 29.0 mm -81.04 126.74 39.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.903 0.382 . . . . 0.0 111.024 -175.826 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 20.2 m -120.1 -171.8 2.22 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.961 -176.792 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 40.2 t -74.2 139.81 18.67 Favored 'Isoleucine or valine' 0 C--O 1.233 0.218 0 N-CA-C 110.145 -0.317 . . . . 0.0 110.145 176.907 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 69.02 32.05 72.86 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.596 -0.811 . . . . 0.0 111.493 179.382 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 9.6 tp10 -104.84 147.9 27.24 Favored 'General case' 0 N--CA 1.444 -0.746 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 -178.77 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 44.4 t -110.1 106.9 21.61 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 N-CA-C 109.492 -0.559 . . . . 0.0 109.492 -179.131 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . 0.479 HG23 HD12 ' A' ' 69' ' ' ILE . 30.5 pt -95.62 154.52 3.46 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.884 -177.2 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . 0.461 ' HB3' ' HA ' ' A' ' 52' ' ' ASN . 64.5 t30 -122.91 108.51 13.05 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.025 -176.797 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . 0.496 HG22 HG21 ' A' ' 48' ' ' ILE . 60.4 mt -106.8 110.75 32.78 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.968 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.501 -175.131 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' THR . . . . . 0.684 ' HG1' HG21 ' A' ' 83' ' ' THR . 25.5 m -89.29 113.89 25.21 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.471 177.144 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' THR . . . . . 0.442 HG23 HG23 ' A' ' 77' ' ' ILE . 71.3 p -120.45 -178.54 3.72 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 121.06 0.457 . . . . 0.0 111.312 -176.323 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -62.81 -26.5 68.77 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.379 -0.828 . . . . 0.0 111.069 173.678 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 26.9 mm-40 -93.55 9.32 37.22 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.04 0.448 . . . . 0.0 111.351 179.758 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 114.95 -177.75 17.53 Favored Glycine 0 N--CA 1.444 -0.782 0 C-N-CA 120.624 -0.798 . . . . 0.0 112.637 176.625 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' THR . . . . . 0.684 HG21 ' HG1' ' A' ' 78' ' ' THR . 10.6 m -97.93 113.47 25.32 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.798 -0.201 . . . . 0.0 110.727 -178.096 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 46.1 m-85 -111.75 148.06 34.31 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 110.18 -0.304 . . . . 0.0 110.18 179.389 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 25.7 p-80 -122.95 125.42 45.27 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-O 120.871 0.367 . . . . 0.0 110.018 175.498 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.47 HD22 HD13 ' A' ' 77' ' ' ILE . 0.7 OUTLIER -130.89 156.99 44.12 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.849 -176.059 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 19.5 ptmt -99.77 146.58 26.4 Favored 'General case' 0 N--CA 1.442 -0.834 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.211 179.206 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 33.3 p -83.92 128.39 34.51 Favored 'General case' 0 C--N 1.315 -0.915 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.732 175.857 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.833 0 C-N-CA 120.936 -0.65 . . . . 0.0 112.207 -178.811 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.469 0.525 0 N-CA-C 112.124 0.416 . . . . 0.0 112.124 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 4.5 t80 -88.24 -55.8 3.59 Favored 'General case' 0 C--N 1.327 -0.412 0 C-N-CA 120.266 -0.574 . . . . 0.0 110.491 178.122 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' MET . . . . . 0.484 ' HE2' HD12 ' A' ' 102' ' ' ILE . 25.2 ttt 59.01 94.74 0.03 OUTLIER 'General case' 0 N--CA 1.468 0.44 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.929 178.784 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -84.44 38.49 2.9 Favored Glycine 0 C--O 1.225 -0.453 0 CA-C-N 115.92 -0.582 . . . . 0.0 114.316 -172.007 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.554 HG22 HG11 ' A' ' 32' ' ' VAL . 2.1 pp -137.92 140.99 39.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 172.43 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . 0.595 ' NE ' ' HA ' ' A' ' 103' ' ' ARG . 0.0 OUTLIER -101.42 141.56 34.11 Favored 'General case' 0 C--N 1.317 -0.838 0 C-N-CA 120.706 -0.398 . . . . 0.0 110.307 -177.067 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.5 p -127.48 151.43 48.86 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.577 -177.847 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 20.0 m -151.26 154.49 36.89 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 174.388 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 37.2 p30 . . . . . 0 C--N 1.32 -0.702 0 CA-C-O 120.574 0.226 . . . . 0.0 111.345 -176.38 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.401 ' OD1' ' HA ' ' A' ' 58' ' ' ASN . 0.0 OUTLIER . . . . . 0 N--CA 1.452 -0.367 0 CA-C-O 120.769 0.318 . . . . 0.0 111.233 . . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 93.74 157.82 33.42 Favored Glycine 0 N--CA 1.444 -0.785 0 C-N-CA 120.93 -0.653 . . . . 0.0 111.485 -178.352 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' VAL . . . . . 0.547 HG22 ' HB ' ' A' ' 48' ' ' ILE . 3.8 m -105.27 118.93 53.59 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.713 0 CA-C-O 121.704 0.764 . . . . 0.0 110.844 -179.164 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 34.8 tp60 -103.69 136.0 44.21 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.271 -0.877 . . . . 0.0 110.841 -177.09 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' ILE . . . . . 0.486 HD11 HD11 ' A' ' 48' ' ' ILE . 42.3 mm -68.98 113.16 4.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.14 175.543 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 24.5 t70 -76.01 -63.53 1.29 Allowed 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 115.749 -0.659 . . . . 0.0 109.623 176.759 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 45.3 t -150.69 150.26 30.85 Favored 'General case' 0 N--CA 1.446 -0.654 0 CA-C-N 115.372 -0.831 . . . . 0.0 111.063 -179.571 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' VAL . . . . . 0.574 HG21 HG21 ' A' ' 102' ' ' ILE . 64.0 t -96.36 112.8 29.25 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.946 0 CA-C-N 114.95 -1.023 . . . . 0.0 109.123 174.577 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.443 ' HA ' ' HD3' ' A' ' 34' ' ' PRO . 19.5 m -83.33 127.12 69.89 Favored Pre-proline 0 C--N 1.324 -0.526 0 CA-C-O 121.065 0.46 . . . . 0.0 111.261 -176.247 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' PRO . . . . . 0.443 ' HD3' ' HA ' ' A' ' 33' ' ' VAL . 21.3 Cg_exo -66.1 146.46 81.98 Favored 'Trans proline' 0 C--O 1.237 0.429 0 C-N-CA 122.982 2.455 . . . . 0.0 112.058 178.288 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 114.24 -25.85 10.24 Favored Glycine 0 N--CA 1.45 -0.393 0 N-CA-C 111.507 -0.637 . . . . 0.0 111.507 -178.302 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 50.4 m -101.77 159.2 30.12 Favored Pre-proline 0 C--N 1.319 -0.721 0 CA-C-N 115.442 -0.379 . . . . 0.0 110.331 178.85 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_exo -60.19 -20.18 60.62 Favored 'Trans proline' 0 C--N 1.347 0.487 0 C-N-CA 123.057 2.505 . . . . 0.0 112.958 -178.102 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -66.15 -25.84 67.15 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.973 -176.808 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 13.4 m -63.2 -22.95 67.2 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.365 -0.38 . . . . 0.0 111.738 -176.224 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 57.4 tttm -110.11 11.53 23.77 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.907 0.384 . . . . 0.0 110.514 -176.465 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 96.5 t -120.73 -55.25 3.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 120.761 0.315 . . . . 0.0 111.275 -177.063 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 97.7 mt -107.69 167.19 10.13 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.083 0.468 . . . . 0.0 111.434 -174.142 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 20.1 p -113.9 148.06 39.09 Favored Pre-proline 0 N--CA 1.446 -0.663 0 CA-C-N 115.323 -0.853 . . . . 0.0 109.626 175.839 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_exo -74.79 141.1 26.89 Favored 'Trans proline' 0 N--CA 1.458 -0.565 0 C-N-CA 122.285 1.99 . . . . 0.0 111.926 -178.054 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 105.36 -2.21 40.06 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.626 -0.797 . . . . 0.0 113.056 179.916 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . 0.435 HD23 ' HB3' ' A' ' 80' ' ' ASP . 72.7 mt -78.65 164.8 24.32 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.257 0.551 . . . . 0.0 111.556 -178.849 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 61.8 t -109.51 138.64 36.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 115.801 -0.636 . . . . 0.0 109.378 174.63 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' ILE . . . . . 0.547 ' HB ' HG22 ' A' ' 27' ' ' VAL . 88.4 mt -94.68 111.84 26.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 120.971 0.415 . . . . 0.0 110.03 177.968 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -75.07 -51.4 13.6 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.484 -178.717 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' SER . . . . . 0.569 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 31.5 p -156.61 156.91 34.35 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.76 -0.655 . . . . 0.0 112.29 -174.912 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . 0.469 HG23 ' H ' ' A' ' 52' ' ' ASN . 9.0 mm -100.07 -171.37 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 173.649 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' ASN . . . . . 0.469 ' H ' HG23 ' A' ' 51' ' ' ILE . 1.7 m-20 -48.72 92.99 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 123.039 0.536 . . . . 0.0 112.089 178.869 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 72.19 -10.07 4.96 Favored Glycine 0 CA--C 1.521 0.461 0 C-N-CA 121.384 -0.436 . . . . 0.0 113.787 175.517 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 71.0 mtm -125.71 112.69 25.02 Favored Pre-proline 0 C--N 1.327 -0.403 0 CA-C-N 117.147 0.474 . . . . 0.0 110.863 -175.882 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . 0.569 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 4.4 Cg_exo -78.65 137.44 14.42 Favored 'Trans proline' 0 N--CA 1.46 -0.488 0 C-N-CA 122.897 2.398 . . . . 0.0 111.661 175.97 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 40.1 p -121.48 116.76 25.31 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.909 0.385 . . . . 0.0 111.77 -178.857 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 30.7 t -86.57 -53.4 4.99 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.32 174.106 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' ASN . . . . . 0.401 ' HA ' ' OD1' ' A' ' 25' ' ' ASP . 15.5 m120 -86.24 157.11 20.03 Favored 'General case' 0 C--N 1.318 -0.762 0 C-N-CA 120.228 -0.589 . . . . 0.0 109.629 -169.799 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' LEU . . . . . 0.56 ' HG ' ' HB2' ' A' ' 106' ' ' ASN . 3.4 mt -65.11 -38.55 91.04 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.1 0.476 . . . . 0.0 110.4 177.992 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 3.3 m -64.44 -38.38 90.84 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.826 -0.624 . . . . 0.0 111.109 179.432 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 11.9 p -71.48 -32.1 67.88 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.958 0.408 . . . . 0.0 110.565 177.733 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 72.2 t80 -65.51 -44.34 87.28 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.893 -0.594 . . . . 0.0 109.789 175.467 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 7.9 t -63.17 -37.52 87.55 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.03 178.062 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.04 -33.07 74.92 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.015 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . 0.495 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -76.9 -40.03 48.83 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.256 0.55 . . . . 0.0 110.204 176.858 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' LEU . . . . . 0.426 HD23 ' SD ' ' A' ' 100' ' ' MET . 0.4 OUTLIER -60.5 -38.06 83.1 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.61 -0.723 . . . . 0.0 111.406 179.444 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -74.24 -6.43 47.87 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.996 -0.547 . . . . 0.0 112.301 -177.614 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 22.5 p -100.4 -12.61 19.25 Favored 'General case' 0 C--N 1.324 -0.541 0 C-N-CA 120.754 -0.379 . . . . 0.0 110.841 174.142 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.495 HG12 ' O ' ' A' ' 65' ' ' ALA . 47.2 mm -80.33 135.62 24.98 Favored 'Isoleucine or valine' 0 C--O 1.234 0.275 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.872 -178.667 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 1.4 m -83.03 165.7 19.4 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.345 -177.027 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 32.5 t -76.75 124.12 34.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.595 174.404 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 79.73 25.62 58.01 Favored Glycine 0 N--CA 1.446 -0.65 0 C-N-CA 120.314 -0.946 . . . . 0.0 111.178 -176.573 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 8.1 tp10 -85.6 147.81 26.22 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 178.423 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 56.9 t -104.61 98.56 6.98 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.978 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 176.05 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 26.0 pt -91.18 164.69 2.07 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.779 0 CA-C-O 121.388 0.613 . . . . 0.0 111.506 -173.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 33.2 t30 -116.06 115.88 26.89 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 115.158 -0.928 . . . . 0.0 109.615 -178.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 24.1 mt -120.61 107.74 21.35 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.315 -175.533 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' THR . . . . . 0.453 ' HA ' ' HA ' ' A' ' 83' ' ' THR . 30.6 m -80.78 118.37 22.25 Favored 'General case' 0 C--N 1.317 -0.807 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 173.381 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 72.6 p -119.81 -173.38 2.53 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.319 0.58 . . . . 0.0 111.891 -173.431 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' ASP . . . . . 0.435 ' HB3' HD23 ' A' ' 46' ' ' LEU . 20.8 t70 -56.71 -36.13 69.32 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 114.713 -1.13 . . . . 0.0 111.44 176.412 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 24.8 mt-30 -93.73 7.6 44.19 Favored 'General case' 0 C--O 1.235 0.295 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.342 -177.259 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 112.67 -169.35 12.97 Favored Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.655 177.779 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' THR . . . . . 0.453 ' HA ' ' HA ' ' A' ' 78' ' ' THR . 9.2 m -77.84 127.16 31.96 Favored 'General case' 0 C--N 1.321 -0.652 0 C-N-CA 122.559 0.344 . . . . 0.0 111.636 -177.973 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 97.7 m-85 -132.11 158.44 41.63 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.898 0.38 . . . . 0.0 110.108 174.69 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 33.1 m-70 -118.51 137.62 53.08 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 176.513 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' LEU . . . . . 0.473 HD21 ' N ' ' A' ' 87' ' ' LYS . 1.6 tt -135.41 138.9 43.72 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-O 120.884 0.373 . . . . 0.0 110.571 -173.237 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' LYS . . . . . 0.473 ' N ' HD21 ' A' ' 86' ' ' LEU . 38.6 ttpt -95.97 123.07 39.41 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 116.09 -0.505 . . . . 0.0 109.963 177.706 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' THR . . . . . 0.473 HG23 HG21 ' A' ' 69' ' ' ILE . 41.1 p -69.4 142.49 53.89 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.902 -0.59 . . . . 0.0 112.033 -174.974 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.823 0 CA-C-N 115.692 -0.686 . . . . 0.0 112.833 -178.367 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' ALA . . . . . 0.44 ' HB1' ' HB ' ' A' ' 88' ' ' THR . . . . . . . . 0 C--O 1.232 0.181 0 N-CA-C 111.945 0.35 . . . . 0.0 111.945 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 35.3 t80 -117.4 -15.67 10.31 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.759 -179.501 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' MET . . . . . 0.426 ' SD ' HD23 ' A' ' 66' ' ' LEU . 82.7 mtp 58.43 -153.97 0.37 Allowed 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.751 -176.858 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -155.53 32.05 0.63 Allowed Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.259 -0.972 . . . . 0.0 112.904 -179.778 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 102' ' ' ILE . . . . . 0.574 HG21 HG21 ' A' ' 32' ' ' VAL . 2.8 pp -144.21 166.26 12.92 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 178.871 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 38.0 mmt180 -108.49 132.49 53.76 Favored 'General case' 0 C--N 1.317 -0.825 0 N-CA-C 109.278 -0.638 . . . . 0.0 109.278 176.201 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -110.76 132.35 54.27 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 121.335 0.588 . . . . 0.0 111.917 -177.962 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 42.3 m -109.89 165.69 11.51 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.235 -0.893 . . . . 0.0 109.799 175.163 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 106' ' ' ASN . . . . . 0.56 ' HB2' ' HG ' ' A' ' 59' ' ' LEU . 2.2 t-20 . . . . . 0 C--N 1.313 -1.011 0 CA-C-O 122.013 0.911 . . . . 0.0 108.582 179.713 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . . . . . . . . . 27.2 mp0 . . . . . 0 N--CA 1.453 -0.325 0 CA-C-O 120.764 0.316 . . . . 0.0 110.701 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.445 ' HB2' HD21 ' A' ' 58' ' ' ASN . 7.4 Cg_exo -72.72 128.3 13.23 Favored 'Trans proline' 0 N--CA 1.461 -0.429 0 C-N-CA 122.604 2.203 . . . . 0.0 110.168 171.812 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 19.1 t70 -147.88 29.18 0.91 Allowed 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.759 0.79 . . . . 0.0 110.395 -171.479 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 115.64 148.89 9.38 Favored Glycine 0 N--CA 1.446 -0.686 0 CA-C-N 115.344 -0.844 . . . . 0.0 111.36 -177.982 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.545 HG23 ' HB ' ' A' ' 48' ' ' ILE . 17.7 m -102.59 129.73 53.68 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 CA-C-O 121.195 0.522 . . . . 0.0 110.511 178.102 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . 0.414 ' HG3' ' O ' ' A' ' 46' ' ' LEU . 61.8 tt0 -110.66 149.73 30.02 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 121.187 0.517 . . . . 0.0 111.298 -175.941 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.487 HG23 HD13 ' A' ' 102' ' ' ILE . 74.3 mt -82.31 117.85 29.0 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 115.361 -0.836 . . . . 0.0 109.93 177.741 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.557 ' HB3' ' HB3' ' A' ' 103' ' ' ARG . 12.6 t70 -79.13 -65.1 1.04 Allowed 'General case' 0 C--N 1.317 -0.837 0 CA-C-N 116.235 -0.439 . . . . 0.0 109.84 178.912 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 5.5 p -150.06 156.53 41.85 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.91 -0.586 . . . . 0.0 111.31 -177.087 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.5 ' CG1' ' HA ' ' A' ' 39' ' ' SER . 56.2 t -116.18 113.73 44.03 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.229 -177.712 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 30.3 m -105.71 153.46 39.94 Favored Pre-proline 0 N--CA 1.445 -0.693 0 CA-C-N 116.512 -0.313 . . . . 0.0 110.569 178.505 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 29.0 Cg_endo -62.7 150.95 86.3 Favored 'Trans proline' 0 C--N 1.346 0.4 0 C-N-CA 123.023 2.482 . . . . 0.0 112.339 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 109.73 3.49 30.34 Favored Glycine 0 N--CA 1.45 -0.371 0 N-CA-C 111.081 -0.808 . . . . 0.0 111.081 -176.029 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' SER . . . . . 0.52 ' HB3' ' HA3' ' A' ' 101' ' ' GLY . 50.8 p -125.26 147.95 59.18 Favored Pre-proline 0 N--CA 1.447 -0.609 0 CA-C-N 115.17 -0.515 . . . . 0.0 109.862 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . 0.426 ' HD3' ' HA2' ' A' ' 89' ' ' GLY . 16.8 Cg_exo -67.31 -23.37 44.78 Favored 'Trans proline' 0 N--CA 1.463 -0.297 0 C-N-CA 122.031 1.82 . . . . 0.0 110.894 175.645 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -75.29 -7.93 55.28 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.179 -0.918 . . . . 0.0 111.927 -177.616 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.5 ' HA ' ' CG1' ' A' ' 32' ' ' VAL . 73.0 m -53.33 -31.24 43.31 Favored 'General case' 0 CA--C 1.533 0.303 0 N-CA-C 112.671 0.619 . . . . 0.0 112.671 -175.152 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 42.2 mtmt -128.99 21.21 5.84 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.822 0.344 . . . . 0.0 111.307 179.838 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 88.3 t -103.68 -50.95 9.06 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-O 120.931 0.396 . . . . 0.0 110.754 179.341 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -112.3 -179.82 3.78 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.383 0.611 . . . . 0.0 111.589 -179.393 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' THR . . . . . 0.573 ' O ' ' HG ' ' A' ' 46' ' ' LEU . 8.5 m -116.47 138.31 24.3 Favored Pre-proline 0 C--N 1.317 -0.823 0 CA-C-N 115.011 -0.995 . . . . 0.0 109.948 -178.851 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 21.0 Cg_endo -64.34 141.87 76.75 Favored 'Trans proline' 0 N--CA 1.46 -0.499 0 C-N-CA 121.665 1.577 . . . . 0.0 111.171 171.525 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 99.49 -7.78 59.91 Favored Glycine 0 C--N 1.32 -0.32 0 C-N-CA 120.6 -0.809 . . . . 0.0 113.159 -179.083 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 0.573 ' HG ' ' O ' ' A' ' 43' ' ' THR . 27.9 mt -81.79 163.29 22.48 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 117.077 0.438 . . . . 0.0 110.612 -178.269 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 44.6 t -113.32 126.73 70.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.415 -178.129 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.545 ' HB ' HG23 ' A' ' 27' ' ' VAL . 75.1 mt -84.59 113.01 22.57 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-O 120.862 0.363 . . . . 0.0 110.141 178.931 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 66.6 mt-10 -83.9 -46.45 12.1 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.8 -177.074 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 17.1 p -162.8 152.09 15.29 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.045 0.45 . . . . 0.0 111.875 -178.449 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.483 HG23 ' OD1' ' A' ' 52' ' ' ASN . 12.1 mt -103.27 172.46 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 175.524 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' ASN . . . . . 0.822 ' HB3' ' HB3' ' A' ' 76' ' ' ASN . 17.8 p-10 -56.08 101.89 0.06 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.275 0.56 . . . . 0.0 112.243 -176.257 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 74.99 1.78 63.77 Favored Glycine 0 N--CA 1.451 -0.311 0 CA-C-N 115.527 -0.76 . . . . 0.0 113.042 178.836 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 49.9 mtm -138.14 96.69 10.03 Favored Pre-proline 0 C--N 1.325 -0.484 0 O-C-N 122.684 -0.304 . . . . 0.0 110.659 -175.652 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -73.88 133.85 19.0 Favored 'Trans proline' 0 N--CA 1.462 -0.344 0 C-N-CA 122.667 2.244 . . . . 0.0 111.968 178.679 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.408 HG22 ' HA ' ' A' ' 62' ' ' TYR . 17.7 p -110.83 83.8 1.82 Allowed 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.247 0.546 . . . . 0.0 111.675 -175.861 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 22.3 m -91.92 -13.48 31.14 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.249 177.011 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . 0.445 HD21 ' HB2' ' A' ' 24' ' ' PRO . 0.6 OUTLIER -128.11 173.79 9.79 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 -175.4 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 65.1 mt -78.72 -39.19 37.08 Favored 'General case' 0 N--CA 1.444 -0.77 0 CA-C-O 121.18 0.514 . . . . 0.0 110.059 177.797 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 3.1 m -67.11 -42.45 84.51 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.552 -0.749 . . . . 0.0 111.236 -178.862 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 1.2 p -65.63 -32.42 73.98 Favored 'General case' 0 C--N 1.333 -0.133 0 CA-C-O 120.797 0.332 . . . . 0.0 111.036 179.802 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' TYR . . . . . 0.408 ' HA ' HG22 ' A' ' 56' ' ' THR . 86.4 t80 -62.06 -44.52 96.5 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.007 -0.542 . . . . 0.0 109.669 174.318 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' SER . . . . . 0.487 ' O ' ' HG3' ' A' ' 67' ' ' LYS . 5.7 t -68.12 -41.68 81.37 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.293 179.732 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -60.69 -34.71 74.75 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 121.161 0.505 . . . . 0.0 110.859 -179.221 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . 0.409 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -73.1 -45.58 56.25 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.119 176.346 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -60.23 -38.24 82.8 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.996 -177.442 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . 0.487 ' HG3' ' O ' ' A' ' 63' ' ' SER . 68.6 mttm -65.4 -14.43 60.87 Favored 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 112.297 0.48 . . . . 0.0 112.297 -176.857 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 68.0 p -99.34 -13.14 19.74 Favored 'General case' 0 C--N 1.326 -0.447 0 C-N-CA 120.814 -0.354 . . . . 0.0 111.528 -179.691 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.409 HG12 ' O ' ' A' ' 65' ' ' ALA . 14.5 mm -88.75 144.24 9.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 120.904 0.383 . . . . 0.0 110.413 -176.445 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 54.4 m -104.06 171.0 7.59 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.534 -0.303 . . . . 0.0 111.351 -178.458 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 39.1 t -81.39 117.98 28.36 Favored 'Isoleucine or valine' 0 C--O 1.233 0.224 0 CA-C-O 120.905 0.383 . . . . 0.0 110.539 -178.397 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 102.58 -1.64 49.38 Favored Glycine 0 N--CA 1.448 -0.527 0 N-CA-C 111.463 -0.655 . . . . 0.0 111.463 -177.498 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 56.0 tt0 -87.65 149.08 24.5 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.35 -0.425 . . . . 0.0 109.878 179.527 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 64.3 t -111.13 124.89 68.33 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.782 -177.139 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 25.2 pt -110.07 164.32 6.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.316 -179.553 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . 0.822 ' HB3' ' HB3' ' A' ' 52' ' ' ASN . 6.7 t30 -107.53 114.94 29.28 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.043 -177.158 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.538 HG21 HG21 ' A' ' 48' ' ' ILE . 70.6 mt -117.48 115.21 47.93 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-O 120.982 0.42 . . . . 0.0 111.153 -175.877 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' THR . . . . . 0.523 ' HA ' ' HA ' ' A' ' 83' ' ' THR . 97.8 m -93.0 125.4 37.57 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.872 -0.604 . . . . 0.0 109.969 176.237 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.523 HG23 ' HA ' ' A' ' 48' ' ' ILE . 68.0 p -124.19 177.46 5.82 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.237 179.095 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -57.86 -33.7 68.96 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.5 0.667 . . . . 0.0 110.251 174.1 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 16.5 mm100 -90.73 17.33 7.78 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-N 115.223 -0.899 . . . . 0.0 111.242 -177.054 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 107.71 178.41 22.31 Favored Glycine 0 N--CA 1.446 -0.687 0 CA-C-N 115.525 -0.761 . . . . 0.0 112.419 175.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' THR . . . . . 0.523 ' HA ' ' HA ' ' A' ' 78' ' ' THR . 63.7 m -94.56 131.57 40.16 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-O 120.775 0.322 . . . . 0.0 110.638 179.035 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 91.1 m-85 -125.23 159.75 30.88 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.249 -0.432 . . . . 0.0 109.995 178.198 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 44.9 m80 -106.57 124.31 49.41 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 174.295 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.446 HD12 ' HA ' ' A' ' 86' ' ' LEU . 2.9 mm? -116.69 135.95 53.36 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-O 121.425 0.631 . . . . 0.0 111.811 -174.836 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 87.4 tttt -95.18 135.84 36.26 Favored 'General case' 0 C--N 1.31 -1.133 0 CA-C-N 114.981 -1.009 . . . . 0.0 109.071 174.12 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' THR . . . . . 0.614 ' HB ' ' HA ' ' A' ' 98' ' ' ALA . 55.1 p -65.14 143.45 57.86 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 120.925 0.393 . . . . 0.0 111.061 179.511 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.539 ' HA3' ' O ' ' A' ' 99' ' ' TYR . . . -72.91 -177.56 32.72 Favored Glycine 0 N--CA 1.439 -1.123 0 CA-C-N 115.647 -0.706 . . . . 0.0 113.411 -175.124 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -103.87 8.35 36.96 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 114.724 -0.738 . . . . 0.0 111.914 -167.533 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' ASN . . . . . 0.537 ' HB3' ' O ' ' A' ' 94' ' ' ASN . 47.8 m-80 66.61 88.69 0.11 Allowed Pre-proline 0 N--CA 1.468 0.451 0 CA-C-N 116.108 -0.496 . . . . 0.0 112.001 177.412 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.401 ' C ' ' H ' ' A' ' 94' ' ' ASN . 9.4 Cg_endo -91.14 134.1 1.67 Allowed 'Trans proline' 0 N--CA 1.452 -0.918 0 C-N-CA 123.275 2.65 . . . . 0.0 111.876 173.581 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 61.9 t30 72.44 -38.53 0.42 Allowed 'General case' 0 N--CA 1.474 0.736 0 C-N-CA 123.931 0.892 . . . . 0.0 112.438 178.394 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . 0.537 ' O ' ' HB3' ' A' ' 91' ' ' ASN . 14.3 m120 -126.49 145.71 50.4 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 120.755 0.312 . . . . 0.0 111.218 -176.115 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 64.4 m -99.62 119.66 38.44 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.596 178.68 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 55.7 m -152.92 -168.94 3.19 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 176.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 16.0 ptp180 -105.94 127.94 53.47 Favored 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 109.682 -0.488 . . . . 0.0 109.682 175.43 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . 0.614 ' HA ' ' HB ' ' A' ' 88' ' ' THR . . . 61.35 90.04 0.07 Allowed 'General case' 0 N--CA 1.462 0.142 0 O-C-N 123.845 0.716 . . . . 0.0 111.504 178.551 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . 0.539 ' O ' ' HA3' ' A' ' 89' ' ' GLY . 2.3 t80 -111.58 95.97 5.82 Favored 'General case' 0 C--N 1.325 -0.466 0 C-N-CA 119.805 -0.758 . . . . 0.0 109.895 -176.829 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' MET . . . . . 0.634 ' HG3' HG12 ' A' ' 102' ' ' ILE . 50.8 tpp -46.95 -54.17 10.69 Favored 'General case' 0 N--CA 1.466 0.35 0 O-C-N 123.746 0.654 . . . . 0.0 112.002 -173.391 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . 0.52 ' HA3' ' HB3' ' A' ' 36' ' ' SER . . . 99.31 -2.24 57.64 Favored Glycine 0 C--O 1.226 -0.375 0 C-N-CA 120.504 -0.855 . . . . 0.0 113.185 175.399 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.634 HG12 ' HG3' ' A' ' 100' ' ' MET . 36.7 pt -114.58 140.6 34.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 N-CA-C 109.633 -0.506 . . . . 0.0 109.633 178.14 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . 0.557 ' HB3' ' HB3' ' A' ' 30' ' ' ASP . 18.4 ttp180 -69.52 125.37 26.49 Favored 'General case' 0 N--CA 1.446 -0.648 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 178.535 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -135.52 142.03 45.35 Favored 'General case' 0 C--N 1.311 -1.104 0 CA-C-N 116.048 -0.523 . . . . 0.0 110.582 -175.465 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 31.9 m -153.39 157.45 39.99 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.05 179.575 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . 0.405 ' HA ' ' HA ' ' A' ' 27' ' ' VAL . 25.5 p-10 -74.75 -8.82 57.57 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.798 -179.653 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 6.1 t-160 57.88 75.98 0.35 Allowed 'General case' 0 C--O 1.233 0.222 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.328 176.454 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 21.3 mt -59.28 141.59 54.01 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.681 0.753 . . . . 0.0 112.056 -179.114 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -67.89 121.07 15.24 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 114.257 -1.338 . . . . 0.0 109.304 -178.727 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 8.4 p -65.96 129.12 29.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 121.634 0.73 . . . . 0.0 111.885 -175.21 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' ARG . . . . . . . . . . . . . 19.6 mtp180 -157.03 175.31 14.26 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 114.333 -1.303 . . . . 0.0 108.936 174.776 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 27.6 m-20 -111.33 82.27 1.58 Allowed 'General case' 0 C--N 1.319 -0.721 0 CA-C-O 120.978 0.418 . . . . 0.0 111.748 -178.214 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 7.4 p -93.48 86.04 5.11 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 168.232 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 29.7 m -67.91 143.01 15.72 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.512 -0.767 . . . . 0.0 112.537 -170.781 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -116.6 85.4 2.3 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.079 -0.964 . . . . 0.0 109.373 175.056 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 9.4 m -74.35 150.14 40.24 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.73 -176.271 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 15.5 m -70.18 126.37 30.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-O 120.998 0.428 . . . . 0.0 110.222 176.477 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 85.7 mt -86.65 -43.31 12.73 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.214 -177.603 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 141.52 146.38 4.7 Favored Glycine 0 N--CA 1.442 -0.909 0 N-CA-C 111.073 -0.811 . . . . 0.0 111.073 -177.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -119.84 117.74 28.94 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 110.126 -0.324 . . . . 0.0 110.126 -177.06 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 8.9 t -82.56 118.06 23.0 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 121.474 0.654 . . . . 0.0 110.481 -178.153 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 89.1 mt -107.25 106.25 57.86 Favored Pre-proline 0 C--N 1.325 -0.476 0 CA-C-N 115.824 -0.626 . . . . 0.0 111.098 -179.156 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -70.85 150.84 62.21 Favored 'Trans proline' 0 N--CA 1.461 -0.428 0 C-N-CA 122.464 2.109 . . . . 0.0 111.357 176.151 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 44.6 t80 -125.08 117.28 23.6 Favored 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 109.468 -0.568 . . . . 0.0 109.468 -178.482 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.972 0 CA-C-O 118.598 -0.715 . . . . 0.0 110.848 -176.148 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . . . . . . . . . 84.1 mt-30 . . . . . 0 N--CA 1.467 0.398 0 CA-C-O 121.111 0.481 . . . . 0.0 111.941 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.537 ' HD2' ' ND2' ' A' ' 58' ' ' ASN . 32.2 Cg_exo -62.21 -173.62 0.13 Allowed 'Trans proline' 0 C--N 1.346 0.42 0 C-N-CA 123.406 2.737 . . . . 0.0 112.389 172.606 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.552 ' HB3' ' HD2' ' A' ' 107' ' ' HIS . 16.8 t70 -148.87 -1.15 0.5 Allowed 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 116.099 -0.501 . . . . 0.0 111.743 -171.516 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.545 ' HA2' ' HA ' ' A' ' 57' ' ' SER . . . 146.68 136.06 2.82 Favored Glycine 0 N--CA 1.444 -0.782 0 N-CA-C 110.932 -0.867 . . . . 0.0 110.932 -174.003 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.49 HG22 ' HB ' ' A' ' 48' ' ' ILE . 30.0 m -80.99 142.38 13.92 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-O 121.272 0.558 . . . . 0.0 110.86 -178.743 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . 0.508 ' HG3' ' O ' ' A' ' 46' ' ' LEU . 5.8 tt0 -116.38 155.4 28.57 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.482 -179.634 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.468 HD11 HD11 ' A' ' 102' ' ' ILE . 45.2 mm -81.56 110.51 17.0 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 178.01 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.45 ' HB3' ' CB ' ' A' ' 103' ' ' ARG . 14.4 t70 -70.43 -63.19 1.14 Allowed 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 115.933 -0.576 . . . . 0.0 109.591 179.479 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 17.3 m -150.03 148.99 29.71 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.734 -178.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.421 ' CG1' ' HA ' ' A' ' 39' ' ' SER . 97.3 t -114.6 114.07 45.55 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 N-CA-C 108.825 -0.805 . . . . 0.0 108.825 173.406 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.508 HG22 ' O ' ' A' ' 101' ' ' GLY . 4.6 m -75.11 153.13 86.43 Favored Pre-proline 0 C--N 1.324 -0.505 0 CA-C-N 116.51 -0.314 . . . . 0.0 111.355 -175.093 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 40.1 Cg_endo -69.77 116.58 4.63 Favored 'Trans proline' 0 N--CA 1.461 -0.404 0 C-N-CA 122.388 2.058 . . . . 0.0 111.033 172.613 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 94.99 -179.56 36.73 Favored Glycine 0 N--CA 1.445 -0.706 0 N-CA-C 110.63 -0.988 . . . . 0.0 110.63 -173.413 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' SER . . . . . 0.722 ' HB3' ' HD2' ' A' ' 37' ' ' PRO . 31.9 m 69.16 168.48 0.12 Allowed Pre-proline 0 CA--C 1.54 0.564 0 CA-C-N 117.072 0.436 . . . . 0.0 110.888 -179.052 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . 0.722 ' HD2' ' HB3' ' A' ' 36' ' ' SER . 32.8 Cg_endo -65.04 155.11 70.04 Favored 'Trans proline' 0 C--N 1.344 0.329 0 C-N-CA 122.348 2.032 . . . . 0.0 112.747 179.035 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.436 ' HB1' HD23 ' A' ' 86' ' ' LEU . . . 76.68 -12.22 1.07 Allowed 'General case' 0 N--CA 1.471 0.621 0 C-N-CA 123.718 0.807 . . . . 0.0 112.146 177.012 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.421 ' HA ' ' CG1' ' A' ' 32' ' ' VAL . 11.4 t -64.31 -30.87 71.9 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.618 -175.554 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -103.96 16.64 25.85 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.024 -175.687 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.431 ' HB ' HD13 ' A' ' 42' ' ' LEU . 30.8 t -125.29 -54.05 2.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 N-CA-C 111.705 0.261 . . . . 0.0 111.705 -177.672 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.431 HD13 ' HB ' ' A' ' 41' ' ' VAL . 7.6 mp -97.47 176.98 5.67 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.373 0.606 . . . . 0.0 111.909 -173.057 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' THR . . . . . 0.424 ' O ' ' HG ' ' A' ' 46' ' ' LEU . 28.5 m -135.5 134.32 20.98 Favored Pre-proline 0 C--N 1.321 -0.64 0 CA-C-N 115.186 -0.915 . . . . 0.0 109.39 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -62.13 139.46 78.51 Favored 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 122.105 1.87 . . . . 0.0 112.474 179.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 105.69 -13.11 46.56 Favored Glycine 0 CA--C 1.521 0.408 0 C-N-CA 120.641 -0.79 . . . . 0.0 113.808 179.308 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 0.508 ' O ' ' HG3' ' A' ' 28' ' ' GLN . 56.9 mt -79.83 163.32 24.49 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 117.481 0.64 . . . . 0.0 111.044 -177.035 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 42.2 t -111.28 137.26 44.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 116.528 -0.306 . . . . 0.0 110.304 178.182 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.49 ' HB ' HG22 ' A' ' 27' ' ' VAL . 61.9 mt -92.62 124.93 45.24 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-O 121.16 0.505 . . . . 0.0 111.23 -178.985 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 11.3 tp10 -77.23 -53.93 7.12 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.624 176.378 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 5.3 p -161.83 156.01 22.1 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.341 -0.845 . . . . 0.0 111.576 -176.184 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.626 HG12 HG12 ' A' ' 77' ' ' ILE . 58.5 mt -123.17 106.86 18.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 115.478 -0.783 . . . . 0.0 109.475 176.396 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' ASN . . . . . 0.44 ' CG ' ' H ' ' A' ' 53' ' ' GLY . 12.0 t-20 61.26 -152.23 0.38 Allowed 'General case' 0 CA--C 1.533 0.307 0 N-CA-C 108.061 -1.089 . . . . 0.0 108.061 -175.425 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.44 ' H ' ' CG ' ' A' ' 52' ' ' ASN . . . -73.61 9.67 7.86 Favored Glycine 0 CA--C 1.525 0.657 0 C-N-CA 120.781 -0.723 . . . . 0.0 113.156 179.533 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 3.3 mpp? -114.96 105.31 53.25 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 120.721 0.296 . . . . 0.0 110.423 178.091 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -73.96 130.42 14.4 Favored 'Trans proline' 0 N--CA 1.458 -0.569 0 C-N-CA 122.04 1.827 . . . . 0.0 111.949 177.615 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.42 ' O ' ' HA2' ' A' ' 26' ' ' GLY . 16.7 p -98.12 75.96 2.34 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 121.249 0.547 . . . . 0.0 111.692 -176.595 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' SER . . . . . 0.545 ' HA ' ' HA2' ' A' ' 26' ' ' GLY . 32.3 t -88.89 -12.2 42.41 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.583 -0.735 . . . . 0.0 109.831 176.033 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . 0.537 ' ND2' ' HD2' ' A' ' 24' ' ' PRO . 8.9 t-20 -129.32 177.89 6.84 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 115.846 -0.615 . . . . 0.0 109.361 -177.234 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.911 ' HG ' ' HB3' ' A' ' 106' ' ' ASN . 3.8 mt -90.08 -34.2 16.01 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-O 121.051 0.453 . . . . 0.0 109.806 176.661 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 28.5 m -63.7 -38.82 92.53 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.249 176.678 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 21.4 p -64.09 -38.07 89.72 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.484 177.851 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 89.1 t80 -65.48 -43.76 89.24 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.893 -0.594 . . . . 0.0 109.898 177.925 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 8.6 t -64.64 -48.03 76.31 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.455 179.684 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -65.54 -31.1 71.97 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.958 -0.564 . . . . 0.0 111.586 -177.223 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . 0.602 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -74.11 -45.04 51.52 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.328 179.6 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 1.6 tt -59.88 -43.8 94.55 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.134 -177.45 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 57.8 mtpt -63.13 -22.65 67.0 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.587 -0.733 . . . . 0.0 112.206 -178.153 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 40.6 p -92.18 -13.58 30.38 Favored 'General case' 0 C--N 1.329 -0.321 0 C-N-CA 120.971 -0.292 . . . . 0.0 111.571 179.465 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.602 HG12 ' O ' ' A' ' 65' ' ' ALA . 44.5 mm -78.14 138.99 19.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.841 0.353 . . . . 0.0 110.105 -179.265 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 6.1 m -88.46 165.7 14.72 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.971 -177.825 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 94.8 t -72.43 133.96 30.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.454 177.112 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 70.95 27.61 71.92 Favored Glycine 0 C--N 1.331 0.257 0 C-N-CA 120.959 -0.639 . . . . 0.0 111.984 179.005 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 9.7 tp10 -99.04 152.52 19.73 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 -177.443 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.413 ' HA ' ' O ' ' A' ' 86' ' ' LEU . 58.9 t -108.24 111.48 36.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.119 -179.459 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.612 HG13 ' HB3' ' A' ' 86' ' ' LEU . 15.0 pt -109.65 154.15 11.2 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.635 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.98 -177.815 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . 0.413 ' O ' ' HA ' ' A' ' 51' ' ' ILE . 19.9 t30 -95.17 114.4 26.19 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 115.302 -0.863 . . . . 0.0 110.726 -179.4 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.626 HG12 HG12 ' A' ' 51' ' ' ILE . 50.9 mt -113.19 104.55 17.2 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-O 121.641 0.734 . . . . 0.0 110.015 177.274 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 11.7 m -89.63 124.57 34.69 Favored 'General case' 0 C--N 1.314 -0.952 0 CA-C-N 115.036 -0.984 . . . . 0.0 109.275 178.075 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 60.0 p -117.17 172.33 7.36 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 121.024 0.44 . . . . 0.0 111.172 -178.004 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -56.45 -32.71 65.18 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.245 -0.889 . . . . 0.0 111.444 177.434 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 30.5 mm-40 -104.39 16.48 26.06 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 112.373 0.508 . . . . 0.0 112.373 -175.507 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 136.6 172.66 12.64 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 119.969 -1.11 . . . . 0.0 113.674 175.528 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 19.6 m -99.19 121.53 41.16 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 110.278 -0.267 . . . . 0.0 110.278 -179.876 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -115.63 158.71 22.32 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.189 0.519 . . . . 0.0 111.153 -177.051 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 23.4 m80 -102.51 125.63 49.3 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.619 -0.719 . . . . 0.0 109.237 179.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.612 ' HB3' HG13 ' A' ' 75' ' ' ILE . 0.4 OUTLIER -114.16 136.71 52.64 Favored 'General case' 0 C--N 1.315 -0.895 0 CA-C-O 120.978 0.418 . . . . 0.0 110.069 -176.848 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.45 ' N ' HD13 ' A' ' 86' ' ' LEU . 78.7 tttt -127.08 115.71 19.59 Favored 'General case' 0 C--N 1.312 -1.046 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 176.45 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' THR . . . . . 0.533 HG21 ' HB2' ' A' ' 98' ' ' ALA . 73.4 p -69.35 142.44 54.0 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.766 -0.652 . . . . 0.0 111.812 -173.199 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -80.01 -164.01 28.87 Favored Glycine 0 N--CA 1.443 -0.9 0 CA-C-N 115.674 -0.693 . . . . 0.0 112.777 -177.701 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.41 ' N ' ' HD2' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -148.01 175.3 11.11 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.621 -0.289 . . . . 0.0 110.42 -173.952 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 59.31 85.88 0.17 Allowed Pre-proline 0 N--CA 1.467 0.424 0 O-C-N 123.956 0.785 . . . . 0.0 111.735 -176.473 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 95.2 Cg_endo -94.42 -166.06 0.13 Allowed 'Trans proline' 0 N--CA 1.452 -0.918 0 C-N-CA 123.017 2.478 . . . . 0.0 111.632 173.005 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 32.9 t-20 -110.31 58.91 0.61 Allowed 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 176.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 17.8 t-20 72.33 130.42 0.04 OUTLIER 'General case' 0 C--O 1.235 0.321 0 CA-C-N 114.374 -1.285 . . . . 0.0 110.351 -177.309 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 21.6 m 65.06 177.17 0.2 Allowed 'General case' 0 CA--C 1.533 0.299 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.687 -176.733 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 14.7 m 66.57 117.01 0.03 OUTLIER 'General case' 0 CA--C 1.534 0.358 0 CA-C-O 121.674 0.75 . . . . 0.0 111.979 179.612 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . 0.549 ' N ' ' HD2' ' A' ' 97' ' ' ARG . 2.8 mpt_? -109.94 159.51 17.19 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 178.515 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . 0.533 ' HB2' HG21 ' A' ' 88' ' ' THR . . . 67.27 86.73 0.13 Allowed 'General case' 0 N--CA 1.461 0.077 0 CA-C-O 121.597 0.713 . . . . 0.0 110.234 -176.975 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 29.1 t80 -81.82 119.98 24.59 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.64 -0.709 . . . . 0.0 110.306 -172.548 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 26.0 mmt -98.66 151.58 20.56 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.597 -179.698 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . 0.508 ' O ' HG22 ' A' ' 33' ' ' VAL . . . -124.36 26.67 5.72 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.45 -0.881 . . . . 0.0 112.555 -179.828 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.468 HD11 HD11 ' A' ' 29' ' ' ILE . 45.6 pt -136.3 162.41 35.82 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-O 121.112 0.482 . . . . 0.0 110.549 179.686 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . 0.45 ' CB ' ' HB3' ' A' ' 30' ' ' ASP . 28.5 mmt85 -102.18 146.34 28.11 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 115.487 -0.779 . . . . 0.0 109.421 176.056 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 16.5 p -131.59 154.49 48.8 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.225 0.536 . . . . 0.0 111.61 -179.6 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 15.7 p -122.88 171.09 9.46 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.903 -0.59 . . . . 0.0 109.692 175.539 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . 0.911 ' HB3' ' HG ' ' A' ' 59' ' ' LEU . 19.8 p-10 -108.97 4.88 23.76 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 111.812 0.301 . . . . 0.0 111.812 -175.943 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . 0.552 ' HD2' ' HB3' ' A' ' 25' ' ' ASP . 76.5 t60 62.84 69.06 0.61 Allowed 'General case' 0 N--CA 1.465 0.288 0 CA-C-O 121.549 0.69 . . . . 0.0 111.421 173.677 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 61.0 mt -135.42 -169.17 2.33 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.826 176.572 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 57.8 mtp180 62.96 69.29 0.59 Allowed 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.087 -0.961 . . . . 0.0 111.113 -177.323 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 7.1 p -158.03 153.6 6.03 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.727 0 CA-C-N 114.916 -1.038 . . . . 0.0 109.045 -178.69 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' ARG . . . . . . . . . . . . . 26.9 mtp180 -106.56 98.98 8.58 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -178.174 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -142.7 143.25 32.21 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.801 -0.636 . . . . 0.0 109.854 -175.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 27.3 t -82.18 83.96 7.21 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.538 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 15.0 m -68.97 137.6 23.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.724 178.143 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -103.1 -44.51 5.19 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.112 -178.888 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 14.5 t -80.43 85.11 5.93 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.252 0.548 . . . . 0.0 109.71 178.568 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 39.0 t -112.74 114.97 48.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.033 179.761 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 6.7 mp -98.95 -14.88 19.34 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.984 0.421 . . . . 0.0 110.33 178.373 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 78.09 -72.95 2.22 Favored Glycine 0 N--CA 1.447 -0.576 0 CA-C-N 115.901 -0.59 . . . . 0.0 111.655 -179.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 15.2 t70 -178.29 -60.48 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 177.626 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 40.6 p 51.91 86.91 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 114.952 -1.022 . . . . 0.0 112.492 -178.533 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 67.8 mt -78.8 139.03 57.72 Favored Pre-proline 0 C--N 1.327 -0.396 0 CA-C-N 115.489 -0.778 . . . . 0.0 110.319 177.065 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_endo -64.16 151.97 83.11 Favored 'Trans proline' 0 C--O 1.234 0.28 0 C-N-CA 122.404 2.069 . . . . 0.0 111.89 177.319 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 38.0 p90 -55.51 144.55 25.68 Favored 'General case' 0 C--O 1.236 0.367 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.348 -178.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.998 0 CA-C-O 118.579 -0.724 . . . . 0.0 109.888 -178.27 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.456 ' HA ' ' HD3' ' A' ' 24' ' ' PRO . 0.9 OUTLIER . . . . . 0 N--CA 1.456 -0.149 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 . . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.456 ' HD3' ' HA ' ' A' ' 23' ' ' GLN . 19.1 Cg_exo -66.44 148.27 83.77 Favored 'Trans proline' 0 C--O 1.233 0.243 0 C-N-CA 122.999 2.466 . . . . 0.0 111.63 178.138 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 16.0 t70 -149.26 -37.49 0.16 Allowed 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.02 0.438 . . . . 0.0 111.134 -176.164 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.561 ' HA2' ' HA ' ' A' ' 57' ' ' SER . . . 165.59 172.04 32.52 Favored Glycine 0 N--CA 1.45 -0.367 0 N-CA-C 111.141 -0.784 . . . . 0.0 111.141 -177.795 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.529 HG22 ' HB ' ' A' ' 48' ' ' ILE . 30.7 m -124.0 148.16 28.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-O 121.242 0.544 . . . . 0.0 111.117 179.147 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . 0.518 ' HG3' ' O ' ' A' ' 46' ' ' LEU . 60.0 tt0 -128.34 152.06 48.59 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.007 -179.248 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.471 HD12 ' HB2' ' A' ' 46' ' ' LEU . 2.8 pt -86.5 122.16 38.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 121.238 0.542 . . . . 0.0 111.245 179.345 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.605 ' HB3' ' CB ' ' A' ' 103' ' ' ARG . 15.8 t70 -64.44 -61.74 2.03 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 114.699 -1.137 . . . . 0.0 110.828 -179.13 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.457 ' HA ' ' CB ' ' A' ' 44' ' ' PRO . 51.3 p -166.94 161.81 15.3 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.602 -0.726 . . . . 0.0 110.936 -175.582 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.543 ' HA ' HG23 ' A' ' 102' ' ' ILE . 85.2 t -98.81 129.14 49.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.788 177.314 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 47.0 t -92.69 129.67 39.52 Favored Pre-proline 0 C--N 1.322 -0.621 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.006 -179.749 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_exo -56.64 123.74 14.58 Favored 'Trans proline' 0 C--O 1.234 0.291 0 C-N-CA 122.584 2.189 . . . . 0.0 111.929 178.07 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 117.27 18.05 5.54 Favored Glycine 0 N--CA 1.447 -0.594 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.379 -176.152 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' SER . . . . . 0.633 ' HB3' ' HA3' ' A' ' 101' ' ' GLY . 54.3 p -121.54 149.79 53.43 Favored Pre-proline 0 C--N 1.322 -0.615 0 CA-C-N 115.58 -0.31 . . . . 0.0 110.801 -177.111 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_endo -71.14 -25.41 22.42 Favored 'Trans proline' 0 N--CA 1.463 -0.271 0 C-N-CA 122.338 2.025 . . . . 0.0 111.949 176.112 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -72.45 -10.62 60.01 Favored 'General case' 0 C--O 1.234 0.245 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.808 -175.611 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.534 ' HA ' HG12 ' A' ' 32' ' ' VAL . 24.7 p -59.16 -28.75 66.88 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.91 -177.85 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 65.0 mttm -110.92 15.06 21.99 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.879 0.371 . . . . 0.0 111.083 179.858 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 53.8 t -101.66 -59.49 3.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-O 120.972 0.415 . . . . 0.0 110.368 178.599 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -130.66 169.28 15.85 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.118 -179.868 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 18.3 p -105.15 138.96 19.68 Favored Pre-proline 0 C--N 1.318 -0.775 0 CA-C-N 115.624 -0.717 . . . . 0.0 110.182 177.705 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.457 ' CB ' ' HA ' ' A' ' 31' ' ' SER . 32.1 Cg_endo -65.18 141.85 71.14 Favored 'Trans proline' 0 N--CA 1.462 -0.373 0 C-N-CA 122.34 2.027 . . . . 0.0 112.31 -179.188 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 110.24 -1.27 29.68 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.8 -177.206 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 0.518 ' O ' ' HG3' ' A' ' 28' ' ' GLN . 90.1 mt -85.36 163.39 18.58 Favored 'General case' 0 C--N 1.328 -0.351 0 O-C-N 122.459 -0.436 . . . . 0.0 110.84 178.938 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.449 ' HB ' ' HB2' ' A' ' 80' ' ' ASP . 47.0 t -105.44 135.2 44.53 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.264 -179.233 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.529 ' HB ' HG22 ' A' ' 27' ' ' VAL . 69.4 mt -95.5 119.12 43.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 N-CA-C 110.118 -0.327 . . . . 0.0 110.118 -179.733 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 29.8 mt-10 -86.66 -46.15 10.33 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.332 -0.394 . . . . 0.0 111.216 -178.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.561 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 36.1 p -159.69 155.07 25.41 Favored 'General case' 0 C--N 1.325 -0.482 0 C-N-CA 120.326 -0.55 . . . . 0.0 112.028 -177.759 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 55.6 mt -112.93 97.38 5.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 115.372 -0.831 . . . . 0.0 111.003 179.195 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 49.2 t30 58.52 35.4 24.6 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.171 -0.922 . . . . 0.0 111.874 171.291 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 108.95 -27.4 13.01 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.057 178.835 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' MET . . . . . 0.411 ' HA ' ' HD3' ' A' ' 55' ' ' PRO . 71.6 mtm -98.88 106.88 40.35 Favored Pre-proline 0 C--N 1.324 -0.51 0 N-CA-C 109.978 -0.378 . . . . 0.0 109.978 178.723 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.561 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 6.1 Cg_exo -77.61 150.02 27.46 Favored 'Trans proline' 0 N--CA 1.457 -0.633 0 C-N-CA 122.669 2.246 . . . . 0.0 112.095 -177.626 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 19.8 p -123.13 106.72 11.02 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 120.915 0.388 . . . . 0.0 111.399 -178.241 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' SER . . . . . 0.561 ' HA ' ' HA2' ' A' ' 26' ' ' GLY . 15.1 p -99.0 -22.16 15.87 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 121.038 0.447 . . . . 0.0 110.788 178.283 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . 0.488 ' HB3' ' OG1' ' A' ' 61' ' ' THR . 17.3 t-20 -117.18 172.23 7.43 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.091 -0.504 . . . . 0.0 109.733 179.264 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 40.3 mt -79.43 -42.6 25.06 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.469 -179.843 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 27.8 m -65.8 -29.49 69.99 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.778 177.652 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' THR . . . . . 0.488 ' OG1' ' HB3' ' A' ' 58' ' ' ASN . 1.5 m -66.56 -37.42 84.93 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.177 0.513 . . . . 0.0 110.009 176.357 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 62.5 t80 -62.91 -45.76 90.98 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.217 -0.902 . . . . 0.0 109.4 174.345 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' SER . . . . . 0.521 ' O ' ' HG2' ' A' ' 67' ' ' LYS . 59.6 m -59.48 -48.77 80.37 Favored 'General case' 0 N--CA 1.444 -0.744 0 CA-C-N 115.243 -0.889 . . . . 0.0 111.695 177.565 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -60.3 -31.08 69.93 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.721 -178.454 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . 0.401 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -76.2 -42.87 44.86 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.334 0.588 . . . . 0.0 109.885 176.995 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . 0.439 HD22 ' HA ' ' A' ' 66' ' ' LEU . 0.2 OUTLIER -58.06 -32.96 68.52 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 114.958 -1.019 . . . . 0.0 111.382 178.803 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . 0.521 ' HG2' ' O ' ' A' ' 63' ' ' SER . 31.5 mmmt -56.01 -35.14 66.48 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.944 -179.938 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 24.5 p -92.84 -12.74 30.3 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 112.317 0.488 . . . . 0.0 112.317 -174.851 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.504 HG23 HG22 ' A' ' 88' ' ' THR . 46.2 mm -74.47 136.92 24.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 120.888 0.375 . . . . 0.0 110.571 -178.129 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' SER . . . . . 0.403 ' HB2' ' HB2' ' A' ' 73' ' ' GLU . 6.0 m -89.17 161.82 16.26 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.748 -178.452 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 11.4 t -80.34 115.12 22.28 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 N-CA-C 108.672 -0.862 . . . . 0.0 108.672 171.848 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 99.13 9.45 51.6 Favored Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 120.751 -0.738 . . . . 0.0 111.271 -173.364 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.403 ' HB2' ' HB2' ' A' ' 70' ' ' SER . 10.7 tp10 -80.81 149.14 29.7 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 179.054 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 58.3 t -111.01 108.13 24.69 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.989 0 N-CA-C 109.273 -0.639 . . . . 0.0 109.273 176.872 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 17.1 pt -101.08 153.62 4.81 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 CA-C-O 121.44 0.638 . . . . 0.0 111.662 -176.366 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 3.9 t30 -107.4 104.41 13.99 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 114.949 -1.023 . . . . 0.0 109.716 -176.226 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 65.0 mt -106.85 110.7 32.64 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.011 0 CA-C-O 121.317 0.58 . . . . 0.0 111.241 -173.799 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' THR . . . . . 0.469 ' HA ' ' HA ' ' A' ' 83' ' ' THR . 91.8 m -85.19 114.34 22.23 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-N 115.595 -0.73 . . . . 0.0 109.271 174.694 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 50.1 p -103.42 175.66 5.41 Favored 'General case' 0 N--CA 1.443 -0.797 0 CA-C-O 121.061 0.458 . . . . 0.0 110.387 179.85 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . 0.449 ' HB2' ' HB ' ' A' ' 47' ' ' VAL . 9.3 t70 -51.71 -33.42 34.25 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.006 -0.997 . . . . 0.0 112.515 179.43 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 5.3 mt-30 -115.29 16.06 16.85 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 112.704 0.631 . . . . 0.0 112.704 -173.27 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 140.58 169.83 11.87 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.237 -0.983 . . . . 0.0 113.073 176.661 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' THR . . . . . 0.469 ' HA ' ' HA ' ' A' ' 78' ' ' THR . 30.0 m -96.59 133.4 41.13 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.794 0.331 . . . . 0.0 111.122 -179.507 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 82.5 m-85 -123.19 157.21 33.52 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.232 177.561 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 1.7 p-80 -108.12 120.11 41.4 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.104 0.478 . . . . 0.0 110.273 176.486 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -109.95 146.95 34.35 Favored 'General case' 0 N--CA 1.444 -0.741 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.852 -176.841 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 77.7 tttt -111.82 124.17 51.8 Favored 'General case' 0 C--N 1.32 -0.693 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 174.516 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' THR . . . . . 0.504 HG22 HG23 ' A' ' 69' ' ' ILE . 13.4 p -80.69 132.26 35.55 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 120.981 0.419 . . . . 0.0 111.562 -178.648 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -127.34 -122.52 2.54 Favored Glycine 0 N--CA 1.446 -0.651 0 C-N-CA 120.977 -0.63 . . . . 0.0 111.863 179.253 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.497 ' HD3' ' N ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -147.85 171.21 16.1 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.044 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' ASN . . . . . 0.46 ' HB2' ' O ' ' A' ' 94' ' ' ASN . 6.9 m120 -71.57 140.48 84.44 Favored Pre-proline 0 C--N 1.324 -0.528 0 CA-C-N 116.604 -0.271 . . . . 0.0 110.361 175.402 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 34.6 Cg_endo -64.76 -27.22 59.96 Favored 'Trans proline' 0 CA--C 1.529 0.262 0 C-N-CA 122.718 2.278 . . . . 0.0 112.97 -177.293 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 -126.51 14.67 7.64 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.956 0.408 . . . . 0.0 110.96 -176.945 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . 0.46 ' O ' ' HB2' ' A' ' 91' ' ' ASN . 26.3 t-20 -151.47 134.99 16.2 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 110.113 -0.329 . . . . 0.0 110.113 -177.234 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 5.1 m -83.19 90.21 7.06 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 121.039 0.447 . . . . 0.0 110.688 -178.721 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 20.9 m -126.57 136.51 52.64 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.25 179.067 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 5.2 ptm180 -75.68 136.14 40.4 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.717 -177.248 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . 54.63 77.0 0.22 Allowed 'General case' 0 N--CA 1.465 0.29 0 O-C-N 123.992 0.807 . . . . 0.0 111.895 172.75 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 11.4 t80 -136.97 134.47 36.71 Favored 'General case' 0 C--N 1.323 -0.561 0 C-N-CA 120.851 -0.339 . . . . 0.0 110.32 -179.751 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' MET . . . . . 0.479 ' SD ' HG21 ' A' ' 88' ' ' THR . 4.3 mpp? -86.92 -16.25 36.48 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.537 -0.301 . . . . 0.0 111.57 -177.468 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . 0.633 ' HA3' ' HB3' ' A' ' 36' ' ' SER . . . 90.58 30.33 12.07 Favored Glycine 0 CA--C 1.519 0.33 0 C-N-CA 120.878 -0.677 . . . . 0.0 112.866 178.931 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.543 HG23 ' HA ' ' A' ' 32' ' ' VAL . 36.6 pt -135.42 167.05 26.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-O 120.908 0.385 . . . . 0.0 110.584 -178.751 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . 0.605 ' CB ' ' HB3' ' A' ' 30' ' ' ASP . 36.9 mtt180 -98.53 155.54 17.23 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.666 173.286 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 3.3 m -139.1 149.98 45.16 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 121.092 0.473 . . . . 0.0 110.345 177.269 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 32.0 m -142.02 178.42 7.54 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 115.365 -0.834 . . . . 0.0 109.198 -178.337 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . 0.462 ' HB2' ' HG ' ' A' ' 108' ' ' LEU . 10.4 p30 -103.69 -24.5 13.35 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.592 0.234 . . . . 0.0 110.874 177.637 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 42.1 t-80 54.16 45.06 28.21 Favored 'General case' 0 N--CA 1.467 0.419 0 CA-C-O 121.235 0.541 . . . . 0.0 110.458 -179.406 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . 0.462 ' HG ' ' HB2' ' A' ' 106' ' ' ASN . 89.0 mt -82.3 -166.21 1.21 Allowed 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.545 0.688 . . . . 0.0 111.528 -178.372 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 58.5 mtt-85 -95.99 103.85 15.76 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.074 -176.522 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 64.6 t -92.19 138.89 18.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-N 115.633 -0.712 . . . . 0.0 111.34 -175.547 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' ARG . . . . . . . . . . . . . 47.0 ttt180 -150.74 134.56 16.62 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 108.814 -0.809 . . . . 0.0 108.814 174.451 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -83.8 110.03 18.01 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.245 0.545 . . . . 0.0 110.031 -177.759 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 4.2 p -90.67 115.35 27.71 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 115.394 -0.821 . . . . 0.0 111.405 -179.586 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 3.0 m -116.48 102.05 13.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 115.712 -0.677 . . . . 0.0 110.422 175.881 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -171.56 103.59 0.2 Allowed 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.208 -178.289 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 8.1 t -124.27 111.15 15.5 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.142 179.635 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 48.6 t -93.23 119.85 41.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.115 178.625 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 94.2 mt -91.07 -73.67 0.53 Allowed 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.916 0.389 . . . . 0.0 110.614 179.844 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 118.96 129.57 3.97 Favored Glycine 0 N--CA 1.447 -0.599 0 N-CA-C 111.194 -0.762 . . . . 0.0 111.194 -175.843 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 50.4 m-20 -102.35 85.29 2.6 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 121.175 0.512 . . . . 0.0 110.491 -178.07 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 1.4 p -91.94 105.66 17.87 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.48 -0.782 . . . . 0.0 110.88 178.246 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 61.6 mt -98.5 104.95 26.72 Favored Pre-proline 0 C--N 1.326 -0.442 0 CA-C-N 115.975 -0.557 . . . . 0.0 109.828 -178.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 5.5 Cg_endo -86.21 110.37 1.02 Allowed 'Trans proline' 0 N--CA 1.455 -0.783 0 C-N-CA 123.162 2.575 . . . . 0.0 112.994 -175.235 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 34.4 p90 -146.48 128.59 15.61 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.627 172.264 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.992 0 CA-C-O 118.576 -0.726 . . . . 0.0 110.399 -175.46 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.47 ' HA ' ' HD3' ' A' ' 24' ' ' PRO . 82.2 mt-30 . . . . . 0 N--CA 1.457 -0.118 0 CA-C-O 120.47 0.176 . . . . 0.0 110.766 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.638 ' HG3' HD21 ' A' ' 58' ' ' ASN . 23.9 Cg_exo -64.48 154.42 71.84 Favored 'Trans proline' 0 C--O 1.234 0.306 0 C-N-CA 123.207 2.605 . . . . 0.0 113.377 -174.666 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 14.5 t70 -153.11 -44.46 0.1 Allowed 'General case' 0 N--CA 1.465 0.283 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.718 178.78 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.475 ' HA2' ' HA ' ' A' ' 57' ' ' SER . . . 156.93 131.8 1.39 Allowed Glycine 0 N--CA 1.449 -0.486 0 CA-C-N 115.745 -0.661 . . . . 0.0 111.694 -179.597 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.449 HG21 ' HB ' ' A' ' 48' ' ' ILE . 31.5 m -72.7 140.15 18.42 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-O 121.218 0.532 . . . . 0.0 111.352 -177.931 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . 0.647 ' HB3' ' HB2' ' A' ' 107' ' ' HIS . 4.1 tp-100 -107.45 133.76 51.48 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.651 -0.704 . . . . 0.0 111.11 -177.977 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.523 HD11 ' HB2' ' A' ' 46' ' ' LEU . 61.5 mt -73.29 105.87 2.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 CA-C-N 115.637 -0.711 . . . . 0.0 109.815 175.524 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 21.3 t70 -62.91 -65.21 0.72 Allowed 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.254 -178.037 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 12.4 p -156.46 152.53 27.55 Favored 'General case' 0 N--CA 1.444 -0.731 0 CA-C-N 115.21 -0.905 . . . . 0.0 110.724 -179.727 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.792 HG23 HG21 ' A' ' 102' ' ' ILE . 66.8 t -87.74 120.47 36.91 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.542 174.903 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.543 HG21 ' O ' ' A' ' 101' ' ' GLY . 22.7 m -82.05 160.53 62.94 Favored Pre-proline 0 C--N 1.325 -0.492 0 CA-C-N 116.777 -0.192 . . . . 0.0 110.534 -177.307 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_exo -66.86 99.24 0.45 Allowed 'Trans proline' 0 C--O 1.236 0.376 0 C-N-CA 122.584 2.19 . . . . 0.0 112.434 178.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.416 ' O ' ' HB2' ' A' ' 39' ' ' SER . . . 145.13 -165.17 27.82 Favored Glycine 0 N--CA 1.447 -0.592 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.566 178.762 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' SER . . . . . 0.446 ' HB3' HD22 ' A' ' 91' ' ' ASN . 51.0 p 64.37 157.76 0.12 Allowed Pre-proline 0 N--CA 1.473 0.682 0 C-N-CA 124.598 1.159 . . . . 0.0 112.168 179.194 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 2.0 Cg_endo -82.78 -5.53 11.51 Favored 'Trans proline' 0 N--CA 1.46 -0.497 0 C-N-CA 122.984 2.456 . . . . 0.0 112.102 175.756 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -96.68 -0.7 47.99 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.414 -176.575 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.416 ' HB2' ' O ' ' A' ' 35' ' ' GLY . 32.1 t -60.87 -30.78 70.34 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.617 -176.224 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 62.9 tttp -107.39 7.72 29.23 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.929 0.395 . . . . 0.0 110.739 -179.326 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 57.6 t -91.2 -55.69 5.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-O 120.962 0.411 . . . . 0.0 110.129 178.755 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 5.2 mp -108.61 162.04 14.51 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.266 -0.425 . . . . 0.0 109.974 178.061 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 20.5 p -112.42 155.64 43.4 Favored Pre-proline 0 C--N 1.317 -0.84 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 177.403 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -70.0 146.05 57.56 Favored 'Trans proline' 0 N--CA 1.459 -0.548 0 C-N-CA 121.65 1.567 . . . . 0.0 111.464 178.133 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 94.84 12.41 55.52 Favored Glycine 0 CA--C 1.522 0.521 0 C-N-CA 120.615 -0.802 . . . . 0.0 113.618 179.938 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 0.523 ' HB2' HD11 ' A' ' 29' ' ' ILE . 86.8 mt -98.0 162.03 13.43 Favored 'General case' 0 C--N 1.334 -0.105 0 CA-C-N 117.499 0.65 . . . . 0.0 110.904 177.063 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 59.6 t -110.79 128.31 67.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.781 -177.608 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.449 ' HB ' HG21 ' A' ' 27' ' ' VAL . 76.4 mt -91.66 121.34 42.04 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.396 179.743 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 61.9 mt-10 -82.54 -50.0 9.28 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.702 -179.279 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.555 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 15.2 p -159.29 153.88 24.32 Favored 'General case' 0 N--CA 1.45 -0.441 0 CA-C-O 121.223 0.535 . . . . 0.0 112.122 -172.757 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 64.2 mt -122.78 101.58 9.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 115.158 -0.928 . . . . 0.0 110.113 176.616 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 35.0 t-20 55.26 67.9 0.95 Allowed 'General case' 0 N--CA 1.464 0.274 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.2 176.443 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 79.59 -46.14 3.02 Favored Glycine 0 CA--C 1.519 0.304 0 CA-C-N 115.559 -0.746 . . . . 0.0 112.944 178.639 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 64.0 mtm -80.96 114.28 47.36 Favored Pre-proline 0 C--N 1.324 -0.511 0 N-CA-C 110.157 -0.312 . . . . 0.0 110.157 -178.838 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.555 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 98.1 Cg_endo -80.02 146.13 17.99 Favored 'Trans proline' 0 N--CA 1.458 -0.597 0 C-N-CA 122.351 2.034 . . . . 0.0 112.573 -176.966 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 22.3 p -110.41 76.26 0.97 Allowed 'General case' 0 N--CA 1.447 -0.618 0 CA-C-O 121.355 0.598 . . . . 0.0 111.062 -179.473 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' SER . . . . . 0.475 ' HA ' ' HA2' ' A' ' 26' ' ' GLY . 16.5 m -84.6 -15.07 46.9 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.175 177.643 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . 0.638 HD21 ' HG3' ' A' ' 24' ' ' PRO . 6.3 t-20 -140.12 175.79 9.3 Favored 'General case' 0 N--CA 1.449 -0.476 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.091 -179.336 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.447 ' HG ' ' OD1' ' A' ' 106' ' ' ASN . 28.6 mt -75.4 -31.35 60.39 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.858 179.508 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 1.5 m -65.39 -43.3 91.07 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.634 178.292 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 7.2 p -64.92 -37.18 86.79 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.055 0.455 . . . . 0.0 110.325 177.083 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' TYR . . . . . 0.43 ' O ' ' HB2' ' A' ' 66' ' ' LEU . 84.4 t80 -62.85 -44.66 95.54 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.771 -0.65 . . . . 0.0 109.857 174.928 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 47.2 m -61.98 -47.16 86.08 Favored 'General case' 0 N--CA 1.446 -0.644 0 CA-C-N 115.286 -0.87 . . . . 0.0 111.997 179.225 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.44 -30.62 71.66 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.187 -178.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . 0.448 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -77.58 -44.2 29.24 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 121.09 0.471 . . . . 0.0 110.011 177.14 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . 0.455 HD22 ' HA ' ' A' ' 66' ' ' LEU . 0.2 OUTLIER -57.47 -36.43 71.45 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.358 -0.837 . . . . 0.0 112.166 -176.768 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 19.7 ptmt -71.95 -18.34 62.01 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 120.772 -0.371 . . . . 0.0 111.662 -177.676 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 44.6 p -92.12 -13.49 30.64 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.978 0.418 . . . . 0.0 110.767 -178.876 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.506 HD13 HG21 ' A' ' 75' ' ' ILE . 19.6 mm -83.35 144.91 9.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.356 -0.384 . . . . 0.0 109.998 -178.888 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 13.0 m -105.28 164.38 11.88 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.497 -0.319 . . . . 0.0 110.469 -179.438 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 36.2 t -77.5 119.48 26.21 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 175.349 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 88.63 22.83 38.35 Favored Glycine 0 N--CA 1.45 -0.409 0 N-CA-C 111.046 -0.822 . . . . 0.0 111.046 -175.57 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 5.2 tp10 -99.65 148.54 24.23 Favored 'General case' 0 C--N 1.324 -0.5 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 -179.826 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 52.9 t -104.39 127.95 58.3 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 177.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.506 HG21 HD13 ' A' ' 69' ' ' ILE . 16.1 pt -125.61 161.22 30.8 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-O 121.342 0.591 . . . . 0.0 111.903 -176.733 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 7.9 t30 -106.92 105.91 16.18 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.211 -0.904 . . . . 0.0 110.285 -179.069 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 72.6 mt -108.36 114.02 45.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-O 121.528 0.68 . . . . 0.0 110.496 -177.232 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' THR . . . . . 0.442 ' HA ' ' HA ' ' A' ' 83' ' ' THR . 10.2 m -95.15 120.4 35.31 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 115.58 -0.737 . . . . 0.0 109.496 -179.559 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 45.8 p -112.61 175.65 5.35 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.535 -0.302 . . . . 0.0 110.522 -178.924 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 15.9 t70 -59.22 -28.24 66.48 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.016 179.296 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 1.5 mp0 -98.05 16.83 19.93 Favored 'General case' 0 C--O 1.235 0.294 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.887 -177.551 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 121.86 177.72 15.53 Favored Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 120.391 -0.909 . . . . 0.0 113.452 174.901 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' THR . . . . . 0.442 ' HA ' ' HA ' ' A' ' 78' ' ' THR . 3.9 m -90.28 119.53 30.66 Favored 'General case' 0 C--N 1.324 -0.526 0 C-N-CA 122.609 0.364 . . . . 0.0 110.782 -178.708 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -116.69 157.18 25.85 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 121.149 0.499 . . . . 0.0 110.554 178.468 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 43.0 p-80 -111.97 129.98 56.01 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-N 115.614 -0.721 . . . . 0.0 109.223 176.8 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 7.5 tt -126.86 149.78 49.57 Favored 'General case' 0 C--N 1.314 -0.957 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.255 -173.716 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 1.7 tmtp? -124.9 124.14 41.42 Favored 'General case' 0 C--N 1.316 -0.874 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.316 179.778 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' THR . . . . . 0.484 HG22 ' HB3' ' A' ' 98' ' ' ALA . 73.5 p -74.73 127.95 34.39 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.592 -177.609 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -159.92 103.34 0.22 Allowed Glycine 0 N--CA 1.445 -0.738 0 C-N-CA 119.564 -1.303 . . . . 0.0 114.457 -177.535 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.497 ' HD2' ' N ' ' A' ' 90' ' ' ARG . 6.9 mpt_? 47.97 119.32 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.83 0 N-CA-C 116.361 1.985 . . . . 0.0 116.361 165.14 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' ASN . . . . . 0.804 ' HB2' ' HB3' ' A' ' 99' ' ' TYR . 4.9 m-20 -154.4 144.27 15.48 Favored Pre-proline 0 C--N 1.326 -0.448 0 CA-C-N 115.096 -0.956 . . . . 0.0 109.406 171.683 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 9.7 Cg_endo -53.08 -55.36 3.76 Favored 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 123.275 2.65 . . . . 0.0 112.927 -176.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 64.3 t30 -148.42 74.58 1.29 Allowed 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.185 0.517 . . . . 0.0 110.659 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -84.56 -52.05 6.42 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 176.508 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 47.1 m -158.12 -68.93 0.09 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.739 -0.664 . . . . 0.0 109.312 177.718 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 8.7 t -171.07 -58.11 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 108.871 -0.789 . . . . 0.0 108.871 177.31 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -124.02 159.83 28.99 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.675 -0.693 . . . . 0.0 109.253 175.558 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . 0.484 ' HB3' HG22 ' A' ' 88' ' ' THR . . . 55.87 84.96 0.07 Allowed 'General case' 0 N--CA 1.465 0.31 0 O-C-N 123.994 0.809 . . . . 0.0 111.788 179.417 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . 0.804 ' HB3' ' HB2' ' A' ' 91' ' ' ASN . 26.8 m-85 -89.23 109.35 20.24 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.457 -178.076 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 61.0 mtm -86.19 -35.27 20.17 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.344 -178.708 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . 0.573 ' HA2' ' ND2' ' A' ' 91' ' ' ASN . . . 114.46 -13.74 20.77 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.382 -0.914 . . . . 0.0 113.755 176.443 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.792 HG21 HG23 ' A' ' 32' ' ' VAL . 2.7 pp -120.06 149.37 22.79 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.791 0 O-C-N 122.429 -0.454 . . . . 0.0 110.422 179.79 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -88.91 137.09 32.63 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 176.291 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -109.48 145.58 36.0 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.317 -177.523 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 32.2 p -137.67 168.27 20.02 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.619 -0.719 . . . . 0.0 109.576 176.256 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . 0.447 ' OD1' ' HG ' ' A' ' 59' ' ' LEU . 1.0 OUTLIER -83.71 -37.32 22.86 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.23 -178.423 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . 0.647 ' HB2' ' HB3' ' A' ' 28' ' ' GLN . 35.7 t60 56.9 35.83 26.89 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 115.51 -0.768 . . . . 0.0 111.138 174.14 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 91.4 mt -89.82 -172.97 3.74 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 121.812 0.815 . . . . 0.0 111.726 -175.319 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . 0.421 HH11 ' HD3' ' A' ' 109' ' ' ARG . 15.5 ttm180 -149.01 123.99 10.02 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 114.251 -1.341 . . . . 0.0 109.251 179.353 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 9.8 p -141.16 147.01 22.85 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-O 121.104 0.478 . . . . 0.0 110.195 175.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' ARG . . . . . . . . . . . . . 22.8 ttt180 -112.33 173.89 6.15 Favored 'General case' 0 C--N 1.313 -0.985 0 N-CA-C 108.264 -1.013 . . . . 0.0 108.264 178.307 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -72.19 72.71 0.91 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.709 0.766 . . . . 0.0 111.015 179.426 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 31.1 m -143.85 112.15 6.36 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 115.029 -0.987 . . . . 0.0 108.956 178.584 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 4.9 m -76.7 94.73 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-O 121.648 0.737 . . . . 0.0 111.45 -177.757 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -113.93 105.65 13.49 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-N 115.125 -0.943 . . . . 0.0 110.273 -178.773 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 12.1 t -138.09 75.08 1.5 Allowed 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 121.417 0.627 . . . . 0.0 109.436 -179.274 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 4.5 p -119.58 114.01 42.92 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.582 0 CA-C-O 121.647 0.737 . . . . 0.0 111.037 -179.054 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 92.5 mt -108.98 -41.42 4.73 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-N 115.31 -0.859 . . . . 0.0 109.409 176.326 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 65.87 22.06 69.96 Favored Glycine 0 N--CA 1.449 -0.443 0 CA-C-N 115.635 -0.712 . . . . 0.0 112.142 -178.779 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 16.7 p-10 -74.0 107.52 6.26 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.521 0.677 . . . . 0.0 110.976 -175.296 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 11.7 t -119.2 134.92 54.93 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.584 -0.735 . . . . 0.0 109.403 178.52 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 93.0 mt -126.74 122.95 23.66 Favored Pre-proline 0 C--N 1.326 -0.451 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.566 -175.717 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -69.79 132.6 23.62 Favored 'Trans proline' 0 CA--C 1.529 0.263 0 C-N-CA 122.656 2.237 . . . . 0.0 112.07 179.185 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -87.28 119.68 27.78 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.304 179.18 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.979 0 CA-C-O 118.912 -0.565 . . . . 0.0 110.309 -179.65 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.429 ' HA ' ' HD3' ' A' ' 24' ' ' PRO . 52.8 tt0 . . . . . 0 N--CA 1.45 -0.44 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.429 ' HD3' ' HA ' ' A' ' 23' ' ' GLN . 17.3 Cg_exo -70.28 -164.47 0.14 Allowed 'Trans proline' 0 C--O 1.231 0.139 0 C-N-CA 123.316 2.677 . . . . 0.0 113.367 -179.195 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.708 ' HA ' ' HB3' ' A' ' 57' ' ' SER . 30.7 t0 75.36 32.07 0.75 Allowed 'General case' 0 N--CA 1.469 0.49 0 CA-C-N 114.767 -1.106 . . . . 0.0 109.255 -175.618 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 146.81 148.8 4.83 Favored Glycine 0 N--CA 1.444 -0.779 0 CA-C-N 114.648 -1.16 . . . . 0.0 111.448 176.041 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.421 HG22 ' HB ' ' A' ' 48' ' ' ILE . 29.3 m -122.51 144.1 33.05 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-O 121.018 0.437 . . . . 0.0 111.085 -179.63 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 35.0 tt0 -112.32 153.32 27.4 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 110.004 -0.369 . . . . 0.0 110.004 175.697 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 60.3 mt -78.86 112.55 17.04 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-N 116.314 -0.403 . . . . 0.0 109.921 178.85 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.612 ' HB3' ' HB2' ' A' ' 103' ' ' ARG . 22.5 t70 -64.32 -65.11 0.72 Allowed 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.789 -0.641 . . . . 0.0 109.713 178.559 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 20.7 p -156.8 154.39 29.85 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.166 -0.925 . . . . 0.0 110.586 179.103 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.601 HG22 HG21 ' A' ' 102' ' ' ILE . 13.5 p -91.25 143.67 10.77 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 176.884 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 61.6 t -97.13 114.88 65.42 Favored Pre-proline 0 C--N 1.321 -0.636 0 N-CA-C 110.16 -0.311 . . . . 0.0 110.16 177.708 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -55.19 122.3 11.47 Favored 'Trans proline' 0 C--N 1.346 0.411 0 C-N-CA 123.094 2.529 . . . . 0.0 112.033 178.761 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 122.05 7.92 7.57 Favored Glycine 0 N--CA 1.446 -0.695 0 CA-C-N 115.55 -0.75 . . . . 0.0 111.711 -176.505 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 72.3 p -121.33 150.19 53.69 Favored Pre-proline 0 C--N 1.325 -0.457 0 CA-C-O 120.676 0.274 . . . . 0.0 110.497 -179.013 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -67.59 -16.33 46.7 Favored 'Trans proline' 0 C--N 1.346 0.421 0 C-N-CA 122.639 2.226 . . . . 0.0 112.513 179.648 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.487 ' HA ' HD13 ' A' ' 86' ' ' LEU . . . -60.34 -36.82 78.87 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.568 -177.518 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 22.9 t -64.69 -23.68 67.33 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.617 -176.533 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 63.4 tttp -82.0 -26.03 34.21 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.027 0.441 . . . . 0.0 110.683 -177.505 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 38.6 t -99.22 -55.86 5.67 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.503 -175.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 1.9 pp -108.81 -178.02 3.47 Favored 'General case' 0 CA--C 1.516 -0.334 0 CA-C-O 121.527 0.68 . . . . 0.0 111.959 -177.472 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 5.4 p -127.85 143.53 48.04 Favored Pre-proline 0 C--N 1.315 -0.894 0 CA-C-N 114.94 -1.027 . . . . 0.0 110.645 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -66.69 146.19 78.13 Favored 'Trans proline' 0 N--CA 1.462 -0.347 0 C-N-CA 122.39 2.06 . . . . 0.0 111.627 175.643 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 102.55 -7.74 54.03 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.568 -178.105 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 89.1 mt -80.63 163.34 23.7 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.91 0.386 . . . . 0.0 110.772 179.061 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.423 ' O ' ' HA ' ' A' ' 79' ' ' THR . 44.3 t -103.24 137.15 32.68 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 N-CA-C 109.422 -0.585 . . . . 0.0 109.422 176.858 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.421 ' HB ' HG22 ' A' ' 27' ' ' VAL . 63.2 mt -103.15 121.26 54.16 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-O 120.786 0.327 . . . . 0.0 110.603 -179.213 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -82.71 -47.44 12.0 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.018 0.437 . . . . 0.0 110.848 177.501 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.596 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 6.1 p -152.15 146.28 25.36 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 121.176 0.512 . . . . 0.0 112.244 -174.185 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 47.4 mm -110.89 101.47 12.6 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-N 114.699 -1.137 . . . . 0.0 108.211 173.488 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 4.6 t-20 66.13 -152.15 0.23 Allowed 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 -172.493 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -73.42 7.28 12.64 Favored Glycine 0 CA--C 1.523 0.554 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.656 177.143 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 2.1 mpt? -111.62 102.53 53.57 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 120.812 0.339 . . . . 0.0 110.131 -179.667 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.596 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 44.5 Cg_endo -71.67 124.27 10.11 Favored 'Trans proline' 0 N--CA 1.46 -0.458 0 C-N-CA 122.146 1.897 . . . . 0.0 112.215 179.661 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 16.8 p -92.13 96.89 10.58 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.877 -0.602 . . . . 0.0 111.358 -176.369 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' SER . . . . . 0.708 ' HB3' ' HA ' ' A' ' 25' ' ' ASP . 14.2 m -94.75 -19.65 20.19 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.303 178.857 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 76.2 m-20 -123.92 164.32 19.53 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.13 -178.886 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 84.5 mt -75.81 -30.47 59.05 Favored 'General case' 0 N--CA 1.443 -0.802 0 CA-C-O 121.185 0.517 . . . . 0.0 109.906 177.924 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 9.6 m -69.17 -39.47 78.74 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.611 -0.722 . . . . 0.0 111.152 178.512 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -71.05 -27.9 63.98 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.628 0.251 . . . . 0.0 111.065 179.909 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 87.1 t80 -64.41 -40.72 96.32 Favored 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 173.069 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' SER . . . . . 0.4 ' O ' ' HD3' ' A' ' 67' ' ' LYS . 7.0 t -66.68 -43.33 84.73 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.732 -0.667 . . . . 0.0 109.855 176.596 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.31 -33.21 74.22 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 121.164 0.507 . . . . 0.0 110.793 179.693 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . 0.679 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -69.01 -49.3 58.96 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.946 -0.57 . . . . 0.0 109.831 176.357 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 11.2 mt -58.57 -36.47 73.99 Favored 'General case' 0 N--CA 1.448 -0.575 0 CA-C-N 116.002 -0.544 . . . . 0.0 112.129 -177.387 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . 0.4 ' HD3' ' O ' ' A' ' 63' ' ' SER . 2.4 mptm? -77.52 -7.04 55.65 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 112.494 0.553 . . . . 0.0 112.494 -179.029 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 9.0 p -110.41 -13.69 14.24 Favored 'General case' 0 C--N 1.323 -0.557 0 C-N-CA 120.807 -0.357 . . . . 0.0 111.785 178.755 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.679 HG12 ' O ' ' A' ' 65' ' ' ALA . 33.4 mm -73.33 148.33 8.91 Favored 'Isoleucine or valine' 0 C--O 1.234 0.237 0 N-CA-C 110.17 -0.307 . . . . 0.0 110.17 177.685 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' SER . . . . . 0.576 ' HB2' ' HB2' ' A' ' 73' ' ' GLU . 3.2 m -84.89 164.63 18.27 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.269 177.675 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 26.7 t -82.2 123.13 37.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 177.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 81.9 21.73 60.84 Favored Glycine 0 N--CA 1.448 -0.548 0 C-N-CA 120.574 -0.822 . . . . 0.0 111.549 -178.496 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.576 ' HB2' ' HB2' ' A' ' 70' ' ' SER . 34.4 tt0 -96.5 150.12 20.98 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -178.561 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 48.0 t -100.33 120.44 49.79 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.759 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.285 -177.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 27.7 pt -113.86 154.53 15.23 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-N 115.998 -0.547 . . . . 0.0 110.913 -179.47 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 13.0 t30 -93.33 118.18 30.97 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.467 179.676 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 51.3 mt -114.34 103.99 16.22 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.832 0 CA-C-O 121.417 0.627 . . . . 0.0 109.85 178.335 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 15.9 m -90.41 111.17 22.32 Favored 'General case' 0 C--N 1.315 -0.929 0 CA-C-N 115.701 -0.682 . . . . 0.0 109.729 179.225 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.423 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 73.3 p -107.63 171.81 7.18 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.961 0.41 . . . . 0.0 111.692 -176.74 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -52.34 -33.37 42.53 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.159 -0.928 . . . . 0.0 112.826 -178.501 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 17.4 mt-30 -127.0 27.07 6.02 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 112.334 0.494 . . . . 0.0 112.334 -174.101 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 161.32 146.23 4.57 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 119.764 -1.208 . . . . 0.0 114.053 174.788 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 8.8 m -98.57 109.75 22.46 Favored 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 175.113 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 59.7 m-85 -115.36 158.53 22.3 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.806 0.336 . . . . 0.0 110.801 -174.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 14.3 p80 -118.9 114.57 22.8 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 121.312 0.577 . . . . 0.0 110.022 174.241 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.487 HD13 ' HA ' ' A' ' 38' ' ' ALA . 3.5 mm? -107.33 148.59 28.84 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-N 115.297 -0.865 . . . . 0.0 111.247 -173.449 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 40.3 ttmt -98.77 130.31 45.22 Favored 'General case' 0 C--N 1.321 -0.664 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 173.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' THR . . . . . 0.472 HG21 HG23 ' A' ' 69' ' ' ILE . 15.1 p -71.05 129.69 39.61 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-O 121.0 0.429 . . . . 0.0 110.558 176.43 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -81.9 178.4 53.64 Favored Glycine 0 N--CA 1.434 -1.457 0 N-CA-C 110.936 -0.865 . . . . 0.0 110.936 -179.776 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -86.88 -53.57 4.83 Favored 'General case' 0 C--N 1.309 -1.155 0 C-N-CA 120.801 -0.36 . . . . 0.0 110.869 -179.92 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' ASN . . . . . . . . . . . . . 26.4 p30 176.03 159.38 0.43 Allowed Pre-proline 0 C--N 1.329 -0.283 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 179.754 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 8.2 Cg_exo -72.69 -74.79 0.01 OUTLIER 'Trans proline' 0 N--CA 1.46 -0.456 0 C-N-CA 122.17 1.913 . . . . 0.0 111.313 175.017 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 5.6 m120 -138.6 -34.66 0.61 Allowed 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.745 177.536 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 3.4 m-20 -77.96 166.23 23.11 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.966 -179.669 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 3.4 p -69.11 110.12 4.37 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.994 -177.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 49.7 m -159.39 167.06 29.72 Favored 'General case' 0 C--O 1.234 0.25 0 CA-C-N 115.962 -0.563 . . . . 0.0 109.859 178.366 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -147.13 149.11 32.37 Favored 'General case' 0 N--CA 1.453 -0.291 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 176.991 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . 53.01 73.44 0.36 Allowed 'General case' 0 N--CA 1.467 0.409 0 O-C-N 123.574 0.546 . . . . 0.0 110.124 -177.56 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 46.4 t80 -120.83 128.35 52.77 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.411 -167.129 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 46.4 tpp -108.06 120.24 41.76 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 173.868 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -86.52 57.17 4.72 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.788 -0.72 . . . . 0.0 114.124 -170.79 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.601 HG21 HG22 ' A' ' 32' ' ' VAL . 2.6 pp -143.82 148.92 18.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 173.066 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . 0.612 ' HB2' ' HB3' ' A' ' 30' ' ' ASP . 43.4 mtp180 -90.87 143.34 26.82 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 116.376 -0.374 . . . . 0.0 110.264 176.749 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 2.1 p -115.82 143.4 45.45 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 121.063 0.458 . . . . 0.0 110.962 178.924 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 37.3 t -136.3 169.57 17.44 Favored 'General case' 0 C--N 1.317 -0.832 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 177.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 5.4 p30 -105.49 37.1 2.3 Favored 'General case' 0 C--N 1.31 -1.109 0 CA-C-O 122.031 0.919 . . . . 0.0 109.692 178.701 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 20.9 t-80 -80.32 92.44 5.78 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 114.884 -1.053 . . . . 0.0 109.926 175.766 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 31.8 mt -77.09 -164.68 0.47 Allowed 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 121.768 0.794 . . . . 0.0 110.713 179.111 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 85.7 mtm180 -89.17 95.77 10.44 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-N 114.897 -1.047 . . . . 0.0 110.096 178.933 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 43.3 t -67.87 130.06 32.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.124 -179.883 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' ARG . . . . . 0.413 HH11 ' HD3' ' A' ' 111' ' ' ARG . 18.6 ptt-85 -120.96 2.51 10.49 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.203 -175.377 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 32.6 t70 -178.91 161.52 1.2 Allowed 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 177.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 42.3 m -69.0 90.37 0.44 Allowed 'General case' 0 C--N 1.318 -0.782 0 CA-C-O 120.885 0.374 . . . . 0.0 110.16 177.598 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 28.3 m -82.84 142.13 14.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.824 -176.237 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . 59.33 -85.3 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 115.235 -0.893 . . . . 0.0 112.418 178.452 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 13.5 p -165.01 99.3 0.75 Allowed 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.157 -0.474 . . . . 0.0 109.939 -178.574 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 7.3 m -108.14 88.76 1.18 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-O 121.762 0.791 . . . . 0.0 111.279 -179.43 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 94.9 mt -120.62 -41.88 2.56 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.331 -0.85 . . . . 0.0 109.678 177.901 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 115.58 140.71 7.14 Favored Glycine 0 N--CA 1.447 -0.605 0 CA-C-N 115.734 -0.666 . . . . 0.0 112.178 178.988 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 15.4 m-20 -76.51 105.68 7.71 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 110.162 -0.31 . . . . 0.0 110.162 177.312 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 17.0 p -69.05 107.32 3.11 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 121.093 0.473 . . . . 0.0 110.361 177.172 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 85.7 mt -73.52 145.43 84.91 Favored Pre-proline 0 C--N 1.323 -0.574 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.028 -177.52 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 7.2 Cg_endo -49.4 115.55 1.82 Allowed 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 123.213 2.609 . . . . 0.0 112.253 -178.393 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 60.1 t80 -115.71 95.2 5.02 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.527 179.36 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.976 0 CA-C-O 118.123 -0.942 . . . . 0.0 110.116 -179.63 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . . . . . . . . . 22.4 mp0 . . . . . 0 CA--C 1.539 0.524 0 CA-C-O 120.649 0.261 . . . . 0.0 111.42 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -80.37 172.6 13.41 Favored 'Trans proline' 0 N--CA 1.461 -0.441 0 C-N-CA 122.088 1.859 . . . . 0.0 111.643 173.046 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 12.1 t70 69.64 39.4 1.54 Allowed 'General case' 0 N--CA 1.467 0.404 0 CA-C-O 121.901 0.858 . . . . 0.0 110.12 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 173.7 140.89 3.35 Favored Glycine 0 N--CA 1.446 -0.662 0 CA-C-N 114.792 -1.094 . . . . 0.0 111.266 177.139 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 28.8 m -120.76 146.4 25.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 116.819 0.309 . . . . 0.0 110.319 179.279 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -123.0 159.45 28.33 Favored 'General case' 0 C--N 1.322 -0.594 0 C-N-CA 120.503 -0.479 . . . . 0.0 110.997 -178.722 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 56.5 mt -81.7 106.14 12.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 115.907 -0.588 . . . . 0.0 109.949 179.641 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 14.8 t70 -68.03 -63.78 0.99 Allowed 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 116.054 -0.521 . . . . 0.0 109.88 -177.568 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 2.2 p -155.41 140.47 17.4 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.912 -0.586 . . . . 0.0 111.829 -177.312 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.624 HG23 HG21 ' A' ' 102' ' ' ILE . 96.5 t -86.91 126.45 40.84 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.208 -0.451 . . . . 0.0 109.819 177.89 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 5.6 m -103.38 129.19 25.94 Favored Pre-proline 0 N--CA 1.451 -0.419 0 CA-C-O 121.117 0.484 . . . . 0.0 111.863 -175.659 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -69.3 164.25 34.81 Favored 'Trans proline' 0 C--O 1.235 0.331 0 C-N-CA 122.743 2.295 . . . . 0.0 112.048 176.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 98.12 -34.13 5.46 Favored Glycine 0 N--CA 1.449 -0.436 0 N-CA-C 110.661 -0.976 . . . . 0.0 110.661 -174.605 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' SER . . . . . 0.403 ' HB2' ' HD2' ' A' ' 37' ' ' PRO . 0.7 OUTLIER -104.84 169.86 6.66 Favored Pre-proline 0 C--N 1.317 -0.835 0 CA-C-N 114.721 -0.74 . . . . 0.0 109.569 175.347 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . 0.403 ' HD2' ' HB2' ' A' ' 36' ' ' SER . 42.3 Cg_endo -68.59 -170.26 0.31 Allowed 'Trans proline' 0 CA--C 1.534 0.492 0 C-N-CA 122.264 1.976 . . . . 0.0 112.74 177.827 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 74.53 6.19 4.53 Favored 'General case' 0 N--CA 1.471 0.577 0 C-N-CA 123.575 0.75 . . . . 0.0 112.343 179.733 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 23.1 t -52.35 -62.18 1.8 Allowed 'General case' 0 C--O 1.233 0.232 0 O-C-N 123.448 0.467 . . . . 0.0 110.608 -179.712 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 3.3 tmtp? -111.24 65.37 0.62 Allowed 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 172.328 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 36.5 t -137.94 -49.77 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.382 -0.826 . . . . 0.0 109.292 175.793 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 6.3 mp -119.58 171.49 8.33 Favored 'General case' 0 C--O 1.234 0.262 0 CA-C-N 115.625 -0.716 . . . . 0.0 109.88 176.079 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' THR . . . . . 0.442 ' HG1' HD11 ' A' ' 46' ' ' LEU . 7.3 p -126.65 146.58 57.47 Favored Pre-proline 0 C--N 1.322 -0.612 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.487 177.474 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 76.9 Cg_endo -76.95 157.03 34.62 Favored 'Trans proline' 0 C--O 1.233 0.246 0 C-N-CA 122.549 2.166 . . . . 0.0 111.975 178.402 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 90.62 11.71 61.84 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.58 -0.819 . . . . 0.0 112.697 179.063 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 0.442 HD11 ' HG1' ' A' ' 43' ' ' THR . 64.7 mt -103.47 164.36 11.7 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.809 0.304 . . . . 0.0 110.207 178.042 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 48.1 t -105.98 137.66 35.0 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 N-CA-C 110.315 -0.254 . . . . 0.0 110.315 176.307 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 60.3 mt -95.72 129.78 45.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 121.097 0.475 . . . . 0.0 110.846 -178.411 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 22.3 tt0 -86.66 -56.02 3.6 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.635 -0.711 . . . . 0.0 110.198 175.612 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.568 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 13.7 p -148.99 152.49 36.4 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.243 -0.889 . . . . 0.0 112.067 -170.556 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 49.7 mm -111.41 85.44 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.043 -0.98 . . . . 0.0 109.742 176.315 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' ASN . . . . . 0.558 ' HB2' ' H ' ' A' ' 76' ' ' ASN . 62.3 t30 54.72 78.88 0.16 Allowed 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 114.843 -1.072 . . . . 0.0 111.949 176.727 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 83.37 -49.06 4.16 Favored Glycine 0 N--CA 1.447 -0.579 0 CA-C-N 115.541 -0.754 . . . . 0.0 112.459 178.976 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 58.4 mtm -85.56 111.78 39.64 Favored Pre-proline 0 C--N 1.324 -0.521 0 N-CA-C 110.387 -0.227 . . . . 0.0 110.387 -179.718 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.568 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 70.6 Cg_endo -75.1 134.04 17.16 Favored 'Trans proline' 0 N--CA 1.458 -0.577 0 C-N-CA 122.054 1.836 . . . . 0.0 111.833 178.921 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 24.5 p -109.34 93.37 4.47 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 121.47 0.652 . . . . 0.0 111.547 -175.497 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 19.3 m -99.74 -14.31 18.92 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 115.229 -0.896 . . . . 0.0 110.155 177.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 52.7 m-80 -125.98 159.27 33.1 Favored 'General case' 0 C--N 1.319 -0.74 0 C-N-CA 120.502 -0.479 . . . . 0.0 109.887 -179.268 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 96.6 mt -70.74 -28.29 64.59 Favored 'General case' 0 N--CA 1.44 -0.954 0 CA-C-N 115.734 -0.666 . . . . 0.0 109.387 177.144 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 5.1 m -69.54 -48.92 58.8 Favored 'General case' 0 N--CA 1.448 -0.565 0 CA-C-N 115.254 -0.884 . . . . 0.0 110.629 178.557 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 1.7 p -67.42 -34.37 77.08 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.77 0.319 . . . . 0.0 111.042 178.095 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 25.8 t80 -62.54 -40.11 95.77 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.308 0.575 . . . . 0.0 109.618 175.381 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' SER . . . . . 0.522 ' O ' ' HG3' ' A' ' 67' ' ' LYS . 8.1 t -67.33 -45.13 77.32 Favored 'General case' 0 N--CA 1.452 -0.37 0 CA-C-N 115.459 -0.791 . . . . 0.0 110.36 178.576 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -60.02 -38.35 82.45 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.811 -179.217 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . 0.507 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -65.11 -46.0 82.84 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.377 -179.49 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 2.3 tt -58.58 -42.3 87.72 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.756 -0.657 . . . . 0.0 110.544 -179.413 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . 0.522 ' HG3' ' O ' ' A' ' 63' ' ' SER . 96.0 mttt -63.33 -23.51 67.45 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.566 -0.743 . . . . 0.0 112.483 -177.102 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 77.5 p -90.9 -13.07 34.3 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.779 0.323 . . . . 0.0 111.35 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.519 HG21 HG23 ' A' ' 88' ' ' THR . 45.9 mm -72.68 136.42 25.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 121.174 0.511 . . . . 0.0 111.265 -176.789 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 4.4 m -82.45 143.99 30.77 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.84 -0.618 . . . . 0.0 109.588 174.957 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 16.8 t -71.72 115.83 12.53 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-N 116.372 -0.377 . . . . 0.0 110.467 -177.074 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . 0.444 ' HA2' ' O ' ' A' ' 88' ' ' THR . . . 98.27 4.88 57.31 Favored Glycine 0 N--CA 1.447 -0.63 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.076 179.71 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -90.68 154.96 19.18 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 120.715 0.293 . . . . 0.0 110.27 -178.087 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 49.0 t -94.32 118.73 40.97 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.582 -178.486 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 32.5 pt -103.01 167.7 2.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.728 178.728 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . 0.558 ' H ' ' HB2' ' A' ' 52' ' ' ASN . 43.3 t30 -120.06 106.56 12.11 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.883 -172.283 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 57.6 mt -105.49 109.32 27.41 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.808 0 CA-C-O 121.328 0.585 . . . . 0.0 110.769 -174.675 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 31.1 m -89.72 114.78 26.5 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.494 -0.775 . . . . 0.0 109.72 176.485 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 69.4 p -112.55 174.15 6.03 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 110.29 -0.263 . . . . 0.0 110.29 179.02 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 12.4 t70 -63.27 -30.36 71.51 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.342 178.244 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 8.2 tp-100 -95.64 14.57 22.57 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.333 0.587 . . . . 0.0 110.891 -176.345 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 127.36 179.67 15.94 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.53 176.941 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 55.6 m -109.92 129.45 55.65 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-O 120.696 0.284 . . . . 0.0 110.561 -178.329 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 23.5 m-85 -128.43 152.42 48.23 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 -179.607 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 7.8 p-80 -109.24 133.21 53.33 Favored 'General case' 0 C--N 1.322 -0.621 0 C-N-CA 120.62 -0.432 . . . . 0.0 110.011 174.041 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.474 HD22 ' N ' ' A' ' 87' ' ' LYS . 5.5 tt -118.97 137.53 53.43 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 115.918 -0.583 . . . . 0.0 109.734 -175.085 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.474 ' N ' HD22 ' A' ' 86' ' ' LEU . 62.1 tttp -98.41 117.05 31.95 Favored 'General case' 0 C--N 1.311 -1.1 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 179.049 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' THR . . . . . 0.519 HG23 HG21 ' A' ' 69' ' ' ILE . 16.9 p -66.95 135.41 53.75 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 121.152 0.501 . . . . 0.0 111.154 -176.465 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -99.66 -157.64 28.63 Favored Glycine 0 N--CA 1.439 -1.155 0 N-CA-C 111.004 -0.838 . . . . 0.0 111.004 177.03 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 5.7 mpt_? -116.62 177.95 4.51 Favored 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 109.716 -0.475 . . . . 0.0 109.716 177.535 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' ASN . . . . . 0.428 ' HA ' ' HD3' ' A' ' 92' ' ' PRO . 47.4 t-20 -75.28 114.57 36.88 Favored Pre-proline 0 C--N 1.322 -0.587 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 169.85 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.428 ' HD3' ' HA ' ' A' ' 91' ' ' ASN . 36.5 Cg_exo -59.67 -19.57 53.88 Favored 'Trans proline' 0 C--O 1.233 0.237 0 C-N-CA 122.887 2.391 . . . . 0.0 112.834 -172.638 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 27.7 t-20 -112.91 -49.11 2.95 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 112.245 0.461 . . . . 0.0 112.245 -176.749 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . 0.419 ' CG ' ' H ' ' A' ' 95' ' ' SER . 4.8 t-20 -111.7 -154.31 0.54 Allowed 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 120.952 -0.299 . . . . 0.0 111.301 -171.551 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' SER . . . . . 0.419 ' H ' ' CG ' ' A' ' 94' ' ' ASN . 25.4 m -52.27 138.3 26.76 Favored 'General case' 0 CA--C 1.53 0.186 0 C-N-CA 123.622 0.769 . . . . 0.0 112.527 -174.463 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 1.7 m -68.69 98.22 0.88 Allowed 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.479 -0.782 . . . . 0.0 112.037 -175.758 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 1.5 tpt180 -106.41 152.61 23.38 Favored 'General case' 0 C--N 1.315 -0.904 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 174.248 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -64.98 95.3 0.15 Allowed 'General case' 0 C--N 1.331 -0.224 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 174.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 46.4 t80 -112.11 128.8 56.32 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 121.304 0.573 . . . . 0.0 111.887 -171.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 20.6 ptp -94.17 141.59 28.38 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.277 174.565 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -84.52 37.15 2.92 Favored Glycine 0 CA--C 1.519 0.319 0 C-N-CA 121.099 -0.572 . . . . 0.0 114.2 -170.836 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.624 HG21 HG23 ' A' ' 32' ' ' VAL . 33.6 pt -138.24 154.06 27.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 117.204 0.502 . . . . 0.0 110.481 178.095 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 55.7 mtp180 -93.66 117.11 29.66 Favored 'General case' 0 C--N 1.318 -0.788 0 N-CA-C 108.336 -0.987 . . . . 0.0 108.336 171.476 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -111.03 137.18 48.99 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-O 121.344 0.592 . . . . 0.0 110.624 -178.017 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 19.1 m -156.97 164.24 38.23 Favored 'General case' 0 C--N 1.31 -1.115 0 CA-C-N 115.543 -0.753 . . . . 0.0 109.462 -178.866 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 14.9 p30 -80.14 -10.55 59.77 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 169.008 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 6.0 t60 47.1 70.72 0.38 Allowed 'General case' 0 C--O 1.231 0.13 0 CA-C-N 114.035 -1.439 . . . . 0.0 111.296 -179.258 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 95.1 mt -108.75 -173.84 2.37 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.477 177.69 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 89.1 mtt180 60.95 105.22 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.404 0 O-C-N 124.37 1.044 . . . . 0.0 112.391 179.287 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 57.4 t -101.67 128.62 53.93 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.824 175.918 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' ARG . . . . . . . . . . . . . 98.5 mtt180 -116.61 140.55 49.27 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.131 -178.766 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 19.5 t70 -115.86 93.41 4.24 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.912 -0.586 . . . . 0.0 109.497 176.43 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 58.6 m -155.16 134.38 12.38 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.597 -179.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 26.9 m -113.16 160.87 12.49 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 173.498 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -68.37 95.24 0.59 Allowed 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.2 0.524 . . . . 0.0 110.495 -178.414 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 13.4 m -105.79 19.5 20.45 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.782 -175.769 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . 0.429 ' HA ' ' OD1' ' A' ' 120' ' ' ASP . 4.8 m -78.46 89.5 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-O 121.674 0.75 . . . . 0.0 110.618 179.793 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 60.9 mt -122.84 -77.08 0.59 Allowed 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.175 -175.757 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -122.94 32.49 4.39 Favored Glycine 0 N--CA 1.451 -0.366 0 N-CA-C 111.105 -0.798 . . . . 0.0 111.105 177.829 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' ASP . . . . . 0.615 ' OD2' ' HG ' ' A' ' 122' ' ' LEU . 3.1 p-10 -72.17 -34.53 68.54 Favored 'General case' 0 C--N 1.324 -0.51 0 C-N-CA 123.006 0.522 . . . . 0.0 111.756 -176.579 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' THR . . . . . 0.534 ' O ' ' HD3' ' A' ' 123' ' ' PRO . 36.6 p 49.19 77.93 0.1 Allowed 'General case' 0 N--CA 1.464 0.226 0 O-C-N 123.744 0.652 . . . . 0.0 111.537 -176.617 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . 0.615 ' HG ' ' OD2' ' A' ' 120' ' ' ASP . 93.7 mt -92.61 106.35 18.2 Favored Pre-proline 0 C--N 1.327 -0.407 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.01 -179.855 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . 0.534 ' HD3' ' O ' ' A' ' 121' ' ' THR . 9.3 Cg_endo -89.53 153.37 5.3 Favored 'Trans proline' 0 N--CA 1.456 -0.727 0 C-N-CA 123.098 2.532 . . . . 0.0 111.659 175.632 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 70.7 t80 -136.63 111.04 8.49 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.559 -0.291 . . . . 0.0 110.332 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.253 1.252 0 O-C-N 123.873 0.733 . . . . 0.0 111.228 179.636 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.444 ' HA ' ' HD3' ' A' ' 24' ' ' PRO . 25.9 tp60 . . . . . 0 N--CA 1.454 -0.234 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.444 ' HD3' ' HA ' ' A' ' 23' ' ' GLN . 4.0 Cg_exo -78.62 115.23 3.6 Favored 'Trans proline' 0 C--O 1.234 0.292 0 C-N-CA 123.051 2.501 . . . . 0.0 112.438 178.176 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.418 ' OD2' ' HA ' ' A' ' 108' ' ' LEU . 17.0 p-10 -137.3 -35.23 0.69 Allowed 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.23 -178.655 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 134.53 162.94 10.05 Favored Glycine 0 N--CA 1.445 -0.73 0 N-CA-C 111.587 -0.605 . . . . 0.0 111.587 -179.255 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.478 HG21 ' HB ' ' A' ' 48' ' ' ILE . 15.3 m -99.73 134.37 39.32 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-O 121.13 0.491 . . . . 0.0 110.957 176.942 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 6.6 tp60 -97.58 133.5 42.06 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.786 -176.577 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.541 ' HB ' ' H ' ' A' ' 46' ' ' LEU . 36.7 mm -72.65 112.66 8.89 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-N 115.706 -0.679 . . . . 0.0 109.773 173.155 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 16.7 t70 -76.15 -69.75 0.48 Allowed 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.09 -179.289 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 7.7 p -148.96 142.66 25.54 Favored 'General case' 0 N--CA 1.447 -0.594 0 CA-C-O 121.398 0.618 . . . . 0.0 111.553 -178.203 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.496 HG13 ' HA ' ' A' ' 39' ' ' SER . 61.4 t -98.55 119.35 46.43 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-N 114.96 -1.018 . . . . 0.0 109.185 173.945 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.502 HG11 ' O ' ' A' ' 101' ' ' GLY . 10.9 p -91.69 131.85 34.74 Favored Pre-proline 0 C--N 1.324 -0.527 0 CA-C-O 120.776 0.322 . . . . 0.0 110.294 -178.329 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -58.34 147.23 86.11 Favored 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.816 2.344 . . . . 0.0 112.226 -179.469 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 91.64 24.74 25.01 Favored Glycine 0 N--CA 1.448 -0.526 0 C-N-CA 120.759 -0.734 . . . . 0.0 111.82 -177.374 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' SER . . . . . 0.535 ' CB ' ' HA3' ' A' ' 101' ' ' GLY . 61.3 p -125.85 157.35 69.32 Favored Pre-proline 0 C--N 1.325 -0.49 0 N-CA-C 110.155 -0.313 . . . . 0.0 110.155 -179.934 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 29.5 Cg_endo -64.07 -30.77 65.97 Favored 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.424 2.082 . . . . 0.0 112.099 176.901 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.48 ' HB2' HD12 ' A' ' 86' ' ' LEU . . . -80.15 -13.52 59.19 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.436 -177.894 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.496 ' HA ' HG13 ' A' ' 32' ' ' VAL . 22.9 t -61.46 -27.95 68.94 Favored 'General case' 0 CA--C 1.532 0.283 0 N-CA-C 112.249 0.463 . . . . 0.0 112.249 -174.468 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 52.2 mtmt -103.18 -13.81 16.63 Favored 'General case' 0 C--N 1.326 -0.44 0 C-N-CA 120.88 -0.328 . . . . 0.0 111.645 -176.334 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.44 ' HB ' HD11 ' A' ' 42' ' ' LEU . 35.3 t -103.92 -38.73 5.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-N 116.565 -0.289 . . . . 0.0 111.519 -174.319 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.44 HD11 ' HB ' ' A' ' 41' ' ' VAL . 6.5 mp -113.8 168.59 9.66 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.131 0.491 . . . . 0.0 111.119 -177.213 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 7.4 p -129.75 156.4 78.93 Favored Pre-proline 0 C--N 1.321 -0.643 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.026 177.17 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -73.56 154.13 49.79 Favored 'Trans proline' 0 N--CA 1.463 -0.273 0 C-N-CA 122.285 1.99 . . . . 0.0 112.368 179.641 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 81.89 28.78 40.73 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.891 -0.671 . . . . 0.0 113.323 177.551 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 0.554 HD22 ' HB2' ' A' ' 81' ' ' GLN . 53.6 mt -109.2 162.01 14.69 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 117.066 0.433 . . . . 0.0 110.519 176.214 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 62.1 t -110.99 130.2 64.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 N-CA-C 110.035 -0.357 . . . . 0.0 110.035 178.227 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.487 HD11 HD11 ' A' ' 29' ' ' ILE . 76.7 mt -89.66 121.19 39.56 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-O 121.042 0.449 . . . . 0.0 110.894 -179.573 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 10.6 tt0 -77.32 -57.0 4.07 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.403 -0.817 . . . . 0.0 110.06 176.208 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.584 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 14.7 p -146.8 152.82 39.38 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.194 -0.912 . . . . 0.0 111.988 -172.126 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 42.9 mm -111.91 97.15 5.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.262 176.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' ASN . . . . . 0.532 ' HA ' ' HB3' ' A' ' 76' ' ' ASN . 6.5 t30 67.43 -80.78 0.03 OUTLIER 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 114.884 -1.053 . . . . 0.0 111.905 174.262 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -126.73 3.39 7.52 Favored Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 120.581 -0.819 . . . . 0.0 112.103 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 54.5 mtm -131.39 117.61 16.78 Favored Pre-proline 0 C--N 1.325 -0.488 0 N-CA-C 110.393 -0.225 . . . . 0.0 110.393 -177.73 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.584 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 56.0 Cg_endo -71.26 130.8 18.05 Favored 'Trans proline' 0 N--CA 1.463 -0.313 0 C-N-CA 122.325 2.017 . . . . 0.0 112.073 178.72 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 25.6 p -108.63 94.63 5.16 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 121.24 0.543 . . . . 0.0 111.269 -176.47 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 5.5 m -95.55 -12.72 25.27 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.574 -0.739 . . . . 0.0 111.118 -177.828 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 6.9 t-20 -129.58 166.78 19.03 Favored 'General case' 0 C--N 1.321 -0.671 0 C-N-CA 120.597 -0.441 . . . . 0.0 109.92 176.769 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.5 ' HB2' ' HB2' ' A' ' 106' ' ' ASN . 0.4 OUTLIER -77.09 -36.45 55.68 Favored 'General case' 0 C--N 1.311 -1.098 0 CA-C-N 115.495 -0.775 . . . . 0.0 109.617 -179.011 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 6.3 m -68.09 -39.09 82.94 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.702 179.621 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 8.0 p -72.23 -37.43 69.18 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.111 0.481 . . . . 0.0 110.456 177.338 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' TYR . . . . . 0.461 ' OH ' ' HE2' ' A' ' 100' ' ' MET . 72.2 t80 -61.04 -43.72 98.47 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.239 175.232 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 4.7 t -65.3 -38.98 91.89 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.396 178.744 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -65.89 -33.91 76.93 Favored 'General case' 0 C--O 1.232 0.153 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.881 179.709 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -71.98 -45.16 62.03 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.253 178.499 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . 0.405 HD23 ' HA ' ' A' ' 66' ' ' LEU . 8.2 mt -62.09 -33.42 74.4 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.245 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 37.0 ttmt -59.26 -21.98 60.45 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.869 -0.605 . . . . 0.0 111.519 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 61.0 p -100.73 -13.88 18.29 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 112.234 0.457 . . . . 0.0 112.234 -176.543 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 45.6 mm -74.5 138.01 21.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.974 0.416 . . . . 0.0 110.557 -176.773 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 7.8 m -104.03 172.92 6.54 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.611 -174.433 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.484 HG22 ' HB3' ' A' ' 96' ' ' SER . 61.3 t -82.94 136.42 22.87 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.139 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.532 177.924 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 87.64 -8.59 76.97 Favored Glycine 0 N--CA 1.448 -0.516 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 -177.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 23.3 tt0 -80.73 145.77 31.37 Favored 'General case' 0 N--CA 1.445 -0.682 0 CA-C-N 114.916 -0.642 . . . . 0.0 109.679 -177.088 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.485 HG23 ' HG3' ' A' ' 87' ' ' LYS . 39.6 t -113.49 116.85 53.79 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 CA-C-N 115.984 -0.553 . . . . 0.0 109.994 -176.839 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 16.4 pt -106.15 153.49 7.52 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-O 121.481 0.658 . . . . 0.0 111.532 -178.739 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . 0.532 ' HB3' ' HA ' ' A' ' 52' ' ' ASN . 15.1 t30 -101.81 104.73 15.51 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 114.881 -1.054 . . . . 0.0 110.219 -178.042 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 52.6 mt -105.1 105.46 18.67 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.883 0 CA-C-O 121.191 0.52 . . . . 0.0 111.001 -174.314 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' THR . . . . . 0.507 ' HG1' HG22 ' A' ' 83' ' ' THR . 35.2 m -85.65 120.48 27.13 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.369 175.062 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 70.7 p -121.37 175.12 6.32 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 120.918 0.39 . . . . 0.0 111.148 -178.038 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -62.42 -18.55 61.94 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.544 -0.753 . . . . 0.0 111.101 176.011 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . 0.554 ' HB2' HD22 ' A' ' 46' ' ' LEU . 7.3 tp-100 -102.84 4.42 37.74 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.147 0.498 . . . . 0.0 111.142 -177.419 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 128.74 175.88 14.23 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 120.57 -0.824 . . . . 0.0 112.623 179.438 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' THR . . . . . 0.507 HG22 ' HG1' ' A' ' 78' ' ' THR . 20.0 m -96.78 109.14 21.87 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-O 120.71 0.29 . . . . 0.0 110.819 -178.455 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 -107.1 169.81 8.33 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.973 0.416 . . . . 0.0 110.622 -178.205 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 7.4 p80 -129.57 126.91 39.59 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 175.96 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.488 HD22 ' N ' ' A' ' 87' ' ' LYS . 4.2 tt -117.89 138.71 51.94 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.113 0.482 . . . . 0.0 110.512 -174.002 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.488 ' N ' HD22 ' A' ' 86' ' ' LEU . 60.5 tttp -116.71 121.02 40.43 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.535 -0.757 . . . . 0.0 109.354 179.831 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 29.6 p -71.57 139.42 49.41 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 120.733 0.302 . . . . 0.0 111.072 -178.844 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -134.22 16.05 4.44 Favored Glycine 0 CA--C 1.511 -0.198 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.558 -174.744 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.467 ' HB2' ' CB ' ' A' ' 99' ' ' TYR . 29.2 tpt180 -62.75 111.89 2.3 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-N 115.303 -0.448 . . . . 0.0 111.898 -177.384 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 -148.18 92.45 4.6 Favored Pre-proline 0 C--N 1.324 -0.528 0 CA-C-O 120.95 0.405 . . . . 0.0 110.611 175.107 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 4.1 Cg_exo -81.14 -72.1 0.01 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.653 0 C-N-CA 122.842 2.362 . . . . 0.0 111.06 173.988 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 35.9 m-20 -149.37 -63.44 0.22 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.28 176.084 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 20.0 m120 -120.3 -72.04 0.71 Allowed 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.826 -178.599 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 11.6 t -60.05 105.82 0.44 Allowed 'General case' 0 C--O 1.234 0.257 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.423 -178.124 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.484 ' HB3' HG22 ' A' ' 71' ' ' VAL . 15.3 m -127.74 122.9 34.03 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.983 -176.941 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 77.5 mtt-85 -129.06 178.3 6.51 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 174.259 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -68.19 109.3 3.5 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 120.573 0.225 . . . . 0.0 111.018 -178.518 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . 0.467 ' CB ' ' HB2' ' A' ' 90' ' ' ARG . 4.1 t80 -121.28 126.97 50.84 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 109.522 -0.548 . . . . 0.0 109.522 179.451 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' MET . . . . . 0.461 ' HE2' ' OH ' ' A' ' 62' ' ' TYR . 63.4 mtm -105.94 -33.22 8.0 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.461 -0.336 . . . . 0.0 111.135 -175.819 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . 0.535 ' HA3' ' CB ' ' A' ' 36' ' ' SER . . . 94.6 27.1 11.97 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.582 -0.818 . . . . 0.0 111.907 179.228 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.454 HG23 ' HA ' ' A' ' 32' ' ' VAL . 2.7 pp -136.01 150.43 28.21 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 178.339 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 4.1 mpt_? -104.18 139.44 39.22 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 175.566 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.9 p -117.63 161.44 19.64 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.8 179.156 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 66.8 m -143.95 161.95 37.41 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.334 175.857 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . 0.5 ' HB2' ' HB2' ' A' ' 59' ' ' LEU . 2.5 t-20 -106.38 61.38 0.64 Allowed 'General case' 0 C--N 1.309 -1.178 0 N-CA-C 107.563 -1.273 . . . . 0.0 107.563 174.286 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 7.6 t-80 -83.49 75.88 9.98 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 114.658 -1.156 . . . . 0.0 109.642 -177.104 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . 0.433 ' CD2' ' HB3' ' A' ' 23' ' ' GLN . 3.7 mp -59.84 153.32 21.09 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.327 -0.851 . . . . 0.0 111.27 -177.371 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . 0.409 HH11 ' HD3' ' A' ' 109' ' ' ARG . 35.9 ttt180 -66.48 99.84 0.61 Allowed 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.048 -0.978 . . . . 0.0 109.511 176.301 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 13.9 p -63.64 146.13 13.2 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.388 -176.302 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' ARG . . . . . . . . . . . . . 71.3 ttt180 -133.33 144.52 49.7 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.127 -178.11 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 60.4 m-20 67.55 81.61 0.19 Allowed 'General case' 0 N--CA 1.467 0.388 0 O-C-N 123.951 0.782 . . . . 0.0 110.843 -177.59 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 14.8 m -106.61 90.85 3.46 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.348 -0.842 . . . . 0.0 109.441 177.662 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 34.2 m -91.86 133.06 34.57 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.151 -176.622 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -83.81 98.6 9.81 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.814 -0.63 . . . . 0.0 109.901 175.949 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 25.7 t -117.96 101.5 8.32 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.19 -178.756 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 48.5 t -110.8 112.03 38.78 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-N 116.091 -0.504 . . . . 0.0 109.845 179.61 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 88.0 mt -88.64 -64.94 1.07 Allowed 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 116.48 -0.327 . . . . 0.0 110.433 -178.446 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . 0.42 ' O ' ' HB2' ' A' ' 120' ' ' ASP . . . 97.73 93.33 1.93 Allowed Glycine 0 N--CA 1.446 -0.658 0 C-N-CA 120.609 -0.805 . . . . 0.0 112.82 178.002 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' ASP . . . . . 0.42 ' HB2' ' O ' ' A' ' 119' ' ' GLY . 3.1 m-20 75.02 152.48 0.13 Allowed 'General case' 0 N--CA 1.468 0.449 0 CA-C-O 122.003 0.906 . . . . 0.0 112.821 175.385 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 1.7 p -119.58 101.5 7.97 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 114.887 -1.051 . . . . 0.0 109.865 175.81 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 88.0 mt -112.89 100.49 51.15 Favored Pre-proline 0 C--N 1.326 -0.418 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.762 -175.787 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_endo -89.82 164.43 5.03 Favored 'Trans proline' 0 N--CA 1.453 -0.861 0 C-N-CA 122.844 2.362 . . . . 0.0 112.321 178.12 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 73.2 m-85 -115.53 166.83 11.47 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.284 175.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.107 0 CA-C-O 118.653 -0.689 . . . . 0.0 110.424 -178.333 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.437 ' HA ' ' HD3' ' A' ' 24' ' ' PRO . 13.8 pt20 . . . . . 0 C--O 1.236 0.378 0 CA-C-O 120.538 0.209 . . . . 0.0 110.795 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.437 ' HD3' ' HA ' ' A' ' 23' ' ' GLN . 9.0 Cg_exo -72.41 169.54 21.46 Favored 'Trans proline' 0 C--O 1.235 0.348 0 C-N-CA 123.156 2.571 . . . . 0.0 111.591 177.64 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 21.2 t70 -173.64 -41.66 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.232 0.539 . . . . 0.0 110.726 -176.473 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.561 ' HA2' ' HA ' ' A' ' 57' ' ' SER . . . 171.27 164.43 26.94 Favored Glycine 0 N--CA 1.442 -0.913 0 CA-C-N 115.263 -0.88 . . . . 0.0 111.188 -178.829 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 33.9 m -109.15 150.8 11.68 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.866 0 CA-C-O 120.768 0.318 . . . . 0.0 110.368 178.076 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -117.82 163.03 17.14 Favored 'General case' 0 C--N 1.32 -0.702 0 C-N-CA 120.751 -0.379 . . . . 0.0 110.45 176.937 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.535 HD12 ' HB2' ' A' ' 46' ' ' LEU . 56.6 mt -78.73 107.44 11.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-O 120.959 0.409 . . . . 0.0 110.273 -178.409 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.606 ' HB3' ' HB2' ' A' ' 103' ' ' ARG . 14.9 t70 -65.67 -70.6 0.23 Allowed 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 115.185 -0.916 . . . . 0.0 110.638 -176.068 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.432 ' HA ' ' HB3' ' A' ' 44' ' ' PRO . 4.2 p -148.59 144.87 27.54 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.596 -0.729 . . . . 0.0 111.128 -178.566 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.528 ' HA ' HG22 ' A' ' 102' ' ' ILE . 96.2 t -94.86 126.54 47.26 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.207 178.606 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 48.4 t -109.0 123.87 35.76 Favored Pre-proline 0 C--N 1.327 -0.379 0 CA-C-N 116.461 -0.336 . . . . 0.0 110.631 179.767 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -58.97 154.39 45.08 Favored 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.972 2.448 . . . . 0.0 112.175 178.1 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 104.26 6.91 41.38 Favored Glycine 0 N--CA 1.45 -0.4 0 N-CA-C 110.849 -0.9 . . . . 0.0 110.849 -175.397 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' SER . . . . . 0.524 ' CB ' ' HA3' ' A' ' 101' ' ' GLY . 60.4 p -130.16 159.17 71.64 Favored Pre-proline 0 C--N 1.322 -0.623 0 CA-C-N 115.185 -0.508 . . . . 0.0 110.054 -179.457 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_exo -66.89 -23.2 47.75 Favored 'Trans proline' 0 N--CA 1.463 -0.27 0 C-N-CA 122.359 2.039 . . . . 0.0 111.669 176.142 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -73.56 -16.77 61.25 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.914 -0.585 . . . . 0.0 111.365 -177.5 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 14.2 m -65.27 -16.84 63.99 Favored 'General case' 0 C--O 1.233 0.192 0 CA-C-O 120.904 0.383 . . . . 0.0 111.051 -179.708 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 35.5 ttpt -116.89 11.42 14.4 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.1 -177.769 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 58.5 t -126.96 -47.99 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.377 -177.427 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 87.1 mt -108.22 161.3 15.12 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.245 0.545 . . . . 0.0 111.412 -175.644 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 15.4 p -126.82 146.38 57.08 Favored Pre-proline 0 C--N 1.319 -0.746 0 CA-C-N 115.022 -0.99 . . . . 0.0 109.844 176.803 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.432 ' HB3' ' HA ' ' A' ' 31' ' ' SER . 53.8 Cg_endo -70.47 149.96 63.18 Favored 'Trans proline' 0 N--CA 1.461 -0.384 0 C-N-CA 122.09 1.86 . . . . 0.0 111.937 -178.064 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 99.23 -13.54 61.63 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.832 179.65 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 0.535 ' HB2' HD12 ' A' ' 29' ' ' ILE . 82.0 mt -72.92 164.45 26.63 Favored 'General case' 0 C--N 1.327 -0.386 0 O-C-N 122.672 -0.31 . . . . 0.0 110.684 179.694 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 42.1 t -115.28 139.95 39.12 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.191 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 65.0 mt -97.83 125.87 50.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 121.181 0.515 . . . . 0.0 110.347 -179.482 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -91.02 -42.52 10.48 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-N 115.834 -0.621 . . . . 0.0 109.894 179.955 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 37.0 p -159.37 153.77 24.0 Favored 'General case' 0 CA--C 1.512 -0.51 0 CA-C-O 120.976 0.417 . . . . 0.0 110.621 178.825 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.776 HG13 HG12 ' A' ' 77' ' ' ILE . 10.8 tt -127.4 123.72 62.33 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 CA-C-N 115.582 -0.735 . . . . 0.0 109.126 174.821 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 2.3 t-20 58.61 -151.85 0.41 Allowed 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 108.922 -0.769 . . . . 0.0 108.922 -177.528 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -81.0 12.7 35.33 Favored Glycine 0 CA--C 1.525 0.681 0 C-N-CA 120.394 -0.908 . . . . 0.0 113.002 177.739 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 2.6 mpp? -124.43 107.26 29.76 Favored Pre-proline 0 C--N 1.333 -0.121 0 CA-C-N 117.227 0.513 . . . . 0.0 111.154 -178.183 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -70.34 121.22 7.79 Favored 'Trans proline' 0 N--CA 1.458 -0.598 0 C-N-CA 121.691 1.594 . . . . 0.0 111.457 174.297 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 20.3 p -97.92 110.17 22.79 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.884 -174.047 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' SER . . . . . 0.561 ' HA ' ' HA2' ' A' ' 26' ' ' GLY . 15.5 m -98.2 -18.96 18.16 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.921 -0.582 . . . . 0.0 111.118 179.831 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 5.3 m120 -115.47 166.33 12.01 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 -179.127 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 39.2 mt -75.8 -34.45 60.17 Favored 'General case' 0 N--CA 1.447 -0.582 0 CA-C-O 121.035 0.445 . . . . 0.0 109.955 171.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 7.9 m -72.22 -40.5 67.76 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.646 -0.706 . . . . 0.0 111.34 -178.514 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 3.2 p -67.76 -32.16 72.56 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.006 0.431 . . . . 0.0 110.425 177.443 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 51.3 t80 -66.74 -39.78 88.06 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.313 0.577 . . . . 0.0 109.497 173.66 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 69.0 m -63.62 -47.52 81.05 Favored 'General case' 0 N--CA 1.447 -0.6 0 CA-C-N 115.485 -0.779 . . . . 0.0 111.348 177.889 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.42 -35.71 78.31 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.619 177.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . 0.52 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -68.17 -41.9 80.82 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.474 178.835 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 6.7 mt -62.32 -33.88 75.54 Favored 'General case' 0 N--CA 1.447 -0.6 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.136 178.273 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 40.4 ttmt -60.16 -37.26 79.61 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.868 179.161 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.6 p -82.26 -11.81 58.43 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 112.345 0.498 . . . . 0.0 112.345 -179.067 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.52 HG12 ' O ' ' A' ' 65' ' ' ALA . 45.8 mm -79.98 137.68 21.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 N-CA-C 110.055 -0.35 . . . . 0.0 110.055 178.313 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 19.1 t -103.36 176.91 4.99 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 110.108 -0.33 . . . . 0.0 110.108 -179.886 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 46.3 t -90.52 125.92 43.33 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.74 -177.653 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 99.93 -0.32 56.32 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.931 -0.652 . . . . 0.0 111.945 179.419 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 35.4 tt0 -90.24 147.31 23.62 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.82 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 39.9 t -106.01 104.34 16.85 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.116 -178.614 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.453 HD12 HD11 ' A' ' 51' ' ' ILE . 15.8 pt -96.08 154.7 3.5 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 121.363 0.602 . . . . 0.0 111.296 -175.916 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 5.5 t30 -91.13 136.6 32.98 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.631 -179.117 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.776 HG12 HG13 ' A' ' 51' ' ' ILE . 60.1 mt -135.46 108.79 9.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-O 121.057 0.456 . . . . 0.0 110.232 178.485 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 4.3 m -84.85 130.17 34.7 Favored 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 176.371 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 76.0 p -126.49 175.77 7.66 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.267 0.556 . . . . 0.0 111.978 -176.204 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 25.2 t70 -49.76 -42.82 47.32 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 114.625 -1.17 . . . . 0.0 112.74 -178.756 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 22.9 mt-30 -117.93 23.67 11.51 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 112.555 0.576 . . . . 0.0 112.555 -172.291 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 152.31 -178.63 29.4 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 119.771 -1.204 . . . . 0.0 112.929 175.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 22.2 m -114.74 126.84 55.32 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-O 120.892 0.377 . . . . 0.0 110.129 179.376 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 99.5 m-85 -121.02 161.33 21.83 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 120.938 0.399 . . . . 0.0 110.696 -178.348 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 44.6 m-70 -125.37 123.93 40.42 Favored 'General case' 0 C--N 1.321 -0.661 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 176.181 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.506 HD21 HD12 ' A' ' 77' ' ' ILE . 3.8 mm? -113.72 140.92 47.86 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.395 -173.886 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -105.14 124.35 49.38 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 115.63 -0.714 . . . . 0.0 109.488 177.467 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 17.8 p -69.92 132.02 45.32 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-O 121.379 0.609 . . . . 0.0 112.038 -176.66 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -104.16 -156.72 23.92 Favored Glycine 0 N--CA 1.445 -0.757 0 CA-C-N 115.433 -0.803 . . . . 0.0 111.418 177.41 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.435 ' HD3' ' N ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -154.04 114.79 4.01 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.238 0.542 . . . . 0.0 111.135 -178.418 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' ASN . . . . . . . . . . . . . 8.5 t30 -154.32 97.59 2.58 Favored Pre-proline 0 C--N 1.322 -0.61 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.175 178.328 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.621 ' HA ' ' HB2' ' A' ' 96' ' ' SER . 87.1 Cg_endo -85.76 129.62 3.56 Favored 'Trans proline' 0 N--CA 1.456 -0.702 0 C-N-CA 122.597 2.198 . . . . 0.0 113.951 -173.695 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 9.6 t30 -90.38 -43.93 9.99 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.064 172.112 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -123.12 -57.65 1.68 Allowed 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 108.52 -0.919 . . . . 0.0 108.52 171.228 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 19.4 t -159.08 83.27 0.79 Allowed 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 107.858 -1.164 . . . . 0.0 107.858 172.309 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.621 ' HB2' ' HA ' ' A' ' 92' ' ' PRO . 1.9 m -111.27 113.02 25.2 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.33 -0.85 . . . . 0.0 110.801 -171.637 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -118.76 151.62 37.69 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.698 -0.683 . . . . 0.0 109.382 178.3 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . 59.3 71.43 0.58 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.743 0.782 . . . . 0.0 109.681 -172.183 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 80.3 t80 -96.36 102.04 13.77 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.611 -170.541 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 81.1 mtp -72.31 -43.22 64.49 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.16 176.469 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . 0.524 ' HA3' ' CB ' ' A' ' 36' ' ' SER . . . 101.56 -12.59 58.18 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.802 176.477 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.528 HG22 ' HA ' ' A' ' 32' ' ' VAL . 2.7 pp -114.89 144.73 21.81 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-O 120.851 0.358 . . . . 0.0 110.322 179.241 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . 0.606 ' HB2' ' HB3' ' A' ' 30' ' ' ASP . 39.3 mtp180 -84.46 147.58 27.01 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.179 178.321 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 14.2 p -124.63 122.1 36.58 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.555 177.331 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 19.3 m -127.59 154.84 44.73 Favored 'General case' 0 C--N 1.318 -0.799 0 N-CA-C 109.165 -0.68 . . . . 0.0 109.165 178.35 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 16.0 p30 -80.22 -21.84 42.44 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-O 121.09 0.472 . . . . 0.0 110.018 177.195 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 9.8 t-80 43.16 55.44 4.6 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-N 114.749 -1.114 . . . . 0.0 110.968 -176.829 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 79.7 mt -71.46 -176.41 1.53 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.685 0.755 . . . . 0.0 112.411 -175.993 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 43.6 ttt-85 -66.86 117.14 8.55 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 114.587 -1.188 . . . . 0.0 110.668 -177.865 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 12.2 p -82.74 157.21 3.88 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.53 -178.575 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' ARG . . . . . . . . . . . . . 6.5 ptp180 49.38 103.12 0.01 OUTLIER 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 125.067 1.347 . . . . 0.0 114.423 177.49 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 23.5 t70 -124.79 97.91 5.48 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.487 -0.779 . . . . 0.0 109.527 170.377 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 49.2 m 50.72 78.74 0.1 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.556 -0.747 . . . . 0.0 112.4 179.899 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 27.2 m -85.8 151.81 3.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.841 177.232 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -90.51 140.42 29.75 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 121.029 0.442 . . . . 0.0 111.125 -178.565 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 15.4 m -103.07 16.74 25.82 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.339 0.59 . . . . 0.0 110.398 179.347 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 7.8 p -108.07 141.12 24.14 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.832 0 CA-C-N 115.323 -0.853 . . . . 0.0 109.708 179.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 92.9 mt -92.67 -67.09 0.88 Allowed 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.651 0.262 . . . . 0.0 110.69 -179.385 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 77.35 -131.49 11.22 Favored Glycine 0 N--CA 1.446 -0.678 0 C-N-CA 120.538 -0.839 . . . . 0.0 111.92 -177.579 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 15.9 m-20 -137.26 160.28 39.47 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.786 0.326 . . . . 0.0 110.644 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 13.2 t -131.98 140.36 48.94 Favored 'General case' 0 C--N 1.321 -0.671 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 174.922 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . 0.445 ' HA ' ' HD3' ' A' ' 123' ' ' PRO . 87.6 mt -106.07 123.14 40.03 Favored Pre-proline 0 C--N 1.323 -0.553 0 CA-C-N 116.6 -0.273 . . . . 0.0 110.867 -177.468 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . 0.445 ' HD3' ' HA ' ' A' ' 122' ' ' LEU . 12.7 Cg_exo -69.99 150.43 66.79 Favored 'Trans proline' 0 N--CA 1.462 -0.373 0 C-N-CA 122.878 2.385 . . . . 0.0 111.478 176.956 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -80.34 116.91 20.66 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.408 0.623 . . . . 0.0 110.998 -175.546 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.246 0.878 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.026 -178.876 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . . . . . . . . . 34.2 mt-30 . . . . . 0 N--CA 1.455 -0.219 0 N-CA-C 110.073 -0.344 . . . . 0.0 110.073 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.745 ' HB3' ' HB2' ' A' ' 58' ' ' ASN . 80.3 Cg_endo -81.76 163.42 18.58 Favored 'Trans proline' 0 C--O 1.238 0.48 0 C-N-CA 123.016 2.477 . . . . 0.0 113.797 -174.703 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 18.6 t70 -167.28 -39.02 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.172 -0.922 . . . . 0.0 109.628 175.273 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.501 ' HA2' ' HA ' ' A' ' 57' ' ' SER . . . 165.21 165.58 22.76 Favored Glycine 0 N--CA 1.447 -0.6 0 N-CA-C 110.574 -1.011 . . . . 0.0 110.574 -177.851 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.568 HG12 HD21 ' A' ' 106' ' ' ASN . 33.6 m -122.54 151.06 26.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 117.44 0.62 . . . . 0.0 110.739 178.675 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . 0.506 ' OE1' ' HB2' ' A' ' 105' ' ' SER . 0.0 OUTLIER -128.19 163.9 23.68 Favored 'General case' 0 C--N 1.324 -0.531 0 C-N-CA 120.703 -0.399 . . . . 0.0 110.767 177.139 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 57.2 mt -90.96 115.7 30.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.951 -176.165 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.72 ' HB3' ' HB2' ' A' ' 103' ' ' ARG . 23.7 t70 -66.65 -58.96 4.06 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.417 0.627 . . . . 0.0 109.873 176.005 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.426 ' HA ' ' HB3' ' A' ' 44' ' ' PRO . 12.4 p -165.19 162.05 19.77 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.22 -0.9 . . . . 0.0 110.204 -178.938 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.568 HG13 ' HA ' ' A' ' 39' ' ' SER . 45.3 t -98.24 138.25 23.45 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 N-CA-C 109.527 -0.545 . . . . 0.0 109.527 177.565 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.536 HG13 ' H ' ' A' ' 35' ' ' GLY . 45.7 t -85.89 118.9 71.35 Favored Pre-proline 0 C--N 1.323 -0.563 0 CA-C-N 116.453 -0.339 . . . . 0.0 110.809 -176.351 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -65.46 -12.94 37.29 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.866 2.377 . . . . 0.0 112.825 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.536 ' H ' HG13 ' A' ' 33' ' ' VAL . . . -95.19 23.02 35.34 Favored Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 120.897 -0.668 . . . . 0.0 111.545 177.935 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' SER . . . . . 0.669 ' HB3' ' HD2' ' A' ' 37' ' ' PRO . 54.1 m -149.36 170.9 6.95 Favored Pre-proline 0 C--N 1.325 -0.458 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.033 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . 0.669 ' HD2' ' HB3' ' A' ' 36' ' ' SER . 56.4 Cg_endo -71.13 -168.26 0.32 Allowed 'Trans proline' 0 C--N 1.349 0.555 0 C-N-CA 122.331 2.021 . . . . 0.0 112.443 177.199 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.476 ' HB2' HD13 ' A' ' 42' ' ' LEU . . . 68.78 -9.71 0.54 Allowed 'General case' 0 N--CA 1.47 0.567 0 N-CA-C 113.017 0.747 . . . . 0.0 113.017 176.63 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.568 ' HA ' HG13 ' A' ' 32' ' ' VAL . 27.8 t -70.08 -6.84 36.66 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.741 0.305 . . . . 0.0 111.293 -177.75 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . 0.674 ' HZ1' ' HB2' ' A' ' 40' ' ' LYS . 0.1 OUTLIER -118.79 12.68 13.03 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 121.003 0.43 . . . . 0.0 110.391 177.103 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.468 ' HB ' HD11 ' A' ' 42' ' ' LEU . 46.8 t -120.76 -55.6 3.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.234 -176.987 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.476 HD13 ' HB2' ' A' ' 38' ' ' ALA . 6.0 mp -96.1 171.49 8.57 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.036 0.446 . . . . 0.0 111.145 -177.159 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 49.1 m -122.72 127.25 25.84 Favored Pre-proline 0 C--N 1.321 -0.639 0 CA-C-N 115.741 -0.663 . . . . 0.0 109.736 176.834 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.426 ' HB3' ' HA ' ' A' ' 31' ' ' SER . 41.7 Cg_endo -68.3 149.02 75.32 Favored 'Trans proline' 0 N--CA 1.464 -0.245 0 C-N-CA 122.294 1.996 . . . . 0.0 111.939 179.123 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 99.05 -2.93 58.23 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.541 -0.838 . . . . 0.0 112.634 -179.307 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 81.0 mt -90.33 164.2 14.44 Favored 'General case' 0 C--N 1.328 -0.366 0 O-C-N 122.583 -0.363 . . . . 0.0 110.765 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 48.0 t -102.45 139.94 22.15 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 N-CA-C 110.022 -0.362 . . . . 0.0 110.022 178.255 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.488 ' HB ' HG22 ' A' ' 27' ' ' VAL . 66.1 mt -93.2 121.71 44.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 121.127 0.489 . . . . 0.0 110.631 -177.601 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 3.4 tm-20 -81.96 -50.8 8.73 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 115.594 -0.73 . . . . 0.0 109.501 178.284 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.555 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 13.6 p -163.94 159.22 20.63 Favored 'General case' 0 C--O 1.236 0.394 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.97 -175.638 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.416 ' HA ' ' O ' ' A' ' 76' ' ' ASN . 61.1 mt -115.96 107.77 23.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 115.556 -0.747 . . . . 0.0 110.545 176.259 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' ASN . . . . . 0.574 ' HA ' ' HB3' ' A' ' 76' ' ' ASN . 15.1 t-20 66.86 -81.66 0.03 OUTLIER 'General case' 0 N--CA 1.468 0.464 0 CA-C-N 115.43 -0.805 . . . . 0.0 110.759 178.816 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -133.46 -5.33 2.95 Favored Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 120.882 -0.675 . . . . 0.0 111.782 177.161 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 60.6 mtm -111.74 115.18 51.47 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 120.743 0.306 . . . . 0.0 110.429 -177.161 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.555 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 72.9 Cg_endo -78.99 132.45 10.55 Favored 'Trans proline' 0 N--CA 1.454 -0.806 0 C-N-CA 122.273 1.982 . . . . 0.0 112.006 177.428 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 3.3 p -95.06 103.43 15.28 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 121.008 0.432 . . . . 0.0 111.69 -177.841 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' SER . . . . . 0.501 ' HA ' ' HA2' ' A' ' 26' ' ' GLY . 32.7 t -93.48 -24.27 18.07 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.747 -0.661 . . . . 0.0 110.482 179.41 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . 0.745 ' HB2' ' HB3' ' A' ' 24' ' ' PRO . 8.4 t-20 -133.18 176.08 8.82 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.519 -0.31 . . . . 0.0 110.385 -179.111 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 97.6 mt -81.47 -33.06 32.23 Favored 'General case' 0 N--CA 1.44 -0.965 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.64 -179.003 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 2.6 m -65.08 -43.68 91.38 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.928 0.395 . . . . 0.0 110.841 179.451 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 12.7 t -67.28 -26.7 66.68 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.103 179.881 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 32.6 t80 -68.16 -47.66 67.42 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.9 -0.591 . . . . 0.0 109.989 173.279 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 8.5 t -60.76 -39.93 90.6 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.486 -0.779 . . . . 0.0 110.358 179.675 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -69.7 -31.97 70.3 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.175 178.003 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . 0.626 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -69.24 -46.64 66.85 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.346 178.217 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 6.6 tp -58.08 -38.45 76.4 Favored 'General case' 0 N--CA 1.447 -0.617 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.338 179.164 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 40.4 ttmt -57.66 -38.49 75.17 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.004 -0.998 . . . . 0.0 111.709 178.426 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 17.7 p -86.87 -13.17 45.66 Favored 'General case' 0 C--N 1.329 -0.31 0 N-CA-C 112.615 0.598 . . . . 0.0 112.615 -175.842 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.626 HG12 ' O ' ' A' ' 65' ' ' ALA . 44.4 mm -76.23 140.84 16.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 C-N-CA 120.906 -0.317 . . . . 0.0 110.167 -179.537 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' SER . . . . . 0.442 ' HB2' ' HB2' ' A' ' 73' ' ' GLU . 4.8 m -94.03 161.26 14.36 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.709 -0.223 . . . . 0.0 110.764 179.357 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.585 HG13 ' HB3' ' A' ' 96' ' ' SER . 2.2 t -82.63 118.37 30.22 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 177.01 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 97.08 8.71 56.56 Favored Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 120.501 -0.857 . . . . 0.0 111.129 -175.477 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.442 ' HB2' ' HB2' ' A' ' 70' ' ' SER . 30.9 tt0 -89.62 145.48 25.22 Favored 'General case' 0 N--CA 1.45 -0.441 0 N-CA-C 109.19 -0.671 . . . . 0.0 109.19 179.563 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 44.4 t -96.2 112.53 28.58 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.022 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.083 -178.865 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 30.8 pt -109.2 154.42 10.62 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-O 121.198 0.523 . . . . 0.0 110.986 -177.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . 0.574 ' HB3' ' HA ' ' A' ' 52' ' ' ASN . 35.5 t-20 -109.63 113.11 25.62 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-N 115.127 -0.942 . . . . 0.0 109.901 -176.617 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.443 HD11 HD22 ' A' ' 86' ' ' LEU . 71.7 mt -104.16 103.73 15.69 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.035 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 175.878 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 30.7 m -88.99 120.14 30.14 Favored 'General case' 0 C--N 1.312 -1.03 0 CA-C-N 115.387 -0.824 . . . . 0.0 109.524 -179.782 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 73.7 p -106.71 171.35 7.41 Favored 'General case' 0 C--N 1.322 -0.606 0 N-CA-C 110.241 -0.281 . . . . 0.0 110.241 179.705 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 19.8 t70 -62.06 -22.56 65.86 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.047 0.451 . . . . 0.0 111.1 -179.819 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 28.7 mt-30 -117.0 17.73 14.85 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 112.548 0.573 . . . . 0.0 112.548 -172.761 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 151.07 163.99 11.74 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 119.909 -1.138 . . . . 0.0 113.748 177.788 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 4.2 m -107.33 137.18 45.86 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 110.056 -0.35 . . . . 0.0 110.056 -179.57 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 26.5 m-85 -134.87 147.39 49.86 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.717 0.294 . . . . 0.0 110.394 177.9 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 4.2 p-80 -130.66 122.52 27.53 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 121.134 0.493 . . . . 0.0 110.086 174.095 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.463 HD23 ' N ' ' A' ' 86' ' ' LEU . 0.9 OUTLIER -130.76 156.87 44.23 Favored 'General case' 0 N--CA 1.444 -0.728 0 CA-C-N 115.571 -0.741 . . . . 0.0 111.115 -173.503 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.447 ' HE2' ' HB3' ' A' ' 87' ' ' LYS . 32.4 ttpt -91.94 132.88 36.17 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.03 177.359 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 32.3 p -73.26 143.44 47.05 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.524 179.688 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -156.8 109.19 0.39 Allowed Glycine 0 N--CA 1.449 -0.464 0 C-N-CA 120.911 -0.662 . . . . 0.0 112.226 177.87 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.644 ' HB3' ' O ' ' A' ' 97' ' ' ARG . 9.0 tpm_? -143.73 97.24 3.03 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-O 120.86 0.362 . . . . 0.0 110.767 -178.878 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' ASN . . . . . . . . . . . . . 28.5 t-20 -109.45 106.9 59.16 Favored Pre-proline 0 C--N 1.321 -0.667 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.183 175.93 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 65.2 Cg_endo -95.33 -154.1 0.04 OUTLIER 'Trans proline' 0 N--CA 1.455 -0.747 0 C-N-CA 123.307 2.671 . . . . 0.0 111.74 177.592 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 7.0 t30 -85.58 41.43 0.9 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.922 0.868 . . . . 0.0 109.613 177.591 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 4.9 t-20 -171.14 -158.68 0.15 Allowed 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.163 -0.926 . . . . 0.0 108.535 -178.539 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 30.3 m -65.53 146.62 54.62 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 120.909 0.385 . . . . 0.0 110.077 177.97 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.585 ' HB3' HG13 ' A' ' 71' ' ' VAL . 50.9 m -68.96 147.26 51.88 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 116.053 -0.521 . . . . 0.0 111.402 -176.179 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . 0.644 ' O ' ' HB3' ' A' ' 90' ' ' ARG . 84.7 mtt180 -126.03 176.88 6.7 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.926 -0.579 . . . . 0.0 109.958 176.719 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -92.42 109.74 21.14 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.798 0.333 . . . . 0.0 111.148 -178.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . 0.556 ' HB3' ' HB2' ' A' ' 90' ' ' ARG . 6.0 t80 -146.17 134.4 21.72 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 178.493 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -94.08 -31.34 14.24 Favored 'General case' 0 C--N 1.326 -0.45 0 C-N-CA 121.2 -0.2 . . . . 0.0 110.933 179.508 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 102.52 45.17 1.71 Allowed Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.285 -0.959 . . . . 0.0 113.811 173.3 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.452 HG22 HG11 ' A' ' 32' ' ' VAL . 32.6 pt -137.69 159.07 34.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-N 117.278 0.539 . . . . 0.0 110.345 175.058 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . 0.72 ' HB2' ' HB3' ' A' ' 30' ' ' ASP . 97.9 mtt180 -88.93 130.46 35.43 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 109.53 -0.544 . . . . 0.0 109.53 174.444 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 2.6 p -110.62 122.86 48.81 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-O 121.204 0.526 . . . . 0.0 111.022 178.803 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.506 ' HB2' ' OE1' ' A' ' 28' ' ' GLN . 45.7 m -116.23 163.55 15.82 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.79 178.162 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . 0.568 HD21 HG12 ' A' ' 27' ' ' VAL . 0.6 OUTLIER -94.29 -30.49 14.51 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-O 121.072 0.463 . . . . 0.0 109.798 -178.806 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 14.9 t60 44.13 73.31 0.15 Allowed 'General case' 0 N--CA 1.469 0.516 0 CA-C-N 114.881 -1.054 . . . . 0.0 111.741 -176.366 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 81.9 mt -87.38 -173.09 4.22 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.147 0.499 . . . . 0.0 110.997 179.64 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . 0.401 HH11 ' HD3' ' A' ' 109' ' ' ARG . 17.8 ptt-85 -76.42 166.31 23.59 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.219 -0.9 . . . . 0.0 111.027 -178.121 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 8.0 p -89.84 140.72 15.42 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-O 121.093 0.473 . . . . 0.0 111.222 -175.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' ARG . . . . . . . . . . . . . 3.8 tpm_? -122.12 125.93 47.25 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.71 178.101 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 11.3 t70 -119.94 113.91 21.26 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 174.823 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 16.8 p -141.63 105.94 4.82 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.279 178.164 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 35.6 m -78.3 151.42 5.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.007 179.758 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -151.28 135.29 16.62 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.382 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 17.8 m -105.72 78.54 1.35 Allowed 'General case' 0 C--N 1.32 -0.688 0 CA-C-O 121.14 0.495 . . . . 0.0 110.184 -179.634 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 40.9 t -115.26 112.43 39.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.32 -177.624 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -84.02 -28.43 27.67 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.001 179.182 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 106.36 -28.12 14.65 Favored Glycine 0 N--CA 1.447 -0.618 0 CA-C-N 115.736 -0.665 . . . . 0.0 111.91 177.866 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 10.8 m-20 -101.91 139.41 37.58 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 120.937 0.399 . . . . 0.0 111.112 -179.082 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 12.0 t -98.28 139.25 34.33 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 108.849 -0.797 . . . . 0.0 108.849 170.827 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 98.1 mt -95.02 124.75 53.22 Favored Pre-proline 0 C--N 1.321 -0.653 0 N-CA-C 110.212 -0.292 . . . . 0.0 110.212 -177.236 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -45.28 125.6 7.36 Favored 'Trans proline' 0 C--N 1.346 0.432 0 C-N-CA 123.794 2.996 . . . . 0.0 112.825 -177.612 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 87.8 m-85 -81.27 122.86 27.96 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.564 -177.545 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.245 0.856 0 CA-C-O 118.512 -0.756 . . . . 0.0 110.078 178.99 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.412 ' HA ' ' HD3' ' A' ' 24' ' ' PRO . 50.4 mt-30 . . . . . 0 C--O 1.234 0.253 0 N-CA-C 110.539 -0.171 . . . . 0.0 110.539 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.412 ' HD3' ' HA ' ' A' ' 23' ' ' GLN . 38.8 Cg_exo -61.67 171.59 4.44 Favored 'Trans proline' 0 C--O 1.235 0.356 0 C-N-CA 122.97 2.447 . . . . 0.0 112.5 177.14 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -160.24 26.15 0.17 Allowed 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.847 0.832 . . . . 0.0 109.751 -172.834 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 136.2 157.34 7.77 Favored Glycine 0 N--CA 1.442 -0.949 0 CA-C-N 114.91 -1.041 . . . . 0.0 110.824 -176.813 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.633 HG23 ' CD2' ' A' ' 62' ' ' TYR . 35.7 m -114.14 149.92 16.31 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.871 0 CA-C-N 116.913 0.356 . . . . 0.0 110.559 178.909 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . 0.697 ' HG2' ' HB3' ' A' ' 107' ' ' HIS . 0.0 OUTLIER -129.67 154.65 46.93 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 174.951 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.583 HG21 HD11 ' A' ' 48' ' ' ILE . 2.2 pt -83.48 110.18 18.01 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.446 0 CA-C-O 121.673 0.749 . . . . 0.0 111.064 179.168 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -64.01 -59.15 4.84 Favored 'General case' 0 C--N 1.319 -0.761 0 CA-C-N 114.235 -1.348 . . . . 0.0 110.925 -177.616 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 49.0 m -153.51 166.71 31.86 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.621 -0.718 . . . . 0.0 111.384 -171.08 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.535 ' HA ' HG21 ' A' ' 102' ' ' ILE . 99.4 t -115.49 134.44 58.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 115.694 -0.685 . . . . 0.0 109.689 176.175 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 53.0 t -103.21 107.28 55.01 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 120.863 0.363 . . . . 0.0 111.089 -177.256 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -61.5 120.81 8.65 Favored 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 122.833 2.355 . . . . 0.0 111.575 178.907 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 126.32 -19.04 6.42 Favored Glycine 0 N--CA 1.447 -0.615 0 N-CA-C 111.011 -0.836 . . . . 0.0 111.011 -175.394 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' SER . . . . . 0.677 ' HB3' ' HD2' ' A' ' 37' ' ' PRO . 32.0 m -114.61 169.53 6.52 Favored Pre-proline 0 C--N 1.32 -0.7 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 176.499 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . 0.677 ' HD2' ' HB3' ' A' ' 36' ' ' SER . 21.1 Cg_endo -61.1 173.24 2.53 Favored 'Trans proline' 0 C--N 1.345 0.359 0 C-N-CA 122.487 2.124 . . . . 0.0 112.893 179.139 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 73.77 -11.29 0.97 Allowed 'General case' 0 N--CA 1.469 0.515 0 CA-C-N 115.541 -0.754 . . . . 0.0 112.403 179.672 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 53.4 m -69.33 2.76 2.69 Favored 'General case' 0 CA--C 1.535 0.377 0 N-CA-C 112.457 0.54 . . . . 0.0 112.457 -177.554 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 50.8 tptt -143.53 19.59 1.86 Allowed 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.43 0.633 . . . . 0.0 109.711 179.168 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 94.1 t -119.91 -63.8 1.76 Allowed 'Isoleucine or valine' 0 C--O 1.237 0.396 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.064 -178.54 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 1.1 pp -97.85 179.85 4.67 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.542 0.687 . . . . 0.0 112.204 -174.717 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 16.7 p -127.31 130.61 23.7 Favored Pre-proline 0 C--N 1.317 -0.831 0 CA-C-N 114.85 -1.068 . . . . 0.0 110.058 178.319 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.431 ' HB3' HG23 ' A' ' 32' ' ' VAL . 50.1 Cg_endo -67.46 159.04 54.26 Favored 'Trans proline' 0 C--O 1.236 0.404 0 C-N-CA 122.425 2.083 . . . . 0.0 112.277 -177.353 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 93.25 0.85 67.31 Favored Glycine 0 CA--C 1.522 0.495 0 C-N-CA 120.752 -0.737 . . . . 0.0 113.849 178.388 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 0.507 ' HB2' HD12 ' A' ' 29' ' ' ILE . 91.2 mt -92.14 167.18 12.23 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 117.43 0.615 . . . . 0.0 111.001 -179.582 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 46.7 t -109.17 138.71 35.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.001 178.675 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.583 HD11 HG21 ' A' ' 29' ' ' ILE . 58.5 mt -101.62 133.7 44.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 C-N-CA 122.33 0.252 . . . . 0.0 110.353 -178.429 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 27.4 tt0 -91.67 -48.52 6.78 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.277 177.854 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.61 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 39.6 p -150.24 157.66 43.32 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 113.147 0.795 . . . . 0.0 113.147 -171.883 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.565 HD12 ' CE2' ' A' ' 62' ' ' TYR . 43.7 mt -116.3 117.53 55.79 Favored 'Isoleucine or valine' 0 C--O 1.235 0.34 0 CA-C-N 114.861 -1.063 . . . . 0.0 110.297 174.553 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' ASN . . . . . 0.545 ' HA ' ' HB3' ' A' ' 76' ' ' ASN . 25.4 t-20 65.6 -81.37 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.744 -0.662 . . . . 0.0 111.417 177.005 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -140.09 1.67 2.25 Favored Glycine 0 N--CA 1.447 -0.583 0 C-N-CA 121.052 -0.594 . . . . 0.0 111.768 177.251 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 59.5 mtm -120.74 123.48 27.98 Favored Pre-proline 0 C--N 1.324 -0.512 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 -177.721 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.61 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 72.7 Cg_endo -74.97 143.28 28.97 Favored 'Trans proline' 0 N--CA 1.459 -0.504 0 C-N-CA 122.353 2.035 . . . . 0.0 112.496 -179.125 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 17.8 p -110.79 95.21 5.41 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.226 0.536 . . . . 0.0 111.35 -177.637 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 5.1 p -91.06 -14.2 31.75 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.747 -0.66 . . . . 0.0 111.385 -178.881 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 34.2 m-80 -131.06 164.26 25.81 Favored 'General case' 0 C--N 1.318 -0.765 0 N-CA-C 109.698 -0.482 . . . . 0.0 109.698 178.464 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.411 HD21 ' HA ' ' A' ' 59' ' ' LEU . 13.1 mt -77.28 -31.14 54.63 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.215 0.531 . . . . 0.0 109.881 179.0 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 2.6 p -65.18 -45.76 83.57 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.647 173.64 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 4.6 m -56.67 -44.52 81.48 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.49 173.762 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' TYR . . . . . 0.633 ' CD2' HG23 ' A' ' 27' ' ' VAL . 11.6 t80 -60.59 -42.27 96.42 Favored 'General case' 0 CA--C 1.529 0.145 0 CA-C-O 121.508 0.67 . . . . 0.0 109.773 177.705 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 57.9 m -62.21 -47.14 85.78 Favored 'General case' 0 N--CA 1.446 -0.652 0 CA-C-N 115.069 -0.968 . . . . 0.0 111.636 178.139 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.89 -33.39 74.13 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.831 179.369 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . 0.583 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -68.22 -46.99 69.06 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.922 -0.581 . . . . 0.0 109.96 176.5 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 13.7 mt -58.49 -38.45 77.65 Favored 'General case' 0 N--CA 1.448 -0.538 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.894 178.22 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 59.7 mmtt -52.48 -37.69 57.72 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.816 -0.629 . . . . 0.0 112.056 176.744 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 50.1 p -87.77 -13.77 41.43 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 111.914 0.338 . . . . 0.0 111.914 -176.558 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.583 HG12 ' O ' ' A' ' 65' ' ' ALA . 36.7 mm -81.64 141.98 14.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-O 120.995 0.426 . . . . 0.0 110.259 -179.067 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 15.4 m -107.22 162.36 13.96 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.738 -178.801 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.401 HG22 ' HA ' ' A' ' 98' ' ' ALA . 97.1 t -77.75 126.69 38.3 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-O 120.987 0.422 . . . . 0.0 110.627 -179.143 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 93.4 22.25 27.34 Favored Glycine 0 N--CA 1.447 -0.576 0 N-CA-C 111.216 -0.753 . . . . 0.0 111.216 -176.217 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 14.8 tp10 -109.5 151.97 26.04 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.262 -0.469 . . . . 0.0 109.847 -179.311 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.405 ' HA ' ' O ' ' A' ' 86' ' ' LEU . 61.1 t -110.98 120.3 61.38 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.752 0 CA-C-N 116.099 -0.5 . . . . 0.0 109.768 179.803 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 23.9 pt -117.05 154.29 18.73 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.026 -178.674 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . 0.545 ' HB3' ' HA ' ' A' ' 52' ' ' ASN . 44.1 t30 -91.05 132.92 35.72 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.845 -0.616 . . . . 0.0 109.947 -179.66 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 66.3 mt -129.74 109.78 18.61 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-O 121.179 0.514 . . . . 0.0 109.621 178.619 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 25.5 m -95.94 110.27 22.5 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.944 178.647 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.468 HG22 HG12 ' A' ' 48' ' ' ILE . 69.2 p -107.28 175.25 5.56 Favored 'General case' 0 N--CA 1.448 -0.556 0 CA-C-O 120.814 0.34 . . . . 0.0 111.057 -179.105 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 27.6 t70 -45.06 -43.64 9.62 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.058 -0.974 . . . . 0.0 113.383 -175.84 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 32.2 mt-30 -132.86 17.62 4.21 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 111.989 0.366 . . . . 0.0 111.989 -176.707 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -157.15 123.8 1.34 Allowed Glycine 0 C--N 1.319 -0.384 0 C-N-CA 119.581 -1.295 . . . . 0.0 113.31 -177.012 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 26.0 m -108.99 106.74 16.83 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 175.535 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 20.7 p90 -133.13 177.39 7.71 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 121.53 0.681 . . . . 0.0 111.59 -174.51 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 4.9 p80 -124.81 127.98 48.01 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-N 114.849 -1.069 . . . . 0.0 110.055 178.863 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.405 ' O ' ' HA ' ' A' ' 74' ' ' VAL . 7.4 tt -106.5 143.6 34.38 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.498 -175.302 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 86.5 tttt -106.79 116.4 31.87 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.447 -0.797 . . . . 0.0 109.392 178.367 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' THR . . . . . 0.632 HG22 ' HB1' ' A' ' 98' ' ' ALA . 55.7 p -67.04 136.53 55.39 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 121.231 0.539 . . . . 0.0 111.872 -175.212 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -104.77 -166.38 24.3 Favored Glycine 0 N--CA 1.442 -0.958 0 CA-C-N 115.664 -0.698 . . . . 0.0 112.18 -179.225 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 10.9 mpt_? -86.76 138.51 31.55 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-O 120.748 0.309 . . . . 0.0 110.815 -178.586 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' ASN . . . . . . . . . . . . . 16.2 p30 -97.43 153.28 38.43 Favored Pre-proline 0 C--N 1.326 -0.45 0 CA-C-N 115.965 -0.562 . . . . 0.0 110.41 178.456 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_endo -72.37 -63.23 0.04 OUTLIER 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.272 1.981 . . . . 0.0 112.631 179.413 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 27.1 t-20 -156.29 -51.46 0.08 Allowed 'General case' 0 N--CA 1.45 -0.428 0 CA-C-O 120.892 0.377 . . . . 0.0 110.941 -179.104 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 26.1 p-10 -84.92 -174.06 5.06 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.793 -0.64 . . . . 0.0 111.448 -175.468 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 50.4 m 68.18 178.42 0.24 Allowed 'General case' 0 C--O 1.234 0.282 0 CA-C-N 115.064 -0.971 . . . . 0.0 111.237 -179.84 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 17.9 m -78.27 177.88 8.08 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.97 -177.754 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 24.7 mmt180 -72.08 154.5 41.07 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 178.19 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . 0.632 ' HB1' HG22 ' A' ' 88' ' ' THR . . . 69.59 104.69 0.06 Allowed 'General case' 0 N--CA 1.462 0.164 0 O-C-N 124.019 0.824 . . . . 0.0 110.67 -176.826 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 27.5 t80 -89.16 114.53 25.82 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.204 0.526 . . . . 0.0 110.452 -173.342 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' MET . . . . . 0.499 ' HE3' HG13 ' A' ' 102' ' ' ILE . 11.3 ptm -70.47 -30.04 66.74 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.351 -0.84 . . . . 0.0 111.725 -178.27 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 86.61 -2.64 87.34 Favored Glycine 0 N--CA 1.453 -0.184 0 C-N-CA 120.991 -0.624 . . . . 0.0 112.918 177.467 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.535 HG21 ' HA ' ' A' ' 32' ' ' VAL . 24.5 pt -132.16 158.31 43.26 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 121.068 0.461 . . . . 0.0 110.695 -177.568 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . 0.418 HH11 ' HD2' ' A' ' 103' ' ' ARG . 18.2 mtp180 -90.36 145.32 25.05 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.796 -0.638 . . . . 0.0 109.591 178.113 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 2.2 p -133.8 151.14 51.48 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 120.708 0.29 . . . . 0.0 111.169 178.397 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 84.1 p -138.49 -174.18 3.75 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.113 -0.494 . . . . 0.0 109.787 177.677 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . 0.475 ' OD1' ' HG ' ' A' ' 108' ' ' LEU . 14.0 p30 -106.89 11.89 29.46 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.527 -0.306 . . . . 0.0 110.86 -179.557 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . 0.697 ' HB3' ' HG2' ' A' ' 28' ' ' GLN . 7.0 p-80 47.3 40.2 10.12 Favored 'General case' 0 N--CA 1.471 0.609 0 C-N-CA 123.723 0.809 . . . . 0.0 112.615 178.19 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . 0.475 ' HG ' ' OD1' ' A' ' 106' ' ' ASN . 15.4 mt -45.38 134.36 6.76 Favored 'General case' 0 CA--C 1.515 -0.386 0 CA-C-O 122.118 0.961 . . . . 0.0 112.55 -176.055 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 46.2 mtm180 -83.23 94.41 7.88 Favored 'General case' 0 C--N 1.313 -0.992 0 CA-C-N 114.031 -1.441 . . . . 0.0 110.387 -177.5 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 60.9 t -89.16 134.6 28.08 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 CA-C-N 115.015 -0.993 . . . . 0.0 111.292 -177.359 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' ARG . . . . . . . . . . . . . 14.1 ptt180 -158.95 84.42 0.8 Allowed 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 121.691 0.757 . . . . 0.0 110.568 172.54 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 35.7 t70 -161.52 125.81 3.38 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 114.781 -1.099 . . . . 0.0 109.535 179.653 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 36.1 t -137.76 143.02 40.94 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.905 -175.854 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 29.2 m -110.36 170.3 3.36 Favored 'Isoleucine or valine' 0 C--O 1.235 0.33 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.4 176.621 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -135.46 119.83 17.94 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.619 -0.264 . . . . 0.0 110.892 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 49.7 m -155.1 163.18 40.6 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 110.149 -0.315 . . . . 0.0 110.149 -179.1 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 62.0 t 67.23 102.04 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.333 -0.142 0 O-C-N 123.945 0.778 . . . . 0.0 111.344 -179.695 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 97.7 mt -90.26 -6.92 54.64 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.759 178.833 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 85.98 162.75 36.97 Favored Glycine 0 N--CA 1.449 -0.495 0 C-N-CA 120.826 -0.702 . . . . 0.0 111.412 -175.048 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -155.58 140.6 17.35 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.994 0.397 . . . . 0.0 110.328 -179.265 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 2.2 p -123.4 89.57 3.12 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.244 0.545 . . . . 0.0 110.19 175.592 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . 0.48 ' HA ' ' HD3' ' A' ' 123' ' ' PRO . 0.4 OUTLIER -107.56 123.41 38.1 Favored Pre-proline 0 C--N 1.325 -0.466 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.578 -177.602 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . 0.48 ' HD3' ' HA ' ' A' ' 122' ' ' LEU . 4.0 Cg_exo -77.23 159.83 33.08 Favored 'Trans proline' 0 N--CA 1.461 -0.389 0 C-N-CA 122.916 2.411 . . . . 0.0 111.495 175.171 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 52.6 t80 -129.85 111.66 12.81 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.308 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.126 0 CA-C-O 118.3 -0.857 . . . . 0.0 110.225 -177.402 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . . . . . . . . . 77.8 mt-30 . . . . . 0 N--CA 1.452 -0.365 0 N-CA-C 110.011 -0.366 . . . . 0.0 110.011 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_endo -69.5 -170.5 0.38 Allowed 'Trans proline' 0 C--O 1.233 0.274 0 C-N-CA 122.724 2.282 . . . . 0.0 112.752 178.901 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.83 ' HA ' ' HB3' ' A' ' 57' ' ' SER . 31.9 t70 75.75 18.9 2.08 Favored 'General case' 0 N--CA 1.468 0.454 0 CA-C-N 115.11 -0.95 . . . . 0.0 109.954 -173.504 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 172.26 151.7 8.04 Favored Glycine 0 N--CA 1.441 -0.967 0 CA-C-N 114.949 -1.023 . . . . 0.0 111.245 176.252 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 28.8 m -137.14 153.88 29.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 120.924 0.392 . . . . 0.0 110.94 -177.686 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . 0.474 ' HB2' ' O ' ' A' ' 46' ' ' LEU . 2.0 pt20 -126.02 161.37 27.71 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 110.124 -0.324 . . . . 0.0 110.124 176.314 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.475 HG23 HD12 ' A' ' 102' ' ' ILE . 65.9 mt -75.19 115.58 16.75 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 N-CA-C 109.009 -0.737 . . . . 0.0 109.009 174.885 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.481 ' HB2' ' HB2' ' A' ' 105' ' ' SER . 22.9 t70 -79.22 -64.77 1.11 Allowed 'General case' 0 C--N 1.317 -0.816 0 CA-C-O 121.014 0.435 . . . . 0.0 110.334 -178.232 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 19.6 m -145.2 153.92 41.86 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.281 -177.685 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.562 HG12 HG23 ' A' ' 102' ' ' ILE . 94.6 t -116.87 131.01 70.78 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.292 -178.458 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 57.5 t -104.51 124.82 35.83 Favored Pre-proline 0 C--N 1.328 -0.367 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.943 -178.432 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -56.11 151.18 44.08 Favored 'Trans proline' 0 C--N 1.346 0.415 0 C-N-CA 123.068 2.512 . . . . 0.0 112.541 178.222 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 128.5 -16.25 5.96 Favored Glycine 0 N--CA 1.447 -0.578 0 C-N-CA 120.889 -0.672 . . . . 0.0 111.508 -177.906 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 35.9 p -124.89 156.36 68.97 Favored Pre-proline 0 C--N 1.322 -0.63 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 177.035 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo -64.9 -15.9 52.72 Favored 'Trans proline' 0 C--N 1.345 0.384 0 C-N-CA 122.342 2.028 . . . . 0.0 111.813 176.829 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -62.74 -23.09 67.02 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.526 -0.761 . . . . 0.0 111.542 -179.103 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.53 ' HA ' HG11 ' A' ' 32' ' ' VAL . 20.2 t -66.8 -22.12 66.02 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.249 -178.363 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 81.5 tttt -107.65 -2.12 20.48 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.03 0.443 . . . . 0.0 110.475 -178.679 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 89.9 t -105.23 -48.86 9.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.442 179.286 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 94.8 mt -94.33 174.35 7.18 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.052 -179.257 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' THR . . . . . 0.454 ' O ' ' HG ' ' A' ' 46' ' ' LEU . 45.0 m -143.57 131.06 10.77 Favored Pre-proline 0 C--N 1.321 -0.655 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 -179.755 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_endo -63.69 142.63 84.2 Favored 'Trans proline' 0 N--CA 1.459 -0.519 0 C-N-CA 122.273 1.982 . . . . 0.0 111.776 178.221 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 94.14 2.64 64.08 Favored Glycine 0 CA--C 1.523 0.548 0 C-N-CA 120.748 -0.739 . . . . 0.0 113.538 -178.546 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 0.507 HD22 ' HG2' ' A' ' 81' ' ' GLN . 66.0 mt -88.63 164.11 15.5 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-N 117.475 0.638 . . . . 0.0 110.805 179.269 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 48.8 t -108.1 130.13 61.14 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.248 0 CA-C-O 120.511 0.196 . . . . 0.0 110.693 -177.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 53.8 mt -98.52 128.29 50.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-O 120.937 0.399 . . . . 0.0 110.881 -176.134 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.5 mm-40 -87.68 -48.32 7.97 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.652 176.823 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.516 ' CB ' ' HA ' ' A' ' 55' ' ' PRO . 16.2 p -171.82 161.59 5.92 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-O 121.013 0.435 . . . . 0.0 111.849 -174.838 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.444 HG23 ' OD1' ' A' ' 52' ' ' ASN . 27.5 mm -103.67 169.44 2.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 N-CA-C 107.929 -1.137 . . . . 0.0 107.929 173.413 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' ASN . . . . . 0.689 ' HB3' ' HB3' ' A' ' 76' ' ' ASN . 24.0 p-10 -53.97 99.97 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.825 0.821 . . . . 0.0 112.251 -175.996 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 75.72 3.77 74.09 Favored Glycine 0 N--CA 1.447 -0.593 0 CA-C-N 115.352 -0.84 . . . . 0.0 112.695 178.46 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' MET . . . . . 0.477 ' HE1' HD12 ' A' ' 69' ' ' ILE . 56.1 mtm -137.32 92.08 13.92 Favored Pre-proline 0 C--N 1.325 -0.467 0 CA-C-O 120.689 0.28 . . . . 0.0 110.504 -176.488 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.516 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 15.8 Cg_exo -66.87 135.28 37.52 Favored 'Trans proline' 0 N--CA 1.46 -0.49 0 C-N-CA 122.311 2.007 . . . . 0.0 111.608 178.606 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.454 HG22 ' CD2' ' A' ' 62' ' ' TYR . 10.9 p -105.24 98.31 8.03 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-O 121.283 0.563 . . . . 0.0 111.731 -175.429 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' SER . . . . . 0.83 ' HB3' ' HA ' ' A' ' 25' ' ' ASP . 4.2 m -101.52 -17.16 16.54 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.774 176.284 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 14.3 m120 -127.24 160.89 29.93 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.142 -177.955 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 96.5 mt -77.62 -31.97 53.19 Favored 'General case' 0 N--CA 1.438 -1.044 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.061 177.583 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 84.7 m -70.42 -37.4 74.43 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.749 -0.659 . . . . 0.0 110.928 176.467 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 16.6 p -69.6 -33.3 72.49 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.867 0.365 . . . . 0.0 110.351 178.561 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' TYR . . . . . 0.454 ' CD2' HG22 ' A' ' 56' ' ' THR . 24.8 t80 -61.52 -45.97 91.95 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.444 0.64 . . . . 0.0 109.427 173.438 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 6.3 m -65.55 -42.69 91.62 Favored 'General case' 0 N--CA 1.449 -0.522 0 CA-C-N 115.108 -0.951 . . . . 0.0 112.126 177.75 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.99 -33.74 76.06 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.994 -179.768 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . 0.553 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -69.52 -45.54 68.61 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.047 -0.524 . . . . 0.0 109.807 177.483 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 14.3 mt -55.2 -38.62 68.62 Favored 'General case' 0 N--CA 1.447 -0.615 0 CA-C-N 115.375 -0.829 . . . . 0.0 111.677 179.184 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 28.0 mmmt -57.29 -28.44 63.03 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.832 -0.622 . . . . 0.0 112.49 179.703 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 28.4 p -99.85 -14.05 18.94 Favored 'General case' 0 C--N 1.327 -0.413 0 N-CA-C 112.373 0.508 . . . . 0.0 112.373 -177.544 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.553 HG12 ' O ' ' A' ' 65' ' ' ALA . 49.1 mm -70.63 128.65 34.17 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-O 121.175 0.512 . . . . 0.0 110.622 -176.658 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 16.3 m -80.62 163.49 23.59 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.372 -176.81 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.477 HG12 ' HB3' ' A' ' 90' ' ' ARG . 57.9 t -84.84 127.64 39.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 115.92 -0.582 . . . . 0.0 109.455 175.773 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 88.32 15.12 60.95 Favored Glycine 0 N--CA 1.448 -0.51 0 N-CA-C 110.571 -1.012 . . . . 0.0 110.571 -173.689 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 7.1 tp10 -87.36 148.16 25.16 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 114.952 -0.624 . . . . 0.0 109.321 178.862 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 59.0 t -113.53 102.13 13.46 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.994 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 174.705 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 29.9 pt -97.37 161.9 2.74 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.855 0 CA-C-N 115.674 -0.694 . . . . 0.0 111.29 -174.314 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . 0.689 ' HB3' ' HB3' ' A' ' 52' ' ' ASN . 11.7 t30 -102.17 122.52 44.32 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 115.389 -0.823 . . . . 0.0 109.999 179.292 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 61.8 mt -122.63 103.94 13.92 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 176.687 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' THR . . . . . 0.433 ' HA ' ' HA ' ' A' ' 83' ' ' THR . 37.7 m -91.98 114.1 26.55 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 115.279 -0.873 . . . . 0.0 109.832 179.411 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 69.6 p -102.66 171.86 7.18 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 176.653 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -72.8 -14.67 61.57 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 121.63 0.729 . . . . 0.0 109.469 176.095 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . 0.507 ' HG2' HD22 ' A' ' 46' ' ' LEU . 2.7 mp0 -95.37 10.07 37.63 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.302 -0.863 . . . . 0.0 110.652 178.979 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 127.27 164.81 11.76 Favored Glycine 0 CA--C 1.519 0.32 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.902 178.473 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' THR . . . . . 0.433 ' HA ' ' HA ' ' A' ' 78' ' ' THR . 28.0 m -90.48 129.86 36.6 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 110.387 -0.227 . . . . 0.0 110.387 177.621 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 60.6 m-85 -128.34 155.45 44.65 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.013 0.435 . . . . 0.0 110.654 179.421 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 38.6 m80 -108.46 136.85 47.4 Favored 'General case' 0 C--N 1.321 -0.674 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 174.553 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 21.2 tp -123.44 138.87 54.5 Favored 'General case' 0 C--N 1.315 -0.899 0 C-N-CA 120.208 -0.597 . . . . 0.0 110.746 -179.782 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 37.0 ttpt -105.67 121.08 43.26 Favored 'General case' 0 C--N 1.313 -0.988 0 CA-C-N 115.316 -0.856 . . . . 0.0 109.139 177.722 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' THR . . . . . 0.587 HG21 ' HB1' ' A' ' 98' ' ' ALA . 43.5 p -78.43 128.67 33.94 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-O 121.275 0.56 . . . . 0.0 111.508 -176.967 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -94.24 -171.72 38.32 Favored Glycine 0 N--CA 1.443 -0.836 0 CA-C-N 115.65 -0.705 . . . . 0.0 111.889 -178.674 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.477 ' HB3' HG12 ' A' ' 71' ' ' VAL . 0.0 OUTLIER -128.34 87.52 2.61 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.794 0.807 . . . . 0.0 111.834 -176.529 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' ASN . . . . . . . . . . . . . 39.8 m-80 -135.86 115.43 11.26 Favored Pre-proline 0 C--N 1.32 -0.695 0 CA-C-N 114.984 -1.007 . . . . 0.0 108.816 172.621 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -57.09 146.95 78.31 Favored 'Trans proline' 0 C--O 1.237 0.439 0 C-N-CA 122.453 2.102 . . . . 0.0 112.574 -178.419 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 6.4 t30 -138.29 31.93 2.36 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 -178.679 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 36.9 m-80 64.23 85.12 0.14 Allowed 'General case' 0 C--O 1.236 0.393 0 CA-C-N 114.747 -1.115 . . . . 0.0 109.911 -169.378 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 10.0 t 70.74 -169.5 0.16 Allowed 'General case' 0 C--O 1.234 0.274 0 CA-C-N 114.637 -1.165 . . . . 0.0 109.685 -175.372 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 35.9 m 72.58 151.08 0.11 Allowed 'General case' 0 N--CA 1.465 0.318 0 C-N-CA 123.434 0.694 . . . . 0.0 111.597 -178.363 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 10.2 mpt_? -119.39 166.01 13.6 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.738 -0.665 . . . . 0.0 109.985 178.866 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . 0.587 ' HB1' HG21 ' A' ' 88' ' ' THR . . . 61.01 89.7 0.07 Allowed 'General case' 0 C--O 1.233 0.2 0 O-C-N 123.892 0.745 . . . . 0.0 111.362 177.502 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 51.3 t80 -79.78 97.23 6.54 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 121.173 0.511 . . . . 0.0 111.299 -173.328 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 50.3 ttm -86.5 -58.41 2.63 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.309 173.626 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 88.27 24.05 35.44 Favored Glycine 0 C--N 1.33 0.23 0 C-N-CA 120.889 -0.672 . . . . 0.0 113.709 171.042 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.562 HG23 HG12 ' A' ' 32' ' ' VAL . 19.0 pt -120.03 145.72 25.9 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 CA-C-N 117.179 0.49 . . . . 0.0 110.488 177.597 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.72 140.81 29.21 Favored 'General case' 0 C--N 1.319 -0.747 0 N-CA-C 108.974 -0.75 . . . . 0.0 108.974 174.868 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.7 m -109.59 149.0 30.31 Favored 'General case' 0 C--N 1.314 -0.966 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 -179.076 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.481 ' HB2' ' HB2' ' A' ' 30' ' ' ASP . 41.0 t -116.67 172.24 7.36 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-N 115.94 -0.573 . . . . 0.0 109.705 -178.3 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . 0.412 HD21 ' HA ' ' A' ' 106' ' ' ASN . 1.1 t-20 -113.67 60.83 0.66 Allowed 'General case' 0 C--N 1.316 -0.872 0 CA-C-O 121.551 0.691 . . . . 0.0 109.53 -172.947 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 1.6 m-70 -117.59 149.49 40.57 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.59 -0.732 . . . . 0.0 111.159 -178.891 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 91.6 mt -92.05 -169.03 2.14 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.49 176.358 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 5.7 ttm180 -83.99 134.85 34.63 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 115.488 -0.778 . . . . 0.0 110.458 -176.666 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 41.5 t -102.94 133.28 47.17 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.118 178.817 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' ARG . . . . . 0.406 HH11 ' HD2' ' A' ' 111' ' ' ARG . 49.6 mtm180 -134.72 -172.4 3.02 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.688 -178.316 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -69.76 95.75 0.92 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.739 -179.151 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 69.4 m -148.51 27.7 0.9 Allowed 'General case' 0 C--N 1.318 -0.797 0 CA-C-O 121.254 0.55 . . . . 0.0 110.318 175.532 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 2.1 t -106.59 122.43 60.5 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.608 -178.544 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -138.44 5.59 2.48 Favored 'General case' 0 C--N 1.314 -0.974 0 CA-C-N 115.625 -0.716 . . . . 0.0 109.959 177.323 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 14.5 m -80.0 149.03 30.9 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.951 -178.308 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 35.7 m -73.57 148.63 8.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.093 174.5 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -83.26 -64.88 1.09 Allowed 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.75 0.309 . . . . 0.0 111.108 -176.843 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 80.52 2.92 90.0 Favored Glycine 0 N--CA 1.455 -0.088 0 C-N-CA 120.84 -0.695 . . . . 0.0 111.776 -177.071 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER 60.45 93.95 0.04 OUTLIER 'General case' 0 CA--C 1.519 -0.241 0 C-N-CA 123.569 0.747 . . . . 0.0 112.779 -179.447 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 11.4 t -77.6 130.76 37.3 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 171.046 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 91.5 mt -112.32 102.63 54.44 Favored Pre-proline 0 C--N 1.32 -0.695 0 CA-C-O 120.823 0.344 . . . . 0.0 111.788 -172.858 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -88.33 -168.28 0.36 Allowed 'Trans proline' 0 N--CA 1.454 -0.828 0 C-N-CA 122.784 2.323 . . . . 0.0 110.817 171.515 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 37.4 t80 -94.01 116.96 29.44 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 177.681 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.052 0 CA-C-O 118.569 -0.729 . . . . 0.0 110.798 -177.55 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . . . . . . . . . 92.4 mt-30 . . . . . 0 N--CA 1.455 -0.213 0 CA-C-O 120.608 0.242 . . . . 0.0 111.322 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 5.7 Cg_exo -77.21 154.11 32.24 Favored 'Trans proline' 0 N--CA 1.46 -0.463 0 C-N-CA 123.045 2.497 . . . . 0.0 110.897 171.728 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -167.59 86.08 0.24 Allowed 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 121.185 0.516 . . . . 0.0 111.147 -176.748 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 82.73 122.55 0.75 Allowed Glycine 0 N--CA 1.448 -0.526 0 CA-C-N 115.321 -0.854 . . . . 0.0 112.621 178.913 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 34.9 m -98.09 149.45 5.22 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.881 0 CA-C-O 120.862 0.363 . . . . 0.0 110.583 -179.641 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . 0.462 ' HB2' ' O ' ' A' ' 46' ' ' LEU . 3.7 pt20 -128.97 159.58 35.44 Favored 'General case' 0 C--N 1.318 -0.779 0 C-N-CA 120.558 -0.457 . . . . 0.0 110.868 176.875 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.578 HG21 HD11 ' A' ' 48' ' ' ILE . 0.2 OUTLIER -82.58 111.62 19.22 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.357 178.42 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 22.8 t70 -71.2 -62.8 1.27 Allowed 'General case' 0 C--N 1.318 -0.784 0 CA-C-N 115.363 -0.835 . . . . 0.0 111.481 -174.978 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 8.4 p -155.31 145.08 21.4 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.681 -176.464 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.556 HG11 ' HA ' ' A' ' 39' ' ' SER . 89.0 t -90.41 132.39 35.16 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.762 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.406 178.964 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.463 ' HA ' ' HD3' ' A' ' 34' ' ' PRO . 17.5 m -107.29 134.07 20.09 Favored Pre-proline 0 N--CA 1.449 -0.524 0 CA-C-O 121.015 0.436 . . . . 0.0 111.476 -178.251 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . 0.463 ' HD3' ' HA ' ' A' ' 33' ' ' VAL . 21.9 Cg_exo -66.44 142.24 64.74 Favored 'Trans proline' 0 C--O 1.236 0.389 0 C-N-CA 123.108 2.539 . . . . 0.0 112.141 178.302 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 112.99 -16.13 23.11 Favored Glycine 0 N--CA 1.448 -0.538 0 N-CA-C 111.232 -0.747 . . . . 0.0 111.232 -176.939 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 26.0 m -123.53 165.22 24.03 Favored Pre-proline 0 C--N 1.324 -0.539 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 179.853 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -74.72 -168.62 0.52 Allowed 'Trans proline' 0 CA--C 1.533 0.428 0 C-N-CA 122.753 2.302 . . . . 0.0 112.489 178.383 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.498 ' HB1' HD11 ' A' ' 86' ' ' LEU . . . 78.62 -6.3 1.93 Allowed 'General case' 0 N--CA 1.468 0.436 0 CA-C-N 115.473 -0.785 . . . . 0.0 112.354 175.457 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.556 ' HA ' HG11 ' A' ' 32' ' ' VAL . 3.8 m -58.69 -30.9 67.74 Favored 'General case' 0 CA--C 1.531 0.243 0 CA-C-O 120.817 0.342 . . . . 0.0 111.661 -177.2 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 64.6 mmtt -119.33 20.7 12.47 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.19 0.519 . . . . 0.0 110.928 -179.675 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 89.6 t -107.84 -47.04 7.82 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 115.938 -0.573 . . . . 0.0 110.043 178.678 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.554 ' HB3' ' CZ ' ' A' ' 84' ' ' PHE . 0.6 OUTLIER -118.61 171.83 7.92 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 121.078 0.466 . . . . 0.0 111.256 178.884 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 11.7 m -115.84 126.15 27.97 Favored Pre-proline 0 C--N 1.315 -0.895 0 CA-C-N 115.452 -0.795 . . . . 0.0 110.061 -179.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_endo -62.2 142.35 91.41 Favored 'Trans proline' 0 N--CA 1.46 -0.461 0 C-N-CA 122.099 1.866 . . . . 0.0 111.422 177.4 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 97.72 -5.42 62.05 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.995 -179.248 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 0.462 ' O ' ' HB2' ' A' ' 28' ' ' GLN . 75.2 mt -85.09 164.03 18.44 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.931 0.366 . . . . 0.0 110.968 179.589 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 47.4 t -101.51 143.28 14.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.457 178.516 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.578 HD11 HG21 ' A' ' 29' ' ' ILE . 60.0 mt -104.36 127.42 58.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 C-N-CA 122.535 0.334 . . . . 0.0 110.209 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 27.9 mt-10 -89.51 -47.88 7.69 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.777 176.382 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.551 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 19.5 p -157.38 153.15 26.81 Favored 'General case' 0 N--CA 1.446 -0.671 0 CA-C-O 121.599 0.714 . . . . 0.0 112.202 -172.877 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.45 HG23 ' H ' ' A' ' 52' ' ' ASN . 16.0 mt -96.86 -179.93 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 169.735 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' ASN . . . . . 0.625 ' HB2' ' H ' ' A' ' 76' ' ' ASN . 36.0 t-20 -49.58 93.67 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 112.264 0.468 . . . . 0.0 112.264 -177.434 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 73.12 -2.59 34.63 Favored Glycine 0 CA--C 1.519 0.321 0 CA-C-N 115.976 -0.557 . . . . 0.0 113.275 179.493 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 36.1 mtt -124.8 98.85 36.13 Favored Pre-proline 0 C--N 1.325 -0.484 0 CA-C-N 116.875 0.337 . . . . 0.0 110.654 -173.096 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.551 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 70.4 Cg_endo -77.27 130.89 11.36 Favored 'Trans proline' 0 N--CA 1.46 -0.447 0 C-N-CA 122.151 1.901 . . . . 0.0 112.005 178.257 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.425 HG22 ' HA ' ' A' ' 62' ' ' TYR . 37.5 p -116.63 103.84 10.79 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 121.089 0.471 . . . . 0.0 111.614 -176.307 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 26.9 t -89.05 -34.63 16.72 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.965 177.207 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 2.3 m-20 -103.34 158.44 16.33 Favored 'General case' 0 C--N 1.318 -0.797 0 O-C-N 122.065 -0.397 . . . . 0.0 110.153 -176.804 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 87.4 mt -68.81 -33.8 74.45 Favored 'General case' 0 N--CA 1.443 -0.801 0 CA-C-O 121.215 0.531 . . . . 0.0 109.955 175.519 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 1.6 m -66.04 -41.82 90.39 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.668 -0.696 . . . . 0.0 111.081 177.547 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 18.4 p -68.07 -28.46 67.38 Favored 'General case' 0 CA--C 1.528 0.114 0 CA-C-O 120.811 0.339 . . . . 0.0 110.55 178.951 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' TYR . . . . . 0.477 ' HH ' ' HG3' ' A' ' 100' ' ' MET . 46.1 t80 -67.19 -38.41 85.31 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 176.105 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 21.6 t -66.07 -48.28 71.53 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.768 179.097 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.03 -32.78 74.22 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.346 -177.773 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . 0.474 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -73.29 -43.88 60.16 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.311 179.586 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 3.2 tt -57.04 -45.99 82.74 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.705 -0.679 . . . . 0.0 110.494 -179.6 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -59.69 -26.88 65.95 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.63 -0.714 . . . . 0.0 112.173 -178.199 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 43.5 p -89.24 -14.03 36.82 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 112.049 0.388 . . . . 0.0 112.049 -177.454 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.474 HG12 ' O ' ' A' ' 65' ' ' ALA . 40.9 mm -74.83 142.81 14.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.652 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' SER . . . . . 0.449 ' HB2' ' HB2' ' A' ' 73' ' ' GLU . 4.9 m -93.18 157.64 16.17 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.673 0.273 . . . . 0.0 111.084 -178.157 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.415 HG13 ' HA ' ' A' ' 90' ' ' ARG . 75.3 t -70.29 129.79 34.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.109 177.146 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 79.63 10.14 86.12 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.612 -0.804 . . . . 0.0 111.606 179.759 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.449 ' HB2' ' HB2' ' A' ' 70' ' ' SER . 23.7 tt0 -92.86 149.57 21.17 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 -179.719 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 44.9 t -105.1 124.05 59.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-O 121.35 0.595 . . . . 0.0 110.579 -175.806 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 15.7 pt -110.27 154.04 11.9 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.122 179.193 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . 0.625 ' H ' ' HB2' ' A' ' 52' ' ' ASN . 6.3 t30 -105.8 110.49 22.8 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 115.312 -0.858 . . . . 0.0 109.736 -177.755 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 65.0 mt -105.95 119.41 55.21 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 CA-C-O 121.34 0.59 . . . . 0.0 110.992 -174.087 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 11.9 m -93.68 118.5 31.47 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.278 -0.873 . . . . 0.0 109.616 177.847 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 43.4 p -120.36 178.12 4.77 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.82 0.343 . . . . 0.0 111.165 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 28.5 t70 -58.59 -34.88 71.6 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.598 -0.728 . . . . 0.0 111.351 178.798 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 10.7 mm100 -96.48 14.24 25.24 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.125 -0.489 . . . . 0.0 112.103 -176.136 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 123.26 -171.51 15.85 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.177 -1.011 . . . . 0.0 112.631 176.246 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 24.1 m -112.06 138.23 49.0 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.75 0.309 . . . . 0.0 110.721 -176.855 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . 0.554 ' CZ ' ' HB3' ' A' ' 42' ' ' LEU . 10.3 p90 -139.16 168.83 18.96 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 121.378 0.609 . . . . 0.0 110.949 175.494 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -109.82 138.34 46.33 Favored 'General case' 0 C--N 1.314 -0.951 0 CA-C-N 115.142 -0.935 . . . . 0.0 110.016 178.158 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.498 HD11 ' HB1' ' A' ' 38' ' ' ALA . 17.8 tp -130.08 143.85 51.02 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.106 -177.755 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 24.3 ttpp -114.18 125.43 53.93 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.093 -178.277 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' THR . . . . . 0.633 HG23 ' HB3' ' A' ' 98' ' ' ALA . 77.0 p -73.99 148.17 42.31 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 115.969 -0.559 . . . . 0.0 111.38 -178.716 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -99.49 -171.88 30.69 Favored Glycine 0 N--CA 1.444 -0.805 0 N-CA-C 110.952 -0.859 . . . . 0.0 110.952 174.866 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.508 ' HG2' ' N ' ' A' ' 91' ' ' ASN . 0.7 OUTLIER -81.15 -60.44 2.28 Favored 'General case' 0 C--N 1.323 -0.555 0 C-N-CA 120.639 -0.424 . . . . 0.0 111.437 -178.477 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' ASN . . . . . 0.508 ' N ' ' HG2' ' A' ' 90' ' ' ARG . 2.1 m-20 178.84 137.25 0.25 Allowed Pre-proline 0 N--CA 1.465 0.297 0 C-N-CA 122.682 0.393 . . . . 0.0 110.241 -178.362 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.403 ' HD3' ' HA ' ' A' ' 91' ' ' ASN . 12.3 Cg_endo -90.65 -74.97 0.0 OUTLIER 'Trans proline' 0 N--CA 1.449 -1.09 0 C-N-CA 122.849 2.366 . . . . 0.0 110.815 170.901 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 63.2 t30 -142.63 68.15 1.31 Allowed 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 173.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 20.8 t-20 -150.18 166.77 28.85 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.311 -0.858 . . . . 0.0 109.485 -172.225 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 49.1 m -115.43 24.5 11.55 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.332 0.587 . . . . 0.0 109.821 178.266 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 25.4 m -100.63 -172.73 2.24 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.402 -0.817 . . . . 0.0 110.179 178.476 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . 0.448 ' HD3' ' N ' ' A' ' 97' ' ' ARG . 0.0 OUTLIER -138.16 145.46 41.57 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 177.093 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . 0.633 ' HB3' HG23 ' A' ' 88' ' ' THR . . . 58.03 68.02 0.89 Allowed 'General case' 0 C--N 1.332 -0.16 0 O-C-N 123.768 0.667 . . . . 0.0 109.903 -176.26 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 29.5 p90 -86.89 148.57 25.3 Favored 'General case' 0 N--CA 1.444 -0.747 0 CA-C-N 115.865 -0.607 . . . . 0.0 112.164 -167.238 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' MET . . . . . 0.477 ' HG3' ' HH ' ' A' ' 62' ' ' TYR . 93.5 mmm -98.06 126.55 43.55 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.05 -0.977 . . . . 0.0 109.341 175.358 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -86.92 35.19 3.43 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.806 -177.046 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.532 HG21 ' HA ' ' A' ' 32' ' ' VAL . 2.8 pp -140.2 162.71 24.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 120.801 0.334 . . . . 0.0 110.434 179.655 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . 0.411 ' NE ' ' HA ' ' A' ' 103' ' ' ARG . 2.9 mmp_? -93.01 142.07 27.7 Favored 'General case' 0 C--N 1.315 -0.915 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 171.377 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.3 m -111.17 150.52 29.38 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-O 121.085 0.469 . . . . 0.0 110.387 179.455 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.411 ' OG ' ' HG3' ' A' ' 28' ' ' GLN . 6.7 p -136.16 169.08 18.2 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.158 175.809 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 2.0 t-20 -112.35 7.88 19.39 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 120.686 0.279 . . . . 0.0 111.261 -172.575 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 48.7 t60 63.6 34.9 12.05 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-O 121.693 0.758 . . . . 0.0 110.495 176.187 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . 0.402 ' HB3' ' H ' ' A' ' 109' ' ' ARG . 92.8 mt -96.67 -163.49 1.05 Allowed 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.182 -0.917 . . . . 0.0 110.845 -179.22 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . 0.402 ' H ' ' HB3' ' A' ' 108' ' ' LEU . 59.8 mmt-85 -113.34 137.91 50.82 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.597 179.074 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 44.2 t -122.01 135.7 61.29 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.043 -179.906 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' ARG . . . . . . . . . . . . . 97.0 mtt180 -88.2 134.56 33.75 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 121.013 0.435 . . . . 0.0 110.878 -179.466 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 6.7 p-10 -112.51 16.77 19.69 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 121.431 0.634 . . . . 0.0 110.583 179.103 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 22.5 t -101.45 129.71 47.54 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-N 115.355 -0.838 . . . . 0.0 110.08 179.361 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 12.0 m -124.33 137.61 56.65 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.53 179.105 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -128.95 79.09 1.89 Allowed 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.774 178.233 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 52.7 m -96.85 98.62 10.27 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.192 0.52 . . . . 0.0 110.165 178.426 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 30.5 m -88.95 167.59 1.67 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.832 -178.644 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -79.44 -51.43 9.38 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.166 -0.47 . . . . 0.0 109.87 178.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 60.49 33.07 79.94 Favored Glycine 0 C--N 1.331 0.301 0 CA-C-N 115.675 -0.693 . . . . 0.0 112.231 -179.68 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -88.89 146.14 25.12 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.127 0.489 . . . . 0.0 111.215 -177.229 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 5.7 t -155.99 99.92 2.0 Allowed 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.328 -0.851 . . . . 0.0 109.123 174.484 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . 0.444 ' HA ' ' HD3' ' A' ' 123' ' ' PRO . 96.5 mt -93.02 117.09 67.41 Favored Pre-proline 0 C--N 1.321 -0.658 0 CA-C-N 115.347 -0.842 . . . . 0.0 111.514 -171.753 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . 0.444 ' HD3' ' HA ' ' A' ' 122' ' ' LEU . 5.1 Cg_exo -78.1 117.05 4.05 Favored 'Trans proline' 0 N--CA 1.458 -0.602 0 C-N-CA 123.011 2.474 . . . . 0.0 111.406 175.636 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 68.5 m-85 -79.25 94.41 5.44 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.14 179.499 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.079 0 CA-C-O 118.473 -0.775 . . . . 0.0 110.648 -177.917 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . . . . . . . . . 29.9 tp60 . . . . . 0 N--CA 1.454 -0.269 0 CA-C-O 120.467 0.175 . . . . 0.0 110.666 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.455 ' HB2' ' OG ' ' A' ' 57' ' ' SER . 68.7 Cg_endo -75.95 157.07 38.9 Favored 'Trans proline' 0 C--O 1.236 0.386 0 C-N-CA 122.501 2.134 . . . . 0.0 111.138 172.566 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 21.4 t70 -148.68 -50.65 0.16 Allowed 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 121.083 0.468 . . . . 0.0 111.447 -176.659 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.56 ' HA2' ' HA ' ' A' ' 57' ' ' SER . . . 157.25 167.2 17.99 Favored Glycine 0 N--CA 1.443 -0.869 0 N-CA-C 111.039 -0.824 . . . . 0.0 111.039 -177.124 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.483 HG21 ' HB ' ' A' ' 48' ' ' ILE . 28.5 m -108.06 127.42 64.26 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 CA-C-O 121.253 0.549 . . . . 0.0 110.984 178.787 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 18.9 tt0 -99.21 142.78 30.26 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.07 178.01 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.428 HG12 ' O ' ' A' ' 46' ' ' LEU . 8.0 pt -87.36 119.52 35.16 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-O 121.612 0.72 . . . . 0.0 111.579 -178.069 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.4 ' HB3' ' CB ' ' A' ' 103' ' ' ARG . 11.4 t70 -61.12 -58.47 8.22 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 114.272 -1.331 . . . . 0.0 109.983 177.23 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.569 ' HA ' ' HB3' ' A' ' 44' ' ' PRO . 7.8 p -159.69 158.96 32.36 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.432 -0.804 . . . . 0.0 111.145 -174.407 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.555 ' HA ' HG22 ' A' ' 102' ' ' ILE . 91.4 t -110.44 119.7 59.83 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 115.689 -0.687 . . . . 0.0 109.404 177.846 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.443 ' C ' ' H ' ' A' ' 35' ' ' GLY . 53.9 t -83.63 123.52 76.3 Favored Pre-proline 0 C--N 1.324 -0.513 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.721 -175.978 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . 0.42 ' HD3' ' HA ' ' A' ' 33' ' ' VAL . 11.4 Cg_exo -72.95 31.16 0.3 Allowed 'Trans proline' 0 CA--C 1.532 0.42 0 C-N-CA 123.269 2.646 . . . . 0.0 112.775 179.291 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.443 ' H ' ' C ' ' A' ' 33' ' ' VAL . . . -121.69 20.43 8.24 Favored Glycine 0 N--CA 1.449 -0.462 0 N-CA-C 111.27 -0.732 . . . . 0.0 111.27 179.172 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 49.1 m -148.17 160.9 36.08 Favored Pre-proline 0 C--N 1.323 -0.578 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 179.425 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_exo -59.81 -13.56 22.92 Favored 'Trans proline' 0 C--N 1.348 0.533 0 C-N-CA 122.985 2.457 . . . . 0.0 113.669 -176.297 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.406 ' HB2' HD11 ' A' ' 42' ' ' LEU . . . -78.6 -6.94 56.97 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 111.794 0.294 . . . . 0.0 111.794 -177.333 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 28.0 t -60.43 -28.45 68.3 Favored 'General case' 0 CA--C 1.533 0.294 0 N-CA-C 112.153 0.427 . . . . 0.0 112.153 -175.657 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 21.0 ttpt -106.96 13.53 27.5 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.947 0.403 . . . . 0.0 110.678 -177.388 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.469 ' HB ' HD12 ' A' ' 42' ' ' LEU . 46.4 t -115.34 -59.2 3.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 C-N-CA 120.776 -0.37 . . . . 0.0 111.65 -175.23 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.469 HD12 ' HB ' ' A' ' 41' ' ' VAL . 6.6 mp -92.45 175.46 6.83 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.291 0.567 . . . . 0.0 111.516 -173.478 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 91.1 m -140.89 123.94 9.91 Favored Pre-proline 0 C--N 1.32 -0.674 0 CA-C-N 115.405 -0.816 . . . . 0.0 108.946 175.544 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.569 ' HB3' ' HA ' ' A' ' 31' ' ' SER . 42.3 Cg_endo -64.52 152.05 83.17 Favored 'Trans proline' 0 CA--C 1.531 0.339 0 C-N-CA 122.893 2.396 . . . . 0.0 112.905 -173.811 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 103.17 -11.92 55.36 Favored Glycine 0 CA--C 1.52 0.368 0 C-N-CA 121.072 -0.585 . . . . 0.0 112.695 -179.496 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 0.698 HD23 ' HB3' ' A' ' 80' ' ' ASP . 81.6 mt -84.74 164.62 18.43 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.975 0.417 . . . . 0.0 111.098 -177.981 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 46.6 t -108.12 135.09 47.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 116.075 -0.511 . . . . 0.0 109.843 177.129 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.483 ' HB ' HG21 ' A' ' 27' ' ' VAL . 69.0 mt -87.65 123.7 40.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-O 121.204 0.526 . . . . 0.0 110.536 179.862 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 6.5 tm-20 -79.22 -47.06 16.62 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.921 -179.54 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.516 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 7.7 p -162.73 153.77 17.32 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.388 -177.648 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 48.5 mm -107.24 102.96 14.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.901 -0.59 . . . . 0.0 109.732 176.679 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' ASN . . . . . 0.575 ' HA ' ' HB3' ' A' ' 76' ' ' ASN . 38.9 t-20 64.08 -85.26 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.384 0 C-N-CA 123.552 0.741 . . . . 0.0 111.056 179.343 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -132.79 8.05 5.21 Favored Glycine 0 N--CA 1.447 -0.569 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 177.005 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 1.5 mpt? -118.59 103.35 48.92 Favored Pre-proline 0 N--CA 1.448 -0.571 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 -178.737 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.516 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 41.8 Cg_endo -68.81 121.68 8.57 Favored 'Trans proline' 0 N--CA 1.462 -0.367 0 C-N-CA 122.124 1.882 . . . . 0.0 112.461 -179.118 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.427 ' HA ' ' HB ' ' A' ' 61' ' ' THR . 6.9 p -89.47 87.99 7.28 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.54 179.834 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' SER . . . . . 0.56 ' HA ' ' HA2' ' A' ' 26' ' ' GLY . 8.6 t -93.53 -14.26 26.82 Favored 'General case' 0 C--N 1.318 -0.797 0 CA-C-N 115.416 -0.811 . . . . 0.0 109.875 -179.476 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 61.1 t30 -140.5 178.23 7.46 Favored 'General case' 0 N--CA 1.445 -0.714 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 178.978 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 68.8 mt -76.16 -33.39 59.37 Favored 'General case' 0 N--CA 1.445 -0.72 0 CA-C-O 120.921 0.391 . . . . 0.0 111.067 -178.424 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 13.1 m -66.48 -34.33 77.68 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.977 179.869 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' THR . . . . . 0.427 ' HB ' ' HA ' ' A' ' 56' ' ' THR . 0.0 OUTLIER -66.0 -35.33 80.26 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.992 0.425 . . . . 0.0 110.372 176.838 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 55.4 t80 -62.33 -37.45 85.66 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.857 176.842 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 33.2 t -68.25 -46.19 71.16 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.52 -0.764 . . . . 0.0 110.435 177.287 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -66.32 -26.34 67.26 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.865 -0.607 . . . . 0.0 112.13 -175.761 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . 0.421 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -79.27 -44.03 22.54 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.078 0.466 . . . . 0.0 110.431 177.487 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . 0.408 ' HG ' ' HE2' ' A' ' 100' ' ' MET . 1.7 tt -63.55 -42.64 98.38 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.556 -0.747 . . . . 0.0 111.357 -175.824 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 22.4 ptmt -60.37 -12.37 9.14 Favored 'General case' 0 CA--C 1.536 0.414 0 N-CA-C 112.899 0.704 . . . . 0.0 112.899 -174.117 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 20.8 p -106.93 -13.17 15.28 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 112.386 0.514 . . . . 0.0 112.386 -178.128 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.45 HG22 HG23 ' A' ' 88' ' ' THR . 37.2 mm -79.73 143.85 11.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.748 -0.205 . . . . 0.0 110.956 -175.256 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 3.2 m -92.45 164.52 13.44 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.508 -0.315 . . . . 0.0 110.471 179.888 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 16.5 t -78.6 118.09 25.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 120.677 0.275 . . . . 0.0 110.266 179.304 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 88.32 23.52 37.03 Favored Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 120.422 -0.894 . . . . 0.0 111.671 -178.846 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 28.6 tt0 -99.56 147.5 25.27 Favored 'General case' 0 C--N 1.323 -0.587 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 -179.851 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 51.0 t -95.14 114.29 31.39 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.779 0 CA-C-O 121.136 0.493 . . . . 0.0 110.56 -179.122 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 26.7 pt -104.21 174.79 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.787 0 CA-C-N 115.637 -0.71 . . . . 0.0 110.87 179.27 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . 0.575 ' HB3' ' HA ' ' A' ' 52' ' ' ASN . 43.6 t30 -122.16 130.54 53.31 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.586 -0.734 . . . . 0.0 109.813 -175.536 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.416 HG23 HG23 ' A' ' 79' ' ' THR . 62.5 mt -134.8 110.33 12.71 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-O 121.212 0.529 . . . . 0.0 111.112 -176.922 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' THR . . . . . 0.609 ' HA ' ' HA ' ' A' ' 83' ' ' THR . 98.1 m -85.91 123.53 31.35 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.986 -0.552 . . . . 0.0 109.685 173.597 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.416 HG23 HG23 ' A' ' 77' ' ' ILE . 67.3 p -124.72 -173.45 2.79 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.922 0.392 . . . . 0.0 111.364 -177.472 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . 0.698 ' HB3' HD23 ' A' ' 46' ' ' LEU . 7.4 t70 -53.78 -41.55 67.34 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.216 -0.902 . . . . 0.0 111.583 177.173 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 28.2 mm-40 -95.23 12.94 27.13 Favored 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 111.931 0.345 . . . . 0.0 111.931 -175.759 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 119.43 -175.32 15.75 Favored Glycine 0 N--CA 1.447 -0.63 0 C-N-CA 120.164 -1.017 . . . . 0.0 113.038 175.342 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' THR . . . . . 0.609 ' HA ' ' HA ' ' A' ' 78' ' ' THR . 32.6 m -92.67 117.17 29.7 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.115 0.484 . . . . 0.0 111.396 -176.565 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 88.9 m-85 -113.89 164.8 13.29 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.43 -178.735 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 19.3 p-80 -117.27 130.01 56.28 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.285 178.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.481 HD23 ' N ' ' A' ' 87' ' ' LYS . 8.2 tt -120.48 145.48 47.23 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 116.231 -0.44 . . . . 0.0 109.947 -173.985 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.481 ' N ' HD23 ' A' ' 86' ' ' LEU . 88.1 tttt -114.66 117.59 31.28 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 109.132 -0.692 . . . . 0.0 109.132 176.216 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' THR . . . . . 0.45 HG23 HG22 ' A' ' 69' ' ' ILE . 22.3 p -64.03 131.92 49.03 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 121.142 0.496 . . . . 0.0 111.729 -174.997 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -102.55 -141.11 11.36 Favored Glycine 0 N--CA 1.441 -1.012 0 C-N-CA 120.975 -0.631 . . . . 0.0 111.797 179.61 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 70.6 mtt180 -115.36 161.34 18.65 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.123 0.487 . . . . 0.0 111.365 -175.124 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' ASN . . . . . 0.625 ' HB3' ' HB2' ' A' ' 99' ' ' TYR . 1.1 p-10 -130.59 107.87 15.77 Favored Pre-proline 0 C--N 1.324 -0.515 0 CA-C-N 115.331 -0.849 . . . . 0.0 111.729 -171.801 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_exo -83.01 -4.71 11.28 Favored 'Trans proline' 0 C--O 1.23 0.101 0 C-N-CA 123.557 2.838 . . . . 0.0 112.079 174.052 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 5.3 t30 -133.95 78.35 1.76 Allowed 'General case' 0 C--N 1.316 -0.885 0 CA-C-N 115.064 -0.971 . . . . 0.0 109.944 -173.48 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 11.5 t-20 71.63 -160.21 0.12 Allowed 'General case' 0 N--CA 1.469 0.48 0 CA-C-N 115.147 -0.933 . . . . 0.0 109.966 173.054 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 14.8 m 76.24 -26.59 0.19 Allowed 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 123.913 0.885 . . . . 0.0 112.559 176.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 55.6 m 71.91 -60.46 0.52 Allowed 'General case' 0 N--CA 1.467 0.39 0 C-N-CA 123.58 0.752 . . . . 0.0 112.374 178.941 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -141.8 153.41 44.51 Favored 'General case' 0 C--N 1.328 -0.369 0 O-C-N 122.292 -0.255 . . . . 0.0 111.592 -177.374 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . 62.24 81.74 0.19 Allowed 'General case' 0 N--CA 1.464 0.254 0 O-C-N 124.089 0.868 . . . . 0.0 112.29 169.573 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . 0.625 ' HB2' ' HB3' ' A' ' 91' ' ' ASN . 14.5 t80 -107.45 120.74 43.0 Favored 'General case' 0 C--N 1.319 -0.718 0 C-N-CA 120.76 -0.376 . . . . 0.0 110.07 -178.58 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' MET . . . . . 0.525 ' HG2' HG12 ' A' ' 102' ' ' ILE . 0.7 OUTLIER -71.86 -20.18 61.85 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.169 -179.038 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 78.91 35.2 31.83 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.866 -0.683 . . . . 0.0 113.113 175.201 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.555 HG22 ' HA ' ' A' ' 32' ' ' VAL . 35.4 pt -142.02 154.01 18.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-O 120.849 0.356 . . . . 0.0 110.063 178.933 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . 0.4 ' CB ' ' HB3' ' A' ' 30' ' ' ASP . 21.4 mtp85 -91.74 134.66 34.53 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 173.463 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 2.8 m -133.21 155.14 49.89 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.962 0.41 . . . . 0.0 111.055 -176.308 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 32.6 t -149.1 -174.88 4.76 Favored 'General case' 0 C--N 1.321 -0.636 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 179.44 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 14.8 p30 -103.24 -34.84 8.66 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 120.635 0.255 . . . . 0.0 111.044 179.211 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 44.3 t-80 55.27 49.72 16.54 Favored 'General case' 0 CA--C 1.531 0.213 0 CA-C-O 121.206 0.527 . . . . 0.0 110.375 -179.771 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 16.9 mt -85.57 139.64 31.28 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.326 -179.25 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 32.3 ttt180 68.78 139.8 0.04 OUTLIER 'General case' 0 N--CA 1.467 0.381 0 O-C-N 124.728 1.267 . . . . 0.0 112.214 178.739 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 14.0 p -69.5 145.79 12.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.118 -0.492 . . . . 0.0 109.841 173.76 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' ARG . . . . . 0.46 ' HD2' ' C ' ' A' ' 111' ' ' ARG . 4.1 ppt_? -106.84 171.58 7.29 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.118 0.485 . . . . 0.0 111.492 -173.657 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -148.29 152.07 36.48 Favored 'General case' 0 C--N 1.323 -0.576 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 175.007 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 50.7 m 72.78 111.44 0.06 Allowed 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.212 0.945 . . . . 0.0 111.849 177.355 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 16.7 m -96.87 133.66 37.49 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.409 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.779 178.074 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -105.86 130.55 53.8 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.032 177.659 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 5.8 t -100.65 85.84 3.0 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.04 0.447 . . . . 0.0 109.891 -177.51 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 52.4 t -128.47 109.39 19.22 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.838 178.558 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 118' ' ' LEU . . . . . 0.453 HD23 ' N ' ' A' ' 118' ' ' LEU . 2.7 mm? -93.29 -48.33 6.48 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.525 -177.33 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 69.99 58.91 5.83 Favored Glycine 0 N--CA 1.449 -0.499 0 C-N-CA 120.687 -0.768 . . . . 0.0 111.213 -175.518 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 9.2 p-10 -74.13 112.42 10.25 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.413 0.625 . . . . 0.0 111.16 -175.506 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 92.1 m -91.27 126.62 36.41 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.427 177.006 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 96.0 mt -110.8 147.77 37.18 Favored Pre-proline 0 C--N 1.324 -0.515 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.578 -177.229 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -65.62 145.68 82.44 Favored 'Trans proline' 0 CA--C 1.527 0.168 0 C-N-CA 122.675 2.25 . . . . 0.0 112.194 178.833 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 32.9 p90 -129.22 147.3 51.04 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 116.409 -0.359 . . . . 0.0 110.723 -178.738 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.93 0 CA-C-O 118.412 -0.804 . . . . 0.0 109.862 -179.658 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . . . . . . . . . 80.7 mt-30 . . . . . 0 N--CA 1.457 -0.11 0 CA-C-O 120.846 0.355 . . . . 0.0 110.982 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 65.4 Cg_endo -87.8 -156.38 0.06 OUTLIER 'Trans proline' 0 N--CA 1.46 -0.473 0 C-N-CA 123.28 2.653 . . . . 0.0 112.602 178.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 27.9 t70 75.94 67.15 0.06 Allowed 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 114.607 -1.179 . . . . 0.0 110.364 178.602 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.45 ' O ' HD11 ' A' ' 108' ' ' LEU . . . 106.52 115.94 4.08 Favored Glycine 0 N--CA 1.445 -0.72 0 CA-C-N 114.471 -1.24 . . . . 0.0 111.751 176.597 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 34.5 m -78.79 153.83 4.92 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 CA-C-O 120.941 0.4 . . . . 0.0 110.721 -178.737 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 4.4 tt0 -115.53 149.24 38.48 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-O 121.293 0.568 . . . . 0.0 111.349 -177.585 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.469 HD11 HD11 ' A' ' 102' ' ' ILE . 26.8 mm -73.11 107.62 3.86 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.214 -0.903 . . . . 0.0 109.432 175.742 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.692 ' HB3' ' HB2' ' A' ' 103' ' ' ARG . 41.9 t0 -69.98 -53.54 17.28 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-O 121.401 0.62 . . . . 0.0 109.529 -178.671 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 51.0 p -161.47 173.51 14.76 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.189 -0.914 . . . . 0.0 110.798 177.103 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.467 HG21 HG22 ' A' ' 102' ' ' ILE . 84.9 t -119.25 124.46 73.1 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 CA-C-N 115.813 -0.631 . . . . 0.0 109.382 175.95 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 7.4 p -106.7 131.02 22.04 Favored Pre-proline 0 C--N 1.323 -0.545 0 CA-C-O 120.783 0.325 . . . . 0.0 110.421 -177.67 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo -64.97 87.85 0.18 Allowed 'Trans proline' 0 C--N 1.343 0.289 0 C-N-CA 122.79 2.327 . . . . 0.0 112.408 179.426 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -164.75 14.21 0.09 OUTLIER Glycine 0 N--CA 1.449 -0.447 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.862 176.032 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' SER . . . . . 0.665 ' HB2' ' HA3' ' A' ' 101' ' ' GLY . 60.4 m -157.65 160.44 30.16 Favored Pre-proline 0 C--N 1.327 -0.401 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 -178.972 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_exo -63.31 -15.34 47.66 Favored 'Trans proline' 0 C--N 1.349 0.568 0 C-N-CA 122.87 2.38 . . . . 0.0 112.71 -178.132 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -67.07 -15.12 63.52 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.922 -177.426 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.44 ' HA ' HG13 ' A' ' 32' ' ' VAL . 47.7 t -65.21 -13.55 58.54 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.71 -177.041 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 23.9 ttmm -128.42 25.39 5.77 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.346 0.594 . . . . 0.0 110.06 179.244 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.529 ' HB ' HD13 ' A' ' 42' ' ' LEU . 45.6 t -122.16 -55.3 2.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.905 179.381 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.529 HD13 ' HB ' ' A' ' 41' ' ' VAL . 5.0 mp -109.17 164.19 12.67 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.789 0.328 . . . . 0.0 110.588 -178.033 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 12.7 p -116.54 144.54 33.39 Favored Pre-proline 0 C--N 1.323 -0.548 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.62 177.1 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.444 ' HA ' ' CG2' ' A' ' 29' ' ' ILE . 57.2 Cg_endo -72.55 149.41 49.53 Favored 'Trans proline' 0 C--O 1.235 0.332 0 C-N-CA 122.299 1.999 . . . . 0.0 112.496 -179.422 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 101.14 -12.52 58.8 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.999 -179.555 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 83.4 mt -77.43 164.27 25.62 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 121.046 0.451 . . . . 0.0 111.46 -179.235 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 46.0 t -108.76 136.19 45.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.785 177.933 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.416 HG21 HG22 ' A' ' 77' ' ' ILE . 70.9 mt -93.79 122.71 45.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-N 116.496 -0.32 . . . . 0.0 110.981 179.55 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -79.82 -44.97 19.6 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.5 -0.318 . . . . 0.0 110.951 174.809 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.58 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 16.4 p -169.03 161.22 10.45 Favored 'General case' 0 CA--C 1.515 -0.404 0 CA-C-O 120.888 0.375 . . . . 0.0 111.408 -174.559 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.509 HD13 HD11 ' A' ' 75' ' ' ILE . 8.1 tt -135.95 122.19 31.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.148 177.473 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 11.0 m120 58.85 22.88 10.69 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-N 115.642 -0.708 . . . . 0.0 112.536 176.094 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 104.71 -26.22 23.19 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.655 -0.783 . . . . 0.0 112.433 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 4.4 mpp? -91.94 112.8 56.6 Favored Pre-proline 0 C--N 1.325 -0.491 0 N-CA-C 109.682 -0.488 . . . . 0.0 109.682 177.577 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.58 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 72.6 Cg_endo -78.02 128.07 8.9 Favored 'Trans proline' 0 N--CA 1.454 -0.799 0 C-N-CA 122.09 1.86 . . . . 0.0 112.501 -178.748 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 21.5 p -91.64 81.13 5.31 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 115.649 -0.705 . . . . 0.0 111.026 -177.944 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 12.6 m -81.34 -18.5 45.49 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.69 178.561 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 42.7 m-80 -138.34 164.85 28.25 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.733 -178.729 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.487 HD22 ' HA ' ' A' ' 105' ' ' SER . 66.2 mt -68.75 -35.14 76.72 Favored 'General case' 0 N--CA 1.446 -0.653 0 CA-C-O 120.908 0.385 . . . . 0.0 110.576 178.222 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 1.5 m -62.22 -35.32 78.53 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.509 176.513 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -66.65 -43.25 85.1 Favored 'General case' 0 N--CA 1.452 -0.356 0 CA-C-N 115.998 -0.547 . . . . 0.0 110.374 178.326 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 33.3 t80 -64.14 -37.53 87.79 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.931 -0.577 . . . . 0.0 109.635 177.473 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 66.8 m -61.46 -50.94 70.75 Favored 'General case' 0 N--CA 1.445 -0.693 0 CA-C-N 115.387 -0.824 . . . . 0.0 111.397 178.012 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.95 -33.93 76.42 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.989 179.623 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . 0.572 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -72.79 -41.27 65.16 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.269 -179.866 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 1.2 tt -57.42 -39.31 75.92 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.252 179.407 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 93.7 mttt -59.23 -39.41 82.65 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.801 179.375 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 17.5 p -77.84 -14.37 59.59 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 111.985 0.365 . . . . 0.0 111.985 -178.701 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.572 HG12 ' O ' ' A' ' 65' ' ' ALA . 43.0 mm -75.29 142.75 14.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 N-CA-C 110.495 -0.187 . . . . 0.0 110.495 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 3.0 m -102.11 168.96 9.04 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.713 0.292 . . . . 0.0 110.925 179.761 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 16.4 t -82.11 122.19 36.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.294 178.809 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 83.32 25.72 46.59 Favored Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 120.61 -0.805 . . . . 0.0 111.807 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 18.9 tt0 -105.81 153.32 22.07 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 179.917 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 26.5 t -97.9 113.78 33.42 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 CA-C-O 120.866 0.365 . . . . 0.0 110.167 -179.014 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.509 HD11 HD13 ' A' ' 51' ' ' ILE . 9.3 pt -101.33 154.8 4.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.164 -179.03 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . 0.433 ' O ' ' HA ' ' A' ' 51' ' ' ILE . 10.8 t30 -119.33 104.95 10.84 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 121.151 0.5 . . . . 0.0 111.076 -173.292 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.466 HD11 HD23 ' A' ' 86' ' ' LEU . 67.1 mt -103.12 118.83 50.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 115.37 -0.832 . . . . 0.0 110.405 -177.459 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 19.6 m -95.62 115.37 27.33 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.628 -0.715 . . . . 0.0 109.664 177.368 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 82.0 p -111.15 169.75 8.57 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.42 -179.736 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -61.98 -25.55 67.69 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.088 179.257 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 8.4 tp-100 -98.51 11.85 37.0 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.171 0.51 . . . . 0.0 111.097 -176.69 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 134.44 176.11 14.21 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.315 -0.945 . . . . 0.0 113.002 176.153 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 18.1 m -105.27 120.11 40.73 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 -179.523 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 63.4 m-85 -126.57 152.16 46.96 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.759 0.314 . . . . 0.0 110.243 -179.426 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -131.49 131.15 43.23 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-O 121.299 0.571 . . . . 0.0 110.422 177.079 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.488 ' N ' HD21 ' A' ' 86' ' ' LEU . 0.9 OUTLIER -127.13 157.42 39.77 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.319 -0.855 . . . . 0.0 111.106 -173.535 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 40.0 ttmt -99.56 130.6 45.81 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.057 178.545 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 33.9 p -71.63 131.19 42.84 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 121.064 0.459 . . . . 0.0 111.036 179.548 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -93.79 -166.97 37.6 Favored Glycine 0 N--CA 1.442 -0.908 0 C-N-CA 120.491 -0.861 . . . . 0.0 112.322 -177.637 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.492 ' HD3' ' N ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -153.59 117.12 4.66 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 121.14 0.495 . . . . 0.0 109.767 179.064 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' ASN . . . . . 1.048 ' HB3' ' HB3' ' A' ' 95' ' ' SER . 59.6 t30 -84.48 139.92 38.57 Favored Pre-proline 0 C--N 1.323 -0.551 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.766 -174.556 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.639 ' HD2' ' OD1' ' A' ' 91' ' ' ASN . 72.7 Cg_exo -38.36 155.97 0.03 OUTLIER 'Trans proline' 0 CA--C 1.532 0.419 0 C-N-CA 124.317 3.345 . . . . 0.0 114.155 170.363 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 8.9 t-20 67.07 14.75 9.93 Favored 'General case' 0 N--CA 1.469 0.503 0 CA-C-N 115.111 -0.949 . . . . 0.0 110.726 178.873 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 44.3 t-20 58.49 71.81 0.56 Allowed 'General case' 0 N--CA 1.465 0.29 0 CA-C-O 121.65 0.738 . . . . 0.0 110.002 -176.947 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' SER . . . . . 1.048 ' HB3' ' HB3' ' A' ' 91' ' ' ASN . 33.4 t -99.71 87.7 3.62 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.551 -0.749 . . . . 0.0 109.996 179.479 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 9.1 t 68.3 172.19 0.28 Allowed 'General case' 0 CA--C 1.532 0.276 0 CA-C-N 115.369 -0.832 . . . . 0.0 111.56 177.048 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 6.7 ptp85 -115.26 145.99 41.91 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.38 176.901 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . 56.23 72.94 0.46 Allowed 'General case' 0 C--N 1.333 -0.152 0 O-C-N 123.807 0.692 . . . . 0.0 110.153 -176.505 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . 0.796 ' CE2' ' HB2' ' A' ' 91' ' ' ASN . 0.1 OUTLIER -70.34 110.75 5.46 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.22 -171.178 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 25.4 mmt -82.84 111.02 18.36 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 173.268 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . 0.665 ' HA3' ' HB2' ' A' ' 36' ' ' SER . . . -81.28 30.22 2.75 Favored Glycine 0 C--O 1.228 -0.236 0 C-N-CA 120.814 -0.707 . . . . 0.0 113.263 -174.958 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.469 HD11 HD11 ' A' ' 29' ' ' ILE . 42.9 pt -147.69 173.29 2.16 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 -179.98 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . 0.692 ' HB2' ' HB3' ' A' ' 30' ' ' ASP . 65.7 mtt-85 -109.94 134.37 52.17 Favored 'General case' 0 C--N 1.317 -0.834 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 173.344 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.5 p -119.79 124.5 46.3 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-O 120.944 0.402 . . . . 0.0 110.72 178.353 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.487 ' HA ' HD22 ' A' ' 59' ' ' LEU . 42.3 m -145.64 163.43 34.86 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.248 -179.083 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 86.6 m-20 -78.17 52.36 1.09 Allowed 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.853 0.835 . . . . 0.0 109.061 173.474 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 42.0 t-80 -78.01 36.2 0.22 Allowed 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 114.541 -1.208 . . . . 0.0 111.378 -175.6 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . 0.45 HD11 ' O ' ' A' ' 26' ' ' GLY . 5.3 mp -80.27 165.32 22.45 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.484 178.815 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . 0.427 ' O ' ' HD2' ' A' ' 109' ' ' ARG . 0.0 OUTLIER -129.47 148.88 51.42 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.171 176.577 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 2.5 p -91.45 120.07 39.84 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-O 121.969 0.89 . . . . 0.0 111.363 -178.867 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' ARG . . . . . . . . . . . . . 2.1 tmt_? -129.16 -27.44 2.47 Favored 'General case' 0 C--N 1.315 -0.9 0 CA-C-N 114.268 -1.333 . . . . 0.0 108.852 177.343 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -81.61 100.67 9.54 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 114.799 -1.091 . . . . 0.0 109.23 175.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 35.4 t -67.13 98.77 0.61 Allowed 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.384 -0.826 . . . . 0.0 111.567 -174.86 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 14.8 m -108.93 149.44 12.17 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.256 175.211 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -138.04 101.27 4.38 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.857 0.36 . . . . 0.0 110.673 -179.616 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 47.2 t -113.21 15.11 19.47 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 121.383 0.611 . . . . 0.0 109.981 177.784 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 3.8 p -102.56 113.87 40.4 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 CA-C-N 115.544 -0.753 . . . . 0.0 110.733 -179.132 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 118' ' ' LEU . . . . . 0.407 ' N ' HD21 ' A' ' 118' ' ' LEU . 2.3 mm? -87.9 -32.21 19.07 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.29 179.77 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 122.49 153.74 8.92 Favored Glycine 0 N--CA 1.448 -0.564 0 CA-C-N 115.678 -0.692 . . . . 0.0 111.476 -179.009 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -105.21 168.63 8.94 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 110.205 -0.294 . . . . 0.0 110.205 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 14.4 p -75.51 109.81 9.37 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.203 -178.816 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . 0.426 ' HA ' ' HD3' ' A' ' 123' ' ' PRO . 62.3 mt -103.76 131.73 21.72 Favored Pre-proline 0 C--N 1.324 -0.536 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.352 -179.142 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . 0.426 ' HD3' ' HA ' ' A' ' 122' ' ' LEU . 9.0 Cg_exo -71.18 142.04 40.86 Favored 'Trans proline' 0 C--O 1.235 0.365 0 C-N-CA 123.093 2.529 . . . . 0.0 114.115 -173.754 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 49.5 p90 -122.49 161.95 22.63 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.121 -0.945 . . . . 0.0 109.474 174.932 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.165 0 CA-C-O 118.594 -0.717 . . . . 0.0 110.416 -179.075 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.762 ' HB2' ' HD3' ' A' ' 24' ' ' PRO . 78.8 mt-30 . . . . . 0 CA--C 1.534 0.361 0 CA-C-O 119.788 -0.149 . . . . 0.0 110.852 . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.762 ' HD3' ' HB2' ' A' ' 23' ' ' GLN . 71.1 Cg_endo -89.83 160.09 5.08 Favored 'Trans proline' 0 N--CA 1.455 -0.763 0 C-N-CA 121.872 1.715 . . . . 0.0 111.447 175.649 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 25.2 t0 -175.44 -29.08 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.353 0 CA-C-O 121.047 0.451 . . . . 0.0 111.164 -176.529 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.423 ' HA2' ' O ' ' A' ' 56' ' ' THR . . . 171.02 134.07 1.71 Allowed Glycine 0 N--CA 1.444 -0.785 0 C-N-CA 120.9 -0.667 . . . . 0.0 111.724 -179.958 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.49 HG21 ' HB ' ' A' ' 48' ' ' ILE . 19.0 m -76.3 153.94 5.89 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-O 120.69 0.281 . . . . 0.0 110.445 179.672 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 31.7 tt0 -115.8 149.51 38.42 Favored 'General case' 0 C--N 1.323 -0.579 0 C-N-CA 120.28 -0.568 . . . . 0.0 110.986 -179.371 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 68.9 mt -80.18 114.5 21.16 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-N 115.814 -0.63 . . . . 0.0 109.878 177.543 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . 0.573 ' HB3' ' HB3' ' A' ' 103' ' ' ARG . 16.2 t70 -70.39 -67.57 0.49 Allowed 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.392 0.615 . . . . 0.0 110.064 -178.95 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 6.9 p -159.14 153.9 24.63 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.109 179.804 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.785 HG21 HG21 ' A' ' 102' ' ' ILE . 95.3 t -82.24 128.63 38.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 177.95 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.404 ' HB ' ' HD2' ' A' ' 34' ' ' PRO . 27.5 m -92.16 159.14 38.08 Favored Pre-proline 0 N--CA 1.446 -0.664 0 CA-C-N 116.575 -0.284 . . . . 0.0 110.382 -178.417 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . 0.404 ' HD2' ' HB ' ' A' ' 33' ' ' VAL . 21.0 Cg_endo -62.88 106.23 0.51 Allowed 'Trans proline' 0 N--CA 1.461 -0.416 0 C-N-CA 122.271 1.981 . . . . 0.0 111.591 174.505 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 135.72 150.58 5.99 Favored Glycine 0 N--CA 1.448 -0.565 0 CA-C-N 115.905 -0.589 . . . . 0.0 112.067 -177.652 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 50.5 m 71.11 153.73 0.15 Allowed Pre-proline 0 CA--C 1.535 0.382 0 C-N-CA 123.038 0.535 . . . . 0.0 111.719 179.704 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -83.22 14.18 2.44 Favored 'Trans proline' 0 C--N 1.347 0.449 0 C-N-CA 122.95 2.434 . . . . 0.0 113.416 -176.267 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.575 ' HB2' ' O ' ' A' ' 100' ' ' MET . . . -59.79 -35.12 74.01 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.865 0.364 . . . . 0.0 111.478 -179.192 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.544 ' HB3' HG13 ' A' ' 32' ' ' VAL . 0.8 OUTLIER -65.93 -22.45 66.49 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.04 -0.527 . . . . 0.0 112.374 -175.063 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 19.8 ptpt -100.27 1.34 41.64 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.691 0.281 . . . . 0.0 110.896 179.829 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 83.6 t -110.59 -55.86 4.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 116.476 -0.329 . . . . 0.0 111.017 -178.23 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 1.2 pp -118.51 -178.81 3.62 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.395 0.617 . . . . 0.0 111.932 -177.051 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 23.3 m -119.95 134.4 23.97 Favored Pre-proline 0 C--N 1.316 -0.864 0 CA-C-N 115.084 -0.962 . . . . 0.0 109.964 -179.609 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.518 ' HB3' HG23 ' A' ' 32' ' ' VAL . 31.4 Cg_endo -65.67 145.58 81.85 Favored 'Trans proline' 0 N--CA 1.464 -0.242 0 C-N-CA 122.131 1.887 . . . . 0.0 111.738 176.553 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 97.83 11.0 51.6 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.517 -0.849 . . . . 0.0 112.917 -178.926 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 80.4 mt -98.04 164.9 12.15 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.772 0.32 . . . . 0.0 110.524 177.276 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.447 ' HB ' ' HB2' ' A' ' 80' ' ' ASP . 39.7 t -97.08 140.94 16.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 116.325 -0.398 . . . . 0.0 109.99 177.633 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.503 HG21 HG22 ' A' ' 77' ' ' ILE . 72.1 mt -103.86 115.51 45.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-O 120.839 0.352 . . . . 0.0 110.519 178.493 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 7.7 tt0 -78.98 -55.11 5.38 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.598 0.713 . . . . 0.0 110.3 177.142 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.58 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 8.0 p -148.15 146.65 28.84 Favored 'General case' 0 C--N 1.315 -0.908 0 CA-C-N 115.423 -0.808 . . . . 0.0 112.157 -173.023 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.476 ' HA ' ' O ' ' A' ' 76' ' ' ASN . 49.1 mt -117.29 114.91 47.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-N 114.96 -1.018 . . . . 0.0 109.225 173.577 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 7.6 t-20 61.91 -152.62 0.36 Allowed 'General case' 0 C--O 1.234 0.25 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 -171.746 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -79.57 21.45 4.5 Favored Glycine 0 CA--C 1.523 0.532 0 C-N-CA 120.307 -0.949 . . . . 0.0 112.258 175.931 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 61.0 mtm -123.66 106.3 32.29 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 120.805 0.336 . . . . 0.0 110.19 -178.835 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.58 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 65.1 Cg_endo -73.99 150.18 43.04 Favored 'Trans proline' 0 N--CA 1.46 -0.48 0 C-N-CA 122.133 1.889 . . . . 0.0 112.602 -179.36 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.423 ' O ' ' HA2' ' A' ' 26' ' ' GLY . 33.5 p -120.72 106.07 11.36 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.74 -178.234 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 12.6 p -96.03 -22.45 17.35 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.927 -179.723 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . 0.425 ' HB3' ' HB3' ' A' ' 24' ' ' PRO . 27.5 p-10 -146.63 -169.41 3.27 Favored 'General case' 0 N--CA 1.447 -0.59 0 CA-C-O 121.271 0.558 . . . . 0.0 110.594 175.457 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.556 ' HG ' ' HB2' ' A' ' 106' ' ' ASN . 19.1 mt -68.43 -35.29 77.41 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.142 -0.935 . . . . 0.0 111.813 -178.683 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 7.7 m -65.77 -45.71 81.51 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.758 0.313 . . . . 0.0 111.324 -177.555 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 1.6 p -66.29 -33.38 75.6 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.137 0.494 . . . . 0.0 110.528 178.257 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 76.1 t80 -62.01 -46.8 87.61 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.311 -0.859 . . . . 0.0 110.526 174.73 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 5.3 t -63.75 -45.1 91.37 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.593 -179.458 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -66.36 -26.8 67.44 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.965 -0.562 . . . . 0.0 111.682 -177.265 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -78.68 -43.64 25.55 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.011 0.434 . . . . 0.0 110.365 176.657 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -59.66 -42.0 91.85 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.456 -0.793 . . . . 0.0 111.354 -176.506 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 15.2 ptmm? -64.97 -6.86 9.48 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 112.595 0.591 . . . . 0.0 112.595 -174.565 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 49.6 p -106.28 -14.59 15.07 Favored 'General case' 0 C--N 1.326 -0.426 0 C-N-CA 120.768 -0.373 . . . . 0.0 111.402 -179.753 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.407 HD11 HG21 ' A' ' 75' ' ' ILE . 45.0 mm -72.06 140.0 18.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 120.863 0.363 . . . . 0.0 111.23 -174.355 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' SER . . . . . 0.601 ' HB2' ' HB2' ' A' ' 73' ' ' GLU . 2.5 m -89.33 151.22 22.2 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.372 179.031 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 48.9 t -73.91 118.2 19.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 120.988 0.423 . . . . 0.0 110.055 177.327 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 93.02 9.07 61.14 Favored Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 120.605 -0.807 . . . . 0.0 111.993 -179.073 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . 0.601 ' HB2' ' HB2' ' A' ' 70' ' ' SER . 35.7 tt0 -86.45 148.75 25.41 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 120.809 0.338 . . . . 0.0 110.092 179.626 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . 0.411 ' HA ' ' HA ' ' A' ' 87' ' ' LYS . 60.1 t -92.1 113.17 26.93 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 176.919 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.407 HG21 HD11 ' A' ' 69' ' ' ILE . 27.3 pt -108.62 154.45 9.93 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-O 121.314 0.578 . . . . 0.0 111.224 -177.441 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . 0.476 ' O ' ' HA ' ' A' ' 51' ' ' ILE . 6.0 t30 -95.85 127.26 41.72 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.151 178.382 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.512 HD11 HD23 ' A' ' 86' ' ' LEU . 54.3 mt -125.26 106.31 16.16 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 CA-C-O 121.288 0.566 . . . . 0.0 109.846 176.362 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 4.3 m -78.59 102.48 7.97 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 115.32 -0.854 . . . . 0.0 109.239 178.302 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 70.7 p -94.6 167.65 11.34 Favored 'General case' 0 C--N 1.323 -0.545 0 C-N-CA 120.474 -0.49 . . . . 0.0 110.697 -178.569 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . 0.447 ' HB2' ' HB ' ' A' ' 47' ' ' VAL . 23.8 t70 -52.52 -33.38 45.0 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.267 -0.878 . . . . 0.0 111.834 -179.858 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 28.1 mt-30 -118.73 28.0 8.57 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 112.185 0.439 . . . . 0.0 112.185 -173.481 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 150.18 151.29 5.49 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.208 -0.996 . . . . 0.0 113.487 173.854 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 26.4 m -94.81 106.72 18.72 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 109.697 -0.483 . . . . 0.0 109.697 176.361 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 84.8 m-85 -114.66 158.52 21.64 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.058 0.456 . . . . 0.0 110.874 -176.395 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 17.4 p-80 -123.66 129.13 50.65 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.814 -0.63 . . . . 0.0 109.508 173.141 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.512 HD23 HD11 ' A' ' 77' ' ' ILE . 0.6 OUTLIER -134.24 156.07 49.05 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 115.989 -0.55 . . . . 0.0 111.031 -176.614 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.411 ' HA ' ' HA ' ' A' ' 74' ' ' VAL . 58.8 tttm -96.35 131.59 42.73 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.675 -179.022 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 39.9 p -69.75 139.46 53.32 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-O 121.158 0.504 . . . . 0.0 111.127 178.714 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -80.65 175.71 54.81 Favored Glycine 0 N--CA 1.433 -1.564 0 N-CA-C 111.146 -0.782 . . . . 0.0 111.146 176.63 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -90.72 163.89 14.33 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-O 121.079 0.466 . . . . 0.0 111.323 -176.027 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -80.63 136.25 52.04 Favored Pre-proline 0 C--N 1.324 -0.527 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.731 177.431 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -53.9 -57.46 1.87 Allowed 'Trans proline' 0 C--N 1.346 0.406 0 C-N-CA 122.843 2.362 . . . . 0.0 111.665 178.332 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 48.1 t-20 -125.86 -84.44 0.63 Allowed 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 174.211 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 15.6 t-20 -164.74 82.89 0.39 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.136 0.493 . . . . 0.0 110.503 176.23 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 41.4 t -141.94 -72.32 0.33 Allowed 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 109.326 -0.62 . . . . 0.0 109.326 175.727 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 27.6 m -98.24 128.57 44.76 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 175.119 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 1.1 mpt_? -108.53 147.84 31.15 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 -175.266 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . 57.87 82.11 0.14 Allowed 'General case' 0 N--CA 1.465 0.281 0 O-C-N 123.793 0.683 . . . . 0.0 110.712 179.774 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -96.49 112.7 24.35 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.406 -171.413 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' MET . . . . . 0.575 ' O ' ' HB2' ' A' ' 38' ' ' ALA . 1.4 pmm? -63.5 -31.09 72.15 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.701 -179.498 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 104.73 1.46 42.91 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.466 -0.873 . . . . 0.0 113.295 175.898 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.785 HG21 HG21 ' A' ' 32' ' ' VAL . 2.8 pp -130.08 148.03 33.19 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.61 0 CA-C-O 121.003 0.43 . . . . 0.0 110.771 179.55 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . 0.573 ' HB3' ' HB3' ' A' ' 30' ' ' ASP . 1.0 OUTLIER -80.73 137.93 36.29 Favored 'General case' 0 C--N 1.321 -0.638 0 N-CA-C 108.242 -1.022 . . . . 0.0 108.242 172.89 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.7 m -112.25 153.23 27.44 Favored 'General case' 0 C--N 1.31 -1.14 0 CA-C-O 120.802 0.334 . . . . 0.0 110.394 -177.491 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 23.8 p -135.67 163.92 29.06 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 115.96 -0.564 . . . . 0.0 109.976 -179.873 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . 0.556 ' HB2' ' HG ' ' A' ' 59' ' ' LEU . 65.8 t30 -94.15 -25.33 17.17 Favored 'General case' 0 C--N 1.317 -0.839 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 -177.111 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 49.0 t-80 63.53 73.44 0.45 Allowed 'General case' 0 C--O 1.232 0.147 0 CA-C-N 114.799 -1.091 . . . . 0.0 111.562 175.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 96.0 mt -100.94 -167.28 1.41 Allowed 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.961 -0.563 . . . . 0.0 109.847 174.055 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 83.0 mtt180 -125.06 122.02 36.03 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.288 178.321 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 38.4 t -117.8 130.41 72.72 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 CA-C-N 115.595 -0.729 . . . . 0.0 110.623 -177.588 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' ARG . . . . . . . . . . . . . 42.8 ttm180 -86.77 117.93 25.84 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.25 176.78 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 7.9 p-10 -97.32 110.35 22.92 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.385 0.612 . . . . 0.0 109.691 178.011 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 50.5 m -118.43 96.19 5.19 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-N 115.844 -0.617 . . . . 0.0 110.309 176.467 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 17.1 m -83.29 115.19 25.26 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 CA-C-O 121.416 0.627 . . . . 0.0 110.569 178.3 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -137.11 82.18 1.92 Allowed 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.57 -0.741 . . . . 0.0 109.902 178.897 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 6.1 m -101.0 150.49 22.84 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-N 115.659 -0.7 . . . . 0.0 110.281 -177.176 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 27.7 m -81.56 127.76 39.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 CA-C-O 121.176 0.512 . . . . 0.0 110.081 174.328 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 81.2 mt -96.81 11.65 34.94 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.751 -176.112 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -100.84 124.09 8.14 Favored Glycine 0 N--CA 1.445 -0.706 0 C-N-CA 120.833 -0.698 . . . . 0.0 111.982 -179.249 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 6.3 p-10 -99.93 179.07 4.62 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 176.531 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 17.4 p -93.19 101.2 13.48 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 121.623 0.725 . . . . 0.0 111.603 -177.528 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 5.0 mp -80.89 130.25 64.43 Favored Pre-proline 0 C--N 1.324 -0.535 0 CA-C-N 115.461 -0.79 . . . . 0.0 110.139 176.801 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 23.9 Cg_exo -64.15 118.95 5.87 Favored 'Trans proline' 0 N--CA 1.46 -0.499 0 C-N-CA 122.51 2.14 . . . . 0.0 110.878 174.343 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 55.0 t80 -82.29 107.11 14.72 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.984 0.421 . . . . 0.0 110.33 -177.862 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.062 0 CA-C-O 118.306 -0.854 . . . . 0.0 109.781 178.019 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . . . . . . . . . 88.5 mt-30 . . . . . 0 CA--C 1.524 -0.034 0 CA-C-O 120.376 0.131 . . . . 0.0 110.689 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 21.9 Cg_exo -66.22 156.24 65.87 Favored 'Trans proline' 0 C--O 1.236 0.391 0 C-N-CA 123.051 2.5 . . . . 0.0 111.889 178.644 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -171.31 -41.31 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.99 0.424 . . . . 0.0 111.544 -175.53 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.546 ' HA2' ' HA ' ' A' ' 57' ' ' SER . . . 167.48 151.3 6.89 Favored Glycine 0 N--CA 1.446 -0.686 0 N-CA-C 111.247 -0.741 . . . . 0.0 111.247 -177.664 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.551 HG21 ' HB ' ' A' ' 48' ' ' ILE . 29.5 m -102.81 145.26 12.49 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-O 121.021 0.439 . . . . 0.0 110.82 -179.038 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 29.4 tt0 -115.82 150.18 37.38 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.704 -178.567 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.453 HD11 ' HB2' ' A' ' 46' ' ' LEU . 48.3 mt -76.85 107.94 8.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.011 178.003 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 22.5 t70 -62.29 -62.19 1.93 Allowed 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.551 0.691 . . . . 0.0 109.871 177.213 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 13.4 p -158.11 149.2 21.0 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.205 -0.907 . . . . 0.0 110.625 179.253 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.49 HG21 HG21 ' A' ' 102' ' ' ILE . 44.8 t -99.11 117.94 44.96 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 N-CA-C 109.519 -0.548 . . . . 0.0 109.519 177.272 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.503 ' HA ' ' HD3' ' A' ' 34' ' ' PRO . 11.9 m -80.91 117.37 67.75 Favored Pre-proline 0 N--CA 1.447 -0.594 0 CA-C-O 120.982 0.42 . . . . 0.0 110.572 -179.95 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . 0.503 ' HD3' ' HA ' ' A' ' 33' ' ' VAL . 16.7 Cg_exo -69.73 25.82 0.17 Allowed 'Trans proline' 0 N--CA 1.478 0.605 0 C-N-CA 123.918 3.079 . . . . 0.0 113.85 -174.208 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . 0.449 ' H ' ' C ' ' A' ' 33' ' ' VAL . . . -120.56 15.08 9.87 Favored Glycine 0 N--CA 1.446 -0.636 0 N-CA-C 110.645 -0.982 . . . . 0.0 110.645 174.339 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 7.5 m -139.1 177.33 2.11 Favored Pre-proline 0 C--N 1.325 -0.477 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 -177.358 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . 0.408 ' C ' ' H ' ' A' ' 39' ' ' SER . 24.8 Cg_exo -64.9 -172.86 0.22 Allowed 'Trans proline' 0 C--N 1.35 0.656 0 C-N-CA 122.255 1.97 . . . . 0.0 112.214 174.107 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.518 ' HB1' HD11 ' A' ' 86' ' ' LEU . . . 72.38 -23.25 0.2 Allowed 'General case' 0 N--CA 1.47 0.538 0 C-N-CA 123.493 0.717 . . . . 0.0 112.867 177.108 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.408 ' H ' ' C ' ' A' ' 37' ' ' PRO . 37.0 m -61.64 -29.61 70.17 Favored 'General case' 0 CA--C 1.531 0.233 0 CA-C-O 121.018 0.437 . . . . 0.0 111.842 -176.439 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 17.0 tppt? -97.06 -6.01 36.2 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.003 0.43 . . . . 0.0 110.51 -178.843 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 46.9 t -102.06 -52.69 8.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.712 -174.117 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 1.2 pp -127.49 -177.54 4.12 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-O 121.366 0.603 . . . . 0.0 112.026 -175.343 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 2.9 p -125.09 151.96 69.92 Favored Pre-proline 0 C--N 1.32 -0.696 0 CA-C-N 115.008 -0.996 . . . . 0.0 110.62 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -70.47 156.01 62.37 Favored 'Trans proline' 0 C--N 1.343 0.278 0 C-N-CA 122.404 2.069 . . . . 0.0 112.191 178.457 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 100.11 -13.36 60.35 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.606 -0.807 . . . . 0.0 112.491 -178.56 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 0.453 ' HB2' HD11 ' A' ' 29' ' ' ILE . 91.9 mt -79.4 164.62 23.86 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.833 0.349 . . . . 0.0 110.803 179.597 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 48.4 t -105.98 135.12 45.45 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.528 -178.368 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.551 ' HB ' HG21 ' A' ' 27' ' ' VAL . 8.4 mm -88.14 100.38 10.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 175.758 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 57.1 mt-10 -78.31 -48.23 16.09 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.049 -177.624 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.555 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 5.4 p -159.92 145.81 15.66 Favored 'General case' 0 N--CA 1.447 -0.592 0 CA-C-O 121.203 0.525 . . . . 0.0 111.797 -176.895 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 67.9 mt -115.38 106.25 20.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-N 115.099 -0.955 . . . . 0.0 108.595 175.791 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' ASN . . . . . 0.428 ' C ' ' H ' ' A' ' 54' ' ' MET . 3.1 m-20 59.96 -152.14 0.4 Allowed 'General case' 0 C--O 1.236 0.392 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 -171.778 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -76.14 28.61 1.41 Allowed Glycine 0 CA--C 1.524 0.63 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.696 176.913 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' MET . . . . . 0.428 ' H ' ' C ' ' A' ' 52' ' ' ASN . 57.4 mtm -130.44 101.83 17.23 Favored Pre-proline 0 C--N 1.326 -0.414 0 N-CA-C 109.676 -0.49 . . . . 0.0 109.676 176.934 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.555 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 60.0 Cg_endo -72.19 150.99 54.48 Favored 'Trans proline' 0 N--CA 1.46 -0.494 0 C-N-CA 122.027 1.818 . . . . 0.0 112.306 179.972 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' THR . . . . . 0.416 ' O ' ' HA2' ' A' ' 26' ' ' GLY . 6.2 p -111.33 83.66 1.81 Allowed 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 121.242 0.544 . . . . 0.0 111.863 -177.326 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' SER . . . . . 0.546 ' HA ' ' HA2' ' A' ' 26' ' ' GLY . 20.9 m -91.11 -13.64 32.69 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.571 -0.74 . . . . 0.0 109.846 176.507 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 5.4 m120 -125.5 164.64 20.06 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.672 -0.694 . . . . 0.0 109.939 -177.877 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 41.5 mt -73.81 -31.75 63.4 Favored 'General case' 0 N--CA 1.446 -0.665 0 CA-C-O 121.516 0.674 . . . . 0.0 109.774 172.0 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -68.28 -40.54 81.79 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.176 -0.92 . . . . 0.0 111.734 178.891 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 12.6 p -60.9 -39.6 89.94 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.72 0.295 . . . . 0.0 110.959 175.857 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 87.3 t80 -62.04 -43.51 98.69 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-O 121.478 0.656 . . . . 0.0 109.676 175.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 61.4 m -65.1 -48.9 72.05 Favored 'General case' 0 N--CA 1.446 -0.638 0 CA-C-N 115.08 -0.964 . . . . 0.0 111.757 179.28 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.53 -32.45 73.91 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.97 -176.575 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . 0.61 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -70.5 -48.34 56.1 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.014 -0.539 . . . . 0.0 109.928 178.58 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . 0.41 ' HA ' HD23 ' A' ' 66' ' ' LEU . 4.0 mt -63.81 -35.28 80.1 Favored 'General case' 0 N--CA 1.449 -0.477 0 CA-C-N 115.451 -0.795 . . . . 0.0 111.94 -176.438 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 59.8 mtpt -70.48 -21.98 62.71 Favored 'General case' 0 C--N 1.33 -0.273 0 N-CA-C 112.115 0.413 . . . . 0.0 112.115 -178.357 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 71.6 p -90.47 -13.54 34.56 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.864 0.364 . . . . 0.0 111.425 -179.636 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.61 HG12 ' O ' ' A' ' 65' ' ' ALA . 41.8 mm -79.85 143.8 11.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.449 -0.342 . . . . 0.0 110.599 -177.758 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 3.5 m -83.72 157.13 22.27 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 176.723 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 25.1 t -74.26 119.68 22.06 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 176.239 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 91.67 21.29 34.56 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.668 -0.777 . . . . 0.0 111.523 -177.422 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 29.9 tt0 -98.91 146.46 25.96 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 179.858 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 57.5 t -98.38 110.81 26.64 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.848 0 CA-C-O 121.052 0.453 . . . . 0.0 110.473 -178.134 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.54 HG13 HD12 ' A' ' 77' ' ' ILE . 23.3 pt -103.84 163.57 3.86 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.679 179.773 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 6.3 t30 -115.9 117.07 29.14 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.782 -177.219 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.54 HD12 HG13 ' A' ' 75' ' ' ILE . 4.6 mp -113.5 118.93 59.53 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-O 121.26 0.552 . . . . 0.0 110.293 -177.301 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 32.5 m -91.93 117.17 29.55 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.39 175.796 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 71.7 p -114.35 170.89 7.97 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 110.179 -0.304 . . . . 0.0 110.179 -179.928 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 9.0 t70 -53.68 -41.75 67.2 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.931 -0.577 . . . . 0.0 112.064 179.54 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 6.7 tp-100 -109.15 31.09 5.98 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.906 0.384 . . . . 0.0 111.451 -171.487 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 140.28 176.17 14.94 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 120.133 -1.032 . . . . 0.0 113.12 173.384 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 7.0 m -117.5 123.89 47.42 Favored 'General case' 0 C--N 1.318 -0.775 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 178.802 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 66.4 m-85 -121.21 154.27 36.5 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.982 0.42 . . . . 0.0 110.726 -176.747 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 56.1 p-80 -111.3 130.88 55.53 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 108.989 -0.745 . . . . 0.0 108.989 173.185 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.518 HD11 ' HB1' ' A' ' 38' ' ' ALA . 3.8 tt -124.09 137.44 54.57 Favored 'General case' 0 C--N 1.311 -1.084 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.053 -172.634 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.446 ' N ' HD23 ' A' ' 86' ' ' LEU . 78.8 tttt -102.67 111.32 23.58 Favored 'General case' 0 C--N 1.311 -1.077 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 178.154 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' THR . . . . . 0.472 HG22 HG22 ' A' ' 69' ' ' ILE . 26.4 p -59.52 142.93 51.51 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.812 -0.631 . . . . 0.0 112.616 -172.405 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -133.03 -133.79 3.43 Favored Glycine 0 N--CA 1.443 -0.887 0 N-CA-C 111.017 -0.833 . . . . 0.0 111.017 176.824 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.443 ' HG3' ' HA ' ' A' ' 93' ' ' ASN . 0.0 OUTLIER -156.36 158.53 37.54 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 176.779 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' ASN . . . . . 0.771 ' HB3' ' HD3' ' A' ' 92' ' ' PRO . 26.2 t-20 -98.34 -57.73 0.16 Allowed Pre-proline 0 C--N 1.324 -0.501 0 CA-C-N 116.471 -0.331 . . . . 0.0 111.844 -176.998 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.771 ' HD3' ' HB3' ' A' ' 91' ' ' ASN . 6.9 Cg_exo -75.0 -27.07 10.32 Favored 'Trans proline' 0 C--N 1.353 0.773 0 C-N-CA 122.153 1.902 . . . . 0.0 112.508 -179.404 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' ASN . . . . . 0.443 ' HA ' ' HG3' ' A' ' 90' ' ' ARG . 8.6 t30 58.58 75.25 0.4 Allowed 'General case' 0 N--CA 1.466 0.338 0 CA-C-O 121.745 0.784 . . . . 0.0 110.223 -175.288 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 25.8 p-10 -144.73 44.92 1.38 Allowed 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 115.026 -0.988 . . . . 0.0 109.338 -178.094 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 42.3 m 57.21 74.18 0.43 Allowed 'General case' 0 CA--C 1.521 -0.159 0 N-CA-C 108.845 -0.798 . . . . 0.0 108.845 -168.78 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 1.8 m -106.89 -178.97 3.8 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.104 -0.953 . . . . 0.0 110.855 -170.442 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 39.0 ttm180 -103.22 169.16 8.72 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 172.724 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -45.15 116.22 1.07 Allowed 'General case' 0 N--CA 1.461 0.123 0 O-C-N 123.689 0.618 . . . . 0.0 112.167 -179.51 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . 0.441 ' HB3' ' HA ' ' A' ' 90' ' ' ARG . 18.6 t80 -120.98 135.55 55.19 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 178.05 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 49.6 ttm -77.35 -53.32 7.83 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.972 -178.231 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 117.31 17.07 5.84 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.162 -1.018 . . . . 0.0 113.398 176.88 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.49 HG21 HG21 ' A' ' 32' ' ' VAL . 39.0 pt -130.17 153.05 38.37 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-O 120.857 0.36 . . . . 0.0 110.67 179.342 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 42.8 mtp85 -82.01 123.36 28.83 Favored 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 108.185 -1.042 . . . . 0.0 108.185 168.191 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -113.77 148.97 35.59 Favored 'General case' 0 C--N 1.314 -0.956 0 C-N-CA 120.643 -0.423 . . . . 0.0 110.479 -177.965 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 54.0 m -155.33 160.29 40.63 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 176.917 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . 0.643 ' HB3' ' HG ' ' A' ' 108' ' ' LEU . 86.8 m-20 -70.09 -33.22 71.61 Favored 'General case' 0 C--N 1.317 -0.83 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 177.604 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 47.7 t-80 53.26 39.93 30.5 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-N 115.338 -0.846 . . . . 0.0 109.793 179.823 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . 0.643 ' HG ' ' HB3' ' A' ' 106' ' ' ASN . 67.3 mt -71.32 172.82 8.69 Favored 'General case' 0 CA--C 1.511 -0.531 0 CA-C-N 115.424 -0.807 . . . . 0.0 111.284 -177.403 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 71.6 mtm180 -78.43 151.79 32.53 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-N 114.817 -1.083 . . . . 0.0 110.497 179.627 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 8.1 p -82.2 140.34 16.58 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 CA-C-O 121.711 0.767 . . . . 0.0 111.899 -172.333 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' ARG . . . . . . . . . . . . . 33.8 ttt85 -134.1 145.01 48.93 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.0 -1.0 . . . . 0.0 108.716 173.202 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 19.0 p-10 -82.32 27.03 0.51 Allowed 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 112.307 0.484 . . . . 0.0 112.307 -171.109 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 36.9 m -91.38 74.2 6.08 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 175.758 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 17.5 m -67.64 128.91 31.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.866 -174.406 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -151.77 124.94 8.7 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.606 -0.724 . . . . 0.0 110.25 178.714 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 42.4 m -140.26 61.65 1.52 Allowed 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.55 0.69 . . . . 0.0 109.507 177.335 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 31.1 t -102.3 142.17 17.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-N 115.263 -0.88 . . . . 0.0 110.118 -175.922 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 80.3 mt -82.21 -33.73 29.25 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.398 -0.364 . . . . 0.0 110.674 -178.557 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 71.96 54.85 7.71 Favored Glycine 0 N--CA 1.445 -0.725 0 N-CA-C 110.635 -0.986 . . . . 0.0 110.635 -175.789 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 11.8 m-20 -71.5 124.94 25.76 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.212 0.529 . . . . 0.0 111.644 -172.6 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 4.5 t -125.16 108.42 11.75 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.635 -0.711 . . . . 0.0 109.177 172.597 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 88.6 mt -73.23 123.28 89.35 Favored Pre-proline 0 C--N 1.327 -0.41 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.991 -177.011 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_exo -66.82 143.26 66.35 Favored 'Trans proline' 0 C--O 1.235 0.346 0 C-N-CA 122.955 2.437 . . . . 0.0 112.222 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 39.6 t80 -96.49 96.75 8.91 Favored 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 177.809 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.084 0 CA-C-O 118.248 -0.882 . . . . 0.0 110.828 -175.686 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.733 ' HB2' HD21 ' A' ' 108' ' ' LEU . 32.4 mt-30 . . . . . 0 CA--C 1.526 0.049 0 CA-C-O 120.601 0.238 . . . . 0.0 111.093 . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 89.9 Cg_endo -99.74 159.33 0.55 Allowed 'Trans proline' 0 N--CA 1.447 -1.245 0 C-N-CA 122.958 2.439 . . . . 0.0 112.019 173.672 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.512 ' HB3' ' HD2' ' A' ' 107' ' ' HIS . 35.9 t70 -178.05 30.61 0.0 OUTLIER 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 177.865 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 90.44 128.39 3.78 Favored Glycine 0 N--CA 1.443 -0.9 0 CA-C-N 115.38 -0.827 . . . . 0.0 111.696 -175.664 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.516 HG23 ' HB ' ' A' ' 48' ' ' ILE . 4.6 m -69.28 141.56 17.17 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 N-CA-C 109.605 -0.516 . . . . 0.0 109.605 178.728 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . 0.433 ' HB3' HG13 ' A' ' 47' ' ' VAL . 8.3 pt20 -125.45 152.99 44.16 Favored 'General case' 0 C--N 1.319 -0.736 0 C-N-CA 119.17 -1.012 . . . . 0.0 111.879 -178.698 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.412 HG12 HD11 ' A' ' 102' ' ' ILE . 50.1 mt -77.32 130.81 35.83 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.61 0 CA-C-N 115.23 -0.896 . . . . 0.0 110.82 -178.784 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -89.94 -50.27 6.13 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.244 174.954 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 23.6 p -161.96 166.78 25.6 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 116.587 -0.279 . . . . 0.0 110.917 -179.301 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.465 HG13 HG22 ' A' ' 102' ' ' ILE . 45.8 t -110.38 140.36 29.78 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 N-CA-C 109.365 -0.605 . . . . 0.0 109.365 174.755 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 7.1 p -60.78 140.12 93.28 Favored Pre-proline 0 CA--C 1.537 0.473 0 N-CA-C 110.317 -0.253 . . . . 0.0 110.317 179.735 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 15.7 Cg_exo -69.46 65.39 1.62 Allowed 'Trans proline' 0 C--N 1.348 0.5 0 C-N-CA 122.925 2.416 . . . . 0.0 112.173 176.175 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 165.59 -169.26 39.92 Favored Glycine 0 N--CA 1.446 -0.7 0 N-CA-C 111.34 -0.704 . . . . 0.0 111.34 -179.707 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' SER . . . . . 0.764 ' HB2' ' HD2' ' A' ' 37' ' ' PRO . 60.6 p 56.39 179.46 0.03 OUTLIER Pre-proline 0 CA--C 1.545 0.761 0 C-N-CA 123.448 0.699 . . . . 0.0 111.513 179.432 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . 0.764 ' HD2' ' HB2' ' A' ' 36' ' ' SER . 58.4 Cg_endo -73.1 -159.45 0.08 OUTLIER 'Trans proline' 0 C--N 1.349 0.586 0 C-N-CA 121.967 1.778 . . . . 0.0 111.636 169.712 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.401 ' HB3' HD12 ' A' ' 86' ' ' LEU . . . 77.36 -33.43 0.19 Allowed 'General case' 0 N--CA 1.471 0.612 0 C-N-CA 123.395 0.678 . . . . 0.0 112.321 172.712 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 35.0 t -65.15 -21.18 66.75 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.595 -0.275 . . . . 0.0 111.082 -178.884 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 61.9 mttp -99.35 -0.06 41.86 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.918 0.39 . . . . 0.0 110.378 178.273 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.491 ' HB ' HD11 ' A' ' 42' ' ' LEU . 45.9 t -105.08 -53.73 6.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.899 -175.928 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.491 HD11 ' HB ' ' A' ' 41' ' ' VAL . 5.2 mp -106.88 164.08 12.42 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.997 0.427 . . . . 0.0 110.55 -178.578 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' THR . . . . . 0.439 ' O ' ' HG ' ' A' ' 46' ' ' LEU . 40.1 m -109.42 124.46 33.81 Favored Pre-proline 0 C--N 1.319 -0.729 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.87 177.109 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo -59.36 134.48 58.99 Favored 'Trans proline' 0 N--CA 1.46 -0.468 0 C-N-CA 122.277 1.985 . . . . 0.0 111.965 177.834 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 107.93 -16.52 36.28 Favored Glycine 0 N--CA 1.446 -0.638 0 C-N-CA 120.631 -0.795 . . . . 0.0 112.976 -179.695 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 0.439 ' HG ' ' O ' ' A' ' 43' ' ' THR . 75.6 mt -71.89 164.16 26.55 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.844 0.354 . . . . 0.0 110.642 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.433 HG13 ' HB3' ' A' ' 28' ' ' GLN . 23.1 t -107.46 142.63 19.72 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 116.194 -0.457 . . . . 0.0 109.939 179.8 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.516 ' HB ' HG23 ' A' ' 27' ' ' VAL . 10.6 mm -84.68 125.7 40.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 179.625 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -90.23 -54.05 4.19 Favored 'General case' 0 C--N 1.321 -0.674 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 176.143 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.461 ' CB ' ' HA ' ' A' ' 55' ' ' PRO . 20.6 m -154.44 152.63 30.37 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.419 -174.536 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.447 HG23 ' N ' ' A' ' 52' ' ' ASN . 46.3 mm -99.47 167.27 1.96 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.823 0 N-CA-C 107.64 -1.245 . . . . 0.0 107.64 171.871 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' ASN . . . . . 0.583 ' HB2' ' H ' ' A' ' 76' ' ' ASN . 54.1 t30 -50.51 103.44 0.05 Allowed 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 112.304 0.483 . . . . 0.0 112.304 -176.86 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 83.18 -15.36 34.05 Favored Glycine 0 N--CA 1.451 -0.343 0 CA-C-N 115.898 -0.592 . . . . 0.0 113.053 176.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 40.7 mtm -130.29 106.95 16.12 Favored Pre-proline 0 C--N 1.326 -0.447 0 O-C-N 122.643 -0.328 . . . . 0.0 110.87 -173.518 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.461 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 42.5 Cg_endo -68.06 148.96 76.61 Favored 'Trans proline' 0 C--N 1.343 0.242 0 C-N-CA 122.552 2.168 . . . . 0.0 112.199 -179.726 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 20.8 p -126.82 97.02 4.83 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 112.102 0.408 . . . . 0.0 112.102 -175.532 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 22.9 t -102.01 -14.18 17.26 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 121.362 0.601 . . . . 0.0 109.734 174.871 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 32.3 m-80 -124.29 167.36 14.43 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.174 -178.57 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 1.6 mt -68.99 -35.27 76.52 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.322 -0.399 . . . . 0.0 109.97 173.387 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 19.5 m -64.11 -38.8 92.36 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.219 179.472 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 3.3 p -66.98 -33.32 75.32 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 120.804 0.335 . . . . 0.0 110.887 178.566 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 55.2 t80 -71.63 -35.14 70.33 Favored 'General case' 0 C--N 1.331 -0.217 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 176.29 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 69.0 m -66.62 -50.06 64.23 Favored 'General case' 0 N--CA 1.444 -0.729 0 CA-C-N 115.365 -0.834 . . . . 0.0 111.296 178.39 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.43 -31.96 73.26 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.747 -0.661 . . . . 0.0 111.39 -178.194 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . 0.471 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -76.93 -34.61 57.65 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.161 0.505 . . . . 0.0 110.639 -179.842 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 1.5 tt -68.71 -44.18 74.45 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.892 -177.445 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 14.6 ptmm? -60.43 -23.47 64.43 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.924 -174.044 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 17.7 p -87.53 -14.15 41.08 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 112.043 0.386 . . . . 0.0 112.043 -179.869 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.471 HG12 ' O ' ' A' ' 65' ' ' ALA . 21.7 mm -85.65 136.81 22.03 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-O 120.84 0.352 . . . . 0.0 110.601 -177.87 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' SER . . . . . 0.656 ' HA ' ' HD2' ' A' ' 97' ' ' ARG . 50.9 m -106.92 162.49 13.78 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.669 178.762 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.76 HG22 ' HB2' ' A' ' 97' ' ' ARG . 79.4 t -62.01 135.22 26.83 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.249 0 O-C-N 123.436 0.46 . . . . 0.0 110.518 175.353 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 94.33 -14.94 64.32 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.873 -0.68 . . . . 0.0 112.655 176.001 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 -80.29 150.3 30.03 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.128 0.49 . . . . 0.0 110.385 -177.379 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 47.3 t -106.34 124.76 61.94 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 CA-C-N 115.67 -0.696 . . . . 0.0 109.643 179.099 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 18.3 pt -119.6 157.34 21.78 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 121.377 0.608 . . . . 0.0 111.886 -176.749 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . 0.583 ' H ' ' HB2' ' A' ' 52' ' ' ASN . 4.5 t30 -99.08 127.16 44.97 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 114.861 -1.063 . . . . 0.0 110.034 179.43 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 72.4 mt -132.36 112.64 19.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-O 121.088 0.47 . . . . 0.0 110.514 -177.471 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' THR . . . . . 0.55 ' HA ' ' HA ' ' A' ' 83' ' ' THR . 93.0 m -91.0 124.72 35.45 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.146 177.32 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 50.8 p -107.77 173.31 6.38 Favored 'General case' 0 C--N 1.319 -0.747 0 N-CA-C 109.457 -0.572 . . . . 0.0 109.457 174.703 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -63.17 -24.43 67.88 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 120.979 0.418 . . . . 0.0 111.259 -178.954 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 -106.77 16.86 23.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.444 -0.344 . . . . 0.0 111.606 -177.74 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 134.08 166.76 11.36 Favored Glycine 0 CA--C 1.516 0.123 0 C-N-CA 120.176 -1.011 . . . . 0.0 113.255 176.035 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' THR . . . . . 0.55 ' HA ' ' HA ' ' A' ' 78' ' ' THR . 35.2 m -98.07 137.83 36.27 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 120.934 0.397 . . . . 0.0 111.204 -179.709 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 74.9 m-85 -130.42 158.32 40.19 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.051 177.517 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 48.2 p-80 -112.43 130.39 56.0 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 174.401 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.401 HD12 ' HB3' ' A' ' 38' ' ' ALA . 28.4 tp -118.19 152.06 36.41 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.989 -173.01 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 60.4 tttp -119.95 123.82 44.47 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 178.152 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 25.7 p -72.62 137.48 46.14 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.325 0.583 . . . . 0.0 111.613 -177.613 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . 0.523 ' H ' ' HE1' ' A' ' 99' ' ' TYR . . . -106.22 -157.33 21.81 Favored Glycine 0 N--CA 1.448 -0.515 0 CA-C-N 115.642 -0.708 . . . . 0.0 111.797 177.123 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.564 ' O ' ' HD3' ' A' ' 92' ' ' PRO . 0.3 OUTLIER -137.0 35.55 2.58 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.725 0.298 . . . . 0.0 111.598 -170.45 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' ASN . . . . . . . . . . . . . 5.0 t30 -106.71 84.81 1.6 Allowed Pre-proline 0 C--N 1.325 -0.481 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 173.165 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.614 ' HB3' ' O ' ' A' ' 96' ' ' SER . 10.2 Cg_endo -88.92 174.69 3.77 Favored 'Trans proline' 0 N--CA 1.456 -0.699 0 C-N-CA 123.133 2.555 . . . . 0.0 113.118 -171.299 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 19.9 t-20 -78.49 -46.93 18.46 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 174.688 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 27.2 t-20 -139.16 -69.89 0.42 Allowed 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.367 -0.833 . . . . 0.0 109.762 173.26 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 45.1 m -135.08 21.43 3.47 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.103 0.478 . . . . 0.0 110.557 179.529 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.614 ' O ' ' HB3' ' A' ' 92' ' ' PRO . 3.0 p -84.07 112.43 20.21 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.807 -177.077 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . 0.76 ' HB2' HG22 ' A' ' 71' ' ' VAL . 9.1 ptt180 -76.61 159.93 29.85 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 176.187 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . 56.72 70.73 0.62 Allowed 'General case' 0 CA--C 1.521 -0.143 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 -174.791 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . 0.523 ' HE1' ' H ' ' A' ' 89' ' ' GLY . 6.2 p90 -67.14 -30.48 70.48 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 114.76 -1.109 . . . . 0.0 113.631 -160.575 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 24.3 mmt 60.45 95.56 0.03 OUTLIER 'General case' 0 N--CA 1.465 0.279 0 CA-C-O 121.313 0.578 . . . . 0.0 110.501 -173.356 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -83.75 29.2 3.77 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.829 -0.701 . . . . 0.0 112.846 -175.362 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.465 HG22 HG13 ' A' ' 32' ' ' VAL . 37.4 pt -136.94 154.54 31.54 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.742 0 CA-C-O 121.066 0.46 . . . . 0.0 109.988 -179.689 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . 0.418 ' HD3' ' HA ' ' A' ' 103' ' ' ARG . 7.8 tpp180 -92.8 144.52 25.2 Favored 'General case' 0 C--N 1.315 -0.908 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 175.809 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.4 t -145.47 154.68 42.5 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-O 121.417 0.627 . . . . 0.0 111.266 178.443 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 9.3 p -128.6 171.44 12.15 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-N 114.643 -1.162 . . . . 0.0 109.884 177.838 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 59.6 t30 -88.96 3.62 50.93 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.579 -174.348 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . 0.512 ' HD2' ' HB3' ' A' ' 25' ' ' ASP . 81.7 t60 65.51 37.34 6.12 Favored 'General case' 0 CA--C 1.535 0.37 0 CA-C-O 121.792 0.806 . . . . 0.0 109.948 -178.199 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . 0.733 HD21 ' HB2' ' A' ' 23' ' ' GLN . 34.6 mt -68.56 167.67 14.52 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.306 -0.861 . . . . 0.0 110.925 176.902 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -110.56 91.74 3.77 Favored 'General case' 0 C--N 1.313 -1.015 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 177.795 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 81.5 t -104.5 142.77 17.21 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.803 0 CA-C-N 115.318 -0.856 . . . . 0.0 110.711 -175.79 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' ARG . . . . . . . . . . . . . 54.8 ttt180 -69.21 148.2 50.19 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.847 -0.615 . . . . 0.0 109.493 176.009 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -53.97 98.35 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.186 0.517 . . . . 0.0 111.58 -177.951 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 4.8 m -140.98 101.25 4.0 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.062 -0.972 . . . . 0.0 108.941 177.425 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 6.4 m -105.78 108.72 25.71 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-O 121.439 0.638 . . . . 0.0 111.795 -175.217 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -148.42 91.42 1.9 Allowed 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.328 -0.851 . . . . 0.0 109.973 176.98 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 46.1 m -140.78 31.13 1.84 Allowed 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.336 0.589 . . . . 0.0 110.491 -178.578 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 4.5 m -76.24 91.63 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-O 121.573 0.701 . . . . 0.0 111.274 -178.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 86.2 mt -82.02 -53.85 5.79 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.61 -0.723 . . . . 0.0 109.97 176.759 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 99.06 -160.87 20.04 Favored Glycine 0 N--CA 1.444 -0.789 0 CA-C-N 115.564 -0.744 . . . . 0.0 112.203 179.202 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 37.0 t70 67.69 160.29 0.16 Allowed 'General case' 0 C--O 1.235 0.31 0 C-N-CA 123.529 0.732 . . . . 0.0 111.828 178.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 121' ' ' THR . . . . . 0.503 ' O ' ' HD3' ' A' ' 123' ' ' PRO . 4.7 t -134.35 126.6 29.97 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 115.33 -0.85 . . . . 0.0 109.101 175.172 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 87.7 mt -111.46 93.96 21.08 Favored Pre-proline 0 C--N 1.324 -0.528 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.558 -176.646 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . 0.503 ' HD3' ' O ' ' A' ' 121' ' ' THR . 9.7 Cg_endo -91.0 109.58 0.33 Allowed 'Trans proline' 0 N--CA 1.449 -1.139 0 C-N-CA 123.379 2.719 . . . . 0.0 111.228 172.506 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 37.8 p90 -92.04 107.64 19.35 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.516 0.674 . . . . 0.0 110.965 -178.278 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.967 0 CA-C-O 118.125 -0.941 . . . . 0.0 109.564 177.102 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . . . . . . . . . 51.1 tp60 . . . . . 0 N--CA 1.455 -0.2 0 N-CA-C 110.1 -0.333 . . . . 0.0 110.1 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_exo -61.58 118.4 5.27 Favored 'Trans proline' 0 C--O 1.235 0.372 0 C-N-CA 122.869 2.379 . . . . 0.0 111.349 174.506 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 28.5 p-10 -119.68 -23.88 6.39 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 115.941 -0.572 . . . . 0.0 112.135 -169.724 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 96.53 133.02 7.5 Favored Glycine 0 N--CA 1.446 -0.689 0 N-CA-C 111.15 -0.78 . . . . 0.0 111.15 -176.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.423 ' HA ' ' HA ' ' A' ' 106' ' ' ASN . 19.6 m -78.78 140.4 16.94 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.742 0 CA-C-O 120.98 0.419 . . . . 0.0 110.842 -176.93 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . 0.472 ' HB2' ' O ' ' A' ' 46' ' ' LEU . 2.8 pt20 -109.84 157.59 19.04 Favored 'General case' 0 C--N 1.317 -0.823 0 C-N-CA 120.22 -0.592 . . . . 0.0 109.778 175.662 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.565 HG23 HD13 ' A' ' 48' ' ' ILE . 2.2 pt -79.84 98.49 3.26 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.14 176.523 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -53.78 -55.64 24.62 Favored 'General case' 0 CA--C 1.504 -0.816 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.13 177.509 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 6.2 p -155.99 144.56 20.18 Favored 'General case' 0 N--CA 1.441 -0.908 0 CA-C-N 115.045 -0.979 . . . . 0.0 111.438 -178.152 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.623 HG23 HG23 ' A' ' 102' ' ' ILE . 52.3 t -87.62 141.34 14.46 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.01 0 CA-C-N 114.965 -1.016 . . . . 0.0 108.664 171.651 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.57 HG21 ' HH ' ' A' ' 99' ' ' TYR . 48.3 t -83.18 105.38 5.12 Favored Pre-proline 0 C--N 1.322 -0.592 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 174.937 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . 0.51 ' HD3' ' O ' ' A' ' 32' ' ' VAL . 31.5 Cg_exo -58.19 113.64 1.62 Allowed 'Trans proline' 0 C--O 1.236 0.406 0 C-N-CA 122.774 2.316 . . . . 0.0 112.179 -175.305 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 133.61 -20.84 4.08 Favored Glycine 0 N--CA 1.446 -0.687 0 N-CA-C 111.227 -0.749 . . . . 0.0 111.227 -178.455 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 56.4 p -81.87 161.13 61.89 Favored Pre-proline 0 C--N 1.323 -0.575 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 177.692 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -59.03 -24.83 75.31 Favored 'Trans proline' 0 C--N 1.344 0.312 0 C-N-CA 122.36 2.04 . . . . 0.0 111.743 175.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -66.78 -27.86 67.93 Favored 'General case' 0 N--CA 1.454 -0.24 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.553 -179.359 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.52 ' HA ' HG11 ' A' ' 32' ' ' VAL . 13.2 m -63.2 -22.39 66.84 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.91 0.386 . . . . 0.0 111.454 -177.65 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 65.3 mttm -97.27 -17.58 19.72 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.487 -175.76 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.634 ' HB ' HD21 ' A' ' 42' ' ' LEU . 60.6 t -98.23 -49.52 11.68 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.871 -172.354 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.634 HD21 ' HB ' ' A' ' 41' ' ' VAL . 0.3 OUTLIER -117.12 178.23 4.43 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.561 0.696 . . . . 0.0 112.343 -173.745 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 56.8 m -128.42 128.99 23.6 Favored Pre-proline 0 C--N 1.322 -0.602 0 CA-C-N 114.693 -1.14 . . . . 0.0 109.593 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -64.66 152.95 79.96 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.611 2.207 . . . . 0.0 112.305 -177.643 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 99.82 -1.92 56.85 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.553 -0.832 . . . . 0.0 112.582 -178.024 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 0.482 ' HB2' HD13 ' A' ' 29' ' ' ILE . 85.1 mt -89.81 164.15 14.75 Favored 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 110.286 -0.264 . . . . 0.0 110.286 177.271 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 40.4 t -103.27 141.1 19.77 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 178.005 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.565 HD13 HG23 ' A' ' 29' ' ' ILE . 57.5 mt -99.76 120.23 48.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 121.051 0.453 . . . . 0.0 110.0 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 14.5 tt0 -78.81 -56.23 4.57 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 121.489 0.661 . . . . 0.0 109.834 176.781 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.656 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 11.8 p -146.89 149.15 32.68 Favored 'General case' 0 N--CA 1.444 -0.741 0 CA-C-N 115.342 -0.844 . . . . 0.0 112.551 -171.001 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.54 ' HA ' ' O ' ' A' ' 76' ' ' ASN . 55.4 mt -126.7 114.03 35.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 114.561 -1.2 . . . . 0.0 108.573 172.751 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 6.4 t-20 63.13 -152.65 0.33 Allowed 'General case' 0 CA--C 1.532 0.278 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 -171.01 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -76.84 3.61 55.82 Favored Glycine 0 CA--C 1.52 0.392 0 C-N-CA 120.533 -0.841 . . . . 0.0 112.97 179.509 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 3.8 mpp? -111.76 105.39 56.59 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 120.725 0.298 . . . . 0.0 110.76 -178.894 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.656 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 47.0 Cg_endo -69.3 148.57 68.35 Favored 'Trans proline' 0 N--CA 1.462 -0.362 0 C-N-CA 122.303 2.002 . . . . 0.0 112.186 176.243 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 20.8 p -109.96 95.71 5.77 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.663 -176.484 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 14.7 p -92.85 -19.87 21.26 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.059 0.457 . . . . 0.0 110.738 177.367 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 14.2 m120 -125.56 173.52 8.89 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 178.153 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -82.48 -33.53 28.35 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 121.225 0.536 . . . . 0.0 110.257 176.683 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 6.1 m -70.08 -29.54 66.55 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.043 179.344 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 24.6 p -67.82 -38.5 83.32 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 121.136 0.493 . . . . 0.0 109.999 176.34 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 67.2 t80 -59.26 -44.15 92.41 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-N 115.437 -0.801 . . . . 0.0 109.709 173.475 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' SER . . . . . 0.415 ' O ' ' HG3' ' A' ' 67' ' ' LYS . 70.3 m -63.71 -46.09 87.03 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.135 -0.938 . . . . 0.0 111.832 179.314 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.85 -33.68 74.62 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.118 179.652 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . 0.41 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -77.77 -36.17 50.83 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.147 0.499 . . . . 0.0 110.194 178.586 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -60.61 -29.91 69.52 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.139 179.124 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . 0.415 ' HG3' ' O ' ' A' ' 63' ' ' SER . 58.7 mtpt -58.79 -32.46 69.34 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.448 178.63 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 34.8 p -91.06 -14.71 30.8 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 112.216 0.45 . . . . 0.0 112.216 -175.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.41 HG12 ' O ' ' A' ' 65' ' ' ALA . 30.5 mm -82.26 140.53 16.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 N-CA-C 110.283 -0.266 . . . . 0.0 110.283 -177.695 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 14.3 t -115.64 178.04 4.45 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 120.958 0.409 . . . . 0.0 110.849 -179.575 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.457 ' CG1' ' HD2' ' A' ' 90' ' ' ARG . 20.9 t -79.99 120.78 32.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.858 -178.105 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 98.17 5.65 57.12 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.645 -0.788 . . . . 0.0 111.879 -179.815 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 15.2 tp10 -81.36 147.98 29.57 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.301 -0.45 . . . . 0.0 109.913 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 57.3 t -109.38 108.95 26.61 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.856 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.37 179.252 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.454 HD12 ' HE1' ' A' ' 100' ' ' MET . 21.6 pt -109.84 153.84 11.5 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.773 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.193 -175.375 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . 0.54 ' O ' ' HA ' ' A' ' 51' ' ' ILE . 5.4 t30 -90.07 132.16 35.55 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.647 177.633 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.43 HG23 HG23 ' A' ' 79' ' ' THR . 61.7 mt -128.53 116.5 41.83 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-O 121.295 0.569 . . . . 0.0 110.465 -179.645 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 4.6 m -99.3 102.25 13.81 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.141 177.783 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.457 HG21 HG12 ' A' ' 48' ' ' ILE . 73.4 p -102.16 170.15 8.28 Favored 'General case' 0 C--N 1.324 -0.519 0 C-N-CA 120.674 -0.41 . . . . 0.0 110.296 178.081 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -51.07 -38.76 53.55 Favored 'General case' 0 N--CA 1.466 0.365 0 O-C-N 123.801 0.688 . . . . 0.0 112.649 -176.279 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 31.4 mt-30 -127.44 20.25 6.74 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 111.92 0.341 . . . . 0.0 111.92 -174.659 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -165.68 119.96 0.9 Allowed Glycine 0 N--CA 1.446 -0.653 0 C-N-CA 119.751 -1.214 . . . . 0.0 113.465 179.04 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 13.6 m -106.3 109.21 21.07 Favored 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 172.479 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . 0.438 ' CZ ' ' HB3' ' A' ' 42' ' ' LEU . 7.3 p90 -145.68 177.46 8.87 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 121.225 0.536 . . . . 0.0 111.807 -172.972 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 1.0 OUTLIER -111.9 150.82 29.93 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.388 -0.823 . . . . 0.0 109.756 172.055 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.425 HD23 ' HG3' ' A' ' 100' ' ' MET . 7.5 tt -134.11 141.39 47.11 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-O 121.218 0.533 . . . . 0.0 110.706 -176.81 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 82.3 tttt -94.21 116.38 28.77 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.044 -0.98 . . . . 0.0 109.275 177.51 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 32.1 p -59.25 123.49 16.87 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.584 0.707 . . . . 0.0 111.414 -176.934 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -96.42 175.38 31.75 Favored Glycine 0 N--CA 1.434 -1.453 0 CA-C-N 114.991 -1.004 . . . . 0.0 111.403 -178.363 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . 0.496 ' HD3' ' N ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -144.06 75.64 1.47 Allowed 'General case' 0 C--N 1.314 -0.939 0 CA-C-O 121.427 0.632 . . . . 0.0 110.293 -178.092 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' ASN . . . . . 0.413 ' N ' ' HD2' ' A' ' 92' ' ' PRO . 17.6 m120 -62.0 -48.54 88.33 Favored Pre-proline 0 C--N 1.327 -0.382 0 CA-C-N 115.789 -0.641 . . . . 0.0 109.687 174.009 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.413 ' HD2' ' N ' ' A' ' 91' ' ' ASN . 56.9 Cg_endo -73.41 128.63 12.97 Favored 'Trans proline' 0 C--N 1.352 0.749 0 C-N-CA 121.614 1.543 . . . . 0.0 110.727 166.615 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -103.89 -25.86 12.89 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 120.915 0.388 . . . . 0.0 110.074 -175.654 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 10.4 t30 -78.85 121.06 24.34 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 174.833 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 22.8 t 67.79 78.09 0.24 Allowed 'General case' 0 C--O 1.234 0.272 0 O-C-N 124.028 0.83 . . . . 0.0 109.038 -173.287 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 11.0 m -69.79 119.55 14.19 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.188 -0.914 . . . . 0.0 111.127 -174.865 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 7.5 ptt85 -149.99 161.61 41.99 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 115.629 -0.714 . . . . 0.0 109.917 175.198 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -58.25 118.25 5.29 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.565 -179.309 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . 0.57 ' HH ' HG21 ' A' ' 33' ' ' VAL . 69.8 t80 -110.88 -23.84 10.76 Favored 'General case' 0 C--N 1.323 -0.559 0 C-N-CA 120.746 -0.382 . . . . 0.0 110.465 -178.21 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' MET . . . . . 0.454 ' HE1' HD12 ' A' ' 75' ' ' ILE . 44.3 ttm 70.63 -59.96 0.51 Allowed 'General case' 0 N--CA 1.468 0.455 0 CA-C-N 115.551 -0.749 . . . . 0.0 111.184 179.46 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 124.21 9.31 5.63 Favored Glycine 0 C--O 1.227 -0.326 0 C-N-CA 121.023 -0.608 . . . . 0.0 113.11 178.259 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.623 HG23 HG23 ' A' ' 32' ' ' VAL . 2.8 pp -136.97 165.71 27.4 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-O 120.909 0.385 . . . . 0.0 110.51 -179.028 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . 0.414 ' HD3' ' HA ' ' A' ' 103' ' ' ARG . 9.1 mmt180 -114.63 129.63 56.7 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.12 172.023 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' THR . . . . . 0.577 HG22 HD12 ' A' ' 102' ' ' ILE . 3.1 p -110.05 143.19 40.43 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.007 0.432 . . . . 0.0 111.724 -177.836 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 18.0 m -151.24 151.11 31.4 Favored 'General case' 0 C--N 1.318 -0.765 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 173.487 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . 0.423 ' HA ' ' HA ' ' A' ' 27' ' ' VAL . 13.4 m120 -69.1 -30.99 69.4 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-O 121.653 0.74 . . . . 0.0 109.845 -178.203 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 4.7 t-160 59.58 36.86 22.8 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 114.449 -1.25 . . . . 0.0 109.494 -170.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 13.5 mt -58.45 157.53 8.72 Favored 'General case' 0 CA--C 1.516 -0.34 0 CA-C-N 115.781 -0.645 . . . . 0.0 109.82 174.768 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -66.15 132.76 49.23 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.088 -177.205 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 11.3 p -55.96 139.06 15.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 115.389 -0.823 . . . . 0.0 111.867 -174.738 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' ARG . . . . . . . . . . . . . 20.1 ptt180 -130.6 146.83 52.19 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.157 -0.929 . . . . 0.0 110.123 -179.43 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 34.2 t70 -116.69 99.13 6.91 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-O 121.111 0.481 . . . . 0.0 109.712 176.04 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 14.9 m -146.49 124.58 12.11 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.539 -0.755 . . . . 0.0 109.631 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 28.3 m -87.19 155.43 3.27 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.728 178.463 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -83.09 154.27 24.45 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 116.3 -0.409 . . . . 0.0 109.943 174.765 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 69.2 m -72.49 122.87 22.01 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 121.097 0.475 . . . . 0.0 110.958 -179.057 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 7.3 p -135.62 128.34 47.22 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.125 176.005 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 7.0 mp -93.46 -49.13 6.06 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.916 -0.584 . . . . 0.0 109.889 179.678 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 77.1 -145.22 30.64 Favored Glycine 0 N--CA 1.446 -0.653 0 CA-C-N 115.511 -0.768 . . . . 0.0 111.959 -179.795 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 4.6 t70 72.47 149.39 0.09 Allowed 'General case' 0 N--CA 1.467 0.402 0 C-N-CA 123.382 0.673 . . . . 0.0 110.867 179.205 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 11.5 m -100.16 100.36 11.19 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-O 121.019 0.437 . . . . 0.0 110.771 -179.07 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 86.3 mt -84.32 121.54 75.28 Favored Pre-proline 0 C--N 1.324 -0.504 0 CA-C-N 115.705 -0.679 . . . . 0.0 110.222 178.6 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 92.5 Cg_endo -79.39 27.89 0.52 Allowed 'Trans proline' 0 CA--C 1.529 0.27 0 C-N-CA 123.034 2.489 . . . . 0.0 113.285 -176.501 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 46.9 m-85 -136.0 129.58 32.27 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.161 0.505 . . . . 0.0 111.207 -179.864 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.975 0 CA-C-N 115.32 -0.854 . . . . 0.0 109.33 177.402 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . . . . . . . . . 26.5 mt-30 . . . . . 0 CA--C 1.527 0.087 0 CA-C-O 121.194 0.521 . . . . 0.0 110.767 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -91.19 105.54 0.27 Allowed 'Trans proline' 0 N--CA 1.449 -1.132 0 C-N-CA 122.825 2.35 . . . . 0.0 111.707 177.311 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -123.59 -24.0 4.64 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.941 -179.094 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.56 ' HA2' ' HA ' ' A' ' 57' ' ' SER . . . 106.81 176.1 23.01 Favored Glycine 0 N--CA 1.443 -0.86 0 N-CA-C 111.208 -0.757 . . . . 0.0 111.208 -175.271 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.525 HG22 ' HB ' ' A' ' 48' ' ' ILE . 19.6 m -102.06 131.08 50.79 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.812 0 CA-C-O 121.393 0.616 . . . . 0.0 110.978 177.717 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 36.4 tp60 -97.04 135.04 39.6 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.456 -0.793 . . . . 0.0 110.557 -178.8 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.536 HD11 ' HB2' ' A' ' 46' ' ' LEU . 57.8 mt -78.59 112.56 16.76 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.546 176.441 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -74.12 -69.22 0.46 Allowed 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.932 -176.921 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 9.6 p -149.49 148.97 30.04 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.434 -177.05 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.554 HG11 HG22 ' A' ' 102' ' ' ILE . 57.4 t -96.07 114.07 31.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-N 115.642 -0.708 . . . . 0.0 109.773 176.915 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 47.0 t -98.2 128.1 34.51 Favored Pre-proline 0 C--N 1.318 -0.779 0 CA-C-N 116.062 -0.517 . . . . 0.0 109.998 -176.403 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo -63.59 86.25 0.13 Allowed 'Trans proline' 0 C--O 1.234 0.32 0 C-N-CA 122.748 2.299 . . . . 0.0 112.494 -179.923 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -151.48 20.08 0.92 Allowed Glycine 0 N--CA 1.446 -0.643 0 CA-C-N 115.529 -0.76 . . . . 0.0 111.455 177.574 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' SER . . . . . 0.436 ' HB2' ' HD2' ' A' ' 37' ' ' PRO . 67.8 p -174.9 160.97 2.43 Favored Pre-proline 0 C--N 1.328 -0.36 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 -178.525 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . 0.436 ' HD2' ' HB2' ' A' ' 36' ' ' SER . 29.4 Cg_endo -63.65 -5.21 8.29 Favored 'Trans proline' 0 CA--C 1.532 0.405 0 C-N-CA 122.581 2.187 . . . . 0.0 112.631 179.075 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -67.95 -23.59 65.08 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.619 -0.264 . . . . 0.0 111.066 -179.862 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' SER . . . . . 0.506 ' HA ' HG13 ' A' ' 32' ' ' VAL . 26.7 m -65.07 -24.87 67.58 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.188 0.518 . . . . 0.0 111.427 -178.687 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 1.6 tmtp? -88.14 -26.76 22.29 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.519 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . 0.518 ' HB ' HD12 ' A' ' 42' ' ' LEU . 46.3 t -92.17 -49.92 12.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.8 -173.217 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.518 HD12 ' HB ' ' A' ' 41' ' ' VAL . 6.6 mp -95.38 168.38 10.75 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.329 0.585 . . . . 0.0 111.638 -172.956 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -133.01 144.03 51.06 Favored Pre-proline 0 C--N 1.322 -0.622 0 CA-C-N 115.204 -0.907 . . . . 0.0 109.861 176.418 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 78.8 Cg_endo -78.69 155.21 27.3 Favored 'Trans proline' 0 N--CA 1.463 -0.316 0 C-N-CA 122.721 2.281 . . . . 0.0 113.389 -176.0 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 94.08 20.99 29.0 Favored Glycine 0 N--CA 1.448 -0.528 0 C-N-CA 120.619 -0.801 . . . . 0.0 113.273 177.646 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 0.536 ' HB2' HD11 ' A' ' 29' ' ' ILE . 44.1 mt -108.33 164.26 12.47 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 117.028 0.414 . . . . 0.0 110.928 -179.226 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 61.5 t -108.42 135.14 48.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.096 177.599 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.525 ' HB ' HG22 ' A' ' 27' ' ' VAL . 64.1 mt -96.29 124.63 49.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-O 120.964 0.411 . . . . 0.0 110.837 -179.594 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -84.51 -50.57 7.61 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.049 178.099 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.604 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 24.2 p -149.17 152.21 35.66 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.919 -0.582 . . . . 0.0 112.234 -175.126 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 45.7 mm -111.98 98.99 7.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 114.954 -1.021 . . . . 0.0 110.489 177.05 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' ASN . . . . . 0.461 ' HA ' ' HB3' ' A' ' 76' ' ' ASN . 6.8 t-20 57.72 41.7 24.84 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-N 115.336 -0.847 . . . . 0.0 111.823 172.867 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 104.99 -30.23 10.36 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.641 176.539 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 72.0 mtm -97.53 112.25 60.76 Favored Pre-proline 0 C--N 1.326 -0.422 0 N-CA-C 109.673 -0.491 . . . . 0.0 109.673 178.308 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.604 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 56.0 Cg_endo -69.67 139.48 40.65 Favored 'Trans proline' 0 N--CA 1.459 -0.537 0 C-N-CA 122.26 1.974 . . . . 0.0 112.794 -175.743 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 31.3 p -113.57 83.27 1.82 Allowed 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.346 0.593 . . . . 0.0 111.149 -178.518 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' SER . . . . . 0.56 ' HA ' ' HA2' ' A' ' 26' ' ' GLY . 48.0 t -91.88 -13.97 30.44 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.419 179.616 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 81.8 m-20 -129.16 -179.85 5.36 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 109.195 -0.669 . . . . 0.0 109.195 -178.674 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.415 HD21 ' HA ' ' A' ' 59' ' ' LEU . 17.5 mt -75.93 -45.42 35.25 Favored 'General case' 0 N--CA 1.447 -0.602 0 CA-C-O 120.793 0.33 . . . . 0.0 110.902 175.104 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 6.9 m -61.62 -36.47 80.84 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.42 -177.552 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 19.3 p -64.5 -37.3 87.08 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.133 0.492 . . . . 0.0 110.498 176.217 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 70.7 t80 -70.43 -39.19 74.52 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.69 -0.686 . . . . 0.0 109.504 179.285 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 61.3 m -62.29 -48.53 79.46 Favored 'General case' 0 N--CA 1.444 -0.732 0 CA-C-N 115.314 -0.857 . . . . 0.0 111.666 176.894 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.62 -34.42 75.63 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.987 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -74.01 -44.35 54.81 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.965 -0.562 . . . . 0.0 110.425 179.239 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -61.9 -35.95 79.88 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.454 -176.738 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -55.86 -34.71 65.71 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.929 -176.807 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 71.3 p -78.94 -14.24 59.33 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.722 0.296 . . . . 0.0 111.719 -177.574 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.479 HD12 HG23 ' A' ' 75' ' ' ILE . 29.0 mm -81.04 126.74 39.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.903 0.382 . . . . 0.0 111.024 -175.826 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 20.2 m -120.1 -171.8 2.22 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.961 -176.792 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . 0.481 HG21 ' HA ' ' A' ' 97' ' ' ARG . 40.2 t -74.2 139.81 18.67 Favored 'Isoleucine or valine' 0 C--O 1.233 0.218 0 N-CA-C 110.145 -0.317 . . . . 0.0 110.145 176.907 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 69.02 32.05 72.86 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.596 -0.811 . . . . 0.0 111.493 179.382 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 9.6 tp10 -104.84 147.9 27.24 Favored 'General case' 0 N--CA 1.444 -0.746 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 -178.77 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 44.4 t -110.1 106.9 21.61 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 N-CA-C 109.492 -0.559 . . . . 0.0 109.492 -179.131 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . 0.479 HG23 HD12 ' A' ' 69' ' ' ILE . 30.5 pt -95.62 154.52 3.46 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.884 -177.2 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . 0.461 ' HB3' ' HA ' ' A' ' 52' ' ' ASN . 64.5 t30 -122.91 108.51 13.05 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.025 -176.797 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . 0.496 HG22 HG21 ' A' ' 48' ' ' ILE . 60.4 mt -106.8 110.75 32.78 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.968 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.501 -175.131 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' THR . . . . . 0.684 ' HG1' HG21 ' A' ' 83' ' ' THR . 25.5 m -89.29 113.89 25.21 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.471 177.144 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' THR . . . . . 0.442 HG23 HG23 ' A' ' 77' ' ' ILE . 71.3 p -120.45 -178.54 3.72 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 121.06 0.457 . . . . 0.0 111.312 -176.323 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -62.81 -26.5 68.77 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.379 -0.828 . . . . 0.0 111.069 173.678 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 26.9 mm-40 -93.55 9.32 37.22 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.04 0.448 . . . . 0.0 111.351 179.758 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 114.95 -177.75 17.53 Favored Glycine 0 N--CA 1.444 -0.782 0 C-N-CA 120.624 -0.798 . . . . 0.0 112.637 176.625 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' THR . . . . . 0.684 HG21 ' HG1' ' A' ' 78' ' ' THR . 10.6 m -97.93 113.47 25.32 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.798 -0.201 . . . . 0.0 110.727 -178.096 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 46.1 m-85 -111.75 148.06 34.31 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 110.18 -0.304 . . . . 0.0 110.18 179.389 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 25.7 p-80 -122.95 125.42 45.27 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-O 120.871 0.367 . . . . 0.0 110.018 175.498 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.47 HD22 HD13 ' A' ' 77' ' ' ILE . 0.7 OUTLIER -130.89 156.99 44.12 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.849 -176.059 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 19.5 ptmt -99.77 146.58 26.4 Favored 'General case' 0 N--CA 1.442 -0.834 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.211 179.206 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 33.3 p -83.92 128.39 34.51 Favored 'General case' 0 C--N 1.315 -0.915 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.732 175.857 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -86.6 -169.51 45.98 Favored Glycine 0 N--CA 1.444 -0.833 0 C-N-CA 120.936 -0.65 . . . . 0.0 112.207 -178.811 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 9.8 mpt_? -90.13 -177.17 5.09 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-O 120.974 0.416 . . . . 0.0 110.846 -178.224 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' ASN . . . . . 0.406 ' HA ' ' CD1' ' A' ' 99' ' ' TYR . 12.5 p-10 -107.89 105.87 57.24 Favored Pre-proline 0 C--N 1.324 -0.54 0 CA-C-N 115.747 -0.661 . . . . 0.0 112.036 -175.682 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.49 ' HD2' ' CE1' ' A' ' 99' ' ' TYR . 20.3 Cg_exo -67.52 -40.91 9.55 Favored 'Trans proline' 0 C--O 1.234 0.278 0 C-N-CA 122.358 2.039 . . . . 0.0 111.47 171.664 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 22.9 t-20 -109.97 -94.21 0.42 Allowed 'General case' 0 CA--C 1.532 0.251 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.84 -178.602 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 10.8 m120 -135.38 110.2 8.71 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.229 0.537 . . . . 0.0 112.126 -178.121 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 2.8 t -179.04 89.63 0.02 OUTLIER 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 107.367 -1.346 . . . . 0.0 107.367 172.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 47.6 m -58.23 -39.08 78.15 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.908 -171.173 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . 0.589 ' HD2' ' O ' ' A' ' 97' ' ' ARG . 6.6 ppt_? -129.87 120.59 25.17 Favored 'General case' 0 N--CA 1.446 -0.641 0 C-N-CA 121.004 -0.279 . . . . 0.0 110.858 178.755 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . 65.9 115.24 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.525 0 CA-C-N 115.586 -0.734 . . . . 0.0 112.124 178.405 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . 0.49 ' CE1' ' HD2' ' A' ' 92' ' ' PRO . 4.5 t80 -88.24 -55.8 3.59 Favored 'General case' 0 C--N 1.327 -0.412 0 C-N-CA 120.266 -0.574 . . . . 0.0 110.491 178.122 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' MET . . . . . 0.484 ' HE2' HD12 ' A' ' 102' ' ' ILE . 25.2 ttt 59.01 94.74 0.03 OUTLIER 'General case' 0 N--CA 1.468 0.44 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.929 178.784 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -84.44 38.49 2.9 Favored Glycine 0 C--O 1.225 -0.453 0 CA-C-N 115.92 -0.582 . . . . 0.0 114.316 -172.007 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.554 HG22 HG11 ' A' ' 32' ' ' VAL . 2.1 pp -137.92 140.99 39.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 172.43 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . 0.595 ' NE ' ' HA ' ' A' ' 103' ' ' ARG . 0.0 OUTLIER -101.42 141.56 34.11 Favored 'General case' 0 C--N 1.317 -0.838 0 C-N-CA 120.706 -0.398 . . . . 0.0 110.307 -177.067 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.5 p -127.48 151.43 48.86 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.577 -177.847 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 20.0 m -151.26 154.49 36.89 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 174.388 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . 0.52 ' HB2' ' HG ' ' A' ' 108' ' ' LEU . 37.2 p30 -68.01 -29.94 69.07 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 120.574 0.226 . . . . 0.0 111.345 -176.38 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 46.2 t60 52.42 40.65 29.91 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-O 121.25 0.548 . . . . 0.0 109.956 -177.329 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . 0.52 ' HG ' ' HB2' ' A' ' 106' ' ' ASN . 47.7 mt -71.06 -175.17 1.1 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.804 0.811 . . . . 0.0 112.439 -176.063 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 6.0 mmt180 -81.54 92.52 6.53 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 114.654 -1.157 . . . . 0.0 109.366 -178.062 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 46.1 t -77.28 115.38 19.01 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.758 0 CA-C-O 121.445 0.641 . . . . 0.0 111.091 -177.35 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' ARG . . . . . . . . . . . . . 26.3 tpt180 -160.12 108.94 1.72 Allowed 'General case' 0 C--N 1.313 -0.981 0 CA-C-N 114.863 -1.062 . . . . 0.0 108.698 178.546 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -156.3 106.73 2.39 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.19 -173.655 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 19.9 m -94.31 115.45 27.68 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.22 -175.595 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 19.4 m -105.69 131.34 55.37 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.015 179.635 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -159.46 134.24 7.96 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.695 -179.824 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 16.6 t -164.41 91.19 0.59 Allowed 'General case' 0 C--N 1.325 -0.462 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 177.28 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 57.6 t -133.99 104.63 6.18 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.737 -178.23 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 89.7 mt -127.58 -76.77 0.57 Allowed 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 109.721 -0.474 . . . . 0.0 109.721 175.758 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 69.81 40.78 75.02 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 121.075 -0.583 . . . . 0.0 112.901 177.002 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -79.67 130.61 35.5 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.657 -0.497 . . . . 0.0 109.657 178.03 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 121' ' ' THR . . . . . 0.443 ' O ' ' HD3' ' A' ' 123' ' ' PRO . 4.9 t -64.18 116.02 5.56 Favored 'General case' 0 N--CA 1.45 -0.43 0 CA-C-O 121.339 0.59 . . . . 0.0 109.976 178.496 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 91.7 mt -104.36 104.82 46.74 Favored Pre-proline 0 C--N 1.321 -0.669 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.287 -176.262 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . 0.443 ' HD3' ' O ' ' A' ' 121' ' ' THR . 24.1 Cg_exo -63.74 107.16 0.7 Allowed 'Trans proline' 0 N--CA 1.458 -0.606 0 C-N-CA 122.54 2.16 . . . . 0.0 110.957 176.768 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 3.2 t80 -116.38 -1.75 12.22 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 121.171 0.51 . . . . 0.0 110.366 -175.851 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.922 0 CA-C-O 118.48 -0.772 . . . . 0.0 110.432 179.934 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.682 ' HB2' ' HD3' ' A' ' 24' ' ' PRO . 35.4 mt-30 . . . . . 0 CA--C 1.533 0.322 0 CA-C-O 119.797 -0.144 . . . . 0.0 111.104 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' PRO . . . . . 0.682 ' HD3' ' HB2' ' A' ' 23' ' ' GLN . 22.9 Cg_exo -64.74 134.66 41.56 Favored 'Trans proline' 0 C--N 1.356 0.94 0 C-N-CA 121.943 1.762 . . . . 0.0 111.507 177.94 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.681 ' HA ' ' CD2' ' A' ' 108' ' ' LEU . 0.0 OUTLIER -91.53 -54.91 3.7 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.233 -174.487 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 93.74 157.82 33.42 Favored Glycine 0 N--CA 1.444 -0.785 0 C-N-CA 120.93 -0.653 . . . . 0.0 111.485 -178.352 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' VAL . . . . . 0.547 HG22 ' HB ' ' A' ' 48' ' ' ILE . 3.8 m -105.27 118.93 53.59 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.713 0 CA-C-O 121.704 0.764 . . . . 0.0 110.844 -179.164 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 34.8 tp60 -103.69 136.0 44.21 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.271 -0.877 . . . . 0.0 110.841 -177.09 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' ILE . . . . . 0.486 HD11 HD11 ' A' ' 48' ' ' ILE . 42.3 mm -68.98 113.16 4.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.14 175.543 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 24.5 t70 -76.01 -63.53 1.29 Allowed 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 115.749 -0.659 . . . . 0.0 109.623 176.759 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 45.3 t -150.69 150.26 30.85 Favored 'General case' 0 N--CA 1.446 -0.654 0 CA-C-N 115.372 -0.831 . . . . 0.0 111.063 -179.571 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' VAL . . . . . 0.574 HG21 HG21 ' A' ' 102' ' ' ILE . 64.0 t -96.36 112.8 29.25 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.946 0 CA-C-N 114.95 -1.023 . . . . 0.0 109.123 174.577 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.443 ' HA ' ' HD3' ' A' ' 34' ' ' PRO . 19.5 m -83.33 127.12 69.89 Favored Pre-proline 0 C--N 1.324 -0.526 0 CA-C-O 121.065 0.46 . . . . 0.0 111.261 -176.247 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' PRO . . . . . 0.443 ' HD3' ' HA ' ' A' ' 33' ' ' VAL . 21.3 Cg_exo -66.1 146.46 81.98 Favored 'Trans proline' 0 C--O 1.237 0.429 0 C-N-CA 122.982 2.455 . . . . 0.0 112.058 178.288 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 114.24 -25.85 10.24 Favored Glycine 0 N--CA 1.45 -0.393 0 N-CA-C 111.507 -0.637 . . . . 0.0 111.507 -178.302 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 50.4 m -101.77 159.2 30.12 Favored Pre-proline 0 C--N 1.319 -0.721 0 CA-C-N 115.442 -0.379 . . . . 0.0 110.331 178.85 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_exo -60.19 -20.18 60.62 Favored 'Trans proline' 0 C--N 1.347 0.487 0 C-N-CA 123.057 2.505 . . . . 0.0 112.958 -178.102 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -66.15 -25.84 67.15 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.973 -176.808 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 13.4 m -63.2 -22.95 67.2 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.365 -0.38 . . . . 0.0 111.738 -176.224 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 57.4 tttm -110.11 11.53 23.77 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.907 0.384 . . . . 0.0 110.514 -176.465 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 96.5 t -120.73 -55.25 3.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 120.761 0.315 . . . . 0.0 111.275 -177.063 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 97.7 mt -107.69 167.19 10.13 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.083 0.468 . . . . 0.0 111.434 -174.142 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 20.1 p -113.9 148.06 39.09 Favored Pre-proline 0 N--CA 1.446 -0.663 0 CA-C-N 115.323 -0.853 . . . . 0.0 109.626 175.839 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_exo -74.79 141.1 26.89 Favored 'Trans proline' 0 N--CA 1.458 -0.565 0 C-N-CA 122.285 1.99 . . . . 0.0 111.926 -178.054 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 105.36 -2.21 40.06 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.626 -0.797 . . . . 0.0 113.056 179.916 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . 0.435 HD23 ' HB3' ' A' ' 80' ' ' ASP . 72.7 mt -78.65 164.8 24.32 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.257 0.551 . . . . 0.0 111.556 -178.849 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 61.8 t -109.51 138.64 36.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 115.801 -0.636 . . . . 0.0 109.378 174.63 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' ILE . . . . . 0.547 ' HB ' HG22 ' A' ' 27' ' ' VAL . 88.4 mt -94.68 111.84 26.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 120.971 0.415 . . . . 0.0 110.03 177.968 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -75.07 -51.4 13.6 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.484 -178.717 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' SER . . . . . 0.569 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 31.5 p -156.61 156.91 34.35 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.76 -0.655 . . . . 0.0 112.29 -174.912 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.469 HG23 ' H ' ' A' ' 52' ' ' ASN . 9.0 mm -100.07 -171.37 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 173.649 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' ASN . . . . . 0.469 ' H ' HG23 ' A' ' 51' ' ' ILE . 1.7 m-20 -48.72 92.99 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 123.039 0.536 . . . . 0.0 112.089 178.869 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 72.19 -10.07 4.96 Favored Glycine 0 CA--C 1.521 0.461 0 C-N-CA 121.384 -0.436 . . . . 0.0 113.787 175.517 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 71.0 mtm -125.71 112.69 25.02 Favored Pre-proline 0 C--N 1.327 -0.403 0 CA-C-N 117.147 0.474 . . . . 0.0 110.863 -175.882 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . 0.569 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 4.4 Cg_exo -78.65 137.44 14.42 Favored 'Trans proline' 0 N--CA 1.46 -0.488 0 C-N-CA 122.897 2.398 . . . . 0.0 111.661 175.97 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 40.1 p -121.48 116.76 25.31 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.909 0.385 . . . . 0.0 111.77 -178.857 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 30.7 t -86.57 -53.4 4.99 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.32 174.106 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' ASN . . . . . 0.401 ' HA ' ' OD1' ' A' ' 25' ' ' ASP . 15.5 m120 -86.24 157.11 20.03 Favored 'General case' 0 C--N 1.318 -0.762 0 C-N-CA 120.228 -0.589 . . . . 0.0 109.629 -169.799 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' LEU . . . . . 0.56 ' HG ' ' HB2' ' A' ' 106' ' ' ASN . 3.4 mt -65.11 -38.55 91.04 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.1 0.476 . . . . 0.0 110.4 177.992 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 3.3 m -64.44 -38.38 90.84 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.826 -0.624 . . . . 0.0 111.109 179.432 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 11.9 p -71.48 -32.1 67.88 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.958 0.408 . . . . 0.0 110.565 177.733 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 72.2 t80 -65.51 -44.34 87.28 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.893 -0.594 . . . . 0.0 109.789 175.467 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 7.9 t -63.17 -37.52 87.55 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.03 178.062 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.04 -33.07 74.92 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.015 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . 0.495 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -76.9 -40.03 48.83 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.256 0.55 . . . . 0.0 110.204 176.858 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' LEU . . . . . 0.426 HD23 ' SD ' ' A' ' 100' ' ' MET . 0.4 OUTLIER -60.5 -38.06 83.1 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.61 -0.723 . . . . 0.0 111.406 179.444 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -74.24 -6.43 47.87 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.996 -0.547 . . . . 0.0 112.301 -177.614 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 22.5 p -100.4 -12.61 19.25 Favored 'General case' 0 C--N 1.324 -0.541 0 C-N-CA 120.754 -0.379 . . . . 0.0 110.841 174.142 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.495 HG12 ' O ' ' A' ' 65' ' ' ALA . 47.2 mm -80.33 135.62 24.98 Favored 'Isoleucine or valine' 0 C--O 1.234 0.275 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.872 -178.667 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 1.4 m -83.03 165.7 19.4 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.345 -177.027 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 32.5 t -76.75 124.12 34.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.595 174.404 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 79.73 25.62 58.01 Favored Glycine 0 N--CA 1.446 -0.65 0 C-N-CA 120.314 -0.946 . . . . 0.0 111.178 -176.573 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 8.1 tp10 -85.6 147.81 26.22 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 178.423 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 56.9 t -104.61 98.56 6.98 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.978 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 176.05 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 26.0 pt -91.18 164.69 2.07 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.779 0 CA-C-O 121.388 0.613 . . . . 0.0 111.506 -173.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 33.2 t30 -116.06 115.88 26.89 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 115.158 -0.928 . . . . 0.0 109.615 -178.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 24.1 mt -120.61 107.74 21.35 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.315 -175.533 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' THR . . . . . 0.453 ' HA ' ' HA ' ' A' ' 83' ' ' THR . 30.6 m -80.78 118.37 22.25 Favored 'General case' 0 C--N 1.317 -0.807 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 173.381 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 72.6 p -119.81 -173.38 2.53 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.319 0.58 . . . . 0.0 111.891 -173.431 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' ASP . . . . . 0.435 ' HB3' HD23 ' A' ' 46' ' ' LEU . 20.8 t70 -56.71 -36.13 69.32 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 114.713 -1.13 . . . . 0.0 111.44 176.412 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 24.8 mt-30 -93.73 7.6 44.19 Favored 'General case' 0 C--O 1.235 0.295 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.342 -177.259 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 112.67 -169.35 12.97 Favored Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.655 177.779 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' THR . . . . . 0.453 ' HA ' ' HA ' ' A' ' 78' ' ' THR . 9.2 m -77.84 127.16 31.96 Favored 'General case' 0 C--N 1.321 -0.652 0 C-N-CA 122.559 0.344 . . . . 0.0 111.636 -177.973 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 97.7 m-85 -132.11 158.44 41.63 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.898 0.38 . . . . 0.0 110.108 174.69 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 33.1 m-70 -118.51 137.62 53.08 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 176.513 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' LEU . . . . . 0.473 HD21 ' N ' ' A' ' 87' ' ' LYS . 1.6 tt -135.41 138.9 43.72 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-O 120.884 0.373 . . . . 0.0 110.571 -173.237 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.473 ' N ' HD21 ' A' ' 86' ' ' LEU . 38.6 ttpt -95.97 123.07 39.41 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 116.09 -0.505 . . . . 0.0 109.963 177.706 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' THR . . . . . 0.473 HG23 HG21 ' A' ' 69' ' ' ILE . 41.1 p -69.4 142.49 53.89 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.902 -0.59 . . . . 0.0 112.033 -174.974 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -76.12 -170.1 29.53 Favored Glycine 0 N--CA 1.444 -0.823 0 CA-C-N 115.692 -0.686 . . . . 0.0 112.833 -178.367 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 6.0 mpt_? -121.03 157.66 29.52 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-O 120.818 0.342 . . . . 0.0 111.487 -172.96 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' ASN . . . . . . . . . . . . . 47.6 m-80 59.15 87.16 0.14 Allowed Pre-proline 0 N--CA 1.469 0.494 0 CA-C-N 114.844 -1.071 . . . . 0.0 113.663 170.438 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' PRO . . . . . 0.53 ' HG2' ' H ' ' A' ' 96' ' ' SER . 92.9 Cg_endo -94.28 -152.35 0.04 OUTLIER 'Trans proline' 0 N--CA 1.456 -0.728 0 C-N-CA 123.447 2.764 . . . . 0.0 110.621 169.166 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 32.5 t30 -99.19 -85.55 0.39 Allowed 'General case' 0 C--N 1.328 -0.332 0 C-N-CA 120.597 -0.441 . . . . 0.0 110.913 178.078 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 23.8 t-20 -100.49 -14.86 18.09 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.991 0.424 . . . . 0.0 110.786 -176.227 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 19.1 m -64.4 -41.49 96.61 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.745 -179.741 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' SER . . . . . 0.53 ' H ' ' HG2' ' A' ' 92' ' ' PRO . 73.5 m 61.52 15.79 7.04 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-O 121.341 0.591 . . . . 0.0 111.91 -178.532 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . 0.419 HH11 ' HD2' ' A' ' 97' ' ' ARG . 53.1 mtt180 -126.35 -164.26 1.31 Allowed 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.414 -0.812 . . . . 0.0 110.565 -175.978 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' ALA . . . . . 0.44 ' HB1' ' HB ' ' A' ' 88' ' ' THR . . . -46.09 139.16 4.68 Favored 'General case' 0 C--N 1.329 -0.325 0 O-C-N 124.019 0.824 . . . . 0.0 111.945 174.971 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 35.3 t80 -117.4 -15.67 10.31 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.759 -179.501 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' MET . . . . . 0.426 ' SD ' HD23 ' A' ' 66' ' ' LEU . 82.7 mtp 58.43 -153.97 0.37 Allowed 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.751 -176.858 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -155.53 32.05 0.63 Allowed Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.259 -0.972 . . . . 0.0 112.904 -179.778 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' ILE . . . . . 0.574 HG21 HG21 ' A' ' 32' ' ' VAL . 2.8 pp -144.21 166.26 12.92 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 178.871 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 38.0 mmt180 -108.49 132.49 53.76 Favored 'General case' 0 C--N 1.317 -0.825 0 N-CA-C 109.278 -0.638 . . . . 0.0 109.278 176.201 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -110.76 132.35 54.27 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 121.335 0.588 . . . . 0.0 111.917 -177.962 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 42.3 m -109.89 165.69 11.51 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.235 -0.893 . . . . 0.0 109.799 175.163 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' ASN . . . . . 0.56 ' HB2' ' HG ' ' A' ' 59' ' ' LEU . 2.2 t-20 -114.6 38.95 2.95 Favored 'General case' 0 C--N 1.313 -1.011 0 CA-C-O 122.013 0.911 . . . . 0.0 108.582 179.713 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 72.6 t60 -81.42 115.88 20.97 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 114.358 -1.292 . . . . 0.0 110.419 -175.262 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' LEU . . . . . 0.681 ' CD2' ' HA ' ' A' ' 25' ' ' ASP . 9.0 mt -55.32 133.9 49.8 Favored 'General case' 0 CA--C 1.515 -0.367 0 CA-C-O 121.489 0.661 . . . . 0.0 110.954 177.588 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 70.7 ttt180 -136.38 130.84 33.4 Favored 'General case' 0 C--N 1.312 -1.058 0 CA-C-N 114.826 -1.079 . . . . 0.0 109.128 -178.353 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' VAL . . . . . 0.529 HG23 ' H ' ' A' ' 112' ' ' ASP . 9.1 p -70.42 131.66 34.05 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-O 121.572 0.701 . . . . 0.0 111.979 -173.891 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' ARG . . . . . . . . . . . . . 28.4 mmm180 -88.19 -15.24 36.53 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.258 -0.883 . . . . 0.0 109.808 177.513 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 112' ' ' ASP . . . . . 0.529 ' H ' HG23 ' A' ' 110' ' ' VAL . 23.1 t0 60.84 29.13 18.81 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 114.795 -1.093 . . . . 0.0 111.737 173.958 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 15.7 t -148.67 -177.48 5.81 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.011 178.138 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 19.2 m -63.53 138.9 22.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-O 121.458 0.647 . . . . 0.0 111.428 -177.243 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -153.35 -55.22 0.11 Allowed 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 177.951 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 5.9 m 63.41 -161.75 0.29 Allowed 'General case' 0 CA--C 1.53 0.191 0 CA-C-N 115.006 -0.997 . . . . 0.0 111.481 172.141 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 48.1 t 64.5 93.74 0.05 OUTLIER 'Isoleucine or valine' 0 C--O 1.234 0.237 0 CA-C-N 115.808 -0.633 . . . . 0.0 111.964 176.597 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 118' ' ' LEU . . . . . 0.441 HD22 ' HG3' ' A' ' 23' ' ' GLN . 84.3 mt -120.4 -49.52 2.26 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.076 175.669 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 105.32 72.25 0.85 Allowed Glycine 0 N--CA 1.445 -0.749 0 C-N-CA 120.589 -0.815 . . . . 0.0 111.69 179.669 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -70.85 95.8 1.19 Allowed 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.014 0.435 . . . . 0.0 110.685 179.511 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 13.9 t -84.8 126.03 33.09 Favored 'General case' 0 N--CA 1.445 -0.719 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 175.777 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 94.7 mt -76.21 125.78 87.4 Favored Pre-proline 0 C--N 1.322 -0.611 0 CA-C-O 121.239 0.542 . . . . 0.0 110.884 -172.061 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -76.63 112.97 3.56 Favored 'Trans proline' 0 N--CA 1.461 -0.433 0 C-N-CA 123.044 2.496 . . . . 0.0 113.448 -172.775 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 90.5 m-85 -130.35 127.19 38.9 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.491 174.075 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.245 0.854 0 CA-C-O 118.357 -0.83 . . . . 0.0 109.815 179.91 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 19.1 t70 . . . . . 0 C--O 1.233 0.188 0 CA-C-O 121.759 0.79 . . . . 0.0 110.395 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 115.64 148.89 9.38 Favored Glycine 0 N--CA 1.446 -0.686 0 CA-C-N 115.344 -0.844 . . . . 0.0 111.36 -177.982 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.617 HG23 ' HB ' ' A' ' 48' ' ' ILE . 17.7 m -102.59 129.73 53.68 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 CA-C-O 121.195 0.522 . . . . 0.0 110.511 178.102 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' GLN . . . . . 0.434 ' HG3' ' O ' ' A' ' 46' ' ' LEU . 61.8 tt0 -110.66 149.73 30.02 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 121.187 0.517 . . . . 0.0 111.298 -175.941 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.517 HG23 HD12 ' A' ' 102' ' ' ILE . 74.3 mt -82.31 117.85 29.0 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 115.361 -0.836 . . . . 0.0 109.93 177.741 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.551 ' HB3' ' HB3' ' A' ' 103' ' ' ARG . 12.6 t70 -79.13 -65.1 1.04 Allowed 'General case' 0 C--N 1.317 -0.837 0 CA-C-N 116.235 -0.439 . . . . 0.0 109.84 178.912 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 5.5 p -150.06 156.53 41.85 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.91 -0.586 . . . . 0.0 111.31 -177.087 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.513 ' CG1' ' HA ' ' A' ' 39' ' ' SER . 56.2 t -116.18 113.73 44.03 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.229 -177.712 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 30.3 m -105.71 153.46 39.94 Favored Pre-proline 0 N--CA 1.445 -0.693 0 CA-C-N 116.512 -0.313 . . . . 0.0 110.569 178.505 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 29.0 Cg_endo -62.7 150.95 86.3 Favored 'Trans proline' 0 C--N 1.346 0.4 0 C-N-CA 123.023 2.482 . . . . 0.0 112.339 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 109.73 3.49 30.34 Favored Glycine 0 N--CA 1.45 -0.371 0 N-CA-C 111.081 -0.808 . . . . 0.0 111.081 -176.029 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.543 ' HB3' ' HA3' ' A' ' 101' ' ' GLY . 50.8 p -125.26 147.95 59.18 Favored Pre-proline 0 N--CA 1.447 -0.609 0 CA-C-N 115.17 -0.515 . . . . 0.0 109.862 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' PRO . . . . . 0.466 ' HD3' ' HA2' ' A' ' 89' ' ' GLY . 16.8 Cg_exo -67.31 -23.37 44.78 Favored 'Trans proline' 0 N--CA 1.463 -0.297 0 C-N-CA 122.031 1.82 . . . . 0.0 110.894 175.645 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -75.29 -7.93 55.28 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.179 -0.918 . . . . 0.0 111.927 -177.616 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.513 ' HA ' ' CG1' ' A' ' 32' ' ' VAL . 73.0 m -53.33 -31.24 43.31 Favored 'General case' 0 CA--C 1.533 0.303 0 N-CA-C 112.671 0.619 . . . . 0.0 112.671 -175.152 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 42.2 mtmt -128.99 21.21 5.84 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.822 0.344 . . . . 0.0 111.307 179.838 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 88.3 t -103.68 -50.95 9.06 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-O 120.931 0.396 . . . . 0.0 110.754 179.341 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -112.3 -179.82 3.78 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.383 0.611 . . . . 0.0 111.589 -179.393 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 43' ' ' THR . . . . . 0.579 ' O ' ' HG ' ' A' ' 46' ' ' LEU . 8.5 m -116.47 138.31 24.3 Favored Pre-proline 0 C--N 1.317 -0.823 0 CA-C-N 115.011 -0.995 . . . . 0.0 109.948 -178.851 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 21.0 Cg_endo -64.34 141.87 76.75 Favored 'Trans proline' 0 N--CA 1.46 -0.499 0 C-N-CA 121.665 1.577 . . . . 0.0 111.171 171.525 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 99.49 -7.78 59.91 Favored Glycine 0 C--N 1.32 -0.32 0 C-N-CA 120.6 -0.809 . . . . 0.0 113.159 -179.083 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.579 ' HG ' ' O ' ' A' ' 43' ' ' THR . 27.9 mt -81.79 163.29 22.48 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 117.077 0.438 . . . . 0.0 110.612 -178.269 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 44.6 t -113.32 126.73 70.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.415 -178.129 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.617 ' HB ' HG23 ' A' ' 27' ' ' VAL . 75.1 mt -84.59 113.01 22.57 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-O 120.862 0.363 . . . . 0.0 110.141 178.931 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 66.6 mt-10 -83.9 -46.45 12.1 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.8 -177.074 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 17.1 p -162.8 152.09 15.29 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.045 0.45 . . . . 0.0 111.875 -178.449 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.529 HG22 ' H ' ' A' ' 52' ' ' ASN . 12.1 mt -103.27 172.46 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 175.524 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 52' ' ' ASN . . . . . 0.843 ' HB3' ' HB3' ' A' ' 76' ' ' ASN . 17.8 p-10 -56.08 101.89 0.06 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.275 0.56 . . . . 0.0 112.243 -176.257 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 74.99 1.78 63.77 Favored Glycine 0 N--CA 1.451 -0.311 0 CA-C-N 115.527 -0.76 . . . . 0.0 113.042 178.836 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 49.9 mtm -138.14 96.69 10.03 Favored Pre-proline 0 C--N 1.325 -0.484 0 O-C-N 122.684 -0.304 . . . . 0.0 110.659 -175.652 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -73.88 133.85 19.0 Favored 'Trans proline' 0 N--CA 1.462 -0.344 0 C-N-CA 122.667 2.244 . . . . 0.0 111.968 178.679 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 17.7 p -110.83 83.8 1.82 Allowed 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.247 0.546 . . . . 0.0 111.675 -175.861 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 22.3 m -91.92 -13.48 31.14 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.249 177.011 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -128.11 173.79 9.79 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 -175.4 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 65.1 mt -78.72 -39.19 37.08 Favored 'General case' 0 N--CA 1.444 -0.77 0 CA-C-O 121.18 0.514 . . . . 0.0 110.059 177.797 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 3.1 m -67.11 -42.45 84.51 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.552 -0.749 . . . . 0.0 111.236 -178.862 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 1.2 p -65.63 -32.42 73.98 Favored 'General case' 0 C--N 1.333 -0.133 0 CA-C-O 120.797 0.332 . . . . 0.0 111.036 179.802 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 86.4 t80 -62.06 -44.52 96.5 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.007 -0.542 . . . . 0.0 109.669 174.318 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' SER . . . . . 0.485 ' O ' ' HG3' ' A' ' 67' ' ' LYS . 5.7 t -68.12 -41.68 81.37 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.293 179.732 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -60.69 -34.71 74.75 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 121.161 0.505 . . . . 0.0 110.859 -179.221 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' ALA . . . . . 0.409 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -73.1 -45.58 56.25 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.119 176.346 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -60.23 -38.24 82.8 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.996 -177.442 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 67' ' ' LYS . . . . . 0.485 ' HG3' ' O ' ' A' ' 63' ' ' SER . 68.6 mttm -65.4 -14.43 60.87 Favored 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 112.297 0.48 . . . . 0.0 112.297 -176.857 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 68.0 p -99.34 -13.14 19.74 Favored 'General case' 0 C--N 1.326 -0.447 0 C-N-CA 120.814 -0.354 . . . . 0.0 111.528 -179.691 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.409 HG12 ' O ' ' A' ' 65' ' ' ALA . 14.5 mm -88.75 144.24 9.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 120.904 0.383 . . . . 0.0 110.413 -176.445 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 54.4 m -104.06 171.0 7.59 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.534 -0.303 . . . . 0.0 111.351 -178.458 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 39.1 t -81.39 117.98 28.36 Favored 'Isoleucine or valine' 0 C--O 1.233 0.224 0 CA-C-O 120.905 0.383 . . . . 0.0 110.539 -178.397 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 102.58 -1.64 49.38 Favored Glycine 0 N--CA 1.448 -0.527 0 N-CA-C 111.463 -0.655 . . . . 0.0 111.463 -177.498 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 56.0 tt0 -87.65 149.08 24.5 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.35 -0.425 . . . . 0.0 109.878 179.527 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 64.3 t -111.13 124.89 68.33 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.782 -177.139 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 25.2 pt -110.07 164.32 6.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.316 -179.553 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 76' ' ' ASN . . . . . 0.843 ' HB3' ' HB3' ' A' ' 52' ' ' ASN . 6.7 t30 -107.53 114.94 29.28 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.043 -177.158 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.549 HG23 HG23 ' A' ' 48' ' ' ILE . 70.6 mt -117.48 115.21 47.93 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-O 120.982 0.42 . . . . 0.0 111.153 -175.877 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 78' ' ' THR . . . . . 0.535 ' HA ' ' HA ' ' A' ' 83' ' ' THR . 97.8 m -93.0 125.4 37.57 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.872 -0.604 . . . . 0.0 109.969 176.237 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.547 HG22 ' HA ' ' A' ' 48' ' ' ILE . 68.0 p -124.19 177.46 5.82 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.237 179.095 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -57.86 -33.7 68.96 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.5 0.667 . . . . 0.0 110.251 174.1 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 81' ' ' GLN . . . . . 0.4 ' CG ' HD22 ' A' ' 46' ' ' LEU . 16.5 mm100 -90.73 17.33 7.78 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-N 115.223 -0.899 . . . . 0.0 111.242 -177.054 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 107.71 178.41 22.31 Favored Glycine 0 N--CA 1.446 -0.687 0 CA-C-N 115.525 -0.761 . . . . 0.0 112.419 175.935 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 83' ' ' THR . . . . . 0.535 ' HA ' ' HA ' ' A' ' 78' ' ' THR . 63.7 m -94.56 131.57 40.16 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-O 120.775 0.322 . . . . 0.0 110.638 179.035 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 91.1 m-85 -125.23 159.75 30.88 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.249 -0.432 . . . . 0.0 109.995 178.198 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 44.9 m80 -106.57 124.31 49.41 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 174.295 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.448 HD13 ' HA ' ' A' ' 86' ' ' LEU . 2.9 mm? -116.69 135.95 53.36 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-O 121.425 0.631 . . . . 0.0 111.811 -174.836 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 87.4 tttt -95.18 135.84 36.26 Favored 'General case' 0 C--N 1.31 -1.133 0 CA-C-N 114.981 -1.009 . . . . 0.0 109.071 174.12 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.622 ' HB ' ' HA ' ' A' ' 98' ' ' ALA . 55.1 p -65.14 143.45 57.86 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 120.925 0.393 . . . . 0.0 111.061 179.511 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.535 ' HA3' ' O ' ' A' ' 99' ' ' TYR . . . . . . . . 0 N--CA 1.439 -1.123 0 CA-C-N 115.647 -0.706 . . . . 0.0 113.411 -175.124 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 98' ' ' ALA . . . . . 0.622 ' HA ' ' HB ' ' A' ' 88' ' ' THR . . . . . . . . 0 N--CA 1.462 0.142 0 CA-C-O 120.77 0.319 . . . . 0.0 111.504 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 99' ' ' TYR . . . . . 0.535 ' O ' ' HA3' ' A' ' 89' ' ' GLY . 2.3 t80 -111.58 95.97 5.82 Favored 'General case' 0 C--N 1.325 -0.466 0 C-N-CA 119.805 -0.758 . . . . 0.0 109.895 -176.829 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 100' ' ' MET . . . . . 0.657 ' HG3' HG12 ' A' ' 102' ' ' ILE . 50.8 tpp -46.95 -54.17 10.69 Favored 'General case' 0 N--CA 1.466 0.35 0 O-C-N 123.746 0.654 . . . . 0.0 112.002 -173.391 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 101' ' ' GLY . . . . . 0.543 ' HA3' ' HB3' ' A' ' 36' ' ' SER . . . 99.31 -2.24 57.64 Favored Glycine 0 C--O 1.226 -0.375 0 C-N-CA 120.504 -0.855 . . . . 0.0 113.185 175.399 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.657 HG12 ' HG3' ' A' ' 100' ' ' MET . 36.7 pt -114.58 140.6 34.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 N-CA-C 109.633 -0.506 . . . . 0.0 109.633 178.14 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 103' ' ' ARG . . . . . 0.551 ' HB3' ' HB3' ' A' ' 30' ' ' ASP . 18.4 ttp180 -69.52 125.37 26.49 Favored 'General case' 0 N--CA 1.446 -0.648 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 178.535 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.417 HG22 ' HA ' ' A' ' 29' ' ' ILE . 0.9 OUTLIER -135.52 142.03 45.35 Favored 'General case' 0 C--N 1.311 -1.104 0 CA-C-N 116.048 -0.523 . . . . 0.0 110.582 -175.465 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 31.9 m -153.39 157.45 39.99 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.05 179.575 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 106' ' ' ASN . . . . . 0.415 ' HA ' ' HA ' ' A' ' 27' ' ' VAL . 25.5 p-10 . . . . . 0 C--N 1.322 -0.623 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.798 -179.653 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 16.8 t70 . . . . . 0 N--CA 1.464 0.251 0 CA-C-O 121.057 0.456 . . . . 0.0 111.743 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.543 ' HA2' ' HA ' ' A' ' 57' ' ' SER . . . 146.68 136.06 2.82 Favored Glycine 0 N--CA 1.444 -0.782 0 N-CA-C 110.932 -0.867 . . . . 0.0 110.932 -174.003 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.532 HG23 ' HB ' ' A' ' 48' ' ' ILE . 30.0 m -80.99 142.38 13.92 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-O 121.272 0.558 . . . . 0.0 110.86 -178.743 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' GLN . . . . . 0.52 ' HG3' ' O ' ' A' ' 46' ' ' LEU . 41.5 tt0 -116.38 155.4 28.57 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.482 -179.634 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.494 HD12 HD12 ' A' ' 102' ' ' ILE . 45.2 mm -81.56 110.51 17.0 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 178.01 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.455 ' HB3' ' CB ' ' A' ' 103' ' ' ARG . 14.4 t70 -70.43 -63.19 1.14 Allowed 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 115.933 -0.576 . . . . 0.0 109.591 179.479 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.425 ' HA ' ' HB3' ' A' ' 44' ' ' PRO . 17.3 m -150.03 148.99 29.71 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.734 -178.937 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.433 ' CG1' ' HA ' ' A' ' 39' ' ' SER . 97.3 t -114.6 114.07 45.55 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 N-CA-C 108.825 -0.805 . . . . 0.0 108.825 173.406 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.501 HG22 ' O ' ' A' ' 101' ' ' GLY . 4.6 m -75.11 153.13 86.43 Favored Pre-proline 0 C--N 1.324 -0.505 0 CA-C-N 116.51 -0.314 . . . . 0.0 111.355 -175.093 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 40.1 Cg_endo -69.77 116.58 4.63 Favored 'Trans proline' 0 N--CA 1.461 -0.404 0 C-N-CA 122.388 2.058 . . . . 0.0 111.033 172.613 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 94.99 -179.56 36.73 Favored Glycine 0 N--CA 1.445 -0.706 0 N-CA-C 110.63 -0.988 . . . . 0.0 110.63 -173.413 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.728 ' HB3' ' HD2' ' A' ' 37' ' ' PRO . 31.9 m 69.16 168.48 0.12 Allowed Pre-proline 0 CA--C 1.54 0.564 0 CA-C-N 117.072 0.436 . . . . 0.0 110.888 -179.052 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' PRO . . . . . 0.728 ' HD2' ' HB3' ' A' ' 36' ' ' SER . 32.8 Cg_endo -65.04 155.11 70.04 Favored 'Trans proline' 0 C--N 1.344 0.329 0 C-N-CA 122.348 2.032 . . . . 0.0 112.747 179.035 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.538 ' HB2' HD21 ' A' ' 86' ' ' LEU . . . 76.68 -12.22 1.07 Allowed 'General case' 0 N--CA 1.471 0.621 0 C-N-CA 123.718 0.807 . . . . 0.0 112.146 177.012 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.433 ' HA ' ' CG1' ' A' ' 32' ' ' VAL . 11.4 t -64.31 -30.87 71.9 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.618 -175.554 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -103.96 16.64 25.85 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.024 -175.687 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.421 ' HB ' HD12 ' A' ' 42' ' ' LEU . 30.8 t -125.29 -54.05 2.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 N-CA-C 111.705 0.261 . . . . 0.0 111.705 -177.672 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.421 HD12 ' HB ' ' A' ' 41' ' ' VAL . 7.6 mp -97.47 176.98 5.67 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.373 0.606 . . . . 0.0 111.909 -173.057 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 43' ' ' THR . . . . . 0.429 ' O ' ' HG ' ' A' ' 46' ' ' LEU . 28.5 m -135.5 134.32 20.98 Favored Pre-proline 0 C--N 1.321 -0.64 0 CA-C-N 115.186 -0.915 . . . . 0.0 109.39 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.425 ' HB3' ' HA ' ' A' ' 31' ' ' SER . 19.3 Cg_endo -62.13 139.46 78.51 Favored 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 122.105 1.87 . . . . 0.0 112.474 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 105.69 -13.11 46.56 Favored Glycine 0 CA--C 1.521 0.408 0 C-N-CA 120.641 -0.79 . . . . 0.0 113.808 179.308 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.52 ' O ' ' HG3' ' A' ' 28' ' ' GLN . 56.9 mt -79.83 163.32 24.49 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 117.481 0.64 . . . . 0.0 111.044 -177.035 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 42.2 t -111.28 137.26 44.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 116.528 -0.306 . . . . 0.0 110.304 178.182 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.532 ' HB ' HG23 ' A' ' 27' ' ' VAL . 61.9 mt -92.62 124.93 45.24 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-O 121.16 0.505 . . . . 0.0 111.23 -178.985 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 11.3 tp10 -77.23 -53.93 7.12 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.624 176.378 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 5.3 p -161.83 156.01 22.1 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.341 -0.845 . . . . 0.0 111.576 -176.184 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.623 HG12 HG12 ' A' ' 77' ' ' ILE . 58.5 mt -123.17 106.86 18.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 115.478 -0.783 . . . . 0.0 109.475 176.396 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 52' ' ' ASN . . . . . 0.406 ' CG ' ' H ' ' A' ' 53' ' ' GLY . 12.0 t-20 61.26 -152.23 0.38 Allowed 'General case' 0 CA--C 1.533 0.307 0 N-CA-C 108.061 -1.089 . . . . 0.0 108.061 -175.425 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.406 ' H ' ' CG ' ' A' ' 52' ' ' ASN . . . -73.61 9.67 7.86 Favored Glycine 0 CA--C 1.525 0.657 0 C-N-CA 120.781 -0.723 . . . . 0.0 113.156 179.533 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 3.3 mpp? -114.96 105.31 53.25 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 120.721 0.296 . . . . 0.0 110.423 178.091 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -73.96 130.42 14.4 Favored 'Trans proline' 0 N--CA 1.458 -0.569 0 C-N-CA 122.04 1.827 . . . . 0.0 111.949 177.615 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.427 ' O ' ' HA2' ' A' ' 26' ' ' GLY . 16.7 p -98.12 75.96 2.34 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 121.249 0.547 . . . . 0.0 111.692 -176.595 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 57' ' ' SER . . . . . 0.543 ' HA ' ' HA2' ' A' ' 26' ' ' GLY . 32.3 t -88.89 -12.2 42.41 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.583 -0.735 . . . . 0.0 109.831 176.033 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 8.9 t-20 -129.32 177.89 6.84 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 115.846 -0.615 . . . . 0.0 109.361 -177.234 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.929 ' HG ' ' HB3' ' A' ' 106' ' ' ASN . 3.8 mt -90.08 -34.2 16.01 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-O 121.051 0.453 . . . . 0.0 109.806 176.661 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 28.5 m -63.7 -38.82 92.53 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.249 176.678 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 21.4 p -64.09 -38.07 89.72 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.484 177.851 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 89.1 t80 -65.48 -43.76 89.24 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.893 -0.594 . . . . 0.0 109.898 177.925 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 8.6 t -64.64 -48.03 76.31 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.455 179.684 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -65.54 -31.1 71.97 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.958 -0.564 . . . . 0.0 111.586 -177.223 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 65' ' ' ALA . . . . . 0.603 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -74.11 -45.04 51.52 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.328 179.6 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 1.6 tt -59.88 -43.8 94.55 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.134 -177.45 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 57.8 mtpt -63.13 -22.65 67.0 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.587 -0.733 . . . . 0.0 112.206 -178.153 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 40.6 p -92.18 -13.58 30.38 Favored 'General case' 0 C--N 1.329 -0.321 0 C-N-CA 120.971 -0.292 . . . . 0.0 111.571 179.465 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.603 HG12 ' O ' ' A' ' 65' ' ' ALA . 44.5 mm -78.14 138.99 19.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.841 0.353 . . . . 0.0 110.105 -179.265 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 6.1 m -88.46 165.7 14.72 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.971 -177.825 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 94.8 t -72.43 133.96 30.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.454 177.112 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 70.95 27.61 71.92 Favored Glycine 0 C--N 1.331 0.257 0 C-N-CA 120.959 -0.639 . . . . 0.0 111.984 179.005 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 9.7 tp10 -99.04 152.52 19.73 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 -177.443 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.407 ' HA ' ' O ' ' A' ' 86' ' ' LEU . 58.9 t -108.24 111.48 36.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.119 -179.459 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.643 HG13 ' HB3' ' A' ' 86' ' ' LEU . 15.0 pt -109.65 154.15 11.2 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.635 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.98 -177.815 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 76' ' ' ASN . . . . . 0.401 ' O ' ' HA ' ' A' ' 51' ' ' ILE . 19.9 t30 -95.17 114.4 26.19 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 115.302 -0.863 . . . . 0.0 110.726 -179.4 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.623 HG12 HG12 ' A' ' 51' ' ' ILE . 50.9 mt -113.19 104.55 17.2 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-O 121.641 0.734 . . . . 0.0 110.015 177.274 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 11.7 m -89.63 124.57 34.69 Favored 'General case' 0 C--N 1.314 -0.952 0 CA-C-N 115.036 -0.984 . . . . 0.0 109.275 178.075 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 60.0 p -117.17 172.33 7.36 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 121.024 0.44 . . . . 0.0 111.172 -178.004 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -56.45 -32.71 65.18 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.245 -0.889 . . . . 0.0 111.444 177.434 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 30.5 mm-40 -104.39 16.48 26.06 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 112.373 0.508 . . . . 0.0 112.373 -175.507 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 136.6 172.66 12.64 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 119.969 -1.11 . . . . 0.0 113.674 175.528 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 19.6 m -99.19 121.53 41.16 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 110.278 -0.267 . . . . 0.0 110.278 -179.876 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -115.63 158.71 22.32 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.189 0.519 . . . . 0.0 111.153 -177.051 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 85' ' ' HIS . . . . . 0.406 ' O ' HG11 ' A' ' 41' ' ' VAL . 23.4 m80 -102.51 125.63 49.3 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.619 -0.719 . . . . 0.0 109.237 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.643 ' HB3' HG13 ' A' ' 75' ' ' ILE . 0.4 OUTLIER -114.16 136.71 52.64 Favored 'General case' 0 C--N 1.315 -0.895 0 CA-C-O 120.978 0.418 . . . . 0.0 110.069 -176.848 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 87' ' ' LYS . . . . . 0.466 ' N ' HD13 ' A' ' 86' ' ' LEU . 78.7 tttt -127.08 115.71 19.59 Favored 'General case' 0 C--N 1.312 -1.046 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 176.45 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.488 HG21 ' HB1' ' A' ' 98' ' ' ALA . 73.4 p -69.35 142.44 54.0 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.766 -0.652 . . . . 0.0 111.812 -173.199 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.9 0 CA-C-N 115.674 -0.693 . . . . 0.0 112.777 -177.701 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 98' ' ' ALA . . . . . 0.488 ' HB1' HG21 ' A' ' 88' ' ' THR . . . . . . . . 0 N--CA 1.461 0.077 0 CA-C-O 121.597 0.713 . . . . 0.0 110.234 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 29.1 t80 -81.82 119.98 24.59 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.64 -0.709 . . . . 0.0 110.306 -172.548 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 26.0 mmt -98.66 151.58 20.56 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.597 -179.698 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 101' ' ' GLY . . . . . 0.501 ' O ' HG22 ' A' ' 33' ' ' VAL . . . -124.36 26.67 5.72 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.45 -0.881 . . . . 0.0 112.555 -179.828 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.494 HD12 HD12 ' A' ' 29' ' ' ILE . 45.6 pt -136.3 162.41 35.82 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-O 121.112 0.482 . . . . 0.0 110.549 179.686 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 103' ' ' ARG . . . . . 0.455 ' CB ' ' HB3' ' A' ' 30' ' ' ASP . 28.5 mmt85 -102.18 146.34 28.11 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 115.487 -0.779 . . . . 0.0 109.421 176.056 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 16.5 p -131.59 154.49 48.8 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.225 0.536 . . . . 0.0 111.61 -179.6 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 15.7 p -122.88 171.09 9.46 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.903 -0.59 . . . . 0.0 109.692 175.539 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 106' ' ' ASN . . . . . 0.929 ' HB3' ' HG ' ' A' ' 59' ' ' LEU . 19.8 p-10 . . . . . 0 C--N 1.321 -0.659 0 N-CA-C 111.812 0.301 . . . . 0.0 111.812 -175.943 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 16.0 t70 . . . . . 0 CA--C 1.528 0.106 0 CA-C-O 121.02 0.438 . . . . 0.0 111.134 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.566 ' HA2' ' HA ' ' A' ' 57' ' ' SER . . . 165.59 172.04 32.52 Favored Glycine 0 N--CA 1.45 -0.367 0 N-CA-C 111.141 -0.784 . . . . 0.0 111.141 -177.795 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.581 HG23 ' HB ' ' A' ' 48' ' ' ILE . 30.7 m -124.0 148.16 28.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-O 121.242 0.544 . . . . 0.0 111.117 179.147 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' GLN . . . . . 0.536 ' HG3' ' O ' ' A' ' 46' ' ' LEU . 60.0 tt0 -128.34 152.06 48.59 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.007 -179.248 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.49 HD11 ' HB2' ' A' ' 46' ' ' LEU . 2.8 pt -86.5 122.16 38.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 121.238 0.542 . . . . 0.0 111.245 179.345 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.615 ' HB3' ' CB ' ' A' ' 103' ' ' ARG . 15.8 t70 -64.44 -61.74 2.03 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 114.699 -1.137 . . . . 0.0 110.828 -179.13 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.475 ' HA ' ' HB3' ' A' ' 44' ' ' PRO . 51.3 p -166.94 161.81 15.3 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.602 -0.726 . . . . 0.0 110.936 -175.582 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.568 ' HA ' HG22 ' A' ' 102' ' ' ILE . 85.2 t -98.81 129.14 49.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.788 177.314 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 47.0 t -92.69 129.67 39.52 Favored Pre-proline 0 C--N 1.322 -0.621 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.006 -179.749 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_exo -56.64 123.74 14.58 Favored 'Trans proline' 0 C--O 1.234 0.291 0 C-N-CA 122.584 2.189 . . . . 0.0 111.929 178.07 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 117.27 18.05 5.54 Favored Glycine 0 N--CA 1.447 -0.594 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.379 -176.152 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.667 ' HB3' ' HA3' ' A' ' 101' ' ' GLY . 54.3 p -121.54 149.79 53.43 Favored Pre-proline 0 C--N 1.322 -0.615 0 CA-C-N 115.58 -0.31 . . . . 0.0 110.801 -177.111 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_endo -71.14 -25.41 22.42 Favored 'Trans proline' 0 N--CA 1.463 -0.271 0 C-N-CA 122.338 2.025 . . . . 0.0 111.949 176.112 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -72.45 -10.62 60.01 Favored 'General case' 0 C--O 1.234 0.245 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.808 -175.611 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.535 ' HA ' HG11 ' A' ' 32' ' ' VAL . 24.7 p -59.16 -28.75 66.88 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.91 -177.85 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 65.0 mttm -110.92 15.06 21.99 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.879 0.371 . . . . 0.0 111.083 179.858 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 53.8 t -101.66 -59.49 3.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-O 120.972 0.415 . . . . 0.0 110.368 178.599 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -130.66 169.28 15.85 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.118 -179.868 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 18.3 p -105.15 138.96 19.68 Favored Pre-proline 0 C--N 1.318 -0.775 0 CA-C-N 115.624 -0.717 . . . . 0.0 110.182 177.705 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.475 ' HB3' ' HA ' ' A' ' 31' ' ' SER . 32.1 Cg_endo -65.18 141.85 71.14 Favored 'Trans proline' 0 N--CA 1.462 -0.373 0 C-N-CA 122.34 2.027 . . . . 0.0 112.31 -179.188 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 110.24 -1.27 29.68 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.8 -177.206 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.536 ' O ' ' HG3' ' A' ' 28' ' ' GLN . 90.1 mt -85.36 163.39 18.58 Favored 'General case' 0 C--N 1.328 -0.351 0 O-C-N 122.459 -0.436 . . . . 0.0 110.84 178.938 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.478 ' HB ' ' HB2' ' A' ' 80' ' ' ASP . 47.0 t -105.44 135.2 44.53 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.264 -179.233 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.581 ' HB ' HG23 ' A' ' 27' ' ' VAL . 69.4 mt -95.5 119.12 43.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 N-CA-C 110.118 -0.327 . . . . 0.0 110.118 -179.733 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 29.8 mt-10 -86.66 -46.15 10.33 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.332 -0.394 . . . . 0.0 111.216 -178.996 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' SER . . . . . 0.567 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 36.1 p -159.69 155.07 25.41 Favored 'General case' 0 C--N 1.325 -0.482 0 C-N-CA 120.326 -0.55 . . . . 0.0 112.028 -177.759 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 55.6 mt -112.93 97.38 5.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 115.372 -0.831 . . . . 0.0 111.003 179.195 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 49.2 t30 58.52 35.4 24.6 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.171 -0.922 . . . . 0.0 111.874 171.291 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 108.95 -27.4 13.01 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.057 178.835 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' MET . . . . . 0.411 ' HA ' ' HD3' ' A' ' 55' ' ' PRO . 71.6 mtm -98.88 106.88 40.35 Favored Pre-proline 0 C--N 1.324 -0.51 0 N-CA-C 109.978 -0.378 . . . . 0.0 109.978 178.723 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.567 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 6.1 Cg_exo -77.61 150.02 27.46 Favored 'Trans proline' 0 N--CA 1.457 -0.633 0 C-N-CA 122.669 2.246 . . . . 0.0 112.095 -177.626 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 19.8 p -123.13 106.72 11.02 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 120.915 0.388 . . . . 0.0 111.399 -178.241 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' SER . . . . . 0.566 ' HA ' ' HA2' ' A' ' 26' ' ' GLY . 15.1 p -99.0 -22.16 15.87 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 121.038 0.447 . . . . 0.0 110.788 178.283 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 58' ' ' ASN . . . . . 0.507 ' HB3' ' OG1' ' A' ' 61' ' ' THR . 17.3 t-20 -117.18 172.23 7.43 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.091 -0.504 . . . . 0.0 109.733 179.264 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 40.3 mt -79.43 -42.6 25.06 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.469 -179.843 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 27.8 m -65.8 -29.49 69.99 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.778 177.652 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' THR . . . . . 0.507 ' OG1' ' HB3' ' A' ' 58' ' ' ASN . 1.5 m -66.56 -37.42 84.93 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.177 0.513 . . . . 0.0 110.009 176.357 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 62.5 t80 -62.91 -45.76 90.98 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.217 -0.902 . . . . 0.0 109.4 174.345 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' SER . . . . . 0.534 ' O ' ' HG2' ' A' ' 67' ' ' LYS . 59.6 m -59.48 -48.77 80.37 Favored 'General case' 0 N--CA 1.444 -0.744 0 CA-C-N 115.243 -0.889 . . . . 0.0 111.695 177.565 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -60.3 -31.08 69.93 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.721 -178.454 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' ALA . . . . . 0.402 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -76.2 -42.87 44.86 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.334 0.588 . . . . 0.0 109.885 176.995 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.433 ' HA ' HD22 ' A' ' 66' ' ' LEU . 0.2 OUTLIER -58.06 -32.96 68.52 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 114.958 -1.019 . . . . 0.0 111.382 178.803 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 67' ' ' LYS . . . . . 0.534 ' HG2' ' O ' ' A' ' 63' ' ' SER . 31.5 mmmt -56.01 -35.14 66.48 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.944 -179.938 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 24.5 p -92.84 -12.74 30.3 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 112.317 0.488 . . . . 0.0 112.317 -174.851 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.596 HG21 HG21 ' A' ' 88' ' ' THR . 46.2 mm -74.47 136.92 24.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 120.888 0.375 . . . . 0.0 110.571 -178.129 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 70' ' ' SER . . . . . 0.406 ' HB2' ' HB2' ' A' ' 73' ' ' GLU . 6.0 m -89.17 161.82 16.26 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.748 -178.452 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 11.4 t -80.34 115.12 22.28 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 N-CA-C 108.672 -0.862 . . . . 0.0 108.672 171.848 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 99.13 9.45 51.6 Favored Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 120.751 -0.738 . . . . 0.0 111.271 -173.364 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.406 ' HB2' ' HB2' ' A' ' 70' ' ' SER . 10.7 tp10 -80.81 149.14 29.7 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 179.054 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 58.3 t -111.01 108.13 24.69 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.989 0 N-CA-C 109.273 -0.639 . . . . 0.0 109.273 176.872 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 17.1 pt -101.08 153.62 4.81 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 CA-C-O 121.44 0.638 . . . . 0.0 111.662 -176.366 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 3.9 t30 -107.4 104.41 13.99 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 114.949 -1.023 . . . . 0.0 109.716 -176.226 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 65.0 mt -106.85 110.7 32.64 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.011 0 CA-C-O 121.317 0.58 . . . . 0.0 111.241 -173.799 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 78' ' ' THR . . . . . 0.479 ' HA ' ' HA ' ' A' ' 83' ' ' THR . 91.8 m -85.19 114.34 22.23 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-N 115.595 -0.73 . . . . 0.0 109.271 174.694 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 50.1 p -103.42 175.66 5.41 Favored 'General case' 0 N--CA 1.443 -0.797 0 CA-C-O 121.061 0.458 . . . . 0.0 110.387 179.85 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 80' ' ' ASP . . . . . 0.478 ' HB2' ' HB ' ' A' ' 47' ' ' VAL . 9.3 t70 -51.71 -33.42 34.25 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.006 -0.997 . . . . 0.0 112.515 179.43 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 5.3 mt-30 -115.29 16.06 16.85 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 112.704 0.631 . . . . 0.0 112.704 -173.27 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 140.58 169.83 11.87 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.237 -0.983 . . . . 0.0 113.073 176.661 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 83' ' ' THR . . . . . 0.479 ' HA ' ' HA ' ' A' ' 78' ' ' THR . 30.0 m -96.59 133.4 41.13 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.794 0.331 . . . . 0.0 111.122 -179.507 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 82.5 m-85 -123.19 157.21 33.52 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.232 177.561 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 3.8 p80 -108.12 120.11 41.4 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.104 0.478 . . . . 0.0 110.273 176.486 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -109.95 146.95 34.35 Favored 'General case' 0 N--CA 1.444 -0.741 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.852 -176.841 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 77.7 tttt -111.82 124.17 51.8 Favored 'General case' 0 C--N 1.32 -0.693 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 174.516 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.596 HG21 HG21 ' A' ' 69' ' ' ILE . 13.4 p -80.69 132.26 35.55 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 120.981 0.419 . . . . 0.0 111.562 -178.648 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.651 0 C-N-CA 120.977 -0.63 . . . . 0.0 111.863 179.253 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.465 0.29 0 CA-C-O 120.957 0.408 . . . . 0.0 111.895 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 11.4 t80 -136.97 134.47 36.71 Favored 'General case' 0 C--N 1.323 -0.561 0 C-N-CA 120.851 -0.339 . . . . 0.0 110.32 -179.751 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 100' ' ' MET . . . . . 0.482 ' O ' ' HB2' ' A' ' 36' ' ' SER . 4.3 mpp? -86.92 -16.25 36.48 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.537 -0.301 . . . . 0.0 111.57 -177.468 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 101' ' ' GLY . . . . . 0.667 ' HA3' ' HB3' ' A' ' 36' ' ' SER . . . 90.58 30.33 12.07 Favored Glycine 0 CA--C 1.519 0.33 0 C-N-CA 120.878 -0.677 . . . . 0.0 112.866 178.931 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.568 HG22 ' HA ' ' A' ' 32' ' ' VAL . 36.6 pt -135.42 167.05 26.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-O 120.908 0.385 . . . . 0.0 110.584 -178.751 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 103' ' ' ARG . . . . . 0.615 ' CB ' ' HB3' ' A' ' 30' ' ' ASP . 36.9 mtt180 -98.53 155.54 17.23 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.666 173.286 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 3.3 m -139.1 149.98 45.16 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 121.092 0.473 . . . . 0.0 110.345 177.269 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 32.0 m -142.02 178.42 7.54 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 115.365 -0.834 . . . . 0.0 109.198 -178.337 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 10.4 p30 . . . . . 0 C--N 1.325 -0.496 0 CA-C-O 120.592 0.234 . . . . 0.0 110.874 177.637 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 14.5 t70 . . . . . 0 N--CA 1.465 0.283 0 CA-C-O 121.155 0.502 . . . . 0.0 110.718 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.487 ' HA2' ' HA ' ' A' ' 57' ' ' SER . . . 156.93 131.8 1.39 Allowed Glycine 0 N--CA 1.449 -0.486 0 CA-C-N 115.745 -0.661 . . . . 0.0 111.694 -179.597 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.467 HG23 ' HB ' ' A' ' 48' ' ' ILE . 31.5 m -72.7 140.15 18.42 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-O 121.218 0.532 . . . . 0.0 111.352 -177.931 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 4.1 tp-100 -107.45 133.76 51.48 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.651 -0.704 . . . . 0.0 111.11 -177.977 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.547 HD12 ' HB2' ' A' ' 46' ' ' LEU . 61.5 mt -73.29 105.87 2.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 CA-C-N 115.637 -0.711 . . . . 0.0 109.815 175.524 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 21.3 t70 -62.91 -65.21 0.72 Allowed 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.254 -178.037 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 12.4 p -156.46 152.53 27.55 Favored 'General case' 0 N--CA 1.444 -0.731 0 CA-C-N 115.21 -0.905 . . . . 0.0 110.724 -179.727 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.814 HG22 HG22 ' A' ' 102' ' ' ILE . 66.8 t -87.74 120.47 36.91 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.542 174.903 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.551 HG22 ' O ' ' A' ' 101' ' ' GLY . 22.7 m -82.05 160.53 62.94 Favored Pre-proline 0 C--N 1.325 -0.492 0 CA-C-N 116.777 -0.192 . . . . 0.0 110.534 -177.307 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_exo -66.86 99.24 0.45 Allowed 'Trans proline' 0 C--O 1.236 0.376 0 C-N-CA 122.584 2.19 . . . . 0.0 112.434 178.981 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.432 ' O ' ' HB2' ' A' ' 39' ' ' SER . . . 145.13 -165.17 27.82 Favored Glycine 0 N--CA 1.447 -0.592 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.566 178.762 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.411 ' OG ' ' HA3' ' A' ' 101' ' ' GLY . 51.0 p 64.37 157.76 0.12 Allowed Pre-proline 0 N--CA 1.473 0.682 0 C-N-CA 124.598 1.159 . . . . 0.0 112.168 179.194 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 2.0 Cg_endo -82.78 -5.53 11.51 Favored 'Trans proline' 0 N--CA 1.46 -0.497 0 C-N-CA 122.984 2.456 . . . . 0.0 112.102 175.756 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -96.68 -0.7 47.99 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.414 -176.575 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.432 ' HB2' ' O ' ' A' ' 35' ' ' GLY . 32.1 t -60.87 -30.78 70.34 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.617 -176.224 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 62.9 tttp -107.39 7.72 29.23 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.929 0.395 . . . . 0.0 110.739 -179.326 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 57.6 t -91.2 -55.69 5.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-O 120.962 0.411 . . . . 0.0 110.129 178.755 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 5.2 mp -108.61 162.04 14.51 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.266 -0.425 . . . . 0.0 109.974 178.061 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 20.5 p -112.42 155.64 43.4 Favored Pre-proline 0 C--N 1.317 -0.84 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 177.403 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -70.0 146.05 57.56 Favored 'Trans proline' 0 N--CA 1.459 -0.548 0 C-N-CA 121.65 1.567 . . . . 0.0 111.464 178.133 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 94.84 12.41 55.52 Favored Glycine 0 CA--C 1.522 0.521 0 C-N-CA 120.615 -0.802 . . . . 0.0 113.618 179.938 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.547 ' HB2' HD12 ' A' ' 29' ' ' ILE . 86.8 mt -98.0 162.03 13.43 Favored 'General case' 0 C--N 1.334 -0.105 0 CA-C-N 117.499 0.65 . . . . 0.0 110.904 177.063 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 59.6 t -110.79 128.31 67.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.781 -177.608 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.467 ' HB ' HG23 ' A' ' 27' ' ' VAL . 76.4 mt -91.66 121.34 42.04 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.396 179.743 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 61.9 mt-10 -82.54 -50.0 9.28 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.702 -179.279 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' SER . . . . . 0.606 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 15.2 p -159.29 153.88 24.32 Favored 'General case' 0 N--CA 1.45 -0.441 0 CA-C-O 121.223 0.535 . . . . 0.0 112.122 -172.757 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 64.2 mt -122.78 101.58 9.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 115.158 -0.928 . . . . 0.0 110.113 176.616 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 35.0 t-20 55.26 67.9 0.95 Allowed 'General case' 0 N--CA 1.464 0.274 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.2 176.443 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 79.59 -46.14 3.02 Favored Glycine 0 CA--C 1.519 0.304 0 CA-C-N 115.559 -0.746 . . . . 0.0 112.944 178.639 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 64.0 mtm -80.96 114.28 47.36 Favored Pre-proline 0 C--N 1.324 -0.511 0 N-CA-C 110.157 -0.312 . . . . 0.0 110.157 -178.838 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.606 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 98.1 Cg_endo -80.02 146.13 17.99 Favored 'Trans proline' 0 N--CA 1.458 -0.597 0 C-N-CA 122.351 2.034 . . . . 0.0 112.573 -176.966 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 22.3 p -110.41 76.26 0.97 Allowed 'General case' 0 N--CA 1.447 -0.618 0 CA-C-O 121.355 0.598 . . . . 0.0 111.062 -179.473 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' SER . . . . . 0.487 ' HA ' ' HA2' ' A' ' 26' ' ' GLY . 16.5 m -84.6 -15.07 46.9 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.175 177.643 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 6.3 t-20 -140.12 175.79 9.3 Favored 'General case' 0 N--CA 1.449 -0.476 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.091 -179.336 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.461 ' HG ' ' OD1' ' A' ' 106' ' ' ASN . 28.6 mt -75.4 -31.35 60.39 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.858 179.508 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 1.5 m -65.39 -43.3 91.07 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.634 178.292 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 7.2 p -64.92 -37.18 86.79 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.055 0.455 . . . . 0.0 110.325 177.083 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' TYR . . . . . 0.436 ' O ' ' HB2' ' A' ' 66' ' ' LEU . 84.4 t80 -62.85 -44.66 95.54 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.771 -0.65 . . . . 0.0 109.857 174.928 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 47.2 m -61.98 -47.16 86.08 Favored 'General case' 0 N--CA 1.446 -0.644 0 CA-C-N 115.286 -0.87 . . . . 0.0 111.997 179.225 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.44 -30.62 71.66 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.187 -178.963 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' ALA . . . . . 0.447 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -77.58 -44.2 29.24 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 121.09 0.471 . . . . 0.0 110.011 177.14 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.436 ' HB2' ' O ' ' A' ' 62' ' ' TYR . 0.2 OUTLIER -57.47 -36.43 71.45 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.358 -0.837 . . . . 0.0 112.166 -176.768 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 19.7 ptmt -71.95 -18.34 62.01 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 120.772 -0.371 . . . . 0.0 111.662 -177.676 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 44.6 p -92.12 -13.49 30.64 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.978 0.418 . . . . 0.0 110.767 -178.876 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.569 HD12 HG21 ' A' ' 75' ' ' ILE . 19.6 mm -83.35 144.91 9.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.356 -0.384 . . . . 0.0 109.998 -178.888 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 13.0 m -105.28 164.38 11.88 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.497 -0.319 . . . . 0.0 110.469 -179.438 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 36.2 t -77.5 119.48 26.21 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 175.349 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 88.63 22.83 38.35 Favored Glycine 0 N--CA 1.45 -0.409 0 N-CA-C 111.046 -0.822 . . . . 0.0 111.046 -175.57 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 5.2 tp10 -99.65 148.54 24.23 Favored 'General case' 0 C--N 1.324 -0.5 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 -179.826 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 52.9 t -104.39 127.95 58.3 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 177.992 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.569 HG21 HD12 ' A' ' 69' ' ' ILE . 16.1 pt -125.61 161.22 30.8 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-O 121.342 0.591 . . . . 0.0 111.903 -176.733 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 7.9 t30 -106.92 105.91 16.18 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.211 -0.904 . . . . 0.0 110.285 -179.069 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 72.6 mt -108.36 114.02 45.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-O 121.528 0.68 . . . . 0.0 110.496 -177.232 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 78' ' ' THR . . . . . 0.462 ' HA ' ' HA ' ' A' ' 83' ' ' THR . 10.2 m -95.15 120.4 35.31 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 115.58 -0.737 . . . . 0.0 109.496 -179.559 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 45.8 p -112.61 175.65 5.35 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.535 -0.302 . . . . 0.0 110.522 -178.924 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 15.9 t70 -59.22 -28.24 66.48 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.016 179.296 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 1.5 mp0 -98.05 16.83 19.93 Favored 'General case' 0 C--O 1.235 0.294 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.887 -177.551 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 121.86 177.72 15.53 Favored Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 120.391 -0.909 . . . . 0.0 113.452 174.901 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 83' ' ' THR . . . . . 0.462 ' HA ' ' HA ' ' A' ' 78' ' ' THR . 3.9 m -90.28 119.53 30.66 Favored 'General case' 0 C--N 1.324 -0.526 0 C-N-CA 122.609 0.364 . . . . 0.0 110.782 -178.708 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -116.69 157.18 25.85 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 121.149 0.499 . . . . 0.0 110.554 178.468 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 43.0 p-80 -111.97 129.98 56.01 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-N 115.614 -0.721 . . . . 0.0 109.223 176.8 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 7.5 tt -126.86 149.78 49.57 Favored 'General case' 0 C--N 1.314 -0.957 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.255 -173.716 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 1.7 tmtp? -124.9 124.14 41.42 Favored 'General case' 0 C--N 1.316 -0.874 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.316 179.778 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.512 HG21 ' HB1' ' A' ' 98' ' ' ALA . 73.5 p -74.73 127.95 34.39 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.592 -177.609 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.445 -0.738 0 C-N-CA 119.564 -1.303 . . . . 0.0 114.457 -177.535 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 98' ' ' ALA . . . . . 0.512 ' HB1' HG21 ' A' ' 88' ' ' THR . . . . . . . . 0 N--CA 1.465 0.31 0 CA-C-O 121.384 0.612 . . . . 0.0 111.788 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 26.8 m-85 -89.23 109.35 20.24 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.457 -178.076 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 61.0 mtm -86.19 -35.27 20.17 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.344 -178.708 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 101' ' ' GLY . . . . . 0.551 ' O ' HG22 ' A' ' 33' ' ' VAL . . . 114.46 -13.74 20.77 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.382 -0.914 . . . . 0.0 113.755 176.443 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.814 HG22 HG22 ' A' ' 32' ' ' VAL . 2.7 pp -120.06 149.37 22.79 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.791 0 O-C-N 122.429 -0.454 . . . . 0.0 110.422 179.79 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -88.91 137.09 32.63 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 176.291 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -109.48 145.58 36.0 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.317 -177.523 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 32.2 p -137.67 168.27 20.02 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.619 -0.719 . . . . 0.0 109.576 176.256 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 106' ' ' ASN . . . . . 0.461 ' OD1' ' HG ' ' A' ' 59' ' ' LEU . 1.0 OUTLIER . . . . . 0 C--N 1.319 -0.758 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.23 -178.423 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.693 ' HA ' ' HB3' ' A' ' 57' ' ' SER . 30.7 t0 . . . . . 0 N--CA 1.469 0.49 0 CA-C-O 122.299 1.047 . . . . 0.0 109.255 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 146.81 148.8 4.83 Favored Glycine 0 N--CA 1.444 -0.779 0 CA-C-N 114.648 -1.16 . . . . 0.0 111.448 176.041 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.458 HG23 ' HB ' ' A' ' 48' ' ' ILE . 29.3 m -122.51 144.1 33.05 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-O 121.018 0.437 . . . . 0.0 111.085 -179.63 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 29.8 tt0 -112.32 153.32 27.4 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 110.004 -0.369 . . . . 0.0 110.004 175.697 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 60.3 mt -78.86 112.55 17.04 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-N 116.314 -0.403 . . . . 0.0 109.921 178.85 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.635 ' HB3' ' HB2' ' A' ' 103' ' ' ARG . 22.5 t70 -64.32 -65.11 0.72 Allowed 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.789 -0.641 . . . . 0.0 109.713 178.559 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 20.7 p -156.8 154.39 29.85 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.166 -0.925 . . . . 0.0 110.586 179.103 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.605 HG23 HG22 ' A' ' 102' ' ' ILE . 13.5 p -91.25 143.67 10.77 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 176.884 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 61.6 t -97.13 114.88 65.42 Favored Pre-proline 0 C--N 1.321 -0.636 0 N-CA-C 110.16 -0.311 . . . . 0.0 110.16 177.708 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -55.19 122.3 11.47 Favored 'Trans proline' 0 C--N 1.346 0.411 0 C-N-CA 123.094 2.529 . . . . 0.0 112.033 178.761 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 122.05 7.92 7.57 Favored Glycine 0 N--CA 1.446 -0.695 0 CA-C-N 115.55 -0.75 . . . . 0.0 111.711 -176.505 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 72.3 p -121.33 150.19 53.69 Favored Pre-proline 0 C--N 1.325 -0.457 0 CA-C-O 120.676 0.274 . . . . 0.0 110.497 -179.013 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -67.59 -16.33 46.7 Favored 'Trans proline' 0 C--N 1.346 0.421 0 C-N-CA 122.639 2.226 . . . . 0.0 112.513 179.648 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.492 ' HA ' HD11 ' A' ' 86' ' ' LEU . . . -60.34 -36.82 78.87 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.568 -177.518 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 22.9 t -64.69 -23.68 67.33 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.617 -176.533 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 63.4 tttp -82.0 -26.03 34.21 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.027 0.441 . . . . 0.0 110.683 -177.505 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 38.6 t -99.22 -55.86 5.67 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.503 -175.978 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 1.9 pp -108.81 -178.02 3.47 Favored 'General case' 0 CA--C 1.516 -0.334 0 CA-C-O 121.527 0.68 . . . . 0.0 111.959 -177.472 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 5.4 p -127.85 143.53 48.04 Favored Pre-proline 0 C--N 1.315 -0.894 0 CA-C-N 114.94 -1.027 . . . . 0.0 110.645 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -66.69 146.19 78.13 Favored 'Trans proline' 0 N--CA 1.462 -0.347 0 C-N-CA 122.39 2.06 . . . . 0.0 111.627 175.643 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 102.55 -7.74 54.03 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.568 -178.105 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 89.1 mt -80.63 163.34 23.7 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.91 0.386 . . . . 0.0 110.772 179.061 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.409 ' O ' ' HA ' ' A' ' 79' ' ' THR . 44.3 t -103.24 137.15 32.68 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 N-CA-C 109.422 -0.585 . . . . 0.0 109.422 176.858 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.458 ' HB ' HG23 ' A' ' 27' ' ' VAL . 63.2 mt -103.15 121.26 54.16 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-O 120.786 0.327 . . . . 0.0 110.603 -179.213 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -82.71 -47.44 12.0 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.018 0.437 . . . . 0.0 110.848 177.501 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' SER . . . . . 0.623 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 6.1 p -152.15 146.28 25.36 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 121.176 0.512 . . . . 0.0 112.244 -174.185 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 47.4 mm -110.89 101.47 12.6 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-N 114.699 -1.137 . . . . 0.0 108.211 173.488 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 4.6 t-20 66.13 -152.15 0.23 Allowed 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 -172.493 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -73.42 7.28 12.64 Favored Glycine 0 CA--C 1.523 0.554 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.656 177.143 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 2.1 mpt? -111.62 102.53 53.57 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 120.812 0.339 . . . . 0.0 110.131 -179.667 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.623 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 44.5 Cg_endo -71.67 124.27 10.11 Favored 'Trans proline' 0 N--CA 1.46 -0.458 0 C-N-CA 122.146 1.897 . . . . 0.0 112.215 179.661 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 16.8 p -92.13 96.89 10.58 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.877 -0.602 . . . . 0.0 111.358 -176.369 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' SER . . . . . 0.693 ' HB3' ' HA ' ' A' ' 25' ' ' ASP . 14.2 m -94.75 -19.65 20.19 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.303 178.857 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 76.2 m-20 -123.92 164.32 19.53 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.13 -178.886 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 84.5 mt -75.81 -30.47 59.05 Favored 'General case' 0 N--CA 1.443 -0.802 0 CA-C-O 121.185 0.517 . . . . 0.0 109.906 177.924 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 9.6 m -69.17 -39.47 78.74 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.611 -0.722 . . . . 0.0 111.152 178.512 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -71.05 -27.9 63.98 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.628 0.251 . . . . 0.0 111.065 179.909 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 87.1 t80 -64.41 -40.72 96.32 Favored 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 173.069 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' SER . . . . . 0.421 ' O ' ' HD3' ' A' ' 67' ' ' LYS . 7.0 t -66.68 -43.33 84.73 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.732 -0.667 . . . . 0.0 109.855 176.596 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.31 -33.21 74.22 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 121.164 0.507 . . . . 0.0 110.793 179.693 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 65' ' ' ALA . . . . . 0.679 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -69.01 -49.3 58.96 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.946 -0.57 . . . . 0.0 109.831 176.357 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.409 ' HA ' HD23 ' A' ' 66' ' ' LEU . 11.2 mt -58.57 -36.47 73.99 Favored 'General case' 0 N--CA 1.448 -0.575 0 CA-C-N 116.002 -0.544 . . . . 0.0 112.129 -177.387 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 67' ' ' LYS . . . . . 0.421 ' HD3' ' O ' ' A' ' 63' ' ' SER . 2.4 mptm? -77.52 -7.04 55.65 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 112.494 0.553 . . . . 0.0 112.494 -179.029 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 9.0 p -110.41 -13.69 14.24 Favored 'General case' 0 C--N 1.323 -0.557 0 C-N-CA 120.807 -0.357 . . . . 0.0 111.785 178.755 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.679 HG12 ' O ' ' A' ' 65' ' ' ALA . 33.4 mm -73.33 148.33 8.91 Favored 'Isoleucine or valine' 0 C--O 1.234 0.237 0 N-CA-C 110.17 -0.307 . . . . 0.0 110.17 177.685 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 70' ' ' SER . . . . . 0.588 ' HB2' ' HB2' ' A' ' 73' ' ' GLU . 3.2 m -84.89 164.63 18.27 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.269 177.675 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 26.7 t -82.2 123.13 37.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 177.965 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 81.9 21.73 60.84 Favored Glycine 0 N--CA 1.448 -0.548 0 C-N-CA 120.574 -0.822 . . . . 0.0 111.549 -178.496 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.588 ' HB2' ' HB2' ' A' ' 70' ' ' SER . 34.4 tt0 -96.5 150.12 20.98 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -178.561 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 48.0 t -100.33 120.44 49.79 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.759 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.285 -177.937 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 27.7 pt -113.86 154.53 15.23 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-N 115.998 -0.547 . . . . 0.0 110.913 -179.47 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 13.0 t30 -93.33 118.18 30.97 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.467 179.676 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 51.3 mt -114.34 103.99 16.22 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.832 0 CA-C-O 121.417 0.627 . . . . 0.0 109.85 178.335 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 15.9 m -90.41 111.17 22.32 Favored 'General case' 0 C--N 1.315 -0.929 0 CA-C-N 115.701 -0.682 . . . . 0.0 109.729 179.225 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.409 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 73.3 p -107.63 171.81 7.18 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.961 0.41 . . . . 0.0 111.692 -176.74 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -52.34 -33.37 42.53 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.159 -0.928 . . . . 0.0 112.826 -178.501 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 17.4 mt-30 -127.0 27.07 6.02 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 112.334 0.494 . . . . 0.0 112.334 -174.101 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 161.32 146.23 4.57 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 119.764 -1.208 . . . . 0.0 114.053 174.788 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 8.8 m -98.57 109.75 22.46 Favored 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 175.113 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 59.7 m-85 -115.36 158.53 22.3 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.806 0.336 . . . . 0.0 110.801 -174.975 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 14.3 p80 -118.9 114.57 22.8 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 121.312 0.577 . . . . 0.0 110.022 174.241 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.492 HD11 ' HA ' ' A' ' 38' ' ' ALA . 3.5 mm? -107.33 148.59 28.84 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-N 115.297 -0.865 . . . . 0.0 111.247 -173.449 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 40.3 ttmt -98.77 130.31 45.22 Favored 'General case' 0 C--N 1.321 -0.664 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 173.941 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.523 HG21 HG21 ' A' ' 69' ' ' ILE . 15.1 p -71.05 129.69 39.61 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-O 121.0 0.429 . . . . 0.0 110.558 176.43 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.434 -1.457 0 N-CA-C 110.936 -0.865 . . . . 0.0 110.936 -179.776 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.467 0.409 0 CA-C-O 121.185 0.517 . . . . 0.0 110.124 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 46.4 t80 -120.83 128.35 52.77 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.411 -167.129 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 46.4 tpp -108.06 120.24 41.76 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 173.868 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -86.52 57.17 4.72 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.788 -0.72 . . . . 0.0 114.124 -170.79 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.605 HG22 HG23 ' A' ' 32' ' ' VAL . 2.6 pp -143.82 148.92 18.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 173.066 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 103' ' ' ARG . . . . . 0.635 ' HB2' ' HB3' ' A' ' 30' ' ' ASP . 43.4 mtp180 -90.87 143.34 26.82 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 116.376 -0.374 . . . . 0.0 110.264 176.749 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 2.1 p -115.82 143.4 45.45 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 121.063 0.458 . . . . 0.0 110.962 178.924 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 37.3 t -136.3 169.57 17.44 Favored 'General case' 0 C--N 1.317 -0.832 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 177.931 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 5.4 p30 . . . . . 0 C--N 1.31 -1.109 0 CA-C-O 122.031 0.919 . . . . 0.0 109.692 178.701 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.404 ' HA ' ' HB3' ' A' ' 57' ' ' SER . 12.1 t70 . . . . . 0 N--CA 1.467 0.404 0 CA-C-O 121.901 0.858 . . . . 0.0 110.12 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 173.7 140.89 3.35 Favored Glycine 0 N--CA 1.446 -0.662 0 CA-C-N 114.792 -1.094 . . . . 0.0 111.266 177.139 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 28.8 m -120.76 146.4 25.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 116.819 0.309 . . . . 0.0 110.319 179.279 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 5.4 pp0? -123.0 159.45 28.33 Favored 'General case' 0 C--N 1.322 -0.594 0 C-N-CA 120.503 -0.479 . . . . 0.0 110.997 -178.722 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 56.5 mt -81.7 106.14 12.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 115.907 -0.588 . . . . 0.0 109.949 179.641 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 14.8 t70 -68.03 -63.78 0.99 Allowed 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 116.054 -0.521 . . . . 0.0 109.88 -177.568 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 2.2 p -155.41 140.47 17.4 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.912 -0.586 . . . . 0.0 111.829 -177.312 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.659 HG22 HG22 ' A' ' 102' ' ' ILE . 96.5 t -86.91 126.45 40.84 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.208 -0.451 . . . . 0.0 109.819 177.89 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 5.6 m -103.38 129.19 25.94 Favored Pre-proline 0 N--CA 1.451 -0.419 0 CA-C-O 121.117 0.484 . . . . 0.0 111.863 -175.659 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -69.3 164.25 34.81 Favored 'Trans proline' 0 C--O 1.235 0.331 0 C-N-CA 122.743 2.295 . . . . 0.0 112.048 176.99 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 98.12 -34.13 5.46 Favored Glycine 0 N--CA 1.449 -0.436 0 N-CA-C 110.661 -0.976 . . . . 0.0 110.661 -174.605 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.414 ' HB2' ' HD2' ' A' ' 37' ' ' PRO . 0.7 OUTLIER -104.84 169.86 6.66 Favored Pre-proline 0 C--N 1.317 -0.835 0 CA-C-N 114.721 -0.74 . . . . 0.0 109.569 175.347 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 37' ' ' PRO . . . . . 0.414 ' HD2' ' HB2' ' A' ' 36' ' ' SER . 42.3 Cg_endo -68.59 -170.26 0.31 Allowed 'Trans proline' 0 CA--C 1.534 0.492 0 C-N-CA 122.264 1.976 . . . . 0.0 112.74 177.827 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 74.53 6.19 4.53 Favored 'General case' 0 N--CA 1.471 0.577 0 C-N-CA 123.575 0.75 . . . . 0.0 112.343 179.733 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 23.1 t -52.35 -62.18 1.8 Allowed 'General case' 0 C--O 1.233 0.232 0 O-C-N 123.448 0.467 . . . . 0.0 110.608 -179.712 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 3.3 tmtp? -111.24 65.37 0.62 Allowed 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 172.328 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.415 HG12 HD12 ' A' ' 42' ' ' LEU . 36.5 t -137.94 -49.77 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.382 -0.826 . . . . 0.0 109.292 175.793 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.415 HD12 HG12 ' A' ' 41' ' ' VAL . 6.3 mp -119.58 171.49 8.33 Favored 'General case' 0 C--O 1.234 0.262 0 CA-C-N 115.625 -0.716 . . . . 0.0 109.88 176.079 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 7.3 p -126.65 146.58 57.47 Favored Pre-proline 0 C--N 1.322 -0.612 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.487 177.474 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 76.9 Cg_endo -76.95 157.03 34.62 Favored 'Trans proline' 0 C--O 1.233 0.246 0 C-N-CA 122.549 2.166 . . . . 0.0 111.975 178.402 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 90.62 11.71 61.84 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.58 -0.819 . . . . 0.0 112.697 179.063 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 64.7 mt -103.47 164.36 11.7 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.809 0.304 . . . . 0.0 110.207 178.042 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 48.1 t -105.98 137.66 35.0 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 N-CA-C 110.315 -0.254 . . . . 0.0 110.315 176.307 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 60.3 mt -95.72 129.78 45.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 121.097 0.475 . . . . 0.0 110.846 -178.411 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 22.3 tt0 -86.66 -56.02 3.6 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.635 -0.711 . . . . 0.0 110.198 175.612 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' SER . . . . . 0.603 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 13.7 p -148.99 152.49 36.4 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.243 -0.889 . . . . 0.0 112.067 -170.556 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 49.7 mm -111.41 85.44 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.043 -0.98 . . . . 0.0 109.742 176.315 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 52' ' ' ASN . . . . . 0.629 ' HB2' ' H ' ' A' ' 76' ' ' ASN . 62.3 t30 54.72 78.88 0.16 Allowed 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 114.843 -1.072 . . . . 0.0 111.949 176.727 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 83.37 -49.06 4.16 Favored Glycine 0 N--CA 1.447 -0.579 0 CA-C-N 115.541 -0.754 . . . . 0.0 112.459 178.976 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 58.4 mtm -85.56 111.78 39.64 Favored Pre-proline 0 C--N 1.324 -0.521 0 N-CA-C 110.387 -0.227 . . . . 0.0 110.387 -179.718 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.603 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 70.6 Cg_endo -75.1 134.04 17.16 Favored 'Trans proline' 0 N--CA 1.458 -0.577 0 C-N-CA 122.054 1.836 . . . . 0.0 111.833 178.921 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 24.5 p -109.34 93.37 4.47 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 121.47 0.652 . . . . 0.0 111.547 -175.497 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' SER . . . . . 0.404 ' HB3' ' HA ' ' A' ' 25' ' ' ASP . 19.3 m -99.74 -14.31 18.92 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 115.229 -0.896 . . . . 0.0 110.155 177.997 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 52.7 m-80 -125.98 159.27 33.1 Favored 'General case' 0 C--N 1.319 -0.74 0 C-N-CA 120.502 -0.479 . . . . 0.0 109.887 -179.268 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 96.6 mt -70.74 -28.29 64.59 Favored 'General case' 0 N--CA 1.44 -0.954 0 CA-C-N 115.734 -0.666 . . . . 0.0 109.387 177.144 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 5.1 m -69.54 -48.92 58.8 Favored 'General case' 0 N--CA 1.448 -0.565 0 CA-C-N 115.254 -0.884 . . . . 0.0 110.629 178.557 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 1.7 p -67.42 -34.37 77.08 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.77 0.319 . . . . 0.0 111.042 178.095 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 25.8 t80 -62.54 -40.11 95.77 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.308 0.575 . . . . 0.0 109.618 175.381 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' SER . . . . . 0.525 ' O ' ' HG3' ' A' ' 67' ' ' LYS . 8.1 t -67.33 -45.13 77.32 Favored 'General case' 0 N--CA 1.452 -0.37 0 CA-C-N 115.459 -0.791 . . . . 0.0 110.36 178.576 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -60.02 -38.35 82.45 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.811 -179.217 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 65' ' ' ALA . . . . . 0.51 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -65.11 -46.0 82.84 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.377 -179.49 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 2.3 tt -58.58 -42.3 87.72 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.756 -0.657 . . . . 0.0 110.544 -179.413 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 67' ' ' LYS . . . . . 0.525 ' HG3' ' O ' ' A' ' 63' ' ' SER . 96.0 mttt -63.33 -23.51 67.45 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.566 -0.743 . . . . 0.0 112.483 -177.102 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 77.5 p -90.9 -13.07 34.3 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.779 0.323 . . . . 0.0 111.35 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.584 HG21 HG21 ' A' ' 88' ' ' THR . 45.9 mm -72.68 136.42 25.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 121.174 0.511 . . . . 0.0 111.265 -176.789 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 70' ' ' SER . . . . . 0.423 ' HB2' ' HB2' ' A' ' 73' ' ' GLU . 4.4 m -82.45 143.99 30.77 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.84 -0.618 . . . . 0.0 109.588 174.957 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 16.8 t -71.72 115.83 12.53 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-N 116.372 -0.377 . . . . 0.0 110.467 -177.074 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 72' ' ' GLY . . . . . 0.441 ' HA2' ' O ' ' A' ' 88' ' ' THR . . . 98.27 4.88 57.31 Favored Glycine 0 N--CA 1.447 -0.63 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.076 179.71 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.423 ' HB2' ' HB2' ' A' ' 70' ' ' SER . 9.0 tp10 -90.68 154.96 19.18 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 120.715 0.293 . . . . 0.0 110.27 -178.087 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 49.0 t -94.32 118.73 40.97 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.582 -178.486 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 32.5 pt -103.01 167.7 2.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.728 178.728 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 76' ' ' ASN . . . . . 0.629 ' H ' ' HB2' ' A' ' 52' ' ' ASN . 43.3 t30 -120.06 106.56 12.11 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.883 -172.283 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 57.6 mt -105.49 109.32 27.41 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.808 0 CA-C-O 121.328 0.585 . . . . 0.0 110.769 -174.675 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 31.1 m -89.72 114.78 26.5 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.494 -0.775 . . . . 0.0 109.72 176.485 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 69.4 p -112.55 174.15 6.03 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 110.29 -0.263 . . . . 0.0 110.29 179.02 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 12.4 t70 -63.27 -30.36 71.51 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.342 178.244 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 48.9 tp60 -95.64 14.57 22.57 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.333 0.587 . . . . 0.0 110.891 -176.345 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 127.36 179.67 15.94 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.53 176.941 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 55.6 m -109.92 129.45 55.65 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-O 120.696 0.284 . . . . 0.0 110.561 -178.329 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 23.5 m-85 -128.43 152.42 48.23 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 -179.607 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 7.8 p-80 -109.24 133.21 53.33 Favored 'General case' 0 C--N 1.322 -0.621 0 C-N-CA 120.62 -0.432 . . . . 0.0 110.011 174.041 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.484 HD23 ' N ' ' A' ' 87' ' ' LYS . 5.5 tt -118.97 137.53 53.43 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 115.918 -0.583 . . . . 0.0 109.734 -175.085 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 87' ' ' LYS . . . . . 0.484 ' N ' HD23 ' A' ' 86' ' ' LEU . 62.1 tttp -98.41 117.05 31.95 Favored 'General case' 0 C--N 1.311 -1.1 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 179.049 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.584 HG21 HG21 ' A' ' 69' ' ' ILE . 16.9 p -66.95 135.41 53.75 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 121.152 0.501 . . . . 0.0 111.154 -176.465 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.439 -1.155 0 N-CA-C 111.004 -0.838 . . . . 0.0 111.004 177.03 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.463 0.2 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 46.4 t80 -112.11 128.8 56.32 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 121.304 0.573 . . . . 0.0 111.887 -171.973 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 20.6 ptp -94.17 141.59 28.38 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.277 174.565 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -84.52 37.15 2.92 Favored Glycine 0 CA--C 1.519 0.319 0 C-N-CA 121.099 -0.572 . . . . 0.0 114.2 -170.836 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.659 HG22 HG22 ' A' ' 32' ' ' VAL . 33.6 pt -138.24 154.06 27.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 117.204 0.502 . . . . 0.0 110.481 178.095 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 55.7 mtp180 -93.66 117.11 29.66 Favored 'General case' 0 C--N 1.318 -0.788 0 N-CA-C 108.336 -0.987 . . . . 0.0 108.336 171.476 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -111.03 137.18 48.99 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-O 121.344 0.592 . . . . 0.0 110.624 -178.017 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 19.1 m -156.97 164.24 38.23 Favored 'General case' 0 C--N 1.31 -1.115 0 CA-C-N 115.543 -0.753 . . . . 0.0 109.462 -178.866 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 14.9 p30 . . . . . 0 C--N 1.319 -0.728 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 169.008 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 17.0 p-10 . . . . . 0 C--O 1.233 0.212 0 CA-C-O 120.969 0.414 . . . . 0.0 111.23 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.414 ' HA2' ' HA ' ' A' ' 57' ' ' SER . . . 134.53 162.94 10.05 Favored Glycine 0 N--CA 1.445 -0.73 0 N-CA-C 111.587 -0.605 . . . . 0.0 111.587 -179.255 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.496 HG23 ' HB ' ' A' ' 48' ' ' ILE . 15.3 m -99.73 134.37 39.32 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-O 121.13 0.491 . . . . 0.0 110.957 176.942 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 6.6 tp60 -97.58 133.5 42.06 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.786 -176.577 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.605 ' HB ' ' H ' ' A' ' 46' ' ' LEU . 36.7 mm -72.65 112.66 8.89 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-N 115.706 -0.679 . . . . 0.0 109.773 173.155 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 16.7 t70 -76.15 -69.75 0.48 Allowed 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.09 -179.289 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 7.7 p -148.96 142.66 25.54 Favored 'General case' 0 N--CA 1.447 -0.594 0 CA-C-O 121.398 0.618 . . . . 0.0 111.553 -178.203 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.524 HG11 ' HA ' ' A' ' 39' ' ' SER . 61.4 t -98.55 119.35 46.43 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-N 114.96 -1.018 . . . . 0.0 109.185 173.945 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.503 HG12 ' O ' ' A' ' 101' ' ' GLY . 10.9 p -91.69 131.85 34.74 Favored Pre-proline 0 C--N 1.324 -0.527 0 CA-C-O 120.776 0.322 . . . . 0.0 110.294 -178.329 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -58.34 147.23 86.11 Favored 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.816 2.344 . . . . 0.0 112.226 -179.469 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 91.64 24.74 25.01 Favored Glycine 0 N--CA 1.448 -0.526 0 C-N-CA 120.759 -0.734 . . . . 0.0 111.82 -177.374 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.544 ' CB ' ' HA3' ' A' ' 101' ' ' GLY . 61.3 p -125.85 157.35 69.32 Favored Pre-proline 0 C--N 1.325 -0.49 0 N-CA-C 110.155 -0.313 . . . . 0.0 110.155 -179.934 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 29.5 Cg_endo -64.07 -30.77 65.97 Favored 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.424 2.082 . . . . 0.0 112.099 176.901 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.531 ' HB2' HD11 ' A' ' 86' ' ' LEU . . . -80.15 -13.52 59.19 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.436 -177.894 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.524 ' HA ' HG11 ' A' ' 32' ' ' VAL . 22.9 t -61.46 -27.95 68.94 Favored 'General case' 0 CA--C 1.532 0.283 0 N-CA-C 112.249 0.463 . . . . 0.0 112.249 -174.468 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 52.2 mtmt -103.18 -13.81 16.63 Favored 'General case' 0 C--N 1.326 -0.44 0 C-N-CA 120.88 -0.328 . . . . 0.0 111.645 -176.334 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.459 ' HB ' HD12 ' A' ' 42' ' ' LEU . 35.3 t -103.92 -38.73 5.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-N 116.565 -0.289 . . . . 0.0 111.519 -174.319 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.459 HD12 ' HB ' ' A' ' 41' ' ' VAL . 6.5 mp -113.8 168.59 9.66 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.131 0.491 . . . . 0.0 111.119 -177.213 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 7.4 p -129.75 156.4 78.93 Favored Pre-proline 0 C--N 1.321 -0.643 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.026 177.17 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -73.56 154.13 49.79 Favored 'Trans proline' 0 N--CA 1.463 -0.273 0 C-N-CA 122.285 1.99 . . . . 0.0 112.368 179.641 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 81.89 28.78 40.73 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.891 -0.671 . . . . 0.0 113.323 177.551 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.641 HD22 ' HB2' ' A' ' 81' ' ' GLN . 53.6 mt -109.2 162.01 14.69 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 117.066 0.433 . . . . 0.0 110.519 176.214 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 62.1 t -110.99 130.2 64.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 N-CA-C 110.035 -0.357 . . . . 0.0 110.035 178.227 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.552 HD11 HD11 ' A' ' 29' ' ' ILE . 76.7 mt -89.66 121.19 39.56 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-O 121.042 0.449 . . . . 0.0 110.894 -179.573 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 10.6 tt0 -77.32 -57.0 4.07 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.403 -0.817 . . . . 0.0 110.06 176.208 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' SER . . . . . 0.628 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 14.7 p -146.8 152.82 39.38 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.194 -0.912 . . . . 0.0 111.988 -172.126 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 42.9 mm -111.91 97.15 5.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.262 176.956 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 52' ' ' ASN . . . . . 0.548 ' HA ' ' HB3' ' A' ' 76' ' ' ASN . 6.5 t30 67.43 -80.78 0.03 OUTLIER 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 114.884 -1.053 . . . . 0.0 111.905 174.262 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -126.73 3.39 7.52 Favored Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 120.581 -0.819 . . . . 0.0 112.103 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 54.5 mtm -131.39 117.61 16.78 Favored Pre-proline 0 C--N 1.325 -0.488 0 N-CA-C 110.393 -0.225 . . . . 0.0 110.393 -177.73 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.628 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 56.0 Cg_endo -71.26 130.8 18.05 Favored 'Trans proline' 0 N--CA 1.463 -0.313 0 C-N-CA 122.325 2.017 . . . . 0.0 112.073 178.72 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 25.6 p -108.63 94.63 5.16 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 121.24 0.543 . . . . 0.0 111.269 -176.47 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' SER . . . . . 0.414 ' HA ' ' HA2' ' A' ' 26' ' ' GLY . 5.5 m -95.55 -12.72 25.27 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.574 -0.739 . . . . 0.0 111.118 -177.828 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 6.9 t-20 -129.58 166.78 19.03 Favored 'General case' 0 C--N 1.321 -0.671 0 C-N-CA 120.597 -0.441 . . . . 0.0 109.92 176.769 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.499 ' HB2' ' HB2' ' A' ' 106' ' ' ASN . 0.4 OUTLIER -77.09 -36.45 55.68 Favored 'General case' 0 C--N 1.311 -1.098 0 CA-C-N 115.495 -0.775 . . . . 0.0 109.617 -179.011 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 6.3 m -68.09 -39.09 82.94 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.702 179.621 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 8.0 p -72.23 -37.43 69.18 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.111 0.481 . . . . 0.0 110.456 177.338 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 72.2 t80 -61.04 -43.72 98.47 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.239 175.232 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 4.7 t -65.3 -38.98 91.89 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.396 178.744 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -65.89 -33.91 76.93 Favored 'General case' 0 C--O 1.232 0.153 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.881 179.709 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -71.98 -45.16 62.03 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.253 178.499 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.412 HD23 ' HA ' ' A' ' 66' ' ' LEU . 8.2 mt -62.09 -33.42 74.4 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.245 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 37.0 ttmt -59.26 -21.98 60.45 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.869 -0.605 . . . . 0.0 111.519 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 61.0 p -100.73 -13.88 18.29 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 112.234 0.457 . . . . 0.0 112.234 -176.543 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 45.6 mm -74.5 138.01 21.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.974 0.416 . . . . 0.0 110.557 -176.773 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 7.8 m -104.03 172.92 6.54 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.611 -174.433 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 61.3 t -82.94 136.42 22.87 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.139 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.532 177.924 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 87.64 -8.59 76.97 Favored Glycine 0 N--CA 1.448 -0.516 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 -177.997 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 23.3 tt0 -80.73 145.77 31.37 Favored 'General case' 0 N--CA 1.445 -0.682 0 CA-C-N 114.916 -0.642 . . . . 0.0 109.679 -177.088 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.466 HG22 ' HG3' ' A' ' 87' ' ' LYS . 39.6 t -113.49 116.85 53.79 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 CA-C-N 115.984 -0.553 . . . . 0.0 109.994 -176.839 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 16.4 pt -106.15 153.49 7.52 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-O 121.481 0.658 . . . . 0.0 111.532 -178.739 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 76' ' ' ASN . . . . . 0.548 ' HB3' ' HA ' ' A' ' 52' ' ' ASN . 15.1 t30 -101.81 104.73 15.51 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 114.881 -1.054 . . . . 0.0 110.219 -178.042 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 52.6 mt -105.1 105.46 18.67 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.883 0 CA-C-O 121.191 0.52 . . . . 0.0 111.001 -174.314 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 78' ' ' THR . . . . . 0.516 ' HA ' ' HA ' ' A' ' 83' ' ' THR . 35.2 m -85.65 120.48 27.13 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.369 175.062 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 70.7 p -121.37 175.12 6.32 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 120.918 0.39 . . . . 0.0 111.148 -178.038 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -62.42 -18.55 61.94 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.544 -0.753 . . . . 0.0 111.101 176.011 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 81' ' ' GLN . . . . . 0.641 ' HB2' HD22 ' A' ' 46' ' ' LEU . 43.5 tp60 -102.84 4.42 37.74 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.147 0.498 . . . . 0.0 111.142 -177.419 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 128.74 175.88 14.23 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 120.57 -0.824 . . . . 0.0 112.623 179.438 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 83' ' ' THR . . . . . 0.516 ' HA ' ' HA ' ' A' ' 78' ' ' THR . 20.0 m -96.78 109.14 21.87 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-O 120.71 0.29 . . . . 0.0 110.819 -178.455 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 -107.1 169.81 8.33 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.973 0.416 . . . . 0.0 110.622 -178.205 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 7.4 p80 -129.57 126.91 39.59 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 175.96 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.531 HD11 ' HB2' ' A' ' 38' ' ' ALA . 4.2 tt -117.89 138.71 51.94 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.113 0.482 . . . . 0.0 110.512 -174.002 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 87' ' ' LYS . . . . . 0.494 ' N ' HD23 ' A' ' 86' ' ' LEU . 60.5 tttp -116.71 121.02 40.43 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.535 -0.757 . . . . 0.0 109.354 179.831 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 29.6 p -71.57 139.42 49.41 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 120.733 0.302 . . . . 0.0 111.072 -178.844 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.511 -0.198 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.558 -174.744 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.457 -0.083 0 CA-C-O 120.573 0.225 . . . . 0.0 111.018 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 4.1 t80 -121.28 126.97 50.84 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 109.522 -0.548 . . . . 0.0 109.522 179.451 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 100' ' ' MET . . . . . 0.429 ' O ' ' HB2' ' A' ' 36' ' ' SER . 63.4 mtm -105.94 -33.22 8.0 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.461 -0.336 . . . . 0.0 111.135 -175.819 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 101' ' ' GLY . . . . . 0.544 ' HA3' ' CB ' ' A' ' 36' ' ' SER . . . 94.6 27.1 11.97 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.582 -0.818 . . . . 0.0 111.907 179.228 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.473 HG22 ' HA ' ' A' ' 32' ' ' VAL . 2.7 pp -136.01 150.43 28.21 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 178.339 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 4.1 mpt_? -104.18 139.44 39.22 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 175.566 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.9 p -117.63 161.44 19.64 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.8 179.156 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 66.8 m -143.95 161.95 37.41 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.334 175.857 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 106' ' ' ASN . . . . . 0.499 ' HB2' ' HB2' ' A' ' 59' ' ' LEU . 66.6 t30 . . . . . 0 C--N 1.309 -1.178 0 N-CA-C 107.563 -1.273 . . . . 0.0 107.563 174.286 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 21.2 t70 . . . . . 0 CA--C 1.515 -0.39 0 CA-C-O 121.232 0.539 . . . . 0.0 110.726 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.569 ' HA2' ' HA ' ' A' ' 57' ' ' SER . . . 171.27 164.43 26.94 Favored Glycine 0 N--CA 1.442 -0.913 0 CA-C-N 115.263 -0.88 . . . . 0.0 111.188 -178.829 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 33.9 m -109.15 150.8 11.68 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.866 0 CA-C-O 120.768 0.318 . . . . 0.0 110.368 178.076 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 5.0 pp0? -117.82 163.03 17.14 Favored 'General case' 0 C--N 1.32 -0.702 0 C-N-CA 120.751 -0.379 . . . . 0.0 110.45 176.937 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.565 HD12 ' HB2' ' A' ' 46' ' ' LEU . 56.6 mt -78.73 107.44 11.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-O 120.959 0.409 . . . . 0.0 110.273 -178.409 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.632 ' HB3' ' HB2' ' A' ' 103' ' ' ARG . 14.9 t70 -65.67 -70.6 0.23 Allowed 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 115.185 -0.916 . . . . 0.0 110.638 -176.068 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.474 ' HA ' ' HB3' ' A' ' 44' ' ' PRO . 4.2 p -148.59 144.87 27.54 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.596 -0.729 . . . . 0.0 111.128 -178.566 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.546 ' HA ' HG22 ' A' ' 102' ' ' ILE . 96.2 t -94.86 126.54 47.26 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.207 178.606 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 48.4 t -109.0 123.87 35.76 Favored Pre-proline 0 C--N 1.327 -0.379 0 CA-C-N 116.461 -0.336 . . . . 0.0 110.631 179.767 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -58.97 154.39 45.08 Favored 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.972 2.448 . . . . 0.0 112.175 178.1 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 104.26 6.91 41.38 Favored Glycine 0 N--CA 1.45 -0.4 0 N-CA-C 110.849 -0.9 . . . . 0.0 110.849 -175.397 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.539 ' CB ' ' HA3' ' A' ' 101' ' ' GLY . 60.4 p -130.16 159.17 71.64 Favored Pre-proline 0 C--N 1.322 -0.623 0 CA-C-N 115.185 -0.508 . . . . 0.0 110.054 -179.457 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_exo -66.89 -23.2 47.75 Favored 'Trans proline' 0 N--CA 1.463 -0.27 0 C-N-CA 122.359 2.039 . . . . 0.0 111.669 176.142 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -73.56 -16.77 61.25 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.914 -0.585 . . . . 0.0 111.365 -177.5 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 14.2 m -65.27 -16.84 63.99 Favored 'General case' 0 C--O 1.233 0.192 0 CA-C-O 120.904 0.383 . . . . 0.0 111.051 -179.708 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 35.5 ttpt -116.89 11.42 14.4 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.1 -177.769 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 58.5 t -126.96 -47.99 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.377 -177.427 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 87.1 mt -108.22 161.3 15.12 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.245 0.545 . . . . 0.0 111.412 -175.644 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 15.4 p -126.82 146.38 57.08 Favored Pre-proline 0 C--N 1.319 -0.746 0 CA-C-N 115.022 -0.99 . . . . 0.0 109.844 176.803 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.474 ' HB3' ' HA ' ' A' ' 31' ' ' SER . 53.8 Cg_endo -70.47 149.96 63.18 Favored 'Trans proline' 0 N--CA 1.461 -0.384 0 C-N-CA 122.09 1.86 . . . . 0.0 111.937 -178.064 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 99.23 -13.54 61.63 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.832 179.65 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.565 ' HB2' HD12 ' A' ' 29' ' ' ILE . 82.0 mt -72.92 164.45 26.63 Favored 'General case' 0 C--N 1.327 -0.386 0 O-C-N 122.672 -0.31 . . . . 0.0 110.684 179.694 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 42.1 t -115.28 139.95 39.12 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.191 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 65.0 mt -97.83 125.87 50.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 121.181 0.515 . . . . 0.0 110.347 -179.482 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -91.02 -42.52 10.48 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-N 115.834 -0.621 . . . . 0.0 109.894 179.955 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 37.0 p -159.37 153.77 24.0 Favored 'General case' 0 CA--C 1.512 -0.51 0 CA-C-O 120.976 0.417 . . . . 0.0 110.621 178.825 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.793 HG13 HG12 ' A' ' 77' ' ' ILE . 10.8 tt -127.4 123.72 62.33 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 CA-C-N 115.582 -0.735 . . . . 0.0 109.126 174.821 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 2.3 t-20 58.61 -151.85 0.41 Allowed 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 108.922 -0.769 . . . . 0.0 108.922 -177.528 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -81.0 12.7 35.33 Favored Glycine 0 CA--C 1.525 0.681 0 C-N-CA 120.394 -0.908 . . . . 0.0 113.002 177.739 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 2.6 mpp? -124.43 107.26 29.76 Favored Pre-proline 0 C--N 1.333 -0.121 0 CA-C-N 117.227 0.513 . . . . 0.0 111.154 -178.183 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -70.34 121.22 7.79 Favored 'Trans proline' 0 N--CA 1.458 -0.598 0 C-N-CA 121.691 1.594 . . . . 0.0 111.457 174.297 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.402 ' O ' ' HA2' ' A' ' 26' ' ' GLY . 20.3 p -97.92 110.17 22.79 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.884 -174.047 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 57' ' ' SER . . . . . 0.569 ' HA ' ' HA2' ' A' ' 26' ' ' GLY . 15.5 m -98.2 -18.96 18.16 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.921 -0.582 . . . . 0.0 111.118 179.831 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 58' ' ' ASN . . . . . 0.412 ' HB2' ' H ' ' A' ' 61' ' ' THR . 5.3 m120 -115.47 166.33 12.01 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 -179.127 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 39.2 mt -75.8 -34.45 60.17 Favored 'General case' 0 N--CA 1.447 -0.582 0 CA-C-O 121.035 0.445 . . . . 0.0 109.955 171.93 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 7.9 m -72.22 -40.5 67.76 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.646 -0.706 . . . . 0.0 111.34 -178.514 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' THR . . . . . 0.412 ' H ' ' HB2' ' A' ' 58' ' ' ASN . 3.2 p -67.76 -32.16 72.56 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.006 0.431 . . . . 0.0 110.425 177.443 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 51.3 t80 -66.74 -39.78 88.06 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.313 0.577 . . . . 0.0 109.497 173.66 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 69.0 m -63.62 -47.52 81.05 Favored 'General case' 0 N--CA 1.447 -0.6 0 CA-C-N 115.485 -0.779 . . . . 0.0 111.348 177.889 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.42 -35.71 78.31 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.619 177.966 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' ALA . . . . . 0.526 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -68.17 -41.9 80.82 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.474 178.835 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 6.7 mt -62.32 -33.88 75.54 Favored 'General case' 0 N--CA 1.447 -0.6 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.136 178.273 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 40.4 ttmt -60.16 -37.26 79.61 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.868 179.161 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.6 p -82.26 -11.81 58.43 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 112.345 0.498 . . . . 0.0 112.345 -179.067 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.526 HG12 ' O ' ' A' ' 65' ' ' ALA . 45.8 mm -79.98 137.68 21.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 N-CA-C 110.055 -0.35 . . . . 0.0 110.055 178.313 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 19.1 t -103.36 176.91 4.99 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 110.108 -0.33 . . . . 0.0 110.108 -179.886 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 46.3 t -90.52 125.92 43.33 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.74 -177.653 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 99.93 -0.32 56.32 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.931 -0.652 . . . . 0.0 111.945 179.419 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 35.4 tt0 -90.24 147.31 23.62 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.82 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 39.9 t -106.01 104.34 16.85 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.116 -178.614 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.5 HD12 HD11 ' A' ' 51' ' ' ILE . 15.8 pt -96.08 154.7 3.5 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 121.363 0.602 . . . . 0.0 111.296 -175.916 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 5.5 t30 -91.13 136.6 32.98 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.631 -179.117 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.793 HG12 HG13 ' A' ' 51' ' ' ILE . 60.1 mt -135.46 108.79 9.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-O 121.057 0.456 . . . . 0.0 110.232 178.485 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 4.3 m -84.85 130.17 34.7 Favored 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 176.371 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 76.0 p -126.49 175.77 7.66 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.267 0.556 . . . . 0.0 111.978 -176.204 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 25.2 t70 -49.76 -42.82 47.32 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 114.625 -1.17 . . . . 0.0 112.74 -178.756 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 22.9 mt-30 -117.93 23.67 11.51 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 112.555 0.576 . . . . 0.0 112.555 -172.291 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 152.31 -178.63 29.4 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 119.771 -1.204 . . . . 0.0 112.929 175.828 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 22.2 m -114.74 126.84 55.32 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-O 120.892 0.377 . . . . 0.0 110.129 179.376 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 99.5 m-85 -121.02 161.33 21.83 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 120.938 0.399 . . . . 0.0 110.696 -178.348 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 44.6 m-70 -125.37 123.93 40.42 Favored 'General case' 0 C--N 1.321 -0.661 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 176.181 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.541 HD23 HD12 ' A' ' 77' ' ' ILE . 3.8 mm? -113.72 140.92 47.86 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.395 -173.886 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -105.14 124.35 49.38 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 115.63 -0.714 . . . . 0.0 109.488 177.467 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 17.8 p -69.92 132.02 45.32 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-O 121.379 0.609 . . . . 0.0 112.038 -176.66 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.445 -0.757 0 CA-C-N 115.433 -0.803 . . . . 0.0 111.418 177.41 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.239 0 CA-C-O 121.743 0.782 . . . . 0.0 109.681 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 80.3 t80 -96.36 102.04 13.77 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.611 -170.541 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 81.1 mtp -72.31 -43.22 64.49 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.16 176.469 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 101' ' ' GLY . . . . . 0.539 ' HA3' ' CB ' ' A' ' 36' ' ' SER . . . 101.56 -12.59 58.18 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.802 176.477 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.546 HG22 ' HA ' ' A' ' 32' ' ' VAL . 2.7 pp -114.89 144.73 21.81 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-O 120.851 0.358 . . . . 0.0 110.322 179.241 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 103' ' ' ARG . . . . . 0.632 ' HB2' ' HB3' ' A' ' 30' ' ' ASP . 39.3 mtp180 -84.46 147.58 27.01 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.179 178.321 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 14.2 p -124.63 122.1 36.58 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.555 177.331 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 19.3 m -127.59 154.84 44.73 Favored 'General case' 0 C--N 1.318 -0.799 0 N-CA-C 109.165 -0.68 . . . . 0.0 109.165 178.35 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 16.0 p30 . . . . . 0 C--N 1.314 -0.958 0 CA-C-O 121.09 0.472 . . . . 0.0 110.018 177.195 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.503 ' N ' ' HG ' ' A' ' 57' ' ' SER . 18.6 t70 . . . . . 0 C--O 1.234 0.241 0 CA-C-O 121.309 0.576 . . . . 0.0 109.628 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.507 ' HA2' ' HA ' ' A' ' 57' ' ' SER . . . 165.21 165.58 22.76 Favored Glycine 0 N--CA 1.447 -0.6 0 N-CA-C 110.574 -1.011 . . . . 0.0 110.574 -177.851 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.514 HG23 ' HB ' ' A' ' 48' ' ' ILE . 33.6 m -122.54 151.06 26.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 117.44 0.62 . . . . 0.0 110.739 178.675 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' GLN . . . . . 0.516 ' OE1' ' HB2' ' A' ' 105' ' ' SER . 0.0 OUTLIER -128.19 163.9 23.68 Favored 'General case' 0 C--N 1.324 -0.531 0 C-N-CA 120.703 -0.399 . . . . 0.0 110.767 177.139 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 57.2 mt -90.96 115.7 30.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.951 -176.165 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.753 ' HB3' ' HB2' ' A' ' 103' ' ' ARG . 23.7 t70 -66.65 -58.96 4.06 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.417 0.627 . . . . 0.0 109.873 176.005 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.467 ' HA ' ' HB3' ' A' ' 44' ' ' PRO . 12.4 p -165.19 162.05 19.77 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.22 -0.9 . . . . 0.0 110.204 -178.938 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.622 HG11 ' HA ' ' A' ' 39' ' ' SER . 45.3 t -98.24 138.25 23.45 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 N-CA-C 109.527 -0.545 . . . . 0.0 109.527 177.565 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.599 HG12 ' H ' ' A' ' 35' ' ' GLY . 45.7 t -85.89 118.9 71.35 Favored Pre-proline 0 C--N 1.323 -0.563 0 CA-C-N 116.453 -0.339 . . . . 0.0 110.809 -176.351 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -65.46 -12.94 37.29 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.866 2.377 . . . . 0.0 112.825 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.599 ' H ' HG12 ' A' ' 33' ' ' VAL . . . -95.19 23.02 35.34 Favored Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 120.897 -0.668 . . . . 0.0 111.545 177.935 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.676 ' HB3' ' HD2' ' A' ' 37' ' ' PRO . 54.1 m -149.36 170.9 6.95 Favored Pre-proline 0 C--N 1.325 -0.458 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.033 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 37' ' ' PRO . . . . . 0.676 ' HD2' ' HB3' ' A' ' 36' ' ' SER . 56.4 Cg_endo -71.13 -168.26 0.32 Allowed 'Trans proline' 0 C--N 1.349 0.555 0 C-N-CA 122.331 2.021 . . . . 0.0 112.443 177.199 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.472 ' HB1' HD13 ' A' ' 42' ' ' LEU . . . 68.78 -9.71 0.54 Allowed 'General case' 0 N--CA 1.47 0.567 0 N-CA-C 113.017 0.747 . . . . 0.0 113.017 176.63 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.622 ' HA ' HG11 ' A' ' 32' ' ' VAL . 27.8 t -70.08 -6.84 36.66 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.741 0.305 . . . . 0.0 111.293 -177.75 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -118.79 12.68 13.03 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 121.003 0.43 . . . . 0.0 110.391 177.103 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.478 ' HB ' HD12 ' A' ' 42' ' ' LEU . 46.8 t -120.76 -55.6 3.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.234 -176.987 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.478 HD12 ' HB ' ' A' ' 41' ' ' VAL . 6.0 mp -96.1 171.49 8.57 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.036 0.446 . . . . 0.0 111.145 -177.159 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 49.1 m -122.72 127.25 25.84 Favored Pre-proline 0 C--N 1.321 -0.639 0 CA-C-N 115.741 -0.663 . . . . 0.0 109.736 176.834 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.467 ' HB3' ' HA ' ' A' ' 31' ' ' SER . 41.7 Cg_endo -68.3 149.02 75.32 Favored 'Trans proline' 0 N--CA 1.464 -0.245 0 C-N-CA 122.294 1.996 . . . . 0.0 111.939 179.123 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 99.05 -2.93 58.23 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.541 -0.838 . . . . 0.0 112.634 -179.307 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 81.0 mt -90.33 164.2 14.44 Favored 'General case' 0 C--N 1.328 -0.366 0 O-C-N 122.583 -0.363 . . . . 0.0 110.765 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 48.0 t -102.45 139.94 22.15 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 N-CA-C 110.022 -0.362 . . . . 0.0 110.022 178.255 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.514 ' HB ' HG23 ' A' ' 27' ' ' VAL . 66.1 mt -93.2 121.71 44.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 121.127 0.489 . . . . 0.0 110.631 -177.601 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 3.4 tm-20 -81.96 -50.8 8.73 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 115.594 -0.73 . . . . 0.0 109.501 178.284 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' SER . . . . . 0.572 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 13.6 p -163.94 159.22 20.63 Favored 'General case' 0 C--O 1.236 0.394 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.97 -175.638 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.412 ' HA ' ' O ' ' A' ' 76' ' ' ASN . 61.1 mt -115.96 107.77 23.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 115.556 -0.747 . . . . 0.0 110.545 176.259 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 52' ' ' ASN . . . . . 0.595 ' HA ' ' HB3' ' A' ' 76' ' ' ASN . 15.1 t-20 66.86 -81.66 0.03 OUTLIER 'General case' 0 N--CA 1.468 0.464 0 CA-C-N 115.43 -0.805 . . . . 0.0 110.759 178.816 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -133.46 -5.33 2.95 Favored Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 120.882 -0.675 . . . . 0.0 111.782 177.161 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 60.6 mtm -111.74 115.18 51.47 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 120.743 0.306 . . . . 0.0 110.429 -177.161 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.572 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 72.9 Cg_endo -78.99 132.45 10.55 Favored 'Trans proline' 0 N--CA 1.454 -0.806 0 C-N-CA 122.273 1.982 . . . . 0.0 112.006 177.428 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 3.3 p -95.06 103.43 15.28 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 121.008 0.432 . . . . 0.0 111.69 -177.841 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' SER . . . . . 0.507 ' HA ' ' HA2' ' A' ' 26' ' ' GLY . 32.7 t -93.48 -24.27 18.07 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.747 -0.661 . . . . 0.0 110.482 179.41 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 8.4 t-20 -133.18 176.08 8.82 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.519 -0.31 . . . . 0.0 110.385 -179.111 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 97.6 mt -81.47 -33.06 32.23 Favored 'General case' 0 N--CA 1.44 -0.965 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.64 -179.003 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 2.6 m -65.08 -43.68 91.38 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.928 0.395 . . . . 0.0 110.841 179.451 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 12.7 t -67.28 -26.7 66.68 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.103 179.881 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 32.6 t80 -68.16 -47.66 67.42 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.9 -0.591 . . . . 0.0 109.989 173.279 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 8.5 t -60.76 -39.93 90.6 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.486 -0.779 . . . . 0.0 110.358 179.675 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -69.7 -31.97 70.3 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.175 178.003 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 65' ' ' ALA . . . . . 0.627 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -69.24 -46.64 66.85 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.346 178.217 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 6.6 tp -58.08 -38.45 76.4 Favored 'General case' 0 N--CA 1.447 -0.617 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.338 179.164 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 40.4 ttmt -57.66 -38.49 75.17 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.004 -0.998 . . . . 0.0 111.709 178.426 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 17.7 p -86.87 -13.17 45.66 Favored 'General case' 0 C--N 1.329 -0.31 0 N-CA-C 112.615 0.598 . . . . 0.0 112.615 -175.842 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.627 HG12 ' O ' ' A' ' 65' ' ' ALA . 44.4 mm -76.23 140.84 16.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 C-N-CA 120.906 -0.317 . . . . 0.0 110.167 -179.537 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 70' ' ' SER . . . . . 0.45 ' HB2' ' HB2' ' A' ' 73' ' ' GLU . 4.8 m -94.03 161.26 14.36 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.709 -0.223 . . . . 0.0 110.764 179.357 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 2.2 t -82.63 118.37 30.22 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 177.01 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 97.08 8.71 56.56 Favored Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 120.501 -0.857 . . . . 0.0 111.129 -175.477 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.45 ' HB2' ' HB2' ' A' ' 70' ' ' SER . 30.9 tt0 -89.62 145.48 25.22 Favored 'General case' 0 N--CA 1.45 -0.441 0 N-CA-C 109.19 -0.671 . . . . 0.0 109.19 179.563 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 44.4 t -96.2 112.53 28.58 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.022 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.083 -178.865 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 30.8 pt -109.2 154.42 10.62 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-O 121.198 0.523 . . . . 0.0 110.986 -177.926 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 76' ' ' ASN . . . . . 0.595 ' HB3' ' HA ' ' A' ' 52' ' ' ASN . 35.5 t-20 -109.63 113.11 25.62 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-N 115.127 -0.942 . . . . 0.0 109.901 -176.617 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.446 HD12 HD21 ' A' ' 86' ' ' LEU . 71.7 mt -104.16 103.73 15.69 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.035 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 175.878 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 30.7 m -88.99 120.14 30.14 Favored 'General case' 0 C--N 1.312 -1.03 0 CA-C-N 115.387 -0.824 . . . . 0.0 109.524 -179.782 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 73.7 p -106.71 171.35 7.41 Favored 'General case' 0 C--N 1.322 -0.606 0 N-CA-C 110.241 -0.281 . . . . 0.0 110.241 179.705 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 19.8 t70 -62.06 -22.56 65.86 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.047 0.451 . . . . 0.0 111.1 -179.819 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 81.1 mt-30 -117.0 17.73 14.85 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 112.548 0.573 . . . . 0.0 112.548 -172.761 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 151.07 163.99 11.74 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 119.909 -1.138 . . . . 0.0 113.748 177.788 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 4.2 m -107.33 137.18 45.86 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 110.056 -0.35 . . . . 0.0 110.056 -179.57 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 26.5 m-85 -134.87 147.39 49.86 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.717 0.294 . . . . 0.0 110.394 177.9 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 4.2 p-80 -130.66 122.52 27.53 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 121.134 0.493 . . . . 0.0 110.086 174.095 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.458 HD23 ' N ' ' A' ' 86' ' ' LEU . 0.9 OUTLIER -130.76 156.87 44.23 Favored 'General case' 0 N--CA 1.444 -0.728 0 CA-C-N 115.571 -0.741 . . . . 0.0 111.115 -173.503 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 87' ' ' LYS . . . . . 0.452 ' HB3' ' HE2' ' A' ' 87' ' ' LYS . 32.4 ttpt -91.94 132.88 36.17 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.03 177.359 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 32.3 p -73.26 143.44 47.05 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.524 179.688 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.464 0 C-N-CA 120.911 -0.662 . . . . 0.0 112.226 177.87 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.455 -0.191 0 CA-C-O 120.798 0.333 . . . . 0.0 111.148 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 6.0 t80 -146.17 134.4 21.72 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 178.493 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -94.08 -31.34 14.24 Favored 'General case' 0 C--N 1.326 -0.45 0 C-N-CA 121.2 -0.2 . . . . 0.0 110.933 179.508 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 102.52 45.17 1.71 Allowed Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.285 -0.959 . . . . 0.0 113.811 173.3 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.468 HG22 HG13 ' A' ' 32' ' ' VAL . 32.6 pt -137.69 159.07 34.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-N 117.278 0.539 . . . . 0.0 110.345 175.058 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 103' ' ' ARG . . . . . 0.753 ' HB2' ' HB3' ' A' ' 30' ' ' ASP . 97.9 mtt180 -88.93 130.46 35.43 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 109.53 -0.544 . . . . 0.0 109.53 174.444 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 2.6 p -110.62 122.86 48.81 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-O 121.204 0.526 . . . . 0.0 111.022 178.803 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.516 ' HB2' ' OE1' ' A' ' 28' ' ' GLN . 45.7 m -116.23 163.55 15.82 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.79 178.162 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 10.3 t30 . . . . . 0 C--N 1.317 -0.825 0 CA-C-O 121.072 0.463 . . . . 0.0 109.798 -178.806 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 2.1 p30 . . . . . 0 C--O 1.231 0.109 0 CA-C-O 121.847 0.832 . . . . 0.0 109.751 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 136.2 157.34 7.77 Favored Glycine 0 N--CA 1.442 -0.949 0 CA-C-N 114.91 -1.041 . . . . 0.0 110.824 -176.813 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.64 HG21 ' CD2' ' A' ' 62' ' ' TYR . 35.7 m -114.14 149.92 16.31 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.871 0 CA-C-N 116.913 0.356 . . . . 0.0 110.559 178.909 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' GLN . . . . . 0.407 HE21 ' HB2' ' A' ' 28' ' ' GLN . 0.0 OUTLIER -129.67 154.65 46.93 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 174.951 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.593 HG23 HD11 ' A' ' 48' ' ' ILE . 2.2 pt -83.48 110.18 18.01 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.446 0 CA-C-O 121.673 0.749 . . . . 0.0 111.064 179.168 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -64.01 -59.15 4.84 Favored 'General case' 0 C--N 1.319 -0.761 0 CA-C-N 114.235 -1.348 . . . . 0.0 110.925 -177.616 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 49.0 m -153.51 166.71 31.86 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.621 -0.718 . . . . 0.0 111.384 -171.08 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.558 ' HA ' HG22 ' A' ' 102' ' ' ILE . 99.4 t -115.49 134.44 58.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 115.694 -0.685 . . . . 0.0 109.689 176.175 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 53.0 t -103.21 107.28 55.01 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 120.863 0.363 . . . . 0.0 111.089 -177.256 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -61.5 120.81 8.65 Favored 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 122.833 2.355 . . . . 0.0 111.575 178.907 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 126.32 -19.04 6.42 Favored Glycine 0 N--CA 1.447 -0.615 0 N-CA-C 111.011 -0.836 . . . . 0.0 111.011 -175.394 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.694 ' HB3' ' HD2' ' A' ' 37' ' ' PRO . 32.0 m -114.61 169.53 6.52 Favored Pre-proline 0 C--N 1.32 -0.7 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 176.499 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 37' ' ' PRO . . . . . 0.694 ' HD2' ' HB3' ' A' ' 36' ' ' SER . 21.1 Cg_endo -61.1 173.24 2.53 Favored 'Trans proline' 0 C--N 1.345 0.359 0 C-N-CA 122.487 2.124 . . . . 0.0 112.893 179.139 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 73.77 -11.29 0.97 Allowed 'General case' 0 N--CA 1.469 0.515 0 CA-C-N 115.541 -0.754 . . . . 0.0 112.403 179.672 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 53.4 m -69.33 2.76 2.69 Favored 'General case' 0 CA--C 1.535 0.377 0 N-CA-C 112.457 0.54 . . . . 0.0 112.457 -177.554 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 50.8 tptt -143.53 19.59 1.86 Allowed 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.43 0.633 . . . . 0.0 109.711 179.168 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 94.1 t -119.91 -63.8 1.76 Allowed 'Isoleucine or valine' 0 C--O 1.237 0.396 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.064 -178.54 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 1.1 pp -97.85 179.85 4.67 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.542 0.687 . . . . 0.0 112.204 -174.717 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 16.7 p -127.31 130.61 23.7 Favored Pre-proline 0 C--N 1.317 -0.831 0 CA-C-N 114.85 -1.068 . . . . 0.0 110.058 178.319 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.429 ' HB3' HG23 ' A' ' 32' ' ' VAL . 50.1 Cg_endo -67.46 159.04 54.26 Favored 'Trans proline' 0 C--O 1.236 0.404 0 C-N-CA 122.425 2.083 . . . . 0.0 112.277 -177.353 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 93.25 0.85 67.31 Favored Glycine 0 CA--C 1.522 0.495 0 C-N-CA 120.752 -0.737 . . . . 0.0 113.849 178.388 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.533 ' HB2' HD11 ' A' ' 29' ' ' ILE . 91.2 mt -92.14 167.18 12.23 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 117.43 0.615 . . . . 0.0 111.001 -179.582 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 46.7 t -109.17 138.71 35.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.001 178.675 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.593 HD11 HG23 ' A' ' 29' ' ' ILE . 58.5 mt -101.62 133.7 44.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 C-N-CA 122.33 0.252 . . . . 0.0 110.353 -178.429 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 27.4 tt0 -91.67 -48.52 6.78 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.277 177.854 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' SER . . . . . 0.618 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 39.6 p -150.24 157.66 43.32 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 113.147 0.795 . . . . 0.0 113.147 -171.883 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.578 HD11 ' CE2' ' A' ' 62' ' ' TYR . 43.7 mt -116.3 117.53 55.79 Favored 'Isoleucine or valine' 0 C--O 1.235 0.34 0 CA-C-N 114.861 -1.063 . . . . 0.0 110.297 174.553 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 52' ' ' ASN . . . . . 0.568 ' HA ' ' HB3' ' A' ' 76' ' ' ASN . 25.4 t-20 65.6 -81.37 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.744 -0.662 . . . . 0.0 111.417 177.005 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -140.09 1.67 2.25 Favored Glycine 0 N--CA 1.447 -0.583 0 C-N-CA 121.052 -0.594 . . . . 0.0 111.768 177.251 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 59.5 mtm -120.74 123.48 27.98 Favored Pre-proline 0 C--N 1.324 -0.512 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 -177.721 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.618 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 72.7 Cg_endo -74.97 143.28 28.97 Favored 'Trans proline' 0 N--CA 1.459 -0.504 0 C-N-CA 122.353 2.035 . . . . 0.0 112.496 -179.125 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 17.8 p -110.79 95.21 5.41 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.226 0.536 . . . . 0.0 111.35 -177.637 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 5.1 p -91.06 -14.2 31.75 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.747 -0.66 . . . . 0.0 111.385 -178.881 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 34.2 m-80 -131.06 164.26 25.81 Favored 'General case' 0 C--N 1.318 -0.765 0 N-CA-C 109.698 -0.482 . . . . 0.0 109.698 178.464 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.426 HD23 ' HA ' ' A' ' 59' ' ' LEU . 13.1 mt -77.28 -31.14 54.63 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.215 0.531 . . . . 0.0 109.881 179.0 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 2.6 p -65.18 -45.76 83.57 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.647 173.64 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 4.6 m -56.67 -44.52 81.48 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.49 173.762 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 62' ' ' TYR . . . . . 0.64 ' CD2' HG21 ' A' ' 27' ' ' VAL . 11.6 t80 -60.59 -42.27 96.42 Favored 'General case' 0 CA--C 1.529 0.145 0 CA-C-O 121.508 0.67 . . . . 0.0 109.773 177.705 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 57.9 m -62.21 -47.14 85.78 Favored 'General case' 0 N--CA 1.446 -0.652 0 CA-C-N 115.069 -0.968 . . . . 0.0 111.636 178.139 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.89 -33.39 74.13 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.831 179.369 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' ALA . . . . . 0.587 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -68.22 -46.99 69.06 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.922 -0.581 . . . . 0.0 109.96 176.5 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 13.7 mt -58.49 -38.45 77.65 Favored 'General case' 0 N--CA 1.448 -0.538 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.894 178.22 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 59.7 mmtt -52.48 -37.69 57.72 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.816 -0.629 . . . . 0.0 112.056 176.744 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 50.1 p -87.77 -13.77 41.43 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 111.914 0.338 . . . . 0.0 111.914 -176.558 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.587 HG12 ' O ' ' A' ' 65' ' ' ALA . 36.7 mm -81.64 141.98 14.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-O 120.995 0.426 . . . . 0.0 110.259 -179.067 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 15.4 m -107.22 162.36 13.96 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.738 -178.801 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 71' ' ' VAL . . . . . 0.407 HG22 ' HA ' ' A' ' 98' ' ' ALA . 97.1 t -77.75 126.69 38.3 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-O 120.987 0.422 . . . . 0.0 110.627 -179.143 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 93.4 22.25 27.34 Favored Glycine 0 N--CA 1.447 -0.576 0 N-CA-C 111.216 -0.753 . . . . 0.0 111.216 -176.217 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 14.8 tp10 -109.5 151.97 26.04 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.262 -0.469 . . . . 0.0 109.847 -179.311 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.405 ' HA ' ' O ' ' A' ' 86' ' ' LEU . 61.1 t -110.98 120.3 61.38 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.752 0 CA-C-N 116.099 -0.5 . . . . 0.0 109.768 179.803 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 23.9 pt -117.05 154.29 18.73 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.026 -178.674 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 76' ' ' ASN . . . . . 0.568 ' HB3' ' HA ' ' A' ' 52' ' ' ASN . 44.1 t30 -91.05 132.92 35.72 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.845 -0.616 . . . . 0.0 109.947 -179.66 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 66.3 mt -129.74 109.78 18.61 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-O 121.179 0.514 . . . . 0.0 109.621 178.619 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 25.5 m -95.94 110.27 22.5 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.944 178.647 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.5 HG22 HG12 ' A' ' 48' ' ' ILE . 69.2 p -107.28 175.25 5.56 Favored 'General case' 0 N--CA 1.448 -0.556 0 CA-C-O 120.814 0.34 . . . . 0.0 111.057 -179.105 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 27.6 t70 -45.06 -43.64 9.62 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.058 -0.974 . . . . 0.0 113.383 -175.84 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 32.2 mt-30 -132.86 17.62 4.21 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 111.989 0.366 . . . . 0.0 111.989 -176.707 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -157.15 123.8 1.34 Allowed Glycine 0 C--N 1.319 -0.384 0 C-N-CA 119.581 -1.295 . . . . 0.0 113.31 -177.012 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 26.0 m -108.99 106.74 16.83 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 175.535 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 20.7 p90 -133.13 177.39 7.71 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 121.53 0.681 . . . . 0.0 111.59 -174.51 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 4.9 p80 -124.81 127.98 48.01 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-N 114.849 -1.069 . . . . 0.0 110.055 178.863 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.405 ' O ' ' HA ' ' A' ' 74' ' ' VAL . 7.4 tt -106.5 143.6 34.38 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.498 -175.302 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 86.5 tttt -106.79 116.4 31.87 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.447 -0.797 . . . . 0.0 109.392 178.367 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.637 HG21 ' HB1' ' A' ' 98' ' ' ALA . 55.7 p -67.04 136.53 55.39 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 121.231 0.539 . . . . 0.0 111.872 -175.212 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.442 -0.958 0 CA-C-N 115.664 -0.698 . . . . 0.0 112.18 -179.225 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 98' ' ' ALA . . . . . 0.637 ' HB1' HG21 ' A' ' 88' ' ' THR . . . . . . . . 0 N--CA 1.462 0.164 0 CA-C-O 121.079 0.466 . . . . 0.0 110.67 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 99' ' ' TYR . . . . . 0.403 ' CE2' ' HA2' ' A' ' 101' ' ' GLY . 27.5 t80 -89.16 114.53 25.82 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.204 0.526 . . . . 0.0 110.452 -173.342 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 100' ' ' MET . . . . . 0.531 ' HG3' ' H ' ' A' ' 102' ' ' ILE . 11.3 ptm -70.47 -30.04 66.74 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.351 -0.84 . . . . 0.0 111.725 -178.27 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 101' ' ' GLY . . . . . 0.403 ' HA2' ' CE2' ' A' ' 99' ' ' TYR . . . 86.61 -2.64 87.34 Favored Glycine 0 N--CA 1.453 -0.184 0 C-N-CA 120.991 -0.624 . . . . 0.0 112.918 177.467 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.558 HG22 ' HA ' ' A' ' 32' ' ' VAL . 24.5 pt -132.16 158.31 43.26 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 121.068 0.461 . . . . 0.0 110.695 -177.568 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 103' ' ' ARG . . . . . 0.429 HH11 ' HD2' ' A' ' 103' ' ' ARG . 18.2 mtp180 -90.36 145.32 25.05 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.796 -0.638 . . . . 0.0 109.591 178.113 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 2.2 p -133.8 151.14 51.48 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 120.708 0.29 . . . . 0.0 111.169 178.397 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 84.1 p -138.49 -174.18 3.75 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.113 -0.494 . . . . 0.0 109.787 177.677 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 14.0 p30 . . . . . 0 C--N 1.321 -0.65 0 CA-C-N 116.527 -0.306 . . . . 0.0 110.86 -179.557 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.839 ' HA ' ' HB3' ' A' ' 57' ' ' SER . 31.9 t70 . . . . . 0 N--CA 1.468 0.454 0 CA-C-O 121.954 0.883 . . . . 0.0 109.954 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 172.26 151.7 8.04 Favored Glycine 0 N--CA 1.441 -0.967 0 CA-C-N 114.949 -1.023 . . . . 0.0 111.245 176.252 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 28.8 m -137.14 153.88 29.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 120.924 0.392 . . . . 0.0 110.94 -177.686 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' GLN . . . . . 0.489 ' HG3' ' HB3' ' A' ' 105' ' ' SER . 20.4 pt20 -126.02 161.37 27.71 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 110.124 -0.324 . . . . 0.0 110.124 176.314 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.499 HG23 HD12 ' A' ' 102' ' ' ILE . 65.9 mt -75.19 115.58 16.75 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 N-CA-C 109.009 -0.737 . . . . 0.0 109.009 174.885 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.495 ' HB2' ' HB2' ' A' ' 105' ' ' SER . 22.9 t70 -79.22 -64.77 1.11 Allowed 'General case' 0 C--N 1.317 -0.816 0 CA-C-O 121.014 0.435 . . . . 0.0 110.334 -178.232 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 19.6 m -145.2 153.92 41.86 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.281 -177.685 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.574 HG13 HG22 ' A' ' 102' ' ' ILE . 94.6 t -116.87 131.01 70.78 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.292 -178.458 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 57.5 t -104.51 124.82 35.83 Favored Pre-proline 0 C--N 1.328 -0.367 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.943 -178.432 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -56.11 151.18 44.08 Favored 'Trans proline' 0 C--N 1.346 0.415 0 C-N-CA 123.068 2.512 . . . . 0.0 112.541 178.222 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 128.5 -16.25 5.96 Favored Glycine 0 N--CA 1.447 -0.578 0 C-N-CA 120.889 -0.672 . . . . 0.0 111.508 -177.906 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 35.9 p -124.89 156.36 68.97 Favored Pre-proline 0 C--N 1.322 -0.63 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 177.035 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo -64.9 -15.9 52.72 Favored 'Trans proline' 0 C--N 1.345 0.384 0 C-N-CA 122.342 2.028 . . . . 0.0 111.813 176.829 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -62.74 -23.09 67.02 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.526 -0.761 . . . . 0.0 111.542 -179.103 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.563 ' HA ' HG11 ' A' ' 32' ' ' VAL . 20.2 t -66.8 -22.12 66.02 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.249 -178.363 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 81.5 tttt -107.65 -2.12 20.48 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.03 0.443 . . . . 0.0 110.475 -178.679 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 89.9 t -105.23 -48.86 9.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.442 179.286 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 94.8 mt -94.33 174.35 7.18 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.052 -179.257 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 43' ' ' THR . . . . . 0.461 ' O ' ' HG ' ' A' ' 46' ' ' LEU . 45.0 m -143.57 131.06 10.77 Favored Pre-proline 0 C--N 1.321 -0.655 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 -179.755 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_endo -63.69 142.63 84.2 Favored 'Trans proline' 0 N--CA 1.459 -0.519 0 C-N-CA 122.273 1.982 . . . . 0.0 111.776 178.221 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 94.14 2.64 64.08 Favored Glycine 0 CA--C 1.523 0.548 0 C-N-CA 120.748 -0.739 . . . . 0.0 113.538 -178.546 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.517 HD22 ' HG2' ' A' ' 81' ' ' GLN . 66.0 mt -88.63 164.11 15.5 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-N 117.475 0.638 . . . . 0.0 110.805 179.269 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 48.8 t -108.1 130.13 61.14 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.248 0 CA-C-O 120.511 0.196 . . . . 0.0 110.693 -177.968 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 53.8 mt -98.52 128.29 50.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-O 120.937 0.399 . . . . 0.0 110.881 -176.134 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.5 mm-40 -87.68 -48.32 7.97 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.652 176.823 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 50' ' ' SER . . . . . 0.496 ' CB ' ' HA ' ' A' ' 55' ' ' PRO . 16.2 p -171.82 161.59 5.92 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-O 121.013 0.435 . . . . 0.0 111.849 -174.838 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.467 HG22 ' H ' ' A' ' 52' ' ' ASN . 27.5 mm -103.67 169.44 2.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 N-CA-C 107.929 -1.137 . . . . 0.0 107.929 173.413 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 52' ' ' ASN . . . . . 0.717 ' HB3' ' HB3' ' A' ' 76' ' ' ASN . 24.0 p-10 -53.97 99.97 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.825 0.821 . . . . 0.0 112.251 -175.996 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 75.72 3.77 74.09 Favored Glycine 0 N--CA 1.447 -0.593 0 CA-C-N 115.352 -0.84 . . . . 0.0 112.695 178.46 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 56.1 mtm -137.32 92.08 13.92 Favored Pre-proline 0 C--N 1.325 -0.467 0 CA-C-O 120.689 0.28 . . . . 0.0 110.504 -176.488 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.496 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 15.8 Cg_exo -66.87 135.28 37.52 Favored 'Trans proline' 0 N--CA 1.46 -0.49 0 C-N-CA 122.311 2.007 . . . . 0.0 111.608 178.606 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.439 HG21 ' CD2' ' A' ' 62' ' ' TYR . 10.9 p -105.24 98.31 8.03 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-O 121.283 0.563 . . . . 0.0 111.731 -175.429 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 57' ' ' SER . . . . . 0.839 ' HB3' ' HA ' ' A' ' 25' ' ' ASP . 4.2 m -101.52 -17.16 16.54 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.774 176.284 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 90.6 m-20 -127.24 160.89 29.93 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.142 -177.955 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 96.5 mt -77.62 -31.97 53.19 Favored 'General case' 0 N--CA 1.438 -1.044 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.061 177.583 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 84.7 m -70.42 -37.4 74.43 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.749 -0.659 . . . . 0.0 110.928 176.467 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 16.6 p -69.6 -33.3 72.49 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.867 0.365 . . . . 0.0 110.351 178.561 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 62' ' ' TYR . . . . . 0.439 ' CD2' HG21 ' A' ' 56' ' ' THR . 24.8 t80 -61.52 -45.97 91.95 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.444 0.64 . . . . 0.0 109.427 173.438 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 6.3 m -65.55 -42.69 91.62 Favored 'General case' 0 N--CA 1.449 -0.522 0 CA-C-N 115.108 -0.951 . . . . 0.0 112.126 177.75 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.99 -33.74 76.06 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.994 -179.768 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 65' ' ' ALA . . . . . 0.563 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -69.52 -45.54 68.61 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.047 -0.524 . . . . 0.0 109.807 177.483 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 14.3 mt -55.2 -38.62 68.62 Favored 'General case' 0 N--CA 1.447 -0.615 0 CA-C-N 115.375 -0.829 . . . . 0.0 111.677 179.184 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 28.0 mmmt -57.29 -28.44 63.03 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.832 -0.622 . . . . 0.0 112.49 179.703 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 28.4 p -99.85 -14.05 18.94 Favored 'General case' 0 C--N 1.327 -0.413 0 N-CA-C 112.373 0.508 . . . . 0.0 112.373 -177.544 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.563 HG12 ' O ' ' A' ' 65' ' ' ALA . 49.1 mm -70.63 128.65 34.17 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-O 121.175 0.512 . . . . 0.0 110.622 -176.658 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 16.3 m -80.62 163.49 23.59 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.372 -176.81 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 57.9 t -84.84 127.64 39.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 115.92 -0.582 . . . . 0.0 109.455 175.773 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 88.32 15.12 60.95 Favored Glycine 0 N--CA 1.448 -0.51 0 N-CA-C 110.571 -1.012 . . . . 0.0 110.571 -173.689 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 7.1 tp10 -87.36 148.16 25.16 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 114.952 -0.624 . . . . 0.0 109.321 178.862 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 59.0 t -113.53 102.13 13.46 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.994 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 174.705 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 29.9 pt -97.37 161.9 2.74 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.855 0 CA-C-N 115.674 -0.694 . . . . 0.0 111.29 -174.314 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 76' ' ' ASN . . . . . 0.717 ' HB3' ' HB3' ' A' ' 52' ' ' ASN . 11.7 t30 -102.17 122.52 44.32 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 115.389 -0.823 . . . . 0.0 109.999 179.292 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 61.8 mt -122.63 103.94 13.92 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 176.687 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 78' ' ' THR . . . . . 0.455 ' HA ' ' HA ' ' A' ' 83' ' ' THR . 37.7 m -91.98 114.1 26.55 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 115.279 -0.873 . . . . 0.0 109.832 179.411 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 69.6 p -102.66 171.86 7.18 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 176.653 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -72.8 -14.67 61.57 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 121.63 0.729 . . . . 0.0 109.469 176.095 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 81' ' ' GLN . . . . . 0.517 ' HG2' HD22 ' A' ' 46' ' ' LEU . 2.7 mp0 -95.37 10.07 37.63 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.302 -0.863 . . . . 0.0 110.652 178.979 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 127.27 164.81 11.76 Favored Glycine 0 CA--C 1.519 0.32 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.902 178.473 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 83' ' ' THR . . . . . 0.455 ' HA ' ' HA ' ' A' ' 78' ' ' THR . 28.0 m -90.48 129.86 36.6 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 110.387 -0.227 . . . . 0.0 110.387 177.621 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 60.6 m-85 -128.34 155.45 44.65 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.013 0.435 . . . . 0.0 110.654 179.421 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 38.6 m80 -108.46 136.85 47.4 Favored 'General case' 0 C--N 1.321 -0.674 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 174.553 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 21.2 tp -123.44 138.87 54.5 Favored 'General case' 0 C--N 1.315 -0.899 0 C-N-CA 120.208 -0.597 . . . . 0.0 110.746 -179.782 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 37.0 ttpt -105.67 121.08 43.26 Favored 'General case' 0 C--N 1.313 -0.988 0 CA-C-N 115.316 -0.856 . . . . 0.0 109.139 177.722 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.58 HG21 ' HB1' ' A' ' 98' ' ' ALA . 43.5 p -78.43 128.67 33.94 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-O 121.275 0.56 . . . . 0.0 111.508 -176.967 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.836 0 CA-C-N 115.65 -0.705 . . . . 0.0 111.889 -178.674 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 98' ' ' ALA . . . . . 0.58 ' HB1' HG21 ' A' ' 88' ' ' THR . . . . . . . . 0 C--O 1.233 0.2 0 CA-C-O 121.25 0.548 . . . . 0.0 111.362 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 51.3 t80 -79.78 97.23 6.54 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 121.173 0.511 . . . . 0.0 111.299 -173.328 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 50.3 ttm -86.5 -58.41 2.63 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.309 173.626 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 88.27 24.05 35.44 Favored Glycine 0 C--N 1.33 0.23 0 C-N-CA 120.889 -0.672 . . . . 0.0 113.709 171.042 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.574 HG22 HG13 ' A' ' 32' ' ' VAL . 19.0 pt -120.03 145.72 25.9 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 CA-C-N 117.179 0.49 . . . . 0.0 110.488 177.597 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.72 140.81 29.21 Favored 'General case' 0 C--N 1.319 -0.747 0 N-CA-C 108.974 -0.75 . . . . 0.0 108.974 174.868 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.7 m -109.59 149.0 30.31 Favored 'General case' 0 C--N 1.314 -0.966 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 -179.076 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.495 ' HB2' ' HB2' ' A' ' 30' ' ' ASP . 41.0 t -116.67 172.24 7.36 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-N 115.94 -0.573 . . . . 0.0 109.705 -178.3 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 25.7 t30 . . . . . 0 C--N 1.316 -0.872 0 CA-C-O 121.551 0.691 . . . . 0.0 109.53 -172.947 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.405 ' HA ' ' OG ' ' A' ' 57' ' ' SER . 38.9 t70 . . . . . 0 C--O 1.232 0.171 0 CA-C-O 121.185 0.516 . . . . 0.0 111.147 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 82.73 122.55 0.75 Allowed Glycine 0 N--CA 1.448 -0.526 0 CA-C-N 115.321 -0.854 . . . . 0.0 112.621 178.913 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 34.9 m -98.09 149.45 5.22 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.881 0 CA-C-O 120.862 0.363 . . . . 0.0 110.583 -179.641 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' GLN . . . . . 0.48 ' HB2' ' O ' ' A' ' 46' ' ' LEU . 26.5 pt20 -128.97 159.58 35.44 Favored 'General case' 0 C--N 1.318 -0.779 0 C-N-CA 120.558 -0.457 . . . . 0.0 110.868 176.875 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.596 HG23 HD11 ' A' ' 48' ' ' ILE . 0.2 OUTLIER -82.58 111.62 19.22 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.357 178.42 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 22.8 t70 -71.2 -62.8 1.27 Allowed 'General case' 0 C--N 1.318 -0.784 0 CA-C-N 115.363 -0.835 . . . . 0.0 111.481 -174.978 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 8.4 p -155.31 145.08 21.4 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.681 -176.464 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.568 HG11 ' HA ' ' A' ' 39' ' ' SER . 89.0 t -90.41 132.39 35.16 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.762 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.406 178.964 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.469 ' HA ' ' HD3' ' A' ' 34' ' ' PRO . 17.5 m -107.29 134.07 20.09 Favored Pre-proline 0 N--CA 1.449 -0.524 0 CA-C-O 121.015 0.436 . . . . 0.0 111.476 -178.251 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 34' ' ' PRO . . . . . 0.469 ' HD3' ' HA ' ' A' ' 33' ' ' VAL . 21.9 Cg_exo -66.44 142.24 64.74 Favored 'Trans proline' 0 C--O 1.236 0.389 0 C-N-CA 123.108 2.539 . . . . 0.0 112.141 178.302 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 112.99 -16.13 23.11 Favored Glycine 0 N--CA 1.448 -0.538 0 N-CA-C 111.232 -0.747 . . . . 0.0 111.232 -176.939 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 26.0 m -123.53 165.22 24.03 Favored Pre-proline 0 C--N 1.324 -0.539 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 179.853 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -74.72 -168.62 0.52 Allowed 'Trans proline' 0 CA--C 1.533 0.428 0 C-N-CA 122.753 2.302 . . . . 0.0 112.489 178.383 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.549 ' HB2' HD11 ' A' ' 86' ' ' LEU . . . 78.62 -6.3 1.93 Allowed 'General case' 0 N--CA 1.468 0.436 0 CA-C-N 115.473 -0.785 . . . . 0.0 112.354 175.457 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.568 ' HA ' HG11 ' A' ' 32' ' ' VAL . 3.8 m -58.69 -30.9 67.74 Favored 'General case' 0 CA--C 1.531 0.243 0 CA-C-O 120.817 0.342 . . . . 0.0 111.661 -177.2 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 64.6 mmtt -119.33 20.7 12.47 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.19 0.519 . . . . 0.0 110.928 -179.675 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 89.6 t -107.84 -47.04 7.82 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 115.938 -0.573 . . . . 0.0 110.043 178.678 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.566 ' HB3' ' CZ ' ' A' ' 84' ' ' PHE . 0.6 OUTLIER -118.61 171.83 7.92 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 121.078 0.466 . . . . 0.0 111.256 178.884 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 11.7 m -115.84 126.15 27.97 Favored Pre-proline 0 C--N 1.315 -0.895 0 CA-C-N 115.452 -0.795 . . . . 0.0 110.061 -179.95 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_endo -62.2 142.35 91.41 Favored 'Trans proline' 0 N--CA 1.46 -0.461 0 C-N-CA 122.099 1.866 . . . . 0.0 111.422 177.4 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 97.72 -5.42 62.05 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.995 -179.248 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.48 ' O ' ' HB2' ' A' ' 28' ' ' GLN . 75.2 mt -85.09 164.03 18.44 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.931 0.366 . . . . 0.0 110.968 179.589 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 47.4 t -101.51 143.28 14.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.457 178.516 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.596 HD11 HG23 ' A' ' 29' ' ' ILE . 60.0 mt -104.36 127.42 58.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 C-N-CA 122.535 0.334 . . . . 0.0 110.209 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 27.9 mt-10 -89.51 -47.88 7.69 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.777 176.382 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' SER . . . . . 0.55 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 19.5 p -157.38 153.15 26.81 Favored 'General case' 0 N--CA 1.446 -0.671 0 CA-C-O 121.599 0.714 . . . . 0.0 112.202 -172.877 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.719 HG22 ' H ' ' A' ' 52' ' ' ASN . 16.0 mt -96.86 -179.93 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 169.735 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 52' ' ' ASN . . . . . 0.719 ' H ' HG22 ' A' ' 51' ' ' ILE . 36.0 t-20 -49.58 93.67 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 112.264 0.468 . . . . 0.0 112.264 -177.434 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 73.12 -2.59 34.63 Favored Glycine 0 CA--C 1.519 0.321 0 CA-C-N 115.976 -0.557 . . . . 0.0 113.275 179.493 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 36.1 mtt -124.8 98.85 36.13 Favored Pre-proline 0 C--N 1.325 -0.484 0 CA-C-N 116.875 0.337 . . . . 0.0 110.654 -173.096 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.55 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 70.4 Cg_endo -77.27 130.89 11.36 Favored 'Trans proline' 0 N--CA 1.46 -0.447 0 C-N-CA 122.151 1.901 . . . . 0.0 112.005 178.257 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.461 HG21 ' HA ' ' A' ' 62' ' ' TYR . 37.5 p -116.63 103.84 10.79 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 121.089 0.471 . . . . 0.0 111.614 -176.307 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 57' ' ' SER . . . . . 0.405 ' OG ' ' HA ' ' A' ' 25' ' ' ASP . 26.9 t -89.05 -34.63 16.72 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.965 177.207 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 2.3 m-20 -103.34 158.44 16.33 Favored 'General case' 0 C--N 1.318 -0.797 0 O-C-N 122.065 -0.397 . . . . 0.0 110.153 -176.804 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 87.4 mt -68.81 -33.8 74.45 Favored 'General case' 0 N--CA 1.443 -0.801 0 CA-C-O 121.215 0.531 . . . . 0.0 109.955 175.519 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 1.6 m -66.04 -41.82 90.39 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.668 -0.696 . . . . 0.0 111.081 177.547 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 18.4 p -68.07 -28.46 67.38 Favored 'General case' 0 CA--C 1.528 0.114 0 CA-C-O 120.811 0.339 . . . . 0.0 110.55 178.951 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' TYR . . . . . 0.461 ' HA ' HG21 ' A' ' 56' ' ' THR . 46.1 t80 -67.19 -38.41 85.31 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 176.105 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 21.6 t -66.07 -48.28 71.53 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.768 179.097 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.03 -32.78 74.22 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.346 -177.773 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 65' ' ' ALA . . . . . 0.476 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -73.29 -43.88 60.16 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.311 179.586 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 3.2 tt -57.04 -45.99 82.74 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.705 -0.679 . . . . 0.0 110.494 -179.6 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -59.69 -26.88 65.95 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.63 -0.714 . . . . 0.0 112.173 -178.199 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 43.5 p -89.24 -14.03 36.82 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 112.049 0.388 . . . . 0.0 112.049 -177.454 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.476 HG12 ' O ' ' A' ' 65' ' ' ALA . 40.9 mm -74.83 142.81 14.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.652 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 70' ' ' SER . . . . . 0.458 ' HB2' ' HB2' ' A' ' 73' ' ' GLU . 4.9 m -93.18 157.64 16.17 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.673 0.273 . . . . 0.0 111.084 -178.157 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 75.3 t -70.29 129.79 34.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.109 177.146 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 79.63 10.14 86.12 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.612 -0.804 . . . . 0.0 111.606 179.759 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.458 ' HB2' ' HB2' ' A' ' 70' ' ' SER . 23.7 tt0 -92.86 149.57 21.17 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 -179.719 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 44.9 t -105.1 124.05 59.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-O 121.35 0.595 . . . . 0.0 110.579 -175.806 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 15.7 pt -110.27 154.04 11.9 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.122 179.193 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 76' ' ' ASN . . . . . 0.626 ' H ' ' HB2' ' A' ' 52' ' ' ASN . 6.3 t30 -105.8 110.49 22.8 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 115.312 -0.858 . . . . 0.0 109.736 -177.755 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 65.0 mt -105.95 119.41 55.21 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 CA-C-O 121.34 0.59 . . . . 0.0 110.992 -174.087 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 11.9 m -93.68 118.5 31.47 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.278 -0.873 . . . . 0.0 109.616 177.847 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 43.4 p -120.36 178.12 4.77 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.82 0.343 . . . . 0.0 111.165 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 28.5 t70 -58.59 -34.88 71.6 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.598 -0.728 . . . . 0.0 111.351 178.798 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 72.1 mm-40 -96.48 14.24 25.24 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.125 -0.489 . . . . 0.0 112.103 -176.136 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 123.26 -171.51 15.85 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.177 -1.011 . . . . 0.0 112.631 176.246 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 24.1 m -112.06 138.23 49.0 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.75 0.309 . . . . 0.0 110.721 -176.855 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 84' ' ' PHE . . . . . 0.566 ' CZ ' ' HB3' ' A' ' 42' ' ' LEU . 10.3 p90 -139.16 168.83 18.96 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 121.378 0.609 . . . . 0.0 110.949 175.494 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 1.8 p-80 -109.82 138.34 46.33 Favored 'General case' 0 C--N 1.314 -0.951 0 CA-C-N 115.142 -0.935 . . . . 0.0 110.016 178.158 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.549 HD11 ' HB2' ' A' ' 38' ' ' ALA . 17.8 tp -130.08 143.85 51.02 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.106 -177.755 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 24.3 ttpp -114.18 125.43 53.93 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.093 -178.277 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.643 HG21 ' HB1' ' A' ' 98' ' ' ALA . 77.0 p -73.99 148.17 42.31 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 115.969 -0.559 . . . . 0.0 111.38 -178.716 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.805 0 N-CA-C 110.952 -0.859 . . . . 0.0 110.952 174.866 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 98' ' ' ALA . . . . . 0.643 ' HB1' HG21 ' A' ' 88' ' ' THR . . . . . . . . 0 CA--C 1.523 -0.083 0 CA-C-O 121.339 0.59 . . . . 0.0 109.903 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 29.5 p90 -86.89 148.57 25.3 Favored 'General case' 0 N--CA 1.444 -0.747 0 CA-C-N 115.865 -0.607 . . . . 0.0 112.164 -167.238 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 93.5 mmm -98.06 126.55 43.55 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.05 -0.977 . . . . 0.0 109.341 175.358 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -86.92 35.19 3.43 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.806 -177.046 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.557 HG22 ' HA ' ' A' ' 32' ' ' VAL . 2.8 pp -140.2 162.71 24.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 120.801 0.334 . . . . 0.0 110.434 179.655 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 103' ' ' ARG . . . . . 0.44 ' NE ' ' HA ' ' A' ' 103' ' ' ARG . 2.9 mmp_? -93.01 142.07 27.7 Favored 'General case' 0 C--N 1.315 -0.915 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 171.377 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.3 m -111.17 150.52 29.38 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-O 121.085 0.469 . . . . 0.0 110.387 179.455 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.43 ' OG ' ' HG3' ' A' ' 28' ' ' GLN . 6.7 p -136.16 169.08 18.2 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.158 175.809 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 47.2 t30 . . . . . 0 C--N 1.32 -0.704 0 CA-C-O 120.686 0.279 . . . . 0.0 111.261 -172.575 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.474 ' N ' ' HG ' ' A' ' 57' ' ' SER . 21.4 t70 . . . . . 0 C--O 1.233 0.218 0 CA-C-O 121.083 0.468 . . . . 0.0 111.447 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.561 ' HA2' ' HA ' ' A' ' 57' ' ' SER . . . 157.25 167.2 17.99 Favored Glycine 0 N--CA 1.443 -0.869 0 N-CA-C 111.039 -0.824 . . . . 0.0 111.039 -177.124 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.479 HG23 ' HB ' ' A' ' 48' ' ' ILE . 28.5 m -108.06 127.42 64.26 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 CA-C-O 121.253 0.549 . . . . 0.0 110.984 178.787 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 18.9 tt0 -99.21 142.78 30.26 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.07 178.01 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.451 HG12 ' O ' ' A' ' 46' ' ' LEU . 8.0 pt -87.36 119.52 35.16 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-O 121.612 0.72 . . . . 0.0 111.579 -178.069 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.409 ' HB3' ' CB ' ' A' ' 103' ' ' ARG . 11.4 t70 -61.12 -58.47 8.22 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 114.272 -1.331 . . . . 0.0 109.983 177.23 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 31' ' ' SER . . . . . 0.619 ' HA ' ' HB3' ' A' ' 44' ' ' PRO . 7.8 p -159.69 158.96 32.36 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.432 -0.804 . . . . 0.0 111.145 -174.407 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.578 ' HA ' HG22 ' A' ' 102' ' ' ILE . 91.4 t -110.44 119.7 59.83 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 115.689 -0.687 . . . . 0.0 109.404 177.846 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.425 ' HA ' ' HD3' ' A' ' 34' ' ' PRO . 53.9 t -83.63 123.52 76.3 Favored Pre-proline 0 C--N 1.324 -0.513 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.721 -175.978 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 34' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' A' ' 33' ' ' VAL . 11.4 Cg_exo -72.95 31.16 0.3 Allowed 'Trans proline' 0 CA--C 1.532 0.42 0 C-N-CA 123.269 2.646 . . . . 0.0 112.775 179.291 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 35' ' ' GLY . . . . . 0.402 ' H ' ' C ' ' A' ' 33' ' ' VAL . . . -121.69 20.43 8.24 Favored Glycine 0 N--CA 1.449 -0.462 0 N-CA-C 111.27 -0.732 . . . . 0.0 111.27 179.172 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 49.1 m -148.17 160.9 36.08 Favored Pre-proline 0 C--N 1.323 -0.578 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 179.425 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_exo -59.81 -13.56 22.92 Favored 'Trans proline' 0 C--N 1.348 0.533 0 C-N-CA 122.985 2.457 . . . . 0.0 113.669 -176.297 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.41 ' HB1' HD13 ' A' ' 42' ' ' LEU . . . -78.6 -6.94 56.97 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 111.794 0.294 . . . . 0.0 111.794 -177.333 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 28.0 t -60.43 -28.45 68.3 Favored 'General case' 0 CA--C 1.533 0.294 0 N-CA-C 112.153 0.427 . . . . 0.0 112.153 -175.657 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 21.0 ttpt -106.96 13.53 27.5 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.947 0.403 . . . . 0.0 110.678 -177.388 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.477 ' HB ' HD12 ' A' ' 42' ' ' LEU . 46.4 t -115.34 -59.2 3.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 C-N-CA 120.776 -0.37 . . . . 0.0 111.65 -175.23 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.48 HD11 HD12 ' A' ' 86' ' ' LEU . 6.6 mp -92.45 175.46 6.83 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.291 0.567 . . . . 0.0 111.516 -173.478 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 91.1 m -140.89 123.94 9.91 Favored Pre-proline 0 C--N 1.32 -0.674 0 CA-C-N 115.405 -0.816 . . . . 0.0 108.946 175.544 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.619 ' HB3' ' HA ' ' A' ' 31' ' ' SER . 42.3 Cg_endo -64.52 152.05 83.17 Favored 'Trans proline' 0 CA--C 1.531 0.339 0 C-N-CA 122.893 2.396 . . . . 0.0 112.905 -173.811 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 103.17 -11.92 55.36 Favored Glycine 0 CA--C 1.52 0.368 0 C-N-CA 121.072 -0.585 . . . . 0.0 112.695 -179.496 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.701 HD22 ' HB3' ' A' ' 80' ' ' ASP . 81.6 mt -84.74 164.62 18.43 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.975 0.417 . . . . 0.0 111.098 -177.981 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 46.6 t -108.12 135.09 47.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 116.075 -0.511 . . . . 0.0 109.843 177.129 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.479 ' HB ' HG23 ' A' ' 27' ' ' VAL . 69.0 mt -87.65 123.7 40.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-O 121.204 0.526 . . . . 0.0 110.536 179.862 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 6.5 tm-20 -79.22 -47.06 16.62 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.921 -179.54 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' SER . . . . . 0.54 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 7.7 p -162.73 153.77 17.32 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.388 -177.648 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 48.5 mm -107.24 102.96 14.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.901 -0.59 . . . . 0.0 109.732 176.679 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 52' ' ' ASN . . . . . 0.591 ' HA ' ' HB3' ' A' ' 76' ' ' ASN . 38.9 t-20 64.08 -85.26 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.384 0 C-N-CA 123.552 0.741 . . . . 0.0 111.056 179.343 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -132.79 8.05 5.21 Favored Glycine 0 N--CA 1.447 -0.569 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 177.005 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 1.5 mpt? -118.59 103.35 48.92 Favored Pre-proline 0 N--CA 1.448 -0.571 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 -178.737 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.54 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 41.8 Cg_endo -68.81 121.68 8.57 Favored 'Trans proline' 0 N--CA 1.462 -0.367 0 C-N-CA 122.124 1.882 . . . . 0.0 112.461 -179.118 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.45 ' HA ' ' HB ' ' A' ' 61' ' ' THR . 6.9 p -89.47 87.99 7.28 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.54 179.834 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 57' ' ' SER . . . . . 0.561 ' HA ' ' HA2' ' A' ' 26' ' ' GLY . 8.6 t -93.53 -14.26 26.82 Favored 'General case' 0 C--N 1.318 -0.797 0 CA-C-N 115.416 -0.811 . . . . 0.0 109.875 -179.476 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 61.1 t30 -140.5 178.23 7.46 Favored 'General case' 0 N--CA 1.445 -0.714 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 178.978 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 68.8 mt -76.16 -33.39 59.37 Favored 'General case' 0 N--CA 1.445 -0.72 0 CA-C-O 120.921 0.391 . . . . 0.0 111.067 -178.424 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 13.1 m -66.48 -34.33 77.68 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.977 179.869 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 61' ' ' THR . . . . . 0.45 ' HB ' ' HA ' ' A' ' 56' ' ' THR . 0.0 OUTLIER -66.0 -35.33 80.26 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.992 0.425 . . . . 0.0 110.372 176.838 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 55.4 t80 -62.33 -37.45 85.66 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.857 176.842 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 33.2 t -68.25 -46.19 71.16 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.52 -0.764 . . . . 0.0 110.435 177.287 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -66.32 -26.34 67.26 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.865 -0.607 . . . . 0.0 112.13 -175.761 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 65' ' ' ALA . . . . . 0.427 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -79.27 -44.03 22.54 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.078 0.466 . . . . 0.0 110.431 177.487 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 1.7 tt -63.55 -42.64 98.38 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.556 -0.747 . . . . 0.0 111.357 -175.824 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 22.4 ptmt -60.37 -12.37 9.14 Favored 'General case' 0 CA--C 1.536 0.414 0 N-CA-C 112.899 0.704 . . . . 0.0 112.899 -174.117 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 20.8 p -106.93 -13.17 15.28 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 112.386 0.514 . . . . 0.0 112.386 -178.128 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.473 HG21 HG21 ' A' ' 88' ' ' THR . 37.2 mm -79.73 143.85 11.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.748 -0.205 . . . . 0.0 110.956 -175.256 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 3.2 m -92.45 164.52 13.44 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.508 -0.315 . . . . 0.0 110.471 179.888 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 16.5 t -78.6 118.09 25.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 120.677 0.275 . . . . 0.0 110.266 179.304 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 88.32 23.52 37.03 Favored Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 120.422 -0.894 . . . . 0.0 111.671 -178.846 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 28.6 tt0 -99.56 147.5 25.27 Favored 'General case' 0 C--N 1.323 -0.587 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 -179.851 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 51.0 t -95.14 114.29 31.39 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.779 0 CA-C-O 121.136 0.493 . . . . 0.0 110.56 -179.122 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 26.7 pt -104.21 174.79 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.787 0 CA-C-N 115.637 -0.71 . . . . 0.0 110.87 179.27 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 76' ' ' ASN . . . . . 0.591 ' HB3' ' HA ' ' A' ' 52' ' ' ASN . 43.6 t30 -122.16 130.54 53.31 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.586 -0.734 . . . . 0.0 109.813 -175.536 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.435 HG22 HG23 ' A' ' 79' ' ' THR . 62.5 mt -134.8 110.33 12.71 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-O 121.212 0.529 . . . . 0.0 111.112 -176.922 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 78' ' ' THR . . . . . 0.628 ' HA ' ' HA ' ' A' ' 83' ' ' THR . 98.1 m -85.91 123.53 31.35 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.986 -0.552 . . . . 0.0 109.685 173.597 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.435 HG23 HG22 ' A' ' 77' ' ' ILE . 67.3 p -124.72 -173.45 2.79 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.922 0.392 . . . . 0.0 111.364 -177.472 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 80' ' ' ASP . . . . . 0.701 ' HB3' HD22 ' A' ' 46' ' ' LEU . 7.4 t70 -53.78 -41.55 67.34 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.216 -0.902 . . . . 0.0 111.583 177.173 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 28.2 mm-40 -95.23 12.94 27.13 Favored 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 111.931 0.345 . . . . 0.0 111.931 -175.759 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 119.43 -175.32 15.75 Favored Glycine 0 N--CA 1.447 -0.63 0 C-N-CA 120.164 -1.017 . . . . 0.0 113.038 175.342 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 83' ' ' THR . . . . . 0.628 ' HA ' ' HA ' ' A' ' 78' ' ' THR . 32.6 m -92.67 117.17 29.7 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.115 0.484 . . . . 0.0 111.396 -176.565 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 88.9 m-85 -113.89 164.8 13.29 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.43 -178.735 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 19.3 p-80 -117.27 130.01 56.28 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.285 178.958 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.49 HD23 ' N ' ' A' ' 87' ' ' LYS . 8.2 tt -120.48 145.48 47.23 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 116.231 -0.44 . . . . 0.0 109.947 -173.985 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 87' ' ' LYS . . . . . 0.49 ' N ' HD23 ' A' ' 86' ' ' LEU . 88.1 tttt -114.66 117.59 31.28 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 109.132 -0.692 . . . . 0.0 109.132 176.216 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.473 HG21 HG21 ' A' ' 69' ' ' ILE . 22.3 p -64.03 131.92 49.03 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 121.142 0.496 . . . . 0.0 111.729 -174.997 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.441 -1.012 0 C-N-CA 120.975 -0.631 . . . . 0.0 111.797 179.61 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.254 0 CA-C-O 121.177 0.513 . . . . 0.0 112.29 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 14.5 t80 -107.45 120.74 43.0 Favored 'General case' 0 C--N 1.319 -0.718 0 C-N-CA 120.76 -0.376 . . . . 0.0 110.07 -178.58 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 100' ' ' MET . . . . . 0.566 ' HG2' HG12 ' A' ' 102' ' ' ILE . 0.7 OUTLIER -71.86 -20.18 61.85 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.169 -179.038 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 78.91 35.2 31.83 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.866 -0.683 . . . . 0.0 113.113 175.201 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.578 HG22 ' HA ' ' A' ' 32' ' ' VAL . 35.4 pt -142.02 154.01 18.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-O 120.849 0.356 . . . . 0.0 110.063 178.933 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 103' ' ' ARG . . . . . 0.409 ' CB ' ' HB3' ' A' ' 30' ' ' ASP . 21.4 mtp85 -91.74 134.66 34.53 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 173.463 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 2.8 m -133.21 155.14 49.89 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.962 0.41 . . . . 0.0 111.055 -176.308 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 32.6 t -149.1 -174.88 4.76 Favored 'General case' 0 C--N 1.321 -0.636 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 179.44 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 14.8 p30 . . . . . 0 C--N 1.324 -0.518 0 CA-C-O 120.635 0.255 . . . . 0.0 111.044 179.211 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 27.9 t70 . . . . . 0 N--CA 1.465 0.323 0 CA-C-O 122.013 0.911 . . . . 0.0 110.364 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.461 ' H ' ' HA ' ' A' ' 57' ' ' SER . . . 106.52 115.94 4.08 Favored Glycine 0 N--CA 1.445 -0.72 0 CA-C-N 114.471 -1.24 . . . . 0.0 111.751 176.597 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 34.5 m -78.79 153.83 4.92 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 CA-C-O 120.941 0.4 . . . . 0.0 110.721 -178.737 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 34.3 tt0 -115.53 149.24 38.48 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-O 121.293 0.568 . . . . 0.0 111.349 -177.585 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.498 HD12 HD12 ' A' ' 102' ' ' ILE . 26.8 mm -73.11 107.62 3.86 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.214 -0.903 . . . . 0.0 109.432 175.742 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.721 ' HB3' ' HB2' ' A' ' 103' ' ' ARG . 41.9 t0 -69.98 -53.54 17.28 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-O 121.401 0.62 . . . . 0.0 109.529 -178.671 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 51.0 p -161.47 173.51 14.76 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.189 -0.914 . . . . 0.0 110.798 177.103 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.522 HG22 HG22 ' A' ' 102' ' ' ILE . 84.9 t -119.25 124.46 73.1 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 CA-C-N 115.813 -0.631 . . . . 0.0 109.382 175.95 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 7.4 p -106.7 131.02 22.04 Favored Pre-proline 0 C--N 1.323 -0.545 0 CA-C-O 120.783 0.325 . . . . 0.0 110.421 -177.67 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo -64.97 87.85 0.18 Allowed 'Trans proline' 0 C--N 1.343 0.289 0 C-N-CA 122.79 2.327 . . . . 0.0 112.408 179.426 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -164.75 14.21 0.09 OUTLIER Glycine 0 N--CA 1.449 -0.447 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.862 176.032 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.679 ' HB2' ' HA3' ' A' ' 101' ' ' GLY . 60.4 m -157.65 160.44 30.16 Favored Pre-proline 0 C--N 1.327 -0.401 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 -178.972 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_exo -63.31 -15.34 47.66 Favored 'Trans proline' 0 C--N 1.349 0.568 0 C-N-CA 122.87 2.38 . . . . 0.0 112.71 -178.132 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -67.07 -15.12 63.52 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.922 -177.426 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.459 ' HA ' HG11 ' A' ' 32' ' ' VAL . 47.7 t -65.21 -13.55 58.54 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.71 -177.041 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 23.9 ttmm -128.42 25.39 5.77 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.346 0.594 . . . . 0.0 110.06 179.244 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.542 ' HB ' HD12 ' A' ' 42' ' ' LEU . 45.6 t -122.16 -55.3 2.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.905 179.381 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.542 HD12 ' HB ' ' A' ' 41' ' ' VAL . 5.0 mp -109.17 164.19 12.67 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.789 0.328 . . . . 0.0 110.588 -178.033 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 12.7 p -116.54 144.54 33.39 Favored Pre-proline 0 C--N 1.323 -0.548 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.62 177.1 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.44 ' HA ' ' CG2' ' A' ' 29' ' ' ILE . 57.2 Cg_endo -72.55 149.41 49.53 Favored 'Trans proline' 0 C--O 1.235 0.332 0 C-N-CA 122.299 1.999 . . . . 0.0 112.496 -179.422 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 101.14 -12.52 58.8 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.999 -179.555 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 83.4 mt -77.43 164.27 25.62 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 121.046 0.451 . . . . 0.0 111.46 -179.235 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 46.0 t -108.76 136.19 45.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.785 177.933 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.439 HG23 HG23 ' A' ' 77' ' ' ILE . 70.9 mt -93.79 122.71 45.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-N 116.496 -0.32 . . . . 0.0 110.981 179.55 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -79.82 -44.97 19.6 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.5 -0.318 . . . . 0.0 110.951 174.809 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' SER . . . . . 0.62 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 16.4 p -169.03 161.22 10.45 Favored 'General case' 0 CA--C 1.515 -0.404 0 CA-C-O 120.888 0.375 . . . . 0.0 111.408 -174.559 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.558 HD11 HD12 ' A' ' 75' ' ' ILE . 8.1 tt -135.95 122.19 31.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.148 177.473 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 11.0 m120 58.85 22.88 10.69 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-N 115.642 -0.708 . . . . 0.0 112.536 176.094 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 104.71 -26.22 23.19 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.655 -0.783 . . . . 0.0 112.433 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 4.4 mpp? -91.94 112.8 56.6 Favored Pre-proline 0 C--N 1.325 -0.491 0 N-CA-C 109.682 -0.488 . . . . 0.0 109.682 177.577 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.62 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 72.6 Cg_endo -78.02 128.07 8.9 Favored 'Trans proline' 0 N--CA 1.454 -0.799 0 C-N-CA 122.09 1.86 . . . . 0.0 112.501 -178.748 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 21.5 p -91.64 81.13 5.31 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 115.649 -0.705 . . . . 0.0 111.026 -177.944 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 57' ' ' SER . . . . . 0.461 ' HA ' ' H ' ' A' ' 26' ' ' GLY . 12.6 m -81.34 -18.5 45.49 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.69 178.561 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 42.7 m-80 -138.34 164.85 28.25 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.733 -178.729 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.511 HD21 ' HA ' ' A' ' 105' ' ' SER . 66.2 mt -68.75 -35.14 76.72 Favored 'General case' 0 N--CA 1.446 -0.653 0 CA-C-O 120.908 0.385 . . . . 0.0 110.576 178.222 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 1.5 m -62.22 -35.32 78.53 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.509 176.513 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -66.65 -43.25 85.1 Favored 'General case' 0 N--CA 1.452 -0.356 0 CA-C-N 115.998 -0.547 . . . . 0.0 110.374 178.326 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 33.3 t80 -64.14 -37.53 87.79 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.931 -0.577 . . . . 0.0 109.635 177.473 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 66.8 m -61.46 -50.94 70.75 Favored 'General case' 0 N--CA 1.445 -0.693 0 CA-C-N 115.387 -0.824 . . . . 0.0 111.397 178.012 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.95 -33.93 76.42 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.989 179.623 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 65' ' ' ALA . . . . . 0.575 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -72.79 -41.27 65.16 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.269 -179.866 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 1.2 tt -57.42 -39.31 75.92 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.252 179.407 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 93.7 mttt -59.23 -39.41 82.65 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.801 179.375 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 17.5 p -77.84 -14.37 59.59 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 111.985 0.365 . . . . 0.0 111.985 -178.701 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.575 HG12 ' O ' ' A' ' 65' ' ' ALA . 43.0 mm -75.29 142.75 14.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 N-CA-C 110.495 -0.187 . . . . 0.0 110.495 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 3.0 m -102.11 168.96 9.04 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.713 0.292 . . . . 0.0 110.925 179.761 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 16.4 t -82.11 122.19 36.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.294 178.809 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 83.32 25.72 46.59 Favored Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 120.61 -0.805 . . . . 0.0 111.807 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 18.9 tt0 -105.81 153.32 22.07 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 179.917 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 26.5 t -97.9 113.78 33.42 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 CA-C-O 120.866 0.365 . . . . 0.0 110.167 -179.014 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.558 HD12 HD11 ' A' ' 51' ' ' ILE . 9.3 pt -101.33 154.8 4.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.164 -179.03 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 76' ' ' ASN . . . . . 0.437 ' O ' ' HA ' ' A' ' 51' ' ' ILE . 10.8 t30 -119.33 104.95 10.84 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 121.151 0.5 . . . . 0.0 111.076 -173.292 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.472 HD12 HD21 ' A' ' 86' ' ' LEU . 67.1 mt -103.12 118.83 50.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 115.37 -0.832 . . . . 0.0 110.405 -177.459 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 19.6 m -95.62 115.37 27.33 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.628 -0.715 . . . . 0.0 109.664 177.368 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 82.0 p -111.15 169.75 8.57 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.42 -179.736 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -61.98 -25.55 67.69 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.088 179.257 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 51.6 tp60 -98.51 11.85 37.0 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.171 0.51 . . . . 0.0 111.097 -176.69 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 134.44 176.11 14.21 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.315 -0.945 . . . . 0.0 113.002 176.153 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 18.1 m -105.27 120.11 40.73 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 -179.523 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 63.4 m-85 -126.57 152.16 46.96 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.759 0.314 . . . . 0.0 110.243 -179.426 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -131.49 131.15 43.23 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-O 121.299 0.571 . . . . 0.0 110.422 177.079 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.473 HD22 HD11 ' A' ' 42' ' ' LEU . 0.9 OUTLIER -127.13 157.42 39.77 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.319 -0.855 . . . . 0.0 111.106 -173.535 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 40.0 ttmt -99.56 130.6 45.81 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.057 178.545 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 33.9 p -71.63 131.19 42.84 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 121.064 0.459 . . . . 0.0 111.036 179.548 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.442 -0.908 0 C-N-CA 120.491 -0.861 . . . . 0.0 112.322 -177.637 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.135 0 CA-C-O 121.174 0.511 . . . . 0.0 110.153 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -70.34 110.75 5.46 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.22 -171.178 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 25.4 mmt -82.84 111.02 18.36 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 173.268 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 101' ' ' GLY . . . . . 0.679 ' HA3' ' HB2' ' A' ' 36' ' ' SER . . . -81.28 30.22 2.75 Favored Glycine 0 C--O 1.228 -0.236 0 C-N-CA 120.814 -0.707 . . . . 0.0 113.263 -174.958 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.522 HG22 HG22 ' A' ' 32' ' ' VAL . 42.9 pt -147.69 173.29 2.16 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 -179.98 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 103' ' ' ARG . . . . . 0.721 ' HB2' ' HB3' ' A' ' 30' ' ' ASP . 65.7 mtt-85 -109.94 134.37 52.17 Favored 'General case' 0 C--N 1.317 -0.834 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 173.344 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.5 p -119.79 124.5 46.3 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-O 120.944 0.402 . . . . 0.0 110.72 178.353 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.511 ' HA ' HD21 ' A' ' 59' ' ' LEU . 42.3 m -145.64 163.43 34.86 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.248 -179.083 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 86.6 m-20 . . . . . 0 C--N 1.325 -0.474 0 CA-C-O 121.853 0.835 . . . . 0.0 109.061 173.474 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 25.2 t0 . . . . . 0 N--CA 1.466 0.353 0 CA-C-O 121.047 0.451 . . . . 0.0 111.164 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.432 ' HA2' ' O ' ' A' ' 56' ' ' THR . . . 171.02 134.07 1.71 Allowed Glycine 0 N--CA 1.444 -0.785 0 C-N-CA 120.9 -0.667 . . . . 0.0 111.724 -179.958 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.527 HG23 ' HB ' ' A' ' 48' ' ' ILE . 19.0 m -76.3 153.94 5.89 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-O 120.69 0.281 . . . . 0.0 110.445 179.672 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 27.9 tt0 -115.8 149.51 38.42 Favored 'General case' 0 C--N 1.323 -0.579 0 C-N-CA 120.28 -0.568 . . . . 0.0 110.986 -179.371 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 68.9 mt -80.18 114.5 21.16 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-N 115.814 -0.63 . . . . 0.0 109.878 177.543 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' ASP . . . . . 0.572 ' HB3' ' HB3' ' A' ' 103' ' ' ARG . 16.2 t70 -70.39 -67.57 0.49 Allowed 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.392 0.615 . . . . 0.0 110.064 -178.95 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 6.9 p -159.14 153.9 24.63 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.109 179.804 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.802 HG22 HG22 ' A' ' 102' ' ' ILE . 95.3 t -82.24 128.63 38.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 177.95 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.405 ' HB ' ' HD2' ' A' ' 34' ' ' PRO . 27.5 m -92.16 159.14 38.08 Favored Pre-proline 0 N--CA 1.446 -0.664 0 CA-C-N 116.575 -0.284 . . . . 0.0 110.382 -178.417 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 34' ' ' PRO . . . . . 0.405 ' HD2' ' HB ' ' A' ' 33' ' ' VAL . 21.0 Cg_endo -62.88 106.23 0.51 Allowed 'Trans proline' 0 N--CA 1.461 -0.416 0 C-N-CA 122.271 1.981 . . . . 0.0 111.591 174.505 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 135.72 150.58 5.99 Favored Glycine 0 N--CA 1.448 -0.565 0 CA-C-N 115.905 -0.589 . . . . 0.0 112.067 -177.652 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 50.5 m 71.11 153.73 0.15 Allowed Pre-proline 0 CA--C 1.535 0.382 0 C-N-CA 123.038 0.535 . . . . 0.0 111.719 179.704 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -83.22 14.18 2.44 Favored 'Trans proline' 0 C--N 1.347 0.449 0 C-N-CA 122.95 2.434 . . . . 0.0 113.416 -176.267 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.568 ' HB2' ' O ' ' A' ' 100' ' ' MET . . . -59.79 -35.12 74.01 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.865 0.364 . . . . 0.0 111.478 -179.192 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.568 ' HB3' HG11 ' A' ' 32' ' ' VAL . 0.8 OUTLIER -65.93 -22.45 66.49 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.04 -0.527 . . . . 0.0 112.374 -175.063 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 19.8 ptpt -100.27 1.34 41.64 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.691 0.281 . . . . 0.0 110.896 179.829 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 83.6 t -110.59 -55.86 4.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 116.476 -0.329 . . . . 0.0 111.017 -178.23 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 1.2 pp -118.51 -178.81 3.62 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.395 0.617 . . . . 0.0 111.932 -177.051 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 23.3 m -119.95 134.4 23.97 Favored Pre-proline 0 C--N 1.316 -0.864 0 CA-C-N 115.084 -0.962 . . . . 0.0 109.964 -179.609 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.508 ' HB3' HG23 ' A' ' 32' ' ' VAL . 31.4 Cg_endo -65.67 145.58 81.85 Favored 'Trans proline' 0 N--CA 1.464 -0.242 0 C-N-CA 122.131 1.887 . . . . 0.0 111.738 176.553 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 97.83 11.0 51.6 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.517 -0.849 . . . . 0.0 112.917 -178.926 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 80.4 mt -98.04 164.9 12.15 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.772 0.32 . . . . 0.0 110.524 177.276 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.46 ' HB ' ' HB2' ' A' ' 80' ' ' ASP . 39.7 t -97.08 140.94 16.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 116.325 -0.398 . . . . 0.0 109.99 177.633 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.527 ' HB ' HG23 ' A' ' 27' ' ' VAL . 72.1 mt -103.86 115.51 45.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-O 120.839 0.352 . . . . 0.0 110.519 178.493 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.401 ' HB3' ' HB ' ' A' ' 78' ' ' THR . 7.7 tt0 -78.98 -55.11 5.38 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.598 0.713 . . . . 0.0 110.3 177.142 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 50' ' ' SER . . . . . 0.611 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 8.0 p -148.15 146.65 28.84 Favored 'General case' 0 C--N 1.315 -0.908 0 CA-C-N 115.423 -0.808 . . . . 0.0 112.157 -173.023 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.457 ' HA ' ' O ' ' A' ' 76' ' ' ASN . 49.1 mt -117.29 114.91 47.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-N 114.96 -1.018 . . . . 0.0 109.225 173.577 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 7.6 t-20 61.91 -152.62 0.36 Allowed 'General case' 0 C--O 1.234 0.25 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 -171.746 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -79.57 21.45 4.5 Favored Glycine 0 CA--C 1.523 0.532 0 C-N-CA 120.307 -0.949 . . . . 0.0 112.258 175.931 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 61.0 mtm -123.66 106.3 32.29 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 120.805 0.336 . . . . 0.0 110.19 -178.835 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.611 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 65.1 Cg_endo -73.99 150.18 43.04 Favored 'Trans proline' 0 N--CA 1.46 -0.48 0 C-N-CA 122.133 1.889 . . . . 0.0 112.602 -179.36 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.432 ' O ' ' HA2' ' A' ' 26' ' ' GLY . 33.5 p -120.72 106.07 11.36 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.74 -178.234 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 12.6 p -96.03 -22.45 17.35 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.927 -179.723 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 27.5 p-10 -146.63 -169.41 3.27 Favored 'General case' 0 N--CA 1.447 -0.59 0 CA-C-O 121.271 0.558 . . . . 0.0 110.594 175.457 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.544 ' HG ' ' HB2' ' A' ' 106' ' ' ASN . 19.1 mt -68.43 -35.29 77.41 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.142 -0.935 . . . . 0.0 111.813 -178.683 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 7.7 m -65.77 -45.71 81.51 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.758 0.313 . . . . 0.0 111.324 -177.555 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 1.6 p -66.29 -33.38 75.6 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.137 0.494 . . . . 0.0 110.528 178.257 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 76.1 t80 -62.01 -46.8 87.61 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.311 -0.859 . . . . 0.0 110.526 174.73 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 5.3 t -63.75 -45.1 91.37 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.593 -179.458 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -66.36 -26.8 67.44 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.965 -0.562 . . . . 0.0 111.682 -177.265 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -78.68 -43.64 25.55 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.011 0.434 . . . . 0.0 110.365 176.657 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -59.66 -42.0 91.85 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.456 -0.793 . . . . 0.0 111.354 -176.506 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 15.2 ptmm? -64.97 -6.86 9.48 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 112.595 0.591 . . . . 0.0 112.595 -174.565 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 49.6 p -106.28 -14.59 15.07 Favored 'General case' 0 C--N 1.326 -0.426 0 C-N-CA 120.768 -0.373 . . . . 0.0 111.402 -179.753 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 45.0 mm -72.06 140.0 18.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 120.863 0.363 . . . . 0.0 111.23 -174.355 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 70' ' ' SER . . . . . 0.607 ' HB2' ' HB2' ' A' ' 73' ' ' GLU . 2.5 m -89.33 151.22 22.2 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.372 179.031 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 48.9 t -73.91 118.2 19.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 120.988 0.423 . . . . 0.0 110.055 177.327 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 93.02 9.07 61.14 Favored Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 120.605 -0.807 . . . . 0.0 111.993 -179.073 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 73' ' ' GLU . . . . . 0.607 ' HB2' ' HB2' ' A' ' 70' ' ' SER . 35.7 tt0 -86.45 148.75 25.41 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 120.809 0.338 . . . . 0.0 110.092 179.626 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 74' ' ' VAL . . . . . 0.424 ' HA ' ' HA ' ' A' ' 87' ' ' LYS . 60.1 t -92.1 113.17 26.93 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 176.919 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 27.3 pt -108.62 154.45 9.93 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-O 121.314 0.578 . . . . 0.0 111.224 -177.441 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 76' ' ' ASN . . . . . 0.457 ' O ' ' HA ' ' A' ' 51' ' ' ILE . 6.0 t30 -95.85 127.26 41.72 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.151 178.382 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.562 HD12 HD21 ' A' ' 86' ' ' LEU . 54.3 mt -125.26 106.31 16.16 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 CA-C-O 121.288 0.566 . . . . 0.0 109.846 176.362 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 78' ' ' THR . . . . . 0.401 ' HB ' ' HB3' ' A' ' 49' ' ' GLU . 4.3 m -78.59 102.48 7.97 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 115.32 -0.854 . . . . 0.0 109.239 178.302 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 70.7 p -94.6 167.65 11.34 Favored 'General case' 0 C--N 1.323 -0.545 0 C-N-CA 120.474 -0.49 . . . . 0.0 110.697 -178.569 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 80' ' ' ASP . . . . . 0.46 ' HB2' ' HB ' ' A' ' 47' ' ' VAL . 23.8 t70 -52.52 -33.38 45.0 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.267 -0.878 . . . . 0.0 111.834 -179.858 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 79.7 mt-30 -118.73 28.0 8.57 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 112.185 0.439 . . . . 0.0 112.185 -173.481 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 150.18 151.29 5.49 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.208 -0.996 . . . . 0.0 113.487 173.854 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 26.4 m -94.81 106.72 18.72 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 109.697 -0.483 . . . . 0.0 109.697 176.361 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 84.8 m-85 -114.66 158.52 21.64 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.058 0.456 . . . . 0.0 110.874 -176.395 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 17.4 p-80 -123.66 129.13 50.65 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.814 -0.63 . . . . 0.0 109.508 173.141 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.562 HD21 HD12 ' A' ' 77' ' ' ILE . 0.6 OUTLIER -134.24 156.07 49.05 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 115.989 -0.55 . . . . 0.0 111.031 -176.614 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 87' ' ' LYS . . . . . 0.424 ' HA ' ' HA ' ' A' ' 74' ' ' VAL . 58.8 tttm -96.35 131.59 42.73 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.675 -179.022 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 39.9 p -69.75 139.46 53.32 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-O 121.158 0.504 . . . . 0.0 111.127 178.714 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.433 -1.564 0 N-CA-C 111.146 -0.782 . . . . 0.0 111.146 176.63 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.465 0.281 0 CA-C-O 121.346 0.593 . . . . 0.0 110.712 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -96.49 112.7 24.35 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.406 -171.413 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 100' ' ' MET . . . . . 0.596 ' HG2' ' H ' ' A' ' 102' ' ' ILE . 1.4 pmm? -63.5 -31.09 72.15 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.701 -179.498 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 104.73 1.46 42.91 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.466 -0.873 . . . . 0.0 113.295 175.898 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.802 HG22 HG22 ' A' ' 32' ' ' VAL . 2.8 pp -130.08 148.03 33.19 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.61 0 CA-C-O 121.003 0.43 . . . . 0.0 110.771 179.55 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 103' ' ' ARG . . . . . 0.572 ' HB3' ' HB3' ' A' ' 30' ' ' ASP . 1.0 OUTLIER -80.73 137.93 36.29 Favored 'General case' 0 C--N 1.321 -0.638 0 N-CA-C 108.242 -1.022 . . . . 0.0 108.242 172.89 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.7 m -112.25 153.23 27.44 Favored 'General case' 0 C--N 1.31 -1.14 0 CA-C-O 120.802 0.334 . . . . 0.0 110.394 -177.491 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 23.8 p -135.67 163.92 29.06 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 115.96 -0.564 . . . . 0.0 109.976 -179.873 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 106' ' ' ASN . . . . . 0.544 ' HB2' ' HG ' ' A' ' 59' ' ' LEU . 65.8 t30 . . . . . 0 C--N 1.317 -0.839 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 -177.111 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 38.9 t70 . . . . . 0 N--CA 1.463 0.194 0 CA-C-O 120.99 0.424 . . . . 0.0 111.544 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.548 ' HA2' ' HA ' ' A' ' 57' ' ' SER . . . 167.48 151.3 6.89 Favored Glycine 0 N--CA 1.446 -0.686 0 N-CA-C 111.247 -0.741 . . . . 0.0 111.247 -177.664 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.621 HG23 ' HB ' ' A' ' 48' ' ' ILE . 29.5 m -102.81 145.26 12.49 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-O 121.021 0.439 . . . . 0.0 110.82 -179.038 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 26.1 tt0 -115.82 150.18 37.38 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.704 -178.567 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.455 HD12 ' HB2' ' A' ' 46' ' ' LEU . 48.3 mt -76.85 107.94 8.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.011 178.003 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 22.5 t70 -62.29 -62.19 1.93 Allowed 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.551 0.691 . . . . 0.0 109.871 177.213 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 13.4 p -158.11 149.2 21.0 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.205 -0.907 . . . . 0.0 110.625 179.253 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.526 HG22 HG22 ' A' ' 102' ' ' ILE . 44.8 t -99.11 117.94 44.96 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 N-CA-C 109.519 -0.548 . . . . 0.0 109.519 177.272 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.503 ' HA ' ' HD3' ' A' ' 34' ' ' PRO . 11.9 m -80.91 117.37 67.75 Favored Pre-proline 0 N--CA 1.447 -0.594 0 CA-C-O 120.982 0.42 . . . . 0.0 110.572 -179.95 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 34' ' ' PRO . . . . . 0.503 ' HD3' ' HA ' ' A' ' 33' ' ' VAL . 16.7 Cg_exo -69.73 25.82 0.17 Allowed 'Trans proline' 0 N--CA 1.478 0.605 0 C-N-CA 123.918 3.079 . . . . 0.0 113.85 -174.208 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -120.56 15.08 9.87 Favored Glycine 0 N--CA 1.446 -0.636 0 N-CA-C 110.645 -0.982 . . . . 0.0 110.645 174.339 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 7.5 m -139.1 177.33 2.11 Favored Pre-proline 0 C--N 1.325 -0.477 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 -177.358 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 24.8 Cg_exo -64.9 -172.86 0.22 Allowed 'Trans proline' 0 C--N 1.35 0.656 0 C-N-CA 122.255 1.97 . . . . 0.0 112.214 174.107 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.605 ' HB2' HD11 ' A' ' 86' ' ' LEU . . . 72.38 -23.25 0.2 Allowed 'General case' 0 N--CA 1.47 0.538 0 C-N-CA 123.493 0.717 . . . . 0.0 112.867 177.108 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 37.0 m -61.64 -29.61 70.17 Favored 'General case' 0 CA--C 1.531 0.233 0 CA-C-O 121.018 0.437 . . . . 0.0 111.842 -176.439 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 17.0 tppt? -97.06 -6.01 36.2 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.003 0.43 . . . . 0.0 110.51 -178.843 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 46.9 t -102.06 -52.69 8.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.712 -174.117 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.456 HD11 ' HB1' ' A' ' 38' ' ' ALA . 1.2 pp -127.49 -177.54 4.12 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-O 121.366 0.603 . . . . 0.0 112.026 -175.343 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 2.9 p -125.09 151.96 69.92 Favored Pre-proline 0 C--N 1.32 -0.696 0 CA-C-N 115.008 -0.996 . . . . 0.0 110.62 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -70.47 156.01 62.37 Favored 'Trans proline' 0 C--N 1.343 0.278 0 C-N-CA 122.404 2.069 . . . . 0.0 112.191 178.457 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 100.11 -13.36 60.35 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.606 -0.807 . . . . 0.0 112.491 -178.56 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.455 ' HB2' HD12 ' A' ' 29' ' ' ILE . 91.9 mt -79.4 164.62 23.86 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.833 0.349 . . . . 0.0 110.803 179.597 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 48.4 t -105.98 135.12 45.45 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.528 -178.368 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.621 ' HB ' HG23 ' A' ' 27' ' ' VAL . 8.4 mm -88.14 100.38 10.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 175.758 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 57.1 mt-10 -78.31 -48.23 16.09 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.049 -177.624 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 50' ' ' SER . . . . . 0.585 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 5.4 p -159.92 145.81 15.66 Favored 'General case' 0 N--CA 1.447 -0.592 0 CA-C-O 121.203 0.525 . . . . 0.0 111.797 -176.895 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 67.9 mt -115.38 106.25 20.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-N 115.099 -0.955 . . . . 0.0 108.595 175.791 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 3.1 m-20 59.96 -152.14 0.4 Allowed 'General case' 0 C--O 1.236 0.392 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 -171.778 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -76.14 28.61 1.41 Allowed Glycine 0 CA--C 1.524 0.63 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.696 176.913 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 57.4 mtm -130.44 101.83 17.23 Favored Pre-proline 0 C--N 1.326 -0.414 0 N-CA-C 109.676 -0.49 . . . . 0.0 109.676 176.934 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.585 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 60.0 Cg_endo -72.19 150.99 54.48 Favored 'Trans proline' 0 N--CA 1.46 -0.494 0 C-N-CA 122.027 1.818 . . . . 0.0 112.306 179.972 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 56' ' ' THR . . . . . 0.426 ' O ' ' HA2' ' A' ' 26' ' ' GLY . 6.2 p -111.33 83.66 1.81 Allowed 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 121.242 0.544 . . . . 0.0 111.863 -177.326 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 57' ' ' SER . . . . . 0.548 ' HA ' ' HA2' ' A' ' 26' ' ' GLY . 20.9 m -91.11 -13.64 32.69 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.571 -0.74 . . . . 0.0 109.846 176.507 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 5.4 m120 -125.5 164.64 20.06 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.672 -0.694 . . . . 0.0 109.939 -177.877 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 41.5 mt -73.81 -31.75 63.4 Favored 'General case' 0 N--CA 1.446 -0.665 0 CA-C-O 121.516 0.674 . . . . 0.0 109.774 172.0 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -68.28 -40.54 81.79 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.176 -0.92 . . . . 0.0 111.734 178.891 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 12.6 p -60.9 -39.6 89.94 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.72 0.295 . . . . 0.0 110.959 175.857 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 87.3 t80 -62.04 -43.51 98.69 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-O 121.478 0.656 . . . . 0.0 109.676 175.948 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 61.4 m -65.1 -48.9 72.05 Favored 'General case' 0 N--CA 1.446 -0.638 0 CA-C-N 115.08 -0.964 . . . . 0.0 111.757 179.28 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.53 -32.45 73.91 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.97 -176.575 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' ALA . . . . . 0.611 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -70.5 -48.34 56.1 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.014 -0.539 . . . . 0.0 109.928 178.58 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.408 HD23 ' HA ' ' A' ' 66' ' ' LEU . 4.0 mt -63.81 -35.28 80.1 Favored 'General case' 0 N--CA 1.449 -0.477 0 CA-C-N 115.451 -0.795 . . . . 0.0 111.94 -176.438 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 59.8 mtpt -70.48 -21.98 62.71 Favored 'General case' 0 C--N 1.33 -0.273 0 N-CA-C 112.115 0.413 . . . . 0.0 112.115 -178.357 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 71.6 p -90.47 -13.54 34.56 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.864 0.364 . . . . 0.0 111.425 -179.636 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.611 HG12 ' O ' ' A' ' 65' ' ' ALA . 41.8 mm -79.85 143.8 11.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.449 -0.342 . . . . 0.0 110.599 -177.758 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 3.5 m -83.72 157.13 22.27 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 176.723 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 25.1 t -74.26 119.68 22.06 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 176.239 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 91.67 21.29 34.56 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.668 -0.777 . . . . 0.0 111.523 -177.422 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 29.9 tt0 -98.91 146.46 25.96 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 179.858 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 57.5 t -98.38 110.81 26.64 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.848 0 CA-C-O 121.052 0.453 . . . . 0.0 110.473 -178.134 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.536 HG13 HD11 ' A' ' 77' ' ' ILE . 23.3 pt -103.84 163.57 3.86 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.679 179.773 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 6.3 t30 -115.9 117.07 29.14 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.782 -177.219 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.536 HD11 HG13 ' A' ' 75' ' ' ILE . 4.6 mp -113.5 118.93 59.53 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-O 121.26 0.552 . . . . 0.0 110.293 -177.301 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 32.5 m -91.93 117.17 29.55 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.39 175.796 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 71.7 p -114.35 170.89 7.97 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 110.179 -0.304 . . . . 0.0 110.179 -179.928 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 9.0 t70 -53.68 -41.75 67.2 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.931 -0.577 . . . . 0.0 112.064 179.54 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 36.8 tp60 -109.15 31.09 5.98 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.906 0.384 . . . . 0.0 111.451 -171.487 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 140.28 176.17 14.94 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 120.133 -1.032 . . . . 0.0 113.12 173.384 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 7.0 m -117.5 123.89 47.42 Favored 'General case' 0 C--N 1.318 -0.775 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 178.802 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 66.4 m-85 -121.21 154.27 36.5 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.982 0.42 . . . . 0.0 110.726 -176.747 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 56.1 p-80 -111.3 130.88 55.53 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 108.989 -0.745 . . . . 0.0 108.989 173.185 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.605 HD11 ' HB2' ' A' ' 38' ' ' ALA . 3.8 tt -124.09 137.44 54.57 Favored 'General case' 0 C--N 1.311 -1.084 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.053 -172.634 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 87' ' ' LYS . . . . . 0.457 ' N ' HD23 ' A' ' 86' ' ' LEU . 78.8 tttt -102.67 111.32 23.58 Favored 'General case' 0 C--N 1.311 -1.077 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 178.154 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.546 HG21 HG21 ' A' ' 69' ' ' ILE . 26.4 p -59.52 142.93 51.51 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.812 -0.631 . . . . 0.0 112.616 -172.405 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.887 0 N-CA-C 111.017 -0.833 . . . . 0.0 111.017 176.824 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.461 0.123 0 CA-C-O 121.056 0.455 . . . . 0.0 112.167 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 18.6 t80 -120.98 135.55 55.19 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 178.05 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 49.6 ttm -77.35 -53.32 7.83 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.972 -178.231 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 117.31 17.07 5.84 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.162 -1.018 . . . . 0.0 113.398 176.88 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.526 HG22 HG22 ' A' ' 32' ' ' VAL . 39.0 pt -130.17 153.05 38.37 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-O 120.857 0.36 . . . . 0.0 110.67 179.342 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 42.8 mtp85 -82.01 123.36 28.83 Favored 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 108.185 -1.042 . . . . 0.0 108.185 168.191 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -113.77 148.97 35.59 Favored 'General case' 0 C--N 1.314 -0.956 0 C-N-CA 120.643 -0.423 . . . . 0.0 110.479 -177.965 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 54.0 m -155.33 160.29 40.63 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 176.917 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 86.8 m-20 . . . . . 0 C--N 1.317 -0.83 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 177.604 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 35.9 t70 . . . . . 0 N--CA 1.463 0.209 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 90.44 128.39 3.78 Favored Glycine 0 N--CA 1.443 -0.9 0 CA-C-N 115.38 -0.827 . . . . 0.0 111.696 -175.664 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.53 HG23 ' HB ' ' A' ' 48' ' ' ILE . 4.6 m -69.28 141.56 17.17 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 N-CA-C 109.605 -0.516 . . . . 0.0 109.605 178.728 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 28' ' ' GLN . . . . . 0.446 ' HB3' HG13 ' A' ' 47' ' ' VAL . 8.3 pt20 -125.45 152.99 44.16 Favored 'General case' 0 C--N 1.319 -0.736 0 C-N-CA 119.17 -1.012 . . . . 0.0 111.879 -178.698 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.415 HG12 HD12 ' A' ' 102' ' ' ILE . 50.1 mt -77.32 130.81 35.83 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.61 0 CA-C-N 115.23 -0.896 . . . . 0.0 110.82 -178.784 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -89.94 -50.27 6.13 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.244 174.954 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 23.6 p -161.96 166.78 25.6 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 116.587 -0.279 . . . . 0.0 110.917 -179.301 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.488 HG13 HG22 ' A' ' 102' ' ' ILE . 45.8 t -110.38 140.36 29.78 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 N-CA-C 109.365 -0.605 . . . . 0.0 109.365 174.755 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 7.1 p -60.78 140.12 93.28 Favored Pre-proline 0 CA--C 1.537 0.473 0 N-CA-C 110.317 -0.253 . . . . 0.0 110.317 179.735 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 15.7 Cg_exo -69.46 65.39 1.62 Allowed 'Trans proline' 0 C--N 1.348 0.5 0 C-N-CA 122.925 2.416 . . . . 0.0 112.173 176.175 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 165.59 -169.26 39.92 Favored Glycine 0 N--CA 1.446 -0.7 0 N-CA-C 111.34 -0.704 . . . . 0.0 111.34 -179.707 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.773 ' HB2' ' HD2' ' A' ' 37' ' ' PRO . 60.6 p 56.39 179.46 0.03 OUTLIER Pre-proline 0 CA--C 1.545 0.761 0 C-N-CA 123.448 0.699 . . . . 0.0 111.513 179.432 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 37' ' ' PRO . . . . . 0.773 ' HD2' ' HB2' ' A' ' 36' ' ' SER . 58.4 Cg_endo -73.1 -159.45 0.08 OUTLIER 'Trans proline' 0 C--N 1.349 0.586 0 C-N-CA 121.967 1.778 . . . . 0.0 111.636 169.712 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.472 ' HB2' HD11 ' A' ' 86' ' ' LEU . . . 77.36 -33.43 0.19 Allowed 'General case' 0 N--CA 1.471 0.612 0 C-N-CA 123.395 0.678 . . . . 0.0 112.321 172.712 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 35.0 t -65.15 -21.18 66.75 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.595 -0.275 . . . . 0.0 111.082 -178.884 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 61.9 mttp -99.35 -0.06 41.86 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.918 0.39 . . . . 0.0 110.378 178.273 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.512 ' HB ' HD12 ' A' ' 42' ' ' LEU . 45.9 t -105.08 -53.73 6.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.899 -175.928 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.512 HD12 ' HB ' ' A' ' 41' ' ' VAL . 5.2 mp -106.88 164.08 12.42 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.997 0.427 . . . . 0.0 110.55 -178.578 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 43' ' ' THR . . . . . 0.449 ' O ' ' HG ' ' A' ' 46' ' ' LEU . 40.1 m -109.42 124.46 33.81 Favored Pre-proline 0 C--N 1.319 -0.729 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.87 177.109 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo -59.36 134.48 58.99 Favored 'Trans proline' 0 N--CA 1.46 -0.468 0 C-N-CA 122.277 1.985 . . . . 0.0 111.965 177.834 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 107.93 -16.52 36.28 Favored Glycine 0 N--CA 1.446 -0.638 0 C-N-CA 120.631 -0.795 . . . . 0.0 112.976 -179.695 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.449 ' HG ' ' O ' ' A' ' 43' ' ' THR . 75.6 mt -71.89 164.16 26.55 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.844 0.354 . . . . 0.0 110.642 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.446 HG13 ' HB3' ' A' ' 28' ' ' GLN . 23.1 t -107.46 142.63 19.72 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 116.194 -0.457 . . . . 0.0 109.939 179.8 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.53 ' HB ' HG23 ' A' ' 27' ' ' VAL . 10.6 mm -84.68 125.7 40.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 179.625 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -90.23 -54.05 4.19 Favored 'General case' 0 C--N 1.321 -0.674 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 176.143 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 50' ' ' SER . . . . . 0.444 ' CB ' ' HA ' ' A' ' 55' ' ' PRO . 20.6 m -154.44 152.63 30.37 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.419 -174.536 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.473 HG22 ' N ' ' A' ' 52' ' ' ASN . 46.3 mm -99.47 167.27 1.96 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.823 0 N-CA-C 107.64 -1.245 . . . . 0.0 107.64 171.871 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 52' ' ' ASN . . . . . 0.657 ' HB2' ' H ' ' A' ' 76' ' ' ASN . 54.1 t30 -50.51 103.44 0.05 Allowed 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 112.304 0.483 . . . . 0.0 112.304 -176.86 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 83.18 -15.36 34.05 Favored Glycine 0 N--CA 1.451 -0.343 0 CA-C-N 115.898 -0.592 . . . . 0.0 113.053 176.993 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 40.7 mtm -130.29 106.95 16.12 Favored Pre-proline 0 C--N 1.326 -0.447 0 O-C-N 122.643 -0.328 . . . . 0.0 110.87 -173.518 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.444 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 42.5 Cg_endo -68.06 148.96 76.61 Favored 'Trans proline' 0 C--N 1.343 0.242 0 C-N-CA 122.552 2.168 . . . . 0.0 112.199 -179.726 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 20.8 p -126.82 97.02 4.83 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 112.102 0.408 . . . . 0.0 112.102 -175.532 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 22.9 t -102.01 -14.18 17.26 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 121.362 0.601 . . . . 0.0 109.734 174.871 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 32.3 m-80 -124.29 167.36 14.43 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.174 -178.57 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 1.6 mt -68.99 -35.27 76.52 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.322 -0.399 . . . . 0.0 109.97 173.387 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 19.5 m -64.11 -38.8 92.36 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.219 179.472 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 3.3 p -66.98 -33.32 75.32 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 120.804 0.335 . . . . 0.0 110.887 178.566 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 55.2 t80 -71.63 -35.14 70.33 Favored 'General case' 0 C--N 1.331 -0.217 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 176.29 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 69.0 m -66.62 -50.06 64.23 Favored 'General case' 0 N--CA 1.444 -0.729 0 CA-C-N 115.365 -0.834 . . . . 0.0 111.296 178.39 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 64' ' ' ALA . . . . . 0.415 ' O ' ' HG2' ' A' ' 67' ' ' LYS . . . -63.43 -31.96 73.26 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.747 -0.661 . . . . 0.0 111.39 -178.194 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 65' ' ' ALA . . . . . 0.474 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -76.93 -34.61 57.65 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.161 0.505 . . . . 0.0 110.639 -179.842 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 1.5 tt -68.71 -44.18 74.45 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.892 -177.445 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 67' ' ' LYS . . . . . 0.415 ' HG2' ' O ' ' A' ' 64' ' ' ALA . 14.6 ptmm? -60.43 -23.47 64.43 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.924 -174.044 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 17.7 p -87.53 -14.15 41.08 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 112.043 0.386 . . . . 0.0 112.043 -179.869 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.474 HG12 ' O ' ' A' ' 65' ' ' ALA . 21.7 mm -85.65 136.81 22.03 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-O 120.84 0.352 . . . . 0.0 110.601 -177.87 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 50.9 m -106.92 162.49 13.78 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.669 178.762 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 79.4 t -62.01 135.22 26.83 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.249 0 O-C-N 123.436 0.46 . . . . 0.0 110.518 175.353 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 94.33 -14.94 64.32 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.873 -0.68 . . . . 0.0 112.655 176.001 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 -80.29 150.3 30.03 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.128 0.49 . . . . 0.0 110.385 -177.379 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 47.3 t -106.34 124.76 61.94 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 CA-C-N 115.67 -0.696 . . . . 0.0 109.643 179.099 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.405 HG21 HD12 ' A' ' 69' ' ' ILE . 18.3 pt -119.6 157.34 21.78 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 121.377 0.608 . . . . 0.0 111.886 -176.749 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 76' ' ' ASN . . . . . 0.657 ' H ' ' HB2' ' A' ' 52' ' ' ASN . 4.5 t30 -99.08 127.16 44.97 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 114.861 -1.063 . . . . 0.0 110.034 179.43 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 72.4 mt -132.36 112.64 19.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-O 121.088 0.47 . . . . 0.0 110.514 -177.471 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 78' ' ' THR . . . . . 0.557 ' HA ' ' HA ' ' A' ' 83' ' ' THR . 93.0 m -91.0 124.72 35.45 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.146 177.32 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 50.8 p -107.77 173.31 6.38 Favored 'General case' 0 C--N 1.319 -0.747 0 N-CA-C 109.457 -0.572 . . . . 0.0 109.457 174.703 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -63.17 -24.43 67.88 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 120.979 0.418 . . . . 0.0 111.259 -178.954 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 -106.77 16.86 23.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.444 -0.344 . . . . 0.0 111.606 -177.74 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 134.08 166.76 11.36 Favored Glycine 0 CA--C 1.516 0.123 0 C-N-CA 120.176 -1.011 . . . . 0.0 113.255 176.035 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 83' ' ' THR . . . . . 0.557 ' HA ' ' HA ' ' A' ' 78' ' ' THR . 35.2 m -98.07 137.83 36.27 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 120.934 0.397 . . . . 0.0 111.204 -179.709 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 74.9 m-85 -130.42 158.32 40.19 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.051 177.517 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 48.2 p-80 -112.43 130.39 56.0 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 174.401 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.472 HD11 ' HB2' ' A' ' 38' ' ' ALA . 28.4 tp -118.19 152.06 36.41 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.989 -173.01 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 60.4 tttp -119.95 123.82 44.47 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 178.152 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 25.7 p -72.62 137.48 46.14 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.325 0.583 . . . . 0.0 111.613 -177.613 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 89' ' ' GLY . . . . . 0.599 ' H ' ' HE1' ' A' ' 99' ' ' TYR . . . . . . . . 0 N--CA 1.448 -0.515 0 CA-C-N 115.642 -0.708 . . . . 0.0 111.797 177.123 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 -0.143 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 99' ' ' TYR . . . . . 0.599 ' HE1' ' H ' ' A' ' 89' ' ' GLY . 6.2 p90 -67.14 -30.48 70.48 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 114.76 -1.109 . . . . 0.0 113.631 -160.575 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 24.3 mmt 60.45 95.56 0.03 OUTLIER 'General case' 0 N--CA 1.465 0.279 0 CA-C-O 121.313 0.578 . . . . 0.0 110.501 -173.356 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -83.75 29.2 3.77 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.829 -0.701 . . . . 0.0 112.846 -175.362 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.488 HG22 HG13 ' A' ' 32' ' ' VAL . 37.4 pt -136.94 154.54 31.54 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.742 0 CA-C-O 121.066 0.46 . . . . 0.0 109.988 -179.689 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 103' ' ' ARG . . . . . 0.424 ' HD3' ' HA ' ' A' ' 103' ' ' ARG . 7.8 tpp180 -92.8 144.52 25.2 Favored 'General case' 0 C--N 1.315 -0.908 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 175.809 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.4 t -145.47 154.68 42.5 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-O 121.417 0.627 . . . . 0.0 111.266 178.443 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 9.3 p -128.6 171.44 12.15 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-N 114.643 -1.162 . . . . 0.0 109.884 177.838 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 59.6 t30 . . . . . 0 C--N 1.317 -0.84 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.579 -174.348 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 28.5 p-10 . . . . . 0 C--O 1.233 0.234 0 N-CA-C 112.135 0.42 . . . . 0.0 112.135 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 96.53 133.02 7.5 Favored Glycine 0 N--CA 1.446 -0.689 0 N-CA-C 111.15 -0.78 . . . . 0.0 111.15 -176.953 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.447 ' HA ' ' HA ' ' A' ' 106' ' ' ASN . 19.6 m -78.78 140.4 16.94 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.742 0 CA-C-O 120.98 0.419 . . . . 0.0 110.842 -176.93 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 28' ' ' GLN . . . . . 0.48 ' HB2' ' O ' ' A' ' 46' ' ' LEU . 25.0 pt20 -109.84 157.59 19.04 Favored 'General case' 0 C--N 1.317 -0.823 0 C-N-CA 120.22 -0.592 . . . . 0.0 109.778 175.662 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.551 HG23 HD11 ' A' ' 48' ' ' ILE . 2.2 pt -79.84 98.49 3.26 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.14 176.523 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -53.78 -55.64 24.62 Favored 'General case' 0 CA--C 1.504 -0.816 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.13 177.509 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 6.2 p -155.99 144.56 20.18 Favored 'General case' 0 N--CA 1.441 -0.908 0 CA-C-N 115.045 -0.979 . . . . 0.0 111.438 -178.152 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.603 ' HA ' HG22 ' A' ' 102' ' ' ILE . 52.3 t -87.62 141.34 14.46 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.01 0 CA-C-N 114.965 -1.016 . . . . 0.0 108.664 171.651 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 48.3 t -83.18 105.38 5.12 Favored Pre-proline 0 C--N 1.322 -0.592 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 174.937 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 34' ' ' PRO . . . . . 0.505 ' HD3' ' O ' ' A' ' 32' ' ' VAL . 31.5 Cg_exo -58.19 113.64 1.62 Allowed 'Trans proline' 0 C--O 1.236 0.406 0 C-N-CA 122.774 2.316 . . . . 0.0 112.179 -175.305 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 133.61 -20.84 4.08 Favored Glycine 0 N--CA 1.446 -0.687 0 N-CA-C 111.227 -0.749 . . . . 0.0 111.227 -178.455 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 56.4 p -81.87 161.13 61.89 Favored Pre-proline 0 C--N 1.323 -0.575 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 177.692 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -59.03 -24.83 75.31 Favored 'Trans proline' 0 C--N 1.344 0.312 0 C-N-CA 122.36 2.04 . . . . 0.0 111.743 175.96 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.404 ' HB2' HD11 ' A' ' 86' ' ' LEU . . . -66.78 -27.86 67.93 Favored 'General case' 0 N--CA 1.454 -0.24 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.553 -179.359 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.533 ' HA ' HG11 ' A' ' 32' ' ' VAL . 13.2 m -63.2 -22.39 66.84 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.91 0.386 . . . . 0.0 111.454 -177.65 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 65.3 mttm -97.27 -17.58 19.72 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.487 -175.76 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.65 ' HB ' HD23 ' A' ' 42' ' ' LEU . 60.6 t -98.23 -49.52 11.68 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.871 -172.354 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.65 HD23 ' HB ' ' A' ' 41' ' ' VAL . 0.3 OUTLIER -117.12 178.23 4.43 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.561 0.696 . . . . 0.0 112.343 -173.745 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 56.8 m -128.42 128.99 23.6 Favored Pre-proline 0 C--N 1.322 -0.602 0 CA-C-N 114.693 -1.14 . . . . 0.0 109.593 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -64.66 152.95 79.96 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.611 2.207 . . . . 0.0 112.305 -177.643 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 99.82 -1.92 56.85 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.553 -0.832 . . . . 0.0 112.582 -178.024 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.495 ' HB2' HD11 ' A' ' 29' ' ' ILE . 85.1 mt -89.81 164.15 14.75 Favored 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 110.286 -0.264 . . . . 0.0 110.286 177.271 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 40.4 t -103.27 141.1 19.77 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 178.005 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.551 HD11 HG23 ' A' ' 29' ' ' ILE . 57.5 mt -99.76 120.23 48.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 121.051 0.453 . . . . 0.0 110.0 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 14.5 tt0 -78.81 -56.23 4.57 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 121.489 0.661 . . . . 0.0 109.834 176.781 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 50' ' ' SER . . . . . 0.677 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 11.8 p -146.89 149.15 32.68 Favored 'General case' 0 N--CA 1.444 -0.741 0 CA-C-N 115.342 -0.844 . . . . 0.0 112.551 -171.001 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.538 ' HA ' ' O ' ' A' ' 76' ' ' ASN . 55.4 mt -126.7 114.03 35.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 114.561 -1.2 . . . . 0.0 108.573 172.751 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 6.4 t-20 63.13 -152.65 0.33 Allowed 'General case' 0 CA--C 1.532 0.278 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 -171.01 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -76.84 3.61 55.82 Favored Glycine 0 CA--C 1.52 0.392 0 C-N-CA 120.533 -0.841 . . . . 0.0 112.97 179.509 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 3.8 mpp? -111.76 105.39 56.59 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 120.725 0.298 . . . . 0.0 110.76 -178.894 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.677 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 47.0 Cg_endo -69.3 148.57 68.35 Favored 'Trans proline' 0 N--CA 1.462 -0.362 0 C-N-CA 122.303 2.002 . . . . 0.0 112.186 176.243 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 20.8 p -109.96 95.71 5.77 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.663 -176.484 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 14.7 p -92.85 -19.87 21.26 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.059 0.457 . . . . 0.0 110.738 177.367 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 93.3 m-20 -125.56 173.52 8.89 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 178.153 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -82.48 -33.53 28.35 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 121.225 0.536 . . . . 0.0 110.257 176.683 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 6.1 m -70.08 -29.54 66.55 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.043 179.344 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 24.6 p -67.82 -38.5 83.32 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 121.136 0.493 . . . . 0.0 109.999 176.34 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 67.2 t80 -59.26 -44.15 92.41 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-N 115.437 -0.801 . . . . 0.0 109.709 173.475 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 63' ' ' SER . . . . . 0.423 ' O ' ' HG3' ' A' ' 67' ' ' LYS . 70.3 m -63.71 -46.09 87.03 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.135 -0.938 . . . . 0.0 111.832 179.314 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.85 -33.68 74.62 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.118 179.652 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 65' ' ' ALA . . . . . 0.416 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -77.77 -36.17 50.83 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.147 0.499 . . . . 0.0 110.194 178.586 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -60.61 -29.91 69.52 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.139 179.124 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 67' ' ' LYS . . . . . 0.423 ' HG3' ' O ' ' A' ' 63' ' ' SER . 58.7 mtpt -58.79 -32.46 69.34 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.448 178.63 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 34.8 p -91.06 -14.71 30.8 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 112.216 0.45 . . . . 0.0 112.216 -175.991 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.416 HG12 ' O ' ' A' ' 65' ' ' ALA . 30.5 mm -82.26 140.53 16.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 N-CA-C 110.283 -0.266 . . . . 0.0 110.283 -177.695 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 14.3 t -115.64 178.04 4.45 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 120.958 0.409 . . . . 0.0 110.849 -179.575 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 20.9 t -79.99 120.78 32.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.858 -178.105 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 98.17 5.65 57.12 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.645 -0.788 . . . . 0.0 111.879 -179.815 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 15.2 tp10 -81.36 147.98 29.57 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.301 -0.45 . . . . 0.0 109.913 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 57.3 t -109.38 108.95 26.61 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.856 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.37 179.252 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 21.6 pt -109.84 153.84 11.5 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.773 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.193 -175.375 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 76' ' ' ASN . . . . . 0.538 ' O ' ' HA ' ' A' ' 51' ' ' ILE . 5.4 t30 -90.07 132.16 35.55 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.647 177.633 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.418 HG22 HG23 ' A' ' 79' ' ' THR . 61.7 mt -128.53 116.5 41.83 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-O 121.295 0.569 . . . . 0.0 110.465 -179.645 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 4.6 m -99.3 102.25 13.81 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.141 177.783 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.483 HG22 HG12 ' A' ' 48' ' ' ILE . 73.4 p -102.16 170.15 8.28 Favored 'General case' 0 C--N 1.324 -0.519 0 C-N-CA 120.674 -0.41 . . . . 0.0 110.296 178.081 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -51.07 -38.76 53.55 Favored 'General case' 0 N--CA 1.466 0.365 0 O-C-N 123.801 0.688 . . . . 0.0 112.649 -176.279 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 31.4 mt-30 -127.44 20.25 6.74 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 111.92 0.341 . . . . 0.0 111.92 -174.659 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -165.68 119.96 0.9 Allowed Glycine 0 N--CA 1.446 -0.653 0 C-N-CA 119.751 -1.214 . . . . 0.0 113.465 179.04 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 13.6 m -106.3 109.21 21.07 Favored 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 172.479 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 84' ' ' PHE . . . . . 0.453 ' CZ ' ' HB3' ' A' ' 42' ' ' LEU . 7.3 p90 -145.68 177.46 8.87 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 121.225 0.536 . . . . 0.0 111.807 -172.972 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -111.9 150.82 29.93 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.388 -0.823 . . . . 0.0 109.756 172.055 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.439 HD22 ' HG3' ' A' ' 100' ' ' MET . 7.5 tt -134.11 141.39 47.11 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-O 121.218 0.533 . . . . 0.0 110.706 -176.81 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 82.3 tttt -94.21 116.38 28.77 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.044 -0.98 . . . . 0.0 109.275 177.51 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 32.1 p -59.25 123.49 16.87 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.584 0.707 . . . . 0.0 111.414 -176.934 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.434 -1.453 0 CA-C-N 114.991 -1.004 . . . . 0.0 111.403 -178.363 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.455 -0.186 0 CA-C-O 120.837 0.351 . . . . 0.0 110.565 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 69.8 t80 -110.88 -23.84 10.76 Favored 'General case' 0 C--N 1.323 -0.559 0 C-N-CA 120.746 -0.382 . . . . 0.0 110.465 -178.21 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 100' ' ' MET . . . . . 0.439 ' HG3' HD22 ' A' ' 86' ' ' LEU . 44.3 ttm 70.63 -59.96 0.51 Allowed 'General case' 0 N--CA 1.468 0.455 0 CA-C-N 115.551 -0.749 . . . . 0.0 111.184 179.46 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 124.21 9.31 5.63 Favored Glycine 0 C--O 1.227 -0.326 0 C-N-CA 121.023 -0.608 . . . . 0.0 113.11 178.259 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.603 HG22 ' HA ' ' A' ' 32' ' ' VAL . 2.8 pp -136.97 165.71 27.4 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-O 120.909 0.385 . . . . 0.0 110.51 -179.028 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 103' ' ' ARG . . . . . 0.428 ' HD3' ' HA ' ' A' ' 103' ' ' ARG . 9.1 mmt180 -114.63 129.63 56.7 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.12 172.023 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 104' ' ' THR . . . . . 0.591 HG23 HD13 ' A' ' 102' ' ' ILE . 3.1 p -110.05 143.19 40.43 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.007 0.432 . . . . 0.0 111.724 -177.836 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 18.0 m -151.24 151.11 31.4 Favored 'General case' 0 C--N 1.318 -0.765 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 173.487 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 106' ' ' ASN . . . . . 0.447 ' HA ' ' HA ' ' A' ' 27' ' ' VAL . 13.4 m120 . . . . . 0 C--N 1.317 -0.845 0 CA-C-O 121.653 0.74 . . . . 0.0 109.845 -178.203 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 . . . . . 0 N--CA 1.466 0.337 0 CA-C-O 120.79 0.328 . . . . 0.0 110.941 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.574 ' HA2' ' HA ' ' A' ' 57' ' ' SER . . . 106.81 176.1 23.01 Favored Glycine 0 N--CA 1.443 -0.86 0 N-CA-C 111.208 -0.757 . . . . 0.0 111.208 -175.271 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.609 HG23 ' HB ' ' A' ' 48' ' ' ILE . 19.6 m -102.06 131.08 50.79 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.812 0 CA-C-O 121.393 0.616 . . . . 0.0 110.978 177.717 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 36.4 tp60 -97.04 135.04 39.6 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.456 -0.793 . . . . 0.0 110.557 -178.8 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.552 HD12 ' HB2' ' A' ' 46' ' ' LEU . 57.8 mt -78.59 112.56 16.76 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.546 176.441 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -74.12 -69.22 0.46 Allowed 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.932 -176.921 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 9.6 p -149.49 148.97 30.04 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.434 -177.05 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.581 HG13 HG22 ' A' ' 102' ' ' ILE . 57.4 t -96.07 114.07 31.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-N 115.642 -0.708 . . . . 0.0 109.773 176.915 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 47.0 t -98.2 128.1 34.51 Favored Pre-proline 0 C--N 1.318 -0.779 0 CA-C-N 116.062 -0.517 . . . . 0.0 109.998 -176.403 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo -63.59 86.25 0.13 Allowed 'Trans proline' 0 C--O 1.234 0.32 0 C-N-CA 122.748 2.299 . . . . 0.0 112.494 -179.923 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -151.48 20.08 0.92 Allowed Glycine 0 N--CA 1.446 -0.643 0 CA-C-N 115.529 -0.76 . . . . 0.0 111.455 177.574 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.447 ' HB2' ' HD2' ' A' ' 37' ' ' PRO . 67.8 p -174.9 160.97 2.43 Favored Pre-proline 0 C--N 1.328 -0.36 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 -178.525 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 37' ' ' PRO . . . . . 0.447 ' HD2' ' HB2' ' A' ' 36' ' ' SER . 29.4 Cg_endo -63.65 -5.21 8.29 Favored 'Trans proline' 0 CA--C 1.532 0.405 0 C-N-CA 122.581 2.187 . . . . 0.0 112.631 179.075 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -67.95 -23.59 65.08 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.619 -0.264 . . . . 0.0 111.066 -179.862 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 39' ' ' SER . . . . . 0.57 ' HA ' HG11 ' A' ' 32' ' ' VAL . 26.7 m -65.07 -24.87 67.58 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.188 0.518 . . . . 0.0 111.427 -178.687 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 1.6 tmtp? -88.14 -26.76 22.29 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.519 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 41' ' ' VAL . . . . . 0.535 ' HB ' HD12 ' A' ' 42' ' ' LEU . 46.3 t -92.17 -49.92 12.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.8 -173.217 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.535 HD12 ' HB ' ' A' ' 41' ' ' VAL . 6.6 mp -95.38 168.38 10.75 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.329 0.585 . . . . 0.0 111.638 -172.956 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -133.01 144.03 51.06 Favored Pre-proline 0 C--N 1.322 -0.622 0 CA-C-N 115.204 -0.907 . . . . 0.0 109.861 176.418 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 78.8 Cg_endo -78.69 155.21 27.3 Favored 'Trans proline' 0 N--CA 1.463 -0.316 0 C-N-CA 122.721 2.281 . . . . 0.0 113.389 -176.0 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 94.08 20.99 29.0 Favored Glycine 0 N--CA 1.448 -0.528 0 C-N-CA 120.619 -0.801 . . . . 0.0 113.273 177.646 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.552 ' HB2' HD12 ' A' ' 29' ' ' ILE . 44.1 mt -108.33 164.26 12.47 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 117.028 0.414 . . . . 0.0 110.928 -179.226 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 61.5 t -108.42 135.14 48.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.096 177.599 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.609 ' HB ' HG23 ' A' ' 27' ' ' VAL . 64.1 mt -96.29 124.63 49.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-O 120.964 0.411 . . . . 0.0 110.837 -179.594 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -84.51 -50.57 7.61 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.049 178.099 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 50' ' ' SER . . . . . 0.638 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 24.2 p -149.17 152.21 35.66 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.919 -0.582 . . . . 0.0 112.234 -175.126 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 45.7 mm -111.98 98.99 7.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 114.954 -1.021 . . . . 0.0 110.489 177.05 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 52' ' ' ASN . . . . . 0.463 ' HA ' ' HB3' ' A' ' 76' ' ' ASN . 6.8 t-20 57.72 41.7 24.84 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-N 115.336 -0.847 . . . . 0.0 111.823 172.867 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 104.99 -30.23 10.36 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.641 176.539 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 72.0 mtm -97.53 112.25 60.76 Favored Pre-proline 0 C--N 1.326 -0.422 0 N-CA-C 109.673 -0.491 . . . . 0.0 109.673 178.308 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.638 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 56.0 Cg_endo -69.67 139.48 40.65 Favored 'Trans proline' 0 N--CA 1.459 -0.537 0 C-N-CA 122.26 1.974 . . . . 0.0 112.794 -175.743 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 31.3 p -113.57 83.27 1.82 Allowed 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.346 0.593 . . . . 0.0 111.149 -178.518 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 57' ' ' SER . . . . . 0.574 ' HA ' ' HA2' ' A' ' 26' ' ' GLY . 48.0 t -91.88 -13.97 30.44 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.419 179.616 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 81.8 m-20 -129.16 -179.85 5.36 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 109.195 -0.669 . . . . 0.0 109.195 -178.674 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.421 HD23 ' HA ' ' A' ' 59' ' ' LEU . 17.5 mt -75.93 -45.42 35.25 Favored 'General case' 0 N--CA 1.447 -0.602 0 CA-C-O 120.793 0.33 . . . . 0.0 110.902 175.104 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 6.9 m -61.62 -36.47 80.84 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.42 -177.552 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 19.3 p -64.5 -37.3 87.08 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.133 0.492 . . . . 0.0 110.498 176.217 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 70.7 t80 -70.43 -39.19 74.52 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.69 -0.686 . . . . 0.0 109.504 179.285 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 61.3 m -62.29 -48.53 79.46 Favored 'General case' 0 N--CA 1.444 -0.732 0 CA-C-N 115.314 -0.857 . . . . 0.0 111.666 176.894 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.62 -34.42 75.63 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.987 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -74.01 -44.35 54.81 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.965 -0.562 . . . . 0.0 110.425 179.239 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -61.9 -35.95 79.88 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.454 -176.738 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -55.86 -34.71 65.71 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.929 -176.807 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 71.3 p -78.94 -14.24 59.33 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.722 0.296 . . . . 0.0 111.719 -177.574 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.51 HD12 HG22 ' A' ' 75' ' ' ILE . 29.0 mm -81.04 126.74 39.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.903 0.382 . . . . 0.0 111.024 -175.826 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 20.2 m -120.1 -171.8 2.22 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.961 -176.792 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 40.2 t -74.2 139.81 18.67 Favored 'Isoleucine or valine' 0 C--O 1.233 0.218 0 N-CA-C 110.145 -0.317 . . . . 0.0 110.145 176.907 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 69.02 32.05 72.86 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.596 -0.811 . . . . 0.0 111.493 179.382 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 9.6 tp10 -104.84 147.9 27.24 Favored 'General case' 0 N--CA 1.444 -0.746 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 -178.77 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 44.4 t -110.1 106.9 21.61 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 N-CA-C 109.492 -0.559 . . . . 0.0 109.492 -179.131 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 75' ' ' ILE . . . . . 0.51 HG22 HD12 ' A' ' 69' ' ' ILE . 30.5 pt -95.62 154.52 3.46 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.884 -177.2 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 76' ' ' ASN . . . . . 0.463 ' HB3' ' HA ' ' A' ' 52' ' ' ASN . 64.5 t30 -122.91 108.51 13.05 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.025 -176.797 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.465 HD12 HD21 ' A' ' 86' ' ' LEU . 60.4 mt -106.8 110.75 32.78 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.968 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.501 -175.131 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 78' ' ' THR . . . . . 0.476 ' HA ' ' HA ' ' A' ' 83' ' ' THR . 25.5 m -89.29 113.89 25.21 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.471 177.144 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 79' ' ' THR . . . . . 0.457 HG23 HG22 ' A' ' 77' ' ' ILE . 71.3 p -120.45 -178.54 3.72 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 121.06 0.457 . . . . 0.0 111.312 -176.323 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -62.81 -26.5 68.77 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.379 -0.828 . . . . 0.0 111.069 173.678 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 26.9 mm-40 -93.55 9.32 37.22 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.04 0.448 . . . . 0.0 111.351 179.758 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 114.95 -177.75 17.53 Favored Glycine 0 N--CA 1.444 -0.782 0 C-N-CA 120.624 -0.798 . . . . 0.0 112.637 176.625 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 83' ' ' THR . . . . . 0.476 ' HA ' ' HA ' ' A' ' 78' ' ' THR . 10.6 m -97.93 113.47 25.32 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.798 -0.201 . . . . 0.0 110.727 -178.096 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 46.1 m-85 -111.75 148.06 34.31 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 110.18 -0.304 . . . . 0.0 110.18 179.389 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 25.7 p-80 -122.95 125.42 45.27 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-O 120.871 0.367 . . . . 0.0 110.018 175.498 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.465 HD21 HD12 ' A' ' 77' ' ' ILE . 0.7 OUTLIER -130.89 156.99 44.12 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.849 -176.059 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 19.5 ptmt -99.77 146.58 26.4 Favored 'General case' 0 N--CA 1.442 -0.834 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.211 179.206 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 33.3 p -83.92 128.39 34.51 Favored 'General case' 0 C--N 1.315 -0.915 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.732 175.857 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.833 0 C-N-CA 120.936 -0.65 . . . . 0.0 112.207 -178.811 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.469 0.525 0 N-CA-C 112.124 0.416 . . . . 0.0 112.124 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 4.5 t80 -88.24 -55.8 3.59 Favored 'General case' 0 C--N 1.327 -0.412 0 C-N-CA 120.266 -0.574 . . . . 0.0 110.491 178.122 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 25.2 ttt 59.01 94.74 0.03 OUTLIER 'General case' 0 N--CA 1.468 0.44 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.929 178.784 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -84.44 38.49 2.9 Favored Glycine 0 C--O 1.225 -0.453 0 CA-C-N 115.92 -0.582 . . . . 0.0 114.316 -172.007 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.581 HG22 HG13 ' A' ' 32' ' ' VAL . 2.1 pp -137.92 140.99 39.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 172.43 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 103' ' ' ARG . . . . . 0.607 ' NE ' ' HA ' ' A' ' 103' ' ' ARG . 0.0 OUTLIER -101.42 141.56 34.11 Favored 'General case' 0 C--N 1.317 -0.838 0 C-N-CA 120.706 -0.398 . . . . 0.0 110.307 -177.067 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.5 p -127.48 151.43 48.86 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.577 -177.847 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 20.0 m -151.26 154.49 36.89 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 174.388 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 37.2 p30 . . . . . 0 C--N 1.32 -0.702 0 CA-C-O 120.574 0.226 . . . . 0.0 111.345 -176.38 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.452 -0.367 0 CA-C-O 120.769 0.318 . . . . 0.0 111.233 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 93.74 157.82 33.42 Favored Glycine 0 N--CA 1.444 -0.785 0 C-N-CA 120.93 -0.653 . . . . 0.0 111.485 -178.352 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' VAL . . . . . 0.637 HG23 ' HB ' ' A' ' 48' ' ' ILE . 3.8 m -105.27 118.93 53.59 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.713 0 CA-C-O 121.704 0.764 . . . . 0.0 110.844 -179.164 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 34.8 tp60 -103.69 136.0 44.21 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.271 -0.877 . . . . 0.0 110.841 -177.09 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' ILE . . . . . 0.531 HD11 HD11 ' A' ' 48' ' ' ILE . 42.3 mm -68.98 113.16 4.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.14 175.543 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 24.5 t70 -76.01 -63.53 1.29 Allowed 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 115.749 -0.659 . . . . 0.0 109.623 176.759 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 45.3 t -150.69 150.26 30.85 Favored 'General case' 0 N--CA 1.446 -0.654 0 CA-C-N 115.372 -0.831 . . . . 0.0 111.063 -179.571 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' VAL . . . . . 0.571 HG22 HG22 ' A' ' 102' ' ' ILE . 64.0 t -96.36 112.8 29.25 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.946 0 CA-C-N 114.95 -1.023 . . . . 0.0 109.123 174.577 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.461 ' HA ' ' HD3' ' A' ' 34' ' ' PRO . 19.5 m -83.33 127.12 69.89 Favored Pre-proline 0 C--N 1.324 -0.526 0 CA-C-O 121.065 0.46 . . . . 0.0 111.261 -176.247 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 34' ' ' PRO . . . . . 0.461 ' HD3' ' HA ' ' A' ' 33' ' ' VAL . 21.3 Cg_exo -66.1 146.46 81.98 Favored 'Trans proline' 0 C--O 1.237 0.429 0 C-N-CA 122.982 2.455 . . . . 0.0 112.058 178.288 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 114.24 -25.85 10.24 Favored Glycine 0 N--CA 1.45 -0.393 0 N-CA-C 111.507 -0.637 . . . . 0.0 111.507 -178.302 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 50.4 m -101.77 159.2 30.12 Favored Pre-proline 0 C--N 1.319 -0.721 0 CA-C-N 115.442 -0.379 . . . . 0.0 110.331 178.85 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_exo -60.19 -20.18 60.62 Favored 'Trans proline' 0 C--N 1.347 0.487 0 C-N-CA 123.057 2.505 . . . . 0.0 112.958 -178.102 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -66.15 -25.84 67.15 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.973 -176.808 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 13.4 m -63.2 -22.95 67.2 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.365 -0.38 . . . . 0.0 111.738 -176.224 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 57.4 tttm -110.11 11.53 23.77 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.907 0.384 . . . . 0.0 110.514 -176.465 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 96.5 t -120.73 -55.25 3.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 120.761 0.315 . . . . 0.0 111.275 -177.063 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 97.7 mt -107.69 167.19 10.13 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.083 0.468 . . . . 0.0 111.434 -174.142 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 43' ' ' THR . . . . . 0.405 ' HA ' ' HD3' ' A' ' 44' ' ' PRO . 20.1 p -113.9 148.06 39.09 Favored Pre-proline 0 N--CA 1.446 -0.663 0 CA-C-N 115.323 -0.853 . . . . 0.0 109.626 175.839 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.405 ' HD3' ' HA ' ' A' ' 43' ' ' THR . 5.1 Cg_exo -74.79 141.1 26.89 Favored 'Trans proline' 0 N--CA 1.458 -0.565 0 C-N-CA 122.285 1.99 . . . . 0.0 111.926 -178.054 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 105.36 -2.21 40.06 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.626 -0.797 . . . . 0.0 113.056 179.916 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 46' ' ' LEU . . . . . 0.453 HD22 ' HB3' ' A' ' 80' ' ' ASP . 72.7 mt -78.65 164.8 24.32 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.257 0.551 . . . . 0.0 111.556 -178.849 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 61.8 t -109.51 138.64 36.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 115.801 -0.636 . . . . 0.0 109.378 174.63 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 48' ' ' ILE . . . . . 0.637 ' HB ' HG23 ' A' ' 27' ' ' VAL . 88.4 mt -94.68 111.84 26.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 120.971 0.415 . . . . 0.0 110.03 177.968 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -75.07 -51.4 13.6 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.484 -178.717 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 50' ' ' SER . . . . . 0.563 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 31.5 p -156.61 156.91 34.35 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.76 -0.655 . . . . 0.0 112.29 -174.912 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.762 HG22 ' H ' ' A' ' 52' ' ' ASN . 9.0 mm -100.07 -171.37 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 173.649 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 52' ' ' ASN . . . . . 0.762 ' H ' HG22 ' A' ' 51' ' ' ILE . 1.7 m-20 -48.72 92.99 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 123.039 0.536 . . . . 0.0 112.089 178.869 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 72.19 -10.07 4.96 Favored Glycine 0 CA--C 1.521 0.461 0 C-N-CA 121.384 -0.436 . . . . 0.0 113.787 175.517 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 71.0 mtm -125.71 112.69 25.02 Favored Pre-proline 0 C--N 1.327 -0.403 0 CA-C-N 117.147 0.474 . . . . 0.0 110.863 -175.882 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 55' ' ' PRO . . . . . 0.563 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 4.4 Cg_exo -78.65 137.44 14.42 Favored 'Trans proline' 0 N--CA 1.46 -0.488 0 C-N-CA 122.897 2.398 . . . . 0.0 111.661 175.97 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 40.1 p -121.48 116.76 25.31 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.909 0.385 . . . . 0.0 111.77 -178.857 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 30.7 t -86.57 -53.4 4.99 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.32 174.106 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 15.5 m120 -86.24 157.11 20.03 Favored 'General case' 0 C--N 1.318 -0.762 0 C-N-CA 120.228 -0.589 . . . . 0.0 109.629 -169.799 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 59' ' ' LEU . . . . . 0.564 ' HG ' ' HB2' ' A' ' 106' ' ' ASN . 3.4 mt -65.11 -38.55 91.04 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.1 0.476 . . . . 0.0 110.4 177.992 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 3.3 m -64.44 -38.38 90.84 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.826 -0.624 . . . . 0.0 111.109 179.432 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 11.9 p -71.48 -32.1 67.88 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.958 0.408 . . . . 0.0 110.565 177.733 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 72.2 t80 -65.51 -44.34 87.28 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.893 -0.594 . . . . 0.0 109.789 175.467 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 7.9 t -63.17 -37.52 87.55 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.03 178.062 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.04 -33.07 74.92 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.015 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 65' ' ' ALA . . . . . 0.505 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -76.9 -40.03 48.83 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.256 0.55 . . . . 0.0 110.204 176.858 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 66' ' ' LEU . . . . . 0.436 HD21 ' SD ' ' A' ' 100' ' ' MET . 0.4 OUTLIER -60.5 -38.06 83.1 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.61 -0.723 . . . . 0.0 111.406 179.444 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -74.24 -6.43 47.87 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.996 -0.547 . . . . 0.0 112.301 -177.614 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 22.5 p -100.4 -12.61 19.25 Favored 'General case' 0 C--N 1.324 -0.541 0 C-N-CA 120.754 -0.379 . . . . 0.0 110.841 174.142 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.505 HG12 ' O ' ' A' ' 65' ' ' ALA . 47.2 mm -80.33 135.62 24.98 Favored 'Isoleucine or valine' 0 C--O 1.234 0.275 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.872 -178.667 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 1.4 m -83.03 165.7 19.4 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.345 -177.027 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 32.5 t -76.75 124.12 34.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.595 174.404 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 79.73 25.62 58.01 Favored Glycine 0 N--CA 1.446 -0.65 0 C-N-CA 120.314 -0.946 . . . . 0.0 111.178 -176.573 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 8.1 tp10 -85.6 147.81 26.22 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 178.423 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 56.9 t -104.61 98.56 6.98 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.978 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 176.05 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 26.0 pt -91.18 164.69 2.07 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.779 0 CA-C-O 121.388 0.613 . . . . 0.0 111.506 -173.956 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 33.2 t30 -116.06 115.88 26.89 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 115.158 -0.928 . . . . 0.0 109.615 -178.929 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 24.1 mt -120.61 107.74 21.35 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.315 -175.533 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 78' ' ' THR . . . . . 0.481 ' HA ' ' HA ' ' A' ' 83' ' ' THR . 30.6 m -80.78 118.37 22.25 Favored 'General case' 0 C--N 1.317 -0.807 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 173.381 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 72.6 p -119.81 -173.38 2.53 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.319 0.58 . . . . 0.0 111.891 -173.431 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 80' ' ' ASP . . . . . 0.453 ' HB3' HD22 ' A' ' 46' ' ' LEU . 20.8 t70 -56.71 -36.13 69.32 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 114.713 -1.13 . . . . 0.0 111.44 176.412 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 96.8 mt-30 -93.73 7.6 44.19 Favored 'General case' 0 C--O 1.235 0.295 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.342 -177.259 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 112.67 -169.35 12.97 Favored Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.655 177.779 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 83' ' ' THR . . . . . 0.481 ' HA ' ' HA ' ' A' ' 78' ' ' THR . 9.2 m -77.84 127.16 31.96 Favored 'General case' 0 C--N 1.321 -0.652 0 C-N-CA 122.559 0.344 . . . . 0.0 111.636 -177.973 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 97.7 m-85 -132.11 158.44 41.63 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.898 0.38 . . . . 0.0 110.108 174.69 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 33.1 m-70 -118.51 137.62 53.08 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 176.513 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 86' ' ' LEU . . . . . 0.493 HD23 ' N ' ' A' ' 87' ' ' LYS . 1.6 tt -135.41 138.9 43.72 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-O 120.884 0.373 . . . . 0.0 110.571 -173.237 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 87' ' ' LYS . . . . . 0.493 ' N ' HD23 ' A' ' 86' ' ' LEU . 38.6 ttpt -95.97 123.07 39.41 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 116.09 -0.505 . . . . 0.0 109.963 177.706 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.44 HG21 HG21 ' A' ' 69' ' ' ILE . 41.1 p -69.4 142.49 53.89 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.902 -0.59 . . . . 0.0 112.033 -174.974 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.823 0 CA-C-N 115.692 -0.686 . . . . 0.0 112.833 -178.367 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.181 0 N-CA-C 111.945 0.35 . . . . 0.0 111.945 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 35.3 t80 -117.4 -15.67 10.31 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.759 -179.501 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 100' ' ' MET . . . . . 0.436 ' SD ' HD21 ' A' ' 66' ' ' LEU . 82.7 mtp 58.43 -153.97 0.37 Allowed 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.751 -176.858 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -155.53 32.05 0.63 Allowed Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.259 -0.972 . . . . 0.0 112.904 -179.778 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 102' ' ' ILE . . . . . 0.571 HG22 HG22 ' A' ' 32' ' ' VAL . 2.8 pp -144.21 166.26 12.92 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 178.871 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 38.0 mmt180 -108.49 132.49 53.76 Favored 'General case' 0 C--N 1.317 -0.825 0 N-CA-C 109.278 -0.638 . . . . 0.0 109.278 176.201 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -110.76 132.35 54.27 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 121.335 0.588 . . . . 0.0 111.917 -177.962 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 42.3 m -109.89 165.69 11.51 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.235 -0.893 . . . . 0.0 109.799 175.163 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 106' ' ' ASN . . . . . 0.564 ' HB2' ' HG ' ' A' ' 59' ' ' LEU . 64.9 t30 . . . . . 0 C--N 1.313 -1.011 0 CA-C-O 122.013 0.911 . . . . 0.0 108.582 179.713 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' GLN . . . . . . . . . . . . . 27.2 mp0 . . . . . 0 N--CA 1.453 -0.325 0 CA-C-O 120.764 0.316 . . . . 0.0 110.701 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.457 ' HB3' ' HA ' ' A' ' 58' ' ' ASN . 7.4 Cg_exo -72.72 128.3 13.23 Favored 'Trans proline' 0 N--CA 1.461 -0.429 0 C-N-CA 122.604 2.203 . . . . 0.0 110.168 171.812 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 19.1 t70 -147.88 29.18 0.91 Allowed 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.759 0.79 . . . . 0.0 110.395 -171.479 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 115.64 148.89 9.38 Favored Glycine 0 N--CA 1.446 -0.686 0 CA-C-N 115.344 -0.844 . . . . 0.0 111.36 -177.982 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.617 HG23 ' HB ' ' A' ' 48' ' ' ILE . 17.7 m -102.59 129.73 53.68 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 CA-C-O 121.195 0.522 . . . . 0.0 110.511 178.102 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' GLN . . . . . 0.434 ' HG3' ' O ' ' A' ' 46' ' ' LEU . 61.8 tt0 -110.66 149.73 30.02 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 121.187 0.517 . . . . 0.0 111.298 -175.941 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.517 HG23 HD12 ' A' ' 102' ' ' ILE . 74.3 mt -82.31 117.85 29.0 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 115.361 -0.836 . . . . 0.0 109.93 177.741 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.551 ' HB3' ' HB3' ' A' ' 103' ' ' ARG . 12.6 t70 -79.13 -65.1 1.04 Allowed 'General case' 0 C--N 1.317 -0.837 0 CA-C-N 116.235 -0.439 . . . . 0.0 109.84 178.912 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 5.5 p -150.06 156.53 41.85 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.91 -0.586 . . . . 0.0 111.31 -177.087 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.513 ' CG1' ' HA ' ' A' ' 39' ' ' SER . 56.2 t -116.18 113.73 44.03 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.229 -177.712 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 30.3 m -105.71 153.46 39.94 Favored Pre-proline 0 N--CA 1.445 -0.693 0 CA-C-N 116.512 -0.313 . . . . 0.0 110.569 178.505 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 29.0 Cg_endo -62.7 150.95 86.3 Favored 'Trans proline' 0 C--N 1.346 0.4 0 C-N-CA 123.023 2.482 . . . . 0.0 112.339 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 109.73 3.49 30.34 Favored Glycine 0 N--CA 1.45 -0.371 0 N-CA-C 111.081 -0.808 . . . . 0.0 111.081 -176.029 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.543 ' HB3' ' HA3' ' A' ' 101' ' ' GLY . 50.8 p -125.26 147.95 59.18 Favored Pre-proline 0 N--CA 1.447 -0.609 0 CA-C-N 115.17 -0.515 . . . . 0.0 109.862 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' PRO . . . . . 0.466 ' HD3' ' HA2' ' A' ' 89' ' ' GLY . 16.8 Cg_exo -67.31 -23.37 44.78 Favored 'Trans proline' 0 N--CA 1.463 -0.297 0 C-N-CA 122.031 1.82 . . . . 0.0 110.894 175.645 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -75.29 -7.93 55.28 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.179 -0.918 . . . . 0.0 111.927 -177.616 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.513 ' HA ' ' CG1' ' A' ' 32' ' ' VAL . 73.0 m -53.33 -31.24 43.31 Favored 'General case' 0 CA--C 1.533 0.303 0 N-CA-C 112.671 0.619 . . . . 0.0 112.671 -175.152 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 42.2 mtmt -128.99 21.21 5.84 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.822 0.344 . . . . 0.0 111.307 179.838 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 88.3 t -103.68 -50.95 9.06 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-O 120.931 0.396 . . . . 0.0 110.754 179.341 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -112.3 -179.82 3.78 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.383 0.611 . . . . 0.0 111.589 -179.393 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' THR . . . . . 0.579 ' O ' ' HG ' ' A' ' 46' ' ' LEU . 8.5 m -116.47 138.31 24.3 Favored Pre-proline 0 C--N 1.317 -0.823 0 CA-C-N 115.011 -0.995 . . . . 0.0 109.948 -178.851 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 21.0 Cg_endo -64.34 141.87 76.75 Favored 'Trans proline' 0 N--CA 1.46 -0.499 0 C-N-CA 121.665 1.577 . . . . 0.0 111.171 171.525 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 99.49 -7.78 59.91 Favored Glycine 0 C--N 1.32 -0.32 0 C-N-CA 120.6 -0.809 . . . . 0.0 113.159 -179.083 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.579 ' HG ' ' O ' ' A' ' 43' ' ' THR . 27.9 mt -81.79 163.29 22.48 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 117.077 0.438 . . . . 0.0 110.612 -178.269 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 44.6 t -113.32 126.73 70.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.415 -178.129 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.617 ' HB ' HG23 ' A' ' 27' ' ' VAL . 75.1 mt -84.59 113.01 22.57 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-O 120.862 0.363 . . . . 0.0 110.141 178.931 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 66.6 mt-10 -83.9 -46.45 12.1 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.8 -177.074 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 17.1 p -162.8 152.09 15.29 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.045 0.45 . . . . 0.0 111.875 -178.449 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.529 HG22 ' H ' ' A' ' 52' ' ' ASN . 12.1 mt -103.27 172.46 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 175.524 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' ASN . . . . . 0.843 ' HB3' ' HB3' ' A' ' 76' ' ' ASN . 17.8 p-10 -56.08 101.89 0.06 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.275 0.56 . . . . 0.0 112.243 -176.257 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 74.99 1.78 63.77 Favored Glycine 0 N--CA 1.451 -0.311 0 CA-C-N 115.527 -0.76 . . . . 0.0 113.042 178.836 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 49.9 mtm -138.14 96.69 10.03 Favored Pre-proline 0 C--N 1.325 -0.484 0 O-C-N 122.684 -0.304 . . . . 0.0 110.659 -175.652 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -73.88 133.85 19.0 Favored 'Trans proline' 0 N--CA 1.462 -0.344 0 C-N-CA 122.667 2.244 . . . . 0.0 111.968 178.679 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 17.7 p -110.83 83.8 1.82 Allowed 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.247 0.546 . . . . 0.0 111.675 -175.861 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 22.3 m -91.92 -13.48 31.14 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.249 177.011 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' ASN . . . . . 0.457 ' HA ' ' HB3' ' A' ' 24' ' ' PRO . 0.4 OUTLIER -128.11 173.79 9.79 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 -175.4 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 65.1 mt -78.72 -39.19 37.08 Favored 'General case' 0 N--CA 1.444 -0.77 0 CA-C-O 121.18 0.514 . . . . 0.0 110.059 177.797 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 3.1 m -67.11 -42.45 84.51 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.552 -0.749 . . . . 0.0 111.236 -178.862 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 1.2 p -65.63 -32.42 73.98 Favored 'General case' 0 C--N 1.333 -0.133 0 CA-C-O 120.797 0.332 . . . . 0.0 111.036 179.802 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 86.4 t80 -62.06 -44.52 96.5 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.007 -0.542 . . . . 0.0 109.669 174.318 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' SER . . . . . 0.485 ' O ' ' HG3' ' A' ' 67' ' ' LYS . 5.7 t -68.12 -41.68 81.37 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.293 179.732 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -60.69 -34.71 74.75 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 121.161 0.505 . . . . 0.0 110.859 -179.221 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' ALA . . . . . 0.409 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -73.1 -45.58 56.25 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.119 176.346 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -60.23 -38.24 82.8 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.996 -177.442 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' LYS . . . . . 0.485 ' HG3' ' O ' ' A' ' 63' ' ' SER . 68.6 mttm -65.4 -14.43 60.87 Favored 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 112.297 0.48 . . . . 0.0 112.297 -176.857 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 68.0 p -99.34 -13.14 19.74 Favored 'General case' 0 C--N 1.326 -0.447 0 C-N-CA 120.814 -0.354 . . . . 0.0 111.528 -179.691 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.409 HG12 ' O ' ' A' ' 65' ' ' ALA . 14.5 mm -88.75 144.24 9.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 120.904 0.383 . . . . 0.0 110.413 -176.445 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 54.4 m -104.06 171.0 7.59 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.534 -0.303 . . . . 0.0 111.351 -178.458 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.483 HG22 ' H ' ' A' ' 98' ' ' ALA . 39.1 t -81.39 117.98 28.36 Favored 'Isoleucine or valine' 0 C--O 1.233 0.224 0 CA-C-O 120.905 0.383 . . . . 0.0 110.539 -178.397 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 102.58 -1.64 49.38 Favored Glycine 0 N--CA 1.448 -0.527 0 N-CA-C 111.463 -0.655 . . . . 0.0 111.463 -177.498 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 56.0 tt0 -87.65 149.08 24.5 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.35 -0.425 . . . . 0.0 109.878 179.527 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 64.3 t -111.13 124.89 68.33 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.782 -177.139 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 25.2 pt -110.07 164.32 6.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.316 -179.553 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' ASN . . . . . 0.843 ' HB3' ' HB3' ' A' ' 52' ' ' ASN . 6.7 t30 -107.53 114.94 29.28 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.043 -177.158 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.549 HG23 HG23 ' A' ' 48' ' ' ILE . 70.6 mt -117.48 115.21 47.93 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-O 120.982 0.42 . . . . 0.0 111.153 -175.877 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' THR . . . . . 0.535 ' HA ' ' HA ' ' A' ' 83' ' ' THR . 97.8 m -93.0 125.4 37.57 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.872 -0.604 . . . . 0.0 109.969 176.237 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.547 HG22 ' HA ' ' A' ' 48' ' ' ILE . 68.0 p -124.19 177.46 5.82 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.237 179.095 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -57.86 -33.7 68.96 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.5 0.667 . . . . 0.0 110.251 174.1 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' GLN . . . . . 0.4 ' CG ' HD22 ' A' ' 46' ' ' LEU . 16.5 mm100 -90.73 17.33 7.78 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-N 115.223 -0.899 . . . . 0.0 111.242 -177.054 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 107.71 178.41 22.31 Favored Glycine 0 N--CA 1.446 -0.687 0 CA-C-N 115.525 -0.761 . . . . 0.0 112.419 175.935 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.535 ' HA ' ' HA ' ' A' ' 78' ' ' THR . 63.7 m -94.56 131.57 40.16 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-O 120.775 0.322 . . . . 0.0 110.638 179.035 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 91.1 m-85 -125.23 159.75 30.88 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.249 -0.432 . . . . 0.0 109.995 178.198 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 44.9 m80 -106.57 124.31 49.41 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 174.295 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.448 HD13 ' HA ' ' A' ' 86' ' ' LEU . 2.9 mm? -116.69 135.95 53.36 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-O 121.425 0.631 . . . . 0.0 111.811 -174.836 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 87.4 tttt -95.18 135.84 36.26 Favored 'General case' 0 C--N 1.31 -1.133 0 CA-C-N 114.981 -1.009 . . . . 0.0 109.071 174.12 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.622 ' HB ' ' HA ' ' A' ' 98' ' ' ALA . 55.1 p -65.14 143.45 57.86 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 120.925 0.393 . . . . 0.0 111.061 179.511 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.535 ' HA3' ' O ' ' A' ' 99' ' ' TYR . . . -72.91 -177.56 32.72 Favored Glycine 0 N--CA 1.439 -1.123 0 CA-C-N 115.647 -0.706 . . . . 0.0 113.411 -175.124 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -103.87 8.35 36.96 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 114.724 -0.738 . . . . 0.0 111.914 -167.533 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 91' ' ' ASN . . . . . 0.545 ' HB3' ' O ' ' A' ' 94' ' ' ASN . 47.8 m-80 66.61 88.69 0.11 Allowed Pre-proline 0 N--CA 1.468 0.451 0 CA-C-N 116.108 -0.496 . . . . 0.0 112.001 177.412 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -91.14 134.1 1.67 Allowed 'Trans proline' 0 N--CA 1.452 -0.918 0 C-N-CA 123.275 2.65 . . . . 0.0 111.876 173.581 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 61.9 t30 72.44 -38.53 0.42 Allowed 'General case' 0 N--CA 1.474 0.736 0 C-N-CA 123.931 0.892 . . . . 0.0 112.438 178.394 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' ASN . . . . . 0.545 ' O ' ' HB3' ' A' ' 91' ' ' ASN . 14.3 m120 -126.49 145.71 50.4 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 120.755 0.312 . . . . 0.0 111.218 -176.115 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 64.4 m -99.62 119.66 38.44 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.596 178.68 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 55.7 m -152.92 -168.94 3.19 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 176.904 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 16.0 ptp180 -105.94 127.94 53.47 Favored 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 109.682 -0.488 . . . . 0.0 109.682 175.43 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' ALA . . . . . 0.622 ' HA ' ' HB ' ' A' ' 88' ' ' THR . . . 61.35 90.04 0.07 Allowed 'General case' 0 N--CA 1.462 0.142 0 O-C-N 123.845 0.716 . . . . 0.0 111.504 178.551 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 99' ' ' TYR . . . . . 0.535 ' O ' ' HA3' ' A' ' 89' ' ' GLY . 2.3 t80 -111.58 95.97 5.82 Favored 'General case' 0 C--N 1.325 -0.466 0 C-N-CA 119.805 -0.758 . . . . 0.0 109.895 -176.829 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 100' ' ' MET . . . . . 0.657 ' HG3' HG12 ' A' ' 102' ' ' ILE . 50.8 tpp -46.95 -54.17 10.69 Favored 'General case' 0 N--CA 1.466 0.35 0 O-C-N 123.746 0.654 . . . . 0.0 112.002 -173.391 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 101' ' ' GLY . . . . . 0.543 ' HA3' ' HB3' ' A' ' 36' ' ' SER . . . 99.31 -2.24 57.64 Favored Glycine 0 C--O 1.226 -0.375 0 C-N-CA 120.504 -0.855 . . . . 0.0 113.185 175.399 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.657 HG12 ' HG3' ' A' ' 100' ' ' MET . 36.7 pt -114.58 140.6 34.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 N-CA-C 109.633 -0.506 . . . . 0.0 109.633 178.14 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 103' ' ' ARG . . . . . 0.551 ' HB3' ' HB3' ' A' ' 30' ' ' ASP . 18.4 ttp180 -69.52 125.37 26.49 Favored 'General case' 0 N--CA 1.446 -0.648 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 178.535 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.417 HG22 ' HA ' ' A' ' 29' ' ' ILE . 0.9 OUTLIER -135.52 142.03 45.35 Favored 'General case' 0 C--N 1.311 -1.104 0 CA-C-N 116.048 -0.523 . . . . 0.0 110.582 -175.465 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 31.9 m -153.39 157.45 39.99 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.05 179.575 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 106' ' ' ASN . . . . . 0.415 ' HA ' ' HA ' ' A' ' 27' ' ' VAL . 25.5 p-10 -74.75 -8.82 57.57 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.798 -179.653 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 6.1 t-160 57.88 75.98 0.35 Allowed 'General case' 0 C--O 1.233 0.222 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.328 176.454 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 21.3 mt -59.28 141.59 54.01 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.681 0.753 . . . . 0.0 112.056 -179.114 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -67.89 121.07 15.24 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 114.257 -1.338 . . . . 0.0 109.304 -178.727 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 8.4 p -65.96 129.12 29.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 121.634 0.73 . . . . 0.0 111.885 -175.21 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 111' ' ' ARG . . . . . . . . . . . . . 19.6 mtp180 -157.03 175.31 14.26 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 114.333 -1.303 . . . . 0.0 108.936 174.776 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 27.6 m-20 -111.33 82.27 1.58 Allowed 'General case' 0 C--N 1.319 -0.721 0 CA-C-O 120.978 0.418 . . . . 0.0 111.748 -178.214 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 7.4 p -93.48 86.04 5.11 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 168.232 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 29.7 m -67.91 143.01 15.72 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.512 -0.767 . . . . 0.0 112.537 -170.781 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -116.6 85.4 2.3 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.079 -0.964 . . . . 0.0 109.373 175.056 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 9.4 m -74.35 150.14 40.24 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.73 -176.271 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 15.5 m -70.18 126.37 30.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-O 120.998 0.428 . . . . 0.0 110.222 176.477 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 85.7 mt -86.65 -43.31 12.73 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.214 -177.603 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 141.52 146.38 4.7 Favored Glycine 0 N--CA 1.442 -0.909 0 N-CA-C 111.073 -0.811 . . . . 0.0 111.073 -177.981 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -119.84 117.74 28.94 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 110.126 -0.324 . . . . 0.0 110.126 -177.06 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 8.9 t -82.56 118.06 23.0 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 121.474 0.654 . . . . 0.0 110.481 -178.153 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 122' ' ' LEU . . . . . 0.403 ' HA ' ' HD2' ' A' ' 123' ' ' PRO . 89.1 mt -107.25 106.25 57.86 Favored Pre-proline 0 C--N 1.325 -0.476 0 CA-C-N 115.824 -0.626 . . . . 0.0 111.098 -179.156 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 123' ' ' PRO . . . . . 0.403 ' HD2' ' HA ' ' A' ' 122' ' ' LEU . 53.5 Cg_endo -70.85 150.84 62.21 Favored 'Trans proline' 0 N--CA 1.461 -0.428 0 C-N-CA 122.464 2.109 . . . . 0.0 111.357 176.151 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 44.6 t80 -125.08 117.28 23.6 Favored 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 109.468 -0.568 . . . . 0.0 109.468 -178.482 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.972 0 CA-C-O 118.598 -0.715 . . . . 0.0 110.848 -176.148 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.403 ' HA ' ' HD3' ' A' ' 24' ' ' PRO . 84.1 mt-30 . . . . . 0 N--CA 1.467 0.398 0 CA-C-O 121.111 0.481 . . . . 0.0 111.941 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.539 ' HD2' ' ND2' ' A' ' 58' ' ' ASN . 32.2 Cg_exo -62.21 -173.62 0.13 Allowed 'Trans proline' 0 C--N 1.346 0.42 0 C-N-CA 123.406 2.737 . . . . 0.0 112.389 172.606 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 16.8 t70 -148.87 -1.15 0.5 Allowed 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 116.099 -0.501 . . . . 0.0 111.743 -171.516 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.543 ' HA2' ' HA ' ' A' ' 57' ' ' SER . . . 146.68 136.06 2.82 Favored Glycine 0 N--CA 1.444 -0.782 0 N-CA-C 110.932 -0.867 . . . . 0.0 110.932 -174.003 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.532 HG23 ' HB ' ' A' ' 48' ' ' ILE . 30.0 m -80.99 142.38 13.92 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-O 121.272 0.558 . . . . 0.0 110.86 -178.743 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' GLN . . . . . 0.52 ' HG3' ' O ' ' A' ' 46' ' ' LEU . 41.5 tt0 -116.38 155.4 28.57 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.482 -179.634 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.494 HD12 HD12 ' A' ' 102' ' ' ILE . 45.2 mm -81.56 110.51 17.0 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 178.01 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.455 ' HB3' ' CB ' ' A' ' 103' ' ' ARG . 14.4 t70 -70.43 -63.19 1.14 Allowed 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 115.933 -0.576 . . . . 0.0 109.591 179.479 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.425 ' HA ' ' HB3' ' A' ' 44' ' ' PRO . 17.3 m -150.03 148.99 29.71 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.734 -178.937 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.433 ' CG1' ' HA ' ' A' ' 39' ' ' SER . 97.3 t -114.6 114.07 45.55 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 N-CA-C 108.825 -0.805 . . . . 0.0 108.825 173.406 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.501 HG22 ' O ' ' A' ' 101' ' ' GLY . 4.6 m -75.11 153.13 86.43 Favored Pre-proline 0 C--N 1.324 -0.505 0 CA-C-N 116.51 -0.314 . . . . 0.0 111.355 -175.093 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 40.1 Cg_endo -69.77 116.58 4.63 Favored 'Trans proline' 0 N--CA 1.461 -0.404 0 C-N-CA 122.388 2.058 . . . . 0.0 111.033 172.613 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 94.99 -179.56 36.73 Favored Glycine 0 N--CA 1.445 -0.706 0 N-CA-C 110.63 -0.988 . . . . 0.0 110.63 -173.413 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.728 ' HB3' ' HD2' ' A' ' 37' ' ' PRO . 31.9 m 69.16 168.48 0.12 Allowed Pre-proline 0 CA--C 1.54 0.564 0 CA-C-N 117.072 0.436 . . . . 0.0 110.888 -179.052 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' PRO . . . . . 0.728 ' HD2' ' HB3' ' A' ' 36' ' ' SER . 32.8 Cg_endo -65.04 155.11 70.04 Favored 'Trans proline' 0 C--N 1.344 0.329 0 C-N-CA 122.348 2.032 . . . . 0.0 112.747 179.035 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.538 ' HB2' HD21 ' A' ' 86' ' ' LEU . . . 76.68 -12.22 1.07 Allowed 'General case' 0 N--CA 1.471 0.621 0 C-N-CA 123.718 0.807 . . . . 0.0 112.146 177.012 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.433 ' HA ' ' CG1' ' A' ' 32' ' ' VAL . 11.4 t -64.31 -30.87 71.9 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.618 -175.554 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -103.96 16.64 25.85 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.024 -175.687 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.421 ' HB ' HD12 ' A' ' 42' ' ' LEU . 30.8 t -125.29 -54.05 2.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 N-CA-C 111.705 0.261 . . . . 0.0 111.705 -177.672 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.421 HD12 ' HB ' ' A' ' 41' ' ' VAL . 7.6 mp -97.47 176.98 5.67 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.373 0.606 . . . . 0.0 111.909 -173.057 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' THR . . . . . 0.429 ' O ' ' HG ' ' A' ' 46' ' ' LEU . 28.5 m -135.5 134.32 20.98 Favored Pre-proline 0 C--N 1.321 -0.64 0 CA-C-N 115.186 -0.915 . . . . 0.0 109.39 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.425 ' HB3' ' HA ' ' A' ' 31' ' ' SER . 19.3 Cg_endo -62.13 139.46 78.51 Favored 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 122.105 1.87 . . . . 0.0 112.474 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 105.69 -13.11 46.56 Favored Glycine 0 CA--C 1.521 0.408 0 C-N-CA 120.641 -0.79 . . . . 0.0 113.808 179.308 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.52 ' O ' ' HG3' ' A' ' 28' ' ' GLN . 56.9 mt -79.83 163.32 24.49 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 117.481 0.64 . . . . 0.0 111.044 -177.035 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 42.2 t -111.28 137.26 44.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 116.528 -0.306 . . . . 0.0 110.304 178.182 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.532 ' HB ' HG23 ' A' ' 27' ' ' VAL . 61.9 mt -92.62 124.93 45.24 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-O 121.16 0.505 . . . . 0.0 111.23 -178.985 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 11.3 tp10 -77.23 -53.93 7.12 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.624 176.378 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 5.3 p -161.83 156.01 22.1 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.341 -0.845 . . . . 0.0 111.576 -176.184 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.623 HG12 HG12 ' A' ' 77' ' ' ILE . 58.5 mt -123.17 106.86 18.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 115.478 -0.783 . . . . 0.0 109.475 176.396 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 52' ' ' ASN . . . . . 0.406 ' CG ' ' H ' ' A' ' 53' ' ' GLY . 12.0 t-20 61.26 -152.23 0.38 Allowed 'General case' 0 CA--C 1.533 0.307 0 N-CA-C 108.061 -1.089 . . . . 0.0 108.061 -175.425 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.406 ' H ' ' CG ' ' A' ' 52' ' ' ASN . . . -73.61 9.67 7.86 Favored Glycine 0 CA--C 1.525 0.657 0 C-N-CA 120.781 -0.723 . . . . 0.0 113.156 179.533 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 3.3 mpp? -114.96 105.31 53.25 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 120.721 0.296 . . . . 0.0 110.423 178.091 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -73.96 130.42 14.4 Favored 'Trans proline' 0 N--CA 1.458 -0.569 0 C-N-CA 122.04 1.827 . . . . 0.0 111.949 177.615 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.427 ' O ' ' HA2' ' A' ' 26' ' ' GLY . 16.7 p -98.12 75.96 2.34 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 121.249 0.547 . . . . 0.0 111.692 -176.595 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' SER . . . . . 0.543 ' HA ' ' HA2' ' A' ' 26' ' ' GLY . 32.3 t -88.89 -12.2 42.41 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.583 -0.735 . . . . 0.0 109.831 176.033 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 58' ' ' ASN . . . . . 0.539 ' ND2' ' HD2' ' A' ' 24' ' ' PRO . 8.9 t-20 -129.32 177.89 6.84 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 115.846 -0.615 . . . . 0.0 109.361 -177.234 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.929 ' HG ' ' HB3' ' A' ' 106' ' ' ASN . 3.8 mt -90.08 -34.2 16.01 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-O 121.051 0.453 . . . . 0.0 109.806 176.661 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 28.5 m -63.7 -38.82 92.53 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.249 176.678 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 21.4 p -64.09 -38.07 89.72 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.484 177.851 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 89.1 t80 -65.48 -43.76 89.24 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.893 -0.594 . . . . 0.0 109.898 177.925 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 8.6 t -64.64 -48.03 76.31 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.455 179.684 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -65.54 -31.1 71.97 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.958 -0.564 . . . . 0.0 111.586 -177.223 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' ALA . . . . . 0.603 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -74.11 -45.04 51.52 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.328 179.6 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 1.6 tt -59.88 -43.8 94.55 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.134 -177.45 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 57.8 mtpt -63.13 -22.65 67.0 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.587 -0.733 . . . . 0.0 112.206 -178.153 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 40.6 p -92.18 -13.58 30.38 Favored 'General case' 0 C--N 1.329 -0.321 0 C-N-CA 120.971 -0.292 . . . . 0.0 111.571 179.465 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.603 HG12 ' O ' ' A' ' 65' ' ' ALA . 44.5 mm -78.14 138.99 19.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.841 0.353 . . . . 0.0 110.105 -179.265 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 6.1 m -88.46 165.7 14.72 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.971 -177.825 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 94.8 t -72.43 133.96 30.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.454 177.112 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 70.95 27.61 71.92 Favored Glycine 0 C--N 1.331 0.257 0 C-N-CA 120.959 -0.639 . . . . 0.0 111.984 179.005 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 9.7 tp10 -99.04 152.52 19.73 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 -177.443 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.407 ' HA ' ' O ' ' A' ' 86' ' ' LEU . 58.9 t -108.24 111.48 36.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.119 -179.459 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.643 HG13 ' HB3' ' A' ' 86' ' ' LEU . 15.0 pt -109.65 154.15 11.2 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.635 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.98 -177.815 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 76' ' ' ASN . . . . . 0.401 ' O ' ' HA ' ' A' ' 51' ' ' ILE . 19.9 t30 -95.17 114.4 26.19 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 115.302 -0.863 . . . . 0.0 110.726 -179.4 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.623 HG12 HG12 ' A' ' 51' ' ' ILE . 50.9 mt -113.19 104.55 17.2 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-O 121.641 0.734 . . . . 0.0 110.015 177.274 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 11.7 m -89.63 124.57 34.69 Favored 'General case' 0 C--N 1.314 -0.952 0 CA-C-N 115.036 -0.984 . . . . 0.0 109.275 178.075 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 60.0 p -117.17 172.33 7.36 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 121.024 0.44 . . . . 0.0 111.172 -178.004 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -56.45 -32.71 65.18 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.245 -0.889 . . . . 0.0 111.444 177.434 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 30.5 mm-40 -104.39 16.48 26.06 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 112.373 0.508 . . . . 0.0 112.373 -175.507 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 136.6 172.66 12.64 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 119.969 -1.11 . . . . 0.0 113.674 175.528 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 19.6 m -99.19 121.53 41.16 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 110.278 -0.267 . . . . 0.0 110.278 -179.876 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -115.63 158.71 22.32 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.189 0.519 . . . . 0.0 111.153 -177.051 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' HIS . . . . . 0.406 ' O ' HG11 ' A' ' 41' ' ' VAL . 23.4 m80 -102.51 125.63 49.3 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.619 -0.719 . . . . 0.0 109.237 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.643 ' HB3' HG13 ' A' ' 75' ' ' ILE . 0.4 OUTLIER -114.16 136.71 52.64 Favored 'General case' 0 C--N 1.315 -0.895 0 CA-C-O 120.978 0.418 . . . . 0.0 110.069 -176.848 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.466 ' N ' HD13 ' A' ' 86' ' ' LEU . 78.7 tttt -127.08 115.71 19.59 Favored 'General case' 0 C--N 1.312 -1.046 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 176.45 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.488 HG21 ' HB1' ' A' ' 98' ' ' ALA . 73.4 p -69.35 142.44 54.0 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.766 -0.652 . . . . 0.0 111.812 -173.199 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -80.01 -164.01 28.87 Favored Glycine 0 N--CA 1.443 -0.9 0 CA-C-N 115.674 -0.693 . . . . 0.0 112.777 -177.701 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.417 ' HD2' ' N ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -148.01 175.3 11.11 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.621 -0.289 . . . . 0.0 110.42 -173.952 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 91' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 59.31 85.88 0.17 Allowed Pre-proline 0 N--CA 1.467 0.424 0 O-C-N 123.956 0.785 . . . . 0.0 111.735 -176.473 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 95.2 Cg_endo -94.42 -166.06 0.13 Allowed 'Trans proline' 0 N--CA 1.452 -0.918 0 C-N-CA 123.017 2.478 . . . . 0.0 111.632 173.005 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 32.9 t-20 -110.31 58.91 0.61 Allowed 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 176.953 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 17.8 t-20 72.33 130.42 0.04 OUTLIER 'General case' 0 C--O 1.235 0.321 0 CA-C-N 114.374 -1.285 . . . . 0.0 110.351 -177.309 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 21.6 m 65.06 177.17 0.2 Allowed 'General case' 0 CA--C 1.533 0.299 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.687 -176.733 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 14.7 m 66.57 117.01 0.03 OUTLIER 'General case' 0 CA--C 1.534 0.358 0 CA-C-O 121.674 0.75 . . . . 0.0 111.979 179.612 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 97' ' ' ARG . . . . . 0.547 ' N ' ' HD2' ' A' ' 97' ' ' ARG . 2.8 mpt_? -109.94 159.51 17.19 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 178.515 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 98' ' ' ALA . . . . . 0.488 ' HB1' HG21 ' A' ' 88' ' ' THR . . . 67.27 86.73 0.13 Allowed 'General case' 0 N--CA 1.461 0.077 0 CA-C-O 121.597 0.713 . . . . 0.0 110.234 -176.975 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 29.1 t80 -81.82 119.98 24.59 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.64 -0.709 . . . . 0.0 110.306 -172.548 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 26.0 mmt -98.66 151.58 20.56 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.597 -179.698 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 101' ' ' GLY . . . . . 0.501 ' O ' HG22 ' A' ' 33' ' ' VAL . . . -124.36 26.67 5.72 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.45 -0.881 . . . . 0.0 112.555 -179.828 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.494 HD12 HD12 ' A' ' 29' ' ' ILE . 45.6 pt -136.3 162.41 35.82 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-O 121.112 0.482 . . . . 0.0 110.549 179.686 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 103' ' ' ARG . . . . . 0.455 ' CB ' ' HB3' ' A' ' 30' ' ' ASP . 28.5 mmt85 -102.18 146.34 28.11 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 115.487 -0.779 . . . . 0.0 109.421 176.056 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 16.5 p -131.59 154.49 48.8 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.225 0.536 . . . . 0.0 111.61 -179.6 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 15.7 p -122.88 171.09 9.46 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.903 -0.59 . . . . 0.0 109.692 175.539 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 106' ' ' ASN . . . . . 0.929 ' HB3' ' HG ' ' A' ' 59' ' ' LEU . 19.8 p-10 -108.97 4.88 23.76 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 111.812 0.301 . . . . 0.0 111.812 -175.943 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 23.6 t-80 62.84 69.06 0.61 Allowed 'General case' 0 N--CA 1.465 0.288 0 CA-C-O 121.549 0.69 . . . . 0.0 111.421 173.677 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 108' ' ' LEU . . . . . 0.416 HD21 ' HA ' ' A' ' 24' ' ' PRO . 61.0 mt -135.42 -169.17 2.33 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.826 176.572 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 57.8 mtp180 62.96 69.29 0.59 Allowed 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.087 -0.961 . . . . 0.0 111.113 -177.323 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 7.1 p -158.03 153.6 6.03 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.727 0 CA-C-N 114.916 -1.038 . . . . 0.0 109.045 -178.69 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 111' ' ' ARG . . . . . . . . . . . . . 26.9 mtp180 -106.56 98.98 8.58 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -178.174 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -142.7 143.25 32.21 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.801 -0.636 . . . . 0.0 109.854 -175.972 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 27.3 t -82.18 83.96 7.21 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.538 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 15.0 m -68.97 137.6 23.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.724 178.143 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -103.1 -44.51 5.19 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.112 -178.888 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 14.5 t -80.43 85.11 5.93 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.252 0.548 . . . . 0.0 109.71 178.568 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 39.0 t -112.74 114.97 48.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.033 179.761 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 6.7 mp -98.95 -14.88 19.34 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.984 0.421 . . . . 0.0 110.33 178.373 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 78.09 -72.95 2.22 Favored Glycine 0 N--CA 1.447 -0.576 0 CA-C-N 115.901 -0.59 . . . . 0.0 111.655 -179.919 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 15.2 t70 -178.29 -60.48 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 177.626 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 40.6 p 51.91 86.91 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 114.952 -1.022 . . . . 0.0 112.492 -178.533 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 67.8 mt -78.8 139.03 57.72 Favored Pre-proline 0 C--N 1.327 -0.396 0 CA-C-N 115.489 -0.778 . . . . 0.0 110.319 177.065 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_endo -64.16 151.97 83.11 Favored 'Trans proline' 0 C--O 1.234 0.28 0 C-N-CA 122.404 2.069 . . . . 0.0 111.89 177.319 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 38.0 p90 -55.51 144.55 25.68 Favored 'General case' 0 C--O 1.236 0.367 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.348 -178.966 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.998 0 CA-C-O 118.579 -0.724 . . . . 0.0 109.888 -178.27 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.461 ' HA ' ' HD3' ' A' ' 24' ' ' PRO . 0.9 OUTLIER . . . . . 0 N--CA 1.456 -0.149 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 . . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.461 ' HD3' ' HA ' ' A' ' 23' ' ' GLN . 19.1 Cg_exo -66.44 148.27 83.77 Favored 'Trans proline' 0 C--O 1.233 0.243 0 C-N-CA 122.999 2.466 . . . . 0.0 111.63 178.138 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 16.0 t70 -149.26 -37.49 0.16 Allowed 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.02 0.438 . . . . 0.0 111.134 -176.164 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.566 ' HA2' ' HA ' ' A' ' 57' ' ' SER . . . 165.59 172.04 32.52 Favored Glycine 0 N--CA 1.45 -0.367 0 N-CA-C 111.141 -0.784 . . . . 0.0 111.141 -177.795 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.581 HG23 ' HB ' ' A' ' 48' ' ' ILE . 30.7 m -124.0 148.16 28.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-O 121.242 0.544 . . . . 0.0 111.117 179.147 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' GLN . . . . . 0.536 ' HG3' ' O ' ' A' ' 46' ' ' LEU . 60.0 tt0 -128.34 152.06 48.59 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.007 -179.248 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.49 HD11 ' HB2' ' A' ' 46' ' ' LEU . 2.8 pt -86.5 122.16 38.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 121.238 0.542 . . . . 0.0 111.245 179.345 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.615 ' HB3' ' CB ' ' A' ' 103' ' ' ARG . 15.8 t70 -64.44 -61.74 2.03 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 114.699 -1.137 . . . . 0.0 110.828 -179.13 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.475 ' HA ' ' HB3' ' A' ' 44' ' ' PRO . 51.3 p -166.94 161.81 15.3 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.602 -0.726 . . . . 0.0 110.936 -175.582 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.568 ' HA ' HG22 ' A' ' 102' ' ' ILE . 85.2 t -98.81 129.14 49.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.788 177.314 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 47.0 t -92.69 129.67 39.52 Favored Pre-proline 0 C--N 1.322 -0.621 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.006 -179.749 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_exo -56.64 123.74 14.58 Favored 'Trans proline' 0 C--O 1.234 0.291 0 C-N-CA 122.584 2.189 . . . . 0.0 111.929 178.07 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 117.27 18.05 5.54 Favored Glycine 0 N--CA 1.447 -0.594 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.379 -176.152 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.667 ' HB3' ' HA3' ' A' ' 101' ' ' GLY . 54.3 p -121.54 149.79 53.43 Favored Pre-proline 0 C--N 1.322 -0.615 0 CA-C-N 115.58 -0.31 . . . . 0.0 110.801 -177.111 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_endo -71.14 -25.41 22.42 Favored 'Trans proline' 0 N--CA 1.463 -0.271 0 C-N-CA 122.338 2.025 . . . . 0.0 111.949 176.112 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -72.45 -10.62 60.01 Favored 'General case' 0 C--O 1.234 0.245 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.808 -175.611 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.535 ' HA ' HG11 ' A' ' 32' ' ' VAL . 24.7 p -59.16 -28.75 66.88 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.91 -177.85 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 65.0 mttm -110.92 15.06 21.99 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.879 0.371 . . . . 0.0 111.083 179.858 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 53.8 t -101.66 -59.49 3.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-O 120.972 0.415 . . . . 0.0 110.368 178.599 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -130.66 169.28 15.85 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.118 -179.868 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 18.3 p -105.15 138.96 19.68 Favored Pre-proline 0 C--N 1.318 -0.775 0 CA-C-N 115.624 -0.717 . . . . 0.0 110.182 177.705 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.475 ' HB3' ' HA ' ' A' ' 31' ' ' SER . 32.1 Cg_endo -65.18 141.85 71.14 Favored 'Trans proline' 0 N--CA 1.462 -0.373 0 C-N-CA 122.34 2.027 . . . . 0.0 112.31 -179.188 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 110.24 -1.27 29.68 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.8 -177.206 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.536 ' O ' ' HG3' ' A' ' 28' ' ' GLN . 90.1 mt -85.36 163.39 18.58 Favored 'General case' 0 C--N 1.328 -0.351 0 O-C-N 122.459 -0.436 . . . . 0.0 110.84 178.938 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.478 ' HB ' ' HB2' ' A' ' 80' ' ' ASP . 47.0 t -105.44 135.2 44.53 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.264 -179.233 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.581 ' HB ' HG23 ' A' ' 27' ' ' VAL . 69.4 mt -95.5 119.12 43.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 N-CA-C 110.118 -0.327 . . . . 0.0 110.118 -179.733 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 29.8 mt-10 -86.66 -46.15 10.33 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.332 -0.394 . . . . 0.0 111.216 -178.996 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.567 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 36.1 p -159.69 155.07 25.41 Favored 'General case' 0 C--N 1.325 -0.482 0 C-N-CA 120.326 -0.55 . . . . 0.0 112.028 -177.759 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 55.6 mt -112.93 97.38 5.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 115.372 -0.831 . . . . 0.0 111.003 179.195 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 49.2 t30 58.52 35.4 24.6 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.171 -0.922 . . . . 0.0 111.874 171.291 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 108.95 -27.4 13.01 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.057 178.835 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' MET . . . . . 0.411 ' HA ' ' HD3' ' A' ' 55' ' ' PRO . 71.6 mtm -98.88 106.88 40.35 Favored Pre-proline 0 C--N 1.324 -0.51 0 N-CA-C 109.978 -0.378 . . . . 0.0 109.978 178.723 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.567 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 6.1 Cg_exo -77.61 150.02 27.46 Favored 'Trans proline' 0 N--CA 1.457 -0.633 0 C-N-CA 122.669 2.246 . . . . 0.0 112.095 -177.626 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 19.8 p -123.13 106.72 11.02 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 120.915 0.388 . . . . 0.0 111.399 -178.241 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' SER . . . . . 0.566 ' HA ' ' HA2' ' A' ' 26' ' ' GLY . 15.1 p -99.0 -22.16 15.87 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 121.038 0.447 . . . . 0.0 110.788 178.283 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 58' ' ' ASN . . . . . 0.507 ' HB3' ' OG1' ' A' ' 61' ' ' THR . 17.3 t-20 -117.18 172.23 7.43 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.091 -0.504 . . . . 0.0 109.733 179.264 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 40.3 mt -79.43 -42.6 25.06 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.469 -179.843 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 27.8 m -65.8 -29.49 69.99 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.778 177.652 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' THR . . . . . 0.507 ' OG1' ' HB3' ' A' ' 58' ' ' ASN . 1.5 m -66.56 -37.42 84.93 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.177 0.513 . . . . 0.0 110.009 176.357 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 62.5 t80 -62.91 -45.76 90.98 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.217 -0.902 . . . . 0.0 109.4 174.345 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' SER . . . . . 0.534 ' O ' ' HG2' ' A' ' 67' ' ' LYS . 59.6 m -59.48 -48.77 80.37 Favored 'General case' 0 N--CA 1.444 -0.744 0 CA-C-N 115.243 -0.889 . . . . 0.0 111.695 177.565 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -60.3 -31.08 69.93 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.721 -178.454 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' ALA . . . . . 0.402 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -76.2 -42.87 44.86 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.334 0.588 . . . . 0.0 109.885 176.995 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.433 ' HA ' HD22 ' A' ' 66' ' ' LEU . 0.2 OUTLIER -58.06 -32.96 68.52 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 114.958 -1.019 . . . . 0.0 111.382 178.803 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 67' ' ' LYS . . . . . 0.534 ' HG2' ' O ' ' A' ' 63' ' ' SER . 31.5 mmmt -56.01 -35.14 66.48 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.944 -179.938 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 24.5 p -92.84 -12.74 30.3 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 112.317 0.488 . . . . 0.0 112.317 -174.851 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.596 HG21 HG21 ' A' ' 88' ' ' THR . 46.2 mm -74.47 136.92 24.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 120.888 0.375 . . . . 0.0 110.571 -178.129 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 70' ' ' SER . . . . . 0.406 ' HB2' ' HB2' ' A' ' 73' ' ' GLU . 6.0 m -89.17 161.82 16.26 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.748 -178.452 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.418 HG22 ' H ' ' A' ' 98' ' ' ALA . 11.4 t -80.34 115.12 22.28 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 N-CA-C 108.672 -0.862 . . . . 0.0 108.672 171.848 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 99.13 9.45 51.6 Favored Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 120.751 -0.738 . . . . 0.0 111.271 -173.364 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.406 ' HB2' ' HB2' ' A' ' 70' ' ' SER . 10.7 tp10 -80.81 149.14 29.7 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 179.054 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 58.3 t -111.01 108.13 24.69 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.989 0 N-CA-C 109.273 -0.639 . . . . 0.0 109.273 176.872 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 17.1 pt -101.08 153.62 4.81 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 CA-C-O 121.44 0.638 . . . . 0.0 111.662 -176.366 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 3.9 t30 -107.4 104.41 13.99 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 114.949 -1.023 . . . . 0.0 109.716 -176.226 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 65.0 mt -106.85 110.7 32.64 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.011 0 CA-C-O 121.317 0.58 . . . . 0.0 111.241 -173.799 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' THR . . . . . 0.479 ' HA ' ' HA ' ' A' ' 83' ' ' THR . 91.8 m -85.19 114.34 22.23 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-N 115.595 -0.73 . . . . 0.0 109.271 174.694 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 50.1 p -103.42 175.66 5.41 Favored 'General case' 0 N--CA 1.443 -0.797 0 CA-C-O 121.061 0.458 . . . . 0.0 110.387 179.85 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' ASP . . . . . 0.478 ' HB2' ' HB ' ' A' ' 47' ' ' VAL . 9.3 t70 -51.71 -33.42 34.25 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.006 -0.997 . . . . 0.0 112.515 179.43 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 5.3 mt-30 -115.29 16.06 16.85 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 112.704 0.631 . . . . 0.0 112.704 -173.27 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 140.58 169.83 11.87 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.237 -0.983 . . . . 0.0 113.073 176.661 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.479 ' HA ' ' HA ' ' A' ' 78' ' ' THR . 30.0 m -96.59 133.4 41.13 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.794 0.331 . . . . 0.0 111.122 -179.507 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 82.5 m-85 -123.19 157.21 33.52 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.232 177.561 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 3.8 p80 -108.12 120.11 41.4 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.104 0.478 . . . . 0.0 110.273 176.486 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -109.95 146.95 34.35 Favored 'General case' 0 N--CA 1.444 -0.741 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.852 -176.841 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 77.7 tttt -111.82 124.17 51.8 Favored 'General case' 0 C--N 1.32 -0.693 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 174.516 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.596 HG21 HG21 ' A' ' 69' ' ' ILE . 13.4 p -80.69 132.26 35.55 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 120.981 0.419 . . . . 0.0 111.562 -178.648 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -127.34 -122.52 2.54 Favored Glycine 0 N--CA 1.446 -0.651 0 C-N-CA 120.977 -0.63 . . . . 0.0 111.863 179.253 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.5 ' HD3' ' N ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -147.85 171.21 16.1 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.044 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 91' ' ' ASN . . . . . 0.479 ' HB2' ' O ' ' A' ' 94' ' ' ASN . 6.9 m120 -71.57 140.48 84.44 Favored Pre-proline 0 C--N 1.324 -0.528 0 CA-C-N 116.604 -0.271 . . . . 0.0 110.361 175.402 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 34.6 Cg_endo -64.76 -27.22 59.96 Favored 'Trans proline' 0 CA--C 1.529 0.262 0 C-N-CA 122.718 2.278 . . . . 0.0 112.97 -177.293 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 66.5 t30 -126.51 14.67 7.64 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.956 0.408 . . . . 0.0 110.96 -176.945 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 94' ' ' ASN . . . . . 0.479 ' O ' ' HB2' ' A' ' 91' ' ' ASN . 26.3 t-20 -151.47 134.99 16.2 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 110.113 -0.329 . . . . 0.0 110.113 -177.234 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 5.1 m -83.19 90.21 7.06 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 121.039 0.447 . . . . 0.0 110.688 -178.721 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 20.9 m -126.57 136.51 52.64 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.25 179.067 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 5.2 ptm180 -75.68 136.14 40.4 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.717 -177.248 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 98' ' ' ALA . . . . . 0.418 ' H ' HG22 ' A' ' 71' ' ' VAL . . . 54.63 77.0 0.22 Allowed 'General case' 0 N--CA 1.465 0.29 0 O-C-N 123.992 0.807 . . . . 0.0 111.895 172.75 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 11.4 t80 -136.97 134.47 36.71 Favored 'General case' 0 C--N 1.323 -0.561 0 C-N-CA 120.851 -0.339 . . . . 0.0 110.32 -179.751 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 100' ' ' MET . . . . . 0.482 ' O ' ' HB2' ' A' ' 36' ' ' SER . 4.3 mpp? -86.92 -16.25 36.48 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.537 -0.301 . . . . 0.0 111.57 -177.468 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 101' ' ' GLY . . . . . 0.667 ' HA3' ' HB3' ' A' ' 36' ' ' SER . . . 90.58 30.33 12.07 Favored Glycine 0 CA--C 1.519 0.33 0 C-N-CA 120.878 -0.677 . . . . 0.0 112.866 178.931 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.568 HG22 ' HA ' ' A' ' 32' ' ' VAL . 36.6 pt -135.42 167.05 26.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-O 120.908 0.385 . . . . 0.0 110.584 -178.751 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 103' ' ' ARG . . . . . 0.615 ' CB ' ' HB3' ' A' ' 30' ' ' ASP . 36.9 mtt180 -98.53 155.54 17.23 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.666 173.286 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 3.3 m -139.1 149.98 45.16 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 121.092 0.473 . . . . 0.0 110.345 177.269 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 32.0 m -142.02 178.42 7.54 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 115.365 -0.834 . . . . 0.0 109.198 -178.337 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 106' ' ' ASN . . . . . 0.461 ' HB2' ' HG ' ' A' ' 108' ' ' LEU . 10.4 p30 -103.69 -24.5 13.35 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.592 0.234 . . . . 0.0 110.874 177.637 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 42.1 t-80 54.16 45.06 28.21 Favored 'General case' 0 N--CA 1.467 0.419 0 CA-C-O 121.235 0.541 . . . . 0.0 110.458 -179.406 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 108' ' ' LEU . . . . . 0.461 ' HG ' ' HB2' ' A' ' 106' ' ' ASN . 89.0 mt -82.3 -166.21 1.21 Allowed 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.545 0.688 . . . . 0.0 111.528 -178.372 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 58.5 mtt-85 -95.99 103.85 15.76 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.074 -176.522 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 64.6 t -92.19 138.89 18.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-N 115.633 -0.712 . . . . 0.0 111.34 -175.547 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 111' ' ' ARG . . . . . . . . . . . . . 47.0 ttt180 -150.74 134.56 16.62 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 108.814 -0.809 . . . . 0.0 108.814 174.451 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -83.8 110.03 18.01 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.245 0.545 . . . . 0.0 110.031 -177.759 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 4.2 p -90.67 115.35 27.71 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 115.394 -0.821 . . . . 0.0 111.405 -179.586 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 3.0 m -116.48 102.05 13.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 115.712 -0.677 . . . . 0.0 110.422 175.881 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -171.56 103.59 0.2 Allowed 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.208 -178.289 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 8.1 t -124.27 111.15 15.5 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.142 179.635 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 48.6 t -93.23 119.85 41.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.115 178.625 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 94.2 mt -91.07 -73.67 0.53 Allowed 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.916 0.389 . . . . 0.0 110.614 179.844 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 118.96 129.57 3.97 Favored Glycine 0 N--CA 1.447 -0.599 0 N-CA-C 111.194 -0.762 . . . . 0.0 111.194 -175.843 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 50.4 m-20 -102.35 85.29 2.6 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 121.175 0.512 . . . . 0.0 110.491 -178.07 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 1.4 p -91.94 105.66 17.87 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.48 -0.782 . . . . 0.0 110.88 178.246 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 122' ' ' LEU . . . . . 0.402 ' HA ' ' HD3' ' A' ' 123' ' ' PRO . 61.6 mt -98.5 104.95 26.72 Favored Pre-proline 0 C--N 1.326 -0.442 0 CA-C-N 115.975 -0.557 . . . . 0.0 109.828 -178.928 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 123' ' ' PRO . . . . . 0.402 ' HD3' ' HA ' ' A' ' 122' ' ' LEU . 5.5 Cg_endo -86.21 110.37 1.02 Allowed 'Trans proline' 0 N--CA 1.455 -0.783 0 C-N-CA 123.162 2.575 . . . . 0.0 112.994 -175.235 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 34.4 p90 -146.48 128.59 15.61 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.627 172.264 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.992 0 CA-C-O 118.576 -0.726 . . . . 0.0 110.399 -175.46 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.495 ' HA ' ' HD3' ' A' ' 24' ' ' PRO . 82.2 mt-30 . . . . . 0 N--CA 1.457 -0.118 0 CA-C-O 120.47 0.176 . . . . 0.0 110.766 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.67 ' HG3' HD22 ' A' ' 58' ' ' ASN . 23.9 Cg_exo -64.48 154.42 71.84 Favored 'Trans proline' 0 C--O 1.234 0.306 0 C-N-CA 123.207 2.605 . . . . 0.0 113.377 -174.666 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 14.5 t70 -153.11 -44.46 0.1 Allowed 'General case' 0 N--CA 1.465 0.283 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.718 178.78 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.487 ' HA2' ' HA ' ' A' ' 57' ' ' SER . . . 156.93 131.8 1.39 Allowed Glycine 0 N--CA 1.449 -0.486 0 CA-C-N 115.745 -0.661 . . . . 0.0 111.694 -179.597 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.467 HG23 ' HB ' ' A' ' 48' ' ' ILE . 31.5 m -72.7 140.15 18.42 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-O 121.218 0.532 . . . . 0.0 111.352 -177.931 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' GLN . . . . . 0.662 ' HB3' ' HB2' ' A' ' 107' ' ' HIS . 4.1 tp-100 -107.45 133.76 51.48 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.651 -0.704 . . . . 0.0 111.11 -177.977 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.547 HD12 ' HB2' ' A' ' 46' ' ' LEU . 61.5 mt -73.29 105.87 2.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 CA-C-N 115.637 -0.711 . . . . 0.0 109.815 175.524 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 21.3 t70 -62.91 -65.21 0.72 Allowed 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.254 -178.037 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 12.4 p -156.46 152.53 27.55 Favored 'General case' 0 N--CA 1.444 -0.731 0 CA-C-N 115.21 -0.905 . . . . 0.0 110.724 -179.727 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.814 HG22 HG22 ' A' ' 102' ' ' ILE . 66.8 t -87.74 120.47 36.91 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.542 174.903 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.551 HG22 ' O ' ' A' ' 101' ' ' GLY . 22.7 m -82.05 160.53 62.94 Favored Pre-proline 0 C--N 1.325 -0.492 0 CA-C-N 116.777 -0.192 . . . . 0.0 110.534 -177.307 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_exo -66.86 99.24 0.45 Allowed 'Trans proline' 0 C--O 1.236 0.376 0 C-N-CA 122.584 2.19 . . . . 0.0 112.434 178.981 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.432 ' O ' ' HB2' ' A' ' 39' ' ' SER . . . 145.13 -165.17 27.82 Favored Glycine 0 N--CA 1.447 -0.592 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.566 178.762 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.454 ' HB3' HD21 ' A' ' 91' ' ' ASN . 51.0 p 64.37 157.76 0.12 Allowed Pre-proline 0 N--CA 1.473 0.682 0 C-N-CA 124.598 1.159 . . . . 0.0 112.168 179.194 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 2.0 Cg_endo -82.78 -5.53 11.51 Favored 'Trans proline' 0 N--CA 1.46 -0.497 0 C-N-CA 122.984 2.456 . . . . 0.0 112.102 175.756 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -96.68 -0.7 47.99 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.414 -176.575 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.432 ' HB2' ' O ' ' A' ' 35' ' ' GLY . 32.1 t -60.87 -30.78 70.34 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.617 -176.224 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 62.9 tttp -107.39 7.72 29.23 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.929 0.395 . . . . 0.0 110.739 -179.326 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 57.6 t -91.2 -55.69 5.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-O 120.962 0.411 . . . . 0.0 110.129 178.755 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 5.2 mp -108.61 162.04 14.51 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.266 -0.425 . . . . 0.0 109.974 178.061 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 20.5 p -112.42 155.64 43.4 Favored Pre-proline 0 C--N 1.317 -0.84 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 177.403 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -70.0 146.05 57.56 Favored 'Trans proline' 0 N--CA 1.459 -0.548 0 C-N-CA 121.65 1.567 . . . . 0.0 111.464 178.133 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 94.84 12.41 55.52 Favored Glycine 0 CA--C 1.522 0.521 0 C-N-CA 120.615 -0.802 . . . . 0.0 113.618 179.938 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.547 ' HB2' HD12 ' A' ' 29' ' ' ILE . 86.8 mt -98.0 162.03 13.43 Favored 'General case' 0 C--N 1.334 -0.105 0 CA-C-N 117.499 0.65 . . . . 0.0 110.904 177.063 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 59.6 t -110.79 128.31 67.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.781 -177.608 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.467 ' HB ' HG23 ' A' ' 27' ' ' VAL . 76.4 mt -91.66 121.34 42.04 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.396 179.743 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 61.9 mt-10 -82.54 -50.0 9.28 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.702 -179.279 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.606 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 15.2 p -159.29 153.88 24.32 Favored 'General case' 0 N--CA 1.45 -0.441 0 CA-C-O 121.223 0.535 . . . . 0.0 112.122 -172.757 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 64.2 mt -122.78 101.58 9.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 115.158 -0.928 . . . . 0.0 110.113 176.616 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 35.0 t-20 55.26 67.9 0.95 Allowed 'General case' 0 N--CA 1.464 0.274 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.2 176.443 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 79.59 -46.14 3.02 Favored Glycine 0 CA--C 1.519 0.304 0 CA-C-N 115.559 -0.746 . . . . 0.0 112.944 178.639 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 64.0 mtm -80.96 114.28 47.36 Favored Pre-proline 0 C--N 1.324 -0.511 0 N-CA-C 110.157 -0.312 . . . . 0.0 110.157 -178.838 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.606 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 98.1 Cg_endo -80.02 146.13 17.99 Favored 'Trans proline' 0 N--CA 1.458 -0.597 0 C-N-CA 122.351 2.034 . . . . 0.0 112.573 -176.966 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 22.3 p -110.41 76.26 0.97 Allowed 'General case' 0 N--CA 1.447 -0.618 0 CA-C-O 121.355 0.598 . . . . 0.0 111.062 -179.473 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' SER . . . . . 0.487 ' HA ' ' HA2' ' A' ' 26' ' ' GLY . 16.5 m -84.6 -15.07 46.9 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.175 177.643 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 58' ' ' ASN . . . . . 0.67 HD22 ' HG3' ' A' ' 24' ' ' PRO . 6.3 t-20 -140.12 175.79 9.3 Favored 'General case' 0 N--CA 1.449 -0.476 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.091 -179.336 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.461 ' HG ' ' OD1' ' A' ' 106' ' ' ASN . 28.6 mt -75.4 -31.35 60.39 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.858 179.508 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 1.5 m -65.39 -43.3 91.07 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.634 178.292 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 7.2 p -64.92 -37.18 86.79 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.055 0.455 . . . . 0.0 110.325 177.083 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' TYR . . . . . 0.436 ' O ' ' HB2' ' A' ' 66' ' ' LEU . 84.4 t80 -62.85 -44.66 95.54 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.771 -0.65 . . . . 0.0 109.857 174.928 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 47.2 m -61.98 -47.16 86.08 Favored 'General case' 0 N--CA 1.446 -0.644 0 CA-C-N 115.286 -0.87 . . . . 0.0 111.997 179.225 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.44 -30.62 71.66 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.187 -178.963 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' ALA . . . . . 0.447 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -77.58 -44.2 29.24 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 121.09 0.471 . . . . 0.0 110.011 177.14 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.436 ' HB2' ' O ' ' A' ' 62' ' ' TYR . 0.2 OUTLIER -57.47 -36.43 71.45 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.358 -0.837 . . . . 0.0 112.166 -176.768 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 19.7 ptmt -71.95 -18.34 62.01 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 120.772 -0.371 . . . . 0.0 111.662 -177.676 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 44.6 p -92.12 -13.49 30.64 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.978 0.418 . . . . 0.0 110.767 -178.876 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.569 HD12 HG21 ' A' ' 75' ' ' ILE . 19.6 mm -83.35 144.91 9.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.356 -0.384 . . . . 0.0 109.998 -178.888 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 13.0 m -105.28 164.38 11.88 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.497 -0.319 . . . . 0.0 110.469 -179.438 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.425 HG22 ' H ' ' A' ' 98' ' ' ALA . 36.2 t -77.5 119.48 26.21 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 175.349 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 88.63 22.83 38.35 Favored Glycine 0 N--CA 1.45 -0.409 0 N-CA-C 111.046 -0.822 . . . . 0.0 111.046 -175.57 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 5.2 tp10 -99.65 148.54 24.23 Favored 'General case' 0 C--N 1.324 -0.5 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 -179.826 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 52.9 t -104.39 127.95 58.3 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 177.992 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.569 HG21 HD12 ' A' ' 69' ' ' ILE . 16.1 pt -125.61 161.22 30.8 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-O 121.342 0.591 . . . . 0.0 111.903 -176.733 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 7.9 t30 -106.92 105.91 16.18 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.211 -0.904 . . . . 0.0 110.285 -179.069 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 72.6 mt -108.36 114.02 45.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-O 121.528 0.68 . . . . 0.0 110.496 -177.232 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' THR . . . . . 0.462 ' HA ' ' HA ' ' A' ' 83' ' ' THR . 10.2 m -95.15 120.4 35.31 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 115.58 -0.737 . . . . 0.0 109.496 -179.559 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 45.8 p -112.61 175.65 5.35 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.535 -0.302 . . . . 0.0 110.522 -178.924 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 15.9 t70 -59.22 -28.24 66.48 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.016 179.296 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 1.5 mp0 -98.05 16.83 19.93 Favored 'General case' 0 C--O 1.235 0.294 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.887 -177.551 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 121.86 177.72 15.53 Favored Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 120.391 -0.909 . . . . 0.0 113.452 174.901 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.462 ' HA ' ' HA ' ' A' ' 78' ' ' THR . 3.9 m -90.28 119.53 30.66 Favored 'General case' 0 C--N 1.324 -0.526 0 C-N-CA 122.609 0.364 . . . . 0.0 110.782 -178.708 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -116.69 157.18 25.85 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 121.149 0.499 . . . . 0.0 110.554 178.468 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 43.0 p-80 -111.97 129.98 56.01 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-N 115.614 -0.721 . . . . 0.0 109.223 176.8 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 7.5 tt -126.86 149.78 49.57 Favored 'General case' 0 C--N 1.314 -0.957 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.255 -173.716 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 1.7 tmtp? -124.9 124.14 41.42 Favored 'General case' 0 C--N 1.316 -0.874 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.316 179.778 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.512 HG21 ' HB1' ' A' ' 98' ' ' ALA . 73.5 p -74.73 127.95 34.39 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.592 -177.609 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -159.92 103.34 0.22 Allowed Glycine 0 N--CA 1.445 -0.738 0 C-N-CA 119.564 -1.303 . . . . 0.0 114.457 -177.535 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.505 ' HD2' ' N ' ' A' ' 90' ' ' ARG . 6.9 mpt_? 47.97 119.32 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.83 0 N-CA-C 116.361 1.985 . . . . 0.0 116.361 165.14 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 91' ' ' ASN . . . . . 0.811 ' HB2' ' HB3' ' A' ' 99' ' ' TYR . 4.9 m-20 -154.4 144.27 15.48 Favored Pre-proline 0 C--N 1.326 -0.448 0 CA-C-N 115.096 -0.956 . . . . 0.0 109.406 171.683 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 9.7 Cg_endo -53.08 -55.36 3.76 Favored 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 123.275 2.65 . . . . 0.0 112.927 -176.936 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 64.3 t30 -148.42 74.58 1.29 Allowed 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.185 0.517 . . . . 0.0 110.659 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 94' ' ' ASN . . . . . 0.407 ' HB3' ' HD1' ' A' ' 99' ' ' TYR . 0.2 OUTLIER -84.56 -52.05 6.42 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 176.508 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 47.1 m -158.12 -68.93 0.09 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.739 -0.664 . . . . 0.0 109.312 177.718 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 8.7 t -171.07 -58.11 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 108.871 -0.789 . . . . 0.0 108.871 177.31 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -124.02 159.83 28.99 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.675 -0.693 . . . . 0.0 109.253 175.558 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 98' ' ' ALA . . . . . 0.512 ' HB1' HG21 ' A' ' 88' ' ' THR . . . 55.87 84.96 0.07 Allowed 'General case' 0 N--CA 1.465 0.31 0 O-C-N 123.994 0.809 . . . . 0.0 111.788 179.417 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 99' ' ' TYR . . . . . 0.811 ' HB3' ' HB2' ' A' ' 91' ' ' ASN . 26.8 m-85 -89.23 109.35 20.24 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.457 -178.076 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 61.0 mtm -86.19 -35.27 20.17 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.344 -178.708 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 101' ' ' GLY . . . . . 0.584 ' HA2' ' ND2' ' A' ' 91' ' ' ASN . . . 114.46 -13.74 20.77 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.382 -0.914 . . . . 0.0 113.755 176.443 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.814 HG22 HG22 ' A' ' 32' ' ' VAL . 2.7 pp -120.06 149.37 22.79 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.791 0 O-C-N 122.429 -0.454 . . . . 0.0 110.422 179.79 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -88.91 137.09 32.63 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 176.291 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -109.48 145.58 36.0 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.317 -177.523 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 32.2 p -137.67 168.27 20.02 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.619 -0.719 . . . . 0.0 109.576 176.256 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 106' ' ' ASN . . . . . 0.461 ' OD1' ' HG ' ' A' ' 59' ' ' LEU . 1.0 OUTLIER -83.71 -37.32 22.86 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.23 -178.423 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 107' ' ' HIS . . . . . 0.662 ' HB2' ' HB3' ' A' ' 28' ' ' GLN . 35.7 t60 56.9 35.83 26.89 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 115.51 -0.768 . . . . 0.0 111.138 174.14 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 91.4 mt -89.82 -172.97 3.74 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 121.812 0.815 . . . . 0.0 111.726 -175.319 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 109' ' ' ARG . . . . . 0.436 HH11 ' HD3' ' A' ' 109' ' ' ARG . 15.5 ttm180 -149.01 123.99 10.02 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 114.251 -1.341 . . . . 0.0 109.251 179.353 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 9.8 p -141.16 147.01 22.85 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-O 121.104 0.478 . . . . 0.0 110.195 175.962 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 111' ' ' ARG . . . . . . . . . . . . . 22.8 ttt180 -112.33 173.89 6.15 Favored 'General case' 0 C--N 1.313 -0.985 0 N-CA-C 108.264 -1.013 . . . . 0.0 108.264 178.307 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -72.19 72.71 0.91 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.709 0.766 . . . . 0.0 111.015 179.426 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 31.1 m -143.85 112.15 6.36 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 115.029 -0.987 . . . . 0.0 108.956 178.584 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 4.9 m -76.7 94.73 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-O 121.648 0.737 . . . . 0.0 111.45 -177.757 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -113.93 105.65 13.49 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-N 115.125 -0.943 . . . . 0.0 110.273 -178.773 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 12.1 t -138.09 75.08 1.5 Allowed 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 121.417 0.627 . . . . 0.0 109.436 -179.274 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 4.5 p -119.58 114.01 42.92 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.582 0 CA-C-O 121.647 0.737 . . . . 0.0 111.037 -179.054 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 92.5 mt -108.98 -41.42 4.73 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-N 115.31 -0.859 . . . . 0.0 109.409 176.326 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 65.87 22.06 69.96 Favored Glycine 0 N--CA 1.449 -0.443 0 CA-C-N 115.635 -0.712 . . . . 0.0 112.142 -178.779 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 16.7 p-10 -74.0 107.52 6.26 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.521 0.677 . . . . 0.0 110.976 -175.296 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 11.7 t -119.2 134.92 54.93 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.584 -0.735 . . . . 0.0 109.403 178.52 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 93.0 mt -126.74 122.95 23.66 Favored Pre-proline 0 C--N 1.326 -0.451 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.566 -175.717 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -69.79 132.6 23.62 Favored 'Trans proline' 0 CA--C 1.529 0.263 0 C-N-CA 122.656 2.237 . . . . 0.0 112.07 179.185 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -87.28 119.68 27.78 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.304 179.18 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.979 0 CA-C-O 118.912 -0.565 . . . . 0.0 110.309 -179.65 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.445 ' HA ' ' HD3' ' A' ' 24' ' ' PRO . 52.8 tt0 . . . . . 0 N--CA 1.45 -0.44 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.445 ' HD3' ' HA ' ' A' ' 23' ' ' GLN . 17.3 Cg_exo -70.28 -164.47 0.14 Allowed 'Trans proline' 0 C--O 1.231 0.139 0 C-N-CA 123.316 2.677 . . . . 0.0 113.367 -179.195 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.693 ' HA ' ' HB3' ' A' ' 57' ' ' SER . 30.7 t0 75.36 32.07 0.75 Allowed 'General case' 0 N--CA 1.469 0.49 0 CA-C-N 114.767 -1.106 . . . . 0.0 109.255 -175.618 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 146.81 148.8 4.83 Favored Glycine 0 N--CA 1.444 -0.779 0 CA-C-N 114.648 -1.16 . . . . 0.0 111.448 176.041 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.458 HG23 ' HB ' ' A' ' 48' ' ' ILE . 29.3 m -122.51 144.1 33.05 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-O 121.018 0.437 . . . . 0.0 111.085 -179.63 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' GLN . . . . . 0.4 HE21 HG22 ' A' ' 47' ' ' VAL . 35.0 tt0 -112.32 153.32 27.4 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 110.004 -0.369 . . . . 0.0 110.004 175.697 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 60.3 mt -78.86 112.55 17.04 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-N 116.314 -0.403 . . . . 0.0 109.921 178.85 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.635 ' HB3' ' HB2' ' A' ' 103' ' ' ARG . 22.5 t70 -64.32 -65.11 0.72 Allowed 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.789 -0.641 . . . . 0.0 109.713 178.559 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 20.7 p -156.8 154.39 29.85 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.166 -0.925 . . . . 0.0 110.586 179.103 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.605 HG23 HG22 ' A' ' 102' ' ' ILE . 13.5 p -91.25 143.67 10.77 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 176.884 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 61.6 t -97.13 114.88 65.42 Favored Pre-proline 0 C--N 1.321 -0.636 0 N-CA-C 110.16 -0.311 . . . . 0.0 110.16 177.708 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -55.19 122.3 11.47 Favored 'Trans proline' 0 C--N 1.346 0.411 0 C-N-CA 123.094 2.529 . . . . 0.0 112.033 178.761 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 122.05 7.92 7.57 Favored Glycine 0 N--CA 1.446 -0.695 0 CA-C-N 115.55 -0.75 . . . . 0.0 111.711 -176.505 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 72.3 p -121.33 150.19 53.69 Favored Pre-proline 0 C--N 1.325 -0.457 0 CA-C-O 120.676 0.274 . . . . 0.0 110.497 -179.013 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -67.59 -16.33 46.7 Favored 'Trans proline' 0 C--N 1.346 0.421 0 C-N-CA 122.639 2.226 . . . . 0.0 112.513 179.648 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.492 ' HA ' HD11 ' A' ' 86' ' ' LEU . . . -60.34 -36.82 78.87 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.568 -177.518 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 22.9 t -64.69 -23.68 67.33 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.617 -176.533 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 63.4 tttp -82.0 -26.03 34.21 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.027 0.441 . . . . 0.0 110.683 -177.505 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 38.6 t -99.22 -55.86 5.67 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.503 -175.978 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 1.9 pp -108.81 -178.02 3.47 Favored 'General case' 0 CA--C 1.516 -0.334 0 CA-C-O 121.527 0.68 . . . . 0.0 111.959 -177.472 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 5.4 p -127.85 143.53 48.04 Favored Pre-proline 0 C--N 1.315 -0.894 0 CA-C-N 114.94 -1.027 . . . . 0.0 110.645 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -66.69 146.19 78.13 Favored 'Trans proline' 0 N--CA 1.462 -0.347 0 C-N-CA 122.39 2.06 . . . . 0.0 111.627 175.643 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 102.55 -7.74 54.03 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.568 -178.105 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 89.1 mt -80.63 163.34 23.7 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.91 0.386 . . . . 0.0 110.772 179.061 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.409 ' O ' ' HA ' ' A' ' 79' ' ' THR . 44.3 t -103.24 137.15 32.68 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 N-CA-C 109.422 -0.585 . . . . 0.0 109.422 176.858 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.458 ' HB ' HG23 ' A' ' 27' ' ' VAL . 63.2 mt -103.15 121.26 54.16 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-O 120.786 0.327 . . . . 0.0 110.603 -179.213 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -82.71 -47.44 12.0 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.018 0.437 . . . . 0.0 110.848 177.501 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.623 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 6.1 p -152.15 146.28 25.36 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 121.176 0.512 . . . . 0.0 112.244 -174.185 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 47.4 mm -110.89 101.47 12.6 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-N 114.699 -1.137 . . . . 0.0 108.211 173.488 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 4.6 t-20 66.13 -152.15 0.23 Allowed 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 -172.493 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -73.42 7.28 12.64 Favored Glycine 0 CA--C 1.523 0.554 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.656 177.143 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 2.1 mpt? -111.62 102.53 53.57 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 120.812 0.339 . . . . 0.0 110.131 -179.667 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.623 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 44.5 Cg_endo -71.67 124.27 10.11 Favored 'Trans proline' 0 N--CA 1.46 -0.458 0 C-N-CA 122.146 1.897 . . . . 0.0 112.215 179.661 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 16.8 p -92.13 96.89 10.58 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.877 -0.602 . . . . 0.0 111.358 -176.369 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' SER . . . . . 0.693 ' HB3' ' HA ' ' A' ' 25' ' ' ASP . 14.2 m -94.75 -19.65 20.19 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.303 178.857 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 76.2 m-20 -123.92 164.32 19.53 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.13 -178.886 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 84.5 mt -75.81 -30.47 59.05 Favored 'General case' 0 N--CA 1.443 -0.802 0 CA-C-O 121.185 0.517 . . . . 0.0 109.906 177.924 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 9.6 m -69.17 -39.47 78.74 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.611 -0.722 . . . . 0.0 111.152 178.512 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -71.05 -27.9 63.98 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.628 0.251 . . . . 0.0 111.065 179.909 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 87.1 t80 -64.41 -40.72 96.32 Favored 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 173.069 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' SER . . . . . 0.421 ' O ' ' HD3' ' A' ' 67' ' ' LYS . 7.0 t -66.68 -43.33 84.73 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.732 -0.667 . . . . 0.0 109.855 176.596 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.31 -33.21 74.22 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 121.164 0.507 . . . . 0.0 110.793 179.693 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' ALA . . . . . 0.679 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -69.01 -49.3 58.96 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.946 -0.57 . . . . 0.0 109.831 176.357 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.409 ' HA ' HD23 ' A' ' 66' ' ' LEU . 11.2 mt -58.57 -36.47 73.99 Favored 'General case' 0 N--CA 1.448 -0.575 0 CA-C-N 116.002 -0.544 . . . . 0.0 112.129 -177.387 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 67' ' ' LYS . . . . . 0.421 ' HD3' ' O ' ' A' ' 63' ' ' SER . 2.4 mptm? -77.52 -7.04 55.65 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 112.494 0.553 . . . . 0.0 112.494 -179.029 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 9.0 p -110.41 -13.69 14.24 Favored 'General case' 0 C--N 1.323 -0.557 0 C-N-CA 120.807 -0.357 . . . . 0.0 111.785 178.755 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.679 HG12 ' O ' ' A' ' 65' ' ' ALA . 33.4 mm -73.33 148.33 8.91 Favored 'Isoleucine or valine' 0 C--O 1.234 0.237 0 N-CA-C 110.17 -0.307 . . . . 0.0 110.17 177.685 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 70' ' ' SER . . . . . 0.588 ' HB2' ' HB2' ' A' ' 73' ' ' GLU . 3.2 m -84.89 164.63 18.27 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.269 177.675 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 26.7 t -82.2 123.13 37.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 177.965 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 81.9 21.73 60.84 Favored Glycine 0 N--CA 1.448 -0.548 0 C-N-CA 120.574 -0.822 . . . . 0.0 111.549 -178.496 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.588 ' HB2' ' HB2' ' A' ' 70' ' ' SER . 34.4 tt0 -96.5 150.12 20.98 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -178.561 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 48.0 t -100.33 120.44 49.79 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.759 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.285 -177.937 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 27.7 pt -113.86 154.53 15.23 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-N 115.998 -0.547 . . . . 0.0 110.913 -179.47 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 13.0 t30 -93.33 118.18 30.97 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.467 179.676 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 51.3 mt -114.34 103.99 16.22 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.832 0 CA-C-O 121.417 0.627 . . . . 0.0 109.85 178.335 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 15.9 m -90.41 111.17 22.32 Favored 'General case' 0 C--N 1.315 -0.929 0 CA-C-N 115.701 -0.682 . . . . 0.0 109.729 179.225 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.409 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 73.3 p -107.63 171.81 7.18 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.961 0.41 . . . . 0.0 111.692 -176.74 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -52.34 -33.37 42.53 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.159 -0.928 . . . . 0.0 112.826 -178.501 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 17.4 mt-30 -127.0 27.07 6.02 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 112.334 0.494 . . . . 0.0 112.334 -174.101 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 161.32 146.23 4.57 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 119.764 -1.208 . . . . 0.0 114.053 174.788 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 8.8 m -98.57 109.75 22.46 Favored 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 175.113 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 59.7 m-85 -115.36 158.53 22.3 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.806 0.336 . . . . 0.0 110.801 -174.975 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 14.3 p80 -118.9 114.57 22.8 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 121.312 0.577 . . . . 0.0 110.022 174.241 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.492 HD11 ' HA ' ' A' ' 38' ' ' ALA . 3.5 mm? -107.33 148.59 28.84 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-N 115.297 -0.865 . . . . 0.0 111.247 -173.449 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 40.3 ttmt -98.77 130.31 45.22 Favored 'General case' 0 C--N 1.321 -0.664 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 173.941 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.523 HG21 HG21 ' A' ' 69' ' ' ILE . 15.1 p -71.05 129.69 39.61 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-O 121.0 0.429 . . . . 0.0 110.558 176.43 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -81.9 178.4 53.64 Favored Glycine 0 N--CA 1.434 -1.457 0 N-CA-C 110.936 -0.865 . . . . 0.0 110.936 -179.776 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.401 ' HG3' ' H ' ' A' ' 90' ' ' ARG . 0.3 OUTLIER -86.88 -53.57 4.83 Favored 'General case' 0 C--N 1.309 -1.155 0 C-N-CA 120.801 -0.36 . . . . 0.0 110.869 -179.92 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 91' ' ' ASN . . . . . . . . . . . . . 26.4 p30 176.03 159.38 0.43 Allowed Pre-proline 0 C--N 1.329 -0.283 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 179.754 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 8.2 Cg_exo -72.69 -74.79 0.01 OUTLIER 'Trans proline' 0 N--CA 1.46 -0.456 0 C-N-CA 122.17 1.913 . . . . 0.0 111.313 175.017 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 5.6 m120 -138.6 -34.66 0.61 Allowed 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.745 177.536 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 3.4 m-20 -77.96 166.23 23.11 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.966 -179.669 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 3.4 p -69.11 110.12 4.37 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.994 -177.952 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 49.7 m -159.39 167.06 29.72 Favored 'General case' 0 C--O 1.234 0.25 0 CA-C-N 115.962 -0.563 . . . . 0.0 109.859 178.366 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -147.13 149.11 32.37 Favored 'General case' 0 N--CA 1.453 -0.291 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 176.991 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . 53.01 73.44 0.36 Allowed 'General case' 0 N--CA 1.467 0.409 0 O-C-N 123.574 0.546 . . . . 0.0 110.124 -177.56 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 46.4 t80 -120.83 128.35 52.77 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.411 -167.129 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 46.4 tpp -108.06 120.24 41.76 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 173.868 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -86.52 57.17 4.72 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.788 -0.72 . . . . 0.0 114.124 -170.79 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.605 HG22 HG23 ' A' ' 32' ' ' VAL . 2.6 pp -143.82 148.92 18.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 173.066 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 103' ' ' ARG . . . . . 0.635 ' HB2' ' HB3' ' A' ' 30' ' ' ASP . 43.4 mtp180 -90.87 143.34 26.82 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 116.376 -0.374 . . . . 0.0 110.264 176.749 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 2.1 p -115.82 143.4 45.45 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 121.063 0.458 . . . . 0.0 110.962 178.924 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 37.3 t -136.3 169.57 17.44 Favored 'General case' 0 C--N 1.317 -0.832 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 177.931 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 5.4 p30 -105.49 37.1 2.3 Favored 'General case' 0 C--N 1.31 -1.109 0 CA-C-O 122.031 0.919 . . . . 0.0 109.692 178.701 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 20.9 t-80 -80.32 92.44 5.78 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 114.884 -1.053 . . . . 0.0 109.926 175.766 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 108' ' ' LEU . . . . . 0.409 HD11 ' O ' ' A' ' 24' ' ' PRO . 31.8 mt -77.09 -164.68 0.47 Allowed 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 121.768 0.794 . . . . 0.0 110.713 179.111 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 85.7 mtm180 -89.17 95.77 10.44 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-N 114.897 -1.047 . . . . 0.0 110.096 178.933 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 43.3 t -67.87 130.06 32.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.124 -179.883 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 111' ' ' ARG . . . . . 0.423 HH11 ' HD3' ' A' ' 111' ' ' ARG . 18.6 ptt-85 -120.96 2.51 10.49 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.203 -175.377 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 32.6 t70 -178.91 161.52 1.2 Allowed 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 177.907 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 42.3 m -69.0 90.37 0.44 Allowed 'General case' 0 C--N 1.318 -0.782 0 CA-C-O 120.885 0.374 . . . . 0.0 110.16 177.598 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 28.3 m -82.84 142.13 14.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.824 -176.237 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . 59.33 -85.3 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 115.235 -0.893 . . . . 0.0 112.418 178.452 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 13.5 p -165.01 99.3 0.75 Allowed 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.157 -0.474 . . . . 0.0 109.939 -178.574 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 7.3 m -108.14 88.76 1.18 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-O 121.762 0.791 . . . . 0.0 111.279 -179.43 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 94.9 mt -120.62 -41.88 2.56 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.331 -0.85 . . . . 0.0 109.678 177.901 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 115.58 140.71 7.14 Favored Glycine 0 N--CA 1.447 -0.605 0 CA-C-N 115.734 -0.666 . . . . 0.0 112.178 178.988 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 15.4 m-20 -76.51 105.68 7.71 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 110.162 -0.31 . . . . 0.0 110.162 177.312 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 17.0 p -69.05 107.32 3.11 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 121.093 0.473 . . . . 0.0 110.361 177.172 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 85.7 mt -73.52 145.43 84.91 Favored Pre-proline 0 C--N 1.323 -0.574 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.028 -177.52 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 7.2 Cg_endo -49.4 115.55 1.82 Allowed 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 123.213 2.609 . . . . 0.0 112.253 -178.393 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 60.1 t80 -115.71 95.2 5.02 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.527 179.36 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.976 0 CA-C-O 118.123 -0.942 . . . . 0.0 110.116 -179.63 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 23' ' ' GLN . . . . . . . . . . . . . 22.4 mp0 . . . . . 0 CA--C 1.539 0.524 0 CA-C-O 120.649 0.261 . . . . 0.0 111.42 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -80.37 172.6 13.41 Favored 'Trans proline' 0 N--CA 1.461 -0.441 0 C-N-CA 122.088 1.859 . . . . 0.0 111.643 173.046 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.404 ' HA ' ' HB3' ' A' ' 57' ' ' SER . 12.1 t70 69.64 39.4 1.54 Allowed 'General case' 0 N--CA 1.467 0.404 0 CA-C-O 121.901 0.858 . . . . 0.0 110.12 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 173.7 140.89 3.35 Favored Glycine 0 N--CA 1.446 -0.662 0 CA-C-N 114.792 -1.094 . . . . 0.0 111.266 177.139 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 28.8 m -120.76 146.4 25.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 116.819 0.309 . . . . 0.0 110.319 179.279 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' GLN . . . . . 0.406 ' HB2' HE21 ' A' ' 28' ' ' GLN . 0.0 OUTLIER -123.0 159.45 28.33 Favored 'General case' 0 C--N 1.322 -0.594 0 C-N-CA 120.503 -0.479 . . . . 0.0 110.997 -178.722 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 56.5 mt -81.7 106.14 12.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 115.907 -0.588 . . . . 0.0 109.949 179.641 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 14.8 t70 -68.03 -63.78 0.99 Allowed 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 116.054 -0.521 . . . . 0.0 109.88 -177.568 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 2.2 p -155.41 140.47 17.4 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.912 -0.586 . . . . 0.0 111.829 -177.312 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.659 HG22 HG22 ' A' ' 102' ' ' ILE . 96.5 t -86.91 126.45 40.84 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.208 -0.451 . . . . 0.0 109.819 177.89 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 5.6 m -103.38 129.19 25.94 Favored Pre-proline 0 N--CA 1.451 -0.419 0 CA-C-O 121.117 0.484 . . . . 0.0 111.863 -175.659 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -69.3 164.25 34.81 Favored 'Trans proline' 0 C--O 1.235 0.331 0 C-N-CA 122.743 2.295 . . . . 0.0 112.048 176.99 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 98.12 -34.13 5.46 Favored Glycine 0 N--CA 1.449 -0.436 0 N-CA-C 110.661 -0.976 . . . . 0.0 110.661 -174.605 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.414 ' HB2' ' HD2' ' A' ' 37' ' ' PRO . 0.7 OUTLIER -104.84 169.86 6.66 Favored Pre-proline 0 C--N 1.317 -0.835 0 CA-C-N 114.721 -0.74 . . . . 0.0 109.569 175.347 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 37' ' ' PRO . . . . . 0.414 ' HD2' ' HB2' ' A' ' 36' ' ' SER . 42.3 Cg_endo -68.59 -170.26 0.31 Allowed 'Trans proline' 0 CA--C 1.534 0.492 0 C-N-CA 122.264 1.976 . . . . 0.0 112.74 177.827 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 74.53 6.19 4.53 Favored 'General case' 0 N--CA 1.471 0.577 0 C-N-CA 123.575 0.75 . . . . 0.0 112.343 179.733 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 23.1 t -52.35 -62.18 1.8 Allowed 'General case' 0 C--O 1.233 0.232 0 O-C-N 123.448 0.467 . . . . 0.0 110.608 -179.712 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 3.3 tmtp? -111.24 65.37 0.62 Allowed 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 172.328 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.415 HG12 HD12 ' A' ' 42' ' ' LEU . 36.5 t -137.94 -49.77 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.382 -0.826 . . . . 0.0 109.292 175.793 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.415 HD12 HG12 ' A' ' 41' ' ' VAL . 6.3 mp -119.58 171.49 8.33 Favored 'General case' 0 C--O 1.234 0.262 0 CA-C-N 115.625 -0.716 . . . . 0.0 109.88 176.079 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 7.3 p -126.65 146.58 57.47 Favored Pre-proline 0 C--N 1.322 -0.612 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.487 177.474 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 76.9 Cg_endo -76.95 157.03 34.62 Favored 'Trans proline' 0 C--O 1.233 0.246 0 C-N-CA 122.549 2.166 . . . . 0.0 111.975 178.402 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 90.62 11.71 61.84 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.58 -0.819 . . . . 0.0 112.697 179.063 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 64.7 mt -103.47 164.36 11.7 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.809 0.304 . . . . 0.0 110.207 178.042 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 48.1 t -105.98 137.66 35.0 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 N-CA-C 110.315 -0.254 . . . . 0.0 110.315 176.307 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 60.3 mt -95.72 129.78 45.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 121.097 0.475 . . . . 0.0 110.846 -178.411 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 22.3 tt0 -86.66 -56.02 3.6 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.635 -0.711 . . . . 0.0 110.198 175.612 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.603 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 13.7 p -148.99 152.49 36.4 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.243 -0.889 . . . . 0.0 112.067 -170.556 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 49.7 mm -111.41 85.44 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.043 -0.98 . . . . 0.0 109.742 176.315 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' ASN . . . . . 0.629 ' HB2' ' H ' ' A' ' 76' ' ' ASN . 62.3 t30 54.72 78.88 0.16 Allowed 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 114.843 -1.072 . . . . 0.0 111.949 176.727 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 83.37 -49.06 4.16 Favored Glycine 0 N--CA 1.447 -0.579 0 CA-C-N 115.541 -0.754 . . . . 0.0 112.459 178.976 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 58.4 mtm -85.56 111.78 39.64 Favored Pre-proline 0 C--N 1.324 -0.521 0 N-CA-C 110.387 -0.227 . . . . 0.0 110.387 -179.718 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.603 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 70.6 Cg_endo -75.1 134.04 17.16 Favored 'Trans proline' 0 N--CA 1.458 -0.577 0 C-N-CA 122.054 1.836 . . . . 0.0 111.833 178.921 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 24.5 p -109.34 93.37 4.47 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 121.47 0.652 . . . . 0.0 111.547 -175.497 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' SER . . . . . 0.404 ' HB3' ' HA ' ' A' ' 25' ' ' ASP . 19.3 m -99.74 -14.31 18.92 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 115.229 -0.896 . . . . 0.0 110.155 177.997 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 52.7 m-80 -125.98 159.27 33.1 Favored 'General case' 0 C--N 1.319 -0.74 0 C-N-CA 120.502 -0.479 . . . . 0.0 109.887 -179.268 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 96.6 mt -70.74 -28.29 64.59 Favored 'General case' 0 N--CA 1.44 -0.954 0 CA-C-N 115.734 -0.666 . . . . 0.0 109.387 177.144 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 5.1 m -69.54 -48.92 58.8 Favored 'General case' 0 N--CA 1.448 -0.565 0 CA-C-N 115.254 -0.884 . . . . 0.0 110.629 178.557 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 1.7 p -67.42 -34.37 77.08 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.77 0.319 . . . . 0.0 111.042 178.095 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 25.8 t80 -62.54 -40.11 95.77 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.308 0.575 . . . . 0.0 109.618 175.381 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' SER . . . . . 0.525 ' O ' ' HG3' ' A' ' 67' ' ' LYS . 8.1 t -67.33 -45.13 77.32 Favored 'General case' 0 N--CA 1.452 -0.37 0 CA-C-N 115.459 -0.791 . . . . 0.0 110.36 178.576 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -60.02 -38.35 82.45 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.811 -179.217 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' ALA . . . . . 0.51 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -65.11 -46.0 82.84 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.377 -179.49 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 2.3 tt -58.58 -42.3 87.72 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.756 -0.657 . . . . 0.0 110.544 -179.413 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' LYS . . . . . 0.525 ' HG3' ' O ' ' A' ' 63' ' ' SER . 96.0 mttt -63.33 -23.51 67.45 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.566 -0.743 . . . . 0.0 112.483 -177.102 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 77.5 p -90.9 -13.07 34.3 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.779 0.323 . . . . 0.0 111.35 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.584 HG21 HG21 ' A' ' 88' ' ' THR . 45.9 mm -72.68 136.42 25.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 121.174 0.511 . . . . 0.0 111.265 -176.789 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 70' ' ' SER . . . . . 0.423 ' HB2' ' HB2' ' A' ' 73' ' ' GLU . 4.4 m -82.45 143.99 30.77 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.84 -0.618 . . . . 0.0 109.588 174.957 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 16.8 t -71.72 115.83 12.53 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-N 116.372 -0.377 . . . . 0.0 110.467 -177.074 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' GLY . . . . . 0.441 ' HA2' ' O ' ' A' ' 88' ' ' THR . . . 98.27 4.88 57.31 Favored Glycine 0 N--CA 1.447 -0.63 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.076 179.71 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.423 ' HB2' ' HB2' ' A' ' 70' ' ' SER . 9.0 tp10 -90.68 154.96 19.18 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 120.715 0.293 . . . . 0.0 110.27 -178.087 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 49.0 t -94.32 118.73 40.97 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.582 -178.486 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 32.5 pt -103.01 167.7 2.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.728 178.728 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' ASN . . . . . 0.629 ' H ' ' HB2' ' A' ' 52' ' ' ASN . 43.3 t30 -120.06 106.56 12.11 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.883 -172.283 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 57.6 mt -105.49 109.32 27.41 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.808 0 CA-C-O 121.328 0.585 . . . . 0.0 110.769 -174.675 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 31.1 m -89.72 114.78 26.5 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.494 -0.775 . . . . 0.0 109.72 176.485 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 69.4 p -112.55 174.15 6.03 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 110.29 -0.263 . . . . 0.0 110.29 179.02 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 12.4 t70 -63.27 -30.36 71.51 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.342 178.244 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 48.9 tp60 -95.64 14.57 22.57 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.333 0.587 . . . . 0.0 110.891 -176.345 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 127.36 179.67 15.94 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.53 176.941 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 55.6 m -109.92 129.45 55.65 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-O 120.696 0.284 . . . . 0.0 110.561 -178.329 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 23.5 m-85 -128.43 152.42 48.23 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 -179.607 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 7.8 p-80 -109.24 133.21 53.33 Favored 'General case' 0 C--N 1.322 -0.621 0 C-N-CA 120.62 -0.432 . . . . 0.0 110.011 174.041 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.484 HD23 ' N ' ' A' ' 87' ' ' LYS . 5.5 tt -118.97 137.53 53.43 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 115.918 -0.583 . . . . 0.0 109.734 -175.085 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.484 ' N ' HD23 ' A' ' 86' ' ' LEU . 62.1 tttp -98.41 117.05 31.95 Favored 'General case' 0 C--N 1.311 -1.1 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 179.049 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.584 HG21 HG21 ' A' ' 69' ' ' ILE . 16.9 p -66.95 135.41 53.75 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 121.152 0.501 . . . . 0.0 111.154 -176.465 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -99.66 -157.64 28.63 Favored Glycine 0 N--CA 1.439 -1.155 0 N-CA-C 111.004 -0.838 . . . . 0.0 111.004 177.03 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 5.7 mpt_? -116.62 177.95 4.51 Favored 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 109.716 -0.475 . . . . 0.0 109.716 177.535 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 91' ' ' ASN . . . . . 0.424 ' HA ' ' HD3' ' A' ' 92' ' ' PRO . 47.4 t-20 -75.28 114.57 36.88 Favored Pre-proline 0 C--N 1.322 -0.587 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 169.85 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.424 ' HD3' ' HA ' ' A' ' 91' ' ' ASN . 36.5 Cg_exo -59.67 -19.57 53.88 Favored 'Trans proline' 0 C--O 1.233 0.237 0 C-N-CA 122.887 2.391 . . . . 0.0 112.834 -172.638 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 27.7 t-20 -112.91 -49.11 2.95 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 112.245 0.461 . . . . 0.0 112.245 -176.749 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 4.8 t-20 -111.7 -154.31 0.54 Allowed 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 120.952 -0.299 . . . . 0.0 111.301 -171.551 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 25.4 m -52.27 138.3 26.76 Favored 'General case' 0 CA--C 1.53 0.186 0 C-N-CA 123.622 0.769 . . . . 0.0 112.527 -174.463 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 1.7 m -68.69 98.22 0.88 Allowed 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.479 -0.782 . . . . 0.0 112.037 -175.758 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 1.5 tpt180 -106.41 152.61 23.38 Favored 'General case' 0 C--N 1.315 -0.904 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 174.248 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -64.98 95.3 0.15 Allowed 'General case' 0 C--N 1.331 -0.224 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 174.953 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 46.4 t80 -112.11 128.8 56.32 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 121.304 0.573 . . . . 0.0 111.887 -171.973 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 20.6 ptp -94.17 141.59 28.38 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.277 174.565 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -84.52 37.15 2.92 Favored Glycine 0 CA--C 1.519 0.319 0 C-N-CA 121.099 -0.572 . . . . 0.0 114.2 -170.836 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.659 HG22 HG22 ' A' ' 32' ' ' VAL . 33.6 pt -138.24 154.06 27.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 117.204 0.502 . . . . 0.0 110.481 178.095 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 55.7 mtp180 -93.66 117.11 29.66 Favored 'General case' 0 C--N 1.318 -0.788 0 N-CA-C 108.336 -0.987 . . . . 0.0 108.336 171.476 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -111.03 137.18 48.99 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-O 121.344 0.592 . . . . 0.0 110.624 -178.017 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 19.1 m -156.97 164.24 38.23 Favored 'General case' 0 C--N 1.31 -1.115 0 CA-C-N 115.543 -0.753 . . . . 0.0 109.462 -178.866 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 14.9 p30 -80.14 -10.55 59.77 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 169.008 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 6.0 t60 47.1 70.72 0.38 Allowed 'General case' 0 C--O 1.231 0.13 0 CA-C-N 114.035 -1.439 . . . . 0.0 111.296 -179.258 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 95.1 mt -108.75 -173.84 2.37 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.477 177.69 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 89.1 mtt180 60.95 105.22 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.404 0 O-C-N 124.37 1.044 . . . . 0.0 112.391 179.287 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 57.4 t -101.67 128.62 53.93 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.824 175.918 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 111' ' ' ARG . . . . . . . . . . . . . 98.5 mtt180 -116.61 140.55 49.27 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.131 -178.766 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 19.5 t70 -115.86 93.41 4.24 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.912 -0.586 . . . . 0.0 109.497 176.43 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 58.6 m -155.16 134.38 12.38 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.597 -179.919 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 26.9 m -113.16 160.87 12.49 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 173.498 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -68.37 95.24 0.59 Allowed 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.2 0.524 . . . . 0.0 110.495 -178.414 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 13.4 m -105.79 19.5 20.45 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.782 -175.769 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.433 ' HA ' ' OD1' ' A' ' 120' ' ' ASP . 4.8 m -78.46 89.5 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-O 121.674 0.75 . . . . 0.0 110.618 179.793 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 60.9 mt -122.84 -77.08 0.59 Allowed 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.175 -175.757 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -122.94 32.49 4.39 Favored Glycine 0 N--CA 1.451 -0.366 0 N-CA-C 111.105 -0.798 . . . . 0.0 111.105 177.829 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 120' ' ' ASP . . . . . 0.625 ' OD2' ' HG ' ' A' ' 122' ' ' LEU . 3.1 p-10 -72.17 -34.53 68.54 Favored 'General case' 0 C--N 1.324 -0.51 0 C-N-CA 123.006 0.522 . . . . 0.0 111.756 -176.579 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 121' ' ' THR . . . . . 0.531 ' O ' ' HD3' ' A' ' 123' ' ' PRO . 36.6 p 49.19 77.93 0.1 Allowed 'General case' 0 N--CA 1.464 0.226 0 O-C-N 123.744 0.652 . . . . 0.0 111.537 -176.617 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 122' ' ' LEU . . . . . 0.625 ' HG ' ' OD2' ' A' ' 120' ' ' ASP . 93.7 mt -92.61 106.35 18.2 Favored Pre-proline 0 C--N 1.327 -0.407 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.01 -179.855 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 123' ' ' PRO . . . . . 0.531 ' HD3' ' O ' ' A' ' 121' ' ' THR . 9.3 Cg_endo -89.53 153.37 5.3 Favored 'Trans proline' 0 N--CA 1.456 -0.727 0 C-N-CA 123.098 2.532 . . . . 0.0 111.659 175.632 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 70.7 t80 -136.63 111.04 8.49 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.559 -0.291 . . . . 0.0 110.332 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.253 1.252 0 O-C-N 123.873 0.733 . . . . 0.0 111.228 179.636 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.444 ' HA ' ' HD3' ' A' ' 24' ' ' PRO . 5.1 tp-100 . . . . . 0 N--CA 1.454 -0.234 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.444 ' HD3' ' HA ' ' A' ' 23' ' ' GLN . 4.0 Cg_exo -78.62 115.23 3.6 Favored 'Trans proline' 0 C--O 1.234 0.292 0 C-N-CA 123.051 2.501 . . . . 0.0 112.438 178.176 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.43 ' OD2' ' HA ' ' A' ' 108' ' ' LEU . 17.0 p-10 -137.3 -35.23 0.69 Allowed 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.23 -178.655 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.414 ' HA2' ' HA ' ' A' ' 57' ' ' SER . . . 134.53 162.94 10.05 Favored Glycine 0 N--CA 1.445 -0.73 0 N-CA-C 111.587 -0.605 . . . . 0.0 111.587 -179.255 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.496 HG23 ' HB ' ' A' ' 48' ' ' ILE . 15.3 m -99.73 134.37 39.32 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-O 121.13 0.491 . . . . 0.0 110.957 176.942 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 6.6 tp60 -97.58 133.5 42.06 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.786 -176.577 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.605 ' HB ' ' H ' ' A' ' 46' ' ' LEU . 36.7 mm -72.65 112.66 8.89 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-N 115.706 -0.679 . . . . 0.0 109.773 173.155 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 16.7 t70 -76.15 -69.75 0.48 Allowed 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.09 -179.289 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 7.7 p -148.96 142.66 25.54 Favored 'General case' 0 N--CA 1.447 -0.594 0 CA-C-O 121.398 0.618 . . . . 0.0 111.553 -178.203 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.524 HG11 ' HA ' ' A' ' 39' ' ' SER . 61.4 t -98.55 119.35 46.43 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-N 114.96 -1.018 . . . . 0.0 109.185 173.945 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.503 HG12 ' O ' ' A' ' 101' ' ' GLY . 10.9 p -91.69 131.85 34.74 Favored Pre-proline 0 C--N 1.324 -0.527 0 CA-C-O 120.776 0.322 . . . . 0.0 110.294 -178.329 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -58.34 147.23 86.11 Favored 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.816 2.344 . . . . 0.0 112.226 -179.469 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 91.64 24.74 25.01 Favored Glycine 0 N--CA 1.448 -0.526 0 C-N-CA 120.759 -0.734 . . . . 0.0 111.82 -177.374 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.544 ' CB ' ' HA3' ' A' ' 101' ' ' GLY . 61.3 p -125.85 157.35 69.32 Favored Pre-proline 0 C--N 1.325 -0.49 0 N-CA-C 110.155 -0.313 . . . . 0.0 110.155 -179.934 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 29.5 Cg_endo -64.07 -30.77 65.97 Favored 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.424 2.082 . . . . 0.0 112.099 176.901 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.531 ' HB2' HD11 ' A' ' 86' ' ' LEU . . . -80.15 -13.52 59.19 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.436 -177.894 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.524 ' HA ' HG11 ' A' ' 32' ' ' VAL . 22.9 t -61.46 -27.95 68.94 Favored 'General case' 0 CA--C 1.532 0.283 0 N-CA-C 112.249 0.463 . . . . 0.0 112.249 -174.468 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 52.2 mtmt -103.18 -13.81 16.63 Favored 'General case' 0 C--N 1.326 -0.44 0 C-N-CA 120.88 -0.328 . . . . 0.0 111.645 -176.334 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.459 ' HB ' HD12 ' A' ' 42' ' ' LEU . 35.3 t -103.92 -38.73 5.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-N 116.565 -0.289 . . . . 0.0 111.519 -174.319 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.459 HD12 ' HB ' ' A' ' 41' ' ' VAL . 6.5 mp -113.8 168.59 9.66 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.131 0.491 . . . . 0.0 111.119 -177.213 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 7.4 p -129.75 156.4 78.93 Favored Pre-proline 0 C--N 1.321 -0.643 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.026 177.17 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -73.56 154.13 49.79 Favored 'Trans proline' 0 N--CA 1.463 -0.273 0 C-N-CA 122.285 1.99 . . . . 0.0 112.368 179.641 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 81.89 28.78 40.73 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.891 -0.671 . . . . 0.0 113.323 177.551 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.641 HD22 ' HB2' ' A' ' 81' ' ' GLN . 53.6 mt -109.2 162.01 14.69 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 117.066 0.433 . . . . 0.0 110.519 176.214 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 62.1 t -110.99 130.2 64.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 N-CA-C 110.035 -0.357 . . . . 0.0 110.035 178.227 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.552 HD11 HD11 ' A' ' 29' ' ' ILE . 76.7 mt -89.66 121.19 39.56 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-O 121.042 0.449 . . . . 0.0 110.894 -179.573 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 10.6 tt0 -77.32 -57.0 4.07 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.403 -0.817 . . . . 0.0 110.06 176.208 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.628 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 14.7 p -146.8 152.82 39.38 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.194 -0.912 . . . . 0.0 111.988 -172.126 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 42.9 mm -111.91 97.15 5.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.262 176.956 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' ASN . . . . . 0.548 ' HA ' ' HB3' ' A' ' 76' ' ' ASN . 6.5 t30 67.43 -80.78 0.03 OUTLIER 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 114.884 -1.053 . . . . 0.0 111.905 174.262 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -126.73 3.39 7.52 Favored Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 120.581 -0.819 . . . . 0.0 112.103 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 54.5 mtm -131.39 117.61 16.78 Favored Pre-proline 0 C--N 1.325 -0.488 0 N-CA-C 110.393 -0.225 . . . . 0.0 110.393 -177.73 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.628 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 56.0 Cg_endo -71.26 130.8 18.05 Favored 'Trans proline' 0 N--CA 1.463 -0.313 0 C-N-CA 122.325 2.017 . . . . 0.0 112.073 178.72 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 25.6 p -108.63 94.63 5.16 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 121.24 0.543 . . . . 0.0 111.269 -176.47 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' SER . . . . . 0.414 ' HA ' ' HA2' ' A' ' 26' ' ' GLY . 5.5 m -95.55 -12.72 25.27 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.574 -0.739 . . . . 0.0 111.118 -177.828 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 6.9 t-20 -129.58 166.78 19.03 Favored 'General case' 0 C--N 1.321 -0.671 0 C-N-CA 120.597 -0.441 . . . . 0.0 109.92 176.769 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.499 ' HB2' ' HB2' ' A' ' 106' ' ' ASN . 0.4 OUTLIER -77.09 -36.45 55.68 Favored 'General case' 0 C--N 1.311 -1.098 0 CA-C-N 115.495 -0.775 . . . . 0.0 109.617 -179.011 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 6.3 m -68.09 -39.09 82.94 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.702 179.621 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 8.0 p -72.23 -37.43 69.18 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.111 0.481 . . . . 0.0 110.456 177.338 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 72.2 t80 -61.04 -43.72 98.47 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.239 175.232 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 4.7 t -65.3 -38.98 91.89 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.396 178.744 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -65.89 -33.91 76.93 Favored 'General case' 0 C--O 1.232 0.153 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.881 179.709 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -71.98 -45.16 62.03 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.253 178.499 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.412 HD23 ' HA ' ' A' ' 66' ' ' LEU . 8.2 mt -62.09 -33.42 74.4 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.245 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 37.0 ttmt -59.26 -21.98 60.45 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.869 -0.605 . . . . 0.0 111.519 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 61.0 p -100.73 -13.88 18.29 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 112.234 0.457 . . . . 0.0 112.234 -176.543 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 45.6 mm -74.5 138.01 21.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.974 0.416 . . . . 0.0 110.557 -176.773 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 7.8 m -104.03 172.92 6.54 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.611 -174.433 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.516 HG21 ' HB3' ' A' ' 96' ' ' SER . 61.3 t -82.94 136.42 22.87 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.139 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.532 177.924 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 87.64 -8.59 76.97 Favored Glycine 0 N--CA 1.448 -0.516 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 -177.997 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 23.3 tt0 -80.73 145.77 31.37 Favored 'General case' 0 N--CA 1.445 -0.682 0 CA-C-N 114.916 -0.642 . . . . 0.0 109.679 -177.088 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.466 HG22 ' HG3' ' A' ' 87' ' ' LYS . 39.6 t -113.49 116.85 53.79 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 CA-C-N 115.984 -0.553 . . . . 0.0 109.994 -176.839 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 16.4 pt -106.15 153.49 7.52 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-O 121.481 0.658 . . . . 0.0 111.532 -178.739 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' ASN . . . . . 0.548 ' HB3' ' HA ' ' A' ' 52' ' ' ASN . 15.1 t30 -101.81 104.73 15.51 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 114.881 -1.054 . . . . 0.0 110.219 -178.042 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 52.6 mt -105.1 105.46 18.67 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.883 0 CA-C-O 121.191 0.52 . . . . 0.0 111.001 -174.314 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' THR . . . . . 0.516 ' HA ' ' HA ' ' A' ' 83' ' ' THR . 35.2 m -85.65 120.48 27.13 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.369 175.062 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 70.7 p -121.37 175.12 6.32 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 120.918 0.39 . . . . 0.0 111.148 -178.038 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -62.42 -18.55 61.94 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.544 -0.753 . . . . 0.0 111.101 176.011 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' GLN . . . . . 0.641 ' HB2' HD22 ' A' ' 46' ' ' LEU . 43.5 tp60 -102.84 4.42 37.74 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.147 0.498 . . . . 0.0 111.142 -177.419 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 128.74 175.88 14.23 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 120.57 -0.824 . . . . 0.0 112.623 179.438 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.516 ' HA ' ' HA ' ' A' ' 78' ' ' THR . 20.0 m -96.78 109.14 21.87 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-O 120.71 0.29 . . . . 0.0 110.819 -178.455 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 -107.1 169.81 8.33 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.973 0.416 . . . . 0.0 110.622 -178.205 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 7.4 p80 -129.57 126.91 39.59 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 175.96 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.531 HD11 ' HB2' ' A' ' 38' ' ' ALA . 4.2 tt -117.89 138.71 51.94 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.113 0.482 . . . . 0.0 110.512 -174.002 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.494 ' N ' HD23 ' A' ' 86' ' ' LEU . 60.5 tttp -116.71 121.02 40.43 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.535 -0.757 . . . . 0.0 109.354 179.831 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 29.6 p -71.57 139.42 49.41 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 120.733 0.302 . . . . 0.0 111.072 -178.844 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -134.22 16.05 4.44 Favored Glycine 0 CA--C 1.511 -0.198 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.558 -174.744 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.469 ' HB2' ' CB ' ' A' ' 99' ' ' TYR . 29.2 tpt180 -62.75 111.89 2.3 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-N 115.303 -0.448 . . . . 0.0 111.898 -177.384 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 91' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 -148.18 92.45 4.6 Favored Pre-proline 0 C--N 1.324 -0.528 0 CA-C-O 120.95 0.405 . . . . 0.0 110.611 175.107 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 4.1 Cg_exo -81.14 -72.1 0.01 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.653 0 C-N-CA 122.842 2.362 . . . . 0.0 111.06 173.988 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 35.9 m-20 -149.37 -63.44 0.22 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.28 176.084 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 20.0 m120 -120.3 -72.04 0.71 Allowed 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.826 -178.599 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 11.6 t -60.05 105.82 0.44 Allowed 'General case' 0 C--O 1.234 0.257 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.423 -178.124 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.516 ' HB3' HG21 ' A' ' 71' ' ' VAL . 15.3 m -127.74 122.9 34.03 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.983 -176.941 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 77.5 mtt-85 -129.06 178.3 6.51 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 174.259 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -68.19 109.3 3.5 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 120.573 0.225 . . . . 0.0 111.018 -178.518 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 99' ' ' TYR . . . . . 0.469 ' CB ' ' HB2' ' A' ' 90' ' ' ARG . 4.1 t80 -121.28 126.97 50.84 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 109.522 -0.548 . . . . 0.0 109.522 179.451 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 100' ' ' MET . . . . . 0.429 ' O ' ' HB2' ' A' ' 36' ' ' SER . 63.4 mtm -105.94 -33.22 8.0 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.461 -0.336 . . . . 0.0 111.135 -175.819 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 101' ' ' GLY . . . . . 0.544 ' HA3' ' CB ' ' A' ' 36' ' ' SER . . . 94.6 27.1 11.97 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.582 -0.818 . . . . 0.0 111.907 179.228 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.473 HG22 ' HA ' ' A' ' 32' ' ' VAL . 2.7 pp -136.01 150.43 28.21 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 178.339 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 4.1 mpt_? -104.18 139.44 39.22 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 175.566 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.9 p -117.63 161.44 19.64 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.8 179.156 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 66.8 m -143.95 161.95 37.41 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.334 175.857 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 106' ' ' ASN . . . . . 0.499 ' HB2' ' HB2' ' A' ' 59' ' ' LEU . 66.6 t30 -106.38 61.38 0.64 Allowed 'General case' 0 C--N 1.309 -1.178 0 N-CA-C 107.563 -1.273 . . . . 0.0 107.563 174.286 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 7.6 t-80 -83.49 75.88 9.98 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 114.658 -1.156 . . . . 0.0 109.642 -177.104 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 108' ' ' LEU . . . . . 0.434 ' CD2' ' HB3' ' A' ' 23' ' ' GLN . 3.7 mp -59.84 153.32 21.09 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.327 -0.851 . . . . 0.0 111.27 -177.371 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 109' ' ' ARG . . . . . 0.422 HH11 ' HD3' ' A' ' 109' ' ' ARG . 35.9 ttt180 -66.48 99.84 0.61 Allowed 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.048 -0.978 . . . . 0.0 109.511 176.301 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 13.9 p -63.64 146.13 13.2 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.388 -176.302 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 111' ' ' ARG . . . . . . . . . . . . . 71.3 ttt180 -133.33 144.52 49.7 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.127 -178.11 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 60.4 m-20 67.55 81.61 0.19 Allowed 'General case' 0 N--CA 1.467 0.388 0 O-C-N 123.951 0.782 . . . . 0.0 110.843 -177.59 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 14.8 m -106.61 90.85 3.46 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.348 -0.842 . . . . 0.0 109.441 177.662 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 34.2 m -91.86 133.06 34.57 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.151 -176.622 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -83.81 98.6 9.81 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.814 -0.63 . . . . 0.0 109.901 175.949 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 25.7 t -117.96 101.5 8.32 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.19 -178.756 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 48.5 t -110.8 112.03 38.78 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-N 116.091 -0.504 . . . . 0.0 109.845 179.61 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 88.0 mt -88.64 -64.94 1.07 Allowed 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 116.48 -0.327 . . . . 0.0 110.433 -178.446 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 119' ' ' GLY . . . . . 0.42 ' O ' ' HB2' ' A' ' 120' ' ' ASP . . . 97.73 93.33 1.93 Allowed Glycine 0 N--CA 1.446 -0.658 0 C-N-CA 120.609 -0.805 . . . . 0.0 112.82 178.002 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 120' ' ' ASP . . . . . 0.42 ' HB2' ' O ' ' A' ' 119' ' ' GLY . 3.1 m-20 75.02 152.48 0.13 Allowed 'General case' 0 N--CA 1.468 0.449 0 CA-C-O 122.003 0.906 . . . . 0.0 112.821 175.385 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 1.7 p -119.58 101.5 7.97 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 114.887 -1.051 . . . . 0.0 109.865 175.81 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 88.0 mt -112.89 100.49 51.15 Favored Pre-proline 0 C--N 1.326 -0.418 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.762 -175.787 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_endo -89.82 164.43 5.03 Favored 'Trans proline' 0 N--CA 1.453 -0.861 0 C-N-CA 122.844 2.362 . . . . 0.0 112.321 178.12 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 73.2 m-85 -115.53 166.83 11.47 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.284 175.989 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.107 0 CA-C-O 118.653 -0.689 . . . . 0.0 110.424 -178.333 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.451 ' HA ' ' HD3' ' A' ' 24' ' ' PRO . 13.8 pt20 . . . . . 0 C--O 1.236 0.378 0 CA-C-O 120.538 0.209 . . . . 0.0 110.795 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.451 ' HD3' ' HA ' ' A' ' 23' ' ' GLN . 9.0 Cg_exo -72.41 169.54 21.46 Favored 'Trans proline' 0 C--O 1.235 0.348 0 C-N-CA 123.156 2.571 . . . . 0.0 111.591 177.64 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 21.2 t70 -173.64 -41.66 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.232 0.539 . . . . 0.0 110.726 -176.473 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.569 ' HA2' ' HA ' ' A' ' 57' ' ' SER . . . 171.27 164.43 26.94 Favored Glycine 0 N--CA 1.442 -0.913 0 CA-C-N 115.263 -0.88 . . . . 0.0 111.188 -178.829 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 33.9 m -109.15 150.8 11.68 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.866 0 CA-C-O 120.768 0.318 . . . . 0.0 110.368 178.076 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' GLN . . . . . 0.406 HE21 ' HB2' ' A' ' 28' ' ' GLN . 0.0 OUTLIER -117.82 163.03 17.14 Favored 'General case' 0 C--N 1.32 -0.702 0 C-N-CA 120.751 -0.379 . . . . 0.0 110.45 176.937 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.565 HD12 ' HB2' ' A' ' 46' ' ' LEU . 56.6 mt -78.73 107.44 11.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-O 120.959 0.409 . . . . 0.0 110.273 -178.409 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.632 ' HB3' ' HB2' ' A' ' 103' ' ' ARG . 14.9 t70 -65.67 -70.6 0.23 Allowed 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 115.185 -0.916 . . . . 0.0 110.638 -176.068 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.474 ' HA ' ' HB3' ' A' ' 44' ' ' PRO . 4.2 p -148.59 144.87 27.54 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.596 -0.729 . . . . 0.0 111.128 -178.566 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.546 ' HA ' HG22 ' A' ' 102' ' ' ILE . 96.2 t -94.86 126.54 47.26 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.207 178.606 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 48.4 t -109.0 123.87 35.76 Favored Pre-proline 0 C--N 1.327 -0.379 0 CA-C-N 116.461 -0.336 . . . . 0.0 110.631 179.767 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -58.97 154.39 45.08 Favored 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.972 2.448 . . . . 0.0 112.175 178.1 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 104.26 6.91 41.38 Favored Glycine 0 N--CA 1.45 -0.4 0 N-CA-C 110.849 -0.9 . . . . 0.0 110.849 -175.397 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.539 ' CB ' ' HA3' ' A' ' 101' ' ' GLY . 60.4 p -130.16 159.17 71.64 Favored Pre-proline 0 C--N 1.322 -0.623 0 CA-C-N 115.185 -0.508 . . . . 0.0 110.054 -179.457 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_exo -66.89 -23.2 47.75 Favored 'Trans proline' 0 N--CA 1.463 -0.27 0 C-N-CA 122.359 2.039 . . . . 0.0 111.669 176.142 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -73.56 -16.77 61.25 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.914 -0.585 . . . . 0.0 111.365 -177.5 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 14.2 m -65.27 -16.84 63.99 Favored 'General case' 0 C--O 1.233 0.192 0 CA-C-O 120.904 0.383 . . . . 0.0 111.051 -179.708 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 35.5 ttpt -116.89 11.42 14.4 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.1 -177.769 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 58.5 t -126.96 -47.99 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.377 -177.427 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 87.1 mt -108.22 161.3 15.12 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.245 0.545 . . . . 0.0 111.412 -175.644 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 15.4 p -126.82 146.38 57.08 Favored Pre-proline 0 C--N 1.319 -0.746 0 CA-C-N 115.022 -0.99 . . . . 0.0 109.844 176.803 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.474 ' HB3' ' HA ' ' A' ' 31' ' ' SER . 53.8 Cg_endo -70.47 149.96 63.18 Favored 'Trans proline' 0 N--CA 1.461 -0.384 0 C-N-CA 122.09 1.86 . . . . 0.0 111.937 -178.064 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 99.23 -13.54 61.63 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.832 179.65 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.565 ' HB2' HD12 ' A' ' 29' ' ' ILE . 82.0 mt -72.92 164.45 26.63 Favored 'General case' 0 C--N 1.327 -0.386 0 O-C-N 122.672 -0.31 . . . . 0.0 110.684 179.694 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 42.1 t -115.28 139.95 39.12 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.191 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 65.0 mt -97.83 125.87 50.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 121.181 0.515 . . . . 0.0 110.347 -179.482 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -91.02 -42.52 10.48 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-N 115.834 -0.621 . . . . 0.0 109.894 179.955 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 37.0 p -159.37 153.77 24.0 Favored 'General case' 0 CA--C 1.512 -0.51 0 CA-C-O 120.976 0.417 . . . . 0.0 110.621 178.825 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.793 HG13 HG12 ' A' ' 77' ' ' ILE . 10.8 tt -127.4 123.72 62.33 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 CA-C-N 115.582 -0.735 . . . . 0.0 109.126 174.821 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 2.3 t-20 58.61 -151.85 0.41 Allowed 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 108.922 -0.769 . . . . 0.0 108.922 -177.528 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -81.0 12.7 35.33 Favored Glycine 0 CA--C 1.525 0.681 0 C-N-CA 120.394 -0.908 . . . . 0.0 113.002 177.739 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 2.6 mpp? -124.43 107.26 29.76 Favored Pre-proline 0 C--N 1.333 -0.121 0 CA-C-N 117.227 0.513 . . . . 0.0 111.154 -178.183 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -70.34 121.22 7.79 Favored 'Trans proline' 0 N--CA 1.458 -0.598 0 C-N-CA 121.691 1.594 . . . . 0.0 111.457 174.297 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.402 ' O ' ' HA2' ' A' ' 26' ' ' GLY . 20.3 p -97.92 110.17 22.79 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.884 -174.047 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 57' ' ' SER . . . . . 0.569 ' HA ' ' HA2' ' A' ' 26' ' ' GLY . 15.5 m -98.2 -18.96 18.16 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.921 -0.582 . . . . 0.0 111.118 179.831 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 58' ' ' ASN . . . . . 0.412 ' HB2' ' H ' ' A' ' 61' ' ' THR . 5.3 m120 -115.47 166.33 12.01 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 -179.127 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 39.2 mt -75.8 -34.45 60.17 Favored 'General case' 0 N--CA 1.447 -0.582 0 CA-C-O 121.035 0.445 . . . . 0.0 109.955 171.93 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 7.9 m -72.22 -40.5 67.76 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.646 -0.706 . . . . 0.0 111.34 -178.514 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' THR . . . . . 0.412 ' H ' ' HB2' ' A' ' 58' ' ' ASN . 3.2 p -67.76 -32.16 72.56 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.006 0.431 . . . . 0.0 110.425 177.443 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 51.3 t80 -66.74 -39.78 88.06 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.313 0.577 . . . . 0.0 109.497 173.66 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 69.0 m -63.62 -47.52 81.05 Favored 'General case' 0 N--CA 1.447 -0.6 0 CA-C-N 115.485 -0.779 . . . . 0.0 111.348 177.889 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.42 -35.71 78.31 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.619 177.966 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' ALA . . . . . 0.526 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -68.17 -41.9 80.82 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.474 178.835 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 6.7 mt -62.32 -33.88 75.54 Favored 'General case' 0 N--CA 1.447 -0.6 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.136 178.273 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 40.4 ttmt -60.16 -37.26 79.61 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.868 179.161 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.6 p -82.26 -11.81 58.43 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 112.345 0.498 . . . . 0.0 112.345 -179.067 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.526 HG12 ' O ' ' A' ' 65' ' ' ALA . 45.8 mm -79.98 137.68 21.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 N-CA-C 110.055 -0.35 . . . . 0.0 110.055 178.313 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 19.1 t -103.36 176.91 4.99 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 110.108 -0.33 . . . . 0.0 110.108 -179.886 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.469 HG22 ' H ' ' A' ' 98' ' ' ALA . 46.3 t -90.52 125.92 43.33 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.74 -177.653 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 99.93 -0.32 56.32 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.931 -0.652 . . . . 0.0 111.945 179.419 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 35.4 tt0 -90.24 147.31 23.62 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.82 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 39.9 t -106.01 104.34 16.85 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.116 -178.614 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.5 HD12 HD11 ' A' ' 51' ' ' ILE . 15.8 pt -96.08 154.7 3.5 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 121.363 0.602 . . . . 0.0 111.296 -175.916 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 5.5 t30 -91.13 136.6 32.98 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.631 -179.117 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.793 HG12 HG13 ' A' ' 51' ' ' ILE . 60.1 mt -135.46 108.79 9.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-O 121.057 0.456 . . . . 0.0 110.232 178.485 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 4.3 m -84.85 130.17 34.7 Favored 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 176.371 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 76.0 p -126.49 175.77 7.66 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.267 0.556 . . . . 0.0 111.978 -176.204 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 25.2 t70 -49.76 -42.82 47.32 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 114.625 -1.17 . . . . 0.0 112.74 -178.756 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 22.9 mt-30 -117.93 23.67 11.51 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 112.555 0.576 . . . . 0.0 112.555 -172.291 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 152.31 -178.63 29.4 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 119.771 -1.204 . . . . 0.0 112.929 175.828 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 22.2 m -114.74 126.84 55.32 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-O 120.892 0.377 . . . . 0.0 110.129 179.376 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 99.5 m-85 -121.02 161.33 21.83 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 120.938 0.399 . . . . 0.0 110.696 -178.348 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 44.6 m-70 -125.37 123.93 40.42 Favored 'General case' 0 C--N 1.321 -0.661 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 176.181 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.541 HD23 HD12 ' A' ' 77' ' ' ILE . 3.8 mm? -113.72 140.92 47.86 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.395 -173.886 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -105.14 124.35 49.38 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 115.63 -0.714 . . . . 0.0 109.488 177.467 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 17.8 p -69.92 132.02 45.32 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-O 121.379 0.609 . . . . 0.0 112.038 -176.66 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -104.16 -156.72 23.92 Favored Glycine 0 N--CA 1.445 -0.757 0 CA-C-N 115.433 -0.803 . . . . 0.0 111.418 177.41 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.442 ' HD3' ' N ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -154.04 114.79 4.01 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.238 0.542 . . . . 0.0 111.135 -178.418 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 91' ' ' ASN . . . . . . . . . . . . . 8.5 t30 -154.32 97.59 2.58 Favored Pre-proline 0 C--N 1.322 -0.61 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.175 178.328 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.607 ' HA ' ' HB2' ' A' ' 96' ' ' SER . 87.1 Cg_endo -85.76 129.62 3.56 Favored 'Trans proline' 0 N--CA 1.456 -0.702 0 C-N-CA 122.597 2.198 . . . . 0.0 113.951 -173.695 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 9.6 t30 -90.38 -43.93 9.99 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.064 172.112 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -123.12 -57.65 1.68 Allowed 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 108.52 -0.919 . . . . 0.0 108.52 171.228 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 19.4 t -159.08 83.27 0.79 Allowed 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 107.858 -1.164 . . . . 0.0 107.858 172.309 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.607 ' HB2' ' HA ' ' A' ' 92' ' ' PRO . 1.9 m -111.27 113.02 25.2 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.33 -0.85 . . . . 0.0 110.801 -171.637 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -118.76 151.62 37.69 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.698 -0.683 . . . . 0.0 109.382 178.3 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 98' ' ' ALA . . . . . 0.469 ' H ' HG22 ' A' ' 71' ' ' VAL . . . 59.3 71.43 0.58 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.743 0.782 . . . . 0.0 109.681 -172.183 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 80.3 t80 -96.36 102.04 13.77 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.611 -170.541 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 81.1 mtp -72.31 -43.22 64.49 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.16 176.469 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 101' ' ' GLY . . . . . 0.539 ' HA3' ' CB ' ' A' ' 36' ' ' SER . . . 101.56 -12.59 58.18 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.802 176.477 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.546 HG22 ' HA ' ' A' ' 32' ' ' VAL . 2.7 pp -114.89 144.73 21.81 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-O 120.851 0.358 . . . . 0.0 110.322 179.241 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 103' ' ' ARG . . . . . 0.632 ' HB2' ' HB3' ' A' ' 30' ' ' ASP . 39.3 mtp180 -84.46 147.58 27.01 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.179 178.321 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 14.2 p -124.63 122.1 36.58 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.555 177.331 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 19.3 m -127.59 154.84 44.73 Favored 'General case' 0 C--N 1.318 -0.799 0 N-CA-C 109.165 -0.68 . . . . 0.0 109.165 178.35 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 16.0 p30 -80.22 -21.84 42.44 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-O 121.09 0.472 . . . . 0.0 110.018 177.195 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 9.8 t-80 43.16 55.44 4.6 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-N 114.749 -1.114 . . . . 0.0 110.968 -176.829 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 79.7 mt -71.46 -176.41 1.53 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.685 0.755 . . . . 0.0 112.411 -175.993 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 109' ' ' ARG . . . . . 0.415 ' HD3' HH11 ' A' ' 109' ' ' ARG . 43.6 ttt-85 -66.86 117.14 8.55 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 114.587 -1.188 . . . . 0.0 110.668 -177.865 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 110' ' ' VAL . . . . . 0.414 HG13 ' HG2' ' A' ' 111' ' ' ARG . 12.2 p -82.74 157.21 3.88 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.53 -178.575 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 111' ' ' ARG . . . . . 0.414 ' HG2' HG13 ' A' ' 110' ' ' VAL . 6.5 ptp180 49.38 103.12 0.01 OUTLIER 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 125.067 1.347 . . . . 0.0 114.423 177.49 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 23.5 t70 -124.79 97.91 5.48 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.487 -0.779 . . . . 0.0 109.527 170.377 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 49.2 m 50.72 78.74 0.1 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.556 -0.747 . . . . 0.0 112.4 179.899 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 27.2 m -85.8 151.81 3.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.841 177.232 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 115' ' ' ALA . . . . . 0.4 ' HB1' HG12 ' A' ' 117' ' ' VAL . . . -90.51 140.42 29.75 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 121.029 0.442 . . . . 0.0 111.125 -178.565 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 15.4 m -103.07 16.74 25.82 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.339 0.59 . . . . 0.0 110.398 179.347 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.4 HG12 ' HB1' ' A' ' 115' ' ' ALA . 7.8 p -108.07 141.12 24.14 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.832 0 CA-C-N 115.323 -0.853 . . . . 0.0 109.708 179.875 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 92.9 mt -92.67 -67.09 0.88 Allowed 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.651 0.262 . . . . 0.0 110.69 -179.385 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 77.35 -131.49 11.22 Favored Glycine 0 N--CA 1.446 -0.678 0 C-N-CA 120.538 -0.839 . . . . 0.0 111.92 -177.579 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 15.9 m-20 -137.26 160.28 39.47 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.786 0.326 . . . . 0.0 110.644 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 13.2 t -131.98 140.36 48.94 Favored 'General case' 0 C--N 1.321 -0.671 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 174.922 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 122' ' ' LEU . . . . . 0.458 ' HA ' ' HD3' ' A' ' 123' ' ' PRO . 87.6 mt -106.07 123.14 40.03 Favored Pre-proline 0 C--N 1.323 -0.553 0 CA-C-N 116.6 -0.273 . . . . 0.0 110.867 -177.468 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 123' ' ' PRO . . . . . 0.458 ' HD3' ' HA ' ' A' ' 122' ' ' LEU . 12.7 Cg_exo -69.99 150.43 66.79 Favored 'Trans proline' 0 N--CA 1.462 -0.373 0 C-N-CA 122.878 2.385 . . . . 0.0 111.478 176.956 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -80.34 116.91 20.66 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.408 0.623 . . . . 0.0 110.998 -175.546 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.246 0.878 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.026 -178.876 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 23' ' ' GLN . . . . . . . . . . . . . 34.2 mt-30 . . . . . 0 N--CA 1.455 -0.219 0 N-CA-C 110.073 -0.344 . . . . 0.0 110.073 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.765 ' HB3' ' HB2' ' A' ' 58' ' ' ASN . 80.3 Cg_endo -81.76 163.42 18.58 Favored 'Trans proline' 0 C--O 1.238 0.48 0 C-N-CA 123.016 2.477 . . . . 0.0 113.797 -174.703 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 18.6 t70 -167.28 -39.02 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.172 -0.922 . . . . 0.0 109.628 175.273 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.507 ' HA2' ' HA ' ' A' ' 57' ' ' SER . . . 165.21 165.58 22.76 Favored Glycine 0 N--CA 1.447 -0.6 0 N-CA-C 110.574 -1.011 . . . . 0.0 110.574 -177.851 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.514 HG23 ' HB ' ' A' ' 48' ' ' ILE . 33.6 m -122.54 151.06 26.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 117.44 0.62 . . . . 0.0 110.739 178.675 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' GLN . . . . . 0.516 ' OE1' ' HB2' ' A' ' 105' ' ' SER . 0.0 OUTLIER -128.19 163.9 23.68 Favored 'General case' 0 C--N 1.324 -0.531 0 C-N-CA 120.703 -0.399 . . . . 0.0 110.767 177.139 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 57.2 mt -90.96 115.7 30.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.951 -176.165 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.753 ' HB3' ' HB2' ' A' ' 103' ' ' ARG . 23.7 t70 -66.65 -58.96 4.06 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.417 0.627 . . . . 0.0 109.873 176.005 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.467 ' HA ' ' HB3' ' A' ' 44' ' ' PRO . 12.4 p -165.19 162.05 19.77 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.22 -0.9 . . . . 0.0 110.204 -178.938 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.622 HG11 ' HA ' ' A' ' 39' ' ' SER . 45.3 t -98.24 138.25 23.45 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 N-CA-C 109.527 -0.545 . . . . 0.0 109.527 177.565 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.599 HG12 ' H ' ' A' ' 35' ' ' GLY . 45.7 t -85.89 118.9 71.35 Favored Pre-proline 0 C--N 1.323 -0.563 0 CA-C-N 116.453 -0.339 . . . . 0.0 110.809 -176.351 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -65.46 -12.94 37.29 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.866 2.377 . . . . 0.0 112.825 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.599 ' H ' HG12 ' A' ' 33' ' ' VAL . . . -95.19 23.02 35.34 Favored Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 120.897 -0.668 . . . . 0.0 111.545 177.935 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.676 ' HB3' ' HD2' ' A' ' 37' ' ' PRO . 54.1 m -149.36 170.9 6.95 Favored Pre-proline 0 C--N 1.325 -0.458 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.033 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 37' ' ' PRO . . . . . 0.676 ' HD2' ' HB3' ' A' ' 36' ' ' SER . 56.4 Cg_endo -71.13 -168.26 0.32 Allowed 'Trans proline' 0 C--N 1.349 0.555 0 C-N-CA 122.331 2.021 . . . . 0.0 112.443 177.199 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.472 ' HB1' HD13 ' A' ' 42' ' ' LEU . . . 68.78 -9.71 0.54 Allowed 'General case' 0 N--CA 1.47 0.567 0 N-CA-C 113.017 0.747 . . . . 0.0 113.017 176.63 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.622 ' HA ' HG11 ' A' ' 32' ' ' VAL . 27.8 t -70.08 -6.84 36.66 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.741 0.305 . . . . 0.0 111.293 -177.75 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -118.79 12.68 13.03 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 121.003 0.43 . . . . 0.0 110.391 177.103 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.478 ' HB ' HD12 ' A' ' 42' ' ' LEU . 46.8 t -120.76 -55.6 3.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.234 -176.987 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.478 HD12 ' HB ' ' A' ' 41' ' ' VAL . 6.0 mp -96.1 171.49 8.57 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.036 0.446 . . . . 0.0 111.145 -177.159 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 49.1 m -122.72 127.25 25.84 Favored Pre-proline 0 C--N 1.321 -0.639 0 CA-C-N 115.741 -0.663 . . . . 0.0 109.736 176.834 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.467 ' HB3' ' HA ' ' A' ' 31' ' ' SER . 41.7 Cg_endo -68.3 149.02 75.32 Favored 'Trans proline' 0 N--CA 1.464 -0.245 0 C-N-CA 122.294 1.996 . . . . 0.0 111.939 179.123 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 99.05 -2.93 58.23 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.541 -0.838 . . . . 0.0 112.634 -179.307 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 81.0 mt -90.33 164.2 14.44 Favored 'General case' 0 C--N 1.328 -0.366 0 O-C-N 122.583 -0.363 . . . . 0.0 110.765 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 48.0 t -102.45 139.94 22.15 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 N-CA-C 110.022 -0.362 . . . . 0.0 110.022 178.255 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.514 ' HB ' HG23 ' A' ' 27' ' ' VAL . 66.1 mt -93.2 121.71 44.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 121.127 0.489 . . . . 0.0 110.631 -177.601 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 3.4 tm-20 -81.96 -50.8 8.73 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 115.594 -0.73 . . . . 0.0 109.501 178.284 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.572 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 13.6 p -163.94 159.22 20.63 Favored 'General case' 0 C--O 1.236 0.394 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.97 -175.638 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.412 ' HA ' ' O ' ' A' ' 76' ' ' ASN . 61.1 mt -115.96 107.77 23.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 115.556 -0.747 . . . . 0.0 110.545 176.259 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 52' ' ' ASN . . . . . 0.595 ' HA ' ' HB3' ' A' ' 76' ' ' ASN . 15.1 t-20 66.86 -81.66 0.03 OUTLIER 'General case' 0 N--CA 1.468 0.464 0 CA-C-N 115.43 -0.805 . . . . 0.0 110.759 178.816 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -133.46 -5.33 2.95 Favored Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 120.882 -0.675 . . . . 0.0 111.782 177.161 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 60.6 mtm -111.74 115.18 51.47 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 120.743 0.306 . . . . 0.0 110.429 -177.161 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.572 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 72.9 Cg_endo -78.99 132.45 10.55 Favored 'Trans proline' 0 N--CA 1.454 -0.806 0 C-N-CA 122.273 1.982 . . . . 0.0 112.006 177.428 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 3.3 p -95.06 103.43 15.28 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 121.008 0.432 . . . . 0.0 111.69 -177.841 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' SER . . . . . 0.507 ' HA ' ' HA2' ' A' ' 26' ' ' GLY . 32.7 t -93.48 -24.27 18.07 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.747 -0.661 . . . . 0.0 110.482 179.41 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 58' ' ' ASN . . . . . 0.765 ' HB2' ' HB3' ' A' ' 24' ' ' PRO . 8.4 t-20 -133.18 176.08 8.82 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.519 -0.31 . . . . 0.0 110.385 -179.111 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 97.6 mt -81.47 -33.06 32.23 Favored 'General case' 0 N--CA 1.44 -0.965 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.64 -179.003 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 2.6 m -65.08 -43.68 91.38 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.928 0.395 . . . . 0.0 110.841 179.451 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 12.7 t -67.28 -26.7 66.68 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.103 179.881 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 32.6 t80 -68.16 -47.66 67.42 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.9 -0.591 . . . . 0.0 109.989 173.279 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 8.5 t -60.76 -39.93 90.6 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.486 -0.779 . . . . 0.0 110.358 179.675 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -69.7 -31.97 70.3 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.175 178.003 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' ALA . . . . . 0.627 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -69.24 -46.64 66.85 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.346 178.217 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 6.6 tp -58.08 -38.45 76.4 Favored 'General case' 0 N--CA 1.447 -0.617 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.338 179.164 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 40.4 ttmt -57.66 -38.49 75.17 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.004 -0.998 . . . . 0.0 111.709 178.426 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 17.7 p -86.87 -13.17 45.66 Favored 'General case' 0 C--N 1.329 -0.31 0 N-CA-C 112.615 0.598 . . . . 0.0 112.615 -175.842 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.627 HG12 ' O ' ' A' ' 65' ' ' ALA . 44.4 mm -76.23 140.84 16.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 C-N-CA 120.906 -0.317 . . . . 0.0 110.167 -179.537 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 70' ' ' SER . . . . . 0.45 ' HB2' ' HB2' ' A' ' 73' ' ' GLU . 4.8 m -94.03 161.26 14.36 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.709 -0.223 . . . . 0.0 110.764 179.357 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.626 HG11 ' HB3' ' A' ' 96' ' ' SER . 2.2 t -82.63 118.37 30.22 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 177.01 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 97.08 8.71 56.56 Favored Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 120.501 -0.857 . . . . 0.0 111.129 -175.477 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.45 ' HB2' ' HB2' ' A' ' 70' ' ' SER . 30.9 tt0 -89.62 145.48 25.22 Favored 'General case' 0 N--CA 1.45 -0.441 0 N-CA-C 109.19 -0.671 . . . . 0.0 109.19 179.563 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 44.4 t -96.2 112.53 28.58 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.022 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.083 -178.865 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 30.8 pt -109.2 154.42 10.62 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-O 121.198 0.523 . . . . 0.0 110.986 -177.926 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' ASN . . . . . 0.595 ' HB3' ' HA ' ' A' ' 52' ' ' ASN . 35.5 t-20 -109.63 113.11 25.62 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-N 115.127 -0.942 . . . . 0.0 109.901 -176.617 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.446 HD12 HD21 ' A' ' 86' ' ' LEU . 71.7 mt -104.16 103.73 15.69 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.035 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 175.878 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 30.7 m -88.99 120.14 30.14 Favored 'General case' 0 C--N 1.312 -1.03 0 CA-C-N 115.387 -0.824 . . . . 0.0 109.524 -179.782 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 73.7 p -106.71 171.35 7.41 Favored 'General case' 0 C--N 1.322 -0.606 0 N-CA-C 110.241 -0.281 . . . . 0.0 110.241 179.705 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 19.8 t70 -62.06 -22.56 65.86 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.047 0.451 . . . . 0.0 111.1 -179.819 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 81.1 mt-30 -117.0 17.73 14.85 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 112.548 0.573 . . . . 0.0 112.548 -172.761 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 151.07 163.99 11.74 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 119.909 -1.138 . . . . 0.0 113.748 177.788 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 4.2 m -107.33 137.18 45.86 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 110.056 -0.35 . . . . 0.0 110.056 -179.57 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 26.5 m-85 -134.87 147.39 49.86 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.717 0.294 . . . . 0.0 110.394 177.9 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 4.2 p-80 -130.66 122.52 27.53 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 121.134 0.493 . . . . 0.0 110.086 174.095 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.458 HD23 ' N ' ' A' ' 86' ' ' LEU . 0.9 OUTLIER -130.76 156.87 44.23 Favored 'General case' 0 N--CA 1.444 -0.728 0 CA-C-N 115.571 -0.741 . . . . 0.0 111.115 -173.503 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.452 ' HB3' ' HE2' ' A' ' 87' ' ' LYS . 32.4 ttpt -91.94 132.88 36.17 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.03 177.359 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 32.3 p -73.26 143.44 47.05 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.524 179.688 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -156.8 109.19 0.39 Allowed Glycine 0 N--CA 1.449 -0.464 0 C-N-CA 120.911 -0.662 . . . . 0.0 112.226 177.87 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.654 ' HB3' ' O ' ' A' ' 97' ' ' ARG . 9.0 tpm_? -143.73 97.24 3.03 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-O 120.86 0.362 . . . . 0.0 110.767 -178.878 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 91' ' ' ASN . . . . . . . . . . . . . 28.5 t-20 -109.45 106.9 59.16 Favored Pre-proline 0 C--N 1.321 -0.667 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.183 175.93 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 65.2 Cg_endo -95.33 -154.1 0.04 OUTLIER 'Trans proline' 0 N--CA 1.455 -0.747 0 C-N-CA 123.307 2.671 . . . . 0.0 111.74 177.592 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 7.0 t30 -85.58 41.43 0.9 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.922 0.868 . . . . 0.0 109.613 177.591 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 4.9 t-20 -171.14 -158.68 0.15 Allowed 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.163 -0.926 . . . . 0.0 108.535 -178.539 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 30.3 m -65.53 146.62 54.62 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 120.909 0.385 . . . . 0.0 110.077 177.97 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.626 ' HB3' HG11 ' A' ' 71' ' ' VAL . 50.9 m -68.96 147.26 51.88 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 116.053 -0.521 . . . . 0.0 111.402 -176.179 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 97' ' ' ARG . . . . . 0.654 ' O ' ' HB3' ' A' ' 90' ' ' ARG . 84.7 mtt180 -126.03 176.88 6.7 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.926 -0.579 . . . . 0.0 109.958 176.719 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -92.42 109.74 21.14 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.798 0.333 . . . . 0.0 111.148 -178.916 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 99' ' ' TYR . . . . . 0.582 ' HB3' ' HB2' ' A' ' 90' ' ' ARG . 6.0 t80 -146.17 134.4 21.72 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 178.493 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -94.08 -31.34 14.24 Favored 'General case' 0 C--N 1.326 -0.45 0 C-N-CA 121.2 -0.2 . . . . 0.0 110.933 179.508 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 102.52 45.17 1.71 Allowed Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.285 -0.959 . . . . 0.0 113.811 173.3 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.468 HG22 HG13 ' A' ' 32' ' ' VAL . 32.6 pt -137.69 159.07 34.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-N 117.278 0.539 . . . . 0.0 110.345 175.058 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 103' ' ' ARG . . . . . 0.753 ' HB2' ' HB3' ' A' ' 30' ' ' ASP . 97.9 mtt180 -88.93 130.46 35.43 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 109.53 -0.544 . . . . 0.0 109.53 174.444 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 2.6 p -110.62 122.86 48.81 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-O 121.204 0.526 . . . . 0.0 111.022 178.803 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.516 ' HB2' ' OE1' ' A' ' 28' ' ' GLN . 45.7 m -116.23 163.55 15.82 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.79 178.162 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 10.3 t30 -94.29 -30.49 14.51 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-O 121.072 0.463 . . . . 0.0 109.798 -178.806 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 14.9 t60 44.13 73.31 0.15 Allowed 'General case' 0 N--CA 1.469 0.516 0 CA-C-N 114.881 -1.054 . . . . 0.0 111.741 -176.366 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 81.9 mt -87.38 -173.09 4.22 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.147 0.499 . . . . 0.0 110.997 179.64 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 109' ' ' ARG . . . . . 0.404 HH11 ' HD3' ' A' ' 109' ' ' ARG . 17.8 ptt-85 -76.42 166.31 23.59 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.219 -0.9 . . . . 0.0 111.027 -178.121 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 8.0 p -89.84 140.72 15.42 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-O 121.093 0.473 . . . . 0.0 111.222 -175.999 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 111' ' ' ARG . . . . . . . . . . . . . 3.8 tpm_? -122.12 125.93 47.25 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.71 178.101 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 11.3 t70 -119.94 113.91 21.26 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 174.823 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 16.8 p -141.63 105.94 4.82 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.279 178.164 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 35.6 m -78.3 151.42 5.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.007 179.758 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -151.28 135.29 16.62 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.382 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 17.8 m -105.72 78.54 1.35 Allowed 'General case' 0 C--N 1.32 -0.688 0 CA-C-O 121.14 0.495 . . . . 0.0 110.184 -179.634 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 40.9 t -115.26 112.43 39.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.32 -177.624 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 118' ' ' LEU . . . . . 0.407 HD22 ' N ' ' A' ' 118' ' ' LEU . 3.1 mm? -84.02 -28.43 27.67 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.001 179.182 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 106.36 -28.12 14.65 Favored Glycine 0 N--CA 1.447 -0.618 0 CA-C-N 115.736 -0.665 . . . . 0.0 111.91 177.866 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 10.8 m-20 -101.91 139.41 37.58 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 120.937 0.399 . . . . 0.0 111.112 -179.082 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 12.0 t -98.28 139.25 34.33 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 108.849 -0.797 . . . . 0.0 108.849 170.827 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 122' ' ' LEU . . . . . 0.41 ' HA ' ' HD2' ' A' ' 123' ' ' PRO . 98.1 mt -95.02 124.75 53.22 Favored Pre-proline 0 C--N 1.321 -0.653 0 N-CA-C 110.212 -0.292 . . . . 0.0 110.212 -177.236 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 123' ' ' PRO . . . . . 0.41 ' HD2' ' HA ' ' A' ' 122' ' ' LEU . 1.3 Cg_endo -45.28 125.6 7.36 Favored 'Trans proline' 0 C--N 1.346 0.432 0 C-N-CA 123.794 2.996 . . . . 0.0 112.825 -177.612 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 87.8 m-85 -81.27 122.86 27.96 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.564 -177.545 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.245 0.856 0 CA-C-O 118.512 -0.756 . . . . 0.0 110.078 178.99 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.421 ' HA ' ' HD3' ' A' ' 24' ' ' PRO . 50.4 mt-30 . . . . . 0 C--O 1.234 0.253 0 N-CA-C 110.539 -0.171 . . . . 0.0 110.539 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.421 ' HD3' ' HA ' ' A' ' 23' ' ' GLN . 38.8 Cg_exo -61.67 171.59 4.44 Favored 'Trans proline' 0 C--O 1.235 0.356 0 C-N-CA 122.97 2.447 . . . . 0.0 112.5 177.14 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -160.24 26.15 0.17 Allowed 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.847 0.832 . . . . 0.0 109.751 -172.834 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 136.2 157.34 7.77 Favored Glycine 0 N--CA 1.442 -0.949 0 CA-C-N 114.91 -1.041 . . . . 0.0 110.824 -176.813 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.64 HG21 ' CD2' ' A' ' 62' ' ' TYR . 35.7 m -114.14 149.92 16.31 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.871 0 CA-C-N 116.913 0.356 . . . . 0.0 110.559 178.909 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' GLN . . . . . 0.73 ' HG2' ' HB3' ' A' ' 107' ' ' HIS . 0.0 OUTLIER -129.67 154.65 46.93 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 174.951 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.593 HG23 HD11 ' A' ' 48' ' ' ILE . 2.2 pt -83.48 110.18 18.01 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.446 0 CA-C-O 121.673 0.749 . . . . 0.0 111.064 179.168 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -64.01 -59.15 4.84 Favored 'General case' 0 C--N 1.319 -0.761 0 CA-C-N 114.235 -1.348 . . . . 0.0 110.925 -177.616 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 49.0 m -153.51 166.71 31.86 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.621 -0.718 . . . . 0.0 111.384 -171.08 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.558 ' HA ' HG22 ' A' ' 102' ' ' ILE . 99.4 t -115.49 134.44 58.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 115.694 -0.685 . . . . 0.0 109.689 176.175 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 53.0 t -103.21 107.28 55.01 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 120.863 0.363 . . . . 0.0 111.089 -177.256 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -61.5 120.81 8.65 Favored 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 122.833 2.355 . . . . 0.0 111.575 178.907 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 126.32 -19.04 6.42 Favored Glycine 0 N--CA 1.447 -0.615 0 N-CA-C 111.011 -0.836 . . . . 0.0 111.011 -175.394 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.694 ' HB3' ' HD2' ' A' ' 37' ' ' PRO . 32.0 m -114.61 169.53 6.52 Favored Pre-proline 0 C--N 1.32 -0.7 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 176.499 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' PRO . . . . . 0.694 ' HD2' ' HB3' ' A' ' 36' ' ' SER . 21.1 Cg_endo -61.1 173.24 2.53 Favored 'Trans proline' 0 C--N 1.345 0.359 0 C-N-CA 122.487 2.124 . . . . 0.0 112.893 179.139 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 73.77 -11.29 0.97 Allowed 'General case' 0 N--CA 1.469 0.515 0 CA-C-N 115.541 -0.754 . . . . 0.0 112.403 179.672 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 53.4 m -69.33 2.76 2.69 Favored 'General case' 0 CA--C 1.535 0.377 0 N-CA-C 112.457 0.54 . . . . 0.0 112.457 -177.554 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 50.8 tptt -143.53 19.59 1.86 Allowed 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.43 0.633 . . . . 0.0 109.711 179.168 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 94.1 t -119.91 -63.8 1.76 Allowed 'Isoleucine or valine' 0 C--O 1.237 0.396 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.064 -178.54 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 1.1 pp -97.85 179.85 4.67 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.542 0.687 . . . . 0.0 112.204 -174.717 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 16.7 p -127.31 130.61 23.7 Favored Pre-proline 0 C--N 1.317 -0.831 0 CA-C-N 114.85 -1.068 . . . . 0.0 110.058 178.319 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.429 ' HB3' HG23 ' A' ' 32' ' ' VAL . 50.1 Cg_endo -67.46 159.04 54.26 Favored 'Trans proline' 0 C--O 1.236 0.404 0 C-N-CA 122.425 2.083 . . . . 0.0 112.277 -177.353 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 93.25 0.85 67.31 Favored Glycine 0 CA--C 1.522 0.495 0 C-N-CA 120.752 -0.737 . . . . 0.0 113.849 178.388 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.533 ' HB2' HD11 ' A' ' 29' ' ' ILE . 91.2 mt -92.14 167.18 12.23 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 117.43 0.615 . . . . 0.0 111.001 -179.582 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 46.7 t -109.17 138.71 35.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.001 178.675 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.593 HD11 HG23 ' A' ' 29' ' ' ILE . 58.5 mt -101.62 133.7 44.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 C-N-CA 122.33 0.252 . . . . 0.0 110.353 -178.429 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 27.4 tt0 -91.67 -48.52 6.78 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.277 177.854 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.618 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 39.6 p -150.24 157.66 43.32 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 113.147 0.795 . . . . 0.0 113.147 -171.883 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.578 HD11 ' CE2' ' A' ' 62' ' ' TYR . 43.7 mt -116.3 117.53 55.79 Favored 'Isoleucine or valine' 0 C--O 1.235 0.34 0 CA-C-N 114.861 -1.063 . . . . 0.0 110.297 174.553 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 52' ' ' ASN . . . . . 0.568 ' HA ' ' HB3' ' A' ' 76' ' ' ASN . 25.4 t-20 65.6 -81.37 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.744 -0.662 . . . . 0.0 111.417 177.005 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -140.09 1.67 2.25 Favored Glycine 0 N--CA 1.447 -0.583 0 C-N-CA 121.052 -0.594 . . . . 0.0 111.768 177.251 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 59.5 mtm -120.74 123.48 27.98 Favored Pre-proline 0 C--N 1.324 -0.512 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 -177.721 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.618 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 72.7 Cg_endo -74.97 143.28 28.97 Favored 'Trans proline' 0 N--CA 1.459 -0.504 0 C-N-CA 122.353 2.035 . . . . 0.0 112.496 -179.125 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 17.8 p -110.79 95.21 5.41 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.226 0.536 . . . . 0.0 111.35 -177.637 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 5.1 p -91.06 -14.2 31.75 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.747 -0.66 . . . . 0.0 111.385 -178.881 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 34.2 m-80 -131.06 164.26 25.81 Favored 'General case' 0 C--N 1.318 -0.765 0 N-CA-C 109.698 -0.482 . . . . 0.0 109.698 178.464 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.426 HD23 ' HA ' ' A' ' 59' ' ' LEU . 13.1 mt -77.28 -31.14 54.63 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.215 0.531 . . . . 0.0 109.881 179.0 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 2.6 p -65.18 -45.76 83.57 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.647 173.64 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 4.6 m -56.67 -44.52 81.48 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.49 173.762 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' TYR . . . . . 0.64 ' CD2' HG21 ' A' ' 27' ' ' VAL . 11.6 t80 -60.59 -42.27 96.42 Favored 'General case' 0 CA--C 1.529 0.145 0 CA-C-O 121.508 0.67 . . . . 0.0 109.773 177.705 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 57.9 m -62.21 -47.14 85.78 Favored 'General case' 0 N--CA 1.446 -0.652 0 CA-C-N 115.069 -0.968 . . . . 0.0 111.636 178.139 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.89 -33.39 74.13 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.831 179.369 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' ALA . . . . . 0.587 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -68.22 -46.99 69.06 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.922 -0.581 . . . . 0.0 109.96 176.5 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 13.7 mt -58.49 -38.45 77.65 Favored 'General case' 0 N--CA 1.448 -0.538 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.894 178.22 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 59.7 mmtt -52.48 -37.69 57.72 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.816 -0.629 . . . . 0.0 112.056 176.744 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 50.1 p -87.77 -13.77 41.43 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 111.914 0.338 . . . . 0.0 111.914 -176.558 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.587 HG12 ' O ' ' A' ' 65' ' ' ALA . 36.7 mm -81.64 141.98 14.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-O 120.995 0.426 . . . . 0.0 110.259 -179.067 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 15.4 m -107.22 162.36 13.96 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.738 -178.801 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.407 HG22 ' HA ' ' A' ' 98' ' ' ALA . 97.1 t -77.75 126.69 38.3 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-O 120.987 0.422 . . . . 0.0 110.627 -179.143 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 93.4 22.25 27.34 Favored Glycine 0 N--CA 1.447 -0.576 0 N-CA-C 111.216 -0.753 . . . . 0.0 111.216 -176.217 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 14.8 tp10 -109.5 151.97 26.04 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.262 -0.469 . . . . 0.0 109.847 -179.311 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.405 ' HA ' ' O ' ' A' ' 86' ' ' LEU . 61.1 t -110.98 120.3 61.38 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.752 0 CA-C-N 116.099 -0.5 . . . . 0.0 109.768 179.803 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 23.9 pt -117.05 154.29 18.73 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.026 -178.674 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' ASN . . . . . 0.568 ' HB3' ' HA ' ' A' ' 52' ' ' ASN . 44.1 t30 -91.05 132.92 35.72 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.845 -0.616 . . . . 0.0 109.947 -179.66 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 66.3 mt -129.74 109.78 18.61 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-O 121.179 0.514 . . . . 0.0 109.621 178.619 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 25.5 m -95.94 110.27 22.5 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.944 178.647 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.5 HG22 HG12 ' A' ' 48' ' ' ILE . 69.2 p -107.28 175.25 5.56 Favored 'General case' 0 N--CA 1.448 -0.556 0 CA-C-O 120.814 0.34 . . . . 0.0 111.057 -179.105 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 27.6 t70 -45.06 -43.64 9.62 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.058 -0.974 . . . . 0.0 113.383 -175.84 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 32.2 mt-30 -132.86 17.62 4.21 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 111.989 0.366 . . . . 0.0 111.989 -176.707 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -157.15 123.8 1.34 Allowed Glycine 0 C--N 1.319 -0.384 0 C-N-CA 119.581 -1.295 . . . . 0.0 113.31 -177.012 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 26.0 m -108.99 106.74 16.83 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 175.535 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 20.7 p90 -133.13 177.39 7.71 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 121.53 0.681 . . . . 0.0 111.59 -174.51 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 4.9 p80 -124.81 127.98 48.01 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-N 114.849 -1.069 . . . . 0.0 110.055 178.863 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.405 ' O ' ' HA ' ' A' ' 74' ' ' VAL . 7.4 tt -106.5 143.6 34.38 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.498 -175.302 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 86.5 tttt -106.79 116.4 31.87 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.447 -0.797 . . . . 0.0 109.392 178.367 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.637 HG21 ' HB1' ' A' ' 98' ' ' ALA . 55.7 p -67.04 136.53 55.39 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 121.231 0.539 . . . . 0.0 111.872 -175.212 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -104.77 -166.38 24.3 Favored Glycine 0 N--CA 1.442 -0.958 0 CA-C-N 115.664 -0.698 . . . . 0.0 112.18 -179.225 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 10.9 mpt_? -86.76 138.51 31.55 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-O 120.748 0.309 . . . . 0.0 110.815 -178.586 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 91' ' ' ASN . . . . . . . . . . . . . 16.2 p30 -97.43 153.28 38.43 Favored Pre-proline 0 C--N 1.326 -0.45 0 CA-C-N 115.965 -0.562 . . . . 0.0 110.41 178.456 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_endo -72.37 -63.23 0.04 OUTLIER 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.272 1.981 . . . . 0.0 112.631 179.413 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 27.1 t-20 -156.29 -51.46 0.08 Allowed 'General case' 0 N--CA 1.45 -0.428 0 CA-C-O 120.892 0.377 . . . . 0.0 110.941 -179.104 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 26.1 p-10 -84.92 -174.06 5.06 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.793 -0.64 . . . . 0.0 111.448 -175.468 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 50.4 m 68.18 178.42 0.24 Allowed 'General case' 0 C--O 1.234 0.282 0 CA-C-N 115.064 -0.971 . . . . 0.0 111.237 -179.84 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 17.9 m -78.27 177.88 8.08 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.97 -177.754 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 24.7 mmt180 -72.08 154.5 41.07 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 178.19 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 98' ' ' ALA . . . . . 0.637 ' HB1' HG21 ' A' ' 88' ' ' THR . . . 69.59 104.69 0.06 Allowed 'General case' 0 N--CA 1.462 0.164 0 O-C-N 124.019 0.824 . . . . 0.0 110.67 -176.826 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 99' ' ' TYR . . . . . 0.403 ' CE2' ' HA2' ' A' ' 101' ' ' GLY . 27.5 t80 -89.16 114.53 25.82 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.204 0.526 . . . . 0.0 110.452 -173.342 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 100' ' ' MET . . . . . 0.531 ' HG3' ' H ' ' A' ' 102' ' ' ILE . 11.3 ptm -70.47 -30.04 66.74 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.351 -0.84 . . . . 0.0 111.725 -178.27 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 101' ' ' GLY . . . . . 0.403 ' HA2' ' CE2' ' A' ' 99' ' ' TYR . . . 86.61 -2.64 87.34 Favored Glycine 0 N--CA 1.453 -0.184 0 C-N-CA 120.991 -0.624 . . . . 0.0 112.918 177.467 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.558 HG22 ' HA ' ' A' ' 32' ' ' VAL . 24.5 pt -132.16 158.31 43.26 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 121.068 0.461 . . . . 0.0 110.695 -177.568 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 103' ' ' ARG . . . . . 0.429 HH11 ' HD2' ' A' ' 103' ' ' ARG . 18.2 mtp180 -90.36 145.32 25.05 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.796 -0.638 . . . . 0.0 109.591 178.113 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 2.2 p -133.8 151.14 51.48 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 120.708 0.29 . . . . 0.0 111.169 178.397 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 84.1 p -138.49 -174.18 3.75 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.113 -0.494 . . . . 0.0 109.787 177.677 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 106' ' ' ASN . . . . . 0.492 ' OD1' ' HG ' ' A' ' 108' ' ' LEU . 14.0 p30 -106.89 11.89 29.46 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.527 -0.306 . . . . 0.0 110.86 -179.557 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 107' ' ' HIS . . . . . 0.73 ' HB3' ' HG2' ' A' ' 28' ' ' GLN . 7.0 p-80 47.3 40.2 10.12 Favored 'General case' 0 N--CA 1.471 0.609 0 C-N-CA 123.723 0.809 . . . . 0.0 112.615 178.19 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 108' ' ' LEU . . . . . 0.492 ' HG ' ' OD1' ' A' ' 106' ' ' ASN . 15.4 mt -45.38 134.36 6.76 Favored 'General case' 0 CA--C 1.515 -0.386 0 CA-C-O 122.118 0.961 . . . . 0.0 112.55 -176.055 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 46.2 mtm180 -83.23 94.41 7.88 Favored 'General case' 0 C--N 1.313 -0.992 0 CA-C-N 114.031 -1.441 . . . . 0.0 110.387 -177.5 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 60.9 t -89.16 134.6 28.08 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 CA-C-N 115.015 -0.993 . . . . 0.0 111.292 -177.359 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 111' ' ' ARG . . . . . . . . . . . . . 14.1 ptt180 -158.95 84.42 0.8 Allowed 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 121.691 0.757 . . . . 0.0 110.568 172.54 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 35.7 t70 -161.52 125.81 3.38 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 114.781 -1.099 . . . . 0.0 109.535 179.653 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 36.1 t -137.76 143.02 40.94 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.905 -175.854 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 29.2 m -110.36 170.3 3.36 Favored 'Isoleucine or valine' 0 C--O 1.235 0.33 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.4 176.621 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -135.46 119.83 17.94 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.619 -0.264 . . . . 0.0 110.892 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 49.7 m -155.1 163.18 40.6 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 110.149 -0.315 . . . . 0.0 110.149 -179.1 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 62.0 t 67.23 102.04 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.333 -0.142 0 O-C-N 123.945 0.778 . . . . 0.0 111.344 -179.695 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 97.7 mt -90.26 -6.92 54.64 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.759 178.833 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 85.98 162.75 36.97 Favored Glycine 0 N--CA 1.449 -0.495 0 C-N-CA 120.826 -0.702 . . . . 0.0 111.412 -175.048 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -155.58 140.6 17.35 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.994 0.397 . . . . 0.0 110.328 -179.265 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 2.2 p -123.4 89.57 3.12 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.244 0.545 . . . . 0.0 110.19 175.592 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 122' ' ' LEU . . . . . 0.499 ' HA ' ' HD3' ' A' ' 123' ' ' PRO . 0.4 OUTLIER -107.56 123.41 38.1 Favored Pre-proline 0 C--N 1.325 -0.466 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.578 -177.602 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 123' ' ' PRO . . . . . 0.499 ' HD3' ' HA ' ' A' ' 122' ' ' LEU . 4.0 Cg_exo -77.23 159.83 33.08 Favored 'Trans proline' 0 N--CA 1.461 -0.389 0 C-N-CA 122.916 2.411 . . . . 0.0 111.495 175.171 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 52.6 t80 -129.85 111.66 12.81 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.308 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.126 0 CA-C-O 118.3 -0.857 . . . . 0.0 110.225 -177.402 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 23' ' ' GLN . . . . . . . . . . . . . 77.8 mt-30 . . . . . 0 N--CA 1.452 -0.365 0 N-CA-C 110.011 -0.366 . . . . 0.0 110.011 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_endo -69.5 -170.5 0.38 Allowed 'Trans proline' 0 C--O 1.233 0.274 0 C-N-CA 122.724 2.282 . . . . 0.0 112.752 178.901 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.839 ' HA ' ' HB3' ' A' ' 57' ' ' SER . 31.9 t70 75.75 18.9 2.08 Favored 'General case' 0 N--CA 1.468 0.454 0 CA-C-N 115.11 -0.95 . . . . 0.0 109.954 -173.504 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 172.26 151.7 8.04 Favored Glycine 0 N--CA 1.441 -0.967 0 CA-C-N 114.949 -1.023 . . . . 0.0 111.245 176.252 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 28.8 m -137.14 153.88 29.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 120.924 0.392 . . . . 0.0 110.94 -177.686 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' GLN . . . . . 0.489 ' HG3' ' HB3' ' A' ' 105' ' ' SER . 20.4 pt20 -126.02 161.37 27.71 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 110.124 -0.324 . . . . 0.0 110.124 176.314 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.499 HG23 HD12 ' A' ' 102' ' ' ILE . 65.9 mt -75.19 115.58 16.75 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 N-CA-C 109.009 -0.737 . . . . 0.0 109.009 174.885 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.495 ' HB2' ' HB2' ' A' ' 105' ' ' SER . 22.9 t70 -79.22 -64.77 1.11 Allowed 'General case' 0 C--N 1.317 -0.816 0 CA-C-O 121.014 0.435 . . . . 0.0 110.334 -178.232 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 19.6 m -145.2 153.92 41.86 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.281 -177.685 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.574 HG13 HG22 ' A' ' 102' ' ' ILE . 94.6 t -116.87 131.01 70.78 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.292 -178.458 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 57.5 t -104.51 124.82 35.83 Favored Pre-proline 0 C--N 1.328 -0.367 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.943 -178.432 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -56.11 151.18 44.08 Favored 'Trans proline' 0 C--N 1.346 0.415 0 C-N-CA 123.068 2.512 . . . . 0.0 112.541 178.222 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 128.5 -16.25 5.96 Favored Glycine 0 N--CA 1.447 -0.578 0 C-N-CA 120.889 -0.672 . . . . 0.0 111.508 -177.906 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 35.9 p -124.89 156.36 68.97 Favored Pre-proline 0 C--N 1.322 -0.63 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 177.035 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo -64.9 -15.9 52.72 Favored 'Trans proline' 0 C--N 1.345 0.384 0 C-N-CA 122.342 2.028 . . . . 0.0 111.813 176.829 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -62.74 -23.09 67.02 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.526 -0.761 . . . . 0.0 111.542 -179.103 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.563 ' HA ' HG11 ' A' ' 32' ' ' VAL . 20.2 t -66.8 -22.12 66.02 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.249 -178.363 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 81.5 tttt -107.65 -2.12 20.48 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.03 0.443 . . . . 0.0 110.475 -178.679 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 89.9 t -105.23 -48.86 9.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.442 179.286 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 94.8 mt -94.33 174.35 7.18 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.052 -179.257 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' THR . . . . . 0.461 ' O ' ' HG ' ' A' ' 46' ' ' LEU . 45.0 m -143.57 131.06 10.77 Favored Pre-proline 0 C--N 1.321 -0.655 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 -179.755 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_endo -63.69 142.63 84.2 Favored 'Trans proline' 0 N--CA 1.459 -0.519 0 C-N-CA 122.273 1.982 . . . . 0.0 111.776 178.221 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 94.14 2.64 64.08 Favored Glycine 0 CA--C 1.523 0.548 0 C-N-CA 120.748 -0.739 . . . . 0.0 113.538 -178.546 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.517 HD22 ' HG2' ' A' ' 81' ' ' GLN . 66.0 mt -88.63 164.11 15.5 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-N 117.475 0.638 . . . . 0.0 110.805 179.269 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 48.8 t -108.1 130.13 61.14 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.248 0 CA-C-O 120.511 0.196 . . . . 0.0 110.693 -177.968 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 53.8 mt -98.52 128.29 50.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-O 120.937 0.399 . . . . 0.0 110.881 -176.134 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.5 mm-40 -87.68 -48.32 7.97 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.652 176.823 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.496 ' CB ' ' HA ' ' A' ' 55' ' ' PRO . 16.2 p -171.82 161.59 5.92 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-O 121.013 0.435 . . . . 0.0 111.849 -174.838 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.467 HG22 ' H ' ' A' ' 52' ' ' ASN . 27.5 mm -103.67 169.44 2.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 N-CA-C 107.929 -1.137 . . . . 0.0 107.929 173.413 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 52' ' ' ASN . . . . . 0.717 ' HB3' ' HB3' ' A' ' 76' ' ' ASN . 24.0 p-10 -53.97 99.97 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.825 0.821 . . . . 0.0 112.251 -175.996 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 75.72 3.77 74.09 Favored Glycine 0 N--CA 1.447 -0.593 0 CA-C-N 115.352 -0.84 . . . . 0.0 112.695 178.46 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 56.1 mtm -137.32 92.08 13.92 Favored Pre-proline 0 C--N 1.325 -0.467 0 CA-C-O 120.689 0.28 . . . . 0.0 110.504 -176.488 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.496 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 15.8 Cg_exo -66.87 135.28 37.52 Favored 'Trans proline' 0 N--CA 1.46 -0.49 0 C-N-CA 122.311 2.007 . . . . 0.0 111.608 178.606 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.439 HG21 ' CD2' ' A' ' 62' ' ' TYR . 10.9 p -105.24 98.31 8.03 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-O 121.283 0.563 . . . . 0.0 111.731 -175.429 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 57' ' ' SER . . . . . 0.839 ' HB3' ' HA ' ' A' ' 25' ' ' ASP . 4.2 m -101.52 -17.16 16.54 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.774 176.284 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 90.6 m-20 -127.24 160.89 29.93 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.142 -177.955 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 96.5 mt -77.62 -31.97 53.19 Favored 'General case' 0 N--CA 1.438 -1.044 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.061 177.583 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 84.7 m -70.42 -37.4 74.43 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.749 -0.659 . . . . 0.0 110.928 176.467 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 16.6 p -69.6 -33.3 72.49 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.867 0.365 . . . . 0.0 110.351 178.561 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' TYR . . . . . 0.439 ' CD2' HG21 ' A' ' 56' ' ' THR . 24.8 t80 -61.52 -45.97 91.95 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.444 0.64 . . . . 0.0 109.427 173.438 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 6.3 m -65.55 -42.69 91.62 Favored 'General case' 0 N--CA 1.449 -0.522 0 CA-C-N 115.108 -0.951 . . . . 0.0 112.126 177.75 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.99 -33.74 76.06 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.994 -179.768 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' ALA . . . . . 0.563 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -69.52 -45.54 68.61 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.047 -0.524 . . . . 0.0 109.807 177.483 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 14.3 mt -55.2 -38.62 68.62 Favored 'General case' 0 N--CA 1.447 -0.615 0 CA-C-N 115.375 -0.829 . . . . 0.0 111.677 179.184 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 28.0 mmmt -57.29 -28.44 63.03 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.832 -0.622 . . . . 0.0 112.49 179.703 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 28.4 p -99.85 -14.05 18.94 Favored 'General case' 0 C--N 1.327 -0.413 0 N-CA-C 112.373 0.508 . . . . 0.0 112.373 -177.544 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.563 HG12 ' O ' ' A' ' 65' ' ' ALA . 49.1 mm -70.63 128.65 34.17 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-O 121.175 0.512 . . . . 0.0 110.622 -176.658 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 16.3 m -80.62 163.49 23.59 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.372 -176.81 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.517 HG11 ' HB3' ' A' ' 90' ' ' ARG . 57.9 t -84.84 127.64 39.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 115.92 -0.582 . . . . 0.0 109.455 175.773 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 88.32 15.12 60.95 Favored Glycine 0 N--CA 1.448 -0.51 0 N-CA-C 110.571 -1.012 . . . . 0.0 110.571 -173.689 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 7.1 tp10 -87.36 148.16 25.16 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 114.952 -0.624 . . . . 0.0 109.321 178.862 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 59.0 t -113.53 102.13 13.46 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.994 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 174.705 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 29.9 pt -97.37 161.9 2.74 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.855 0 CA-C-N 115.674 -0.694 . . . . 0.0 111.29 -174.314 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' ASN . . . . . 0.717 ' HB3' ' HB3' ' A' ' 52' ' ' ASN . 11.7 t30 -102.17 122.52 44.32 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 115.389 -0.823 . . . . 0.0 109.999 179.292 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 61.8 mt -122.63 103.94 13.92 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 176.687 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 78' ' ' THR . . . . . 0.455 ' HA ' ' HA ' ' A' ' 83' ' ' THR . 37.7 m -91.98 114.1 26.55 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 115.279 -0.873 . . . . 0.0 109.832 179.411 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 69.6 p -102.66 171.86 7.18 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 176.653 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -72.8 -14.67 61.57 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 121.63 0.729 . . . . 0.0 109.469 176.095 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 81' ' ' GLN . . . . . 0.517 ' HG2' HD22 ' A' ' 46' ' ' LEU . 2.7 mp0 -95.37 10.07 37.63 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.302 -0.863 . . . . 0.0 110.652 178.979 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 127.27 164.81 11.76 Favored Glycine 0 CA--C 1.519 0.32 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.902 178.473 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.455 ' HA ' ' HA ' ' A' ' 78' ' ' THR . 28.0 m -90.48 129.86 36.6 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 110.387 -0.227 . . . . 0.0 110.387 177.621 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 60.6 m-85 -128.34 155.45 44.65 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.013 0.435 . . . . 0.0 110.654 179.421 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 38.6 m80 -108.46 136.85 47.4 Favored 'General case' 0 C--N 1.321 -0.674 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 174.553 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 21.2 tp -123.44 138.87 54.5 Favored 'General case' 0 C--N 1.315 -0.899 0 C-N-CA 120.208 -0.597 . . . . 0.0 110.746 -179.782 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 37.0 ttpt -105.67 121.08 43.26 Favored 'General case' 0 C--N 1.313 -0.988 0 CA-C-N 115.316 -0.856 . . . . 0.0 109.139 177.722 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.58 HG21 ' HB1' ' A' ' 98' ' ' ALA . 43.5 p -78.43 128.67 33.94 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-O 121.275 0.56 . . . . 0.0 111.508 -176.967 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -94.24 -171.72 38.32 Favored Glycine 0 N--CA 1.443 -0.836 0 CA-C-N 115.65 -0.705 . . . . 0.0 111.889 -178.674 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.517 ' HB3' HG11 ' A' ' 71' ' ' VAL . 0.0 OUTLIER -128.34 87.52 2.61 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.794 0.807 . . . . 0.0 111.834 -176.529 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 91' ' ' ASN . . . . . . . . . . . . . 39.8 m-80 -135.86 115.43 11.26 Favored Pre-proline 0 C--N 1.32 -0.695 0 CA-C-N 114.984 -1.007 . . . . 0.0 108.816 172.621 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -57.09 146.95 78.31 Favored 'Trans proline' 0 C--O 1.237 0.439 0 C-N-CA 122.453 2.102 . . . . 0.0 112.574 -178.419 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 6.4 t30 -138.29 31.93 2.36 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 -178.679 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 36.9 m-80 64.23 85.12 0.14 Allowed 'General case' 0 C--O 1.236 0.393 0 CA-C-N 114.747 -1.115 . . . . 0.0 109.911 -169.378 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 10.0 t 70.74 -169.5 0.16 Allowed 'General case' 0 C--O 1.234 0.274 0 CA-C-N 114.637 -1.165 . . . . 0.0 109.685 -175.372 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 35.9 m 72.58 151.08 0.11 Allowed 'General case' 0 N--CA 1.465 0.318 0 C-N-CA 123.434 0.694 . . . . 0.0 111.597 -178.363 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 10.2 mpt_? -119.39 166.01 13.6 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.738 -0.665 . . . . 0.0 109.985 178.866 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 98' ' ' ALA . . . . . 0.58 ' HB1' HG21 ' A' ' 88' ' ' THR . . . 61.01 89.7 0.07 Allowed 'General case' 0 C--O 1.233 0.2 0 O-C-N 123.892 0.745 . . . . 0.0 111.362 177.502 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 51.3 t80 -79.78 97.23 6.54 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 121.173 0.511 . . . . 0.0 111.299 -173.328 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 50.3 ttm -86.5 -58.41 2.63 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.309 173.626 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 88.27 24.05 35.44 Favored Glycine 0 C--N 1.33 0.23 0 C-N-CA 120.889 -0.672 . . . . 0.0 113.709 171.042 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.574 HG22 HG13 ' A' ' 32' ' ' VAL . 19.0 pt -120.03 145.72 25.9 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 CA-C-N 117.179 0.49 . . . . 0.0 110.488 177.597 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.72 140.81 29.21 Favored 'General case' 0 C--N 1.319 -0.747 0 N-CA-C 108.974 -0.75 . . . . 0.0 108.974 174.868 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.7 m -109.59 149.0 30.31 Favored 'General case' 0 C--N 1.314 -0.966 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 -179.076 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.495 ' HB2' ' HB2' ' A' ' 30' ' ' ASP . 41.0 t -116.67 172.24 7.36 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-N 115.94 -0.573 . . . . 0.0 109.705 -178.3 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 25.7 t30 -113.67 60.83 0.66 Allowed 'General case' 0 C--N 1.316 -0.872 0 CA-C-O 121.551 0.691 . . . . 0.0 109.53 -172.947 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 1.6 m-70 -117.59 149.49 40.57 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.59 -0.732 . . . . 0.0 111.159 -178.891 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 91.6 mt -92.05 -169.03 2.14 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.49 176.358 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 5.7 ttm180 -83.99 134.85 34.63 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 115.488 -0.778 . . . . 0.0 110.458 -176.666 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 41.5 t -102.94 133.28 47.17 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.118 178.817 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 111' ' ' ARG . . . . . 0.416 HH11 ' HD2' ' A' ' 111' ' ' ARG . 49.6 mtm180 -134.72 -172.4 3.02 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.688 -178.316 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -69.76 95.75 0.92 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.739 -179.151 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 69.4 m -148.51 27.7 0.9 Allowed 'General case' 0 C--N 1.318 -0.797 0 CA-C-O 121.254 0.55 . . . . 0.0 110.318 175.532 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 2.1 t -106.59 122.43 60.5 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.608 -178.544 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -138.44 5.59 2.48 Favored 'General case' 0 C--N 1.314 -0.974 0 CA-C-N 115.625 -0.716 . . . . 0.0 109.959 177.323 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 14.5 m -80.0 149.03 30.9 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.951 -178.308 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 35.7 m -73.57 148.63 8.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.093 174.5 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -83.26 -64.88 1.09 Allowed 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.75 0.309 . . . . 0.0 111.108 -176.843 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 80.52 2.92 90.0 Favored Glycine 0 N--CA 1.455 -0.088 0 C-N-CA 120.84 -0.695 . . . . 0.0 111.776 -177.071 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER 60.45 93.95 0.04 OUTLIER 'General case' 0 CA--C 1.519 -0.241 0 C-N-CA 123.569 0.747 . . . . 0.0 112.779 -179.447 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 11.4 t -77.6 130.76 37.3 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 171.046 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 91.5 mt -112.32 102.63 54.44 Favored Pre-proline 0 C--N 1.32 -0.695 0 CA-C-O 120.823 0.344 . . . . 0.0 111.788 -172.858 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -88.33 -168.28 0.36 Allowed 'Trans proline' 0 N--CA 1.454 -0.828 0 C-N-CA 122.784 2.323 . . . . 0.0 110.817 171.515 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 37.4 t80 -94.01 116.96 29.44 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 177.681 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.052 0 CA-C-O 118.569 -0.729 . . . . 0.0 110.798 -177.55 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 23' ' ' GLN . . . . . . . . . . . . . 92.4 mt-30 . . . . . 0 N--CA 1.455 -0.213 0 CA-C-O 120.608 0.242 . . . . 0.0 111.322 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.43 ' HB2' ' HA ' ' A' ' 58' ' ' ASN . 5.7 Cg_exo -77.21 154.11 32.24 Favored 'Trans proline' 0 N--CA 1.46 -0.463 0 C-N-CA 123.045 2.497 . . . . 0.0 110.897 171.728 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.405 ' HA ' ' OG ' ' A' ' 57' ' ' SER . 38.9 t70 -167.59 86.08 0.24 Allowed 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 121.185 0.516 . . . . 0.0 111.147 -176.748 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 82.73 122.55 0.75 Allowed Glycine 0 N--CA 1.448 -0.526 0 CA-C-N 115.321 -0.854 . . . . 0.0 112.621 178.913 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 34.9 m -98.09 149.45 5.22 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.881 0 CA-C-O 120.862 0.363 . . . . 0.0 110.583 -179.641 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' GLN . . . . . 0.48 ' HB2' ' O ' ' A' ' 46' ' ' LEU . 3.7 pt20 -128.97 159.58 35.44 Favored 'General case' 0 C--N 1.318 -0.779 0 C-N-CA 120.558 -0.457 . . . . 0.0 110.868 176.875 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.596 HG23 HD11 ' A' ' 48' ' ' ILE . 0.2 OUTLIER -82.58 111.62 19.22 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.357 178.42 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 22.8 t70 -71.2 -62.8 1.27 Allowed 'General case' 0 C--N 1.318 -0.784 0 CA-C-N 115.363 -0.835 . . . . 0.0 111.481 -174.978 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 8.4 p -155.31 145.08 21.4 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.681 -176.464 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.568 HG11 ' HA ' ' A' ' 39' ' ' SER . 89.0 t -90.41 132.39 35.16 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.762 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.406 178.964 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.469 ' HA ' ' HD3' ' A' ' 34' ' ' PRO . 17.5 m -107.29 134.07 20.09 Favored Pre-proline 0 N--CA 1.449 -0.524 0 CA-C-O 121.015 0.436 . . . . 0.0 111.476 -178.251 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' PRO . . . . . 0.469 ' HD3' ' HA ' ' A' ' 33' ' ' VAL . 21.9 Cg_exo -66.44 142.24 64.74 Favored 'Trans proline' 0 C--O 1.236 0.389 0 C-N-CA 123.108 2.539 . . . . 0.0 112.141 178.302 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 112.99 -16.13 23.11 Favored Glycine 0 N--CA 1.448 -0.538 0 N-CA-C 111.232 -0.747 . . . . 0.0 111.232 -176.939 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 26.0 m -123.53 165.22 24.03 Favored Pre-proline 0 C--N 1.324 -0.539 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 179.853 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -74.72 -168.62 0.52 Allowed 'Trans proline' 0 CA--C 1.533 0.428 0 C-N-CA 122.753 2.302 . . . . 0.0 112.489 178.383 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.549 ' HB2' HD11 ' A' ' 86' ' ' LEU . . . 78.62 -6.3 1.93 Allowed 'General case' 0 N--CA 1.468 0.436 0 CA-C-N 115.473 -0.785 . . . . 0.0 112.354 175.457 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.568 ' HA ' HG11 ' A' ' 32' ' ' VAL . 3.8 m -58.69 -30.9 67.74 Favored 'General case' 0 CA--C 1.531 0.243 0 CA-C-O 120.817 0.342 . . . . 0.0 111.661 -177.2 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 64.6 mmtt -119.33 20.7 12.47 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.19 0.519 . . . . 0.0 110.928 -179.675 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 89.6 t -107.84 -47.04 7.82 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 115.938 -0.573 . . . . 0.0 110.043 178.678 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.566 ' HB3' ' CZ ' ' A' ' 84' ' ' PHE . 0.6 OUTLIER -118.61 171.83 7.92 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 121.078 0.466 . . . . 0.0 111.256 178.884 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 11.7 m -115.84 126.15 27.97 Favored Pre-proline 0 C--N 1.315 -0.895 0 CA-C-N 115.452 -0.795 . . . . 0.0 110.061 -179.95 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_endo -62.2 142.35 91.41 Favored 'Trans proline' 0 N--CA 1.46 -0.461 0 C-N-CA 122.099 1.866 . . . . 0.0 111.422 177.4 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 97.72 -5.42 62.05 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.995 -179.248 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.48 ' O ' ' HB2' ' A' ' 28' ' ' GLN . 75.2 mt -85.09 164.03 18.44 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.931 0.366 . . . . 0.0 110.968 179.589 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 47.4 t -101.51 143.28 14.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.457 178.516 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.596 HD11 HG23 ' A' ' 29' ' ' ILE . 60.0 mt -104.36 127.42 58.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 C-N-CA 122.535 0.334 . . . . 0.0 110.209 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 27.9 mt-10 -89.51 -47.88 7.69 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.777 176.382 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.55 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 19.5 p -157.38 153.15 26.81 Favored 'General case' 0 N--CA 1.446 -0.671 0 CA-C-O 121.599 0.714 . . . . 0.0 112.202 -172.877 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.719 HG22 ' H ' ' A' ' 52' ' ' ASN . 16.0 mt -96.86 -179.93 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 169.735 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 52' ' ' ASN . . . . . 0.719 ' H ' HG22 ' A' ' 51' ' ' ILE . 36.0 t-20 -49.58 93.67 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 112.264 0.468 . . . . 0.0 112.264 -177.434 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 73.12 -2.59 34.63 Favored Glycine 0 CA--C 1.519 0.321 0 CA-C-N 115.976 -0.557 . . . . 0.0 113.275 179.493 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 36.1 mtt -124.8 98.85 36.13 Favored Pre-proline 0 C--N 1.325 -0.484 0 CA-C-N 116.875 0.337 . . . . 0.0 110.654 -173.096 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.55 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 70.4 Cg_endo -77.27 130.89 11.36 Favored 'Trans proline' 0 N--CA 1.46 -0.447 0 C-N-CA 122.151 1.901 . . . . 0.0 112.005 178.257 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.461 HG21 ' HA ' ' A' ' 62' ' ' TYR . 37.5 p -116.63 103.84 10.79 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 121.089 0.471 . . . . 0.0 111.614 -176.307 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 57' ' ' SER . . . . . 0.405 ' OG ' ' HA ' ' A' ' 25' ' ' ASP . 26.9 t -89.05 -34.63 16.72 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.965 177.207 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 58' ' ' ASN . . . . . 0.43 ' HA ' ' HB2' ' A' ' 24' ' ' PRO . 2.3 m-20 -103.34 158.44 16.33 Favored 'General case' 0 C--N 1.318 -0.797 0 O-C-N 122.065 -0.397 . . . . 0.0 110.153 -176.804 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 87.4 mt -68.81 -33.8 74.45 Favored 'General case' 0 N--CA 1.443 -0.801 0 CA-C-O 121.215 0.531 . . . . 0.0 109.955 175.519 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 1.6 m -66.04 -41.82 90.39 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.668 -0.696 . . . . 0.0 111.081 177.547 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 18.4 p -68.07 -28.46 67.38 Favored 'General case' 0 CA--C 1.528 0.114 0 CA-C-O 120.811 0.339 . . . . 0.0 110.55 178.951 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' TYR . . . . . 0.461 ' HA ' HG21 ' A' ' 56' ' ' THR . 46.1 t80 -67.19 -38.41 85.31 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 176.105 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 21.6 t -66.07 -48.28 71.53 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.768 179.097 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.03 -32.78 74.22 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.346 -177.773 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' ALA . . . . . 0.476 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -73.29 -43.88 60.16 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.311 179.586 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 3.2 tt -57.04 -45.99 82.74 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.705 -0.679 . . . . 0.0 110.494 -179.6 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -59.69 -26.88 65.95 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.63 -0.714 . . . . 0.0 112.173 -178.199 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 43.5 p -89.24 -14.03 36.82 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 112.049 0.388 . . . . 0.0 112.049 -177.454 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.476 HG12 ' O ' ' A' ' 65' ' ' ALA . 40.9 mm -74.83 142.81 14.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.652 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 70' ' ' SER . . . . . 0.458 ' HB2' ' HB2' ' A' ' 73' ' ' GLU . 4.9 m -93.18 157.64 16.17 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.673 0.273 . . . . 0.0 111.084 -178.157 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.441 HG22 ' H ' ' A' ' 98' ' ' ALA . 75.3 t -70.29 129.79 34.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.109 177.146 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 79.63 10.14 86.12 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.612 -0.804 . . . . 0.0 111.606 179.759 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.458 ' HB2' ' HB2' ' A' ' 70' ' ' SER . 23.7 tt0 -92.86 149.57 21.17 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 -179.719 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 44.9 t -105.1 124.05 59.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-O 121.35 0.595 . . . . 0.0 110.579 -175.806 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 15.7 pt -110.27 154.04 11.9 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.122 179.193 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' ASN . . . . . 0.626 ' H ' ' HB2' ' A' ' 52' ' ' ASN . 6.3 t30 -105.8 110.49 22.8 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 115.312 -0.858 . . . . 0.0 109.736 -177.755 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 65.0 mt -105.95 119.41 55.21 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 CA-C-O 121.34 0.59 . . . . 0.0 110.992 -174.087 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 11.9 m -93.68 118.5 31.47 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.278 -0.873 . . . . 0.0 109.616 177.847 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 43.4 p -120.36 178.12 4.77 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.82 0.343 . . . . 0.0 111.165 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 28.5 t70 -58.59 -34.88 71.6 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.598 -0.728 . . . . 0.0 111.351 178.798 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 72.1 mm-40 -96.48 14.24 25.24 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.125 -0.489 . . . . 0.0 112.103 -176.136 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 123.26 -171.51 15.85 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.177 -1.011 . . . . 0.0 112.631 176.246 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 24.1 m -112.06 138.23 49.0 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.75 0.309 . . . . 0.0 110.721 -176.855 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 84' ' ' PHE . . . . . 0.566 ' CZ ' ' HB3' ' A' ' 42' ' ' LEU . 10.3 p90 -139.16 168.83 18.96 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 121.378 0.609 . . . . 0.0 110.949 175.494 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 1.8 p-80 -109.82 138.34 46.33 Favored 'General case' 0 C--N 1.314 -0.951 0 CA-C-N 115.142 -0.935 . . . . 0.0 110.016 178.158 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.549 HD11 ' HB2' ' A' ' 38' ' ' ALA . 17.8 tp -130.08 143.85 51.02 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.106 -177.755 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 24.3 ttpp -114.18 125.43 53.93 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.093 -178.277 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.643 HG21 ' HB1' ' A' ' 98' ' ' ALA . 77.0 p -73.99 148.17 42.31 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 115.969 -0.559 . . . . 0.0 111.38 -178.716 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -99.49 -171.88 30.69 Favored Glycine 0 N--CA 1.444 -0.805 0 N-CA-C 110.952 -0.859 . . . . 0.0 110.952 174.866 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.495 ' HD2' ' H ' ' A' ' 90' ' ' ARG . 0.7 OUTLIER -81.15 -60.44 2.28 Favored 'General case' 0 C--N 1.323 -0.555 0 C-N-CA 120.639 -0.424 . . . . 0.0 111.437 -178.477 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 91' ' ' ASN . . . . . 0.494 ' N ' ' HG2' ' A' ' 90' ' ' ARG . 2.1 m-20 178.84 137.25 0.25 Allowed Pre-proline 0 N--CA 1.465 0.297 0 C-N-CA 122.682 0.393 . . . . 0.0 110.241 -178.362 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.413 ' HD3' ' HA ' ' A' ' 91' ' ' ASN . 12.3 Cg_endo -90.65 -74.97 0.0 OUTLIER 'Trans proline' 0 N--CA 1.449 -1.09 0 C-N-CA 122.849 2.366 . . . . 0.0 110.815 170.901 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 63.2 t30 -142.63 68.15 1.31 Allowed 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 173.957 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 20.8 t-20 -150.18 166.77 28.85 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.311 -0.858 . . . . 0.0 109.485 -172.225 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 49.1 m -115.43 24.5 11.55 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.332 0.587 . . . . 0.0 109.821 178.266 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 25.4 m -100.63 -172.73 2.24 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.402 -0.817 . . . . 0.0 110.179 178.476 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 97' ' ' ARG . . . . . 0.453 ' HD3' ' N ' ' A' ' 97' ' ' ARG . 0.0 OUTLIER -138.16 145.46 41.57 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 177.093 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 98' ' ' ALA . . . . . 0.643 ' HB1' HG21 ' A' ' 88' ' ' THR . . . 58.03 68.02 0.89 Allowed 'General case' 0 C--N 1.332 -0.16 0 O-C-N 123.768 0.667 . . . . 0.0 109.903 -176.26 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 29.5 p90 -86.89 148.57 25.3 Favored 'General case' 0 N--CA 1.444 -0.747 0 CA-C-N 115.865 -0.607 . . . . 0.0 112.164 -167.238 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 93.5 mmm -98.06 126.55 43.55 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.05 -0.977 . . . . 0.0 109.341 175.358 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -86.92 35.19 3.43 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.806 -177.046 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.557 HG22 ' HA ' ' A' ' 32' ' ' VAL . 2.8 pp -140.2 162.71 24.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 120.801 0.334 . . . . 0.0 110.434 179.655 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 103' ' ' ARG . . . . . 0.44 ' NE ' ' HA ' ' A' ' 103' ' ' ARG . 2.9 mmp_? -93.01 142.07 27.7 Favored 'General case' 0 C--N 1.315 -0.915 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 171.377 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.3 m -111.17 150.52 29.38 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-O 121.085 0.469 . . . . 0.0 110.387 179.455 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.43 ' OG ' ' HG3' ' A' ' 28' ' ' GLN . 6.7 p -136.16 169.08 18.2 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.158 175.809 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 106' ' ' ASN . . . . . 0.403 HD22 ' HA ' ' A' ' 106' ' ' ASN . 2.0 t-20 -112.35 7.88 19.39 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 120.686 0.279 . . . . 0.0 111.261 -172.575 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 48.7 t60 63.6 34.9 12.05 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-O 121.693 0.758 . . . . 0.0 110.495 176.187 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 92.8 mt -96.67 -163.49 1.05 Allowed 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.182 -0.917 . . . . 0.0 110.845 -179.22 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 59.8 mmt-85 -113.34 137.91 50.82 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.597 179.074 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 44.2 t -122.01 135.7 61.29 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.043 -179.906 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 111' ' ' ARG . . . . . . . . . . . . . 97.0 mtt180 -88.2 134.56 33.75 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 121.013 0.435 . . . . 0.0 110.878 -179.466 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 6.7 p-10 -112.51 16.77 19.69 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 121.431 0.634 . . . . 0.0 110.583 179.103 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 22.5 t -101.45 129.71 47.54 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-N 115.355 -0.838 . . . . 0.0 110.08 179.361 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 12.0 m -124.33 137.61 56.65 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.53 179.105 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -128.95 79.09 1.89 Allowed 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.774 178.233 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 52.7 m -96.85 98.62 10.27 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.192 0.52 . . . . 0.0 110.165 178.426 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 30.5 m -88.95 167.59 1.67 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.832 -178.644 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -79.44 -51.43 9.38 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.166 -0.47 . . . . 0.0 109.87 178.97 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 60.49 33.07 79.94 Favored Glycine 0 C--N 1.331 0.301 0 CA-C-N 115.675 -0.693 . . . . 0.0 112.231 -179.68 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -88.89 146.14 25.12 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.127 0.489 . . . . 0.0 111.215 -177.229 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 5.7 t -155.99 99.92 2.0 Allowed 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.328 -0.851 . . . . 0.0 109.123 174.484 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 122' ' ' LEU . . . . . 0.465 ' HA ' ' HD3' ' A' ' 123' ' ' PRO . 96.5 mt -93.02 117.09 67.41 Favored Pre-proline 0 C--N 1.321 -0.658 0 CA-C-N 115.347 -0.842 . . . . 0.0 111.514 -171.753 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 123' ' ' PRO . . . . . 0.465 ' HD3' ' HA ' ' A' ' 122' ' ' LEU . 5.1 Cg_exo -78.1 117.05 4.05 Favored 'Trans proline' 0 N--CA 1.458 -0.602 0 C-N-CA 123.011 2.474 . . . . 0.0 111.406 175.636 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 68.5 m-85 -79.25 94.41 5.44 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.14 179.499 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.079 0 CA-C-O 118.473 -0.775 . . . . 0.0 110.648 -177.917 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 23' ' ' GLN . . . . . . . . . . . . . 29.9 tp60 . . . . . 0 N--CA 1.454 -0.269 0 CA-C-O 120.467 0.175 . . . . 0.0 110.666 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.45 ' HB2' ' OG ' ' A' ' 57' ' ' SER . 68.7 Cg_endo -75.95 157.07 38.9 Favored 'Trans proline' 0 C--O 1.236 0.386 0 C-N-CA 122.501 2.134 . . . . 0.0 111.138 172.566 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 21.4 t70 -148.68 -50.65 0.16 Allowed 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 121.083 0.468 . . . . 0.0 111.447 -176.659 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.561 ' HA2' ' HA ' ' A' ' 57' ' ' SER . . . 157.25 167.2 17.99 Favored Glycine 0 N--CA 1.443 -0.869 0 N-CA-C 111.039 -0.824 . . . . 0.0 111.039 -177.124 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.479 HG23 ' HB ' ' A' ' 48' ' ' ILE . 28.5 m -108.06 127.42 64.26 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 CA-C-O 121.253 0.549 . . . . 0.0 110.984 178.787 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 18.9 tt0 -99.21 142.78 30.26 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.07 178.01 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.451 HG12 ' O ' ' A' ' 46' ' ' LEU . 8.0 pt -87.36 119.52 35.16 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-O 121.612 0.72 . . . . 0.0 111.579 -178.069 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.409 ' HB3' ' CB ' ' A' ' 103' ' ' ARG . 11.4 t70 -61.12 -58.47 8.22 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 114.272 -1.331 . . . . 0.0 109.983 177.23 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 31' ' ' SER . . . . . 0.619 ' HA ' ' HB3' ' A' ' 44' ' ' PRO . 7.8 p -159.69 158.96 32.36 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.432 -0.804 . . . . 0.0 111.145 -174.407 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.578 ' HA ' HG22 ' A' ' 102' ' ' ILE . 91.4 t -110.44 119.7 59.83 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 115.689 -0.687 . . . . 0.0 109.404 177.846 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.425 ' HA ' ' HD3' ' A' ' 34' ' ' PRO . 53.9 t -83.63 123.52 76.3 Favored Pre-proline 0 C--N 1.324 -0.513 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.721 -175.978 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 34' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' A' ' 33' ' ' VAL . 11.4 Cg_exo -72.95 31.16 0.3 Allowed 'Trans proline' 0 CA--C 1.532 0.42 0 C-N-CA 123.269 2.646 . . . . 0.0 112.775 179.291 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 35' ' ' GLY . . . . . 0.402 ' H ' ' C ' ' A' ' 33' ' ' VAL . . . -121.69 20.43 8.24 Favored Glycine 0 N--CA 1.449 -0.462 0 N-CA-C 111.27 -0.732 . . . . 0.0 111.27 179.172 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 49.1 m -148.17 160.9 36.08 Favored Pre-proline 0 C--N 1.323 -0.578 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 179.425 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_exo -59.81 -13.56 22.92 Favored 'Trans proline' 0 C--N 1.348 0.533 0 C-N-CA 122.985 2.457 . . . . 0.0 113.669 -176.297 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.41 ' HB1' HD13 ' A' ' 42' ' ' LEU . . . -78.6 -6.94 56.97 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 111.794 0.294 . . . . 0.0 111.794 -177.333 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 28.0 t -60.43 -28.45 68.3 Favored 'General case' 0 CA--C 1.533 0.294 0 N-CA-C 112.153 0.427 . . . . 0.0 112.153 -175.657 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 21.0 ttpt -106.96 13.53 27.5 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.947 0.403 . . . . 0.0 110.678 -177.388 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.477 ' HB ' HD12 ' A' ' 42' ' ' LEU . 46.4 t -115.34 -59.2 3.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 C-N-CA 120.776 -0.37 . . . . 0.0 111.65 -175.23 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.48 HD11 HD12 ' A' ' 86' ' ' LEU . 6.6 mp -92.45 175.46 6.83 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.291 0.567 . . . . 0.0 111.516 -173.478 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 91.1 m -140.89 123.94 9.91 Favored Pre-proline 0 C--N 1.32 -0.674 0 CA-C-N 115.405 -0.816 . . . . 0.0 108.946 175.544 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.619 ' HB3' ' HA ' ' A' ' 31' ' ' SER . 42.3 Cg_endo -64.52 152.05 83.17 Favored 'Trans proline' 0 CA--C 1.531 0.339 0 C-N-CA 122.893 2.396 . . . . 0.0 112.905 -173.811 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 103.17 -11.92 55.36 Favored Glycine 0 CA--C 1.52 0.368 0 C-N-CA 121.072 -0.585 . . . . 0.0 112.695 -179.496 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.701 HD22 ' HB3' ' A' ' 80' ' ' ASP . 81.6 mt -84.74 164.62 18.43 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.975 0.417 . . . . 0.0 111.098 -177.981 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 46.6 t -108.12 135.09 47.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 116.075 -0.511 . . . . 0.0 109.843 177.129 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.479 ' HB ' HG23 ' A' ' 27' ' ' VAL . 69.0 mt -87.65 123.7 40.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-O 121.204 0.526 . . . . 0.0 110.536 179.862 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 6.5 tm-20 -79.22 -47.06 16.62 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.921 -179.54 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.54 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 7.7 p -162.73 153.77 17.32 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.388 -177.648 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 48.5 mm -107.24 102.96 14.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.901 -0.59 . . . . 0.0 109.732 176.679 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' ASN . . . . . 0.591 ' HA ' ' HB3' ' A' ' 76' ' ' ASN . 38.9 t-20 64.08 -85.26 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.384 0 C-N-CA 123.552 0.741 . . . . 0.0 111.056 179.343 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -132.79 8.05 5.21 Favored Glycine 0 N--CA 1.447 -0.569 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 177.005 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 1.5 mpt? -118.59 103.35 48.92 Favored Pre-proline 0 N--CA 1.448 -0.571 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 -178.737 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.54 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 41.8 Cg_endo -68.81 121.68 8.57 Favored 'Trans proline' 0 N--CA 1.462 -0.367 0 C-N-CA 122.124 1.882 . . . . 0.0 112.461 -179.118 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.45 ' HA ' ' HB ' ' A' ' 61' ' ' THR . 6.9 p -89.47 87.99 7.28 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.54 179.834 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 57' ' ' SER . . . . . 0.561 ' HA ' ' HA2' ' A' ' 26' ' ' GLY . 8.6 t -93.53 -14.26 26.82 Favored 'General case' 0 C--N 1.318 -0.797 0 CA-C-N 115.416 -0.811 . . . . 0.0 109.875 -179.476 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 61.1 t30 -140.5 178.23 7.46 Favored 'General case' 0 N--CA 1.445 -0.714 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 178.978 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 68.8 mt -76.16 -33.39 59.37 Favored 'General case' 0 N--CA 1.445 -0.72 0 CA-C-O 120.921 0.391 . . . . 0.0 111.067 -178.424 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 13.1 m -66.48 -34.33 77.68 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.977 179.869 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' THR . . . . . 0.45 ' HB ' ' HA ' ' A' ' 56' ' ' THR . 0.0 OUTLIER -66.0 -35.33 80.26 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.992 0.425 . . . . 0.0 110.372 176.838 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 55.4 t80 -62.33 -37.45 85.66 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.857 176.842 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 33.2 t -68.25 -46.19 71.16 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.52 -0.764 . . . . 0.0 110.435 177.287 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -66.32 -26.34 67.26 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.865 -0.607 . . . . 0.0 112.13 -175.761 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 65' ' ' ALA . . . . . 0.427 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -79.27 -44.03 22.54 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.078 0.466 . . . . 0.0 110.431 177.487 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 1.7 tt -63.55 -42.64 98.38 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.556 -0.747 . . . . 0.0 111.357 -175.824 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 22.4 ptmt -60.37 -12.37 9.14 Favored 'General case' 0 CA--C 1.536 0.414 0 N-CA-C 112.899 0.704 . . . . 0.0 112.899 -174.117 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 20.8 p -106.93 -13.17 15.28 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 112.386 0.514 . . . . 0.0 112.386 -178.128 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.473 HG21 HG21 ' A' ' 88' ' ' THR . 37.2 mm -79.73 143.85 11.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.748 -0.205 . . . . 0.0 110.956 -175.256 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 3.2 m -92.45 164.52 13.44 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.508 -0.315 . . . . 0.0 110.471 179.888 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.408 HG22 ' H ' ' A' ' 98' ' ' ALA . 16.5 t -78.6 118.09 25.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 120.677 0.275 . . . . 0.0 110.266 179.304 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 88.32 23.52 37.03 Favored Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 120.422 -0.894 . . . . 0.0 111.671 -178.846 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 28.6 tt0 -99.56 147.5 25.27 Favored 'General case' 0 C--N 1.323 -0.587 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 -179.851 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 51.0 t -95.14 114.29 31.39 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.779 0 CA-C-O 121.136 0.493 . . . . 0.0 110.56 -179.122 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 26.7 pt -104.21 174.79 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.787 0 CA-C-N 115.637 -0.71 . . . . 0.0 110.87 179.27 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 76' ' ' ASN . . . . . 0.591 ' HB3' ' HA ' ' A' ' 52' ' ' ASN . 43.6 t30 -122.16 130.54 53.31 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.586 -0.734 . . . . 0.0 109.813 -175.536 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.435 HG22 HG23 ' A' ' 79' ' ' THR . 62.5 mt -134.8 110.33 12.71 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-O 121.212 0.529 . . . . 0.0 111.112 -176.922 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 78' ' ' THR . . . . . 0.628 ' HA ' ' HA ' ' A' ' 83' ' ' THR . 98.1 m -85.91 123.53 31.35 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.986 -0.552 . . . . 0.0 109.685 173.597 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.435 HG23 HG22 ' A' ' 77' ' ' ILE . 67.3 p -124.72 -173.45 2.79 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.922 0.392 . . . . 0.0 111.364 -177.472 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 80' ' ' ASP . . . . . 0.701 ' HB3' HD22 ' A' ' 46' ' ' LEU . 7.4 t70 -53.78 -41.55 67.34 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.216 -0.902 . . . . 0.0 111.583 177.173 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 28.2 mm-40 -95.23 12.94 27.13 Favored 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 111.931 0.345 . . . . 0.0 111.931 -175.759 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 119.43 -175.32 15.75 Favored Glycine 0 N--CA 1.447 -0.63 0 C-N-CA 120.164 -1.017 . . . . 0.0 113.038 175.342 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.628 ' HA ' ' HA ' ' A' ' 78' ' ' THR . 32.6 m -92.67 117.17 29.7 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.115 0.484 . . . . 0.0 111.396 -176.565 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 88.9 m-85 -113.89 164.8 13.29 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.43 -178.735 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 19.3 p-80 -117.27 130.01 56.28 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.285 178.958 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.49 HD23 ' N ' ' A' ' 87' ' ' LYS . 8.2 tt -120.48 145.48 47.23 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 116.231 -0.44 . . . . 0.0 109.947 -173.985 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.49 ' N ' HD23 ' A' ' 86' ' ' LEU . 88.1 tttt -114.66 117.59 31.28 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 109.132 -0.692 . . . . 0.0 109.132 176.216 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.473 HG21 HG21 ' A' ' 69' ' ' ILE . 22.3 p -64.03 131.92 49.03 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 121.142 0.496 . . . . 0.0 111.729 -174.997 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -102.55 -141.11 11.36 Favored Glycine 0 N--CA 1.441 -1.012 0 C-N-CA 120.975 -0.631 . . . . 0.0 111.797 179.61 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 70.6 mtt180 -115.36 161.34 18.65 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.123 0.487 . . . . 0.0 111.365 -175.124 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 91' ' ' ASN . . . . . 0.613 ' HB3' ' HB2' ' A' ' 99' ' ' TYR . 1.1 p-10 -130.59 107.87 15.77 Favored Pre-proline 0 C--N 1.324 -0.515 0 CA-C-N 115.331 -0.849 . . . . 0.0 111.729 -171.801 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_exo -83.01 -4.71 11.28 Favored 'Trans proline' 0 C--O 1.23 0.101 0 C-N-CA 123.557 2.838 . . . . 0.0 112.079 174.052 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 5.3 t30 -133.95 78.35 1.76 Allowed 'General case' 0 C--N 1.316 -0.885 0 CA-C-N 115.064 -0.971 . . . . 0.0 109.944 -173.48 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 11.5 t-20 71.63 -160.21 0.12 Allowed 'General case' 0 N--CA 1.469 0.48 0 CA-C-N 115.147 -0.933 . . . . 0.0 109.966 173.054 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 14.8 m 76.24 -26.59 0.19 Allowed 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 123.913 0.885 . . . . 0.0 112.559 176.958 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 55.6 m 71.91 -60.46 0.52 Allowed 'General case' 0 N--CA 1.467 0.39 0 C-N-CA 123.58 0.752 . . . . 0.0 112.374 178.941 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -141.8 153.41 44.51 Favored 'General case' 0 C--N 1.328 -0.369 0 O-C-N 122.292 -0.255 . . . . 0.0 111.592 -177.374 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 98' ' ' ALA . . . . . 0.408 ' H ' HG22 ' A' ' 71' ' ' VAL . . . 62.24 81.74 0.19 Allowed 'General case' 0 N--CA 1.464 0.254 0 O-C-N 124.089 0.868 . . . . 0.0 112.29 169.573 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 99' ' ' TYR . . . . . 0.613 ' HB2' ' HB3' ' A' ' 91' ' ' ASN . 14.5 t80 -107.45 120.74 43.0 Favored 'General case' 0 C--N 1.319 -0.718 0 C-N-CA 120.76 -0.376 . . . . 0.0 110.07 -178.58 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 100' ' ' MET . . . . . 0.566 ' HG2' HG12 ' A' ' 102' ' ' ILE . 0.7 OUTLIER -71.86 -20.18 61.85 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.169 -179.038 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 78.91 35.2 31.83 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.866 -0.683 . . . . 0.0 113.113 175.201 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.578 HG22 ' HA ' ' A' ' 32' ' ' VAL . 35.4 pt -142.02 154.01 18.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-O 120.849 0.356 . . . . 0.0 110.063 178.933 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 103' ' ' ARG . . . . . 0.409 ' CB ' ' HB3' ' A' ' 30' ' ' ASP . 21.4 mtp85 -91.74 134.66 34.53 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 173.463 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 2.8 m -133.21 155.14 49.89 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.962 0.41 . . . . 0.0 111.055 -176.308 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 32.6 t -149.1 -174.88 4.76 Favored 'General case' 0 C--N 1.321 -0.636 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 179.44 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 14.8 p30 -103.24 -34.84 8.66 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 120.635 0.255 . . . . 0.0 111.044 179.211 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 44.3 t-80 55.27 49.72 16.54 Favored 'General case' 0 CA--C 1.531 0.213 0 CA-C-O 121.206 0.527 . . . . 0.0 110.375 -179.771 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 16.9 mt -85.57 139.64 31.28 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.326 -179.25 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 32.3 ttt180 68.78 139.8 0.04 OUTLIER 'General case' 0 N--CA 1.467 0.381 0 O-C-N 124.728 1.267 . . . . 0.0 112.214 178.739 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 14.0 p -69.5 145.79 12.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.118 -0.492 . . . . 0.0 109.841 173.76 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 111' ' ' ARG . . . . . 0.461 ' HD2' ' C ' ' A' ' 111' ' ' ARG . 4.1 ppt_? -106.84 171.58 7.29 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.118 0.485 . . . . 0.0 111.492 -173.657 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -148.29 152.07 36.48 Favored 'General case' 0 C--N 1.323 -0.576 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 175.007 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 50.7 m 72.78 111.44 0.06 Allowed 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.212 0.945 . . . . 0.0 111.849 177.355 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 16.7 m -96.87 133.66 37.49 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.409 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.779 178.074 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -105.86 130.55 53.8 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.032 177.659 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 5.8 t -100.65 85.84 3.0 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.04 0.447 . . . . 0.0 109.891 -177.51 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 52.4 t -128.47 109.39 19.22 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.838 178.558 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 118' ' ' LEU . . . . . 0.466 HD22 ' N ' ' A' ' 118' ' ' LEU . 2.7 mm? -93.29 -48.33 6.48 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.525 -177.33 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 69.99 58.91 5.83 Favored Glycine 0 N--CA 1.449 -0.499 0 C-N-CA 120.687 -0.768 . . . . 0.0 111.213 -175.518 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 9.2 p-10 -74.13 112.42 10.25 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.413 0.625 . . . . 0.0 111.16 -175.506 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 92.1 m -91.27 126.62 36.41 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.427 177.006 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 96.0 mt -110.8 147.77 37.18 Favored Pre-proline 0 C--N 1.324 -0.515 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.578 -177.229 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -65.62 145.68 82.44 Favored 'Trans proline' 0 CA--C 1.527 0.168 0 C-N-CA 122.675 2.25 . . . . 0.0 112.194 178.833 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 32.9 p90 -129.22 147.3 51.04 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 116.409 -0.359 . . . . 0.0 110.723 -178.738 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.93 0 CA-C-O 118.412 -0.804 . . . . 0.0 109.862 -179.658 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 23' ' ' GLN . . . . . . . . . . . . . 80.7 mt-30 . . . . . 0 N--CA 1.457 -0.11 0 CA-C-O 120.846 0.355 . . . . 0.0 110.982 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 65.4 Cg_endo -87.8 -156.38 0.06 OUTLIER 'Trans proline' 0 N--CA 1.46 -0.473 0 C-N-CA 123.28 2.653 . . . . 0.0 112.602 178.965 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 27.9 t70 75.94 67.15 0.06 Allowed 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 114.607 -1.179 . . . . 0.0 110.364 178.602 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.461 ' H ' ' HA ' ' A' ' 57' ' ' SER . . . 106.52 115.94 4.08 Favored Glycine 0 N--CA 1.445 -0.72 0 CA-C-N 114.471 -1.24 . . . . 0.0 111.751 176.597 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 34.5 m -78.79 153.83 4.92 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 CA-C-O 120.941 0.4 . . . . 0.0 110.721 -178.737 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 4.4 tt0 -115.53 149.24 38.48 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-O 121.293 0.568 . . . . 0.0 111.349 -177.585 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.498 HD12 HD12 ' A' ' 102' ' ' ILE . 26.8 mm -73.11 107.62 3.86 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.214 -0.903 . . . . 0.0 109.432 175.742 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.721 ' HB3' ' HB2' ' A' ' 103' ' ' ARG . 41.9 t0 -69.98 -53.54 17.28 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-O 121.401 0.62 . . . . 0.0 109.529 -178.671 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 51.0 p -161.47 173.51 14.76 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.189 -0.914 . . . . 0.0 110.798 177.103 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.522 HG22 HG22 ' A' ' 102' ' ' ILE . 84.9 t -119.25 124.46 73.1 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 CA-C-N 115.813 -0.631 . . . . 0.0 109.382 175.95 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 7.4 p -106.7 131.02 22.04 Favored Pre-proline 0 C--N 1.323 -0.545 0 CA-C-O 120.783 0.325 . . . . 0.0 110.421 -177.67 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo -64.97 87.85 0.18 Allowed 'Trans proline' 0 C--N 1.343 0.289 0 C-N-CA 122.79 2.327 . . . . 0.0 112.408 179.426 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -164.75 14.21 0.09 OUTLIER Glycine 0 N--CA 1.449 -0.447 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.862 176.032 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.679 ' HB2' ' HA3' ' A' ' 101' ' ' GLY . 60.4 m -157.65 160.44 30.16 Favored Pre-proline 0 C--N 1.327 -0.401 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 -178.972 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_exo -63.31 -15.34 47.66 Favored 'Trans proline' 0 C--N 1.349 0.568 0 C-N-CA 122.87 2.38 . . . . 0.0 112.71 -178.132 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -67.07 -15.12 63.52 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.922 -177.426 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.459 ' HA ' HG11 ' A' ' 32' ' ' VAL . 47.7 t -65.21 -13.55 58.54 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.71 -177.041 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 23.9 ttmm -128.42 25.39 5.77 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.346 0.594 . . . . 0.0 110.06 179.244 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.542 ' HB ' HD12 ' A' ' 42' ' ' LEU . 45.6 t -122.16 -55.3 2.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.905 179.381 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.542 HD12 ' HB ' ' A' ' 41' ' ' VAL . 5.0 mp -109.17 164.19 12.67 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.789 0.328 . . . . 0.0 110.588 -178.033 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 12.7 p -116.54 144.54 33.39 Favored Pre-proline 0 C--N 1.323 -0.548 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.62 177.1 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.44 ' HA ' ' CG2' ' A' ' 29' ' ' ILE . 57.2 Cg_endo -72.55 149.41 49.53 Favored 'Trans proline' 0 C--O 1.235 0.332 0 C-N-CA 122.299 1.999 . . . . 0.0 112.496 -179.422 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 101.14 -12.52 58.8 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.999 -179.555 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 83.4 mt -77.43 164.27 25.62 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 121.046 0.451 . . . . 0.0 111.46 -179.235 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 46.0 t -108.76 136.19 45.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.785 177.933 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.439 HG23 HG23 ' A' ' 77' ' ' ILE . 70.9 mt -93.79 122.71 45.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-N 116.496 -0.32 . . . . 0.0 110.981 179.55 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -79.82 -44.97 19.6 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.5 -0.318 . . . . 0.0 110.951 174.809 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.62 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 16.4 p -169.03 161.22 10.45 Favored 'General case' 0 CA--C 1.515 -0.404 0 CA-C-O 120.888 0.375 . . . . 0.0 111.408 -174.559 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.558 HD11 HD12 ' A' ' 75' ' ' ILE . 8.1 tt -135.95 122.19 31.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.148 177.473 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 11.0 m120 58.85 22.88 10.69 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-N 115.642 -0.708 . . . . 0.0 112.536 176.094 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 104.71 -26.22 23.19 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.655 -0.783 . . . . 0.0 112.433 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 4.4 mpp? -91.94 112.8 56.6 Favored Pre-proline 0 C--N 1.325 -0.491 0 N-CA-C 109.682 -0.488 . . . . 0.0 109.682 177.577 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.62 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 72.6 Cg_endo -78.02 128.07 8.9 Favored 'Trans proline' 0 N--CA 1.454 -0.799 0 C-N-CA 122.09 1.86 . . . . 0.0 112.501 -178.748 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 21.5 p -91.64 81.13 5.31 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 115.649 -0.705 . . . . 0.0 111.026 -177.944 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' SER . . . . . 0.461 ' HA ' ' H ' ' A' ' 26' ' ' GLY . 12.6 m -81.34 -18.5 45.49 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.69 178.561 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 42.7 m-80 -138.34 164.85 28.25 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.733 -178.729 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.511 HD21 ' HA ' ' A' ' 105' ' ' SER . 66.2 mt -68.75 -35.14 76.72 Favored 'General case' 0 N--CA 1.446 -0.653 0 CA-C-O 120.908 0.385 . . . . 0.0 110.576 178.222 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 1.5 m -62.22 -35.32 78.53 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.509 176.513 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -66.65 -43.25 85.1 Favored 'General case' 0 N--CA 1.452 -0.356 0 CA-C-N 115.998 -0.547 . . . . 0.0 110.374 178.326 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 33.3 t80 -64.14 -37.53 87.79 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.931 -0.577 . . . . 0.0 109.635 177.473 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 66.8 m -61.46 -50.94 70.75 Favored 'General case' 0 N--CA 1.445 -0.693 0 CA-C-N 115.387 -0.824 . . . . 0.0 111.397 178.012 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.95 -33.93 76.42 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.989 179.623 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 65' ' ' ALA . . . . . 0.575 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -72.79 -41.27 65.16 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.269 -179.866 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 1.2 tt -57.42 -39.31 75.92 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.252 179.407 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 93.7 mttt -59.23 -39.41 82.65 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.801 179.375 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 17.5 p -77.84 -14.37 59.59 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 111.985 0.365 . . . . 0.0 111.985 -178.701 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.575 HG12 ' O ' ' A' ' 65' ' ' ALA . 43.0 mm -75.29 142.75 14.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 N-CA-C 110.495 -0.187 . . . . 0.0 110.495 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 3.0 m -102.11 168.96 9.04 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.713 0.292 . . . . 0.0 110.925 179.761 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.413 HG22 ' H ' ' A' ' 98' ' ' ALA . 16.4 t -82.11 122.19 36.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.294 178.809 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 83.32 25.72 46.59 Favored Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 120.61 -0.805 . . . . 0.0 111.807 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 18.9 tt0 -105.81 153.32 22.07 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 179.917 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 26.5 t -97.9 113.78 33.42 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 CA-C-O 120.866 0.365 . . . . 0.0 110.167 -179.014 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.558 HD12 HD11 ' A' ' 51' ' ' ILE . 9.3 pt -101.33 154.8 4.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.164 -179.03 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 76' ' ' ASN . . . . . 0.437 ' O ' ' HA ' ' A' ' 51' ' ' ILE . 10.8 t30 -119.33 104.95 10.84 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 121.151 0.5 . . . . 0.0 111.076 -173.292 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.472 HD12 HD21 ' A' ' 86' ' ' LEU . 67.1 mt -103.12 118.83 50.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 115.37 -0.832 . . . . 0.0 110.405 -177.459 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 19.6 m -95.62 115.37 27.33 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.628 -0.715 . . . . 0.0 109.664 177.368 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 82.0 p -111.15 169.75 8.57 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.42 -179.736 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -61.98 -25.55 67.69 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.088 179.257 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 51.6 tp60 -98.51 11.85 37.0 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.171 0.51 . . . . 0.0 111.097 -176.69 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 134.44 176.11 14.21 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.315 -0.945 . . . . 0.0 113.002 176.153 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 18.1 m -105.27 120.11 40.73 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 -179.523 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 63.4 m-85 -126.57 152.16 46.96 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.759 0.314 . . . . 0.0 110.243 -179.426 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -131.49 131.15 43.23 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-O 121.299 0.571 . . . . 0.0 110.422 177.079 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.473 HD22 HD11 ' A' ' 42' ' ' LEU . 0.9 OUTLIER -127.13 157.42 39.77 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.319 -0.855 . . . . 0.0 111.106 -173.535 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 40.0 ttmt -99.56 130.6 45.81 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.057 178.545 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 33.9 p -71.63 131.19 42.84 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 121.064 0.459 . . . . 0.0 111.036 179.548 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -93.79 -166.97 37.6 Favored Glycine 0 N--CA 1.442 -0.908 0 C-N-CA 120.491 -0.861 . . . . 0.0 112.322 -177.637 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.495 ' HD3' ' N ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -153.59 117.12 4.66 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 121.14 0.495 . . . . 0.0 109.767 179.064 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 91' ' ' ASN . . . . . 1.055 ' HB3' ' HB3' ' A' ' 95' ' ' SER . 59.6 t30 -84.48 139.92 38.57 Favored Pre-proline 0 C--N 1.323 -0.551 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.766 -174.556 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.639 ' HD2' ' OD1' ' A' ' 91' ' ' ASN . 72.7 Cg_exo -38.36 155.97 0.03 OUTLIER 'Trans proline' 0 CA--C 1.532 0.419 0 C-N-CA 124.317 3.345 . . . . 0.0 114.155 170.363 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 8.9 t-20 67.07 14.75 9.93 Favored 'General case' 0 N--CA 1.469 0.503 0 CA-C-N 115.111 -0.949 . . . . 0.0 110.726 178.873 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 44.3 t-20 58.49 71.81 0.56 Allowed 'General case' 0 N--CA 1.465 0.29 0 CA-C-O 121.65 0.738 . . . . 0.0 110.002 -176.947 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 95' ' ' SER . . . . . 1.055 ' HB3' ' HB3' ' A' ' 91' ' ' ASN . 33.4 t -99.71 87.7 3.62 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.551 -0.749 . . . . 0.0 109.996 179.479 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 9.1 t 68.3 172.19 0.28 Allowed 'General case' 0 CA--C 1.532 0.276 0 CA-C-N 115.369 -0.832 . . . . 0.0 111.56 177.048 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 6.7 ptp85 -115.26 145.99 41.91 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.38 176.901 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 98' ' ' ALA . . . . . 0.413 ' H ' HG22 ' A' ' 71' ' ' VAL . . . 56.23 72.94 0.46 Allowed 'General case' 0 C--N 1.333 -0.152 0 O-C-N 123.807 0.692 . . . . 0.0 110.153 -176.505 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 99' ' ' TYR . . . . . 0.8 ' CE2' ' HB2' ' A' ' 91' ' ' ASN . 0.1 OUTLIER -70.34 110.75 5.46 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.22 -171.178 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 25.4 mmt -82.84 111.02 18.36 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 173.268 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 101' ' ' GLY . . . . . 0.679 ' HA3' ' HB2' ' A' ' 36' ' ' SER . . . -81.28 30.22 2.75 Favored Glycine 0 C--O 1.228 -0.236 0 C-N-CA 120.814 -0.707 . . . . 0.0 113.263 -174.958 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.522 HG22 HG22 ' A' ' 32' ' ' VAL . 42.9 pt -147.69 173.29 2.16 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 -179.98 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 103' ' ' ARG . . . . . 0.721 ' HB2' ' HB3' ' A' ' 30' ' ' ASP . 65.7 mtt-85 -109.94 134.37 52.17 Favored 'General case' 0 C--N 1.317 -0.834 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 173.344 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.5 p -119.79 124.5 46.3 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-O 120.944 0.402 . . . . 0.0 110.72 178.353 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.511 ' HA ' HD21 ' A' ' 59' ' ' LEU . 42.3 m -145.64 163.43 34.86 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.248 -179.083 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 86.6 m-20 -78.17 52.36 1.09 Allowed 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.853 0.835 . . . . 0.0 109.061 173.474 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 42.0 t-80 -78.01 36.2 0.22 Allowed 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 114.541 -1.208 . . . . 0.0 111.378 -175.6 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 108' ' ' LEU . . . . . 0.458 HD11 ' O ' ' A' ' 26' ' ' GLY . 5.3 mp -80.27 165.32 22.45 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.484 178.815 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 109' ' ' ARG . . . . . 0.441 ' O ' ' HD2' ' A' ' 109' ' ' ARG . 0.0 OUTLIER -129.47 148.88 51.42 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.171 176.577 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 2.5 p -91.45 120.07 39.84 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-O 121.969 0.89 . . . . 0.0 111.363 -178.867 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 111' ' ' ARG . . . . . . . . . . . . . 2.1 tmt_? -129.16 -27.44 2.47 Favored 'General case' 0 C--N 1.315 -0.9 0 CA-C-N 114.268 -1.333 . . . . 0.0 108.852 177.343 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -81.61 100.67 9.54 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 114.799 -1.091 . . . . 0.0 109.23 175.938 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 35.4 t -67.13 98.77 0.61 Allowed 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.384 -0.826 . . . . 0.0 111.567 -174.86 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 14.8 m -108.93 149.44 12.17 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.256 175.211 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -138.04 101.27 4.38 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.857 0.36 . . . . 0.0 110.673 -179.616 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 47.2 t -113.21 15.11 19.47 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 121.383 0.611 . . . . 0.0 109.981 177.784 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 3.8 p -102.56 113.87 40.4 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 CA-C-N 115.544 -0.753 . . . . 0.0 110.733 -179.132 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 118' ' ' LEU . . . . . 0.412 HD22 ' N ' ' A' ' 118' ' ' LEU . 2.3 mm? -87.9 -32.21 19.07 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.29 179.77 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 122.49 153.74 8.92 Favored Glycine 0 N--CA 1.448 -0.564 0 CA-C-N 115.678 -0.692 . . . . 0.0 111.476 -179.009 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -105.21 168.63 8.94 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 110.205 -0.294 . . . . 0.0 110.205 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 14.4 p -75.51 109.81 9.37 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.203 -178.816 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 122' ' ' LEU . . . . . 0.451 ' HA ' ' HD3' ' A' ' 123' ' ' PRO . 62.3 mt -103.76 131.73 21.72 Favored Pre-proline 0 C--N 1.324 -0.536 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.352 -179.142 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 123' ' ' PRO . . . . . 0.451 ' HD3' ' HA ' ' A' ' 122' ' ' LEU . 9.0 Cg_exo -71.18 142.04 40.86 Favored 'Trans proline' 0 C--O 1.235 0.365 0 C-N-CA 123.093 2.529 . . . . 0.0 114.115 -173.754 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 49.5 p90 -122.49 161.95 22.63 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.121 -0.945 . . . . 0.0 109.474 174.932 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.165 0 CA-C-O 118.594 -0.717 . . . . 0.0 110.416 -179.075 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.792 ' HB2' ' HD3' ' A' ' 24' ' ' PRO . 78.8 mt-30 . . . . . 0 CA--C 1.534 0.361 0 CA-C-O 119.788 -0.149 . . . . 0.0 110.852 . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.792 ' HD3' ' HB2' ' A' ' 23' ' ' GLN . 71.1 Cg_endo -89.83 160.09 5.08 Favored 'Trans proline' 0 N--CA 1.455 -0.763 0 C-N-CA 121.872 1.715 . . . . 0.0 111.447 175.649 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 25.2 t0 -175.44 -29.08 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.353 0 CA-C-O 121.047 0.451 . . . . 0.0 111.164 -176.529 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.432 ' HA2' ' O ' ' A' ' 56' ' ' THR . . . 171.02 134.07 1.71 Allowed Glycine 0 N--CA 1.444 -0.785 0 C-N-CA 120.9 -0.667 . . . . 0.0 111.724 -179.958 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.527 HG23 ' HB ' ' A' ' 48' ' ' ILE . 19.0 m -76.3 153.94 5.89 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-O 120.69 0.281 . . . . 0.0 110.445 179.672 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 27.9 tt0 -115.8 149.51 38.42 Favored 'General case' 0 C--N 1.323 -0.579 0 C-N-CA 120.28 -0.568 . . . . 0.0 110.986 -179.371 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 68.9 mt -80.18 114.5 21.16 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-N 115.814 -0.63 . . . . 0.0 109.878 177.543 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' ASP . . . . . 0.572 ' HB3' ' HB3' ' A' ' 103' ' ' ARG . 16.2 t70 -70.39 -67.57 0.49 Allowed 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.392 0.615 . . . . 0.0 110.064 -178.95 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 6.9 p -159.14 153.9 24.63 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.109 179.804 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.802 HG22 HG22 ' A' ' 102' ' ' ILE . 95.3 t -82.24 128.63 38.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 177.95 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.405 ' HB ' ' HD2' ' A' ' 34' ' ' PRO . 27.5 m -92.16 159.14 38.08 Favored Pre-proline 0 N--CA 1.446 -0.664 0 CA-C-N 116.575 -0.284 . . . . 0.0 110.382 -178.417 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 34' ' ' PRO . . . . . 0.405 ' HD2' ' HB ' ' A' ' 33' ' ' VAL . 21.0 Cg_endo -62.88 106.23 0.51 Allowed 'Trans proline' 0 N--CA 1.461 -0.416 0 C-N-CA 122.271 1.981 . . . . 0.0 111.591 174.505 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 135.72 150.58 5.99 Favored Glycine 0 N--CA 1.448 -0.565 0 CA-C-N 115.905 -0.589 . . . . 0.0 112.067 -177.652 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 50.5 m 71.11 153.73 0.15 Allowed Pre-proline 0 CA--C 1.535 0.382 0 C-N-CA 123.038 0.535 . . . . 0.0 111.719 179.704 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -83.22 14.18 2.44 Favored 'Trans proline' 0 C--N 1.347 0.449 0 C-N-CA 122.95 2.434 . . . . 0.0 113.416 -176.267 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.568 ' HB2' ' O ' ' A' ' 100' ' ' MET . . . -59.79 -35.12 74.01 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.865 0.364 . . . . 0.0 111.478 -179.192 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.568 ' HB3' HG11 ' A' ' 32' ' ' VAL . 0.8 OUTLIER -65.93 -22.45 66.49 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.04 -0.527 . . . . 0.0 112.374 -175.063 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 19.8 ptpt -100.27 1.34 41.64 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.691 0.281 . . . . 0.0 110.896 179.829 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 83.6 t -110.59 -55.86 4.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 116.476 -0.329 . . . . 0.0 111.017 -178.23 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 1.2 pp -118.51 -178.81 3.62 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.395 0.617 . . . . 0.0 111.932 -177.051 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 23.3 m -119.95 134.4 23.97 Favored Pre-proline 0 C--N 1.316 -0.864 0 CA-C-N 115.084 -0.962 . . . . 0.0 109.964 -179.609 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.508 ' HB3' HG23 ' A' ' 32' ' ' VAL . 31.4 Cg_endo -65.67 145.58 81.85 Favored 'Trans proline' 0 N--CA 1.464 -0.242 0 C-N-CA 122.131 1.887 . . . . 0.0 111.738 176.553 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 97.83 11.0 51.6 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.517 -0.849 . . . . 0.0 112.917 -178.926 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 80.4 mt -98.04 164.9 12.15 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.772 0.32 . . . . 0.0 110.524 177.276 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.46 ' HB ' ' HB2' ' A' ' 80' ' ' ASP . 39.7 t -97.08 140.94 16.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 116.325 -0.398 . . . . 0.0 109.99 177.633 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.527 ' HB ' HG23 ' A' ' 27' ' ' VAL . 72.1 mt -103.86 115.51 45.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-O 120.839 0.352 . . . . 0.0 110.519 178.493 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.401 ' HB3' ' HB ' ' A' ' 78' ' ' THR . 7.7 tt0 -78.98 -55.11 5.38 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.598 0.713 . . . . 0.0 110.3 177.142 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.611 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 8.0 p -148.15 146.65 28.84 Favored 'General case' 0 C--N 1.315 -0.908 0 CA-C-N 115.423 -0.808 . . . . 0.0 112.157 -173.023 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.457 ' HA ' ' O ' ' A' ' 76' ' ' ASN . 49.1 mt -117.29 114.91 47.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-N 114.96 -1.018 . . . . 0.0 109.225 173.577 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 7.6 t-20 61.91 -152.62 0.36 Allowed 'General case' 0 C--O 1.234 0.25 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 -171.746 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -79.57 21.45 4.5 Favored Glycine 0 CA--C 1.523 0.532 0 C-N-CA 120.307 -0.949 . . . . 0.0 112.258 175.931 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 61.0 mtm -123.66 106.3 32.29 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 120.805 0.336 . . . . 0.0 110.19 -178.835 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.611 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 65.1 Cg_endo -73.99 150.18 43.04 Favored 'Trans proline' 0 N--CA 1.46 -0.48 0 C-N-CA 122.133 1.889 . . . . 0.0 112.602 -179.36 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.432 ' O ' ' HA2' ' A' ' 26' ' ' GLY . 33.5 p -120.72 106.07 11.36 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.74 -178.234 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 12.6 p -96.03 -22.45 17.35 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.927 -179.723 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' ASN . . . . . 0.473 ' HB3' ' HB3' ' A' ' 24' ' ' PRO . 27.5 p-10 -146.63 -169.41 3.27 Favored 'General case' 0 N--CA 1.447 -0.59 0 CA-C-O 121.271 0.558 . . . . 0.0 110.594 175.457 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.544 ' HG ' ' HB2' ' A' ' 106' ' ' ASN . 19.1 mt -68.43 -35.29 77.41 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.142 -0.935 . . . . 0.0 111.813 -178.683 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 7.7 m -65.77 -45.71 81.51 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.758 0.313 . . . . 0.0 111.324 -177.555 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 1.6 p -66.29 -33.38 75.6 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.137 0.494 . . . . 0.0 110.528 178.257 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 76.1 t80 -62.01 -46.8 87.61 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.311 -0.859 . . . . 0.0 110.526 174.73 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 5.3 t -63.75 -45.1 91.37 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.593 -179.458 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -66.36 -26.8 67.44 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.965 -0.562 . . . . 0.0 111.682 -177.265 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -78.68 -43.64 25.55 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.011 0.434 . . . . 0.0 110.365 176.657 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -59.66 -42.0 91.85 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.456 -0.793 . . . . 0.0 111.354 -176.506 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 15.2 ptmm? -64.97 -6.86 9.48 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 112.595 0.591 . . . . 0.0 112.595 -174.565 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 49.6 p -106.28 -14.59 15.07 Favored 'General case' 0 C--N 1.326 -0.426 0 C-N-CA 120.768 -0.373 . . . . 0.0 111.402 -179.753 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 45.0 mm -72.06 140.0 18.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 120.863 0.363 . . . . 0.0 111.23 -174.355 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 70' ' ' SER . . . . . 0.607 ' HB2' ' HB2' ' A' ' 73' ' ' GLU . 2.5 m -89.33 151.22 22.2 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.372 179.031 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.432 HG22 ' H ' ' A' ' 98' ' ' ALA . 48.9 t -73.91 118.2 19.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 120.988 0.423 . . . . 0.0 110.055 177.327 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 93.02 9.07 61.14 Favored Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 120.605 -0.807 . . . . 0.0 111.993 -179.073 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 73' ' ' GLU . . . . . 0.607 ' HB2' ' HB2' ' A' ' 70' ' ' SER . 35.7 tt0 -86.45 148.75 25.41 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 120.809 0.338 . . . . 0.0 110.092 179.626 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 74' ' ' VAL . . . . . 0.424 ' HA ' ' HA ' ' A' ' 87' ' ' LYS . 60.1 t -92.1 113.17 26.93 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 176.919 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 27.3 pt -108.62 154.45 9.93 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-O 121.314 0.578 . . . . 0.0 111.224 -177.441 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 76' ' ' ASN . . . . . 0.457 ' O ' ' HA ' ' A' ' 51' ' ' ILE . 6.0 t30 -95.85 127.26 41.72 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.151 178.382 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.562 HD12 HD21 ' A' ' 86' ' ' LEU . 54.3 mt -125.26 106.31 16.16 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 CA-C-O 121.288 0.566 . . . . 0.0 109.846 176.362 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 78' ' ' THR . . . . . 0.401 ' HB ' ' HB3' ' A' ' 49' ' ' GLU . 4.3 m -78.59 102.48 7.97 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 115.32 -0.854 . . . . 0.0 109.239 178.302 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 70.7 p -94.6 167.65 11.34 Favored 'General case' 0 C--N 1.323 -0.545 0 C-N-CA 120.474 -0.49 . . . . 0.0 110.697 -178.569 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 80' ' ' ASP . . . . . 0.46 ' HB2' ' HB ' ' A' ' 47' ' ' VAL . 23.8 t70 -52.52 -33.38 45.0 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.267 -0.878 . . . . 0.0 111.834 -179.858 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 79.7 mt-30 -118.73 28.0 8.57 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 112.185 0.439 . . . . 0.0 112.185 -173.481 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 150.18 151.29 5.49 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.208 -0.996 . . . . 0.0 113.487 173.854 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 26.4 m -94.81 106.72 18.72 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 109.697 -0.483 . . . . 0.0 109.697 176.361 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 84.8 m-85 -114.66 158.52 21.64 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.058 0.456 . . . . 0.0 110.874 -176.395 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 17.4 p-80 -123.66 129.13 50.65 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.814 -0.63 . . . . 0.0 109.508 173.141 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.562 HD21 HD12 ' A' ' 77' ' ' ILE . 0.6 OUTLIER -134.24 156.07 49.05 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 115.989 -0.55 . . . . 0.0 111.031 -176.614 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.424 ' HA ' ' HA ' ' A' ' 74' ' ' VAL . 58.8 tttm -96.35 131.59 42.73 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.675 -179.022 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 39.9 p -69.75 139.46 53.32 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-O 121.158 0.504 . . . . 0.0 111.127 178.714 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -80.65 175.71 54.81 Favored Glycine 0 N--CA 1.433 -1.564 0 N-CA-C 111.146 -0.782 . . . . 0.0 111.146 176.63 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.415 ' HA ' HG13 ' A' ' 71' ' ' VAL . 0.3 OUTLIER -90.72 163.89 14.33 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-O 121.079 0.466 . . . . 0.0 111.323 -176.027 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 91' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -80.63 136.25 52.04 Favored Pre-proline 0 C--N 1.324 -0.527 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.731 177.431 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -53.9 -57.46 1.87 Allowed 'Trans proline' 0 C--N 1.346 0.406 0 C-N-CA 122.843 2.362 . . . . 0.0 111.665 178.332 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 48.1 t-20 -125.86 -84.44 0.63 Allowed 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 174.211 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 15.6 t-20 -164.74 82.89 0.39 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.136 0.493 . . . . 0.0 110.503 176.23 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 41.4 t -141.94 -72.32 0.33 Allowed 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 109.326 -0.62 . . . . 0.0 109.326 175.727 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 27.6 m -98.24 128.57 44.76 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 175.119 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 1.1 mpt_? -108.53 147.84 31.15 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 -175.266 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 98' ' ' ALA . . . . . 0.432 ' H ' HG22 ' A' ' 71' ' ' VAL . . . 57.87 82.11 0.14 Allowed 'General case' 0 N--CA 1.465 0.281 0 O-C-N 123.793 0.683 . . . . 0.0 110.712 179.774 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -96.49 112.7 24.35 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.406 -171.413 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 100' ' ' MET . . . . . 0.596 ' HG2' ' H ' ' A' ' 102' ' ' ILE . 1.4 pmm? -63.5 -31.09 72.15 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.701 -179.498 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 104.73 1.46 42.91 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.466 -0.873 . . . . 0.0 113.295 175.898 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.802 HG22 HG22 ' A' ' 32' ' ' VAL . 2.8 pp -130.08 148.03 33.19 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.61 0 CA-C-O 121.003 0.43 . . . . 0.0 110.771 179.55 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 103' ' ' ARG . . . . . 0.572 ' HB3' ' HB3' ' A' ' 30' ' ' ASP . 1.0 OUTLIER -80.73 137.93 36.29 Favored 'General case' 0 C--N 1.321 -0.638 0 N-CA-C 108.242 -1.022 . . . . 0.0 108.242 172.89 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.7 m -112.25 153.23 27.44 Favored 'General case' 0 C--N 1.31 -1.14 0 CA-C-O 120.802 0.334 . . . . 0.0 110.394 -177.491 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 23.8 p -135.67 163.92 29.06 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 115.96 -0.564 . . . . 0.0 109.976 -179.873 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 106' ' ' ASN . . . . . 0.544 ' HB2' ' HG ' ' A' ' 59' ' ' LEU . 65.8 t30 -94.15 -25.33 17.17 Favored 'General case' 0 C--N 1.317 -0.839 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 -177.111 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 49.0 t-80 63.53 73.44 0.45 Allowed 'General case' 0 C--O 1.232 0.147 0 CA-C-N 114.799 -1.091 . . . . 0.0 111.562 175.971 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 96.0 mt -100.94 -167.28 1.41 Allowed 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.961 -0.563 . . . . 0.0 109.847 174.055 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 83.0 mtt180 -125.06 122.02 36.03 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.288 178.321 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 38.4 t -117.8 130.41 72.72 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 CA-C-N 115.595 -0.729 . . . . 0.0 110.623 -177.588 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 111' ' ' ARG . . . . . . . . . . . . . 42.8 ttm180 -86.77 117.93 25.84 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.25 176.78 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 7.9 p-10 -97.32 110.35 22.92 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.385 0.612 . . . . 0.0 109.691 178.011 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 50.5 m -118.43 96.19 5.19 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-N 115.844 -0.617 . . . . 0.0 110.309 176.467 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 17.1 m -83.29 115.19 25.26 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 CA-C-O 121.416 0.627 . . . . 0.0 110.569 178.3 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -137.11 82.18 1.92 Allowed 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.57 -0.741 . . . . 0.0 109.902 178.897 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 6.1 m -101.0 150.49 22.84 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-N 115.659 -0.7 . . . . 0.0 110.281 -177.176 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 27.7 m -81.56 127.76 39.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 CA-C-O 121.176 0.512 . . . . 0.0 110.081 174.328 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 81.2 mt -96.81 11.65 34.94 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.751 -176.112 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -100.84 124.09 8.14 Favored Glycine 0 N--CA 1.445 -0.706 0 C-N-CA 120.833 -0.698 . . . . 0.0 111.982 -179.249 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 6.3 p-10 -99.93 179.07 4.62 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 176.531 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 17.4 p -93.19 101.2 13.48 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 121.623 0.725 . . . . 0.0 111.603 -177.528 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 122' ' ' LEU . . . . . 0.424 ' H ' HD12 ' A' ' 122' ' ' LEU . 5.0 mp -80.89 130.25 64.43 Favored Pre-proline 0 C--N 1.324 -0.535 0 CA-C-N 115.461 -0.79 . . . . 0.0 110.139 176.801 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 23.9 Cg_exo -64.15 118.95 5.87 Favored 'Trans proline' 0 N--CA 1.46 -0.499 0 C-N-CA 122.51 2.14 . . . . 0.0 110.878 174.343 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 55.0 t80 -82.29 107.11 14.72 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.984 0.421 . . . . 0.0 110.33 -177.862 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.062 0 CA-C-O 118.306 -0.854 . . . . 0.0 109.781 178.019 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 23' ' ' GLN . . . . . . . . . . . . . 88.5 mt-30 . . . . . 0 CA--C 1.524 -0.034 0 CA-C-O 120.376 0.131 . . . . 0.0 110.689 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 21.9 Cg_exo -66.22 156.24 65.87 Favored 'Trans proline' 0 C--O 1.236 0.391 0 C-N-CA 123.051 2.5 . . . . 0.0 111.889 178.644 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -171.31 -41.31 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.99 0.424 . . . . 0.0 111.544 -175.53 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.548 ' HA2' ' HA ' ' A' ' 57' ' ' SER . . . 167.48 151.3 6.89 Favored Glycine 0 N--CA 1.446 -0.686 0 N-CA-C 111.247 -0.741 . . . . 0.0 111.247 -177.664 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.621 HG23 ' HB ' ' A' ' 48' ' ' ILE . 29.5 m -102.81 145.26 12.49 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-O 121.021 0.439 . . . . 0.0 110.82 -179.038 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 29.4 tt0 -115.82 150.18 37.38 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.704 -178.567 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.455 HD12 ' HB2' ' A' ' 46' ' ' LEU . 48.3 mt -76.85 107.94 8.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.011 178.003 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 22.5 t70 -62.29 -62.19 1.93 Allowed 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.551 0.691 . . . . 0.0 109.871 177.213 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 13.4 p -158.11 149.2 21.0 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.205 -0.907 . . . . 0.0 110.625 179.253 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.526 HG22 HG22 ' A' ' 102' ' ' ILE . 44.8 t -99.11 117.94 44.96 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 N-CA-C 109.519 -0.548 . . . . 0.0 109.519 177.272 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.503 ' HA ' ' HD3' ' A' ' 34' ' ' PRO . 11.9 m -80.91 117.37 67.75 Favored Pre-proline 0 N--CA 1.447 -0.594 0 CA-C-O 120.982 0.42 . . . . 0.0 110.572 -179.95 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' PRO . . . . . 0.503 ' HD3' ' HA ' ' A' ' 33' ' ' VAL . 16.7 Cg_exo -69.73 25.82 0.17 Allowed 'Trans proline' 0 N--CA 1.478 0.605 0 C-N-CA 123.918 3.079 . . . . 0.0 113.85 -174.208 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -120.56 15.08 9.87 Favored Glycine 0 N--CA 1.446 -0.636 0 N-CA-C 110.645 -0.982 . . . . 0.0 110.645 174.339 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 7.5 m -139.1 177.33 2.11 Favored Pre-proline 0 C--N 1.325 -0.477 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 -177.358 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 24.8 Cg_exo -64.9 -172.86 0.22 Allowed 'Trans proline' 0 C--N 1.35 0.656 0 C-N-CA 122.255 1.97 . . . . 0.0 112.214 174.107 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.605 ' HB2' HD11 ' A' ' 86' ' ' LEU . . . 72.38 -23.25 0.2 Allowed 'General case' 0 N--CA 1.47 0.538 0 C-N-CA 123.493 0.717 . . . . 0.0 112.867 177.108 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 37.0 m -61.64 -29.61 70.17 Favored 'General case' 0 CA--C 1.531 0.233 0 CA-C-O 121.018 0.437 . . . . 0.0 111.842 -176.439 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 17.0 tppt? -97.06 -6.01 36.2 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.003 0.43 . . . . 0.0 110.51 -178.843 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 46.9 t -102.06 -52.69 8.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.712 -174.117 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.456 HD11 ' HB1' ' A' ' 38' ' ' ALA . 1.2 pp -127.49 -177.54 4.12 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-O 121.366 0.603 . . . . 0.0 112.026 -175.343 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 2.9 p -125.09 151.96 69.92 Favored Pre-proline 0 C--N 1.32 -0.696 0 CA-C-N 115.008 -0.996 . . . . 0.0 110.62 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -70.47 156.01 62.37 Favored 'Trans proline' 0 C--N 1.343 0.278 0 C-N-CA 122.404 2.069 . . . . 0.0 112.191 178.457 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 100.11 -13.36 60.35 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.606 -0.807 . . . . 0.0 112.491 -178.56 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.455 ' HB2' HD12 ' A' ' 29' ' ' ILE . 91.9 mt -79.4 164.62 23.86 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.833 0.349 . . . . 0.0 110.803 179.597 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 48.4 t -105.98 135.12 45.45 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.528 -178.368 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.621 ' HB ' HG23 ' A' ' 27' ' ' VAL . 8.4 mm -88.14 100.38 10.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 175.758 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 57.1 mt-10 -78.31 -48.23 16.09 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.049 -177.624 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.585 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 5.4 p -159.92 145.81 15.66 Favored 'General case' 0 N--CA 1.447 -0.592 0 CA-C-O 121.203 0.525 . . . . 0.0 111.797 -176.895 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 67.9 mt -115.38 106.25 20.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-N 115.099 -0.955 . . . . 0.0 108.595 175.791 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 3.1 m-20 59.96 -152.14 0.4 Allowed 'General case' 0 C--O 1.236 0.392 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 -171.778 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -76.14 28.61 1.41 Allowed Glycine 0 CA--C 1.524 0.63 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.696 176.913 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 57.4 mtm -130.44 101.83 17.23 Favored Pre-proline 0 C--N 1.326 -0.414 0 N-CA-C 109.676 -0.49 . . . . 0.0 109.676 176.934 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.585 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 60.0 Cg_endo -72.19 150.99 54.48 Favored 'Trans proline' 0 N--CA 1.46 -0.494 0 C-N-CA 122.027 1.818 . . . . 0.0 112.306 179.972 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 56' ' ' THR . . . . . 0.426 ' O ' ' HA2' ' A' ' 26' ' ' GLY . 6.2 p -111.33 83.66 1.81 Allowed 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 121.242 0.544 . . . . 0.0 111.863 -177.326 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 57' ' ' SER . . . . . 0.548 ' HA ' ' HA2' ' A' ' 26' ' ' GLY . 20.9 m -91.11 -13.64 32.69 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.571 -0.74 . . . . 0.0 109.846 176.507 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 5.4 m120 -125.5 164.64 20.06 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.672 -0.694 . . . . 0.0 109.939 -177.877 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 41.5 mt -73.81 -31.75 63.4 Favored 'General case' 0 N--CA 1.446 -0.665 0 CA-C-O 121.516 0.674 . . . . 0.0 109.774 172.0 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -68.28 -40.54 81.79 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.176 -0.92 . . . . 0.0 111.734 178.891 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 12.6 p -60.9 -39.6 89.94 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.72 0.295 . . . . 0.0 110.959 175.857 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 87.3 t80 -62.04 -43.51 98.69 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-O 121.478 0.656 . . . . 0.0 109.676 175.948 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 61.4 m -65.1 -48.9 72.05 Favored 'General case' 0 N--CA 1.446 -0.638 0 CA-C-N 115.08 -0.964 . . . . 0.0 111.757 179.28 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.53 -32.45 73.91 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.97 -176.575 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' ALA . . . . . 0.611 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -70.5 -48.34 56.1 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.014 -0.539 . . . . 0.0 109.928 178.58 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.408 ' HA ' HD23 ' A' ' 66' ' ' LEU . 4.0 mt -63.81 -35.28 80.1 Favored 'General case' 0 N--CA 1.449 -0.477 0 CA-C-N 115.451 -0.795 . . . . 0.0 111.94 -176.438 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 59.8 mtpt -70.48 -21.98 62.71 Favored 'General case' 0 C--N 1.33 -0.273 0 N-CA-C 112.115 0.413 . . . . 0.0 112.115 -178.357 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 71.6 p -90.47 -13.54 34.56 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.864 0.364 . . . . 0.0 111.425 -179.636 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.611 HG12 ' O ' ' A' ' 65' ' ' ALA . 41.8 mm -79.85 143.8 11.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.449 -0.342 . . . . 0.0 110.599 -177.758 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 3.5 m -83.72 157.13 22.27 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 176.723 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 25.1 t -74.26 119.68 22.06 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 176.239 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 91.67 21.29 34.56 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.668 -0.777 . . . . 0.0 111.523 -177.422 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 29.9 tt0 -98.91 146.46 25.96 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 179.858 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 57.5 t -98.38 110.81 26.64 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.848 0 CA-C-O 121.052 0.453 . . . . 0.0 110.473 -178.134 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.536 HG13 HD11 ' A' ' 77' ' ' ILE . 23.3 pt -103.84 163.57 3.86 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.679 179.773 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 6.3 t30 -115.9 117.07 29.14 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.782 -177.219 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.536 HD11 HG13 ' A' ' 75' ' ' ILE . 4.6 mp -113.5 118.93 59.53 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-O 121.26 0.552 . . . . 0.0 110.293 -177.301 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 32.5 m -91.93 117.17 29.55 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.39 175.796 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 71.7 p -114.35 170.89 7.97 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 110.179 -0.304 . . . . 0.0 110.179 -179.928 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 9.0 t70 -53.68 -41.75 67.2 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.931 -0.577 . . . . 0.0 112.064 179.54 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 36.8 tp60 -109.15 31.09 5.98 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.906 0.384 . . . . 0.0 111.451 -171.487 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 140.28 176.17 14.94 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 120.133 -1.032 . . . . 0.0 113.12 173.384 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 7.0 m -117.5 123.89 47.42 Favored 'General case' 0 C--N 1.318 -0.775 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 178.802 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 66.4 m-85 -121.21 154.27 36.5 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.982 0.42 . . . . 0.0 110.726 -176.747 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 56.1 p-80 -111.3 130.88 55.53 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 108.989 -0.745 . . . . 0.0 108.989 173.185 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.605 HD11 ' HB2' ' A' ' 38' ' ' ALA . 3.8 tt -124.09 137.44 54.57 Favored 'General case' 0 C--N 1.311 -1.084 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.053 -172.634 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.457 ' N ' HD23 ' A' ' 86' ' ' LEU . 78.8 tttt -102.67 111.32 23.58 Favored 'General case' 0 C--N 1.311 -1.077 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 178.154 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.546 HG21 HG21 ' A' ' 69' ' ' ILE . 26.4 p -59.52 142.93 51.51 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.812 -0.631 . . . . 0.0 112.616 -172.405 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -133.03 -133.79 3.43 Favored Glycine 0 N--CA 1.443 -0.887 0 N-CA-C 111.017 -0.833 . . . . 0.0 111.017 176.824 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.474 ' HG3' ' HA ' ' A' ' 93' ' ' ASN . 0.0 OUTLIER -156.36 158.53 37.54 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 176.779 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 91' ' ' ASN . . . . . 0.763 ' HB3' ' HD3' ' A' ' 92' ' ' PRO . 26.2 t-20 -98.34 -57.73 0.16 Allowed Pre-proline 0 C--N 1.324 -0.501 0 CA-C-N 116.471 -0.331 . . . . 0.0 111.844 -176.998 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.763 ' HD3' ' HB3' ' A' ' 91' ' ' ASN . 6.9 Cg_exo -75.0 -27.07 10.32 Favored 'Trans proline' 0 C--N 1.353 0.773 0 C-N-CA 122.153 1.902 . . . . 0.0 112.508 -179.404 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 93' ' ' ASN . . . . . 0.474 ' HA ' ' HG3' ' A' ' 90' ' ' ARG . 8.6 t30 58.58 75.25 0.4 Allowed 'General case' 0 N--CA 1.466 0.338 0 CA-C-O 121.745 0.784 . . . . 0.0 110.223 -175.288 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 25.8 p-10 -144.73 44.92 1.38 Allowed 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 115.026 -0.988 . . . . 0.0 109.338 -178.094 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 42.3 m 57.21 74.18 0.43 Allowed 'General case' 0 CA--C 1.521 -0.159 0 N-CA-C 108.845 -0.798 . . . . 0.0 108.845 -168.78 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 1.8 m -106.89 -178.97 3.8 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.104 -0.953 . . . . 0.0 110.855 -170.442 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 39.0 ttm180 -103.22 169.16 8.72 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 172.724 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -45.15 116.22 1.07 Allowed 'General case' 0 N--CA 1.461 0.123 0 O-C-N 123.689 0.618 . . . . 0.0 112.167 -179.51 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 99' ' ' TYR . . . . . 0.446 ' HB3' ' HA ' ' A' ' 90' ' ' ARG . 18.6 t80 -120.98 135.55 55.19 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 178.05 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 49.6 ttm -77.35 -53.32 7.83 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.972 -178.231 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 117.31 17.07 5.84 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.162 -1.018 . . . . 0.0 113.398 176.88 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.526 HG22 HG22 ' A' ' 32' ' ' VAL . 39.0 pt -130.17 153.05 38.37 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-O 120.857 0.36 . . . . 0.0 110.67 179.342 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 42.8 mtp85 -82.01 123.36 28.83 Favored 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 108.185 -1.042 . . . . 0.0 108.185 168.191 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -113.77 148.97 35.59 Favored 'General case' 0 C--N 1.314 -0.956 0 C-N-CA 120.643 -0.423 . . . . 0.0 110.479 -177.965 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 54.0 m -155.33 160.29 40.63 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 176.917 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 106' ' ' ASN . . . . . 0.676 ' HB3' ' HG ' ' A' ' 108' ' ' LEU . 86.8 m-20 -70.09 -33.22 71.61 Favored 'General case' 0 C--N 1.317 -0.83 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 177.604 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 47.7 t-80 53.26 39.93 30.5 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-N 115.338 -0.846 . . . . 0.0 109.793 179.823 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 108' ' ' LEU . . . . . 0.676 ' HG ' ' HB3' ' A' ' 106' ' ' ASN . 67.3 mt -71.32 172.82 8.69 Favored 'General case' 0 CA--C 1.511 -0.531 0 CA-C-N 115.424 -0.807 . . . . 0.0 111.284 -177.403 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 71.6 mtm180 -78.43 151.79 32.53 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-N 114.817 -1.083 . . . . 0.0 110.497 179.627 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 8.1 p -82.2 140.34 16.58 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 CA-C-O 121.711 0.767 . . . . 0.0 111.899 -172.333 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 111' ' ' ARG . . . . . . . . . . . . . 33.8 ttt85 -134.1 145.01 48.93 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.0 -1.0 . . . . 0.0 108.716 173.202 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 19.0 p-10 -82.32 27.03 0.51 Allowed 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 112.307 0.484 . . . . 0.0 112.307 -171.109 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 36.9 m -91.38 74.2 6.08 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 175.758 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 17.5 m -67.64 128.91 31.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.866 -174.406 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -151.77 124.94 8.7 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.606 -0.724 . . . . 0.0 110.25 178.714 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 42.4 m -140.26 61.65 1.52 Allowed 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.55 0.69 . . . . 0.0 109.507 177.335 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 117' ' ' VAL . . . . . 0.449 HG12 ' H ' ' A' ' 119' ' ' GLY . 31.1 t -102.3 142.17 17.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-N 115.263 -0.88 . . . . 0.0 110.118 -175.922 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 80.3 mt -82.21 -33.73 29.25 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.398 -0.364 . . . . 0.0 110.674 -178.557 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 119' ' ' GLY . . . . . 0.449 ' H ' HG12 ' A' ' 117' ' ' VAL . . . 71.96 54.85 7.71 Favored Glycine 0 N--CA 1.445 -0.725 0 N-CA-C 110.635 -0.986 . . . . 0.0 110.635 -175.789 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 11.8 m-20 -71.5 124.94 25.76 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.212 0.529 . . . . 0.0 111.644 -172.6 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 4.5 t -125.16 108.42 11.75 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.635 -0.711 . . . . 0.0 109.177 172.597 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 88.6 mt -73.23 123.28 89.35 Favored Pre-proline 0 C--N 1.327 -0.41 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.991 -177.011 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_exo -66.82 143.26 66.35 Favored 'Trans proline' 0 C--O 1.235 0.346 0 C-N-CA 122.955 2.437 . . . . 0.0 112.222 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 39.6 t80 -96.49 96.75 8.91 Favored 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 177.809 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.084 0 CA-C-O 118.248 -0.882 . . . . 0.0 110.828 -175.686 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.753 ' HB2' HD23 ' A' ' 108' ' ' LEU . 31.5 mt-30 . . . . . 0 CA--C 1.526 0.049 0 CA-C-O 120.601 0.238 . . . . 0.0 111.093 . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 89.9 Cg_endo -99.74 159.33 0.55 Allowed 'Trans proline' 0 N--CA 1.447 -1.245 0 C-N-CA 122.958 2.439 . . . . 0.0 112.019 173.672 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.528 ' HB3' ' HD2' ' A' ' 107' ' ' HIS . 35.9 t70 -178.05 30.61 0.0 OUTLIER 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 177.865 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 90.44 128.39 3.78 Favored Glycine 0 N--CA 1.443 -0.9 0 CA-C-N 115.38 -0.827 . . . . 0.0 111.696 -175.664 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.53 HG23 ' HB ' ' A' ' 48' ' ' ILE . 4.6 m -69.28 141.56 17.17 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 N-CA-C 109.605 -0.516 . . . . 0.0 109.605 178.728 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' GLN . . . . . 0.446 ' HB3' HG13 ' A' ' 47' ' ' VAL . 8.3 pt20 -125.45 152.99 44.16 Favored 'General case' 0 C--N 1.319 -0.736 0 C-N-CA 119.17 -1.012 . . . . 0.0 111.879 -178.698 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.415 HG12 HD12 ' A' ' 102' ' ' ILE . 50.1 mt -77.32 130.81 35.83 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.61 0 CA-C-N 115.23 -0.896 . . . . 0.0 110.82 -178.784 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -89.94 -50.27 6.13 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.244 174.954 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 23.6 p -161.96 166.78 25.6 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 116.587 -0.279 . . . . 0.0 110.917 -179.301 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.488 HG13 HG22 ' A' ' 102' ' ' ILE . 45.8 t -110.38 140.36 29.78 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 N-CA-C 109.365 -0.605 . . . . 0.0 109.365 174.755 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 7.1 p -60.78 140.12 93.28 Favored Pre-proline 0 CA--C 1.537 0.473 0 N-CA-C 110.317 -0.253 . . . . 0.0 110.317 179.735 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 15.7 Cg_exo -69.46 65.39 1.62 Allowed 'Trans proline' 0 C--N 1.348 0.5 0 C-N-CA 122.925 2.416 . . . . 0.0 112.173 176.175 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 165.59 -169.26 39.92 Favored Glycine 0 N--CA 1.446 -0.7 0 N-CA-C 111.34 -0.704 . . . . 0.0 111.34 -179.707 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.773 ' HB2' ' HD2' ' A' ' 37' ' ' PRO . 60.6 p 56.39 179.46 0.03 OUTLIER Pre-proline 0 CA--C 1.545 0.761 0 C-N-CA 123.448 0.699 . . . . 0.0 111.513 179.432 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 37' ' ' PRO . . . . . 0.773 ' HD2' ' HB2' ' A' ' 36' ' ' SER . 58.4 Cg_endo -73.1 -159.45 0.08 OUTLIER 'Trans proline' 0 C--N 1.349 0.586 0 C-N-CA 121.967 1.778 . . . . 0.0 111.636 169.712 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.472 ' HB2' HD11 ' A' ' 86' ' ' LEU . . . 77.36 -33.43 0.19 Allowed 'General case' 0 N--CA 1.471 0.612 0 C-N-CA 123.395 0.678 . . . . 0.0 112.321 172.712 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 35.0 t -65.15 -21.18 66.75 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.595 -0.275 . . . . 0.0 111.082 -178.884 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 61.9 mttp -99.35 -0.06 41.86 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.918 0.39 . . . . 0.0 110.378 178.273 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.512 ' HB ' HD12 ' A' ' 42' ' ' LEU . 45.9 t -105.08 -53.73 6.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.899 -175.928 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.512 HD12 ' HB ' ' A' ' 41' ' ' VAL . 5.2 mp -106.88 164.08 12.42 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.997 0.427 . . . . 0.0 110.55 -178.578 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 43' ' ' THR . . . . . 0.449 ' O ' ' HG ' ' A' ' 46' ' ' LEU . 40.1 m -109.42 124.46 33.81 Favored Pre-proline 0 C--N 1.319 -0.729 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.87 177.109 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo -59.36 134.48 58.99 Favored 'Trans proline' 0 N--CA 1.46 -0.468 0 C-N-CA 122.277 1.985 . . . . 0.0 111.965 177.834 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 107.93 -16.52 36.28 Favored Glycine 0 N--CA 1.446 -0.638 0 C-N-CA 120.631 -0.795 . . . . 0.0 112.976 -179.695 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.449 ' HG ' ' O ' ' A' ' 43' ' ' THR . 75.6 mt -71.89 164.16 26.55 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.844 0.354 . . . . 0.0 110.642 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.446 HG13 ' HB3' ' A' ' 28' ' ' GLN . 23.1 t -107.46 142.63 19.72 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 116.194 -0.457 . . . . 0.0 109.939 179.8 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.53 ' HB ' HG23 ' A' ' 27' ' ' VAL . 10.6 mm -84.68 125.7 40.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 179.625 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -90.23 -54.05 4.19 Favored 'General case' 0 C--N 1.321 -0.674 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 176.143 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.444 ' CB ' ' HA ' ' A' ' 55' ' ' PRO . 20.6 m -154.44 152.63 30.37 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.419 -174.536 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.473 HG22 ' N ' ' A' ' 52' ' ' ASN . 46.3 mm -99.47 167.27 1.96 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.823 0 N-CA-C 107.64 -1.245 . . . . 0.0 107.64 171.871 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 52' ' ' ASN . . . . . 0.657 ' HB2' ' H ' ' A' ' 76' ' ' ASN . 54.1 t30 -50.51 103.44 0.05 Allowed 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 112.304 0.483 . . . . 0.0 112.304 -176.86 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 83.18 -15.36 34.05 Favored Glycine 0 N--CA 1.451 -0.343 0 CA-C-N 115.898 -0.592 . . . . 0.0 113.053 176.993 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 40.7 mtm -130.29 106.95 16.12 Favored Pre-proline 0 C--N 1.326 -0.447 0 O-C-N 122.643 -0.328 . . . . 0.0 110.87 -173.518 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.444 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 42.5 Cg_endo -68.06 148.96 76.61 Favored 'Trans proline' 0 C--N 1.343 0.242 0 C-N-CA 122.552 2.168 . . . . 0.0 112.199 -179.726 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 20.8 p -126.82 97.02 4.83 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 112.102 0.408 . . . . 0.0 112.102 -175.532 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 22.9 t -102.01 -14.18 17.26 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 121.362 0.601 . . . . 0.0 109.734 174.871 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 32.3 m-80 -124.29 167.36 14.43 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.174 -178.57 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 1.6 mt -68.99 -35.27 76.52 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.322 -0.399 . . . . 0.0 109.97 173.387 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 19.5 m -64.11 -38.8 92.36 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.219 179.472 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 3.3 p -66.98 -33.32 75.32 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 120.804 0.335 . . . . 0.0 110.887 178.566 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 55.2 t80 -71.63 -35.14 70.33 Favored 'General case' 0 C--N 1.331 -0.217 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 176.29 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 69.0 m -66.62 -50.06 64.23 Favored 'General case' 0 N--CA 1.444 -0.729 0 CA-C-N 115.365 -0.834 . . . . 0.0 111.296 178.39 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 64' ' ' ALA . . . . . 0.415 ' O ' ' HG2' ' A' ' 67' ' ' LYS . . . -63.43 -31.96 73.26 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.747 -0.661 . . . . 0.0 111.39 -178.194 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 65' ' ' ALA . . . . . 0.474 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -76.93 -34.61 57.65 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.161 0.505 . . . . 0.0 110.639 -179.842 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 1.5 tt -68.71 -44.18 74.45 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.892 -177.445 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 67' ' ' LYS . . . . . 0.415 ' HG2' ' O ' ' A' ' 64' ' ' ALA . 14.6 ptmm? -60.43 -23.47 64.43 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.924 -174.044 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 17.7 p -87.53 -14.15 41.08 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 112.043 0.386 . . . . 0.0 112.043 -179.869 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.474 HG12 ' O ' ' A' ' 65' ' ' ALA . 21.7 mm -85.65 136.81 22.03 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-O 120.84 0.352 . . . . 0.0 110.601 -177.87 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 70' ' ' SER . . . . . 0.654 ' HA ' ' HD2' ' A' ' 97' ' ' ARG . 50.9 m -106.92 162.49 13.78 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.669 178.762 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.782 HG23 ' HB2' ' A' ' 97' ' ' ARG . 79.4 t -62.01 135.22 26.83 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.249 0 O-C-N 123.436 0.46 . . . . 0.0 110.518 175.353 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 94.33 -14.94 64.32 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.873 -0.68 . . . . 0.0 112.655 176.001 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 -80.29 150.3 30.03 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.128 0.49 . . . . 0.0 110.385 -177.379 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 47.3 t -106.34 124.76 61.94 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 CA-C-N 115.67 -0.696 . . . . 0.0 109.643 179.099 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.405 HG21 HD12 ' A' ' 69' ' ' ILE . 18.3 pt -119.6 157.34 21.78 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 121.377 0.608 . . . . 0.0 111.886 -176.749 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 76' ' ' ASN . . . . . 0.657 ' H ' ' HB2' ' A' ' 52' ' ' ASN . 4.5 t30 -99.08 127.16 44.97 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 114.861 -1.063 . . . . 0.0 110.034 179.43 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 72.4 mt -132.36 112.64 19.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-O 121.088 0.47 . . . . 0.0 110.514 -177.471 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 78' ' ' THR . . . . . 0.557 ' HA ' ' HA ' ' A' ' 83' ' ' THR . 93.0 m -91.0 124.72 35.45 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.146 177.32 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 50.8 p -107.77 173.31 6.38 Favored 'General case' 0 C--N 1.319 -0.747 0 N-CA-C 109.457 -0.572 . . . . 0.0 109.457 174.703 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -63.17 -24.43 67.88 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 120.979 0.418 . . . . 0.0 111.259 -178.954 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 -106.77 16.86 23.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.444 -0.344 . . . . 0.0 111.606 -177.74 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 134.08 166.76 11.36 Favored Glycine 0 CA--C 1.516 0.123 0 C-N-CA 120.176 -1.011 . . . . 0.0 113.255 176.035 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.557 ' HA ' ' HA ' ' A' ' 78' ' ' THR . 35.2 m -98.07 137.83 36.27 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 120.934 0.397 . . . . 0.0 111.204 -179.709 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 74.9 m-85 -130.42 158.32 40.19 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.051 177.517 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 48.2 p-80 -112.43 130.39 56.0 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 174.401 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.472 HD11 ' HB2' ' A' ' 38' ' ' ALA . 28.4 tp -118.19 152.06 36.41 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.989 -173.01 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 60.4 tttp -119.95 123.82 44.47 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 178.152 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 25.7 p -72.62 137.48 46.14 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.325 0.583 . . . . 0.0 111.613 -177.613 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 89' ' ' GLY . . . . . 0.599 ' H ' ' HE1' ' A' ' 99' ' ' TYR . . . -106.22 -157.33 21.81 Favored Glycine 0 N--CA 1.448 -0.515 0 CA-C-N 115.642 -0.708 . . . . 0.0 111.797 177.123 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.567 ' O ' ' HD3' ' A' ' 92' ' ' PRO . 0.3 OUTLIER -137.0 35.55 2.58 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.725 0.298 . . . . 0.0 111.598 -170.45 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 91' ' ' ASN . . . . . . . . . . . . . 5.0 t30 -106.71 84.81 1.6 Allowed Pre-proline 0 C--N 1.325 -0.481 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 173.165 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.617 ' HB3' ' O ' ' A' ' 96' ' ' SER . 10.2 Cg_endo -88.92 174.69 3.77 Favored 'Trans proline' 0 N--CA 1.456 -0.699 0 C-N-CA 123.133 2.555 . . . . 0.0 113.118 -171.299 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 19.9 t-20 -78.49 -46.93 18.46 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 174.688 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 27.2 t-20 -139.16 -69.89 0.42 Allowed 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.367 -0.833 . . . . 0.0 109.762 173.26 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 45.1 m -135.08 21.43 3.47 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.103 0.478 . . . . 0.0 110.557 179.529 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.617 ' O ' ' HB3' ' A' ' 92' ' ' PRO . 3.0 p -84.07 112.43 20.21 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.807 -177.077 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 97' ' ' ARG . . . . . 0.782 ' HB2' HG23 ' A' ' 71' ' ' VAL . 9.1 ptt180 -76.61 159.93 29.85 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 176.187 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . 56.72 70.73 0.62 Allowed 'General case' 0 CA--C 1.521 -0.143 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 -174.791 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 99' ' ' TYR . . . . . 0.599 ' HE1' ' H ' ' A' ' 89' ' ' GLY . 6.2 p90 -67.14 -30.48 70.48 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 114.76 -1.109 . . . . 0.0 113.631 -160.575 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 24.3 mmt 60.45 95.56 0.03 OUTLIER 'General case' 0 N--CA 1.465 0.279 0 CA-C-O 121.313 0.578 . . . . 0.0 110.501 -173.356 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -83.75 29.2 3.77 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.829 -0.701 . . . . 0.0 112.846 -175.362 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.488 HG22 HG13 ' A' ' 32' ' ' VAL . 37.4 pt -136.94 154.54 31.54 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.742 0 CA-C-O 121.066 0.46 . . . . 0.0 109.988 -179.689 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 103' ' ' ARG . . . . . 0.424 ' HD3' ' HA ' ' A' ' 103' ' ' ARG . 7.8 tpp180 -92.8 144.52 25.2 Favored 'General case' 0 C--N 1.315 -0.908 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 175.809 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.4 t -145.47 154.68 42.5 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-O 121.417 0.627 . . . . 0.0 111.266 178.443 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 9.3 p -128.6 171.44 12.15 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-N 114.643 -1.162 . . . . 0.0 109.884 177.838 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 59.6 t30 -88.96 3.62 50.93 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.579 -174.348 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 107' ' ' HIS . . . . . 0.528 ' HD2' ' HB3' ' A' ' 25' ' ' ASP . 81.7 t60 65.51 37.34 6.12 Favored 'General case' 0 CA--C 1.535 0.37 0 CA-C-O 121.792 0.806 . . . . 0.0 109.948 -178.199 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 108' ' ' LEU . . . . . 0.753 HD23 ' HB2' ' A' ' 23' ' ' GLN . 34.6 mt -68.56 167.67 14.52 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.306 -0.861 . . . . 0.0 110.925 176.902 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -110.56 91.74 3.77 Favored 'General case' 0 C--N 1.313 -1.015 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 177.795 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 81.5 t -104.5 142.77 17.21 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.803 0 CA-C-N 115.318 -0.856 . . . . 0.0 110.711 -175.79 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 111' ' ' ARG . . . . . . . . . . . . . 54.8 ttt180 -69.21 148.2 50.19 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.847 -0.615 . . . . 0.0 109.493 176.009 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -53.97 98.35 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.186 0.517 . . . . 0.0 111.58 -177.951 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 4.8 m -140.98 101.25 4.0 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.062 -0.972 . . . . 0.0 108.941 177.425 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 6.4 m -105.78 108.72 25.71 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-O 121.439 0.638 . . . . 0.0 111.795 -175.217 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -148.42 91.42 1.9 Allowed 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.328 -0.851 . . . . 0.0 109.973 176.98 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 46.1 m -140.78 31.13 1.84 Allowed 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.336 0.589 . . . . 0.0 110.491 -178.578 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 4.5 m -76.24 91.63 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-O 121.573 0.701 . . . . 0.0 111.274 -178.958 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 86.2 mt -82.02 -53.85 5.79 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.61 -0.723 . . . . 0.0 109.97 176.759 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 99.06 -160.87 20.04 Favored Glycine 0 N--CA 1.444 -0.789 0 CA-C-N 115.564 -0.744 . . . . 0.0 112.203 179.202 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 37.0 t70 67.69 160.29 0.16 Allowed 'General case' 0 C--O 1.235 0.31 0 C-N-CA 123.529 0.732 . . . . 0.0 111.828 178.958 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 121' ' ' THR . . . . . 0.52 ' O ' ' HD3' ' A' ' 123' ' ' PRO . 4.7 t -134.35 126.6 29.97 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 115.33 -0.85 . . . . 0.0 109.101 175.172 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 87.7 mt -111.46 93.96 21.08 Favored Pre-proline 0 C--N 1.324 -0.528 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.558 -176.646 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 123' ' ' PRO . . . . . 0.52 ' HD3' ' O ' ' A' ' 121' ' ' THR . 9.7 Cg_endo -91.0 109.58 0.33 Allowed 'Trans proline' 0 N--CA 1.449 -1.139 0 C-N-CA 123.379 2.719 . . . . 0.0 111.228 172.506 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 37.8 p90 -92.04 107.64 19.35 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.516 0.674 . . . . 0.0 110.965 -178.278 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.967 0 CA-C-O 118.125 -0.941 . . . . 0.0 109.564 177.102 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 23' ' ' GLN . . . . . . . . . . . . . 51.1 tp60 . . . . . 0 N--CA 1.455 -0.2 0 N-CA-C 110.1 -0.333 . . . . 0.0 110.1 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_exo -61.58 118.4 5.27 Favored 'Trans proline' 0 C--O 1.235 0.372 0 C-N-CA 122.869 2.379 . . . . 0.0 111.349 174.506 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 28.5 p-10 -119.68 -23.88 6.39 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 115.941 -0.572 . . . . 0.0 112.135 -169.724 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 96.53 133.02 7.5 Favored Glycine 0 N--CA 1.446 -0.689 0 N-CA-C 111.15 -0.78 . . . . 0.0 111.15 -176.953 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.447 ' HA ' ' HA ' ' A' ' 106' ' ' ASN . 19.6 m -78.78 140.4 16.94 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.742 0 CA-C-O 120.98 0.419 . . . . 0.0 110.842 -176.93 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' GLN . . . . . 0.48 ' HB2' ' O ' ' A' ' 46' ' ' LEU . 2.8 pt20 -109.84 157.59 19.04 Favored 'General case' 0 C--N 1.317 -0.823 0 C-N-CA 120.22 -0.592 . . . . 0.0 109.778 175.662 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.551 HG23 HD11 ' A' ' 48' ' ' ILE . 2.2 pt -79.84 98.49 3.26 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.14 176.523 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -53.78 -55.64 24.62 Favored 'General case' 0 CA--C 1.504 -0.816 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.13 177.509 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 6.2 p -155.99 144.56 20.18 Favored 'General case' 0 N--CA 1.441 -0.908 0 CA-C-N 115.045 -0.979 . . . . 0.0 111.438 -178.152 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.603 ' HA ' HG22 ' A' ' 102' ' ' ILE . 52.3 t -87.62 141.34 14.46 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.01 0 CA-C-N 114.965 -1.016 . . . . 0.0 108.664 171.651 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 48.3 t -83.18 105.38 5.12 Favored Pre-proline 0 C--N 1.322 -0.592 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 174.937 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 34' ' ' PRO . . . . . 0.505 ' HD3' ' O ' ' A' ' 32' ' ' VAL . 31.5 Cg_exo -58.19 113.64 1.62 Allowed 'Trans proline' 0 C--O 1.236 0.406 0 C-N-CA 122.774 2.316 . . . . 0.0 112.179 -175.305 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 133.61 -20.84 4.08 Favored Glycine 0 N--CA 1.446 -0.687 0 N-CA-C 111.227 -0.749 . . . . 0.0 111.227 -178.455 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 56.4 p -81.87 161.13 61.89 Favored Pre-proline 0 C--N 1.323 -0.575 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 177.692 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -59.03 -24.83 75.31 Favored 'Trans proline' 0 C--N 1.344 0.312 0 C-N-CA 122.36 2.04 . . . . 0.0 111.743 175.96 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.404 ' HB2' HD11 ' A' ' 86' ' ' LEU . . . -66.78 -27.86 67.93 Favored 'General case' 0 N--CA 1.454 -0.24 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.553 -179.359 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.533 ' HA ' HG11 ' A' ' 32' ' ' VAL . 13.2 m -63.2 -22.39 66.84 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.91 0.386 . . . . 0.0 111.454 -177.65 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 65.3 mttm -97.27 -17.58 19.72 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.487 -175.76 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.65 ' HB ' HD23 ' A' ' 42' ' ' LEU . 60.6 t -98.23 -49.52 11.68 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.871 -172.354 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.65 HD23 ' HB ' ' A' ' 41' ' ' VAL . 0.3 OUTLIER -117.12 178.23 4.43 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.561 0.696 . . . . 0.0 112.343 -173.745 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 56.8 m -128.42 128.99 23.6 Favored Pre-proline 0 C--N 1.322 -0.602 0 CA-C-N 114.693 -1.14 . . . . 0.0 109.593 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -64.66 152.95 79.96 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.611 2.207 . . . . 0.0 112.305 -177.643 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 99.82 -1.92 56.85 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.553 -0.832 . . . . 0.0 112.582 -178.024 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.495 ' HB2' HD11 ' A' ' 29' ' ' ILE . 85.1 mt -89.81 164.15 14.75 Favored 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 110.286 -0.264 . . . . 0.0 110.286 177.271 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 40.4 t -103.27 141.1 19.77 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 178.005 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.551 HD11 HG23 ' A' ' 29' ' ' ILE . 57.5 mt -99.76 120.23 48.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 121.051 0.453 . . . . 0.0 110.0 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 14.5 tt0 -78.81 -56.23 4.57 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 121.489 0.661 . . . . 0.0 109.834 176.781 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.677 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 11.8 p -146.89 149.15 32.68 Favored 'General case' 0 N--CA 1.444 -0.741 0 CA-C-N 115.342 -0.844 . . . . 0.0 112.551 -171.001 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.538 ' HA ' ' O ' ' A' ' 76' ' ' ASN . 55.4 mt -126.7 114.03 35.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 114.561 -1.2 . . . . 0.0 108.573 172.751 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 6.4 t-20 63.13 -152.65 0.33 Allowed 'General case' 0 CA--C 1.532 0.278 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 -171.01 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -76.84 3.61 55.82 Favored Glycine 0 CA--C 1.52 0.392 0 C-N-CA 120.533 -0.841 . . . . 0.0 112.97 179.509 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 3.8 mpp? -111.76 105.39 56.59 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 120.725 0.298 . . . . 0.0 110.76 -178.894 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.677 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 47.0 Cg_endo -69.3 148.57 68.35 Favored 'Trans proline' 0 N--CA 1.462 -0.362 0 C-N-CA 122.303 2.002 . . . . 0.0 112.186 176.243 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 20.8 p -109.96 95.71 5.77 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.663 -176.484 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 14.7 p -92.85 -19.87 21.26 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.059 0.457 . . . . 0.0 110.738 177.367 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 93.3 m-20 -125.56 173.52 8.89 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 178.153 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -82.48 -33.53 28.35 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 121.225 0.536 . . . . 0.0 110.257 176.683 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 6.1 m -70.08 -29.54 66.55 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.043 179.344 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 24.6 p -67.82 -38.5 83.32 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 121.136 0.493 . . . . 0.0 109.999 176.34 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 67.2 t80 -59.26 -44.15 92.41 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-N 115.437 -0.801 . . . . 0.0 109.709 173.475 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 63' ' ' SER . . . . . 0.423 ' O ' ' HG3' ' A' ' 67' ' ' LYS . 70.3 m -63.71 -46.09 87.03 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.135 -0.938 . . . . 0.0 111.832 179.314 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.85 -33.68 74.62 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.118 179.652 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 65' ' ' ALA . . . . . 0.416 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -77.77 -36.17 50.83 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.147 0.499 . . . . 0.0 110.194 178.586 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -60.61 -29.91 69.52 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.139 179.124 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 67' ' ' LYS . . . . . 0.423 ' HG3' ' O ' ' A' ' 63' ' ' SER . 58.7 mtpt -58.79 -32.46 69.34 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.448 178.63 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 34.8 p -91.06 -14.71 30.8 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 112.216 0.45 . . . . 0.0 112.216 -175.991 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.416 HG12 ' O ' ' A' ' 65' ' ' ALA . 30.5 mm -82.26 140.53 16.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 N-CA-C 110.283 -0.266 . . . . 0.0 110.283 -177.695 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 14.3 t -115.64 178.04 4.45 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 120.958 0.409 . . . . 0.0 110.849 -179.575 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.457 ' CG1' ' HD2' ' A' ' 90' ' ' ARG . 20.9 t -79.99 120.78 32.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.858 -178.105 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 98.17 5.65 57.12 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.645 -0.788 . . . . 0.0 111.879 -179.815 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 15.2 tp10 -81.36 147.98 29.57 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.301 -0.45 . . . . 0.0 109.913 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 57.3 t -109.38 108.95 26.61 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.856 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.37 179.252 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 21.6 pt -109.84 153.84 11.5 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.773 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.193 -175.375 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 76' ' ' ASN . . . . . 0.538 ' O ' ' HA ' ' A' ' 51' ' ' ILE . 5.4 t30 -90.07 132.16 35.55 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.647 177.633 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.418 HG22 HG23 ' A' ' 79' ' ' THR . 61.7 mt -128.53 116.5 41.83 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-O 121.295 0.569 . . . . 0.0 110.465 -179.645 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 4.6 m -99.3 102.25 13.81 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.141 177.783 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.483 HG22 HG12 ' A' ' 48' ' ' ILE . 73.4 p -102.16 170.15 8.28 Favored 'General case' 0 C--N 1.324 -0.519 0 C-N-CA 120.674 -0.41 . . . . 0.0 110.296 178.081 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -51.07 -38.76 53.55 Favored 'General case' 0 N--CA 1.466 0.365 0 O-C-N 123.801 0.688 . . . . 0.0 112.649 -176.279 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 31.4 mt-30 -127.44 20.25 6.74 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 111.92 0.341 . . . . 0.0 111.92 -174.659 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -165.68 119.96 0.9 Allowed Glycine 0 N--CA 1.446 -0.653 0 C-N-CA 119.751 -1.214 . . . . 0.0 113.465 179.04 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 13.6 m -106.3 109.21 21.07 Favored 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 172.479 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 84' ' ' PHE . . . . . 0.453 ' CZ ' ' HB3' ' A' ' 42' ' ' LEU . 7.3 p90 -145.68 177.46 8.87 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 121.225 0.536 . . . . 0.0 111.807 -172.972 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -111.9 150.82 29.93 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.388 -0.823 . . . . 0.0 109.756 172.055 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.439 HD22 ' HG3' ' A' ' 100' ' ' MET . 7.5 tt -134.11 141.39 47.11 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-O 121.218 0.533 . . . . 0.0 110.706 -176.81 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 82.3 tttt -94.21 116.38 28.77 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.044 -0.98 . . . . 0.0 109.275 177.51 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 32.1 p -59.25 123.49 16.87 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.584 0.707 . . . . 0.0 111.414 -176.934 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -96.42 175.38 31.75 Favored Glycine 0 N--CA 1.434 -1.453 0 CA-C-N 114.991 -1.004 . . . . 0.0 111.403 -178.363 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 90' ' ' ARG . . . . . 0.499 ' HD3' ' N ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -144.06 75.64 1.47 Allowed 'General case' 0 C--N 1.314 -0.939 0 CA-C-O 121.427 0.632 . . . . 0.0 110.293 -178.092 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 91' ' ' ASN . . . . . 0.423 ' N ' ' HD2' ' A' ' 92' ' ' PRO . 17.6 m120 -62.0 -48.54 88.33 Favored Pre-proline 0 C--N 1.327 -0.382 0 CA-C-N 115.789 -0.641 . . . . 0.0 109.687 174.009 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.423 ' HD2' ' N ' ' A' ' 91' ' ' ASN . 56.9 Cg_endo -73.41 128.63 12.97 Favored 'Trans proline' 0 C--N 1.352 0.749 0 C-N-CA 121.614 1.543 . . . . 0.0 110.727 166.615 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -103.89 -25.86 12.89 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 120.915 0.388 . . . . 0.0 110.074 -175.654 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 10.4 t30 -78.85 121.06 24.34 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 174.833 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 22.8 t 67.79 78.09 0.24 Allowed 'General case' 0 C--O 1.234 0.272 0 O-C-N 124.028 0.83 . . . . 0.0 109.038 -173.287 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 11.0 m -69.79 119.55 14.19 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.188 -0.914 . . . . 0.0 111.127 -174.865 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 7.5 ptt85 -149.99 161.61 41.99 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 115.629 -0.714 . . . . 0.0 109.917 175.198 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -58.25 118.25 5.29 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.565 -179.309 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 69.8 t80 -110.88 -23.84 10.76 Favored 'General case' 0 C--N 1.323 -0.559 0 C-N-CA 120.746 -0.382 . . . . 0.0 110.465 -178.21 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 100' ' ' MET . . . . . 0.439 ' HG3' HD22 ' A' ' 86' ' ' LEU . 44.3 ttm 70.63 -59.96 0.51 Allowed 'General case' 0 N--CA 1.468 0.455 0 CA-C-N 115.551 -0.749 . . . . 0.0 111.184 179.46 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 124.21 9.31 5.63 Favored Glycine 0 C--O 1.227 -0.326 0 C-N-CA 121.023 -0.608 . . . . 0.0 113.11 178.259 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.603 HG22 ' HA ' ' A' ' 32' ' ' VAL . 2.8 pp -136.97 165.71 27.4 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-O 120.909 0.385 . . . . 0.0 110.51 -179.028 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 103' ' ' ARG . . . . . 0.428 ' HD3' ' HA ' ' A' ' 103' ' ' ARG . 9.1 mmt180 -114.63 129.63 56.7 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.12 172.023 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 104' ' ' THR . . . . . 0.591 HG23 HD13 ' A' ' 102' ' ' ILE . 3.1 p -110.05 143.19 40.43 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.007 0.432 . . . . 0.0 111.724 -177.836 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 18.0 m -151.24 151.11 31.4 Favored 'General case' 0 C--N 1.318 -0.765 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 173.487 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 106' ' ' ASN . . . . . 0.447 ' HA ' ' HA ' ' A' ' 27' ' ' VAL . 13.4 m120 -69.1 -30.99 69.4 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-O 121.653 0.74 . . . . 0.0 109.845 -178.203 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 4.7 t-160 59.58 36.86 22.8 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 114.449 -1.25 . . . . 0.0 109.494 -170.93 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 13.5 mt -58.45 157.53 8.72 Favored 'General case' 0 CA--C 1.516 -0.34 0 CA-C-N 115.781 -0.645 . . . . 0.0 109.82 174.768 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -66.15 132.76 49.23 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.088 -177.205 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 11.3 p -55.96 139.06 15.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 115.389 -0.823 . . . . 0.0 111.867 -174.738 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 111' ' ' ARG . . . . . . . . . . . . . 20.1 ptt180 -130.6 146.83 52.19 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.157 -0.929 . . . . 0.0 110.123 -179.43 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 34.2 t70 -116.69 99.13 6.91 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-O 121.111 0.481 . . . . 0.0 109.712 176.04 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 14.9 m -146.49 124.58 12.11 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.539 -0.755 . . . . 0.0 109.631 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 28.3 m -87.19 155.43 3.27 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.728 178.463 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -83.09 154.27 24.45 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 116.3 -0.409 . . . . 0.0 109.943 174.765 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 69.2 m -72.49 122.87 22.01 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 121.097 0.475 . . . . 0.0 110.958 -179.057 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 7.3 p -135.62 128.34 47.22 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.125 176.005 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 7.0 mp -93.46 -49.13 6.06 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.916 -0.584 . . . . 0.0 109.889 179.678 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 77.1 -145.22 30.64 Favored Glycine 0 N--CA 1.446 -0.653 0 CA-C-N 115.511 -0.768 . . . . 0.0 111.959 -179.795 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 4.6 t70 72.47 149.39 0.09 Allowed 'General case' 0 N--CA 1.467 0.402 0 C-N-CA 123.382 0.673 . . . . 0.0 110.867 179.205 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 11.5 m -100.16 100.36 11.19 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-O 121.019 0.437 . . . . 0.0 110.771 -179.07 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 86.3 mt -84.32 121.54 75.28 Favored Pre-proline 0 C--N 1.324 -0.504 0 CA-C-N 115.705 -0.679 . . . . 0.0 110.222 178.6 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 92.5 Cg_endo -79.39 27.89 0.52 Allowed 'Trans proline' 0 CA--C 1.529 0.27 0 C-N-CA 123.034 2.489 . . . . 0.0 113.285 -176.501 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 46.9 m-85 -136.0 129.58 32.27 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.161 0.505 . . . . 0.0 111.207 -179.864 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.975 0 CA-C-N 115.32 -0.854 . . . . 0.0 109.33 177.402 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 23' ' ' GLN . . . . . . . . . . . . . 95.1 mt-30 . . . . . 0 CA--C 1.527 0.087 0 CA-C-O 121.194 0.521 . . . . 0.0 110.767 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -91.19 105.54 0.27 Allowed 'Trans proline' 0 N--CA 1.449 -1.132 0 C-N-CA 122.825 2.35 . . . . 0.0 111.707 177.311 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -123.59 -24.0 4.64 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.941 -179.094 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.574 ' HA2' ' HA ' ' A' ' 57' ' ' SER . . . 106.81 176.1 23.01 Favored Glycine 0 N--CA 1.443 -0.86 0 N-CA-C 111.208 -0.757 . . . . 0.0 111.208 -175.271 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.609 HG23 ' HB ' ' A' ' 48' ' ' ILE . 19.6 m -102.06 131.08 50.79 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.812 0 CA-C-O 121.393 0.616 . . . . 0.0 110.978 177.717 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 36.4 tp60 -97.04 135.04 39.6 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.456 -0.793 . . . . 0.0 110.557 -178.8 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.552 HD12 ' HB2' ' A' ' 46' ' ' LEU . 57.8 mt -78.59 112.56 16.76 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.546 176.441 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -74.12 -69.22 0.46 Allowed 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.932 -176.921 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 9.6 p -149.49 148.97 30.04 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.434 -177.05 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.581 HG13 HG22 ' A' ' 102' ' ' ILE . 57.4 t -96.07 114.07 31.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-N 115.642 -0.708 . . . . 0.0 109.773 176.915 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 47.0 t -98.2 128.1 34.51 Favored Pre-proline 0 C--N 1.318 -0.779 0 CA-C-N 116.062 -0.517 . . . . 0.0 109.998 -176.403 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo -63.59 86.25 0.13 Allowed 'Trans proline' 0 C--O 1.234 0.32 0 C-N-CA 122.748 2.299 . . . . 0.0 112.494 -179.923 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -151.48 20.08 0.92 Allowed Glycine 0 N--CA 1.446 -0.643 0 CA-C-N 115.529 -0.76 . . . . 0.0 111.455 177.574 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.447 ' HB2' ' HD2' ' A' ' 37' ' ' PRO . 67.8 p -174.9 160.97 2.43 Favored Pre-proline 0 C--N 1.328 -0.36 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 -178.525 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 37' ' ' PRO . . . . . 0.447 ' HD2' ' HB2' ' A' ' 36' ' ' SER . 29.4 Cg_endo -63.65 -5.21 8.29 Favored 'Trans proline' 0 CA--C 1.532 0.405 0 C-N-CA 122.581 2.187 . . . . 0.0 112.631 179.075 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -67.95 -23.59 65.08 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.619 -0.264 . . . . 0.0 111.066 -179.862 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' SER . . . . . 0.57 ' HA ' HG11 ' A' ' 32' ' ' VAL . 26.7 m -65.07 -24.87 67.58 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.188 0.518 . . . . 0.0 111.427 -178.687 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 1.6 tmtp? -88.14 -26.76 22.29 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.519 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 41' ' ' VAL . . . . . 0.535 ' HB ' HD12 ' A' ' 42' ' ' LEU . 46.3 t -92.17 -49.92 12.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.8 -173.217 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.535 HD12 ' HB ' ' A' ' 41' ' ' VAL . 6.6 mp -95.38 168.38 10.75 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.329 0.585 . . . . 0.0 111.638 -172.956 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -133.01 144.03 51.06 Favored Pre-proline 0 C--N 1.322 -0.622 0 CA-C-N 115.204 -0.907 . . . . 0.0 109.861 176.418 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 78.8 Cg_endo -78.69 155.21 27.3 Favored 'Trans proline' 0 N--CA 1.463 -0.316 0 C-N-CA 122.721 2.281 . . . . 0.0 113.389 -176.0 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 94.08 20.99 29.0 Favored Glycine 0 N--CA 1.448 -0.528 0 C-N-CA 120.619 -0.801 . . . . 0.0 113.273 177.646 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.552 ' HB2' HD12 ' A' ' 29' ' ' ILE . 44.1 mt -108.33 164.26 12.47 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 117.028 0.414 . . . . 0.0 110.928 -179.226 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 61.5 t -108.42 135.14 48.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.096 177.599 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.609 ' HB ' HG23 ' A' ' 27' ' ' VAL . 64.1 mt -96.29 124.63 49.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-O 120.964 0.411 . . . . 0.0 110.837 -179.594 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -84.51 -50.57 7.61 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.049 178.099 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.638 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 24.2 p -149.17 152.21 35.66 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.919 -0.582 . . . . 0.0 112.234 -175.126 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 45.7 mm -111.98 98.99 7.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 114.954 -1.021 . . . . 0.0 110.489 177.05 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' ASN . . . . . 0.463 ' HA ' ' HB3' ' A' ' 76' ' ' ASN . 6.8 t-20 57.72 41.7 24.84 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-N 115.336 -0.847 . . . . 0.0 111.823 172.867 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 104.99 -30.23 10.36 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.641 176.539 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 72.0 mtm -97.53 112.25 60.76 Favored Pre-proline 0 C--N 1.326 -0.422 0 N-CA-C 109.673 -0.491 . . . . 0.0 109.673 178.308 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.638 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 56.0 Cg_endo -69.67 139.48 40.65 Favored 'Trans proline' 0 N--CA 1.459 -0.537 0 C-N-CA 122.26 1.974 . . . . 0.0 112.794 -175.743 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 31.3 p -113.57 83.27 1.82 Allowed 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.346 0.593 . . . . 0.0 111.149 -178.518 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 57' ' ' SER . . . . . 0.574 ' HA ' ' HA2' ' A' ' 26' ' ' GLY . 48.0 t -91.88 -13.97 30.44 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.419 179.616 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 81.8 m-20 -129.16 -179.85 5.36 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 109.195 -0.669 . . . . 0.0 109.195 -178.674 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.421 HD23 ' HA ' ' A' ' 59' ' ' LEU . 17.5 mt -75.93 -45.42 35.25 Favored 'General case' 0 N--CA 1.447 -0.602 0 CA-C-O 120.793 0.33 . . . . 0.0 110.902 175.104 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 6.9 m -61.62 -36.47 80.84 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.42 -177.552 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 19.3 p -64.5 -37.3 87.08 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.133 0.492 . . . . 0.0 110.498 176.217 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 70.7 t80 -70.43 -39.19 74.52 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.69 -0.686 . . . . 0.0 109.504 179.285 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 61.3 m -62.29 -48.53 79.46 Favored 'General case' 0 N--CA 1.444 -0.732 0 CA-C-N 115.314 -0.857 . . . . 0.0 111.666 176.894 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.62 -34.42 75.63 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.987 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -74.01 -44.35 54.81 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.965 -0.562 . . . . 0.0 110.425 179.239 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -61.9 -35.95 79.88 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.454 -176.738 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -55.86 -34.71 65.71 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.929 -176.807 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 71.3 p -78.94 -14.24 59.33 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.722 0.296 . . . . 0.0 111.719 -177.574 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.51 HD12 HG22 ' A' ' 75' ' ' ILE . 29.0 mm -81.04 126.74 39.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.903 0.382 . . . . 0.0 111.024 -175.826 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 20.2 m -120.1 -171.8 2.22 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.961 -176.792 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 71' ' ' VAL . . . . . 0.495 HG23 ' HA ' ' A' ' 97' ' ' ARG . 40.2 t -74.2 139.81 18.67 Favored 'Isoleucine or valine' 0 C--O 1.233 0.218 0 N-CA-C 110.145 -0.317 . . . . 0.0 110.145 176.907 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 69.02 32.05 72.86 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.596 -0.811 . . . . 0.0 111.493 179.382 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 9.6 tp10 -104.84 147.9 27.24 Favored 'General case' 0 N--CA 1.444 -0.746 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 -178.77 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 44.4 t -110.1 106.9 21.61 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 N-CA-C 109.492 -0.559 . . . . 0.0 109.492 -179.131 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 75' ' ' ILE . . . . . 0.51 HG22 HD12 ' A' ' 69' ' ' ILE . 30.5 pt -95.62 154.52 3.46 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.884 -177.2 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 76' ' ' ASN . . . . . 0.463 ' HB3' ' HA ' ' A' ' 52' ' ' ASN . 64.5 t30 -122.91 108.51 13.05 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.025 -176.797 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.465 HD12 HD21 ' A' ' 86' ' ' LEU . 60.4 mt -106.8 110.75 32.78 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.968 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.501 -175.131 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 78' ' ' THR . . . . . 0.476 ' HA ' ' HA ' ' A' ' 83' ' ' THR . 25.5 m -89.29 113.89 25.21 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.471 177.144 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 79' ' ' THR . . . . . 0.457 HG23 HG22 ' A' ' 77' ' ' ILE . 71.3 p -120.45 -178.54 3.72 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 121.06 0.457 . . . . 0.0 111.312 -176.323 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -62.81 -26.5 68.77 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.379 -0.828 . . . . 0.0 111.069 173.678 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 26.9 mm-40 -93.55 9.32 37.22 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.04 0.448 . . . . 0.0 111.351 179.758 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 114.95 -177.75 17.53 Favored Glycine 0 N--CA 1.444 -0.782 0 C-N-CA 120.624 -0.798 . . . . 0.0 112.637 176.625 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.476 ' HA ' ' HA ' ' A' ' 78' ' ' THR . 10.6 m -97.93 113.47 25.32 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.798 -0.201 . . . . 0.0 110.727 -178.096 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 46.1 m-85 -111.75 148.06 34.31 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 110.18 -0.304 . . . . 0.0 110.18 179.389 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 25.7 p-80 -122.95 125.42 45.27 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-O 120.871 0.367 . . . . 0.0 110.018 175.498 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.465 HD21 HD12 ' A' ' 77' ' ' ILE . 0.7 OUTLIER -130.89 156.99 44.12 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.849 -176.059 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 19.5 ptmt -99.77 146.58 26.4 Favored 'General case' 0 N--CA 1.442 -0.834 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.211 179.206 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 33.3 p -83.92 128.39 34.51 Favored 'General case' 0 C--N 1.315 -0.915 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.732 175.857 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -86.6 -169.51 45.98 Favored Glycine 0 N--CA 1.444 -0.833 0 C-N-CA 120.936 -0.65 . . . . 0.0 112.207 -178.811 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 9.8 mpt_? -90.13 -177.17 5.09 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-O 120.974 0.416 . . . . 0.0 110.846 -178.224 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 91' ' ' ASN . . . . . 0.404 ' HA ' ' CD1' ' A' ' 99' ' ' TYR . 12.5 p-10 -107.89 105.87 57.24 Favored Pre-proline 0 C--N 1.324 -0.54 0 CA-C-N 115.747 -0.661 . . . . 0.0 112.036 -175.682 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.513 ' HD2' ' CE1' ' A' ' 99' ' ' TYR . 20.3 Cg_exo -67.52 -40.91 9.55 Favored 'Trans proline' 0 C--O 1.234 0.278 0 C-N-CA 122.358 2.039 . . . . 0.0 111.47 171.664 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 22.9 t-20 -109.97 -94.21 0.42 Allowed 'General case' 0 CA--C 1.532 0.251 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.84 -178.602 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 30.5 m-80 -135.38 110.2 8.71 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.229 0.537 . . . . 0.0 112.126 -178.121 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 95' ' ' SER . . . . . 0.401 ' O ' ' HB3' ' A' ' 91' ' ' ASN . 2.8 t -179.04 89.63 0.02 OUTLIER 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 107.367 -1.346 . . . . 0.0 107.367 172.969 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 47.6 m -58.23 -39.08 78.15 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.908 -171.173 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 97' ' ' ARG . . . . . 0.587 ' HD2' ' O ' ' A' ' 97' ' ' ARG . 6.6 ppt_? -129.87 120.59 25.17 Favored 'General case' 0 N--CA 1.446 -0.641 0 C-N-CA 121.004 -0.279 . . . . 0.0 110.858 178.755 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . 65.9 115.24 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.525 0 CA-C-N 115.586 -0.734 . . . . 0.0 112.124 178.405 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 99' ' ' TYR . . . . . 0.513 ' CE1' ' HD2' ' A' ' 92' ' ' PRO . 4.5 t80 -88.24 -55.8 3.59 Favored 'General case' 0 C--N 1.327 -0.412 0 C-N-CA 120.266 -0.574 . . . . 0.0 110.491 178.122 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 25.2 ttt 59.01 94.74 0.03 OUTLIER 'General case' 0 N--CA 1.468 0.44 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.929 178.784 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -84.44 38.49 2.9 Favored Glycine 0 C--O 1.225 -0.453 0 CA-C-N 115.92 -0.582 . . . . 0.0 114.316 -172.007 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.581 HG22 HG13 ' A' ' 32' ' ' VAL . 2.1 pp -137.92 140.99 39.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 172.43 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 103' ' ' ARG . . . . . 0.607 ' NE ' ' HA ' ' A' ' 103' ' ' ARG . 0.0 OUTLIER -101.42 141.56 34.11 Favored 'General case' 0 C--N 1.317 -0.838 0 C-N-CA 120.706 -0.398 . . . . 0.0 110.307 -177.067 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.5 p -127.48 151.43 48.86 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.577 -177.847 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 20.0 m -151.26 154.49 36.89 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 174.388 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 106' ' ' ASN . . . . . 0.525 ' HB2' ' HG ' ' A' ' 108' ' ' LEU . 37.2 p30 -68.01 -29.94 69.07 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 120.574 0.226 . . . . 0.0 111.345 -176.38 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 46.2 t60 52.42 40.65 29.91 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-O 121.25 0.548 . . . . 0.0 109.956 -177.329 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 108' ' ' LEU . . . . . 0.525 ' HG ' ' HB2' ' A' ' 106' ' ' ASN . 47.7 mt -71.06 -175.17 1.1 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.804 0.811 . . . . 0.0 112.439 -176.063 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 6.0 mmt180 -81.54 92.52 6.53 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 114.654 -1.157 . . . . 0.0 109.366 -178.062 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 46.1 t -77.28 115.38 19.01 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.758 0 CA-C-O 121.445 0.641 . . . . 0.0 111.091 -177.35 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 111' ' ' ARG . . . . . . . . . . . . . 26.3 tpt180 -160.12 108.94 1.72 Allowed 'General case' 0 C--N 1.313 -0.981 0 CA-C-N 114.863 -1.062 . . . . 0.0 108.698 178.546 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -156.3 106.73 2.39 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.19 -173.655 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 19.9 m -94.31 115.45 27.68 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.22 -175.595 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 19.4 m -105.69 131.34 55.37 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.015 179.635 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -159.46 134.24 7.96 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.695 -179.824 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 16.6 t -164.41 91.19 0.59 Allowed 'General case' 0 C--N 1.325 -0.462 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 177.28 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 57.6 t -133.99 104.63 6.18 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.737 -178.23 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 89.7 mt -127.58 -76.77 0.57 Allowed 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 109.721 -0.474 . . . . 0.0 109.721 175.758 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 69.81 40.78 75.02 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 121.075 -0.583 . . . . 0.0 112.901 177.002 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -79.67 130.61 35.5 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.657 -0.497 . . . . 0.0 109.657 178.03 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 121' ' ' THR . . . . . 0.453 ' O ' ' HD3' ' A' ' 123' ' ' PRO . 4.9 t -64.18 116.02 5.56 Favored 'General case' 0 N--CA 1.45 -0.43 0 CA-C-O 121.339 0.59 . . . . 0.0 109.976 178.496 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 91.7 mt -104.36 104.82 46.74 Favored Pre-proline 0 C--N 1.321 -0.669 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.287 -176.262 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 123' ' ' PRO . . . . . 0.453 ' HD3' ' O ' ' A' ' 121' ' ' THR . 24.1 Cg_exo -63.74 107.16 0.7 Allowed 'Trans proline' 0 N--CA 1.458 -0.606 0 C-N-CA 122.54 2.16 . . . . 0.0 110.957 176.768 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 3.2 t80 -116.38 -1.75 12.22 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 121.171 0.51 . . . . 0.0 110.366 -175.851 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.922 0 CA-C-O 118.48 -0.772 . . . . 0.0 110.432 179.934 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.686 ' HB2' ' HD3' ' A' ' 24' ' ' PRO . 35.4 mt-30 . . . . . 0 CA--C 1.533 0.322 0 CA-C-O 119.797 -0.144 . . . . 0.0 111.104 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' PRO . . . . . 0.686 ' HD3' ' HB2' ' A' ' 23' ' ' GLN . 22.9 Cg_exo -64.74 134.66 41.56 Favored 'Trans proline' 0 C--N 1.356 0.94 0 C-N-CA 121.943 1.762 . . . . 0.0 111.507 177.94 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.696 ' HA ' ' CD2' ' A' ' 108' ' ' LEU . 0.0 OUTLIER -91.53 -54.91 3.7 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.233 -174.487 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 93.74 157.82 33.42 Favored Glycine 0 N--CA 1.444 -0.785 0 C-N-CA 120.93 -0.653 . . . . 0.0 111.485 -178.352 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' VAL . . . . . 0.637 HG23 ' HB ' ' A' ' 48' ' ' ILE . 3.8 m -105.27 118.93 53.59 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.713 0 CA-C-O 121.704 0.764 . . . . 0.0 110.844 -179.164 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 34.8 tp60 -103.69 136.0 44.21 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.271 -0.877 . . . . 0.0 110.841 -177.09 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' ILE . . . . . 0.531 HD11 HD11 ' A' ' 48' ' ' ILE . 42.3 mm -68.98 113.16 4.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.14 175.543 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 24.5 t70 -76.01 -63.53 1.29 Allowed 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 115.749 -0.659 . . . . 0.0 109.623 176.759 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 45.3 t -150.69 150.26 30.85 Favored 'General case' 0 N--CA 1.446 -0.654 0 CA-C-N 115.372 -0.831 . . . . 0.0 111.063 -179.571 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' VAL . . . . . 0.571 HG22 HG22 ' A' ' 102' ' ' ILE . 64.0 t -96.36 112.8 29.25 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.946 0 CA-C-N 114.95 -1.023 . . . . 0.0 109.123 174.577 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.461 ' HA ' ' HD3' ' A' ' 34' ' ' PRO . 19.5 m -83.33 127.12 69.89 Favored Pre-proline 0 C--N 1.324 -0.526 0 CA-C-O 121.065 0.46 . . . . 0.0 111.261 -176.247 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 34' ' ' PRO . . . . . 0.461 ' HD3' ' HA ' ' A' ' 33' ' ' VAL . 21.3 Cg_exo -66.1 146.46 81.98 Favored 'Trans proline' 0 C--O 1.237 0.429 0 C-N-CA 122.982 2.455 . . . . 0.0 112.058 178.288 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 114.24 -25.85 10.24 Favored Glycine 0 N--CA 1.45 -0.393 0 N-CA-C 111.507 -0.637 . . . . 0.0 111.507 -178.302 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 50.4 m -101.77 159.2 30.12 Favored Pre-proline 0 C--N 1.319 -0.721 0 CA-C-N 115.442 -0.379 . . . . 0.0 110.331 178.85 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_exo -60.19 -20.18 60.62 Favored 'Trans proline' 0 C--N 1.347 0.487 0 C-N-CA 123.057 2.505 . . . . 0.0 112.958 -178.102 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -66.15 -25.84 67.15 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.973 -176.808 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 13.4 m -63.2 -22.95 67.2 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.365 -0.38 . . . . 0.0 111.738 -176.224 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 57.4 tttm -110.11 11.53 23.77 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.907 0.384 . . . . 0.0 110.514 -176.465 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 96.5 t -120.73 -55.25 3.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 120.761 0.315 . . . . 0.0 111.275 -177.063 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 97.7 mt -107.69 167.19 10.13 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.083 0.468 . . . . 0.0 111.434 -174.142 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' THR . . . . . 0.405 ' HA ' ' HD3' ' A' ' 44' ' ' PRO . 20.1 p -113.9 148.06 39.09 Favored Pre-proline 0 N--CA 1.446 -0.663 0 CA-C-N 115.323 -0.853 . . . . 0.0 109.626 175.839 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.405 ' HD3' ' HA ' ' A' ' 43' ' ' THR . 5.1 Cg_exo -74.79 141.1 26.89 Favored 'Trans proline' 0 N--CA 1.458 -0.565 0 C-N-CA 122.285 1.99 . . . . 0.0 111.926 -178.054 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 105.36 -2.21 40.06 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.626 -0.797 . . . . 0.0 113.056 179.916 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' LEU . . . . . 0.453 HD22 ' HB3' ' A' ' 80' ' ' ASP . 72.7 mt -78.65 164.8 24.32 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.257 0.551 . . . . 0.0 111.556 -178.849 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 61.8 t -109.51 138.64 36.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 115.801 -0.636 . . . . 0.0 109.378 174.63 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 48' ' ' ILE . . . . . 0.637 ' HB ' HG23 ' A' ' 27' ' ' VAL . 88.4 mt -94.68 111.84 26.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 120.971 0.415 . . . . 0.0 110.03 177.968 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -75.07 -51.4 13.6 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.484 -178.717 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' SER . . . . . 0.563 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 31.5 p -156.61 156.91 34.35 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.76 -0.655 . . . . 0.0 112.29 -174.912 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.762 HG22 ' H ' ' A' ' 52' ' ' ASN . 9.0 mm -100.07 -171.37 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 173.649 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 52' ' ' ASN . . . . . 0.762 ' H ' HG22 ' A' ' 51' ' ' ILE . 1.7 m-20 -48.72 92.99 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 123.039 0.536 . . . . 0.0 112.089 178.869 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 72.19 -10.07 4.96 Favored Glycine 0 CA--C 1.521 0.461 0 C-N-CA 121.384 -0.436 . . . . 0.0 113.787 175.517 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 71.0 mtm -125.71 112.69 25.02 Favored Pre-proline 0 C--N 1.327 -0.403 0 CA-C-N 117.147 0.474 . . . . 0.0 110.863 -175.882 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 55' ' ' PRO . . . . . 0.563 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 4.4 Cg_exo -78.65 137.44 14.42 Favored 'Trans proline' 0 N--CA 1.46 -0.488 0 C-N-CA 122.897 2.398 . . . . 0.0 111.661 175.97 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 40.1 p -121.48 116.76 25.31 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.909 0.385 . . . . 0.0 111.77 -178.857 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 30.7 t -86.57 -53.4 4.99 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.32 174.106 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 15.5 m120 -86.24 157.11 20.03 Favored 'General case' 0 C--N 1.318 -0.762 0 C-N-CA 120.228 -0.589 . . . . 0.0 109.629 -169.799 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 59' ' ' LEU . . . . . 0.564 ' HG ' ' HB2' ' A' ' 106' ' ' ASN . 3.4 mt -65.11 -38.55 91.04 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.1 0.476 . . . . 0.0 110.4 177.992 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 3.3 m -64.44 -38.38 90.84 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.826 -0.624 . . . . 0.0 111.109 179.432 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 11.9 p -71.48 -32.1 67.88 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.958 0.408 . . . . 0.0 110.565 177.733 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 72.2 t80 -65.51 -44.34 87.28 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.893 -0.594 . . . . 0.0 109.789 175.467 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 7.9 t -63.17 -37.52 87.55 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.03 178.062 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.04 -33.07 74.92 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.015 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 65' ' ' ALA . . . . . 0.505 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -76.9 -40.03 48.83 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.256 0.55 . . . . 0.0 110.204 176.858 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 66' ' ' LEU . . . . . 0.436 HD21 ' SD ' ' A' ' 100' ' ' MET . 0.4 OUTLIER -60.5 -38.06 83.1 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.61 -0.723 . . . . 0.0 111.406 179.444 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -74.24 -6.43 47.87 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.996 -0.547 . . . . 0.0 112.301 -177.614 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 22.5 p -100.4 -12.61 19.25 Favored 'General case' 0 C--N 1.324 -0.541 0 C-N-CA 120.754 -0.379 . . . . 0.0 110.841 174.142 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.505 HG12 ' O ' ' A' ' 65' ' ' ALA . 47.2 mm -80.33 135.62 24.98 Favored 'Isoleucine or valine' 0 C--O 1.234 0.275 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.872 -178.667 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 1.4 m -83.03 165.7 19.4 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.345 -177.027 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 32.5 t -76.75 124.12 34.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.595 174.404 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 79.73 25.62 58.01 Favored Glycine 0 N--CA 1.446 -0.65 0 C-N-CA 120.314 -0.946 . . . . 0.0 111.178 -176.573 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 8.1 tp10 -85.6 147.81 26.22 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 178.423 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 56.9 t -104.61 98.56 6.98 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.978 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 176.05 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 26.0 pt -91.18 164.69 2.07 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.779 0 CA-C-O 121.388 0.613 . . . . 0.0 111.506 -173.956 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 33.2 t30 -116.06 115.88 26.89 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 115.158 -0.928 . . . . 0.0 109.615 -178.929 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 24.1 mt -120.61 107.74 21.35 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.315 -175.533 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 78' ' ' THR . . . . . 0.481 ' HA ' ' HA ' ' A' ' 83' ' ' THR . 30.6 m -80.78 118.37 22.25 Favored 'General case' 0 C--N 1.317 -0.807 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 173.381 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 72.6 p -119.81 -173.38 2.53 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.319 0.58 . . . . 0.0 111.891 -173.431 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 80' ' ' ASP . . . . . 0.453 ' HB3' HD22 ' A' ' 46' ' ' LEU . 20.8 t70 -56.71 -36.13 69.32 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 114.713 -1.13 . . . . 0.0 111.44 176.412 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 96.8 mt-30 -93.73 7.6 44.19 Favored 'General case' 0 C--O 1.235 0.295 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.342 -177.259 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 112.67 -169.35 12.97 Favored Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.655 177.779 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 83' ' ' THR . . . . . 0.481 ' HA ' ' HA ' ' A' ' 78' ' ' THR . 9.2 m -77.84 127.16 31.96 Favored 'General case' 0 C--N 1.321 -0.652 0 C-N-CA 122.559 0.344 . . . . 0.0 111.636 -177.973 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 97.7 m-85 -132.11 158.44 41.63 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.898 0.38 . . . . 0.0 110.108 174.69 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 33.1 m-70 -118.51 137.62 53.08 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 176.513 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 86' ' ' LEU . . . . . 0.493 HD23 ' N ' ' A' ' 87' ' ' LYS . 1.6 tt -135.41 138.9 43.72 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-O 120.884 0.373 . . . . 0.0 110.571 -173.237 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.493 ' N ' HD23 ' A' ' 86' ' ' LEU . 38.6 ttpt -95.97 123.07 39.41 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 116.09 -0.505 . . . . 0.0 109.963 177.706 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.44 HG21 HG21 ' A' ' 69' ' ' ILE . 41.1 p -69.4 142.49 53.89 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.902 -0.59 . . . . 0.0 112.033 -174.974 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -76.12 -170.1 29.53 Favored Glycine 0 N--CA 1.444 -0.823 0 CA-C-N 115.692 -0.686 . . . . 0.0 112.833 -178.367 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 6.0 mpt_? -121.03 157.66 29.52 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-O 120.818 0.342 . . . . 0.0 111.487 -172.96 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 91' ' ' ASN . . . . . . . . . . . . . 26.4 m120 59.15 87.16 0.14 Allowed Pre-proline 0 N--CA 1.469 0.494 0 CA-C-N 114.844 -1.071 . . . . 0.0 113.663 170.438 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 92' ' ' PRO . . . . . 0.597 ' HG2' ' H ' ' A' ' 96' ' ' SER . 92.9 Cg_endo -94.28 -152.35 0.04 OUTLIER 'Trans proline' 0 N--CA 1.456 -0.728 0 C-N-CA 123.447 2.764 . . . . 0.0 110.621 169.166 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 32.5 t30 -99.19 -85.55 0.39 Allowed 'General case' 0 C--N 1.328 -0.332 0 C-N-CA 120.597 -0.441 . . . . 0.0 110.913 178.078 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 23.8 t-20 -100.49 -14.86 18.09 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.991 0.424 . . . . 0.0 110.786 -176.227 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 19.1 m -64.4 -41.49 96.61 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.745 -179.741 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 96' ' ' SER . . . . . 0.597 ' H ' ' HG2' ' A' ' 92' ' ' PRO . 73.5 m 61.52 15.79 7.04 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-O 121.341 0.591 . . . . 0.0 111.91 -178.532 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 97' ' ' ARG . . . . . 0.436 HH11 ' HD2' ' A' ' 97' ' ' ARG . 53.1 mtt180 -126.35 -164.26 1.31 Allowed 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.414 -0.812 . . . . 0.0 110.565 -175.978 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -46.09 139.16 4.68 Favored 'General case' 0 C--N 1.329 -0.325 0 O-C-N 124.019 0.824 . . . . 0.0 111.945 174.971 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 35.3 t80 -117.4 -15.67 10.31 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.759 -179.501 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 100' ' ' MET . . . . . 0.436 ' SD ' HD21 ' A' ' 66' ' ' LEU . 82.7 mtp 58.43 -153.97 0.37 Allowed 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.751 -176.858 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -155.53 32.05 0.63 Allowed Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.259 -0.972 . . . . 0.0 112.904 -179.778 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 102' ' ' ILE . . . . . 0.571 HG22 HG22 ' A' ' 32' ' ' VAL . 2.8 pp -144.21 166.26 12.92 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 178.871 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 38.0 mmt180 -108.49 132.49 53.76 Favored 'General case' 0 C--N 1.317 -0.825 0 N-CA-C 109.278 -0.638 . . . . 0.0 109.278 176.201 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -110.76 132.35 54.27 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 121.335 0.588 . . . . 0.0 111.917 -177.962 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 42.3 m -109.89 165.69 11.51 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.235 -0.893 . . . . 0.0 109.799 175.163 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 106' ' ' ASN . . . . . 0.564 ' HB2' ' HG ' ' A' ' 59' ' ' LEU . 64.9 t30 -114.6 38.95 2.95 Favored 'General case' 0 C--N 1.313 -1.011 0 CA-C-O 122.013 0.911 . . . . 0.0 108.582 179.713 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 72.6 t60 -81.42 115.88 20.97 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 114.358 -1.292 . . . . 0.0 110.419 -175.262 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 108' ' ' LEU . . . . . 0.696 ' CD2' ' HA ' ' A' ' 25' ' ' ASP . 9.0 mt -55.32 133.9 49.8 Favored 'General case' 0 CA--C 1.515 -0.367 0 CA-C-O 121.489 0.661 . . . . 0.0 110.954 177.588 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 70.7 ttt180 -136.38 130.84 33.4 Favored 'General case' 0 C--N 1.312 -1.058 0 CA-C-N 114.826 -1.079 . . . . 0.0 109.128 -178.353 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 110' ' ' VAL . . . . . 0.56 HG22 ' H ' ' A' ' 112' ' ' ASP . 9.1 p -70.42 131.66 34.05 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-O 121.572 0.701 . . . . 0.0 111.979 -173.891 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 111' ' ' ARG . . . . . . . . . . . . . 28.4 mmm180 -88.19 -15.24 36.53 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.258 -0.883 . . . . 0.0 109.808 177.513 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 112' ' ' ASP . . . . . 0.56 ' H ' HG22 ' A' ' 110' ' ' VAL . 23.1 t0 60.84 29.13 18.81 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 114.795 -1.093 . . . . 0.0 111.737 173.958 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 15.7 t -148.67 -177.48 5.81 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.011 178.138 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 19.2 m -63.53 138.9 22.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-O 121.458 0.647 . . . . 0.0 111.428 -177.243 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -153.35 -55.22 0.11 Allowed 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 177.951 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 5.9 m 63.41 -161.75 0.29 Allowed 'General case' 0 CA--C 1.53 0.191 0 CA-C-N 115.006 -0.997 . . . . 0.0 111.481 172.141 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 48.1 t 64.5 93.74 0.05 OUTLIER 'Isoleucine or valine' 0 C--O 1.234 0.237 0 CA-C-N 115.808 -0.633 . . . . 0.0 111.964 176.597 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 118' ' ' LEU . . . . . 0.474 HD23 ' HG3' ' A' ' 23' ' ' GLN . 84.3 mt -120.4 -49.52 2.26 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.076 175.669 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 105.32 72.25 0.85 Allowed Glycine 0 N--CA 1.445 -0.749 0 C-N-CA 120.589 -0.815 . . . . 0.0 111.69 179.669 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -70.85 95.8 1.19 Allowed 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.014 0.435 . . . . 0.0 110.685 179.511 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 13.9 t -84.8 126.03 33.09 Favored 'General case' 0 N--CA 1.445 -0.719 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 175.777 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 94.7 mt -76.21 125.78 87.4 Favored Pre-proline 0 C--N 1.322 -0.611 0 CA-C-O 121.239 0.542 . . . . 0.0 110.884 -172.061 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -76.63 112.97 3.56 Favored 'Trans proline' 0 N--CA 1.461 -0.433 0 C-N-CA 123.044 2.496 . . . . 0.0 113.448 -172.775 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 90.5 m-85 -130.35 127.19 38.9 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.491 174.075 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.245 0.854 0 CA-C-O 118.357 -0.83 . . . . 0.0 109.815 179.91 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 19.1 t70 . . . . . 0 C--O 1.233 0.188 0 CA-C-O 121.759 0.79 . . . . 0.0 110.395 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 115.64 148.89 9.38 Favored Glycine 0 N--CA 1.446 -0.686 0 CA-C-N 115.344 -0.844 . . . . 0.0 111.36 -177.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.617 HG23 ' HB ' ' A' ' 48' ' ' ILE . 17.7 m -102.59 129.73 53.68 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 CA-C-O 121.195 0.522 . . . . 0.0 110.511 178.102 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . 0.434 ' HG3' ' O ' ' A' ' 46' ' ' LEU . 61.8 tt0 -110.66 149.73 30.02 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 121.187 0.517 . . . . 0.0 111.298 -175.941 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.517 HG23 HD12 ' A' ' 102' ' ' ILE . 74.3 mt -82.31 117.85 29.0 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 115.361 -0.836 . . . . 0.0 109.93 177.741 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.551 ' HB3' ' HB3' ' A' ' 103' ' ' ARG . 12.6 t70 -79.13 -65.1 1.04 Allowed 'General case' 0 C--N 1.317 -0.837 0 CA-C-N 116.235 -0.439 . . . . 0.0 109.84 178.912 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 5.5 p -150.06 156.53 41.85 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.91 -0.586 . . . . 0.0 111.31 -177.087 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.513 ' CG1' ' HA ' ' A' ' 39' ' ' SER . 56.2 t -116.18 113.73 44.03 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.229 -177.712 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 30.3 m -105.71 153.46 39.94 Favored Pre-proline 0 N--CA 1.445 -0.693 0 CA-C-N 116.512 -0.313 . . . . 0.0 110.569 178.505 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 29.0 Cg_endo -62.7 150.95 86.3 Favored 'Trans proline' 0 C--N 1.346 0.4 0 C-N-CA 123.023 2.482 . . . . 0.0 112.339 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 109.73 3.49 30.34 Favored Glycine 0 N--CA 1.45 -0.371 0 N-CA-C 111.081 -0.808 . . . . 0.0 111.081 -176.029 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.543 ' HB3' ' HA3' ' A' ' 101' ' ' GLY . 50.8 p -125.26 147.95 59.18 Favored Pre-proline 0 N--CA 1.447 -0.609 0 CA-C-N 115.17 -0.515 . . . . 0.0 109.862 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . 0.466 ' HD3' ' HA2' ' A' ' 89' ' ' GLY . 16.8 Cg_exo -67.31 -23.37 44.78 Favored 'Trans proline' 0 N--CA 1.463 -0.297 0 C-N-CA 122.031 1.82 . . . . 0.0 110.894 175.645 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -75.29 -7.93 55.28 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.179 -0.918 . . . . 0.0 111.927 -177.616 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.513 ' HA ' ' CG1' ' A' ' 32' ' ' VAL . 73.0 m -53.33 -31.24 43.31 Favored 'General case' 0 CA--C 1.533 0.303 0 N-CA-C 112.671 0.619 . . . . 0.0 112.671 -175.152 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 42.2 mtmt -128.99 21.21 5.84 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.822 0.344 . . . . 0.0 111.307 179.838 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 88.3 t -103.68 -50.95 9.06 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-O 120.931 0.396 . . . . 0.0 110.754 179.341 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -112.3 -179.82 3.78 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.383 0.611 . . . . 0.0 111.589 -179.393 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . 0.579 ' O ' ' HG ' ' A' ' 46' ' ' LEU . 8.5 m -116.47 138.31 24.3 Favored Pre-proline 0 C--N 1.317 -0.823 0 CA-C-N 115.011 -0.995 . . . . 0.0 109.948 -178.851 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 21.0 Cg_endo -64.34 141.87 76.75 Favored 'Trans proline' 0 N--CA 1.46 -0.499 0 C-N-CA 121.665 1.577 . . . . 0.0 111.171 171.525 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 99.49 -7.78 59.91 Favored Glycine 0 C--N 1.32 -0.32 0 C-N-CA 120.6 -0.809 . . . . 0.0 113.159 -179.083 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.579 ' HG ' ' O ' ' A' ' 43' ' ' THR . 27.9 mt -81.79 163.29 22.48 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 117.077 0.438 . . . . 0.0 110.612 -178.269 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 44.6 t -113.32 126.73 70.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.415 -178.129 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.617 ' HB ' HG23 ' A' ' 27' ' ' VAL . 75.1 mt -84.59 113.01 22.57 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-O 120.862 0.363 . . . . 0.0 110.141 178.931 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 66.6 mt-10 -83.9 -46.45 12.1 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.8 -177.074 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 17.1 p -162.8 152.09 15.29 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.045 0.45 . . . . 0.0 111.875 -178.449 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.529 HG22 ' H ' ' A' ' 52' ' ' ASN . 12.1 mt -103.27 172.46 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 175.524 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' ASN . . . . . 0.843 ' HB3' ' HB3' ' A' ' 76' ' ' ASN . 17.8 p-10 -56.08 101.89 0.06 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.275 0.56 . . . . 0.0 112.243 -176.257 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 74.99 1.78 63.77 Favored Glycine 0 N--CA 1.451 -0.311 0 CA-C-N 115.527 -0.76 . . . . 0.0 113.042 178.836 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 49.9 mtm -138.14 96.69 10.03 Favored Pre-proline 0 C--N 1.325 -0.484 0 O-C-N 122.684 -0.304 . . . . 0.0 110.659 -175.652 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -73.88 133.85 19.0 Favored 'Trans proline' 0 N--CA 1.462 -0.344 0 C-N-CA 122.667 2.244 . . . . 0.0 111.968 178.679 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 17.7 p -110.83 83.8 1.82 Allowed 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.247 0.546 . . . . 0.0 111.675 -175.861 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 22.3 m -91.92 -13.48 31.14 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.249 177.011 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -128.11 173.79 9.79 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 -175.4 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 65.1 mt -78.72 -39.19 37.08 Favored 'General case' 0 N--CA 1.444 -0.77 0 CA-C-O 121.18 0.514 . . . . 0.0 110.059 177.797 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 3.1 m -67.11 -42.45 84.51 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.552 -0.749 . . . . 0.0 111.236 -178.862 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 1.2 p -65.63 -32.42 73.98 Favored 'General case' 0 C--N 1.333 -0.133 0 CA-C-O 120.797 0.332 . . . . 0.0 111.036 179.802 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 86.4 t80 -62.06 -44.52 96.5 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.007 -0.542 . . . . 0.0 109.669 174.318 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . 0.485 ' O ' ' HG3' ' A' ' 67' ' ' LYS . 5.7 t -68.12 -41.68 81.37 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.293 179.732 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -60.69 -34.71 74.75 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 121.161 0.505 . . . . 0.0 110.859 -179.221 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . 0.409 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -73.1 -45.58 56.25 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.119 176.346 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -60.23 -38.24 82.8 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.996 -177.442 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . 0.485 ' HG3' ' O ' ' A' ' 63' ' ' SER . 68.6 mttm -65.4 -14.43 60.87 Favored 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 112.297 0.48 . . . . 0.0 112.297 -176.857 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 68.0 p -99.34 -13.14 19.74 Favored 'General case' 0 C--N 1.326 -0.447 0 C-N-CA 120.814 -0.354 . . . . 0.0 111.528 -179.691 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.409 HG12 ' O ' ' A' ' 65' ' ' ALA . 14.5 mm -88.75 144.24 9.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 120.904 0.383 . . . . 0.0 110.413 -176.445 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 54.4 m -104.06 171.0 7.59 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.534 -0.303 . . . . 0.0 111.351 -178.458 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 39.1 t -81.39 117.98 28.36 Favored 'Isoleucine or valine' 0 C--O 1.233 0.224 0 CA-C-O 120.905 0.383 . . . . 0.0 110.539 -178.397 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 102.58 -1.64 49.38 Favored Glycine 0 N--CA 1.448 -0.527 0 N-CA-C 111.463 -0.655 . . . . 0.0 111.463 -177.498 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 56.0 tt0 -87.65 149.08 24.5 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.35 -0.425 . . . . 0.0 109.878 179.527 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 64.3 t -111.13 124.89 68.33 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.782 -177.139 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 25.2 pt -110.07 164.32 6.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.316 -179.553 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . 0.843 ' HB3' ' HB3' ' A' ' 52' ' ' ASN . 6.7 t30 -107.53 114.94 29.28 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.043 -177.158 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.549 HG23 HG23 ' A' ' 48' ' ' ILE . 70.6 mt -117.48 115.21 47.93 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-O 120.982 0.42 . . . . 0.0 111.153 -175.877 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . 0.535 ' HA ' ' HA ' ' A' ' 83' ' ' THR . 97.8 m -93.0 125.4 37.57 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.872 -0.604 . . . . 0.0 109.969 176.237 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.547 HG22 ' HA ' ' A' ' 48' ' ' ILE . 68.0 p -124.19 177.46 5.82 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.237 179.095 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -57.86 -33.7 68.96 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.5 0.667 . . . . 0.0 110.251 174.1 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . 0.4 ' CG ' HD22 ' A' ' 46' ' ' LEU . 16.5 mm100 -90.73 17.33 7.78 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-N 115.223 -0.899 . . . . 0.0 111.242 -177.054 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 107.71 178.41 22.31 Favored Glycine 0 N--CA 1.446 -0.687 0 CA-C-N 115.525 -0.761 . . . . 0.0 112.419 175.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . 0.535 ' HA ' ' HA ' ' A' ' 78' ' ' THR . 63.7 m -94.56 131.57 40.16 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-O 120.775 0.322 . . . . 0.0 110.638 179.035 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 91.1 m-85 -125.23 159.75 30.88 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.249 -0.432 . . . . 0.0 109.995 178.198 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 44.9 m80 -106.57 124.31 49.41 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 174.295 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.448 HD13 ' HA ' ' A' ' 86' ' ' LEU . 2.9 mm? -116.69 135.95 53.36 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-O 121.425 0.631 . . . . 0.0 111.811 -174.836 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 87.4 tttt -95.18 135.84 36.26 Favored 'General case' 0 C--N 1.31 -1.133 0 CA-C-N 114.981 -1.009 . . . . 0.0 109.071 174.12 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.622 ' HB ' ' HA ' ' A' ' 98' ' ' ALA . 55.1 p -65.14 143.45 57.86 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 120.925 0.393 . . . . 0.0 111.061 179.511 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.535 ' HA3' ' O ' ' A' ' 99' ' ' TYR . . . . . . . . 0 N--CA 1.439 -1.123 0 CA-C-N 115.647 -0.706 . . . . 0.0 113.411 -175.124 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . 0.622 ' HA ' ' HB ' ' A' ' 88' ' ' THR . . . . . . . . 0 N--CA 1.462 0.142 0 CA-C-O 120.77 0.319 . . . . 0.0 111.504 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . 0.535 ' O ' ' HA3' ' A' ' 89' ' ' GLY . 2.3 t80 -111.58 95.97 5.82 Favored 'General case' 0 C--N 1.325 -0.466 0 C-N-CA 119.805 -0.758 . . . . 0.0 109.895 -176.829 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' MET . . . . . 0.657 ' HG3' HG12 ' A' ' 102' ' ' ILE . 50.8 tpp -46.95 -54.17 10.69 Favored 'General case' 0 N--CA 1.466 0.35 0 O-C-N 123.746 0.654 . . . . 0.0 112.002 -173.391 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . 0.543 ' HA3' ' HB3' ' A' ' 36' ' ' SER . . . 99.31 -2.24 57.64 Favored Glycine 0 C--O 1.226 -0.375 0 C-N-CA 120.504 -0.855 . . . . 0.0 113.185 175.399 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.657 HG12 ' HG3' ' A' ' 100' ' ' MET . 36.7 pt -114.58 140.6 34.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 N-CA-C 109.633 -0.506 . . . . 0.0 109.633 178.14 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . 0.551 ' HB3' ' HB3' ' A' ' 30' ' ' ASP . 18.4 ttp180 -69.52 125.37 26.49 Favored 'General case' 0 N--CA 1.446 -0.648 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 178.535 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.417 HG22 ' HA ' ' A' ' 29' ' ' ILE . 0.9 OUTLIER -135.52 142.03 45.35 Favored 'General case' 0 C--N 1.311 -1.104 0 CA-C-N 116.048 -0.523 . . . . 0.0 110.582 -175.465 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 31.9 m -153.39 157.45 39.99 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.05 179.575 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . 0.415 ' HA ' ' HA ' ' A' ' 27' ' ' VAL . 25.5 p-10 . . . . . 0 C--N 1.322 -0.623 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.798 -179.653 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 16.8 t70 . . . . . 0 N--CA 1.464 0.251 0 CA-C-O 121.057 0.456 . . . . 0.0 111.743 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.543 ' HA2' ' HA ' ' A' ' 57' ' ' SER . . . 146.68 136.06 2.82 Favored Glycine 0 N--CA 1.444 -0.782 0 N-CA-C 110.932 -0.867 . . . . 0.0 110.932 -174.003 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.532 HG23 ' HB ' ' A' ' 48' ' ' ILE . 30.0 m -80.99 142.38 13.92 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-O 121.272 0.558 . . . . 0.0 110.86 -178.743 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . 0.52 ' HG3' ' O ' ' A' ' 46' ' ' LEU . 5.8 tt0 -116.38 155.4 28.57 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.482 -179.634 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.494 HD12 HD12 ' A' ' 102' ' ' ILE . 45.2 mm -81.56 110.51 17.0 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 178.01 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.455 ' HB3' ' CB ' ' A' ' 103' ' ' ARG . 14.4 t70 -70.43 -63.19 1.14 Allowed 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 115.933 -0.576 . . . . 0.0 109.591 179.479 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.425 ' HA ' ' HB3' ' A' ' 44' ' ' PRO . 17.3 m -150.03 148.99 29.71 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.734 -178.937 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.433 ' CG1' ' HA ' ' A' ' 39' ' ' SER . 97.3 t -114.6 114.07 45.55 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 N-CA-C 108.825 -0.805 . . . . 0.0 108.825 173.406 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.501 HG22 ' O ' ' A' ' 101' ' ' GLY . 4.6 m -75.11 153.13 86.43 Favored Pre-proline 0 C--N 1.324 -0.505 0 CA-C-N 116.51 -0.314 . . . . 0.0 111.355 -175.093 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 40.1 Cg_endo -69.77 116.58 4.63 Favored 'Trans proline' 0 N--CA 1.461 -0.404 0 C-N-CA 122.388 2.058 . . . . 0.0 111.033 172.613 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 94.99 -179.56 36.73 Favored Glycine 0 N--CA 1.445 -0.706 0 N-CA-C 110.63 -0.988 . . . . 0.0 110.63 -173.413 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.728 ' HB3' ' HD2' ' A' ' 37' ' ' PRO . 31.9 m 69.16 168.48 0.12 Allowed Pre-proline 0 CA--C 1.54 0.564 0 CA-C-N 117.072 0.436 . . . . 0.0 110.888 -179.052 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . 0.728 ' HD2' ' HB3' ' A' ' 36' ' ' SER . 32.8 Cg_endo -65.04 155.11 70.04 Favored 'Trans proline' 0 C--N 1.344 0.329 0 C-N-CA 122.348 2.032 . . . . 0.0 112.747 179.035 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.538 ' HB2' HD21 ' A' ' 86' ' ' LEU . . . 76.68 -12.22 1.07 Allowed 'General case' 0 N--CA 1.471 0.621 0 C-N-CA 123.718 0.807 . . . . 0.0 112.146 177.012 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.433 ' HA ' ' CG1' ' A' ' 32' ' ' VAL . 11.4 t -64.31 -30.87 71.9 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.618 -175.554 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -103.96 16.64 25.85 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.024 -175.687 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.421 ' HB ' HD12 ' A' ' 42' ' ' LEU . 30.8 t -125.29 -54.05 2.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 N-CA-C 111.705 0.261 . . . . 0.0 111.705 -177.672 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.421 HD12 ' HB ' ' A' ' 41' ' ' VAL . 7.6 mp -97.47 176.98 5.67 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.373 0.606 . . . . 0.0 111.909 -173.057 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . 0.429 ' O ' ' HG ' ' A' ' 46' ' ' LEU . 28.5 m -135.5 134.32 20.98 Favored Pre-proline 0 C--N 1.321 -0.64 0 CA-C-N 115.186 -0.915 . . . . 0.0 109.39 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.425 ' HB3' ' HA ' ' A' ' 31' ' ' SER . 19.3 Cg_endo -62.13 139.46 78.51 Favored 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 122.105 1.87 . . . . 0.0 112.474 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 105.69 -13.11 46.56 Favored Glycine 0 CA--C 1.521 0.408 0 C-N-CA 120.641 -0.79 . . . . 0.0 113.808 179.308 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.52 ' O ' ' HG3' ' A' ' 28' ' ' GLN . 56.9 mt -79.83 163.32 24.49 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 117.481 0.64 . . . . 0.0 111.044 -177.035 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 42.2 t -111.28 137.26 44.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 116.528 -0.306 . . . . 0.0 110.304 178.182 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.532 ' HB ' HG23 ' A' ' 27' ' ' VAL . 61.9 mt -92.62 124.93 45.24 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-O 121.16 0.505 . . . . 0.0 111.23 -178.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 11.3 tp10 -77.23 -53.93 7.12 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.624 176.378 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 5.3 p -161.83 156.01 22.1 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.341 -0.845 . . . . 0.0 111.576 -176.184 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.623 HG12 HG12 ' A' ' 77' ' ' ILE . 58.5 mt -123.17 106.86 18.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 115.478 -0.783 . . . . 0.0 109.475 176.396 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' ASN . . . . . 0.406 ' CG ' ' H ' ' A' ' 53' ' ' GLY . 12.0 t-20 61.26 -152.23 0.38 Allowed 'General case' 0 CA--C 1.533 0.307 0 N-CA-C 108.061 -1.089 . . . . 0.0 108.061 -175.425 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.406 ' H ' ' CG ' ' A' ' 52' ' ' ASN . . . -73.61 9.67 7.86 Favored Glycine 0 CA--C 1.525 0.657 0 C-N-CA 120.781 -0.723 . . . . 0.0 113.156 179.533 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 3.3 mpp? -114.96 105.31 53.25 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 120.721 0.296 . . . . 0.0 110.423 178.091 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -73.96 130.42 14.4 Favored 'Trans proline' 0 N--CA 1.458 -0.569 0 C-N-CA 122.04 1.827 . . . . 0.0 111.949 177.615 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.427 ' O ' ' HA2' ' A' ' 26' ' ' GLY . 16.7 p -98.12 75.96 2.34 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 121.249 0.547 . . . . 0.0 111.692 -176.595 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . 0.543 ' HA ' ' HA2' ' A' ' 26' ' ' GLY . 32.3 t -88.89 -12.2 42.41 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.583 -0.735 . . . . 0.0 109.831 176.033 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 8.9 t-20 -129.32 177.89 6.84 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 115.846 -0.615 . . . . 0.0 109.361 -177.234 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.929 ' HG ' ' HB3' ' A' ' 106' ' ' ASN . 3.8 mt -90.08 -34.2 16.01 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-O 121.051 0.453 . . . . 0.0 109.806 176.661 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 28.5 m -63.7 -38.82 92.53 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.249 176.678 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 21.4 p -64.09 -38.07 89.72 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.484 177.851 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 89.1 t80 -65.48 -43.76 89.24 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.893 -0.594 . . . . 0.0 109.898 177.925 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 8.6 t -64.64 -48.03 76.31 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.455 179.684 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -65.54 -31.1 71.97 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.958 -0.564 . . . . 0.0 111.586 -177.223 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . 0.603 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -74.11 -45.04 51.52 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.328 179.6 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 1.6 tt -59.88 -43.8 94.55 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.134 -177.45 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 57.8 mtpt -63.13 -22.65 67.0 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.587 -0.733 . . . . 0.0 112.206 -178.153 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 40.6 p -92.18 -13.58 30.38 Favored 'General case' 0 C--N 1.329 -0.321 0 C-N-CA 120.971 -0.292 . . . . 0.0 111.571 179.465 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.603 HG12 ' O ' ' A' ' 65' ' ' ALA . 44.5 mm -78.14 138.99 19.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.841 0.353 . . . . 0.0 110.105 -179.265 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 6.1 m -88.46 165.7 14.72 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.971 -177.825 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 94.8 t -72.43 133.96 30.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.454 177.112 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 70.95 27.61 71.92 Favored Glycine 0 C--N 1.331 0.257 0 C-N-CA 120.959 -0.639 . . . . 0.0 111.984 179.005 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 9.7 tp10 -99.04 152.52 19.73 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 -177.443 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.407 ' HA ' ' O ' ' A' ' 86' ' ' LEU . 58.9 t -108.24 111.48 36.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.119 -179.459 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.643 HG13 ' HB3' ' A' ' 86' ' ' LEU . 15.0 pt -109.65 154.15 11.2 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.635 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.98 -177.815 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . 0.401 ' O ' ' HA ' ' A' ' 51' ' ' ILE . 19.9 t30 -95.17 114.4 26.19 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 115.302 -0.863 . . . . 0.0 110.726 -179.4 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.623 HG12 HG12 ' A' ' 51' ' ' ILE . 50.9 mt -113.19 104.55 17.2 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-O 121.641 0.734 . . . . 0.0 110.015 177.274 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 11.7 m -89.63 124.57 34.69 Favored 'General case' 0 C--N 1.314 -0.952 0 CA-C-N 115.036 -0.984 . . . . 0.0 109.275 178.075 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 60.0 p -117.17 172.33 7.36 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 121.024 0.44 . . . . 0.0 111.172 -178.004 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -56.45 -32.71 65.18 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.245 -0.889 . . . . 0.0 111.444 177.434 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 30.5 mm-40 -104.39 16.48 26.06 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 112.373 0.508 . . . . 0.0 112.373 -175.507 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 136.6 172.66 12.64 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 119.969 -1.11 . . . . 0.0 113.674 175.528 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 19.6 m -99.19 121.53 41.16 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 110.278 -0.267 . . . . 0.0 110.278 -179.876 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -115.63 158.71 22.32 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.189 0.519 . . . . 0.0 111.153 -177.051 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . 0.406 ' O ' HG11 ' A' ' 41' ' ' VAL . 23.4 m80 -102.51 125.63 49.3 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.619 -0.719 . . . . 0.0 109.237 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.643 ' HB3' HG13 ' A' ' 75' ' ' ILE . 0.4 OUTLIER -114.16 136.71 52.64 Favored 'General case' 0 C--N 1.315 -0.895 0 CA-C-O 120.978 0.418 . . . . 0.0 110.069 -176.848 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' LYS . . . . . 0.466 ' N ' HD13 ' A' ' 86' ' ' LEU . 78.7 tttt -127.08 115.71 19.59 Favored 'General case' 0 C--N 1.312 -1.046 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 176.45 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.488 HG21 ' HB1' ' A' ' 98' ' ' ALA . 73.4 p -69.35 142.44 54.0 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.766 -0.652 . . . . 0.0 111.812 -173.199 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.9 0 CA-C-N 115.674 -0.693 . . . . 0.0 112.777 -177.701 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . 0.488 ' HB1' HG21 ' A' ' 88' ' ' THR . . . . . . . . 0 N--CA 1.461 0.077 0 CA-C-O 121.597 0.713 . . . . 0.0 110.234 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 29.1 t80 -81.82 119.98 24.59 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.64 -0.709 . . . . 0.0 110.306 -172.548 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 26.0 mmt -98.66 151.58 20.56 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.597 -179.698 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . 0.501 ' O ' HG22 ' A' ' 33' ' ' VAL . . . -124.36 26.67 5.72 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.45 -0.881 . . . . 0.0 112.555 -179.828 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.494 HD12 HD12 ' A' ' 29' ' ' ILE . 45.6 pt -136.3 162.41 35.82 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-O 121.112 0.482 . . . . 0.0 110.549 179.686 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . 0.455 ' CB ' ' HB3' ' A' ' 30' ' ' ASP . 28.5 mmt85 -102.18 146.34 28.11 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 115.487 -0.779 . . . . 0.0 109.421 176.056 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 16.5 p -131.59 154.49 48.8 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.225 0.536 . . . . 0.0 111.61 -179.6 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 15.7 p -122.88 171.09 9.46 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.903 -0.59 . . . . 0.0 109.692 175.539 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . 0.929 ' HB3' ' HG ' ' A' ' 59' ' ' LEU . 19.8 p-10 . . . . . 0 C--N 1.321 -0.659 0 N-CA-C 111.812 0.301 . . . . 0.0 111.812 -175.943 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 16.0 t70 . . . . . 0 CA--C 1.528 0.106 0 CA-C-O 121.02 0.438 . . . . 0.0 111.134 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.566 ' HA2' ' HA ' ' A' ' 57' ' ' SER . . . 165.59 172.04 32.52 Favored Glycine 0 N--CA 1.45 -0.367 0 N-CA-C 111.141 -0.784 . . . . 0.0 111.141 -177.795 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.581 HG23 ' HB ' ' A' ' 48' ' ' ILE . 30.7 m -124.0 148.16 28.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-O 121.242 0.544 . . . . 0.0 111.117 179.147 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . 0.536 ' HG3' ' O ' ' A' ' 46' ' ' LEU . 60.0 tt0 -128.34 152.06 48.59 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.007 -179.248 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.49 HD11 ' HB2' ' A' ' 46' ' ' LEU . 2.8 pt -86.5 122.16 38.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 121.238 0.542 . . . . 0.0 111.245 179.345 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.615 ' HB3' ' CB ' ' A' ' 103' ' ' ARG . 15.8 t70 -64.44 -61.74 2.03 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 114.699 -1.137 . . . . 0.0 110.828 -179.13 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.475 ' HA ' ' HB3' ' A' ' 44' ' ' PRO . 51.3 p -166.94 161.81 15.3 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.602 -0.726 . . . . 0.0 110.936 -175.582 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.568 ' HA ' HG22 ' A' ' 102' ' ' ILE . 85.2 t -98.81 129.14 49.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.788 177.314 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 47.0 t -92.69 129.67 39.52 Favored Pre-proline 0 C--N 1.322 -0.621 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.006 -179.749 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_exo -56.64 123.74 14.58 Favored 'Trans proline' 0 C--O 1.234 0.291 0 C-N-CA 122.584 2.189 . . . . 0.0 111.929 178.07 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 117.27 18.05 5.54 Favored Glycine 0 N--CA 1.447 -0.594 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.379 -176.152 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.667 ' HB3' ' HA3' ' A' ' 101' ' ' GLY . 54.3 p -121.54 149.79 53.43 Favored Pre-proline 0 C--N 1.322 -0.615 0 CA-C-N 115.58 -0.31 . . . . 0.0 110.801 -177.111 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_endo -71.14 -25.41 22.42 Favored 'Trans proline' 0 N--CA 1.463 -0.271 0 C-N-CA 122.338 2.025 . . . . 0.0 111.949 176.112 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -72.45 -10.62 60.01 Favored 'General case' 0 C--O 1.234 0.245 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.808 -175.611 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.535 ' HA ' HG11 ' A' ' 32' ' ' VAL . 24.7 p -59.16 -28.75 66.88 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.91 -177.85 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 65.0 mttm -110.92 15.06 21.99 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.879 0.371 . . . . 0.0 111.083 179.858 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 53.8 t -101.66 -59.49 3.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-O 120.972 0.415 . . . . 0.0 110.368 178.599 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -130.66 169.28 15.85 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.118 -179.868 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 18.3 p -105.15 138.96 19.68 Favored Pre-proline 0 C--N 1.318 -0.775 0 CA-C-N 115.624 -0.717 . . . . 0.0 110.182 177.705 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.475 ' HB3' ' HA ' ' A' ' 31' ' ' SER . 32.1 Cg_endo -65.18 141.85 71.14 Favored 'Trans proline' 0 N--CA 1.462 -0.373 0 C-N-CA 122.34 2.027 . . . . 0.0 112.31 -179.188 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 110.24 -1.27 29.68 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.8 -177.206 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.536 ' O ' ' HG3' ' A' ' 28' ' ' GLN . 90.1 mt -85.36 163.39 18.58 Favored 'General case' 0 C--N 1.328 -0.351 0 O-C-N 122.459 -0.436 . . . . 0.0 110.84 178.938 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.478 ' HB ' ' HB2' ' A' ' 80' ' ' ASP . 47.0 t -105.44 135.2 44.53 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.264 -179.233 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.581 ' HB ' HG23 ' A' ' 27' ' ' VAL . 69.4 mt -95.5 119.12 43.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 N-CA-C 110.118 -0.327 . . . . 0.0 110.118 -179.733 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 29.8 mt-10 -86.66 -46.15 10.33 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.332 -0.394 . . . . 0.0 111.216 -178.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . 0.567 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 36.1 p -159.69 155.07 25.41 Favored 'General case' 0 C--N 1.325 -0.482 0 C-N-CA 120.326 -0.55 . . . . 0.0 112.028 -177.759 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 55.6 mt -112.93 97.38 5.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 115.372 -0.831 . . . . 0.0 111.003 179.195 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 49.2 t30 58.52 35.4 24.6 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.171 -0.922 . . . . 0.0 111.874 171.291 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 108.95 -27.4 13.01 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.057 178.835 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' MET . . . . . 0.411 ' HA ' ' HD3' ' A' ' 55' ' ' PRO . 71.6 mtm -98.88 106.88 40.35 Favored Pre-proline 0 C--N 1.324 -0.51 0 N-CA-C 109.978 -0.378 . . . . 0.0 109.978 178.723 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.567 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 6.1 Cg_exo -77.61 150.02 27.46 Favored 'Trans proline' 0 N--CA 1.457 -0.633 0 C-N-CA 122.669 2.246 . . . . 0.0 112.095 -177.626 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 19.8 p -123.13 106.72 11.02 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 120.915 0.388 . . . . 0.0 111.399 -178.241 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . 0.566 ' HA ' ' HA2' ' A' ' 26' ' ' GLY . 15.1 p -99.0 -22.16 15.87 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 121.038 0.447 . . . . 0.0 110.788 178.283 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . 0.507 ' HB3' ' OG1' ' A' ' 61' ' ' THR . 17.3 t-20 -117.18 172.23 7.43 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.091 -0.504 . . . . 0.0 109.733 179.264 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 40.3 mt -79.43 -42.6 25.06 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.469 -179.843 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 27.8 m -65.8 -29.49 69.99 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.778 177.652 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . 0.507 ' OG1' ' HB3' ' A' ' 58' ' ' ASN . 1.5 m -66.56 -37.42 84.93 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.177 0.513 . . . . 0.0 110.009 176.357 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 62.5 t80 -62.91 -45.76 90.98 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.217 -0.902 . . . . 0.0 109.4 174.345 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . 0.534 ' O ' ' HG2' ' A' ' 67' ' ' LYS . 59.6 m -59.48 -48.77 80.37 Favored 'General case' 0 N--CA 1.444 -0.744 0 CA-C-N 115.243 -0.889 . . . . 0.0 111.695 177.565 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -60.3 -31.08 69.93 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.721 -178.454 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . 0.402 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -76.2 -42.87 44.86 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.334 0.588 . . . . 0.0 109.885 176.995 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.433 ' HA ' HD22 ' A' ' 66' ' ' LEU . 0.2 OUTLIER -58.06 -32.96 68.52 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 114.958 -1.019 . . . . 0.0 111.382 178.803 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . 0.534 ' HG2' ' O ' ' A' ' 63' ' ' SER . 31.5 mmmt -56.01 -35.14 66.48 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.944 -179.938 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 24.5 p -92.84 -12.74 30.3 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 112.317 0.488 . . . . 0.0 112.317 -174.851 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.596 HG21 HG21 ' A' ' 88' ' ' THR . 46.2 mm -74.47 136.92 24.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 120.888 0.375 . . . . 0.0 110.571 -178.129 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . 0.406 ' HB2' ' HB2' ' A' ' 73' ' ' GLU . 6.0 m -89.17 161.82 16.26 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.748 -178.452 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 11.4 t -80.34 115.12 22.28 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 N-CA-C 108.672 -0.862 . . . . 0.0 108.672 171.848 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 99.13 9.45 51.6 Favored Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 120.751 -0.738 . . . . 0.0 111.271 -173.364 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.406 ' HB2' ' HB2' ' A' ' 70' ' ' SER . 10.7 tp10 -80.81 149.14 29.7 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 179.054 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 58.3 t -111.01 108.13 24.69 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.989 0 N-CA-C 109.273 -0.639 . . . . 0.0 109.273 176.872 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 17.1 pt -101.08 153.62 4.81 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 CA-C-O 121.44 0.638 . . . . 0.0 111.662 -176.366 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 3.9 t30 -107.4 104.41 13.99 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 114.949 -1.023 . . . . 0.0 109.716 -176.226 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 65.0 mt -106.85 110.7 32.64 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.011 0 CA-C-O 121.317 0.58 . . . . 0.0 111.241 -173.799 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . 0.479 ' HA ' ' HA ' ' A' ' 83' ' ' THR . 91.8 m -85.19 114.34 22.23 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-N 115.595 -0.73 . . . . 0.0 109.271 174.694 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 50.1 p -103.42 175.66 5.41 Favored 'General case' 0 N--CA 1.443 -0.797 0 CA-C-O 121.061 0.458 . . . . 0.0 110.387 179.85 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . 0.478 ' HB2' ' HB ' ' A' ' 47' ' ' VAL . 9.3 t70 -51.71 -33.42 34.25 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.006 -0.997 . . . . 0.0 112.515 179.43 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 5.3 mt-30 -115.29 16.06 16.85 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 112.704 0.631 . . . . 0.0 112.704 -173.27 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 140.58 169.83 11.87 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.237 -0.983 . . . . 0.0 113.073 176.661 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . 0.479 ' HA ' ' HA ' ' A' ' 78' ' ' THR . 30.0 m -96.59 133.4 41.13 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.794 0.331 . . . . 0.0 111.122 -179.507 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 82.5 m-85 -123.19 157.21 33.52 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.232 177.561 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 1.7 p-80 -108.12 120.11 41.4 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.104 0.478 . . . . 0.0 110.273 176.486 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -109.95 146.95 34.35 Favored 'General case' 0 N--CA 1.444 -0.741 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.852 -176.841 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 77.7 tttt -111.82 124.17 51.8 Favored 'General case' 0 C--N 1.32 -0.693 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 174.516 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.596 HG21 HG21 ' A' ' 69' ' ' ILE . 13.4 p -80.69 132.26 35.55 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 120.981 0.419 . . . . 0.0 111.562 -178.648 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.651 0 C-N-CA 120.977 -0.63 . . . . 0.0 111.863 179.253 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.465 0.29 0 CA-C-O 120.957 0.408 . . . . 0.0 111.895 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 11.4 t80 -136.97 134.47 36.71 Favored 'General case' 0 C--N 1.323 -0.561 0 C-N-CA 120.851 -0.339 . . . . 0.0 110.32 -179.751 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' MET . . . . . 0.482 ' O ' ' HB2' ' A' ' 36' ' ' SER . 4.3 mpp? -86.92 -16.25 36.48 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.537 -0.301 . . . . 0.0 111.57 -177.468 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . 0.667 ' HA3' ' HB3' ' A' ' 36' ' ' SER . . . 90.58 30.33 12.07 Favored Glycine 0 CA--C 1.519 0.33 0 C-N-CA 120.878 -0.677 . . . . 0.0 112.866 178.931 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.568 HG22 ' HA ' ' A' ' 32' ' ' VAL . 36.6 pt -135.42 167.05 26.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-O 120.908 0.385 . . . . 0.0 110.584 -178.751 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . 0.615 ' CB ' ' HB3' ' A' ' 30' ' ' ASP . 36.9 mtt180 -98.53 155.54 17.23 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.666 173.286 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 3.3 m -139.1 149.98 45.16 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 121.092 0.473 . . . . 0.0 110.345 177.269 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 32.0 m -142.02 178.42 7.54 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 115.365 -0.834 . . . . 0.0 109.198 -178.337 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 10.4 p30 . . . . . 0 C--N 1.325 -0.496 0 CA-C-O 120.592 0.234 . . . . 0.0 110.874 177.637 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 14.5 t70 . . . . . 0 N--CA 1.465 0.283 0 CA-C-O 121.155 0.502 . . . . 0.0 110.718 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.487 ' HA2' ' HA ' ' A' ' 57' ' ' SER . . . 156.93 131.8 1.39 Allowed Glycine 0 N--CA 1.449 -0.486 0 CA-C-N 115.745 -0.661 . . . . 0.0 111.694 -179.597 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.467 HG23 ' HB ' ' A' ' 48' ' ' ILE . 31.5 m -72.7 140.15 18.42 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-O 121.218 0.532 . . . . 0.0 111.352 -177.931 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 4.1 tp-100 -107.45 133.76 51.48 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.651 -0.704 . . . . 0.0 111.11 -177.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.547 HD12 ' HB2' ' A' ' 46' ' ' LEU . 61.5 mt -73.29 105.87 2.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 CA-C-N 115.637 -0.711 . . . . 0.0 109.815 175.524 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 21.3 t70 -62.91 -65.21 0.72 Allowed 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.254 -178.037 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 12.4 p -156.46 152.53 27.55 Favored 'General case' 0 N--CA 1.444 -0.731 0 CA-C-N 115.21 -0.905 . . . . 0.0 110.724 -179.727 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.814 HG22 HG22 ' A' ' 102' ' ' ILE . 66.8 t -87.74 120.47 36.91 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.542 174.903 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.551 HG22 ' O ' ' A' ' 101' ' ' GLY . 22.7 m -82.05 160.53 62.94 Favored Pre-proline 0 C--N 1.325 -0.492 0 CA-C-N 116.777 -0.192 . . . . 0.0 110.534 -177.307 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_exo -66.86 99.24 0.45 Allowed 'Trans proline' 0 C--O 1.236 0.376 0 C-N-CA 122.584 2.19 . . . . 0.0 112.434 178.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.432 ' O ' ' HB2' ' A' ' 39' ' ' SER . . . 145.13 -165.17 27.82 Favored Glycine 0 N--CA 1.447 -0.592 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.566 178.762 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.411 ' OG ' ' HA3' ' A' ' 101' ' ' GLY . 51.0 p 64.37 157.76 0.12 Allowed Pre-proline 0 N--CA 1.473 0.682 0 C-N-CA 124.598 1.159 . . . . 0.0 112.168 179.194 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 2.0 Cg_endo -82.78 -5.53 11.51 Favored 'Trans proline' 0 N--CA 1.46 -0.497 0 C-N-CA 122.984 2.456 . . . . 0.0 112.102 175.756 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -96.68 -0.7 47.99 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.414 -176.575 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.432 ' HB2' ' O ' ' A' ' 35' ' ' GLY . 32.1 t -60.87 -30.78 70.34 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.617 -176.224 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 62.9 tttp -107.39 7.72 29.23 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.929 0.395 . . . . 0.0 110.739 -179.326 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 57.6 t -91.2 -55.69 5.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-O 120.962 0.411 . . . . 0.0 110.129 178.755 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 5.2 mp -108.61 162.04 14.51 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.266 -0.425 . . . . 0.0 109.974 178.061 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 20.5 p -112.42 155.64 43.4 Favored Pre-proline 0 C--N 1.317 -0.84 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 177.403 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -70.0 146.05 57.56 Favored 'Trans proline' 0 N--CA 1.459 -0.548 0 C-N-CA 121.65 1.567 . . . . 0.0 111.464 178.133 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 94.84 12.41 55.52 Favored Glycine 0 CA--C 1.522 0.521 0 C-N-CA 120.615 -0.802 . . . . 0.0 113.618 179.938 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.547 ' HB2' HD12 ' A' ' 29' ' ' ILE . 86.8 mt -98.0 162.03 13.43 Favored 'General case' 0 C--N 1.334 -0.105 0 CA-C-N 117.499 0.65 . . . . 0.0 110.904 177.063 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 59.6 t -110.79 128.31 67.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.781 -177.608 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.467 ' HB ' HG23 ' A' ' 27' ' ' VAL . 76.4 mt -91.66 121.34 42.04 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.396 179.743 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 61.9 mt-10 -82.54 -50.0 9.28 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.702 -179.279 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . 0.606 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 15.2 p -159.29 153.88 24.32 Favored 'General case' 0 N--CA 1.45 -0.441 0 CA-C-O 121.223 0.535 . . . . 0.0 112.122 -172.757 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 64.2 mt -122.78 101.58 9.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 115.158 -0.928 . . . . 0.0 110.113 176.616 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 35.0 t-20 55.26 67.9 0.95 Allowed 'General case' 0 N--CA 1.464 0.274 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.2 176.443 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 79.59 -46.14 3.02 Favored Glycine 0 CA--C 1.519 0.304 0 CA-C-N 115.559 -0.746 . . . . 0.0 112.944 178.639 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 64.0 mtm -80.96 114.28 47.36 Favored Pre-proline 0 C--N 1.324 -0.511 0 N-CA-C 110.157 -0.312 . . . . 0.0 110.157 -178.838 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.606 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 98.1 Cg_endo -80.02 146.13 17.99 Favored 'Trans proline' 0 N--CA 1.458 -0.597 0 C-N-CA 122.351 2.034 . . . . 0.0 112.573 -176.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 22.3 p -110.41 76.26 0.97 Allowed 'General case' 0 N--CA 1.447 -0.618 0 CA-C-O 121.355 0.598 . . . . 0.0 111.062 -179.473 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . 0.487 ' HA ' ' HA2' ' A' ' 26' ' ' GLY . 16.5 m -84.6 -15.07 46.9 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.175 177.643 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 6.3 t-20 -140.12 175.79 9.3 Favored 'General case' 0 N--CA 1.449 -0.476 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.091 -179.336 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.461 ' HG ' ' OD1' ' A' ' 106' ' ' ASN . 28.6 mt -75.4 -31.35 60.39 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.858 179.508 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 1.5 m -65.39 -43.3 91.07 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.634 178.292 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 7.2 p -64.92 -37.18 86.79 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.055 0.455 . . . . 0.0 110.325 177.083 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' TYR . . . . . 0.436 ' O ' ' HB2' ' A' ' 66' ' ' LEU . 84.4 t80 -62.85 -44.66 95.54 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.771 -0.65 . . . . 0.0 109.857 174.928 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 47.2 m -61.98 -47.16 86.08 Favored 'General case' 0 N--CA 1.446 -0.644 0 CA-C-N 115.286 -0.87 . . . . 0.0 111.997 179.225 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.44 -30.62 71.66 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.187 -178.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . 0.447 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -77.58 -44.2 29.24 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 121.09 0.471 . . . . 0.0 110.011 177.14 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.436 ' HB2' ' O ' ' A' ' 62' ' ' TYR . 0.2 OUTLIER -57.47 -36.43 71.45 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.358 -0.837 . . . . 0.0 112.166 -176.768 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 19.7 ptmt -71.95 -18.34 62.01 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 120.772 -0.371 . . . . 0.0 111.662 -177.676 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 44.6 p -92.12 -13.49 30.64 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.978 0.418 . . . . 0.0 110.767 -178.876 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.569 HD12 HG21 ' A' ' 75' ' ' ILE . 19.6 mm -83.35 144.91 9.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.356 -0.384 . . . . 0.0 109.998 -178.888 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 13.0 m -105.28 164.38 11.88 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.497 -0.319 . . . . 0.0 110.469 -179.438 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 36.2 t -77.5 119.48 26.21 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 175.349 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 88.63 22.83 38.35 Favored Glycine 0 N--CA 1.45 -0.409 0 N-CA-C 111.046 -0.822 . . . . 0.0 111.046 -175.57 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 5.2 tp10 -99.65 148.54 24.23 Favored 'General case' 0 C--N 1.324 -0.5 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 -179.826 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 52.9 t -104.39 127.95 58.3 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 177.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.569 HG21 HD12 ' A' ' 69' ' ' ILE . 16.1 pt -125.61 161.22 30.8 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-O 121.342 0.591 . . . . 0.0 111.903 -176.733 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 7.9 t30 -106.92 105.91 16.18 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.211 -0.904 . . . . 0.0 110.285 -179.069 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 72.6 mt -108.36 114.02 45.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-O 121.528 0.68 . . . . 0.0 110.496 -177.232 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . 0.462 ' HA ' ' HA ' ' A' ' 83' ' ' THR . 10.2 m -95.15 120.4 35.31 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 115.58 -0.737 . . . . 0.0 109.496 -179.559 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 45.8 p -112.61 175.65 5.35 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.535 -0.302 . . . . 0.0 110.522 -178.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 15.9 t70 -59.22 -28.24 66.48 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.016 179.296 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 1.5 mp0 -98.05 16.83 19.93 Favored 'General case' 0 C--O 1.235 0.294 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.887 -177.551 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 121.86 177.72 15.53 Favored Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 120.391 -0.909 . . . . 0.0 113.452 174.901 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . 0.462 ' HA ' ' HA ' ' A' ' 78' ' ' THR . 3.9 m -90.28 119.53 30.66 Favored 'General case' 0 C--N 1.324 -0.526 0 C-N-CA 122.609 0.364 . . . . 0.0 110.782 -178.708 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -116.69 157.18 25.85 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 121.149 0.499 . . . . 0.0 110.554 178.468 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 43.0 p-80 -111.97 129.98 56.01 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-N 115.614 -0.721 . . . . 0.0 109.223 176.8 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 7.5 tt -126.86 149.78 49.57 Favored 'General case' 0 C--N 1.314 -0.957 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.255 -173.716 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 1.7 tmtp? -124.9 124.14 41.42 Favored 'General case' 0 C--N 1.316 -0.874 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.316 179.778 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.512 HG21 ' HB1' ' A' ' 98' ' ' ALA . 73.5 p -74.73 127.95 34.39 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.592 -177.609 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.445 -0.738 0 C-N-CA 119.564 -1.303 . . . . 0.0 114.457 -177.535 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . 0.512 ' HB1' HG21 ' A' ' 88' ' ' THR . . . . . . . . 0 N--CA 1.465 0.31 0 CA-C-O 121.384 0.612 . . . . 0.0 111.788 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 26.8 m-85 -89.23 109.35 20.24 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.457 -178.076 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 61.0 mtm -86.19 -35.27 20.17 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.344 -178.708 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . 0.551 ' O ' HG22 ' A' ' 33' ' ' VAL . . . 114.46 -13.74 20.77 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.382 -0.914 . . . . 0.0 113.755 176.443 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.814 HG22 HG22 ' A' ' 32' ' ' VAL . 2.7 pp -120.06 149.37 22.79 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.791 0 O-C-N 122.429 -0.454 . . . . 0.0 110.422 179.79 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -88.91 137.09 32.63 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 176.291 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -109.48 145.58 36.0 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.317 -177.523 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 32.2 p -137.67 168.27 20.02 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.619 -0.719 . . . . 0.0 109.576 176.256 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . 0.461 ' OD1' ' HG ' ' A' ' 59' ' ' LEU . 1.0 OUTLIER . . . . . 0 C--N 1.319 -0.758 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.23 -178.423 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.693 ' HA ' ' HB3' ' A' ' 57' ' ' SER . 30.7 t0 . . . . . 0 N--CA 1.469 0.49 0 CA-C-O 122.299 1.047 . . . . 0.0 109.255 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 146.81 148.8 4.83 Favored Glycine 0 N--CA 1.444 -0.779 0 CA-C-N 114.648 -1.16 . . . . 0.0 111.448 176.041 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.458 HG23 ' HB ' ' A' ' 48' ' ' ILE . 29.3 m -122.51 144.1 33.05 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-O 121.018 0.437 . . . . 0.0 111.085 -179.63 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . 0.4 HE21 HG22 ' A' ' 47' ' ' VAL . 35.0 tt0 -112.32 153.32 27.4 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 110.004 -0.369 . . . . 0.0 110.004 175.697 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 60.3 mt -78.86 112.55 17.04 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-N 116.314 -0.403 . . . . 0.0 109.921 178.85 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.635 ' HB3' ' HB2' ' A' ' 103' ' ' ARG . 22.5 t70 -64.32 -65.11 0.72 Allowed 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.789 -0.641 . . . . 0.0 109.713 178.559 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 20.7 p -156.8 154.39 29.85 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.166 -0.925 . . . . 0.0 110.586 179.103 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.605 HG23 HG22 ' A' ' 102' ' ' ILE . 13.5 p -91.25 143.67 10.77 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 176.884 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 61.6 t -97.13 114.88 65.42 Favored Pre-proline 0 C--N 1.321 -0.636 0 N-CA-C 110.16 -0.311 . . . . 0.0 110.16 177.708 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -55.19 122.3 11.47 Favored 'Trans proline' 0 C--N 1.346 0.411 0 C-N-CA 123.094 2.529 . . . . 0.0 112.033 178.761 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 122.05 7.92 7.57 Favored Glycine 0 N--CA 1.446 -0.695 0 CA-C-N 115.55 -0.75 . . . . 0.0 111.711 -176.505 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 72.3 p -121.33 150.19 53.69 Favored Pre-proline 0 C--N 1.325 -0.457 0 CA-C-O 120.676 0.274 . . . . 0.0 110.497 -179.013 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -67.59 -16.33 46.7 Favored 'Trans proline' 0 C--N 1.346 0.421 0 C-N-CA 122.639 2.226 . . . . 0.0 112.513 179.648 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.492 ' HA ' HD11 ' A' ' 86' ' ' LEU . . . -60.34 -36.82 78.87 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.568 -177.518 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 22.9 t -64.69 -23.68 67.33 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.617 -176.533 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 63.4 tttp -82.0 -26.03 34.21 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.027 0.441 . . . . 0.0 110.683 -177.505 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 38.6 t -99.22 -55.86 5.67 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.503 -175.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 1.9 pp -108.81 -178.02 3.47 Favored 'General case' 0 CA--C 1.516 -0.334 0 CA-C-O 121.527 0.68 . . . . 0.0 111.959 -177.472 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 5.4 p -127.85 143.53 48.04 Favored Pre-proline 0 C--N 1.315 -0.894 0 CA-C-N 114.94 -1.027 . . . . 0.0 110.645 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -66.69 146.19 78.13 Favored 'Trans proline' 0 N--CA 1.462 -0.347 0 C-N-CA 122.39 2.06 . . . . 0.0 111.627 175.643 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 102.55 -7.74 54.03 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.568 -178.105 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 89.1 mt -80.63 163.34 23.7 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.91 0.386 . . . . 0.0 110.772 179.061 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.409 ' O ' ' HA ' ' A' ' 79' ' ' THR . 44.3 t -103.24 137.15 32.68 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 N-CA-C 109.422 -0.585 . . . . 0.0 109.422 176.858 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.458 ' HB ' HG23 ' A' ' 27' ' ' VAL . 63.2 mt -103.15 121.26 54.16 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-O 120.786 0.327 . . . . 0.0 110.603 -179.213 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -82.71 -47.44 12.0 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.018 0.437 . . . . 0.0 110.848 177.501 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . 0.623 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 6.1 p -152.15 146.28 25.36 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 121.176 0.512 . . . . 0.0 112.244 -174.185 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 47.4 mm -110.89 101.47 12.6 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-N 114.699 -1.137 . . . . 0.0 108.211 173.488 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 4.6 t-20 66.13 -152.15 0.23 Allowed 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 -172.493 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -73.42 7.28 12.64 Favored Glycine 0 CA--C 1.523 0.554 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.656 177.143 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 2.1 mpt? -111.62 102.53 53.57 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 120.812 0.339 . . . . 0.0 110.131 -179.667 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.623 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 44.5 Cg_endo -71.67 124.27 10.11 Favored 'Trans proline' 0 N--CA 1.46 -0.458 0 C-N-CA 122.146 1.897 . . . . 0.0 112.215 179.661 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 16.8 p -92.13 96.89 10.58 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.877 -0.602 . . . . 0.0 111.358 -176.369 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . 0.693 ' HB3' ' HA ' ' A' ' 25' ' ' ASP . 14.2 m -94.75 -19.65 20.19 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.303 178.857 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 76.2 m-20 -123.92 164.32 19.53 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.13 -178.886 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 84.5 mt -75.81 -30.47 59.05 Favored 'General case' 0 N--CA 1.443 -0.802 0 CA-C-O 121.185 0.517 . . . . 0.0 109.906 177.924 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 9.6 m -69.17 -39.47 78.74 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.611 -0.722 . . . . 0.0 111.152 178.512 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -71.05 -27.9 63.98 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.628 0.251 . . . . 0.0 111.065 179.909 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 87.1 t80 -64.41 -40.72 96.32 Favored 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 173.069 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . 0.421 ' O ' ' HD3' ' A' ' 67' ' ' LYS . 7.0 t -66.68 -43.33 84.73 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.732 -0.667 . . . . 0.0 109.855 176.596 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.31 -33.21 74.22 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 121.164 0.507 . . . . 0.0 110.793 179.693 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . 0.679 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -69.01 -49.3 58.96 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.946 -0.57 . . . . 0.0 109.831 176.357 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.409 ' HA ' HD23 ' A' ' 66' ' ' LEU . 11.2 mt -58.57 -36.47 73.99 Favored 'General case' 0 N--CA 1.448 -0.575 0 CA-C-N 116.002 -0.544 . . . . 0.0 112.129 -177.387 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . 0.421 ' HD3' ' O ' ' A' ' 63' ' ' SER . 2.4 mptm? -77.52 -7.04 55.65 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 112.494 0.553 . . . . 0.0 112.494 -179.029 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 9.0 p -110.41 -13.69 14.24 Favored 'General case' 0 C--N 1.323 -0.557 0 C-N-CA 120.807 -0.357 . . . . 0.0 111.785 178.755 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.679 HG12 ' O ' ' A' ' 65' ' ' ALA . 33.4 mm -73.33 148.33 8.91 Favored 'Isoleucine or valine' 0 C--O 1.234 0.237 0 N-CA-C 110.17 -0.307 . . . . 0.0 110.17 177.685 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . 0.588 ' HB2' ' HB2' ' A' ' 73' ' ' GLU . 3.2 m -84.89 164.63 18.27 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.269 177.675 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 26.7 t -82.2 123.13 37.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 177.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 81.9 21.73 60.84 Favored Glycine 0 N--CA 1.448 -0.548 0 C-N-CA 120.574 -0.822 . . . . 0.0 111.549 -178.496 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.588 ' HB2' ' HB2' ' A' ' 70' ' ' SER . 34.4 tt0 -96.5 150.12 20.98 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -178.561 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 48.0 t -100.33 120.44 49.79 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.759 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.285 -177.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 27.7 pt -113.86 154.53 15.23 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-N 115.998 -0.547 . . . . 0.0 110.913 -179.47 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 13.0 t30 -93.33 118.18 30.97 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.467 179.676 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 51.3 mt -114.34 103.99 16.22 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.832 0 CA-C-O 121.417 0.627 . . . . 0.0 109.85 178.335 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 15.9 m -90.41 111.17 22.32 Favored 'General case' 0 C--N 1.315 -0.929 0 CA-C-N 115.701 -0.682 . . . . 0.0 109.729 179.225 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.409 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 73.3 p -107.63 171.81 7.18 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.961 0.41 . . . . 0.0 111.692 -176.74 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -52.34 -33.37 42.53 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.159 -0.928 . . . . 0.0 112.826 -178.501 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 17.4 mt-30 -127.0 27.07 6.02 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 112.334 0.494 . . . . 0.0 112.334 -174.101 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 161.32 146.23 4.57 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 119.764 -1.208 . . . . 0.0 114.053 174.788 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 8.8 m -98.57 109.75 22.46 Favored 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 175.113 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 59.7 m-85 -115.36 158.53 22.3 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.806 0.336 . . . . 0.0 110.801 -174.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 14.3 p80 -118.9 114.57 22.8 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 121.312 0.577 . . . . 0.0 110.022 174.241 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.492 HD11 ' HA ' ' A' ' 38' ' ' ALA . 3.5 mm? -107.33 148.59 28.84 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-N 115.297 -0.865 . . . . 0.0 111.247 -173.449 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 40.3 ttmt -98.77 130.31 45.22 Favored 'General case' 0 C--N 1.321 -0.664 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 173.941 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.523 HG21 HG21 ' A' ' 69' ' ' ILE . 15.1 p -71.05 129.69 39.61 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-O 121.0 0.429 . . . . 0.0 110.558 176.43 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.434 -1.457 0 N-CA-C 110.936 -0.865 . . . . 0.0 110.936 -179.776 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.467 0.409 0 CA-C-O 121.185 0.517 . . . . 0.0 110.124 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 46.4 t80 -120.83 128.35 52.77 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.411 -167.129 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 46.4 tpp -108.06 120.24 41.76 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 173.868 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -86.52 57.17 4.72 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.788 -0.72 . . . . 0.0 114.124 -170.79 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.605 HG22 HG23 ' A' ' 32' ' ' VAL . 2.6 pp -143.82 148.92 18.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 173.066 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . 0.635 ' HB2' ' HB3' ' A' ' 30' ' ' ASP . 43.4 mtp180 -90.87 143.34 26.82 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 116.376 -0.374 . . . . 0.0 110.264 176.749 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 2.1 p -115.82 143.4 45.45 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 121.063 0.458 . . . . 0.0 110.962 178.924 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 37.3 t -136.3 169.57 17.44 Favored 'General case' 0 C--N 1.317 -0.832 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 177.931 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 5.4 p30 . . . . . 0 C--N 1.31 -1.109 0 CA-C-O 122.031 0.919 . . . . 0.0 109.692 178.701 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.404 ' HA ' ' HB3' ' A' ' 57' ' ' SER . 12.1 t70 . . . . . 0 N--CA 1.467 0.404 0 CA-C-O 121.901 0.858 . . . . 0.0 110.12 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 173.7 140.89 3.35 Favored Glycine 0 N--CA 1.446 -0.662 0 CA-C-N 114.792 -1.094 . . . . 0.0 111.266 177.139 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 28.8 m -120.76 146.4 25.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 116.819 0.309 . . . . 0.0 110.319 179.279 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . 0.406 ' HB2' HE21 ' A' ' 28' ' ' GLN . 0.0 OUTLIER -123.0 159.45 28.33 Favored 'General case' 0 C--N 1.322 -0.594 0 C-N-CA 120.503 -0.479 . . . . 0.0 110.997 -178.722 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 56.5 mt -81.7 106.14 12.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 115.907 -0.588 . . . . 0.0 109.949 179.641 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 14.8 t70 -68.03 -63.78 0.99 Allowed 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 116.054 -0.521 . . . . 0.0 109.88 -177.568 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 2.2 p -155.41 140.47 17.4 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.912 -0.586 . . . . 0.0 111.829 -177.312 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.659 HG22 HG22 ' A' ' 102' ' ' ILE . 96.5 t -86.91 126.45 40.84 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.208 -0.451 . . . . 0.0 109.819 177.89 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 5.6 m -103.38 129.19 25.94 Favored Pre-proline 0 N--CA 1.451 -0.419 0 CA-C-O 121.117 0.484 . . . . 0.0 111.863 -175.659 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -69.3 164.25 34.81 Favored 'Trans proline' 0 C--O 1.235 0.331 0 C-N-CA 122.743 2.295 . . . . 0.0 112.048 176.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 98.12 -34.13 5.46 Favored Glycine 0 N--CA 1.449 -0.436 0 N-CA-C 110.661 -0.976 . . . . 0.0 110.661 -174.605 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.414 ' HB2' ' HD2' ' A' ' 37' ' ' PRO . 0.7 OUTLIER -104.84 169.86 6.66 Favored Pre-proline 0 C--N 1.317 -0.835 0 CA-C-N 114.721 -0.74 . . . . 0.0 109.569 175.347 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . 0.414 ' HD2' ' HB2' ' A' ' 36' ' ' SER . 42.3 Cg_endo -68.59 -170.26 0.31 Allowed 'Trans proline' 0 CA--C 1.534 0.492 0 C-N-CA 122.264 1.976 . . . . 0.0 112.74 177.827 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 74.53 6.19 4.53 Favored 'General case' 0 N--CA 1.471 0.577 0 C-N-CA 123.575 0.75 . . . . 0.0 112.343 179.733 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 23.1 t -52.35 -62.18 1.8 Allowed 'General case' 0 C--O 1.233 0.232 0 O-C-N 123.448 0.467 . . . . 0.0 110.608 -179.712 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 3.3 tmtp? -111.24 65.37 0.62 Allowed 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 172.328 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.415 HG12 HD12 ' A' ' 42' ' ' LEU . 36.5 t -137.94 -49.77 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.382 -0.826 . . . . 0.0 109.292 175.793 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.415 HD12 HG12 ' A' ' 41' ' ' VAL . 6.3 mp -119.58 171.49 8.33 Favored 'General case' 0 C--O 1.234 0.262 0 CA-C-N 115.625 -0.716 . . . . 0.0 109.88 176.079 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 7.3 p -126.65 146.58 57.47 Favored Pre-proline 0 C--N 1.322 -0.612 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.487 177.474 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 76.9 Cg_endo -76.95 157.03 34.62 Favored 'Trans proline' 0 C--O 1.233 0.246 0 C-N-CA 122.549 2.166 . . . . 0.0 111.975 178.402 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 90.62 11.71 61.84 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.58 -0.819 . . . . 0.0 112.697 179.063 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 64.7 mt -103.47 164.36 11.7 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.809 0.304 . . . . 0.0 110.207 178.042 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 48.1 t -105.98 137.66 35.0 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 N-CA-C 110.315 -0.254 . . . . 0.0 110.315 176.307 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 60.3 mt -95.72 129.78 45.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 121.097 0.475 . . . . 0.0 110.846 -178.411 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 22.3 tt0 -86.66 -56.02 3.6 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.635 -0.711 . . . . 0.0 110.198 175.612 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . 0.603 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 13.7 p -148.99 152.49 36.4 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.243 -0.889 . . . . 0.0 112.067 -170.556 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 49.7 mm -111.41 85.44 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.043 -0.98 . . . . 0.0 109.742 176.315 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' ASN . . . . . 0.629 ' HB2' ' H ' ' A' ' 76' ' ' ASN . 62.3 t30 54.72 78.88 0.16 Allowed 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 114.843 -1.072 . . . . 0.0 111.949 176.727 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 83.37 -49.06 4.16 Favored Glycine 0 N--CA 1.447 -0.579 0 CA-C-N 115.541 -0.754 . . . . 0.0 112.459 178.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 58.4 mtm -85.56 111.78 39.64 Favored Pre-proline 0 C--N 1.324 -0.521 0 N-CA-C 110.387 -0.227 . . . . 0.0 110.387 -179.718 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.603 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 70.6 Cg_endo -75.1 134.04 17.16 Favored 'Trans proline' 0 N--CA 1.458 -0.577 0 C-N-CA 122.054 1.836 . . . . 0.0 111.833 178.921 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 24.5 p -109.34 93.37 4.47 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 121.47 0.652 . . . . 0.0 111.547 -175.497 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . 0.404 ' HB3' ' HA ' ' A' ' 25' ' ' ASP . 19.3 m -99.74 -14.31 18.92 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 115.229 -0.896 . . . . 0.0 110.155 177.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 52.7 m-80 -125.98 159.27 33.1 Favored 'General case' 0 C--N 1.319 -0.74 0 C-N-CA 120.502 -0.479 . . . . 0.0 109.887 -179.268 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 96.6 mt -70.74 -28.29 64.59 Favored 'General case' 0 N--CA 1.44 -0.954 0 CA-C-N 115.734 -0.666 . . . . 0.0 109.387 177.144 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 5.1 m -69.54 -48.92 58.8 Favored 'General case' 0 N--CA 1.448 -0.565 0 CA-C-N 115.254 -0.884 . . . . 0.0 110.629 178.557 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 1.7 p -67.42 -34.37 77.08 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.77 0.319 . . . . 0.0 111.042 178.095 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 25.8 t80 -62.54 -40.11 95.77 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.308 0.575 . . . . 0.0 109.618 175.381 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . 0.525 ' O ' ' HG3' ' A' ' 67' ' ' LYS . 8.1 t -67.33 -45.13 77.32 Favored 'General case' 0 N--CA 1.452 -0.37 0 CA-C-N 115.459 -0.791 . . . . 0.0 110.36 178.576 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -60.02 -38.35 82.45 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.811 -179.217 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . 0.51 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -65.11 -46.0 82.84 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.377 -179.49 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 2.3 tt -58.58 -42.3 87.72 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.756 -0.657 . . . . 0.0 110.544 -179.413 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . 0.525 ' HG3' ' O ' ' A' ' 63' ' ' SER . 96.0 mttt -63.33 -23.51 67.45 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.566 -0.743 . . . . 0.0 112.483 -177.102 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 77.5 p -90.9 -13.07 34.3 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.779 0.323 . . . . 0.0 111.35 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.584 HG21 HG21 ' A' ' 88' ' ' THR . 45.9 mm -72.68 136.42 25.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 121.174 0.511 . . . . 0.0 111.265 -176.789 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . 0.423 ' HB2' ' HB2' ' A' ' 73' ' ' GLU . 4.4 m -82.45 143.99 30.77 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.84 -0.618 . . . . 0.0 109.588 174.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 16.8 t -71.72 115.83 12.53 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-N 116.372 -0.377 . . . . 0.0 110.467 -177.074 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . 0.441 ' HA2' ' O ' ' A' ' 88' ' ' THR . . . 98.27 4.88 57.31 Favored Glycine 0 N--CA 1.447 -0.63 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.076 179.71 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.423 ' HB2' ' HB2' ' A' ' 70' ' ' SER . 9.0 tp10 -90.68 154.96 19.18 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 120.715 0.293 . . . . 0.0 110.27 -178.087 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 49.0 t -94.32 118.73 40.97 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.582 -178.486 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 32.5 pt -103.01 167.7 2.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.728 178.728 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . 0.629 ' H ' ' HB2' ' A' ' 52' ' ' ASN . 43.3 t30 -120.06 106.56 12.11 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.883 -172.283 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 57.6 mt -105.49 109.32 27.41 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.808 0 CA-C-O 121.328 0.585 . . . . 0.0 110.769 -174.675 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 31.1 m -89.72 114.78 26.5 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.494 -0.775 . . . . 0.0 109.72 176.485 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 69.4 p -112.55 174.15 6.03 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 110.29 -0.263 . . . . 0.0 110.29 179.02 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 12.4 t70 -63.27 -30.36 71.51 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.342 178.244 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 8.2 tp-100 -95.64 14.57 22.57 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.333 0.587 . . . . 0.0 110.891 -176.345 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 127.36 179.67 15.94 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.53 176.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 55.6 m -109.92 129.45 55.65 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-O 120.696 0.284 . . . . 0.0 110.561 -178.329 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 23.5 m-85 -128.43 152.42 48.23 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 -179.607 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 7.8 p-80 -109.24 133.21 53.33 Favored 'General case' 0 C--N 1.322 -0.621 0 C-N-CA 120.62 -0.432 . . . . 0.0 110.011 174.041 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.484 HD23 ' N ' ' A' ' 87' ' ' LYS . 5.5 tt -118.97 137.53 53.43 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 115.918 -0.583 . . . . 0.0 109.734 -175.085 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' LYS . . . . . 0.484 ' N ' HD23 ' A' ' 86' ' ' LEU . 62.1 tttp -98.41 117.05 31.95 Favored 'General case' 0 C--N 1.311 -1.1 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 179.049 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.584 HG21 HG21 ' A' ' 69' ' ' ILE . 16.9 p -66.95 135.41 53.75 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 121.152 0.501 . . . . 0.0 111.154 -176.465 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.439 -1.155 0 N-CA-C 111.004 -0.838 . . . . 0.0 111.004 177.03 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.463 0.2 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 46.4 t80 -112.11 128.8 56.32 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 121.304 0.573 . . . . 0.0 111.887 -171.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 20.6 ptp -94.17 141.59 28.38 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.277 174.565 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -84.52 37.15 2.92 Favored Glycine 0 CA--C 1.519 0.319 0 C-N-CA 121.099 -0.572 . . . . 0.0 114.2 -170.836 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.659 HG22 HG22 ' A' ' 32' ' ' VAL . 33.6 pt -138.24 154.06 27.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 117.204 0.502 . . . . 0.0 110.481 178.095 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 55.7 mtp180 -93.66 117.11 29.66 Favored 'General case' 0 C--N 1.318 -0.788 0 N-CA-C 108.336 -0.987 . . . . 0.0 108.336 171.476 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -111.03 137.18 48.99 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-O 121.344 0.592 . . . . 0.0 110.624 -178.017 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 19.1 m -156.97 164.24 38.23 Favored 'General case' 0 C--N 1.31 -1.115 0 CA-C-N 115.543 -0.753 . . . . 0.0 109.462 -178.866 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 14.9 p30 . . . . . 0 C--N 1.319 -0.728 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 169.008 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 17.0 p-10 . . . . . 0 C--O 1.233 0.212 0 CA-C-O 120.969 0.414 . . . . 0.0 111.23 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.414 ' HA2' ' HA ' ' A' ' 57' ' ' SER . . . 134.53 162.94 10.05 Favored Glycine 0 N--CA 1.445 -0.73 0 N-CA-C 111.587 -0.605 . . . . 0.0 111.587 -179.255 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.496 HG23 ' HB ' ' A' ' 48' ' ' ILE . 15.3 m -99.73 134.37 39.32 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-O 121.13 0.491 . . . . 0.0 110.957 176.942 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 6.6 tp60 -97.58 133.5 42.06 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.786 -176.577 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.605 ' HB ' ' H ' ' A' ' 46' ' ' LEU . 36.7 mm -72.65 112.66 8.89 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-N 115.706 -0.679 . . . . 0.0 109.773 173.155 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 16.7 t70 -76.15 -69.75 0.48 Allowed 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.09 -179.289 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 7.7 p -148.96 142.66 25.54 Favored 'General case' 0 N--CA 1.447 -0.594 0 CA-C-O 121.398 0.618 . . . . 0.0 111.553 -178.203 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.524 HG11 ' HA ' ' A' ' 39' ' ' SER . 61.4 t -98.55 119.35 46.43 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-N 114.96 -1.018 . . . . 0.0 109.185 173.945 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.503 HG12 ' O ' ' A' ' 101' ' ' GLY . 10.9 p -91.69 131.85 34.74 Favored Pre-proline 0 C--N 1.324 -0.527 0 CA-C-O 120.776 0.322 . . . . 0.0 110.294 -178.329 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -58.34 147.23 86.11 Favored 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.816 2.344 . . . . 0.0 112.226 -179.469 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 91.64 24.74 25.01 Favored Glycine 0 N--CA 1.448 -0.526 0 C-N-CA 120.759 -0.734 . . . . 0.0 111.82 -177.374 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.544 ' CB ' ' HA3' ' A' ' 101' ' ' GLY . 61.3 p -125.85 157.35 69.32 Favored Pre-proline 0 C--N 1.325 -0.49 0 N-CA-C 110.155 -0.313 . . . . 0.0 110.155 -179.934 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 29.5 Cg_endo -64.07 -30.77 65.97 Favored 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.424 2.082 . . . . 0.0 112.099 176.901 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.531 ' HB2' HD11 ' A' ' 86' ' ' LEU . . . -80.15 -13.52 59.19 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.436 -177.894 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.524 ' HA ' HG11 ' A' ' 32' ' ' VAL . 22.9 t -61.46 -27.95 68.94 Favored 'General case' 0 CA--C 1.532 0.283 0 N-CA-C 112.249 0.463 . . . . 0.0 112.249 -174.468 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 52.2 mtmt -103.18 -13.81 16.63 Favored 'General case' 0 C--N 1.326 -0.44 0 C-N-CA 120.88 -0.328 . . . . 0.0 111.645 -176.334 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.459 ' HB ' HD12 ' A' ' 42' ' ' LEU . 35.3 t -103.92 -38.73 5.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-N 116.565 -0.289 . . . . 0.0 111.519 -174.319 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.459 HD12 ' HB ' ' A' ' 41' ' ' VAL . 6.5 mp -113.8 168.59 9.66 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.131 0.491 . . . . 0.0 111.119 -177.213 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 7.4 p -129.75 156.4 78.93 Favored Pre-proline 0 C--N 1.321 -0.643 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.026 177.17 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -73.56 154.13 49.79 Favored 'Trans proline' 0 N--CA 1.463 -0.273 0 C-N-CA 122.285 1.99 . . . . 0.0 112.368 179.641 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 81.89 28.78 40.73 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.891 -0.671 . . . . 0.0 113.323 177.551 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.641 HD22 ' HB2' ' A' ' 81' ' ' GLN . 53.6 mt -109.2 162.01 14.69 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 117.066 0.433 . . . . 0.0 110.519 176.214 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 62.1 t -110.99 130.2 64.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 N-CA-C 110.035 -0.357 . . . . 0.0 110.035 178.227 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.552 HD11 HD11 ' A' ' 29' ' ' ILE . 76.7 mt -89.66 121.19 39.56 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-O 121.042 0.449 . . . . 0.0 110.894 -179.573 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 10.6 tt0 -77.32 -57.0 4.07 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.403 -0.817 . . . . 0.0 110.06 176.208 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . 0.628 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 14.7 p -146.8 152.82 39.38 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.194 -0.912 . . . . 0.0 111.988 -172.126 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 42.9 mm -111.91 97.15 5.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.262 176.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' ASN . . . . . 0.548 ' HA ' ' HB3' ' A' ' 76' ' ' ASN . 6.5 t30 67.43 -80.78 0.03 OUTLIER 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 114.884 -1.053 . . . . 0.0 111.905 174.262 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -126.73 3.39 7.52 Favored Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 120.581 -0.819 . . . . 0.0 112.103 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 54.5 mtm -131.39 117.61 16.78 Favored Pre-proline 0 C--N 1.325 -0.488 0 N-CA-C 110.393 -0.225 . . . . 0.0 110.393 -177.73 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.628 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 56.0 Cg_endo -71.26 130.8 18.05 Favored 'Trans proline' 0 N--CA 1.463 -0.313 0 C-N-CA 122.325 2.017 . . . . 0.0 112.073 178.72 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 25.6 p -108.63 94.63 5.16 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 121.24 0.543 . . . . 0.0 111.269 -176.47 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . 0.414 ' HA ' ' HA2' ' A' ' 26' ' ' GLY . 5.5 m -95.55 -12.72 25.27 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.574 -0.739 . . . . 0.0 111.118 -177.828 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 6.9 t-20 -129.58 166.78 19.03 Favored 'General case' 0 C--N 1.321 -0.671 0 C-N-CA 120.597 -0.441 . . . . 0.0 109.92 176.769 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.499 ' HB2' ' HB2' ' A' ' 106' ' ' ASN . 0.4 OUTLIER -77.09 -36.45 55.68 Favored 'General case' 0 C--N 1.311 -1.098 0 CA-C-N 115.495 -0.775 . . . . 0.0 109.617 -179.011 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 6.3 m -68.09 -39.09 82.94 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.702 179.621 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 8.0 p -72.23 -37.43 69.18 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.111 0.481 . . . . 0.0 110.456 177.338 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 72.2 t80 -61.04 -43.72 98.47 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.239 175.232 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 4.7 t -65.3 -38.98 91.89 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.396 178.744 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -65.89 -33.91 76.93 Favored 'General case' 0 C--O 1.232 0.153 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.881 179.709 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -71.98 -45.16 62.03 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.253 178.499 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.412 HD23 ' HA ' ' A' ' 66' ' ' LEU . 8.2 mt -62.09 -33.42 74.4 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.245 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 37.0 ttmt -59.26 -21.98 60.45 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.869 -0.605 . . . . 0.0 111.519 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 61.0 p -100.73 -13.88 18.29 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 112.234 0.457 . . . . 0.0 112.234 -176.543 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 45.6 mm -74.5 138.01 21.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.974 0.416 . . . . 0.0 110.557 -176.773 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 7.8 m -104.03 172.92 6.54 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.611 -174.433 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 61.3 t -82.94 136.42 22.87 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.139 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.532 177.924 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 87.64 -8.59 76.97 Favored Glycine 0 N--CA 1.448 -0.516 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 -177.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 23.3 tt0 -80.73 145.77 31.37 Favored 'General case' 0 N--CA 1.445 -0.682 0 CA-C-N 114.916 -0.642 . . . . 0.0 109.679 -177.088 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.466 HG22 ' HG3' ' A' ' 87' ' ' LYS . 39.6 t -113.49 116.85 53.79 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 CA-C-N 115.984 -0.553 . . . . 0.0 109.994 -176.839 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 16.4 pt -106.15 153.49 7.52 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-O 121.481 0.658 . . . . 0.0 111.532 -178.739 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . 0.548 ' HB3' ' HA ' ' A' ' 52' ' ' ASN . 15.1 t30 -101.81 104.73 15.51 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 114.881 -1.054 . . . . 0.0 110.219 -178.042 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 52.6 mt -105.1 105.46 18.67 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.883 0 CA-C-O 121.191 0.52 . . . . 0.0 111.001 -174.314 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . 0.516 ' HA ' ' HA ' ' A' ' 83' ' ' THR . 35.2 m -85.65 120.48 27.13 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.369 175.062 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 70.7 p -121.37 175.12 6.32 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 120.918 0.39 . . . . 0.0 111.148 -178.038 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -62.42 -18.55 61.94 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.544 -0.753 . . . . 0.0 111.101 176.011 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . 0.641 ' HB2' HD22 ' A' ' 46' ' ' LEU . 7.3 tp-100 -102.84 4.42 37.74 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.147 0.498 . . . . 0.0 111.142 -177.419 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 128.74 175.88 14.23 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 120.57 -0.824 . . . . 0.0 112.623 179.438 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . 0.516 ' HA ' ' HA ' ' A' ' 78' ' ' THR . 20.0 m -96.78 109.14 21.87 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-O 120.71 0.29 . . . . 0.0 110.819 -178.455 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 -107.1 169.81 8.33 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.973 0.416 . . . . 0.0 110.622 -178.205 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 7.4 p80 -129.57 126.91 39.59 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 175.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.531 HD11 ' HB2' ' A' ' 38' ' ' ALA . 4.2 tt -117.89 138.71 51.94 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.113 0.482 . . . . 0.0 110.512 -174.002 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' LYS . . . . . 0.494 ' N ' HD23 ' A' ' 86' ' ' LEU . 60.5 tttp -116.71 121.02 40.43 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.535 -0.757 . . . . 0.0 109.354 179.831 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 29.6 p -71.57 139.42 49.41 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 120.733 0.302 . . . . 0.0 111.072 -178.844 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.511 -0.198 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.558 -174.744 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.457 -0.083 0 CA-C-O 120.573 0.225 . . . . 0.0 111.018 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 4.1 t80 -121.28 126.97 50.84 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 109.522 -0.548 . . . . 0.0 109.522 179.451 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' MET . . . . . 0.429 ' O ' ' HB2' ' A' ' 36' ' ' SER . 63.4 mtm -105.94 -33.22 8.0 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.461 -0.336 . . . . 0.0 111.135 -175.819 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . 0.544 ' HA3' ' CB ' ' A' ' 36' ' ' SER . . . 94.6 27.1 11.97 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.582 -0.818 . . . . 0.0 111.907 179.228 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.473 HG22 ' HA ' ' A' ' 32' ' ' VAL . 2.7 pp -136.01 150.43 28.21 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 178.339 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 4.1 mpt_? -104.18 139.44 39.22 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 175.566 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.9 p -117.63 161.44 19.64 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.8 179.156 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 66.8 m -143.95 161.95 37.41 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.334 175.857 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . 0.499 ' HB2' ' HB2' ' A' ' 59' ' ' LEU . 2.5 t-20 . . . . . 0 C--N 1.309 -1.178 0 N-CA-C 107.563 -1.273 . . . . 0.0 107.563 174.286 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 21.2 t70 . . . . . 0 CA--C 1.515 -0.39 0 CA-C-O 121.232 0.539 . . . . 0.0 110.726 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.569 ' HA2' ' HA ' ' A' ' 57' ' ' SER . . . 171.27 164.43 26.94 Favored Glycine 0 N--CA 1.442 -0.913 0 CA-C-N 115.263 -0.88 . . . . 0.0 111.188 -178.829 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 33.9 m -109.15 150.8 11.68 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.866 0 CA-C-O 120.768 0.318 . . . . 0.0 110.368 178.076 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . 0.406 HE21 ' HB2' ' A' ' 28' ' ' GLN . 0.0 OUTLIER -117.82 163.03 17.14 Favored 'General case' 0 C--N 1.32 -0.702 0 C-N-CA 120.751 -0.379 . . . . 0.0 110.45 176.937 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.565 HD12 ' HB2' ' A' ' 46' ' ' LEU . 56.6 mt -78.73 107.44 11.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-O 120.959 0.409 . . . . 0.0 110.273 -178.409 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.632 ' HB3' ' HB2' ' A' ' 103' ' ' ARG . 14.9 t70 -65.67 -70.6 0.23 Allowed 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 115.185 -0.916 . . . . 0.0 110.638 -176.068 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.474 ' HA ' ' HB3' ' A' ' 44' ' ' PRO . 4.2 p -148.59 144.87 27.54 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.596 -0.729 . . . . 0.0 111.128 -178.566 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.546 ' HA ' HG22 ' A' ' 102' ' ' ILE . 96.2 t -94.86 126.54 47.26 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.207 178.606 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 48.4 t -109.0 123.87 35.76 Favored Pre-proline 0 C--N 1.327 -0.379 0 CA-C-N 116.461 -0.336 . . . . 0.0 110.631 179.767 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -58.97 154.39 45.08 Favored 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.972 2.448 . . . . 0.0 112.175 178.1 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 104.26 6.91 41.38 Favored Glycine 0 N--CA 1.45 -0.4 0 N-CA-C 110.849 -0.9 . . . . 0.0 110.849 -175.397 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.539 ' CB ' ' HA3' ' A' ' 101' ' ' GLY . 60.4 p -130.16 159.17 71.64 Favored Pre-proline 0 C--N 1.322 -0.623 0 CA-C-N 115.185 -0.508 . . . . 0.0 110.054 -179.457 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_exo -66.89 -23.2 47.75 Favored 'Trans proline' 0 N--CA 1.463 -0.27 0 C-N-CA 122.359 2.039 . . . . 0.0 111.669 176.142 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -73.56 -16.77 61.25 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.914 -0.585 . . . . 0.0 111.365 -177.5 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 14.2 m -65.27 -16.84 63.99 Favored 'General case' 0 C--O 1.233 0.192 0 CA-C-O 120.904 0.383 . . . . 0.0 111.051 -179.708 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 35.5 ttpt -116.89 11.42 14.4 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.1 -177.769 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 58.5 t -126.96 -47.99 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.377 -177.427 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 87.1 mt -108.22 161.3 15.12 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.245 0.545 . . . . 0.0 111.412 -175.644 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 15.4 p -126.82 146.38 57.08 Favored Pre-proline 0 C--N 1.319 -0.746 0 CA-C-N 115.022 -0.99 . . . . 0.0 109.844 176.803 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.474 ' HB3' ' HA ' ' A' ' 31' ' ' SER . 53.8 Cg_endo -70.47 149.96 63.18 Favored 'Trans proline' 0 N--CA 1.461 -0.384 0 C-N-CA 122.09 1.86 . . . . 0.0 111.937 -178.064 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 99.23 -13.54 61.63 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.832 179.65 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.565 ' HB2' HD12 ' A' ' 29' ' ' ILE . 82.0 mt -72.92 164.45 26.63 Favored 'General case' 0 C--N 1.327 -0.386 0 O-C-N 122.672 -0.31 . . . . 0.0 110.684 179.694 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 42.1 t -115.28 139.95 39.12 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.191 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 65.0 mt -97.83 125.87 50.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 121.181 0.515 . . . . 0.0 110.347 -179.482 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -91.02 -42.52 10.48 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-N 115.834 -0.621 . . . . 0.0 109.894 179.955 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 37.0 p -159.37 153.77 24.0 Favored 'General case' 0 CA--C 1.512 -0.51 0 CA-C-O 120.976 0.417 . . . . 0.0 110.621 178.825 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.793 HG13 HG12 ' A' ' 77' ' ' ILE . 10.8 tt -127.4 123.72 62.33 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 CA-C-N 115.582 -0.735 . . . . 0.0 109.126 174.821 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 2.3 t-20 58.61 -151.85 0.41 Allowed 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 108.922 -0.769 . . . . 0.0 108.922 -177.528 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -81.0 12.7 35.33 Favored Glycine 0 CA--C 1.525 0.681 0 C-N-CA 120.394 -0.908 . . . . 0.0 113.002 177.739 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 2.6 mpp? -124.43 107.26 29.76 Favored Pre-proline 0 C--N 1.333 -0.121 0 CA-C-N 117.227 0.513 . . . . 0.0 111.154 -178.183 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -70.34 121.22 7.79 Favored 'Trans proline' 0 N--CA 1.458 -0.598 0 C-N-CA 121.691 1.594 . . . . 0.0 111.457 174.297 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.402 ' O ' ' HA2' ' A' ' 26' ' ' GLY . 20.3 p -97.92 110.17 22.79 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.884 -174.047 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . 0.569 ' HA ' ' HA2' ' A' ' 26' ' ' GLY . 15.5 m -98.2 -18.96 18.16 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.921 -0.582 . . . . 0.0 111.118 179.831 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . 0.412 ' HB2' ' H ' ' A' ' 61' ' ' THR . 5.3 m120 -115.47 166.33 12.01 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 -179.127 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 39.2 mt -75.8 -34.45 60.17 Favored 'General case' 0 N--CA 1.447 -0.582 0 CA-C-O 121.035 0.445 . . . . 0.0 109.955 171.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 7.9 m -72.22 -40.5 67.76 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.646 -0.706 . . . . 0.0 111.34 -178.514 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . 0.412 ' H ' ' HB2' ' A' ' 58' ' ' ASN . 3.2 p -67.76 -32.16 72.56 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.006 0.431 . . . . 0.0 110.425 177.443 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 51.3 t80 -66.74 -39.78 88.06 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.313 0.577 . . . . 0.0 109.497 173.66 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 69.0 m -63.62 -47.52 81.05 Favored 'General case' 0 N--CA 1.447 -0.6 0 CA-C-N 115.485 -0.779 . . . . 0.0 111.348 177.889 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.42 -35.71 78.31 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.619 177.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . 0.526 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -68.17 -41.9 80.82 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.474 178.835 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 6.7 mt -62.32 -33.88 75.54 Favored 'General case' 0 N--CA 1.447 -0.6 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.136 178.273 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 40.4 ttmt -60.16 -37.26 79.61 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.868 179.161 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.6 p -82.26 -11.81 58.43 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 112.345 0.498 . . . . 0.0 112.345 -179.067 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.526 HG12 ' O ' ' A' ' 65' ' ' ALA . 45.8 mm -79.98 137.68 21.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 N-CA-C 110.055 -0.35 . . . . 0.0 110.055 178.313 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 19.1 t -103.36 176.91 4.99 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 110.108 -0.33 . . . . 0.0 110.108 -179.886 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 46.3 t -90.52 125.92 43.33 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.74 -177.653 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 99.93 -0.32 56.32 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.931 -0.652 . . . . 0.0 111.945 179.419 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 35.4 tt0 -90.24 147.31 23.62 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.82 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 39.9 t -106.01 104.34 16.85 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.116 -178.614 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.5 HD12 HD11 ' A' ' 51' ' ' ILE . 15.8 pt -96.08 154.7 3.5 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 121.363 0.602 . . . . 0.0 111.296 -175.916 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 5.5 t30 -91.13 136.6 32.98 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.631 -179.117 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.793 HG12 HG13 ' A' ' 51' ' ' ILE . 60.1 mt -135.46 108.79 9.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-O 121.057 0.456 . . . . 0.0 110.232 178.485 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 4.3 m -84.85 130.17 34.7 Favored 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 176.371 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 76.0 p -126.49 175.77 7.66 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.267 0.556 . . . . 0.0 111.978 -176.204 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 25.2 t70 -49.76 -42.82 47.32 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 114.625 -1.17 . . . . 0.0 112.74 -178.756 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 22.9 mt-30 -117.93 23.67 11.51 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 112.555 0.576 . . . . 0.0 112.555 -172.291 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 152.31 -178.63 29.4 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 119.771 -1.204 . . . . 0.0 112.929 175.828 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 22.2 m -114.74 126.84 55.32 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-O 120.892 0.377 . . . . 0.0 110.129 179.376 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 99.5 m-85 -121.02 161.33 21.83 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 120.938 0.399 . . . . 0.0 110.696 -178.348 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 44.6 m-70 -125.37 123.93 40.42 Favored 'General case' 0 C--N 1.321 -0.661 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 176.181 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.541 HD23 HD12 ' A' ' 77' ' ' ILE . 3.8 mm? -113.72 140.92 47.86 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.395 -173.886 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -105.14 124.35 49.38 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 115.63 -0.714 . . . . 0.0 109.488 177.467 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 17.8 p -69.92 132.02 45.32 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-O 121.379 0.609 . . . . 0.0 112.038 -176.66 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.445 -0.757 0 CA-C-N 115.433 -0.803 . . . . 0.0 111.418 177.41 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.239 0 CA-C-O 121.743 0.782 . . . . 0.0 109.681 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 80.3 t80 -96.36 102.04 13.77 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.611 -170.541 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 81.1 mtp -72.31 -43.22 64.49 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.16 176.469 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . 0.539 ' HA3' ' CB ' ' A' ' 36' ' ' SER . . . 101.56 -12.59 58.18 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.802 176.477 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.546 HG22 ' HA ' ' A' ' 32' ' ' VAL . 2.7 pp -114.89 144.73 21.81 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-O 120.851 0.358 . . . . 0.0 110.322 179.241 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . 0.632 ' HB2' ' HB3' ' A' ' 30' ' ' ASP . 39.3 mtp180 -84.46 147.58 27.01 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.179 178.321 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 14.2 p -124.63 122.1 36.58 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.555 177.331 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 19.3 m -127.59 154.84 44.73 Favored 'General case' 0 C--N 1.318 -0.799 0 N-CA-C 109.165 -0.68 . . . . 0.0 109.165 178.35 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 16.0 p30 . . . . . 0 C--N 1.314 -0.958 0 CA-C-O 121.09 0.472 . . . . 0.0 110.018 177.195 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.503 ' N ' ' HG ' ' A' ' 57' ' ' SER . 18.6 t70 . . . . . 0 C--O 1.234 0.241 0 CA-C-O 121.309 0.576 . . . . 0.0 109.628 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.507 ' HA2' ' HA ' ' A' ' 57' ' ' SER . . . 165.21 165.58 22.76 Favored Glycine 0 N--CA 1.447 -0.6 0 N-CA-C 110.574 -1.011 . . . . 0.0 110.574 -177.851 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.621 HG12 HD22 ' A' ' 106' ' ' ASN . 33.6 m -122.54 151.06 26.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 117.44 0.62 . . . . 0.0 110.739 178.675 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . 0.516 ' OE1' ' HB2' ' A' ' 105' ' ' SER . 0.0 OUTLIER -128.19 163.9 23.68 Favored 'General case' 0 C--N 1.324 -0.531 0 C-N-CA 120.703 -0.399 . . . . 0.0 110.767 177.139 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 57.2 mt -90.96 115.7 30.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.951 -176.165 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.753 ' HB3' ' HB2' ' A' ' 103' ' ' ARG . 23.7 t70 -66.65 -58.96 4.06 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.417 0.627 . . . . 0.0 109.873 176.005 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.467 ' HA ' ' HB3' ' A' ' 44' ' ' PRO . 12.4 p -165.19 162.05 19.77 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.22 -0.9 . . . . 0.0 110.204 -178.938 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.622 HG11 ' HA ' ' A' ' 39' ' ' SER . 45.3 t -98.24 138.25 23.45 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 N-CA-C 109.527 -0.545 . . . . 0.0 109.527 177.565 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.599 HG12 ' H ' ' A' ' 35' ' ' GLY . 45.7 t -85.89 118.9 71.35 Favored Pre-proline 0 C--N 1.323 -0.563 0 CA-C-N 116.453 -0.339 . . . . 0.0 110.809 -176.351 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -65.46 -12.94 37.29 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.866 2.377 . . . . 0.0 112.825 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.599 ' H ' HG12 ' A' ' 33' ' ' VAL . . . -95.19 23.02 35.34 Favored Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 120.897 -0.668 . . . . 0.0 111.545 177.935 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.676 ' HB3' ' HD2' ' A' ' 37' ' ' PRO . 54.1 m -149.36 170.9 6.95 Favored Pre-proline 0 C--N 1.325 -0.458 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.033 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . 0.676 ' HD2' ' HB3' ' A' ' 36' ' ' SER . 56.4 Cg_endo -71.13 -168.26 0.32 Allowed 'Trans proline' 0 C--N 1.349 0.555 0 C-N-CA 122.331 2.021 . . . . 0.0 112.443 177.199 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.472 ' HB1' HD13 ' A' ' 42' ' ' LEU . . . 68.78 -9.71 0.54 Allowed 'General case' 0 N--CA 1.47 0.567 0 N-CA-C 113.017 0.747 . . . . 0.0 113.017 176.63 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.622 ' HA ' HG11 ' A' ' 32' ' ' VAL . 27.8 t -70.08 -6.84 36.66 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.741 0.305 . . . . 0.0 111.293 -177.75 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -118.79 12.68 13.03 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 121.003 0.43 . . . . 0.0 110.391 177.103 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.478 ' HB ' HD12 ' A' ' 42' ' ' LEU . 46.8 t -120.76 -55.6 3.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.234 -176.987 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.478 HD12 ' HB ' ' A' ' 41' ' ' VAL . 6.0 mp -96.1 171.49 8.57 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.036 0.446 . . . . 0.0 111.145 -177.159 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 49.1 m -122.72 127.25 25.84 Favored Pre-proline 0 C--N 1.321 -0.639 0 CA-C-N 115.741 -0.663 . . . . 0.0 109.736 176.834 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.467 ' HB3' ' HA ' ' A' ' 31' ' ' SER . 41.7 Cg_endo -68.3 149.02 75.32 Favored 'Trans proline' 0 N--CA 1.464 -0.245 0 C-N-CA 122.294 1.996 . . . . 0.0 111.939 179.123 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 99.05 -2.93 58.23 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.541 -0.838 . . . . 0.0 112.634 -179.307 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 81.0 mt -90.33 164.2 14.44 Favored 'General case' 0 C--N 1.328 -0.366 0 O-C-N 122.583 -0.363 . . . . 0.0 110.765 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 48.0 t -102.45 139.94 22.15 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 N-CA-C 110.022 -0.362 . . . . 0.0 110.022 178.255 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.514 ' HB ' HG23 ' A' ' 27' ' ' VAL . 66.1 mt -93.2 121.71 44.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 121.127 0.489 . . . . 0.0 110.631 -177.601 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 3.4 tm-20 -81.96 -50.8 8.73 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 115.594 -0.73 . . . . 0.0 109.501 178.284 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . 0.572 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 13.6 p -163.94 159.22 20.63 Favored 'General case' 0 C--O 1.236 0.394 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.97 -175.638 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.412 ' HA ' ' O ' ' A' ' 76' ' ' ASN . 61.1 mt -115.96 107.77 23.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 115.556 -0.747 . . . . 0.0 110.545 176.259 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' ASN . . . . . 0.595 ' HA ' ' HB3' ' A' ' 76' ' ' ASN . 15.1 t-20 66.86 -81.66 0.03 OUTLIER 'General case' 0 N--CA 1.468 0.464 0 CA-C-N 115.43 -0.805 . . . . 0.0 110.759 178.816 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -133.46 -5.33 2.95 Favored Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 120.882 -0.675 . . . . 0.0 111.782 177.161 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 60.6 mtm -111.74 115.18 51.47 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 120.743 0.306 . . . . 0.0 110.429 -177.161 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.572 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 72.9 Cg_endo -78.99 132.45 10.55 Favored 'Trans proline' 0 N--CA 1.454 -0.806 0 C-N-CA 122.273 1.982 . . . . 0.0 112.006 177.428 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 3.3 p -95.06 103.43 15.28 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 121.008 0.432 . . . . 0.0 111.69 -177.841 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . 0.507 ' HA ' ' HA2' ' A' ' 26' ' ' GLY . 32.7 t -93.48 -24.27 18.07 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.747 -0.661 . . . . 0.0 110.482 179.41 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 8.4 t-20 -133.18 176.08 8.82 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.519 -0.31 . . . . 0.0 110.385 -179.111 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 97.6 mt -81.47 -33.06 32.23 Favored 'General case' 0 N--CA 1.44 -0.965 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.64 -179.003 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 2.6 m -65.08 -43.68 91.38 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.928 0.395 . . . . 0.0 110.841 179.451 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 12.7 t -67.28 -26.7 66.68 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.103 179.881 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 32.6 t80 -68.16 -47.66 67.42 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.9 -0.591 . . . . 0.0 109.989 173.279 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 8.5 t -60.76 -39.93 90.6 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.486 -0.779 . . . . 0.0 110.358 179.675 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -69.7 -31.97 70.3 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.175 178.003 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . 0.627 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -69.24 -46.64 66.85 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.346 178.217 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 6.6 tp -58.08 -38.45 76.4 Favored 'General case' 0 N--CA 1.447 -0.617 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.338 179.164 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 40.4 ttmt -57.66 -38.49 75.17 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.004 -0.998 . . . . 0.0 111.709 178.426 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 17.7 p -86.87 -13.17 45.66 Favored 'General case' 0 C--N 1.329 -0.31 0 N-CA-C 112.615 0.598 . . . . 0.0 112.615 -175.842 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.627 HG12 ' O ' ' A' ' 65' ' ' ALA . 44.4 mm -76.23 140.84 16.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 C-N-CA 120.906 -0.317 . . . . 0.0 110.167 -179.537 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . 0.45 ' HB2' ' HB2' ' A' ' 73' ' ' GLU . 4.8 m -94.03 161.26 14.36 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.709 -0.223 . . . . 0.0 110.764 179.357 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 2.2 t -82.63 118.37 30.22 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 177.01 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 97.08 8.71 56.56 Favored Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 120.501 -0.857 . . . . 0.0 111.129 -175.477 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.45 ' HB2' ' HB2' ' A' ' 70' ' ' SER . 30.9 tt0 -89.62 145.48 25.22 Favored 'General case' 0 N--CA 1.45 -0.441 0 N-CA-C 109.19 -0.671 . . . . 0.0 109.19 179.563 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 44.4 t -96.2 112.53 28.58 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.022 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.083 -178.865 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 30.8 pt -109.2 154.42 10.62 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-O 121.198 0.523 . . . . 0.0 110.986 -177.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . 0.595 ' HB3' ' HA ' ' A' ' 52' ' ' ASN . 35.5 t-20 -109.63 113.11 25.62 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-N 115.127 -0.942 . . . . 0.0 109.901 -176.617 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.446 HD12 HD21 ' A' ' 86' ' ' LEU . 71.7 mt -104.16 103.73 15.69 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.035 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 175.878 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 30.7 m -88.99 120.14 30.14 Favored 'General case' 0 C--N 1.312 -1.03 0 CA-C-N 115.387 -0.824 . . . . 0.0 109.524 -179.782 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 73.7 p -106.71 171.35 7.41 Favored 'General case' 0 C--N 1.322 -0.606 0 N-CA-C 110.241 -0.281 . . . . 0.0 110.241 179.705 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 19.8 t70 -62.06 -22.56 65.86 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.047 0.451 . . . . 0.0 111.1 -179.819 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 28.7 mt-30 -117.0 17.73 14.85 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 112.548 0.573 . . . . 0.0 112.548 -172.761 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 151.07 163.99 11.74 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 119.909 -1.138 . . . . 0.0 113.748 177.788 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 4.2 m -107.33 137.18 45.86 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 110.056 -0.35 . . . . 0.0 110.056 -179.57 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 26.5 m-85 -134.87 147.39 49.86 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.717 0.294 . . . . 0.0 110.394 177.9 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 4.2 p-80 -130.66 122.52 27.53 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 121.134 0.493 . . . . 0.0 110.086 174.095 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.458 HD23 ' N ' ' A' ' 86' ' ' LEU . 0.9 OUTLIER -130.76 156.87 44.23 Favored 'General case' 0 N--CA 1.444 -0.728 0 CA-C-N 115.571 -0.741 . . . . 0.0 111.115 -173.503 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' LYS . . . . . 0.452 ' HB3' ' HE2' ' A' ' 87' ' ' LYS . 32.4 ttpt -91.94 132.88 36.17 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.03 177.359 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 32.3 p -73.26 143.44 47.05 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.524 179.688 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.464 0 C-N-CA 120.911 -0.662 . . . . 0.0 112.226 177.87 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.455 -0.191 0 CA-C-O 120.798 0.333 . . . . 0.0 111.148 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 6.0 t80 -146.17 134.4 21.72 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 178.493 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -94.08 -31.34 14.24 Favored 'General case' 0 C--N 1.326 -0.45 0 C-N-CA 121.2 -0.2 . . . . 0.0 110.933 179.508 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 102.52 45.17 1.71 Allowed Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.285 -0.959 . . . . 0.0 113.811 173.3 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.468 HG22 HG13 ' A' ' 32' ' ' VAL . 32.6 pt -137.69 159.07 34.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-N 117.278 0.539 . . . . 0.0 110.345 175.058 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . 0.753 ' HB2' ' HB3' ' A' ' 30' ' ' ASP . 97.9 mtt180 -88.93 130.46 35.43 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 109.53 -0.544 . . . . 0.0 109.53 174.444 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 2.6 p -110.62 122.86 48.81 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-O 121.204 0.526 . . . . 0.0 111.022 178.803 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.516 ' HB2' ' OE1' ' A' ' 28' ' ' GLN . 45.7 m -116.23 163.55 15.82 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.79 178.162 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . 0.621 HD22 HG12 ' A' ' 27' ' ' VAL . 0.6 OUTLIER . . . . . 0 C--N 1.317 -0.825 0 CA-C-O 121.072 0.463 . . . . 0.0 109.798 -178.806 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 2.1 p30 . . . . . 0 C--O 1.231 0.109 0 CA-C-O 121.847 0.832 . . . . 0.0 109.751 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 136.2 157.34 7.77 Favored Glycine 0 N--CA 1.442 -0.949 0 CA-C-N 114.91 -1.041 . . . . 0.0 110.824 -176.813 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.64 HG21 ' CD2' ' A' ' 62' ' ' TYR . 35.7 m -114.14 149.92 16.31 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.871 0 CA-C-N 116.913 0.356 . . . . 0.0 110.559 178.909 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . 0.407 HE21 ' HB2' ' A' ' 28' ' ' GLN . 0.0 OUTLIER -129.67 154.65 46.93 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 174.951 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.593 HG23 HD11 ' A' ' 48' ' ' ILE . 2.2 pt -83.48 110.18 18.01 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.446 0 CA-C-O 121.673 0.749 . . . . 0.0 111.064 179.168 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -64.01 -59.15 4.84 Favored 'General case' 0 C--N 1.319 -0.761 0 CA-C-N 114.235 -1.348 . . . . 0.0 110.925 -177.616 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 49.0 m -153.51 166.71 31.86 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.621 -0.718 . . . . 0.0 111.384 -171.08 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.558 ' HA ' HG22 ' A' ' 102' ' ' ILE . 99.4 t -115.49 134.44 58.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 115.694 -0.685 . . . . 0.0 109.689 176.175 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 53.0 t -103.21 107.28 55.01 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 120.863 0.363 . . . . 0.0 111.089 -177.256 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -61.5 120.81 8.65 Favored 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 122.833 2.355 . . . . 0.0 111.575 178.907 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 126.32 -19.04 6.42 Favored Glycine 0 N--CA 1.447 -0.615 0 N-CA-C 111.011 -0.836 . . . . 0.0 111.011 -175.394 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.694 ' HB3' ' HD2' ' A' ' 37' ' ' PRO . 32.0 m -114.61 169.53 6.52 Favored Pre-proline 0 C--N 1.32 -0.7 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 176.499 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . 0.694 ' HD2' ' HB3' ' A' ' 36' ' ' SER . 21.1 Cg_endo -61.1 173.24 2.53 Favored 'Trans proline' 0 C--N 1.345 0.359 0 C-N-CA 122.487 2.124 . . . . 0.0 112.893 179.139 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 73.77 -11.29 0.97 Allowed 'General case' 0 N--CA 1.469 0.515 0 CA-C-N 115.541 -0.754 . . . . 0.0 112.403 179.672 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 53.4 m -69.33 2.76 2.69 Favored 'General case' 0 CA--C 1.535 0.377 0 N-CA-C 112.457 0.54 . . . . 0.0 112.457 -177.554 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 50.8 tptt -143.53 19.59 1.86 Allowed 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.43 0.633 . . . . 0.0 109.711 179.168 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 94.1 t -119.91 -63.8 1.76 Allowed 'Isoleucine or valine' 0 C--O 1.237 0.396 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.064 -178.54 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 1.1 pp -97.85 179.85 4.67 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.542 0.687 . . . . 0.0 112.204 -174.717 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 16.7 p -127.31 130.61 23.7 Favored Pre-proline 0 C--N 1.317 -0.831 0 CA-C-N 114.85 -1.068 . . . . 0.0 110.058 178.319 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.429 ' HB3' HG23 ' A' ' 32' ' ' VAL . 50.1 Cg_endo -67.46 159.04 54.26 Favored 'Trans proline' 0 C--O 1.236 0.404 0 C-N-CA 122.425 2.083 . . . . 0.0 112.277 -177.353 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 93.25 0.85 67.31 Favored Glycine 0 CA--C 1.522 0.495 0 C-N-CA 120.752 -0.737 . . . . 0.0 113.849 178.388 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.533 ' HB2' HD11 ' A' ' 29' ' ' ILE . 91.2 mt -92.14 167.18 12.23 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 117.43 0.615 . . . . 0.0 111.001 -179.582 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 46.7 t -109.17 138.71 35.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.001 178.675 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.593 HD11 HG23 ' A' ' 29' ' ' ILE . 58.5 mt -101.62 133.7 44.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 C-N-CA 122.33 0.252 . . . . 0.0 110.353 -178.429 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 27.4 tt0 -91.67 -48.52 6.78 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.277 177.854 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . 0.618 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 39.6 p -150.24 157.66 43.32 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 113.147 0.795 . . . . 0.0 113.147 -171.883 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.578 HD11 ' CE2' ' A' ' 62' ' ' TYR . 43.7 mt -116.3 117.53 55.79 Favored 'Isoleucine or valine' 0 C--O 1.235 0.34 0 CA-C-N 114.861 -1.063 . . . . 0.0 110.297 174.553 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' ASN . . . . . 0.568 ' HA ' ' HB3' ' A' ' 76' ' ' ASN . 25.4 t-20 65.6 -81.37 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.744 -0.662 . . . . 0.0 111.417 177.005 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -140.09 1.67 2.25 Favored Glycine 0 N--CA 1.447 -0.583 0 C-N-CA 121.052 -0.594 . . . . 0.0 111.768 177.251 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 59.5 mtm -120.74 123.48 27.98 Favored Pre-proline 0 C--N 1.324 -0.512 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 -177.721 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.618 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 72.7 Cg_endo -74.97 143.28 28.97 Favored 'Trans proline' 0 N--CA 1.459 -0.504 0 C-N-CA 122.353 2.035 . . . . 0.0 112.496 -179.125 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 17.8 p -110.79 95.21 5.41 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.226 0.536 . . . . 0.0 111.35 -177.637 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 5.1 p -91.06 -14.2 31.75 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.747 -0.66 . . . . 0.0 111.385 -178.881 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 34.2 m-80 -131.06 164.26 25.81 Favored 'General case' 0 C--N 1.318 -0.765 0 N-CA-C 109.698 -0.482 . . . . 0.0 109.698 178.464 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.426 HD23 ' HA ' ' A' ' 59' ' ' LEU . 13.1 mt -77.28 -31.14 54.63 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.215 0.531 . . . . 0.0 109.881 179.0 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 2.6 p -65.18 -45.76 83.57 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.647 173.64 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 4.6 m -56.67 -44.52 81.48 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.49 173.762 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' TYR . . . . . 0.64 ' CD2' HG21 ' A' ' 27' ' ' VAL . 11.6 t80 -60.59 -42.27 96.42 Favored 'General case' 0 CA--C 1.529 0.145 0 CA-C-O 121.508 0.67 . . . . 0.0 109.773 177.705 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 57.9 m -62.21 -47.14 85.78 Favored 'General case' 0 N--CA 1.446 -0.652 0 CA-C-N 115.069 -0.968 . . . . 0.0 111.636 178.139 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.89 -33.39 74.13 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.831 179.369 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . 0.587 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -68.22 -46.99 69.06 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.922 -0.581 . . . . 0.0 109.96 176.5 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 13.7 mt -58.49 -38.45 77.65 Favored 'General case' 0 N--CA 1.448 -0.538 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.894 178.22 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 59.7 mmtt -52.48 -37.69 57.72 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.816 -0.629 . . . . 0.0 112.056 176.744 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 50.1 p -87.77 -13.77 41.43 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 111.914 0.338 . . . . 0.0 111.914 -176.558 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.587 HG12 ' O ' ' A' ' 65' ' ' ALA . 36.7 mm -81.64 141.98 14.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-O 120.995 0.426 . . . . 0.0 110.259 -179.067 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 15.4 m -107.22 162.36 13.96 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.738 -178.801 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . 0.407 HG22 ' HA ' ' A' ' 98' ' ' ALA . 97.1 t -77.75 126.69 38.3 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-O 120.987 0.422 . . . . 0.0 110.627 -179.143 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 93.4 22.25 27.34 Favored Glycine 0 N--CA 1.447 -0.576 0 N-CA-C 111.216 -0.753 . . . . 0.0 111.216 -176.217 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 14.8 tp10 -109.5 151.97 26.04 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.262 -0.469 . . . . 0.0 109.847 -179.311 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.405 ' HA ' ' O ' ' A' ' 86' ' ' LEU . 61.1 t -110.98 120.3 61.38 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.752 0 CA-C-N 116.099 -0.5 . . . . 0.0 109.768 179.803 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 23.9 pt -117.05 154.29 18.73 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.026 -178.674 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . 0.568 ' HB3' ' HA ' ' A' ' 52' ' ' ASN . 44.1 t30 -91.05 132.92 35.72 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.845 -0.616 . . . . 0.0 109.947 -179.66 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 66.3 mt -129.74 109.78 18.61 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-O 121.179 0.514 . . . . 0.0 109.621 178.619 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 25.5 m -95.94 110.27 22.5 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.944 178.647 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.5 HG22 HG12 ' A' ' 48' ' ' ILE . 69.2 p -107.28 175.25 5.56 Favored 'General case' 0 N--CA 1.448 -0.556 0 CA-C-O 120.814 0.34 . . . . 0.0 111.057 -179.105 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 27.6 t70 -45.06 -43.64 9.62 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.058 -0.974 . . . . 0.0 113.383 -175.84 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 32.2 mt-30 -132.86 17.62 4.21 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 111.989 0.366 . . . . 0.0 111.989 -176.707 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -157.15 123.8 1.34 Allowed Glycine 0 C--N 1.319 -0.384 0 C-N-CA 119.581 -1.295 . . . . 0.0 113.31 -177.012 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 26.0 m -108.99 106.74 16.83 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 175.535 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 20.7 p90 -133.13 177.39 7.71 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 121.53 0.681 . . . . 0.0 111.59 -174.51 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 4.9 p80 -124.81 127.98 48.01 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-N 114.849 -1.069 . . . . 0.0 110.055 178.863 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.405 ' O ' ' HA ' ' A' ' 74' ' ' VAL . 7.4 tt -106.5 143.6 34.38 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.498 -175.302 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 86.5 tttt -106.79 116.4 31.87 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.447 -0.797 . . . . 0.0 109.392 178.367 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.637 HG21 ' HB1' ' A' ' 98' ' ' ALA . 55.7 p -67.04 136.53 55.39 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 121.231 0.539 . . . . 0.0 111.872 -175.212 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.442 -0.958 0 CA-C-N 115.664 -0.698 . . . . 0.0 112.18 -179.225 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . 0.637 ' HB1' HG21 ' A' ' 88' ' ' THR . . . . . . . . 0 N--CA 1.462 0.164 0 CA-C-O 121.079 0.466 . . . . 0.0 110.67 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . 0.403 ' CE2' ' HA2' ' A' ' 101' ' ' GLY . 27.5 t80 -89.16 114.53 25.82 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.204 0.526 . . . . 0.0 110.452 -173.342 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' MET . . . . . 0.531 ' HG3' ' H ' ' A' ' 102' ' ' ILE . 11.3 ptm -70.47 -30.04 66.74 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.351 -0.84 . . . . 0.0 111.725 -178.27 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . 0.403 ' HA2' ' CE2' ' A' ' 99' ' ' TYR . . . 86.61 -2.64 87.34 Favored Glycine 0 N--CA 1.453 -0.184 0 C-N-CA 120.991 -0.624 . . . . 0.0 112.918 177.467 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.558 HG22 ' HA ' ' A' ' 32' ' ' VAL . 24.5 pt -132.16 158.31 43.26 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 121.068 0.461 . . . . 0.0 110.695 -177.568 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . 0.429 HH11 ' HD2' ' A' ' 103' ' ' ARG . 18.2 mtp180 -90.36 145.32 25.05 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.796 -0.638 . . . . 0.0 109.591 178.113 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 2.2 p -133.8 151.14 51.48 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 120.708 0.29 . . . . 0.0 111.169 178.397 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 84.1 p -138.49 -174.18 3.75 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.113 -0.494 . . . . 0.0 109.787 177.677 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 14.0 p30 . . . . . 0 C--N 1.321 -0.65 0 CA-C-N 116.527 -0.306 . . . . 0.0 110.86 -179.557 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.839 ' HA ' ' HB3' ' A' ' 57' ' ' SER . 31.9 t70 . . . . . 0 N--CA 1.468 0.454 0 CA-C-O 121.954 0.883 . . . . 0.0 109.954 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 172.26 151.7 8.04 Favored Glycine 0 N--CA 1.441 -0.967 0 CA-C-N 114.949 -1.023 . . . . 0.0 111.245 176.252 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 28.8 m -137.14 153.88 29.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 120.924 0.392 . . . . 0.0 110.94 -177.686 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . 0.489 ' HG3' ' HB3' ' A' ' 105' ' ' SER . 2.0 pt20 -126.02 161.37 27.71 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 110.124 -0.324 . . . . 0.0 110.124 176.314 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.499 HG23 HD12 ' A' ' 102' ' ' ILE . 65.9 mt -75.19 115.58 16.75 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 N-CA-C 109.009 -0.737 . . . . 0.0 109.009 174.885 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.495 ' HB2' ' HB2' ' A' ' 105' ' ' SER . 22.9 t70 -79.22 -64.77 1.11 Allowed 'General case' 0 C--N 1.317 -0.816 0 CA-C-O 121.014 0.435 . . . . 0.0 110.334 -178.232 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 19.6 m -145.2 153.92 41.86 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.281 -177.685 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.574 HG13 HG22 ' A' ' 102' ' ' ILE . 94.6 t -116.87 131.01 70.78 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.292 -178.458 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 57.5 t -104.51 124.82 35.83 Favored Pre-proline 0 C--N 1.328 -0.367 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.943 -178.432 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -56.11 151.18 44.08 Favored 'Trans proline' 0 C--N 1.346 0.415 0 C-N-CA 123.068 2.512 . . . . 0.0 112.541 178.222 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 128.5 -16.25 5.96 Favored Glycine 0 N--CA 1.447 -0.578 0 C-N-CA 120.889 -0.672 . . . . 0.0 111.508 -177.906 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 35.9 p -124.89 156.36 68.97 Favored Pre-proline 0 C--N 1.322 -0.63 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 177.035 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo -64.9 -15.9 52.72 Favored 'Trans proline' 0 C--N 1.345 0.384 0 C-N-CA 122.342 2.028 . . . . 0.0 111.813 176.829 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -62.74 -23.09 67.02 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.526 -0.761 . . . . 0.0 111.542 -179.103 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.563 ' HA ' HG11 ' A' ' 32' ' ' VAL . 20.2 t -66.8 -22.12 66.02 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.249 -178.363 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 81.5 tttt -107.65 -2.12 20.48 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.03 0.443 . . . . 0.0 110.475 -178.679 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 89.9 t -105.23 -48.86 9.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.442 179.286 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 94.8 mt -94.33 174.35 7.18 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.052 -179.257 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . 0.461 ' O ' ' HG ' ' A' ' 46' ' ' LEU . 45.0 m -143.57 131.06 10.77 Favored Pre-proline 0 C--N 1.321 -0.655 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 -179.755 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_endo -63.69 142.63 84.2 Favored 'Trans proline' 0 N--CA 1.459 -0.519 0 C-N-CA 122.273 1.982 . . . . 0.0 111.776 178.221 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 94.14 2.64 64.08 Favored Glycine 0 CA--C 1.523 0.548 0 C-N-CA 120.748 -0.739 . . . . 0.0 113.538 -178.546 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.517 HD22 ' HG2' ' A' ' 81' ' ' GLN . 66.0 mt -88.63 164.11 15.5 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-N 117.475 0.638 . . . . 0.0 110.805 179.269 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 48.8 t -108.1 130.13 61.14 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.248 0 CA-C-O 120.511 0.196 . . . . 0.0 110.693 -177.968 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 53.8 mt -98.52 128.29 50.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-O 120.937 0.399 . . . . 0.0 110.881 -176.134 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.5 mm-40 -87.68 -48.32 7.97 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.652 176.823 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . 0.496 ' CB ' ' HA ' ' A' ' 55' ' ' PRO . 16.2 p -171.82 161.59 5.92 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-O 121.013 0.435 . . . . 0.0 111.849 -174.838 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.467 HG22 ' H ' ' A' ' 52' ' ' ASN . 27.5 mm -103.67 169.44 2.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 N-CA-C 107.929 -1.137 . . . . 0.0 107.929 173.413 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' ASN . . . . . 0.717 ' HB3' ' HB3' ' A' ' 76' ' ' ASN . 24.0 p-10 -53.97 99.97 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.825 0.821 . . . . 0.0 112.251 -175.996 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 75.72 3.77 74.09 Favored Glycine 0 N--CA 1.447 -0.593 0 CA-C-N 115.352 -0.84 . . . . 0.0 112.695 178.46 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 56.1 mtm -137.32 92.08 13.92 Favored Pre-proline 0 C--N 1.325 -0.467 0 CA-C-O 120.689 0.28 . . . . 0.0 110.504 -176.488 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.496 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 15.8 Cg_exo -66.87 135.28 37.52 Favored 'Trans proline' 0 N--CA 1.46 -0.49 0 C-N-CA 122.311 2.007 . . . . 0.0 111.608 178.606 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.439 HG21 ' CD2' ' A' ' 62' ' ' TYR . 10.9 p -105.24 98.31 8.03 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-O 121.283 0.563 . . . . 0.0 111.731 -175.429 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . 0.839 ' HB3' ' HA ' ' A' ' 25' ' ' ASP . 4.2 m -101.52 -17.16 16.54 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.774 176.284 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 14.3 m120 -127.24 160.89 29.93 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.142 -177.955 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 96.5 mt -77.62 -31.97 53.19 Favored 'General case' 0 N--CA 1.438 -1.044 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.061 177.583 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 84.7 m -70.42 -37.4 74.43 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.749 -0.659 . . . . 0.0 110.928 176.467 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 16.6 p -69.6 -33.3 72.49 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.867 0.365 . . . . 0.0 110.351 178.561 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' TYR . . . . . 0.439 ' CD2' HG21 ' A' ' 56' ' ' THR . 24.8 t80 -61.52 -45.97 91.95 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.444 0.64 . . . . 0.0 109.427 173.438 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 6.3 m -65.55 -42.69 91.62 Favored 'General case' 0 N--CA 1.449 -0.522 0 CA-C-N 115.108 -0.951 . . . . 0.0 112.126 177.75 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.99 -33.74 76.06 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.994 -179.768 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . 0.563 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -69.52 -45.54 68.61 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.047 -0.524 . . . . 0.0 109.807 177.483 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 14.3 mt -55.2 -38.62 68.62 Favored 'General case' 0 N--CA 1.447 -0.615 0 CA-C-N 115.375 -0.829 . . . . 0.0 111.677 179.184 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 28.0 mmmt -57.29 -28.44 63.03 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.832 -0.622 . . . . 0.0 112.49 179.703 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 28.4 p -99.85 -14.05 18.94 Favored 'General case' 0 C--N 1.327 -0.413 0 N-CA-C 112.373 0.508 . . . . 0.0 112.373 -177.544 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.563 HG12 ' O ' ' A' ' 65' ' ' ALA . 49.1 mm -70.63 128.65 34.17 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-O 121.175 0.512 . . . . 0.0 110.622 -176.658 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 16.3 m -80.62 163.49 23.59 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.372 -176.81 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 57.9 t -84.84 127.64 39.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 115.92 -0.582 . . . . 0.0 109.455 175.773 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 88.32 15.12 60.95 Favored Glycine 0 N--CA 1.448 -0.51 0 N-CA-C 110.571 -1.012 . . . . 0.0 110.571 -173.689 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 7.1 tp10 -87.36 148.16 25.16 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 114.952 -0.624 . . . . 0.0 109.321 178.862 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 59.0 t -113.53 102.13 13.46 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.994 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 174.705 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 29.9 pt -97.37 161.9 2.74 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.855 0 CA-C-N 115.674 -0.694 . . . . 0.0 111.29 -174.314 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . 0.717 ' HB3' ' HB3' ' A' ' 52' ' ' ASN . 11.7 t30 -102.17 122.52 44.32 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 115.389 -0.823 . . . . 0.0 109.999 179.292 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 61.8 mt -122.63 103.94 13.92 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 176.687 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . 0.455 ' HA ' ' HA ' ' A' ' 83' ' ' THR . 37.7 m -91.98 114.1 26.55 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 115.279 -0.873 . . . . 0.0 109.832 179.411 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 69.6 p -102.66 171.86 7.18 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 176.653 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -72.8 -14.67 61.57 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 121.63 0.729 . . . . 0.0 109.469 176.095 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . 0.517 ' HG2' HD22 ' A' ' 46' ' ' LEU . 2.7 mp0 -95.37 10.07 37.63 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.302 -0.863 . . . . 0.0 110.652 178.979 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 127.27 164.81 11.76 Favored Glycine 0 CA--C 1.519 0.32 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.902 178.473 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . 0.455 ' HA ' ' HA ' ' A' ' 78' ' ' THR . 28.0 m -90.48 129.86 36.6 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 110.387 -0.227 . . . . 0.0 110.387 177.621 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 60.6 m-85 -128.34 155.45 44.65 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.013 0.435 . . . . 0.0 110.654 179.421 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 38.6 m80 -108.46 136.85 47.4 Favored 'General case' 0 C--N 1.321 -0.674 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 174.553 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 21.2 tp -123.44 138.87 54.5 Favored 'General case' 0 C--N 1.315 -0.899 0 C-N-CA 120.208 -0.597 . . . . 0.0 110.746 -179.782 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 37.0 ttpt -105.67 121.08 43.26 Favored 'General case' 0 C--N 1.313 -0.988 0 CA-C-N 115.316 -0.856 . . . . 0.0 109.139 177.722 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.58 HG21 ' HB1' ' A' ' 98' ' ' ALA . 43.5 p -78.43 128.67 33.94 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-O 121.275 0.56 . . . . 0.0 111.508 -176.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.836 0 CA-C-N 115.65 -0.705 . . . . 0.0 111.889 -178.674 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . 0.58 ' HB1' HG21 ' A' ' 88' ' ' THR . . . . . . . . 0 C--O 1.233 0.2 0 CA-C-O 121.25 0.548 . . . . 0.0 111.362 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 51.3 t80 -79.78 97.23 6.54 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 121.173 0.511 . . . . 0.0 111.299 -173.328 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 50.3 ttm -86.5 -58.41 2.63 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.309 173.626 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 88.27 24.05 35.44 Favored Glycine 0 C--N 1.33 0.23 0 C-N-CA 120.889 -0.672 . . . . 0.0 113.709 171.042 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.574 HG22 HG13 ' A' ' 32' ' ' VAL . 19.0 pt -120.03 145.72 25.9 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 CA-C-N 117.179 0.49 . . . . 0.0 110.488 177.597 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.72 140.81 29.21 Favored 'General case' 0 C--N 1.319 -0.747 0 N-CA-C 108.974 -0.75 . . . . 0.0 108.974 174.868 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.7 m -109.59 149.0 30.31 Favored 'General case' 0 C--N 1.314 -0.966 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 -179.076 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.495 ' HB2' ' HB2' ' A' ' 30' ' ' ASP . 41.0 t -116.67 172.24 7.36 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-N 115.94 -0.573 . . . . 0.0 109.705 -178.3 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . 0.436 HD22 ' HA ' ' A' ' 106' ' ' ASN . 1.1 t-20 . . . . . 0 C--N 1.316 -0.872 0 CA-C-O 121.551 0.691 . . . . 0.0 109.53 -172.947 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.405 ' HA ' ' OG ' ' A' ' 57' ' ' SER . 38.9 t70 . . . . . 0 C--O 1.232 0.171 0 CA-C-O 121.185 0.516 . . . . 0.0 111.147 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 82.73 122.55 0.75 Allowed Glycine 0 N--CA 1.448 -0.526 0 CA-C-N 115.321 -0.854 . . . . 0.0 112.621 178.913 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 34.9 m -98.09 149.45 5.22 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.881 0 CA-C-O 120.862 0.363 . . . . 0.0 110.583 -179.641 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . 0.48 ' HB2' ' O ' ' A' ' 46' ' ' LEU . 3.7 pt20 -128.97 159.58 35.44 Favored 'General case' 0 C--N 1.318 -0.779 0 C-N-CA 120.558 -0.457 . . . . 0.0 110.868 176.875 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.596 HG23 HD11 ' A' ' 48' ' ' ILE . 0.2 OUTLIER -82.58 111.62 19.22 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.357 178.42 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 22.8 t70 -71.2 -62.8 1.27 Allowed 'General case' 0 C--N 1.318 -0.784 0 CA-C-N 115.363 -0.835 . . . . 0.0 111.481 -174.978 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 8.4 p -155.31 145.08 21.4 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.681 -176.464 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.568 HG11 ' HA ' ' A' ' 39' ' ' SER . 89.0 t -90.41 132.39 35.16 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.762 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.406 178.964 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.469 ' HA ' ' HD3' ' A' ' 34' ' ' PRO . 17.5 m -107.29 134.07 20.09 Favored Pre-proline 0 N--CA 1.449 -0.524 0 CA-C-O 121.015 0.436 . . . . 0.0 111.476 -178.251 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . 0.469 ' HD3' ' HA ' ' A' ' 33' ' ' VAL . 21.9 Cg_exo -66.44 142.24 64.74 Favored 'Trans proline' 0 C--O 1.236 0.389 0 C-N-CA 123.108 2.539 . . . . 0.0 112.141 178.302 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 112.99 -16.13 23.11 Favored Glycine 0 N--CA 1.448 -0.538 0 N-CA-C 111.232 -0.747 . . . . 0.0 111.232 -176.939 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 26.0 m -123.53 165.22 24.03 Favored Pre-proline 0 C--N 1.324 -0.539 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 179.853 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -74.72 -168.62 0.52 Allowed 'Trans proline' 0 CA--C 1.533 0.428 0 C-N-CA 122.753 2.302 . . . . 0.0 112.489 178.383 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.549 ' HB2' HD11 ' A' ' 86' ' ' LEU . . . 78.62 -6.3 1.93 Allowed 'General case' 0 N--CA 1.468 0.436 0 CA-C-N 115.473 -0.785 . . . . 0.0 112.354 175.457 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.568 ' HA ' HG11 ' A' ' 32' ' ' VAL . 3.8 m -58.69 -30.9 67.74 Favored 'General case' 0 CA--C 1.531 0.243 0 CA-C-O 120.817 0.342 . . . . 0.0 111.661 -177.2 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 64.6 mmtt -119.33 20.7 12.47 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.19 0.519 . . . . 0.0 110.928 -179.675 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 89.6 t -107.84 -47.04 7.82 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 115.938 -0.573 . . . . 0.0 110.043 178.678 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.566 ' HB3' ' CZ ' ' A' ' 84' ' ' PHE . 0.6 OUTLIER -118.61 171.83 7.92 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 121.078 0.466 . . . . 0.0 111.256 178.884 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 11.7 m -115.84 126.15 27.97 Favored Pre-proline 0 C--N 1.315 -0.895 0 CA-C-N 115.452 -0.795 . . . . 0.0 110.061 -179.95 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_endo -62.2 142.35 91.41 Favored 'Trans proline' 0 N--CA 1.46 -0.461 0 C-N-CA 122.099 1.866 . . . . 0.0 111.422 177.4 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 97.72 -5.42 62.05 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.995 -179.248 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.48 ' O ' ' HB2' ' A' ' 28' ' ' GLN . 75.2 mt -85.09 164.03 18.44 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.931 0.366 . . . . 0.0 110.968 179.589 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 47.4 t -101.51 143.28 14.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.457 178.516 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.596 HD11 HG23 ' A' ' 29' ' ' ILE . 60.0 mt -104.36 127.42 58.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 C-N-CA 122.535 0.334 . . . . 0.0 110.209 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 27.9 mt-10 -89.51 -47.88 7.69 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.777 176.382 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . 0.55 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 19.5 p -157.38 153.15 26.81 Favored 'General case' 0 N--CA 1.446 -0.671 0 CA-C-O 121.599 0.714 . . . . 0.0 112.202 -172.877 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.719 HG22 ' H ' ' A' ' 52' ' ' ASN . 16.0 mt -96.86 -179.93 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 169.735 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' ASN . . . . . 0.719 ' H ' HG22 ' A' ' 51' ' ' ILE . 36.0 t-20 -49.58 93.67 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 112.264 0.468 . . . . 0.0 112.264 -177.434 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 73.12 -2.59 34.63 Favored Glycine 0 CA--C 1.519 0.321 0 CA-C-N 115.976 -0.557 . . . . 0.0 113.275 179.493 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 36.1 mtt -124.8 98.85 36.13 Favored Pre-proline 0 C--N 1.325 -0.484 0 CA-C-N 116.875 0.337 . . . . 0.0 110.654 -173.096 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.55 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 70.4 Cg_endo -77.27 130.89 11.36 Favored 'Trans proline' 0 N--CA 1.46 -0.447 0 C-N-CA 122.151 1.901 . . . . 0.0 112.005 178.257 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.461 HG21 ' HA ' ' A' ' 62' ' ' TYR . 37.5 p -116.63 103.84 10.79 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 121.089 0.471 . . . . 0.0 111.614 -176.307 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . 0.405 ' OG ' ' HA ' ' A' ' 25' ' ' ASP . 26.9 t -89.05 -34.63 16.72 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.965 177.207 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 2.3 m-20 -103.34 158.44 16.33 Favored 'General case' 0 C--N 1.318 -0.797 0 O-C-N 122.065 -0.397 . . . . 0.0 110.153 -176.804 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 87.4 mt -68.81 -33.8 74.45 Favored 'General case' 0 N--CA 1.443 -0.801 0 CA-C-O 121.215 0.531 . . . . 0.0 109.955 175.519 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 1.6 m -66.04 -41.82 90.39 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.668 -0.696 . . . . 0.0 111.081 177.547 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 18.4 p -68.07 -28.46 67.38 Favored 'General case' 0 CA--C 1.528 0.114 0 CA-C-O 120.811 0.339 . . . . 0.0 110.55 178.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' TYR . . . . . 0.461 ' HA ' HG21 ' A' ' 56' ' ' THR . 46.1 t80 -67.19 -38.41 85.31 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 176.105 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 21.6 t -66.07 -48.28 71.53 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.768 179.097 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.03 -32.78 74.22 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.346 -177.773 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . 0.476 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -73.29 -43.88 60.16 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.311 179.586 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 3.2 tt -57.04 -45.99 82.74 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.705 -0.679 . . . . 0.0 110.494 -179.6 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -59.69 -26.88 65.95 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.63 -0.714 . . . . 0.0 112.173 -178.199 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 43.5 p -89.24 -14.03 36.82 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 112.049 0.388 . . . . 0.0 112.049 -177.454 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.476 HG12 ' O ' ' A' ' 65' ' ' ALA . 40.9 mm -74.83 142.81 14.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.652 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . 0.458 ' HB2' ' HB2' ' A' ' 73' ' ' GLU . 4.9 m -93.18 157.64 16.17 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.673 0.273 . . . . 0.0 111.084 -178.157 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 75.3 t -70.29 129.79 34.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.109 177.146 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 79.63 10.14 86.12 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.612 -0.804 . . . . 0.0 111.606 179.759 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.458 ' HB2' ' HB2' ' A' ' 70' ' ' SER . 23.7 tt0 -92.86 149.57 21.17 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 -179.719 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 44.9 t -105.1 124.05 59.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-O 121.35 0.595 . . . . 0.0 110.579 -175.806 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 15.7 pt -110.27 154.04 11.9 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.122 179.193 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . 0.626 ' H ' ' HB2' ' A' ' 52' ' ' ASN . 6.3 t30 -105.8 110.49 22.8 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 115.312 -0.858 . . . . 0.0 109.736 -177.755 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 65.0 mt -105.95 119.41 55.21 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 CA-C-O 121.34 0.59 . . . . 0.0 110.992 -174.087 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 11.9 m -93.68 118.5 31.47 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.278 -0.873 . . . . 0.0 109.616 177.847 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 43.4 p -120.36 178.12 4.77 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.82 0.343 . . . . 0.0 111.165 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 28.5 t70 -58.59 -34.88 71.6 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.598 -0.728 . . . . 0.0 111.351 178.798 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 10.7 mm100 -96.48 14.24 25.24 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.125 -0.489 . . . . 0.0 112.103 -176.136 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 123.26 -171.51 15.85 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.177 -1.011 . . . . 0.0 112.631 176.246 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 24.1 m -112.06 138.23 49.0 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.75 0.309 . . . . 0.0 110.721 -176.855 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . 0.566 ' CZ ' ' HB3' ' A' ' 42' ' ' LEU . 10.3 p90 -139.16 168.83 18.96 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 121.378 0.609 . . . . 0.0 110.949 175.494 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -109.82 138.34 46.33 Favored 'General case' 0 C--N 1.314 -0.951 0 CA-C-N 115.142 -0.935 . . . . 0.0 110.016 178.158 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.549 HD11 ' HB2' ' A' ' 38' ' ' ALA . 17.8 tp -130.08 143.85 51.02 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.106 -177.755 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 24.3 ttpp -114.18 125.43 53.93 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.093 -178.277 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.643 HG21 ' HB1' ' A' ' 98' ' ' ALA . 77.0 p -73.99 148.17 42.31 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 115.969 -0.559 . . . . 0.0 111.38 -178.716 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.805 0 N-CA-C 110.952 -0.859 . . . . 0.0 110.952 174.866 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . 0.643 ' HB1' HG21 ' A' ' 88' ' ' THR . . . . . . . . 0 CA--C 1.523 -0.083 0 CA-C-O 121.339 0.59 . . . . 0.0 109.903 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 29.5 p90 -86.89 148.57 25.3 Favored 'General case' 0 N--CA 1.444 -0.747 0 CA-C-N 115.865 -0.607 . . . . 0.0 112.164 -167.238 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 93.5 mmm -98.06 126.55 43.55 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.05 -0.977 . . . . 0.0 109.341 175.358 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -86.92 35.19 3.43 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.806 -177.046 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.557 HG22 ' HA ' ' A' ' 32' ' ' VAL . 2.8 pp -140.2 162.71 24.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 120.801 0.334 . . . . 0.0 110.434 179.655 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . 0.44 ' NE ' ' HA ' ' A' ' 103' ' ' ARG . 2.9 mmp_? -93.01 142.07 27.7 Favored 'General case' 0 C--N 1.315 -0.915 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 171.377 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.3 m -111.17 150.52 29.38 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-O 121.085 0.469 . . . . 0.0 110.387 179.455 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.43 ' OG ' ' HG3' ' A' ' 28' ' ' GLN . 6.7 p -136.16 169.08 18.2 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.158 175.809 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . 0.403 HD22 ' HA ' ' A' ' 106' ' ' ASN . 2.0 t-20 . . . . . 0 C--N 1.32 -0.704 0 CA-C-O 120.686 0.279 . . . . 0.0 111.261 -172.575 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.474 ' N ' ' HG ' ' A' ' 57' ' ' SER . 21.4 t70 . . . . . 0 C--O 1.233 0.218 0 CA-C-O 121.083 0.468 . . . . 0.0 111.447 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.561 ' HA2' ' HA ' ' A' ' 57' ' ' SER . . . 157.25 167.2 17.99 Favored Glycine 0 N--CA 1.443 -0.869 0 N-CA-C 111.039 -0.824 . . . . 0.0 111.039 -177.124 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.479 HG23 ' HB ' ' A' ' 48' ' ' ILE . 28.5 m -108.06 127.42 64.26 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 CA-C-O 121.253 0.549 . . . . 0.0 110.984 178.787 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 18.9 tt0 -99.21 142.78 30.26 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.07 178.01 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.451 HG12 ' O ' ' A' ' 46' ' ' LEU . 8.0 pt -87.36 119.52 35.16 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-O 121.612 0.72 . . . . 0.0 111.579 -178.069 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.409 ' HB3' ' CB ' ' A' ' 103' ' ' ARG . 11.4 t70 -61.12 -58.47 8.22 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 114.272 -1.331 . . . . 0.0 109.983 177.23 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . 0.619 ' HA ' ' HB3' ' A' ' 44' ' ' PRO . 7.8 p -159.69 158.96 32.36 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.432 -0.804 . . . . 0.0 111.145 -174.407 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.578 ' HA ' HG22 ' A' ' 102' ' ' ILE . 91.4 t -110.44 119.7 59.83 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 115.689 -0.687 . . . . 0.0 109.404 177.846 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.425 ' HA ' ' HD3' ' A' ' 34' ' ' PRO . 53.9 t -83.63 123.52 76.3 Favored Pre-proline 0 C--N 1.324 -0.513 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.721 -175.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' A' ' 33' ' ' VAL . 11.4 Cg_exo -72.95 31.16 0.3 Allowed 'Trans proline' 0 CA--C 1.532 0.42 0 C-N-CA 123.269 2.646 . . . . 0.0 112.775 179.291 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . 0.402 ' H ' ' C ' ' A' ' 33' ' ' VAL . . . -121.69 20.43 8.24 Favored Glycine 0 N--CA 1.449 -0.462 0 N-CA-C 111.27 -0.732 . . . . 0.0 111.27 179.172 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 49.1 m -148.17 160.9 36.08 Favored Pre-proline 0 C--N 1.323 -0.578 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 179.425 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_exo -59.81 -13.56 22.92 Favored 'Trans proline' 0 C--N 1.348 0.533 0 C-N-CA 122.985 2.457 . . . . 0.0 113.669 -176.297 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.41 ' HB1' HD13 ' A' ' 42' ' ' LEU . . . -78.6 -6.94 56.97 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 111.794 0.294 . . . . 0.0 111.794 -177.333 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 28.0 t -60.43 -28.45 68.3 Favored 'General case' 0 CA--C 1.533 0.294 0 N-CA-C 112.153 0.427 . . . . 0.0 112.153 -175.657 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 21.0 ttpt -106.96 13.53 27.5 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.947 0.403 . . . . 0.0 110.678 -177.388 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.477 ' HB ' HD12 ' A' ' 42' ' ' LEU . 46.4 t -115.34 -59.2 3.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 C-N-CA 120.776 -0.37 . . . . 0.0 111.65 -175.23 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.48 HD11 HD12 ' A' ' 86' ' ' LEU . 6.6 mp -92.45 175.46 6.83 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.291 0.567 . . . . 0.0 111.516 -173.478 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 91.1 m -140.89 123.94 9.91 Favored Pre-proline 0 C--N 1.32 -0.674 0 CA-C-N 115.405 -0.816 . . . . 0.0 108.946 175.544 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.619 ' HB3' ' HA ' ' A' ' 31' ' ' SER . 42.3 Cg_endo -64.52 152.05 83.17 Favored 'Trans proline' 0 CA--C 1.531 0.339 0 C-N-CA 122.893 2.396 . . . . 0.0 112.905 -173.811 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 103.17 -11.92 55.36 Favored Glycine 0 CA--C 1.52 0.368 0 C-N-CA 121.072 -0.585 . . . . 0.0 112.695 -179.496 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.701 HD22 ' HB3' ' A' ' 80' ' ' ASP . 81.6 mt -84.74 164.62 18.43 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.975 0.417 . . . . 0.0 111.098 -177.981 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 46.6 t -108.12 135.09 47.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 116.075 -0.511 . . . . 0.0 109.843 177.129 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.479 ' HB ' HG23 ' A' ' 27' ' ' VAL . 69.0 mt -87.65 123.7 40.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-O 121.204 0.526 . . . . 0.0 110.536 179.862 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 6.5 tm-20 -79.22 -47.06 16.62 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.921 -179.54 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . 0.54 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 7.7 p -162.73 153.77 17.32 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.388 -177.648 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 48.5 mm -107.24 102.96 14.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.901 -0.59 . . . . 0.0 109.732 176.679 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' ASN . . . . . 0.591 ' HA ' ' HB3' ' A' ' 76' ' ' ASN . 38.9 t-20 64.08 -85.26 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.384 0 C-N-CA 123.552 0.741 . . . . 0.0 111.056 179.343 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -132.79 8.05 5.21 Favored Glycine 0 N--CA 1.447 -0.569 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 177.005 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 1.5 mpt? -118.59 103.35 48.92 Favored Pre-proline 0 N--CA 1.448 -0.571 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 -178.737 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.54 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 41.8 Cg_endo -68.81 121.68 8.57 Favored 'Trans proline' 0 N--CA 1.462 -0.367 0 C-N-CA 122.124 1.882 . . . . 0.0 112.461 -179.118 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.45 ' HA ' ' HB ' ' A' ' 61' ' ' THR . 6.9 p -89.47 87.99 7.28 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.54 179.834 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . 0.561 ' HA ' ' HA2' ' A' ' 26' ' ' GLY . 8.6 t -93.53 -14.26 26.82 Favored 'General case' 0 C--N 1.318 -0.797 0 CA-C-N 115.416 -0.811 . . . . 0.0 109.875 -179.476 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 61.1 t30 -140.5 178.23 7.46 Favored 'General case' 0 N--CA 1.445 -0.714 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 178.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 68.8 mt -76.16 -33.39 59.37 Favored 'General case' 0 N--CA 1.445 -0.72 0 CA-C-O 120.921 0.391 . . . . 0.0 111.067 -178.424 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 13.1 m -66.48 -34.33 77.68 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.977 179.869 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . 0.45 ' HB ' ' HA ' ' A' ' 56' ' ' THR . 0.0 OUTLIER -66.0 -35.33 80.26 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.992 0.425 . . . . 0.0 110.372 176.838 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 55.4 t80 -62.33 -37.45 85.66 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.857 176.842 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 33.2 t -68.25 -46.19 71.16 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.52 -0.764 . . . . 0.0 110.435 177.287 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -66.32 -26.34 67.26 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.865 -0.607 . . . . 0.0 112.13 -175.761 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . 0.427 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -79.27 -44.03 22.54 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.078 0.466 . . . . 0.0 110.431 177.487 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 1.7 tt -63.55 -42.64 98.38 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.556 -0.747 . . . . 0.0 111.357 -175.824 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 22.4 ptmt -60.37 -12.37 9.14 Favored 'General case' 0 CA--C 1.536 0.414 0 N-CA-C 112.899 0.704 . . . . 0.0 112.899 -174.117 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 20.8 p -106.93 -13.17 15.28 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 112.386 0.514 . . . . 0.0 112.386 -178.128 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.473 HG21 HG21 ' A' ' 88' ' ' THR . 37.2 mm -79.73 143.85 11.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.748 -0.205 . . . . 0.0 110.956 -175.256 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 3.2 m -92.45 164.52 13.44 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.508 -0.315 . . . . 0.0 110.471 179.888 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 16.5 t -78.6 118.09 25.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 120.677 0.275 . . . . 0.0 110.266 179.304 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 88.32 23.52 37.03 Favored Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 120.422 -0.894 . . . . 0.0 111.671 -178.846 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 28.6 tt0 -99.56 147.5 25.27 Favored 'General case' 0 C--N 1.323 -0.587 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 -179.851 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 51.0 t -95.14 114.29 31.39 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.779 0 CA-C-O 121.136 0.493 . . . . 0.0 110.56 -179.122 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 26.7 pt -104.21 174.79 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.787 0 CA-C-N 115.637 -0.71 . . . . 0.0 110.87 179.27 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . 0.591 ' HB3' ' HA ' ' A' ' 52' ' ' ASN . 43.6 t30 -122.16 130.54 53.31 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.586 -0.734 . . . . 0.0 109.813 -175.536 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.435 HG22 HG23 ' A' ' 79' ' ' THR . 62.5 mt -134.8 110.33 12.71 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-O 121.212 0.529 . . . . 0.0 111.112 -176.922 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . 0.628 ' HA ' ' HA ' ' A' ' 83' ' ' THR . 98.1 m -85.91 123.53 31.35 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.986 -0.552 . . . . 0.0 109.685 173.597 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.435 HG23 HG22 ' A' ' 77' ' ' ILE . 67.3 p -124.72 -173.45 2.79 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.922 0.392 . . . . 0.0 111.364 -177.472 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . 0.701 ' HB3' HD22 ' A' ' 46' ' ' LEU . 7.4 t70 -53.78 -41.55 67.34 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.216 -0.902 . . . . 0.0 111.583 177.173 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 28.2 mm-40 -95.23 12.94 27.13 Favored 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 111.931 0.345 . . . . 0.0 111.931 -175.759 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 119.43 -175.32 15.75 Favored Glycine 0 N--CA 1.447 -0.63 0 C-N-CA 120.164 -1.017 . . . . 0.0 113.038 175.342 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . 0.628 ' HA ' ' HA ' ' A' ' 78' ' ' THR . 32.6 m -92.67 117.17 29.7 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.115 0.484 . . . . 0.0 111.396 -176.565 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 88.9 m-85 -113.89 164.8 13.29 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.43 -178.735 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 19.3 p-80 -117.27 130.01 56.28 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.285 178.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.49 HD23 ' N ' ' A' ' 87' ' ' LYS . 8.2 tt -120.48 145.48 47.23 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 116.231 -0.44 . . . . 0.0 109.947 -173.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' LYS . . . . . 0.49 ' N ' HD23 ' A' ' 86' ' ' LEU . 88.1 tttt -114.66 117.59 31.28 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 109.132 -0.692 . . . . 0.0 109.132 176.216 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.473 HG21 HG21 ' A' ' 69' ' ' ILE . 22.3 p -64.03 131.92 49.03 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 121.142 0.496 . . . . 0.0 111.729 -174.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.441 -1.012 0 C-N-CA 120.975 -0.631 . . . . 0.0 111.797 179.61 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.464 0.254 0 CA-C-O 121.177 0.513 . . . . 0.0 112.29 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 14.5 t80 -107.45 120.74 43.0 Favored 'General case' 0 C--N 1.319 -0.718 0 C-N-CA 120.76 -0.376 . . . . 0.0 110.07 -178.58 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' MET . . . . . 0.566 ' HG2' HG12 ' A' ' 102' ' ' ILE . 0.7 OUTLIER -71.86 -20.18 61.85 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.169 -179.038 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 78.91 35.2 31.83 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.866 -0.683 . . . . 0.0 113.113 175.201 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.578 HG22 ' HA ' ' A' ' 32' ' ' VAL . 35.4 pt -142.02 154.01 18.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-O 120.849 0.356 . . . . 0.0 110.063 178.933 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . 0.409 ' CB ' ' HB3' ' A' ' 30' ' ' ASP . 21.4 mtp85 -91.74 134.66 34.53 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 173.463 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 2.8 m -133.21 155.14 49.89 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.962 0.41 . . . . 0.0 111.055 -176.308 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 32.6 t -149.1 -174.88 4.76 Favored 'General case' 0 C--N 1.321 -0.636 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 179.44 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 14.8 p30 . . . . . 0 C--N 1.324 -0.518 0 CA-C-O 120.635 0.255 . . . . 0.0 111.044 179.211 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 27.9 t70 . . . . . 0 N--CA 1.465 0.323 0 CA-C-O 122.013 0.911 . . . . 0.0 110.364 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.461 ' H ' ' HA ' ' A' ' 57' ' ' SER . . . 106.52 115.94 4.08 Favored Glycine 0 N--CA 1.445 -0.72 0 CA-C-N 114.471 -1.24 . . . . 0.0 111.751 176.597 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 34.5 m -78.79 153.83 4.92 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 CA-C-O 120.941 0.4 . . . . 0.0 110.721 -178.737 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 4.4 tt0 -115.53 149.24 38.48 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-O 121.293 0.568 . . . . 0.0 111.349 -177.585 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.498 HD12 HD12 ' A' ' 102' ' ' ILE . 26.8 mm -73.11 107.62 3.86 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.214 -0.903 . . . . 0.0 109.432 175.742 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.721 ' HB3' ' HB2' ' A' ' 103' ' ' ARG . 41.9 t0 -69.98 -53.54 17.28 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-O 121.401 0.62 . . . . 0.0 109.529 -178.671 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 51.0 p -161.47 173.51 14.76 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.189 -0.914 . . . . 0.0 110.798 177.103 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.522 HG22 HG22 ' A' ' 102' ' ' ILE . 84.9 t -119.25 124.46 73.1 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 CA-C-N 115.813 -0.631 . . . . 0.0 109.382 175.95 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 7.4 p -106.7 131.02 22.04 Favored Pre-proline 0 C--N 1.323 -0.545 0 CA-C-O 120.783 0.325 . . . . 0.0 110.421 -177.67 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo -64.97 87.85 0.18 Allowed 'Trans proline' 0 C--N 1.343 0.289 0 C-N-CA 122.79 2.327 . . . . 0.0 112.408 179.426 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -164.75 14.21 0.09 OUTLIER Glycine 0 N--CA 1.449 -0.447 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.862 176.032 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.679 ' HB2' ' HA3' ' A' ' 101' ' ' GLY . 60.4 m -157.65 160.44 30.16 Favored Pre-proline 0 C--N 1.327 -0.401 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 -178.972 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_exo -63.31 -15.34 47.66 Favored 'Trans proline' 0 C--N 1.349 0.568 0 C-N-CA 122.87 2.38 . . . . 0.0 112.71 -178.132 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -67.07 -15.12 63.52 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.922 -177.426 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.459 ' HA ' HG11 ' A' ' 32' ' ' VAL . 47.7 t -65.21 -13.55 58.54 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.71 -177.041 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 23.9 ttmm -128.42 25.39 5.77 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.346 0.594 . . . . 0.0 110.06 179.244 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.542 ' HB ' HD12 ' A' ' 42' ' ' LEU . 45.6 t -122.16 -55.3 2.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.905 179.381 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.542 HD12 ' HB ' ' A' ' 41' ' ' VAL . 5.0 mp -109.17 164.19 12.67 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.789 0.328 . . . . 0.0 110.588 -178.033 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 12.7 p -116.54 144.54 33.39 Favored Pre-proline 0 C--N 1.323 -0.548 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.62 177.1 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.44 ' HA ' ' CG2' ' A' ' 29' ' ' ILE . 57.2 Cg_endo -72.55 149.41 49.53 Favored 'Trans proline' 0 C--O 1.235 0.332 0 C-N-CA 122.299 1.999 . . . . 0.0 112.496 -179.422 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 101.14 -12.52 58.8 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.999 -179.555 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 83.4 mt -77.43 164.27 25.62 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 121.046 0.451 . . . . 0.0 111.46 -179.235 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 46.0 t -108.76 136.19 45.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.785 177.933 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.439 HG23 HG23 ' A' ' 77' ' ' ILE . 70.9 mt -93.79 122.71 45.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-N 116.496 -0.32 . . . . 0.0 110.981 179.55 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -79.82 -44.97 19.6 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.5 -0.318 . . . . 0.0 110.951 174.809 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . 0.62 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 16.4 p -169.03 161.22 10.45 Favored 'General case' 0 CA--C 1.515 -0.404 0 CA-C-O 120.888 0.375 . . . . 0.0 111.408 -174.559 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.558 HD11 HD12 ' A' ' 75' ' ' ILE . 8.1 tt -135.95 122.19 31.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.148 177.473 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 11.0 m120 58.85 22.88 10.69 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-N 115.642 -0.708 . . . . 0.0 112.536 176.094 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 104.71 -26.22 23.19 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.655 -0.783 . . . . 0.0 112.433 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 4.4 mpp? -91.94 112.8 56.6 Favored Pre-proline 0 C--N 1.325 -0.491 0 N-CA-C 109.682 -0.488 . . . . 0.0 109.682 177.577 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.62 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 72.6 Cg_endo -78.02 128.07 8.9 Favored 'Trans proline' 0 N--CA 1.454 -0.799 0 C-N-CA 122.09 1.86 . . . . 0.0 112.501 -178.748 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 21.5 p -91.64 81.13 5.31 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 115.649 -0.705 . . . . 0.0 111.026 -177.944 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . 0.461 ' HA ' ' H ' ' A' ' 26' ' ' GLY . 12.6 m -81.34 -18.5 45.49 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.69 178.561 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 42.7 m-80 -138.34 164.85 28.25 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.733 -178.729 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.511 HD21 ' HA ' ' A' ' 105' ' ' SER . 66.2 mt -68.75 -35.14 76.72 Favored 'General case' 0 N--CA 1.446 -0.653 0 CA-C-O 120.908 0.385 . . . . 0.0 110.576 178.222 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 1.5 m -62.22 -35.32 78.53 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.509 176.513 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -66.65 -43.25 85.1 Favored 'General case' 0 N--CA 1.452 -0.356 0 CA-C-N 115.998 -0.547 . . . . 0.0 110.374 178.326 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 33.3 t80 -64.14 -37.53 87.79 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.931 -0.577 . . . . 0.0 109.635 177.473 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 66.8 m -61.46 -50.94 70.75 Favored 'General case' 0 N--CA 1.445 -0.693 0 CA-C-N 115.387 -0.824 . . . . 0.0 111.397 178.012 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.95 -33.93 76.42 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.989 179.623 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . 0.575 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -72.79 -41.27 65.16 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.269 -179.866 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 1.2 tt -57.42 -39.31 75.92 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.252 179.407 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 93.7 mttt -59.23 -39.41 82.65 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.801 179.375 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 17.5 p -77.84 -14.37 59.59 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 111.985 0.365 . . . . 0.0 111.985 -178.701 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.575 HG12 ' O ' ' A' ' 65' ' ' ALA . 43.0 mm -75.29 142.75 14.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 N-CA-C 110.495 -0.187 . . . . 0.0 110.495 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 3.0 m -102.11 168.96 9.04 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.713 0.292 . . . . 0.0 110.925 179.761 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 16.4 t -82.11 122.19 36.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.294 178.809 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 83.32 25.72 46.59 Favored Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 120.61 -0.805 . . . . 0.0 111.807 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 18.9 tt0 -105.81 153.32 22.07 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 179.917 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 26.5 t -97.9 113.78 33.42 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 CA-C-O 120.866 0.365 . . . . 0.0 110.167 -179.014 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.558 HD12 HD11 ' A' ' 51' ' ' ILE . 9.3 pt -101.33 154.8 4.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.164 -179.03 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . 0.437 ' O ' ' HA ' ' A' ' 51' ' ' ILE . 10.8 t30 -119.33 104.95 10.84 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 121.151 0.5 . . . . 0.0 111.076 -173.292 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.472 HD12 HD21 ' A' ' 86' ' ' LEU . 67.1 mt -103.12 118.83 50.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 115.37 -0.832 . . . . 0.0 110.405 -177.459 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 19.6 m -95.62 115.37 27.33 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.628 -0.715 . . . . 0.0 109.664 177.368 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 82.0 p -111.15 169.75 8.57 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.42 -179.736 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -61.98 -25.55 67.69 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.088 179.257 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 8.4 tp-100 -98.51 11.85 37.0 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.171 0.51 . . . . 0.0 111.097 -176.69 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 134.44 176.11 14.21 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.315 -0.945 . . . . 0.0 113.002 176.153 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 18.1 m -105.27 120.11 40.73 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 -179.523 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 63.4 m-85 -126.57 152.16 46.96 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.759 0.314 . . . . 0.0 110.243 -179.426 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -131.49 131.15 43.23 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-O 121.299 0.571 . . . . 0.0 110.422 177.079 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.473 HD22 HD11 ' A' ' 42' ' ' LEU . 0.9 OUTLIER -127.13 157.42 39.77 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.319 -0.855 . . . . 0.0 111.106 -173.535 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 40.0 ttmt -99.56 130.6 45.81 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.057 178.545 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 33.9 p -71.63 131.19 42.84 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 121.064 0.459 . . . . 0.0 111.036 179.548 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.442 -0.908 0 C-N-CA 120.491 -0.861 . . . . 0.0 112.322 -177.637 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.135 0 CA-C-O 121.174 0.511 . . . . 0.0 110.153 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 0.1 OUTLIER -70.34 110.75 5.46 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.22 -171.178 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 25.4 mmt -82.84 111.02 18.36 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 173.268 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . 0.679 ' HA3' ' HB2' ' A' ' 36' ' ' SER . . . -81.28 30.22 2.75 Favored Glycine 0 C--O 1.228 -0.236 0 C-N-CA 120.814 -0.707 . . . . 0.0 113.263 -174.958 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.522 HG22 HG22 ' A' ' 32' ' ' VAL . 42.9 pt -147.69 173.29 2.16 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 -179.98 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . 0.721 ' HB2' ' HB3' ' A' ' 30' ' ' ASP . 65.7 mtt-85 -109.94 134.37 52.17 Favored 'General case' 0 C--N 1.317 -0.834 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 173.344 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.5 p -119.79 124.5 46.3 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-O 120.944 0.402 . . . . 0.0 110.72 178.353 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.511 ' HA ' HD21 ' A' ' 59' ' ' LEU . 42.3 m -145.64 163.43 34.86 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.248 -179.083 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 86.6 m-20 . . . . . 0 C--N 1.325 -0.474 0 CA-C-O 121.853 0.835 . . . . 0.0 109.061 173.474 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 25.2 t0 . . . . . 0 N--CA 1.466 0.353 0 CA-C-O 121.047 0.451 . . . . 0.0 111.164 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.432 ' HA2' ' O ' ' A' ' 56' ' ' THR . . . 171.02 134.07 1.71 Allowed Glycine 0 N--CA 1.444 -0.785 0 C-N-CA 120.9 -0.667 . . . . 0.0 111.724 -179.958 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.527 HG23 ' HB ' ' A' ' 48' ' ' ILE . 19.0 m -76.3 153.94 5.89 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-O 120.69 0.281 . . . . 0.0 110.445 179.672 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 31.7 tt0 -115.8 149.51 38.42 Favored 'General case' 0 C--N 1.323 -0.579 0 C-N-CA 120.28 -0.568 . . . . 0.0 110.986 -179.371 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 68.9 mt -80.18 114.5 21.16 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-N 115.814 -0.63 . . . . 0.0 109.878 177.543 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . 0.572 ' HB3' ' HB3' ' A' ' 103' ' ' ARG . 16.2 t70 -70.39 -67.57 0.49 Allowed 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.392 0.615 . . . . 0.0 110.064 -178.95 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 6.9 p -159.14 153.9 24.63 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.109 179.804 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.802 HG22 HG22 ' A' ' 102' ' ' ILE . 95.3 t -82.24 128.63 38.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 177.95 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.405 ' HB ' ' HD2' ' A' ' 34' ' ' PRO . 27.5 m -92.16 159.14 38.08 Favored Pre-proline 0 N--CA 1.446 -0.664 0 CA-C-N 116.575 -0.284 . . . . 0.0 110.382 -178.417 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . 0.405 ' HD2' ' HB ' ' A' ' 33' ' ' VAL . 21.0 Cg_endo -62.88 106.23 0.51 Allowed 'Trans proline' 0 N--CA 1.461 -0.416 0 C-N-CA 122.271 1.981 . . . . 0.0 111.591 174.505 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 135.72 150.58 5.99 Favored Glycine 0 N--CA 1.448 -0.565 0 CA-C-N 115.905 -0.589 . . . . 0.0 112.067 -177.652 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 50.5 m 71.11 153.73 0.15 Allowed Pre-proline 0 CA--C 1.535 0.382 0 C-N-CA 123.038 0.535 . . . . 0.0 111.719 179.704 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -83.22 14.18 2.44 Favored 'Trans proline' 0 C--N 1.347 0.449 0 C-N-CA 122.95 2.434 . . . . 0.0 113.416 -176.267 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.568 ' HB2' ' O ' ' A' ' 100' ' ' MET . . . -59.79 -35.12 74.01 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.865 0.364 . . . . 0.0 111.478 -179.192 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.568 ' HB3' HG11 ' A' ' 32' ' ' VAL . 0.8 OUTLIER -65.93 -22.45 66.49 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.04 -0.527 . . . . 0.0 112.374 -175.063 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 19.8 ptpt -100.27 1.34 41.64 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.691 0.281 . . . . 0.0 110.896 179.829 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 83.6 t -110.59 -55.86 4.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 116.476 -0.329 . . . . 0.0 111.017 -178.23 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 1.2 pp -118.51 -178.81 3.62 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.395 0.617 . . . . 0.0 111.932 -177.051 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 23.3 m -119.95 134.4 23.97 Favored Pre-proline 0 C--N 1.316 -0.864 0 CA-C-N 115.084 -0.962 . . . . 0.0 109.964 -179.609 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.508 ' HB3' HG23 ' A' ' 32' ' ' VAL . 31.4 Cg_endo -65.67 145.58 81.85 Favored 'Trans proline' 0 N--CA 1.464 -0.242 0 C-N-CA 122.131 1.887 . . . . 0.0 111.738 176.553 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 97.83 11.0 51.6 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.517 -0.849 . . . . 0.0 112.917 -178.926 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 80.4 mt -98.04 164.9 12.15 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.772 0.32 . . . . 0.0 110.524 177.276 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.46 ' HB ' ' HB2' ' A' ' 80' ' ' ASP . 39.7 t -97.08 140.94 16.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 116.325 -0.398 . . . . 0.0 109.99 177.633 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.527 ' HB ' HG23 ' A' ' 27' ' ' VAL . 72.1 mt -103.86 115.51 45.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-O 120.839 0.352 . . . . 0.0 110.519 178.493 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.401 ' HB3' ' HB ' ' A' ' 78' ' ' THR . 7.7 tt0 -78.98 -55.11 5.38 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.598 0.713 . . . . 0.0 110.3 177.142 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . 0.611 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 8.0 p -148.15 146.65 28.84 Favored 'General case' 0 C--N 1.315 -0.908 0 CA-C-N 115.423 -0.808 . . . . 0.0 112.157 -173.023 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.457 ' HA ' ' O ' ' A' ' 76' ' ' ASN . 49.1 mt -117.29 114.91 47.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-N 114.96 -1.018 . . . . 0.0 109.225 173.577 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 7.6 t-20 61.91 -152.62 0.36 Allowed 'General case' 0 C--O 1.234 0.25 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 -171.746 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -79.57 21.45 4.5 Favored Glycine 0 CA--C 1.523 0.532 0 C-N-CA 120.307 -0.949 . . . . 0.0 112.258 175.931 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 61.0 mtm -123.66 106.3 32.29 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 120.805 0.336 . . . . 0.0 110.19 -178.835 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.611 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 65.1 Cg_endo -73.99 150.18 43.04 Favored 'Trans proline' 0 N--CA 1.46 -0.48 0 C-N-CA 122.133 1.889 . . . . 0.0 112.602 -179.36 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.432 ' O ' ' HA2' ' A' ' 26' ' ' GLY . 33.5 p -120.72 106.07 11.36 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.74 -178.234 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 12.6 p -96.03 -22.45 17.35 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.927 -179.723 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 27.5 p-10 -146.63 -169.41 3.27 Favored 'General case' 0 N--CA 1.447 -0.59 0 CA-C-O 121.271 0.558 . . . . 0.0 110.594 175.457 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.544 ' HG ' ' HB2' ' A' ' 106' ' ' ASN . 19.1 mt -68.43 -35.29 77.41 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.142 -0.935 . . . . 0.0 111.813 -178.683 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 7.7 m -65.77 -45.71 81.51 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.758 0.313 . . . . 0.0 111.324 -177.555 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 1.6 p -66.29 -33.38 75.6 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.137 0.494 . . . . 0.0 110.528 178.257 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 76.1 t80 -62.01 -46.8 87.61 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.311 -0.859 . . . . 0.0 110.526 174.73 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 5.3 t -63.75 -45.1 91.37 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.593 -179.458 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -66.36 -26.8 67.44 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.965 -0.562 . . . . 0.0 111.682 -177.265 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -78.68 -43.64 25.55 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.011 0.434 . . . . 0.0 110.365 176.657 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -59.66 -42.0 91.85 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.456 -0.793 . . . . 0.0 111.354 -176.506 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 15.2 ptmm? -64.97 -6.86 9.48 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 112.595 0.591 . . . . 0.0 112.595 -174.565 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 49.6 p -106.28 -14.59 15.07 Favored 'General case' 0 C--N 1.326 -0.426 0 C-N-CA 120.768 -0.373 . . . . 0.0 111.402 -179.753 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 45.0 mm -72.06 140.0 18.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 120.863 0.363 . . . . 0.0 111.23 -174.355 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . 0.607 ' HB2' ' HB2' ' A' ' 73' ' ' GLU . 2.5 m -89.33 151.22 22.2 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.372 179.031 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 48.9 t -73.91 118.2 19.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 120.988 0.423 . . . . 0.0 110.055 177.327 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 93.02 9.07 61.14 Favored Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 120.605 -0.807 . . . . 0.0 111.993 -179.073 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . 0.607 ' HB2' ' HB2' ' A' ' 70' ' ' SER . 35.7 tt0 -86.45 148.75 25.41 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 120.809 0.338 . . . . 0.0 110.092 179.626 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . 0.424 ' HA ' ' HA ' ' A' ' 87' ' ' LYS . 60.1 t -92.1 113.17 26.93 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 176.919 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 27.3 pt -108.62 154.45 9.93 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-O 121.314 0.578 . . . . 0.0 111.224 -177.441 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . 0.457 ' O ' ' HA ' ' A' ' 51' ' ' ILE . 6.0 t30 -95.85 127.26 41.72 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.151 178.382 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.562 HD12 HD21 ' A' ' 86' ' ' LEU . 54.3 mt -125.26 106.31 16.16 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 CA-C-O 121.288 0.566 . . . . 0.0 109.846 176.362 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . 0.401 ' HB ' ' HB3' ' A' ' 49' ' ' GLU . 4.3 m -78.59 102.48 7.97 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 115.32 -0.854 . . . . 0.0 109.239 178.302 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 70.7 p -94.6 167.65 11.34 Favored 'General case' 0 C--N 1.323 -0.545 0 C-N-CA 120.474 -0.49 . . . . 0.0 110.697 -178.569 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . 0.46 ' HB2' ' HB ' ' A' ' 47' ' ' VAL . 23.8 t70 -52.52 -33.38 45.0 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.267 -0.878 . . . . 0.0 111.834 -179.858 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 28.1 mt-30 -118.73 28.0 8.57 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 112.185 0.439 . . . . 0.0 112.185 -173.481 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 150.18 151.29 5.49 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.208 -0.996 . . . . 0.0 113.487 173.854 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 26.4 m -94.81 106.72 18.72 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 109.697 -0.483 . . . . 0.0 109.697 176.361 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 84.8 m-85 -114.66 158.52 21.64 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.058 0.456 . . . . 0.0 110.874 -176.395 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 17.4 p-80 -123.66 129.13 50.65 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.814 -0.63 . . . . 0.0 109.508 173.141 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.562 HD21 HD12 ' A' ' 77' ' ' ILE . 0.6 OUTLIER -134.24 156.07 49.05 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 115.989 -0.55 . . . . 0.0 111.031 -176.614 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' LYS . . . . . 0.424 ' HA ' ' HA ' ' A' ' 74' ' ' VAL . 58.8 tttm -96.35 131.59 42.73 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.675 -179.022 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 39.9 p -69.75 139.46 53.32 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-O 121.158 0.504 . . . . 0.0 111.127 178.714 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.433 -1.564 0 N-CA-C 111.146 -0.782 . . . . 0.0 111.146 176.63 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.465 0.281 0 CA-C-O 121.346 0.593 . . . . 0.0 110.712 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -96.49 112.7 24.35 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.406 -171.413 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' MET . . . . . 0.596 ' HG2' ' H ' ' A' ' 102' ' ' ILE . 1.4 pmm? -63.5 -31.09 72.15 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.701 -179.498 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 104.73 1.46 42.91 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.466 -0.873 . . . . 0.0 113.295 175.898 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.802 HG22 HG22 ' A' ' 32' ' ' VAL . 2.8 pp -130.08 148.03 33.19 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.61 0 CA-C-O 121.003 0.43 . . . . 0.0 110.771 179.55 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . 0.572 ' HB3' ' HB3' ' A' ' 30' ' ' ASP . 1.0 OUTLIER -80.73 137.93 36.29 Favored 'General case' 0 C--N 1.321 -0.638 0 N-CA-C 108.242 -1.022 . . . . 0.0 108.242 172.89 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.7 m -112.25 153.23 27.44 Favored 'General case' 0 C--N 1.31 -1.14 0 CA-C-O 120.802 0.334 . . . . 0.0 110.394 -177.491 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 23.8 p -135.67 163.92 29.06 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 115.96 -0.564 . . . . 0.0 109.976 -179.873 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . 0.544 ' HB2' ' HG ' ' A' ' 59' ' ' LEU . 65.8 t30 . . . . . 0 C--N 1.317 -0.839 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 -177.111 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 38.9 t70 . . . . . 0 N--CA 1.463 0.194 0 CA-C-O 120.99 0.424 . . . . 0.0 111.544 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.548 ' HA2' ' HA ' ' A' ' 57' ' ' SER . . . 167.48 151.3 6.89 Favored Glycine 0 N--CA 1.446 -0.686 0 N-CA-C 111.247 -0.741 . . . . 0.0 111.247 -177.664 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.621 HG23 ' HB ' ' A' ' 48' ' ' ILE . 29.5 m -102.81 145.26 12.49 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-O 121.021 0.439 . . . . 0.0 110.82 -179.038 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 29.4 tt0 -115.82 150.18 37.38 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.704 -178.567 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.455 HD12 ' HB2' ' A' ' 46' ' ' LEU . 48.3 mt -76.85 107.94 8.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.011 178.003 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 22.5 t70 -62.29 -62.19 1.93 Allowed 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.551 0.691 . . . . 0.0 109.871 177.213 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 13.4 p -158.11 149.2 21.0 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.205 -0.907 . . . . 0.0 110.625 179.253 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.526 HG22 HG22 ' A' ' 102' ' ' ILE . 44.8 t -99.11 117.94 44.96 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 N-CA-C 109.519 -0.548 . . . . 0.0 109.519 177.272 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.503 ' HA ' ' HD3' ' A' ' 34' ' ' PRO . 11.9 m -80.91 117.37 67.75 Favored Pre-proline 0 N--CA 1.447 -0.594 0 CA-C-O 120.982 0.42 . . . . 0.0 110.572 -179.95 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . 0.503 ' HD3' ' HA ' ' A' ' 33' ' ' VAL . 16.7 Cg_exo -69.73 25.82 0.17 Allowed 'Trans proline' 0 N--CA 1.478 0.605 0 C-N-CA 123.918 3.079 . . . . 0.0 113.85 -174.208 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -120.56 15.08 9.87 Favored Glycine 0 N--CA 1.446 -0.636 0 N-CA-C 110.645 -0.982 . . . . 0.0 110.645 174.339 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 7.5 m -139.1 177.33 2.11 Favored Pre-proline 0 C--N 1.325 -0.477 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 -177.358 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 24.8 Cg_exo -64.9 -172.86 0.22 Allowed 'Trans proline' 0 C--N 1.35 0.656 0 C-N-CA 122.255 1.97 . . . . 0.0 112.214 174.107 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.605 ' HB2' HD11 ' A' ' 86' ' ' LEU . . . 72.38 -23.25 0.2 Allowed 'General case' 0 N--CA 1.47 0.538 0 C-N-CA 123.493 0.717 . . . . 0.0 112.867 177.108 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 37.0 m -61.64 -29.61 70.17 Favored 'General case' 0 CA--C 1.531 0.233 0 CA-C-O 121.018 0.437 . . . . 0.0 111.842 -176.439 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 17.0 tppt? -97.06 -6.01 36.2 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.003 0.43 . . . . 0.0 110.51 -178.843 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 46.9 t -102.06 -52.69 8.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.712 -174.117 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.456 HD11 ' HB1' ' A' ' 38' ' ' ALA . 1.2 pp -127.49 -177.54 4.12 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-O 121.366 0.603 . . . . 0.0 112.026 -175.343 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 2.9 p -125.09 151.96 69.92 Favored Pre-proline 0 C--N 1.32 -0.696 0 CA-C-N 115.008 -0.996 . . . . 0.0 110.62 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -70.47 156.01 62.37 Favored 'Trans proline' 0 C--N 1.343 0.278 0 C-N-CA 122.404 2.069 . . . . 0.0 112.191 178.457 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 100.11 -13.36 60.35 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.606 -0.807 . . . . 0.0 112.491 -178.56 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.455 ' HB2' HD12 ' A' ' 29' ' ' ILE . 91.9 mt -79.4 164.62 23.86 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.833 0.349 . . . . 0.0 110.803 179.597 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 48.4 t -105.98 135.12 45.45 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.528 -178.368 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.621 ' HB ' HG23 ' A' ' 27' ' ' VAL . 8.4 mm -88.14 100.38 10.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 175.758 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 57.1 mt-10 -78.31 -48.23 16.09 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.049 -177.624 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . 0.585 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 5.4 p -159.92 145.81 15.66 Favored 'General case' 0 N--CA 1.447 -0.592 0 CA-C-O 121.203 0.525 . . . . 0.0 111.797 -176.895 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 67.9 mt -115.38 106.25 20.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-N 115.099 -0.955 . . . . 0.0 108.595 175.791 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 3.1 m-20 59.96 -152.14 0.4 Allowed 'General case' 0 C--O 1.236 0.392 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 -171.778 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -76.14 28.61 1.41 Allowed Glycine 0 CA--C 1.524 0.63 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.696 176.913 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 57.4 mtm -130.44 101.83 17.23 Favored Pre-proline 0 C--N 1.326 -0.414 0 N-CA-C 109.676 -0.49 . . . . 0.0 109.676 176.934 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.585 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 60.0 Cg_endo -72.19 150.99 54.48 Favored 'Trans proline' 0 N--CA 1.46 -0.494 0 C-N-CA 122.027 1.818 . . . . 0.0 112.306 179.972 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . 0.426 ' O ' ' HA2' ' A' ' 26' ' ' GLY . 6.2 p -111.33 83.66 1.81 Allowed 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 121.242 0.544 . . . . 0.0 111.863 -177.326 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . 0.548 ' HA ' ' HA2' ' A' ' 26' ' ' GLY . 20.9 m -91.11 -13.64 32.69 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.571 -0.74 . . . . 0.0 109.846 176.507 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 5.4 m120 -125.5 164.64 20.06 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.672 -0.694 . . . . 0.0 109.939 -177.877 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 41.5 mt -73.81 -31.75 63.4 Favored 'General case' 0 N--CA 1.446 -0.665 0 CA-C-O 121.516 0.674 . . . . 0.0 109.774 172.0 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -68.28 -40.54 81.79 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.176 -0.92 . . . . 0.0 111.734 178.891 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 12.6 p -60.9 -39.6 89.94 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.72 0.295 . . . . 0.0 110.959 175.857 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 87.3 t80 -62.04 -43.51 98.69 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-O 121.478 0.656 . . . . 0.0 109.676 175.948 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 61.4 m -65.1 -48.9 72.05 Favored 'General case' 0 N--CA 1.446 -0.638 0 CA-C-N 115.08 -0.964 . . . . 0.0 111.757 179.28 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.53 -32.45 73.91 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.97 -176.575 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . 0.611 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -70.5 -48.34 56.1 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.014 -0.539 . . . . 0.0 109.928 178.58 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.408 HD23 ' HA ' ' A' ' 66' ' ' LEU . 4.0 mt -63.81 -35.28 80.1 Favored 'General case' 0 N--CA 1.449 -0.477 0 CA-C-N 115.451 -0.795 . . . . 0.0 111.94 -176.438 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 59.8 mtpt -70.48 -21.98 62.71 Favored 'General case' 0 C--N 1.33 -0.273 0 N-CA-C 112.115 0.413 . . . . 0.0 112.115 -178.357 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 71.6 p -90.47 -13.54 34.56 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.864 0.364 . . . . 0.0 111.425 -179.636 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.611 HG12 ' O ' ' A' ' 65' ' ' ALA . 41.8 mm -79.85 143.8 11.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.449 -0.342 . . . . 0.0 110.599 -177.758 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 3.5 m -83.72 157.13 22.27 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 176.723 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 25.1 t -74.26 119.68 22.06 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 176.239 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 91.67 21.29 34.56 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.668 -0.777 . . . . 0.0 111.523 -177.422 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 29.9 tt0 -98.91 146.46 25.96 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 179.858 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 57.5 t -98.38 110.81 26.64 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.848 0 CA-C-O 121.052 0.453 . . . . 0.0 110.473 -178.134 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.536 HG13 HD11 ' A' ' 77' ' ' ILE . 23.3 pt -103.84 163.57 3.86 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.679 179.773 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 6.3 t30 -115.9 117.07 29.14 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.782 -177.219 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.536 HD11 HG13 ' A' ' 75' ' ' ILE . 4.6 mp -113.5 118.93 59.53 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-O 121.26 0.552 . . . . 0.0 110.293 -177.301 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 32.5 m -91.93 117.17 29.55 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.39 175.796 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 71.7 p -114.35 170.89 7.97 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 110.179 -0.304 . . . . 0.0 110.179 -179.928 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 9.0 t70 -53.68 -41.75 67.2 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.931 -0.577 . . . . 0.0 112.064 179.54 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 6.7 tp-100 -109.15 31.09 5.98 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.906 0.384 . . . . 0.0 111.451 -171.487 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 140.28 176.17 14.94 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 120.133 -1.032 . . . . 0.0 113.12 173.384 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 7.0 m -117.5 123.89 47.42 Favored 'General case' 0 C--N 1.318 -0.775 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 178.802 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 66.4 m-85 -121.21 154.27 36.5 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.982 0.42 . . . . 0.0 110.726 -176.747 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 56.1 p-80 -111.3 130.88 55.53 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 108.989 -0.745 . . . . 0.0 108.989 173.185 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.605 HD11 ' HB2' ' A' ' 38' ' ' ALA . 3.8 tt -124.09 137.44 54.57 Favored 'General case' 0 C--N 1.311 -1.084 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.053 -172.634 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' LYS . . . . . 0.457 ' N ' HD23 ' A' ' 86' ' ' LEU . 78.8 tttt -102.67 111.32 23.58 Favored 'General case' 0 C--N 1.311 -1.077 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 178.154 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.546 HG21 HG21 ' A' ' 69' ' ' ILE . 26.4 p -59.52 142.93 51.51 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.812 -0.631 . . . . 0.0 112.616 -172.405 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.443 -0.887 0 N-CA-C 111.017 -0.833 . . . . 0.0 111.017 176.824 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.461 0.123 0 CA-C-O 121.056 0.455 . . . . 0.0 112.167 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 18.6 t80 -120.98 135.55 55.19 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 178.05 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 49.6 ttm -77.35 -53.32 7.83 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.972 -178.231 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 117.31 17.07 5.84 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.162 -1.018 . . . . 0.0 113.398 176.88 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.526 HG22 HG22 ' A' ' 32' ' ' VAL . 39.0 pt -130.17 153.05 38.37 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-O 120.857 0.36 . . . . 0.0 110.67 179.342 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 42.8 mtp85 -82.01 123.36 28.83 Favored 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 108.185 -1.042 . . . . 0.0 108.185 168.191 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -113.77 148.97 35.59 Favored 'General case' 0 C--N 1.314 -0.956 0 C-N-CA 120.643 -0.423 . . . . 0.0 110.479 -177.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 54.0 m -155.33 160.29 40.63 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 176.917 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 86.8 m-20 . . . . . 0 C--N 1.317 -0.83 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 177.604 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 35.9 t70 . . . . . 0 N--CA 1.463 0.209 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 90.44 128.39 3.78 Favored Glycine 0 N--CA 1.443 -0.9 0 CA-C-N 115.38 -0.827 . . . . 0.0 111.696 -175.664 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.53 HG23 ' HB ' ' A' ' 48' ' ' ILE . 4.6 m -69.28 141.56 17.17 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 N-CA-C 109.605 -0.516 . . . . 0.0 109.605 178.728 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . 0.446 ' HB3' HG13 ' A' ' 47' ' ' VAL . 8.3 pt20 -125.45 152.99 44.16 Favored 'General case' 0 C--N 1.319 -0.736 0 C-N-CA 119.17 -1.012 . . . . 0.0 111.879 -178.698 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.415 HG12 HD12 ' A' ' 102' ' ' ILE . 50.1 mt -77.32 130.81 35.83 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.61 0 CA-C-N 115.23 -0.896 . . . . 0.0 110.82 -178.784 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -89.94 -50.27 6.13 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.244 174.954 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 23.6 p -161.96 166.78 25.6 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 116.587 -0.279 . . . . 0.0 110.917 -179.301 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.488 HG13 HG22 ' A' ' 102' ' ' ILE . 45.8 t -110.38 140.36 29.78 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 N-CA-C 109.365 -0.605 . . . . 0.0 109.365 174.755 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 7.1 p -60.78 140.12 93.28 Favored Pre-proline 0 CA--C 1.537 0.473 0 N-CA-C 110.317 -0.253 . . . . 0.0 110.317 179.735 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 15.7 Cg_exo -69.46 65.39 1.62 Allowed 'Trans proline' 0 C--N 1.348 0.5 0 C-N-CA 122.925 2.416 . . . . 0.0 112.173 176.175 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 165.59 -169.26 39.92 Favored Glycine 0 N--CA 1.446 -0.7 0 N-CA-C 111.34 -0.704 . . . . 0.0 111.34 -179.707 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.773 ' HB2' ' HD2' ' A' ' 37' ' ' PRO . 60.6 p 56.39 179.46 0.03 OUTLIER Pre-proline 0 CA--C 1.545 0.761 0 C-N-CA 123.448 0.699 . . . . 0.0 111.513 179.432 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . 0.773 ' HD2' ' HB2' ' A' ' 36' ' ' SER . 58.4 Cg_endo -73.1 -159.45 0.08 OUTLIER 'Trans proline' 0 C--N 1.349 0.586 0 C-N-CA 121.967 1.778 . . . . 0.0 111.636 169.712 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.472 ' HB2' HD11 ' A' ' 86' ' ' LEU . . . 77.36 -33.43 0.19 Allowed 'General case' 0 N--CA 1.471 0.612 0 C-N-CA 123.395 0.678 . . . . 0.0 112.321 172.712 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 35.0 t -65.15 -21.18 66.75 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.595 -0.275 . . . . 0.0 111.082 -178.884 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 61.9 mttp -99.35 -0.06 41.86 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.918 0.39 . . . . 0.0 110.378 178.273 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.512 ' HB ' HD12 ' A' ' 42' ' ' LEU . 45.9 t -105.08 -53.73 6.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.899 -175.928 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.512 HD12 ' HB ' ' A' ' 41' ' ' VAL . 5.2 mp -106.88 164.08 12.42 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.997 0.427 . . . . 0.0 110.55 -178.578 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . 0.449 ' O ' ' HG ' ' A' ' 46' ' ' LEU . 40.1 m -109.42 124.46 33.81 Favored Pre-proline 0 C--N 1.319 -0.729 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.87 177.109 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo -59.36 134.48 58.99 Favored 'Trans proline' 0 N--CA 1.46 -0.468 0 C-N-CA 122.277 1.985 . . . . 0.0 111.965 177.834 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 107.93 -16.52 36.28 Favored Glycine 0 N--CA 1.446 -0.638 0 C-N-CA 120.631 -0.795 . . . . 0.0 112.976 -179.695 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.449 ' HG ' ' O ' ' A' ' 43' ' ' THR . 75.6 mt -71.89 164.16 26.55 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.844 0.354 . . . . 0.0 110.642 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.446 HG13 ' HB3' ' A' ' 28' ' ' GLN . 23.1 t -107.46 142.63 19.72 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 116.194 -0.457 . . . . 0.0 109.939 179.8 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.53 ' HB ' HG23 ' A' ' 27' ' ' VAL . 10.6 mm -84.68 125.7 40.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 179.625 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -90.23 -54.05 4.19 Favored 'General case' 0 C--N 1.321 -0.674 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 176.143 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . 0.444 ' CB ' ' HA ' ' A' ' 55' ' ' PRO . 20.6 m -154.44 152.63 30.37 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.419 -174.536 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.473 HG22 ' N ' ' A' ' 52' ' ' ASN . 46.3 mm -99.47 167.27 1.96 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.823 0 N-CA-C 107.64 -1.245 . . . . 0.0 107.64 171.871 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' ASN . . . . . 0.657 ' HB2' ' H ' ' A' ' 76' ' ' ASN . 54.1 t30 -50.51 103.44 0.05 Allowed 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 112.304 0.483 . . . . 0.0 112.304 -176.86 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 83.18 -15.36 34.05 Favored Glycine 0 N--CA 1.451 -0.343 0 CA-C-N 115.898 -0.592 . . . . 0.0 113.053 176.993 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 40.7 mtm -130.29 106.95 16.12 Favored Pre-proline 0 C--N 1.326 -0.447 0 O-C-N 122.643 -0.328 . . . . 0.0 110.87 -173.518 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.444 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 42.5 Cg_endo -68.06 148.96 76.61 Favored 'Trans proline' 0 C--N 1.343 0.242 0 C-N-CA 122.552 2.168 . . . . 0.0 112.199 -179.726 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 20.8 p -126.82 97.02 4.83 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 112.102 0.408 . . . . 0.0 112.102 -175.532 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 22.9 t -102.01 -14.18 17.26 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 121.362 0.601 . . . . 0.0 109.734 174.871 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 32.3 m-80 -124.29 167.36 14.43 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.174 -178.57 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 1.6 mt -68.99 -35.27 76.52 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.322 -0.399 . . . . 0.0 109.97 173.387 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 19.5 m -64.11 -38.8 92.36 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.219 179.472 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 3.3 p -66.98 -33.32 75.32 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 120.804 0.335 . . . . 0.0 110.887 178.566 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 55.2 t80 -71.63 -35.14 70.33 Favored 'General case' 0 C--N 1.331 -0.217 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 176.29 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 69.0 m -66.62 -50.06 64.23 Favored 'General case' 0 N--CA 1.444 -0.729 0 CA-C-N 115.365 -0.834 . . . . 0.0 111.296 178.39 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . 0.415 ' O ' ' HG2' ' A' ' 67' ' ' LYS . . . -63.43 -31.96 73.26 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.747 -0.661 . . . . 0.0 111.39 -178.194 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . 0.474 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -76.93 -34.61 57.65 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.161 0.505 . . . . 0.0 110.639 -179.842 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 1.5 tt -68.71 -44.18 74.45 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.892 -177.445 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . 0.415 ' HG2' ' O ' ' A' ' 64' ' ' ALA . 14.6 ptmm? -60.43 -23.47 64.43 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.924 -174.044 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 17.7 p -87.53 -14.15 41.08 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 112.043 0.386 . . . . 0.0 112.043 -179.869 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.474 HG12 ' O ' ' A' ' 65' ' ' ALA . 21.7 mm -85.65 136.81 22.03 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-O 120.84 0.352 . . . . 0.0 110.601 -177.87 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 50.9 m -106.92 162.49 13.78 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.669 178.762 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 79.4 t -62.01 135.22 26.83 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.249 0 O-C-N 123.436 0.46 . . . . 0.0 110.518 175.353 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 94.33 -14.94 64.32 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.873 -0.68 . . . . 0.0 112.655 176.001 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 -80.29 150.3 30.03 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.128 0.49 . . . . 0.0 110.385 -177.379 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 47.3 t -106.34 124.76 61.94 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 CA-C-N 115.67 -0.696 . . . . 0.0 109.643 179.099 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.405 HG21 HD12 ' A' ' 69' ' ' ILE . 18.3 pt -119.6 157.34 21.78 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 121.377 0.608 . . . . 0.0 111.886 -176.749 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . 0.657 ' H ' ' HB2' ' A' ' 52' ' ' ASN . 4.5 t30 -99.08 127.16 44.97 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 114.861 -1.063 . . . . 0.0 110.034 179.43 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 72.4 mt -132.36 112.64 19.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-O 121.088 0.47 . . . . 0.0 110.514 -177.471 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . 0.557 ' HA ' ' HA ' ' A' ' 83' ' ' THR . 93.0 m -91.0 124.72 35.45 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.146 177.32 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 50.8 p -107.77 173.31 6.38 Favored 'General case' 0 C--N 1.319 -0.747 0 N-CA-C 109.457 -0.572 . . . . 0.0 109.457 174.703 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -63.17 -24.43 67.88 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 120.979 0.418 . . . . 0.0 111.259 -178.954 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 -106.77 16.86 23.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.444 -0.344 . . . . 0.0 111.606 -177.74 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 134.08 166.76 11.36 Favored Glycine 0 CA--C 1.516 0.123 0 C-N-CA 120.176 -1.011 . . . . 0.0 113.255 176.035 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . 0.557 ' HA ' ' HA ' ' A' ' 78' ' ' THR . 35.2 m -98.07 137.83 36.27 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 120.934 0.397 . . . . 0.0 111.204 -179.709 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 74.9 m-85 -130.42 158.32 40.19 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.051 177.517 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 48.2 p-80 -112.43 130.39 56.0 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 174.401 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.472 HD11 ' HB2' ' A' ' 38' ' ' ALA . 28.4 tp -118.19 152.06 36.41 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.989 -173.01 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 60.4 tttp -119.95 123.82 44.47 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 178.152 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 25.7 p -72.62 137.48 46.14 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.325 0.583 . . . . 0.0 111.613 -177.613 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . 0.599 ' H ' ' HE1' ' A' ' 99' ' ' TYR . . . . . . . . 0 N--CA 1.448 -0.515 0 CA-C-N 115.642 -0.708 . . . . 0.0 111.797 177.123 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.521 -0.143 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . 0.599 ' HE1' ' H ' ' A' ' 89' ' ' GLY . 6.2 p90 -67.14 -30.48 70.48 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 114.76 -1.109 . . . . 0.0 113.631 -160.575 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 24.3 mmt 60.45 95.56 0.03 OUTLIER 'General case' 0 N--CA 1.465 0.279 0 CA-C-O 121.313 0.578 . . . . 0.0 110.501 -173.356 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -83.75 29.2 3.77 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.829 -0.701 . . . . 0.0 112.846 -175.362 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.488 HG22 HG13 ' A' ' 32' ' ' VAL . 37.4 pt -136.94 154.54 31.54 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.742 0 CA-C-O 121.066 0.46 . . . . 0.0 109.988 -179.689 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . 0.424 ' HD3' ' HA ' ' A' ' 103' ' ' ARG . 7.8 tpp180 -92.8 144.52 25.2 Favored 'General case' 0 C--N 1.315 -0.908 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 175.809 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.4 t -145.47 154.68 42.5 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-O 121.417 0.627 . . . . 0.0 111.266 178.443 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 9.3 p -128.6 171.44 12.15 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-N 114.643 -1.162 . . . . 0.0 109.884 177.838 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 59.6 t30 . . . . . 0 C--N 1.317 -0.84 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.579 -174.348 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 28.5 p-10 . . . . . 0 C--O 1.233 0.234 0 N-CA-C 112.135 0.42 . . . . 0.0 112.135 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 96.53 133.02 7.5 Favored Glycine 0 N--CA 1.446 -0.689 0 N-CA-C 111.15 -0.78 . . . . 0.0 111.15 -176.953 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.447 ' HA ' ' HA ' ' A' ' 106' ' ' ASN . 19.6 m -78.78 140.4 16.94 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.742 0 CA-C-O 120.98 0.419 . . . . 0.0 110.842 -176.93 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . 0.48 ' HB2' ' O ' ' A' ' 46' ' ' LEU . 2.8 pt20 -109.84 157.59 19.04 Favored 'General case' 0 C--N 1.317 -0.823 0 C-N-CA 120.22 -0.592 . . . . 0.0 109.778 175.662 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.551 HG23 HD11 ' A' ' 48' ' ' ILE . 2.2 pt -79.84 98.49 3.26 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.14 176.523 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -53.78 -55.64 24.62 Favored 'General case' 0 CA--C 1.504 -0.816 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.13 177.509 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 6.2 p -155.99 144.56 20.18 Favored 'General case' 0 N--CA 1.441 -0.908 0 CA-C-N 115.045 -0.979 . . . . 0.0 111.438 -178.152 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.603 ' HA ' HG22 ' A' ' 102' ' ' ILE . 52.3 t -87.62 141.34 14.46 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.01 0 CA-C-N 114.965 -1.016 . . . . 0.0 108.664 171.651 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 48.3 t -83.18 105.38 5.12 Favored Pre-proline 0 C--N 1.322 -0.592 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 174.937 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . 0.505 ' HD3' ' O ' ' A' ' 32' ' ' VAL . 31.5 Cg_exo -58.19 113.64 1.62 Allowed 'Trans proline' 0 C--O 1.236 0.406 0 C-N-CA 122.774 2.316 . . . . 0.0 112.179 -175.305 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 133.61 -20.84 4.08 Favored Glycine 0 N--CA 1.446 -0.687 0 N-CA-C 111.227 -0.749 . . . . 0.0 111.227 -178.455 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 56.4 p -81.87 161.13 61.89 Favored Pre-proline 0 C--N 1.323 -0.575 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 177.692 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -59.03 -24.83 75.31 Favored 'Trans proline' 0 C--N 1.344 0.312 0 C-N-CA 122.36 2.04 . . . . 0.0 111.743 175.96 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.404 ' HB2' HD11 ' A' ' 86' ' ' LEU . . . -66.78 -27.86 67.93 Favored 'General case' 0 N--CA 1.454 -0.24 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.553 -179.359 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.533 ' HA ' HG11 ' A' ' 32' ' ' VAL . 13.2 m -63.2 -22.39 66.84 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.91 0.386 . . . . 0.0 111.454 -177.65 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 65.3 mttm -97.27 -17.58 19.72 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.487 -175.76 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.65 ' HB ' HD23 ' A' ' 42' ' ' LEU . 60.6 t -98.23 -49.52 11.68 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.871 -172.354 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.65 HD23 ' HB ' ' A' ' 41' ' ' VAL . 0.3 OUTLIER -117.12 178.23 4.43 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.561 0.696 . . . . 0.0 112.343 -173.745 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 56.8 m -128.42 128.99 23.6 Favored Pre-proline 0 C--N 1.322 -0.602 0 CA-C-N 114.693 -1.14 . . . . 0.0 109.593 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -64.66 152.95 79.96 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.611 2.207 . . . . 0.0 112.305 -177.643 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 99.82 -1.92 56.85 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.553 -0.832 . . . . 0.0 112.582 -178.024 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.495 ' HB2' HD11 ' A' ' 29' ' ' ILE . 85.1 mt -89.81 164.15 14.75 Favored 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 110.286 -0.264 . . . . 0.0 110.286 177.271 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 40.4 t -103.27 141.1 19.77 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 178.005 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.551 HD11 HG23 ' A' ' 29' ' ' ILE . 57.5 mt -99.76 120.23 48.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 121.051 0.453 . . . . 0.0 110.0 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 14.5 tt0 -78.81 -56.23 4.57 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 121.489 0.661 . . . . 0.0 109.834 176.781 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . 0.677 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 11.8 p -146.89 149.15 32.68 Favored 'General case' 0 N--CA 1.444 -0.741 0 CA-C-N 115.342 -0.844 . . . . 0.0 112.551 -171.001 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.538 ' HA ' ' O ' ' A' ' 76' ' ' ASN . 55.4 mt -126.7 114.03 35.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 114.561 -1.2 . . . . 0.0 108.573 172.751 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 6.4 t-20 63.13 -152.65 0.33 Allowed 'General case' 0 CA--C 1.532 0.278 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 -171.01 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -76.84 3.61 55.82 Favored Glycine 0 CA--C 1.52 0.392 0 C-N-CA 120.533 -0.841 . . . . 0.0 112.97 179.509 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 3.8 mpp? -111.76 105.39 56.59 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 120.725 0.298 . . . . 0.0 110.76 -178.894 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.677 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 47.0 Cg_endo -69.3 148.57 68.35 Favored 'Trans proline' 0 N--CA 1.462 -0.362 0 C-N-CA 122.303 2.002 . . . . 0.0 112.186 176.243 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 20.8 p -109.96 95.71 5.77 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.663 -176.484 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 14.7 p -92.85 -19.87 21.26 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.059 0.457 . . . . 0.0 110.738 177.367 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 14.2 m120 -125.56 173.52 8.89 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 178.153 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -82.48 -33.53 28.35 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 121.225 0.536 . . . . 0.0 110.257 176.683 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 6.1 m -70.08 -29.54 66.55 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.043 179.344 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 24.6 p -67.82 -38.5 83.32 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 121.136 0.493 . . . . 0.0 109.999 176.34 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 67.2 t80 -59.26 -44.15 92.41 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-N 115.437 -0.801 . . . . 0.0 109.709 173.475 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . 0.423 ' O ' ' HG3' ' A' ' 67' ' ' LYS . 70.3 m -63.71 -46.09 87.03 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.135 -0.938 . . . . 0.0 111.832 179.314 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.85 -33.68 74.62 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.118 179.652 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . 0.416 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -77.77 -36.17 50.83 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.147 0.499 . . . . 0.0 110.194 178.586 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -60.61 -29.91 69.52 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.139 179.124 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . 0.423 ' HG3' ' O ' ' A' ' 63' ' ' SER . 58.7 mtpt -58.79 -32.46 69.34 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.448 178.63 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 34.8 p -91.06 -14.71 30.8 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 112.216 0.45 . . . . 0.0 112.216 -175.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.416 HG12 ' O ' ' A' ' 65' ' ' ALA . 30.5 mm -82.26 140.53 16.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 N-CA-C 110.283 -0.266 . . . . 0.0 110.283 -177.695 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 14.3 t -115.64 178.04 4.45 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 120.958 0.409 . . . . 0.0 110.849 -179.575 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 20.9 t -79.99 120.78 32.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.858 -178.105 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 98.17 5.65 57.12 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.645 -0.788 . . . . 0.0 111.879 -179.815 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 15.2 tp10 -81.36 147.98 29.57 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.301 -0.45 . . . . 0.0 109.913 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 57.3 t -109.38 108.95 26.61 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.856 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.37 179.252 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 21.6 pt -109.84 153.84 11.5 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.773 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.193 -175.375 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . 0.538 ' O ' ' HA ' ' A' ' 51' ' ' ILE . 5.4 t30 -90.07 132.16 35.55 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.647 177.633 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.418 HG22 HG23 ' A' ' 79' ' ' THR . 61.7 mt -128.53 116.5 41.83 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-O 121.295 0.569 . . . . 0.0 110.465 -179.645 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 4.6 m -99.3 102.25 13.81 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.141 177.783 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.483 HG22 HG12 ' A' ' 48' ' ' ILE . 73.4 p -102.16 170.15 8.28 Favored 'General case' 0 C--N 1.324 -0.519 0 C-N-CA 120.674 -0.41 . . . . 0.0 110.296 178.081 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -51.07 -38.76 53.55 Favored 'General case' 0 N--CA 1.466 0.365 0 O-C-N 123.801 0.688 . . . . 0.0 112.649 -176.279 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 31.4 mt-30 -127.44 20.25 6.74 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 111.92 0.341 . . . . 0.0 111.92 -174.659 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -165.68 119.96 0.9 Allowed Glycine 0 N--CA 1.446 -0.653 0 C-N-CA 119.751 -1.214 . . . . 0.0 113.465 179.04 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 13.6 m -106.3 109.21 21.07 Favored 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 172.479 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . 0.453 ' CZ ' ' HB3' ' A' ' 42' ' ' LEU . 7.3 p90 -145.68 177.46 8.87 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 121.225 0.536 . . . . 0.0 111.807 -172.972 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 1.0 OUTLIER -111.9 150.82 29.93 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.388 -0.823 . . . . 0.0 109.756 172.055 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.439 HD22 ' HG3' ' A' ' 100' ' ' MET . 7.5 tt -134.11 141.39 47.11 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-O 121.218 0.533 . . . . 0.0 110.706 -176.81 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 82.3 tttt -94.21 116.38 28.77 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.044 -0.98 . . . . 0.0 109.275 177.51 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 32.1 p -59.25 123.49 16.87 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.584 0.707 . . . . 0.0 111.414 -176.934 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.434 -1.453 0 CA-C-N 114.991 -1.004 . . . . 0.0 111.403 -178.363 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.455 -0.186 0 CA-C-O 120.837 0.351 . . . . 0.0 110.565 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 69.8 t80 -110.88 -23.84 10.76 Favored 'General case' 0 C--N 1.323 -0.559 0 C-N-CA 120.746 -0.382 . . . . 0.0 110.465 -178.21 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' MET . . . . . 0.439 ' HG3' HD22 ' A' ' 86' ' ' LEU . 44.3 ttm 70.63 -59.96 0.51 Allowed 'General case' 0 N--CA 1.468 0.455 0 CA-C-N 115.551 -0.749 . . . . 0.0 111.184 179.46 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 124.21 9.31 5.63 Favored Glycine 0 C--O 1.227 -0.326 0 C-N-CA 121.023 -0.608 . . . . 0.0 113.11 178.259 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.603 HG22 ' HA ' ' A' ' 32' ' ' VAL . 2.8 pp -136.97 165.71 27.4 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-O 120.909 0.385 . . . . 0.0 110.51 -179.028 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . 0.428 ' HD3' ' HA ' ' A' ' 103' ' ' ARG . 9.1 mmt180 -114.63 129.63 56.7 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.12 172.023 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . 0.591 HG23 HD13 ' A' ' 102' ' ' ILE . 3.1 p -110.05 143.19 40.43 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.007 0.432 . . . . 0.0 111.724 -177.836 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 18.0 m -151.24 151.11 31.4 Favored 'General case' 0 C--N 1.318 -0.765 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 173.487 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . 0.447 ' HA ' ' HA ' ' A' ' 27' ' ' VAL . 13.4 m120 . . . . . 0 C--N 1.317 -0.845 0 CA-C-O 121.653 0.74 . . . . 0.0 109.845 -178.203 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 . . . . . 0 N--CA 1.466 0.337 0 CA-C-O 120.79 0.328 . . . . 0.0 110.941 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.574 ' HA2' ' HA ' ' A' ' 57' ' ' SER . . . 106.81 176.1 23.01 Favored Glycine 0 N--CA 1.443 -0.86 0 N-CA-C 111.208 -0.757 . . . . 0.0 111.208 -175.271 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.609 HG23 ' HB ' ' A' ' 48' ' ' ILE . 19.6 m -102.06 131.08 50.79 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.812 0 CA-C-O 121.393 0.616 . . . . 0.0 110.978 177.717 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 36.4 tp60 -97.04 135.04 39.6 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.456 -0.793 . . . . 0.0 110.557 -178.8 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.552 HD12 ' HB2' ' A' ' 46' ' ' LEU . 57.8 mt -78.59 112.56 16.76 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.546 176.441 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -74.12 -69.22 0.46 Allowed 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.932 -176.921 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 9.6 p -149.49 148.97 30.04 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.434 -177.05 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.581 HG13 HG22 ' A' ' 102' ' ' ILE . 57.4 t -96.07 114.07 31.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-N 115.642 -0.708 . . . . 0.0 109.773 176.915 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 47.0 t -98.2 128.1 34.51 Favored Pre-proline 0 C--N 1.318 -0.779 0 CA-C-N 116.062 -0.517 . . . . 0.0 109.998 -176.403 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo -63.59 86.25 0.13 Allowed 'Trans proline' 0 C--O 1.234 0.32 0 C-N-CA 122.748 2.299 . . . . 0.0 112.494 -179.923 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -151.48 20.08 0.92 Allowed Glycine 0 N--CA 1.446 -0.643 0 CA-C-N 115.529 -0.76 . . . . 0.0 111.455 177.574 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.447 ' HB2' ' HD2' ' A' ' 37' ' ' PRO . 67.8 p -174.9 160.97 2.43 Favored Pre-proline 0 C--N 1.328 -0.36 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 -178.525 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . 0.447 ' HD2' ' HB2' ' A' ' 36' ' ' SER . 29.4 Cg_endo -63.65 -5.21 8.29 Favored 'Trans proline' 0 CA--C 1.532 0.405 0 C-N-CA 122.581 2.187 . . . . 0.0 112.631 179.075 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -67.95 -23.59 65.08 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.619 -0.264 . . . . 0.0 111.066 -179.862 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . 0.57 ' HA ' HG11 ' A' ' 32' ' ' VAL . 26.7 m -65.07 -24.87 67.58 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.188 0.518 . . . . 0.0 111.427 -178.687 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 1.6 tmtp? -88.14 -26.76 22.29 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.519 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . 0.535 ' HB ' HD12 ' A' ' 42' ' ' LEU . 46.3 t -92.17 -49.92 12.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.8 -173.217 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.535 HD12 ' HB ' ' A' ' 41' ' ' VAL . 6.6 mp -95.38 168.38 10.75 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.329 0.585 . . . . 0.0 111.638 -172.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -133.01 144.03 51.06 Favored Pre-proline 0 C--N 1.322 -0.622 0 CA-C-N 115.204 -0.907 . . . . 0.0 109.861 176.418 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 78.8 Cg_endo -78.69 155.21 27.3 Favored 'Trans proline' 0 N--CA 1.463 -0.316 0 C-N-CA 122.721 2.281 . . . . 0.0 113.389 -176.0 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 94.08 20.99 29.0 Favored Glycine 0 N--CA 1.448 -0.528 0 C-N-CA 120.619 -0.801 . . . . 0.0 113.273 177.646 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.552 ' HB2' HD12 ' A' ' 29' ' ' ILE . 44.1 mt -108.33 164.26 12.47 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 117.028 0.414 . . . . 0.0 110.928 -179.226 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 61.5 t -108.42 135.14 48.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.096 177.599 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.609 ' HB ' HG23 ' A' ' 27' ' ' VAL . 64.1 mt -96.29 124.63 49.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-O 120.964 0.411 . . . . 0.0 110.837 -179.594 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -84.51 -50.57 7.61 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.049 178.099 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . 0.638 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 24.2 p -149.17 152.21 35.66 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.919 -0.582 . . . . 0.0 112.234 -175.126 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 45.7 mm -111.98 98.99 7.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 114.954 -1.021 . . . . 0.0 110.489 177.05 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' ASN . . . . . 0.463 ' HA ' ' HB3' ' A' ' 76' ' ' ASN . 6.8 t-20 57.72 41.7 24.84 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-N 115.336 -0.847 . . . . 0.0 111.823 172.867 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 104.99 -30.23 10.36 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.641 176.539 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 72.0 mtm -97.53 112.25 60.76 Favored Pre-proline 0 C--N 1.326 -0.422 0 N-CA-C 109.673 -0.491 . . . . 0.0 109.673 178.308 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.638 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 56.0 Cg_endo -69.67 139.48 40.65 Favored 'Trans proline' 0 N--CA 1.459 -0.537 0 C-N-CA 122.26 1.974 . . . . 0.0 112.794 -175.743 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 31.3 p -113.57 83.27 1.82 Allowed 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.346 0.593 . . . . 0.0 111.149 -178.518 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . 0.574 ' HA ' ' HA2' ' A' ' 26' ' ' GLY . 48.0 t -91.88 -13.97 30.44 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.419 179.616 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 81.8 m-20 -129.16 -179.85 5.36 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 109.195 -0.669 . . . . 0.0 109.195 -178.674 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.421 HD23 ' HA ' ' A' ' 59' ' ' LEU . 17.5 mt -75.93 -45.42 35.25 Favored 'General case' 0 N--CA 1.447 -0.602 0 CA-C-O 120.793 0.33 . . . . 0.0 110.902 175.104 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 6.9 m -61.62 -36.47 80.84 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.42 -177.552 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 19.3 p -64.5 -37.3 87.08 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.133 0.492 . . . . 0.0 110.498 176.217 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 70.7 t80 -70.43 -39.19 74.52 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.69 -0.686 . . . . 0.0 109.504 179.285 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 61.3 m -62.29 -48.53 79.46 Favored 'General case' 0 N--CA 1.444 -0.732 0 CA-C-N 115.314 -0.857 . . . . 0.0 111.666 176.894 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.62 -34.42 75.63 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.987 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -74.01 -44.35 54.81 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.965 -0.562 . . . . 0.0 110.425 179.239 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -61.9 -35.95 79.88 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.454 -176.738 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -55.86 -34.71 65.71 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.929 -176.807 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 71.3 p -78.94 -14.24 59.33 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.722 0.296 . . . . 0.0 111.719 -177.574 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.51 HD12 HG22 ' A' ' 75' ' ' ILE . 29.0 mm -81.04 126.74 39.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.903 0.382 . . . . 0.0 111.024 -175.826 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 20.2 m -120.1 -171.8 2.22 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.961 -176.792 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 40.2 t -74.2 139.81 18.67 Favored 'Isoleucine or valine' 0 C--O 1.233 0.218 0 N-CA-C 110.145 -0.317 . . . . 0.0 110.145 176.907 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 69.02 32.05 72.86 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.596 -0.811 . . . . 0.0 111.493 179.382 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 9.6 tp10 -104.84 147.9 27.24 Favored 'General case' 0 N--CA 1.444 -0.746 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 -178.77 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 44.4 t -110.1 106.9 21.61 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 N-CA-C 109.492 -0.559 . . . . 0.0 109.492 -179.131 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . 0.51 HG22 HD12 ' A' ' 69' ' ' ILE . 30.5 pt -95.62 154.52 3.46 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.884 -177.2 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . 0.463 ' HB3' ' HA ' ' A' ' 52' ' ' ASN . 64.5 t30 -122.91 108.51 13.05 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.025 -176.797 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.465 HD12 HD21 ' A' ' 86' ' ' LEU . 60.4 mt -106.8 110.75 32.78 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.968 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.501 -175.131 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . 0.476 ' HA ' ' HA ' ' A' ' 83' ' ' THR . 25.5 m -89.29 113.89 25.21 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.471 177.144 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . 0.457 HG23 HG22 ' A' ' 77' ' ' ILE . 71.3 p -120.45 -178.54 3.72 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 121.06 0.457 . . . . 0.0 111.312 -176.323 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -62.81 -26.5 68.77 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.379 -0.828 . . . . 0.0 111.069 173.678 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 26.9 mm-40 -93.55 9.32 37.22 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.04 0.448 . . . . 0.0 111.351 179.758 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 114.95 -177.75 17.53 Favored Glycine 0 N--CA 1.444 -0.782 0 C-N-CA 120.624 -0.798 . . . . 0.0 112.637 176.625 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . 0.476 ' HA ' ' HA ' ' A' ' 78' ' ' THR . 10.6 m -97.93 113.47 25.32 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.798 -0.201 . . . . 0.0 110.727 -178.096 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 46.1 m-85 -111.75 148.06 34.31 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 110.18 -0.304 . . . . 0.0 110.18 179.389 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 25.7 p-80 -122.95 125.42 45.27 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-O 120.871 0.367 . . . . 0.0 110.018 175.498 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.465 HD21 HD12 ' A' ' 77' ' ' ILE . 0.7 OUTLIER -130.89 156.99 44.12 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.849 -176.059 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 19.5 ptmt -99.77 146.58 26.4 Favored 'General case' 0 N--CA 1.442 -0.834 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.211 179.206 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 33.3 p -83.92 128.39 34.51 Favored 'General case' 0 C--N 1.315 -0.915 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.732 175.857 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.833 0 C-N-CA 120.936 -0.65 . . . . 0.0 112.207 -178.811 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.469 0.525 0 N-CA-C 112.124 0.416 . . . . 0.0 112.124 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 4.5 t80 -88.24 -55.8 3.59 Favored 'General case' 0 C--N 1.327 -0.412 0 C-N-CA 120.266 -0.574 . . . . 0.0 110.491 178.122 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 25.2 ttt 59.01 94.74 0.03 OUTLIER 'General case' 0 N--CA 1.468 0.44 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.929 178.784 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -84.44 38.49 2.9 Favored Glycine 0 C--O 1.225 -0.453 0 CA-C-N 115.92 -0.582 . . . . 0.0 114.316 -172.007 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.581 HG22 HG13 ' A' ' 32' ' ' VAL . 2.1 pp -137.92 140.99 39.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 172.43 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . 0.607 ' NE ' ' HA ' ' A' ' 103' ' ' ARG . 0.0 OUTLIER -101.42 141.56 34.11 Favored 'General case' 0 C--N 1.317 -0.838 0 C-N-CA 120.706 -0.398 . . . . 0.0 110.307 -177.067 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.5 p -127.48 151.43 48.86 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.577 -177.847 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 20.0 m -151.26 154.49 36.89 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 174.388 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 37.2 p30 . . . . . 0 C--N 1.32 -0.702 0 CA-C-O 120.574 0.226 . . . . 0.0 111.345 -176.38 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.452 -0.367 0 CA-C-O 120.769 0.318 . . . . 0.0 111.233 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 93.74 157.82 33.42 Favored Glycine 0 N--CA 1.444 -0.785 0 C-N-CA 120.93 -0.653 . . . . 0.0 111.485 -178.352 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' VAL . . . . . 0.637 HG23 ' HB ' ' A' ' 48' ' ' ILE . 3.8 m -105.27 118.93 53.59 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.713 0 CA-C-O 121.704 0.764 . . . . 0.0 110.844 -179.164 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 34.8 tp60 -103.69 136.0 44.21 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.271 -0.877 . . . . 0.0 110.841 -177.09 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' ILE . . . . . 0.531 HD11 HD11 ' A' ' 48' ' ' ILE . 42.3 mm -68.98 113.16 4.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.14 175.543 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 24.5 t70 -76.01 -63.53 1.29 Allowed 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 115.749 -0.659 . . . . 0.0 109.623 176.759 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 45.3 t -150.69 150.26 30.85 Favored 'General case' 0 N--CA 1.446 -0.654 0 CA-C-N 115.372 -0.831 . . . . 0.0 111.063 -179.571 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' VAL . . . . . 0.571 HG22 HG22 ' A' ' 102' ' ' ILE . 64.0 t -96.36 112.8 29.25 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.946 0 CA-C-N 114.95 -1.023 . . . . 0.0 109.123 174.577 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.461 ' HA ' ' HD3' ' A' ' 34' ' ' PRO . 19.5 m -83.33 127.12 69.89 Favored Pre-proline 0 C--N 1.324 -0.526 0 CA-C-O 121.065 0.46 . . . . 0.0 111.261 -176.247 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' PRO . . . . . 0.461 ' HD3' ' HA ' ' A' ' 33' ' ' VAL . 21.3 Cg_exo -66.1 146.46 81.98 Favored 'Trans proline' 0 C--O 1.237 0.429 0 C-N-CA 122.982 2.455 . . . . 0.0 112.058 178.288 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 114.24 -25.85 10.24 Favored Glycine 0 N--CA 1.45 -0.393 0 N-CA-C 111.507 -0.637 . . . . 0.0 111.507 -178.302 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 50.4 m -101.77 159.2 30.12 Favored Pre-proline 0 C--N 1.319 -0.721 0 CA-C-N 115.442 -0.379 . . . . 0.0 110.331 178.85 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_exo -60.19 -20.18 60.62 Favored 'Trans proline' 0 C--N 1.347 0.487 0 C-N-CA 123.057 2.505 . . . . 0.0 112.958 -178.102 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -66.15 -25.84 67.15 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.973 -176.808 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 13.4 m -63.2 -22.95 67.2 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.365 -0.38 . . . . 0.0 111.738 -176.224 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 57.4 tttm -110.11 11.53 23.77 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.907 0.384 . . . . 0.0 110.514 -176.465 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 96.5 t -120.73 -55.25 3.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 120.761 0.315 . . . . 0.0 111.275 -177.063 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 97.7 mt -107.69 167.19 10.13 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.083 0.468 . . . . 0.0 111.434 -174.142 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' THR . . . . . 0.405 ' HA ' ' HD3' ' A' ' 44' ' ' PRO . 20.1 p -113.9 148.06 39.09 Favored Pre-proline 0 N--CA 1.446 -0.663 0 CA-C-N 115.323 -0.853 . . . . 0.0 109.626 175.839 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.405 ' HD3' ' HA ' ' A' ' 43' ' ' THR . 5.1 Cg_exo -74.79 141.1 26.89 Favored 'Trans proline' 0 N--CA 1.458 -0.565 0 C-N-CA 122.285 1.99 . . . . 0.0 111.926 -178.054 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 105.36 -2.21 40.06 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.626 -0.797 . . . . 0.0 113.056 179.916 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . 0.453 HD22 ' HB3' ' A' ' 80' ' ' ASP . 72.7 mt -78.65 164.8 24.32 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.257 0.551 . . . . 0.0 111.556 -178.849 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 61.8 t -109.51 138.64 36.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 115.801 -0.636 . . . . 0.0 109.378 174.63 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' ILE . . . . . 0.637 ' HB ' HG23 ' A' ' 27' ' ' VAL . 88.4 mt -94.68 111.84 26.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 120.971 0.415 . . . . 0.0 110.03 177.968 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -75.07 -51.4 13.6 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.484 -178.717 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' SER . . . . . 0.563 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 31.5 p -156.61 156.91 34.35 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.76 -0.655 . . . . 0.0 112.29 -174.912 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.762 HG22 ' H ' ' A' ' 52' ' ' ASN . 9.0 mm -100.07 -171.37 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 173.649 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' ASN . . . . . 0.762 ' H ' HG22 ' A' ' 51' ' ' ILE . 1.7 m-20 -48.72 92.99 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 123.039 0.536 . . . . 0.0 112.089 178.869 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 72.19 -10.07 4.96 Favored Glycine 0 CA--C 1.521 0.461 0 C-N-CA 121.384 -0.436 . . . . 0.0 113.787 175.517 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 71.0 mtm -125.71 112.69 25.02 Favored Pre-proline 0 C--N 1.327 -0.403 0 CA-C-N 117.147 0.474 . . . . 0.0 110.863 -175.882 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . 0.563 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 4.4 Cg_exo -78.65 137.44 14.42 Favored 'Trans proline' 0 N--CA 1.46 -0.488 0 C-N-CA 122.897 2.398 . . . . 0.0 111.661 175.97 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 40.1 p -121.48 116.76 25.31 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.909 0.385 . . . . 0.0 111.77 -178.857 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 30.7 t -86.57 -53.4 4.99 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.32 174.106 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 15.5 m120 -86.24 157.11 20.03 Favored 'General case' 0 C--N 1.318 -0.762 0 C-N-CA 120.228 -0.589 . . . . 0.0 109.629 -169.799 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' LEU . . . . . 0.564 ' HG ' ' HB2' ' A' ' 106' ' ' ASN . 3.4 mt -65.11 -38.55 91.04 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.1 0.476 . . . . 0.0 110.4 177.992 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 3.3 m -64.44 -38.38 90.84 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.826 -0.624 . . . . 0.0 111.109 179.432 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 11.9 p -71.48 -32.1 67.88 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.958 0.408 . . . . 0.0 110.565 177.733 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 72.2 t80 -65.51 -44.34 87.28 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.893 -0.594 . . . . 0.0 109.789 175.467 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 7.9 t -63.17 -37.52 87.55 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.03 178.062 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.04 -33.07 74.92 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.015 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . 0.505 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -76.9 -40.03 48.83 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.256 0.55 . . . . 0.0 110.204 176.858 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' LEU . . . . . 0.436 HD21 ' SD ' ' A' ' 100' ' ' MET . 0.4 OUTLIER -60.5 -38.06 83.1 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.61 -0.723 . . . . 0.0 111.406 179.444 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -74.24 -6.43 47.87 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.996 -0.547 . . . . 0.0 112.301 -177.614 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 22.5 p -100.4 -12.61 19.25 Favored 'General case' 0 C--N 1.324 -0.541 0 C-N-CA 120.754 -0.379 . . . . 0.0 110.841 174.142 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.505 HG12 ' O ' ' A' ' 65' ' ' ALA . 47.2 mm -80.33 135.62 24.98 Favored 'Isoleucine or valine' 0 C--O 1.234 0.275 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.872 -178.667 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 1.4 m -83.03 165.7 19.4 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.345 -177.027 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 32.5 t -76.75 124.12 34.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.595 174.404 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 79.73 25.62 58.01 Favored Glycine 0 N--CA 1.446 -0.65 0 C-N-CA 120.314 -0.946 . . . . 0.0 111.178 -176.573 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 8.1 tp10 -85.6 147.81 26.22 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 178.423 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 56.9 t -104.61 98.56 6.98 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.978 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 176.05 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 26.0 pt -91.18 164.69 2.07 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.779 0 CA-C-O 121.388 0.613 . . . . 0.0 111.506 -173.956 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 33.2 t30 -116.06 115.88 26.89 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 115.158 -0.928 . . . . 0.0 109.615 -178.929 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 24.1 mt -120.61 107.74 21.35 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.315 -175.533 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' THR . . . . . 0.481 ' HA ' ' HA ' ' A' ' 83' ' ' THR . 30.6 m -80.78 118.37 22.25 Favored 'General case' 0 C--N 1.317 -0.807 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 173.381 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 72.6 p -119.81 -173.38 2.53 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.319 0.58 . . . . 0.0 111.891 -173.431 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' ASP . . . . . 0.453 ' HB3' HD22 ' A' ' 46' ' ' LEU . 20.8 t70 -56.71 -36.13 69.32 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 114.713 -1.13 . . . . 0.0 111.44 176.412 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 24.8 mt-30 -93.73 7.6 44.19 Favored 'General case' 0 C--O 1.235 0.295 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.342 -177.259 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 112.67 -169.35 12.97 Favored Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.655 177.779 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' THR . . . . . 0.481 ' HA ' ' HA ' ' A' ' 78' ' ' THR . 9.2 m -77.84 127.16 31.96 Favored 'General case' 0 C--N 1.321 -0.652 0 C-N-CA 122.559 0.344 . . . . 0.0 111.636 -177.973 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 97.7 m-85 -132.11 158.44 41.63 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.898 0.38 . . . . 0.0 110.108 174.69 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 33.1 m-70 -118.51 137.62 53.08 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 176.513 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' LEU . . . . . 0.493 HD23 ' N ' ' A' ' 87' ' ' LYS . 1.6 tt -135.41 138.9 43.72 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-O 120.884 0.373 . . . . 0.0 110.571 -173.237 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' LYS . . . . . 0.493 ' N ' HD23 ' A' ' 86' ' ' LEU . 38.6 ttpt -95.97 123.07 39.41 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 116.09 -0.505 . . . . 0.0 109.963 177.706 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.44 HG21 HG21 ' A' ' 69' ' ' ILE . 41.1 p -69.4 142.49 53.89 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.902 -0.59 . . . . 0.0 112.033 -174.974 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.823 0 CA-C-N 115.692 -0.686 . . . . 0.0 112.833 -178.367 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.232 0.181 0 N-CA-C 111.945 0.35 . . . . 0.0 111.945 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 35.3 t80 -117.4 -15.67 10.31 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.759 -179.501 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' MET . . . . . 0.436 ' SD ' HD21 ' A' ' 66' ' ' LEU . 82.7 mtp 58.43 -153.97 0.37 Allowed 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.751 -176.858 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -155.53 32.05 0.63 Allowed Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.259 -0.972 . . . . 0.0 112.904 -179.778 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 102' ' ' ILE . . . . . 0.571 HG22 HG22 ' A' ' 32' ' ' VAL . 2.8 pp -144.21 166.26 12.92 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 178.871 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 38.0 mmt180 -108.49 132.49 53.76 Favored 'General case' 0 C--N 1.317 -0.825 0 N-CA-C 109.278 -0.638 . . . . 0.0 109.278 176.201 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -110.76 132.35 54.27 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 121.335 0.588 . . . . 0.0 111.917 -177.962 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 42.3 m -109.89 165.69 11.51 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.235 -0.893 . . . . 0.0 109.799 175.163 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 106' ' ' ASN . . . . . 0.564 ' HB2' ' HG ' ' A' ' 59' ' ' LEU . 2.2 t-20 . . . . . 0 C--N 1.313 -1.011 0 CA-C-O 122.013 0.911 . . . . 0.0 108.582 179.713 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . . . . . . . . . 27.2 mp0 . . . . . 0 N--CA 1.453 -0.325 0 CA-C-O 120.764 0.316 . . . . 0.0 110.701 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.499 ' HB2' HD22 ' A' ' 58' ' ' ASN . 7.4 Cg_exo -72.72 128.3 13.23 Favored 'Trans proline' 0 N--CA 1.461 -0.429 0 C-N-CA 122.604 2.203 . . . . 0.0 110.168 171.812 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 19.1 t70 -147.88 29.18 0.91 Allowed 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 121.759 0.79 . . . . 0.0 110.395 -171.479 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 115.64 148.89 9.38 Favored Glycine 0 N--CA 1.446 -0.686 0 CA-C-N 115.344 -0.844 . . . . 0.0 111.36 -177.982 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.617 HG23 ' HB ' ' A' ' 48' ' ' ILE . 17.7 m -102.59 129.73 53.68 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 CA-C-O 121.195 0.522 . . . . 0.0 110.511 178.102 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . 0.434 ' HG3' ' O ' ' A' ' 46' ' ' LEU . 61.8 tt0 -110.66 149.73 30.02 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 121.187 0.517 . . . . 0.0 111.298 -175.941 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.517 HG23 HD12 ' A' ' 102' ' ' ILE . 74.3 mt -82.31 117.85 29.0 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 115.361 -0.836 . . . . 0.0 109.93 177.741 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.551 ' HB3' ' HB3' ' A' ' 103' ' ' ARG . 12.6 t70 -79.13 -65.1 1.04 Allowed 'General case' 0 C--N 1.317 -0.837 0 CA-C-N 116.235 -0.439 . . . . 0.0 109.84 178.912 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 5.5 p -150.06 156.53 41.85 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.91 -0.586 . . . . 0.0 111.31 -177.087 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.513 ' CG1' ' HA ' ' A' ' 39' ' ' SER . 56.2 t -116.18 113.73 44.03 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 115.715 -0.675 . . . . 0.0 110.229 -177.712 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 30.3 m -105.71 153.46 39.94 Favored Pre-proline 0 N--CA 1.445 -0.693 0 CA-C-N 116.512 -0.313 . . . . 0.0 110.569 178.505 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 29.0 Cg_endo -62.7 150.95 86.3 Favored 'Trans proline' 0 C--N 1.346 0.4 0 C-N-CA 123.023 2.482 . . . . 0.0 112.339 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 109.73 3.49 30.34 Favored Glycine 0 N--CA 1.45 -0.371 0 N-CA-C 111.081 -0.808 . . . . 0.0 111.081 -176.029 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.543 ' HB3' ' HA3' ' A' ' 101' ' ' GLY . 50.8 p -125.26 147.95 59.18 Favored Pre-proline 0 N--CA 1.447 -0.609 0 CA-C-N 115.17 -0.515 . . . . 0.0 109.862 179.975 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . 0.466 ' HD3' ' HA2' ' A' ' 89' ' ' GLY . 16.8 Cg_exo -67.31 -23.37 44.78 Favored 'Trans proline' 0 N--CA 1.463 -0.297 0 C-N-CA 122.031 1.82 . . . . 0.0 110.894 175.645 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -75.29 -7.93 55.28 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.179 -0.918 . . . . 0.0 111.927 -177.616 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.513 ' HA ' ' CG1' ' A' ' 32' ' ' VAL . 73.0 m -53.33 -31.24 43.31 Favored 'General case' 0 CA--C 1.533 0.303 0 N-CA-C 112.671 0.619 . . . . 0.0 112.671 -175.152 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 42.2 mtmt -128.99 21.21 5.84 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.822 0.344 . . . . 0.0 111.307 179.838 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 88.3 t -103.68 -50.95 9.06 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-O 120.931 0.396 . . . . 0.0 110.754 179.341 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -112.3 -179.82 3.78 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.383 0.611 . . . . 0.0 111.589 -179.393 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . 0.579 ' O ' ' HG ' ' A' ' 46' ' ' LEU . 8.5 m -116.47 138.31 24.3 Favored Pre-proline 0 C--N 1.317 -0.823 0 CA-C-N 115.011 -0.995 . . . . 0.0 109.948 -178.851 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 21.0 Cg_endo -64.34 141.87 76.75 Favored 'Trans proline' 0 N--CA 1.46 -0.499 0 C-N-CA 121.665 1.577 . . . . 0.0 111.171 171.525 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 99.49 -7.78 59.91 Favored Glycine 0 C--N 1.32 -0.32 0 C-N-CA 120.6 -0.809 . . . . 0.0 113.159 -179.083 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.579 ' HG ' ' O ' ' A' ' 43' ' ' THR . 27.9 mt -81.79 163.29 22.48 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 117.077 0.438 . . . . 0.0 110.612 -178.269 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 44.6 t -113.32 126.73 70.79 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.489 0 CA-C-N 116.384 -0.371 . . . . 0.0 110.415 -178.129 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.617 ' HB ' HG23 ' A' ' 27' ' ' VAL . 75.1 mt -84.59 113.01 22.57 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.469 0 CA-C-O 120.862 0.363 . . . . 0.0 110.141 178.931 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 66.6 mt-10 -83.9 -46.45 12.1 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.8 -177.074 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 17.1 p -162.8 152.09 15.29 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.045 0.45 . . . . 0.0 111.875 -178.449 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.529 HG22 ' H ' ' A' ' 52' ' ' ASN . 12.1 mt -103.27 172.46 1.43 Allowed 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 175.524 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' ASN . . . . . 0.843 ' HB3' ' HB3' ' A' ' 76' ' ' ASN . 17.8 p-10 -56.08 101.89 0.06 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.275 0.56 . . . . 0.0 112.243 -176.257 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 74.99 1.78 63.77 Favored Glycine 0 N--CA 1.451 -0.311 0 CA-C-N 115.527 -0.76 . . . . 0.0 113.042 178.836 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 49.9 mtm -138.14 96.69 10.03 Favored Pre-proline 0 C--N 1.325 -0.484 0 O-C-N 122.684 -0.304 . . . . 0.0 110.659 -175.652 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -73.88 133.85 19.0 Favored 'Trans proline' 0 N--CA 1.462 -0.344 0 C-N-CA 122.667 2.244 . . . . 0.0 111.968 178.679 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 17.7 p -110.83 83.8 1.82 Allowed 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.247 0.546 . . . . 0.0 111.675 -175.861 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 22.3 m -91.92 -13.48 31.14 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.249 177.011 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . 0.499 HD22 ' HB2' ' A' ' 24' ' ' PRO . 0.6 OUTLIER -128.11 173.79 9.79 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 -175.4 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 65.1 mt -78.72 -39.19 37.08 Favored 'General case' 0 N--CA 1.444 -0.77 0 CA-C-O 121.18 0.514 . . . . 0.0 110.059 177.797 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 3.1 m -67.11 -42.45 84.51 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.552 -0.749 . . . . 0.0 111.236 -178.862 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 1.2 p -65.63 -32.42 73.98 Favored 'General case' 0 C--N 1.333 -0.133 0 CA-C-O 120.797 0.332 . . . . 0.0 111.036 179.802 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 86.4 t80 -62.06 -44.52 96.5 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.007 -0.542 . . . . 0.0 109.669 174.318 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . 0.485 ' O ' ' HG3' ' A' ' 67' ' ' LYS . 5.7 t -68.12 -41.68 81.37 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.293 179.732 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -60.69 -34.71 74.75 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-O 121.161 0.505 . . . . 0.0 110.859 -179.221 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . 0.409 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -73.1 -45.58 56.25 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.119 176.346 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 1.7 mm? -60.23 -38.24 82.8 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 115.413 -0.812 . . . . 0.0 111.996 -177.442 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . 0.485 ' HG3' ' O ' ' A' ' 63' ' ' SER . 68.6 mttm -65.4 -14.43 60.87 Favored 'General case' 0 C--N 1.328 -0.341 0 N-CA-C 112.297 0.48 . . . . 0.0 112.297 -176.857 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 68.0 p -99.34 -13.14 19.74 Favored 'General case' 0 C--N 1.326 -0.447 0 C-N-CA 120.814 -0.354 . . . . 0.0 111.528 -179.691 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.409 HG12 ' O ' ' A' ' 65' ' ' ALA . 14.5 mm -88.75 144.24 9.53 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-O 120.904 0.383 . . . . 0.0 110.413 -176.445 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 54.4 m -104.06 171.0 7.59 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 116.534 -0.303 . . . . 0.0 111.351 -178.458 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.483 HG22 ' H ' ' A' ' 98' ' ' ALA . 39.1 t -81.39 117.98 28.36 Favored 'Isoleucine or valine' 0 C--O 1.233 0.224 0 CA-C-O 120.905 0.383 . . . . 0.0 110.539 -178.397 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 102.58 -1.64 49.38 Favored Glycine 0 N--CA 1.448 -0.527 0 N-CA-C 111.463 -0.655 . . . . 0.0 111.463 -177.498 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 56.0 tt0 -87.65 149.08 24.5 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.35 -0.425 . . . . 0.0 109.878 179.527 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 64.3 t -111.13 124.89 68.33 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.782 -177.139 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 25.2 pt -110.07 164.32 6.43 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.561 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.316 -179.553 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . 0.843 ' HB3' ' HB3' ' A' ' 52' ' ' ASN . 6.7 t30 -107.53 114.94 29.28 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.043 -177.158 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.549 HG23 HG23 ' A' ' 48' ' ' ILE . 70.6 mt -117.48 115.21 47.93 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.574 0 CA-C-O 120.982 0.42 . . . . 0.0 111.153 -175.877 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . 0.535 ' HA ' ' HA ' ' A' ' 83' ' ' THR . 97.8 m -93.0 125.4 37.57 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.872 -0.604 . . . . 0.0 109.969 176.237 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.547 HG22 ' HA ' ' A' ' 48' ' ' ILE . 68.0 p -124.19 177.46 5.82 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.237 179.095 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -57.86 -33.7 68.96 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 121.5 0.667 . . . . 0.0 110.251 174.1 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . 0.4 ' CG ' HD22 ' A' ' 46' ' ' LEU . 16.5 mm100 -90.73 17.33 7.78 Favored 'General case' 0 N--CA 1.449 -0.487 0 CA-C-N 115.223 -0.899 . . . . 0.0 111.242 -177.054 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 107.71 178.41 22.31 Favored Glycine 0 N--CA 1.446 -0.687 0 CA-C-N 115.525 -0.761 . . . . 0.0 112.419 175.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.535 ' HA ' ' HA ' ' A' ' 78' ' ' THR . 63.7 m -94.56 131.57 40.16 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-O 120.775 0.322 . . . . 0.0 110.638 179.035 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 91.1 m-85 -125.23 159.75 30.88 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.249 -0.432 . . . . 0.0 109.995 178.198 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 44.9 m80 -106.57 124.31 49.41 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 174.295 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.448 HD13 ' HA ' ' A' ' 86' ' ' LEU . 2.9 mm? -116.69 135.95 53.36 Favored 'General case' 0 C--N 1.314 -0.941 0 CA-C-O 121.425 0.631 . . . . 0.0 111.811 -174.836 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 87.4 tttt -95.18 135.84 36.26 Favored 'General case' 0 C--N 1.31 -1.133 0 CA-C-N 114.981 -1.009 . . . . 0.0 109.071 174.12 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.622 ' HB ' ' HA ' ' A' ' 98' ' ' ALA . 55.1 p -65.14 143.45 57.86 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 120.925 0.393 . . . . 0.0 111.061 179.511 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.535 ' HA3' ' O ' ' A' ' 99' ' ' TYR . . . -72.91 -177.56 32.72 Favored Glycine 0 N--CA 1.439 -1.123 0 CA-C-N 115.647 -0.706 . . . . 0.0 113.411 -175.124 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -103.87 8.35 36.96 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 114.724 -0.738 . . . . 0.0 111.914 -167.533 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' ASN . . . . . 0.545 ' HB3' ' O ' ' A' ' 94' ' ' ASN . 47.8 m-80 66.61 88.69 0.11 Allowed Pre-proline 0 N--CA 1.468 0.451 0 CA-C-N 116.108 -0.496 . . . . 0.0 112.001 177.412 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -91.14 134.1 1.67 Allowed 'Trans proline' 0 N--CA 1.452 -0.918 0 C-N-CA 123.275 2.65 . . . . 0.0 111.876 173.581 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 61.9 t30 72.44 -38.53 0.42 Allowed 'General case' 0 N--CA 1.474 0.736 0 C-N-CA 123.931 0.892 . . . . 0.0 112.438 178.394 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . 0.545 ' O ' ' HB3' ' A' ' 91' ' ' ASN . 14.3 m120 -126.49 145.71 50.4 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 120.755 0.312 . . . . 0.0 111.218 -176.115 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 64.4 m -99.62 119.66 38.44 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.596 178.68 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 55.7 m -152.92 -168.94 3.19 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 176.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 16.0 ptp180 -105.94 127.94 53.47 Favored 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 109.682 -0.488 . . . . 0.0 109.682 175.43 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . 0.622 ' HA ' ' HB ' ' A' ' 88' ' ' THR . . . 61.35 90.04 0.07 Allowed 'General case' 0 N--CA 1.462 0.142 0 O-C-N 123.845 0.716 . . . . 0.0 111.504 178.551 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . 0.535 ' O ' ' HA3' ' A' ' 89' ' ' GLY . 2.3 t80 -111.58 95.97 5.82 Favored 'General case' 0 C--N 1.325 -0.466 0 C-N-CA 119.805 -0.758 . . . . 0.0 109.895 -176.829 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' MET . . . . . 0.657 ' HG3' HG12 ' A' ' 102' ' ' ILE . 50.8 tpp -46.95 -54.17 10.69 Favored 'General case' 0 N--CA 1.466 0.35 0 O-C-N 123.746 0.654 . . . . 0.0 112.002 -173.391 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . 0.543 ' HA3' ' HB3' ' A' ' 36' ' ' SER . . . 99.31 -2.24 57.64 Favored Glycine 0 C--O 1.226 -0.375 0 C-N-CA 120.504 -0.855 . . . . 0.0 113.185 175.399 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.657 HG12 ' HG3' ' A' ' 100' ' ' MET . 36.7 pt -114.58 140.6 34.71 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.611 0 N-CA-C 109.633 -0.506 . . . . 0.0 109.633 178.14 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . 0.551 ' HB3' ' HB3' ' A' ' 30' ' ' ASP . 18.4 ttp180 -69.52 125.37 26.49 Favored 'General case' 0 N--CA 1.446 -0.648 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 178.535 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.417 HG22 ' HA ' ' A' ' 29' ' ' ILE . 0.9 OUTLIER -135.52 142.03 45.35 Favored 'General case' 0 C--N 1.311 -1.104 0 CA-C-N 116.048 -0.523 . . . . 0.0 110.582 -175.465 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 31.9 m -153.39 157.45 39.99 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.05 179.575 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . 0.415 ' HA ' ' HA ' ' A' ' 27' ' ' VAL . 25.5 p-10 -74.75 -8.82 57.57 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 116.078 -0.51 . . . . 0.0 110.798 -179.653 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 6.1 t-160 57.88 75.98 0.35 Allowed 'General case' 0 C--O 1.233 0.222 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.328 176.454 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 21.3 mt -59.28 141.59 54.01 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-O 121.681 0.753 . . . . 0.0 112.056 -179.114 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -67.89 121.07 15.24 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 114.257 -1.338 . . . . 0.0 109.304 -178.727 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 8.4 p -65.96 129.12 29.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-O 121.634 0.73 . . . . 0.0 111.885 -175.21 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' ARG . . . . . . . . . . . . . 19.6 mtp180 -157.03 175.31 14.26 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 114.333 -1.303 . . . . 0.0 108.936 174.776 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 27.6 m-20 -111.33 82.27 1.58 Allowed 'General case' 0 C--N 1.319 -0.721 0 CA-C-O 120.978 0.418 . . . . 0.0 111.748 -178.214 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 7.4 p -93.48 86.04 5.11 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 108.3 -1.0 . . . . 0.0 108.3 168.232 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 29.7 m -67.91 143.01 15.72 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.512 -0.767 . . . . 0.0 112.537 -170.781 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -116.6 85.4 2.3 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.079 -0.964 . . . . 0.0 109.373 175.056 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 9.4 m -74.35 150.14 40.24 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.73 -176.271 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 15.5 m -70.18 126.37 30.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-O 120.998 0.428 . . . . 0.0 110.222 176.477 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 85.7 mt -86.65 -43.31 12.73 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.214 -177.603 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 141.52 146.38 4.7 Favored Glycine 0 N--CA 1.442 -0.909 0 N-CA-C 111.073 -0.811 . . . . 0.0 111.073 -177.981 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 10.9 t70 -119.84 117.74 28.94 Favored 'General case' 0 C--N 1.319 -0.726 0 N-CA-C 110.126 -0.324 . . . . 0.0 110.126 -177.06 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 8.9 t -82.56 118.06 23.0 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-O 121.474 0.654 . . . . 0.0 110.481 -178.153 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . 0.403 ' HA ' ' HD2' ' A' ' 123' ' ' PRO . 89.1 mt -107.25 106.25 57.86 Favored Pre-proline 0 C--N 1.325 -0.476 0 CA-C-N 115.824 -0.626 . . . . 0.0 111.098 -179.156 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . 0.403 ' HD2' ' HA ' ' A' ' 122' ' ' LEU . 53.5 Cg_endo -70.85 150.84 62.21 Favored 'Trans proline' 0 N--CA 1.461 -0.428 0 C-N-CA 122.464 2.109 . . . . 0.0 111.357 176.151 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 44.6 t80 -125.08 117.28 23.6 Favored 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 109.468 -0.568 . . . . 0.0 109.468 -178.482 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.972 0 CA-C-O 118.598 -0.715 . . . . 0.0 110.848 -176.148 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.403 ' HA ' ' HD3' ' A' ' 24' ' ' PRO . 84.1 mt-30 . . . . . 0 N--CA 1.467 0.398 0 CA-C-O 121.111 0.481 . . . . 0.0 111.941 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.539 ' HD2' ' ND2' ' A' ' 58' ' ' ASN . 32.2 Cg_exo -62.21 -173.62 0.13 Allowed 'Trans proline' 0 C--N 1.346 0.42 0 C-N-CA 123.406 2.737 . . . . 0.0 112.389 172.606 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.573 ' HB3' ' HD2' ' A' ' 107' ' ' HIS . 16.8 t70 -148.87 -1.15 0.5 Allowed 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 116.099 -0.501 . . . . 0.0 111.743 -171.516 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.543 ' HA2' ' HA ' ' A' ' 57' ' ' SER . . . 146.68 136.06 2.82 Favored Glycine 0 N--CA 1.444 -0.782 0 N-CA-C 110.932 -0.867 . . . . 0.0 110.932 -174.003 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.532 HG23 ' HB ' ' A' ' 48' ' ' ILE . 30.0 m -80.99 142.38 13.92 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-O 121.272 0.558 . . . . 0.0 110.86 -178.743 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . 0.52 ' HG3' ' O ' ' A' ' 46' ' ' LEU . 5.8 tt0 -116.38 155.4 28.57 Favored 'General case' 0 C--N 1.318 -0.772 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.482 -179.634 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.494 HD12 HD12 ' A' ' 102' ' ' ILE . 45.2 mm -81.56 110.51 17.0 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 N-CA-C 109.649 -0.5 . . . . 0.0 109.649 178.01 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.455 ' HB3' ' CB ' ' A' ' 103' ' ' ARG . 14.4 t70 -70.43 -63.19 1.14 Allowed 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 115.933 -0.576 . . . . 0.0 109.591 179.479 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.425 ' HA ' ' HB3' ' A' ' 44' ' ' PRO . 17.3 m -150.03 148.99 29.71 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.734 -178.937 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.433 ' CG1' ' HA ' ' A' ' 39' ' ' SER . 97.3 t -114.6 114.07 45.55 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 N-CA-C 108.825 -0.805 . . . . 0.0 108.825 173.406 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.501 HG22 ' O ' ' A' ' 101' ' ' GLY . 4.6 m -75.11 153.13 86.43 Favored Pre-proline 0 C--N 1.324 -0.505 0 CA-C-N 116.51 -0.314 . . . . 0.0 111.355 -175.093 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 40.1 Cg_endo -69.77 116.58 4.63 Favored 'Trans proline' 0 N--CA 1.461 -0.404 0 C-N-CA 122.388 2.058 . . . . 0.0 111.033 172.613 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 94.99 -179.56 36.73 Favored Glycine 0 N--CA 1.445 -0.706 0 N-CA-C 110.63 -0.988 . . . . 0.0 110.63 -173.413 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.728 ' HB3' ' HD2' ' A' ' 37' ' ' PRO . 31.9 m 69.16 168.48 0.12 Allowed Pre-proline 0 CA--C 1.54 0.564 0 CA-C-N 117.072 0.436 . . . . 0.0 110.888 -179.052 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . 0.728 ' HD2' ' HB3' ' A' ' 36' ' ' SER . 32.8 Cg_endo -65.04 155.11 70.04 Favored 'Trans proline' 0 C--N 1.344 0.329 0 C-N-CA 122.348 2.032 . . . . 0.0 112.747 179.035 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.538 ' HB2' HD21 ' A' ' 86' ' ' LEU . . . 76.68 -12.22 1.07 Allowed 'General case' 0 N--CA 1.471 0.621 0 C-N-CA 123.718 0.807 . . . . 0.0 112.146 177.012 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.433 ' HA ' ' CG1' ' A' ' 32' ' ' VAL . 11.4 t -64.31 -30.87 71.9 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.618 -175.554 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -103.96 16.64 25.85 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 116.452 -0.34 . . . . 0.0 111.024 -175.687 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.421 ' HB ' HD12 ' A' ' 42' ' ' LEU . 30.8 t -125.29 -54.05 2.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 N-CA-C 111.705 0.261 . . . . 0.0 111.705 -177.672 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.421 HD12 ' HB ' ' A' ' 41' ' ' VAL . 7.6 mp -97.47 176.98 5.67 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.373 0.606 . . . . 0.0 111.909 -173.057 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . 0.429 ' O ' ' HG ' ' A' ' 46' ' ' LEU . 28.5 m -135.5 134.32 20.98 Favored Pre-proline 0 C--N 1.321 -0.64 0 CA-C-N 115.186 -0.915 . . . . 0.0 109.39 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.425 ' HB3' ' HA ' ' A' ' 31' ' ' SER . 19.3 Cg_endo -62.13 139.46 78.51 Favored 'Trans proline' 0 C--N 1.345 0.361 0 C-N-CA 122.105 1.87 . . . . 0.0 112.474 179.929 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 105.69 -13.11 46.56 Favored Glycine 0 CA--C 1.521 0.408 0 C-N-CA 120.641 -0.79 . . . . 0.0 113.808 179.308 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.52 ' O ' ' HG3' ' A' ' 28' ' ' GLN . 56.9 mt -79.83 163.32 24.49 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 117.481 0.64 . . . . 0.0 111.044 -177.035 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 42.2 t -111.28 137.26 44.54 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-N 116.528 -0.306 . . . . 0.0 110.304 178.182 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.532 ' HB ' HG23 ' A' ' 27' ' ' VAL . 61.9 mt -92.62 124.93 45.24 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.494 0 CA-C-O 121.16 0.505 . . . . 0.0 111.23 -178.985 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 11.3 tp10 -77.23 -53.93 7.12 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.624 176.378 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 5.3 p -161.83 156.01 22.1 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.341 -0.845 . . . . 0.0 111.576 -176.184 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.623 HG12 HG12 ' A' ' 77' ' ' ILE . 58.5 mt -123.17 106.86 18.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.365 0 CA-C-N 115.478 -0.783 . . . . 0.0 109.475 176.396 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' ASN . . . . . 0.406 ' CG ' ' H ' ' A' ' 53' ' ' GLY . 12.0 t-20 61.26 -152.23 0.38 Allowed 'General case' 0 CA--C 1.533 0.307 0 N-CA-C 108.061 -1.089 . . . . 0.0 108.061 -175.425 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.406 ' H ' ' CG ' ' A' ' 52' ' ' ASN . . . -73.61 9.67 7.86 Favored Glycine 0 CA--C 1.525 0.657 0 C-N-CA 120.781 -0.723 . . . . 0.0 113.156 179.533 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 3.3 mpp? -114.96 105.31 53.25 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 120.721 0.296 . . . . 0.0 110.423 178.091 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -73.96 130.42 14.4 Favored 'Trans proline' 0 N--CA 1.458 -0.569 0 C-N-CA 122.04 1.827 . . . . 0.0 111.949 177.615 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.427 ' O ' ' HA2' ' A' ' 26' ' ' GLY . 16.7 p -98.12 75.96 2.34 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 121.249 0.547 . . . . 0.0 111.692 -176.595 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . 0.543 ' HA ' ' HA2' ' A' ' 26' ' ' GLY . 32.3 t -88.89 -12.2 42.41 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-N 115.583 -0.735 . . . . 0.0 109.831 176.033 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . 0.539 ' ND2' ' HD2' ' A' ' 24' ' ' PRO . 8.9 t-20 -129.32 177.89 6.84 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-N 115.846 -0.615 . . . . 0.0 109.361 -177.234 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.929 ' HG ' ' HB3' ' A' ' 106' ' ' ASN . 3.8 mt -90.08 -34.2 16.01 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-O 121.051 0.453 . . . . 0.0 109.806 176.661 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 28.5 m -63.7 -38.82 92.53 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.249 176.678 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 21.4 p -64.09 -38.07 89.72 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.484 177.851 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 89.1 t80 -65.48 -43.76 89.24 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.893 -0.594 . . . . 0.0 109.898 177.925 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 8.6 t -64.64 -48.03 76.31 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.665 -0.698 . . . . 0.0 110.455 179.684 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -65.54 -31.1 71.97 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.958 -0.564 . . . . 0.0 111.586 -177.223 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . 0.603 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -74.11 -45.04 51.52 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.328 179.6 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 1.6 tt -59.88 -43.8 94.55 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.134 -177.45 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 57.8 mtpt -63.13 -22.65 67.0 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.587 -0.733 . . . . 0.0 112.206 -178.153 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 40.6 p -92.18 -13.58 30.38 Favored 'General case' 0 C--N 1.329 -0.321 0 C-N-CA 120.971 -0.292 . . . . 0.0 111.571 179.465 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.603 HG12 ' O ' ' A' ' 65' ' ' ALA . 44.5 mm -78.14 138.99 19.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.841 0.353 . . . . 0.0 110.105 -179.265 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 6.1 m -88.46 165.7 14.72 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.971 -177.825 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 94.8 t -72.43 133.96 30.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.454 177.112 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 70.95 27.61 71.92 Favored Glycine 0 C--N 1.331 0.257 0 C-N-CA 120.959 -0.639 . . . . 0.0 111.984 179.005 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 9.7 tp10 -99.04 152.52 19.73 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.849 -0.426 . . . . 0.0 109.849 -177.443 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.407 ' HA ' ' O ' ' A' ' 86' ' ' LEU . 58.9 t -108.24 111.48 36.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.688 0 CA-C-N 116.266 -0.425 . . . . 0.0 110.119 -179.459 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.643 HG13 ' HB3' ' A' ' 86' ' ' LEU . 15.0 pt -109.65 154.15 11.2 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.635 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.98 -177.815 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . 0.401 ' O ' ' HA ' ' A' ' 51' ' ' ILE . 19.9 t30 -95.17 114.4 26.19 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 115.302 -0.863 . . . . 0.0 110.726 -179.4 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.623 HG12 HG12 ' A' ' 51' ' ' ILE . 50.9 mt -113.19 104.55 17.2 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-O 121.641 0.734 . . . . 0.0 110.015 177.274 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 11.7 m -89.63 124.57 34.69 Favored 'General case' 0 C--N 1.314 -0.952 0 CA-C-N 115.036 -0.984 . . . . 0.0 109.275 178.075 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 60.0 p -117.17 172.33 7.36 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-O 121.024 0.44 . . . . 0.0 111.172 -178.004 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 3.3 t70 -56.45 -32.71 65.18 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.245 -0.889 . . . . 0.0 111.444 177.434 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 30.5 mm-40 -104.39 16.48 26.06 Favored 'General case' 0 C--N 1.327 -0.401 0 N-CA-C 112.373 0.508 . . . . 0.0 112.373 -175.507 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 136.6 172.66 12.64 Favored Glycine 0 N--CA 1.45 -0.394 0 C-N-CA 119.969 -1.11 . . . . 0.0 113.674 175.528 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 19.6 m -99.19 121.53 41.16 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 110.278 -0.267 . . . . 0.0 110.278 -179.876 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 97.4 m-85 -115.63 158.71 22.32 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.189 0.519 . . . . 0.0 111.153 -177.051 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . 0.406 ' O ' HG11 ' A' ' 41' ' ' VAL . 23.4 m80 -102.51 125.63 49.3 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.619 -0.719 . . . . 0.0 109.237 179.931 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.643 ' HB3' HG13 ' A' ' 75' ' ' ILE . 0.4 OUTLIER -114.16 136.71 52.64 Favored 'General case' 0 C--N 1.315 -0.895 0 CA-C-O 120.978 0.418 . . . . 0.0 110.069 -176.848 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.466 ' N ' HD13 ' A' ' 86' ' ' LEU . 78.7 tttt -127.08 115.71 19.59 Favored 'General case' 0 C--N 1.312 -1.046 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 176.45 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.488 HG21 ' HB1' ' A' ' 98' ' ' ALA . 73.4 p -69.35 142.44 54.0 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.766 -0.652 . . . . 0.0 111.812 -173.199 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -80.01 -164.01 28.87 Favored Glycine 0 N--CA 1.443 -0.9 0 CA-C-N 115.674 -0.693 . . . . 0.0 112.777 -177.701 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.417 ' HD2' ' N ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -148.01 175.3 11.11 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.621 -0.289 . . . . 0.0 110.42 -173.952 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' ASN . . . . . . . . . . . . . 29.0 t-20 59.31 85.88 0.17 Allowed Pre-proline 0 N--CA 1.467 0.424 0 O-C-N 123.956 0.785 . . . . 0.0 111.735 -176.473 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 95.2 Cg_endo -94.42 -166.06 0.13 Allowed 'Trans proline' 0 N--CA 1.452 -0.918 0 C-N-CA 123.017 2.478 . . . . 0.0 111.632 173.005 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 32.9 t-20 -110.31 58.91 0.61 Allowed 'General case' 0 C--N 1.326 -0.435 0 N-CA-C 108.786 -0.82 . . . . 0.0 108.786 176.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 17.8 t-20 72.33 130.42 0.04 OUTLIER 'General case' 0 C--O 1.235 0.321 0 CA-C-N 114.374 -1.285 . . . . 0.0 110.351 -177.309 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 21.6 m 65.06 177.17 0.2 Allowed 'General case' 0 CA--C 1.533 0.299 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.687 -176.733 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 14.7 m 66.57 117.01 0.03 OUTLIER 'General case' 0 CA--C 1.534 0.358 0 CA-C-O 121.674 0.75 . . . . 0.0 111.979 179.612 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . 0.547 ' N ' ' HD2' ' A' ' 97' ' ' ARG . 2.8 mpt_? -109.94 159.51 17.19 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 109.205 -0.665 . . . . 0.0 109.205 178.515 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . 0.488 ' HB1' HG21 ' A' ' 88' ' ' THR . . . 67.27 86.73 0.13 Allowed 'General case' 0 N--CA 1.461 0.077 0 CA-C-O 121.597 0.713 . . . . 0.0 110.234 -176.975 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 29.1 t80 -81.82 119.98 24.59 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 115.64 -0.709 . . . . 0.0 110.306 -172.548 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 26.0 mmt -98.66 151.58 20.56 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.597 -179.698 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . 0.501 ' O ' HG22 ' A' ' 33' ' ' VAL . . . -124.36 26.67 5.72 Favored Glycine 0 N--CA 1.45 -0.408 0 C-N-CA 120.45 -0.881 . . . . 0.0 112.555 -179.828 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.494 HD12 HD12 ' A' ' 29' ' ' ILE . 45.6 pt -136.3 162.41 35.82 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-O 121.112 0.482 . . . . 0.0 110.549 179.686 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . 0.455 ' CB ' ' HB3' ' A' ' 30' ' ' ASP . 28.5 mmt85 -102.18 146.34 28.11 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 115.487 -0.779 . . . . 0.0 109.421 176.056 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 16.5 p -131.59 154.49 48.8 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.225 0.536 . . . . 0.0 111.61 -179.6 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 15.7 p -122.88 171.09 9.46 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.903 -0.59 . . . . 0.0 109.692 175.539 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . 0.929 ' HB3' ' HG ' ' A' ' 59' ' ' LEU . 19.8 p-10 -108.97 4.88 23.76 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 111.812 0.301 . . . . 0.0 111.812 -175.943 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . 0.573 ' HD2' ' HB3' ' A' ' 25' ' ' ASP . 76.5 t60 62.84 69.06 0.61 Allowed 'General case' 0 N--CA 1.465 0.288 0 CA-C-O 121.549 0.69 . . . . 0.0 111.421 173.677 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . 0.416 HD21 ' HA ' ' A' ' 24' ' ' PRO . 61.0 mt -135.42 -169.17 2.33 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.826 176.572 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 57.8 mtp180 62.96 69.29 0.59 Allowed 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.087 -0.961 . . . . 0.0 111.113 -177.323 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 7.1 p -158.03 153.6 6.03 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.727 0 CA-C-N 114.916 -1.038 . . . . 0.0 109.045 -178.69 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' ARG . . . . . . . . . . . . . 26.9 mtp180 -106.56 98.98 8.58 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 109.751 -0.463 . . . . 0.0 109.751 -178.174 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -142.7 143.25 32.21 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.801 -0.636 . . . . 0.0 109.854 -175.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 27.3 t -82.18 83.96 7.21 Favored 'General case' 0 C--N 1.317 -0.81 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.538 -179.977 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 15.0 m -68.97 137.6 23.99 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.724 178.143 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -103.1 -44.51 5.19 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.112 -178.888 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 14.5 t -80.43 85.11 5.93 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.252 0.548 . . . . 0.0 109.71 178.568 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 39.0 t -112.74 114.97 48.52 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.033 179.761 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 6.7 mp -98.95 -14.88 19.34 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 120.984 0.421 . . . . 0.0 110.33 178.373 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 78.09 -72.95 2.22 Favored Glycine 0 N--CA 1.447 -0.576 0 CA-C-N 115.901 -0.59 . . . . 0.0 111.655 -179.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 15.2 t70 -178.29 -60.48 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 177.626 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 40.6 p 51.91 86.91 0.03 OUTLIER 'General case' 0 N--CA 1.466 0.328 0 CA-C-N 114.952 -1.022 . . . . 0.0 112.492 -178.533 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 67.8 mt -78.8 139.03 57.72 Favored Pre-proline 0 C--N 1.327 -0.396 0 CA-C-N 115.489 -0.778 . . . . 0.0 110.319 177.065 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_endo -64.16 151.97 83.11 Favored 'Trans proline' 0 C--O 1.234 0.28 0 C-N-CA 122.404 2.069 . . . . 0.0 111.89 177.319 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 38.0 p90 -55.51 144.55 25.68 Favored 'General case' 0 C--O 1.236 0.367 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.348 -178.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.998 0 CA-C-O 118.579 -0.724 . . . . 0.0 109.888 -178.27 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.461 ' HA ' ' HD3' ' A' ' 24' ' ' PRO . 0.9 OUTLIER . . . . . 0 N--CA 1.456 -0.149 0 N-CA-C 109.823 -0.436 . . . . 0.0 109.823 . . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.461 ' HD3' ' HA ' ' A' ' 23' ' ' GLN . 19.1 Cg_exo -66.44 148.27 83.77 Favored 'Trans proline' 0 C--O 1.233 0.243 0 C-N-CA 122.999 2.466 . . . . 0.0 111.63 178.138 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 16.0 t70 -149.26 -37.49 0.16 Allowed 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 121.02 0.438 . . . . 0.0 111.134 -176.164 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.566 ' HA2' ' HA ' ' A' ' 57' ' ' SER . . . 165.59 172.04 32.52 Favored Glycine 0 N--CA 1.45 -0.367 0 N-CA-C 111.141 -0.784 . . . . 0.0 111.141 -177.795 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.581 HG23 ' HB ' ' A' ' 48' ' ' ILE . 30.7 m -124.0 148.16 28.23 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-O 121.242 0.544 . . . . 0.0 111.117 179.147 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . 0.536 ' HG3' ' O ' ' A' ' 46' ' ' LEU . 60.0 tt0 -128.34 152.06 48.59 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.882 -0.599 . . . . 0.0 110.007 -179.248 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.49 HD11 ' HB2' ' A' ' 46' ' ' LEU . 2.8 pt -86.5 122.16 38.42 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 121.238 0.542 . . . . 0.0 111.245 179.345 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.615 ' HB3' ' CB ' ' A' ' 103' ' ' ARG . 15.8 t70 -64.44 -61.74 2.03 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 114.699 -1.137 . . . . 0.0 110.828 -179.13 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.475 ' HA ' ' HB3' ' A' ' 44' ' ' PRO . 51.3 p -166.94 161.81 15.3 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.602 -0.726 . . . . 0.0 110.936 -175.582 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.568 ' HA ' HG22 ' A' ' 102' ' ' ILE . 85.2 t -98.81 129.14 49.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.788 177.314 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 47.0 t -92.69 129.67 39.52 Favored Pre-proline 0 C--N 1.322 -0.621 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.006 -179.749 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_exo -56.64 123.74 14.58 Favored 'Trans proline' 0 C--O 1.234 0.291 0 C-N-CA 122.584 2.189 . . . . 0.0 111.929 178.07 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 117.27 18.05 5.54 Favored Glycine 0 N--CA 1.447 -0.594 0 CA-C-N 115.662 -0.699 . . . . 0.0 111.379 -176.152 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.667 ' HB3' ' HA3' ' A' ' 101' ' ' GLY . 54.3 p -121.54 149.79 53.43 Favored Pre-proline 0 C--N 1.322 -0.615 0 CA-C-N 115.58 -0.31 . . . . 0.0 110.801 -177.111 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_endo -71.14 -25.41 22.42 Favored 'Trans proline' 0 N--CA 1.463 -0.271 0 C-N-CA 122.338 2.025 . . . . 0.0 111.949 176.112 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -72.45 -10.62 60.01 Favored 'General case' 0 C--O 1.234 0.245 0 CA-C-N 116.087 -0.506 . . . . 0.0 111.808 -175.611 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.535 ' HA ' HG11 ' A' ' 32' ' ' VAL . 24.7 p -59.16 -28.75 66.88 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.319 -0.4 . . . . 0.0 111.91 -177.85 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 65.0 mttm -110.92 15.06 21.99 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.879 0.371 . . . . 0.0 111.083 179.858 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 53.8 t -101.66 -59.49 3.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-O 120.972 0.415 . . . . 0.0 110.368 178.599 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -130.66 169.28 15.85 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 116.132 -0.485 . . . . 0.0 111.118 -179.868 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 18.3 p -105.15 138.96 19.68 Favored Pre-proline 0 C--N 1.318 -0.775 0 CA-C-N 115.624 -0.717 . . . . 0.0 110.182 177.705 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.475 ' HB3' ' HA ' ' A' ' 31' ' ' SER . 32.1 Cg_endo -65.18 141.85 71.14 Favored 'Trans proline' 0 N--CA 1.462 -0.373 0 C-N-CA 122.34 2.027 . . . . 0.0 112.31 -179.188 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 110.24 -1.27 29.68 Favored Glycine 0 N--CA 1.451 -0.338 0 C-N-CA 120.834 -0.698 . . . . 0.0 112.8 -177.206 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.536 ' O ' ' HG3' ' A' ' 28' ' ' GLN . 90.1 mt -85.36 163.39 18.58 Favored 'General case' 0 C--N 1.328 -0.351 0 O-C-N 122.459 -0.436 . . . . 0.0 110.84 178.938 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.478 ' HB ' ' HB2' ' A' ' 80' ' ' ASP . 47.0 t -105.44 135.2 44.53 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.264 -179.233 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.581 ' HB ' HG23 ' A' ' 27' ' ' VAL . 69.4 mt -95.5 119.12 43.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 N-CA-C 110.118 -0.327 . . . . 0.0 110.118 -179.733 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 29.8 mt-10 -86.66 -46.15 10.33 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 116.332 -0.394 . . . . 0.0 111.216 -178.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.567 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 36.1 p -159.69 155.07 25.41 Favored 'General case' 0 C--N 1.325 -0.482 0 C-N-CA 120.326 -0.55 . . . . 0.0 112.028 -177.759 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 55.6 mt -112.93 97.38 5.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-N 115.372 -0.831 . . . . 0.0 111.003 179.195 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 49.2 t30 58.52 35.4 24.6 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.171 -0.922 . . . . 0.0 111.874 171.291 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 108.95 -27.4 13.01 Favored Glycine 0 N--CA 1.45 -0.42 0 C-N-CA 120.664 -0.779 . . . . 0.0 112.057 178.835 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' MET . . . . . 0.411 ' HA ' ' HD3' ' A' ' 55' ' ' PRO . 71.6 mtm -98.88 106.88 40.35 Favored Pre-proline 0 C--N 1.324 -0.51 0 N-CA-C 109.978 -0.378 . . . . 0.0 109.978 178.723 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.567 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 6.1 Cg_exo -77.61 150.02 27.46 Favored 'Trans proline' 0 N--CA 1.457 -0.633 0 C-N-CA 122.669 2.246 . . . . 0.0 112.095 -177.626 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 19.8 p -123.13 106.72 11.02 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-O 120.915 0.388 . . . . 0.0 111.399 -178.241 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . 0.566 ' HA ' ' HA2' ' A' ' 26' ' ' GLY . 15.1 p -99.0 -22.16 15.87 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-O 121.038 0.447 . . . . 0.0 110.788 178.283 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . 0.507 ' HB3' ' OG1' ' A' ' 61' ' ' THR . 17.3 t-20 -117.18 172.23 7.43 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 116.091 -0.504 . . . . 0.0 109.733 179.264 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 40.3 mt -79.43 -42.6 25.06 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 116.064 -0.517 . . . . 0.0 110.469 -179.843 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 27.8 m -65.8 -29.49 69.99 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.778 177.652 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . 0.507 ' OG1' ' HB3' ' A' ' 58' ' ' ASN . 1.5 m -66.56 -37.42 84.93 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.177 0.513 . . . . 0.0 110.009 176.357 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 62.5 t80 -62.91 -45.76 90.98 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.217 -0.902 . . . . 0.0 109.4 174.345 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . 0.534 ' O ' ' HG2' ' A' ' 67' ' ' LYS . 59.6 m -59.48 -48.77 80.37 Favored 'General case' 0 N--CA 1.444 -0.744 0 CA-C-N 115.243 -0.889 . . . . 0.0 111.695 177.565 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -60.3 -31.08 69.93 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.979 -0.555 . . . . 0.0 111.721 -178.454 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . 0.402 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -76.2 -42.87 44.86 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.334 0.588 . . . . 0.0 109.885 176.995 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.433 ' HA ' HD22 ' A' ' 66' ' ' LEU . 0.2 OUTLIER -58.06 -32.96 68.52 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 114.958 -1.019 . . . . 0.0 111.382 178.803 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . 0.534 ' HG2' ' O ' ' A' ' 63' ' ' SER . 31.5 mmmt -56.01 -35.14 66.48 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.944 -179.938 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 24.5 p -92.84 -12.74 30.3 Favored 'General case' 0 C--N 1.325 -0.488 0 N-CA-C 112.317 0.488 . . . . 0.0 112.317 -174.851 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.596 HG21 HG21 ' A' ' 88' ' ' THR . 46.2 mm -74.47 136.92 24.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 120.888 0.375 . . . . 0.0 110.571 -178.129 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . 0.406 ' HB2' ' HB2' ' A' ' 73' ' ' GLU . 6.0 m -89.17 161.82 16.26 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.748 -178.452 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.418 HG22 ' H ' ' A' ' 98' ' ' ALA . 11.4 t -80.34 115.12 22.28 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 N-CA-C 108.672 -0.862 . . . . 0.0 108.672 171.848 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 99.13 9.45 51.6 Favored Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 120.751 -0.738 . . . . 0.0 111.271 -173.364 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.406 ' HB2' ' HB2' ' A' ' 70' ' ' SER . 10.7 tp10 -80.81 149.14 29.7 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 179.054 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 58.3 t -111.01 108.13 24.69 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.989 0 N-CA-C 109.273 -0.639 . . . . 0.0 109.273 176.872 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 17.1 pt -101.08 153.62 4.81 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 CA-C-O 121.44 0.638 . . . . 0.0 111.662 -176.366 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 3.9 t30 -107.4 104.41 13.99 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 114.949 -1.023 . . . . 0.0 109.716 -176.226 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 65.0 mt -106.85 110.7 32.64 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.011 0 CA-C-O 121.317 0.58 . . . . 0.0 111.241 -173.799 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . 0.479 ' HA ' ' HA ' ' A' ' 83' ' ' THR . 91.8 m -85.19 114.34 22.23 Favored 'General case' 0 C--N 1.316 -0.867 0 CA-C-N 115.595 -0.73 . . . . 0.0 109.271 174.694 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 50.1 p -103.42 175.66 5.41 Favored 'General case' 0 N--CA 1.443 -0.797 0 CA-C-O 121.061 0.458 . . . . 0.0 110.387 179.85 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . 0.478 ' HB2' ' HB ' ' A' ' 47' ' ' VAL . 9.3 t70 -51.71 -33.42 34.25 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.006 -0.997 . . . . 0.0 112.515 179.43 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 5.3 mt-30 -115.29 16.06 16.85 Favored 'General case' 0 C--N 1.327 -0.385 0 N-CA-C 112.704 0.631 . . . . 0.0 112.704 -173.27 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 140.58 169.83 11.87 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.237 -0.983 . . . . 0.0 113.073 176.661 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.479 ' HA ' ' HA ' ' A' ' 78' ' ' THR . 30.0 m -96.59 133.4 41.13 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-O 120.794 0.331 . . . . 0.0 111.122 -179.507 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 82.5 m-85 -123.19 157.21 33.52 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.232 177.561 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 1.7 p-80 -108.12 120.11 41.4 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-O 121.104 0.478 . . . . 0.0 110.273 176.486 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -109.95 146.95 34.35 Favored 'General case' 0 N--CA 1.444 -0.741 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.852 -176.841 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 77.7 tttt -111.82 124.17 51.8 Favored 'General case' 0 C--N 1.32 -0.693 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 174.516 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.596 HG21 HG21 ' A' ' 69' ' ' ILE . 13.4 p -80.69 132.26 35.55 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 120.981 0.419 . . . . 0.0 111.562 -178.648 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -127.34 -122.52 2.54 Favored Glycine 0 N--CA 1.446 -0.651 0 C-N-CA 120.977 -0.63 . . . . 0.0 111.863 179.253 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.5 ' HD3' ' N ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -147.85 171.21 16.1 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 109.765 -0.457 . . . . 0.0 109.765 179.044 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' ASN . . . . . 0.479 ' HB2' ' O ' ' A' ' 94' ' ' ASN . 6.9 m120 -71.57 140.48 84.44 Favored Pre-proline 0 C--N 1.324 -0.528 0 CA-C-N 116.604 -0.271 . . . . 0.0 110.361 175.402 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 34.6 Cg_endo -64.76 -27.22 59.96 Favored 'Trans proline' 0 CA--C 1.529 0.262 0 C-N-CA 122.718 2.278 . . . . 0.0 112.97 -177.293 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 -126.51 14.67 7.64 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.956 0.408 . . . . 0.0 110.96 -176.945 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . 0.479 ' O ' ' HB2' ' A' ' 91' ' ' ASN . 26.3 t-20 -151.47 134.99 16.2 Favored 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 110.113 -0.329 . . . . 0.0 110.113 -177.234 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 5.1 m -83.19 90.21 7.06 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 121.039 0.447 . . . . 0.0 110.688 -178.721 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 20.9 m -126.57 136.51 52.64 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.25 179.067 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 5.2 ptm180 -75.68 136.14 40.4 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.717 -177.248 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . 0.418 ' H ' HG22 ' A' ' 71' ' ' VAL . . . 54.63 77.0 0.22 Allowed 'General case' 0 N--CA 1.465 0.29 0 O-C-N 123.992 0.807 . . . . 0.0 111.895 172.75 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 11.4 t80 -136.97 134.47 36.71 Favored 'General case' 0 C--N 1.323 -0.561 0 C-N-CA 120.851 -0.339 . . . . 0.0 110.32 -179.751 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' MET . . . . . 0.482 ' O ' ' HB2' ' A' ' 36' ' ' SER . 4.3 mpp? -86.92 -16.25 36.48 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.537 -0.301 . . . . 0.0 111.57 -177.468 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . 0.667 ' HA3' ' HB3' ' A' ' 36' ' ' SER . . . 90.58 30.33 12.07 Favored Glycine 0 CA--C 1.519 0.33 0 C-N-CA 120.878 -0.677 . . . . 0.0 112.866 178.931 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.568 HG22 ' HA ' ' A' ' 32' ' ' VAL . 36.6 pt -135.42 167.05 26.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-O 120.908 0.385 . . . . 0.0 110.584 -178.751 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . 0.615 ' CB ' ' HB3' ' A' ' 30' ' ' ASP . 36.9 mtt180 -98.53 155.54 17.23 Favored 'General case' 0 C--N 1.321 -0.671 0 CA-C-N 115.886 -0.597 . . . . 0.0 109.666 173.286 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 3.3 m -139.1 149.98 45.16 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 121.092 0.473 . . . . 0.0 110.345 177.269 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 32.0 m -142.02 178.42 7.54 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 115.365 -0.834 . . . . 0.0 109.198 -178.337 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . 0.461 ' HB2' ' HG ' ' A' ' 108' ' ' LEU . 10.4 p30 -103.69 -24.5 13.35 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 120.592 0.234 . . . . 0.0 110.874 177.637 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 42.1 t-80 54.16 45.06 28.21 Favored 'General case' 0 N--CA 1.467 0.419 0 CA-C-O 121.235 0.541 . . . . 0.0 110.458 -179.406 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . 0.461 ' HG ' ' HB2' ' A' ' 106' ' ' ASN . 89.0 mt -82.3 -166.21 1.21 Allowed 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 121.545 0.688 . . . . 0.0 111.528 -178.372 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 58.5 mtt-85 -95.99 103.85 15.76 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.074 -176.522 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 64.6 t -92.19 138.89 18.91 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-N 115.633 -0.712 . . . . 0.0 111.34 -175.547 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' ARG . . . . . . . . . . . . . 47.0 ttt180 -150.74 134.56 16.62 Favored 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 108.814 -0.809 . . . . 0.0 108.814 174.451 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -83.8 110.03 18.01 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.245 0.545 . . . . 0.0 110.031 -177.759 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 4.2 p -90.67 115.35 27.71 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 115.394 -0.821 . . . . 0.0 111.405 -179.586 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 3.0 m -116.48 102.05 13.05 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.356 0 CA-C-N 115.712 -0.677 . . . . 0.0 110.422 175.881 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -171.56 103.59 0.2 Allowed 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.208 -178.289 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 8.1 t -124.27 111.15 15.5 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.142 179.635 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 48.6 t -93.23 119.85 41.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.115 178.625 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 94.2 mt -91.07 -73.67 0.53 Allowed 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 120.916 0.389 . . . . 0.0 110.614 179.844 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 118.96 129.57 3.97 Favored Glycine 0 N--CA 1.447 -0.599 0 N-CA-C 111.194 -0.762 . . . . 0.0 111.194 -175.843 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 50.4 m-20 -102.35 85.29 2.6 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 121.175 0.512 . . . . 0.0 110.491 -178.07 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 1.4 p -91.94 105.66 17.87 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.48 -0.782 . . . . 0.0 110.88 178.246 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . 0.402 ' HA ' ' HD3' ' A' ' 123' ' ' PRO . 61.6 mt -98.5 104.95 26.72 Favored Pre-proline 0 C--N 1.326 -0.442 0 CA-C-N 115.975 -0.557 . . . . 0.0 109.828 -178.928 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . 0.402 ' HD3' ' HA ' ' A' ' 122' ' ' LEU . 5.5 Cg_endo -86.21 110.37 1.02 Allowed 'Trans proline' 0 N--CA 1.455 -0.783 0 C-N-CA 123.162 2.575 . . . . 0.0 112.994 -175.235 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 34.4 p90 -146.48 128.59 15.61 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.627 172.264 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.992 0 CA-C-O 118.576 -0.726 . . . . 0.0 110.399 -175.46 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.495 ' HA ' ' HD3' ' A' ' 24' ' ' PRO . 82.2 mt-30 . . . . . 0 N--CA 1.457 -0.118 0 CA-C-O 120.47 0.176 . . . . 0.0 110.766 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.67 ' HG3' HD22 ' A' ' 58' ' ' ASN . 23.9 Cg_exo -64.48 154.42 71.84 Favored 'Trans proline' 0 C--O 1.234 0.306 0 C-N-CA 123.207 2.605 . . . . 0.0 113.377 -174.666 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 14.5 t70 -153.11 -44.46 0.1 Allowed 'General case' 0 N--CA 1.465 0.283 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.718 178.78 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.487 ' HA2' ' HA ' ' A' ' 57' ' ' SER . . . 156.93 131.8 1.39 Allowed Glycine 0 N--CA 1.449 -0.486 0 CA-C-N 115.745 -0.661 . . . . 0.0 111.694 -179.597 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.467 HG23 ' HB ' ' A' ' 48' ' ' ILE . 31.5 m -72.7 140.15 18.42 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-O 121.218 0.532 . . . . 0.0 111.352 -177.931 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . 0.662 ' HB3' ' HB2' ' A' ' 107' ' ' HIS . 4.1 tp-100 -107.45 133.76 51.48 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.651 -0.704 . . . . 0.0 111.11 -177.977 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.547 HD12 ' HB2' ' A' ' 46' ' ' LEU . 61.5 mt -73.29 105.87 2.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 CA-C-N 115.637 -0.711 . . . . 0.0 109.815 175.524 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 21.3 t70 -62.91 -65.21 0.72 Allowed 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.254 -178.037 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 12.4 p -156.46 152.53 27.55 Favored 'General case' 0 N--CA 1.444 -0.731 0 CA-C-N 115.21 -0.905 . . . . 0.0 110.724 -179.727 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.814 HG22 HG22 ' A' ' 102' ' ' ILE . 66.8 t -87.74 120.47 36.91 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.542 174.903 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.551 HG22 ' O ' ' A' ' 101' ' ' GLY . 22.7 m -82.05 160.53 62.94 Favored Pre-proline 0 C--N 1.325 -0.492 0 CA-C-N 116.777 -0.192 . . . . 0.0 110.534 -177.307 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 18.3 Cg_exo -66.86 99.24 0.45 Allowed 'Trans proline' 0 C--O 1.236 0.376 0 C-N-CA 122.584 2.19 . . . . 0.0 112.434 178.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.432 ' O ' ' HB2' ' A' ' 39' ' ' SER . . . 145.13 -165.17 27.82 Favored Glycine 0 N--CA 1.447 -0.592 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.566 178.762 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.454 ' HB3' HD21 ' A' ' 91' ' ' ASN . 51.0 p 64.37 157.76 0.12 Allowed Pre-proline 0 N--CA 1.473 0.682 0 C-N-CA 124.598 1.159 . . . . 0.0 112.168 179.194 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 2.0 Cg_endo -82.78 -5.53 11.51 Favored 'Trans proline' 0 N--CA 1.46 -0.497 0 C-N-CA 122.984 2.456 . . . . 0.0 112.102 175.756 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -96.68 -0.7 47.99 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.256 -0.429 . . . . 0.0 111.414 -176.575 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.432 ' HB2' ' O ' ' A' ' 35' ' ' GLY . 32.1 t -60.87 -30.78 70.34 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.253 -0.431 . . . . 0.0 111.617 -176.224 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 62.9 tttp -107.39 7.72 29.23 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.929 0.395 . . . . 0.0 110.739 -179.326 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 57.6 t -91.2 -55.69 5.94 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-O 120.962 0.411 . . . . 0.0 110.129 178.755 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 5.2 mp -108.61 162.04 14.51 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.266 -0.425 . . . . 0.0 109.974 178.061 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 20.5 p -112.42 155.64 43.4 Favored Pre-proline 0 C--N 1.317 -0.84 0 N-CA-C 109.614 -0.513 . . . . 0.0 109.614 177.403 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -70.0 146.05 57.56 Favored 'Trans proline' 0 N--CA 1.459 -0.548 0 C-N-CA 121.65 1.567 . . . . 0.0 111.464 178.133 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 94.84 12.41 55.52 Favored Glycine 0 CA--C 1.522 0.521 0 C-N-CA 120.615 -0.802 . . . . 0.0 113.618 179.938 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.547 ' HB2' HD12 ' A' ' 29' ' ' ILE . 86.8 mt -98.0 162.03 13.43 Favored 'General case' 0 C--N 1.334 -0.105 0 CA-C-N 117.499 0.65 . . . . 0.0 110.904 177.063 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 59.6 t -110.79 128.31 67.25 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.453 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.781 -177.608 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.467 ' HB ' HG23 ' A' ' 27' ' ' VAL . 76.4 mt -91.66 121.34 42.04 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.396 179.743 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 61.9 mt-10 -82.54 -50.0 9.28 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.702 -179.279 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.606 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 15.2 p -159.29 153.88 24.32 Favored 'General case' 0 N--CA 1.45 -0.441 0 CA-C-O 121.223 0.535 . . . . 0.0 112.122 -172.757 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 64.2 mt -122.78 101.58 9.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.523 0 CA-C-N 115.158 -0.928 . . . . 0.0 110.113 176.616 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 35.0 t-20 55.26 67.9 0.95 Allowed 'General case' 0 N--CA 1.464 0.274 0 CA-C-N 115.623 -0.717 . . . . 0.0 111.2 176.443 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 79.59 -46.14 3.02 Favored Glycine 0 CA--C 1.519 0.304 0 CA-C-N 115.559 -0.746 . . . . 0.0 112.944 178.639 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 64.0 mtm -80.96 114.28 47.36 Favored Pre-proline 0 C--N 1.324 -0.511 0 N-CA-C 110.157 -0.312 . . . . 0.0 110.157 -178.838 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.606 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 98.1 Cg_endo -80.02 146.13 17.99 Favored 'Trans proline' 0 N--CA 1.458 -0.597 0 C-N-CA 122.351 2.034 . . . . 0.0 112.573 -176.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 22.3 p -110.41 76.26 0.97 Allowed 'General case' 0 N--CA 1.447 -0.618 0 CA-C-O 121.355 0.598 . . . . 0.0 111.062 -179.473 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . 0.487 ' HA ' ' HA2' ' A' ' 26' ' ' GLY . 16.5 m -84.6 -15.07 46.9 Favored 'General case' 0 C--N 1.317 -0.806 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.175 177.643 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . 0.67 HD22 ' HG3' ' A' ' 24' ' ' PRO . 6.3 t-20 -140.12 175.79 9.3 Favored 'General case' 0 N--CA 1.449 -0.476 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.091 -179.336 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.461 ' HG ' ' OD1' ' A' ' 106' ' ' ASN . 28.6 mt -75.4 -31.35 60.39 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.858 179.508 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 1.5 m -65.39 -43.3 91.07 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.634 178.292 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 7.2 p -64.92 -37.18 86.79 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 121.055 0.455 . . . . 0.0 110.325 177.083 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' TYR . . . . . 0.436 ' O ' ' HB2' ' A' ' 66' ' ' LEU . 84.4 t80 -62.85 -44.66 95.54 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.771 -0.65 . . . . 0.0 109.857 174.928 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 47.2 m -61.98 -47.16 86.08 Favored 'General case' 0 N--CA 1.446 -0.644 0 CA-C-N 115.286 -0.87 . . . . 0.0 111.997 179.225 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.44 -30.62 71.66 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.106 -0.497 . . . . 0.0 111.187 -178.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . 0.447 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -77.58 -44.2 29.24 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 121.09 0.471 . . . . 0.0 110.011 177.14 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.436 ' HB2' ' O ' ' A' ' 62' ' ' TYR . 0.2 OUTLIER -57.47 -36.43 71.45 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.358 -0.837 . . . . 0.0 112.166 -176.768 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 19.7 ptmt -71.95 -18.34 62.01 Favored 'General case' 0 C--N 1.328 -0.357 0 C-N-CA 120.772 -0.371 . . . . 0.0 111.662 -177.676 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 44.6 p -92.12 -13.49 30.64 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 120.978 0.418 . . . . 0.0 110.767 -178.876 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.569 HD12 HG21 ' A' ' 75' ' ' ILE . 19.6 mm -83.35 144.91 9.17 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.356 -0.384 . . . . 0.0 109.998 -178.888 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 13.0 m -105.28 164.38 11.88 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.497 -0.319 . . . . 0.0 110.469 -179.438 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.425 HG22 ' H ' ' A' ' 98' ' ' ALA . 36.2 t -77.5 119.48 26.21 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 N-CA-C 109.462 -0.57 . . . . 0.0 109.462 175.349 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 88.63 22.83 38.35 Favored Glycine 0 N--CA 1.45 -0.409 0 N-CA-C 111.046 -0.822 . . . . 0.0 111.046 -175.57 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 5.2 tp10 -99.65 148.54 24.23 Favored 'General case' 0 C--N 1.324 -0.5 0 N-CA-C 109.586 -0.524 . . . . 0.0 109.586 -179.826 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 52.9 t -104.39 127.95 58.3 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.738 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 177.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.569 HG21 HD12 ' A' ' 69' ' ' ILE . 16.1 pt -125.61 161.22 30.8 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-O 121.342 0.591 . . . . 0.0 111.903 -176.733 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 7.9 t30 -106.92 105.91 16.18 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-N 115.211 -0.904 . . . . 0.0 110.285 -179.069 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 72.6 mt -108.36 114.02 45.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.552 0 CA-C-O 121.528 0.68 . . . . 0.0 110.496 -177.232 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . 0.462 ' HA ' ' HA ' ' A' ' 83' ' ' THR . 10.2 m -95.15 120.4 35.31 Favored 'General case' 0 C--N 1.314 -0.944 0 CA-C-N 115.58 -0.737 . . . . 0.0 109.496 -179.559 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 45.8 p -112.61 175.65 5.35 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 116.535 -0.302 . . . . 0.0 110.522 -178.924 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 15.9 t70 -59.22 -28.24 66.48 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.016 179.296 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 1.5 mp0 -98.05 16.83 19.93 Favored 'General case' 0 C--O 1.235 0.294 0 CA-C-N 116.207 -0.452 . . . . 0.0 111.887 -177.551 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 121.86 177.72 15.53 Favored Glycine 0 N--CA 1.448 -0.538 0 C-N-CA 120.391 -0.909 . . . . 0.0 113.452 174.901 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.462 ' HA ' ' HA ' ' A' ' 78' ' ' THR . 3.9 m -90.28 119.53 30.66 Favored 'General case' 0 C--N 1.324 -0.526 0 C-N-CA 122.609 0.364 . . . . 0.0 110.782 -178.708 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 97.2 m-85 -116.69 157.18 25.85 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 121.149 0.499 . . . . 0.0 110.554 178.468 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 43.0 p-80 -111.97 129.98 56.01 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-N 115.614 -0.721 . . . . 0.0 109.223 176.8 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 7.5 tt -126.86 149.78 49.57 Favored 'General case' 0 C--N 1.314 -0.957 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.255 -173.716 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 1.7 tmtp? -124.9 124.14 41.42 Favored 'General case' 0 C--N 1.316 -0.874 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.316 179.778 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.512 HG21 ' HB1' ' A' ' 98' ' ' ALA . 73.5 p -74.73 127.95 34.39 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.592 -177.609 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -159.92 103.34 0.22 Allowed Glycine 0 N--CA 1.445 -0.738 0 C-N-CA 119.564 -1.303 . . . . 0.0 114.457 -177.535 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.505 ' HD2' ' N ' ' A' ' 90' ' ' ARG . 6.9 mpt_? 47.97 119.32 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.83 0 N-CA-C 116.361 1.985 . . . . 0.0 116.361 165.14 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' ASN . . . . . 0.811 ' HB2' ' HB3' ' A' ' 99' ' ' TYR . 4.9 m-20 -154.4 144.27 15.48 Favored Pre-proline 0 C--N 1.326 -0.448 0 CA-C-N 115.096 -0.956 . . . . 0.0 109.406 171.683 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 9.7 Cg_endo -53.08 -55.36 3.76 Favored 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 123.275 2.65 . . . . 0.0 112.927 -176.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 64.3 t30 -148.42 74.58 1.29 Allowed 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.185 0.517 . . . . 0.0 110.659 179.968 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . 0.407 ' HB3' ' HD1' ' A' ' 99' ' ' TYR . 0.2 OUTLIER -84.56 -52.05 6.42 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 109.334 -0.617 . . . . 0.0 109.334 176.508 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 47.1 m -158.12 -68.93 0.09 Allowed 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 115.739 -0.664 . . . . 0.0 109.312 177.718 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 8.7 t -171.07 -58.11 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 N-CA-C 108.871 -0.789 . . . . 0.0 108.871 177.31 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -124.02 159.83 28.99 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.675 -0.693 . . . . 0.0 109.253 175.558 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . 0.512 ' HB1' HG21 ' A' ' 88' ' ' THR . . . 55.87 84.96 0.07 Allowed 'General case' 0 N--CA 1.465 0.31 0 O-C-N 123.994 0.809 . . . . 0.0 111.788 179.417 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . 0.811 ' HB3' ' HB2' ' A' ' 91' ' ' ASN . 26.8 m-85 -89.23 109.35 20.24 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.457 -178.076 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 61.0 mtm -86.19 -35.27 20.17 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.361 -0.381 . . . . 0.0 111.344 -178.708 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . 0.584 ' HA2' ' ND2' ' A' ' 91' ' ' ASN . . . 114.46 -13.74 20.77 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.382 -0.914 . . . . 0.0 113.755 176.443 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.814 HG22 HG22 ' A' ' 32' ' ' VAL . 2.7 pp -120.06 149.37 22.79 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.791 0 O-C-N 122.429 -0.454 . . . . 0.0 110.422 179.79 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -88.91 137.09 32.63 Favored 'General case' 0 C--N 1.321 -0.646 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 176.291 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -109.48 145.58 36.0 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 116.299 -0.41 . . . . 0.0 111.317 -177.523 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 32.2 p -137.67 168.27 20.02 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.619 -0.719 . . . . 0.0 109.576 176.256 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . 0.461 ' OD1' ' HG ' ' A' ' 59' ' ' LEU . 1.0 OUTLIER -83.71 -37.32 22.86 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.23 -178.423 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . 0.662 ' HB2' ' HB3' ' A' ' 28' ' ' GLN . 35.7 t60 56.9 35.83 26.89 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 115.51 -0.768 . . . . 0.0 111.138 174.14 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 91.4 mt -89.82 -172.97 3.74 Favored 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 121.812 0.815 . . . . 0.0 111.726 -175.319 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . 0.436 HH11 ' HD3' ' A' ' 109' ' ' ARG . 15.5 ttm180 -149.01 123.99 10.02 Favored 'General case' 0 C--N 1.317 -0.843 0 CA-C-N 114.251 -1.341 . . . . 0.0 109.251 179.353 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 9.8 p -141.16 147.01 22.85 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-O 121.104 0.478 . . . . 0.0 110.195 175.962 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' ARG . . . . . . . . . . . . . 22.8 ttt180 -112.33 173.89 6.15 Favored 'General case' 0 C--N 1.313 -0.985 0 N-CA-C 108.264 -1.013 . . . . 0.0 108.264 178.307 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 9.1 m-20 -72.19 72.71 0.91 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.709 0.766 . . . . 0.0 111.015 179.426 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 31.1 m -143.85 112.15 6.36 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 115.029 -0.987 . . . . 0.0 108.956 178.584 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 4.9 m -76.7 94.73 1.23 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-O 121.648 0.737 . . . . 0.0 111.45 -177.757 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -113.93 105.65 13.49 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-N 115.125 -0.943 . . . . 0.0 110.273 -178.773 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 12.1 t -138.09 75.08 1.5 Allowed 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 121.417 0.627 . . . . 0.0 109.436 -179.274 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 4.5 p -119.58 114.01 42.92 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.582 0 CA-C-O 121.647 0.737 . . . . 0.0 111.037 -179.054 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 92.5 mt -108.98 -41.42 4.73 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-N 115.31 -0.859 . . . . 0.0 109.409 176.326 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 65.87 22.06 69.96 Favored Glycine 0 N--CA 1.449 -0.443 0 CA-C-N 115.635 -0.712 . . . . 0.0 112.142 -178.779 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 16.7 p-10 -74.0 107.52 6.26 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.521 0.677 . . . . 0.0 110.976 -175.296 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 11.7 t -119.2 134.92 54.93 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.584 -0.735 . . . . 0.0 109.403 178.52 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 93.0 mt -126.74 122.95 23.66 Favored Pre-proline 0 C--N 1.326 -0.451 0 CA-C-N 116.402 -0.363 . . . . 0.0 110.566 -175.717 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 48.6 Cg_endo -69.79 132.6 23.62 Favored 'Trans proline' 0 CA--C 1.529 0.263 0 C-N-CA 122.656 2.237 . . . . 0.0 112.07 179.185 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 98.0 m-85 -87.28 119.68 27.78 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.304 179.18 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.979 0 CA-C-O 118.912 -0.565 . . . . 0.0 110.309 -179.65 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.445 ' HA ' ' HD3' ' A' ' 24' ' ' PRO . 52.8 tt0 . . . . . 0 N--CA 1.45 -0.44 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.445 ' HD3' ' HA ' ' A' ' 23' ' ' GLN . 17.3 Cg_exo -70.28 -164.47 0.14 Allowed 'Trans proline' 0 C--O 1.231 0.139 0 C-N-CA 123.316 2.677 . . . . 0.0 113.367 -179.195 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.693 ' HA ' ' HB3' ' A' ' 57' ' ' SER . 30.7 t0 75.36 32.07 0.75 Allowed 'General case' 0 N--CA 1.469 0.49 0 CA-C-N 114.767 -1.106 . . . . 0.0 109.255 -175.618 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 146.81 148.8 4.83 Favored Glycine 0 N--CA 1.444 -0.779 0 CA-C-N 114.648 -1.16 . . . . 0.0 111.448 176.041 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.458 HG23 ' HB ' ' A' ' 48' ' ' ILE . 29.3 m -122.51 144.1 33.05 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.665 0 CA-C-O 121.018 0.437 . . . . 0.0 111.085 -179.63 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . 0.4 HE21 HG22 ' A' ' 47' ' ' VAL . 35.0 tt0 -112.32 153.32 27.4 Favored 'General case' 0 C--N 1.322 -0.615 0 N-CA-C 110.004 -0.369 . . . . 0.0 110.004 175.697 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 60.3 mt -78.86 112.55 17.04 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-N 116.314 -0.403 . . . . 0.0 109.921 178.85 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.635 ' HB3' ' HB2' ' A' ' 103' ' ' ARG . 22.5 t70 -64.32 -65.11 0.72 Allowed 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.789 -0.641 . . . . 0.0 109.713 178.559 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 20.7 p -156.8 154.39 29.85 Favored 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.166 -0.925 . . . . 0.0 110.586 179.103 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.605 HG23 HG22 ' A' ' 102' ' ' ILE . 13.5 p -91.25 143.67 10.77 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 N-CA-C 109.506 -0.553 . . . . 0.0 109.506 176.884 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 61.6 t -97.13 114.88 65.42 Favored Pre-proline 0 C--N 1.321 -0.636 0 N-CA-C 110.16 -0.311 . . . . 0.0 110.16 177.708 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -55.19 122.3 11.47 Favored 'Trans proline' 0 C--N 1.346 0.411 0 C-N-CA 123.094 2.529 . . . . 0.0 112.033 178.761 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 122.05 7.92 7.57 Favored Glycine 0 N--CA 1.446 -0.695 0 CA-C-N 115.55 -0.75 . . . . 0.0 111.711 -176.505 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 72.3 p -121.33 150.19 53.69 Favored Pre-proline 0 C--N 1.325 -0.457 0 CA-C-O 120.676 0.274 . . . . 0.0 110.497 -179.013 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -67.59 -16.33 46.7 Favored 'Trans proline' 0 C--N 1.346 0.421 0 C-N-CA 122.639 2.226 . . . . 0.0 112.513 179.648 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.492 ' HA ' HD11 ' A' ' 86' ' ' LEU . . . -60.34 -36.82 78.87 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.984 -0.553 . . . . 0.0 111.568 -177.518 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 22.9 t -64.69 -23.68 67.33 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.617 -176.533 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 63.4 tttp -82.0 -26.03 34.21 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.027 0.441 . . . . 0.0 110.683 -177.505 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 38.6 t -99.22 -55.86 5.67 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.409 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.503 -175.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 1.9 pp -108.81 -178.02 3.47 Favored 'General case' 0 CA--C 1.516 -0.334 0 CA-C-O 121.527 0.68 . . . . 0.0 111.959 -177.472 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 5.4 p -127.85 143.53 48.04 Favored Pre-proline 0 C--N 1.315 -0.894 0 CA-C-N 114.94 -1.027 . . . . 0.0 110.645 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -66.69 146.19 78.13 Favored 'Trans proline' 0 N--CA 1.462 -0.347 0 C-N-CA 122.39 2.06 . . . . 0.0 111.627 175.643 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 102.55 -7.74 54.03 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.568 -178.105 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 89.1 mt -80.63 163.34 23.7 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 120.91 0.386 . . . . 0.0 110.772 179.061 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.409 ' O ' ' HA ' ' A' ' 79' ' ' THR . 44.3 t -103.24 137.15 32.68 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 N-CA-C 109.422 -0.585 . . . . 0.0 109.422 176.858 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.458 ' HB ' HG23 ' A' ' 27' ' ' VAL . 63.2 mt -103.15 121.26 54.16 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.509 0 CA-C-O 120.786 0.327 . . . . 0.0 110.603 -179.213 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -82.71 -47.44 12.0 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.018 0.437 . . . . 0.0 110.848 177.501 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.623 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 6.1 p -152.15 146.28 25.36 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 121.176 0.512 . . . . 0.0 112.244 -174.185 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 47.4 mm -110.89 101.47 12.6 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-N 114.699 -1.137 . . . . 0.0 108.211 173.488 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 4.6 t-20 66.13 -152.15 0.23 Allowed 'General case' 0 C--N 1.331 -0.232 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 -172.493 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -73.42 7.28 12.64 Favored Glycine 0 CA--C 1.523 0.554 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.656 177.143 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 2.1 mpt? -111.62 102.53 53.57 Favored Pre-proline 0 C--N 1.329 -0.308 0 CA-C-O 120.812 0.339 . . . . 0.0 110.131 -179.667 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.623 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 44.5 Cg_endo -71.67 124.27 10.11 Favored 'Trans proline' 0 N--CA 1.46 -0.458 0 C-N-CA 122.146 1.897 . . . . 0.0 112.215 179.661 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 16.8 p -92.13 96.89 10.58 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 115.877 -0.602 . . . . 0.0 111.358 -176.369 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . 0.693 ' HB3' ' HA ' ' A' ' 25' ' ' ASP . 14.2 m -94.75 -19.65 20.19 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.803 -0.635 . . . . 0.0 110.303 178.857 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 76.2 m-20 -123.92 164.32 19.53 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.13 -178.886 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 84.5 mt -75.81 -30.47 59.05 Favored 'General case' 0 N--CA 1.443 -0.802 0 CA-C-O 121.185 0.517 . . . . 0.0 109.906 177.924 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 9.6 m -69.17 -39.47 78.74 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.611 -0.722 . . . . 0.0 111.152 178.512 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -71.05 -27.9 63.98 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-O 120.628 0.251 . . . . 0.0 111.065 179.909 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 87.1 t80 -64.41 -40.72 96.32 Favored 'General case' 0 C--N 1.329 -0.304 0 N-CA-C 109.618 -0.512 . . . . 0.0 109.618 173.069 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . 0.421 ' O ' ' HD3' ' A' ' 67' ' ' LYS . 7.0 t -66.68 -43.33 84.73 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.732 -0.667 . . . . 0.0 109.855 176.596 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.31 -33.21 74.22 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-O 121.164 0.507 . . . . 0.0 110.793 179.693 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . 0.679 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -69.01 -49.3 58.96 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.946 -0.57 . . . . 0.0 109.831 176.357 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.409 ' HA ' HD23 ' A' ' 66' ' ' LEU . 11.2 mt -58.57 -36.47 73.99 Favored 'General case' 0 N--CA 1.448 -0.575 0 CA-C-N 116.002 -0.544 . . . . 0.0 112.129 -177.387 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . 0.421 ' HD3' ' O ' ' A' ' 63' ' ' SER . 2.4 mptm? -77.52 -7.04 55.65 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 112.494 0.553 . . . . 0.0 112.494 -179.029 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 9.0 p -110.41 -13.69 14.24 Favored 'General case' 0 C--N 1.323 -0.557 0 C-N-CA 120.807 -0.357 . . . . 0.0 111.785 178.755 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.679 HG12 ' O ' ' A' ' 65' ' ' ALA . 33.4 mm -73.33 148.33 8.91 Favored 'Isoleucine or valine' 0 C--O 1.234 0.237 0 N-CA-C 110.17 -0.307 . . . . 0.0 110.17 177.685 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . 0.588 ' HB2' ' HB2' ' A' ' 73' ' ' GLU . 3.2 m -84.89 164.63 18.27 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.269 177.675 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 26.7 t -82.2 123.13 37.91 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.504 0 N-CA-C 109.972 -0.381 . . . . 0.0 109.972 177.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 81.9 21.73 60.84 Favored Glycine 0 N--CA 1.448 -0.548 0 C-N-CA 120.574 -0.822 . . . . 0.0 111.549 -178.496 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.588 ' HB2' ' HB2' ' A' ' 70' ' ' SER . 34.4 tt0 -96.5 150.12 20.98 Favored 'General case' 0 C--N 1.325 -0.463 0 N-CA-C 109.755 -0.461 . . . . 0.0 109.755 -178.561 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 48.0 t -100.33 120.44 49.79 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.759 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.285 -177.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 27.7 pt -113.86 154.53 15.23 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.651 0 CA-C-N 115.998 -0.547 . . . . 0.0 110.913 -179.47 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 13.0 t30 -93.33 118.18 30.97 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.467 179.676 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 51.3 mt -114.34 103.99 16.22 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.832 0 CA-C-O 121.417 0.627 . . . . 0.0 109.85 178.335 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 15.9 m -90.41 111.17 22.32 Favored 'General case' 0 C--N 1.315 -0.929 0 CA-C-N 115.701 -0.682 . . . . 0.0 109.729 179.225 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.409 ' HA ' ' O ' ' A' ' 47' ' ' VAL . 73.3 p -107.63 171.81 7.18 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.961 0.41 . . . . 0.0 111.692 -176.74 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -52.34 -33.37 42.53 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.159 -0.928 . . . . 0.0 112.826 -178.501 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 17.4 mt-30 -127.0 27.07 6.02 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 112.334 0.494 . . . . 0.0 112.334 -174.101 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 161.32 146.23 4.57 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 119.764 -1.208 . . . . 0.0 114.053 174.788 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 8.8 m -98.57 109.75 22.46 Favored 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 175.113 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 59.7 m-85 -115.36 158.53 22.3 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.806 0.336 . . . . 0.0 110.801 -174.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 14.3 p80 -118.9 114.57 22.8 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 121.312 0.577 . . . . 0.0 110.022 174.241 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.492 HD11 ' HA ' ' A' ' 38' ' ' ALA . 3.5 mm? -107.33 148.59 28.84 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-N 115.297 -0.865 . . . . 0.0 111.247 -173.449 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 40.3 ttmt -98.77 130.31 45.22 Favored 'General case' 0 C--N 1.321 -0.664 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 173.941 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.523 HG21 HG21 ' A' ' 69' ' ' ILE . 15.1 p -71.05 129.69 39.61 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-O 121.0 0.429 . . . . 0.0 110.558 176.43 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -81.9 178.4 53.64 Favored Glycine 0 N--CA 1.434 -1.457 0 N-CA-C 110.936 -0.865 . . . . 0.0 110.936 -179.776 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.401 ' HG3' ' H ' ' A' ' 90' ' ' ARG . 0.3 OUTLIER -86.88 -53.57 4.83 Favored 'General case' 0 C--N 1.309 -1.155 0 C-N-CA 120.801 -0.36 . . . . 0.0 110.869 -179.92 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' ASN . . . . . . . . . . . . . 26.4 p30 176.03 159.38 0.43 Allowed Pre-proline 0 C--N 1.329 -0.283 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 179.754 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 8.2 Cg_exo -72.69 -74.79 0.01 OUTLIER 'Trans proline' 0 N--CA 1.46 -0.456 0 C-N-CA 122.17 1.913 . . . . 0.0 111.313 175.017 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 5.6 m120 -138.6 -34.66 0.61 Allowed 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.745 177.536 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 3.4 m-20 -77.96 166.23 23.11 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.966 -179.669 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 3.4 p -69.11 110.12 4.37 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 115.877 -0.601 . . . . 0.0 111.994 -177.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 49.7 m -159.39 167.06 29.72 Favored 'General case' 0 C--O 1.234 0.25 0 CA-C-N 115.962 -0.563 . . . . 0.0 109.859 178.366 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -147.13 149.11 32.37 Favored 'General case' 0 N--CA 1.453 -0.291 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 176.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . 53.01 73.44 0.36 Allowed 'General case' 0 N--CA 1.467 0.409 0 O-C-N 123.574 0.546 . . . . 0.0 110.124 -177.56 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 46.4 t80 -120.83 128.35 52.77 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.86 -0.609 . . . . 0.0 111.411 -167.129 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 46.4 tpp -108.06 120.24 41.76 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 173.868 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -86.52 57.17 4.72 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.788 -0.72 . . . . 0.0 114.124 -170.79 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.605 HG22 HG23 ' A' ' 32' ' ' VAL . 2.6 pp -143.82 148.92 18.32 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 N-CA-C 109.488 -0.56 . . . . 0.0 109.488 173.066 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . 0.635 ' HB2' ' HB3' ' A' ' 30' ' ' ASP . 43.4 mtp180 -90.87 143.34 26.82 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 116.376 -0.374 . . . . 0.0 110.264 176.749 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 2.1 p -115.82 143.4 45.45 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-O 121.063 0.458 . . . . 0.0 110.962 178.924 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 37.3 t -136.3 169.57 17.44 Favored 'General case' 0 C--N 1.317 -0.832 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 177.931 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 5.4 p30 -105.49 37.1 2.3 Favored 'General case' 0 C--N 1.31 -1.109 0 CA-C-O 122.031 0.919 . . . . 0.0 109.692 178.701 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 20.9 t-80 -80.32 92.44 5.78 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 114.884 -1.053 . . . . 0.0 109.926 175.766 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . 0.409 HD11 ' O ' ' A' ' 24' ' ' PRO . 31.8 mt -77.09 -164.68 0.47 Allowed 'General case' 0 C--N 1.325 -0.499 0 CA-C-O 121.768 0.794 . . . . 0.0 110.713 179.111 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 85.7 mtm180 -89.17 95.77 10.44 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-N 114.897 -1.047 . . . . 0.0 110.096 178.933 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 43.3 t -67.87 130.06 32.84 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.124 -179.883 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' ARG . . . . . 0.423 HH11 ' HD3' ' A' ' 111' ' ' ARG . 18.6 ptt-85 -120.96 2.51 10.49 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.203 -175.377 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 32.6 t70 -178.91 161.52 1.2 Allowed 'General case' 0 C--N 1.327 -0.395 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 177.907 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 42.3 m -69.0 90.37 0.44 Allowed 'General case' 0 C--N 1.318 -0.782 0 CA-C-O 120.885 0.374 . . . . 0.0 110.16 177.598 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 28.3 m -82.84 142.13 14.0 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 CA-C-N 116.101 -0.499 . . . . 0.0 111.824 -176.237 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . 59.33 -85.3 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 115.235 -0.893 . . . . 0.0 112.418 178.452 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 13.5 p -165.01 99.3 0.75 Allowed 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 116.157 -0.474 . . . . 0.0 109.939 -178.574 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 7.3 m -108.14 88.76 1.18 Allowed 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-O 121.762 0.791 . . . . 0.0 111.279 -179.43 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 94.9 mt -120.62 -41.88 2.56 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.331 -0.85 . . . . 0.0 109.678 177.901 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 115.58 140.71 7.14 Favored Glycine 0 N--CA 1.447 -0.605 0 CA-C-N 115.734 -0.666 . . . . 0.0 112.178 178.988 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 15.4 m-20 -76.51 105.68 7.71 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 110.162 -0.31 . . . . 0.0 110.162 177.312 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 17.0 p -69.05 107.32 3.11 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 121.093 0.473 . . . . 0.0 110.361 177.172 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 85.7 mt -73.52 145.43 84.91 Favored Pre-proline 0 C--N 1.323 -0.574 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.028 -177.52 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 7.2 Cg_endo -49.4 115.55 1.82 Allowed 'Trans proline' 0 C--N 1.345 0.368 0 C-N-CA 123.213 2.609 . . . . 0.0 112.253 -178.393 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 60.1 t80 -115.71 95.2 5.02 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.963 -0.562 . . . . 0.0 109.527 179.36 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.976 0 CA-C-O 118.123 -0.942 . . . . 0.0 110.116 -179.63 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . . . . . . . . . 22.4 mp0 . . . . . 0 CA--C 1.539 0.524 0 CA-C-O 120.649 0.261 . . . . 0.0 111.42 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -80.37 172.6 13.41 Favored 'Trans proline' 0 N--CA 1.461 -0.441 0 C-N-CA 122.088 1.859 . . . . 0.0 111.643 173.046 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.404 ' HA ' ' HB3' ' A' ' 57' ' ' SER . 12.1 t70 69.64 39.4 1.54 Allowed 'General case' 0 N--CA 1.467 0.404 0 CA-C-O 121.901 0.858 . . . . 0.0 110.12 179.939 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 173.7 140.89 3.35 Favored Glycine 0 N--CA 1.446 -0.662 0 CA-C-N 114.792 -1.094 . . . . 0.0 111.266 177.139 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 28.8 m -120.76 146.4 25.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 116.819 0.309 . . . . 0.0 110.319 179.279 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . 0.406 ' HB2' HE21 ' A' ' 28' ' ' GLN . 0.0 OUTLIER -123.0 159.45 28.33 Favored 'General case' 0 C--N 1.322 -0.594 0 C-N-CA 120.503 -0.479 . . . . 0.0 110.997 -178.722 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 56.5 mt -81.7 106.14 12.4 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 115.907 -0.588 . . . . 0.0 109.949 179.641 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 14.8 t70 -68.03 -63.78 0.99 Allowed 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 116.054 -0.521 . . . . 0.0 109.88 -177.568 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 2.2 p -155.41 140.47 17.4 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.912 -0.586 . . . . 0.0 111.829 -177.312 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.659 HG22 HG22 ' A' ' 102' ' ' ILE . 96.5 t -86.91 126.45 40.84 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 116.208 -0.451 . . . . 0.0 109.819 177.89 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 5.6 m -103.38 129.19 25.94 Favored Pre-proline 0 N--CA 1.451 -0.419 0 CA-C-O 121.117 0.484 . . . . 0.0 111.863 -175.659 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -69.3 164.25 34.81 Favored 'Trans proline' 0 C--O 1.235 0.331 0 C-N-CA 122.743 2.295 . . . . 0.0 112.048 176.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 98.12 -34.13 5.46 Favored Glycine 0 N--CA 1.449 -0.436 0 N-CA-C 110.661 -0.976 . . . . 0.0 110.661 -174.605 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.414 ' HB2' ' HD2' ' A' ' 37' ' ' PRO . 0.7 OUTLIER -104.84 169.86 6.66 Favored Pre-proline 0 C--N 1.317 -0.835 0 CA-C-N 114.721 -0.74 . . . . 0.0 109.569 175.347 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . 0.414 ' HD2' ' HB2' ' A' ' 36' ' ' SER . 42.3 Cg_endo -68.59 -170.26 0.31 Allowed 'Trans proline' 0 CA--C 1.534 0.492 0 C-N-CA 122.264 1.976 . . . . 0.0 112.74 177.827 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 74.53 6.19 4.53 Favored 'General case' 0 N--CA 1.471 0.577 0 C-N-CA 123.575 0.75 . . . . 0.0 112.343 179.733 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 23.1 t -52.35 -62.18 1.8 Allowed 'General case' 0 C--O 1.233 0.232 0 O-C-N 123.448 0.467 . . . . 0.0 110.608 -179.712 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 3.3 tmtp? -111.24 65.37 0.62 Allowed 'General case' 0 C--N 1.327 -0.374 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 172.328 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.415 HG12 HD12 ' A' ' 42' ' ' LEU . 36.5 t -137.94 -49.77 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.41 0 CA-C-N 115.382 -0.826 . . . . 0.0 109.292 175.793 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.415 HD12 HG12 ' A' ' 41' ' ' VAL . 6.3 mp -119.58 171.49 8.33 Favored 'General case' 0 C--O 1.234 0.262 0 CA-C-N 115.625 -0.716 . . . . 0.0 109.88 176.079 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 7.3 p -126.65 146.58 57.47 Favored Pre-proline 0 C--N 1.322 -0.612 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.487 177.474 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 76.9 Cg_endo -76.95 157.03 34.62 Favored 'Trans proline' 0 C--O 1.233 0.246 0 C-N-CA 122.549 2.166 . . . . 0.0 111.975 178.402 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 90.62 11.71 61.84 Favored Glycine 0 N--CA 1.451 -0.364 0 C-N-CA 120.58 -0.819 . . . . 0.0 112.697 179.063 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 64.7 mt -103.47 164.36 11.7 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 116.809 0.304 . . . . 0.0 110.207 178.042 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 48.1 t -105.98 137.66 35.0 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.55 0 N-CA-C 110.315 -0.254 . . . . 0.0 110.315 176.307 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 60.3 mt -95.72 129.78 45.35 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 121.097 0.475 . . . . 0.0 110.846 -178.411 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 22.3 tt0 -86.66 -56.02 3.6 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.635 -0.711 . . . . 0.0 110.198 175.612 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.603 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 13.7 p -148.99 152.49 36.4 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.243 -0.889 . . . . 0.0 112.067 -170.556 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 49.7 mm -111.41 85.44 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.043 -0.98 . . . . 0.0 109.742 176.315 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' ASN . . . . . 0.629 ' HB2' ' H ' ' A' ' 76' ' ' ASN . 62.3 t30 54.72 78.88 0.16 Allowed 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 114.843 -1.072 . . . . 0.0 111.949 176.727 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 83.37 -49.06 4.16 Favored Glycine 0 N--CA 1.447 -0.579 0 CA-C-N 115.541 -0.754 . . . . 0.0 112.459 178.976 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 58.4 mtm -85.56 111.78 39.64 Favored Pre-proline 0 C--N 1.324 -0.521 0 N-CA-C 110.387 -0.227 . . . . 0.0 110.387 -179.718 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.603 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 70.6 Cg_endo -75.1 134.04 17.16 Favored 'Trans proline' 0 N--CA 1.458 -0.577 0 C-N-CA 122.054 1.836 . . . . 0.0 111.833 178.921 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 24.5 p -109.34 93.37 4.47 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-O 121.47 0.652 . . . . 0.0 111.547 -175.497 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . 0.404 ' HB3' ' HA ' ' A' ' 25' ' ' ASP . 19.3 m -99.74 -14.31 18.92 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 115.229 -0.896 . . . . 0.0 110.155 177.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 52.7 m-80 -125.98 159.27 33.1 Favored 'General case' 0 C--N 1.319 -0.74 0 C-N-CA 120.502 -0.479 . . . . 0.0 109.887 -179.268 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 96.6 mt -70.74 -28.29 64.59 Favored 'General case' 0 N--CA 1.44 -0.954 0 CA-C-N 115.734 -0.666 . . . . 0.0 109.387 177.144 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 5.1 m -69.54 -48.92 58.8 Favored 'General case' 0 N--CA 1.448 -0.565 0 CA-C-N 115.254 -0.884 . . . . 0.0 110.629 178.557 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 1.7 p -67.42 -34.37 77.08 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-O 120.77 0.319 . . . . 0.0 111.042 178.095 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 25.8 t80 -62.54 -40.11 95.77 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.308 0.575 . . . . 0.0 109.618 175.381 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . 0.525 ' O ' ' HG3' ' A' ' 67' ' ' LYS . 8.1 t -67.33 -45.13 77.32 Favored 'General case' 0 N--CA 1.452 -0.37 0 CA-C-N 115.459 -0.791 . . . . 0.0 110.36 178.576 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -60.02 -38.35 82.45 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.808 -0.633 . . . . 0.0 110.811 -179.217 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . 0.51 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -65.11 -46.0 82.84 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.377 -179.49 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 2.3 tt -58.58 -42.3 87.72 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.756 -0.657 . . . . 0.0 110.544 -179.413 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . 0.525 ' HG3' ' O ' ' A' ' 63' ' ' SER . 96.0 mttt -63.33 -23.51 67.45 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 115.566 -0.743 . . . . 0.0 112.483 -177.102 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 77.5 p -90.9 -13.07 34.3 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.779 0.323 . . . . 0.0 111.35 -179.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.584 HG21 HG21 ' A' ' 88' ' ' THR . 45.9 mm -72.68 136.42 25.62 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-O 121.174 0.511 . . . . 0.0 111.265 -176.789 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . 0.423 ' HB2' ' HB2' ' A' ' 73' ' ' GLU . 4.4 m -82.45 143.99 30.77 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.84 -0.618 . . . . 0.0 109.588 174.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 16.8 t -71.72 115.83 12.53 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.63 0 CA-C-N 116.372 -0.377 . . . . 0.0 110.467 -177.074 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . 0.441 ' HA2' ' O ' ' A' ' 88' ' ' THR . . . 98.27 4.88 57.31 Favored Glycine 0 N--CA 1.447 -0.63 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.076 179.71 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.423 ' HB2' ' HB2' ' A' ' 70' ' ' SER . 9.0 tp10 -90.68 154.96 19.18 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-O 120.715 0.293 . . . . 0.0 110.27 -178.087 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 49.0 t -94.32 118.73 40.97 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.58 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.582 -178.486 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 32.5 pt -103.01 167.7 2.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.728 178.728 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . 0.629 ' H ' ' HB2' ' A' ' 52' ' ' ASN . 43.3 t30 -120.06 106.56 12.11 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.883 -172.283 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 57.6 mt -105.49 109.32 27.41 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.808 0 CA-C-O 121.328 0.585 . . . . 0.0 110.769 -174.675 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 31.1 m -89.72 114.78 26.5 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.494 -0.775 . . . . 0.0 109.72 176.485 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 69.4 p -112.55 174.15 6.03 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 110.29 -0.263 . . . . 0.0 110.29 179.02 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 12.4 t70 -63.27 -30.36 71.51 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 116.108 -0.496 . . . . 0.0 111.342 178.244 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 8.2 tp-100 -95.64 14.57 22.57 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.333 0.587 . . . . 0.0 110.891 -176.345 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 127.36 179.67 15.94 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.776 -0.726 . . . . 0.0 112.53 176.941 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 55.6 m -109.92 129.45 55.65 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-O 120.696 0.284 . . . . 0.0 110.561 -178.329 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 23.5 m-85 -128.43 152.42 48.23 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 -179.607 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 7.8 p-80 -109.24 133.21 53.33 Favored 'General case' 0 C--N 1.322 -0.621 0 C-N-CA 120.62 -0.432 . . . . 0.0 110.011 174.041 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.484 HD23 ' N ' ' A' ' 87' ' ' LYS . 5.5 tt -118.97 137.53 53.43 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 115.918 -0.583 . . . . 0.0 109.734 -175.085 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.484 ' N ' HD23 ' A' ' 86' ' ' LEU . 62.1 tttp -98.41 117.05 31.95 Favored 'General case' 0 C--N 1.311 -1.1 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 179.049 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.584 HG21 HG21 ' A' ' 69' ' ' ILE . 16.9 p -66.95 135.41 53.75 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 121.152 0.501 . . . . 0.0 111.154 -176.465 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -99.66 -157.64 28.63 Favored Glycine 0 N--CA 1.439 -1.155 0 N-CA-C 111.004 -0.838 . . . . 0.0 111.004 177.03 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 5.7 mpt_? -116.62 177.95 4.51 Favored 'General case' 0 C--N 1.319 -0.735 0 N-CA-C 109.716 -0.475 . . . . 0.0 109.716 177.535 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' ASN . . . . . 0.424 ' HA ' ' HD3' ' A' ' 92' ' ' PRO . 47.4 t-20 -75.28 114.57 36.88 Favored Pre-proline 0 C--N 1.322 -0.587 0 N-CA-C 107.531 -1.285 . . . . 0.0 107.531 169.85 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.424 ' HD3' ' HA ' ' A' ' 91' ' ' ASN . 36.5 Cg_exo -59.67 -19.57 53.88 Favored 'Trans proline' 0 C--O 1.233 0.237 0 C-N-CA 122.887 2.391 . . . . 0.0 112.834 -172.638 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 27.7 t-20 -112.91 -49.11 2.95 Favored 'General case' 0 C--N 1.322 -0.622 0 N-CA-C 112.245 0.461 . . . . 0.0 112.245 -176.749 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 4.8 t-20 -111.7 -154.31 0.54 Allowed 'General case' 0 CA--C 1.535 0.373 0 C-N-CA 120.952 -0.299 . . . . 0.0 111.301 -171.551 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 25.4 m -52.27 138.3 26.76 Favored 'General case' 0 CA--C 1.53 0.186 0 C-N-CA 123.622 0.769 . . . . 0.0 112.527 -174.463 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 1.7 m -68.69 98.22 0.88 Allowed 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.479 -0.782 . . . . 0.0 112.037 -175.758 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 1.5 tpt180 -106.41 152.61 23.38 Favored 'General case' 0 C--N 1.315 -0.904 0 N-CA-C 109.191 -0.67 . . . . 0.0 109.191 174.248 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -64.98 95.3 0.15 Allowed 'General case' 0 C--N 1.331 -0.224 0 N-CA-C 109.851 -0.426 . . . . 0.0 109.851 174.953 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 46.4 t80 -112.11 128.8 56.32 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 121.304 0.573 . . . . 0.0 111.887 -171.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 20.6 ptp -94.17 141.59 28.38 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.523 -0.762 . . . . 0.0 109.277 174.565 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -84.52 37.15 2.92 Favored Glycine 0 CA--C 1.519 0.319 0 C-N-CA 121.099 -0.572 . . . . 0.0 114.2 -170.836 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.659 HG22 HG22 ' A' ' 32' ' ' VAL . 33.6 pt -138.24 154.06 27.45 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.437 0 CA-C-N 117.204 0.502 . . . . 0.0 110.481 178.095 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 55.7 mtp180 -93.66 117.11 29.66 Favored 'General case' 0 C--N 1.318 -0.788 0 N-CA-C 108.336 -0.987 . . . . 0.0 108.336 171.476 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -111.03 137.18 48.99 Favored 'General case' 0 C--N 1.317 -0.844 0 CA-C-O 121.344 0.592 . . . . 0.0 110.624 -178.017 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 19.1 m -156.97 164.24 38.23 Favored 'General case' 0 C--N 1.31 -1.115 0 CA-C-N 115.543 -0.753 . . . . 0.0 109.462 -178.866 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 14.9 p30 -80.14 -10.55 59.77 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 169.008 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 6.0 t60 47.1 70.72 0.38 Allowed 'General case' 0 C--O 1.231 0.13 0 CA-C-N 114.035 -1.439 . . . . 0.0 111.296 -179.258 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 95.1 mt -108.75 -173.84 2.37 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.477 177.69 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 89.1 mtt180 60.95 105.22 0.02 OUTLIER 'General case' 0 N--CA 1.467 0.404 0 O-C-N 124.37 1.044 . . . . 0.0 112.391 179.287 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 57.4 t -101.67 128.62 53.93 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.678 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.824 175.918 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' ARG . . . . . . . . . . . . . 98.5 mtt180 -116.61 140.55 49.27 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.131 -178.766 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 19.5 t70 -115.86 93.41 4.24 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.912 -0.586 . . . . 0.0 109.497 176.43 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 58.6 m -155.16 134.38 12.38 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.597 -179.919 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 26.9 m -113.16 160.87 12.49 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 173.498 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -68.37 95.24 0.59 Allowed 'General case' 0 C--N 1.324 -0.541 0 CA-C-O 121.2 0.524 . . . . 0.0 110.495 -178.414 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 13.4 m -105.79 19.5 20.45 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.782 -175.769 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.433 ' HA ' ' OD1' ' A' ' 120' ' ' ASP . 4.8 m -78.46 89.5 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 CA-C-O 121.674 0.75 . . . . 0.0 110.618 179.793 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 60.9 mt -122.84 -77.08 0.59 Allowed 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.508 -0.769 . . . . 0.0 110.175 -175.757 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -122.94 32.49 4.39 Favored Glycine 0 N--CA 1.451 -0.366 0 N-CA-C 111.105 -0.798 . . . . 0.0 111.105 177.829 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' ASP . . . . . 0.625 ' OD2' ' HG ' ' A' ' 122' ' ' LEU . 3.1 p-10 -72.17 -34.53 68.54 Favored 'General case' 0 C--N 1.324 -0.51 0 C-N-CA 123.006 0.522 . . . . 0.0 111.756 -176.579 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' THR . . . . . 0.531 ' O ' ' HD3' ' A' ' 123' ' ' PRO . 36.6 p 49.19 77.93 0.1 Allowed 'General case' 0 N--CA 1.464 0.226 0 O-C-N 123.744 0.652 . . . . 0.0 111.537 -176.617 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . 0.625 ' HG ' ' OD2' ' A' ' 120' ' ' ASP . 93.7 mt -92.61 106.35 18.2 Favored Pre-proline 0 C--N 1.327 -0.407 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.01 -179.855 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . 0.531 ' HD3' ' O ' ' A' ' 121' ' ' THR . 9.3 Cg_endo -89.53 153.37 5.3 Favored 'Trans proline' 0 N--CA 1.456 -0.727 0 C-N-CA 123.098 2.532 . . . . 0.0 111.659 175.632 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 70.7 t80 -136.63 111.04 8.49 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.559 -0.291 . . . . 0.0 110.332 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.253 1.252 0 O-C-N 123.873 0.733 . . . . 0.0 111.228 179.636 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.444 ' HA ' ' HD3' ' A' ' 24' ' ' PRO . 25.9 tp60 . . . . . 0 N--CA 1.454 -0.234 0 N-CA-C 109.475 -0.565 . . . . 0.0 109.475 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.444 ' HD3' ' HA ' ' A' ' 23' ' ' GLN . 4.0 Cg_exo -78.62 115.23 3.6 Favored 'Trans proline' 0 C--O 1.234 0.292 0 C-N-CA 123.051 2.501 . . . . 0.0 112.438 178.176 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.43 ' OD2' ' HA ' ' A' ' 108' ' ' LEU . 17.0 p-10 -137.3 -35.23 0.69 Allowed 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.23 -178.655 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.414 ' HA2' ' HA ' ' A' ' 57' ' ' SER . . . 134.53 162.94 10.05 Favored Glycine 0 N--CA 1.445 -0.73 0 N-CA-C 111.587 -0.605 . . . . 0.0 111.587 -179.255 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.496 HG23 ' HB ' ' A' ' 48' ' ' ILE . 15.3 m -99.73 134.37 39.32 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.735 0 CA-C-O 121.13 0.491 . . . . 0.0 110.957 176.942 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 6.6 tp60 -97.58 133.5 42.06 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.786 -176.577 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.605 ' HB ' ' H ' ' A' ' 46' ' ' LEU . 36.7 mm -72.65 112.66 8.89 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-N 115.706 -0.679 . . . . 0.0 109.773 173.155 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 16.7 t70 -76.15 -69.75 0.48 Allowed 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.09 -179.289 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 7.7 p -148.96 142.66 25.54 Favored 'General case' 0 N--CA 1.447 -0.594 0 CA-C-O 121.398 0.618 . . . . 0.0 111.553 -178.203 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.524 HG11 ' HA ' ' A' ' 39' ' ' SER . 61.4 t -98.55 119.35 46.43 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-N 114.96 -1.018 . . . . 0.0 109.185 173.945 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.503 HG12 ' O ' ' A' ' 101' ' ' GLY . 10.9 p -91.69 131.85 34.74 Favored Pre-proline 0 C--N 1.324 -0.527 0 CA-C-O 120.776 0.322 . . . . 0.0 110.294 -178.329 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -58.34 147.23 86.11 Favored 'Trans proline' 0 C--N 1.344 0.328 0 C-N-CA 122.816 2.344 . . . . 0.0 112.226 -179.469 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 91.64 24.74 25.01 Favored Glycine 0 N--CA 1.448 -0.526 0 C-N-CA 120.759 -0.734 . . . . 0.0 111.82 -177.374 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.544 ' CB ' ' HA3' ' A' ' 101' ' ' GLY . 61.3 p -125.85 157.35 69.32 Favored Pre-proline 0 C--N 1.325 -0.49 0 N-CA-C 110.155 -0.313 . . . . 0.0 110.155 -179.934 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 29.5 Cg_endo -64.07 -30.77 65.97 Favored 'Trans proline' 0 C--N 1.344 0.308 0 C-N-CA 122.424 2.082 . . . . 0.0 112.099 176.901 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.531 ' HB2' HD11 ' A' ' 86' ' ' LEU . . . -80.15 -13.52 59.19 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.436 -177.894 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.524 ' HA ' HG11 ' A' ' 32' ' ' VAL . 22.9 t -61.46 -27.95 68.94 Favored 'General case' 0 CA--C 1.532 0.283 0 N-CA-C 112.249 0.463 . . . . 0.0 112.249 -174.468 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 52.2 mtmt -103.18 -13.81 16.63 Favored 'General case' 0 C--N 1.326 -0.44 0 C-N-CA 120.88 -0.328 . . . . 0.0 111.645 -176.334 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.459 ' HB ' HD12 ' A' ' 42' ' ' LEU . 35.3 t -103.92 -38.73 5.22 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.477 0 CA-C-N 116.565 -0.289 . . . . 0.0 111.519 -174.319 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.459 HD12 ' HB ' ' A' ' 41' ' ' VAL . 6.5 mp -113.8 168.59 9.66 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.131 0.491 . . . . 0.0 111.119 -177.213 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 7.4 p -129.75 156.4 78.93 Favored Pre-proline 0 C--N 1.321 -0.643 0 CA-C-N 115.612 -0.722 . . . . 0.0 110.026 177.17 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 60.7 Cg_endo -73.56 154.13 49.79 Favored 'Trans proline' 0 N--CA 1.463 -0.273 0 C-N-CA 122.285 1.99 . . . . 0.0 112.368 179.641 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 81.89 28.78 40.73 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.891 -0.671 . . . . 0.0 113.323 177.551 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.641 HD22 ' HB2' ' A' ' 81' ' ' GLN . 53.6 mt -109.2 162.01 14.69 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 117.066 0.433 . . . . 0.0 110.519 176.214 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 62.1 t -110.99 130.2 64.84 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 N-CA-C 110.035 -0.357 . . . . 0.0 110.035 178.227 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.552 HD11 HD11 ' A' ' 29' ' ' ILE . 76.7 mt -89.66 121.19 39.56 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-O 121.042 0.449 . . . . 0.0 110.894 -179.573 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 10.6 tt0 -77.32 -57.0 4.07 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-N 115.403 -0.817 . . . . 0.0 110.06 176.208 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.628 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 14.7 p -146.8 152.82 39.38 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.194 -0.912 . . . . 0.0 111.988 -172.126 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 42.9 mm -111.91 97.15 5.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.262 176.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' ASN . . . . . 0.548 ' HA ' ' HB3' ' A' ' 76' ' ' ASN . 6.5 t30 67.43 -80.78 0.03 OUTLIER 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 114.884 -1.053 . . . . 0.0 111.905 174.262 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -126.73 3.39 7.52 Favored Glycine 0 N--CA 1.45 -0.425 0 C-N-CA 120.581 -0.819 . . . . 0.0 112.103 179.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 54.5 mtm -131.39 117.61 16.78 Favored Pre-proline 0 C--N 1.325 -0.488 0 N-CA-C 110.393 -0.225 . . . . 0.0 110.393 -177.73 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.628 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 56.0 Cg_endo -71.26 130.8 18.05 Favored 'Trans proline' 0 N--CA 1.463 -0.313 0 C-N-CA 122.325 2.017 . . . . 0.0 112.073 178.72 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 25.6 p -108.63 94.63 5.16 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-O 121.24 0.543 . . . . 0.0 111.269 -176.47 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . 0.414 ' HA ' ' HA2' ' A' ' 26' ' ' GLY . 5.5 m -95.55 -12.72 25.27 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 115.574 -0.739 . . . . 0.0 111.118 -177.828 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 6.9 t-20 -129.58 166.78 19.03 Favored 'General case' 0 C--N 1.321 -0.671 0 C-N-CA 120.597 -0.441 . . . . 0.0 109.92 176.769 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.499 ' HB2' ' HB2' ' A' ' 106' ' ' ASN . 0.4 OUTLIER -77.09 -36.45 55.68 Favored 'General case' 0 C--N 1.311 -1.098 0 CA-C-N 115.495 -0.775 . . . . 0.0 109.617 -179.011 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 6.3 m -68.09 -39.09 82.94 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.702 179.621 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 8.0 p -72.23 -37.43 69.18 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.111 0.481 . . . . 0.0 110.456 177.338 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 72.2 t80 -61.04 -43.72 98.47 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.239 175.232 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 4.7 t -65.3 -38.98 91.89 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.745 -0.661 . . . . 0.0 110.396 178.744 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -65.89 -33.91 76.93 Favored 'General case' 0 C--O 1.232 0.153 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.881 179.709 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -71.98 -45.16 62.03 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.253 178.499 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.412 HD23 ' HA ' ' A' ' 66' ' ' LEU . 8.2 mt -62.09 -33.42 74.4 Favored 'General case' 0 N--CA 1.448 -0.527 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.245 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 37.0 ttmt -59.26 -21.98 60.45 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.869 -0.605 . . . . 0.0 111.519 -179.92 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 61.0 p -100.73 -13.88 18.29 Favored 'General case' 0 C--N 1.329 -0.311 0 N-CA-C 112.234 0.457 . . . . 0.0 112.234 -176.543 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 45.6 mm -74.5 138.01 21.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.974 0.416 . . . . 0.0 110.557 -176.773 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 7.8 m -104.03 172.92 6.54 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.262 -0.426 . . . . 0.0 111.611 -174.433 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.516 HG21 ' HB3' ' A' ' 96' ' ' SER . 61.3 t -82.94 136.42 22.87 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.139 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.532 177.924 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 87.64 -8.59 76.97 Favored Glycine 0 N--CA 1.448 -0.516 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 -177.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 23.3 tt0 -80.73 145.77 31.37 Favored 'General case' 0 N--CA 1.445 -0.682 0 CA-C-N 114.916 -0.642 . . . . 0.0 109.679 -177.088 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.466 HG22 ' HG3' ' A' ' 87' ' ' LYS . 39.6 t -113.49 116.85 53.79 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.811 0 CA-C-N 115.984 -0.553 . . . . 0.0 109.994 -176.839 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 16.4 pt -106.15 153.49 7.52 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.684 0 CA-C-O 121.481 0.658 . . . . 0.0 111.532 -178.739 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . 0.548 ' HB3' ' HA ' ' A' ' 52' ' ' ASN . 15.1 t30 -101.81 104.73 15.51 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 114.881 -1.054 . . . . 0.0 110.219 -178.042 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 52.6 mt -105.1 105.46 18.67 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.883 0 CA-C-O 121.191 0.52 . . . . 0.0 111.001 -174.314 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . 0.516 ' HA ' ' HA ' ' A' ' 83' ' ' THR . 35.2 m -85.65 120.48 27.13 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.863 -0.608 . . . . 0.0 109.369 175.062 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 70.7 p -121.37 175.12 6.32 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 120.918 0.39 . . . . 0.0 111.148 -178.038 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -62.42 -18.55 61.94 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.544 -0.753 . . . . 0.0 111.101 176.011 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . 0.641 ' HB2' HD22 ' A' ' 46' ' ' LEU . 7.3 tp-100 -102.84 4.42 37.74 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-O 121.147 0.498 . . . . 0.0 111.142 -177.419 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 128.74 175.88 14.23 Favored Glycine 0 N--CA 1.449 -0.472 0 C-N-CA 120.57 -0.824 . . . . 0.0 112.623 179.438 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.516 ' HA ' ' HA ' ' A' ' 78' ' ' THR . 20.0 m -96.78 109.14 21.87 Favored 'General case' 0 C--N 1.322 -0.627 0 CA-C-O 120.71 0.29 . . . . 0.0 110.819 -178.455 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 89.6 m-85 -107.1 169.81 8.33 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 120.973 0.416 . . . . 0.0 110.622 -178.205 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 7.4 p80 -129.57 126.91 39.59 Favored 'General case' 0 C--N 1.321 -0.633 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 175.96 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.531 HD11 ' HB2' ' A' ' 38' ' ' ALA . 4.2 tt -117.89 138.71 51.94 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.113 0.482 . . . . 0.0 110.512 -174.002 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.494 ' N ' HD23 ' A' ' 86' ' ' LEU . 60.5 tttp -116.71 121.02 40.43 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.535 -0.757 . . . . 0.0 109.354 179.831 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 29.6 p -71.57 139.42 49.41 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 120.733 0.302 . . . . 0.0 111.072 -178.844 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -134.22 16.05 4.44 Favored Glycine 0 CA--C 1.511 -0.198 0 C-N-CA 120.782 -0.723 . . . . 0.0 112.558 -174.744 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.469 ' HB2' ' CB ' ' A' ' 99' ' ' TYR . 29.2 tpt180 -62.75 111.89 2.3 Favored 'General case' 0 C--N 1.316 -0.873 0 CA-C-N 115.303 -0.448 . . . . 0.0 111.898 -177.384 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' ASN . . . . . . . . . . . . . 28.7 t-20 -148.18 92.45 4.6 Favored Pre-proline 0 C--N 1.324 -0.528 0 CA-C-O 120.95 0.405 . . . . 0.0 110.611 175.107 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 4.1 Cg_exo -81.14 -72.1 0.01 OUTLIER 'Trans proline' 0 N--CA 1.457 -0.653 0 C-N-CA 122.842 2.362 . . . . 0.0 111.06 173.988 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 35.9 m-20 -149.37 -63.44 0.22 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.67 -0.695 . . . . 0.0 110.28 176.084 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 20.0 m120 -120.3 -72.04 0.71 Allowed 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.826 -178.599 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 11.6 t -60.05 105.82 0.44 Allowed 'General case' 0 C--O 1.234 0.257 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.423 -178.124 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.516 ' HB3' HG21 ' A' ' 71' ' ' VAL . 15.3 m -127.74 122.9 34.03 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 115.87 -0.605 . . . . 0.0 110.983 -176.941 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 77.5 mtt-85 -129.06 178.3 6.51 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.245 -0.65 . . . . 0.0 109.245 174.259 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -68.19 109.3 3.5 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 120.573 0.225 . . . . 0.0 111.018 -178.518 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . 0.469 ' CB ' ' HB2' ' A' ' 90' ' ' ARG . 4.1 t80 -121.28 126.97 50.84 Favored 'General case' 0 C--N 1.327 -0.373 0 N-CA-C 109.522 -0.548 . . . . 0.0 109.522 179.451 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' MET . . . . . 0.429 ' O ' ' HB2' ' A' ' 36' ' ' SER . 63.4 mtm -105.94 -33.22 8.0 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 116.461 -0.336 . . . . 0.0 111.135 -175.819 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . 0.544 ' HA3' ' CB ' ' A' ' 36' ' ' SER . . . 94.6 27.1 11.97 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.582 -0.818 . . . . 0.0 111.907 179.228 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.473 HG22 ' HA ' ' A' ' 32' ' ' VAL . 2.7 pp -136.01 150.43 28.21 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.501 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 178.339 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 4.1 mpt_? -104.18 139.44 39.22 Favored 'General case' 0 C--N 1.318 -0.772 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 175.566 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.9 p -117.63 161.44 19.64 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.8 179.156 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 66.8 m -143.95 161.95 37.41 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.334 175.857 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . 0.499 ' HB2' ' HB2' ' A' ' 59' ' ' LEU . 2.5 t-20 -106.38 61.38 0.64 Allowed 'General case' 0 C--N 1.309 -1.178 0 N-CA-C 107.563 -1.273 . . . . 0.0 107.563 174.286 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 7.6 t-80 -83.49 75.88 9.98 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 114.658 -1.156 . . . . 0.0 109.642 -177.104 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . 0.434 ' CD2' ' HB3' ' A' ' 23' ' ' GLN . 3.7 mp -59.84 153.32 21.09 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.327 -0.851 . . . . 0.0 111.27 -177.371 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . 0.422 HH11 ' HD3' ' A' ' 109' ' ' ARG . 35.9 ttt180 -66.48 99.84 0.61 Allowed 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.048 -0.978 . . . . 0.0 109.511 176.301 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 13.9 p -63.64 146.13 13.2 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-N 115.904 -0.589 . . . . 0.0 111.388 -176.302 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' ARG . . . . . . . . . . . . . 71.3 ttt180 -133.33 144.52 49.7 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.905 -0.589 . . . . 0.0 110.127 -178.11 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 60.4 m-20 67.55 81.61 0.19 Allowed 'General case' 0 N--CA 1.467 0.388 0 O-C-N 123.951 0.782 . . . . 0.0 110.843 -177.59 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 14.8 m -106.61 90.85 3.46 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.348 -0.842 . . . . 0.0 109.441 177.662 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 34.2 m -91.86 133.06 34.57 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.151 -176.622 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -83.81 98.6 9.81 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.814 -0.63 . . . . 0.0 109.901 175.949 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 25.7 t -117.96 101.5 8.32 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.19 -178.756 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 48.5 t -110.8 112.03 38.78 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-N 116.091 -0.504 . . . . 0.0 109.845 179.61 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 88.0 mt -88.64 -64.94 1.07 Allowed 'General case' 0 C--N 1.323 -0.561 0 CA-C-N 116.48 -0.327 . . . . 0.0 110.433 -178.446 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . 0.42 ' O ' ' HB2' ' A' ' 120' ' ' ASP . . . 97.73 93.33 1.93 Allowed Glycine 0 N--CA 1.446 -0.658 0 C-N-CA 120.609 -0.805 . . . . 0.0 112.82 178.002 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' ASP . . . . . 0.42 ' HB2' ' O ' ' A' ' 119' ' ' GLY . 3.1 m-20 75.02 152.48 0.13 Allowed 'General case' 0 N--CA 1.468 0.449 0 CA-C-O 122.003 0.906 . . . . 0.0 112.821 175.385 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 1.7 p -119.58 101.5 7.97 Favored 'General case' 0 C--N 1.32 -0.696 0 CA-C-N 114.887 -1.051 . . . . 0.0 109.865 175.81 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 88.0 mt -112.89 100.49 51.15 Favored Pre-proline 0 C--N 1.326 -0.418 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.762 -175.787 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 87.5 Cg_endo -89.82 164.43 5.03 Favored 'Trans proline' 0 N--CA 1.453 -0.861 0 C-N-CA 122.844 2.362 . . . . 0.0 112.321 178.12 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 73.2 m-85 -115.53 166.83 11.47 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.284 175.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.107 0 CA-C-O 118.653 -0.689 . . . . 0.0 110.424 -178.333 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.451 ' HA ' ' HD3' ' A' ' 24' ' ' PRO . 13.8 pt20 . . . . . 0 C--O 1.236 0.378 0 CA-C-O 120.538 0.209 . . . . 0.0 110.795 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.451 ' HD3' ' HA ' ' A' ' 23' ' ' GLN . 9.0 Cg_exo -72.41 169.54 21.46 Favored 'Trans proline' 0 C--O 1.235 0.348 0 C-N-CA 123.156 2.571 . . . . 0.0 111.591 177.64 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 21.2 t70 -173.64 -41.66 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 121.232 0.539 . . . . 0.0 110.726 -176.473 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.569 ' HA2' ' HA ' ' A' ' 57' ' ' SER . . . 171.27 164.43 26.94 Favored Glycine 0 N--CA 1.442 -0.913 0 CA-C-N 115.263 -0.88 . . . . 0.0 111.188 -178.829 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 33.9 m -109.15 150.8 11.68 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.866 0 CA-C-O 120.768 0.318 . . . . 0.0 110.368 178.076 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . 0.406 HE21 ' HB2' ' A' ' 28' ' ' GLN . 0.0 OUTLIER -117.82 163.03 17.14 Favored 'General case' 0 C--N 1.32 -0.702 0 C-N-CA 120.751 -0.379 . . . . 0.0 110.45 176.937 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.565 HD12 ' HB2' ' A' ' 46' ' ' LEU . 56.6 mt -78.73 107.44 11.04 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-O 120.959 0.409 . . . . 0.0 110.273 -178.409 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.632 ' HB3' ' HB2' ' A' ' 103' ' ' ARG . 14.9 t70 -65.67 -70.6 0.23 Allowed 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 115.185 -0.916 . . . . 0.0 110.638 -176.068 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.474 ' HA ' ' HB3' ' A' ' 44' ' ' PRO . 4.2 p -148.59 144.87 27.54 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.596 -0.729 . . . . 0.0 111.128 -178.566 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.546 ' HA ' HG22 ' A' ' 102' ' ' ILE . 96.2 t -94.86 126.54 47.26 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.207 178.606 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 48.4 t -109.0 123.87 35.76 Favored Pre-proline 0 C--N 1.327 -0.379 0 CA-C-N 116.461 -0.336 . . . . 0.0 110.631 179.767 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -58.97 154.39 45.08 Favored 'Trans proline' 0 C--N 1.345 0.347 0 C-N-CA 122.972 2.448 . . . . 0.0 112.175 178.1 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 104.26 6.91 41.38 Favored Glycine 0 N--CA 1.45 -0.4 0 N-CA-C 110.849 -0.9 . . . . 0.0 110.849 -175.397 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.539 ' CB ' ' HA3' ' A' ' 101' ' ' GLY . 60.4 p -130.16 159.17 71.64 Favored Pre-proline 0 C--N 1.322 -0.623 0 CA-C-N 115.185 -0.508 . . . . 0.0 110.054 -179.457 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_exo -66.89 -23.2 47.75 Favored 'Trans proline' 0 N--CA 1.463 -0.27 0 C-N-CA 122.359 2.039 . . . . 0.0 111.669 176.142 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -73.56 -16.77 61.25 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.914 -0.585 . . . . 0.0 111.365 -177.5 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 14.2 m -65.27 -16.84 63.99 Favored 'General case' 0 C--O 1.233 0.192 0 CA-C-O 120.904 0.383 . . . . 0.0 111.051 -179.708 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 35.5 ttpt -116.89 11.42 14.4 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.1 -177.769 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 58.5 t -126.96 -47.99 1.39 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-N 116.221 -0.445 . . . . 0.0 111.377 -177.427 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 87.1 mt -108.22 161.3 15.12 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.245 0.545 . . . . 0.0 111.412 -175.644 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 15.4 p -126.82 146.38 57.08 Favored Pre-proline 0 C--N 1.319 -0.746 0 CA-C-N 115.022 -0.99 . . . . 0.0 109.844 176.803 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.474 ' HB3' ' HA ' ' A' ' 31' ' ' SER . 53.8 Cg_endo -70.47 149.96 63.18 Favored 'Trans proline' 0 N--CA 1.461 -0.384 0 C-N-CA 122.09 1.86 . . . . 0.0 111.937 -178.064 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 99.23 -13.54 61.63 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.752 -0.737 . . . . 0.0 112.832 179.65 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.565 ' HB2' HD12 ' A' ' 29' ' ' ILE . 82.0 mt -72.92 164.45 26.63 Favored 'General case' 0 C--N 1.327 -0.386 0 O-C-N 122.672 -0.31 . . . . 0.0 110.684 179.694 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 42.1 t -115.28 139.95 39.12 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.575 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.191 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 65.0 mt -97.83 125.87 50.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 121.181 0.515 . . . . 0.0 110.347 -179.482 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -91.02 -42.52 10.48 Favored 'General case' 0 C--N 1.318 -0.78 0 CA-C-N 115.834 -0.621 . . . . 0.0 109.894 179.955 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . . . . . . . . . 37.0 p -159.37 153.77 24.0 Favored 'General case' 0 CA--C 1.512 -0.51 0 CA-C-O 120.976 0.417 . . . . 0.0 110.621 178.825 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.793 HG13 HG12 ' A' ' 77' ' ' ILE . 10.8 tt -127.4 123.72 62.33 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.771 0 CA-C-N 115.582 -0.735 . . . . 0.0 109.126 174.821 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 2.3 t-20 58.61 -151.85 0.41 Allowed 'General case' 0 C--N 1.323 -0.561 0 N-CA-C 108.922 -0.769 . . . . 0.0 108.922 -177.528 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -81.0 12.7 35.33 Favored Glycine 0 CA--C 1.525 0.681 0 C-N-CA 120.394 -0.908 . . . . 0.0 113.002 177.739 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 2.6 mpp? -124.43 107.26 29.76 Favored Pre-proline 0 C--N 1.333 -0.121 0 CA-C-N 117.227 0.513 . . . . 0.0 111.154 -178.183 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 41.1 Cg_endo -70.34 121.22 7.79 Favored 'Trans proline' 0 N--CA 1.458 -0.598 0 C-N-CA 121.691 1.594 . . . . 0.0 111.457 174.297 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.402 ' O ' ' HA2' ' A' ' 26' ' ' GLY . 20.3 p -97.92 110.17 22.79 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.939 -0.573 . . . . 0.0 111.884 -174.047 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . 0.569 ' HA ' ' HA2' ' A' ' 26' ' ' GLY . 15.5 m -98.2 -18.96 18.16 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.921 -0.582 . . . . 0.0 111.118 179.831 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . 0.412 ' HB2' ' H ' ' A' ' 61' ' ' THR . 5.3 m120 -115.47 166.33 12.01 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 -179.127 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 39.2 mt -75.8 -34.45 60.17 Favored 'General case' 0 N--CA 1.447 -0.582 0 CA-C-O 121.035 0.445 . . . . 0.0 109.955 171.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 7.9 m -72.22 -40.5 67.76 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.646 -0.706 . . . . 0.0 111.34 -178.514 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . 0.412 ' H ' ' HB2' ' A' ' 58' ' ' ASN . 3.2 p -67.76 -32.16 72.56 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.006 0.431 . . . . 0.0 110.425 177.443 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 51.3 t80 -66.74 -39.78 88.06 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 121.313 0.577 . . . . 0.0 109.497 173.66 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 69.0 m -63.62 -47.52 81.05 Favored 'General case' 0 N--CA 1.447 -0.6 0 CA-C-N 115.485 -0.779 . . . . 0.0 111.348 177.889 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.42 -35.71 78.31 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.619 177.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . 0.526 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -68.17 -41.9 80.82 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.474 178.835 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 6.7 mt -62.32 -33.88 75.54 Favored 'General case' 0 N--CA 1.447 -0.6 0 CA-C-N 115.722 -0.672 . . . . 0.0 111.136 178.273 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 40.4 ttmt -60.16 -37.26 79.61 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.868 179.161 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 3.6 p -82.26 -11.81 58.43 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 112.345 0.498 . . . . 0.0 112.345 -179.067 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.526 HG12 ' O ' ' A' ' 65' ' ' ALA . 45.8 mm -79.98 137.68 21.18 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 N-CA-C 110.055 -0.35 . . . . 0.0 110.055 178.313 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 19.1 t -103.36 176.91 4.99 Favored 'General case' 0 C--N 1.328 -0.348 0 N-CA-C 110.108 -0.33 . . . . 0.0 110.108 -179.886 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.469 HG22 ' H ' ' A' ' 98' ' ' ALA . 46.3 t -90.52 125.92 43.33 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.74 -177.653 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 99.93 -0.32 56.32 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.931 -0.652 . . . . 0.0 111.945 179.419 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 35.4 tt0 -90.24 147.31 23.62 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 179.82 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 39.9 t -106.01 104.34 16.85 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.116 -178.614 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.5 HD12 HD11 ' A' ' 51' ' ' ILE . 15.8 pt -96.08 154.7 3.5 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 121.363 0.602 . . . . 0.0 111.296 -175.916 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 5.5 t30 -91.13 136.6 32.98 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.631 -179.117 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.793 HG12 HG13 ' A' ' 51' ' ' ILE . 60.1 mt -135.46 108.79 9.63 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-O 121.057 0.456 . . . . 0.0 110.232 178.485 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 4.3 m -84.85 130.17 34.7 Favored 'General case' 0 C--N 1.32 -0.709 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 176.371 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 76.0 p -126.49 175.77 7.66 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 121.267 0.556 . . . . 0.0 111.978 -176.204 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 25.2 t70 -49.76 -42.82 47.32 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 114.625 -1.17 . . . . 0.0 112.74 -178.756 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 22.9 mt-30 -117.93 23.67 11.51 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 112.555 0.576 . . . . 0.0 112.555 -172.291 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 152.31 -178.63 29.4 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 119.771 -1.204 . . . . 0.0 112.929 175.828 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 22.2 m -114.74 126.84 55.32 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-O 120.892 0.377 . . . . 0.0 110.129 179.376 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 99.5 m-85 -121.02 161.33 21.83 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 120.938 0.399 . . . . 0.0 110.696 -178.348 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 44.6 m-70 -125.37 123.93 40.42 Favored 'General case' 0 C--N 1.321 -0.661 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 176.181 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.541 HD23 HD12 ' A' ' 77' ' ' ILE . 3.8 mm? -113.72 140.92 47.86 Favored 'General case' 0 C--N 1.314 -0.937 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.395 -173.886 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 88.2 tttt -105.14 124.35 49.38 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 115.63 -0.714 . . . . 0.0 109.488 177.467 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 17.8 p -69.92 132.02 45.32 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-O 121.379 0.609 . . . . 0.0 112.038 -176.66 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -104.16 -156.72 23.92 Favored Glycine 0 N--CA 1.445 -0.757 0 CA-C-N 115.433 -0.803 . . . . 0.0 111.418 177.41 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.442 ' HD3' ' N ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -154.04 114.79 4.01 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.238 0.542 . . . . 0.0 111.135 -178.418 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' ASN . . . . . . . . . . . . . 8.5 t30 -154.32 97.59 2.58 Favored Pre-proline 0 C--N 1.322 -0.61 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.175 178.328 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.607 ' HA ' ' HB2' ' A' ' 96' ' ' SER . 87.1 Cg_endo -85.76 129.62 3.56 Favored 'Trans proline' 0 N--CA 1.456 -0.702 0 C-N-CA 122.597 2.198 . . . . 0.0 113.951 -173.695 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 9.6 t30 -90.38 -43.93 9.99 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.611 -0.722 . . . . 0.0 109.064 172.112 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -123.12 -57.65 1.68 Allowed 'General case' 0 C--N 1.323 -0.545 0 N-CA-C 108.52 -0.919 . . . . 0.0 108.52 171.228 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 19.4 t -159.08 83.27 0.79 Allowed 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 107.858 -1.164 . . . . 0.0 107.858 172.309 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.607 ' HB2' ' HA ' ' A' ' 92' ' ' PRO . 1.9 m -111.27 113.02 25.2 Favored 'General case' 0 C--N 1.321 -0.665 0 CA-C-N 115.33 -0.85 . . . . 0.0 110.801 -171.637 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -118.76 151.62 37.69 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.698 -0.683 . . . . 0.0 109.382 178.3 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . 0.469 ' H ' HG22 ' A' ' 71' ' ' VAL . . . 59.3 71.43 0.58 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 121.743 0.782 . . . . 0.0 109.681 -172.183 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 80.3 t80 -96.36 102.04 13.77 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.611 -170.541 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 81.1 mtp -72.31 -43.22 64.49 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.16 176.469 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . 0.539 ' HA3' ' CB ' ' A' ' 36' ' ' SER . . . 101.56 -12.59 58.18 Favored Glycine 0 N--CA 1.451 -0.323 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.802 176.477 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.546 HG22 ' HA ' ' A' ' 32' ' ' VAL . 2.7 pp -114.89 144.73 21.81 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.694 0 CA-C-O 120.851 0.358 . . . . 0.0 110.322 179.241 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . 0.632 ' HB2' ' HB3' ' A' ' 30' ' ' ASP . 39.3 mtp180 -84.46 147.58 27.01 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.179 178.321 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 14.2 p -124.63 122.1 36.58 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.555 177.331 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 19.3 m -127.59 154.84 44.73 Favored 'General case' 0 C--N 1.318 -0.799 0 N-CA-C 109.165 -0.68 . . . . 0.0 109.165 178.35 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 16.0 p30 -80.22 -21.84 42.44 Favored 'General case' 0 C--N 1.314 -0.958 0 CA-C-O 121.09 0.472 . . . . 0.0 110.018 177.195 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 9.8 t-80 43.16 55.44 4.6 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-N 114.749 -1.114 . . . . 0.0 110.968 -176.829 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 79.7 mt -71.46 -176.41 1.53 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 121.685 0.755 . . . . 0.0 112.411 -175.993 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . 0.415 ' HD3' HH11 ' A' ' 109' ' ' ARG . 43.6 ttt-85 -66.86 117.14 8.55 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 114.587 -1.188 . . . . 0.0 110.668 -177.865 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . 0.414 HG13 ' HG2' ' A' ' 111' ' ' ARG . 12.2 p -82.74 157.21 3.88 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.559 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.53 -178.575 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' ARG . . . . . 0.414 ' HG2' HG13 ' A' ' 110' ' ' VAL . 6.5 ptp180 49.38 103.12 0.01 OUTLIER 'General case' 0 N--CA 1.478 0.926 0 C-N-CA 125.067 1.347 . . . . 0.0 114.423 177.49 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 23.5 t70 -124.79 97.91 5.48 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.487 -0.779 . . . . 0.0 109.527 170.377 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 49.2 m 50.72 78.74 0.1 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.556 -0.747 . . . . 0.0 112.4 179.899 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 27.2 m -85.8 151.81 3.65 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.454 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.841 177.232 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . 0.4 ' HB1' HG12 ' A' ' 117' ' ' VAL . . . -90.51 140.42 29.75 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 121.029 0.442 . . . . 0.0 111.125 -178.565 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 15.4 m -103.07 16.74 25.82 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-O 121.339 0.59 . . . . 0.0 110.398 179.347 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.4 HG12 ' HB1' ' A' ' 115' ' ' ALA . 7.8 p -108.07 141.12 24.14 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.832 0 CA-C-N 115.323 -0.853 . . . . 0.0 109.708 179.875 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 92.9 mt -92.67 -67.09 0.88 Allowed 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 120.651 0.262 . . . . 0.0 110.69 -179.385 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 77.35 -131.49 11.22 Favored Glycine 0 N--CA 1.446 -0.678 0 C-N-CA 120.538 -0.839 . . . . 0.0 111.92 -177.579 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 15.9 m-20 -137.26 160.28 39.47 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.786 0.326 . . . . 0.0 110.644 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 13.2 t -131.98 140.36 48.94 Favored 'General case' 0 C--N 1.321 -0.671 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 174.922 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . 0.458 ' HA ' ' HD3' ' A' ' 123' ' ' PRO . 87.6 mt -106.07 123.14 40.03 Favored Pre-proline 0 C--N 1.323 -0.553 0 CA-C-N 116.6 -0.273 . . . . 0.0 110.867 -177.468 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . 0.458 ' HD3' ' HA ' ' A' ' 122' ' ' LEU . 12.7 Cg_exo -69.99 150.43 66.79 Favored 'Trans proline' 0 N--CA 1.462 -0.373 0 C-N-CA 122.878 2.385 . . . . 0.0 111.478 176.956 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 97.0 m-85 -80.34 116.91 20.66 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.408 0.623 . . . . 0.0 110.998 -175.546 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.246 0.878 0 CA-C-N 115.539 -0.755 . . . . 0.0 110.026 -178.876 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . . . . . . . . . 34.2 mt-30 . . . . . 0 N--CA 1.455 -0.219 0 N-CA-C 110.073 -0.344 . . . . 0.0 110.073 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.765 ' HB3' ' HB2' ' A' ' 58' ' ' ASN . 80.3 Cg_endo -81.76 163.42 18.58 Favored 'Trans proline' 0 C--O 1.238 0.48 0 C-N-CA 123.016 2.477 . . . . 0.0 113.797 -174.703 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 18.6 t70 -167.28 -39.02 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.172 -0.922 . . . . 0.0 109.628 175.273 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.507 ' HA2' ' HA ' ' A' ' 57' ' ' SER . . . 165.21 165.58 22.76 Favored Glycine 0 N--CA 1.447 -0.6 0 N-CA-C 110.574 -1.011 . . . . 0.0 110.574 -177.851 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.621 HG12 HD22 ' A' ' 106' ' ' ASN . 33.6 m -122.54 151.06 26.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-N 117.44 0.62 . . . . 0.0 110.739 178.675 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . 0.516 ' OE1' ' HB2' ' A' ' 105' ' ' SER . 0.0 OUTLIER -128.19 163.9 23.68 Favored 'General case' 0 C--N 1.324 -0.531 0 C-N-CA 120.703 -0.399 . . . . 0.0 110.767 177.139 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 57.2 mt -90.96 115.7 30.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.951 -176.165 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.753 ' HB3' ' HB2' ' A' ' 103' ' ' ARG . 23.7 t70 -66.65 -58.96 4.06 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.417 0.627 . . . . 0.0 109.873 176.005 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.467 ' HA ' ' HB3' ' A' ' 44' ' ' PRO . 12.4 p -165.19 162.05 19.77 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 115.22 -0.9 . . . . 0.0 110.204 -178.938 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.622 HG11 ' HA ' ' A' ' 39' ' ' SER . 45.3 t -98.24 138.25 23.45 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 N-CA-C 109.527 -0.545 . . . . 0.0 109.527 177.565 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.599 HG12 ' H ' ' A' ' 35' ' ' GLY . 45.7 t -85.89 118.9 71.35 Favored Pre-proline 0 C--N 1.323 -0.563 0 CA-C-N 116.453 -0.339 . . . . 0.0 110.809 -176.351 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 34.7 Cg_endo -65.46 -12.94 37.29 Favored 'Trans proline' 0 C--N 1.344 0.324 0 C-N-CA 122.866 2.377 . . . . 0.0 112.825 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.599 ' H ' HG12 ' A' ' 33' ' ' VAL . . . -95.19 23.02 35.34 Favored Glycine 0 N--CA 1.449 -0.45 0 C-N-CA 120.897 -0.668 . . . . 0.0 111.545 177.935 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.676 ' HB3' ' HD2' ' A' ' 37' ' ' PRO . 54.1 m -149.36 170.9 6.95 Favored Pre-proline 0 C--N 1.325 -0.458 0 N-CA-C 109.845 -0.428 . . . . 0.0 109.845 -179.033 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . 0.676 ' HD2' ' HB3' ' A' ' 36' ' ' SER . 56.4 Cg_endo -71.13 -168.26 0.32 Allowed 'Trans proline' 0 C--N 1.349 0.555 0 C-N-CA 122.331 2.021 . . . . 0.0 112.443 177.199 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.472 ' HB1' HD13 ' A' ' 42' ' ' LEU . . . 68.78 -9.71 0.54 Allowed 'General case' 0 N--CA 1.47 0.567 0 N-CA-C 113.017 0.747 . . . . 0.0 113.017 176.63 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.622 ' HA ' HG11 ' A' ' 32' ' ' VAL . 27.8 t -70.08 -6.84 36.66 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.741 0.305 . . . . 0.0 111.293 -177.75 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -118.79 12.68 13.03 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 121.003 0.43 . . . . 0.0 110.391 177.103 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.478 ' HB ' HD12 ' A' ' 42' ' ' LEU . 46.8 t -120.76 -55.6 3.33 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.25 -0.432 . . . . 0.0 111.234 -176.987 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.478 HD12 ' HB ' ' A' ' 41' ' ' VAL . 6.0 mp -96.1 171.49 8.57 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.036 0.446 . . . . 0.0 111.145 -177.159 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 49.1 m -122.72 127.25 25.84 Favored Pre-proline 0 C--N 1.321 -0.639 0 CA-C-N 115.741 -0.663 . . . . 0.0 109.736 176.834 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.467 ' HB3' ' HA ' ' A' ' 31' ' ' SER . 41.7 Cg_endo -68.3 149.02 75.32 Favored 'Trans proline' 0 N--CA 1.464 -0.245 0 C-N-CA 122.294 1.996 . . . . 0.0 111.939 179.123 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 99.05 -2.93 58.23 Favored Glycine 0 N--CA 1.449 -0.461 0 C-N-CA 120.541 -0.838 . . . . 0.0 112.634 -179.307 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 81.0 mt -90.33 164.2 14.44 Favored 'General case' 0 C--N 1.328 -0.366 0 O-C-N 122.583 -0.363 . . . . 0.0 110.765 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 48.0 t -102.45 139.94 22.15 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.598 0 N-CA-C 110.022 -0.362 . . . . 0.0 110.022 178.255 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.514 ' HB ' HG23 ' A' ' 27' ' ' VAL . 66.1 mt -93.2 121.71 44.11 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.37 0 CA-C-O 121.127 0.489 . . . . 0.0 110.631 -177.601 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 3.4 tm-20 -81.96 -50.8 8.73 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 115.594 -0.73 . . . . 0.0 109.501 178.284 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.572 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 13.6 p -163.94 159.22 20.63 Favored 'General case' 0 C--O 1.236 0.394 0 CA-C-N 116.112 -0.495 . . . . 0.0 111.97 -175.638 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.412 ' HA ' ' O ' ' A' ' 76' ' ' ASN . 61.1 mt -115.96 107.77 23.47 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 115.556 -0.747 . . . . 0.0 110.545 176.259 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' ASN . . . . . 0.595 ' HA ' ' HB3' ' A' ' 76' ' ' ASN . 15.1 t-20 66.86 -81.66 0.03 OUTLIER 'General case' 0 N--CA 1.468 0.464 0 CA-C-N 115.43 -0.805 . . . . 0.0 110.759 178.816 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -133.46 -5.33 2.95 Favored Glycine 0 N--CA 1.446 -0.649 0 C-N-CA 120.882 -0.675 . . . . 0.0 111.782 177.161 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 60.6 mtm -111.74 115.18 51.47 Favored Pre-proline 0 C--N 1.329 -0.325 0 CA-C-O 120.743 0.306 . . . . 0.0 110.429 -177.161 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.572 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 72.9 Cg_endo -78.99 132.45 10.55 Favored 'Trans proline' 0 N--CA 1.454 -0.806 0 C-N-CA 122.273 1.982 . . . . 0.0 112.006 177.428 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 3.3 p -95.06 103.43 15.28 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 121.008 0.432 . . . . 0.0 111.69 -177.841 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . 0.507 ' HA ' ' HA2' ' A' ' 26' ' ' GLY . 32.7 t -93.48 -24.27 18.07 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 115.747 -0.661 . . . . 0.0 110.482 179.41 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . 0.765 ' HB2' ' HB3' ' A' ' 24' ' ' PRO . 8.4 t-20 -133.18 176.08 8.82 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.519 -0.31 . . . . 0.0 110.385 -179.111 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 97.6 mt -81.47 -33.06 32.23 Favored 'General case' 0 N--CA 1.44 -0.965 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.64 -179.003 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 2.6 m -65.08 -43.68 91.38 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.928 0.395 . . . . 0.0 110.841 179.451 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 12.7 t -67.28 -26.7 66.68 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.103 179.881 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 32.6 t80 -68.16 -47.66 67.42 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.9 -0.591 . . . . 0.0 109.989 173.279 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 8.5 t -60.76 -39.93 90.6 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.486 -0.779 . . . . 0.0 110.358 179.675 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -69.7 -31.97 70.3 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.04 -0.527 . . . . 0.0 111.175 178.003 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . 0.627 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -69.24 -46.64 66.85 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.346 178.217 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 6.6 tp -58.08 -38.45 76.4 Favored 'General case' 0 N--CA 1.447 -0.617 0 CA-C-N 115.739 -0.664 . . . . 0.0 110.338 179.164 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 40.4 ttmt -57.66 -38.49 75.17 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.004 -0.998 . . . . 0.0 111.709 178.426 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 17.7 p -86.87 -13.17 45.66 Favored 'General case' 0 C--N 1.329 -0.31 0 N-CA-C 112.615 0.598 . . . . 0.0 112.615 -175.842 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.627 HG12 ' O ' ' A' ' 65' ' ' ALA . 44.4 mm -76.23 140.84 16.59 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 C-N-CA 120.906 -0.317 . . . . 0.0 110.167 -179.537 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . 0.45 ' HB2' ' HB2' ' A' ' 73' ' ' GLU . 4.8 m -94.03 161.26 14.36 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.709 -0.223 . . . . 0.0 110.764 179.357 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.626 HG11 ' HB3' ' A' ' 96' ' ' SER . 2.2 t -82.63 118.37 30.22 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 177.01 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 97.08 8.71 56.56 Favored Glycine 0 N--CA 1.449 -0.485 0 C-N-CA 120.501 -0.857 . . . . 0.0 111.129 -175.477 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.45 ' HB2' ' HB2' ' A' ' 70' ' ' SER . 30.9 tt0 -89.62 145.48 25.22 Favored 'General case' 0 N--CA 1.45 -0.441 0 N-CA-C 109.19 -0.671 . . . . 0.0 109.19 179.563 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 44.4 t -96.2 112.53 28.58 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.022 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.083 -178.865 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 30.8 pt -109.2 154.42 10.62 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-O 121.198 0.523 . . . . 0.0 110.986 -177.926 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . 0.595 ' HB3' ' HA ' ' A' ' 52' ' ' ASN . 35.5 t-20 -109.63 113.11 25.62 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-N 115.127 -0.942 . . . . 0.0 109.901 -176.617 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.446 HD12 HD21 ' A' ' 86' ' ' LEU . 71.7 mt -104.16 103.73 15.69 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.035 0 N-CA-C 109.053 -0.721 . . . . 0.0 109.053 175.878 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 30.7 m -88.99 120.14 30.14 Favored 'General case' 0 C--N 1.312 -1.03 0 CA-C-N 115.387 -0.824 . . . . 0.0 109.524 -179.782 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 73.7 p -106.71 171.35 7.41 Favored 'General case' 0 C--N 1.322 -0.606 0 N-CA-C 110.241 -0.281 . . . . 0.0 110.241 179.705 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 19.8 t70 -62.06 -22.56 65.86 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 121.047 0.451 . . . . 0.0 111.1 -179.819 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 28.7 mt-30 -117.0 17.73 14.85 Favored 'General case' 0 C--N 1.325 -0.497 0 N-CA-C 112.548 0.573 . . . . 0.0 112.548 -172.761 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 151.07 163.99 11.74 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 119.909 -1.138 . . . . 0.0 113.748 177.788 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 4.2 m -107.33 137.18 45.86 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 110.056 -0.35 . . . . 0.0 110.056 -179.57 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 26.5 m-85 -134.87 147.39 49.86 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.717 0.294 . . . . 0.0 110.394 177.9 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 4.2 p-80 -130.66 122.52 27.53 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-O 121.134 0.493 . . . . 0.0 110.086 174.095 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.458 HD23 ' N ' ' A' ' 86' ' ' LEU . 0.9 OUTLIER -130.76 156.87 44.23 Favored 'General case' 0 N--CA 1.444 -0.728 0 CA-C-N 115.571 -0.741 . . . . 0.0 111.115 -173.503 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.452 ' HB3' ' HE2' ' A' ' 87' ' ' LYS . 32.4 ttpt -91.94 132.88 36.17 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.03 177.359 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 32.3 p -73.26 143.44 47.05 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.524 179.688 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -156.8 109.19 0.39 Allowed Glycine 0 N--CA 1.449 -0.464 0 C-N-CA 120.911 -0.662 . . . . 0.0 112.226 177.87 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.654 ' HB3' ' O ' ' A' ' 97' ' ' ARG . 9.0 tpm_? -143.73 97.24 3.03 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-O 120.86 0.362 . . . . 0.0 110.767 -178.878 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' ASN . . . . . . . . . . . . . 28.5 t-20 -109.45 106.9 59.16 Favored Pre-proline 0 C--N 1.321 -0.667 0 CA-C-N 116.255 -0.43 . . . . 0.0 110.183 175.93 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 65.2 Cg_endo -95.33 -154.1 0.04 OUTLIER 'Trans proline' 0 N--CA 1.455 -0.747 0 C-N-CA 123.307 2.671 . . . . 0.0 111.74 177.592 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 7.0 t30 -85.58 41.43 0.9 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 121.922 0.868 . . . . 0.0 109.613 177.591 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 4.9 t-20 -171.14 -158.68 0.15 Allowed 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 115.163 -0.926 . . . . 0.0 108.535 -178.539 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 30.3 m -65.53 146.62 54.62 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-O 120.909 0.385 . . . . 0.0 110.077 177.97 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.626 ' HB3' HG11 ' A' ' 71' ' ' VAL . 50.9 m -68.96 147.26 51.88 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 116.053 -0.521 . . . . 0.0 111.402 -176.179 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . 0.654 ' O ' ' HB3' ' A' ' 90' ' ' ARG . 84.7 mtt180 -126.03 176.88 6.7 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.926 -0.579 . . . . 0.0 109.958 176.719 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -92.42 109.74 21.14 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.798 0.333 . . . . 0.0 111.148 -178.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . 0.582 ' HB3' ' HB2' ' A' ' 90' ' ' ARG . 6.0 t80 -146.17 134.4 21.72 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 178.493 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -94.08 -31.34 14.24 Favored 'General case' 0 C--N 1.326 -0.45 0 C-N-CA 121.2 -0.2 . . . . 0.0 110.933 179.508 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 102.52 45.17 1.71 Allowed Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.285 -0.959 . . . . 0.0 113.811 173.3 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.468 HG22 HG13 ' A' ' 32' ' ' VAL . 32.6 pt -137.69 159.07 34.41 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 CA-C-N 117.278 0.539 . . . . 0.0 110.345 175.058 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . 0.753 ' HB2' ' HB3' ' A' ' 30' ' ' ASP . 97.9 mtt180 -88.93 130.46 35.43 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 109.53 -0.544 . . . . 0.0 109.53 174.444 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 2.6 p -110.62 122.86 48.81 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-O 121.204 0.526 . . . . 0.0 111.022 178.803 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.516 ' HB2' ' OE1' ' A' ' 28' ' ' GLN . 45.7 m -116.23 163.55 15.82 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.799 -0.637 . . . . 0.0 109.79 178.162 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . 0.621 HD22 HG12 ' A' ' 27' ' ' VAL . 0.6 OUTLIER -94.29 -30.49 14.51 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-O 121.072 0.463 . . . . 0.0 109.798 -178.806 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 14.9 t60 44.13 73.31 0.15 Allowed 'General case' 0 N--CA 1.469 0.516 0 CA-C-N 114.881 -1.054 . . . . 0.0 111.741 -176.366 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 81.9 mt -87.38 -173.09 4.22 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.147 0.499 . . . . 0.0 110.997 179.64 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . 0.404 HH11 ' HD3' ' A' ' 109' ' ' ARG . 17.8 ptt-85 -76.42 166.31 23.59 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.219 -0.9 . . . . 0.0 111.027 -178.121 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 8.0 p -89.84 140.72 15.42 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-O 121.093 0.473 . . . . 0.0 111.222 -175.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' ARG . . . . . . . . . . . . . 3.8 tpm_? -122.12 125.93 47.25 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.638 -0.71 . . . . 0.0 109.71 178.101 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 11.3 t70 -119.94 113.91 21.26 Favored 'General case' 0 C--N 1.322 -0.628 0 N-CA-C 109.839 -0.43 . . . . 0.0 109.839 174.823 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 16.8 p -141.63 105.94 4.82 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.279 178.164 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 35.6 m -78.3 151.42 5.27 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.007 179.758 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -151.28 135.29 16.62 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.382 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 17.8 m -105.72 78.54 1.35 Allowed 'General case' 0 C--N 1.32 -0.688 0 CA-C-O 121.14 0.495 . . . . 0.0 110.184 -179.634 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 40.9 t -115.26 112.43 39.87 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.534 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.32 -177.624 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' LEU . . . . . 0.407 HD22 ' N ' ' A' ' 118' ' ' LEU . 3.1 mm? -84.02 -28.43 27.67 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.001 179.182 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 106.36 -28.12 14.65 Favored Glycine 0 N--CA 1.447 -0.618 0 CA-C-N 115.736 -0.665 . . . . 0.0 111.91 177.866 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 10.8 m-20 -101.91 139.41 37.58 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-O 120.937 0.399 . . . . 0.0 111.112 -179.082 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 12.0 t -98.28 139.25 34.33 Favored 'General case' 0 C--N 1.32 -0.689 0 N-CA-C 108.849 -0.797 . . . . 0.0 108.849 170.827 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . 0.41 ' HA ' ' HD2' ' A' ' 123' ' ' PRO . 98.1 mt -95.02 124.75 53.22 Favored Pre-proline 0 C--N 1.321 -0.653 0 N-CA-C 110.212 -0.292 . . . . 0.0 110.212 -177.236 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . 0.41 ' HD2' ' HA ' ' A' ' 122' ' ' LEU . 1.3 Cg_endo -45.28 125.6 7.36 Favored 'Trans proline' 0 C--N 1.346 0.432 0 C-N-CA 123.794 2.996 . . . . 0.0 112.825 -177.612 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 87.8 m-85 -81.27 122.86 27.96 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.564 -177.545 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.245 0.856 0 CA-C-O 118.512 -0.756 . . . . 0.0 110.078 178.99 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.421 ' HA ' ' HD3' ' A' ' 24' ' ' PRO . 50.4 mt-30 . . . . . 0 C--O 1.234 0.253 0 N-CA-C 110.539 -0.171 . . . . 0.0 110.539 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.421 ' HD3' ' HA ' ' A' ' 23' ' ' GLN . 38.8 Cg_exo -61.67 171.59 4.44 Favored 'Trans proline' 0 C--O 1.235 0.356 0 C-N-CA 122.97 2.447 . . . . 0.0 112.5 177.14 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 2.1 p30 -160.24 26.15 0.17 Allowed 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.847 0.832 . . . . 0.0 109.751 -172.834 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 136.2 157.34 7.77 Favored Glycine 0 N--CA 1.442 -0.949 0 CA-C-N 114.91 -1.041 . . . . 0.0 110.824 -176.813 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.64 HG21 ' CD2' ' A' ' 62' ' ' TYR . 35.7 m -114.14 149.92 16.31 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.871 0 CA-C-N 116.913 0.356 . . . . 0.0 110.559 178.909 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . 0.73 ' HG2' ' HB3' ' A' ' 107' ' ' HIS . 0.0 OUTLIER -129.67 154.65 46.93 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 174.951 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.593 HG23 HD11 ' A' ' 48' ' ' ILE . 2.2 pt -83.48 110.18 18.01 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.446 0 CA-C-O 121.673 0.749 . . . . 0.0 111.064 179.168 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -64.01 -59.15 4.84 Favored 'General case' 0 C--N 1.319 -0.761 0 CA-C-N 114.235 -1.348 . . . . 0.0 110.925 -177.616 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 49.0 m -153.51 166.71 31.86 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 115.621 -0.718 . . . . 0.0 111.384 -171.08 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.558 ' HA ' HG22 ' A' ' 102' ' ' ILE . 99.4 t -115.49 134.44 58.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.525 0 CA-C-N 115.694 -0.685 . . . . 0.0 109.689 176.175 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 53.0 t -103.21 107.28 55.01 Favored Pre-proline 0 C--N 1.329 -0.288 0 CA-C-O 120.863 0.363 . . . . 0.0 111.089 -177.256 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -61.5 120.81 8.65 Favored 'Trans proline' 0 C--N 1.345 0.375 0 C-N-CA 122.833 2.355 . . . . 0.0 111.575 178.907 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 126.32 -19.04 6.42 Favored Glycine 0 N--CA 1.447 -0.615 0 N-CA-C 111.011 -0.836 . . . . 0.0 111.011 -175.394 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.694 ' HB3' ' HD2' ' A' ' 37' ' ' PRO . 32.0 m -114.61 169.53 6.52 Favored Pre-proline 0 C--N 1.32 -0.7 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 176.499 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . 0.694 ' HD2' ' HB3' ' A' ' 36' ' ' SER . 21.1 Cg_endo -61.1 173.24 2.53 Favored 'Trans proline' 0 C--N 1.345 0.359 0 C-N-CA 122.487 2.124 . . . . 0.0 112.893 179.139 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . 73.77 -11.29 0.97 Allowed 'General case' 0 N--CA 1.469 0.515 0 CA-C-N 115.541 -0.754 . . . . 0.0 112.403 179.672 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 53.4 m -69.33 2.76 2.69 Favored 'General case' 0 CA--C 1.535 0.377 0 N-CA-C 112.457 0.54 . . . . 0.0 112.457 -177.554 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 50.8 tptt -143.53 19.59 1.86 Allowed 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.43 0.633 . . . . 0.0 109.711 179.168 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 94.1 t -119.91 -63.8 1.76 Allowed 'Isoleucine or valine' 0 C--O 1.237 0.396 0 CA-C-N 115.911 -0.586 . . . . 0.0 111.064 -178.54 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 1.1 pp -97.85 179.85 4.67 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-O 121.542 0.687 . . . . 0.0 112.204 -174.717 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 16.7 p -127.31 130.61 23.7 Favored Pre-proline 0 C--N 1.317 -0.831 0 CA-C-N 114.85 -1.068 . . . . 0.0 110.058 178.319 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.429 ' HB3' HG23 ' A' ' 32' ' ' VAL . 50.1 Cg_endo -67.46 159.04 54.26 Favored 'Trans proline' 0 C--O 1.236 0.404 0 C-N-CA 122.425 2.083 . . . . 0.0 112.277 -177.353 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 93.25 0.85 67.31 Favored Glycine 0 CA--C 1.522 0.495 0 C-N-CA 120.752 -0.737 . . . . 0.0 113.849 178.388 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.533 ' HB2' HD11 ' A' ' 29' ' ' ILE . 91.2 mt -92.14 167.18 12.23 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 117.43 0.615 . . . . 0.0 111.001 -179.582 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 46.7 t -109.17 138.71 35.15 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.478 0 CA-C-N 116.36 -0.382 . . . . 0.0 110.001 178.675 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.593 HD11 HG23 ' A' ' 29' ' ' ILE . 58.5 mt -101.62 133.7 44.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 C-N-CA 122.33 0.252 . . . . 0.0 110.353 -178.429 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 27.4 tt0 -91.67 -48.52 6.78 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.277 177.854 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.618 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 39.6 p -150.24 157.66 43.32 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 113.147 0.795 . . . . 0.0 113.147 -171.883 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.578 HD11 ' CE2' ' A' ' 62' ' ' TYR . 43.7 mt -116.3 117.53 55.79 Favored 'Isoleucine or valine' 0 C--O 1.235 0.34 0 CA-C-N 114.861 -1.063 . . . . 0.0 110.297 174.553 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' ASN . . . . . 0.568 ' HA ' ' HB3' ' A' ' 76' ' ' ASN . 25.4 t-20 65.6 -81.37 0.03 OUTLIER 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 115.744 -0.662 . . . . 0.0 111.417 177.005 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -140.09 1.67 2.25 Favored Glycine 0 N--CA 1.447 -0.583 0 C-N-CA 121.052 -0.594 . . . . 0.0 111.768 177.251 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 59.5 mtm -120.74 123.48 27.98 Favored Pre-proline 0 C--N 1.324 -0.512 0 N-CA-C 109.626 -0.509 . . . . 0.0 109.626 -177.721 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.618 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 72.7 Cg_endo -74.97 143.28 28.97 Favored 'Trans proline' 0 N--CA 1.459 -0.504 0 C-N-CA 122.353 2.035 . . . . 0.0 112.496 -179.125 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 17.8 p -110.79 95.21 5.41 Favored 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 121.226 0.536 . . . . 0.0 111.35 -177.637 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 5.1 p -91.06 -14.2 31.75 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 115.747 -0.66 . . . . 0.0 111.385 -178.881 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 34.2 m-80 -131.06 164.26 25.81 Favored 'General case' 0 C--N 1.318 -0.765 0 N-CA-C 109.698 -0.482 . . . . 0.0 109.698 178.464 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.426 HD23 ' HA ' ' A' ' 59' ' ' LEU . 13.1 mt -77.28 -31.14 54.63 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.215 0.531 . . . . 0.0 109.881 179.0 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 2.6 p -65.18 -45.76 83.57 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.622 -0.717 . . . . 0.0 110.647 173.64 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 4.6 m -56.67 -44.52 81.48 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.49 173.762 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' TYR . . . . . 0.64 ' CD2' HG21 ' A' ' 27' ' ' VAL . 11.6 t80 -60.59 -42.27 96.42 Favored 'General case' 0 CA--C 1.529 0.145 0 CA-C-O 121.508 0.67 . . . . 0.0 109.773 177.705 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 57.9 m -62.21 -47.14 85.78 Favored 'General case' 0 N--CA 1.446 -0.652 0 CA-C-N 115.069 -0.968 . . . . 0.0 111.636 178.139 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.89 -33.39 74.13 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.831 179.369 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . 0.587 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -68.22 -46.99 69.06 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.922 -0.581 . . . . 0.0 109.96 176.5 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 13.7 mt -58.49 -38.45 77.65 Favored 'General case' 0 N--CA 1.448 -0.538 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.894 178.22 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 59.7 mmtt -52.48 -37.69 57.72 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.816 -0.629 . . . . 0.0 112.056 176.744 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 50.1 p -87.77 -13.77 41.43 Favored 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 111.914 0.338 . . . . 0.0 111.914 -176.558 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.587 HG12 ' O ' ' A' ' 65' ' ' ALA . 36.7 mm -81.64 141.98 14.36 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 CA-C-O 120.995 0.426 . . . . 0.0 110.259 -179.067 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 15.4 m -107.22 162.36 13.96 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 116.298 -0.41 . . . . 0.0 110.738 -178.801 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.407 HG22 ' HA ' ' A' ' 98' ' ' ALA . 97.1 t -77.75 126.69 38.3 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.458 0 CA-C-O 120.987 0.422 . . . . 0.0 110.627 -179.143 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 93.4 22.25 27.34 Favored Glycine 0 N--CA 1.447 -0.576 0 N-CA-C 111.216 -0.753 . . . . 0.0 111.216 -176.217 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 14.8 tp10 -109.5 151.97 26.04 Favored 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.262 -0.469 . . . . 0.0 109.847 -179.311 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.405 ' HA ' ' O ' ' A' ' 86' ' ' LEU . 61.1 t -110.98 120.3 61.38 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.752 0 CA-C-N 116.099 -0.5 . . . . 0.0 109.768 179.803 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 23.9 pt -117.05 154.29 18.73 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.026 -178.674 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . 0.568 ' HB3' ' HA ' ' A' ' 52' ' ' ASN . 44.1 t30 -91.05 132.92 35.72 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-N 115.845 -0.616 . . . . 0.0 109.947 -179.66 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 66.3 mt -129.74 109.78 18.61 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-O 121.179 0.514 . . . . 0.0 109.621 178.619 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 25.5 m -95.94 110.27 22.5 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.644 -0.707 . . . . 0.0 109.944 178.647 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.5 HG22 HG12 ' A' ' 48' ' ' ILE . 69.2 p -107.28 175.25 5.56 Favored 'General case' 0 N--CA 1.448 -0.556 0 CA-C-O 120.814 0.34 . . . . 0.0 111.057 -179.105 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 27.6 t70 -45.06 -43.64 9.62 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.058 -0.974 . . . . 0.0 113.383 -175.84 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 32.2 mt-30 -132.86 17.62 4.21 Favored 'General case' 0 C--N 1.33 -0.282 0 N-CA-C 111.989 0.366 . . . . 0.0 111.989 -176.707 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -157.15 123.8 1.34 Allowed Glycine 0 C--N 1.319 -0.384 0 C-N-CA 119.581 -1.295 . . . . 0.0 113.31 -177.012 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 26.0 m -108.99 106.74 16.83 Favored 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 175.535 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 20.7 p90 -133.13 177.39 7.71 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 121.53 0.681 . . . . 0.0 111.59 -174.51 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 4.9 p80 -124.81 127.98 48.01 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-N 114.849 -1.069 . . . . 0.0 110.055 178.863 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.405 ' O ' ' HA ' ' A' ' 74' ' ' VAL . 7.4 tt -106.5 143.6 34.38 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.498 -175.302 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 86.5 tttt -106.79 116.4 31.87 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.447 -0.797 . . . . 0.0 109.392 178.367 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.637 HG21 ' HB1' ' A' ' 98' ' ' ALA . 55.7 p -67.04 136.53 55.39 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 121.231 0.539 . . . . 0.0 111.872 -175.212 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -104.77 -166.38 24.3 Favored Glycine 0 N--CA 1.442 -0.958 0 CA-C-N 115.664 -0.698 . . . . 0.0 112.18 -179.225 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 10.9 mpt_? -86.76 138.51 31.55 Favored 'General case' 0 C--N 1.32 -0.679 0 CA-C-O 120.748 0.309 . . . . 0.0 110.815 -178.586 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' ASN . . . . . . . . . . . . . 16.2 p30 -97.43 153.28 38.43 Favored Pre-proline 0 C--N 1.326 -0.45 0 CA-C-N 115.965 -0.562 . . . . 0.0 110.41 178.456 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_endo -72.37 -63.23 0.04 OUTLIER 'Trans proline' 0 C--N 1.346 0.401 0 C-N-CA 122.272 1.981 . . . . 0.0 112.631 179.413 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 27.1 t-20 -156.29 -51.46 0.08 Allowed 'General case' 0 N--CA 1.45 -0.428 0 CA-C-O 120.892 0.377 . . . . 0.0 110.941 -179.104 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 26.1 p-10 -84.92 -174.06 5.06 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.793 -0.64 . . . . 0.0 111.448 -175.468 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 50.4 m 68.18 178.42 0.24 Allowed 'General case' 0 C--O 1.234 0.282 0 CA-C-N 115.064 -0.971 . . . . 0.0 111.237 -179.84 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 17.9 m -78.27 177.88 8.08 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.97 -177.754 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 24.7 mmt180 -72.08 154.5 41.07 Favored 'General case' 0 C--N 1.326 -0.445 0 N-CA-C 109.785 -0.45 . . . . 0.0 109.785 178.19 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . 0.637 ' HB1' HG21 ' A' ' 88' ' ' THR . . . 69.59 104.69 0.06 Allowed 'General case' 0 N--CA 1.462 0.164 0 O-C-N 124.019 0.824 . . . . 0.0 110.67 -176.826 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . 0.403 ' CE2' ' HA2' ' A' ' 101' ' ' GLY . 27.5 t80 -89.16 114.53 25.82 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.204 0.526 . . . . 0.0 110.452 -173.342 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' MET . . . . . 0.531 ' HG3' ' H ' ' A' ' 102' ' ' ILE . 11.3 ptm -70.47 -30.04 66.74 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-N 115.351 -0.84 . . . . 0.0 111.725 -178.27 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . 0.403 ' HA2' ' CE2' ' A' ' 99' ' ' TYR . . . 86.61 -2.64 87.34 Favored Glycine 0 N--CA 1.453 -0.184 0 C-N-CA 120.991 -0.624 . . . . 0.0 112.918 177.467 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.558 HG22 ' HA ' ' A' ' 32' ' ' VAL . 24.5 pt -132.16 158.31 43.26 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 121.068 0.461 . . . . 0.0 110.695 -177.568 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . 0.429 HH11 ' HD2' ' A' ' 103' ' ' ARG . 18.2 mtp180 -90.36 145.32 25.05 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.796 -0.638 . . . . 0.0 109.591 178.113 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 2.2 p -133.8 151.14 51.48 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 120.708 0.29 . . . . 0.0 111.169 178.397 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 84.1 p -138.49 -174.18 3.75 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 116.113 -0.494 . . . . 0.0 109.787 177.677 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . 0.492 ' OD1' ' HG ' ' A' ' 108' ' ' LEU . 14.0 p30 -106.89 11.89 29.46 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 116.527 -0.306 . . . . 0.0 110.86 -179.557 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . 0.73 ' HB3' ' HG2' ' A' ' 28' ' ' GLN . 7.0 p-80 47.3 40.2 10.12 Favored 'General case' 0 N--CA 1.471 0.609 0 C-N-CA 123.723 0.809 . . . . 0.0 112.615 178.19 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . 0.492 ' HG ' ' OD1' ' A' ' 106' ' ' ASN . 15.4 mt -45.38 134.36 6.76 Favored 'General case' 0 CA--C 1.515 -0.386 0 CA-C-O 122.118 0.961 . . . . 0.0 112.55 -176.055 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 46.2 mtm180 -83.23 94.41 7.88 Favored 'General case' 0 C--N 1.313 -0.992 0 CA-C-N 114.031 -1.441 . . . . 0.0 110.387 -177.5 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 60.9 t -89.16 134.6 28.08 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 CA-C-N 115.015 -0.993 . . . . 0.0 111.292 -177.359 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' ARG . . . . . . . . . . . . . 14.1 ptt180 -158.95 84.42 0.8 Allowed 'General case' 0 C--N 1.323 -0.554 0 CA-C-O 121.691 0.757 . . . . 0.0 110.568 172.54 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 35.7 t70 -161.52 125.81 3.38 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 114.781 -1.099 . . . . 0.0 109.535 179.653 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 36.1 t -137.76 143.02 40.94 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.905 -175.854 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 29.2 m -110.36 170.3 3.36 Favored 'Isoleucine or valine' 0 C--O 1.235 0.33 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.4 176.621 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -135.46 119.83 17.94 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.619 -0.264 . . . . 0.0 110.892 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 49.7 m -155.1 163.18 40.6 Favored 'General case' 0 C--N 1.327 -0.379 0 N-CA-C 110.149 -0.315 . . . . 0.0 110.149 -179.1 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 62.0 t 67.23 102.04 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.333 -0.142 0 O-C-N 123.945 0.778 . . . . 0.0 111.344 -179.695 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 97.7 mt -90.26 -6.92 54.64 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.759 178.833 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 85.98 162.75 36.97 Favored Glycine 0 N--CA 1.449 -0.495 0 C-N-CA 120.826 -0.702 . . . . 0.0 111.412 -175.048 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 8.3 t70 -155.58 140.6 17.35 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.994 0.397 . . . . 0.0 110.328 -179.265 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 2.2 p -123.4 89.57 3.12 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.244 0.545 . . . . 0.0 110.19 175.592 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . 0.499 ' HA ' ' HD3' ' A' ' 123' ' ' PRO . 0.4 OUTLIER -107.56 123.41 38.1 Favored Pre-proline 0 C--N 1.325 -0.466 0 CA-C-N 115.887 -0.597 . . . . 0.0 111.578 -177.602 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . 0.499 ' HD3' ' HA ' ' A' ' 122' ' ' LEU . 4.0 Cg_exo -77.23 159.83 33.08 Favored 'Trans proline' 0 N--CA 1.461 -0.389 0 C-N-CA 122.916 2.411 . . . . 0.0 111.495 175.171 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 52.6 t80 -129.85 111.66 12.81 Favored 'General case' 0 C--N 1.323 -0.573 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 179.308 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.126 0 CA-C-O 118.3 -0.857 . . . . 0.0 110.225 -177.402 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . . . . . . . . . 77.8 mt-30 . . . . . 0 N--CA 1.452 -0.365 0 N-CA-C 110.011 -0.366 . . . . 0.0 110.011 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_endo -69.5 -170.5 0.38 Allowed 'Trans proline' 0 C--O 1.233 0.274 0 C-N-CA 122.724 2.282 . . . . 0.0 112.752 178.901 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.839 ' HA ' ' HB3' ' A' ' 57' ' ' SER . 31.9 t70 75.75 18.9 2.08 Favored 'General case' 0 N--CA 1.468 0.454 0 CA-C-N 115.11 -0.95 . . . . 0.0 109.954 -173.504 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 172.26 151.7 8.04 Favored Glycine 0 N--CA 1.441 -0.967 0 CA-C-N 114.949 -1.023 . . . . 0.0 111.245 176.252 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 28.8 m -137.14 153.88 29.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.358 0 CA-C-O 120.924 0.392 . . . . 0.0 110.94 -177.686 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . 0.489 ' HG3' ' HB3' ' A' ' 105' ' ' SER . 2.0 pt20 -126.02 161.37 27.71 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 110.124 -0.324 . . . . 0.0 110.124 176.314 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.499 HG23 HD12 ' A' ' 102' ' ' ILE . 65.9 mt -75.19 115.58 16.75 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.662 0 N-CA-C 109.009 -0.737 . . . . 0.0 109.009 174.885 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.495 ' HB2' ' HB2' ' A' ' 105' ' ' SER . 22.9 t70 -79.22 -64.77 1.11 Allowed 'General case' 0 C--N 1.317 -0.816 0 CA-C-O 121.014 0.435 . . . . 0.0 110.334 -178.232 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 19.6 m -145.2 153.92 41.86 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.805 -0.634 . . . . 0.0 110.281 -177.685 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.574 HG13 HG22 ' A' ' 102' ' ' ILE . 94.6 t -116.87 131.01 70.78 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.689 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.292 -178.458 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 57.5 t -104.51 124.82 35.83 Favored Pre-proline 0 C--N 1.328 -0.367 0 CA-C-N 116.457 -0.338 . . . . 0.0 110.943 -178.432 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -56.11 151.18 44.08 Favored 'Trans proline' 0 C--N 1.346 0.415 0 C-N-CA 123.068 2.512 . . . . 0.0 112.541 178.222 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 128.5 -16.25 5.96 Favored Glycine 0 N--CA 1.447 -0.578 0 C-N-CA 120.889 -0.672 . . . . 0.0 111.508 -177.906 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 35.9 p -124.89 156.36 68.97 Favored Pre-proline 0 C--N 1.322 -0.63 0 N-CA-C 109.8 -0.444 . . . . 0.0 109.8 177.035 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo -64.9 -15.9 52.72 Favored 'Trans proline' 0 C--N 1.345 0.384 0 C-N-CA 122.342 2.028 . . . . 0.0 111.813 176.829 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -62.74 -23.09 67.02 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.526 -0.761 . . . . 0.0 111.542 -179.103 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.563 ' HA ' HG11 ' A' ' 32' ' ' VAL . 20.2 t -66.8 -22.12 66.02 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.249 -178.363 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 81.5 tttt -107.65 -2.12 20.48 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 121.03 0.443 . . . . 0.0 110.475 -178.679 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 89.9 t -105.23 -48.86 9.25 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.374 0 CA-C-N 115.907 -0.588 . . . . 0.0 110.442 179.286 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 94.8 mt -94.33 174.35 7.18 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.052 -179.257 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . 0.461 ' O ' ' HG ' ' A' ' 46' ' ' LEU . 45.0 m -143.57 131.06 10.77 Favored Pre-proline 0 C--N 1.321 -0.655 0 N-CA-C 110.082 -0.34 . . . . 0.0 110.082 -179.755 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_endo -63.69 142.63 84.2 Favored 'Trans proline' 0 N--CA 1.459 -0.519 0 C-N-CA 122.273 1.982 . . . . 0.0 111.776 178.221 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 94.14 2.64 64.08 Favored Glycine 0 CA--C 1.523 0.548 0 C-N-CA 120.748 -0.739 . . . . 0.0 113.538 -178.546 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.517 HD22 ' HG2' ' A' ' 81' ' ' GLN . 66.0 mt -88.63 164.11 15.5 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-N 117.475 0.638 . . . . 0.0 110.805 179.269 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 48.8 t -108.1 130.13 61.14 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.248 0 CA-C-O 120.511 0.196 . . . . 0.0 110.693 -177.968 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . . . . . . . . . 53.8 mt -98.52 128.29 50.19 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-O 120.937 0.399 . . . . 0.0 110.881 -176.134 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.5 mm-40 -87.68 -48.32 7.97 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.652 176.823 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.496 ' CB ' ' HA ' ' A' ' 55' ' ' PRO . 16.2 p -171.82 161.59 5.92 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-O 121.013 0.435 . . . . 0.0 111.849 -174.838 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.467 HG22 ' H ' ' A' ' 52' ' ' ASN . 27.5 mm -103.67 169.44 2.07 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.464 0 N-CA-C 107.929 -1.137 . . . . 0.0 107.929 173.413 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' ASN . . . . . 0.717 ' HB3' ' HB3' ' A' ' 76' ' ' ASN . 24.0 p-10 -53.97 99.97 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.825 0.821 . . . . 0.0 112.251 -175.996 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 75.72 3.77 74.09 Favored Glycine 0 N--CA 1.447 -0.593 0 CA-C-N 115.352 -0.84 . . . . 0.0 112.695 178.46 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 56.1 mtm -137.32 92.08 13.92 Favored Pre-proline 0 C--N 1.325 -0.467 0 CA-C-O 120.689 0.28 . . . . 0.0 110.504 -176.488 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.496 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 15.8 Cg_exo -66.87 135.28 37.52 Favored 'Trans proline' 0 N--CA 1.46 -0.49 0 C-N-CA 122.311 2.007 . . . . 0.0 111.608 178.606 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.439 HG21 ' CD2' ' A' ' 62' ' ' TYR . 10.9 p -105.24 98.31 8.03 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-O 121.283 0.563 . . . . 0.0 111.731 -175.429 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . 0.839 ' HB3' ' HA ' ' A' ' 25' ' ' ASP . 4.2 m -101.52 -17.16 16.54 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.774 176.284 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 14.3 m120 -127.24 160.89 29.93 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.142 -177.955 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 96.5 mt -77.62 -31.97 53.19 Favored 'General case' 0 N--CA 1.438 -1.044 0 CA-C-N 116.079 -0.51 . . . . 0.0 110.061 177.583 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 84.7 m -70.42 -37.4 74.43 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.749 -0.659 . . . . 0.0 110.928 176.467 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 16.6 p -69.6 -33.3 72.49 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.867 0.365 . . . . 0.0 110.351 178.561 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' TYR . . . . . 0.439 ' CD2' HG21 ' A' ' 56' ' ' THR . 24.8 t80 -61.52 -45.97 91.95 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.444 0.64 . . . . 0.0 109.427 173.438 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 6.3 m -65.55 -42.69 91.62 Favored 'General case' 0 N--CA 1.449 -0.522 0 CA-C-N 115.108 -0.951 . . . . 0.0 112.126 177.75 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.99 -33.74 76.06 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.994 -179.768 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . 0.563 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -69.52 -45.54 68.61 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.047 -0.524 . . . . 0.0 109.807 177.483 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 14.3 mt -55.2 -38.62 68.62 Favored 'General case' 0 N--CA 1.447 -0.615 0 CA-C-N 115.375 -0.829 . . . . 0.0 111.677 179.184 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 28.0 mmmt -57.29 -28.44 63.03 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.832 -0.622 . . . . 0.0 112.49 179.703 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 28.4 p -99.85 -14.05 18.94 Favored 'General case' 0 C--N 1.327 -0.413 0 N-CA-C 112.373 0.508 . . . . 0.0 112.373 -177.544 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.563 HG12 ' O ' ' A' ' 65' ' ' ALA . 49.1 mm -70.63 128.65 34.17 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.38 0 CA-C-O 121.175 0.512 . . . . 0.0 110.622 -176.658 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 16.3 m -80.62 163.49 23.59 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.945 -0.57 . . . . 0.0 111.372 -176.81 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.517 HG11 ' HB3' ' A' ' 90' ' ' ARG . 57.9 t -84.84 127.64 39.69 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 CA-C-N 115.92 -0.582 . . . . 0.0 109.455 175.773 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 88.32 15.12 60.95 Favored Glycine 0 N--CA 1.448 -0.51 0 N-CA-C 110.571 -1.012 . . . . 0.0 110.571 -173.689 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 7.1 tp10 -87.36 148.16 25.16 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 114.952 -0.624 . . . . 0.0 109.321 178.862 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 59.0 t -113.53 102.13 13.46 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.994 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 174.705 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 29.9 pt -97.37 161.9 2.74 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.855 0 CA-C-N 115.674 -0.694 . . . . 0.0 111.29 -174.314 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . 0.717 ' HB3' ' HB3' ' A' ' 52' ' ' ASN . 11.7 t30 -102.17 122.52 44.32 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 115.389 -0.823 . . . . 0.0 109.999 179.292 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 61.8 mt -122.63 103.94 13.92 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 176.687 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . 0.455 ' HA ' ' HA ' ' A' ' 83' ' ' THR . 37.7 m -91.98 114.1 26.55 Favored 'General case' 0 C--N 1.315 -0.922 0 CA-C-N 115.279 -0.873 . . . . 0.0 109.832 179.411 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 69.6 p -102.66 171.86 7.18 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 176.653 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 34.3 t70 -72.8 -14.67 61.57 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 121.63 0.729 . . . . 0.0 109.469 176.095 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . 0.517 ' HG2' HD22 ' A' ' 46' ' ' LEU . 2.7 mp0 -95.37 10.07 37.63 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.302 -0.863 . . . . 0.0 110.652 178.979 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 127.27 164.81 11.76 Favored Glycine 0 CA--C 1.519 0.32 0 C-N-CA 120.804 -0.712 . . . . 0.0 112.902 178.473 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.455 ' HA ' ' HA ' ' A' ' 78' ' ' THR . 28.0 m -90.48 129.86 36.6 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 110.387 -0.227 . . . . 0.0 110.387 177.621 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 60.6 m-85 -128.34 155.45 44.65 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.013 0.435 . . . . 0.0 110.654 179.421 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 38.6 m80 -108.46 136.85 47.4 Favored 'General case' 0 C--N 1.321 -0.674 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 174.553 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . . . . . . . . . 21.2 tp -123.44 138.87 54.5 Favored 'General case' 0 C--N 1.315 -0.899 0 C-N-CA 120.208 -0.597 . . . . 0.0 110.746 -179.782 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 37.0 ttpt -105.67 121.08 43.26 Favored 'General case' 0 C--N 1.313 -0.988 0 CA-C-N 115.316 -0.856 . . . . 0.0 109.139 177.722 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.58 HG21 ' HB1' ' A' ' 98' ' ' ALA . 43.5 p -78.43 128.67 33.94 Favored 'General case' 0 C--N 1.319 -0.755 0 CA-C-O 121.275 0.56 . . . . 0.0 111.508 -176.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -94.24 -171.72 38.32 Favored Glycine 0 N--CA 1.443 -0.836 0 CA-C-N 115.65 -0.705 . . . . 0.0 111.889 -178.674 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.517 ' HB3' HG11 ' A' ' 71' ' ' VAL . 0.0 OUTLIER -128.34 87.52 2.61 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.794 0.807 . . . . 0.0 111.834 -176.529 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' ASN . . . . . . . . . . . . . 39.8 m-80 -135.86 115.43 11.26 Favored Pre-proline 0 C--N 1.32 -0.695 0 CA-C-N 114.984 -1.007 . . . . 0.0 108.816 172.621 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -57.09 146.95 78.31 Favored 'Trans proline' 0 C--O 1.237 0.439 0 C-N-CA 122.453 2.102 . . . . 0.0 112.574 -178.419 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 6.4 t30 -138.29 31.93 2.36 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 -178.679 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 36.9 m-80 64.23 85.12 0.14 Allowed 'General case' 0 C--O 1.236 0.393 0 CA-C-N 114.747 -1.115 . . . . 0.0 109.911 -169.378 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 10.0 t 70.74 -169.5 0.16 Allowed 'General case' 0 C--O 1.234 0.274 0 CA-C-N 114.637 -1.165 . . . . 0.0 109.685 -175.372 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 35.9 m 72.58 151.08 0.11 Allowed 'General case' 0 N--CA 1.465 0.318 0 C-N-CA 123.434 0.694 . . . . 0.0 111.597 -178.363 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 10.2 mpt_? -119.39 166.01 13.6 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.738 -0.665 . . . . 0.0 109.985 178.866 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . 0.58 ' HB1' HG21 ' A' ' 88' ' ' THR . . . 61.01 89.7 0.07 Allowed 'General case' 0 C--O 1.233 0.2 0 O-C-N 123.892 0.745 . . . . 0.0 111.362 177.502 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 51.3 t80 -79.78 97.23 6.54 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 121.173 0.511 . . . . 0.0 111.299 -173.328 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 50.3 ttm -86.5 -58.41 2.63 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-N 115.521 -0.763 . . . . 0.0 109.309 173.626 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 88.27 24.05 35.44 Favored Glycine 0 C--N 1.33 0.23 0 C-N-CA 120.889 -0.672 . . . . 0.0 113.709 171.042 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.574 HG22 HG13 ' A' ' 32' ' ' VAL . 19.0 pt -120.03 145.72 25.9 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.648 0 CA-C-N 117.179 0.49 . . . . 0.0 110.488 177.597 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.72 140.81 29.21 Favored 'General case' 0 C--N 1.319 -0.747 0 N-CA-C 108.974 -0.75 . . . . 0.0 108.974 174.868 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.7 m -109.59 149.0 30.31 Favored 'General case' 0 C--N 1.314 -0.966 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 -179.076 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.495 ' HB2' ' HB2' ' A' ' 30' ' ' ASP . 41.0 t -116.67 172.24 7.36 Favored 'General case' 0 C--N 1.313 -0.994 0 CA-C-N 115.94 -0.573 . . . . 0.0 109.705 -178.3 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . 0.436 HD22 ' HA ' ' A' ' 106' ' ' ASN . 1.1 t-20 -113.67 60.83 0.66 Allowed 'General case' 0 C--N 1.316 -0.872 0 CA-C-O 121.551 0.691 . . . . 0.0 109.53 -172.947 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 1.6 m-70 -117.59 149.49 40.57 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.59 -0.732 . . . . 0.0 111.159 -178.891 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 91.6 mt -92.05 -169.03 2.14 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.49 176.358 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 5.7 ttm180 -83.99 134.85 34.63 Favored 'General case' 0 C--N 1.319 -0.754 0 CA-C-N 115.488 -0.778 . . . . 0.0 110.458 -176.666 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 41.5 t -102.94 133.28 47.17 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.621 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.118 178.817 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' ARG . . . . . 0.416 HH11 ' HD2' ' A' ' 111' ' ' ARG . 49.6 mtm180 -134.72 -172.4 3.02 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.688 -178.316 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -69.76 95.75 0.92 Allowed 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.739 -179.151 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 69.4 m -148.51 27.7 0.9 Allowed 'General case' 0 C--N 1.318 -0.797 0 CA-C-O 121.254 0.55 . . . . 0.0 110.318 175.532 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 2.1 t -106.59 122.43 60.5 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.405 0 CA-C-N 115.782 -0.644 . . . . 0.0 110.608 -178.544 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -138.44 5.59 2.48 Favored 'General case' 0 C--N 1.314 -0.974 0 CA-C-N 115.625 -0.716 . . . . 0.0 109.959 177.323 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 14.5 m -80.0 149.03 30.9 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.951 -178.308 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 35.7 m -73.57 148.63 8.52 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.435 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.093 174.5 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -83.26 -64.88 1.09 Allowed 'General case' 0 C--N 1.323 -0.547 0 CA-C-O 120.75 0.309 . . . . 0.0 111.108 -176.843 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 80.52 2.92 90.0 Favored Glycine 0 N--CA 1.455 -0.088 0 C-N-CA 120.84 -0.695 . . . . 0.0 111.776 -177.071 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER 60.45 93.95 0.04 OUTLIER 'General case' 0 CA--C 1.519 -0.241 0 C-N-CA 123.569 0.747 . . . . 0.0 112.779 -179.447 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 11.4 t -77.6 130.76 37.3 Favored 'General case' 0 C--N 1.321 -0.644 0 N-CA-C 108.148 -1.056 . . . . 0.0 108.148 171.046 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 91.5 mt -112.32 102.63 54.44 Favored Pre-proline 0 C--N 1.32 -0.695 0 CA-C-O 120.823 0.344 . . . . 0.0 111.788 -172.858 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 91.2 Cg_endo -88.33 -168.28 0.36 Allowed 'Trans proline' 0 N--CA 1.454 -0.828 0 C-N-CA 122.784 2.323 . . . . 0.0 110.817 171.515 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 37.4 t80 -94.01 116.96 29.44 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 109.566 -0.531 . . . . 0.0 109.566 177.681 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.052 0 CA-C-O 118.569 -0.729 . . . . 0.0 110.798 -177.55 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . . . . . . . . . 92.4 mt-30 . . . . . 0 N--CA 1.455 -0.213 0 CA-C-O 120.608 0.242 . . . . 0.0 111.322 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.43 ' HB2' ' HA ' ' A' ' 58' ' ' ASN . 5.7 Cg_exo -77.21 154.11 32.24 Favored 'Trans proline' 0 N--CA 1.46 -0.463 0 C-N-CA 123.045 2.497 . . . . 0.0 110.897 171.728 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.405 ' HA ' ' OG ' ' A' ' 57' ' ' SER . 38.9 t70 -167.59 86.08 0.24 Allowed 'General case' 0 C--N 1.326 -0.442 0 CA-C-O 121.185 0.516 . . . . 0.0 111.147 -176.748 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 82.73 122.55 0.75 Allowed Glycine 0 N--CA 1.448 -0.526 0 CA-C-N 115.321 -0.854 . . . . 0.0 112.621 178.913 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 34.9 m -98.09 149.45 5.22 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.881 0 CA-C-O 120.862 0.363 . . . . 0.0 110.583 -179.641 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . 0.48 ' HB2' ' O ' ' A' ' 46' ' ' LEU . 3.7 pt20 -128.97 159.58 35.44 Favored 'General case' 0 C--N 1.318 -0.779 0 C-N-CA 120.558 -0.457 . . . . 0.0 110.868 176.875 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.596 HG23 HD11 ' A' ' 48' ' ' ILE . 0.2 OUTLIER -82.58 111.62 19.22 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.392 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.357 178.42 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 22.8 t70 -71.2 -62.8 1.27 Allowed 'General case' 0 C--N 1.318 -0.784 0 CA-C-N 115.363 -0.835 . . . . 0.0 111.481 -174.978 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 8.4 p -155.31 145.08 21.4 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.756 -0.656 . . . . 0.0 111.681 -176.464 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.568 HG11 ' HA ' ' A' ' 39' ' ' SER . 89.0 t -90.41 132.39 35.16 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.762 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.406 178.964 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.469 ' HA ' ' HD3' ' A' ' 34' ' ' PRO . 17.5 m -107.29 134.07 20.09 Favored Pre-proline 0 N--CA 1.449 -0.524 0 CA-C-O 121.015 0.436 . . . . 0.0 111.476 -178.251 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . 0.469 ' HD3' ' HA ' ' A' ' 33' ' ' VAL . 21.9 Cg_exo -66.44 142.24 64.74 Favored 'Trans proline' 0 C--O 1.236 0.389 0 C-N-CA 123.108 2.539 . . . . 0.0 112.141 178.302 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 112.99 -16.13 23.11 Favored Glycine 0 N--CA 1.448 -0.538 0 N-CA-C 111.232 -0.747 . . . . 0.0 111.232 -176.939 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 26.0 m -123.53 165.22 24.03 Favored Pre-proline 0 C--N 1.324 -0.539 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 179.853 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -74.72 -168.62 0.52 Allowed 'Trans proline' 0 CA--C 1.533 0.428 0 C-N-CA 122.753 2.302 . . . . 0.0 112.489 178.383 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.549 ' HB2' HD11 ' A' ' 86' ' ' LEU . . . 78.62 -6.3 1.93 Allowed 'General case' 0 N--CA 1.468 0.436 0 CA-C-N 115.473 -0.785 . . . . 0.0 112.354 175.457 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.568 ' HA ' HG11 ' A' ' 32' ' ' VAL . 3.8 m -58.69 -30.9 67.74 Favored 'General case' 0 CA--C 1.531 0.243 0 CA-C-O 120.817 0.342 . . . . 0.0 111.661 -177.2 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 64.6 mmtt -119.33 20.7 12.47 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.19 0.519 . . . . 0.0 110.928 -179.675 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 89.6 t -107.84 -47.04 7.82 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.596 0 CA-C-N 115.938 -0.573 . . . . 0.0 110.043 178.678 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.566 ' HB3' ' CZ ' ' A' ' 84' ' ' PHE . 0.6 OUTLIER -118.61 171.83 7.92 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-O 121.078 0.466 . . . . 0.0 111.256 178.884 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 11.7 m -115.84 126.15 27.97 Favored Pre-proline 0 C--N 1.315 -0.895 0 CA-C-N 115.452 -0.795 . . . . 0.0 110.061 -179.95 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_endo -62.2 142.35 91.41 Favored 'Trans proline' 0 N--CA 1.46 -0.461 0 C-N-CA 122.099 1.866 . . . . 0.0 111.422 177.4 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 97.72 -5.42 62.05 Favored Glycine 0 N--CA 1.45 -0.399 0 C-N-CA 120.685 -0.769 . . . . 0.0 112.995 -179.248 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.48 ' O ' ' HB2' ' A' ' 28' ' ' GLN . 75.2 mt -85.09 164.03 18.44 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.931 0.366 . . . . 0.0 110.968 179.589 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 47.4 t -101.51 143.28 14.73 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.457 178.516 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.596 HD11 HG23 ' A' ' 29' ' ' ILE . 60.0 mt -104.36 127.42 58.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 C-N-CA 122.535 0.334 . . . . 0.0 110.209 -179.962 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 27.9 mt-10 -89.51 -47.88 7.69 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.777 176.382 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.55 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 19.5 p -157.38 153.15 26.81 Favored 'General case' 0 N--CA 1.446 -0.671 0 CA-C-O 121.599 0.714 . . . . 0.0 112.202 -172.877 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.719 HG22 ' H ' ' A' ' 52' ' ' ASN . 16.0 mt -96.86 -179.93 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.32 -0.706 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 169.735 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' ASN . . . . . 0.719 ' H ' HG22 ' A' ' 51' ' ' ILE . 36.0 t-20 -49.58 93.67 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.365 0 N-CA-C 112.264 0.468 . . . . 0.0 112.264 -177.434 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 73.12 -2.59 34.63 Favored Glycine 0 CA--C 1.519 0.321 0 CA-C-N 115.976 -0.557 . . . . 0.0 113.275 179.493 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 36.1 mtt -124.8 98.85 36.13 Favored Pre-proline 0 C--N 1.325 -0.484 0 CA-C-N 116.875 0.337 . . . . 0.0 110.654 -173.096 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.55 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 70.4 Cg_endo -77.27 130.89 11.36 Favored 'Trans proline' 0 N--CA 1.46 -0.447 0 C-N-CA 122.151 1.901 . . . . 0.0 112.005 178.257 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.461 HG21 ' HA ' ' A' ' 62' ' ' TYR . 37.5 p -116.63 103.84 10.79 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-O 121.089 0.471 . . . . 0.0 111.614 -176.307 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . 0.405 ' OG ' ' HA ' ' A' ' 25' ' ' ASP . 26.9 t -89.05 -34.63 16.72 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.965 177.207 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . 0.43 ' HA ' ' HB2' ' A' ' 24' ' ' PRO . 2.3 m-20 -103.34 158.44 16.33 Favored 'General case' 0 C--N 1.318 -0.797 0 O-C-N 122.065 -0.397 . . . . 0.0 110.153 -176.804 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 87.4 mt -68.81 -33.8 74.45 Favored 'General case' 0 N--CA 1.443 -0.801 0 CA-C-O 121.215 0.531 . . . . 0.0 109.955 175.519 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 1.6 m -66.04 -41.82 90.39 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.668 -0.696 . . . . 0.0 111.081 177.547 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 18.4 p -68.07 -28.46 67.38 Favored 'General case' 0 CA--C 1.528 0.114 0 CA-C-O 120.811 0.339 . . . . 0.0 110.55 178.951 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' TYR . . . . . 0.461 ' HA ' HG21 ' A' ' 56' ' ' THR . 46.1 t80 -67.19 -38.41 85.31 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 109.269 -0.641 . . . . 0.0 109.269 176.105 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 21.6 t -66.07 -48.28 71.53 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.768 179.097 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.03 -32.78 74.22 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.246 -0.434 . . . . 0.0 111.346 -177.773 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . 0.476 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -73.29 -43.88 60.16 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.311 179.586 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 3.2 tt -57.04 -45.99 82.74 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.705 -0.679 . . . . 0.0 110.494 -179.6 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -59.69 -26.88 65.95 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.63 -0.714 . . . . 0.0 112.173 -178.199 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 43.5 p -89.24 -14.03 36.82 Favored 'General case' 0 C--N 1.327 -0.372 0 N-CA-C 112.049 0.388 . . . . 0.0 112.049 -177.454 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.476 HG12 ' O ' ' A' ' 65' ' ' ALA . 40.9 mm -74.83 142.81 14.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 N-CA-C 109.9 -0.407 . . . . 0.0 109.9 179.652 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . 0.458 ' HB2' ' HB2' ' A' ' 73' ' ' GLU . 4.9 m -93.18 157.64 16.17 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-O 120.673 0.273 . . . . 0.0 111.084 -178.157 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.441 HG22 ' H ' ' A' ' 98' ' ' ALA . 75.3 t -70.29 129.79 34.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.109 177.146 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 79.63 10.14 86.12 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.612 -0.804 . . . . 0.0 111.606 179.759 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.458 ' HB2' ' HB2' ' A' ' 70' ' ' SER . 23.7 tt0 -92.86 149.57 21.17 Favored 'General case' 0 C--N 1.322 -0.595 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 -179.719 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 44.9 t -105.1 124.05 59.62 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.609 0 CA-C-O 121.35 0.595 . . . . 0.0 110.579 -175.806 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 15.7 pt -110.27 154.04 11.9 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.122 179.193 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . 0.626 ' H ' ' HB2' ' A' ' 52' ' ' ASN . 6.3 t30 -105.8 110.49 22.8 Favored 'General case' 0 C--N 1.317 -0.808 0 CA-C-N 115.312 -0.858 . . . . 0.0 109.736 -177.755 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 65.0 mt -105.95 119.41 55.21 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.712 0 CA-C-O 121.34 0.59 . . . . 0.0 110.992 -174.087 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 11.9 m -93.68 118.5 31.47 Favored 'General case' 0 C--N 1.322 -0.63 0 CA-C-N 115.278 -0.873 . . . . 0.0 109.616 177.847 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 43.4 p -120.36 178.12 4.77 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.82 0.343 . . . . 0.0 111.165 179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 28.5 t70 -58.59 -34.88 71.6 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.598 -0.728 . . . . 0.0 111.351 178.798 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 10.7 mm100 -96.48 14.24 25.24 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.125 -0.489 . . . . 0.0 112.103 -176.136 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 123.26 -171.51 15.85 Favored Glycine 0 N--CA 1.449 -0.443 0 C-N-CA 120.177 -1.011 . . . . 0.0 112.631 176.246 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 24.1 m -112.06 138.23 49.0 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.75 0.309 . . . . 0.0 110.721 -176.855 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . 0.566 ' CZ ' ' HB3' ' A' ' 42' ' ' LEU . 10.3 p90 -139.16 168.83 18.96 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 121.378 0.609 . . . . 0.0 110.949 175.494 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -109.82 138.34 46.33 Favored 'General case' 0 C--N 1.314 -0.951 0 CA-C-N 115.142 -0.935 . . . . 0.0 110.016 178.158 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.549 HD11 ' HB2' ' A' ' 38' ' ' ALA . 17.8 tp -130.08 143.85 51.02 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.106 -177.755 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 24.3 ttpp -114.18 125.43 53.93 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.093 -178.277 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.643 HG21 ' HB1' ' A' ' 98' ' ' ALA . 77.0 p -73.99 148.17 42.31 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 115.969 -0.559 . . . . 0.0 111.38 -178.716 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -99.49 -171.88 30.69 Favored Glycine 0 N--CA 1.444 -0.805 0 N-CA-C 110.952 -0.859 . . . . 0.0 110.952 174.866 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.495 ' HD2' ' H ' ' A' ' 90' ' ' ARG . 0.7 OUTLIER -81.15 -60.44 2.28 Favored 'General case' 0 C--N 1.323 -0.555 0 C-N-CA 120.639 -0.424 . . . . 0.0 111.437 -178.477 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' ASN . . . . . 0.494 ' N ' ' HG2' ' A' ' 90' ' ' ARG . 2.1 m-20 178.84 137.25 0.25 Allowed Pre-proline 0 N--CA 1.465 0.297 0 C-N-CA 122.682 0.393 . . . . 0.0 110.241 -178.362 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.413 ' HD3' ' HA ' ' A' ' 91' ' ' ASN . 12.3 Cg_endo -90.65 -74.97 0.0 OUTLIER 'Trans proline' 0 N--CA 1.449 -1.09 0 C-N-CA 122.849 2.366 . . . . 0.0 110.815 170.901 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 63.2 t30 -142.63 68.15 1.31 Allowed 'General case' 0 C--N 1.327 -0.411 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 173.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 20.8 t-20 -150.18 166.77 28.85 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.311 -0.858 . . . . 0.0 109.485 -172.225 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 49.1 m -115.43 24.5 11.55 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-O 121.332 0.587 . . . . 0.0 109.821 178.266 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 25.4 m -100.63 -172.73 2.24 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.402 -0.817 . . . . 0.0 110.179 178.476 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . 0.453 ' HD3' ' N ' ' A' ' 97' ' ' ARG . 0.0 OUTLIER -138.16 145.46 41.57 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 177.093 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . 0.643 ' HB1' HG21 ' A' ' 88' ' ' THR . . . 58.03 68.02 0.89 Allowed 'General case' 0 C--N 1.332 -0.16 0 O-C-N 123.768 0.667 . . . . 0.0 109.903 -176.26 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 29.5 p90 -86.89 148.57 25.3 Favored 'General case' 0 N--CA 1.444 -0.747 0 CA-C-N 115.865 -0.607 . . . . 0.0 112.164 -167.238 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 93.5 mmm -98.06 126.55 43.55 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.05 -0.977 . . . . 0.0 109.341 175.358 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -86.92 35.19 3.43 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.907 -0.663 . . . . 0.0 112.806 -177.046 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.557 HG22 ' HA ' ' A' ' 32' ' ' VAL . 2.8 pp -140.2 162.71 24.45 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-O 120.801 0.334 . . . . 0.0 110.434 179.655 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . 0.44 ' NE ' ' HA ' ' A' ' 103' ' ' ARG . 2.9 mmp_? -93.01 142.07 27.7 Favored 'General case' 0 C--N 1.315 -0.915 0 N-CA-C 108.87 -0.789 . . . . 0.0 108.87 171.377 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.3 m -111.17 150.52 29.38 Favored 'General case' 0 C--N 1.317 -0.825 0 CA-C-O 121.085 0.469 . . . . 0.0 110.387 179.455 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.43 ' OG ' ' HG3' ' A' ' 28' ' ' GLN . 6.7 p -136.16 169.08 18.2 Favored 'General case' 0 C--N 1.315 -0.899 0 CA-C-N 115.669 -0.696 . . . . 0.0 109.158 175.809 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . 0.403 HD22 ' HA ' ' A' ' 106' ' ' ASN . 2.0 t-20 -112.35 7.88 19.39 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 120.686 0.279 . . . . 0.0 111.261 -172.575 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 48.7 t60 63.6 34.9 12.05 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-O 121.693 0.758 . . . . 0.0 110.495 176.187 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 92.8 mt -96.67 -163.49 1.05 Allowed 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.182 -0.917 . . . . 0.0 110.845 -179.22 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 59.8 mmt-85 -113.34 137.91 50.82 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.597 179.074 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 44.2 t -122.01 135.7 61.29 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 115.779 -0.646 . . . . 0.0 110.043 -179.906 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' ARG . . . . . . . . . . . . . 97.0 mtt180 -88.2 134.56 33.75 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 121.013 0.435 . . . . 0.0 110.878 -179.466 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 6.7 p-10 -112.51 16.77 19.69 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-O 121.431 0.634 . . . . 0.0 110.583 179.103 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 22.5 t -101.45 129.71 47.54 Favored 'General case' 0 C--N 1.315 -0.905 0 CA-C-N 115.355 -0.838 . . . . 0.0 110.08 179.361 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 12.0 m -124.33 137.61 56.65 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.692 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.53 179.105 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -128.95 79.09 1.89 Allowed 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.774 178.233 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 52.7 m -96.85 98.62 10.27 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.192 0.52 . . . . 0.0 110.165 178.426 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 30.5 m -88.95 167.59 1.67 Allowed 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.832 -178.644 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -79.44 -51.43 9.38 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 116.166 -0.47 . . . . 0.0 109.87 178.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 60.49 33.07 79.94 Favored Glycine 0 C--N 1.331 0.301 0 CA-C-N 115.675 -0.693 . . . . 0.0 112.231 -179.68 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 4.9 p-10 -88.89 146.14 25.12 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.127 0.489 . . . . 0.0 111.215 -177.229 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 5.7 t -155.99 99.92 2.0 Allowed 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 115.328 -0.851 . . . . 0.0 109.123 174.484 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . 0.465 ' HA ' ' HD3' ' A' ' 123' ' ' PRO . 96.5 mt -93.02 117.09 67.41 Favored Pre-proline 0 C--N 1.321 -0.658 0 CA-C-N 115.347 -0.842 . . . . 0.0 111.514 -171.753 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . 0.465 ' HD3' ' HA ' ' A' ' 122' ' ' LEU . 5.1 Cg_exo -78.1 117.05 4.05 Favored 'Trans proline' 0 N--CA 1.458 -0.602 0 C-N-CA 123.011 2.474 . . . . 0.0 111.406 175.636 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 68.5 m-85 -79.25 94.41 5.44 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.14 179.499 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.079 0 CA-C-O 118.473 -0.775 . . . . 0.0 110.648 -177.917 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . . . . . . . . . 29.9 tp60 . . . . . 0 N--CA 1.454 -0.269 0 CA-C-O 120.467 0.175 . . . . 0.0 110.666 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.45 ' HB2' ' OG ' ' A' ' 57' ' ' SER . 68.7 Cg_endo -75.95 157.07 38.9 Favored 'Trans proline' 0 C--O 1.236 0.386 0 C-N-CA 122.501 2.134 . . . . 0.0 111.138 172.566 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 21.4 t70 -148.68 -50.65 0.16 Allowed 'General case' 0 C--N 1.327 -0.38 0 CA-C-O 121.083 0.468 . . . . 0.0 111.447 -176.659 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.561 ' HA2' ' HA ' ' A' ' 57' ' ' SER . . . 157.25 167.2 17.99 Favored Glycine 0 N--CA 1.443 -0.869 0 N-CA-C 111.039 -0.824 . . . . 0.0 111.039 -177.124 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.479 HG23 ' HB ' ' A' ' 48' ' ' ILE . 28.5 m -108.06 127.42 64.26 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.74 0 CA-C-O 121.253 0.549 . . . . 0.0 110.984 178.787 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 18.9 tt0 -99.21 142.78 30.26 Favored 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.928 -0.578 . . . . 0.0 110.07 178.01 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.451 HG12 ' O ' ' A' ' 46' ' ' LEU . 8.0 pt -87.36 119.52 35.16 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-O 121.612 0.72 . . . . 0.0 111.579 -178.069 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.409 ' HB3' ' CB ' ' A' ' 103' ' ' ARG . 11.4 t70 -61.12 -58.47 8.22 Favored 'General case' 0 C--N 1.32 -0.7 0 CA-C-N 114.272 -1.331 . . . . 0.0 109.983 177.23 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . 0.619 ' HA ' ' HB3' ' A' ' 44' ' ' PRO . 7.8 p -159.69 158.96 32.36 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 115.432 -0.804 . . . . 0.0 111.145 -174.407 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.578 ' HA ' HG22 ' A' ' 102' ' ' ILE . 91.4 t -110.44 119.7 59.83 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.544 0 CA-C-N 115.689 -0.687 . . . . 0.0 109.404 177.846 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.425 ' HA ' ' HD3' ' A' ' 34' ' ' PRO . 53.9 t -83.63 123.52 76.3 Favored Pre-proline 0 C--N 1.324 -0.513 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.721 -175.978 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' A' ' 33' ' ' VAL . 11.4 Cg_exo -72.95 31.16 0.3 Allowed 'Trans proline' 0 CA--C 1.532 0.42 0 C-N-CA 123.269 2.646 . . . . 0.0 112.775 179.291 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . 0.402 ' H ' ' C ' ' A' ' 33' ' ' VAL . . . -121.69 20.43 8.24 Favored Glycine 0 N--CA 1.449 -0.462 0 N-CA-C 111.27 -0.732 . . . . 0.0 111.27 179.172 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 49.1 m -148.17 160.9 36.08 Favored Pre-proline 0 C--N 1.323 -0.578 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 179.425 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 31.1 Cg_exo -59.81 -13.56 22.92 Favored 'Trans proline' 0 C--N 1.348 0.533 0 C-N-CA 122.985 2.457 . . . . 0.0 113.669 -176.297 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.41 ' HB1' HD13 ' A' ' 42' ' ' LEU . . . -78.6 -6.94 56.97 Favored 'General case' 0 C--N 1.328 -0.329 0 N-CA-C 111.794 0.294 . . . . 0.0 111.794 -177.333 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 28.0 t -60.43 -28.45 68.3 Favored 'General case' 0 CA--C 1.533 0.294 0 N-CA-C 112.153 0.427 . . . . 0.0 112.153 -175.657 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 21.0 ttpt -106.96 13.53 27.5 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 120.947 0.403 . . . . 0.0 110.678 -177.388 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.477 ' HB ' HD12 ' A' ' 42' ' ' LEU . 46.4 t -115.34 -59.2 3.25 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.536 0 C-N-CA 120.776 -0.37 . . . . 0.0 111.65 -175.23 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.48 HD11 HD12 ' A' ' 86' ' ' LEU . 6.6 mp -92.45 175.46 6.83 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.291 0.567 . . . . 0.0 111.516 -173.478 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 91.1 m -140.89 123.94 9.91 Favored Pre-proline 0 C--N 1.32 -0.674 0 CA-C-N 115.405 -0.816 . . . . 0.0 108.946 175.544 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.619 ' HB3' ' HA ' ' A' ' 31' ' ' SER . 42.3 Cg_endo -64.52 152.05 83.17 Favored 'Trans proline' 0 CA--C 1.531 0.339 0 C-N-CA 122.893 2.396 . . . . 0.0 112.905 -173.811 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 103.17 -11.92 55.36 Favored Glycine 0 CA--C 1.52 0.368 0 C-N-CA 121.072 -0.585 . . . . 0.0 112.695 -179.496 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.701 HD22 ' HB3' ' A' ' 80' ' ' ASP . 81.6 mt -84.74 164.62 18.43 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.975 0.417 . . . . 0.0 111.098 -177.981 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 46.6 t -108.12 135.09 47.95 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.456 0 CA-C-N 116.075 -0.511 . . . . 0.0 109.843 177.129 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.479 ' HB ' HG23 ' A' ' 27' ' ' VAL . 69.0 mt -87.65 123.7 40.47 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 CA-C-O 121.204 0.526 . . . . 0.0 110.536 179.862 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 6.5 tm-20 -79.22 -47.06 16.62 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 115.394 -0.821 . . . . 0.0 109.921 -179.54 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.54 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 7.7 p -162.73 153.77 17.32 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.388 -177.648 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 48.5 mm -107.24 102.96 14.72 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-N 115.901 -0.59 . . . . 0.0 109.732 176.679 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' ASN . . . . . 0.591 ' HA ' ' HB3' ' A' ' 76' ' ' ASN . 38.9 t-20 64.08 -85.26 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.384 0 C-N-CA 123.552 0.741 . . . . 0.0 111.056 179.343 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -132.79 8.05 5.21 Favored Glycine 0 N--CA 1.447 -0.569 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 177.005 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 1.5 mpt? -118.59 103.35 48.92 Favored Pre-proline 0 N--CA 1.448 -0.571 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 -178.737 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.54 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 41.8 Cg_endo -68.81 121.68 8.57 Favored 'Trans proline' 0 N--CA 1.462 -0.367 0 C-N-CA 122.124 1.882 . . . . 0.0 112.461 -179.118 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.45 ' HA ' ' HB ' ' A' ' 61' ' ' THR . 6.9 p -89.47 87.99 7.28 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.54 179.834 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . 0.561 ' HA ' ' HA2' ' A' ' 26' ' ' GLY . 8.6 t -93.53 -14.26 26.82 Favored 'General case' 0 C--N 1.318 -0.797 0 CA-C-N 115.416 -0.811 . . . . 0.0 109.875 -179.476 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 61.1 t30 -140.5 178.23 7.46 Favored 'General case' 0 N--CA 1.445 -0.714 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 178.978 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 68.8 mt -76.16 -33.39 59.37 Favored 'General case' 0 N--CA 1.445 -0.72 0 CA-C-O 120.921 0.391 . . . . 0.0 111.067 -178.424 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 13.1 m -66.48 -34.33 77.68 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.977 179.869 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . 0.45 ' HB ' ' HA ' ' A' ' 56' ' ' THR . 0.0 OUTLIER -66.0 -35.33 80.26 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-O 120.992 0.425 . . . . 0.0 110.372 176.838 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 55.4 t80 -62.33 -37.45 85.66 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.857 176.842 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 33.2 t -68.25 -46.19 71.16 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 115.52 -0.764 . . . . 0.0 110.435 177.287 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -66.32 -26.34 67.26 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.865 -0.607 . . . . 0.0 112.13 -175.761 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . 0.427 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -79.27 -44.03 22.54 Favored 'General case' 0 C--N 1.323 -0.568 0 CA-C-O 121.078 0.466 . . . . 0.0 110.431 177.487 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 1.7 tt -63.55 -42.64 98.38 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.556 -0.747 . . . . 0.0 111.357 -175.824 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 22.4 ptmt -60.37 -12.37 9.14 Favored 'General case' 0 CA--C 1.536 0.414 0 N-CA-C 112.899 0.704 . . . . 0.0 112.899 -174.117 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 20.8 p -106.93 -13.17 15.28 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 112.386 0.514 . . . . 0.0 112.386 -178.128 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.473 HG21 HG21 ' A' ' 88' ' ' THR . 37.2 mm -79.73 143.85 11.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.748 -0.205 . . . . 0.0 110.956 -175.256 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 3.2 m -92.45 164.52 13.44 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.508 -0.315 . . . . 0.0 110.471 179.888 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.408 HG22 ' H ' ' A' ' 98' ' ' ALA . 16.5 t -78.6 118.09 25.23 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-O 120.677 0.275 . . . . 0.0 110.266 179.304 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 88.32 23.52 37.03 Favored Glycine 0 N--CA 1.448 -0.525 0 C-N-CA 120.422 -0.894 . . . . 0.0 111.671 -178.846 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 28.6 tt0 -99.56 147.5 25.27 Favored 'General case' 0 C--N 1.323 -0.587 0 N-CA-C 109.415 -0.587 . . . . 0.0 109.415 -179.851 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 51.0 t -95.14 114.29 31.39 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.779 0 CA-C-O 121.136 0.493 . . . . 0.0 110.56 -179.122 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 26.7 pt -104.21 174.79 1.16 Allowed 'Isoleucine or valine' 0 C--N 1.318 -0.787 0 CA-C-N 115.637 -0.71 . . . . 0.0 110.87 179.27 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . 0.591 ' HB3' ' HA ' ' A' ' 52' ' ' ASN . 43.6 t30 -122.16 130.54 53.31 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.586 -0.734 . . . . 0.0 109.813 -175.536 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.435 HG22 HG23 ' A' ' 79' ' ' THR . 62.5 mt -134.8 110.33 12.71 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.479 0 CA-C-O 121.212 0.529 . . . . 0.0 111.112 -176.922 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . 0.628 ' HA ' ' HA ' ' A' ' 83' ' ' THR . 98.1 m -85.91 123.53 31.35 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.986 -0.552 . . . . 0.0 109.685 173.597 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.435 HG23 HG22 ' A' ' 77' ' ' ILE . 67.3 p -124.72 -173.45 2.79 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 120.922 0.392 . . . . 0.0 111.364 -177.472 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . 0.701 ' HB3' HD22 ' A' ' 46' ' ' LEU . 7.4 t70 -53.78 -41.55 67.34 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.216 -0.902 . . . . 0.0 111.583 177.173 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 28.2 mm-40 -95.23 12.94 27.13 Favored 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 111.931 0.345 . . . . 0.0 111.931 -175.759 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 119.43 -175.32 15.75 Favored Glycine 0 N--CA 1.447 -0.63 0 C-N-CA 120.164 -1.017 . . . . 0.0 113.038 175.342 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.628 ' HA ' ' HA ' ' A' ' 78' ' ' THR . 32.6 m -92.67 117.17 29.7 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 121.115 0.484 . . . . 0.0 111.396 -176.565 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 88.9 m-85 -113.89 164.8 13.29 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.43 -178.735 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 19.3 p-80 -117.27 130.01 56.28 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.285 178.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.49 HD23 ' N ' ' A' ' 87' ' ' LYS . 8.2 tt -120.48 145.48 47.23 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 116.231 -0.44 . . . . 0.0 109.947 -173.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.49 ' N ' HD23 ' A' ' 86' ' ' LEU . 88.1 tttt -114.66 117.59 31.28 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 109.132 -0.692 . . . . 0.0 109.132 176.216 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.473 HG21 HG21 ' A' ' 69' ' ' ILE . 22.3 p -64.03 131.92 49.03 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-O 121.142 0.496 . . . . 0.0 111.729 -174.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -102.55 -141.11 11.36 Favored Glycine 0 N--CA 1.441 -1.012 0 C-N-CA 120.975 -0.631 . . . . 0.0 111.797 179.61 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 70.6 mtt180 -115.36 161.34 18.65 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 121.123 0.487 . . . . 0.0 111.365 -175.124 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' ASN . . . . . 0.613 ' HB3' ' HB2' ' A' ' 99' ' ' TYR . 1.1 p-10 -130.59 107.87 15.77 Favored Pre-proline 0 C--N 1.324 -0.515 0 CA-C-N 115.331 -0.849 . . . . 0.0 111.729 -171.801 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_exo -83.01 -4.71 11.28 Favored 'Trans proline' 0 C--O 1.23 0.101 0 C-N-CA 123.557 2.838 . . . . 0.0 112.079 174.052 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 5.3 t30 -133.95 78.35 1.76 Allowed 'General case' 0 C--N 1.316 -0.885 0 CA-C-N 115.064 -0.971 . . . . 0.0 109.944 -173.48 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 11.5 t-20 71.63 -160.21 0.12 Allowed 'General case' 0 N--CA 1.469 0.48 0 CA-C-N 115.147 -0.933 . . . . 0.0 109.966 173.054 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 14.8 m 76.24 -26.59 0.19 Allowed 'General case' 0 N--CA 1.473 0.714 0 C-N-CA 123.913 0.885 . . . . 0.0 112.559 176.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 55.6 m 71.91 -60.46 0.52 Allowed 'General case' 0 N--CA 1.467 0.39 0 C-N-CA 123.58 0.752 . . . . 0.0 112.374 178.941 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -141.8 153.41 44.51 Favored 'General case' 0 C--N 1.328 -0.369 0 O-C-N 122.292 -0.255 . . . . 0.0 111.592 -177.374 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . 0.408 ' H ' HG22 ' A' ' 71' ' ' VAL . . . 62.24 81.74 0.19 Allowed 'General case' 0 N--CA 1.464 0.254 0 O-C-N 124.089 0.868 . . . . 0.0 112.29 169.573 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . 0.613 ' HB2' ' HB3' ' A' ' 91' ' ' ASN . 14.5 t80 -107.45 120.74 43.0 Favored 'General case' 0 C--N 1.319 -0.718 0 C-N-CA 120.76 -0.376 . . . . 0.0 110.07 -178.58 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' MET . . . . . 0.566 ' HG2' HG12 ' A' ' 102' ' ' ILE . 0.7 OUTLIER -71.86 -20.18 61.85 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.169 -179.038 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 78.91 35.2 31.83 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.866 -0.683 . . . . 0.0 113.113 175.201 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.578 HG22 ' HA ' ' A' ' 32' ' ' VAL . 35.4 pt -142.02 154.01 18.92 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 CA-C-O 120.849 0.356 . . . . 0.0 110.063 178.933 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . 0.409 ' CB ' ' HB3' ' A' ' 30' ' ' ASP . 21.4 mtp85 -91.74 134.66 34.53 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 108.909 -0.774 . . . . 0.0 108.909 173.463 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 2.8 m -133.21 155.14 49.89 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-O 120.962 0.41 . . . . 0.0 111.055 -176.308 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 32.6 t -149.1 -174.88 4.76 Favored 'General case' 0 C--N 1.321 -0.636 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 179.44 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 14.8 p30 -103.24 -34.84 8.66 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-O 120.635 0.255 . . . . 0.0 111.044 179.211 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 44.3 t-80 55.27 49.72 16.54 Favored 'General case' 0 CA--C 1.531 0.213 0 CA-C-O 121.206 0.527 . . . . 0.0 110.375 -179.771 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 16.9 mt -85.57 139.64 31.28 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.326 -179.25 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 32.3 ttt180 68.78 139.8 0.04 OUTLIER 'General case' 0 N--CA 1.467 0.381 0 O-C-N 124.728 1.267 . . . . 0.0 112.214 178.739 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 14.0 p -69.5 145.79 12.96 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.264 0 CA-C-N 116.118 -0.492 . . . . 0.0 109.841 173.76 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' ARG . . . . . 0.461 ' HD2' ' C ' ' A' ' 111' ' ' ARG . 4.1 ppt_? -106.84 171.58 7.29 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.118 0.485 . . . . 0.0 111.492 -173.657 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -148.29 152.07 36.48 Favored 'General case' 0 C--N 1.323 -0.576 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 175.007 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 50.7 m 72.78 111.44 0.06 Allowed 'General case' 0 C--N 1.325 -0.481 0 O-C-N 124.212 0.945 . . . . 0.0 111.849 177.355 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 16.7 m -96.87 133.66 37.49 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.409 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.779 178.074 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -105.86 130.55 53.8 Favored 'General case' 0 C--N 1.323 -0.567 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.032 177.659 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 5.8 t -100.65 85.84 3.0 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-O 121.04 0.447 . . . . 0.0 109.891 -177.51 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 52.4 t -128.47 109.39 19.22 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.422 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.838 178.558 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 118' ' ' LEU . . . . . 0.466 HD22 ' N ' ' A' ' 118' ' ' LEU . 2.7 mm? -93.29 -48.33 6.48 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.525 -177.33 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 69.99 58.91 5.83 Favored Glycine 0 N--CA 1.449 -0.499 0 C-N-CA 120.687 -0.768 . . . . 0.0 111.213 -175.518 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 9.2 p-10 -74.13 112.42 10.25 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.413 0.625 . . . . 0.0 111.16 -175.506 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 92.1 m -91.27 126.62 36.41 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.427 177.006 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 96.0 mt -110.8 147.77 37.18 Favored Pre-proline 0 C--N 1.324 -0.515 0 CA-C-N 115.979 -0.555 . . . . 0.0 110.578 -177.229 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 36.9 Cg_endo -65.62 145.68 82.44 Favored 'Trans proline' 0 CA--C 1.527 0.168 0 C-N-CA 122.675 2.25 . . . . 0.0 112.194 178.833 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 32.9 p90 -129.22 147.3 51.04 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 116.409 -0.359 . . . . 0.0 110.723 -178.738 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.93 0 CA-C-O 118.412 -0.804 . . . . 0.0 109.862 -179.658 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . . . . . . . . . 80.7 mt-30 . . . . . 0 N--CA 1.457 -0.11 0 CA-C-O 120.846 0.355 . . . . 0.0 110.982 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 65.4 Cg_endo -87.8 -156.38 0.06 OUTLIER 'Trans proline' 0 N--CA 1.46 -0.473 0 C-N-CA 123.28 2.653 . . . . 0.0 112.602 178.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 27.9 t70 75.94 67.15 0.06 Allowed 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 114.607 -1.179 . . . . 0.0 110.364 178.602 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.461 ' H ' ' HA ' ' A' ' 57' ' ' SER . . . 106.52 115.94 4.08 Favored Glycine 0 N--CA 1.445 -0.72 0 CA-C-N 114.471 -1.24 . . . . 0.0 111.751 176.597 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . . . . . . . . . 34.5 m -78.79 153.83 4.92 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 CA-C-O 120.941 0.4 . . . . 0.0 110.721 -178.737 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 4.4 tt0 -115.53 149.24 38.48 Favored 'General case' 0 C--N 1.317 -0.814 0 CA-C-O 121.293 0.568 . . . . 0.0 111.349 -177.585 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.498 HD12 HD12 ' A' ' 102' ' ' ILE . 26.8 mm -73.11 107.62 3.86 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.541 0 CA-C-N 115.214 -0.903 . . . . 0.0 109.432 175.742 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.721 ' HB3' ' HB2' ' A' ' 103' ' ' ARG . 41.9 t0 -69.98 -53.54 17.28 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-O 121.401 0.62 . . . . 0.0 109.529 -178.671 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 51.0 p -161.47 173.51 14.76 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.189 -0.914 . . . . 0.0 110.798 177.103 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.522 HG22 HG22 ' A' ' 102' ' ' ILE . 84.9 t -119.25 124.46 73.1 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.699 0 CA-C-N 115.813 -0.631 . . . . 0.0 109.382 175.95 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 7.4 p -106.7 131.02 22.04 Favored Pre-proline 0 C--N 1.323 -0.545 0 CA-C-O 120.783 0.325 . . . . 0.0 110.421 -177.67 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo -64.97 87.85 0.18 Allowed 'Trans proline' 0 C--N 1.343 0.289 0 C-N-CA 122.79 2.327 . . . . 0.0 112.408 179.426 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -164.75 14.21 0.09 OUTLIER Glycine 0 N--CA 1.449 -0.447 0 CA-C-N 115.755 -0.657 . . . . 0.0 111.862 176.032 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.679 ' HB2' ' HA3' ' A' ' 101' ' ' GLY . 60.4 m -157.65 160.44 30.16 Favored Pre-proline 0 C--N 1.327 -0.401 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 -178.972 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_exo -63.31 -15.34 47.66 Favored 'Trans proline' 0 C--N 1.349 0.568 0 C-N-CA 122.87 2.38 . . . . 0.0 112.71 -178.132 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -67.07 -15.12 63.52 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.982 -0.554 . . . . 0.0 111.922 -177.426 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.459 ' HA ' HG11 ' A' ' 32' ' ' VAL . 47.7 t -65.21 -13.55 58.54 Favored 'General case' 0 N--CA 1.463 0.185 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.71 -177.041 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 23.9 ttmm -128.42 25.39 5.77 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 121.346 0.594 . . . . 0.0 110.06 179.244 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.542 ' HB ' HD12 ' A' ' 42' ' ' LEU . 45.6 t -122.16 -55.3 2.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.008 -0.542 . . . . 0.0 110.905 179.381 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.542 HD12 ' HB ' ' A' ' 41' ' ' VAL . 5.0 mp -109.17 164.19 12.67 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-O 120.789 0.328 . . . . 0.0 110.588 -178.033 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 12.7 p -116.54 144.54 33.39 Favored Pre-proline 0 C--N 1.323 -0.548 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.62 177.1 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.44 ' HA ' ' CG2' ' A' ' 29' ' ' ILE . 57.2 Cg_endo -72.55 149.41 49.53 Favored 'Trans proline' 0 C--O 1.235 0.332 0 C-N-CA 122.299 1.999 . . . . 0.0 112.496 -179.422 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 101.14 -12.52 58.8 Favored Glycine 0 N--CA 1.45 -0.403 0 C-N-CA 120.699 -0.763 . . . . 0.0 112.999 -179.555 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 83.4 mt -77.43 164.27 25.62 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-O 121.046 0.451 . . . . 0.0 111.46 -179.235 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 46.0 t -108.76 136.19 45.27 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.485 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.785 177.933 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.439 HG23 HG23 ' A' ' 77' ' ' ILE . 70.9 mt -93.79 122.71 45.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.549 0 CA-C-N 116.496 -0.32 . . . . 0.0 110.981 179.55 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.6 mp0 -79.82 -44.97 19.6 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.5 -0.318 . . . . 0.0 110.951 174.809 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.62 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 16.4 p -169.03 161.22 10.45 Favored 'General case' 0 CA--C 1.515 -0.404 0 CA-C-O 120.888 0.375 . . . . 0.0 111.408 -174.559 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.558 HD11 HD12 ' A' ' 75' ' ' ILE . 8.1 tt -135.95 122.19 31.24 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.148 177.473 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 11.0 m120 58.85 22.88 10.69 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-N 115.642 -0.708 . . . . 0.0 112.536 176.094 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 104.71 -26.22 23.19 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.655 -0.783 . . . . 0.0 112.433 179.935 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 4.4 mpp? -91.94 112.8 56.6 Favored Pre-proline 0 C--N 1.325 -0.491 0 N-CA-C 109.682 -0.488 . . . . 0.0 109.682 177.577 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.62 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 72.6 Cg_endo -78.02 128.07 8.9 Favored 'Trans proline' 0 N--CA 1.454 -0.799 0 C-N-CA 122.09 1.86 . . . . 0.0 112.501 -178.748 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 21.5 p -91.64 81.13 5.31 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 115.649 -0.705 . . . . 0.0 111.026 -177.944 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . 0.461 ' HA ' ' H ' ' A' ' 26' ' ' GLY . 12.6 m -81.34 -18.5 45.49 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.69 178.561 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 42.7 m-80 -138.34 164.85 28.25 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.074 -0.512 . . . . 0.0 109.733 -178.729 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.511 HD21 ' HA ' ' A' ' 105' ' ' SER . 66.2 mt -68.75 -35.14 76.72 Favored 'General case' 0 N--CA 1.446 -0.653 0 CA-C-O 120.908 0.385 . . . . 0.0 110.576 178.222 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 1.5 m -62.22 -35.32 78.53 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.509 176.513 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -66.65 -43.25 85.1 Favored 'General case' 0 N--CA 1.452 -0.356 0 CA-C-N 115.998 -0.547 . . . . 0.0 110.374 178.326 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 33.3 t80 -64.14 -37.53 87.79 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.931 -0.577 . . . . 0.0 109.635 177.473 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 66.8 m -61.46 -50.94 70.75 Favored 'General case' 0 N--CA 1.445 -0.693 0 CA-C-N 115.387 -0.824 . . . . 0.0 111.397 178.012 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -62.95 -33.93 76.42 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.938 -0.574 . . . . 0.0 110.989 179.623 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . 0.575 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -72.79 -41.27 65.16 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.269 -179.866 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 1.2 tt -57.42 -39.31 75.92 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.252 179.407 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 93.7 mttt -59.23 -39.41 82.65 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.871 -0.604 . . . . 0.0 111.801 179.375 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 17.5 p -77.84 -14.37 59.59 Favored 'General case' 0 C--N 1.326 -0.433 0 N-CA-C 111.985 0.365 . . . . 0.0 111.985 -178.701 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.575 HG12 ' O ' ' A' ' 65' ' ' ALA . 43.0 mm -75.29 142.75 14.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 N-CA-C 110.495 -0.187 . . . . 0.0 110.495 -179.951 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 3.0 m -102.11 168.96 9.04 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.713 0.292 . . . . 0.0 110.925 179.761 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.413 HG22 ' H ' ' A' ' 98' ' ' ALA . 16.4 t -82.11 122.19 36.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.294 178.809 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 83.32 25.72 46.59 Favored Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 120.61 -0.805 . . . . 0.0 111.807 -179.978 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 18.9 tt0 -105.81 153.32 22.07 Favored 'General case' 0 C--N 1.324 -0.536 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 179.917 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 26.5 t -97.9 113.78 33.42 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.668 0 CA-C-O 120.866 0.365 . . . . 0.0 110.167 -179.014 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.558 HD12 HD11 ' A' ' 51' ' ' ILE . 9.3 pt -101.33 154.8 4.71 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.164 -179.03 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . 0.437 ' O ' ' HA ' ' A' ' 51' ' ' ILE . 10.8 t30 -119.33 104.95 10.84 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-O 121.151 0.5 . . . . 0.0 111.076 -173.292 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.472 HD12 HD21 ' A' ' 86' ' ' LEU . 67.1 mt -103.12 118.83 50.68 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 115.37 -0.832 . . . . 0.0 110.405 -177.459 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 19.6 m -95.62 115.37 27.33 Favored 'General case' 0 C--N 1.316 -0.866 0 CA-C-N 115.628 -0.715 . . . . 0.0 109.664 177.368 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 82.0 p -111.15 169.75 8.57 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.42 -179.736 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 24.4 t70 -61.98 -25.55 67.69 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.941 -0.572 . . . . 0.0 111.088 179.257 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 8.4 tp-100 -98.51 11.85 37.0 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.171 0.51 . . . . 0.0 111.097 -176.69 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 134.44 176.11 14.21 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.315 -0.945 . . . . 0.0 113.002 176.153 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 18.1 m -105.27 120.11 40.73 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 110.042 -0.355 . . . . 0.0 110.042 -179.523 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 63.4 m-85 -126.57 152.16 46.96 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-O 120.759 0.314 . . . . 0.0 110.243 -179.426 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -131.49 131.15 43.23 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-O 121.299 0.571 . . . . 0.0 110.422 177.079 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.473 HD22 HD11 ' A' ' 42' ' ' LEU . 0.9 OUTLIER -127.13 157.42 39.77 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.319 -0.855 . . . . 0.0 111.106 -173.535 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 40.0 ttmt -99.56 130.6 45.81 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.894 -0.594 . . . . 0.0 110.057 178.545 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 33.9 p -71.63 131.19 42.84 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 121.064 0.459 . . . . 0.0 111.036 179.548 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -93.79 -166.97 37.6 Favored Glycine 0 N--CA 1.442 -0.908 0 C-N-CA 120.491 -0.861 . . . . 0.0 112.322 -177.637 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.495 ' HD3' ' N ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -153.59 117.12 4.66 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 121.14 0.495 . . . . 0.0 109.767 179.064 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' ASN . . . . . 1.055 ' HB3' ' HB3' ' A' ' 95' ' ' SER . 59.6 t30 -84.48 139.92 38.57 Favored Pre-proline 0 C--N 1.323 -0.551 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.766 -174.556 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.639 ' HD2' ' OD1' ' A' ' 91' ' ' ASN . 72.7 Cg_exo -38.36 155.97 0.03 OUTLIER 'Trans proline' 0 CA--C 1.532 0.419 0 C-N-CA 124.317 3.345 . . . . 0.0 114.155 170.363 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 8.9 t-20 67.07 14.75 9.93 Favored 'General case' 0 N--CA 1.469 0.503 0 CA-C-N 115.111 -0.949 . . . . 0.0 110.726 178.873 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 44.3 t-20 58.49 71.81 0.56 Allowed 'General case' 0 N--CA 1.465 0.29 0 CA-C-O 121.65 0.738 . . . . 0.0 110.002 -176.947 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . 1.055 ' HB3' ' HB3' ' A' ' 91' ' ' ASN . 33.4 t -99.71 87.7 3.62 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.551 -0.749 . . . . 0.0 109.996 179.479 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 9.1 t 68.3 172.19 0.28 Allowed 'General case' 0 CA--C 1.532 0.276 0 CA-C-N 115.369 -0.832 . . . . 0.0 111.56 177.048 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 6.7 ptp85 -115.26 145.99 41.91 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.565 -0.743 . . . . 0.0 109.38 176.901 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . 0.413 ' H ' HG22 ' A' ' 71' ' ' VAL . . . 56.23 72.94 0.46 Allowed 'General case' 0 C--N 1.333 -0.152 0 O-C-N 123.807 0.692 . . . . 0.0 110.153 -176.505 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . 0.8 ' CE2' ' HB2' ' A' ' 91' ' ' ASN . 0.1 OUTLIER -70.34 110.75 5.46 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.821 -0.627 . . . . 0.0 111.22 -171.178 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 25.4 mmt -82.84 111.02 18.36 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 108.733 -0.84 . . . . 0.0 108.733 173.268 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . 0.679 ' HA3' ' HB2' ' A' ' 36' ' ' SER . . . -81.28 30.22 2.75 Favored Glycine 0 C--O 1.228 -0.236 0 C-N-CA 120.814 -0.707 . . . . 0.0 113.263 -174.958 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.522 HG22 HG22 ' A' ' 32' ' ' VAL . 42.9 pt -147.69 173.29 2.16 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.593 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 -179.98 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . 0.721 ' HB2' ' HB3' ' A' ' 30' ' ' ASP . 65.7 mtt-85 -109.94 134.37 52.17 Favored 'General case' 0 C--N 1.317 -0.834 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 173.344 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.5 p -119.79 124.5 46.3 Favored 'General case' 0 C--N 1.318 -0.784 0 CA-C-O 120.944 0.402 . . . . 0.0 110.72 178.353 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.511 ' HA ' HD21 ' A' ' 59' ' ' LEU . 42.3 m -145.64 163.43 34.86 Favored 'General case' 0 C--N 1.324 -0.539 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.248 -179.083 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 86.6 m-20 -78.17 52.36 1.09 Allowed 'General case' 0 C--N 1.325 -0.474 0 CA-C-O 121.853 0.835 . . . . 0.0 109.061 173.474 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 42.0 t-80 -78.01 36.2 0.22 Allowed 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 114.541 -1.208 . . . . 0.0 111.378 -175.6 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . 0.458 HD11 ' O ' ' A' ' 26' ' ' GLY . 5.3 mp -80.27 165.32 22.45 Favored 'General case' 0 C--N 1.323 -0.554 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.484 178.815 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . 0.441 ' O ' ' HD2' ' A' ' 109' ' ' ARG . 0.0 OUTLIER -129.47 148.88 51.42 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.171 176.577 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 2.5 p -91.45 120.07 39.84 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.487 0 CA-C-O 121.969 0.89 . . . . 0.0 111.363 -178.867 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' ARG . . . . . . . . . . . . . 2.1 tmt_? -129.16 -27.44 2.47 Favored 'General case' 0 C--N 1.315 -0.9 0 CA-C-N 114.268 -1.333 . . . . 0.0 108.852 177.343 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 35.1 t70 -81.61 100.67 9.54 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 114.799 -1.091 . . . . 0.0 109.23 175.938 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 35.4 t -67.13 98.77 0.61 Allowed 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 115.384 -0.826 . . . . 0.0 111.567 -174.86 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 14.8 m -108.93 149.44 12.17 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.256 175.211 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -138.04 101.27 4.38 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 120.857 0.36 . . . . 0.0 110.673 -179.616 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 47.2 t -113.21 15.11 19.47 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 121.383 0.611 . . . . 0.0 109.981 177.784 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 3.8 p -102.56 113.87 40.4 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.75 0 CA-C-N 115.544 -0.753 . . . . 0.0 110.733 -179.132 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 118' ' ' LEU . . . . . 0.412 HD22 ' N ' ' A' ' 118' ' ' LEU . 2.3 mm? -87.9 -32.21 19.07 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.29 179.77 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 122.49 153.74 8.92 Favored Glycine 0 N--CA 1.448 -0.564 0 CA-C-N 115.678 -0.692 . . . . 0.0 111.476 -179.009 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -105.21 168.63 8.94 Favored 'General case' 0 C--N 1.321 -0.673 0 N-CA-C 110.205 -0.294 . . . . 0.0 110.205 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 14.4 p -75.51 109.81 9.37 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 116.109 -0.496 . . . . 0.0 111.203 -178.816 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . 0.451 ' HA ' ' HD3' ' A' ' 123' ' ' PRO . 62.3 mt -103.76 131.73 21.72 Favored Pre-proline 0 C--N 1.324 -0.536 0 CA-C-N 115.796 -0.638 . . . . 0.0 110.352 -179.142 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . 0.451 ' HD3' ' HA ' ' A' ' 122' ' ' LEU . 9.0 Cg_exo -71.18 142.04 40.86 Favored 'Trans proline' 0 C--O 1.235 0.365 0 C-N-CA 123.093 2.529 . . . . 0.0 114.115 -173.754 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 49.5 p90 -122.49 161.95 22.63 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.121 -0.945 . . . . 0.0 109.474 174.932 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.251 1.165 0 CA-C-O 118.594 -0.717 . . . . 0.0 110.416 -179.075 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.792 ' HB2' ' HD3' ' A' ' 24' ' ' PRO . 78.8 mt-30 . . . . . 0 CA--C 1.534 0.361 0 CA-C-O 119.788 -0.149 . . . . 0.0 110.852 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.792 ' HD3' ' HB2' ' A' ' 23' ' ' GLN . 71.1 Cg_endo -89.83 160.09 5.08 Favored 'Trans proline' 0 N--CA 1.455 -0.763 0 C-N-CA 121.872 1.715 . . . . 0.0 111.447 175.649 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 25.2 t0 -175.44 -29.08 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.353 0 CA-C-O 121.047 0.451 . . . . 0.0 111.164 -176.529 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.432 ' HA2' ' O ' ' A' ' 56' ' ' THR . . . 171.02 134.07 1.71 Allowed Glycine 0 N--CA 1.444 -0.785 0 C-N-CA 120.9 -0.667 . . . . 0.0 111.724 -179.958 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.527 HG23 ' HB ' ' A' ' 48' ' ' ILE . 19.0 m -76.3 153.94 5.89 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-O 120.69 0.281 . . . . 0.0 110.445 179.672 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 31.7 tt0 -115.8 149.51 38.42 Favored 'General case' 0 C--N 1.323 -0.579 0 C-N-CA 120.28 -0.568 . . . . 0.0 110.986 -179.371 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . . . . . . . . . 68.9 mt -80.18 114.5 21.16 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-N 115.814 -0.63 . . . . 0.0 109.878 177.543 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . 0.572 ' HB3' ' HB3' ' A' ' 103' ' ' ARG . 16.2 t70 -70.39 -67.57 0.49 Allowed 'General case' 0 C--N 1.32 -0.675 0 CA-C-O 121.392 0.615 . . . . 0.0 110.064 -178.95 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 6.9 p -159.14 153.9 24.63 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.109 179.804 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.802 HG22 HG22 ' A' ' 102' ' ' ILE . 95.3 t -82.24 128.63 38.54 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.553 0 N-CA-C 109.607 -0.516 . . . . 0.0 109.607 177.95 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.405 ' HB ' ' HD2' ' A' ' 34' ' ' PRO . 27.5 m -92.16 159.14 38.08 Favored Pre-proline 0 N--CA 1.446 -0.664 0 CA-C-N 116.575 -0.284 . . . . 0.0 110.382 -178.417 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . 0.405 ' HD2' ' HB ' ' A' ' 33' ' ' VAL . 21.0 Cg_endo -62.88 106.23 0.51 Allowed 'Trans proline' 0 N--CA 1.461 -0.416 0 C-N-CA 122.271 1.981 . . . . 0.0 111.591 174.505 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 135.72 150.58 5.99 Favored Glycine 0 N--CA 1.448 -0.565 0 CA-C-N 115.905 -0.589 . . . . 0.0 112.067 -177.652 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 50.5 m 71.11 153.73 0.15 Allowed Pre-proline 0 CA--C 1.535 0.382 0 C-N-CA 123.038 0.535 . . . . 0.0 111.719 179.704 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 88.5 Cg_endo -83.22 14.18 2.44 Favored 'Trans proline' 0 C--N 1.347 0.449 0 C-N-CA 122.95 2.434 . . . . 0.0 113.416 -176.267 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.568 ' HB2' ' O ' ' A' ' 100' ' ' MET . . . -59.79 -35.12 74.01 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-O 120.865 0.364 . . . . 0.0 111.478 -179.192 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.568 ' HB3' HG11 ' A' ' 32' ' ' VAL . 0.8 OUTLIER -65.93 -22.45 66.49 Favored 'General case' 0 C--N 1.325 -0.467 0 CA-C-N 116.04 -0.527 . . . . 0.0 112.374 -175.063 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 19.8 ptpt -100.27 1.34 41.64 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.691 0.281 . . . . 0.0 110.896 179.829 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 83.6 t -110.59 -55.86 4.71 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.455 0 CA-C-N 116.476 -0.329 . . . . 0.0 111.017 -178.23 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 1.2 pp -118.51 -178.81 3.62 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 121.395 0.617 . . . . 0.0 111.932 -177.051 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 23.3 m -119.95 134.4 23.97 Favored Pre-proline 0 C--N 1.316 -0.864 0 CA-C-N 115.084 -0.962 . . . . 0.0 109.964 -179.609 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.508 ' HB3' HG23 ' A' ' 32' ' ' VAL . 31.4 Cg_endo -65.67 145.58 81.85 Favored 'Trans proline' 0 N--CA 1.464 -0.242 0 C-N-CA 122.131 1.887 . . . . 0.0 111.738 176.553 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 97.83 11.0 51.6 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.517 -0.849 . . . . 0.0 112.917 -178.926 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 80.4 mt -98.04 164.9 12.15 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.772 0.32 . . . . 0.0 110.524 177.276 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.46 ' HB ' ' HB2' ' A' ' 80' ' ' ASP . 39.7 t -97.08 140.94 16.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.514 0 CA-C-N 116.325 -0.398 . . . . 0.0 109.99 177.633 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.527 ' HB ' HG23 ' A' ' 27' ' ' VAL . 72.1 mt -103.86 115.51 45.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.449 0 CA-C-O 120.839 0.352 . . . . 0.0 110.519 178.493 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.401 ' HB3' ' HB ' ' A' ' 78' ' ' THR . 7.7 tt0 -78.98 -55.11 5.38 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.598 0.713 . . . . 0.0 110.3 177.142 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.611 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 8.0 p -148.15 146.65 28.84 Favored 'General case' 0 C--N 1.315 -0.908 0 CA-C-N 115.423 -0.808 . . . . 0.0 112.157 -173.023 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.457 ' HA ' ' O ' ' A' ' 76' ' ' ASN . 49.1 mt -117.29 114.91 47.07 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.563 0 CA-C-N 114.96 -1.018 . . . . 0.0 109.225 173.577 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 7.6 t-20 61.91 -152.62 0.36 Allowed 'General case' 0 C--O 1.234 0.25 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 -171.746 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -79.57 21.45 4.5 Favored Glycine 0 CA--C 1.523 0.532 0 C-N-CA 120.307 -0.949 . . . . 0.0 112.258 175.931 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 61.0 mtm -123.66 106.3 32.29 Favored Pre-proline 0 C--N 1.329 -0.32 0 CA-C-O 120.805 0.336 . . . . 0.0 110.19 -178.835 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.611 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 65.1 Cg_endo -73.99 150.18 43.04 Favored 'Trans proline' 0 N--CA 1.46 -0.48 0 C-N-CA 122.133 1.889 . . . . 0.0 112.602 -179.36 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.432 ' O ' ' HA2' ' A' ' 26' ' ' GLY . 33.5 p -120.72 106.07 11.36 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 116.006 -0.543 . . . . 0.0 110.74 -178.234 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 12.6 p -96.03 -22.45 17.35 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-N 116.469 -0.332 . . . . 0.0 110.927 -179.723 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . 0.473 ' HB3' ' HB3' ' A' ' 24' ' ' PRO . 27.5 p-10 -146.63 -169.41 3.27 Favored 'General case' 0 N--CA 1.447 -0.59 0 CA-C-O 121.271 0.558 . . . . 0.0 110.594 175.457 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.544 ' HG ' ' HB2' ' A' ' 106' ' ' ASN . 19.1 mt -68.43 -35.29 77.41 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.142 -0.935 . . . . 0.0 111.813 -178.683 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 7.7 m -65.77 -45.71 81.51 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-O 120.758 0.313 . . . . 0.0 111.324 -177.555 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 1.6 p -66.29 -33.38 75.6 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.137 0.494 . . . . 0.0 110.528 178.257 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 76.1 t80 -62.01 -46.8 87.61 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.311 -0.859 . . . . 0.0 110.526 174.73 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 5.3 t -63.75 -45.1 91.37 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.593 -179.458 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -66.36 -26.8 67.44 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.965 -0.562 . . . . 0.0 111.682 -177.265 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -78.68 -43.64 25.55 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-O 121.011 0.434 . . . . 0.0 110.365 176.657 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -59.66 -42.0 91.85 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.456 -0.793 . . . . 0.0 111.354 -176.506 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 15.2 ptmm? -64.97 -6.86 9.48 Favored 'General case' 0 C--N 1.328 -0.347 0 N-CA-C 112.595 0.591 . . . . 0.0 112.595 -174.565 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 49.6 p -106.28 -14.59 15.07 Favored 'General case' 0 C--N 1.326 -0.426 0 C-N-CA 120.768 -0.373 . . . . 0.0 111.402 -179.753 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 45.0 mm -72.06 140.0 18.8 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-O 120.863 0.363 . . . . 0.0 111.23 -174.355 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . 0.607 ' HB2' ' HB2' ' A' ' 73' ' ' GLU . 2.5 m -89.33 151.22 22.2 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.372 179.031 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.432 HG22 ' H ' ' A' ' 98' ' ' ALA . 48.9 t -73.91 118.2 19.02 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 120.988 0.423 . . . . 0.0 110.055 177.327 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 93.02 9.07 61.14 Favored Glycine 0 N--CA 1.447 -0.59 0 C-N-CA 120.605 -0.807 . . . . 0.0 111.993 -179.073 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . 0.607 ' HB2' ' HB2' ' A' ' 70' ' ' SER . 35.7 tt0 -86.45 148.75 25.41 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 120.809 0.338 . . . . 0.0 110.092 179.626 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . 0.424 ' HA ' ' HA ' ' A' ' 87' ' ' LYS . 60.1 t -92.1 113.17 26.93 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 N-CA-C 109.429 -0.582 . . . . 0.0 109.429 176.919 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 27.3 pt -108.62 154.45 9.93 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.591 0 CA-C-O 121.314 0.578 . . . . 0.0 111.224 -177.441 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . 0.457 ' O ' ' HA ' ' A' ' 51' ' ' ILE . 6.0 t30 -95.85 127.26 41.72 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.151 178.382 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.562 HD12 HD21 ' A' ' 86' ' ' LEU . 54.3 mt -125.26 106.31 16.16 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.783 0 CA-C-O 121.288 0.566 . . . . 0.0 109.846 176.362 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . 0.401 ' HB ' ' HB3' ' A' ' 49' ' ' GLU . 4.3 m -78.59 102.48 7.97 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 115.32 -0.854 . . . . 0.0 109.239 178.302 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 70.7 p -94.6 167.65 11.34 Favored 'General case' 0 C--N 1.323 -0.545 0 C-N-CA 120.474 -0.49 . . . . 0.0 110.697 -178.569 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . 0.46 ' HB2' ' HB ' ' A' ' 47' ' ' VAL . 23.8 t70 -52.52 -33.38 45.0 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.267 -0.878 . . . . 0.0 111.834 -179.858 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 28.1 mt-30 -118.73 28.0 8.57 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 112.185 0.439 . . . . 0.0 112.185 -173.481 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 150.18 151.29 5.49 Favored Glycine 0 N--CA 1.45 -0.377 0 C-N-CA 120.208 -0.996 . . . . 0.0 113.487 173.854 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 26.4 m -94.81 106.72 18.72 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 109.697 -0.483 . . . . 0.0 109.697 176.361 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 84.8 m-85 -114.66 158.52 21.64 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.058 0.456 . . . . 0.0 110.874 -176.395 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 17.4 p-80 -123.66 129.13 50.65 Favored 'General case' 0 C--N 1.322 -0.616 0 CA-C-N 115.814 -0.63 . . . . 0.0 109.508 173.141 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.562 HD21 HD12 ' A' ' 77' ' ' ILE . 0.6 OUTLIER -134.24 156.07 49.05 Favored 'General case' 0 C--N 1.315 -0.907 0 CA-C-N 115.989 -0.55 . . . . 0.0 111.031 -176.614 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.424 ' HA ' ' HA ' ' A' ' 74' ' ' VAL . 58.8 tttm -96.35 131.59 42.73 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.675 -179.022 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 39.9 p -69.75 139.46 53.32 Favored 'General case' 0 C--O 1.238 0.498 0 CA-C-O 121.158 0.504 . . . . 0.0 111.127 178.714 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -80.65 175.71 54.81 Favored Glycine 0 N--CA 1.433 -1.564 0 N-CA-C 111.146 -0.782 . . . . 0.0 111.146 176.63 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.415 ' HA ' HG13 ' A' ' 71' ' ' VAL . 0.3 OUTLIER -90.72 163.89 14.33 Favored 'General case' 0 C--N 1.312 -1.04 0 CA-C-O 121.079 0.466 . . . . 0.0 111.323 -176.027 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -80.63 136.25 52.04 Favored Pre-proline 0 C--N 1.324 -0.527 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.731 177.431 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . . . . . . . . . 52.5 Cg_exo -53.9 -57.46 1.87 Allowed 'Trans proline' 0 C--N 1.346 0.406 0 C-N-CA 122.843 2.362 . . . . 0.0 111.665 178.332 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 48.1 t-20 -125.86 -84.44 0.63 Allowed 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 174.211 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 15.6 t-20 -164.74 82.89 0.39 Allowed 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.136 0.493 . . . . 0.0 110.503 176.23 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 41.4 t -141.94 -72.32 0.33 Allowed 'General case' 0 C--N 1.322 -0.608 0 N-CA-C 109.326 -0.62 . . . . 0.0 109.326 175.727 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 27.6 m -98.24 128.57 44.76 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 175.119 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 1.1 mpt_? -108.53 147.84 31.15 Favored 'General case' 0 C--N 1.328 -0.36 0 N-CA-C 109.937 -0.394 . . . . 0.0 109.937 -175.266 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . 0.432 ' H ' HG22 ' A' ' 71' ' ' VAL . . . 57.87 82.11 0.14 Allowed 'General case' 0 N--CA 1.465 0.281 0 O-C-N 123.793 0.683 . . . . 0.0 110.712 179.774 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -96.49 112.7 24.35 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 116.024 -0.535 . . . . 0.0 110.406 -171.413 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' MET . . . . . 0.596 ' HG2' ' H ' ' A' ' 102' ' ' ILE . 1.4 pmm? -63.5 -31.09 72.15 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-N 115.742 -0.663 . . . . 0.0 110.701 -179.498 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 104.73 1.46 42.91 Favored Glycine 0 N--CA 1.45 -0.409 0 C-N-CA 120.466 -0.873 . . . . 0.0 113.295 175.898 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.802 HG22 HG22 ' A' ' 32' ' ' VAL . 2.8 pp -130.08 148.03 33.19 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.61 0 CA-C-O 121.003 0.43 . . . . 0.0 110.771 179.55 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . 0.572 ' HB3' ' HB3' ' A' ' 30' ' ' ASP . 1.0 OUTLIER -80.73 137.93 36.29 Favored 'General case' 0 C--N 1.321 -0.638 0 N-CA-C 108.242 -1.022 . . . . 0.0 108.242 172.89 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.7 m -112.25 153.23 27.44 Favored 'General case' 0 C--N 1.31 -1.14 0 CA-C-O 120.802 0.334 . . . . 0.0 110.394 -177.491 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 23.8 p -135.67 163.92 29.06 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 115.96 -0.564 . . . . 0.0 109.976 -179.873 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . 0.544 ' HB2' ' HG ' ' A' ' 59' ' ' LEU . 65.8 t30 -94.15 -25.33 17.17 Favored 'General case' 0 C--N 1.317 -0.839 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 -177.111 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 49.0 t-80 63.53 73.44 0.45 Allowed 'General case' 0 C--O 1.232 0.147 0 CA-C-N 114.799 -1.091 . . . . 0.0 111.562 175.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 96.0 mt -100.94 -167.28 1.41 Allowed 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.961 -0.563 . . . . 0.0 109.847 174.055 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 83.0 mtt180 -125.06 122.02 36.03 Favored 'General case' 0 C--N 1.314 -0.96 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.288 178.321 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 38.4 t -117.8 130.41 72.72 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.653 0 CA-C-N 115.595 -0.729 . . . . 0.0 110.623 -177.588 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' ARG . . . . . . . . . . . . . 42.8 ttm180 -86.77 117.93 25.84 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.25 176.78 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 7.9 p-10 -97.32 110.35 22.92 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-O 121.385 0.612 . . . . 0.0 109.691 178.011 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 50.5 m -118.43 96.19 5.19 Favored 'General case' 0 C--N 1.316 -0.888 0 CA-C-N 115.844 -0.617 . . . . 0.0 110.309 176.467 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 17.1 m -83.29 115.19 25.26 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.486 0 CA-C-O 121.416 0.627 . . . . 0.0 110.569 178.3 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -137.11 82.18 1.92 Allowed 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.57 -0.741 . . . . 0.0 109.902 178.897 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 6.1 m -101.0 150.49 22.84 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-N 115.659 -0.7 . . . . 0.0 110.281 -177.176 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 27.7 m -81.56 127.76 39.3 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 CA-C-O 121.176 0.512 . . . . 0.0 110.081 174.328 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 81.2 mt -96.81 11.65 34.94 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.751 -176.112 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . -100.84 124.09 8.14 Favored Glycine 0 N--CA 1.445 -0.706 0 C-N-CA 120.833 -0.698 . . . . 0.0 111.982 -179.249 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 6.3 p-10 -99.93 179.07 4.62 Favored 'General case' 0 C--N 1.323 -0.575 0 N-CA-C 109.575 -0.528 . . . . 0.0 109.575 176.531 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 17.4 p -93.19 101.2 13.48 Favored 'General case' 0 C--N 1.324 -0.528 0 CA-C-O 121.623 0.725 . . . . 0.0 111.603 -177.528 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . 0.424 ' H ' HD12 ' A' ' 122' ' ' LEU . 5.0 mp -80.89 130.25 64.43 Favored Pre-proline 0 C--N 1.324 -0.535 0 CA-C-N 115.461 -0.79 . . . . 0.0 110.139 176.801 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 23.9 Cg_exo -64.15 118.95 5.87 Favored 'Trans proline' 0 N--CA 1.46 -0.499 0 C-N-CA 122.51 2.14 . . . . 0.0 110.878 174.343 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 55.0 t80 -82.29 107.11 14.72 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.984 0.421 . . . . 0.0 110.33 -177.862 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.249 1.062 0 CA-C-O 118.306 -0.854 . . . . 0.0 109.781 178.019 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . . . . . . . . . 88.5 mt-30 . . . . . 0 CA--C 1.524 -0.034 0 CA-C-O 120.376 0.131 . . . . 0.0 110.689 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 21.9 Cg_exo -66.22 156.24 65.87 Favored 'Trans proline' 0 C--O 1.236 0.391 0 C-N-CA 123.051 2.5 . . . . 0.0 111.889 178.644 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -171.31 -41.31 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.99 0.424 . . . . 0.0 111.544 -175.53 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.548 ' HA2' ' HA ' ' A' ' 57' ' ' SER . . . 167.48 151.3 6.89 Favored Glycine 0 N--CA 1.446 -0.686 0 N-CA-C 111.247 -0.741 . . . . 0.0 111.247 -177.664 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.621 HG23 ' HB ' ' A' ' 48' ' ' ILE . 29.5 m -102.81 145.26 12.49 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-O 121.021 0.439 . . . . 0.0 110.82 -179.038 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 29.4 tt0 -115.82 150.18 37.38 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-N 116.039 -0.528 . . . . 0.0 110.704 -178.567 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.455 HD12 ' HB2' ' A' ' 46' ' ' LEU . 48.3 mt -76.85 107.94 8.97 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.011 178.003 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 22.5 t70 -62.29 -62.19 1.93 Allowed 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.551 0.691 . . . . 0.0 109.871 177.213 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 13.4 p -158.11 149.2 21.0 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.205 -0.907 . . . . 0.0 110.625 179.253 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.526 HG22 HG22 ' A' ' 102' ' ' ILE . 44.8 t -99.11 117.94 44.96 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.775 0 N-CA-C 109.519 -0.548 . . . . 0.0 109.519 177.272 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.503 ' HA ' ' HD3' ' A' ' 34' ' ' PRO . 11.9 m -80.91 117.37 67.75 Favored Pre-proline 0 N--CA 1.447 -0.594 0 CA-C-O 120.982 0.42 . . . . 0.0 110.572 -179.95 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . 0.503 ' HD3' ' HA ' ' A' ' 33' ' ' VAL . 16.7 Cg_exo -69.73 25.82 0.17 Allowed 'Trans proline' 0 N--CA 1.478 0.605 0 C-N-CA 123.918 3.079 . . . . 0.0 113.85 -174.208 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -120.56 15.08 9.87 Favored Glycine 0 N--CA 1.446 -0.636 0 N-CA-C 110.645 -0.982 . . . . 0.0 110.645 174.339 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 7.5 m -139.1 177.33 2.11 Favored Pre-proline 0 C--N 1.325 -0.477 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 -177.358 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 24.8 Cg_exo -64.9 -172.86 0.22 Allowed 'Trans proline' 0 C--N 1.35 0.656 0 C-N-CA 122.255 1.97 . . . . 0.0 112.214 174.107 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.605 ' HB2' HD11 ' A' ' 86' ' ' LEU . . . 72.38 -23.25 0.2 Allowed 'General case' 0 N--CA 1.47 0.538 0 C-N-CA 123.493 0.717 . . . . 0.0 112.867 177.108 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 37.0 m -61.64 -29.61 70.17 Favored 'General case' 0 CA--C 1.531 0.233 0 CA-C-O 121.018 0.437 . . . . 0.0 111.842 -176.439 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 17.0 tppt? -97.06 -6.01 36.2 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.003 0.43 . . . . 0.0 110.51 -178.843 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 46.9 t -102.06 -52.69 8.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.394 0 CA-C-N 116.382 -0.372 . . . . 0.0 111.712 -174.117 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.456 HD11 ' HB1' ' A' ' 38' ' ' ALA . 1.2 pp -127.49 -177.54 4.12 Favored 'General case' 0 N--CA 1.451 -0.405 0 CA-C-O 121.366 0.603 . . . . 0.0 112.026 -175.343 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 2.9 p -125.09 151.96 69.92 Favored Pre-proline 0 C--N 1.32 -0.696 0 CA-C-N 115.008 -0.996 . . . . 0.0 110.62 -179.955 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 57.4 Cg_endo -70.47 156.01 62.37 Favored 'Trans proline' 0 C--N 1.343 0.278 0 C-N-CA 122.404 2.069 . . . . 0.0 112.191 178.457 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 100.11 -13.36 60.35 Favored Glycine 0 N--CA 1.449 -0.445 0 C-N-CA 120.606 -0.807 . . . . 0.0 112.491 -178.56 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.455 ' HB2' HD12 ' A' ' 29' ' ' ILE . 91.9 mt -79.4 164.62 23.86 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.833 0.349 . . . . 0.0 110.803 179.597 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 48.4 t -105.98 135.12 45.45 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.528 -178.368 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.621 ' HB ' HG23 ' A' ' 27' ' ' VAL . 8.4 mm -88.14 100.38 10.26 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 175.758 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 57.1 mt-10 -78.31 -48.23 16.09 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 116.36 -0.382 . . . . 0.0 111.049 -177.624 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.585 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 5.4 p -159.92 145.81 15.66 Favored 'General case' 0 N--CA 1.447 -0.592 0 CA-C-O 121.203 0.525 . . . . 0.0 111.797 -176.895 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 67.9 mt -115.38 106.25 20.15 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.695 0 CA-C-N 115.099 -0.955 . . . . 0.0 108.595 175.791 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 3.1 m-20 59.96 -152.14 0.4 Allowed 'General case' 0 C--O 1.236 0.392 0 N-CA-C 108.939 -0.763 . . . . 0.0 108.939 -171.778 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -76.14 28.61 1.41 Allowed Glycine 0 CA--C 1.524 0.63 0 C-N-CA 120.681 -0.771 . . . . 0.0 112.696 176.913 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 57.4 mtm -130.44 101.83 17.23 Favored Pre-proline 0 C--N 1.326 -0.414 0 N-CA-C 109.676 -0.49 . . . . 0.0 109.676 176.934 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.585 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 60.0 Cg_endo -72.19 150.99 54.48 Favored 'Trans proline' 0 N--CA 1.46 -0.494 0 C-N-CA 122.027 1.818 . . . . 0.0 112.306 179.972 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . 0.426 ' O ' ' HA2' ' A' ' 26' ' ' GLY . 6.2 p -111.33 83.66 1.81 Allowed 'General case' 0 C--N 1.32 -0.708 0 CA-C-O 121.242 0.544 . . . . 0.0 111.863 -177.326 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . 0.548 ' HA ' ' HA2' ' A' ' 26' ' ' GLY . 20.9 m -91.11 -13.64 32.69 Favored 'General case' 0 C--N 1.32 -0.675 0 CA-C-N 115.571 -0.74 . . . . 0.0 109.846 176.507 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 5.4 m120 -125.5 164.64 20.06 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.672 -0.694 . . . . 0.0 109.939 -177.877 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 41.5 mt -73.81 -31.75 63.4 Favored 'General case' 0 N--CA 1.446 -0.665 0 CA-C-O 121.516 0.674 . . . . 0.0 109.774 172.0 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -68.28 -40.54 81.79 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 115.176 -0.92 . . . . 0.0 111.734 178.891 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 12.6 p -60.9 -39.6 89.94 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.72 0.295 . . . . 0.0 110.959 175.857 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 87.3 t80 -62.04 -43.51 98.69 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-O 121.478 0.656 . . . . 0.0 109.676 175.948 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 61.4 m -65.1 -48.9 72.05 Favored 'General case' 0 N--CA 1.446 -0.638 0 CA-C-N 115.08 -0.964 . . . . 0.0 111.757 179.28 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -63.53 -32.45 73.91 Favored 'General case' 0 C--N 1.323 -0.548 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.97 -176.575 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . 0.611 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -70.5 -48.34 56.1 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.014 -0.539 . . . . 0.0 109.928 178.58 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.408 ' HA ' HD23 ' A' ' 66' ' ' LEU . 4.0 mt -63.81 -35.28 80.1 Favored 'General case' 0 N--CA 1.449 -0.477 0 CA-C-N 115.451 -0.795 . . . . 0.0 111.94 -176.438 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 59.8 mtpt -70.48 -21.98 62.71 Favored 'General case' 0 C--N 1.33 -0.273 0 N-CA-C 112.115 0.413 . . . . 0.0 112.115 -178.357 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 71.6 p -90.47 -13.54 34.56 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.864 0.364 . . . . 0.0 111.425 -179.636 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.611 HG12 ' O ' ' A' ' 65' ' ' ALA . 41.8 mm -79.85 143.8 11.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.407 0 CA-C-N 116.449 -0.342 . . . . 0.0 110.599 -177.758 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 3.5 m -83.72 157.13 22.27 Favored 'General case' 0 C--N 1.325 -0.494 0 N-CA-C 109.737 -0.468 . . . . 0.0 109.737 176.723 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 25.1 t -74.26 119.68 22.06 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.522 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 176.239 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 91.67 21.29 34.56 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.668 -0.777 . . . . 0.0 111.523 -177.422 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 29.9 tt0 -98.91 146.46 25.96 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 179.858 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 57.5 t -98.38 110.81 26.64 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.848 0 CA-C-O 121.052 0.453 . . . . 0.0 110.473 -178.134 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.536 HG13 HD11 ' A' ' 77' ' ' ILE . 23.3 pt -103.84 163.57 3.86 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-N 115.822 -0.626 . . . . 0.0 110.679 179.773 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 6.3 t30 -115.9 117.07 29.14 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.782 -177.219 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.536 HD11 HG13 ' A' ' 75' ' ' ILE . 4.6 mp -113.5 118.93 59.53 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 CA-C-O 121.26 0.552 . . . . 0.0 110.293 -177.301 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 32.5 m -91.93 117.17 29.55 Favored 'General case' 0 C--N 1.318 -0.762 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.39 175.796 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 71.7 p -114.35 170.89 7.97 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 110.179 -0.304 . . . . 0.0 110.179 -179.928 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 9.0 t70 -53.68 -41.75 67.2 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.931 -0.577 . . . . 0.0 112.064 179.54 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 6.7 tp-100 -109.15 31.09 5.98 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 120.906 0.384 . . . . 0.0 111.451 -171.487 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 140.28 176.17 14.94 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 120.133 -1.032 . . . . 0.0 113.12 173.384 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 7.0 m -117.5 123.89 47.42 Favored 'General case' 0 C--N 1.318 -0.775 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 178.802 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 66.4 m-85 -121.21 154.27 36.5 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 120.982 0.42 . . . . 0.0 110.726 -176.747 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 56.1 p-80 -111.3 130.88 55.53 Favored 'General case' 0 C--N 1.319 -0.727 0 N-CA-C 108.989 -0.745 . . . . 0.0 108.989 173.185 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.605 HD11 ' HB2' ' A' ' 38' ' ' ALA . 3.8 tt -124.09 137.44 54.57 Favored 'General case' 0 C--N 1.311 -1.084 0 CA-C-N 115.834 -0.621 . . . . 0.0 110.053 -172.634 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.457 ' N ' HD23 ' A' ' 86' ' ' LEU . 78.8 tttt -102.67 111.32 23.58 Favored 'General case' 0 C--N 1.311 -1.077 0 N-CA-C 109.038 -0.727 . . . . 0.0 109.038 178.154 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.546 HG21 HG21 ' A' ' 69' ' ' ILE . 26.4 p -59.52 142.93 51.51 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 115.812 -0.631 . . . . 0.0 112.616 -172.405 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -133.03 -133.79 3.43 Favored Glycine 0 N--CA 1.443 -0.887 0 N-CA-C 111.017 -0.833 . . . . 0.0 111.017 176.824 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.474 ' HG3' ' HA ' ' A' ' 93' ' ' ASN . 0.0 OUTLIER -156.36 158.53 37.54 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 176.779 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' ASN . . . . . 0.763 ' HB3' ' HD3' ' A' ' 92' ' ' PRO . 26.2 t-20 -98.34 -57.73 0.16 Allowed Pre-proline 0 C--N 1.324 -0.501 0 CA-C-N 116.471 -0.331 . . . . 0.0 111.844 -176.998 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.763 ' HD3' ' HB3' ' A' ' 91' ' ' ASN . 6.9 Cg_exo -75.0 -27.07 10.32 Favored 'Trans proline' 0 C--N 1.353 0.773 0 C-N-CA 122.153 1.902 . . . . 0.0 112.508 -179.404 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' ASN . . . . . 0.474 ' HA ' ' HG3' ' A' ' 90' ' ' ARG . 8.6 t30 58.58 75.25 0.4 Allowed 'General case' 0 N--CA 1.466 0.338 0 CA-C-O 121.745 0.784 . . . . 0.0 110.223 -175.288 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 25.8 p-10 -144.73 44.92 1.38 Allowed 'General case' 0 C--N 1.319 -0.755 0 CA-C-N 115.026 -0.988 . . . . 0.0 109.338 -178.094 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 42.3 m 57.21 74.18 0.43 Allowed 'General case' 0 CA--C 1.521 -0.159 0 N-CA-C 108.845 -0.798 . . . . 0.0 108.845 -168.78 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 1.8 m -106.89 -178.97 3.8 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-N 115.104 -0.953 . . . . 0.0 110.855 -170.442 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 39.0 ttm180 -103.22 169.16 8.72 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 172.724 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -45.15 116.22 1.07 Allowed 'General case' 0 N--CA 1.461 0.123 0 O-C-N 123.689 0.618 . . . . 0.0 112.167 -179.51 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . 0.446 ' HB3' ' HA ' ' A' ' 90' ' ' ARG . 18.6 t80 -120.98 135.55 55.19 Favored 'General case' 0 C--N 1.325 -0.475 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 178.05 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 49.6 ttm -77.35 -53.32 7.83 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.972 -178.231 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 117.31 17.07 5.84 Favored Glycine 0 N--CA 1.452 -0.261 0 C-N-CA 120.162 -1.018 . . . . 0.0 113.398 176.88 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.526 HG22 HG22 ' A' ' 32' ' ' VAL . 39.0 pt -130.17 153.05 38.37 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.558 0 CA-C-O 120.857 0.36 . . . . 0.0 110.67 179.342 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 42.8 mtp85 -82.01 123.36 28.83 Favored 'General case' 0 C--N 1.321 -0.651 0 N-CA-C 108.185 -1.042 . . . . 0.0 108.185 168.191 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -113.77 148.97 35.59 Favored 'General case' 0 C--N 1.314 -0.956 0 C-N-CA 120.643 -0.423 . . . . 0.0 110.479 -177.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 54.0 m -155.33 160.29 40.63 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 109.026 -0.731 . . . . 0.0 109.026 176.917 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . 0.676 ' HB3' ' HG ' ' A' ' 108' ' ' LEU . 86.8 m-20 -70.09 -33.22 71.61 Favored 'General case' 0 C--N 1.317 -0.83 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 177.604 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 47.7 t-80 53.26 39.93 30.5 Favored 'General case' 0 N--CA 1.465 0.299 0 CA-C-N 115.338 -0.846 . . . . 0.0 109.793 179.823 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . 0.676 ' HG ' ' HB3' ' A' ' 106' ' ' ASN . 67.3 mt -71.32 172.82 8.69 Favored 'General case' 0 CA--C 1.511 -0.531 0 CA-C-N 115.424 -0.807 . . . . 0.0 111.284 -177.403 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 71.6 mtm180 -78.43 151.79 32.53 Favored 'General case' 0 C--N 1.313 -0.99 0 CA-C-N 114.817 -1.083 . . . . 0.0 110.497 179.627 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 8.1 p -82.2 140.34 16.58 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.744 0 CA-C-O 121.711 0.767 . . . . 0.0 111.899 -172.333 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' ARG . . . . . . . . . . . . . 33.8 ttt85 -134.1 145.01 48.93 Favored 'General case' 0 C--N 1.32 -0.713 0 CA-C-N 115.0 -1.0 . . . . 0.0 108.716 173.202 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 19.0 p-10 -82.32 27.03 0.51 Allowed 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 112.307 0.484 . . . . 0.0 112.307 -171.109 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 36.9 m -91.38 74.2 6.08 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 175.758 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 17.5 m -67.64 128.91 31.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.003 -0.544 . . . . 0.0 111.866 -174.406 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -151.77 124.94 8.7 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.606 -0.724 . . . . 0.0 110.25 178.714 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 42.4 m -140.26 61.65 1.52 Allowed 'General case' 0 C--N 1.324 -0.503 0 CA-C-O 121.55 0.69 . . . . 0.0 109.507 177.335 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . 0.449 HG12 ' H ' ' A' ' 119' ' ' GLY . 31.1 t -102.3 142.17 17.09 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-N 115.263 -0.88 . . . . 0.0 110.118 -175.922 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 80.3 mt -82.21 -33.73 29.25 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.398 -0.364 . . . . 0.0 110.674 -178.557 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . 0.449 ' H ' HG12 ' A' ' 117' ' ' VAL . . . 71.96 54.85 7.71 Favored Glycine 0 N--CA 1.445 -0.725 0 N-CA-C 110.635 -0.986 . . . . 0.0 110.635 -175.789 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 11.8 m-20 -71.5 124.94 25.76 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.212 0.529 . . . . 0.0 111.644 -172.6 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 4.5 t -125.16 108.42 11.75 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.635 -0.711 . . . . 0.0 109.177 172.597 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 88.6 mt -73.23 123.28 89.35 Favored Pre-proline 0 C--N 1.327 -0.41 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.991 -177.011 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 17.2 Cg_exo -66.82 143.26 66.35 Favored 'Trans proline' 0 C--O 1.235 0.346 0 C-N-CA 122.955 2.437 . . . . 0.0 112.222 179.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 39.6 t80 -96.49 96.75 8.91 Favored 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 109.112 -0.699 . . . . 0.0 109.112 177.809 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.25 1.084 0 CA-C-O 118.248 -0.882 . . . . 0.0 110.828 -175.686 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.753 ' HB2' HD23 ' A' ' 108' ' ' LEU . 32.4 mt-30 . . . . . 0 CA--C 1.526 0.049 0 CA-C-O 120.601 0.238 . . . . 0.0 111.093 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 89.9 Cg_endo -99.74 159.33 0.55 Allowed 'Trans proline' 0 N--CA 1.447 -1.245 0 C-N-CA 122.958 2.439 . . . . 0.0 112.019 173.672 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.528 ' HB3' ' HD2' ' A' ' 107' ' ' HIS . 35.9 t70 -178.05 30.61 0.0 OUTLIER 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 177.865 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 90.44 128.39 3.78 Favored Glycine 0 N--CA 1.443 -0.9 0 CA-C-N 115.38 -0.827 . . . . 0.0 111.696 -175.664 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.53 HG23 ' HB ' ' A' ' 48' ' ' ILE . 4.6 m -69.28 141.56 17.17 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.69 0 N-CA-C 109.605 -0.516 . . . . 0.0 109.605 178.728 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . 0.446 ' HB3' HG13 ' A' ' 47' ' ' VAL . 8.3 pt20 -125.45 152.99 44.16 Favored 'General case' 0 C--N 1.319 -0.736 0 C-N-CA 119.17 -1.012 . . . . 0.0 111.879 -178.698 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.415 HG12 HD12 ' A' ' 102' ' ' ILE . 50.1 mt -77.32 130.81 35.83 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.61 0 CA-C-N 115.23 -0.896 . . . . 0.0 110.82 -178.784 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -89.94 -50.27 6.13 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.244 174.954 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 23.6 p -161.96 166.78 25.6 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 116.587 -0.279 . . . . 0.0 110.917 -179.301 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.488 HG13 HG22 ' A' ' 102' ' ' ILE . 45.8 t -110.38 140.36 29.78 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.557 0 N-CA-C 109.365 -0.605 . . . . 0.0 109.365 174.755 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 7.1 p -60.78 140.12 93.28 Favored Pre-proline 0 CA--C 1.537 0.473 0 N-CA-C 110.317 -0.253 . . . . 0.0 110.317 179.735 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 15.7 Cg_exo -69.46 65.39 1.62 Allowed 'Trans proline' 0 C--N 1.348 0.5 0 C-N-CA 122.925 2.416 . . . . 0.0 112.173 176.175 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 165.59 -169.26 39.92 Favored Glycine 0 N--CA 1.446 -0.7 0 N-CA-C 111.34 -0.704 . . . . 0.0 111.34 -179.707 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.773 ' HB2' ' HD2' ' A' ' 37' ' ' PRO . 60.6 p 56.39 179.46 0.03 OUTLIER Pre-proline 0 CA--C 1.545 0.761 0 C-N-CA 123.448 0.699 . . . . 0.0 111.513 179.432 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . 0.773 ' HD2' ' HB2' ' A' ' 36' ' ' SER . 58.4 Cg_endo -73.1 -159.45 0.08 OUTLIER 'Trans proline' 0 C--N 1.349 0.586 0 C-N-CA 121.967 1.778 . . . . 0.0 111.636 169.712 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.472 ' HB2' HD11 ' A' ' 86' ' ' LEU . . . 77.36 -33.43 0.19 Allowed 'General case' 0 N--CA 1.471 0.612 0 C-N-CA 123.395 0.678 . . . . 0.0 112.321 172.712 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 35.0 t -65.15 -21.18 66.75 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-N 116.595 -0.275 . . . . 0.0 111.082 -178.884 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 61.9 mttp -99.35 -0.06 41.86 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.918 0.39 . . . . 0.0 110.378 178.273 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.512 ' HB ' HD12 ' A' ' 42' ' ' LEU . 45.9 t -105.08 -53.73 6.79 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.408 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.899 -175.928 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.512 HD12 ' HB ' ' A' ' 41' ' ' VAL . 5.2 mp -106.88 164.08 12.42 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.997 0.427 . . . . 0.0 110.55 -178.578 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . 0.449 ' O ' ' HG ' ' A' ' 46' ' ' LEU . 40.1 m -109.42 124.46 33.81 Favored Pre-proline 0 C--N 1.319 -0.729 0 CA-C-N 115.831 -0.622 . . . . 0.0 109.87 177.109 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 12.4 Cg_endo -59.36 134.48 58.99 Favored 'Trans proline' 0 N--CA 1.46 -0.468 0 C-N-CA 122.277 1.985 . . . . 0.0 111.965 177.834 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 107.93 -16.52 36.28 Favored Glycine 0 N--CA 1.446 -0.638 0 C-N-CA 120.631 -0.795 . . . . 0.0 112.976 -179.695 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.449 ' HG ' ' O ' ' A' ' 43' ' ' THR . 75.6 mt -71.89 164.16 26.55 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 120.844 0.354 . . . . 0.0 110.642 179.99 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.446 HG13 ' HB3' ' A' ' 28' ' ' GLN . 23.1 t -107.46 142.63 19.72 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 CA-C-N 116.194 -0.457 . . . . 0.0 109.939 179.8 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.53 ' HB ' HG23 ' A' ' 27' ' ' VAL . 10.6 mm -84.68 125.7 40.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.413 0 N-CA-C 109.73 -0.47 . . . . 0.0 109.73 179.625 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -90.23 -54.05 4.19 Favored 'General case' 0 C--N 1.321 -0.674 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 176.143 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.444 ' CB ' ' HA ' ' A' ' 55' ' ' PRO . 20.6 m -154.44 152.63 30.37 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.419 -174.536 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.473 HG22 ' N ' ' A' ' 52' ' ' ASN . 46.3 mm -99.47 167.27 1.96 Allowed 'Isoleucine or valine' 0 C--N 1.317 -0.823 0 N-CA-C 107.64 -1.245 . . . . 0.0 107.64 171.871 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' ASN . . . . . 0.657 ' HB2' ' H ' ' A' ' 76' ' ' ASN . 54.1 t30 -50.51 103.44 0.05 Allowed 'General case' 0 C--N 1.324 -0.501 0 N-CA-C 112.304 0.483 . . . . 0.0 112.304 -176.86 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 83.18 -15.36 34.05 Favored Glycine 0 N--CA 1.451 -0.343 0 CA-C-N 115.898 -0.592 . . . . 0.0 113.053 176.993 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 40.7 mtm -130.29 106.95 16.12 Favored Pre-proline 0 C--N 1.326 -0.447 0 O-C-N 122.643 -0.328 . . . . 0.0 110.87 -173.518 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.444 ' HA ' ' CB ' ' A' ' 50' ' ' SER . 42.5 Cg_endo -68.06 148.96 76.61 Favored 'Trans proline' 0 C--N 1.343 0.242 0 C-N-CA 122.552 2.168 . . . . 0.0 112.199 -179.726 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 20.8 p -126.82 97.02 4.83 Favored 'General case' 0 C--N 1.326 -0.436 0 N-CA-C 112.102 0.408 . . . . 0.0 112.102 -175.532 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 22.9 t -102.01 -14.18 17.26 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 121.362 0.601 . . . . 0.0 109.734 174.871 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 32.3 m-80 -124.29 167.36 14.43 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.748 -0.66 . . . . 0.0 110.174 -178.57 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 1.6 mt -68.99 -35.27 76.52 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 116.322 -0.399 . . . . 0.0 109.97 173.387 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 19.5 m -64.11 -38.8 92.36 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.866 -0.606 . . . . 0.0 111.219 179.472 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 3.3 p -66.98 -33.32 75.32 Favored 'General case' 0 C--N 1.332 -0.154 0 CA-C-O 120.804 0.335 . . . . 0.0 110.887 178.566 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 55.2 t80 -71.63 -35.14 70.33 Favored 'General case' 0 C--N 1.331 -0.217 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 176.29 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 69.0 m -66.62 -50.06 64.23 Favored 'General case' 0 N--CA 1.444 -0.729 0 CA-C-N 115.365 -0.834 . . . . 0.0 111.296 178.39 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . 0.415 ' O ' ' HG2' ' A' ' 67' ' ' LYS . . . -63.43 -31.96 73.26 Favored 'General case' 0 C--N 1.326 -0.43 0 CA-C-N 115.747 -0.661 . . . . 0.0 111.39 -178.194 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . 0.474 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -76.93 -34.61 57.65 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.161 0.505 . . . . 0.0 110.639 -179.842 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 1.5 tt -68.71 -44.18 74.45 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.817 -0.629 . . . . 0.0 110.892 -177.445 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . 0.415 ' HG2' ' O ' ' A' ' 64' ' ' ALA . 14.6 ptmm? -60.43 -23.47 64.43 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.076 -0.511 . . . . 0.0 111.924 -174.044 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 17.7 p -87.53 -14.15 41.08 Favored 'General case' 0 C--N 1.325 -0.479 0 N-CA-C 112.043 0.386 . . . . 0.0 112.043 -179.869 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.474 HG12 ' O ' ' A' ' 65' ' ' ALA . 21.7 mm -85.65 136.81 22.03 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-O 120.84 0.352 . . . . 0.0 110.601 -177.87 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . 0.654 ' HA ' ' HD2' ' A' ' 97' ' ' ARG . 50.9 m -106.92 162.49 13.78 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.377 -0.374 . . . . 0.0 110.669 178.762 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.782 HG23 ' HB2' ' A' ' 97' ' ' ARG . 79.4 t -62.01 135.22 26.83 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.249 0 O-C-N 123.436 0.46 . . . . 0.0 110.518 175.353 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 94.33 -14.94 64.32 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.873 -0.68 . . . . 0.0 112.655 176.001 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 10.2 tp10 -80.29 150.3 30.03 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-O 121.128 0.49 . . . . 0.0 110.385 -177.379 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 47.3 t -106.34 124.76 61.94 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.701 0 CA-C-N 115.67 -0.696 . . . . 0.0 109.643 179.099 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.405 HG21 HD12 ' A' ' 69' ' ' ILE . 18.3 pt -119.6 157.34 21.78 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-O 121.377 0.608 . . . . 0.0 111.886 -176.749 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . 0.657 ' H ' ' HB2' ' A' ' 52' ' ' ASN . 4.5 t30 -99.08 127.16 44.97 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 114.861 -1.063 . . . . 0.0 110.034 179.43 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 72.4 mt -132.36 112.64 19.74 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-O 121.088 0.47 . . . . 0.0 110.514 -177.471 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . 0.557 ' HA ' ' HA ' ' A' ' 83' ' ' THR . 93.0 m -91.0 124.72 35.45 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.146 177.32 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 50.8 p -107.77 173.31 6.38 Favored 'General case' 0 C--N 1.319 -0.747 0 N-CA-C 109.457 -0.572 . . . . 0.0 109.457 174.703 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -63.17 -24.43 67.88 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-O 120.979 0.418 . . . . 0.0 111.259 -178.954 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 -106.77 16.86 23.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.444 -0.344 . . . . 0.0 111.606 -177.74 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 134.08 166.76 11.36 Favored Glycine 0 CA--C 1.516 0.123 0 C-N-CA 120.176 -1.011 . . . . 0.0 113.255 176.035 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.557 ' HA ' ' HA ' ' A' ' 78' ' ' THR . 35.2 m -98.07 137.83 36.27 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 120.934 0.397 . . . . 0.0 111.204 -179.709 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 74.9 m-85 -130.42 158.32 40.19 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.051 177.517 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 48.2 p-80 -112.43 130.39 56.0 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 109.643 -0.503 . . . . 0.0 109.643 174.401 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.472 HD11 ' HB2' ' A' ' 38' ' ' ALA . 28.4 tp -118.19 152.06 36.41 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.989 -173.01 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 60.4 tttp -119.95 123.82 44.47 Favored 'General case' 0 C--N 1.322 -0.597 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 178.152 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 25.7 p -72.62 137.48 46.14 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.325 0.583 . . . . 0.0 111.613 -177.613 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . 0.599 ' H ' ' HE1' ' A' ' 99' ' ' TYR . . . -106.22 -157.33 21.81 Favored Glycine 0 N--CA 1.448 -0.515 0 CA-C-N 115.642 -0.708 . . . . 0.0 111.797 177.123 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.567 ' O ' ' HD3' ' A' ' 92' ' ' PRO . 0.3 OUTLIER -137.0 35.55 2.58 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.725 0.298 . . . . 0.0 111.598 -170.45 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' ASN . . . . . . . . . . . . . 5.0 t30 -106.71 84.81 1.6 Allowed Pre-proline 0 C--N 1.325 -0.481 0 N-CA-C 109.147 -0.686 . . . . 0.0 109.147 173.165 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.617 ' HB3' ' O ' ' A' ' 96' ' ' SER . 10.2 Cg_endo -88.92 174.69 3.77 Favored 'Trans proline' 0 N--CA 1.456 -0.699 0 C-N-CA 123.133 2.555 . . . . 0.0 113.118 -171.299 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 19.9 t-20 -78.49 -46.93 18.46 Favored 'General case' 0 C--N 1.327 -0.404 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 174.688 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 27.2 t-20 -139.16 -69.89 0.42 Allowed 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.367 -0.833 . . . . 0.0 109.762 173.26 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 45.1 m -135.08 21.43 3.47 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 121.103 0.478 . . . . 0.0 110.557 179.529 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.617 ' O ' ' HB3' ' A' ' 92' ' ' PRO . 3.0 p -84.07 112.43 20.21 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.807 -177.077 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . 0.782 ' HB2' HG23 ' A' ' 71' ' ' VAL . 9.1 ptt180 -76.61 159.93 29.85 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 176.187 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . 56.72 70.73 0.62 Allowed 'General case' 0 CA--C 1.521 -0.143 0 N-CA-C 108.445 -0.946 . . . . 0.0 108.445 -174.791 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . 0.599 ' HE1' ' H ' ' A' ' 89' ' ' GLY . 6.2 p90 -67.14 -30.48 70.48 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 114.76 -1.109 . . . . 0.0 113.631 -160.575 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 24.3 mmt 60.45 95.56 0.03 OUTLIER 'General case' 0 N--CA 1.465 0.279 0 CA-C-O 121.313 0.578 . . . . 0.0 110.501 -173.356 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -83.75 29.2 3.77 Favored Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.829 -0.701 . . . . 0.0 112.846 -175.362 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.488 HG22 HG13 ' A' ' 32' ' ' VAL . 37.4 pt -136.94 154.54 31.54 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.742 0 CA-C-O 121.066 0.46 . . . . 0.0 109.988 -179.689 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . 0.424 ' HD3' ' HA ' ' A' ' 103' ' ' ARG . 7.8 tpp180 -92.8 144.52 25.2 Favored 'General case' 0 C--N 1.315 -0.908 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 175.809 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.4 t -145.47 154.68 42.5 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-O 121.417 0.627 . . . . 0.0 111.266 178.443 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 9.3 p -128.6 171.44 12.15 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-N 114.643 -1.162 . . . . 0.0 109.884 177.838 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . . . . . . . . . 59.6 t30 -88.96 3.62 50.93 Favored 'General case' 0 C--N 1.317 -0.84 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.579 -174.348 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . 0.528 ' HD2' ' HB3' ' A' ' 25' ' ' ASP . 81.7 t60 65.51 37.34 6.12 Favored 'General case' 0 CA--C 1.535 0.37 0 CA-C-O 121.792 0.806 . . . . 0.0 109.948 -178.199 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . 0.753 HD23 ' HB2' ' A' ' 23' ' ' GLN . 34.6 mt -68.56 167.67 14.52 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.306 -0.861 . . . . 0.0 110.925 176.902 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . 0.414 ' HB3' HE22 ' A' ' 23' ' ' GLN . 0.0 OUTLIER -110.56 91.74 3.77 Favored 'General case' 0 C--N 1.313 -1.015 0 N-CA-C 109.196 -0.668 . . . . 0.0 109.196 177.795 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 81.5 t -104.5 142.77 17.21 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.803 0 CA-C-N 115.318 -0.856 . . . . 0.0 110.711 -175.79 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' ARG . . . . . . . . . . . . . 54.8 ttt180 -69.21 148.2 50.19 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.847 -0.615 . . . . 0.0 109.493 176.009 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -53.97 98.35 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.186 0.517 . . . . 0.0 111.58 -177.951 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 4.8 m -140.98 101.25 4.0 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.062 -0.972 . . . . 0.0 108.941 177.425 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 6.4 m -105.78 108.72 25.71 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.461 0 CA-C-O 121.439 0.638 . . . . 0.0 111.795 -175.217 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -148.42 91.42 1.9 Allowed 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.328 -0.851 . . . . 0.0 109.973 176.98 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 46.1 m -140.78 31.13 1.84 Allowed 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.336 0.589 . . . . 0.0 110.491 -178.578 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 4.5 m -76.24 91.63 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.438 0 CA-C-O 121.573 0.701 . . . . 0.0 111.274 -178.958 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 86.2 mt -82.02 -53.85 5.79 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.61 -0.723 . . . . 0.0 109.97 176.759 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 99.06 -160.87 20.04 Favored Glycine 0 N--CA 1.444 -0.789 0 CA-C-N 115.564 -0.744 . . . . 0.0 112.203 179.202 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 37.0 t70 67.69 160.29 0.16 Allowed 'General case' 0 C--O 1.235 0.31 0 C-N-CA 123.529 0.732 . . . . 0.0 111.828 178.958 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 121' ' ' THR . . . . . 0.52 ' O ' ' HD3' ' A' ' 123' ' ' PRO . 4.7 t -134.35 126.6 29.97 Favored 'General case' 0 C--N 1.318 -0.787 0 CA-C-N 115.33 -0.85 . . . . 0.0 109.101 175.172 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 87.7 mt -111.46 93.96 21.08 Favored Pre-proline 0 C--N 1.324 -0.528 0 CA-C-N 116.425 -0.352 . . . . 0.0 111.558 -176.646 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . 0.52 ' HD3' ' O ' ' A' ' 121' ' ' THR . 9.7 Cg_endo -91.0 109.58 0.33 Allowed 'Trans proline' 0 N--CA 1.449 -1.139 0 C-N-CA 123.379 2.719 . . . . 0.0 111.228 172.506 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 37.8 p90 -92.04 107.64 19.35 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.516 0.674 . . . . 0.0 110.965 -178.278 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.967 0 CA-C-O 118.125 -0.941 . . . . 0.0 109.564 177.102 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . . . . . . . . . 51.1 tp60 . . . . . 0 N--CA 1.455 -0.2 0 N-CA-C 110.1 -0.333 . . . . 0.0 110.1 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_exo -61.58 118.4 5.27 Favored 'Trans proline' 0 C--O 1.235 0.372 0 C-N-CA 122.869 2.379 . . . . 0.0 111.349 174.506 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 28.5 p-10 -119.68 -23.88 6.39 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 115.941 -0.572 . . . . 0.0 112.135 -169.724 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 96.53 133.02 7.5 Favored Glycine 0 N--CA 1.446 -0.689 0 N-CA-C 111.15 -0.78 . . . . 0.0 111.15 -176.953 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.447 ' HA ' ' HA ' ' A' ' 106' ' ' ASN . 19.6 m -78.78 140.4 16.94 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.742 0 CA-C-O 120.98 0.419 . . . . 0.0 110.842 -176.93 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . 0.48 ' HB2' ' O ' ' A' ' 46' ' ' LEU . 2.8 pt20 -109.84 157.59 19.04 Favored 'General case' 0 C--N 1.317 -0.823 0 C-N-CA 120.22 -0.592 . . . . 0.0 109.778 175.662 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.551 HG23 HD11 ' A' ' 48' ' ' ILE . 2.2 pt -79.84 98.49 3.26 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.627 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.14 176.523 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 24.6 t70 -53.78 -55.64 24.62 Favored 'General case' 0 CA--C 1.504 -0.816 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.13 177.509 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 6.2 p -155.99 144.56 20.18 Favored 'General case' 0 N--CA 1.441 -0.908 0 CA-C-N 115.045 -0.979 . . . . 0.0 111.438 -178.152 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.603 ' HA ' HG22 ' A' ' 102' ' ' ILE . 52.3 t -87.62 141.34 14.46 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.01 0 CA-C-N 114.965 -1.016 . . . . 0.0 108.664 171.651 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 48.3 t -83.18 105.38 5.12 Favored Pre-proline 0 C--N 1.322 -0.592 0 N-CA-C 109.528 -0.545 . . . . 0.0 109.528 174.937 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . 0.505 ' HD3' ' O ' ' A' ' 32' ' ' VAL . 31.5 Cg_exo -58.19 113.64 1.62 Allowed 'Trans proline' 0 C--O 1.236 0.406 0 C-N-CA 122.774 2.316 . . . . 0.0 112.179 -175.305 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 133.61 -20.84 4.08 Favored Glycine 0 N--CA 1.446 -0.687 0 N-CA-C 111.227 -0.749 . . . . 0.0 111.227 -178.455 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 56.4 p -81.87 161.13 61.89 Favored Pre-proline 0 C--N 1.323 -0.575 0 N-CA-C 109.909 -0.404 . . . . 0.0 109.909 177.692 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 19.2 Cg_endo -59.03 -24.83 75.31 Favored 'Trans proline' 0 C--N 1.344 0.312 0 C-N-CA 122.36 2.04 . . . . 0.0 111.743 175.96 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.404 ' HB2' HD11 ' A' ' 86' ' ' LEU . . . -66.78 -27.86 67.93 Favored 'General case' 0 N--CA 1.454 -0.24 0 CA-C-N 115.922 -0.581 . . . . 0.0 111.553 -179.359 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.533 ' HA ' HG11 ' A' ' 32' ' ' VAL . 13.2 m -63.2 -22.39 66.84 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.91 0.386 . . . . 0.0 111.454 -177.65 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 65.3 mttm -97.27 -17.58 19.72 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.487 -175.76 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.65 ' HB ' HD23 ' A' ' 42' ' ' LEU . 60.6 t -98.23 -49.52 11.68 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.411 0 CA-C-N 116.345 -0.389 . . . . 0.0 111.871 -172.354 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.65 HD23 ' HB ' ' A' ' 41' ' ' VAL . 0.3 OUTLIER -117.12 178.23 4.43 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 121.561 0.696 . . . . 0.0 112.343 -173.745 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 56.8 m -128.42 128.99 23.6 Favored Pre-proline 0 C--N 1.322 -0.602 0 CA-C-N 114.693 -1.14 . . . . 0.0 109.593 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 38.0 Cg_endo -64.66 152.95 79.96 Favored 'Trans proline' 0 C--N 1.342 0.196 0 C-N-CA 122.611 2.207 . . . . 0.0 112.305 -177.643 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 99.82 -1.92 56.85 Favored Glycine 0 N--CA 1.449 -0.449 0 C-N-CA 120.553 -0.832 . . . . 0.0 112.582 -178.024 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.495 ' HB2' HD11 ' A' ' 29' ' ' ILE . 85.1 mt -89.81 164.15 14.75 Favored 'General case' 0 C--N 1.328 -0.367 0 N-CA-C 110.286 -0.264 . . . . 0.0 110.286 177.271 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 40.4 t -103.27 141.1 19.77 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.583 0 N-CA-C 109.628 -0.508 . . . . 0.0 109.628 178.005 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.551 HD11 HG23 ' A' ' 29' ' ' ILE . 57.5 mt -99.76 120.23 48.87 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.384 0 CA-C-O 121.051 0.453 . . . . 0.0 110.0 -179.999 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 14.5 tt0 -78.81 -56.23 4.57 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 121.489 0.661 . . . . 0.0 109.834 176.781 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.677 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 11.8 p -146.89 149.15 32.68 Favored 'General case' 0 N--CA 1.444 -0.741 0 CA-C-N 115.342 -0.844 . . . . 0.0 112.551 -171.001 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.538 ' HA ' ' O ' ' A' ' 76' ' ' ASN . 55.4 mt -126.7 114.03 35.88 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.599 0 CA-C-N 114.561 -1.2 . . . . 0.0 108.573 172.751 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' ASN . . . . . . . . . . . . . 6.4 t-20 63.13 -152.65 0.33 Allowed 'General case' 0 CA--C 1.532 0.278 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 -171.01 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -76.84 3.61 55.82 Favored Glycine 0 CA--C 1.52 0.392 0 C-N-CA 120.533 -0.841 . . . . 0.0 112.97 179.509 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 3.8 mpp? -111.76 105.39 56.59 Favored Pre-proline 0 C--N 1.328 -0.344 0 CA-C-O 120.725 0.298 . . . . 0.0 110.76 -178.894 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.677 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 47.0 Cg_endo -69.3 148.57 68.35 Favored 'Trans proline' 0 N--CA 1.462 -0.362 0 C-N-CA 122.303 2.002 . . . . 0.0 112.186 176.243 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 20.8 p -109.96 95.71 5.77 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.663 -176.484 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 14.7 p -92.85 -19.87 21.26 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-O 121.059 0.457 . . . . 0.0 110.738 177.367 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 14.2 m120 -125.56 173.52 8.89 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 178.153 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -82.48 -33.53 28.35 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 121.225 0.536 . . . . 0.0 110.257 176.683 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 6.1 m -70.08 -29.54 66.55 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.043 179.344 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 24.6 p -67.82 -38.5 83.32 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-O 121.136 0.493 . . . . 0.0 109.999 176.34 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 67.2 t80 -59.26 -44.15 92.41 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-N 115.437 -0.801 . . . . 0.0 109.709 173.475 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . 0.423 ' O ' ' HG3' ' A' ' 67' ' ' LYS . 70.3 m -63.71 -46.09 87.03 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.135 -0.938 . . . . 0.0 111.832 179.314 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.85 -33.68 74.62 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-N 115.957 -0.565 . . . . 0.0 111.118 179.652 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . 0.416 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -77.77 -36.17 50.83 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.147 0.499 . . . . 0.0 110.194 178.586 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -60.61 -29.91 69.52 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.62 -0.718 . . . . 0.0 111.139 179.124 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . 0.423 ' HG3' ' O ' ' A' ' 63' ' ' SER . 58.7 mtpt -58.79 -32.46 69.34 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.448 178.63 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 34.8 p -91.06 -14.71 30.8 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 112.216 0.45 . . . . 0.0 112.216 -175.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.416 HG12 ' O ' ' A' ' 65' ' ' ALA . 30.5 mm -82.26 140.53 16.3 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 N-CA-C 110.283 -0.266 . . . . 0.0 110.283 -177.695 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 14.3 t -115.64 178.04 4.45 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 120.958 0.409 . . . . 0.0 110.849 -179.575 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.457 ' CG1' ' HD2' ' A' ' 90' ' ' ARG . 20.9 t -79.99 120.78 32.08 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.39 0 CA-C-N 115.77 -0.65 . . . . 0.0 110.858 -178.105 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 98.17 5.65 57.12 Favored Glycine 0 N--CA 1.449 -0.465 0 C-N-CA 120.645 -0.788 . . . . 0.0 111.879 -179.815 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 15.2 tp10 -81.36 147.98 29.57 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.301 -0.45 . . . . 0.0 109.913 179.934 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 57.3 t -109.38 108.95 26.61 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.856 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.37 179.252 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 21.6 pt -109.84 153.84 11.5 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.773 0 CA-C-N 116.163 -0.472 . . . . 0.0 111.193 -175.375 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . 0.538 ' O ' ' HA ' ' A' ' 51' ' ' ILE . 5.4 t30 -90.07 132.16 35.55 Favored 'General case' 0 C--N 1.322 -0.594 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.647 177.633 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.418 HG22 HG23 ' A' ' 79' ' ' THR . 61.7 mt -128.53 116.5 41.83 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.606 0 CA-C-O 121.295 0.569 . . . . 0.0 110.465 -179.645 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . . . . . . . . . 4.6 m -99.3 102.25 13.81 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.141 177.783 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.483 HG22 HG12 ' A' ' 48' ' ' ILE . 73.4 p -102.16 170.15 8.28 Favored 'General case' 0 C--N 1.324 -0.519 0 C-N-CA 120.674 -0.41 . . . . 0.0 110.296 178.081 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -51.07 -38.76 53.55 Favored 'General case' 0 N--CA 1.466 0.365 0 O-C-N 123.801 0.688 . . . . 0.0 112.649 -176.279 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 31.4 mt-30 -127.44 20.25 6.74 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 111.92 0.341 . . . . 0.0 111.92 -174.659 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -165.68 119.96 0.9 Allowed Glycine 0 N--CA 1.446 -0.653 0 C-N-CA 119.751 -1.214 . . . . 0.0 113.465 179.04 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . . . . . . . . . 13.6 m -106.3 109.21 21.07 Favored 'General case' 0 C--N 1.321 -0.635 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 172.479 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . 0.453 ' CZ ' ' HB3' ' A' ' 42' ' ' LEU . 7.3 p90 -145.68 177.46 8.87 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-O 121.225 0.536 . . . . 0.0 111.807 -172.972 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 1.0 OUTLIER -111.9 150.82 29.93 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.388 -0.823 . . . . 0.0 109.756 172.055 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.439 HD22 ' HG3' ' A' ' 100' ' ' MET . 7.5 tt -134.11 141.39 47.11 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-O 121.218 0.533 . . . . 0.0 110.706 -176.81 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 82.3 tttt -94.21 116.38 28.77 Favored 'General case' 0 C--N 1.317 -0.828 0 CA-C-N 115.044 -0.98 . . . . 0.0 109.275 177.51 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 32.1 p -59.25 123.49 16.87 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-O 121.584 0.707 . . . . 0.0 111.414 -176.934 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -96.42 175.38 31.75 Favored Glycine 0 N--CA 1.434 -1.453 0 CA-C-N 114.991 -1.004 . . . . 0.0 111.403 -178.363 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . 0.499 ' HD3' ' N ' ' A' ' 90' ' ' ARG . 0.0 OUTLIER -144.06 75.64 1.47 Allowed 'General case' 0 C--N 1.314 -0.939 0 CA-C-O 121.427 0.632 . . . . 0.0 110.293 -178.092 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' ASN . . . . . 0.423 ' N ' ' HD2' ' A' ' 92' ' ' PRO . 17.6 m120 -62.0 -48.54 88.33 Favored Pre-proline 0 C--N 1.327 -0.382 0 CA-C-N 115.789 -0.641 . . . . 0.0 109.687 174.009 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.423 ' HD2' ' N ' ' A' ' 91' ' ' ASN . 56.9 Cg_endo -73.41 128.63 12.97 Favored 'Trans proline' 0 C--N 1.352 0.749 0 C-N-CA 121.614 1.543 . . . . 0.0 110.727 166.615 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -103.89 -25.86 12.89 Favored 'General case' 0 C--N 1.32 -0.681 0 CA-C-O 120.915 0.388 . . . . 0.0 110.074 -175.654 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 10.4 t30 -78.85 121.06 24.34 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 109.282 -0.636 . . . . 0.0 109.282 174.833 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 22.8 t 67.79 78.09 0.24 Allowed 'General case' 0 C--O 1.234 0.272 0 O-C-N 124.028 0.83 . . . . 0.0 109.038 -173.287 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 11.0 m -69.79 119.55 14.19 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.188 -0.914 . . . . 0.0 111.127 -174.865 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 7.5 ptt85 -149.99 161.61 41.99 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 115.629 -0.714 . . . . 0.0 109.917 175.198 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -58.25 118.25 5.29 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.565 -179.309 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 69.8 t80 -110.88 -23.84 10.76 Favored 'General case' 0 C--N 1.323 -0.559 0 C-N-CA 120.746 -0.382 . . . . 0.0 110.465 -178.21 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' MET . . . . . 0.439 ' HG3' HD22 ' A' ' 86' ' ' LEU . 44.3 ttm 70.63 -59.96 0.51 Allowed 'General case' 0 N--CA 1.468 0.455 0 CA-C-N 115.551 -0.749 . . . . 0.0 111.184 179.46 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . 124.21 9.31 5.63 Favored Glycine 0 C--O 1.227 -0.326 0 C-N-CA 121.023 -0.608 . . . . 0.0 113.11 178.259 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.603 HG22 ' HA ' ' A' ' 32' ' ' VAL . 2.8 pp -136.97 165.71 27.4 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 CA-C-O 120.909 0.385 . . . . 0.0 110.51 -179.028 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . 0.428 ' HD3' ' HA ' ' A' ' 103' ' ' ARG . 9.1 mmt180 -114.63 129.63 56.7 Favored 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 115.912 -0.585 . . . . 0.0 110.12 172.023 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . 0.591 HG23 HD13 ' A' ' 102' ' ' ILE . 3.1 p -110.05 143.19 40.43 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.007 0.432 . . . . 0.0 111.724 -177.836 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 18.0 m -151.24 151.11 31.4 Favored 'General case' 0 C--N 1.318 -0.765 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 173.487 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . 0.447 ' HA ' ' HA ' ' A' ' 27' ' ' VAL . 13.4 m120 -69.1 -30.99 69.4 Favored 'General case' 0 C--N 1.317 -0.845 0 CA-C-O 121.653 0.74 . . . . 0.0 109.845 -178.203 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 4.7 t-160 59.58 36.86 22.8 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 114.449 -1.25 . . . . 0.0 109.494 -170.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . . . . . . . . . 13.5 mt -58.45 157.53 8.72 Favored 'General case' 0 CA--C 1.516 -0.34 0 CA-C-N 115.781 -0.645 . . . . 0.0 109.82 174.768 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER -66.15 132.76 49.23 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.088 -177.205 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 11.3 p -55.96 139.06 15.73 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.386 0 CA-C-N 115.389 -0.823 . . . . 0.0 111.867 -174.738 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' ARG . . . . . . . . . . . . . 20.1 ptt180 -130.6 146.83 52.19 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 115.157 -0.929 . . . . 0.0 110.123 -179.43 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 34.2 t70 -116.69 99.13 6.91 Favored 'General case' 0 C--N 1.32 -0.693 0 CA-C-O 121.111 0.481 . . . . 0.0 109.712 176.04 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 14.9 m -146.49 124.58 12.11 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.539 -0.755 . . . . 0.0 109.631 -179.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 28.3 m -87.19 155.43 3.27 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-N 116.481 -0.327 . . . . 0.0 110.728 178.463 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -83.09 154.27 24.45 Favored 'General case' 0 C--N 1.322 -0.597 0 CA-C-N 116.3 -0.409 . . . . 0.0 109.943 174.765 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 69.2 m -72.49 122.87 22.01 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-O 121.097 0.475 . . . . 0.0 110.958 -179.057 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 7.3 p -135.62 128.34 47.22 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.545 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.125 176.005 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 7.0 mp -93.46 -49.13 6.06 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 115.916 -0.584 . . . . 0.0 109.889 179.678 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 77.1 -145.22 30.64 Favored Glycine 0 N--CA 1.446 -0.653 0 CA-C-N 115.511 -0.768 . . . . 0.0 111.959 -179.795 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 4.6 t70 72.47 149.39 0.09 Allowed 'General case' 0 N--CA 1.467 0.402 0 C-N-CA 123.382 0.673 . . . . 0.0 110.867 179.205 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 11.5 m -100.16 100.36 11.19 Favored 'General case' 0 C--N 1.319 -0.756 0 CA-C-O 121.019 0.437 . . . . 0.0 110.771 -179.07 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 86.3 mt -84.32 121.54 75.28 Favored Pre-proline 0 C--N 1.324 -0.504 0 CA-C-N 115.705 -0.679 . . . . 0.0 110.222 178.6 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 92.5 Cg_endo -79.39 27.89 0.52 Allowed 'Trans proline' 0 CA--C 1.529 0.27 0 C-N-CA 123.034 2.489 . . . . 0.0 113.285 -176.501 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 46.9 m-85 -136.0 129.58 32.27 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.161 0.505 . . . . 0.0 111.207 -179.864 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.248 0.975 0 CA-C-N 115.32 -0.854 . . . . 0.0 109.33 177.402 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . . . . . . . . . 26.5 mt-30 . . . . . 0 CA--C 1.527 0.087 0 CA-C-O 121.194 0.521 . . . . 0.0 110.767 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -91.19 105.54 0.27 Allowed 'Trans proline' 0 N--CA 1.449 -1.132 0 C-N-CA 122.825 2.35 . . . . 0.0 111.707 177.311 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 5.7 m-20 -123.59 -24.0 4.64 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.941 -179.094 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.574 ' HA2' ' HA ' ' A' ' 57' ' ' SER . . . 106.81 176.1 23.01 Favored Glycine 0 N--CA 1.443 -0.86 0 N-CA-C 111.208 -0.757 . . . . 0.0 111.208 -175.271 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.609 HG23 ' HB ' ' A' ' 48' ' ' ILE . 19.6 m -102.06 131.08 50.79 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.812 0 CA-C-O 121.393 0.616 . . . . 0.0 110.978 177.717 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 36.4 tp60 -97.04 135.04 39.6 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 115.456 -0.793 . . . . 0.0 110.557 -178.8 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.552 HD12 ' HB2' ' A' ' 46' ' ' LEU . 57.8 mt -78.59 112.56 16.76 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-N 115.972 -0.558 . . . . 0.0 109.546 176.441 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -74.12 -69.22 0.46 Allowed 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.629 -0.714 . . . . 0.0 110.932 -176.921 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 9.6 p -149.49 148.97 30.04 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.434 -177.05 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.581 HG13 HG22 ' A' ' 102' ' ' ILE . 57.4 t -96.07 114.07 31.96 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-N 115.642 -0.708 . . . . 0.0 109.773 176.915 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 47.0 t -98.2 128.1 34.51 Favored Pre-proline 0 C--N 1.318 -0.779 0 CA-C-N 116.062 -0.517 . . . . 0.0 109.998 -176.403 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo -63.59 86.25 0.13 Allowed 'Trans proline' 0 C--O 1.234 0.32 0 C-N-CA 122.748 2.299 . . . . 0.0 112.494 -179.923 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -151.48 20.08 0.92 Allowed Glycine 0 N--CA 1.446 -0.643 0 CA-C-N 115.529 -0.76 . . . . 0.0 111.455 177.574 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.447 ' HB2' ' HD2' ' A' ' 37' ' ' PRO . 67.8 p -174.9 160.97 2.43 Favored Pre-proline 0 C--N 1.328 -0.36 0 N-CA-C 109.188 -0.671 . . . . 0.0 109.188 -178.525 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . 0.447 ' HD2' ' HB2' ' A' ' 36' ' ' SER . 29.4 Cg_endo -63.65 -5.21 8.29 Favored 'Trans proline' 0 CA--C 1.532 0.405 0 C-N-CA 122.581 2.187 . . . . 0.0 112.631 179.075 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -67.95 -23.59 65.08 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.619 -0.264 . . . . 0.0 111.066 -179.862 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . 0.57 ' HA ' HG11 ' A' ' 32' ' ' VAL . 26.7 m -65.07 -24.87 67.58 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.188 0.518 . . . . 0.0 111.427 -178.687 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 1.6 tmtp? -88.14 -26.76 22.29 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.519 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . 0.535 ' HB ' HD12 ' A' ' 42' ' ' LEU . 46.3 t -92.17 -49.92 12.81 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.48 0 CA-C-N 116.247 -0.433 . . . . 0.0 111.8 -173.217 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.535 HD12 ' HB ' ' A' ' 41' ' ' VAL . 6.6 mp -95.38 168.38 10.75 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 121.329 0.585 . . . . 0.0 111.638 -172.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -133.01 144.03 51.06 Favored Pre-proline 0 C--N 1.322 -0.622 0 CA-C-N 115.204 -0.907 . . . . 0.0 109.861 176.418 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 78.8 Cg_endo -78.69 155.21 27.3 Favored 'Trans proline' 0 N--CA 1.463 -0.316 0 C-N-CA 122.721 2.281 . . . . 0.0 113.389 -176.0 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 94.08 20.99 29.0 Favored Glycine 0 N--CA 1.448 -0.528 0 C-N-CA 120.619 -0.801 . . . . 0.0 113.273 177.646 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.552 ' HB2' HD12 ' A' ' 29' ' ' ILE . 44.1 mt -108.33 164.26 12.47 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 117.028 0.414 . . . . 0.0 110.928 -179.226 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 61.5 t -108.42 135.14 48.14 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.397 0 CA-C-N 116.37 -0.377 . . . . 0.0 110.096 177.599 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.609 ' HB ' HG23 ' A' ' 27' ' ' VAL . 64.1 mt -96.29 124.63 49.1 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.432 0 CA-C-O 120.964 0.411 . . . . 0.0 110.837 -179.594 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 37.3 tt0 -84.51 -50.57 7.61 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 115.761 -0.654 . . . . 0.0 110.049 178.099 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.638 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 24.2 p -149.17 152.21 35.66 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.919 -0.582 . . . . 0.0 112.234 -175.126 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 45.7 mm -111.98 98.99 7.76 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.538 0 CA-C-N 114.954 -1.021 . . . . 0.0 110.489 177.05 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' ASN . . . . . 0.463 ' HA ' ' HB3' ' A' ' 76' ' ' ASN . 6.8 t-20 57.72 41.7 24.84 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-N 115.336 -0.847 . . . . 0.0 111.823 172.867 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 104.99 -30.23 10.36 Favored Glycine 0 N--CA 1.45 -0.416 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.641 176.539 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 72.0 mtm -97.53 112.25 60.76 Favored Pre-proline 0 C--N 1.326 -0.422 0 N-CA-C 109.673 -0.491 . . . . 0.0 109.673 178.308 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.638 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 56.0 Cg_endo -69.67 139.48 40.65 Favored 'Trans proline' 0 N--CA 1.459 -0.537 0 C-N-CA 122.26 1.974 . . . . 0.0 112.794 -175.743 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 31.3 p -113.57 83.27 1.82 Allowed 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.346 0.593 . . . . 0.0 111.149 -178.518 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . 0.574 ' HA ' ' HA2' ' A' ' 26' ' ' GLY . 48.0 t -91.88 -13.97 30.44 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.419 179.616 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 81.8 m-20 -129.16 -179.85 5.36 Favored 'General case' 0 C--N 1.326 -0.432 0 N-CA-C 109.195 -0.669 . . . . 0.0 109.195 -178.674 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.421 HD23 ' HA ' ' A' ' 59' ' ' LEU . 17.5 mt -75.93 -45.42 35.25 Favored 'General case' 0 N--CA 1.447 -0.602 0 CA-C-O 120.793 0.33 . . . . 0.0 110.902 175.104 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 6.9 m -61.62 -36.47 80.84 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.42 -177.552 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 19.3 p -64.5 -37.3 87.08 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.133 0.492 . . . . 0.0 110.498 176.217 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 70.7 t80 -70.43 -39.19 74.52 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.69 -0.686 . . . . 0.0 109.504 179.285 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 61.3 m -62.29 -48.53 79.46 Favored 'General case' 0 N--CA 1.444 -0.732 0 CA-C-N 115.314 -0.857 . . . . 0.0 111.666 176.894 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -61.62 -34.42 75.63 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.987 -179.994 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . . . . . . . . . . . -74.01 -44.35 54.81 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.965 -0.562 . . . . 0.0 110.425 179.239 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -61.9 -35.95 79.88 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.752 -0.658 . . . . 0.0 111.454 -176.738 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 88.5 tttt -55.86 -34.71 65.71 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.438 -0.346 . . . . 0.0 111.929 -176.807 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 71.3 p -78.94 -14.24 59.33 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-O 120.722 0.296 . . . . 0.0 111.719 -177.574 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.51 HD12 HG22 ' A' ' 75' ' ' ILE . 29.0 mm -81.04 126.74 39.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-O 120.903 0.382 . . . . 0.0 111.024 -175.826 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 20.2 m -120.1 -171.8 2.22 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.961 -176.792 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . 0.495 HG23 ' HA ' ' A' ' 97' ' ' ARG . 40.2 t -74.2 139.81 18.67 Favored 'Isoleucine or valine' 0 C--O 1.233 0.218 0 N-CA-C 110.145 -0.317 . . . . 0.0 110.145 176.907 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 69.02 32.05 72.86 Favored Glycine 0 N--CA 1.449 -0.482 0 C-N-CA 120.596 -0.811 . . . . 0.0 111.493 179.382 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 9.6 tp10 -104.84 147.9 27.24 Favored 'General case' 0 N--CA 1.444 -0.746 0 N-CA-C 109.402 -0.592 . . . . 0.0 109.402 -178.77 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 44.4 t -110.1 106.9 21.61 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 N-CA-C 109.492 -0.559 . . . . 0.0 109.492 -179.131 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . 0.51 HG22 HD12 ' A' ' 69' ' ' ILE . 30.5 pt -95.62 154.52 3.46 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.789 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.884 -177.2 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . 0.463 ' HB3' ' HA ' ' A' ' 52' ' ' ASN . 64.5 t30 -122.91 108.51 13.05 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.025 -176.797 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.465 HD12 HD21 ' A' ' 86' ' ' LEU . 60.4 mt -106.8 110.75 32.78 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.968 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.501 -175.131 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . 0.476 ' HA ' ' HA ' ' A' ' 83' ' ' THR . 25.5 m -89.29 113.89 25.21 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.701 -0.681 . . . . 0.0 109.471 177.144 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . 0.457 HG23 HG22 ' A' ' 77' ' ' ILE . 71.3 p -120.45 -178.54 3.72 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-O 121.06 0.457 . . . . 0.0 111.312 -176.323 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -62.81 -26.5 68.77 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.379 -0.828 . . . . 0.0 111.069 173.678 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 26.9 mm-40 -93.55 9.32 37.22 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.04 0.448 . . . . 0.0 111.351 179.758 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 114.95 -177.75 17.53 Favored Glycine 0 N--CA 1.444 -0.782 0 C-N-CA 120.624 -0.798 . . . . 0.0 112.637 176.625 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.476 ' HA ' ' HA ' ' A' ' 78' ' ' THR . 10.6 m -97.93 113.47 25.32 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.798 -0.201 . . . . 0.0 110.727 -178.096 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 46.1 m-85 -111.75 148.06 34.31 Favored 'General case' 0 C--N 1.326 -0.419 0 N-CA-C 110.18 -0.304 . . . . 0.0 110.18 179.389 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 25.7 p-80 -122.95 125.42 45.27 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-O 120.871 0.367 . . . . 0.0 110.018 175.498 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.465 HD21 HD12 ' A' ' 77' ' ' ILE . 0.7 OUTLIER -130.89 156.99 44.12 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.889 -0.596 . . . . 0.0 110.849 -176.059 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 19.5 ptmt -99.77 146.58 26.4 Favored 'General case' 0 N--CA 1.442 -0.834 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.211 179.206 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 33.3 p -83.92 128.39 34.51 Favored 'General case' 0 C--N 1.315 -0.915 0 CA-C-N 116.013 -0.54 . . . . 0.0 110.732 175.857 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -86.6 -169.51 45.98 Favored Glycine 0 N--CA 1.444 -0.833 0 C-N-CA 120.936 -0.65 . . . . 0.0 112.207 -178.811 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 9.8 mpt_? -90.13 -177.17 5.09 Favored 'General case' 0 C--N 1.32 -0.715 0 CA-C-O 120.974 0.416 . . . . 0.0 110.846 -178.224 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' ASN . . . . . 0.404 ' HA ' ' CD1' ' A' ' 99' ' ' TYR . 12.5 p-10 -107.89 105.87 57.24 Favored Pre-proline 0 C--N 1.324 -0.54 0 CA-C-N 115.747 -0.661 . . . . 0.0 112.036 -175.682 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.513 ' HD2' ' CE1' ' A' ' 99' ' ' TYR . 20.3 Cg_exo -67.52 -40.91 9.55 Favored 'Trans proline' 0 C--O 1.234 0.278 0 C-N-CA 122.358 2.039 . . . . 0.0 111.47 171.664 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 22.9 t-20 -109.97 -94.21 0.42 Allowed 'General case' 0 CA--C 1.532 0.251 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.84 -178.602 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 10.8 m120 -135.38 110.2 8.71 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.229 0.537 . . . . 0.0 112.126 -178.121 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . 0.401 ' O ' ' HB3' ' A' ' 91' ' ' ASN . 2.8 t -179.04 89.63 0.02 OUTLIER 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 107.367 -1.346 . . . . 0.0 107.367 172.969 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . . . . . . . . . 47.6 m -58.23 -39.08 78.15 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.822 -0.626 . . . . 0.0 111.908 -171.173 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . 0.587 ' HD2' ' O ' ' A' ' 97' ' ' ARG . 6.6 ppt_? -129.87 120.59 25.17 Favored 'General case' 0 N--CA 1.446 -0.641 0 C-N-CA 121.004 -0.279 . . . . 0.0 110.858 178.755 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . 65.9 115.24 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.525 0 CA-C-N 115.586 -0.734 . . . . 0.0 112.124 178.405 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . 0.513 ' CE1' ' HD2' ' A' ' 92' ' ' PRO . 4.5 t80 -88.24 -55.8 3.59 Favored 'General case' 0 C--N 1.327 -0.412 0 C-N-CA 120.266 -0.574 . . . . 0.0 110.491 178.122 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' MET . . . . . . . . . . . . . 25.2 ttt 59.01 94.74 0.03 OUTLIER 'General case' 0 N--CA 1.468 0.44 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.929 178.784 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -84.44 38.49 2.9 Favored Glycine 0 C--O 1.225 -0.453 0 CA-C-N 115.92 -0.582 . . . . 0.0 114.316 -172.007 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.581 HG22 HG13 ' A' ' 32' ' ' VAL . 2.1 pp -137.92 140.99 39.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.569 0 N-CA-C 108.985 -0.746 . . . . 0.0 108.985 172.43 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . 0.607 ' NE ' ' HA ' ' A' ' 103' ' ' ARG . 0.0 OUTLIER -101.42 141.56 34.11 Favored 'General case' 0 C--N 1.317 -0.838 0 C-N-CA 120.706 -0.398 . . . . 0.0 110.307 -177.067 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 1.5 p -127.48 151.43 48.86 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.577 -177.847 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 20.0 m -151.26 154.49 36.89 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 174.388 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . 0.525 ' HB2' ' HG ' ' A' ' 108' ' ' LEU . 37.2 p30 -68.01 -29.94 69.07 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-O 120.574 0.226 . . . . 0.0 111.345 -176.38 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 46.2 t60 52.42 40.65 29.91 Favored 'General case' 0 CA--C 1.532 0.268 0 CA-C-O 121.25 0.548 . . . . 0.0 109.956 -177.329 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . 0.525 ' HG ' ' HB2' ' A' ' 106' ' ' ASN . 47.7 mt -71.06 -175.17 1.1 Allowed 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 121.804 0.811 . . . . 0.0 112.439 -176.063 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 6.0 mmt180 -81.54 92.52 6.53 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 114.654 -1.157 . . . . 0.0 109.366 -178.062 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . . . . . . . . . 46.1 t -77.28 115.38 19.01 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.758 0 CA-C-O 121.445 0.641 . . . . 0.0 111.091 -177.35 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' ARG . . . . . . . . . . . . . 26.3 tpt180 -160.12 108.94 1.72 Allowed 'General case' 0 C--N 1.313 -0.981 0 CA-C-N 114.863 -1.062 . . . . 0.0 108.698 178.546 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -156.3 106.73 2.39 Favored 'General case' 0 C--N 1.318 -0.802 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.19 -173.655 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 19.9 m -94.31 115.45 27.68 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.907 -0.588 . . . . 0.0 111.22 -175.595 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 19.4 m -105.69 131.34 55.37 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.372 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.015 179.635 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -159.46 134.24 7.96 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.695 -179.824 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 16.6 t -164.41 91.19 0.59 Allowed 'General case' 0 C--N 1.325 -0.462 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 177.28 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 57.6 t -133.99 104.63 6.18 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.498 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.737 -178.23 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 118' ' ' LEU . . . . . . . . . . . . . 89.7 mt -127.58 -76.77 0.57 Allowed 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 109.721 -0.474 . . . . 0.0 109.721 175.758 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 69.81 40.78 75.02 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 121.075 -0.583 . . . . 0.0 112.901 177.002 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -79.67 130.61 35.5 Favored 'General case' 0 C--N 1.325 -0.467 0 N-CA-C 109.657 -0.497 . . . . 0.0 109.657 178.03 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 121' ' ' THR . . . . . 0.453 ' O ' ' HD3' ' A' ' 123' ' ' PRO . 4.9 t -64.18 116.02 5.56 Favored 'General case' 0 N--CA 1.45 -0.43 0 CA-C-O 121.339 0.59 . . . . 0.0 109.976 178.496 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 91.7 mt -104.36 104.82 46.74 Favored Pre-proline 0 C--N 1.321 -0.669 0 CA-C-N 115.848 -0.615 . . . . 0.0 110.287 -176.262 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . 0.453 ' HD3' ' O ' ' A' ' 121' ' ' THR . 24.1 Cg_exo -63.74 107.16 0.7 Allowed 'Trans proline' 0 N--CA 1.458 -0.606 0 C-N-CA 122.54 2.16 . . . . 0.0 110.957 176.768 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 3.2 t80 -116.38 -1.75 12.22 Favored 'General case' 0 C--N 1.322 -0.588 0 CA-C-O 121.171 0.51 . . . . 0.0 110.366 -175.851 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.247 0.922 0 CA-C-O 118.48 -0.772 . . . . 0.0 110.432 179.934 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.686 ' HB2' ' HD3' ' A' ' 24' ' ' PRO . 35.4 mt-30 . . . . . 0 CA--C 1.533 0.322 0 CA-C-O 119.797 -0.144 . . . . 0.0 111.104 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' PRO . . . . . 0.686 ' HD3' ' HB2' ' A' ' 23' ' ' GLN . 22.9 Cg_exo -64.74 134.66 41.56 Favored 'Trans proline' 0 C--N 1.356 0.94 0 C-N-CA 121.943 1.762 . . . . 0.0 111.507 177.94 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.696 ' HA ' ' CD2' ' A' ' 108' ' ' LEU . 0.0 OUTLIER -91.53 -54.91 3.7 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.233 -174.487 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 93.74 157.82 33.42 Favored Glycine 0 N--CA 1.444 -0.785 0 C-N-CA 120.93 -0.653 . . . . 0.0 111.485 -178.352 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' VAL . . . . . 0.637 HG23 ' HB ' ' A' ' 48' ' ' ILE . 3.8 m -105.27 118.93 53.59 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.713 0 CA-C-O 121.704 0.764 . . . . 0.0 110.844 -179.164 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' GLN . . . . . . . . . . . . . 34.8 tp60 -103.69 136.0 44.21 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.271 -0.877 . . . . 0.0 110.841 -177.09 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' ILE . . . . . 0.531 HD11 HD11 ' A' ' 48' ' ' ILE . 42.3 mm -68.98 113.16 4.34 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.14 175.543 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' ASP . . . . . . . . . . . . . 24.5 t70 -76.01 -63.53 1.29 Allowed 'General case' 0 C--N 1.317 -0.832 0 CA-C-N 115.749 -0.659 . . . . 0.0 109.623 176.759 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 45.3 t -150.69 150.26 30.85 Favored 'General case' 0 N--CA 1.446 -0.654 0 CA-C-N 115.372 -0.831 . . . . 0.0 111.063 -179.571 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' VAL . . . . . 0.571 HG22 HG22 ' A' ' 102' ' ' ILE . 64.0 t -96.36 112.8 29.25 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.946 0 CA-C-N 114.95 -1.023 . . . . 0.0 109.123 174.577 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.461 ' HA ' ' HD3' ' A' ' 34' ' ' PRO . 19.5 m -83.33 127.12 69.89 Favored Pre-proline 0 C--N 1.324 -0.526 0 CA-C-O 121.065 0.46 . . . . 0.0 111.261 -176.247 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' PRO . . . . . 0.461 ' HD3' ' HA ' ' A' ' 33' ' ' VAL . 21.3 Cg_exo -66.1 146.46 81.98 Favored 'Trans proline' 0 C--O 1.237 0.429 0 C-N-CA 122.982 2.455 . . . . 0.0 112.058 178.288 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . 114.24 -25.85 10.24 Favored Glycine 0 N--CA 1.45 -0.393 0 N-CA-C 111.507 -0.637 . . . . 0.0 111.507 -178.302 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 50.4 m -101.77 159.2 30.12 Favored Pre-proline 0 C--N 1.319 -0.721 0 CA-C-N 115.442 -0.379 . . . . 0.0 110.331 178.85 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' PRO . . . . . . . . . . . . . 33.6 Cg_exo -60.19 -20.18 60.62 Favored 'Trans proline' 0 C--N 1.347 0.487 0 C-N-CA 123.057 2.505 . . . . 0.0 112.958 -178.102 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -66.15 -25.84 67.15 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.973 -176.808 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' SER . . . . . . . . . . . . . 13.4 m -63.2 -22.95 67.2 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.365 -0.38 . . . . 0.0 111.738 -176.224 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' LYS . . . . . . . . . . . . . 57.4 tttm -110.11 11.53 23.77 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.907 0.384 . . . . 0.0 110.514 -176.465 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' VAL . . . . . . . . . . . . . 96.5 t -120.73 -55.25 3.39 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.401 0 CA-C-O 120.761 0.315 . . . . 0.0 111.275 -177.063 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 97.7 mt -107.69 167.19 10.13 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.083 0.468 . . . . 0.0 111.434 -174.142 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' THR . . . . . 0.405 ' HA ' ' HD3' ' A' ' 44' ' ' PRO . 20.1 p -113.9 148.06 39.09 Favored Pre-proline 0 N--CA 1.446 -0.663 0 CA-C-N 115.323 -0.853 . . . . 0.0 109.626 175.839 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.405 ' HD3' ' HA ' ' A' ' 43' ' ' THR . 5.1 Cg_exo -74.79 141.1 26.89 Favored 'Trans proline' 0 N--CA 1.458 -0.565 0 C-N-CA 122.285 1.99 . . . . 0.0 111.926 -178.054 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' GLY . . . . . . . . . . . . . . . 105.36 -2.21 40.06 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.626 -0.797 . . . . 0.0 113.056 179.916 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . 0.453 HD22 ' HB3' ' A' ' 80' ' ' ASP . 72.7 mt -78.65 164.8 24.32 Favored 'General case' 0 C--N 1.325 -0.471 0 CA-C-O 121.257 0.551 . . . . 0.0 111.556 -178.849 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 61.8 t -109.51 138.64 36.03 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.546 0 CA-C-N 115.801 -0.636 . . . . 0.0 109.378 174.63 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' ILE . . . . . 0.637 ' HB ' HG23 ' A' ' 27' ' ' VAL . 88.4 mt -94.68 111.84 26.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.52 0 CA-C-O 120.971 0.415 . . . . 0.0 110.03 177.968 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -75.07 -51.4 13.6 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.484 -178.717 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' SER . . . . . 0.563 ' HA ' ' HA ' ' A' ' 55' ' ' PRO . 31.5 p -156.61 156.91 34.35 Favored 'General case' 0 C--N 1.321 -0.658 0 CA-C-N 115.76 -0.655 . . . . 0.0 112.29 -174.912 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.762 HG22 ' H ' ' A' ' 52' ' ' ASN . 9.0 mm -100.07 -171.37 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.436 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 173.649 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' ASN . . . . . 0.762 ' H ' HG22 ' A' ' 51' ' ' ILE . 1.7 m-20 -48.72 92.99 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.56 0 C-N-CA 123.039 0.536 . . . . 0.0 112.089 178.869 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 72.19 -10.07 4.96 Favored Glycine 0 CA--C 1.521 0.461 0 C-N-CA 121.384 -0.436 . . . . 0.0 113.787 175.517 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' MET . . . . . . . . . . . . . 71.0 mtm -125.71 112.69 25.02 Favored Pre-proline 0 C--N 1.327 -0.403 0 CA-C-N 117.147 0.474 . . . . 0.0 110.863 -175.882 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . 0.563 ' HA ' ' HA ' ' A' ' 50' ' ' SER . 4.4 Cg_exo -78.65 137.44 14.42 Favored 'Trans proline' 0 N--CA 1.46 -0.488 0 C-N-CA 122.897 2.398 . . . . 0.0 111.661 175.97 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' THR . . . . . . . . . . . . . 40.1 p -121.48 116.76 25.31 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.909 0.385 . . . . 0.0 111.77 -178.857 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' SER . . . . . . . . . . . . . 30.7 t -86.57 -53.4 4.99 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.32 174.106 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' ASN . . . . . . . . . . . . . 15.5 m120 -86.24 157.11 20.03 Favored 'General case' 0 C--N 1.318 -0.762 0 C-N-CA 120.228 -0.589 . . . . 0.0 109.629 -169.799 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' LEU . . . . . 0.564 ' HG ' ' HB2' ' A' ' 106' ' ' ASN . 3.4 mt -65.11 -38.55 91.04 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 121.1 0.476 . . . . 0.0 110.4 177.992 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' THR . . . . . . . . . . . . . 3.3 m -64.44 -38.38 90.84 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.826 -0.624 . . . . 0.0 111.109 179.432 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' THR . . . . . . . . . . . . . 11.9 p -71.48 -32.1 67.88 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.958 0.408 . . . . 0.0 110.565 177.733 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' TYR . . . . . . . . . . . . . 72.2 t80 -65.51 -44.34 87.28 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.893 -0.594 . . . . 0.0 109.789 175.467 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' SER . . . . . . . . . . . . . 7.9 t -63.17 -37.52 87.55 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.03 178.062 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' ALA . . . . . . . . . . . . . . . -64.04 -33.07 74.92 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.156 -0.474 . . . . 0.0 111.015 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . 0.505 ' O ' HG12 ' A' ' 69' ' ' ILE . . . -76.9 -40.03 48.83 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.256 0.55 . . . . 0.0 110.204 176.858 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' LEU . . . . . 0.436 HD21 ' SD ' ' A' ' 100' ' ' MET . 0.4 OUTLIER -60.5 -38.06 83.1 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-N 115.61 -0.723 . . . . 0.0 111.406 179.444 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 97.8 mttt -74.24 -6.43 47.87 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.996 -0.547 . . . . 0.0 112.301 -177.614 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' THR . . . . . . . . . . . . . 22.5 p -100.4 -12.61 19.25 Favored 'General case' 0 C--N 1.324 -0.541 0 C-N-CA 120.754 -0.379 . . . . 0.0 110.841 174.142 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.505 HG12 ' O ' ' A' ' 65' ' ' ALA . 47.2 mm -80.33 135.62 24.98 Favored 'Isoleucine or valine' 0 C--O 1.234 0.275 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.872 -178.667 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' SER . . . . . . . . . . . . . 1.4 m -83.03 165.7 19.4 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 115.962 -0.563 . . . . 0.0 111.345 -177.027 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' VAL . . . . . . . . . . . . . 32.5 t -76.75 124.12 34.49 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 115.902 -0.59 . . . . 0.0 109.595 174.404 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 79.73 25.62 58.01 Favored Glycine 0 N--CA 1.446 -0.65 0 C-N-CA 120.314 -0.946 . . . . 0.0 111.178 -176.573 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' GLU . . . . . . . . . . . . . 8.1 tp10 -85.6 147.81 26.22 Favored 'General case' 0 C--N 1.322 -0.589 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 178.423 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' VAL . . . . . . . . . . . . . 56.9 t -104.61 98.56 6.98 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.978 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 176.05 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' ILE . . . . . . . . . . . . . 26.0 pt -91.18 164.69 2.07 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.779 0 CA-C-O 121.388 0.613 . . . . 0.0 111.506 -173.956 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' ASN . . . . . . . . . . . . . 33.2 t30 -116.06 115.88 26.89 Favored 'General case' 0 C--N 1.316 -0.853 0 CA-C-N 115.158 -0.928 . . . . 0.0 109.615 -178.929 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 24.1 mt -120.61 107.74 21.35 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.666 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.315 -175.533 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' THR . . . . . 0.481 ' HA ' ' HA ' ' A' ' 83' ' ' THR . 30.6 m -80.78 118.37 22.25 Favored 'General case' 0 C--N 1.317 -0.807 0 N-CA-C 108.883 -0.784 . . . . 0.0 108.883 173.381 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' THR . . . . . . . . . . . . . 72.6 p -119.81 -173.38 2.53 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.319 0.58 . . . . 0.0 111.891 -173.431 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' ASP . . . . . 0.453 ' HB3' HD22 ' A' ' 46' ' ' LEU . 20.8 t70 -56.71 -36.13 69.32 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 114.713 -1.13 . . . . 0.0 111.44 176.412 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' GLN . . . . . . . . . . . . . 24.8 mt-30 -93.73 7.6 44.19 Favored 'General case' 0 C--O 1.235 0.295 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.342 -177.259 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 112.67 -169.35 12.97 Favored Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.655 177.779 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' THR . . . . . 0.481 ' HA ' ' HA ' ' A' ' 78' ' ' THR . 9.2 m -77.84 127.16 31.96 Favored 'General case' 0 C--N 1.321 -0.652 0 C-N-CA 122.559 0.344 . . . . 0.0 111.636 -177.973 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 97.7 m-85 -132.11 158.44 41.63 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 120.898 0.38 . . . . 0.0 110.108 174.69 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' HIS . . . . . . . . . . . . . 33.1 m-70 -118.51 137.62 53.08 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 109.436 -0.579 . . . . 0.0 109.436 176.513 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' LEU . . . . . 0.493 HD23 ' N ' ' A' ' 87' ' ' LYS . 1.6 tt -135.41 138.9 43.72 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-O 120.884 0.373 . . . . 0.0 110.571 -173.237 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.493 ' N ' HD23 ' A' ' 86' ' ' LEU . 38.6 ttpt -95.97 123.07 39.41 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-N 116.09 -0.505 . . . . 0.0 109.963 177.706 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.44 HG21 HG21 ' A' ' 69' ' ' ILE . 41.1 p -69.4 142.49 53.89 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.902 -0.59 . . . . 0.0 112.033 -174.974 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' GLY . . . . . . . . . . . . . . . -76.12 -170.1 29.53 Favored Glycine 0 N--CA 1.444 -0.823 0 CA-C-N 115.692 -0.686 . . . . 0.0 112.833 -178.367 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' ARG . . . . . . . . . . . . . 6.0 mpt_? -121.03 157.66 29.52 Favored 'General case' 0 C--N 1.319 -0.741 0 CA-C-O 120.818 0.342 . . . . 0.0 111.487 -172.96 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' ASN . . . . . . . . . . . . . 47.6 m-80 59.15 87.16 0.14 Allowed Pre-proline 0 N--CA 1.469 0.494 0 CA-C-N 114.844 -1.071 . . . . 0.0 113.663 170.438 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' PRO . . . . . 0.597 ' HG2' ' H ' ' A' ' 96' ' ' SER . 92.9 Cg_endo -94.28 -152.35 0.04 OUTLIER 'Trans proline' 0 N--CA 1.456 -0.728 0 C-N-CA 123.447 2.764 . . . . 0.0 110.621 169.166 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' ASN . . . . . . . . . . . . . 32.5 t30 -99.19 -85.55 0.39 Allowed 'General case' 0 C--N 1.328 -0.332 0 C-N-CA 120.597 -0.441 . . . . 0.0 110.913 178.078 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' ASN . . . . . . . . . . . . . 23.8 t-20 -100.49 -14.86 18.09 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.991 0.424 . . . . 0.0 110.786 -176.227 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 19.1 m -64.4 -41.49 96.61 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.745 -179.741 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' SER . . . . . 0.597 ' H ' ' HG2' ' A' ' 92' ' ' PRO . 73.5 m 61.52 15.79 7.04 Favored 'General case' 0 N--CA 1.469 0.476 0 CA-C-O 121.341 0.591 . . . . 0.0 111.91 -178.532 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . 0.436 HH11 ' HD2' ' A' ' 97' ' ' ARG . 53.1 mtt180 -126.35 -164.26 1.31 Allowed 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 115.414 -0.812 . . . . 0.0 110.565 -175.978 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' ALA . . . . . . . . . . . . . . . -46.09 139.16 4.68 Favored 'General case' 0 C--N 1.329 -0.325 0 O-C-N 124.019 0.824 . . . . 0.0 111.945 174.971 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' TYR . . . . . . . . . . . . . 35.3 t80 -117.4 -15.67 10.31 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 116.431 -0.349 . . . . 0.0 110.759 -179.501 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' MET . . . . . 0.436 ' SD ' HD21 ' A' ' 66' ' ' LEU . 82.7 mtp 58.43 -153.97 0.37 Allowed 'General case' 0 N--CA 1.467 0.399 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.751 -176.858 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' GLY . . . . . . . . . . . . . . . -155.53 32.05 0.63 Allowed Glycine 0 N--CA 1.449 -0.441 0 C-N-CA 120.259 -0.972 . . . . 0.0 112.904 -179.778 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' ILE . . . . . 0.571 HG22 HG22 ' A' ' 32' ' ' VAL . 2.8 pp -144.21 166.26 12.92 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 N-CA-C 109.929 -0.397 . . . . 0.0 109.929 178.871 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' ARG . . . . . . . . . . . . . 38.0 mmt180 -108.49 132.49 53.76 Favored 'General case' 0 C--N 1.317 -0.825 0 N-CA-C 109.278 -0.638 . . . . 0.0 109.278 176.201 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -110.76 132.35 54.27 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-O 121.335 0.588 . . . . 0.0 111.917 -177.962 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 42.3 m -109.89 165.69 11.51 Favored 'General case' 0 C--N 1.319 -0.728 0 CA-C-N 115.235 -0.893 . . . . 0.0 109.799 175.163 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' ASN . . . . . 0.564 ' HB2' ' HG ' ' A' ' 59' ' ' LEU . 2.2 t-20 -114.6 38.95 2.95 Favored 'General case' 0 C--N 1.313 -1.011 0 CA-C-O 122.013 0.911 . . . . 0.0 108.582 179.713 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' HIS . . . . . . . . . . . . . 72.6 t60 -81.42 115.88 20.97 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 114.358 -1.292 . . . . 0.0 110.419 -175.262 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' LEU . . . . . 0.696 ' CD2' ' HA ' ' A' ' 25' ' ' ASP . 9.0 mt -55.32 133.9 49.8 Favored 'General case' 0 CA--C 1.515 -0.367 0 CA-C-O 121.489 0.661 . . . . 0.0 110.954 177.588 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' ARG . . . . . . . . . . . . . 70.7 ttt180 -136.38 130.84 33.4 Favored 'General case' 0 C--N 1.312 -1.058 0 CA-C-N 114.826 -1.079 . . . . 0.0 109.128 -178.353 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' VAL . . . . . 0.56 HG22 ' H ' ' A' ' 112' ' ' ASP . 9.1 p -70.42 131.66 34.05 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-O 121.572 0.701 . . . . 0.0 111.979 -173.891 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' ARG . . . . . . . . . . . . . 28.4 mmm180 -88.19 -15.24 36.53 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.258 -0.883 . . . . 0.0 109.808 177.513 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 112' ' ' ASP . . . . . 0.56 ' H ' HG22 ' A' ' 110' ' ' VAL . 23.1 t0 60.84 29.13 18.81 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 114.795 -1.093 . . . . 0.0 111.737 173.958 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 15.7 t -148.67 -177.48 5.81 Favored 'General case' 0 C--N 1.32 -0.677 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.011 178.138 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 114' ' ' VAL . . . . . . . . . . . . . 19.2 m -63.53 138.9 22.19 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 CA-C-O 121.458 0.647 . . . . 0.0 111.428 -177.243 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 115' ' ' ALA . . . . . . . . . . . . . . . -153.35 -55.22 0.11 Allowed 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 177.951 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 116' ' ' SER . . . . . . . . . . . . . 5.9 m 63.41 -161.75 0.29 Allowed 'General case' 0 CA--C 1.53 0.191 0 CA-C-N 115.006 -0.997 . . . . 0.0 111.481 172.141 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 117' ' ' VAL . . . . . . . . . . . . . 48.1 t 64.5 93.74 0.05 OUTLIER 'Isoleucine or valine' 0 C--O 1.234 0.237 0 CA-C-N 115.808 -0.633 . . . . 0.0 111.964 176.597 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 118' ' ' LEU . . . . . 0.474 HD23 ' HG3' ' A' ' 23' ' ' GLN . 84.3 mt -120.4 -49.52 2.26 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.076 175.669 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 119' ' ' GLY . . . . . . . . . . . . . . . 105.32 72.25 0.85 Allowed Glycine 0 N--CA 1.445 -0.749 0 C-N-CA 120.589 -0.815 . . . . 0.0 111.69 179.669 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 120' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -70.85 95.8 1.19 Allowed 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.014 0.435 . . . . 0.0 110.685 179.511 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 121' ' ' THR . . . . . . . . . . . . . 13.9 t -84.8 126.03 33.09 Favored 'General case' 0 N--CA 1.445 -0.719 0 N-CA-C 109.108 -0.701 . . . . 0.0 109.108 175.777 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 122' ' ' LEU . . . . . . . . . . . . . 94.7 mt -76.21 125.78 87.4 Favored Pre-proline 0 C--N 1.322 -0.611 0 CA-C-O 121.239 0.542 . . . . 0.0 110.884 -172.061 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 123' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -76.63 112.97 3.56 Favored 'Trans proline' 0 N--CA 1.461 -0.433 0 C-N-CA 123.044 2.496 . . . . 0.0 113.448 -172.775 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 124' ' ' PHE . . . . . . . . . . . . . 90.5 m-85 -130.35 127.19 38.9 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-N 115.557 -0.747 . . . . 0.0 109.491 174.075 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 125' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.245 0.854 0 CA-C-O 118.357 -0.83 . . . . 0.0 109.815 179.91 . . . . . . . . 0 0 . 1 stop_ save_